15485686	A novel SCN5A mutation manifests as a malignant form of long QT syndrome with perinatal onset of tachycardia / bradycardia .|OBJECTIVE : Congenital long QT syndrome ( LQTS ) with in utero onset of the rhythm disturbances is associated with a poor prognosis .|In this study we investigated a newborn patient with fetal bradycardia , 2 : 1 atrioventricular block and ventricular tachycardia soon after birth .|METHODS : Mutational analysis and DNA sequencing were conducted in a newborn .|The 2 : 1 atrioventricular block improved to 1 : 1 conduction only after intravenous lidocaine infusion or a high dose of mexiletine , which also controlled the ventricular tachycardia .|RESULTS : A novel , spontaneous LQTS - 3 mutation was identified in the transmembrane segment 6 of domain IV of the Na ( v ) 1 . 5 cardiac sodium channel , with a G - - > A substitution at codon 1763 , which changed a valine ( GTG ) to a methionine ( ATG ) .|The proband was heterozygous but the mutation was absent in the parents and the sister .|Expression of this mutant channel in tsA201 mammalian cells by site - directed mutagenesis revealed a persistent tetrodotoxin - sensitive but lidocaine - resistant current that was associated with a positive shift of the steady - state inactivation curve , steeper activation curve and faster recovery from inactivation .|We also found a similar electrophysiological profile for the neighboring V1764M mutant .|But , the other neighboring I1762A mutant had no persistent current and was still associated with a positive shift of inactivation .|CONCLUSIONS : These findings suggest that the Na ( v ) 1 . 5 / V1763M channel dysfunction and possible neighboring mutants contribute to a persistent inward current due to altered inactivation kinetics and clinically congenital LQTS with perinatal onset of arrhythmias that responded to lidocaine and mexiletine .	1:Association:2	R2L	NON-CROSS	10-13	2-3	D008133	long QT syndrome|long QT syndrome|LQTS|LQTS|LQTS	DiseaseOrPhenotypicFeature	10:24:28:119:308	13:27:29:120:309	0:1:1:5:10	6331	SCN5A|Na ( v ) 1 . 5|Na ( v ) 1 . 5	GeneOrGeneProduct	2:135:279	3:142:286	0:5:10	1:Association:2	R2L	NON-CROSS	17-18	2-3	D013610	tachycardia	DiseaseOrPhenotypicFeature	17	18	0	6331	SCN5A|Na ( v ) 1 . 5|Na ( v ) 1 . 5	GeneOrGeneProduct	2:135:279	3:142:286	0:5:10	1:Association:2	R2L	NON-CROSS	19-20	2-3	D001919	bradycardia|bradycardia	DiseaseOrPhenotypicFeature	19:55	20:56	0:2	6331	SCN5A|Na ( v ) 1 . 5|Na ( v ) 1 . 5	GeneOrGeneProduct	2:135:279	3:142:286	0:5:10	1:NR:2	L2R	CROSS	86-88	135-142	6331	SCN5A|Na ( v ) 1 . 5|Na ( v ) 1 . 5	GeneOrGeneProduct	2:135:279	3:142:286	0:5:10	D054537	atrioventricular block|atrioventricular block	DiseaseOrPhenotypicFeature	60:86	62:88	2:4	1:NR:2	L2R	CROSS	110-112	135-142	6331	SCN5A|Na ( v ) 1 . 5|Na ( v ) 1 . 5	GeneOrGeneProduct	2:135:279	3:142:286	0:5:10	D017180	ventricular tachycardia|ventricular tachycardia	DiseaseOrPhenotypicFeature	63:110	65:112	2:4	1:NR:2	L2R	NON-CROSS	279-286	317-318	6331	SCN5A|Na ( v ) 1 . 5|Na ( v ) 1 . 5	GeneOrGeneProduct	2:135:279	3:142:286	0:5:10	D008012	lidocaine|lidocaine|lidocaine	ChemicalEntity	97:209:317	98:210:318	4:7:10	1:NR:2	L2R	NON-CROSS	279-286	319-320	6331	SCN5A|Na ( v ) 1 . 5|Na ( v ) 1 . 5	GeneOrGeneProduct	2:135:279	3:142:286	0:5:10	D008801	mexiletine|mexiletine	ChemicalEntity	104:319	105:320	4:10	1:NR:2	L2R	NON-CROSS	135-142	143-144	6331	SCN5A|Na ( v ) 1 . 5|Na ( v ) 1 . 5	GeneOrGeneProduct	2:135:279	3:142:286	0:5:10	D012964	sodium	ChemicalEntity	143	144	5	1:NR:2	L2R	CROSS	135-142	205-206	6331	SCN5A|Na ( v ) 1 . 5|Na ( v ) 1 . 5	GeneOrGeneProduct	2:135:279	3:142:286	0:5:10	D013779	tetrodotoxin	ChemicalEntity	205	206	7	1:Association:2	L2R	NON-CROSS	279-286	313-314	6331	SCN5A|Na ( v ) 1 . 5|Na ( v ) 1 . 5	GeneOrGeneProduct	2:135:279	3:142:286	0:5:10	D001145	arrhythmias	DiseaseOrPhenotypicFeature	313	314	10	1:Negative_Correlation:2	L2R	NON-CROSS	308-309	317-318	D008133	long QT syndrome|long QT syndrome|LQTS|LQTS|LQTS	DiseaseOrPhenotypicFeature	10:24:28:119:308	13:27:29:120:309	0:1:1:5:10	D008012	lidocaine|lidocaine|lidocaine	ChemicalEntity	97:209:317	98:210:318	4:7:10	1:Negative_Correlation:2	L2R	NON-CROSS	308-309	319-320	D008133	long QT syndrome|long QT syndrome|LQTS|LQTS|LQTS	DiseaseOrPhenotypicFeature	10:24:28:119:308	13:27:29:120:309	0:1:1:5:10	D008801	mexiletine|mexiletine	ChemicalEntity	104:319	105:320	4:10	1:NR:2	L2R	NON-CROSS	119-120	143-144	D008133	long QT syndrome|long QT syndrome|LQTS|LQTS|LQTS	DiseaseOrPhenotypicFeature	10:24:28:119:308	13:27:29:120:309	0:1:1:5:10	D012964	sodium	ChemicalEntity	143	144	5	1:Association:2	L2R	NON-CROSS	119-120	148-157	D008133	long QT syndrome|long QT syndrome|LQTS|LQTS|LQTS	DiseaseOrPhenotypicFeature	10:24:28:119:308	13:27:29:120:309	0:1:1:5:10	c|SUB|G|CODON1763|A	G - - > A substitution at codon 1763	SequenceVariant	148	157	5	1:Association:2	L2R	NON-CROSS	119-120	161-171	D008133	long QT syndrome|long QT syndrome|LQTS|LQTS|LQTS	DiseaseOrPhenotypicFeature	10:24:28:119:308	13:27:29:120:309	0:1:1:5:10	p|SUB|V||M	valine ( GTG ) to a methionine ( ATG )	SequenceVariant	161	171	5	1:NR:2	L2R	CROSS	119-120	205-206	D008133	long QT syndrome|long QT syndrome|LQTS|LQTS|LQTS	DiseaseOrPhenotypicFeature	10:24:28:119:308	13:27:29:120:309	0:1:1:5:10	D013779	tetrodotoxin	ChemicalEntity	205	206	7	1:NR:2	L2R	CROSS	247-248	308-309	D008133	long QT syndrome|long QT syndrome|LQTS|LQTS|LQTS	DiseaseOrPhenotypicFeature	10:24:28:119:308	13:27:29:120:309	0:1:1:5:10	p|SUB|V|1764|M	V1764M	SequenceVariant	247	248	8	1:NR:2	L2R	CROSS	255-256	308-309	D008133	long QT syndrome|long QT syndrome|LQTS|LQTS|LQTS	DiseaseOrPhenotypicFeature	10:24:28:119:308	13:27:29:120:309	0:1:1:5:10	p|SUB|I|1762|A	I1762A	SequenceVariant	255	256	9	1:Positive_Correlation:2	R2L	NON-CROSS	308-309	287-288	p|SUB|V|1763|M	V1763M	SequenceVariant	287	288	10	D008133	long QT syndrome|long QT syndrome|LQTS|LQTS|LQTS	DiseaseOrPhenotypicFeature	10:24:28:119:308	13:27:29:120:309	0:1:1:5:10	1:NR:2	L2R	CROSS	17-18	97-98	D013610	tachycardia	DiseaseOrPhenotypicFeature	17	18	0	D008012	lidocaine|lidocaine|lidocaine	ChemicalEntity	97:209:317	98:210:318	4:7:10	1:NR:2	L2R	CROSS	17-18	104-105	D013610	tachycardia	DiseaseOrPhenotypicFeature	17	18	0	D008801	mexiletine|mexiletine	ChemicalEntity	104:319	105:320	4:10	1:NR:2	L2R	CROSS	17-18	143-144	D013610	tachycardia	DiseaseOrPhenotypicFeature	17	18	0	D012964	sodium	ChemicalEntity	143	144	5	1:NR:2	L2R	CROSS	17-18	148-157	D013610	tachycardia	DiseaseOrPhenotypicFeature	17	18	0	c|SUB|G|CODON1763|A	G - - > A substitution at codon 1763	SequenceVariant	148	157	5	1:NR:2	L2R	CROSS	17-18	161-171	D013610	tachycardia	DiseaseOrPhenotypicFeature	17	18	0	p|SUB|V||M	valine ( GTG ) to a methionine ( ATG )	SequenceVariant	161	171	5	1:NR:2	L2R	CROSS	17-18	205-206	D013610	tachycardia	DiseaseOrPhenotypicFeature	17	18	0	D013779	tetrodotoxin	ChemicalEntity	205	206	7	1:NR:2	L2R	CROSS	17-18	247-248	D013610	tachycardia	DiseaseOrPhenotypicFeature	17	18	0	p|SUB|V|1764|M	V1764M	SequenceVariant	247	248	8	1:NR:2	L2R	CROSS	17-18	255-256	D013610	tachycardia	DiseaseOrPhenotypicFeature	17	18	0	p|SUB|I|1762|A	I1762A	SequenceVariant	255	256	9	1:Positive_Correlation:2	L2R	CROSS	17-18	287-288	D013610	tachycardia	DiseaseOrPhenotypicFeature	17	18	0	p|SUB|V|1763|M	V1763M	SequenceVariant	287	288	10	1:NR:2	L2R	CROSS	55-56	97-98	D001919	bradycardia|bradycardia	DiseaseOrPhenotypicFeature	19:55	20:56	0:2	D008012	lidocaine|lidocaine|lidocaine	ChemicalEntity	97:209:317	98:210:318	4:7:10	1:NR:2	L2R	CROSS	55-56	104-105	D001919	bradycardia|bradycardia	DiseaseOrPhenotypicFeature	19:55	20:56	0:2	D008801	mexiletine|mexiletine	ChemicalEntity	104:319	105:320	4:10	1:NR:2	L2R	CROSS	55-56	143-144	D001919	bradycardia|bradycardia	DiseaseOrPhenotypicFeature	19:55	20:56	0:2	D012964	sodium	ChemicalEntity	143	144	5	1:NR:2	L2R	CROSS	55-56	148-157	D001919	bradycardia|bradycardia	DiseaseOrPhenotypicFeature	19:55	20:56	0:2	c|SUB|G|CODON1763|A	G - - > A substitution at codon 1763	SequenceVariant	148	157	5	1:NR:2	L2R	CROSS	55-56	161-171	D001919	bradycardia|bradycardia	DiseaseOrPhenotypicFeature	19:55	20:56	0:2	p|SUB|V||M	valine ( GTG ) to a methionine ( ATG )	SequenceVariant	161	171	5	1:NR:2	L2R	CROSS	55-56	205-206	D001919	bradycardia|bradycardia	DiseaseOrPhenotypicFeature	19:55	20:56	0:2	D013779	tetrodotoxin	ChemicalEntity	205	206	7	1:NR:2	L2R	CROSS	55-56	247-248	D001919	bradycardia|bradycardia	DiseaseOrPhenotypicFeature	19:55	20:56	0:2	p|SUB|V|1764|M	V1764M	SequenceVariant	247	248	8	1:NR:2	L2R	CROSS	55-56	255-256	D001919	bradycardia|bradycardia	DiseaseOrPhenotypicFeature	19:55	20:56	0:2	p|SUB|I|1762|A	I1762A	SequenceVariant	255	256	9	1:Positive_Correlation:2	L2R	CROSS	55-56	287-288	D001919	bradycardia|bradycardia	DiseaseOrPhenotypicFeature	19:55	20:56	0:2	p|SUB|V|1763|M	V1763M	SequenceVariant	287	288	10	1:Negative_Correlation:2	L2R	NON-CROSS	86-88	97-98	D054537	atrioventricular block|atrioventricular block	DiseaseOrPhenotypicFeature	60:86	62:88	2:4	D008012	lidocaine|lidocaine|lidocaine	ChemicalEntity	97:209:317	98:210:318	4:7:10	1:Negative_Correlation:2	L2R	NON-CROSS	86-88	104-105	D054537	atrioventricular block|atrioventricular block	DiseaseOrPhenotypicFeature	60:86	62:88	2:4	D008801	mexiletine|mexiletine	ChemicalEntity	104:319	105:320	4:10	1:NR:2	L2R	CROSS	86-88	143-144	D054537	atrioventricular block|atrioventricular block	DiseaseOrPhenotypicFeature	60:86	62:88	2:4	D012964	sodium	ChemicalEntity	143	144	5	1:NR:2	L2R	CROSS	86-88	148-157	D054537	atrioventricular block|atrioventricular block	DiseaseOrPhenotypicFeature	60:86	62:88	2:4	c|SUB|G|CODON1763|A	G - - > A substitution at codon 1763	SequenceVariant	148	157	5	1:NR:2	L2R	CROSS	86-88	161-171	D054537	atrioventricular block|atrioventricular block	DiseaseOrPhenotypicFeature	60:86	62:88	2:4	p|SUB|V||M	valine ( GTG ) to a methionine ( ATG )	SequenceVariant	161	171	5	1:NR:2	L2R	CROSS	86-88	205-206	D054537	atrioventricular block|atrioventricular block	DiseaseOrPhenotypicFeature	60:86	62:88	2:4	D013779	tetrodotoxin	ChemicalEntity	205	206	7	1:NR:2	L2R	CROSS	86-88	247-248	D054537	atrioventricular block|atrioventricular block	DiseaseOrPhenotypicFeature	60:86	62:88	2:4	p|SUB|V|1764|M	V1764M	SequenceVariant	247	248	8	1:NR:2	L2R	CROSS	86-88	255-256	D054537	atrioventricular block|atrioventricular block	DiseaseOrPhenotypicFeature	60:86	62:88	2:4	p|SUB|I|1762|A	I1762A	SequenceVariant	255	256	9	1:NR:2	L2R	CROSS	86-88	287-288	D054537	atrioventricular block|atrioventricular block	DiseaseOrPhenotypicFeature	60:86	62:88	2:4	p|SUB|V|1763|M	V1763M	SequenceVariant	287	288	10	1:Negative_Correlation:2	R2L	NON-CROSS	110-112	97-98	D008012	lidocaine|lidocaine|lidocaine	ChemicalEntity	97:209:317	98:210:318	4:7:10	D017180	ventricular tachycardia|ventricular tachycardia	DiseaseOrPhenotypicFeature	63:110	65:112	2:4	1:Negative_Correlation:2	R2L	NON-CROSS	110-112	104-105	D008801	mexiletine|mexiletine	ChemicalEntity	104:319	105:320	4:10	D017180	ventricular tachycardia|ventricular tachycardia	DiseaseOrPhenotypicFeature	63:110	65:112	2:4	1:NR:2	L2R	CROSS	110-112	143-144	D017180	ventricular tachycardia|ventricular tachycardia	DiseaseOrPhenotypicFeature	63:110	65:112	2:4	D012964	sodium	ChemicalEntity	143	144	5	1:NR:2	L2R	CROSS	110-112	148-157	D017180	ventricular tachycardia|ventricular tachycardia	DiseaseOrPhenotypicFeature	63:110	65:112	2:4	c|SUB|G|CODON1763|A	G - - > A substitution at codon 1763	SequenceVariant	148	157	5	1:NR:2	L2R	CROSS	110-112	161-171	D017180	ventricular tachycardia|ventricular tachycardia	DiseaseOrPhenotypicFeature	63:110	65:112	2:4	p|SUB|V||M	valine ( GTG ) to a methionine ( ATG )	SequenceVariant	161	171	5	1:NR:2	L2R	CROSS	110-112	205-206	D017180	ventricular tachycardia|ventricular tachycardia	DiseaseOrPhenotypicFeature	63:110	65:112	2:4	D013779	tetrodotoxin	ChemicalEntity	205	206	7	1:NR:2	L2R	CROSS	110-112	247-248	D017180	ventricular tachycardia|ventricular tachycardia	DiseaseOrPhenotypicFeature	63:110	65:112	2:4	p|SUB|V|1764|M	V1764M	SequenceVariant	247	248	8	1:NR:2	L2R	CROSS	110-112	255-256	D017180	ventricular tachycardia|ventricular tachycardia	DiseaseOrPhenotypicFeature	63:110	65:112	2:4	p|SUB|I|1762|A	I1762A	SequenceVariant	255	256	9	1:NR:2	L2R	CROSS	110-112	287-288	D017180	ventricular tachycardia|ventricular tachycardia	DiseaseOrPhenotypicFeature	63:110	65:112	2:4	p|SUB|V|1763|M	V1763M	SequenceVariant	287	288	10	1:NR:2	L2R	NON-CROSS	317-318	319-320	D008012	lidocaine|lidocaine|lidocaine	ChemicalEntity	97:209:317	98:210:318	4:7:10	D008801	mexiletine|mexiletine	ChemicalEntity	104:319	105:320	4:10	1:NR:2	L2R	CROSS	97-98	143-144	D008012	lidocaine|lidocaine|lidocaine	ChemicalEntity	97:209:317	98:210:318	4:7:10	D012964	sodium	ChemicalEntity	143	144	5	1:NR:2	L2R	CROSS	97-98	148-157	D008012	lidocaine|lidocaine|lidocaine	ChemicalEntity	97:209:317	98:210:318	4:7:10	c|SUB|G|CODON1763|A	G - - > A substitution at codon 1763	SequenceVariant	148	157	5	1:NR:2	L2R	CROSS	161-171	209-210	D008012	lidocaine|lidocaine|lidocaine	ChemicalEntity	97:209:317	98:210:318	4:7:10	p|SUB|V||M	valine ( GTG ) to a methionine ( ATG )	SequenceVariant	161	171	5	1:NR:2	L2R	NON-CROSS	205-206	209-210	D008012	lidocaine|lidocaine|lidocaine	ChemicalEntity	97:209:317	98:210:318	4:7:10	D013779	tetrodotoxin	ChemicalEntity	205	206	7	1:NR:2	L2R	CROSS	209-210	247-248	D008012	lidocaine|lidocaine|lidocaine	ChemicalEntity	97:209:317	98:210:318	4:7:10	p|SUB|V|1764|M	V1764M	SequenceVariant	247	248	8	1:NR:2	L2R	CROSS	209-210	255-256	D008012	lidocaine|lidocaine|lidocaine	ChemicalEntity	97:209:317	98:210:318	4:7:10	p|SUB|I|1762|A	I1762A	SequenceVariant	255	256	9	1:NR:2	L2R	NON-CROSS	287-288	317-318	D008012	lidocaine|lidocaine|lidocaine	ChemicalEntity	97:209:317	98:210:318	4:7:10	p|SUB|V|1763|M	V1763M	SequenceVariant	287	288	10	1:Negative_Correlation:2	R2L	NON-CROSS	317-318	313-314	D001145	arrhythmias	DiseaseOrPhenotypicFeature	313	314	10	D008012	lidocaine|lidocaine|lidocaine	ChemicalEntity	97:209:317	98:210:318	4:7:10	1:NR:2	L2R	CROSS	104-105	143-144	D008801	mexiletine|mexiletine	ChemicalEntity	104:319	105:320	4:10	D012964	sodium	ChemicalEntity	143	144	5	1:NR:2	L2R	CROSS	104-105	148-157	D008801	mexiletine|mexiletine	ChemicalEntity	104:319	105:320	4:10	c|SUB|G|CODON1763|A	G - - > A substitution at codon 1763	SequenceVariant	148	157	5	1:NR:2	L2R	CROSS	104-105	161-171	D008801	mexiletine|mexiletine	ChemicalEntity	104:319	105:320	4:10	p|SUB|V||M	valine ( GTG ) to a methionine ( ATG )	SequenceVariant	161	171	5	1:NR:2	L2R	CROSS	104-105	205-206	D008801	mexiletine|mexiletine	ChemicalEntity	104:319	105:320	4:10	D013779	tetrodotoxin	ChemicalEntity	205	206	7	1:NR:2	L2R	CROSS	247-248	319-320	D008801	mexiletine|mexiletine	ChemicalEntity	104:319	105:320	4:10	p|SUB|V|1764|M	V1764M	SequenceVariant	247	248	8	1:NR:2	L2R	CROSS	255-256	319-320	D008801	mexiletine|mexiletine	ChemicalEntity	104:319	105:320	4:10	p|SUB|I|1762|A	I1762A	SequenceVariant	255	256	9	1:NR:2	L2R	NON-CROSS	287-288	319-320	D008801	mexiletine|mexiletine	ChemicalEntity	104:319	105:320	4:10	p|SUB|V|1763|M	V1763M	SequenceVariant	287	288	10	1:Negative_Correlation:2	R2L	NON-CROSS	319-320	313-314	D001145	arrhythmias	DiseaseOrPhenotypicFeature	313	314	10	D008801	mexiletine|mexiletine	ChemicalEntity	104:319	105:320	4:10	1:NR:2	L2R	NON-CROSS	143-144	148-157	D012964	sodium	ChemicalEntity	143	144	5	c|SUB|G|CODON1763|A	G - - > A substitution at codon 1763	SequenceVariant	148	157	5	1:NR:2	L2R	NON-CROSS	143-144	161-171	D012964	sodium	ChemicalEntity	143	144	5	p|SUB|V||M	valine ( GTG ) to a methionine ( ATG )	SequenceVariant	161	171	5	1:NR:2	L2R	CROSS	143-144	205-206	D012964	sodium	ChemicalEntity	143	144	5	D013779	tetrodotoxin	ChemicalEntity	205	206	7	1:NR:2	L2R	CROSS	143-144	247-248	D012964	sodium	ChemicalEntity	143	144	5	p|SUB|V|1764|M	V1764M	SequenceVariant	247	248	8	1:NR:2	L2R	CROSS	143-144	255-256	D012964	sodium	ChemicalEntity	143	144	5	p|SUB|I|1762|A	I1762A	SequenceVariant	255	256	9	1:NR:2	L2R	CROSS	143-144	287-288	D012964	sodium	ChemicalEntity	143	144	5	p|SUB|V|1763|M	V1763M	SequenceVariant	287	288	10	1:NR:2	L2R	CROSS	143-144	313-314	D012964	sodium	ChemicalEntity	143	144	5	D001145	arrhythmias	DiseaseOrPhenotypicFeature	313	314	10	1:NR:2	L2R	CROSS	148-157	205-206	c|SUB|G|CODON1763|A	G - - > A substitution at codon 1763	SequenceVariant	148	157	5	D013779	tetrodotoxin	ChemicalEntity	205	206	7	1:NR:2	L2R	CROSS	148-157	313-314	c|SUB|G|CODON1763|A	G - - > A substitution at codon 1763	SequenceVariant	148	157	5	D001145	arrhythmias	DiseaseOrPhenotypicFeature	313	314	10	1:NR:2	L2R	CROSS	161-171	205-206	p|SUB|V||M	valine ( GTG ) to a methionine ( ATG )	SequenceVariant	161	171	5	D013779	tetrodotoxin	ChemicalEntity	205	206	7	1:NR:2	L2R	CROSS	161-171	313-314	p|SUB|V||M	valine ( GTG ) to a methionine ( ATG )	SequenceVariant	161	171	5	D001145	arrhythmias	DiseaseOrPhenotypicFeature	313	314	10	1:NR:2	L2R	CROSS	205-206	247-248	D013779	tetrodotoxin	ChemicalEntity	205	206	7	p|SUB|V|1764|M	V1764M	SequenceVariant	247	248	8	1:NR:2	L2R	CROSS	205-206	255-256	D013779	tetrodotoxin	ChemicalEntity	205	206	7	p|SUB|I|1762|A	I1762A	SequenceVariant	255	256	9	1:NR:2	L2R	CROSS	205-206	287-288	D013779	tetrodotoxin	ChemicalEntity	205	206	7	p|SUB|V|1763|M	V1763M	SequenceVariant	287	288	10	1:NR:2	L2R	CROSS	205-206	313-314	D013779	tetrodotoxin	ChemicalEntity	205	206	7	D001145	arrhythmias	DiseaseOrPhenotypicFeature	313	314	10	1:NR:2	L2R	CROSS	247-248	313-314	p|SUB|V|1764|M	V1764M	SequenceVariant	247	248	8	D001145	arrhythmias	DiseaseOrPhenotypicFeature	313	314	10	1:NR:2	L2R	CROSS	255-256	313-314	p|SUB|I|1762|A	I1762A	SequenceVariant	255	256	9	D001145	arrhythmias	DiseaseOrPhenotypicFeature	313	314	10	1:Positive_Correlation:2	L2R	NON-CROSS	287-288	313-314	p|SUB|V|1763|M	V1763M	SequenceVariant	287	288	10	D001145	arrhythmias	DiseaseOrPhenotypicFeature	313	314	10
16046395	Allelic expression imbalance of human mu opioid receptor ( OPRM1 ) caused by variant A118G .|As a primary target for opioid drugs and peptides , the mu opioid receptor ( OPRM1 ) plays a key role in pain perception and addiction .|Genetic variants of OPRM1 have been implicated in predisposition to drug addiction , in particular the single nucleotide polymorphism A118G , leading to an N40D substitution , with an allele frequency of 10 - 32 % , and uncertain functions .|We have measured allele - specific mRNA expression of OPRM1 in human autopsy brain tissues , using A118G as a marker .|In 8 heterozygous samples measured , the A118 mRNA allele was 1 . 5 - 2 . 5 - fold more abundant than the G118 allele .|Transfection into Chinese hamster ovary cells of a cDNA representing only the coding region of OPRM1 , carrying adenosine , guanosine , cytidine , and thymidine in position 118 , resulted in 1 . 5 - fold lower mRNA levels only for OPRM1 - G118 , and more than 10 - fold lower OPRM1 protein levels , measured by Western blotting and receptor binding assay .|After transfection and inhibition of transcription with actinomycin D , analysis of mRNA turnover failed to reveal differences in mRNA stability between A118 and G118 alleles , indicating a defect in transcription or mRNA maturation .|These results indicate that OPRM1 - G118 is a functional variant with deleterious effects on both mRNA and protein yield .|Clarifying the functional relevance of polymorphisms associated with susceptibility to a complex disorder such as drug addiction provides a foundation for clinical association studies .	1:Association:2	L2R	NON-CROSS	31-32	38-39	4988	mu opioid receptor|OPRM1|mu opioid receptor|OPRM1|OPRM1|OPRM1	GeneOrGeneProduct	5:9:27:31:46:93	8:10:30:32:47:94	0:0:1:1:2:3	D010146	pain	DiseaseOrPhenotypicFeature	38	39	1	1:Association:2	L2R	NON-CROSS	46-47	53-55	4988	mu opioid receptor|OPRM1|mu opioid receptor|OPRM1|OPRM1|OPRM1	GeneOrGeneProduct	5:9:27:31:46:93	8:10:30:32:47:94	0:0:1:1:2:3	D019966	drug addiction|drug addiction	DiseaseOrPhenotypicFeature	53:271	55:273	2:8	1:NR:2	L2R	CROSS	93-94	148-149	4988	mu opioid receptor|OPRM1|mu opioid receptor|OPRM1|OPRM1|OPRM1	GeneOrGeneProduct	5:9:27:31:46:93	8:10:30:32:47:94	0:0:1:1:2:3	100770962	OPRM1|OPRM1|OPRM1|OPRM1	GeneOrGeneProduct	148:175:186:239	149:176:187:240	5:5:5:7	1:NR:2	L2R	CROSS	93-94	206-208	4988	mu opioid receptor|OPRM1|mu opioid receptor|OPRM1|OPRM1|OPRM1	GeneOrGeneProduct	5:9:27:31:46:93	8:10:30:32:47:94	0:0:1:1:2:3	D003609	actinomycin D	ChemicalEntity	206	208	6	1:NR:2	L2R	CROSS	14-15	38-39	rs1799971	A118G|A118G|N40D|A118G|A118|G118|adenosine , guanosine , cytidine , and thymidine in position 118|G118|A118|G118|G118	SequenceVariant	14:62:67:101:113:130:151:177:221:223:241	15:63:68:102:114:131:162:178:222:224:242	0:2:2:3:4:4:5:5:6:6:7	D010146	pain	DiseaseOrPhenotypicFeature	38	39	1	1:Association:2	R2L	NON-CROSS	62-63	53-55	D019966	drug addiction|drug addiction	DiseaseOrPhenotypicFeature	53:271	55:273	2:8	rs1799971	A118G|A118G|N40D|A118G|A118|G118|adenosine , guanosine , cytidine , and thymidine in position 118|G118|A118|G118|G118	SequenceVariant	14:62:67:101:113:130:151:177:221:223:241	15:63:68:102:114:131:162:178:222:224:242	0:2:2:3:4:4:5:5:6:6:7	1:NR:2	L2R	NON-CROSS	206-208	221-222	rs1799971	A118G|A118G|N40D|A118G|A118|G118|adenosine , guanosine , cytidine , and thymidine in position 118|G118|A118|G118|G118	SequenceVariant	14:62:67:101:113:130:151:177:221:223:241	15:63:68:102:114:131:162:178:222:224:242	0:2:2:3:4:4:5:5:6:6:7	D003609	actinomycin D	ChemicalEntity	206	208	6	1:NR:2	L2R	CROSS	38-39	148-149	D010146	pain	DiseaseOrPhenotypicFeature	38	39	1	100770962	OPRM1|OPRM1|OPRM1|OPRM1	GeneOrGeneProduct	148:175:186:239	149:176:187:240	5:5:5:7	1:NR:2	L2R	CROSS	38-39	206-208	D010146	pain	DiseaseOrPhenotypicFeature	38	39	1	D003609	actinomycin D	ChemicalEntity	206	208	6	1:NR:2	L2R	CROSS	239-240	271-273	D019966	drug addiction|drug addiction	DiseaseOrPhenotypicFeature	53:271	55:273	2:8	100770962	OPRM1|OPRM1|OPRM1|OPRM1	GeneOrGeneProduct	148:175:186:239	149:176:187:240	5:5:5:7	1:NR:2	L2R	CROSS	206-208	271-273	D019966	drug addiction|drug addiction	DiseaseOrPhenotypicFeature	53:271	55:273	2:8	D003609	actinomycin D	ChemicalEntity	206	208	6	1:NR:2	L2R	CROSS	186-187	206-208	100770962	OPRM1|OPRM1|OPRM1|OPRM1	GeneOrGeneProduct	148:175:186:239	149:176:187:240	5:5:5:7	D003609	actinomycin D	ChemicalEntity	206	208	6
18457324	Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD ( P ) H : quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline - related congestive heart failure after childhood cancer .|BACKGROUND : Exposure to anthracyclines as part of cancer therapy has been associated with the development of congestive heart failure ( CHF ) .|The potential role of genetic risk factors in anthracycline - related CHF remains to be defined .|Thus , in this study , the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of anthracyclines ( in particular , the nicotinamide adenine dinucleotide phosphate : quinone oxidoreductase 1 gene NQO1 and the carbonyl reductase 3 gene CBR3 ) had an impact on the risk of anthracycline - related CHF .|METHODS : A nested case - control study was conducted within a cohort of 1979 patients enrolled in the Childhood Cancer Survivor Study who received treatment with anthracyclines and had available DNA .|Thirty patients with CHF ( cases ) and 115 matched controls were genotyped for polymorphisms in NQO1 ( NQO1 * 2 ) and CBR3 ( the CBR3 valine [ V ] to methionine [ M ] substitution at position 244 [ V244M ] ) .|Enzyme activity assays with recombinant CBR3 isoforms ( CBR3 V244 and CBR3 M244 ) and the anthracycline substrate doxorubicin were used to investigate the functional impact of the CBR3 V244M polymorphism .|RESULTS : Multivariate analyses adjusted for sex and primary disease recurrence were used to test for associations between the candidate genetic polymorphisms ( NQO1 * 2 and CBR3 V244M ) and the risk of CHF .|Analyses indicated no association between the NQO1 * 2 polymorphism and the risk of anthracycline - related CHF ( odds ratio [ OR ] , 1 . 04 ; P = . 97 ) .|There was a trend toward an association between the CBR3 V244M polymorphism and the risk of CHF ( OR , 8 . 16 ; P = . 056 for G / G vs A / A ; OR , 5 . 44 ; P = . 092 for G / A vs A / A ) .|In line , recombinant CBR3 V244 ( G allele ) synthesized 2 . 6 - fold more cardiotoxic doxorubicinol per unit of time than CBR3 M244 ( A allele ; CBR3 V244 [ 8 . 26 + / - 3 . 57 nmol / hour . mg ] vs CBR3 M244 [ 3 . 22 + / - 0 . 67 nmol / hour . mg ] ; P = . 01 ) .|CONCLUSIONS : The functional CBR3 V244M polymorphism may have an impact on the risk of anthracycline - related CHF among childhood cancer survivors by modulating the intracardiac formation of cardiotoxic anthracycline alcohol metabolites .|Larger confirmatory case - control studies are warranted .	1:NR:2	L2R	NON-CROSS	8-9	11-20	874	carbonyl reductase 3|CBR3|carbonyl reductase 3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3	GeneOrGeneProduct	4:8:115:119:189:192:216:219:222:239:270:323:375:395:401:420:449	7:9:118:120:190:193:217:220:223:240:271:324:376:396:402:421:450	0:0:3:3:5:5:6:6:6:6:7:9:10:10:10:10:11	1728	NAD ( P ) H : quinone oxidoreductase 1|NQO1|nicotinamide adenine dinucleotide phosphate : quinone oxidoreductase 1|NQO1|NQO1|NQO1|NQO1|NQO1	GeneOrGeneProduct	11:21:103:112:182:184:266:285	20:22:111:113:183:185:267:286	0:0:3:3:5:5:7:8	1:Association:2	L2R	NON-CROSS	222-223	227-228	874	carbonyl reductase 3|CBR3|carbonyl reductase 3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3	GeneOrGeneProduct	4:8:115:119:189:192:216:219:222:239:270:323:375:395:401:420:449	7:9:118:120:190:193:217:220:223:240:271:324:376:396:402:421:450	0:0:3:3:5:5:6:6:6:6:7:9:10:10:10:10:11	D018943	anthracycline|anthracyclines|anthracycline|anthracyclines|anthracycline|anthracyclines|anthracycline|anthracycline|anthracycline	ChemicalEntity	26:40:68:97:128:160:227:293:460	27:41:69:98:129:161:228:294:461	0:1:2:3:3:4:6:8:11	1:Association:2	L2R	NON-CROSS	270-271	277-278	874	carbonyl reductase 3|CBR3|carbonyl reductase 3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3	GeneOrGeneProduct	4:8:115:119:189:192:216:219:222:239:270:323:375:395:401:420:449	7:9:118:120:190:193:217:220:223:240:271:324:376:396:402:421:450	0:0:3:3:5:5:6:6:6:6:7:9:10:10:10:10:11	D006333	congestive heart failure|congestive heart failure|CHF|CHF|CHF|CHF|CHF|CHF|CHF|CHF	DiseaseOrPhenotypicFeature	29:53:57:71:131:169:277:296:330:463	32:56:58:72:132:170:278:297:331:464	0:1:1:2:3:5:7:8:9:11	1:NR:2	L2R	NON-CROSS	449-450	466-467	874	carbonyl reductase 3|CBR3|carbonyl reductase 3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3	GeneOrGeneProduct	4:8:115:119:189:192:216:219:222:239:270:323:375:395:401:420:449	7:9:118:120:190:193:217:220:223:240:271:324:376:396:402:421:450	0:0:3:3:5:5:6:6:6:6:7:9:10:10:10:10:11	D009369	cancer|cancer|cancer	DiseaseOrPhenotypicFeature	34:44:466	35:45:467	0:1:11	1:NR:2	L2R	NON-CROSS	222-223	229-230	874	carbonyl reductase 3|CBR3|carbonyl reductase 3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3	GeneOrGeneProduct	4:8:115:119:189:192:216:219:222:239:270:323:375:395:401:420:449	7:9:118:120:190:193:217:220:223:240:271:324:376:396:402:421:450	0:0:3:3:5:5:6:6:6:6:7:9:10:10:10:10:11	D004317	doxorubicin	ChemicalEntity	229	230	6	1:Association:2	L2R	NON-CROSS	388-389	395-396	874	carbonyl reductase 3|CBR3|carbonyl reductase 3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3	GeneOrGeneProduct	4:8:115:119:189:192:216:219:222:239:270:323:375:395:401:420:449	7:9:118:120:190:193:217:220:223:240:271:324:376:396:402:421:450	0:0:3:3:5:5:6:6:6:6:7:9:10:10:10:10:11	D066126	cardiotoxic|cardiotoxic	DiseaseOrPhenotypicFeature	388:474	389:475	10:11	1:Association:2	L2R	NON-CROSS	389-390	395-396	874	carbonyl reductase 3|CBR3|carbonyl reductase 3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3	GeneOrGeneProduct	4:8:115:119:189:192:216:219:222:239:270:323:375:395:401:420:449	7:9:118:120:190:193:217:220:223:240:271:324:376:396:402:421:450	0:0:3:3:5:5:6:6:6:6:7:9:10:10:10:10:11	C010013	doxorubicinol	ChemicalEntity	389	390	10	1:NR:2	L2R	NON-CROSS	449-450	475-477	874	carbonyl reductase 3|CBR3|carbonyl reductase 3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3|CBR3	GeneOrGeneProduct	4:8:115:119:189:192:216:219:222:239:270:323:375:395:401:420:449	7:9:118:120:190:193:217:220:223:240:271:324:376:396:402:421:450	0:0:3:3:5:5:6:6:6:6:7:9:10:10:10:10:11	D000438,D018943	anthracycline alcohol	ChemicalEntity	475	477	11	1:NR:2	L2R	NON-CROSS	21-22	26-27	1728	NAD ( P ) H : quinone oxidoreductase 1|NQO1|nicotinamide adenine dinucleotide phosphate : quinone oxidoreductase 1|NQO1|NQO1|NQO1|NQO1|NQO1	GeneOrGeneProduct	11:21:103:112:182:184:266:285	20:22:111:113:183:185:267:286	0:0:3:3:5:5:7:8	D018943	anthracycline|anthracyclines|anthracycline|anthracyclines|anthracycline|anthracyclines|anthracycline|anthracycline|anthracycline	ChemicalEntity	26:40:68:97:128:160:227:293:460	27:41:69:98:129:161:228:294:461	0:1:2:3:3:4:6:8:11	1:NR:2	L2R	NON-CROSS	21-22	29-32	1728	NAD ( P ) H : quinone oxidoreductase 1|NQO1|nicotinamide adenine dinucleotide phosphate : quinone oxidoreductase 1|NQO1|NQO1|NQO1|NQO1|NQO1	GeneOrGeneProduct	11:21:103:112:182:184:266:285	20:22:111:113:183:185:267:286	0:0:3:3:5:5:7:8	D006333	congestive heart failure|congestive heart failure|CHF|CHF|CHF|CHF|CHF|CHF|CHF|CHF	DiseaseOrPhenotypicFeature	29:53:57:71:131:169:277:296:330:463	32:56:58:72:132:170:278:297:331:464	0:1:1:2:3:5:7:8:9:11	1:NR:2	L2R	NON-CROSS	21-22	34-35	1728	NAD ( P ) H : quinone oxidoreductase 1|NQO1|nicotinamide adenine dinucleotide phosphate : quinone oxidoreductase 1|NQO1|NQO1|NQO1|NQO1|NQO1	GeneOrGeneProduct	11:21:103:112:182:184:266:285	20:22:111:113:183:185:267:286	0:0:3:3:5:5:7:8	D009369	cancer|cancer|cancer	DiseaseOrPhenotypicFeature	34:44:466	35:45:467	0:1:11	1:NR:2	L2R	CROSS	229-230	266-267	1728	NAD ( P ) H : quinone oxidoreductase 1|NQO1|nicotinamide adenine dinucleotide phosphate : quinone oxidoreductase 1|NQO1|NQO1|NQO1|NQO1|NQO1	GeneOrGeneProduct	11:21:103:112:182:184:266:285	20:22:111:113:183:185:267:286	0:0:3:3:5:5:7:8	D004317	doxorubicin	ChemicalEntity	229	230	6	1:NR:2	L2R	CROSS	285-286	388-389	1728	NAD ( P ) H : quinone oxidoreductase 1|NQO1|nicotinamide adenine dinucleotide phosphate : quinone oxidoreductase 1|NQO1|NQO1|NQO1|NQO1|NQO1	GeneOrGeneProduct	11:21:103:112:182:184:266:285	20:22:111:113:183:185:267:286	0:0:3:3:5:5:7:8	D066126	cardiotoxic|cardiotoxic	DiseaseOrPhenotypicFeature	388:474	389:475	10:11	1:NR:2	L2R	CROSS	285-286	389-390	1728	NAD ( P ) H : quinone oxidoreductase 1|NQO1|nicotinamide adenine dinucleotide phosphate : quinone oxidoreductase 1|NQO1|NQO1|NQO1|NQO1|NQO1	GeneOrGeneProduct	11:21:103:112:182:184:266:285	20:22:111:113:183:185:267:286	0:0:3:3:5:5:7:8	C010013	doxorubicinol	ChemicalEntity	389	390	10	1:NR:2	L2R	CROSS	285-286	475-477	1728	NAD ( P ) H : quinone oxidoreductase 1|NQO1|nicotinamide adenine dinucleotide phosphate : quinone oxidoreductase 1|NQO1|NQO1|NQO1|NQO1|NQO1	GeneOrGeneProduct	11:21:103:112:182:184:266:285	20:22:111:113:183:185:267:286	0:0:3:3:5:5:7:8	D000438,D018943	anthracycline alcohol	ChemicalEntity	475	477	11	1:Positive_Correlation:2	L2R	NON-CROSS	26-27	29-32	D018943	anthracycline|anthracyclines|anthracycline|anthracyclines|anthracycline|anthracyclines|anthracycline|anthracycline|anthracycline	ChemicalEntity	26:40:68:97:128:160:227:293:460	27:41:69:98:129:161:228:294:461	0:1:2:3:3:4:6:8:11	D006333	congestive heart failure|congestive heart failure|CHF|CHF|CHF|CHF|CHF|CHF|CHF|CHF	DiseaseOrPhenotypicFeature	29:53:57:71:131:169:277:296:330:463	32:56:58:72:132:170:278:297:331:464	0:1:1:2:3:5:7:8:9:11	1:Negative_Correlation:2	L2R	NON-CROSS	40-41	44-45	D018943	anthracycline|anthracyclines|anthracycline|anthracyclines|anthracycline|anthracyclines|anthracycline|anthracycline|anthracycline	ChemicalEntity	26:40:68:97:128:160:227:293:460	27:41:69:98:129:161:228:294:461	0:1:2:3:3:4:6:8:11	D009369	cancer|cancer|cancer	DiseaseOrPhenotypicFeature	34:44:466	35:45:467	0:1:11	1:Association:2	R2L	NON-CROSS	227-228	223-224	rs1056892	valine [ V ] to methionine [ M ] substitution at position 244|V244M|V244|M244|V244M|V244M|V244M|V244|M244|V244|M244|V244M	SequenceVariant	193:207:220:223:240:271:324:376:396:402:421:450	206:208:221:224:241:272:325:377:397:403:422:451	5:5:6:6:6:7:9:10:10:10:10:11	D018943	anthracycline|anthracyclines|anthracycline|anthracyclines|anthracycline|anthracyclines|anthracycline|anthracycline|anthracycline	ChemicalEntity	26:40:68:97:128:160:227:293:460	27:41:69:98:129:161:228:294:461	0:1:2:3:3:4:6:8:11	1:NR:2	L2R	NON-CROSS	227-228	229-230	D018943	anthracycline|anthracyclines|anthracycline|anthracyclines|anthracycline|anthracyclines|anthracycline|anthracycline|anthracycline	ChemicalEntity	26:40:68:97:128:160:227:293:460	27:41:69:98:129:161:228:294:461	0:1:2:3:3:4:6:8:11	D004317	doxorubicin	ChemicalEntity	229	230	6	1:Positive_Correlation:2	L2R	NON-CROSS	460-461	474-475	D018943	anthracycline|anthracyclines|anthracycline|anthracyclines|anthracycline|anthracyclines|anthracycline|anthracycline|anthracycline	ChemicalEntity	26:40:68:97:128:160:227:293:460	27:41:69:98:129:161:228:294:461	0:1:2:3:3:4:6:8:11	D066126	cardiotoxic|cardiotoxic	DiseaseOrPhenotypicFeature	388:474	389:475	10:11	1:NR:2	L2R	CROSS	389-390	460-461	D018943	anthracycline|anthracyclines|anthracycline|anthracyclines|anthracycline|anthracyclines|anthracycline|anthracycline|anthracycline	ChemicalEntity	26:40:68:97:128:160:227:293:460	27:41:69:98:129:161:228:294:461	0:1:2:3:3:4:6:8:11	C010013	doxorubicinol	ChemicalEntity	389	390	10	1:NR:2	L2R	NON-CROSS	460-461	475-477	D018943	anthracycline|anthracyclines|anthracycline|anthracyclines|anthracycline|anthracyclines|anthracycline|anthracycline|anthracycline	ChemicalEntity	26:40:68:97:128:160:227:293:460	27:41:69:98:129:161:228:294:461	0:1:2:3:3:4:6:8:11	D000438,D018943	anthracycline alcohol	ChemicalEntity	475	477	11	1:Positive_Correlation:2	R2L	NON-CROSS	277-278	271-272	rs1056892	valine [ V ] to methionine [ M ] substitution at position 244|V244M|V244|M244|V244M|V244M|V244M|V244|M244|V244|M244|V244M	SequenceVariant	193:207:220:223:240:271:324:376:396:402:421:450	206:208:221:224:241:272:325:377:397:403:422:451	5:5:6:6:6:7:9:10:10:10:10:11	D006333	congestive heart failure|congestive heart failure|CHF|CHF|CHF|CHF|CHF|CHF|CHF|CHF	DiseaseOrPhenotypicFeature	29:53:57:71:131:169:277:296:330:463	32:56:58:72:132:170:278:297:331:464	0:1:1:2:3:5:7:8:9:11	1:NR:2	L2R	CROSS	229-230	277-278	D006333	congestive heart failure|congestive heart failure|CHF|CHF|CHF|CHF|CHF|CHF|CHF|CHF	DiseaseOrPhenotypicFeature	29:53:57:71:131:169:277:296:330:463	32:56:58:72:132:170:278:297:331:464	0:1:1:2:3:5:7:8:9:11	D004317	doxorubicin	ChemicalEntity	229	230	6	1:NR:2	L2R	CROSS	330-331	389-390	D006333	congestive heart failure|congestive heart failure|CHF|CHF|CHF|CHF|CHF|CHF|CHF|CHF	DiseaseOrPhenotypicFeature	29:53:57:71:131:169:277:296:330:463	32:56:58:72:132:170:278:297:331:464	0:1:1:2:3:5:7:8:9:11	C010013	doxorubicinol	ChemicalEntity	389	390	10	1:NR:2	L2R	NON-CROSS	463-464	475-477	D006333	congestive heart failure|congestive heart failure|CHF|CHF|CHF|CHF|CHF|CHF|CHF|CHF	DiseaseOrPhenotypicFeature	29:53:57:71:131:169:277:296:330:463	32:56:58:72:132:170:278:297:331:464	0:1:1:2:3:5:7:8:9:11	D000438,D018943	anthracycline alcohol	ChemicalEntity	475	477	11	1:NR:2	L2R	NON-CROSS	450-451	466-467	D009369	cancer|cancer|cancer	DiseaseOrPhenotypicFeature	34:44:466	35:45:467	0:1:11	rs1056892	valine [ V ] to methionine [ M ] substitution at position 244|V244M|V244|M244|V244M|V244M|V244M|V244|M244|V244|M244|V244M	SequenceVariant	193:207:220:223:240:271:324:376:396:402:421:450	206:208:221:224:241:272:325:377:397:403:422:451	5:5:6:6:6:7:9:10:10:10:10:11	1:NR:2	L2R	CROSS	44-45	229-230	D009369	cancer|cancer|cancer	DiseaseOrPhenotypicFeature	34:44:466	35:45:467	0:1:11	D004317	doxorubicin	ChemicalEntity	229	230	6	1:NR:2	L2R	CROSS	389-390	466-467	D009369	cancer|cancer|cancer	DiseaseOrPhenotypicFeature	34:44:466	35:45:467	0:1:11	C010013	doxorubicinol	ChemicalEntity	389	390	10	1:NR:2	L2R	NON-CROSS	466-467	475-477	D009369	cancer|cancer|cancer	DiseaseOrPhenotypicFeature	34:44:466	35:45:467	0:1:11	D000438,D018943	anthracycline alcohol	ChemicalEntity	475	477	11	1:NR:2	L2R	NON-CROSS	223-224	229-230	rs1056892	valine [ V ] to methionine [ M ] substitution at position 244|V244M|V244|M244|V244M|V244M|V244M|V244|M244|V244|M244|V244M	SequenceVariant	193:207:220:223:240:271:324:376:396:402:421:450	206:208:221:224:241:272:325:377:397:403:422:451	5:5:6:6:6:7:9:10:10:10:10:11	D004317	doxorubicin	ChemicalEntity	229	230	6	1:NR:2	L2R	NON-CROSS	388-389	396-397	rs1056892	valine [ V ] to methionine [ M ] substitution at position 244|V244M|V244|M244|V244M|V244M|V244M|V244|M244|V244|M244|V244M	SequenceVariant	193:207:220:223:240:271:324:376:396:402:421:450	206:208:221:224:241:272:325:377:397:403:422:451	5:5:6:6:6:7:9:10:10:10:10:11	D066126	cardiotoxic|cardiotoxic	DiseaseOrPhenotypicFeature	388:474	389:475	10:11	1:Association:2	L2R	NON-CROSS	389-390	396-397	rs1056892	valine [ V ] to methionine [ M ] substitution at position 244|V244M|V244|M244|V244M|V244M|V244M|V244|M244|V244|M244|V244M	SequenceVariant	193:207:220:223:240:271:324:376:396:402:421:450	206:208:221:224:241:272:325:377:397:403:422:451	5:5:6:6:6:7:9:10:10:10:10:11	C010013	doxorubicinol	ChemicalEntity	389	390	10	1:NR:2	L2R	NON-CROSS	450-451	475-477	rs1056892	valine [ V ] to methionine [ M ] substitution at position 244|V244M|V244|M244|V244M|V244M|V244M|V244|M244|V244|M244|V244M	SequenceVariant	193:207:220:223:240:271:324:376:396:402:421:450	206:208:221:224:241:272:325:377:397:403:422:451	5:5:6:6:6:7:9:10:10:10:10:11	D000438,D018943	anthracycline alcohol	ChemicalEntity	475	477	11	1:NR:2	L2R	CROSS	229-230	388-389	D004317	doxorubicin	ChemicalEntity	229	230	6	D066126	cardiotoxic|cardiotoxic	DiseaseOrPhenotypicFeature	388:474	389:475	10:11	1:NR:2	L2R	CROSS	229-230	389-390	D004317	doxorubicin	ChemicalEntity	229	230	6	C010013	doxorubicinol	ChemicalEntity	389	390	10	1:NR:2	L2R	CROSS	229-230	475-477	D004317	doxorubicin	ChemicalEntity	229	230	6	D000438,D018943	anthracycline alcohol	ChemicalEntity	475	477	11	1:Positive_Correlation:2	L2R	NON-CROSS	388-389	389-390	D066126	cardiotoxic|cardiotoxic	DiseaseOrPhenotypicFeature	388:474	389:475	10:11	C010013	doxorubicinol	ChemicalEntity	389	390	10	1:NR:2	L2R	NON-CROSS	474-475	475-477	D066126	cardiotoxic|cardiotoxic	DiseaseOrPhenotypicFeature	388:474	389:475	10:11	D000438,D018943	anthracycline alcohol	ChemicalEntity	475	477	11	1:NR:2	L2R	CROSS	389-390	475-477	C010013	doxorubicinol	ChemicalEntity	389	390	10	D000438,D018943	anthracycline alcohol	ChemicalEntity	475	477	11
1848636	Debrisoquine phenotype and the pharmacokinetics and beta - 2 receptor pharmacodynamics of metoprolol and its enantiomers .|The metabolism of the cardioselective beta - blocker metoprolol is under genetic control of the debrisoquine / sparteine type .|The two metabolic phenotypes , extensive ( EM ) and poor metabolizers ( PM ) , show different stereoselective metabolism , resulting in apparently higher beta - 1 adrenoceptor antagonistic potency of racemic metoprolol in EMs .|We investigated if the latter also applies to the beta - 2 adrenoceptor antagonism by metoprolol .|The drug effect studied was the antagonism by metoprolol of terbutaline - induced hypokalemia .|By using pharmacokinetic pharmacodynamic modeling the pharmacodynamics of racemic metoprolol and the active S - isomer , were quantitated in EMs and PMs in terms of IC50 values , representing metoprolol plasma concentrations resulting in half - maximum receptor occupancy .|Six EMs received 0 . 5 mg of terbutaline s . c .|on two different occasions : 1 ) 1 hr after administration of a placebo and 2 ) 1 hr after 150 mg of metoprolol p . o .|Five PMs were studied according to the same protocol , except for a higher terbutaline dose ( 0 . 75 mg ) on day 2 .|Blood samples for the analysis of plasma potassium , terbutaline , metoprolol ( racemic , R - and S - isomer ) , and alpha - hydroxymetoprolol concentrations were taken at regular time intervals , during 8 hr after metoprolol .|In PMs , metoprolol increased the terbutaline area under the plasma concentration vs . time curve ( + 67 % ) .|Higher metoprolol / alpha - hydroxymetoprolol ratios in PMs were predictive for higher R - / S - isomer ratios of unchanged drug .|There was a difference in metoprolol potency with higher racemic metoprolol IC50 values in PMs ( 72 + / - 7 ng . ml - 1 ) than EMs ( 42 + / - 8 ng . ml - 1 , P less than . 001 ) . ( ABSTRACT TRUNCATED AT 250 WORDS )	1:NR:2	L2R	NON-CROSS	0-1	6-10	D003647	Debrisoquine|debrisoquine	ChemicalEntity	0:32	1:33	0:1	154	beta - 2 receptor|beta - 2 adrenoceptor	GeneOrGeneProduct	6:83	10:87	0:3	1:Association:2	R2L	NON-CROSS	32-33	25-26	D008790	metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol	ChemicalEntity	12:25:70:89:99:115:136:183:225:253:258:278:306:311	13:26:71:90:100:116:137:184:226:254:259:279:307:312	0:1:2:3:4:5:5:7:9:9:10:11:12:12	D003647	Debrisoquine|debrisoquine	ChemicalEntity	0:32	1:33	0:1	1:NR:2	L2R	NON-CROSS	32-33	34-35	D003647	Debrisoquine|debrisoquine	ChemicalEntity	0:32	1:33	0:1	D013034	sparteine	ChemicalEntity	34	35	1	1:NR:2	L2R	CROSS	32-33	62-66	D003647	Debrisoquine|debrisoquine	ChemicalEntity	0:32	1:33	0:1	153	beta - 1 adrenoceptor	GeneOrGeneProduct	62	66	2	1:NR:2	L2R	CROSS	32-33	101-102	D003647	Debrisoquine|debrisoquine	ChemicalEntity	0:32	1:33	0:1	D013726	terbutaline|terbutaline|terbutaline|terbutaline|terbutaline	ChemicalEntity	101:155:202:223:261	102:156:203:224:262	4:6:8:9:10	1:NR:2	L2R	CROSS	32-33	104-105	D003647	Debrisoquine|debrisoquine	ChemicalEntity	0:32	1:33	0:1	D007008	hypokalemia	DiseaseOrPhenotypicFeature	104	105	4	1:NR:2	L2R	CROSS	32-33	221-222	D003647	Debrisoquine|debrisoquine	ChemicalEntity	0:32	1:33	0:1	D011188	potassium	ChemicalEntity	221	222	9	1:NR:2	L2R	CROSS	32-33	238-241	D003647	Debrisoquine|debrisoquine	ChemicalEntity	0:32	1:33	0:1	C029504	alpha - hydroxymetoprolol|alpha - hydroxymetoprolol	ChemicalEntity	238:280	241:283	9:11	1:Negative_Correlation:2	R2L	NON-CROSS	12-13	6-10	D008790	metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol	ChemicalEntity	12:25:70:89:99:115:136:183:225:253:258:278:306:311	13:26:71:90:100:116:137:184:226:254:259:279:307:312	0:1:2:3:4:5:5:7:9:9:10:11:12:12	154	beta - 2 receptor|beta - 2 adrenoceptor	GeneOrGeneProduct	6:83	10:87	0:3	1:NR:2	L2R	CROSS	6-10	34-35	154	beta - 2 receptor|beta - 2 adrenoceptor	GeneOrGeneProduct	6:83	10:87	0:3	D013034	sparteine	ChemicalEntity	34	35	1	1:NR:2	L2R	CROSS	62-66	83-87	154	beta - 2 receptor|beta - 2 adrenoceptor	GeneOrGeneProduct	6:83	10:87	0:3	153	beta - 1 adrenoceptor	GeneOrGeneProduct	62	66	2	1:NR:2	L2R	CROSS	83-87	101-102	154	beta - 2 receptor|beta - 2 adrenoceptor	GeneOrGeneProduct	6:83	10:87	0:3	D013726	terbutaline|terbutaline|terbutaline|terbutaline|terbutaline	ChemicalEntity	101:155:202:223:261	102:156:203:224:262	4:6:8:9:10	1:NR:2	L2R	CROSS	83-87	104-105	154	beta - 2 receptor|beta - 2 adrenoceptor	GeneOrGeneProduct	6:83	10:87	0:3	D007008	hypokalemia	DiseaseOrPhenotypicFeature	104	105	4	1:NR:2	L2R	CROSS	83-87	221-222	154	beta - 2 receptor|beta - 2 adrenoceptor	GeneOrGeneProduct	6:83	10:87	0:3	D011188	potassium	ChemicalEntity	221	222	9	1:NR:2	L2R	CROSS	83-87	238-241	154	beta - 2 receptor|beta - 2 adrenoceptor	GeneOrGeneProduct	6:83	10:87	0:3	C029504	alpha - hydroxymetoprolol|alpha - hydroxymetoprolol	ChemicalEntity	238:280	241:283	9:11	1:Association:2	L2R	NON-CROSS	25-26	34-35	D008790	metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol	ChemicalEntity	12:25:70:89:99:115:136:183:225:253:258:278:306:311	13:26:71:90:100:116:137:184:226:254:259:279:307:312	0:1:2:3:4:5:5:7:9:9:10:11:12:12	D013034	sparteine	ChemicalEntity	34	35	1	1:Negative_Correlation:2	R2L	NON-CROSS	70-71	62-66	153	beta - 1 adrenoceptor	GeneOrGeneProduct	62	66	2	D008790	metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol	ChemicalEntity	12:25:70:89:99:115:136:183:225:253:258:278:306:311	13:26:71:90:100:116:137:184:226:254:259:279:307:312	0:1:2:3:4:5:5:7:9:9:10:11:12:12	1:Positive_Correlation:2	L2R	NON-CROSS	99-100	101-102	D008790	metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol	ChemicalEntity	12:25:70:89:99:115:136:183:225:253:258:278:306:311	13:26:71:90:100:116:137:184:226:254:259:279:307:312	0:1:2:3:4:5:5:7:9:9:10:11:12:12	D013726	terbutaline|terbutaline|terbutaline|terbutaline|terbutaline	ChemicalEntity	101:155:202:223:261	102:156:203:224:262	4:6:8:9:10	1:Negative_Correlation:2	L2R	NON-CROSS	99-100	104-105	D008790	metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol	ChemicalEntity	12:25:70:89:99:115:136:183:225:253:258:278:306:311	13:26:71:90:100:116:137:184:226:254:259:279:307:312	0:1:2:3:4:5:5:7:9:9:10:11:12:12	D007008	hypokalemia	DiseaseOrPhenotypicFeature	104	105	4	1:NR:2	L2R	NON-CROSS	221-222	225-226	D008790	metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol	ChemicalEntity	12:25:70:89:99:115:136:183:225:253:258:278:306:311	13:26:71:90:100:116:137:184:226:254:259:279:307:312	0:1:2:3:4:5:5:7:9:9:10:11:12:12	D011188	potassium	ChemicalEntity	221	222	9	1:NR:2	L2R	NON-CROSS	278-279	280-283	D008790	metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol|metoprolol	ChemicalEntity	12:25:70:89:99:115:136:183:225:253:258:278:306:311	13:26:71:90:100:116:137:184:226:254:259:279:307:312	0:1:2:3:4:5:5:7:9:9:10:11:12:12	C029504	alpha - hydroxymetoprolol|alpha - hydroxymetoprolol	ChemicalEntity	238:280	241:283	9:11	1:NR:2	L2R	CROSS	34-35	62-66	D013034	sparteine	ChemicalEntity	34	35	1	153	beta - 1 adrenoceptor	GeneOrGeneProduct	62	66	2	1:NR:2	L2R	CROSS	34-35	101-102	D013034	sparteine	ChemicalEntity	34	35	1	D013726	terbutaline|terbutaline|terbutaline|terbutaline|terbutaline	ChemicalEntity	101:155:202:223:261	102:156:203:224:262	4:6:8:9:10	1:NR:2	L2R	CROSS	34-35	104-105	D013034	sparteine	ChemicalEntity	34	35	1	D007008	hypokalemia	DiseaseOrPhenotypicFeature	104	105	4	1:NR:2	L2R	CROSS	34-35	221-222	D013034	sparteine	ChemicalEntity	34	35	1	D011188	potassium	ChemicalEntity	221	222	9	1:NR:2	L2R	CROSS	34-35	238-241	D013034	sparteine	ChemicalEntity	34	35	1	C029504	alpha - hydroxymetoprolol|alpha - hydroxymetoprolol	ChemicalEntity	238:280	241:283	9:11	1:NR:2	L2R	CROSS	62-66	101-102	153	beta - 1 adrenoceptor	GeneOrGeneProduct	62	66	2	D013726	terbutaline|terbutaline|terbutaline|terbutaline|terbutaline	ChemicalEntity	101:155:202:223:261	102:156:203:224:262	4:6:8:9:10	1:NR:2	L2R	CROSS	62-66	104-105	153	beta - 1 adrenoceptor	GeneOrGeneProduct	62	66	2	D007008	hypokalemia	DiseaseOrPhenotypicFeature	104	105	4	1:NR:2	L2R	CROSS	62-66	221-222	153	beta - 1 adrenoceptor	GeneOrGeneProduct	62	66	2	D011188	potassium	ChemicalEntity	221	222	9	1:NR:2	L2R	CROSS	62-66	238-241	153	beta - 1 adrenoceptor	GeneOrGeneProduct	62	66	2	C029504	alpha - hydroxymetoprolol|alpha - hydroxymetoprolol	ChemicalEntity	238:280	241:283	9:11	1:Positive_Correlation:2	L2R	NON-CROSS	101-102	104-105	D013726	terbutaline|terbutaline|terbutaline|terbutaline|terbutaline	ChemicalEntity	101:155:202:223:261	102:156:203:224:262	4:6:8:9:10	D007008	hypokalemia	DiseaseOrPhenotypicFeature	104	105	4	1:NR:2	L2R	NON-CROSS	221-222	223-224	D013726	terbutaline|terbutaline|terbutaline|terbutaline|terbutaline	ChemicalEntity	101:155:202:223:261	102:156:203:224:262	4:6:8:9:10	D011188	potassium	ChemicalEntity	221	222	9	1:NR:2	L2R	NON-CROSS	223-224	238-241	D013726	terbutaline|terbutaline|terbutaline|terbutaline|terbutaline	ChemicalEntity	101:155:202:223:261	102:156:203:224:262	4:6:8:9:10	C029504	alpha - hydroxymetoprolol|alpha - hydroxymetoprolol	ChemicalEntity	238:280	241:283	9:11	1:NR:2	L2R	CROSS	104-105	221-222	D007008	hypokalemia	DiseaseOrPhenotypicFeature	104	105	4	D011188	potassium	ChemicalEntity	221	222	9	1:NR:2	L2R	CROSS	104-105	238-241	D007008	hypokalemia	DiseaseOrPhenotypicFeature	104	105	4	C029504	alpha - hydroxymetoprolol|alpha - hydroxymetoprolol	ChemicalEntity	238:280	241:283	9:11	1:NR:2	L2R	NON-CROSS	221-222	238-241	D011188	potassium	ChemicalEntity	221	222	9	C029504	alpha - hydroxymetoprolol|alpha - hydroxymetoprolol	ChemicalEntity	238:280	241:283	9:11
19394258	The first founder DGUOK mutation associated with hepatocerebral mitochondrial DNA depletion syndrome .|Deoxyguanosine kinase ( dGK ) deficiency is a frequent cause of mitochondrial DNA depletion associated with a hepatocerebral phenotype .|In this study , we describe a new splice site mutation in the DGUOK gene and the clinical , radiologic , and genetic features of these DGUOK patients .|This new DGUOK homozygous mutation ( c . 444 - 62C > A ) was identified in three patients from two North - African consanguineous families with combined respiratory chain deficiencies and mitochondrial DNA depletion in the liver .|Brain MRIs are normal in DGUOK patients in the literature .|Interestingly , we found subtentorial abnormal myelination and moderate hyperintensity in the bilateral pallidi in our patients .|This new mutation creates a cryptic splice site in intron 3 ( in position - 62 ) and is predicted to result in a larger protein with an in - frame insertion of 20 amino acids .|In silico analysis of the putative impact of the insertion shows serious clashes in protein conformation : this insertion disrupts the alpha5 helix of the dGK kinase domain , rendering the protein unable to bind purine deoxyribonucleosides .|In addition , a common haplotype that segregated with the disease in both families was detected by haplotype reconstruction with 10 markers ( microsatellites and SNPs ) , which span 4 . 6 Mb of DNA covering the DGUOK locus .|In conclusion , we report a new DGUOK splice site mutation that provide insight into a critical protein domain ( dGK kinase domain ) and the first founder mutation in a North - African population .	1:Association:2	L2R	NON-CROSS	3-4	7-12	1716	DGUOK|DGUOK|DGUOK|DGUOK|DGUOK|dGK|DGUOK|DGUOK|dGK	GeneOrGeneProduct	3:46:59:64:106:192:243:253:266	4:47:60:65:107:193:244:254:267	0:2:2:3:4:7:8:9:9	C580039	hepatocerebral mitochondrial DNA depletion syndrome|Deoxyguanosine kinase ( dGK ) deficiency|mitochondrial DNA depletion|mitochondrial DNA depletion	DiseaseOrPhenotypicFeature	7:13:24:94	12:19:27:97	0:1:1:3	1:Association:2	L2R	NON-CROSS	90-93	106-107	1716	DGUOK|DGUOK|DGUOK|DGUOK|DGUOK|dGK|DGUOK|DGUOK|dGK	GeneOrGeneProduct	3:46:59:64:106:192:243:253:266	4:47:60:65:107:193:244:254:267	0:2:2:3:4:7:8:9:9	D028361	respiratory chain deficiencies	DiseaseOrPhenotypicFeature	90	93	3	1:NR:2	L2R	CROSS	106-107	116-119	1716	DGUOK|DGUOK|DGUOK|DGUOK|DGUOK|dGK|DGUOK|DGUOK|dGK	GeneOrGeneProduct	3:46:59:64:106:192:243:253:266	4:47:60:65:107:193:244:254:267	0:2:2:3:4:7:8:9:9	-	subtentorial abnormal myelination	DiseaseOrPhenotypicFeature	116	119	5	1:NR:2	L2R	CROSS	106-107	120-122	1716	DGUOK|DGUOK|DGUOK|DGUOK|DGUOK|dGK|DGUOK|DGUOK|dGK	GeneOrGeneProduct	3:46:59:64:106:192:243:253:266	4:47:60:65:107:193:244:254:267	0:2:2:3:4:7:8:9:9	D006973	moderate hyperintensity	DiseaseOrPhenotypicFeature	120	122	5	1:NR:2	L2R	NON-CROSS	192-193	203-204	1716	DGUOK|DGUOK|DGUOK|DGUOK|DGUOK|dGK|DGUOK|DGUOK|dGK	GeneOrGeneProduct	3:46:59:64:106:192:243:253:266	4:47:60:65:107:193:244:254:267	0:2:2:3:4:7:8:9:9	D003853	deoxyribonucleosides	ChemicalEntity	203	204	7	1:Association:2	R2L	NON-CROSS	94-97	68-75	c|SUB|C|444-62|A	c . 444 - 62C > A	SequenceVariant	68	75	3	C580039	hepatocerebral mitochondrial DNA depletion syndrome|Deoxyguanosine kinase ( dGK ) deficiency|mitochondrial DNA depletion|mitochondrial DNA depletion	DiseaseOrPhenotypicFeature	7:13:24:94	12:19:27:97	0:1:1:3	1:NR:2	L2R	CROSS	94-97	203-204	C580039	hepatocerebral mitochondrial DNA depletion syndrome|Deoxyguanosine kinase ( dGK ) deficiency|mitochondrial DNA depletion|mitochondrial DNA depletion	DiseaseOrPhenotypicFeature	7:13:24:94	12:19:27:97	0:1:1:3	D003853	deoxyribonucleosides	ChemicalEntity	203	204	7	1:Association:2	L2R	NON-CROSS	68-75	90-93	c|SUB|C|444-62|A	c . 444 - 62C > A	SequenceVariant	68	75	3	D028361	respiratory chain deficiencies	DiseaseOrPhenotypicFeature	90	93	3	1:NR:2	L2R	CROSS	68-75	116-119	c|SUB|C|444-62|A	c . 444 - 62C > A	SequenceVariant	68	75	3	-	subtentorial abnormal myelination	DiseaseOrPhenotypicFeature	116	119	5	1:NR:2	L2R	CROSS	68-75	120-122	c|SUB|C|444-62|A	c . 444 - 62C > A	SequenceVariant	68	75	3	D006973	moderate hyperintensity	DiseaseOrPhenotypicFeature	120	122	5	1:NR:2	L2R	CROSS	68-75	203-204	c|SUB|C|444-62|A	c . 444 - 62C > A	SequenceVariant	68	75	3	D003853	deoxyribonucleosides	ChemicalEntity	203	204	7	1:NR:2	L2R	CROSS	90-93	203-204	D028361	respiratory chain deficiencies	DiseaseOrPhenotypicFeature	90	93	3	D003853	deoxyribonucleosides	ChemicalEntity	203	204	7	1:NR:2	L2R	CROSS	116-119	203-204	-	subtentorial abnormal myelination	DiseaseOrPhenotypicFeature	116	119	5	D003853	deoxyribonucleosides	ChemicalEntity	203	204	7	1:NR:2	L2R	CROSS	120-122	203-204	D006973	moderate hyperintensity	DiseaseOrPhenotypicFeature	120	122	5	D003853	deoxyribonucleosides	ChemicalEntity	203	204	7
19565319	Adenosine A ( 2A ) receptor gene ( ADORA2A ) variants may increase autistic symptoms and anxiety in autism spectrum disorder .|Autism spectrum disorders ( ASDs ) are heterogeneous disorders presenting with increased rates of anxiety .|The adenosine A ( 2A ) receptor gene ( ADORA2A ) is associated with panic disorder and is located on chromosome 22q11 . 23 .|Its gene product , the adenosine A ( 2A ) receptor , is strongly expressed in the caudate nucleus , which also is involved in ASD .|As autistic symptoms are increased in individuals with 22q11 . 2 deletion syndrome , and large 22q11 . 2 deletions and duplications have been observed in ASD individuals , in this study , 98 individuals with ASD and 234 control individuals were genotyped for eight single - nucleotide polymorphisms in ADORA2A .|Nominal association with the disorder was observed for rs2236624 - CC , and phenotypic variability in ASD symptoms was influenced by rs3761422 , rs5751876 and rs35320474 .|In addition , association of ADORA2A variants with anxiety was replicated for individuals with ASD .|Findings point toward a possible mediating role of ADORA2A variants on phenotypic expression in ASD that need to be replicated in a larger sample .	1:Association:2	L2R	NON-CROSS	8-9	13-15	135	Adenosine A ( 2A ) receptor|ADORA2A|adenosine A ( 2A ) receptor|ADORA2A|adenosine A ( 2A ) receptor|ADORA2A|ADORA2A|ADORA2A	GeneOrGeneProduct	0:8:39:47:68:140:174:193	6:9:45:48:74:141:175:194	0:0:2:2:3:4:6:7	D001321	autistic symptoms|autistic symptoms	DiseaseOrPhenotypicFeature	13:91	15:93	0:4	1:Association:2	L2R	NON-CROSS	174-175	177-178	135	Adenosine A ( 2A ) receptor|ADORA2A|adenosine A ( 2A ) receptor|ADORA2A|adenosine A ( 2A ) receptor|ADORA2A|ADORA2A|ADORA2A	GeneOrGeneProduct	0:8:39:47:68:140:174:193	6:9:45:48:74:141:175:194	0:0:2:2:3:4:6:7	D001008	anxiety|anxiety|anxiety	DiseaseOrPhenotypicFeature	16:36:177	17:37:178	0:1:6	1:Association:2	L2R	NON-CROSS	193-194	199-200	135	Adenosine A ( 2A ) receptor|ADORA2A|adenosine A ( 2A ) receptor|ADORA2A|adenosine A ( 2A ) receptor|ADORA2A|ADORA2A|ADORA2A	GeneOrGeneProduct	0:8:39:47:68:140:174:193	6:9:45:48:74:141:175:194	0:0:2:2:3:4:6:7	D000067877	autism spectrum disorder|Autism spectrum disorders|ASDs|ASD|ASD|ASD|ASD|ASD|ASD	DiseaseOrPhenotypicFeature	18:22:26:88:116:126:158:183:199	21:25:27:89:117:127:159:184:200	0:1:1:3:4:4:5:6:7	1:Association:2	L2R	NON-CROSS	47-48	52-54	135	Adenosine A ( 2A ) receptor|ADORA2A|adenosine A ( 2A ) receptor|ADORA2A|adenosine A ( 2A ) receptor|ADORA2A|ADORA2A|ADORA2A	GeneOrGeneProduct	0:8:39:47:68:140:174:193	6:9:45:48:74:141:175:194	0:0:2:2:3:4:6:7	D016584	panic disorder	DiseaseOrPhenotypicFeature	52	54	2	1:NR:2	L2R	NON-CROSS	68-74	98-103	135	Adenosine A ( 2A ) receptor|ADORA2A|adenosine A ( 2A ) receptor|ADORA2A|adenosine A ( 2A ) receptor|ADORA2A|ADORA2A|ADORA2A	GeneOrGeneProduct	0:8:39:47:68:140:174:193	6:9:45:48:74:141:175:194	0:0:2:2:3:4:6:7	D004062	22q11 . 2 deletion syndrome|22q11 . 2 deletions	DiseaseOrPhenotypicFeature	98:106	103:110	4:4	1:NR:2	L2R	CROSS	91-93	150-151	D001321	autistic symptoms|autistic symptoms	DiseaseOrPhenotypicFeature	13:91	15:93	0:4	rs2236624	rs2236624	SequenceVariant	150	151	5	1:Positive_Correlation:2	R2L	CROSS	163-164	91-93	rs3761422	rs3761422	SequenceVariant	163	164	5	D001321	autistic symptoms|autistic symptoms	DiseaseOrPhenotypicFeature	13:91	15:93	0:4	1:Positive_Correlation:2	R2L	CROSS	165-166	91-93	rs5751876	rs5751876	SequenceVariant	165	166	5	D001321	autistic symptoms|autistic symptoms	DiseaseOrPhenotypicFeature	13:91	15:93	0:4	1:Positive_Correlation:2	R2L	CROSS	167-168	91-93	rs35320474	rs35320474	SequenceVariant	167	168	5	D001321	autistic symptoms|autistic symptoms	DiseaseOrPhenotypicFeature	13:91	15:93	0:4	1:NR:2	L2R	CROSS	150-151	177-178	D001008	anxiety|anxiety|anxiety	DiseaseOrPhenotypicFeature	16:36:177	17:37:178	0:1:6	rs2236624	rs2236624	SequenceVariant	150	151	5	1:Positive_Correlation:2	L2R	CROSS	163-164	177-178	D001008	anxiety|anxiety|anxiety	DiseaseOrPhenotypicFeature	16:36:177	17:37:178	0:1:6	rs3761422	rs3761422	SequenceVariant	163	164	5	1:Positive_Correlation:2	L2R	CROSS	165-166	177-178	D001008	anxiety|anxiety|anxiety	DiseaseOrPhenotypicFeature	16:36:177	17:37:178	0:1:6	rs5751876	rs5751876	SequenceVariant	165	166	5	1:Positive_Correlation:2	L2R	CROSS	167-168	177-178	D001008	anxiety|anxiety|anxiety	DiseaseOrPhenotypicFeature	16:36:177	17:37:178	0:1:6	rs35320474	rs35320474	SequenceVariant	167	168	5	1:Association:2	L2R	NON-CROSS	150-151	158-159	D000067877	autism spectrum disorder|Autism spectrum disorders|ASDs|ASD|ASD|ASD|ASD|ASD|ASD	DiseaseOrPhenotypicFeature	18:22:26:88:116:126:158:183:199	21:25:27:89:117:127:159:184:200	0:1:1:3:4:4:5:6:7	rs2236624	rs2236624	SequenceVariant	150	151	5	1:NR:2	L2R	NON-CROSS	158-159	163-164	D000067877	autism spectrum disorder|Autism spectrum disorders|ASDs|ASD|ASD|ASD|ASD|ASD|ASD	DiseaseOrPhenotypicFeature	18:22:26:88:116:126:158:183:199	21:25:27:89:117:127:159:184:200	0:1:1:3:4:4:5:6:7	rs3761422	rs3761422	SequenceVariant	163	164	5	1:NR:2	L2R	NON-CROSS	158-159	165-166	D000067877	autism spectrum disorder|Autism spectrum disorders|ASDs|ASD|ASD|ASD|ASD|ASD|ASD	DiseaseOrPhenotypicFeature	18:22:26:88:116:126:158:183:199	21:25:27:89:117:127:159:184:200	0:1:1:3:4:4:5:6:7	rs5751876	rs5751876	SequenceVariant	165	166	5	1:NR:2	L2R	NON-CROSS	158-159	167-168	D000067877	autism spectrum disorder|Autism spectrum disorders|ASDs|ASD|ASD|ASD|ASD|ASD|ASD	DiseaseOrPhenotypicFeature	18:22:26:88:116:126:158:183:199	21:25:27:89:117:127:159:184:200	0:1:1:3:4:4:5:6:7	rs35320474	rs35320474	SequenceVariant	167	168	5	1:NR:2	L2R	CROSS	52-54	150-151	D016584	panic disorder	DiseaseOrPhenotypicFeature	52	54	2	rs2236624	rs2236624	SequenceVariant	150	151	5	1:NR:2	L2R	CROSS	52-54	163-164	D016584	panic disorder	DiseaseOrPhenotypicFeature	52	54	2	rs3761422	rs3761422	SequenceVariant	163	164	5	1:NR:2	L2R	CROSS	52-54	165-166	D016584	panic disorder	DiseaseOrPhenotypicFeature	52	54	2	rs5751876	rs5751876	SequenceVariant	165	166	5	1:NR:2	L2R	CROSS	52-54	167-168	D016584	panic disorder	DiseaseOrPhenotypicFeature	52	54	2	rs35320474	rs35320474	SequenceVariant	167	168	5	1:NR:2	L2R	CROSS	106-110	150-151	D004062	22q11 . 2 deletion syndrome|22q11 . 2 deletions	DiseaseOrPhenotypicFeature	98:106	103:110	4:4	rs2236624	rs2236624	SequenceVariant	150	151	5	1:NR:2	L2R	CROSS	106-110	163-164	D004062	22q11 . 2 deletion syndrome|22q11 . 2 deletions	DiseaseOrPhenotypicFeature	98:106	103:110	4:4	rs3761422	rs3761422	SequenceVariant	163	164	5	1:NR:2	L2R	CROSS	106-110	165-166	D004062	22q11 . 2 deletion syndrome|22q11 . 2 deletions	DiseaseOrPhenotypicFeature	98:106	103:110	4:4	rs5751876	rs5751876	SequenceVariant	165	166	5	1:NR:2	L2R	CROSS	106-110	167-168	D004062	22q11 . 2 deletion syndrome|22q11 . 2 deletions	DiseaseOrPhenotypicFeature	98:106	103:110	4:4	rs35320474	rs35320474	SequenceVariant	167	168	5
20648600	High frequency of lamivudine resistance mutations in Brazilian patients co - infected with HIV and hepatitis B .|This study analyzed the genotype distribution and frequency of lamivudine ( LAM ) and tenofovir ( TDF ) resistance mutations in a group of patients co - infected with HIV and hepatitis B virus ( HBV ) .|A cross - sectional study of 847 patients with HIV was conducted .|Patients provided blood samples for HBsAg detection .|The load of HBV was determined using an " in - house " real - time polymerase chain reaction .|HBV genotypes / subgenotypes , antiviral resistance , basal core promoter ( BCP ) , and precore mutations were detected by DNA sequencing .|Twenty - eight patients with co - infection were identified .|The distribution of HBV genotypes among these patients was A ( n = 9 ; 50 % ) , D ( n = 4 ; 22 . 2 % ) , G ( n = 3 ; 16 . 7 % ) , and F ( n = 2 ; 11 . 1 % ) .|Eighteen patients were treated with LAM and six patients were treated with LAM plus TDF .|The length of exposure to LAM and TDF varied from 4 to 216 months .|LAM resistance substitutions ( rtL180M + rtM204V ) were detected in 10 ( 50 % ) of the 20 patients with viremia .|This pattern and an accompanying rtV173L mutation was found in four patients .|Three patients with the triple polymerase substitution pattern ( rtV173L + rtL180M + rtM204V ) had associated changes in the envelope gene ( sE164D + sI195M ) .|Mutations in the BCP region ( A1762T , G1764A ) and in the precore region ( G1896A , G1899A ) were also found .|No putative TDF resistance substitution was detected .|The data suggest that prolonged LAM use is associated with the emergence of particular changes in the HBV genome , including substitutions that may elicit a vaccine escape phenotype .|No putative TDF resistance change was detected after prolonged use of TDF .	1:NR:2	L2R	NON-CROSS	3-4	9-17	D019259	lamivudine|lamivudine|LAM|LAM|LAM|LAM|LAM|LAM	ChemicalEntity	3:27:29:193:200:209:219:320	4:28:30:194:201:210:220:321	0:1:1:8:8:9:10:15	D006509,D015658	co - infected with HIV and hepatitis B|co - infected with HIV and hepatitis B virus	DiseaseOrPhenotypicFeature	9:43	17:52	0:1	1:Comparison:2	L2R	NON-CROSS	200-201	202-203	D019259	lamivudine|lamivudine|LAM|LAM|LAM|LAM|LAM|LAM	ChemicalEntity	3:27:29:193:200:209:219:320	4:28:30:194:201:210:220:321	0:1:1:8:8:9:10:15	D000068698	tenofovir|TDF|TDF|TDF|TDF|TDF|TDF	ChemicalEntity	32:34:202:211:309:347:356	33:35:203:212:310:348:357	1:1:8:9:14:16:16	1:NR:2	L2R	CROSS	29-30	74-75	D019259	lamivudine|lamivudine|LAM|LAM|LAM|LAM|LAM|LAM	ChemicalEntity	3:27:29:193:200:209:219:320	4:28:30:194:201:210:220:321	0:1:1:8:8:9:10:15	D006514	HBsAg	ChemicalEntity	74	75	3	1:NR:2	L2R	CROSS	296-297	320-321	D019259	lamivudine|lamivudine|LAM|LAM|LAM|LAM|LAM|LAM	ChemicalEntity	3:27:29:193:200:209:219:320	4:28:30:194:201:210:220:321	0:1:1:8:8:9:10:15	944568	precore|precore	GeneOrGeneProduct	113:296	114:297	5:13	1:NR:2	L2R	CROSS	128-129	193-194	D019259	lamivudine|lamivudine|LAM|LAM|LAM|LAM|LAM|LAM	ChemicalEntity	3:27:29:193:200:209:219:320	4:28:30:194:201:210:220:321	0:1:1:8:8:9:10:15	D007239	infection	DiseaseOrPhenotypicFeature	128	129	6	1:Negative_Correlation:2	L2R	NON-CROSS	219-220	223-224	D019259	lamivudine|lamivudine|LAM|LAM|LAM|LAM|LAM|LAM	ChemicalEntity	3:27:29:193:200:209:219:320	4:28:30:194:201:210:220:321	0:1:1:8:8:9:10:15	p|SUB|L|180|M	L180M|L180M	SequenceVariant	223:266	224:267	10:12	1:Negative_Correlation:2	L2R	NON-CROSS	219-220	225-226	D019259	lamivudine|lamivudine|LAM|LAM|LAM|LAM|LAM|LAM	ChemicalEntity	3:27:29:193:200:209:219:320	4:28:30:194:201:210:220:321	0:1:1:8:8:9:10:15	p|SUB|M|204|V	M204V|M204V	SequenceVariant	225:268	226:269	10:12	1:Negative_Correlation:2	L2R	NON-CROSS	219-220	240-241	D019259	lamivudine|lamivudine|LAM|LAM|LAM|LAM|LAM|LAM	ChemicalEntity	3:27:29:193:200:209:219:320	4:28:30:194:201:210:220:321	0:1:1:8:8:9:10:15	D014766	viremia	DiseaseOrPhenotypicFeature	240	241	10	1:Negative_Correlation:2	L2R	CROSS	219-220	247-248	D019259	lamivudine|lamivudine|LAM|LAM|LAM|LAM|LAM|LAM	ChemicalEntity	3:27:29:193:200:209:219:320	4:28:30:194:201:210:220:321	0:1:1:8:8:9:10:15	p|SUB|V|173|L	V173L|V173L	SequenceVariant	247:264	248:265	11:12	1:Association:2	L2R	CROSS	219-220	260-261	D019259	lamivudine|lamivudine|LAM|LAM|LAM|LAM|LAM|LAM	ChemicalEntity	3:27:29:193:200:209:219:320	4:28:30:194:201:210:220:321	0:1:1:8:8:9:10:15	944565	polymerase	GeneOrGeneProduct	260	261	12	1:NR:2	L2R	CROSS	275-276	320-321	D019259	lamivudine|lamivudine|LAM|LAM|LAM|LAM|LAM|LAM	ChemicalEntity	3:27:29:193:200:209:219:320	4:28:30:194:201:210:220:321	0:1:1:8:8:9:10:15	944569	envelope	GeneOrGeneProduct	275	276	12	1:NR:2	L2R	CROSS	278-279	320-321	D019259	lamivudine|lamivudine|LAM|LAM|LAM|LAM|LAM|LAM	ChemicalEntity	3:27:29:193:200:209:219:320	4:28:30:194:201:210:220:321	0:1:1:8:8:9:10:15	p|SUB|E|164|D	E164D	SequenceVariant	278	279	12	1:NR:2	L2R	CROSS	280-281	320-321	D019259	lamivudine|lamivudine|LAM|LAM|LAM|LAM|LAM|LAM	ChemicalEntity	3:27:29:193:200:209:219:320	4:28:30:194:201:210:220:321	0:1:1:8:8:9:10:15	p|SUB|I|195|M	I195M	SequenceVariant	280	281	12	1:NR:2	L2R	CROSS	289-290	320-321	D019259	lamivudine|lamivudine|LAM|LAM|LAM|LAM|LAM|LAM	ChemicalEntity	3:27:29:193:200:209:219:320	4:28:30:194:201:210:220:321	0:1:1:8:8:9:10:15	g|SUB|A|1762|T	A1762T	SequenceVariant	289	290	13	1:NR:2	L2R	CROSS	291-292	320-321	D019259	lamivudine|lamivudine|LAM|LAM|LAM|LAM|LAM|LAM	ChemicalEntity	3:27:29:193:200:209:219:320	4:28:30:194:201:210:220:321	0:1:1:8:8:9:10:15	g|SUB|G|1764|A	G1764A	SequenceVariant	291	292	13	1:NR:2	L2R	CROSS	299-300	320-321	D019259	lamivudine|lamivudine|LAM|LAM|LAM|LAM|LAM|LAM	ChemicalEntity	3:27:29:193:200:209:219:320	4:28:30:194:201:210:220:321	0:1:1:8:8:9:10:15	g|SUB|G|1896|A	G1896A	SequenceVariant	299	300	13	1:NR:2	L2R	CROSS	301-302	320-321	D019259	lamivudine|lamivudine|LAM|LAM|LAM|LAM|LAM|LAM	ChemicalEntity	3:27:29:193:200:209:219:320	4:28:30:194:201:210:220:321	0:1:1:8:8:9:10:15	g|SUB|G|1899|A	G1899A	SequenceVariant	301	302	13	1:NR:2	L2R	NON-CROSS	34-35	43-52	D006509,D015658	co - infected with HIV and hepatitis B|co - infected with HIV and hepatitis B virus	DiseaseOrPhenotypicFeature	9:43	17:52	0:1	D000068698	tenofovir|TDF|TDF|TDF|TDF|TDF|TDF	ChemicalEntity	32:34:202:211:309:347:356	33:35:203:212:310:348:357	1:1:8:9:14:16:16	1:NR:2	L2R	CROSS	43-52	74-75	D006509,D015658	co - infected with HIV and hepatitis B|co - infected with HIV and hepatitis B virus	DiseaseOrPhenotypicFeature	9:43	17:52	0:1	D006514	HBsAg	ChemicalEntity	74	75	3	1:NR:2	L2R	CROSS	43-52	113-114	D006509,D015658	co - infected with HIV and hepatitis B|co - infected with HIV and hepatitis B virus	DiseaseOrPhenotypicFeature	9:43	17:52	0:1	944568	precore|precore	GeneOrGeneProduct	113:296	114:297	5:13	1:NR:2	L2R	CROSS	43-52	223-224	D006509,D015658	co - infected with HIV and hepatitis B|co - infected with HIV and hepatitis B virus	DiseaseOrPhenotypicFeature	9:43	17:52	0:1	p|SUB|L|180|M	L180M|L180M	SequenceVariant	223:266	224:267	10:12	1:NR:2	L2R	CROSS	43-52	225-226	D006509,D015658	co - infected with HIV and hepatitis B|co - infected with HIV and hepatitis B virus	DiseaseOrPhenotypicFeature	9:43	17:52	0:1	p|SUB|M|204|V	M204V|M204V	SequenceVariant	225:268	226:269	10:12	1:NR:2	L2R	CROSS	43-52	247-248	D006509,D015658	co - infected with HIV and hepatitis B|co - infected with HIV and hepatitis B virus	DiseaseOrPhenotypicFeature	9:43	17:52	0:1	p|SUB|V|173|L	V173L|V173L	SequenceVariant	247:264	248:265	11:12	1:NR:2	L2R	CROSS	43-52	260-261	D006509,D015658	co - infected with HIV and hepatitis B|co - infected with HIV and hepatitis B virus	DiseaseOrPhenotypicFeature	9:43	17:52	0:1	944565	polymerase	GeneOrGeneProduct	260	261	12	1:NR:2	L2R	CROSS	43-52	275-276	D006509,D015658	co - infected with HIV and hepatitis B|co - infected with HIV and hepatitis B virus	DiseaseOrPhenotypicFeature	9:43	17:52	0:1	944569	envelope	GeneOrGeneProduct	275	276	12	1:NR:2	L2R	CROSS	43-52	278-279	D006509,D015658	co - infected with HIV and hepatitis B|co - infected with HIV and hepatitis B virus	DiseaseOrPhenotypicFeature	9:43	17:52	0:1	p|SUB|E|164|D	E164D	SequenceVariant	278	279	12	1:NR:2	L2R	CROSS	43-52	280-281	D006509,D015658	co - infected with HIV and hepatitis B|co - infected with HIV and hepatitis B virus	DiseaseOrPhenotypicFeature	9:43	17:52	0:1	p|SUB|I|195|M	I195M	SequenceVariant	280	281	12	1:NR:2	L2R	CROSS	43-52	289-290	D006509,D015658	co - infected with HIV and hepatitis B|co - infected with HIV and hepatitis B virus	DiseaseOrPhenotypicFeature	9:43	17:52	0:1	g|SUB|A|1762|T	A1762T	SequenceVariant	289	290	13	1:NR:2	L2R	CROSS	43-52	291-292	D006509,D015658	co - infected with HIV and hepatitis B|co - infected with HIV and hepatitis B virus	DiseaseOrPhenotypicFeature	9:43	17:52	0:1	g|SUB|G|1764|A	G1764A	SequenceVariant	291	292	13	1:NR:2	L2R	CROSS	43-52	299-300	D006509,D015658	co - infected with HIV and hepatitis B|co - infected with HIV and hepatitis B virus	DiseaseOrPhenotypicFeature	9:43	17:52	0:1	g|SUB|G|1896|A	G1896A	SequenceVariant	299	300	13	1:NR:2	L2R	CROSS	43-52	301-302	D006509,D015658	co - infected with HIV and hepatitis B|co - infected with HIV and hepatitis B virus	DiseaseOrPhenotypicFeature	9:43	17:52	0:1	g|SUB|G|1899|A	G1899A	SequenceVariant	301	302	13	1:NR:2	L2R	CROSS	34-35	74-75	D000068698	tenofovir|TDF|TDF|TDF|TDF|TDF|TDF	ChemicalEntity	32:34:202:211:309:347:356	33:35:203:212:310:348:357	1:1:8:9:14:16:16	D006514	HBsAg	ChemicalEntity	74	75	3	1:NR:2	L2R	CROSS	296-297	309-310	D000068698	tenofovir|TDF|TDF|TDF|TDF|TDF|TDF	ChemicalEntity	32:34:202:211:309:347:356	33:35:203:212:310:348:357	1:1:8:9:14:16:16	944568	precore|precore	GeneOrGeneProduct	113:296	114:297	5:13	1:NR:2	L2R	CROSS	128-129	202-203	D000068698	tenofovir|TDF|TDF|TDF|TDF|TDF|TDF	ChemicalEntity	32:34:202:211:309:347:356	33:35:203:212:310:348:357	1:1:8:9:14:16:16	D007239	infection	DiseaseOrPhenotypicFeature	128	129	6	1:NR:2	L2R	CROSS	211-212	223-224	D000068698	tenofovir|TDF|TDF|TDF|TDF|TDF|TDF	ChemicalEntity	32:34:202:211:309:347:356	33:35:203:212:310:348:357	1:1:8:9:14:16:16	p|SUB|L|180|M	L180M|L180M	SequenceVariant	223:266	224:267	10:12	1:NR:2	L2R	CROSS	211-212	225-226	D000068698	tenofovir|TDF|TDF|TDF|TDF|TDF|TDF	ChemicalEntity	32:34:202:211:309:347:356	33:35:203:212:310:348:357	1:1:8:9:14:16:16	p|SUB|M|204|V	M204V|M204V	SequenceVariant	225:268	226:269	10:12	1:NR:2	L2R	CROSS	211-212	240-241	D000068698	tenofovir|TDF|TDF|TDF|TDF|TDF|TDF	ChemicalEntity	32:34:202:211:309:347:356	33:35:203:212:310:348:357	1:1:8:9:14:16:16	D014766	viremia	DiseaseOrPhenotypicFeature	240	241	10	1:NR:2	L2R	CROSS	211-212	247-248	D000068698	tenofovir|TDF|TDF|TDF|TDF|TDF|TDF	ChemicalEntity	32:34:202:211:309:347:356	33:35:203:212:310:348:357	1:1:8:9:14:16:16	p|SUB|V|173|L	V173L|V173L	SequenceVariant	247:264	248:265	11:12	1:NR:2	L2R	CROSS	211-212	260-261	D000068698	tenofovir|TDF|TDF|TDF|TDF|TDF|TDF	ChemicalEntity	32:34:202:211:309:347:356	33:35:203:212:310:348:357	1:1:8:9:14:16:16	944565	polymerase	GeneOrGeneProduct	260	261	12	1:NR:2	L2R	CROSS	275-276	309-310	D000068698	tenofovir|TDF|TDF|TDF|TDF|TDF|TDF	ChemicalEntity	32:34:202:211:309:347:356	33:35:203:212:310:348:357	1:1:8:9:14:16:16	944569	envelope	GeneOrGeneProduct	275	276	12	1:NR:2	L2R	CROSS	278-279	309-310	D000068698	tenofovir|TDF|TDF|TDF|TDF|TDF|TDF	ChemicalEntity	32:34:202:211:309:347:356	33:35:203:212:310:348:357	1:1:8:9:14:16:16	p|SUB|E|164|D	E164D	SequenceVariant	278	279	12	1:NR:2	L2R	CROSS	280-281	309-310	D000068698	tenofovir|TDF|TDF|TDF|TDF|TDF|TDF	ChemicalEntity	32:34:202:211:309:347:356	33:35:203:212:310:348:357	1:1:8:9:14:16:16	p|SUB|I|195|M	I195M	SequenceVariant	280	281	12	1:NR:2	L2R	CROSS	289-290	309-310	D000068698	tenofovir|TDF|TDF|TDF|TDF|TDF|TDF	ChemicalEntity	32:34:202:211:309:347:356	33:35:203:212:310:348:357	1:1:8:9:14:16:16	g|SUB|A|1762|T	A1762T	SequenceVariant	289	290	13	1:NR:2	L2R	CROSS	291-292	309-310	D000068698	tenofovir|TDF|TDF|TDF|TDF|TDF|TDF	ChemicalEntity	32:34:202:211:309:347:356	33:35:203:212:310:348:357	1:1:8:9:14:16:16	g|SUB|G|1764|A	G1764A	SequenceVariant	291	292	13	1:NR:2	L2R	CROSS	299-300	309-310	D000068698	tenofovir|TDF|TDF|TDF|TDF|TDF|TDF	ChemicalEntity	32:34:202:211:309:347:356	33:35:203:212:310:348:357	1:1:8:9:14:16:16	g|SUB|G|1896|A	G1896A	SequenceVariant	299	300	13	1:NR:2	L2R	CROSS	301-302	309-310	D000068698	tenofovir|TDF|TDF|TDF|TDF|TDF|TDF	ChemicalEntity	32:34:202:211:309:347:356	33:35:203:212:310:348:357	1:1:8:9:14:16:16	g|SUB|G|1899|A	G1899A	SequenceVariant	301	302	13	1:NR:2	L2R	CROSS	74-75	113-114	D006514	HBsAg	ChemicalEntity	74	75	3	944568	precore|precore	GeneOrGeneProduct	113:296	114:297	5:13	1:NR:2	L2R	CROSS	74-75	128-129	D006514	HBsAg	ChemicalEntity	74	75	3	D007239	infection	DiseaseOrPhenotypicFeature	128	129	6	1:NR:2	L2R	CROSS	74-75	223-224	D006514	HBsAg	ChemicalEntity	74	75	3	p|SUB|L|180|M	L180M|L180M	SequenceVariant	223:266	224:267	10:12	1:NR:2	L2R	CROSS	74-75	225-226	D006514	HBsAg	ChemicalEntity	74	75	3	p|SUB|M|204|V	M204V|M204V	SequenceVariant	225:268	226:269	10:12	1:NR:2	L2R	CROSS	74-75	240-241	D006514	HBsAg	ChemicalEntity	74	75	3	D014766	viremia	DiseaseOrPhenotypicFeature	240	241	10	1:NR:2	L2R	CROSS	74-75	247-248	D006514	HBsAg	ChemicalEntity	74	75	3	p|SUB|V|173|L	V173L|V173L	SequenceVariant	247:264	248:265	11:12	1:NR:2	L2R	CROSS	74-75	260-261	D006514	HBsAg	ChemicalEntity	74	75	3	944565	polymerase	GeneOrGeneProduct	260	261	12	1:NR:2	L2R	CROSS	74-75	275-276	D006514	HBsAg	ChemicalEntity	74	75	3	944569	envelope	GeneOrGeneProduct	275	276	12	1:NR:2	L2R	CROSS	74-75	278-279	D006514	HBsAg	ChemicalEntity	74	75	3	p|SUB|E|164|D	E164D	SequenceVariant	278	279	12	1:NR:2	L2R	CROSS	74-75	280-281	D006514	HBsAg	ChemicalEntity	74	75	3	p|SUB|I|195|M	I195M	SequenceVariant	280	281	12	1:NR:2	L2R	CROSS	74-75	289-290	D006514	HBsAg	ChemicalEntity	74	75	3	g|SUB|A|1762|T	A1762T	SequenceVariant	289	290	13	1:NR:2	L2R	CROSS	74-75	291-292	D006514	HBsAg	ChemicalEntity	74	75	3	g|SUB|G|1764|A	G1764A	SequenceVariant	291	292	13	1:NR:2	L2R	CROSS	74-75	299-300	D006514	HBsAg	ChemicalEntity	74	75	3	g|SUB|G|1896|A	G1896A	SequenceVariant	299	300	13	1:NR:2	L2R	CROSS	74-75	301-302	D006514	HBsAg	ChemicalEntity	74	75	3	g|SUB|G|1899|A	G1899A	SequenceVariant	301	302	13	1:NR:2	L2R	CROSS	113-114	128-129	944568	precore|precore	GeneOrGeneProduct	113:296	114:297	5:13	D007239	infection	DiseaseOrPhenotypicFeature	128	129	6	1:NR:2	L2R	CROSS	240-241	296-297	944568	precore|precore	GeneOrGeneProduct	113:296	114:297	5:13	D014766	viremia	DiseaseOrPhenotypicFeature	240	241	10	1:NR:2	L2R	CROSS	260-261	296-297	944568	precore|precore	GeneOrGeneProduct	113:296	114:297	5:13	944565	polymerase	GeneOrGeneProduct	260	261	12	1:NR:2	L2R	CROSS	275-276	296-297	944568	precore|precore	GeneOrGeneProduct	113:296	114:297	5:13	944569	envelope	GeneOrGeneProduct	275	276	12	1:NR:2	L2R	CROSS	128-129	223-224	D007239	infection	DiseaseOrPhenotypicFeature	128	129	6	p|SUB|L|180|M	L180M|L180M	SequenceVariant	223:266	224:267	10:12	1:NR:2	L2R	CROSS	128-129	225-226	D007239	infection	DiseaseOrPhenotypicFeature	128	129	6	p|SUB|M|204|V	M204V|M204V	SequenceVariant	225:268	226:269	10:12	1:NR:2	L2R	CROSS	128-129	247-248	D007239	infection	DiseaseOrPhenotypicFeature	128	129	6	p|SUB|V|173|L	V173L|V173L	SequenceVariant	247:264	248:265	11:12	1:NR:2	L2R	CROSS	128-129	260-261	D007239	infection	DiseaseOrPhenotypicFeature	128	129	6	944565	polymerase	GeneOrGeneProduct	260	261	12	1:NR:2	L2R	CROSS	128-129	275-276	D007239	infection	DiseaseOrPhenotypicFeature	128	129	6	944569	envelope	GeneOrGeneProduct	275	276	12	1:NR:2	L2R	CROSS	128-129	278-279	D007239	infection	DiseaseOrPhenotypicFeature	128	129	6	p|SUB|E|164|D	E164D	SequenceVariant	278	279	12	1:NR:2	L2R	CROSS	128-129	280-281	D007239	infection	DiseaseOrPhenotypicFeature	128	129	6	p|SUB|I|195|M	I195M	SequenceVariant	280	281	12	1:NR:2	L2R	CROSS	128-129	289-290	D007239	infection	DiseaseOrPhenotypicFeature	128	129	6	g|SUB|A|1762|T	A1762T	SequenceVariant	289	290	13	1:NR:2	L2R	CROSS	128-129	291-292	D007239	infection	DiseaseOrPhenotypicFeature	128	129	6	g|SUB|G|1764|A	G1764A	SequenceVariant	291	292	13	1:NR:2	L2R	CROSS	128-129	299-300	D007239	infection	DiseaseOrPhenotypicFeature	128	129	6	g|SUB|G|1896|A	G1896A	SequenceVariant	299	300	13	1:NR:2	L2R	CROSS	128-129	301-302	D007239	infection	DiseaseOrPhenotypicFeature	128	129	6	g|SUB|G|1899|A	G1899A	SequenceVariant	301	302	13	1:Association:2	L2R	NON-CROSS	223-224	225-226	p|SUB|L|180|M	L180M|L180M	SequenceVariant	223:266	224:267	10:12	p|SUB|M|204|V	M204V|M204V	SequenceVariant	225:268	226:269	10:12	1:Association:2	L2R	NON-CROSS	223-224	240-241	p|SUB|L|180|M	L180M|L180M	SequenceVariant	223:266	224:267	10:12	D014766	viremia	DiseaseOrPhenotypicFeature	240	241	10	1:Association:2	R2L	NON-CROSS	266-267	264-265	p|SUB|V|173|L	V173L|V173L	SequenceVariant	247:264	248:265	11:12	p|SUB|L|180|M	L180M|L180M	SequenceVariant	223:266	224:267	10:12	1:Association:2	L2R	NON-CROSS	266-267	278-279	p|SUB|L|180|M	L180M|L180M	SequenceVariant	223:266	224:267	10:12	p|SUB|E|164|D	E164D	SequenceVariant	278	279	12	1:Association:2	L2R	NON-CROSS	266-267	280-281	p|SUB|L|180|M	L180M|L180M	SequenceVariant	223:266	224:267	10:12	p|SUB|I|195|M	I195M	SequenceVariant	280	281	12	1:Association:2	L2R	NON-CROSS	225-226	240-241	p|SUB|M|204|V	M204V|M204V	SequenceVariant	225:268	226:269	10:12	D014766	viremia	DiseaseOrPhenotypicFeature	240	241	10	1:Association:2	R2L	NON-CROSS	268-269	264-265	p|SUB|V|173|L	V173L|V173L	SequenceVariant	247:264	248:265	11:12	p|SUB|M|204|V	M204V|M204V	SequenceVariant	225:268	226:269	10:12	1:Association:2	L2R	NON-CROSS	268-269	278-279	p|SUB|M|204|V	M204V|M204V	SequenceVariant	225:268	226:269	10:12	p|SUB|E|164|D	E164D	SequenceVariant	278	279	12	1:Association:2	L2R	NON-CROSS	268-269	280-281	p|SUB|M|204|V	M204V|M204V	SequenceVariant	225:268	226:269	10:12	p|SUB|I|195|M	I195M	SequenceVariant	280	281	12	1:NR:2	L2R	CROSS	240-241	247-248	D014766	viremia	DiseaseOrPhenotypicFeature	240	241	10	p|SUB|V|173|L	V173L|V173L	SequenceVariant	247:264	248:265	11:12	1:Association:2	L2R	CROSS	240-241	260-261	D014766	viremia	DiseaseOrPhenotypicFeature	240	241	10	944565	polymerase	GeneOrGeneProduct	260	261	12	1:NR:2	L2R	CROSS	240-241	275-276	D014766	viremia	DiseaseOrPhenotypicFeature	240	241	10	944569	envelope	GeneOrGeneProduct	275	276	12	1:NR:2	L2R	CROSS	240-241	278-279	D014766	viremia	DiseaseOrPhenotypicFeature	240	241	10	p|SUB|E|164|D	E164D	SequenceVariant	278	279	12	1:NR:2	L2R	CROSS	240-241	280-281	D014766	viremia	DiseaseOrPhenotypicFeature	240	241	10	p|SUB|I|195|M	I195M	SequenceVariant	280	281	12	1:NR:2	L2R	CROSS	240-241	289-290	D014766	viremia	DiseaseOrPhenotypicFeature	240	241	10	g|SUB|A|1762|T	A1762T	SequenceVariant	289	290	13	1:NR:2	L2R	CROSS	240-241	291-292	D014766	viremia	DiseaseOrPhenotypicFeature	240	241	10	g|SUB|G|1764|A	G1764A	SequenceVariant	291	292	13	1:NR:2	L2R	CROSS	240-241	299-300	D014766	viremia	DiseaseOrPhenotypicFeature	240	241	10	g|SUB|G|1896|A	G1896A	SequenceVariant	299	300	13	1:NR:2	L2R	CROSS	240-241	301-302	D014766	viremia	DiseaseOrPhenotypicFeature	240	241	10	g|SUB|G|1899|A	G1899A	SequenceVariant	301	302	13	1:Association:2	L2R	NON-CROSS	264-265	278-279	p|SUB|V|173|L	V173L|V173L	SequenceVariant	247:264	248:265	11:12	p|SUB|E|164|D	E164D	SequenceVariant	278	279	12	1:Association:2	L2R	NON-CROSS	264-265	280-281	p|SUB|V|173|L	V173L|V173L	SequenceVariant	247:264	248:265	11:12	p|SUB|I|195|M	I195M	SequenceVariant	280	281	12	1:Association:2	L2R	NON-CROSS	260-261	275-276	944565	polymerase	GeneOrGeneProduct	260	261	12	944569	envelope	GeneOrGeneProduct	275	276	12	1:Association:2	L2R	NON-CROSS	278-279	280-281	p|SUB|E|164|D	E164D	SequenceVariant	278	279	12	p|SUB|I|195|M	I195M	SequenceVariant	280	281	12
21976953	Identification of a novel FBN1 gene mutation in a Chinese family with Marfan syndrome .|PURPOSE : To identify the mutation in the fibrillin - 1 gene ( FBN1 ) in a Chinese family with Marfan syndrome ( MFS ) .|METHODS : Patients and family members were given complete physical , ophthalmic , and cardiovascular examinations .|Genomic DNA was extracted from leukocytes of venous blood of six individuals in the family and 170 healthy Chinese individuals .|All of the 65 coding exons and their flanking intronic boundaries of FBN1 were amplified in the proband by polymerase chain reaction and followed by direct sequencing .|The mutation identified in the proband was screened in the other family members and the 170 healthy Chinese individuals by direct sequencing .|Protein conservation analysis was performed in six species using an online ClustalW tool .|Protein structure was modeled based on the Protein data bank and mutated in DeepView v4 . 0 . 1 to predict the functional consequences of the mutation .|RESULTS : A novel heterozygous c . 3703T > C change in exon 29 of FBN1 was detected in the proband , which resulted in the substitution of serine by proline at codon 1235 ( p . S1235P ) .|This mutation was also present in two family members but absent in the other , unaffected family members and the 170 healthy Chinese individuals .|The mutant residue located in the calcium binding epidermal growth factor - like # 15 domain is highly conserved among mammalian species and could probably induce conformation change of the domain .|CONCLUSIONS : We indentified a novel p . S1235P mutation in FBN1 , which is the causative mutation for MFS in this family .|Our result expands the mutation spectrum of FBN1 and contributes to the study of the molecular pathogenesis of Marfan syndrome .	1:Association:2	L2R	NON-CROSS	28-29	35-37	2200	FBN1|fibrillin - 1|FBN1|FBN1|FBN1|FBN1|FBN1	GeneOrGeneProduct	4:23:28:91:187:280:300	5:26:29:92:188:281:301	0:1:1:4:8:11:12	D008382	Marfan syndrome|Marfan syndrome|MFS|MFS|Marfan syndrome	DiseaseOrPhenotypicFeature	12:35:38:288:311	14:37:39:289:313	0:1:1:11:12	1:NR:2	L2R	CROSS	243-244	280-281	2200	FBN1|fibrillin - 1|FBN1|FBN1|FBN1|FBN1|FBN1	GeneOrGeneProduct	4:23:28:91:187:280:300	5:26:29:92:188:281:301	0:1:1:4:8:11:12	D002118	calcium	ChemicalEntity	243	244	10	1:NR:2	L2R	CROSS	245-248	280-281	2200	FBN1|fibrillin - 1|FBN1|FBN1|FBN1|FBN1|FBN1	GeneOrGeneProduct	4:23:28:91:187:280:300	5:26:29:92:188:281:301	0:1:1:4:8:11:12	1956	epidermal growth factor	GeneOrGeneProduct	245	248	10	1:Positive_Correlation:2	L2R	CROSS	177-182	288-289	D008382	Marfan syndrome|Marfan syndrome|MFS|MFS|Marfan syndrome	DiseaseOrPhenotypicFeature	12:35:38:288:311	14:37:39:289:313	0:1:1:11:12	c|SUB|T|3703|C	c . 3703T > C	SequenceVariant	177	182	8	1:Positive_Correlation:2	L2R	NON-CROSS	275-278	288-289	D008382	Marfan syndrome|Marfan syndrome|MFS|MFS|Marfan syndrome	DiseaseOrPhenotypicFeature	12:35:38:288:311	14:37:39:289:313	0:1:1:11:12	p|SUB|S|1235|P	serine by proline at codon 1235|p . S1235P|p . S1235P	SequenceVariant	200:207:275	206:210:278	8:8:11	1:NR:2	L2R	CROSS	243-244	288-289	D008382	Marfan syndrome|Marfan syndrome|MFS|MFS|Marfan syndrome	DiseaseOrPhenotypicFeature	12:35:38:288:311	14:37:39:289:313	0:1:1:11:12	D002118	calcium	ChemicalEntity	243	244	10	1:NR:2	L2R	CROSS	245-248	288-289	D008382	Marfan syndrome|Marfan syndrome|MFS|MFS|Marfan syndrome	DiseaseOrPhenotypicFeature	12:35:38:288:311	14:37:39:289:313	0:1:1:11:12	1956	epidermal growth factor	GeneOrGeneProduct	245	248	10	1:NR:2	L2R	CROSS	177-182	243-244	c|SUB|T|3703|C	c . 3703T > C	SequenceVariant	177	182	8	D002118	calcium	ChemicalEntity	243	244	10	1:NR:2	L2R	CROSS	243-244	275-278	p|SUB|S|1235|P	serine by proline at codon 1235|p . S1235P|p . S1235P	SequenceVariant	200:207:275	206:210:278	8:8:11	D002118	calcium	ChemicalEntity	243	244	10	1:NR:2	L2R	NON-CROSS	243-244	245-248	D002118	calcium	ChemicalEntity	243	244	10	1956	epidermal growth factor	GeneOrGeneProduct	245	248	10
2491010	Molecular and phenotypic analysis of patients with deletions within the deletion - rich region of the Duchenne muscular dystrophy ( DMD ) gene .|Eighty unrelated individuals with Duchenne muscular dystrophy ( DMD ) or Becker muscular dystrophy ( BMD ) were found to have deletions in the major deletion - rich region of the DMD locus .|This region includes the last five exons detected by cDNA5b - 7 , all exons detected by cDNA8 , and the first two exons detected by cDNA9 .|These 80 individuals account for approximately 75 % of 109 deletions of the gene , detected among 181 patients analyzed with the entire dystrophin cDNA .|Endpoints for many of these deletions were further characterized using two genomic probes , p20 ( DXS269 ; Wapenaar et al . ) and GMGX11 ( DXS239 ; present paper ) .|Clinical findings are presented for all 80 patients allowing a correlation of phenotypic severity with the genotype .|Thirty - eight independent patients were old enough to be classified as DMD , BMD , or intermediate phenotype and had deletions of exons with sequenced intron / exon boundaries .|Of these , eight BMD patients and one intermediate patient had gene deletions predicted to leave the reading frame intact , while 21 DMD patients , 7 intermediate patients , and 1 BMD patient had gene deletions predicted to disrupt the reading frame .|Thus , with two exceptions , frameshift deletions of the gene resulted in more severe phenotype than did in - frame deletions .|This is in agreement with recent findings by Baumbach et al . and Koenig et al . but is in contrast to findings , by Malhotra et al . at the 5 ' end of the gene .	1:Association:2	L2R	NON-CROSS	16-23	28-31	1756	Duchenne muscular dystrophy ( DMD ) gene|DMD|dystrophin	GeneOrGeneProduct	16:55:109	23:56:110	0:1:3	D020388	Duchenne muscular dystrophy|DMD|Becker muscular dystrophy|BMD|DMD|BMD|BMD|DMD|BMD	DiseaseOrPhenotypicFeature	28:32:35:39:174:176:197:216:225	31:33:38:40:175:177:198:217:226	1:1:1:1:6:6:7:7:7
25006961	Absence of PKC - alpha attenuates lithium - induced nephrogenic diabetes insipidus .|Lithium , an effective antipsychotic , induces nephrogenic diabetes insipidus ( NDI ) in 40 % of patients .|The decreased capacity to concentrate urine is likely due to lithium acutely disrupting the cAMP pathway and chronically reducing urea transporter ( UT - A1 ) and water channel ( AQP2 ) expression in the inner medulla .|Targeting an alternative signaling pathway , such as PKC - mediated signaling , may be an effective method of treating lithium - induced polyuria .|PKC - alpha null mice ( PKCa KO ) and strain - matched wild type ( WT ) controls were treated with lithium for 0 , 3 or 5 days .|WT mice had increased urine output and lowered urine osmolality after 3 and 5 days of treatment whereas PKCa KO mice had no change in urine output or concentration .|Western blot analysis revealed that AQP2 expression in medullary tissues was lowered after 3 and 5 days in WT mice ; however , AQP2 was unchanged in PKCa KO .|Similar results were observed with UT - A1 expression .|Animals were also treated with lithium for 6 weeks .|Lithium - treated WT mice had 19 - fold increased urine output whereas treated PKCa KO animals had a 4 - fold increase in output .|AQP2 and UT - A1 expression was lowered in 6 week lithium - treated WT animals whereas in treated PKCa KO mice , AQP2 was only reduced by 2 - fold and UT - A1 expression was unaffected .|Urinary sodium , potassium and calcium were elevated in lithium - fed WT but not in lithium - fed PKCa KO mice .|Our data show that ablation of PKCa preserves AQP2 and UT - A1 protein expression and localization in lithium - induced NDI , and prevents the development of the severe polyuria associated with lithium therapy .	1:Positive_Correlation:2	L2R	NON-CROSS	2-5	6-7	18750	PKC - alpha|PKC|PKC - alpha|PKCa|PKCa|PKCa|PKCa|PKCa|PKCa|PKCa	GeneOrGeneProduct	2:78:95:101:144:183:220:251:290:300	5:79:98:102:145:184:221:252:291:301	0:3:4:4:5:6:9:10:11:12	D008094	lithium|Lithium|lithium|lithium|lithium|lithium|Lithium|lithium|lithium|lithium|lithium|lithium	ChemicalEntity	6:13:42:90:117:201:206:243:280:287:312:327	7:14:43:91:118:202:207:244:281:288:313:328	0:1:2:3:4:8:9:10:11:11:12:12	1:Positive_Correlation:2	L2R	NON-CROSS	2-5	9-12	18750	PKC - alpha|PKC|PKC - alpha|PKCa|PKCa|PKCa|PKCa|PKCa|PKCa|PKCa	GeneOrGeneProduct	2:78:95:101:144:183:220:251:290:300	5:79:98:102:145:184:221:252:291:301	0:3:4:4:5:6:9:10:11:12	D018500	nephrogenic diabetes insipidus|nephrogenic diabetes insipidus|NDI|NDI	DiseaseOrPhenotypicFeature	9:20:24:315	12:23:25:316	0:1:1:12	1:NR:2	L2R	CROSS	46-47	78-79	18750	PKC - alpha|PKC|PKC - alpha|PKCa|PKCa|PKCa|PKCa|PKCa|PKCa|PKCa	GeneOrGeneProduct	2:78:95:101:144:183:220:251:290:300	5:79:98:102:145:184:221:252:291:301	0:3:4:4:5:6:9:10:11:12	D000242	cAMP	ChemicalEntity	46	47	2	1:Negative_Correlation:2	L2R	NON-CROSS	300-301	304-307	18750	PKC - alpha|PKC|PKC - alpha|PKCa|PKCa|PKCa|PKCa|PKCa|PKCa|PKCa	GeneOrGeneProduct	2:78:95:101:144:183:220:251:290:300	5:79:98:102:145:184:221:252:291:301	0:3:4:4:5:6:9:10:11:12	27411	urea transporter|UT - A1|UT - A1|UT - A1|UT - A1|UT - A1	GeneOrGeneProduct	51:54:191:234:264:304	53:57:194:237:267:307	2:2:7:10:10:12	1:Negative_Correlation:2	R2L	NON-CROSS	302-303	300-301	11827	AQP2|AQP2|AQP2|AQP2|AQP2|AQP2	GeneOrGeneProduct	62:161:179:232:255:302	63:162:180:233:256:303	2:6:6:10:10:12	18750	PKC - alpha|PKC|PKC - alpha|PKCa|PKCa|PKCa|PKCa|PKCa|PKCa|PKCa	GeneOrGeneProduct	2:78:95:101:144:183:220:251:290:300	5:79:98:102:145:184:221:252:291:301	0:3:4:4:5:6:9:10:11:12	1:Association:2	R2L	NON-CROSS	95-98	93-94	D011141	polyuria|polyuria	DiseaseOrPhenotypicFeature	93:324	94:325	3:12	18750	PKC - alpha|PKC|PKC - alpha|PKCa|PKCa|PKCa|PKCa|PKCa|PKCa|PKCa	GeneOrGeneProduct	2:78:95:101:144:183:220:251:290:300	5:79:98:102:145:184:221:252:291:301	0:3:4:4:5:6:9:10:11:12	1:NR:2	L2R	NON-CROSS	272-273	290-291	18750	PKC - alpha|PKC|PKC - alpha|PKCa|PKCa|PKCa|PKCa|PKCa|PKCa|PKCa	GeneOrGeneProduct	2:78:95:101:144:183:220:251:290:300	5:79:98:102:145:184:221:252:291:301	0:3:4:4:5:6:9:10:11:12	D012964	sodium	ChemicalEntity	272	273	11	1:NR:2	L2R	NON-CROSS	274-275	290-291	18750	PKC - alpha|PKC|PKC - alpha|PKCa|PKCa|PKCa|PKCa|PKCa|PKCa|PKCa	GeneOrGeneProduct	2:78:95:101:144:183:220:251:290:300	5:79:98:102:145:184:221:252:291:301	0:3:4:4:5:6:9:10:11:12	D011188	potassium	ChemicalEntity	274	275	11	1:NR:2	L2R	NON-CROSS	276-277	290-291	18750	PKC - alpha|PKC|PKC - alpha|PKCa|PKCa|PKCa|PKCa|PKCa|PKCa|PKCa	GeneOrGeneProduct	2:78:95:101:144:183:220:251:290:300	5:79:98:102:145:184:221:252:291:301	0:3:4:4:5:6:9:10:11:12	D002118	calcium	ChemicalEntity	276	277	11	1:Positive_Correlation:2	L2R	NON-CROSS	312-313	315-316	D008094	lithium|Lithium|lithium|lithium|lithium|lithium|Lithium|lithium|lithium|lithium|lithium|lithium	ChemicalEntity	6:13:42:90:117:201:206:243:280:287:312:327	7:14:43:91:118:202:207:244:281:288:313:328	0:1:2:3:4:8:9:10:11:11:12:12	D018500	nephrogenic diabetes insipidus|nephrogenic diabetes insipidus|NDI|NDI	DiseaseOrPhenotypicFeature	9:20:24:315	12:23:25:316	0:1:1:12	1:NR:2	L2R	NON-CROSS	42-43	46-47	D008094	lithium|Lithium|lithium|lithium|lithium|lithium|Lithium|lithium|lithium|lithium|lithium|lithium	ChemicalEntity	6:13:42:90:117:201:206:243:280:287:312:327	7:14:43:91:118:202:207:244:281:288:313:328	0:1:2:3:4:8:9:10:11:11:12:12	D000242	cAMP	ChemicalEntity	46	47	2	1:Negative_Correlation:2	R2L	NON-CROSS	312-313	304-307	27411	urea transporter|UT - A1|UT - A1|UT - A1|UT - A1|UT - A1	GeneOrGeneProduct	51:54:191:234:264:304	53:57:194:237:267:307	2:2:7:10:10:12	D008094	lithium|Lithium|lithium|lithium|lithium|lithium|Lithium|lithium|lithium|lithium|lithium|lithium	ChemicalEntity	6:13:42:90:117:201:206:243:280:287:312:327	7:14:43:91:118:202:207:244:281:288:313:328	0:1:2:3:4:8:9:10:11:11:12:12	1:Negative_Correlation:2	L2R	NON-CROSS	302-303	312-313	D008094	lithium|Lithium|lithium|lithium|lithium|lithium|Lithium|lithium|lithium|lithium|lithium|lithium	ChemicalEntity	6:13:42:90:117:201:206:243:280:287:312:327	7:14:43:91:118:202:207:244:281:288:313:328	0:1:2:3:4:8:9:10:11:11:12:12	11827	AQP2|AQP2|AQP2|AQP2|AQP2|AQP2	GeneOrGeneProduct	62:161:179:232:255:302	63:162:180:233:256:303	2:6:6:10:10:12	1:Positive_Correlation:2	L2R	NON-CROSS	90-91	93-94	D008094	lithium|Lithium|lithium|lithium|lithium|lithium|Lithium|lithium|lithium|lithium|lithium|lithium	ChemicalEntity	6:13:42:90:117:201:206:243:280:287:312:327	7:14:43:91:118:202:207:244:281:288:313:328	0:1:2:3:4:8:9:10:11:11:12:12	D011141	polyuria|polyuria	DiseaseOrPhenotypicFeature	93:324	94:325	3:12	1:Association:2	L2R	NON-CROSS	272-273	280-281	D008094	lithium|Lithium|lithium|lithium|lithium|lithium|Lithium|lithium|lithium|lithium|lithium|lithium	ChemicalEntity	6:13:42:90:117:201:206:243:280:287:312:327	7:14:43:91:118:202:207:244:281:288:313:328	0:1:2:3:4:8:9:10:11:11:12:12	D012964	sodium	ChemicalEntity	272	273	11	1:Association:2	L2R	NON-CROSS	274-275	280-281	D008094	lithium|Lithium|lithium|lithium|lithium|lithium|Lithium|lithium|lithium|lithium|lithium|lithium	ChemicalEntity	6:13:42:90:117:201:206:243:280:287:312:327	7:14:43:91:118:202:207:244:281:288:313:328	0:1:2:3:4:8:9:10:11:11:12:12	D011188	potassium	ChemicalEntity	274	275	11	1:Association:2	R2L	NON-CROSS	280-281	276-277	D002118	calcium	ChemicalEntity	276	277	11	D008094	lithium|Lithium|lithium|lithium|lithium|lithium|Lithium|lithium|lithium|lithium|lithium|lithium	ChemicalEntity	6:13:42:90:117:201:206:243:280:287:312:327	7:14:43:91:118:202:207:244:281:288:313:328	0:1:2:3:4:8:9:10:11:11:12:12	1:NR:2	L2R	CROSS	24-25	46-47	D018500	nephrogenic diabetes insipidus|nephrogenic diabetes insipidus|NDI|NDI	DiseaseOrPhenotypicFeature	9:20:24:315	12:23:25:316	0:1:1:12	D000242	cAMP	ChemicalEntity	46	47	2	1:NR:2	L2R	NON-CROSS	304-307	315-316	D018500	nephrogenic diabetes insipidus|nephrogenic diabetes insipidus|NDI|NDI	DiseaseOrPhenotypicFeature	9:20:24:315	12:23:25:316	0:1:1:12	27411	urea transporter|UT - A1|UT - A1|UT - A1|UT - A1|UT - A1	GeneOrGeneProduct	51:54:191:234:264:304	53:57:194:237:267:307	2:2:7:10:10:12	1:NR:2	L2R	NON-CROSS	302-303	315-316	D018500	nephrogenic diabetes insipidus|nephrogenic diabetes insipidus|NDI|NDI	DiseaseOrPhenotypicFeature	9:20:24:315	12:23:25:316	0:1:1:12	11827	AQP2|AQP2|AQP2|AQP2|AQP2|AQP2	GeneOrGeneProduct	62:161:179:232:255:302	63:162:180:233:256:303	2:6:6:10:10:12	1:NR:2	L2R	CROSS	272-273	315-316	D018500	nephrogenic diabetes insipidus|nephrogenic diabetes insipidus|NDI|NDI	DiseaseOrPhenotypicFeature	9:20:24:315	12:23:25:316	0:1:1:12	D012964	sodium	ChemicalEntity	272	273	11	1:NR:2	L2R	CROSS	274-275	315-316	D018500	nephrogenic diabetes insipidus|nephrogenic diabetes insipidus|NDI|NDI	DiseaseOrPhenotypicFeature	9:20:24:315	12:23:25:316	0:1:1:12	D011188	potassium	ChemicalEntity	274	275	11	1:NR:2	L2R	CROSS	276-277	315-316	D018500	nephrogenic diabetes insipidus|nephrogenic diabetes insipidus|NDI|NDI	DiseaseOrPhenotypicFeature	9:20:24:315	12:23:25:316	0:1:1:12	D002118	calcium	ChemicalEntity	276	277	11	1:NR:2	L2R	NON-CROSS	46-47	51-53	D000242	cAMP	ChemicalEntity	46	47	2	27411	urea transporter|UT - A1|UT - A1|UT - A1|UT - A1|UT - A1	GeneOrGeneProduct	51:54:191:234:264:304	53:57:194:237:267:307	2:2:7:10:10:12	1:NR:2	L2R	NON-CROSS	46-47	62-63	D000242	cAMP	ChemicalEntity	46	47	2	11827	AQP2|AQP2|AQP2|AQP2|AQP2|AQP2	GeneOrGeneProduct	62:161:179:232:255:302	63:162:180:233:256:303	2:6:6:10:10:12	1:NR:2	L2R	CROSS	46-47	93-94	D000242	cAMP	ChemicalEntity	46	47	2	D011141	polyuria|polyuria	DiseaseOrPhenotypicFeature	93:324	94:325	3:12	1:NR:2	L2R	CROSS	46-47	272-273	D000242	cAMP	ChemicalEntity	46	47	2	D012964	sodium	ChemicalEntity	272	273	11	1:NR:2	L2R	CROSS	46-47	274-275	D000242	cAMP	ChemicalEntity	46	47	2	D011188	potassium	ChemicalEntity	274	275	11	1:NR:2	L2R	CROSS	46-47	276-277	D000242	cAMP	ChemicalEntity	46	47	2	D002118	calcium	ChemicalEntity	276	277	11	1:NR:2	L2R	NON-CROSS	302-303	304-307	27411	urea transporter|UT - A1|UT - A1|UT - A1|UT - A1|UT - A1	GeneOrGeneProduct	51:54:191:234:264:304	53:57:194:237:267:307	2:2:7:10:10:12	11827	AQP2|AQP2|AQP2|AQP2|AQP2|AQP2	GeneOrGeneProduct	62:161:179:232:255:302	63:162:180:233:256:303	2:6:6:10:10:12	1:NR:2	L2R	NON-CROSS	304-307	324-325	27411	urea transporter|UT - A1|UT - A1|UT - A1|UT - A1|UT - A1	GeneOrGeneProduct	51:54:191:234:264:304	53:57:194:237:267:307	2:2:7:10:10:12	D011141	polyuria|polyuria	DiseaseOrPhenotypicFeature	93:324	94:325	3:12	1:NR:2	L2R	CROSS	264-267	272-273	27411	urea transporter|UT - A1|UT - A1|UT - A1|UT - A1|UT - A1	GeneOrGeneProduct	51:54:191:234:264:304	53:57:194:237:267:307	2:2:7:10:10:12	D012964	sodium	ChemicalEntity	272	273	11	1:NR:2	L2R	CROSS	264-267	274-275	27411	urea transporter|UT - A1|UT - A1|UT - A1|UT - A1|UT - A1	GeneOrGeneProduct	51:54:191:234:264:304	53:57:194:237:267:307	2:2:7:10:10:12	D011188	potassium	ChemicalEntity	274	275	11	1:NR:2	L2R	CROSS	264-267	276-277	27411	urea transporter|UT - A1|UT - A1|UT - A1|UT - A1|UT - A1	GeneOrGeneProduct	51:54:191:234:264:304	53:57:194:237:267:307	2:2:7:10:10:12	D002118	calcium	ChemicalEntity	276	277	11	1:NR:2	L2R	NON-CROSS	302-303	324-325	11827	AQP2|AQP2|AQP2|AQP2|AQP2|AQP2	GeneOrGeneProduct	62:161:179:232:255:302	63:162:180:233:256:303	2:6:6:10:10:12	D011141	polyuria|polyuria	DiseaseOrPhenotypicFeature	93:324	94:325	3:12	1:NR:2	L2R	CROSS	255-256	272-273	11827	AQP2|AQP2|AQP2|AQP2|AQP2|AQP2	GeneOrGeneProduct	62:161:179:232:255:302	63:162:180:233:256:303	2:6:6:10:10:12	D012964	sodium	ChemicalEntity	272	273	11	1:NR:2	L2R	CROSS	255-256	274-275	11827	AQP2|AQP2|AQP2|AQP2|AQP2|AQP2	GeneOrGeneProduct	62:161:179:232:255:302	63:162:180:233:256:303	2:6:6:10:10:12	D011188	potassium	ChemicalEntity	274	275	11	1:NR:2	L2R	CROSS	255-256	276-277	11827	AQP2|AQP2|AQP2|AQP2|AQP2|AQP2	GeneOrGeneProduct	62:161:179:232:255:302	63:162:180:233:256:303	2:6:6:10:10:12	D002118	calcium	ChemicalEntity	276	277	11	1:NR:2	L2R	CROSS	272-273	324-325	D011141	polyuria|polyuria	DiseaseOrPhenotypicFeature	93:324	94:325	3:12	D012964	sodium	ChemicalEntity	272	273	11	1:NR:2	L2R	CROSS	274-275	324-325	D011141	polyuria|polyuria	DiseaseOrPhenotypicFeature	93:324	94:325	3:12	D011188	potassium	ChemicalEntity	274	275	11	1:NR:2	L2R	CROSS	276-277	324-325	D011141	polyuria|polyuria	DiseaseOrPhenotypicFeature	93:324	94:325	3:12	D002118	calcium	ChemicalEntity	276	277	11	1:NR:2	L2R	NON-CROSS	272-273	274-275	D012964	sodium	ChemicalEntity	272	273	11	D011188	potassium	ChemicalEntity	274	275	11	1:NR:2	L2R	NON-CROSS	272-273	276-277	D012964	sodium	ChemicalEntity	272	273	11	D002118	calcium	ChemicalEntity	276	277	11	1:NR:2	L2R	NON-CROSS	274-275	276-277	D011188	potassium	ChemicalEntity	274	275	11	D002118	calcium	ChemicalEntity	276	277	11
27464336	Decreased Whole - Body Fat Mass Produced by Chronic Alcohol Consumption is Associated with Activation of S6K1 - Mediated Protein Synthesis and Increased Autophagy in Epididymal White Adipose Tissue .|BACKGROUND : Chronic alcohol consumption leads to a loss of white adipose tissue ( WAT ) but the underlying mechanisms for this lipodystrophy are not fully elucidated .|This study tested the hypothesis that the reduction in WAT mass in chronic alcohol - fed mice is associated with a decreased protein synthesis specifically related to impaired function of mammalian target of rapamycin ( mTOR ) .|METHODS : Adult male mice were provided an alcohol - containing liquid diet for 24 weeks or an isonitrogenous isocaloric control diet .|In vivo protein synthesis was determined at this time and thereafter epididymal WAT ( eWAT ) was excised for analysis of signal transduction pathways central to controling protein synthesis and degradation .|RESULTS : While chronic alcohol feeding decreased whole - body and eWAT mass , this was associated with a discordant increase in protein synthesis in eWAT .|This increase was not associated with a change in mTOR , 4E - BP1 , Akt , or PRAS40 phosphorylation .|Instead , a selective increase in phosphorylation of S6K1 and its downstream substrates , S6 and eIF4B was detected in alcohol - fed mice .|Alcohol also increased eEF2K phosphorylation and decreased eEF2 phosphorylation consistent with increased translation elongation .|Alcohol increased Atg12 - 5 , LC3B - I and - II , and ULK1 S555 phosphorylation , suggesting increased autophagy , while markers of apoptosis ( cleaved caspase - 3 and - 9 , and PARP ) were unchanged .|Lipolytic enzymes ( ATGL and HSL phosphorylation ) were increased and lipogenic regulators ( PPARgamma and C / EBPalpha ) were decreased in eWAT by alcohol .|Although alcohol increased TNF - alpha , IL - 6 , and IL - 1beta mRNA , no change in key components of the NLRP3 inflammasome ( NLRP3 , ACS , and cleaved caspase - 1 ) was detected suggesting alcohol did not increase pyroptosis .|Plasma insulin did not differ between groups .|CONCLUSIONS : These results demonstrate that the alcohol - induced decrease in whole - body fat mass resulted in part from activation of autophagy in eWAT as protein synthesis was increased and mediated by the specific increase in the activity of S6K1 .	1:Association:2	L2R	NON-CROSS	9-10	16-17	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|Alcohol|Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	9:33:71:104:155:219:224:239:305:308:347:368	10:34:72:105:156:220:225:240:306:309:348:369	0:1:2:3:5:7:8:9:10:11:11:13	72508	S6K1|S6K1|S6K1	GeneOrGeneProduct	16:207:402	17:208:403	0:7:13	1:NR:2	L2R	NON-CROSS	33-34	52-53	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|Alcohol|Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	9:33:71:104:155:219:224:239:305:308:347:368	10:34:72:105:156:220:225:240:306:309:348:369	0:1:2:3:5:7:8:9:10:11:11:13	D008060	lipodystrophy	DiseaseOrPhenotypicFeature	52	53	1	1:NR:2	L2R	NON-CROSS	93-94	104-105	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|Alcohol|Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	9:33:71:104:155:219:224:239:305:308:347:368	10:34:72:105:156:220:225:240:306:309:348:369	0:1:2:3:5:7:8:9:10:11:11:13	56717	mammalian target of rapamycin|mTOR|mTOR	GeneOrGeneProduct	88:93:187	92:94:188	2:2:6	1:NR:2	L2R	CROSS	189-192	219-220	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|Alcohol|Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	9:33:71:104:155:219:224:239:305:308:347:368	10:34:72:105:156:220:225:240:306:309:348:369	0:1:2:3:5:7:8:9:10:11:11:13	13685	4E - BP1	GeneOrGeneProduct	189	192	6	1:NR:2	L2R	CROSS	193-194	219-220	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|Alcohol|Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	9:33:71:104:155:219:224:239:305:308:347:368	10:34:72:105:156:220:225:240:306:309:348:369	0:1:2:3:5:7:8:9:10:11:11:13	11651	Akt	GeneOrGeneProduct	193	194	6	1:NR:2	L2R	CROSS	196-197	219-220	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|Alcohol|Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	9:33:71:104:155:219:224:239:305:308:347:368	10:34:72:105:156:220:225:240:306:309:348:369	0:1:2:3:5:7:8:9:10:11:11:13	67605	PRAS40	GeneOrGeneProduct	196	197	6	1:Positive_Correlation:2	L2R	NON-CROSS	213-214	219-220	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|Alcohol|Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	9:33:71:104:155:219:224:239:305:308:347:368	10:34:72:105:156:220:225:240:306:309:348:369	0:1:2:3:5:7:8:9:10:11:11:13	20104	S6	GeneOrGeneProduct	213	214	7	1:Positive_Correlation:2	L2R	NON-CROSS	215-216	219-220	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|Alcohol|Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	9:33:71:104:155:219:224:239:305:308:347:368	10:34:72:105:156:220:225:240:306:309:348:369	0:1:2:3:5:7:8:9:10:11:11:13	75705	eIF4B	GeneOrGeneProduct	215	216	7	1:NR:2	L2R	NON-CROSS	224-225	227-228	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|Alcohol|Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	9:33:71:104:155:219:224:239:305:308:347:368	10:34:72:105:156:220:225:240:306:309:348:369	0:1:2:3:5:7:8:9:10:11:11:13	13631	eEF2K	GeneOrGeneProduct	227	228	8	1:NR:2	L2R	NON-CROSS	224-225	231-232	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|Alcohol|Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	9:33:71:104:155:219:224:239:305:308:347:368	10:34:72:105:156:220:225:240:306:309:348:369	0:1:2:3:5:7:8:9:10:11:11:13	13629	eEF2	GeneOrGeneProduct	231	232	8	1:NR:2	L2R	NON-CROSS	239-240	241-244	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|Alcohol|Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	9:33:71:104:155:219:224:239:305:308:347:368	10:34:72:105:156:220:225:240:306:309:348:369	0:1:2:3:5:7:8:9:10:11:11:13	11793,67526	Atg12 - 5	GeneOrGeneProduct	241	244	9	1:Positive_Correlation:2	L2R	NON-CROSS	239-240	245-251	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|Alcohol|Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	9:33:71:104:155:219:224:239:305:308:347:368	10:34:72:105:156:220:225:240:306:309:348:369	0:1:2:3:5:7:8:9:10:11:11:13	67443	LC3B - I and - II	GeneOrGeneProduct	245	251	9	1:Positive_Correlation:2	L2R	NON-CROSS	239-240	253-254	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|Alcohol|Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	9:33:71:104:155:219:224:239:305:308:347:368	10:34:72:105:156:220:225:240:306:309:348:369	0:1:2:3:5:7:8:9:10:11:11:13	22241	ULK1	GeneOrGeneProduct	253	254	9	1:NR:2	L2R	NON-CROSS	239-240	254-255	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|Alcohol|Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	9:33:71:104:155:219:224:239:305:308:347:368	10:34:72:105:156:220:225:240:306:309:348:369	0:1:2:3:5:7:8:9:10:11:11:13	p|Allele|S|555	S555	SequenceVariant	254	255	9	1:NR:2	L2R	NON-CROSS	239-240	267-273	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|Alcohol|Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	9:33:71:104:155:219:224:239:305:308:347:368	10:34:72:105:156:220:225:240:306:309:348:369	0:1:2:3:5:7:8:9:10:11:11:13	12367,12371	caspase - 3 and - 9	GeneOrGeneProduct	267	273	9	1:NR:2	L2R	NON-CROSS	275-276	305-306	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|Alcohol|Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	9:33:71:104:155:219:224:239:305:308:347:368	10:34:72:105:156:220:225:240:306:309:348:369	0:1:2:3:5:7:8:9:10:11:11:13	11545	PARP	GeneOrGeneProduct	275	276	9	1:Positive_Correlation:2	L2R	NON-CROSS	283-284	305-306	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|Alcohol|Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	9:33:71:104:155:219:224:239:305:308:347:368	10:34:72:105:156:220:225:240:306:309:348:369	0:1:2:3:5:7:8:9:10:11:11:13	66853	ATGL	GeneOrGeneProduct	283	284	10	1:Positive_Correlation:2	L2R	NON-CROSS	285-286	305-306	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|Alcohol|Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	9:33:71:104:155:219:224:239:305:308:347:368	10:34:72:105:156:220:225:240:306:309:348:369	0:1:2:3:5:7:8:9:10:11:11:13	16890	HSL	GeneOrGeneProduct	285	286	10	1:Negative_Correlation:2	L2R	NON-CROSS	294-295	305-306	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|Alcohol|Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	9:33:71:104:155:219:224:239:305:308:347:368	10:34:72:105:156:220:225:240:306:309:348:369	0:1:2:3:5:7:8:9:10:11:11:13	19016	PPARgamma	GeneOrGeneProduct	294	295	10	1:Negative_Correlation:2	L2R	NON-CROSS	296-299	305-306	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|Alcohol|Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	9:33:71:104:155:219:224:239:305:308:347:368	10:34:72:105:156:220:225:240:306:309:348:369	0:1:2:3:5:7:8:9:10:11:11:13	12606	C / EBPalpha	GeneOrGeneProduct	296	299	10	1:Positive_Correlation:2	L2R	NON-CROSS	308-309	310-313	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|Alcohol|Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	9:33:71:104:155:219:224:239:305:308:347:368	10:34:72:105:156:220:225:240:306:309:348:369	0:1:2:3:5:7:8:9:10:11:11:13	21926	TNF - alpha	GeneOrGeneProduct	310	313	11	1:Positive_Correlation:2	L2R	NON-CROSS	308-309	314-317	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|Alcohol|Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	9:33:71:104:155:219:224:239:305:308:347:368	10:34:72:105:156:220:225:240:306:309:348:369	0:1:2:3:5:7:8:9:10:11:11:13	16193	IL - 6	GeneOrGeneProduct	314	317	11	1:Positive_Correlation:2	L2R	NON-CROSS	308-309	319-322	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|Alcohol|Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	9:33:71:104:155:219:224:239:305:308:347:368	10:34:72:105:156:220:225:240:306:309:348:369	0:1:2:3:5:7:8:9:10:11:11:13	16176	IL - 1beta	GeneOrGeneProduct	319	322	11	1:NR:2	L2R	NON-CROSS	334-335	347-348	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|Alcohol|Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	9:33:71:104:155:219:224:239:305:308:347:368	10:34:72:105:156:220:225:240:306:309:348:369	0:1:2:3:5:7:8:9:10:11:11:13	216799	NLRP3|NLRP3	GeneOrGeneProduct	331:334	332:335	11:11	1:NR:2	L2R	NON-CROSS	336-337	347-348	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|Alcohol|Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	9:33:71:104:155:219:224:239:305:308:347:368	10:34:72:105:156:220:225:240:306:309:348:369	0:1:2:3:5:7:8:9:10:11:11:13	66824	ACS	GeneOrGeneProduct	336	337	11	1:NR:2	L2R	NON-CROSS	340-343	347-348	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|Alcohol|Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	9:33:71:104:155:219:224:239:305:308:347:368	10:34:72:105:156:220:225:240:306:309:348:369	0:1:2:3:5:7:8:9:10:11:11:13	12362	caspase - 1	GeneOrGeneProduct	340	343	11	1:NR:2	L2R	CROSS	347-348	354-355	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol|alcohol|Alcohol|Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	9:33:71:104:155:219:224:239:305:308:347:368	10:34:72:105:156:220:225:240:306:309:348:369	0:1:2:3:5:7:8:9:10:11:11:13	16334	insulin	GeneOrGeneProduct	354	355	12	1:NR:2	L2R	CROSS	16-17	52-53	72508	S6K1|S6K1|S6K1	GeneOrGeneProduct	16:207:402	17:208:403	0:7:13	D008060	lipodystrophy	DiseaseOrPhenotypicFeature	52	53	1	1:NR:2	L2R	CROSS	187-188	207-208	72508	S6K1|S6K1|S6K1	GeneOrGeneProduct	16:207:402	17:208:403	0:7:13	56717	mammalian target of rapamycin|mTOR|mTOR	GeneOrGeneProduct	88:93:187	92:94:188	2:2:6	1:NR:2	L2R	CROSS	189-192	207-208	72508	S6K1|S6K1|S6K1	GeneOrGeneProduct	16:207:402	17:208:403	0:7:13	13685	4E - BP1	GeneOrGeneProduct	189	192	6	1:NR:2	L2R	CROSS	193-194	207-208	72508	S6K1|S6K1|S6K1	GeneOrGeneProduct	16:207:402	17:208:403	0:7:13	11651	Akt	GeneOrGeneProduct	193	194	6	1:NR:2	L2R	CROSS	196-197	207-208	72508	S6K1|S6K1|S6K1	GeneOrGeneProduct	16:207:402	17:208:403	0:7:13	67605	PRAS40	GeneOrGeneProduct	196	197	6	1:NR:2	L2R	NON-CROSS	207-208	213-214	72508	S6K1|S6K1|S6K1	GeneOrGeneProduct	16:207:402	17:208:403	0:7:13	20104	S6	GeneOrGeneProduct	213	214	7	1:NR:2	L2R	NON-CROSS	207-208	215-216	72508	S6K1|S6K1|S6K1	GeneOrGeneProduct	16:207:402	17:208:403	0:7:13	75705	eIF4B	GeneOrGeneProduct	215	216	7	1:NR:2	L2R	CROSS	207-208	227-228	72508	S6K1|S6K1|S6K1	GeneOrGeneProduct	16:207:402	17:208:403	0:7:13	13631	eEF2K	GeneOrGeneProduct	227	228	8	1:NR:2	L2R	CROSS	207-208	231-232	72508	S6K1|S6K1|S6K1	GeneOrGeneProduct	16:207:402	17:208:403	0:7:13	13629	eEF2	GeneOrGeneProduct	231	232	8	1:NR:2	L2R	CROSS	207-208	241-244	72508	S6K1|S6K1|S6K1	GeneOrGeneProduct	16:207:402	17:208:403	0:7:13	11793,67526	Atg12 - 5	GeneOrGeneProduct	241	244	9	1:NR:2	L2R	CROSS	207-208	245-251	72508	S6K1|S6K1|S6K1	GeneOrGeneProduct	16:207:402	17:208:403	0:7:13	67443	LC3B - I and - II	GeneOrGeneProduct	245	251	9	1:NR:2	L2R	CROSS	207-208	253-254	72508	S6K1|S6K1|S6K1	GeneOrGeneProduct	16:207:402	17:208:403	0:7:13	22241	ULK1	GeneOrGeneProduct	253	254	9	1:NR:2	L2R	CROSS	207-208	267-273	72508	S6K1|S6K1|S6K1	GeneOrGeneProduct	16:207:402	17:208:403	0:7:13	12367,12371	caspase - 3 and - 9	GeneOrGeneProduct	267	273	9	1:NR:2	L2R	CROSS	207-208	275-276	72508	S6K1|S6K1|S6K1	GeneOrGeneProduct	16:207:402	17:208:403	0:7:13	11545	PARP	GeneOrGeneProduct	275	276	9	1:NR:2	L2R	CROSS	207-208	283-284	72508	S6K1|S6K1|S6K1	GeneOrGeneProduct	16:207:402	17:208:403	0:7:13	66853	ATGL	GeneOrGeneProduct	283	284	10	1:NR:2	L2R	CROSS	207-208	285-286	72508	S6K1|S6K1|S6K1	GeneOrGeneProduct	16:207:402	17:208:403	0:7:13	16890	HSL	GeneOrGeneProduct	285	286	10	1:NR:2	L2R	CROSS	207-208	294-295	72508	S6K1|S6K1|S6K1	GeneOrGeneProduct	16:207:402	17:208:403	0:7:13	19016	PPARgamma	GeneOrGeneProduct	294	295	10	1:NR:2	L2R	CROSS	207-208	296-299	72508	S6K1|S6K1|S6K1	GeneOrGeneProduct	16:207:402	17:208:403	0:7:13	12606	C / EBPalpha	GeneOrGeneProduct	296	299	10	1:NR:2	L2R	CROSS	310-313	402-403	72508	S6K1|S6K1|S6K1	GeneOrGeneProduct	16:207:402	17:208:403	0:7:13	21926	TNF - alpha	GeneOrGeneProduct	310	313	11	1:NR:2	L2R	CROSS	314-317	402-403	72508	S6K1|S6K1|S6K1	GeneOrGeneProduct	16:207:402	17:208:403	0:7:13	16193	IL - 6	GeneOrGeneProduct	314	317	11	1:NR:2	L2R	CROSS	319-322	402-403	72508	S6K1|S6K1|S6K1	GeneOrGeneProduct	16:207:402	17:208:403	0:7:13	16176	IL - 1beta	GeneOrGeneProduct	319	322	11	1:NR:2	L2R	CROSS	334-335	402-403	72508	S6K1|S6K1|S6K1	GeneOrGeneProduct	16:207:402	17:208:403	0:7:13	216799	NLRP3|NLRP3	GeneOrGeneProduct	331:334	332:335	11:11	1:NR:2	L2R	CROSS	336-337	402-403	72508	S6K1|S6K1|S6K1	GeneOrGeneProduct	16:207:402	17:208:403	0:7:13	66824	ACS	GeneOrGeneProduct	336	337	11	1:NR:2	L2R	CROSS	340-343	402-403	72508	S6K1|S6K1|S6K1	GeneOrGeneProduct	16:207:402	17:208:403	0:7:13	12362	caspase - 1	GeneOrGeneProduct	340	343	11	1:NR:2	L2R	CROSS	354-355	402-403	72508	S6K1|S6K1|S6K1	GeneOrGeneProduct	16:207:402	17:208:403	0:7:13	16334	insulin	GeneOrGeneProduct	354	355	12	1:NR:2	L2R	CROSS	52-53	88-92	D008060	lipodystrophy	DiseaseOrPhenotypicFeature	52	53	1	56717	mammalian target of rapamycin|mTOR|mTOR	GeneOrGeneProduct	88:93:187	92:94:188	2:2:6	1:NR:2	L2R	CROSS	52-53	189-192	D008060	lipodystrophy	DiseaseOrPhenotypicFeature	52	53	1	13685	4E - BP1	GeneOrGeneProduct	189	192	6	1:NR:2	L2R	CROSS	52-53	193-194	D008060	lipodystrophy	DiseaseOrPhenotypicFeature	52	53	1	11651	Akt	GeneOrGeneProduct	193	194	6	1:NR:2	L2R	CROSS	52-53	196-197	D008060	lipodystrophy	DiseaseOrPhenotypicFeature	52	53	1	67605	PRAS40	GeneOrGeneProduct	196	197	6	1:NR:2	L2R	CROSS	52-53	213-214	D008060	lipodystrophy	DiseaseOrPhenotypicFeature	52	53	1	20104	S6	GeneOrGeneProduct	213	214	7	1:NR:2	L2R	CROSS	52-53	215-216	D008060	lipodystrophy	DiseaseOrPhenotypicFeature	52	53	1	75705	eIF4B	GeneOrGeneProduct	215	216	7	1:NR:2	L2R	CROSS	52-53	227-228	D008060	lipodystrophy	DiseaseOrPhenotypicFeature	52	53	1	13631	eEF2K	GeneOrGeneProduct	227	228	8	1:NR:2	L2R	CROSS	52-53	231-232	D008060	lipodystrophy	DiseaseOrPhenotypicFeature	52	53	1	13629	eEF2	GeneOrGeneProduct	231	232	8	1:NR:2	L2R	CROSS	52-53	241-244	D008060	lipodystrophy	DiseaseOrPhenotypicFeature	52	53	1	11793,67526	Atg12 - 5	GeneOrGeneProduct	241	244	9	1:NR:2	L2R	CROSS	52-53	245-251	D008060	lipodystrophy	DiseaseOrPhenotypicFeature	52	53	1	67443	LC3B - I and - II	GeneOrGeneProduct	245	251	9	1:NR:2	L2R	CROSS	52-53	253-254	D008060	lipodystrophy	DiseaseOrPhenotypicFeature	52	53	1	22241	ULK1	GeneOrGeneProduct	253	254	9	1:NR:2	L2R	CROSS	52-53	254-255	D008060	lipodystrophy	DiseaseOrPhenotypicFeature	52	53	1	p|Allele|S|555	S555	SequenceVariant	254	255	9	1:NR:2	L2R	CROSS	52-53	267-273	D008060	lipodystrophy	DiseaseOrPhenotypicFeature	52	53	1	12367,12371	caspase - 3 and - 9	GeneOrGeneProduct	267	273	9	1:NR:2	L2R	CROSS	52-53	275-276	D008060	lipodystrophy	DiseaseOrPhenotypicFeature	52	53	1	11545	PARP	GeneOrGeneProduct	275	276	9	1:NR:2	L2R	CROSS	52-53	283-284	D008060	lipodystrophy	DiseaseOrPhenotypicFeature	52	53	1	66853	ATGL	GeneOrGeneProduct	283	284	10	1:NR:2	L2R	CROSS	52-53	285-286	D008060	lipodystrophy	DiseaseOrPhenotypicFeature	52	53	1	16890	HSL	GeneOrGeneProduct	285	286	10	1:NR:2	L2R	CROSS	52-53	294-295	D008060	lipodystrophy	DiseaseOrPhenotypicFeature	52	53	1	19016	PPARgamma	GeneOrGeneProduct	294	295	10	1:NR:2	L2R	CROSS	52-53	296-299	D008060	lipodystrophy	DiseaseOrPhenotypicFeature	52	53	1	12606	C / EBPalpha	GeneOrGeneProduct	296	299	10	1:NR:2	L2R	CROSS	52-53	310-313	D008060	lipodystrophy	DiseaseOrPhenotypicFeature	52	53	1	21926	TNF - alpha	GeneOrGeneProduct	310	313	11	1:NR:2	L2R	CROSS	52-53	314-317	D008060	lipodystrophy	DiseaseOrPhenotypicFeature	52	53	1	16193	IL - 6	GeneOrGeneProduct	314	317	11	1:NR:2	L2R	CROSS	52-53	319-322	D008060	lipodystrophy	DiseaseOrPhenotypicFeature	52	53	1	16176	IL - 1beta	GeneOrGeneProduct	319	322	11	1:NR:2	L2R	CROSS	52-53	331-332	D008060	lipodystrophy	DiseaseOrPhenotypicFeature	52	53	1	216799	NLRP3|NLRP3	GeneOrGeneProduct	331:334	332:335	11:11	1:NR:2	L2R	CROSS	52-53	336-337	D008060	lipodystrophy	DiseaseOrPhenotypicFeature	52	53	1	66824	ACS	GeneOrGeneProduct	336	337	11	1:NR:2	L2R	CROSS	52-53	340-343	D008060	lipodystrophy	DiseaseOrPhenotypicFeature	52	53	1	12362	caspase - 1	GeneOrGeneProduct	340	343	11	1:NR:2	L2R	CROSS	52-53	354-355	D008060	lipodystrophy	DiseaseOrPhenotypicFeature	52	53	1	16334	insulin	GeneOrGeneProduct	354	355	12	1:NR:2	L2R	NON-CROSS	187-188	189-192	56717	mammalian target of rapamycin|mTOR|mTOR	GeneOrGeneProduct	88:93:187	92:94:188	2:2:6	13685	4E - BP1	GeneOrGeneProduct	189	192	6	1:NR:2	L2R	NON-CROSS	187-188	193-194	56717	mammalian target of rapamycin|mTOR|mTOR	GeneOrGeneProduct	88:93:187	92:94:188	2:2:6	11651	Akt	GeneOrGeneProduct	193	194	6	1:NR:2	L2R	NON-CROSS	187-188	196-197	56717	mammalian target of rapamycin|mTOR|mTOR	GeneOrGeneProduct	88:93:187	92:94:188	2:2:6	67605	PRAS40	GeneOrGeneProduct	196	197	6	1:NR:2	L2R	CROSS	187-188	213-214	56717	mammalian target of rapamycin|mTOR|mTOR	GeneOrGeneProduct	88:93:187	92:94:188	2:2:6	20104	S6	GeneOrGeneProduct	213	214	7	1:NR:2	L2R	CROSS	187-188	215-216	56717	mammalian target of rapamycin|mTOR|mTOR	GeneOrGeneProduct	88:93:187	92:94:188	2:2:6	75705	eIF4B	GeneOrGeneProduct	215	216	7	1:NR:2	L2R	CROSS	187-188	227-228	56717	mammalian target of rapamycin|mTOR|mTOR	GeneOrGeneProduct	88:93:187	92:94:188	2:2:6	13631	eEF2K	GeneOrGeneProduct	227	228	8	1:NR:2	L2R	CROSS	187-188	231-232	56717	mammalian target of rapamycin|mTOR|mTOR	GeneOrGeneProduct	88:93:187	92:94:188	2:2:6	13629	eEF2	GeneOrGeneProduct	231	232	8	1:NR:2	L2R	CROSS	187-188	241-244	56717	mammalian target of rapamycin|mTOR|mTOR	GeneOrGeneProduct	88:93:187	92:94:188	2:2:6	11793,67526	Atg12 - 5	GeneOrGeneProduct	241	244	9	1:NR:2	L2R	CROSS	187-188	245-251	56717	mammalian target of rapamycin|mTOR|mTOR	GeneOrGeneProduct	88:93:187	92:94:188	2:2:6	67443	LC3B - I and - II	GeneOrGeneProduct	245	251	9	1:NR:2	L2R	CROSS	187-188	253-254	56717	mammalian target of rapamycin|mTOR|mTOR	GeneOrGeneProduct	88:93:187	92:94:188	2:2:6	22241	ULK1	GeneOrGeneProduct	253	254	9	1:NR:2	L2R	CROSS	187-188	267-273	56717	mammalian target of rapamycin|mTOR|mTOR	GeneOrGeneProduct	88:93:187	92:94:188	2:2:6	12367,12371	caspase - 3 and - 9	GeneOrGeneProduct	267	273	9	1:NR:2	L2R	CROSS	187-188	275-276	56717	mammalian target of rapamycin|mTOR|mTOR	GeneOrGeneProduct	88:93:187	92:94:188	2:2:6	11545	PARP	GeneOrGeneProduct	275	276	9	1:NR:2	L2R	CROSS	187-188	283-284	56717	mammalian target of rapamycin|mTOR|mTOR	GeneOrGeneProduct	88:93:187	92:94:188	2:2:6	66853	ATGL	GeneOrGeneProduct	283	284	10	1:NR:2	L2R	CROSS	187-188	285-286	56717	mammalian target of rapamycin|mTOR|mTOR	GeneOrGeneProduct	88:93:187	92:94:188	2:2:6	16890	HSL	GeneOrGeneProduct	285	286	10	1:NR:2	L2R	CROSS	187-188	294-295	56717	mammalian target of rapamycin|mTOR|mTOR	GeneOrGeneProduct	88:93:187	92:94:188	2:2:6	19016	PPARgamma	GeneOrGeneProduct	294	295	10	1:NR:2	L2R	CROSS	187-188	296-299	56717	mammalian target of rapamycin|mTOR|mTOR	GeneOrGeneProduct	88:93:187	92:94:188	2:2:6	12606	C / EBPalpha	GeneOrGeneProduct	296	299	10	1:NR:2	L2R	CROSS	187-188	310-313	56717	mammalian target of rapamycin|mTOR|mTOR	GeneOrGeneProduct	88:93:187	92:94:188	2:2:6	21926	TNF - alpha	GeneOrGeneProduct	310	313	11	1:NR:2	L2R	CROSS	187-188	314-317	56717	mammalian target of rapamycin|mTOR|mTOR	GeneOrGeneProduct	88:93:187	92:94:188	2:2:6	16193	IL - 6	GeneOrGeneProduct	314	317	11	1:NR:2	L2R	CROSS	187-188	319-322	56717	mammalian target of rapamycin|mTOR|mTOR	GeneOrGeneProduct	88:93:187	92:94:188	2:2:6	16176	IL - 1beta	GeneOrGeneProduct	319	322	11	1:NR:2	L2R	CROSS	187-188	331-332	56717	mammalian target of rapamycin|mTOR|mTOR	GeneOrGeneProduct	88:93:187	92:94:188	2:2:6	216799	NLRP3|NLRP3	GeneOrGeneProduct	331:334	332:335	11:11	1:NR:2	L2R	CROSS	187-188	336-337	56717	mammalian target of rapamycin|mTOR|mTOR	GeneOrGeneProduct	88:93:187	92:94:188	2:2:6	66824	ACS	GeneOrGeneProduct	336	337	11	1:NR:2	L2R	CROSS	187-188	340-343	56717	mammalian target of rapamycin|mTOR|mTOR	GeneOrGeneProduct	88:93:187	92:94:188	2:2:6	12362	caspase - 1	GeneOrGeneProduct	340	343	11	1:NR:2	L2R	CROSS	187-188	354-355	56717	mammalian target of rapamycin|mTOR|mTOR	GeneOrGeneProduct	88:93:187	92:94:188	2:2:6	16334	insulin	GeneOrGeneProduct	354	355	12	1:NR:2	L2R	NON-CROSS	189-192	193-194	13685	4E - BP1	GeneOrGeneProduct	189	192	6	11651	Akt	GeneOrGeneProduct	193	194	6	1:NR:2	L2R	NON-CROSS	189-192	196-197	13685	4E - BP1	GeneOrGeneProduct	189	192	6	67605	PRAS40	GeneOrGeneProduct	196	197	6	1:NR:2	L2R	CROSS	189-192	213-214	13685	4E - BP1	GeneOrGeneProduct	189	192	6	20104	S6	GeneOrGeneProduct	213	214	7	1:NR:2	L2R	CROSS	189-192	215-216	13685	4E - BP1	GeneOrGeneProduct	189	192	6	75705	eIF4B	GeneOrGeneProduct	215	216	7	1:NR:2	L2R	CROSS	189-192	227-228	13685	4E - BP1	GeneOrGeneProduct	189	192	6	13631	eEF2K	GeneOrGeneProduct	227	228	8	1:NR:2	L2R	CROSS	189-192	231-232	13685	4E - BP1	GeneOrGeneProduct	189	192	6	13629	eEF2	GeneOrGeneProduct	231	232	8	1:NR:2	L2R	CROSS	189-192	241-244	13685	4E - BP1	GeneOrGeneProduct	189	192	6	11793,67526	Atg12 - 5	GeneOrGeneProduct	241	244	9	1:NR:2	L2R	CROSS	189-192	245-251	13685	4E - BP1	GeneOrGeneProduct	189	192	6	67443	LC3B - I and - II	GeneOrGeneProduct	245	251	9	1:NR:2	L2R	CROSS	189-192	253-254	13685	4E - BP1	GeneOrGeneProduct	189	192	6	22241	ULK1	GeneOrGeneProduct	253	254	9	1:NR:2	L2R	CROSS	189-192	267-273	13685	4E - BP1	GeneOrGeneProduct	189	192	6	12367,12371	caspase - 3 and - 9	GeneOrGeneProduct	267	273	9	1:NR:2	L2R	CROSS	189-192	275-276	13685	4E - BP1	GeneOrGeneProduct	189	192	6	11545	PARP	GeneOrGeneProduct	275	276	9	1:NR:2	L2R	CROSS	189-192	283-284	13685	4E - BP1	GeneOrGeneProduct	189	192	6	66853	ATGL	GeneOrGeneProduct	283	284	10	1:NR:2	L2R	CROSS	189-192	285-286	13685	4E - BP1	GeneOrGeneProduct	189	192	6	16890	HSL	GeneOrGeneProduct	285	286	10	1:NR:2	L2R	CROSS	189-192	294-295	13685	4E - BP1	GeneOrGeneProduct	189	192	6	19016	PPARgamma	GeneOrGeneProduct	294	295	10	1:NR:2	L2R	CROSS	189-192	296-299	13685	4E - BP1	GeneOrGeneProduct	189	192	6	12606	C / EBPalpha	GeneOrGeneProduct	296	299	10	1:NR:2	L2R	CROSS	189-192	310-313	13685	4E - BP1	GeneOrGeneProduct	189	192	6	21926	TNF - alpha	GeneOrGeneProduct	310	313	11	1:NR:2	L2R	CROSS	189-192	314-317	13685	4E - BP1	GeneOrGeneProduct	189	192	6	16193	IL - 6	GeneOrGeneProduct	314	317	11	1:NR:2	L2R	CROSS	189-192	319-322	13685	4E - BP1	GeneOrGeneProduct	189	192	6	16176	IL - 1beta	GeneOrGeneProduct	319	322	11	1:NR:2	L2R	CROSS	189-192	331-332	13685	4E - BP1	GeneOrGeneProduct	189	192	6	216799	NLRP3|NLRP3	GeneOrGeneProduct	331:334	332:335	11:11	1:NR:2	L2R	CROSS	189-192	336-337	13685	4E - BP1	GeneOrGeneProduct	189	192	6	66824	ACS	GeneOrGeneProduct	336	337	11	1:NR:2	L2R	CROSS	189-192	340-343	13685	4E - BP1	GeneOrGeneProduct	189	192	6	12362	caspase - 1	GeneOrGeneProduct	340	343	11	1:NR:2	L2R	CROSS	189-192	354-355	13685	4E - BP1	GeneOrGeneProduct	189	192	6	16334	insulin	GeneOrGeneProduct	354	355	12	1:NR:2	L2R	NON-CROSS	193-194	196-197	11651	Akt	GeneOrGeneProduct	193	194	6	67605	PRAS40	GeneOrGeneProduct	196	197	6	1:NR:2	L2R	CROSS	193-194	213-214	11651	Akt	GeneOrGeneProduct	193	194	6	20104	S6	GeneOrGeneProduct	213	214	7	1:NR:2	L2R	CROSS	193-194	215-216	11651	Akt	GeneOrGeneProduct	193	194	6	75705	eIF4B	GeneOrGeneProduct	215	216	7	1:NR:2	L2R	CROSS	193-194	227-228	11651	Akt	GeneOrGeneProduct	193	194	6	13631	eEF2K	GeneOrGeneProduct	227	228	8	1:NR:2	L2R	CROSS	193-194	231-232	11651	Akt	GeneOrGeneProduct	193	194	6	13629	eEF2	GeneOrGeneProduct	231	232	8	1:NR:2	L2R	CROSS	193-194	241-244	11651	Akt	GeneOrGeneProduct	193	194	6	11793,67526	Atg12 - 5	GeneOrGeneProduct	241	244	9	1:NR:2	L2R	CROSS	193-194	245-251	11651	Akt	GeneOrGeneProduct	193	194	6	67443	LC3B - I and - II	GeneOrGeneProduct	245	251	9	1:NR:2	L2R	CROSS	193-194	253-254	11651	Akt	GeneOrGeneProduct	193	194	6	22241	ULK1	GeneOrGeneProduct	253	254	9	1:NR:2	L2R	CROSS	193-194	267-273	11651	Akt	GeneOrGeneProduct	193	194	6	12367,12371	caspase - 3 and - 9	GeneOrGeneProduct	267	273	9	1:NR:2	L2R	CROSS	193-194	275-276	11651	Akt	GeneOrGeneProduct	193	194	6	11545	PARP	GeneOrGeneProduct	275	276	9	1:NR:2	L2R	CROSS	193-194	283-284	11651	Akt	GeneOrGeneProduct	193	194	6	66853	ATGL	GeneOrGeneProduct	283	284	10	1:NR:2	L2R	CROSS	193-194	285-286	11651	Akt	GeneOrGeneProduct	193	194	6	16890	HSL	GeneOrGeneProduct	285	286	10	1:NR:2	L2R	CROSS	193-194	294-295	11651	Akt	GeneOrGeneProduct	193	194	6	19016	PPARgamma	GeneOrGeneProduct	294	295	10	1:NR:2	L2R	CROSS	193-194	296-299	11651	Akt	GeneOrGeneProduct	193	194	6	12606	C / EBPalpha	GeneOrGeneProduct	296	299	10	1:NR:2	L2R	CROSS	193-194	310-313	11651	Akt	GeneOrGeneProduct	193	194	6	21926	TNF - alpha	GeneOrGeneProduct	310	313	11	1:NR:2	L2R	CROSS	193-194	314-317	11651	Akt	GeneOrGeneProduct	193	194	6	16193	IL - 6	GeneOrGeneProduct	314	317	11	1:NR:2	L2R	CROSS	193-194	319-322	11651	Akt	GeneOrGeneProduct	193	194	6	16176	IL - 1beta	GeneOrGeneProduct	319	322	11	1:NR:2	L2R	CROSS	193-194	331-332	11651	Akt	GeneOrGeneProduct	193	194	6	216799	NLRP3|NLRP3	GeneOrGeneProduct	331:334	332:335	11:11	1:NR:2	L2R	CROSS	193-194	336-337	11651	Akt	GeneOrGeneProduct	193	194	6	66824	ACS	GeneOrGeneProduct	336	337	11	1:NR:2	L2R	CROSS	193-194	340-343	11651	Akt	GeneOrGeneProduct	193	194	6	12362	caspase - 1	GeneOrGeneProduct	340	343	11	1:NR:2	L2R	CROSS	193-194	354-355	11651	Akt	GeneOrGeneProduct	193	194	6	16334	insulin	GeneOrGeneProduct	354	355	12	1:NR:2	L2R	CROSS	196-197	213-214	67605	PRAS40	GeneOrGeneProduct	196	197	6	20104	S6	GeneOrGeneProduct	213	214	7	1:NR:2	L2R	CROSS	196-197	215-216	67605	PRAS40	GeneOrGeneProduct	196	197	6	75705	eIF4B	GeneOrGeneProduct	215	216	7	1:NR:2	L2R	CROSS	196-197	227-228	67605	PRAS40	GeneOrGeneProduct	196	197	6	13631	eEF2K	GeneOrGeneProduct	227	228	8	1:NR:2	L2R	CROSS	196-197	231-232	67605	PRAS40	GeneOrGeneProduct	196	197	6	13629	eEF2	GeneOrGeneProduct	231	232	8	1:NR:2	L2R	CROSS	196-197	241-244	67605	PRAS40	GeneOrGeneProduct	196	197	6	11793,67526	Atg12 - 5	GeneOrGeneProduct	241	244	9	1:NR:2	L2R	CROSS	196-197	245-251	67605	PRAS40	GeneOrGeneProduct	196	197	6	67443	LC3B - I and - II	GeneOrGeneProduct	245	251	9	1:NR:2	L2R	CROSS	196-197	253-254	67605	PRAS40	GeneOrGeneProduct	196	197	6	22241	ULK1	GeneOrGeneProduct	253	254	9	1:NR:2	L2R	CROSS	196-197	267-273	67605	PRAS40	GeneOrGeneProduct	196	197	6	12367,12371	caspase - 3 and - 9	GeneOrGeneProduct	267	273	9	1:NR:2	L2R	CROSS	196-197	275-276	67605	PRAS40	GeneOrGeneProduct	196	197	6	11545	PARP	GeneOrGeneProduct	275	276	9	1:NR:2	L2R	CROSS	196-197	283-284	67605	PRAS40	GeneOrGeneProduct	196	197	6	66853	ATGL	GeneOrGeneProduct	283	284	10	1:NR:2	L2R	CROSS	196-197	285-286	67605	PRAS40	GeneOrGeneProduct	196	197	6	16890	HSL	GeneOrGeneProduct	285	286	10	1:NR:2	L2R	CROSS	196-197	294-295	67605	PRAS40	GeneOrGeneProduct	196	197	6	19016	PPARgamma	GeneOrGeneProduct	294	295	10	1:NR:2	L2R	CROSS	196-197	296-299	67605	PRAS40	GeneOrGeneProduct	196	197	6	12606	C / EBPalpha	GeneOrGeneProduct	296	299	10	1:NR:2	L2R	CROSS	196-197	310-313	67605	PRAS40	GeneOrGeneProduct	196	197	6	21926	TNF - alpha	GeneOrGeneProduct	310	313	11	1:NR:2	L2R	CROSS	196-197	314-317	67605	PRAS40	GeneOrGeneProduct	196	197	6	16193	IL - 6	GeneOrGeneProduct	314	317	11	1:NR:2	L2R	CROSS	196-197	319-322	67605	PRAS40	GeneOrGeneProduct	196	197	6	16176	IL - 1beta	GeneOrGeneProduct	319	322	11	1:NR:2	L2R	CROSS	196-197	331-332	67605	PRAS40	GeneOrGeneProduct	196	197	6	216799	NLRP3|NLRP3	GeneOrGeneProduct	331:334	332:335	11:11	1:NR:2	L2R	CROSS	196-197	336-337	67605	PRAS40	GeneOrGeneProduct	196	197	6	66824	ACS	GeneOrGeneProduct	336	337	11	1:NR:2	L2R	CROSS	196-197	340-343	67605	PRAS40	GeneOrGeneProduct	196	197	6	12362	caspase - 1	GeneOrGeneProduct	340	343	11	1:NR:2	L2R	CROSS	196-197	354-355	67605	PRAS40	GeneOrGeneProduct	196	197	6	16334	insulin	GeneOrGeneProduct	354	355	12	1:NR:2	L2R	NON-CROSS	213-214	215-216	20104	S6	GeneOrGeneProduct	213	214	7	75705	eIF4B	GeneOrGeneProduct	215	216	7	1:NR:2	L2R	CROSS	213-214	227-228	20104	S6	GeneOrGeneProduct	213	214	7	13631	eEF2K	GeneOrGeneProduct	227	228	8	1:NR:2	L2R	CROSS	213-214	231-232	20104	S6	GeneOrGeneProduct	213	214	7	13629	eEF2	GeneOrGeneProduct	231	232	8	1:NR:2	L2R	CROSS	213-214	241-244	20104	S6	GeneOrGeneProduct	213	214	7	11793,67526	Atg12 - 5	GeneOrGeneProduct	241	244	9	1:NR:2	L2R	CROSS	213-214	245-251	20104	S6	GeneOrGeneProduct	213	214	7	67443	LC3B - I and - II	GeneOrGeneProduct	245	251	9	1:NR:2	L2R	CROSS	213-214	253-254	20104	S6	GeneOrGeneProduct	213	214	7	22241	ULK1	GeneOrGeneProduct	253	254	9	1:NR:2	L2R	CROSS	213-214	267-273	20104	S6	GeneOrGeneProduct	213	214	7	12367,12371	caspase - 3 and - 9	GeneOrGeneProduct	267	273	9	1:NR:2	L2R	CROSS	213-214	275-276	20104	S6	GeneOrGeneProduct	213	214	7	11545	PARP	GeneOrGeneProduct	275	276	9	1:NR:2	L2R	CROSS	213-214	283-284	20104	S6	GeneOrGeneProduct	213	214	7	66853	ATGL	GeneOrGeneProduct	283	284	10	1:NR:2	L2R	CROSS	213-214	285-286	20104	S6	GeneOrGeneProduct	213	214	7	16890	HSL	GeneOrGeneProduct	285	286	10	1:NR:2	L2R	CROSS	213-214	294-295	20104	S6	GeneOrGeneProduct	213	214	7	19016	PPARgamma	GeneOrGeneProduct	294	295	10	1:NR:2	L2R	CROSS	213-214	296-299	20104	S6	GeneOrGeneProduct	213	214	7	12606	C / EBPalpha	GeneOrGeneProduct	296	299	10	1:NR:2	L2R	CROSS	213-214	310-313	20104	S6	GeneOrGeneProduct	213	214	7	21926	TNF - alpha	GeneOrGeneProduct	310	313	11	1:NR:2	L2R	CROSS	213-214	314-317	20104	S6	GeneOrGeneProduct	213	214	7	16193	IL - 6	GeneOrGeneProduct	314	317	11	1:NR:2	L2R	CROSS	213-214	319-322	20104	S6	GeneOrGeneProduct	213	214	7	16176	IL - 1beta	GeneOrGeneProduct	319	322	11	1:NR:2	L2R	CROSS	213-214	331-332	20104	S6	GeneOrGeneProduct	213	214	7	216799	NLRP3|NLRP3	GeneOrGeneProduct	331:334	332:335	11:11	1:NR:2	L2R	CROSS	213-214	336-337	20104	S6	GeneOrGeneProduct	213	214	7	66824	ACS	GeneOrGeneProduct	336	337	11	1:NR:2	L2R	CROSS	213-214	340-343	20104	S6	GeneOrGeneProduct	213	214	7	12362	caspase - 1	GeneOrGeneProduct	340	343	11	1:NR:2	L2R	CROSS	213-214	354-355	20104	S6	GeneOrGeneProduct	213	214	7	16334	insulin	GeneOrGeneProduct	354	355	12	1:NR:2	L2R	CROSS	215-216	227-228	75705	eIF4B	GeneOrGeneProduct	215	216	7	13631	eEF2K	GeneOrGeneProduct	227	228	8	1:NR:2	L2R	CROSS	215-216	231-232	75705	eIF4B	GeneOrGeneProduct	215	216	7	13629	eEF2	GeneOrGeneProduct	231	232	8	1:NR:2	L2R	CROSS	215-216	241-244	75705	eIF4B	GeneOrGeneProduct	215	216	7	11793,67526	Atg12 - 5	GeneOrGeneProduct	241	244	9	1:NR:2	L2R	CROSS	215-216	245-251	75705	eIF4B	GeneOrGeneProduct	215	216	7	67443	LC3B - I and - II	GeneOrGeneProduct	245	251	9	1:NR:2	L2R	CROSS	215-216	253-254	75705	eIF4B	GeneOrGeneProduct	215	216	7	22241	ULK1	GeneOrGeneProduct	253	254	9	1:NR:2	L2R	CROSS	215-216	267-273	75705	eIF4B	GeneOrGeneProduct	215	216	7	12367,12371	caspase - 3 and - 9	GeneOrGeneProduct	267	273	9	1:NR:2	L2R	CROSS	215-216	275-276	75705	eIF4B	GeneOrGeneProduct	215	216	7	11545	PARP	GeneOrGeneProduct	275	276	9	1:NR:2	L2R	CROSS	215-216	283-284	75705	eIF4B	GeneOrGeneProduct	215	216	7	66853	ATGL	GeneOrGeneProduct	283	284	10	1:NR:2	L2R	CROSS	215-216	285-286	75705	eIF4B	GeneOrGeneProduct	215	216	7	16890	HSL	GeneOrGeneProduct	285	286	10	1:NR:2	L2R	CROSS	215-216	294-295	75705	eIF4B	GeneOrGeneProduct	215	216	7	19016	PPARgamma	GeneOrGeneProduct	294	295	10	1:NR:2	L2R	CROSS	215-216	296-299	75705	eIF4B	GeneOrGeneProduct	215	216	7	12606	C / EBPalpha	GeneOrGeneProduct	296	299	10	1:NR:2	L2R	CROSS	215-216	310-313	75705	eIF4B	GeneOrGeneProduct	215	216	7	21926	TNF - alpha	GeneOrGeneProduct	310	313	11	1:NR:2	L2R	CROSS	215-216	314-317	75705	eIF4B	GeneOrGeneProduct	215	216	7	16193	IL - 6	GeneOrGeneProduct	314	317	11	1:NR:2	L2R	CROSS	215-216	319-322	75705	eIF4B	GeneOrGeneProduct	215	216	7	16176	IL - 1beta	GeneOrGeneProduct	319	322	11	1:NR:2	L2R	CROSS	215-216	331-332	75705	eIF4B	GeneOrGeneProduct	215	216	7	216799	NLRP3|NLRP3	GeneOrGeneProduct	331:334	332:335	11:11	1:NR:2	L2R	CROSS	215-216	336-337	75705	eIF4B	GeneOrGeneProduct	215	216	7	66824	ACS	GeneOrGeneProduct	336	337	11	1:NR:2	L2R	CROSS	215-216	340-343	75705	eIF4B	GeneOrGeneProduct	215	216	7	12362	caspase - 1	GeneOrGeneProduct	340	343	11	1:NR:2	L2R	CROSS	215-216	354-355	75705	eIF4B	GeneOrGeneProduct	215	216	7	16334	insulin	GeneOrGeneProduct	354	355	12	1:NR:2	L2R	NON-CROSS	227-228	231-232	13631	eEF2K	GeneOrGeneProduct	227	228	8	13629	eEF2	GeneOrGeneProduct	231	232	8	1:NR:2	L2R	CROSS	227-228	241-244	13631	eEF2K	GeneOrGeneProduct	227	228	8	11793,67526	Atg12 - 5	GeneOrGeneProduct	241	244	9	1:NR:2	L2R	CROSS	227-228	245-251	13631	eEF2K	GeneOrGeneProduct	227	228	8	67443	LC3B - I and - II	GeneOrGeneProduct	245	251	9	1:NR:2	L2R	CROSS	227-228	253-254	13631	eEF2K	GeneOrGeneProduct	227	228	8	22241	ULK1	GeneOrGeneProduct	253	254	9	1:NR:2	L2R	CROSS	227-228	267-273	13631	eEF2K	GeneOrGeneProduct	227	228	8	12367,12371	caspase - 3 and - 9	GeneOrGeneProduct	267	273	9	1:NR:2	L2R	CROSS	227-228	275-276	13631	eEF2K	GeneOrGeneProduct	227	228	8	11545	PARP	GeneOrGeneProduct	275	276	9	1:NR:2	L2R	CROSS	227-228	283-284	13631	eEF2K	GeneOrGeneProduct	227	228	8	66853	ATGL	GeneOrGeneProduct	283	284	10	1:NR:2	L2R	CROSS	227-228	285-286	13631	eEF2K	GeneOrGeneProduct	227	228	8	16890	HSL	GeneOrGeneProduct	285	286	10	1:NR:2	L2R	CROSS	227-228	294-295	13631	eEF2K	GeneOrGeneProduct	227	228	8	19016	PPARgamma	GeneOrGeneProduct	294	295	10	1:NR:2	L2R	CROSS	227-228	296-299	13631	eEF2K	GeneOrGeneProduct	227	228	8	12606	C / EBPalpha	GeneOrGeneProduct	296	299	10	1:NR:2	L2R	CROSS	227-228	310-313	13631	eEF2K	GeneOrGeneProduct	227	228	8	21926	TNF - alpha	GeneOrGeneProduct	310	313	11	1:NR:2	L2R	CROSS	227-228	314-317	13631	eEF2K	GeneOrGeneProduct	227	228	8	16193	IL - 6	GeneOrGeneProduct	314	317	11	1:NR:2	L2R	CROSS	227-228	319-322	13631	eEF2K	GeneOrGeneProduct	227	228	8	16176	IL - 1beta	GeneOrGeneProduct	319	322	11	1:NR:2	L2R	CROSS	227-228	331-332	13631	eEF2K	GeneOrGeneProduct	227	228	8	216799	NLRP3|NLRP3	GeneOrGeneProduct	331:334	332:335	11:11	1:NR:2	L2R	CROSS	227-228	336-337	13631	eEF2K	GeneOrGeneProduct	227	228	8	66824	ACS	GeneOrGeneProduct	336	337	11	1:NR:2	L2R	CROSS	227-228	340-343	13631	eEF2K	GeneOrGeneProduct	227	228	8	12362	caspase - 1	GeneOrGeneProduct	340	343	11	1:NR:2	L2R	CROSS	227-228	354-355	13631	eEF2K	GeneOrGeneProduct	227	228	8	16334	insulin	GeneOrGeneProduct	354	355	12	1:NR:2	L2R	CROSS	231-232	241-244	13629	eEF2	GeneOrGeneProduct	231	232	8	11793,67526	Atg12 - 5	GeneOrGeneProduct	241	244	9	1:NR:2	L2R	CROSS	231-232	245-251	13629	eEF2	GeneOrGeneProduct	231	232	8	67443	LC3B - I and - II	GeneOrGeneProduct	245	251	9	1:NR:2	L2R	CROSS	231-232	253-254	13629	eEF2	GeneOrGeneProduct	231	232	8	22241	ULK1	GeneOrGeneProduct	253	254	9	1:NR:2	L2R	CROSS	231-232	267-273	13629	eEF2	GeneOrGeneProduct	231	232	8	12367,12371	caspase - 3 and - 9	GeneOrGeneProduct	267	273	9	1:NR:2	L2R	CROSS	231-232	275-276	13629	eEF2	GeneOrGeneProduct	231	232	8	11545	PARP	GeneOrGeneProduct	275	276	9	1:NR:2	L2R	CROSS	231-232	283-284	13629	eEF2	GeneOrGeneProduct	231	232	8	66853	ATGL	GeneOrGeneProduct	283	284	10	1:NR:2	L2R	CROSS	231-232	285-286	13629	eEF2	GeneOrGeneProduct	231	232	8	16890	HSL	GeneOrGeneProduct	285	286	10	1:NR:2	L2R	CROSS	231-232	294-295	13629	eEF2	GeneOrGeneProduct	231	232	8	19016	PPARgamma	GeneOrGeneProduct	294	295	10	1:NR:2	L2R	CROSS	231-232	296-299	13629	eEF2	GeneOrGeneProduct	231	232	8	12606	C / EBPalpha	GeneOrGeneProduct	296	299	10	1:NR:2	L2R	CROSS	231-232	310-313	13629	eEF2	GeneOrGeneProduct	231	232	8	21926	TNF - alpha	GeneOrGeneProduct	310	313	11	1:NR:2	L2R	CROSS	231-232	314-317	13629	eEF2	GeneOrGeneProduct	231	232	8	16193	IL - 6	GeneOrGeneProduct	314	317	11	1:NR:2	L2R	CROSS	231-232	319-322	13629	eEF2	GeneOrGeneProduct	231	232	8	16176	IL - 1beta	GeneOrGeneProduct	319	322	11	1:NR:2	L2R	CROSS	231-232	331-332	13629	eEF2	GeneOrGeneProduct	231	232	8	216799	NLRP3|NLRP3	GeneOrGeneProduct	331:334	332:335	11:11	1:NR:2	L2R	CROSS	231-232	336-337	13629	eEF2	GeneOrGeneProduct	231	232	8	66824	ACS	GeneOrGeneProduct	336	337	11	1:NR:2	L2R	CROSS	231-232	340-343	13629	eEF2	GeneOrGeneProduct	231	232	8	12362	caspase - 1	GeneOrGeneProduct	340	343	11	1:NR:2	L2R	CROSS	231-232	354-355	13629	eEF2	GeneOrGeneProduct	231	232	8	16334	insulin	GeneOrGeneProduct	354	355	12	1:NR:2	L2R	NON-CROSS	241-244	245-251	11793,67526	Atg12 - 5	GeneOrGeneProduct	241	244	9	67443	LC3B - I and - II	GeneOrGeneProduct	245	251	9	1:NR:2	L2R	NON-CROSS	241-244	253-254	11793,67526	Atg12 - 5	GeneOrGeneProduct	241	244	9	22241	ULK1	GeneOrGeneProduct	253	254	9	1:NR:2	L2R	NON-CROSS	241-244	267-273	11793,67526	Atg12 - 5	GeneOrGeneProduct	241	244	9	12367,12371	caspase - 3 and - 9	GeneOrGeneProduct	267	273	9	1:NR:2	L2R	NON-CROSS	241-244	275-276	11793,67526	Atg12 - 5	GeneOrGeneProduct	241	244	9	11545	PARP	GeneOrGeneProduct	275	276	9	1:NR:2	L2R	CROSS	241-244	283-284	11793,67526	Atg12 - 5	GeneOrGeneProduct	241	244	9	66853	ATGL	GeneOrGeneProduct	283	284	10	1:NR:2	L2R	CROSS	241-244	285-286	11793,67526	Atg12 - 5	GeneOrGeneProduct	241	244	9	16890	HSL	GeneOrGeneProduct	285	286	10	1:NR:2	L2R	CROSS	241-244	294-295	11793,67526	Atg12 - 5	GeneOrGeneProduct	241	244	9	19016	PPARgamma	GeneOrGeneProduct	294	295	10	1:NR:2	L2R	CROSS	241-244	296-299	11793,67526	Atg12 - 5	GeneOrGeneProduct	241	244	9	12606	C / EBPalpha	GeneOrGeneProduct	296	299	10	1:NR:2	L2R	CROSS	241-244	310-313	11793,67526	Atg12 - 5	GeneOrGeneProduct	241	244	9	21926	TNF - alpha	GeneOrGeneProduct	310	313	11	1:NR:2	L2R	CROSS	241-244	314-317	11793,67526	Atg12 - 5	GeneOrGeneProduct	241	244	9	16193	IL - 6	GeneOrGeneProduct	314	317	11	1:NR:2	L2R	CROSS	241-244	319-322	11793,67526	Atg12 - 5	GeneOrGeneProduct	241	244	9	16176	IL - 1beta	GeneOrGeneProduct	319	322	11	1:NR:2	L2R	CROSS	241-244	331-332	11793,67526	Atg12 - 5	GeneOrGeneProduct	241	244	9	216799	NLRP3|NLRP3	GeneOrGeneProduct	331:334	332:335	11:11	1:NR:2	L2R	CROSS	241-244	336-337	11793,67526	Atg12 - 5	GeneOrGeneProduct	241	244	9	66824	ACS	GeneOrGeneProduct	336	337	11	1:NR:2	L2R	CROSS	241-244	340-343	11793,67526	Atg12 - 5	GeneOrGeneProduct	241	244	9	12362	caspase - 1	GeneOrGeneProduct	340	343	11	1:NR:2	L2R	CROSS	241-244	354-355	11793,67526	Atg12 - 5	GeneOrGeneProduct	241	244	9	16334	insulin	GeneOrGeneProduct	354	355	12	1:NR:2	L2R	NON-CROSS	245-251	253-254	67443	LC3B - I and - II	GeneOrGeneProduct	245	251	9	22241	ULK1	GeneOrGeneProduct	253	254	9	1:NR:2	L2R	NON-CROSS	245-251	267-273	67443	LC3B - I and - II	GeneOrGeneProduct	245	251	9	12367,12371	caspase - 3 and - 9	GeneOrGeneProduct	267	273	9	1:NR:2	L2R	NON-CROSS	245-251	275-276	67443	LC3B - I and - II	GeneOrGeneProduct	245	251	9	11545	PARP	GeneOrGeneProduct	275	276	9	1:NR:2	L2R	CROSS	245-251	283-284	67443	LC3B - I and - II	GeneOrGeneProduct	245	251	9	66853	ATGL	GeneOrGeneProduct	283	284	10	1:NR:2	L2R	CROSS	245-251	285-286	67443	LC3B - I and - II	GeneOrGeneProduct	245	251	9	16890	HSL	GeneOrGeneProduct	285	286	10	1:NR:2	L2R	CROSS	245-251	294-295	67443	LC3B - I and - II	GeneOrGeneProduct	245	251	9	19016	PPARgamma	GeneOrGeneProduct	294	295	10	1:NR:2	L2R	CROSS	245-251	296-299	67443	LC3B - I and - II	GeneOrGeneProduct	245	251	9	12606	C / EBPalpha	GeneOrGeneProduct	296	299	10	1:NR:2	L2R	CROSS	245-251	310-313	67443	LC3B - I and - II	GeneOrGeneProduct	245	251	9	21926	TNF - alpha	GeneOrGeneProduct	310	313	11	1:NR:2	L2R	CROSS	245-251	314-317	67443	LC3B - I and - II	GeneOrGeneProduct	245	251	9	16193	IL - 6	GeneOrGeneProduct	314	317	11	1:NR:2	L2R	CROSS	245-251	319-322	67443	LC3B - I and - II	GeneOrGeneProduct	245	251	9	16176	IL - 1beta	GeneOrGeneProduct	319	322	11	1:NR:2	L2R	CROSS	245-251	331-332	67443	LC3B - I and - II	GeneOrGeneProduct	245	251	9	216799	NLRP3|NLRP3	GeneOrGeneProduct	331:334	332:335	11:11	1:NR:2	L2R	CROSS	245-251	336-337	67443	LC3B - I and - II	GeneOrGeneProduct	245	251	9	66824	ACS	GeneOrGeneProduct	336	337	11	1:NR:2	L2R	CROSS	245-251	340-343	67443	LC3B - I and - II	GeneOrGeneProduct	245	251	9	12362	caspase - 1	GeneOrGeneProduct	340	343	11	1:NR:2	L2R	CROSS	245-251	354-355	67443	LC3B - I and - II	GeneOrGeneProduct	245	251	9	16334	insulin	GeneOrGeneProduct	354	355	12	1:NR:2	L2R	NON-CROSS	253-254	267-273	22241	ULK1	GeneOrGeneProduct	253	254	9	12367,12371	caspase - 3 and - 9	GeneOrGeneProduct	267	273	9	1:NR:2	L2R	NON-CROSS	253-254	275-276	22241	ULK1	GeneOrGeneProduct	253	254	9	11545	PARP	GeneOrGeneProduct	275	276	9	1:NR:2	L2R	CROSS	253-254	283-284	22241	ULK1	GeneOrGeneProduct	253	254	9	66853	ATGL	GeneOrGeneProduct	283	284	10	1:NR:2	L2R	CROSS	253-254	285-286	22241	ULK1	GeneOrGeneProduct	253	254	9	16890	HSL	GeneOrGeneProduct	285	286	10	1:NR:2	L2R	CROSS	253-254	294-295	22241	ULK1	GeneOrGeneProduct	253	254	9	19016	PPARgamma	GeneOrGeneProduct	294	295	10	1:NR:2	L2R	CROSS	253-254	296-299	22241	ULK1	GeneOrGeneProduct	253	254	9	12606	C / EBPalpha	GeneOrGeneProduct	296	299	10	1:NR:2	L2R	CROSS	253-254	310-313	22241	ULK1	GeneOrGeneProduct	253	254	9	21926	TNF - alpha	GeneOrGeneProduct	310	313	11	1:NR:2	L2R	CROSS	253-254	314-317	22241	ULK1	GeneOrGeneProduct	253	254	9	16193	IL - 6	GeneOrGeneProduct	314	317	11	1:NR:2	L2R	CROSS	253-254	319-322	22241	ULK1	GeneOrGeneProduct	253	254	9	16176	IL - 1beta	GeneOrGeneProduct	319	322	11	1:NR:2	L2R	CROSS	253-254	331-332	22241	ULK1	GeneOrGeneProduct	253	254	9	216799	NLRP3|NLRP3	GeneOrGeneProduct	331:334	332:335	11:11	1:NR:2	L2R	CROSS	253-254	336-337	22241	ULK1	GeneOrGeneProduct	253	254	9	66824	ACS	GeneOrGeneProduct	336	337	11	1:NR:2	L2R	CROSS	253-254	340-343	22241	ULK1	GeneOrGeneProduct	253	254	9	12362	caspase - 1	GeneOrGeneProduct	340	343	11	1:NR:2	L2R	CROSS	253-254	354-355	22241	ULK1	GeneOrGeneProduct	253	254	9	16334	insulin	GeneOrGeneProduct	354	355	12	1:NR:2	L2R	NON-CROSS	267-273	275-276	12367,12371	caspase - 3 and - 9	GeneOrGeneProduct	267	273	9	11545	PARP	GeneOrGeneProduct	275	276	9	1:NR:2	L2R	CROSS	267-273	283-284	12367,12371	caspase - 3 and - 9	GeneOrGeneProduct	267	273	9	66853	ATGL	GeneOrGeneProduct	283	284	10	1:NR:2	L2R	CROSS	267-273	285-286	12367,12371	caspase - 3 and - 9	GeneOrGeneProduct	267	273	9	16890	HSL	GeneOrGeneProduct	285	286	10	1:NR:2	L2R	CROSS	267-273	294-295	12367,12371	caspase - 3 and - 9	GeneOrGeneProduct	267	273	9	19016	PPARgamma	GeneOrGeneProduct	294	295	10	1:NR:2	L2R	CROSS	267-273	296-299	12367,12371	caspase - 3 and - 9	GeneOrGeneProduct	267	273	9	12606	C / EBPalpha	GeneOrGeneProduct	296	299	10	1:NR:2	L2R	CROSS	267-273	310-313	12367,12371	caspase - 3 and - 9	GeneOrGeneProduct	267	273	9	21926	TNF - alpha	GeneOrGeneProduct	310	313	11	1:NR:2	L2R	CROSS	267-273	314-317	12367,12371	caspase - 3 and - 9	GeneOrGeneProduct	267	273	9	16193	IL - 6	GeneOrGeneProduct	314	317	11	1:NR:2	L2R	CROSS	267-273	319-322	12367,12371	caspase - 3 and - 9	GeneOrGeneProduct	267	273	9	16176	IL - 1beta	GeneOrGeneProduct	319	322	11	1:NR:2	L2R	CROSS	267-273	331-332	12367,12371	caspase - 3 and - 9	GeneOrGeneProduct	267	273	9	216799	NLRP3|NLRP3	GeneOrGeneProduct	331:334	332:335	11:11	1:NR:2	L2R	CROSS	267-273	336-337	12367,12371	caspase - 3 and - 9	GeneOrGeneProduct	267	273	9	66824	ACS	GeneOrGeneProduct	336	337	11	1:NR:2	L2R	CROSS	267-273	340-343	12367,12371	caspase - 3 and - 9	GeneOrGeneProduct	267	273	9	12362	caspase - 1	GeneOrGeneProduct	340	343	11	1:NR:2	L2R	CROSS	267-273	354-355	12367,12371	caspase - 3 and - 9	GeneOrGeneProduct	267	273	9	16334	insulin	GeneOrGeneProduct	354	355	12	1:NR:2	L2R	CROSS	275-276	283-284	11545	PARP	GeneOrGeneProduct	275	276	9	66853	ATGL	GeneOrGeneProduct	283	284	10	1:NR:2	L2R	CROSS	275-276	285-286	11545	PARP	GeneOrGeneProduct	275	276	9	16890	HSL	GeneOrGeneProduct	285	286	10	1:NR:2	L2R	CROSS	275-276	294-295	11545	PARP	GeneOrGeneProduct	275	276	9	19016	PPARgamma	GeneOrGeneProduct	294	295	10	1:NR:2	L2R	CROSS	275-276	296-299	11545	PARP	GeneOrGeneProduct	275	276	9	12606	C / EBPalpha	GeneOrGeneProduct	296	299	10	1:NR:2	L2R	CROSS	275-276	310-313	11545	PARP	GeneOrGeneProduct	275	276	9	21926	TNF - alpha	GeneOrGeneProduct	310	313	11	1:NR:2	L2R	CROSS	275-276	314-317	11545	PARP	GeneOrGeneProduct	275	276	9	16193	IL - 6	GeneOrGeneProduct	314	317	11	1:NR:2	L2R	CROSS	275-276	319-322	11545	PARP	GeneOrGeneProduct	275	276	9	16176	IL - 1beta	GeneOrGeneProduct	319	322	11	1:NR:2	L2R	CROSS	275-276	331-332	11545	PARP	GeneOrGeneProduct	275	276	9	216799	NLRP3|NLRP3	GeneOrGeneProduct	331:334	332:335	11:11	1:NR:2	L2R	CROSS	275-276	336-337	11545	PARP	GeneOrGeneProduct	275	276	9	66824	ACS	GeneOrGeneProduct	336	337	11	1:NR:2	L2R	CROSS	275-276	340-343	11545	PARP	GeneOrGeneProduct	275	276	9	12362	caspase - 1	GeneOrGeneProduct	340	343	11	1:NR:2	L2R	CROSS	275-276	354-355	11545	PARP	GeneOrGeneProduct	275	276	9	16334	insulin	GeneOrGeneProduct	354	355	12	1:NR:2	L2R	NON-CROSS	283-284	285-286	66853	ATGL	GeneOrGeneProduct	283	284	10	16890	HSL	GeneOrGeneProduct	285	286	10	1:NR:2	L2R	NON-CROSS	283-284	294-295	66853	ATGL	GeneOrGeneProduct	283	284	10	19016	PPARgamma	GeneOrGeneProduct	294	295	10	1:NR:2	L2R	NON-CROSS	283-284	296-299	66853	ATGL	GeneOrGeneProduct	283	284	10	12606	C / EBPalpha	GeneOrGeneProduct	296	299	10	1:NR:2	L2R	CROSS	283-284	310-313	66853	ATGL	GeneOrGeneProduct	283	284	10	21926	TNF - alpha	GeneOrGeneProduct	310	313	11	1:NR:2	L2R	CROSS	283-284	314-317	66853	ATGL	GeneOrGeneProduct	283	284	10	16193	IL - 6	GeneOrGeneProduct	314	317	11	1:NR:2	L2R	CROSS	283-284	319-322	66853	ATGL	GeneOrGeneProduct	283	284	10	16176	IL - 1beta	GeneOrGeneProduct	319	322	11	1:NR:2	L2R	CROSS	283-284	331-332	66853	ATGL	GeneOrGeneProduct	283	284	10	216799	NLRP3|NLRP3	GeneOrGeneProduct	331:334	332:335	11:11	1:NR:2	L2R	CROSS	283-284	336-337	66853	ATGL	GeneOrGeneProduct	283	284	10	66824	ACS	GeneOrGeneProduct	336	337	11	1:NR:2	L2R	CROSS	283-284	340-343	66853	ATGL	GeneOrGeneProduct	283	284	10	12362	caspase - 1	GeneOrGeneProduct	340	343	11	1:NR:2	L2R	CROSS	283-284	354-355	66853	ATGL	GeneOrGeneProduct	283	284	10	16334	insulin	GeneOrGeneProduct	354	355	12	1:NR:2	L2R	NON-CROSS	285-286	294-295	16890	HSL	GeneOrGeneProduct	285	286	10	19016	PPARgamma	GeneOrGeneProduct	294	295	10	1:NR:2	L2R	NON-CROSS	285-286	296-299	16890	HSL	GeneOrGeneProduct	285	286	10	12606	C / EBPalpha	GeneOrGeneProduct	296	299	10	1:NR:2	L2R	CROSS	285-286	310-313	16890	HSL	GeneOrGeneProduct	285	286	10	21926	TNF - alpha	GeneOrGeneProduct	310	313	11	1:NR:2	L2R	CROSS	285-286	314-317	16890	HSL	GeneOrGeneProduct	285	286	10	16193	IL - 6	GeneOrGeneProduct	314	317	11	1:NR:2	L2R	CROSS	285-286	319-322	16890	HSL	GeneOrGeneProduct	285	286	10	16176	IL - 1beta	GeneOrGeneProduct	319	322	11	1:NR:2	L2R	CROSS	285-286	331-332	16890	HSL	GeneOrGeneProduct	285	286	10	216799	NLRP3|NLRP3	GeneOrGeneProduct	331:334	332:335	11:11	1:NR:2	L2R	CROSS	285-286	336-337	16890	HSL	GeneOrGeneProduct	285	286	10	66824	ACS	GeneOrGeneProduct	336	337	11	1:NR:2	L2R	CROSS	285-286	340-343	16890	HSL	GeneOrGeneProduct	285	286	10	12362	caspase - 1	GeneOrGeneProduct	340	343	11	1:NR:2	L2R	CROSS	285-286	354-355	16890	HSL	GeneOrGeneProduct	285	286	10	16334	insulin	GeneOrGeneProduct	354	355	12	1:NR:2	L2R	NON-CROSS	294-295	296-299	19016	PPARgamma	GeneOrGeneProduct	294	295	10	12606	C / EBPalpha	GeneOrGeneProduct	296	299	10	1:NR:2	L2R	CROSS	294-295	310-313	19016	PPARgamma	GeneOrGeneProduct	294	295	10	21926	TNF - alpha	GeneOrGeneProduct	310	313	11	1:NR:2	L2R	CROSS	294-295	314-317	19016	PPARgamma	GeneOrGeneProduct	294	295	10	16193	IL - 6	GeneOrGeneProduct	314	317	11	1:NR:2	L2R	CROSS	294-295	319-322	19016	PPARgamma	GeneOrGeneProduct	294	295	10	16176	IL - 1beta	GeneOrGeneProduct	319	322	11	1:NR:2	L2R	CROSS	294-295	331-332	19016	PPARgamma	GeneOrGeneProduct	294	295	10	216799	NLRP3|NLRP3	GeneOrGeneProduct	331:334	332:335	11:11	1:NR:2	L2R	CROSS	294-295	336-337	19016	PPARgamma	GeneOrGeneProduct	294	295	10	66824	ACS	GeneOrGeneProduct	336	337	11	1:NR:2	L2R	CROSS	294-295	340-343	19016	PPARgamma	GeneOrGeneProduct	294	295	10	12362	caspase - 1	GeneOrGeneProduct	340	343	11	1:NR:2	L2R	CROSS	294-295	354-355	19016	PPARgamma	GeneOrGeneProduct	294	295	10	16334	insulin	GeneOrGeneProduct	354	355	12	1:NR:2	L2R	CROSS	296-299	310-313	12606	C / EBPalpha	GeneOrGeneProduct	296	299	10	21926	TNF - alpha	GeneOrGeneProduct	310	313	11	1:NR:2	L2R	CROSS	296-299	314-317	12606	C / EBPalpha	GeneOrGeneProduct	296	299	10	16193	IL - 6	GeneOrGeneProduct	314	317	11	1:NR:2	L2R	CROSS	296-299	319-322	12606	C / EBPalpha	GeneOrGeneProduct	296	299	10	16176	IL - 1beta	GeneOrGeneProduct	319	322	11	1:NR:2	L2R	CROSS	296-299	331-332	12606	C / EBPalpha	GeneOrGeneProduct	296	299	10	216799	NLRP3|NLRP3	GeneOrGeneProduct	331:334	332:335	11:11	1:NR:2	L2R	CROSS	296-299	336-337	12606	C / EBPalpha	GeneOrGeneProduct	296	299	10	66824	ACS	GeneOrGeneProduct	336	337	11	1:NR:2	L2R	CROSS	296-299	340-343	12606	C / EBPalpha	GeneOrGeneProduct	296	299	10	12362	caspase - 1	GeneOrGeneProduct	340	343	11	1:NR:2	L2R	CROSS	296-299	354-355	12606	C / EBPalpha	GeneOrGeneProduct	296	299	10	16334	insulin	GeneOrGeneProduct	354	355	12	1:NR:2	L2R	NON-CROSS	310-313	314-317	21926	TNF - alpha	GeneOrGeneProduct	310	313	11	16193	IL - 6	GeneOrGeneProduct	314	317	11	1:NR:2	L2R	NON-CROSS	310-313	319-322	21926	TNF - alpha	GeneOrGeneProduct	310	313	11	16176	IL - 1beta	GeneOrGeneProduct	319	322	11	1:NR:2	L2R	NON-CROSS	310-313	331-332	21926	TNF - alpha	GeneOrGeneProduct	310	313	11	216799	NLRP3|NLRP3	GeneOrGeneProduct	331:334	332:335	11:11	1:NR:2	L2R	NON-CROSS	310-313	336-337	21926	TNF - alpha	GeneOrGeneProduct	310	313	11	66824	ACS	GeneOrGeneProduct	336	337	11	1:NR:2	L2R	NON-CROSS	310-313	340-343	21926	TNF - alpha	GeneOrGeneProduct	310	313	11	12362	caspase - 1	GeneOrGeneProduct	340	343	11	1:NR:2	L2R	CROSS	310-313	354-355	21926	TNF - alpha	GeneOrGeneProduct	310	313	11	16334	insulin	GeneOrGeneProduct	354	355	12	1:NR:2	L2R	NON-CROSS	314-317	319-322	16193	IL - 6	GeneOrGeneProduct	314	317	11	16176	IL - 1beta	GeneOrGeneProduct	319	322	11	1:NR:2	L2R	NON-CROSS	314-317	331-332	16193	IL - 6	GeneOrGeneProduct	314	317	11	216799	NLRP3|NLRP3	GeneOrGeneProduct	331:334	332:335	11:11	1:NR:2	L2R	NON-CROSS	314-317	336-337	16193	IL - 6	GeneOrGeneProduct	314	317	11	66824	ACS	GeneOrGeneProduct	336	337	11	1:NR:2	L2R	NON-CROSS	314-317	340-343	16193	IL - 6	GeneOrGeneProduct	314	317	11	12362	caspase - 1	GeneOrGeneProduct	340	343	11	1:NR:2	L2R	CROSS	314-317	354-355	16193	IL - 6	GeneOrGeneProduct	314	317	11	16334	insulin	GeneOrGeneProduct	354	355	12	1:NR:2	L2R	NON-CROSS	319-322	331-332	16176	IL - 1beta	GeneOrGeneProduct	319	322	11	216799	NLRP3|NLRP3	GeneOrGeneProduct	331:334	332:335	11:11	1:NR:2	L2R	NON-CROSS	319-322	336-337	16176	IL - 1beta	GeneOrGeneProduct	319	322	11	66824	ACS	GeneOrGeneProduct	336	337	11	1:NR:2	L2R	NON-CROSS	319-322	340-343	16176	IL - 1beta	GeneOrGeneProduct	319	322	11	12362	caspase - 1	GeneOrGeneProduct	340	343	11	1:NR:2	L2R	CROSS	319-322	354-355	16176	IL - 1beta	GeneOrGeneProduct	319	322	11	16334	insulin	GeneOrGeneProduct	354	355	12	1:NR:2	L2R	NON-CROSS	334-335	336-337	216799	NLRP3|NLRP3	GeneOrGeneProduct	331:334	332:335	11:11	66824	ACS	GeneOrGeneProduct	336	337	11	1:NR:2	L2R	NON-CROSS	334-335	340-343	216799	NLRP3|NLRP3	GeneOrGeneProduct	331:334	332:335	11:11	12362	caspase - 1	GeneOrGeneProduct	340	343	11	1:NR:2	L2R	CROSS	334-335	354-355	216799	NLRP3|NLRP3	GeneOrGeneProduct	331:334	332:335	11:11	16334	insulin	GeneOrGeneProduct	354	355	12	1:NR:2	L2R	NON-CROSS	336-337	340-343	66824	ACS	GeneOrGeneProduct	336	337	11	12362	caspase - 1	GeneOrGeneProduct	340	343	11	1:NR:2	L2R	CROSS	336-337	354-355	66824	ACS	GeneOrGeneProduct	336	337	11	16334	insulin	GeneOrGeneProduct	354	355	12	1:NR:2	L2R	CROSS	340-343	354-355	12362	caspase - 1	GeneOrGeneProduct	340	343	11	16334	insulin	GeneOrGeneProduct	354	355	12
8829135	Nefiracetam ( DM - 9384 ) reverses apomorphine - induced amnesia of a passive avoidance response : delayed emergence of the memory retention effects .|Nefiracetam is a novel pyrrolidone derivative which attenuates scopolamine - induced learning and post - training consolidation deficits .|Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10 - 12h post - training period , we evaluated the ability of nefiracetam to attenuate amnesia induced by dopaminergic agonism .|A step - down passive avoidance paradigm was employed and nefiracetam ( 3 mg / kg ) and apomorphine ( 0 . 5 mg / kg ) were given alone or in combination during training and at the 10 - 12h post - training period of consolidation .|Co - administration of nefiracetam and apomorphine during training or 10h thereafter produced no significant anti - amnesic effect .|However , administration of nefiracetam during training completely reversed the amnesia induced by apomorphine at the 10h post - training time and the converse was also true .|These effects were not mediated by a dopaminergic mechanism as nefiracetam , at millimolar concentrations , failed to displace either [ 3H ] SCH 23390 or [ 3H ] spiperone binding from D1 or D2 dopamine receptor subtypes , respectively .|It is suggested that nefiracetam augments molecular processes in the early stages of events which ultimately lead to consolidation of memory .	1:Negative_Correlation:2	L2R	NON-CROSS	133-134	135-136	C058876	Nefiracetam|DM - 9384|Nefiracetam|nefiracetam|nefiracetam|nefiracetam|nefiracetam|nefiracetam|nefiracetam	ChemicalEntity	0:2:25:72:91:133:153:187:222	1:5:26:73:92:134:154:188:223	0:0:1:2:3:4:5:6:7	D001058	apomorphine|apomorphine|apomorphine|apomorphine|apomorphine	ChemicalEntity	7:46:99:135:162	8:47:100:136:163	0:2:3:4:5	1:Negative_Correlation:2	L2R	NON-CROSS	72-73	75-76	C058876	Nefiracetam|DM - 9384|Nefiracetam|nefiracetam|nefiracetam|nefiracetam|nefiracetam|nefiracetam|nefiracetam	ChemicalEntity	0:2:25:72:91:133:153:187:222	1:5:26:73:92:134:154:188:223	0:0:1:2:3:4:5:6:7	D000647	amnesia|amnesia|amnesic|amnesia	DiseaseOrPhenotypicFeature	10:75:146:159	11:76:147:160	0:2:4:5	1:NR:2	L2R	NON-CROSS	25-26	29-30	C058876	Nefiracetam|DM - 9384|Nefiracetam|nefiracetam|nefiracetam|nefiracetam|nefiracetam|nefiracetam|nefiracetam	ChemicalEntity	0:2:25:72:91:133:153:187:222	1:5:26:73:92:134:154:188:223	0:0:1:2:3:4:5:6:7	D011760	pyrrolidone	ChemicalEntity	29	30	1	1:Negative_Correlation:2	L2R	NON-CROSS	25-26	33-34	C058876	Nefiracetam|DM - 9384|Nefiracetam|nefiracetam|nefiracetam|nefiracetam|nefiracetam|nefiracetam|nefiracetam	ChemicalEntity	0:2:25:72:91:133:153:187:222	1:5:26:73:92:134:154:188:223	0:0:1:2:3:4:5:6:7	D012601	scopolamine	ChemicalEntity	33	34	1	1:Negative_Correlation:2	L2R	NON-CROSS	25-26	36-43	C058876	Nefiracetam|DM - 9384|Nefiracetam|nefiracetam|nefiracetam|nefiracetam|nefiracetam|nefiracetam|nefiracetam	ChemicalEntity	0:2:25:72:91:133:153:187:222	1:5:26:73:92:134:154:188:223	0:0:1:2:3:4:5:6:7	D007859	learning and post - training consolidation deficits	DiseaseOrPhenotypicFeature	36	43	1	1:Negative_Correlation:2	L2R	NON-CROSS	72-73	78-80	C058876	Nefiracetam|DM - 9384|Nefiracetam|nefiracetam|nefiracetam|nefiracetam|nefiracetam|nefiracetam|nefiracetam	ChemicalEntity	0:2:25:72:91:133:153:187:222	1:5:26:73:92:134:154:188:223	0:0:1:2:3:4:5:6:7	D018491	dopaminergic agonism	ChemicalEntity	78	80	2	1:NR:2	L2R	NON-CROSS	187-188	198-199	C058876	Nefiracetam|DM - 9384|Nefiracetam|nefiracetam|nefiracetam|nefiracetam|nefiracetam|nefiracetam|nefiracetam	ChemicalEntity	0:2:25:72:91:133:153:187:222	1:5:26:73:92:134:154:188:223	0:0:1:2:3:4:5:6:7	D014316	3H|3H	ChemicalEntity	198:204	199:205	6:6	1:NR:2	L2R	NON-CROSS	187-188	200-202	C058876	Nefiracetam|DM - 9384|Nefiracetam|nefiracetam|nefiracetam|nefiracetam|nefiracetam|nefiracetam|nefiracetam	ChemicalEntity	0:2:25:72:91:133:153:187:222	1:5:26:73:92:134:154:188:223	0:0:1:2:3:4:5:6:7	C534628	SCH 23390	ChemicalEntity	200	202	6	1:NR:2	L2R	NON-CROSS	206-207	222-223	C058876	Nefiracetam|DM - 9384|Nefiracetam|nefiracetam|nefiracetam|nefiracetam|nefiracetam|nefiracetam|nefiracetam	ChemicalEntity	0:2:25:72:91:133:153:187:222	1:5:26:73:92:134:154:188:223	0:0:1:2:3:4:5:6:7	D013134	spiperone	ChemicalEntity	206	207	6	1:NR:2	L2R	NON-CROSS	209-214	222-223	C058876	Nefiracetam|DM - 9384|Nefiracetam|nefiracetam|nefiracetam|nefiracetam|nefiracetam|nefiracetam|nefiracetam	ChemicalEntity	0:2:25:72:91:133:153:187:222	1:5:26:73:92:134:154:188:223	0:0:1:2:3:4:5:6:7	1812,1813	D1 or D2 dopamine receptor	GeneOrGeneProduct	209	214	6	1:Positive_Correlation:2	R2L	NON-CROSS	10-11	7-8	D000647	amnesia|amnesia|amnesic|amnesia	DiseaseOrPhenotypicFeature	10:75:146:159	11:76:147:160	0:2:4:5	D001058	apomorphine|apomorphine|apomorphine|apomorphine|apomorphine	ChemicalEntity	7:46:99:135:162	8:47:100:136:163	0:2:3:4:5	1:NR:2	L2R	CROSS	29-30	46-47	D001058	apomorphine|apomorphine|apomorphine|apomorphine|apomorphine	ChemicalEntity	7:46:99:135:162	8:47:100:136:163	0:2:3:4:5	D011760	pyrrolidone	ChemicalEntity	29	30	1	1:NR:2	L2R	CROSS	33-34	46-47	D001058	apomorphine|apomorphine|apomorphine|apomorphine|apomorphine	ChemicalEntity	7:46:99:135:162	8:47:100:136:163	0:2:3:4:5	D012601	scopolamine	ChemicalEntity	33	34	1	1:NR:2	L2R	CROSS	36-43	46-47	D001058	apomorphine|apomorphine|apomorphine|apomorphine|apomorphine	ChemicalEntity	7:46:99:135:162	8:47:100:136:163	0:2:3:4:5	D007859	learning and post - training consolidation deficits	DiseaseOrPhenotypicFeature	36	43	1	1:NR:2	L2R	NON-CROSS	78-80	99-100	D001058	apomorphine|apomorphine|apomorphine|apomorphine|apomorphine	ChemicalEntity	7:46:99:135:162	8:47:100:136:163	0:2:3:4:5	D018491	dopaminergic agonism	ChemicalEntity	78	80	2	1:NR:2	L2R	CROSS	162-163	198-199	D001058	apomorphine|apomorphine|apomorphine|apomorphine|apomorphine	ChemicalEntity	7:46:99:135:162	8:47:100:136:163	0:2:3:4:5	D014316	3H|3H	ChemicalEntity	198:204	199:205	6:6	1:NR:2	L2R	CROSS	162-163	200-202	D001058	apomorphine|apomorphine|apomorphine|apomorphine|apomorphine	ChemicalEntity	7:46:99:135:162	8:47:100:136:163	0:2:3:4:5	C534628	SCH 23390	ChemicalEntity	200	202	6	1:NR:2	L2R	CROSS	162-163	206-207	D001058	apomorphine|apomorphine|apomorphine|apomorphine|apomorphine	ChemicalEntity	7:46:99:135:162	8:47:100:136:163	0:2:3:4:5	D013134	spiperone	ChemicalEntity	206	207	6	1:NR:2	L2R	CROSS	162-163	209-214	D001058	apomorphine|apomorphine|apomorphine|apomorphine|apomorphine	ChemicalEntity	7:46:99:135:162	8:47:100:136:163	0:2:3:4:5	1812,1813	D1 or D2 dopamine receptor	GeneOrGeneProduct	209	214	6	1:NR:2	L2R	CROSS	10-11	29-30	D000647	amnesia|amnesia|amnesic|amnesia	DiseaseOrPhenotypicFeature	10:75:146:159	11:76:147:160	0:2:4:5	D011760	pyrrolidone	ChemicalEntity	29	30	1	1:NR:2	L2R	CROSS	10-11	33-34	D000647	amnesia|amnesia|amnesic|amnesia	DiseaseOrPhenotypicFeature	10:75:146:159	11:76:147:160	0:2:4:5	D012601	scopolamine	ChemicalEntity	33	34	1	1:Positive_Correlation:2	R2L	NON-CROSS	78-80	75-76	D018491	dopaminergic agonism	ChemicalEntity	78	80	2	D000647	amnesia|amnesia|amnesic|amnesia	DiseaseOrPhenotypicFeature	10:75:146:159	11:76:147:160	0:2:4:5	1:NR:2	L2R	CROSS	159-160	198-199	D000647	amnesia|amnesia|amnesic|amnesia	DiseaseOrPhenotypicFeature	10:75:146:159	11:76:147:160	0:2:4:5	D014316	3H|3H	ChemicalEntity	198:204	199:205	6:6	1:NR:2	L2R	CROSS	159-160	200-202	D000647	amnesia|amnesia|amnesic|amnesia	DiseaseOrPhenotypicFeature	10:75:146:159	11:76:147:160	0:2:4:5	C534628	SCH 23390	ChemicalEntity	200	202	6	1:NR:2	L2R	CROSS	159-160	206-207	D000647	amnesia|amnesia|amnesic|amnesia	DiseaseOrPhenotypicFeature	10:75:146:159	11:76:147:160	0:2:4:5	D013134	spiperone	ChemicalEntity	206	207	6	1:NR:2	L2R	CROSS	159-160	209-214	D000647	amnesia|amnesia|amnesic|amnesia	DiseaseOrPhenotypicFeature	10:75:146:159	11:76:147:160	0:2:4:5	1812,1813	D1 or D2 dopamine receptor	GeneOrGeneProduct	209	214	6	1:NR:2	L2R	NON-CROSS	29-30	33-34	D011760	pyrrolidone	ChemicalEntity	29	30	1	D012601	scopolamine	ChemicalEntity	33	34	1	1:NR:2	L2R	NON-CROSS	29-30	36-43	D011760	pyrrolidone	ChemicalEntity	29	30	1	D007859	learning and post - training consolidation deficits	DiseaseOrPhenotypicFeature	36	43	1	1:NR:2	L2R	CROSS	29-30	78-80	D011760	pyrrolidone	ChemicalEntity	29	30	1	D018491	dopaminergic agonism	ChemicalEntity	78	80	2	1:NR:2	L2R	CROSS	29-30	198-199	D011760	pyrrolidone	ChemicalEntity	29	30	1	D014316	3H|3H	ChemicalEntity	198:204	199:205	6:6	1:NR:2	L2R	CROSS	29-30	200-202	D011760	pyrrolidone	ChemicalEntity	29	30	1	C534628	SCH 23390	ChemicalEntity	200	202	6	1:NR:2	L2R	CROSS	29-30	206-207	D011760	pyrrolidone	ChemicalEntity	29	30	1	D013134	spiperone	ChemicalEntity	206	207	6	1:NR:2	L2R	CROSS	29-30	209-214	D011760	pyrrolidone	ChemicalEntity	29	30	1	1812,1813	D1 or D2 dopamine receptor	GeneOrGeneProduct	209	214	6	1:Positive_Correlation:2	L2R	NON-CROSS	33-34	36-43	D012601	scopolamine	ChemicalEntity	33	34	1	D007859	learning and post - training consolidation deficits	DiseaseOrPhenotypicFeature	36	43	1	1:NR:2	L2R	CROSS	33-34	78-80	D012601	scopolamine	ChemicalEntity	33	34	1	D018491	dopaminergic agonism	ChemicalEntity	78	80	2	1:NR:2	L2R	CROSS	33-34	198-199	D012601	scopolamine	ChemicalEntity	33	34	1	D014316	3H|3H	ChemicalEntity	198:204	199:205	6:6	1:NR:2	L2R	CROSS	33-34	200-202	D012601	scopolamine	ChemicalEntity	33	34	1	C534628	SCH 23390	ChemicalEntity	200	202	6	1:NR:2	L2R	CROSS	33-34	206-207	D012601	scopolamine	ChemicalEntity	33	34	1	D013134	spiperone	ChemicalEntity	206	207	6	1:NR:2	L2R	CROSS	33-34	209-214	D012601	scopolamine	ChemicalEntity	33	34	1	1812,1813	D1 or D2 dopamine receptor	GeneOrGeneProduct	209	214	6	1:NR:2	L2R	CROSS	36-43	78-80	D007859	learning and post - training consolidation deficits	DiseaseOrPhenotypicFeature	36	43	1	D018491	dopaminergic agonism	ChemicalEntity	78	80	2	1:NR:2	L2R	CROSS	36-43	198-199	D007859	learning and post - training consolidation deficits	DiseaseOrPhenotypicFeature	36	43	1	D014316	3H|3H	ChemicalEntity	198:204	199:205	6:6	1:NR:2	L2R	CROSS	36-43	200-202	D007859	learning and post - training consolidation deficits	DiseaseOrPhenotypicFeature	36	43	1	C534628	SCH 23390	ChemicalEntity	200	202	6	1:NR:2	L2R	CROSS	36-43	206-207	D007859	learning and post - training consolidation deficits	DiseaseOrPhenotypicFeature	36	43	1	D013134	spiperone	ChemicalEntity	206	207	6	1:NR:2	L2R	CROSS	36-43	209-214	D007859	learning and post - training consolidation deficits	DiseaseOrPhenotypicFeature	36	43	1	1812,1813	D1 or D2 dopamine receptor	GeneOrGeneProduct	209	214	6	1:NR:2	L2R	CROSS	78-80	198-199	D018491	dopaminergic agonism	ChemicalEntity	78	80	2	D014316	3H|3H	ChemicalEntity	198:204	199:205	6:6	1:NR:2	L2R	CROSS	78-80	200-202	D018491	dopaminergic agonism	ChemicalEntity	78	80	2	C534628	SCH 23390	ChemicalEntity	200	202	6	1:NR:2	L2R	CROSS	78-80	206-207	D018491	dopaminergic agonism	ChemicalEntity	78	80	2	D013134	spiperone	ChemicalEntity	206	207	6	1:NR:2	L2R	CROSS	78-80	209-214	D018491	dopaminergic agonism	ChemicalEntity	78	80	2	1812,1813	D1 or D2 dopamine receptor	GeneOrGeneProduct	209	214	6	1:NR:2	L2R	NON-CROSS	198-199	200-202	D014316	3H|3H	ChemicalEntity	198:204	199:205	6:6	C534628	SCH 23390	ChemicalEntity	200	202	6	1:NR:2	L2R	NON-CROSS	204-205	206-207	D014316	3H|3H	ChemicalEntity	198:204	199:205	6:6	D013134	spiperone	ChemicalEntity	206	207	6	1:NR:2	L2R	NON-CROSS	204-205	209-214	D014316	3H|3H	ChemicalEntity	198:204	199:205	6:6	1812,1813	D1 or D2 dopamine receptor	GeneOrGeneProduct	209	214	6	1:NR:2	L2R	NON-CROSS	200-202	206-207	C534628	SCH 23390	ChemicalEntity	200	202	6	D013134	spiperone	ChemicalEntity	206	207	6	1:NR:2	L2R	NON-CROSS	200-202	209-214	C534628	SCH 23390	ChemicalEntity	200	202	6	1812,1813	D1 or D2 dopamine receptor	GeneOrGeneProduct	209	214	6	1:NR:2	L2R	NON-CROSS	206-207	209-214	D013134	spiperone	ChemicalEntity	206	207	6	1812,1813	D1 or D2 dopamine receptor	GeneOrGeneProduct	209	214	6
9672936	Pethidine - associated seizure in a healthy adolescent receiving pethidine for postoperative pain control .|A healthy 17 - year - old male received standard intermittent doses of pethidine via a patient - controlled analgesia ( PCA ) pump for management of postoperative pain control .|Twenty - three h postoperatively he developed a brief self - limited seizure .|Both plasma pethidine and norpethidine were elevated in the range associated with clinical manifestations of central nervous system excitation .|No other risk factors for CNS toxicity were identified .|This method allowed frequent self - dosing of pethidine at short time intervals and rapid accumulation of pethidine and norpethidine .|The routine use of pethidine via PCA even for a brief postoperative analgesia should be reconsidered .	1:Association:2	L2R	NON-CROSS	0-1	3-4	D008614	Pethidine|pethidine|pethidine|pethidine|pethidine|pethidine|pethidine	ChemicalEntity	0:9:28:62:98:107:115	1:10:29:63:99:108:116	0:0:1:3:5:5:6	D012640	seizure|seizure	DiseaseOrPhenotypicFeature	3:58	4:59	0:2	1:Negative_Correlation:2	L2R	NON-CROSS	9-10	11-13	D008614	Pethidine|pethidine|pethidine|pethidine|pethidine|pethidine|pethidine	ChemicalEntity	0:9:28:62:98:107:115	1:10:29:63:99:108:116	0:0:1:3:5:5:6	D010149	postoperative pain|postoperative pain|postoperative analgesia	DiseaseOrPhenotypicFeature	11:42:122	13:44:124	0:1:6	1:NR:2	L2R	NON-CROSS	62-63	64-65	D008614	Pethidine|pethidine|pethidine|pethidine|pethidine|pethidine|pethidine	ChemicalEntity	0:9:28:62:98:107:115	1:10:29:63:99:108:116	0:0:1:3:5:5:6	C002752	norpethidine|norpethidine	ChemicalEntity	64:109	65:110	3:5	1:NR:2	L2R	CROSS	86-87	98-99	D008614	Pethidine|pethidine|pethidine|pethidine|pethidine|pethidine|pethidine	ChemicalEntity	0:9:28:62:98:107:115	1:10:29:63:99:108:116	0:0:1:3:5:5:6	D064420	toxicity	DiseaseOrPhenotypicFeature	86	87	4	1:NR:2	L2R	CROSS	58-59	64-65	D012640	seizure|seizure	DiseaseOrPhenotypicFeature	3:58	4:59	0:2	C002752	norpethidine|norpethidine	ChemicalEntity	64:109	65:110	3:5	1:NR:2	L2R	CROSS	109-110	122-124	D010149	postoperative pain|postoperative pain|postoperative analgesia	DiseaseOrPhenotypicFeature	11:42:122	13:44:124	0:1:6	C002752	norpethidine|norpethidine	ChemicalEntity	64:109	65:110	3:5	1:NR:2	L2R	CROSS	64-65	86-87	C002752	norpethidine|norpethidine	ChemicalEntity	64:109	65:110	3:5	D064420	toxicity	DiseaseOrPhenotypicFeature	86	87	4
18503483	Recovery of tacrolimus - associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient - - case report and review of the literature .|TAC has been shown to be a potent immunosuppressive agent for solid organ transplantation in pediatrics .|Neurotoxicity is a potentially serious toxic effect .|It is characterized by encephalopathy , headaches , seizures , or neurological deficits .|Here , we describe an eight - and - a - half - yr - old male renal transplant recipient with right BN .|MRI demonstrated hyperintense T2 signals in the cervical cord and right brachial plexus roots indicative of both myelitis and right brachial plexitis .|Symptoms persisted for three months despite TAC dose reduction , administration of IVIG and four doses of methylprednisolone pulse therapy .|Improvement and eventually full recovery only occurred after TAC was completely discontinued and successfully replaced by everolimus .	1:Positive_Correlation:2	L2R	NON-CROSS	2-3	5-7	D016559	tacrolimus|TAC|TAC|TAC	ChemicalEntity	2:27:119:142	3:28:120:143	0:1:6:7	D020968	brachial neuritis|brachial plexitis	DiseaseOrPhenotypicFeature	5:110	7:112	0:5	1:Conversion:2	L2R	NON-CROSS	2-3	10-11	D016559	tacrolimus|TAC|TAC|TAC	ChemicalEntity	2:27:119:142	3:28:120:143	0:1:6:7	D000068338	everolimus|everolimus	ChemicalEntity	10:150	11:151	0:7	1:Positive_Correlation:2	L2R	CROSS	27-28	44-45	D016559	tacrolimus|TAC|TAC|TAC	ChemicalEntity	2:27:119:142	3:28:120:143	0:1:6:7	D020258	Neurotoxicity	DiseaseOrPhenotypicFeature	44	45	2	1:NR:2	L2R	CROSS	27-28	56-57	D016559	tacrolimus|TAC|TAC|TAC	ChemicalEntity	2:27:119:142	3:28:120:143	0:1:6:7	D001927	encephalopathy	DiseaseOrPhenotypicFeature	56	57	3	1:NR:2	L2R	CROSS	27-28	58-59	D016559	tacrolimus|TAC|TAC|TAC	ChemicalEntity	2:27:119:142	3:28:120:143	0:1:6:7	D006261	headaches	DiseaseOrPhenotypicFeature	58	59	3	1:NR:2	L2R	CROSS	27-28	60-61	D016559	tacrolimus|TAC|TAC|TAC	ChemicalEntity	2:27:119:142	3:28:120:143	0:1:6:7	D012640	seizures	DiseaseOrPhenotypicFeature	60	61	3	1:NR:2	L2R	CROSS	27-28	63-65	D016559	tacrolimus|TAC|TAC|TAC	ChemicalEntity	2:27:119:142	3:28:120:143	0:1:6:7	D009461	neurological deficits	DiseaseOrPhenotypicFeature	63	65	3	1:Positive_Correlation:2	R2L	CROSS	119-120	107-108	D009187	myelitis	DiseaseOrPhenotypicFeature	107	108	5	D016559	tacrolimus|TAC|TAC|TAC	ChemicalEntity	2:27:119:142	3:28:120:143	0:1:6:7	1:NR:2	L2R	NON-CROSS	119-120	130-131	D016559	tacrolimus|TAC|TAC|TAC	ChemicalEntity	2:27:119:142	3:28:120:143	0:1:6:7	D008775	methylprednisolone	ChemicalEntity	130	131	6	1:Negative_Correlation:2	R2L	NON-CROSS	10-11	5-7	D000068338	everolimus|everolimus	ChemicalEntity	10:150	11:151	0:7	D020968	brachial neuritis|brachial plexitis	DiseaseOrPhenotypicFeature	5:110	7:112	0:5	1:NR:2	L2R	CROSS	110-112	130-131	D020968	brachial neuritis|brachial plexitis	DiseaseOrPhenotypicFeature	5:110	7:112	0:5	D008775	methylprednisolone	ChemicalEntity	130	131	6	1:NR:2	L2R	CROSS	10-11	44-45	D000068338	everolimus|everolimus	ChemicalEntity	10:150	11:151	0:7	D020258	Neurotoxicity	DiseaseOrPhenotypicFeature	44	45	2	1:NR:2	L2R	CROSS	10-11	56-57	D000068338	everolimus|everolimus	ChemicalEntity	10:150	11:151	0:7	D001927	encephalopathy	DiseaseOrPhenotypicFeature	56	57	3	1:NR:2	L2R	CROSS	10-11	58-59	D000068338	everolimus|everolimus	ChemicalEntity	10:150	11:151	0:7	D006261	headaches	DiseaseOrPhenotypicFeature	58	59	3	1:NR:2	L2R	CROSS	10-11	60-61	D000068338	everolimus|everolimus	ChemicalEntity	10:150	11:151	0:7	D012640	seizures	DiseaseOrPhenotypicFeature	60	61	3	1:NR:2	L2R	CROSS	10-11	63-65	D000068338	everolimus|everolimus	ChemicalEntity	10:150	11:151	0:7	D009461	neurological deficits	DiseaseOrPhenotypicFeature	63	65	3	1:Negative_Correlation:2	R2L	CROSS	150-151	107-108	D009187	myelitis	DiseaseOrPhenotypicFeature	107	108	5	D000068338	everolimus|everolimus	ChemicalEntity	10:150	11:151	0:7	1:NR:2	L2R	CROSS	130-131	150-151	D000068338	everolimus|everolimus	ChemicalEntity	10:150	11:151	0:7	D008775	methylprednisolone	ChemicalEntity	130	131	6	1:NR:2	L2R	CROSS	44-45	130-131	D020258	Neurotoxicity	DiseaseOrPhenotypicFeature	44	45	2	D008775	methylprednisolone	ChemicalEntity	130	131	6	1:NR:2	L2R	CROSS	56-57	130-131	D001927	encephalopathy	DiseaseOrPhenotypicFeature	56	57	3	D008775	methylprednisolone	ChemicalEntity	130	131	6	1:NR:2	L2R	CROSS	58-59	130-131	D006261	headaches	DiseaseOrPhenotypicFeature	58	59	3	D008775	methylprednisolone	ChemicalEntity	130	131	6	1:NR:2	L2R	CROSS	60-61	130-131	D012640	seizures	DiseaseOrPhenotypicFeature	60	61	3	D008775	methylprednisolone	ChemicalEntity	130	131	6	1:NR:2	L2R	CROSS	63-65	130-131	D009461	neurological deficits	DiseaseOrPhenotypicFeature	63	65	3	D008775	methylprednisolone	ChemicalEntity	130	131	6	1:NR:2	L2R	CROSS	107-108	130-131	D009187	myelitis	DiseaseOrPhenotypicFeature	107	108	5	D008775	methylprednisolone	ChemicalEntity	130	131	6
26991973	MOL1 is required for cambium homeostasis in Arabidopsis .|Plants maintain pools of pluripotent stem cells which allow them to constantly produce new tissues and organs .|Stem cell homeostasis in shoot and root tips depends on negative regulation by ligand - receptor pairs of the CLE peptide and leucine - rich repeat receptor - like kinase ( LRR - RLK ) families .|However , regulation of the cambium , the stem cell niche required for lateral growth of shoots and roots , is poorly characterized .|Here we show that the LRR - RLK MOL1 is necessary for cambium homeostasis in Arabidopsis thaliana .|By employing promoter reporter lines , we reveal that MOL1 is active in a domain that is distinct from the domain of the positively acting CLE41 / PXY signaling module .|In particular , we show that MOL1 acts in an opposing manner to the CLE41 / PXY module and that changing the domain or level of MOL1 expression both result in disturbed cambium organization .|Underlining discrete roles of MOL1 and PXY , both LRR - RLKs are not able to replace each other when their expression domains are interchanged .|Furthermore , MOL1 but not PXY is able to rescue CLV1 deficiency in the shoot apical meristem .|By identifying genes mis - expressed in mol1 mutants , we demonstrate that MOL1 represses genes associated with stress - related ethylene and jasmonic acid hormone signaling pathways which have known roles in coordinating lateral growth of the Arabidopsis stem .|Our findings provide evidence that common regulatory mechanisms in different plant stem cell niches are adapted to specific niche anatomies and emphasize the importance of a complex spatial organization of intercellular signaling cascades for a strictly bidirectional tissue production .	1:NR:2	L2R	CROSS	0-1	46-48	835209	MOL1|MOL1|MOL1|MOL1|MOL1|MOL1|MOL1|mol1|MOL1	GeneOrGeneProduct	0:96:115:143:163:176:200:223:229	1:97:116:144:164:177:201:224:230	0:4:5:6:6:7:8:9:9	820713,821957,832170	CLE peptide	GeneOrGeneProduct	46	48	2	1:NR:2	L2R	NON-CROSS	93-96	96-97	835209	MOL1|MOL1|MOL1|MOL1|MOL1|MOL1|MOL1|mol1|MOL1	GeneOrGeneProduct	0:96:115:143:163:176:200:223:229	1:97:116:144:164:177:201:224:230	0:4:5:6:6:7:8:9:9	835209,836269	leucine - rich repeat receptor - like kinase|LRR - RLK|LRR - RLK|LRR - RLKs	GeneOrGeneProduct	49:58:93:181	57:61:96:184	2:2:4:7	1:NR:2	L2R	NON-CROSS	143-144	151-152	835209	MOL1|MOL1|MOL1|MOL1|MOL1|MOL1|MOL1|mol1|MOL1	GeneOrGeneProduct	0:96:115:143:163:176:200:223:229	1:97:116:144:164:177:201:224:230	0:4:5:6:6:7:8:9:9	822075	CLE41|CLE41	GeneOrGeneProduct	131:151	132:152	5:6	1:NR:2	L2R	NON-CROSS	176-177	178-179	835209	MOL1|MOL1|MOL1|MOL1|MOL1|MOL1|MOL1|mol1|MOL1	GeneOrGeneProduct	0:96:115:143:163:176:200:223:229	1:97:116:144:164:177:201:224:230	0:4:5:6:6:7:8:9:9	836269	PXY|PXY|PXY|PXY	GeneOrGeneProduct	133:153:178:203	134:154:179:204	5:6:7:8	1:Positive_Correlation:2	L2R	NON-CROSS	200-201	208-209	835209	MOL1|MOL1|MOL1|MOL1|MOL1|MOL1|MOL1|mol1|MOL1	GeneOrGeneProduct	0:96:115:143:163:176:200:223:229	1:97:116:144:164:177:201:224:230	0:4:5:6:6:7:8:9:9	843915	CLV1	GeneOrGeneProduct	208	209	8	1:Association:2	L2R	NON-CROSS	229-230	237-238	835209	MOL1|MOL1|MOL1|MOL1|MOL1|MOL1|MOL1|mol1|MOL1	GeneOrGeneProduct	0:96:115:143:163:176:200:223:229	1:97:116:144:164:177:201:224:230	0:4:5:6:6:7:8:9:9	D005030	ethylene	ChemicalEntity	237	238	9	1:Association:2	L2R	NON-CROSS	229-230	239-241	835209	MOL1|MOL1|MOL1|MOL1|MOL1|MOL1|MOL1|mol1|MOL1	GeneOrGeneProduct	0:96:115:143:163:176:200:223:229	1:97:116:144:164:177:201:224:230	0:4:5:6:6:7:8:9:9	C011006	jasmonic acid	ChemicalEntity	239	241	9	1:NR:2	L2R	NON-CROSS	46-48	49-57	820713,821957,832170	CLE peptide	GeneOrGeneProduct	46	48	2	835209,836269	leucine - rich repeat receptor - like kinase|LRR - RLK|LRR - RLK|LRR - RLKs	GeneOrGeneProduct	49:58:93:181	57:61:96:184	2:2:4:7	1:NR:2	L2R	CROSS	46-48	131-132	820713,821957,832170	CLE peptide	GeneOrGeneProduct	46	48	2	822075	CLE41|CLE41	GeneOrGeneProduct	131:151	132:152	5:6	1:NR:2	L2R	CROSS	46-48	133-134	820713,821957,832170	CLE peptide	GeneOrGeneProduct	46	48	2	836269	PXY|PXY|PXY|PXY	GeneOrGeneProduct	133:153:178:203	134:154:179:204	5:6:7:8	1:NR:2	L2R	CROSS	46-48	208-209	820713,821957,832170	CLE peptide	GeneOrGeneProduct	46	48	2	843915	CLV1	GeneOrGeneProduct	208	209	8	1:NR:2	L2R	CROSS	46-48	237-238	820713,821957,832170	CLE peptide	GeneOrGeneProduct	46	48	2	D005030	ethylene	ChemicalEntity	237	238	9	1:NR:2	L2R	CROSS	46-48	239-241	820713,821957,832170	CLE peptide	GeneOrGeneProduct	46	48	2	C011006	jasmonic acid	ChemicalEntity	239	241	9	1:NR:2	L2R	CROSS	151-152	181-184	835209,836269	leucine - rich repeat receptor - like kinase|LRR - RLK|LRR - RLK|LRR - RLKs	GeneOrGeneProduct	49:58:93:181	57:61:96:184	2:2:4:7	822075	CLE41|CLE41	GeneOrGeneProduct	131:151	132:152	5:6	1:NR:2	L2R	NON-CROSS	178-179	181-184	835209,836269	leucine - rich repeat receptor - like kinase|LRR - RLK|LRR - RLK|LRR - RLKs	GeneOrGeneProduct	49:58:93:181	57:61:96:184	2:2:4:7	836269	PXY|PXY|PXY|PXY	GeneOrGeneProduct	133:153:178:203	134:154:179:204	5:6:7:8	1:NR:2	L2R	CROSS	181-184	208-209	835209,836269	leucine - rich repeat receptor - like kinase|LRR - RLK|LRR - RLK|LRR - RLKs	GeneOrGeneProduct	49:58:93:181	57:61:96:184	2:2:4:7	843915	CLV1	GeneOrGeneProduct	208	209	8	1:NR:2	L2R	CROSS	181-184	237-238	835209,836269	leucine - rich repeat receptor - like kinase|LRR - RLK|LRR - RLK|LRR - RLKs	GeneOrGeneProduct	49:58:93:181	57:61:96:184	2:2:4:7	D005030	ethylene	ChemicalEntity	237	238	9	1:NR:2	L2R	CROSS	181-184	239-241	835209,836269	leucine - rich repeat receptor - like kinase|LRR - RLK|LRR - RLK|LRR - RLKs	GeneOrGeneProduct	49:58:93:181	57:61:96:184	2:2:4:7	C011006	jasmonic acid	ChemicalEntity	239	241	9	1:Bind:2	L2R	NON-CROSS	131-132	133-134	822075	CLE41|CLE41	GeneOrGeneProduct	131:151	132:152	5:6	836269	PXY|PXY|PXY|PXY	GeneOrGeneProduct	133:153:178:203	134:154:179:204	5:6:7:8	1:NR:2	L2R	CROSS	151-152	208-209	822075	CLE41|CLE41	GeneOrGeneProduct	131:151	132:152	5:6	843915	CLV1	GeneOrGeneProduct	208	209	8	1:NR:2	L2R	CROSS	151-152	237-238	822075	CLE41|CLE41	GeneOrGeneProduct	131:151	132:152	5:6	D005030	ethylene	ChemicalEntity	237	238	9	1:NR:2	L2R	CROSS	151-152	239-241	822075	CLE41|CLE41	GeneOrGeneProduct	131:151	132:152	5:6	C011006	jasmonic acid	ChemicalEntity	239	241	9	1:NR:2	L2R	NON-CROSS	203-204	208-209	836269	PXY|PXY|PXY|PXY	GeneOrGeneProduct	133:153:178:203	134:154:179:204	5:6:7:8	843915	CLV1	GeneOrGeneProduct	208	209	8	1:NR:2	L2R	CROSS	203-204	237-238	836269	PXY|PXY|PXY|PXY	GeneOrGeneProduct	133:153:178:203	134:154:179:204	5:6:7:8	D005030	ethylene	ChemicalEntity	237	238	9	1:NR:2	L2R	CROSS	203-204	239-241	836269	PXY|PXY|PXY|PXY	GeneOrGeneProduct	133:153:178:203	134:154:179:204	5:6:7:8	C011006	jasmonic acid	ChemicalEntity	239	241	9	1:NR:2	L2R	CROSS	208-209	237-238	843915	CLV1	GeneOrGeneProduct	208	209	8	D005030	ethylene	ChemicalEntity	237	238	9	1:NR:2	L2R	CROSS	208-209	239-241	843915	CLV1	GeneOrGeneProduct	208	209	8	C011006	jasmonic acid	ChemicalEntity	239	241	9	1:NR:2	L2R	NON-CROSS	237-238	239-241	D005030	ethylene	ChemicalEntity	237	238	9	C011006	jasmonic acid	ChemicalEntity	239	241	9
16112787	In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin - induced nephrotoxicity : protection by erdosteine .|The aims of this study were to examine vancomycin ( VCM ) - induced oxidative stress that promotes production of reactive oxygen species ( ROS ) and to investigate the role of erdosteine , an expectorant agent , which has also antioxidant properties , on kidney tissue against the possible VCM - induced renal impairment in rats .|Rats were divided into three groups : sham , VCM and VCM plus erdosteine .|VCM was administrated intraperitoneally ( i . p . ) with 200mgkg ( - 1 ) twice daily for 7 days .|Erdosteine was administered orally .|VCM administration to control rats significantly increased renal malondialdehyde ( MDA ) and urinary N - acetyl - beta - d - glucosaminidase ( NAG , a marker of renal tubular injury ) excretion but decreased superoxide dismutase ( SOD ) and catalase ( CAT ) activities .|Erdosteine administration with VCM injections caused significantly decreased renal MDA and urinary NAG excretion , and increased SOD activity , but not CAT activity in renal tissue when compared with VCM alone .|Erdosteine showed histopathological protection against VCM - induced nephrotoxicity .|There were a significant dilatation of tubular lumens , extensive epithelial cell vacuolization , atrophy , desquamation , and necrosis in VCM - treated rats more than those of the control and the erdosteine groups .|Erdosteine caused a marked reduction in the extent of tubular damage .|It is concluded that oxidative tubular damage plays an important role in the VCM - induced nephrotoxicity and the modulation of oxidative stress with erdosteine reduces the VCM - induced kidney damage both at the biochemical and histological levels .	1:Positive_Correlation:2	L2R	NON-CROSS	12-13	15-16	D014640	vancomycin|vancomycin|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM	ChemicalEntity	12:29:31:71:88:90:94:121:172:199:207:233:273:287	13:30:32:72:89:91:95:122:173:200:208:234:274:288	0:1:1:1:2:2:3:5:6:6:7:8:10:10	D007674	nephrotoxicity|renal impairment|renal tubular injury|nephrotoxicity|nephrotoxicity|kidney damage	DiseaseOrPhenotypicFeature	15:74:150:210:276:290	16:76:153:211:277:292	0:1:5:7:10:10	1:Negative_Correlation:2	L2R	NON-CROSS	90-91	92-93	D014640	vancomycin|vancomycin|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM	ChemicalEntity	12:29:31:71:88:90:94:121:172:199:207:233:273:287	13:30:32:72:89:91:95:122:173:200:208:234:274:288	0:1:1:1:2:2:3:5:6:6:7:8:10:10	C048498	erdosteine|erdosteine|erdosteine|Erdosteine|Erdosteine|Erdosteine|erdosteine|Erdosteine|erdosteine	ChemicalEntity	19:53:92:116:169:202:245:248:284	20:54:93:117:170:203:246:249:285	0:1:2:4:6:7:8:9:10	1:Association:2	L2R	NON-CROSS	31-32	41-44	D014640	vancomycin|vancomycin|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM	ChemicalEntity	12:29:31:71:88:90:94:121:172:199:207:233:273:287	13:30:32:72:89:91:95:122:173:200:208:234:274:288	0:1:1:1:2:2:3:5:6:6:7:8:10:10	D017382	reactive oxygen species|ROS	ChemicalEntity	41:45	44:46	1:1	1:NR:2	L2R	NON-CROSS	62-63	71-72	D014640	vancomycin|vancomycin|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM	ChemicalEntity	12:29:31:71:88:90:94:121:172:199:207:233:273:287	13:30:32:72:89:91:95:122:173:200:208:234:274:288	0:1:1:1:2:2:3:5:6:6:7:8:10:10	D000975	antioxidant	ChemicalEntity	62	63	1	1:Positive_Correlation:2	L2R	NON-CROSS	172-173	178-179	D014640	vancomycin|vancomycin|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM	ChemicalEntity	12:29:31:71:88:90:94:121:172:199:207:233:273:287	13:30:32:72:89:91:95:122:173:200:208:234:274:288	0:1:1:1:2:2:3:5:6:6:7:8:10:10	D008315	malondialdehyde|MDA|MDA	ChemicalEntity	129:131:178	130:132:179	5:5:6	1:Positive_Correlation:2	L2R	NON-CROSS	172-173	181-182	D014640	vancomycin|vancomycin|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM	ChemicalEntity	12:29:31:71:88:90:94:121:172:199:207:233:273:287	13:30:32:72:89:91:95:122:173:200:208:234:274:288	0:1:1:1:2:2:3:5:6:6:7:8:10:10	154968	N - acetyl - beta - d - glucosaminidase|NAG|NAG	GeneOrGeneProduct	135:145:181	144:146:182	5:5:6	1:Negative_Correlation:2	L2R	NON-CROSS	160-161	172-173	D014640	vancomycin|vancomycin|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM	ChemicalEntity	12:29:31:71:88:90:94:121:172:199:207:233:273:287	13:30:32:72:89:91:95:122:173:200:208:234:274:288	0:1:1:1:2:2:3:5:6:6:7:8:10:10	D013482	superoxide dismutase|SOD|SOD	ChemicalEntity	157:160:186	159:161:187	5:5:6	1:Negative_Correlation:2	R2L	NON-CROSS	172-173	165-166	24248	catalase|CAT|CAT	GeneOrGeneProduct	163:165:191	164:166:192	5:5:6	D014640	vancomycin|vancomycin|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM	ChemicalEntity	12:29:31:71:88:90:94:121:172:199:207:233:273:287	13:30:32:72:89:91:95:122:173:200:208:234:274:288	0:1:1:1:2:2:3:5:6:6:7:8:10:10	1:Positive_Correlation:2	L2R	NON-CROSS	226-227	233-234	D014640	vancomycin|vancomycin|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM	ChemicalEntity	12:29:31:71:88:90:94:121:172:199:207:233:273:287	13:30:32:72:89:91:95:122:173:200:208:234:274:288	0:1:1:1:2:2:3:5:6:6:7:8:10:10	D001284	atrophy	DiseaseOrPhenotypicFeature	226	227	8	1:Positive_Correlation:2	L2R	NON-CROSS	228-229	233-234	D014640	vancomycin|vancomycin|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM	ChemicalEntity	12:29:31:71:88:90:94:121:172:199:207:233:273:287	13:30:32:72:89:91:95:122:173:200:208:234:274:288	0:1:1:1:2:2:3:5:6:6:7:8:10:10	D012871	desquamation	DiseaseOrPhenotypicFeature	228	229	8	1:Positive_Correlation:2	L2R	NON-CROSS	231-232	233-234	D014640	vancomycin|vancomycin|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM|VCM	ChemicalEntity	12:29:31:71:88:90:94:121:172:199:207:233:273:287	13:30:32:72:89:91:95:122:173:200:208:234:274:288	0:1:1:1:2:2:3:5:6:6:7:8:10:10	D009336	necrosis	DiseaseOrPhenotypicFeature	231	232	8	1:Negative_Correlation:2	R2L	NON-CROSS	19-20	15-16	C048498	erdosteine|erdosteine|erdosteine|Erdosteine|Erdosteine|Erdosteine|erdosteine|Erdosteine|erdosteine	ChemicalEntity	19:53:92:116:169:202:245:248:284	20:54:93:117:170:203:246:249:285	0:1:2:4:6:7:8:9:10	D007674	nephrotoxicity|renal impairment|renal tubular injury|nephrotoxicity|nephrotoxicity|kidney damage	DiseaseOrPhenotypicFeature	15:74:150:210:276:290	16:76:153:211:277:292	0:1:5:7:10:10	1:NR:2	L2R	NON-CROSS	15-16	41-44	D007674	nephrotoxicity|renal impairment|renal tubular injury|nephrotoxicity|nephrotoxicity|kidney damage	DiseaseOrPhenotypicFeature	15:74:150:210:276:290	16:76:153:211:277:292	0:1:5:7:10:10	D017382	reactive oxygen species|ROS	ChemicalEntity	41:45	44:46	1:1	1:NR:2	L2R	NON-CROSS	62-63	74-76	D007674	nephrotoxicity|renal impairment|renal tubular injury|nephrotoxicity|nephrotoxicity|kidney damage	DiseaseOrPhenotypicFeature	15:74:150:210:276:290	16:76:153:211:277:292	0:1:5:7:10:10	D000975	antioxidant	ChemicalEntity	62	63	1	1:NR:2	L2R	NON-CROSS	131-132	150-153	D007674	nephrotoxicity|renal impairment|renal tubular injury|nephrotoxicity|nephrotoxicity|kidney damage	DiseaseOrPhenotypicFeature	15:74:150:210:276:290	16:76:153:211:277:292	0:1:5:7:10:10	D008315	malondialdehyde|MDA|MDA	ChemicalEntity	129:131:178	130:132:179	5:5:6	1:Association:2	R2L	NON-CROSS	150-153	145-146	154968	N - acetyl - beta - d - glucosaminidase|NAG|NAG	GeneOrGeneProduct	135:145:181	144:146:182	5:5:6	D007674	nephrotoxicity|renal impairment|renal tubular injury|nephrotoxicity|nephrotoxicity|kidney damage	DiseaseOrPhenotypicFeature	15:74:150:210:276:290	16:76:153:211:277:292	0:1:5:7:10:10	1:NR:2	L2R	NON-CROSS	150-153	157-159	D007674	nephrotoxicity|renal impairment|renal tubular injury|nephrotoxicity|nephrotoxicity|kidney damage	DiseaseOrPhenotypicFeature	15:74:150:210:276:290	16:76:153:211:277:292	0:1:5:7:10:10	D013482	superoxide dismutase|SOD|SOD	ChemicalEntity	157:160:186	159:161:187	5:5:6	1:NR:2	L2R	NON-CROSS	150-153	163-164	D007674	nephrotoxicity|renal impairment|renal tubular injury|nephrotoxicity|nephrotoxicity|kidney damage	DiseaseOrPhenotypicFeature	15:74:150:210:276:290	16:76:153:211:277:292	0:1:5:7:10:10	24248	catalase|CAT|CAT	GeneOrGeneProduct	163:165:191	164:166:192	5:5:6	1:NR:2	L2R	NON-CROSS	45-46	53-54	C048498	erdosteine|erdosteine|erdosteine|Erdosteine|Erdosteine|Erdosteine|erdosteine|Erdosteine|erdosteine	ChemicalEntity	19:53:92:116:169:202:245:248:284	20:54:93:117:170:203:246:249:285	0:1:2:4:6:7:8:9:10	D017382	reactive oxygen species|ROS	ChemicalEntity	41:45	44:46	1:1	1:NR:2	L2R	NON-CROSS	53-54	62-63	C048498	erdosteine|erdosteine|erdosteine|Erdosteine|Erdosteine|Erdosteine|erdosteine|Erdosteine|erdosteine	ChemicalEntity	19:53:92:116:169:202:245:248:284	20:54:93:117:170:203:246:249:285	0:1:2:4:6:7:8:9:10	D000975	antioxidant	ChemicalEntity	62	63	1	1:Negative_Correlation:2	L2R	NON-CROSS	169-170	178-179	C048498	erdosteine|erdosteine|erdosteine|Erdosteine|Erdosteine|Erdosteine|erdosteine|Erdosteine|erdosteine	ChemicalEntity	19:53:92:116:169:202:245:248:284	20:54:93:117:170:203:246:249:285	0:1:2:4:6:7:8:9:10	D008315	malondialdehyde|MDA|MDA	ChemicalEntity	129:131:178	130:132:179	5:5:6	1:Negative_Correlation:2	L2R	NON-CROSS	169-170	181-182	C048498	erdosteine|erdosteine|erdosteine|Erdosteine|Erdosteine|Erdosteine|erdosteine|Erdosteine|erdosteine	ChemicalEntity	19:53:92:116:169:202:245:248:284	20:54:93:117:170:203:246:249:285	0:1:2:4:6:7:8:9:10	154968	N - acetyl - beta - d - glucosaminidase|NAG|NAG	GeneOrGeneProduct	135:145:181	144:146:182	5:5:6	1:Positive_Correlation:2	R2L	NON-CROSS	169-170	160-161	D013482	superoxide dismutase|SOD|SOD	ChemicalEntity	157:160:186	159:161:187	5:5:6	C048498	erdosteine|erdosteine|erdosteine|Erdosteine|Erdosteine|Erdosteine|erdosteine|Erdosteine|erdosteine	ChemicalEntity	19:53:92:116:169:202:245:248:284	20:54:93:117:170:203:246:249:285	0:1:2:4:6:7:8:9:10	1:NR:2	L2R	NON-CROSS	165-166	169-170	C048498	erdosteine|erdosteine|erdosteine|Erdosteine|Erdosteine|Erdosteine|erdosteine|Erdosteine|erdosteine	ChemicalEntity	19:53:92:116:169:202:245:248:284	20:54:93:117:170:203:246:249:285	0:1:2:4:6:7:8:9:10	24248	catalase|CAT|CAT	GeneOrGeneProduct	163:165:191	164:166:192	5:5:6	1:NR:2	L2R	NON-CROSS	226-227	245-246	C048498	erdosteine|erdosteine|erdosteine|Erdosteine|Erdosteine|Erdosteine|erdosteine|Erdosteine|erdosteine	ChemicalEntity	19:53:92:116:169:202:245:248:284	20:54:93:117:170:203:246:249:285	0:1:2:4:6:7:8:9:10	D001284	atrophy	DiseaseOrPhenotypicFeature	226	227	8	1:NR:2	L2R	NON-CROSS	228-229	245-246	C048498	erdosteine|erdosteine|erdosteine|Erdosteine|Erdosteine|Erdosteine|erdosteine|Erdosteine|erdosteine	ChemicalEntity	19:53:92:116:169:202:245:248:284	20:54:93:117:170:203:246:249:285	0:1:2:4:6:7:8:9:10	D012871	desquamation	DiseaseOrPhenotypicFeature	228	229	8	1:NR:2	L2R	NON-CROSS	231-232	245-246	C048498	erdosteine|erdosteine|erdosteine|Erdosteine|Erdosteine|Erdosteine|erdosteine|Erdosteine|erdosteine	ChemicalEntity	19:53:92:116:169:202:245:248:284	20:54:93:117:170:203:246:249:285	0:1:2:4:6:7:8:9:10	D009336	necrosis	DiseaseOrPhenotypicFeature	231	232	8	1:NR:2	L2R	NON-CROSS	45-46	62-63	D017382	reactive oxygen species|ROS	ChemicalEntity	41:45	44:46	1:1	D000975	antioxidant	ChemicalEntity	62	63	1	1:NR:2	L2R	CROSS	45-46	129-130	D017382	reactive oxygen species|ROS	ChemicalEntity	41:45	44:46	1:1	D008315	malondialdehyde|MDA|MDA	ChemicalEntity	129:131:178	130:132:179	5:5:6	1:NR:2	L2R	CROSS	45-46	135-144	D017382	reactive oxygen species|ROS	ChemicalEntity	41:45	44:46	1:1	154968	N - acetyl - beta - d - glucosaminidase|NAG|NAG	GeneOrGeneProduct	135:145:181	144:146:182	5:5:6	1:NR:2	L2R	CROSS	45-46	157-159	D017382	reactive oxygen species|ROS	ChemicalEntity	41:45	44:46	1:1	D013482	superoxide dismutase|SOD|SOD	ChemicalEntity	157:160:186	159:161:187	5:5:6	1:NR:2	L2R	CROSS	45-46	163-164	D017382	reactive oxygen species|ROS	ChemicalEntity	41:45	44:46	1:1	24248	catalase|CAT|CAT	GeneOrGeneProduct	163:165:191	164:166:192	5:5:6	1:NR:2	L2R	CROSS	45-46	226-227	D017382	reactive oxygen species|ROS	ChemicalEntity	41:45	44:46	1:1	D001284	atrophy	DiseaseOrPhenotypicFeature	226	227	8	1:NR:2	L2R	CROSS	45-46	228-229	D017382	reactive oxygen species|ROS	ChemicalEntity	41:45	44:46	1:1	D012871	desquamation	DiseaseOrPhenotypicFeature	228	229	8	1:NR:2	L2R	CROSS	45-46	231-232	D017382	reactive oxygen species|ROS	ChemicalEntity	41:45	44:46	1:1	D009336	necrosis	DiseaseOrPhenotypicFeature	231	232	8	1:NR:2	L2R	CROSS	62-63	129-130	D000975	antioxidant	ChemicalEntity	62	63	1	D008315	malondialdehyde|MDA|MDA	ChemicalEntity	129:131:178	130:132:179	5:5:6	1:NR:2	L2R	CROSS	62-63	135-144	D000975	antioxidant	ChemicalEntity	62	63	1	154968	N - acetyl - beta - d - glucosaminidase|NAG|NAG	GeneOrGeneProduct	135:145:181	144:146:182	5:5:6	1:NR:2	L2R	CROSS	62-63	157-159	D000975	antioxidant	ChemicalEntity	62	63	1	D013482	superoxide dismutase|SOD|SOD	ChemicalEntity	157:160:186	159:161:187	5:5:6	1:NR:2	L2R	CROSS	62-63	163-164	D000975	antioxidant	ChemicalEntity	62	63	1	24248	catalase|CAT|CAT	GeneOrGeneProduct	163:165:191	164:166:192	5:5:6	1:NR:2	L2R	CROSS	62-63	226-227	D000975	antioxidant	ChemicalEntity	62	63	1	D001284	atrophy	DiseaseOrPhenotypicFeature	226	227	8	1:NR:2	L2R	CROSS	62-63	228-229	D000975	antioxidant	ChemicalEntity	62	63	1	D012871	desquamation	DiseaseOrPhenotypicFeature	228	229	8	1:NR:2	L2R	CROSS	62-63	231-232	D000975	antioxidant	ChemicalEntity	62	63	1	D009336	necrosis	DiseaseOrPhenotypicFeature	231	232	8	1:NR:2	L2R	NON-CROSS	178-179	181-182	D008315	malondialdehyde|MDA|MDA	ChemicalEntity	129:131:178	130:132:179	5:5:6	154968	N - acetyl - beta - d - glucosaminidase|NAG|NAG	GeneOrGeneProduct	135:145:181	144:146:182	5:5:6	1:NR:2	L2R	NON-CROSS	178-179	186-187	D008315	malondialdehyde|MDA|MDA	ChemicalEntity	129:131:178	130:132:179	5:5:6	D013482	superoxide dismutase|SOD|SOD	ChemicalEntity	157:160:186	159:161:187	5:5:6	1:NR:2	L2R	NON-CROSS	165-166	178-179	D008315	malondialdehyde|MDA|MDA	ChemicalEntity	129:131:178	130:132:179	5:5:6	24248	catalase|CAT|CAT	GeneOrGeneProduct	163:165:191	164:166:192	5:5:6	1:NR:2	L2R	CROSS	178-179	226-227	D008315	malondialdehyde|MDA|MDA	ChemicalEntity	129:131:178	130:132:179	5:5:6	D001284	atrophy	DiseaseOrPhenotypicFeature	226	227	8	1:NR:2	L2R	CROSS	178-179	228-229	D008315	malondialdehyde|MDA|MDA	ChemicalEntity	129:131:178	130:132:179	5:5:6	D012871	desquamation	DiseaseOrPhenotypicFeature	228	229	8	1:NR:2	L2R	CROSS	178-179	231-232	D008315	malondialdehyde|MDA|MDA	ChemicalEntity	129:131:178	130:132:179	5:5:6	D009336	necrosis	DiseaseOrPhenotypicFeature	231	232	8	1:NR:2	L2R	NON-CROSS	181-182	186-187	154968	N - acetyl - beta - d - glucosaminidase|NAG|NAG	GeneOrGeneProduct	135:145:181	144:146:182	5:5:6	D013482	superoxide dismutase|SOD|SOD	ChemicalEntity	157:160:186	159:161:187	5:5:6	1:NR:2	L2R	NON-CROSS	181-182	191-192	154968	N - acetyl - beta - d - glucosaminidase|NAG|NAG	GeneOrGeneProduct	135:145:181	144:146:182	5:5:6	24248	catalase|CAT|CAT	GeneOrGeneProduct	163:165:191	164:166:192	5:5:6	1:NR:2	L2R	CROSS	181-182	226-227	154968	N - acetyl - beta - d - glucosaminidase|NAG|NAG	GeneOrGeneProduct	135:145:181	144:146:182	5:5:6	D001284	atrophy	DiseaseOrPhenotypicFeature	226	227	8	1:NR:2	L2R	CROSS	181-182	228-229	154968	N - acetyl - beta - d - glucosaminidase|NAG|NAG	GeneOrGeneProduct	135:145:181	144:146:182	5:5:6	D012871	desquamation	DiseaseOrPhenotypicFeature	228	229	8	1:NR:2	L2R	CROSS	181-182	231-232	154968	N - acetyl - beta - d - glucosaminidase|NAG|NAG	GeneOrGeneProduct	135:145:181	144:146:182	5:5:6	D009336	necrosis	DiseaseOrPhenotypicFeature	231	232	8	1:NR:2	L2R	NON-CROSS	160-161	163-164	D013482	superoxide dismutase|SOD|SOD	ChemicalEntity	157:160:186	159:161:187	5:5:6	24248	catalase|CAT|CAT	GeneOrGeneProduct	163:165:191	164:166:192	5:5:6	1:NR:2	L2R	CROSS	186-187	226-227	D013482	superoxide dismutase|SOD|SOD	ChemicalEntity	157:160:186	159:161:187	5:5:6	D001284	atrophy	DiseaseOrPhenotypicFeature	226	227	8	1:NR:2	L2R	CROSS	186-187	228-229	D013482	superoxide dismutase|SOD|SOD	ChemicalEntity	157:160:186	159:161:187	5:5:6	D012871	desquamation	DiseaseOrPhenotypicFeature	228	229	8	1:NR:2	L2R	CROSS	186-187	231-232	D013482	superoxide dismutase|SOD|SOD	ChemicalEntity	157:160:186	159:161:187	5:5:6	D009336	necrosis	DiseaseOrPhenotypicFeature	231	232	8	1:NR:2	L2R	CROSS	191-192	226-227	24248	catalase|CAT|CAT	GeneOrGeneProduct	163:165:191	164:166:192	5:5:6	D001284	atrophy	DiseaseOrPhenotypicFeature	226	227	8	1:NR:2	L2R	CROSS	191-192	228-229	24248	catalase|CAT|CAT	GeneOrGeneProduct	163:165:191	164:166:192	5:5:6	D012871	desquamation	DiseaseOrPhenotypicFeature	228	229	8	1:NR:2	L2R	CROSS	191-192	231-232	24248	catalase|CAT|CAT	GeneOrGeneProduct	163:165:191	164:166:192	5:5:6	D009336	necrosis	DiseaseOrPhenotypicFeature	231	232	8
21405999	Mutation screening of the GUCA1B gene in patients with autosomal dominant cone and cone rod dystrophy .|Background : Heterozygous mutations in GUCA1A ( MIM # 600364 ) have been identified to cause autosomal dominantly inherited cone dystrophy , cone rod dystrophy and macular dystrophy .|However , the role of GUCA1B gene mutations in inherited retinal disease has been controversial .|We therefore performed a mutation analysis of the GUCA1B gene in a clinically well characterized group of patients of European and North - American geographical origin with autosomal dominantly inherited cone dystrophy and cone rod dystrophy .|Material and Methods : Twenty - four unrelated patients diagnosed with cone dystrophy or cone rod dystrophy according to standard diagnostic criteria and a family history consistent with an autosomal dominant mode of inheritance were included in the study .|Mutation analysis of all coding exons of the GUCA1B gene was performed by polymerase chain reaction amplification of genomic DNA and subsequent DNA sequencing .|Results : Three different sequence variants , c . - 17T > C , c . 171T > C , c . 465G > T were identified .|The sequence variant c . 465G > T encodes a conservative amino acid substitution , p . Glu155Asp , located in EF - hand 4 , the calcium binding site of GCAP2 protein .|All sequence variants were previously reported in healthy subjects .|Conclusion : The absence of clearly pathogenic mutations in the selected patient group suggests that the GUCA1B gene is a minor cause for retinal degenerations in Europeans or North - Americans .	1:NR:2	L2R	NON-CROSS	4-5	11-16	2979	GUCA1B|GUCA1B|GUCA1B|GUCA1B|GCAP2|GUCA1B	GeneOrGeneProduct	4:51:70:147:223:252	5:52:71:148:224:253	0:2:3:5:7:9	D000071700,D000077765	cone and cone rod dystrophy	DiseaseOrPhenotypicFeature	11	16	0	1:NR:2	L2R	CROSS	4-5	22-23	2979	GUCA1B|GUCA1B|GUCA1B|GUCA1B|GCAP2|GUCA1B	GeneOrGeneProduct	4:51:70:147:223:252	5:52:71:148:224:253	0:2:3:5:7:9	2978	GUCA1A	GeneOrGeneProduct	22	23	1	1:Association:2	L2R	NON-CROSS	36-38	51-52	2979	GUCA1B|GUCA1B|GUCA1B|GUCA1B|GCAP2|GUCA1B	GeneOrGeneProduct	4:51:70:147:223:252	5:52:71:148:224:253	0:2:3:5:7:9	D000077765	cone dystrophy|cone dystrophy|cone dystrophy	DiseaseOrPhenotypicFeature	36:92:110	38:94:112	1:3:4	1:Association:2	L2R	NON-CROSS	39-42	51-52	2979	GUCA1B|GUCA1B|GUCA1B|GUCA1B|GCAP2|GUCA1B	GeneOrGeneProduct	4:51:70:147:223:252	5:52:71:148:224:253	0:2:3:5:7:9	D000071700	cone rod dystrophy|cone rod dystrophy|cone rod dystrophy	DiseaseOrPhenotypicFeature	39:95:113	42:98:116	1:3:4	1:NR:2	L2R	CROSS	43-45	51-52	2979	GUCA1B|GUCA1B|GUCA1B|GUCA1B|GCAP2|GUCA1B	GeneOrGeneProduct	4:51:70:147:223:252	5:52:71:148:224:253	0:2:3:5:7:9	D008268	macular dystrophy	DiseaseOrPhenotypicFeature	43	45	1	1:Association:2	L2R	NON-CROSS	51-52	56-58	2979	GUCA1B|GUCA1B|GUCA1B|GUCA1B|GCAP2|GUCA1B	GeneOrGeneProduct	4:51:70:147:223:252	5:52:71:148:224:253	0:2:3:5:7:9	D012164	retinal disease	DiseaseOrPhenotypicFeature	56	58	2	1:Bind:2	R2L	NON-CROSS	223-224	219-220	D002118	calcium	ChemicalEntity	219	220	7	2979	GUCA1B|GUCA1B|GUCA1B|GUCA1B|GCAP2|GUCA1B	GeneOrGeneProduct	4:51:70:147:223:252	5:52:71:148:224:253	0:2:3:5:7:9	1:Association:2	L2R	NON-CROSS	252-253	259-261	2979	GUCA1B|GUCA1B|GUCA1B|GUCA1B|GCAP2|GUCA1B	GeneOrGeneProduct	4:51:70:147:223:252	5:52:71:148:224:253	0:2:3:5:7:9	D012162	retinal degenerations	DiseaseOrPhenotypicFeature	259	261	9	1:NR:2	L2R	CROSS	11-16	22-23	D000071700,D000077765	cone and cone rod dystrophy	DiseaseOrPhenotypicFeature	11	16	0	2978	GUCA1A	GeneOrGeneProduct	22	23	1	1:NR:2	L2R	CROSS	11-16	171-177	D000071700,D000077765	cone and cone rod dystrophy	DiseaseOrPhenotypicFeature	11	16	0	rs1474867	c . - 17T > C	SequenceVariant	171	177	6	1:NR:2	L2R	CROSS	11-16	178-183	D000071700,D000077765	cone and cone rod dystrophy	DiseaseOrPhenotypicFeature	11	16	0	rs3749921	c . 171T > C	SequenceVariant	178	183	6	1:NR:2	L2R	CROSS	11-16	184-189	D000071700,D000077765	cone and cone rod dystrophy	DiseaseOrPhenotypicFeature	11	16	0	rs139923590	c . 465G > T|c . 465G > T|p . Glu155Asp	SequenceVariant	184:195:207	189:200:210	6:7:7	1:NR:2	L2R	CROSS	11-16	219-220	D000071700,D000077765	cone and cone rod dystrophy	DiseaseOrPhenotypicFeature	11	16	0	D002118	calcium	ChemicalEntity	219	220	7	1:Association:2	R2L	NON-CROSS	36-38	22-23	D000077765	cone dystrophy|cone dystrophy|cone dystrophy	DiseaseOrPhenotypicFeature	36:92:110	38:94:112	1:3:4	2978	GUCA1A	GeneOrGeneProduct	22	23	1	1:Association:2	R2L	NON-CROSS	39-42	22-23	D000071700	cone rod dystrophy|cone rod dystrophy|cone rod dystrophy	DiseaseOrPhenotypicFeature	39:95:113	42:98:116	1:3:4	2978	GUCA1A	GeneOrGeneProduct	22	23	1	1:Association:2	R2L	NON-CROSS	43-45	22-23	D008268	macular dystrophy	DiseaseOrPhenotypicFeature	43	45	1	2978	GUCA1A	GeneOrGeneProduct	22	23	1	1:NR:2	L2R	CROSS	22-23	56-58	2978	GUCA1A	GeneOrGeneProduct	22	23	1	D012164	retinal disease	DiseaseOrPhenotypicFeature	56	58	2	1:NR:2	L2R	CROSS	22-23	219-220	2978	GUCA1A	GeneOrGeneProduct	22	23	1	D002118	calcium	ChemicalEntity	219	220	7	1:NR:2	L2R	CROSS	22-23	259-261	2978	GUCA1A	GeneOrGeneProduct	22	23	1	D012162	retinal degenerations	DiseaseOrPhenotypicFeature	259	261	9	1:Positive_Correlation:2	L2R	CROSS	110-112	171-177	D000077765	cone dystrophy|cone dystrophy|cone dystrophy	DiseaseOrPhenotypicFeature	36:92:110	38:94:112	1:3:4	rs1474867	c . - 17T > C	SequenceVariant	171	177	6	1:Positive_Correlation:2	L2R	CROSS	110-112	178-183	D000077765	cone dystrophy|cone dystrophy|cone dystrophy	DiseaseOrPhenotypicFeature	36:92:110	38:94:112	1:3:4	rs3749921	c . 171T > C	SequenceVariant	178	183	6	1:Positive_Correlation:2	L2R	CROSS	110-112	184-189	D000077765	cone dystrophy|cone dystrophy|cone dystrophy	DiseaseOrPhenotypicFeature	36:92:110	38:94:112	1:3:4	rs139923590	c . 465G > T|c . 465G > T|p . Glu155Asp	SequenceVariant	184:195:207	189:200:210	6:7:7	1:NR:2	L2R	CROSS	110-112	219-220	D000077765	cone dystrophy|cone dystrophy|cone dystrophy	DiseaseOrPhenotypicFeature	36:92:110	38:94:112	1:3:4	D002118	calcium	ChemicalEntity	219	220	7	1:Positive_Correlation:2	L2R	CROSS	113-116	171-177	D000071700	cone rod dystrophy|cone rod dystrophy|cone rod dystrophy	DiseaseOrPhenotypicFeature	39:95:113	42:98:116	1:3:4	rs1474867	c . - 17T > C	SequenceVariant	171	177	6	1:Positive_Correlation:2	L2R	CROSS	113-116	178-183	D000071700	cone rod dystrophy|cone rod dystrophy|cone rod dystrophy	DiseaseOrPhenotypicFeature	39:95:113	42:98:116	1:3:4	rs3749921	c . 171T > C	SequenceVariant	178	183	6	1:Positive_Correlation:2	L2R	CROSS	113-116	184-189	D000071700	cone rod dystrophy|cone rod dystrophy|cone rod dystrophy	DiseaseOrPhenotypicFeature	39:95:113	42:98:116	1:3:4	rs139923590	c . 465G > T|c . 465G > T|p . Glu155Asp	SequenceVariant	184:195:207	189:200:210	6:7:7	1:NR:2	L2R	CROSS	113-116	219-220	D000071700	cone rod dystrophy|cone rod dystrophy|cone rod dystrophy	DiseaseOrPhenotypicFeature	39:95:113	42:98:116	1:3:4	D002118	calcium	ChemicalEntity	219	220	7	1:NR:2	L2R	CROSS	43-45	171-177	D008268	macular dystrophy	DiseaseOrPhenotypicFeature	43	45	1	rs1474867	c . - 17T > C	SequenceVariant	171	177	6	1:NR:2	L2R	CROSS	43-45	178-183	D008268	macular dystrophy	DiseaseOrPhenotypicFeature	43	45	1	rs3749921	c . 171T > C	SequenceVariant	178	183	6	1:NR:2	L2R	CROSS	43-45	184-189	D008268	macular dystrophy	DiseaseOrPhenotypicFeature	43	45	1	rs139923590	c . 465G > T|c . 465G > T|p . Glu155Asp	SequenceVariant	184:195:207	189:200:210	6:7:7	1:NR:2	L2R	CROSS	43-45	219-220	D008268	macular dystrophy	DiseaseOrPhenotypicFeature	43	45	1	D002118	calcium	ChemicalEntity	219	220	7	1:NR:2	L2R	CROSS	56-58	171-177	D012164	retinal disease	DiseaseOrPhenotypicFeature	56	58	2	rs1474867	c . - 17T > C	SequenceVariant	171	177	6	1:NR:2	L2R	CROSS	56-58	178-183	D012164	retinal disease	DiseaseOrPhenotypicFeature	56	58	2	rs3749921	c . 171T > C	SequenceVariant	178	183	6	1:NR:2	L2R	CROSS	56-58	184-189	D012164	retinal disease	DiseaseOrPhenotypicFeature	56	58	2	rs139923590	c . 465G > T|c . 465G > T|p . Glu155Asp	SequenceVariant	184:195:207	189:200:210	6:7:7	1:NR:2	L2R	CROSS	56-58	219-220	D012164	retinal disease	DiseaseOrPhenotypicFeature	56	58	2	D002118	calcium	ChemicalEntity	219	220	7	1:NR:2	L2R	CROSS	171-177	219-220	rs1474867	c . - 17T > C	SequenceVariant	171	177	6	D002118	calcium	ChemicalEntity	219	220	7	1:NR:2	L2R	CROSS	171-177	259-261	rs1474867	c . - 17T > C	SequenceVariant	171	177	6	D012162	retinal degenerations	DiseaseOrPhenotypicFeature	259	261	9	1:NR:2	L2R	CROSS	178-183	219-220	rs3749921	c . 171T > C	SequenceVariant	178	183	6	D002118	calcium	ChemicalEntity	219	220	7	1:NR:2	L2R	CROSS	178-183	259-261	rs3749921	c . 171T > C	SequenceVariant	178	183	6	D012162	retinal degenerations	DiseaseOrPhenotypicFeature	259	261	9	1:Association:2	L2R	NON-CROSS	207-210	219-220	rs139923590	c . 465G > T|c . 465G > T|p . Glu155Asp	SequenceVariant	184:195:207	189:200:210	6:7:7	D002118	calcium	ChemicalEntity	219	220	7	1:NR:2	L2R	CROSS	207-210	259-261	rs139923590	c . 465G > T|c . 465G > T|p . Glu155Asp	SequenceVariant	184:195:207	189:200:210	6:7:7	D012162	retinal degenerations	DiseaseOrPhenotypicFeature	259	261	9	1:NR:2	L2R	CROSS	219-220	259-261	D002118	calcium	ChemicalEntity	219	220	7	D012162	retinal degenerations	DiseaseOrPhenotypicFeature	259	261	9
15233872	Cardioprotective effect of tincture of Crataegus on isoproterenol - induced myocardial infarction in rats .|Tincture of Crataegus ( TCR ) , an alcoholic extract of the berries of hawthorn ( Crataegus oxycantha ) , is used in herbal and homeopathic medicine .|The present study was done to investigate the protective effect of TCR on experimentally induced myocardial infarction in rats .|Pretreatment of TCR , at a dose of 0 . 5 mL / 100 g bodyweight per day , orally for 30 days , prevented the increase in lipid peroxidation and activity of marker enzymes observed in isoproterenol - induced rats ( 85 mg kg ( - 1 ) s .|c .|for 2 days at an interval of 24 h ) .|TCR prevented the isoproterenol - induced decrease in antioxidant enzymes in the heart and increased the rate of ADP - stimulated oxygen uptake and respiratory coupling ratio .|TCR protected against pathological changes induced by isoproterenol in rat heart .|The results show that pretreatment with TCR may be useful in preventing the damage induced by isoproterenol in rat heart .	1:Negative_Correlation:2	L2R	NON-CROSS	3-6	7-8	C007145	tincture of Crataegus|Tincture of Crataegus|TCR|alcoholic extract of the berries of hawthorn|Crataegus oxycantha|TCR|TCR|TCR|TCR|TCR	ChemicalEntity	3:15:19:23:31:54:65:127:155:173	6:18:20:30:33:55:66:128:156:174	0:1:1:1:1:2:3:6:7:8	D007545	isoproterenol|isoproterenol|isoproterenol|isoproterenol|isoproterenol	ChemicalEntity	7:100:130:162:183	8:101:131:163:184	0:3:6:7:8	1:Negative_Correlation:2	L2R	NON-CROSS	54-55	58-60	C007145	tincture of Crataegus|Tincture of Crataegus|TCR|alcoholic extract of the berries of hawthorn|Crataegus oxycantha|TCR|TCR|TCR|TCR|TCR	ChemicalEntity	3:15:19:23:31:54:65:127:155:173	6:18:20:30:33:55:66:128:156:174	0:1:1:1:1:2:3:6:7:8	D009203	myocardial infarction|myocardial infarction	DiseaseOrPhenotypicFeature	10:58	12:60	0:2	1:Association:2	L2R	NON-CROSS	65-66	91-92	C007145	tincture of Crataegus|Tincture of Crataegus|TCR|alcoholic extract of the berries of hawthorn|Crataegus oxycantha|TCR|TCR|TCR|TCR|TCR	ChemicalEntity	3:15:19:23:31:54:65:127:155:173	6:18:20:30:33:55:66:128:156:174	0:1:1:1:1:2:3:6:7:8	D008055	lipid	ChemicalEntity	91	92	3	1:Positive_Correlation:2	L2R	NON-CROSS	145-146	155-156	C007145	tincture of Crataegus|Tincture of Crataegus|TCR|alcoholic extract of the berries of hawthorn|Crataegus oxycantha|TCR|TCR|TCR|TCR|TCR	ChemicalEntity	3:15:19:23:31:54:65:127:155:173	6:18:20:30:33:55:66:128:156:174	0:1:1:1:1:2:3:6:7:8	D000244	ADP	ChemicalEntity	145	146	6	1:Positive_Correlation:2	L2R	NON-CROSS	148-149	155-156	C007145	tincture of Crataegus|Tincture of Crataegus|TCR|alcoholic extract of the berries of hawthorn|Crataegus oxycantha|TCR|TCR|TCR|TCR|TCR	ChemicalEntity	3:15:19:23:31:54:65:127:155:173	6:18:20:30:33:55:66:128:156:174	0:1:1:1:1:2:3:6:7:8	D010100	oxygen	ChemicalEntity	148	149	6	1:Positive_Correlation:2	L2R	NON-CROSS	7-8	10-12	D007545	isoproterenol|isoproterenol|isoproterenol|isoproterenol|isoproterenol	ChemicalEntity	7:100:130:162:183	8:101:131:163:184	0:3:6:7:8	D009203	myocardial infarction|myocardial infarction	DiseaseOrPhenotypicFeature	10:58	12:60	0:2	1:NR:2	L2R	NON-CROSS	91-92	100-101	D007545	isoproterenol|isoproterenol|isoproterenol|isoproterenol|isoproterenol	ChemicalEntity	7:100:130:162:183	8:101:131:163:184	0:3:6:7:8	D008055	lipid	ChemicalEntity	91	92	3	1:NR:2	L2R	NON-CROSS	130-131	145-146	D007545	isoproterenol|isoproterenol|isoproterenol|isoproterenol|isoproterenol	ChemicalEntity	7:100:130:162:183	8:101:131:163:184	0:3:6:7:8	D000244	ADP	ChemicalEntity	145	146	6	1:NR:2	L2R	NON-CROSS	148-149	162-163	D007545	isoproterenol|isoproterenol|isoproterenol|isoproterenol|isoproterenol	ChemicalEntity	7:100:130:162:183	8:101:131:163:184	0:3:6:7:8	D010100	oxygen	ChemicalEntity	148	149	6	1:NR:2	L2R	CROSS	58-60	91-92	D009203	myocardial infarction|myocardial infarction	DiseaseOrPhenotypicFeature	10:58	12:60	0:2	D008055	lipid	ChemicalEntity	91	92	3	1:NR:2	L2R	CROSS	58-60	145-146	D009203	myocardial infarction|myocardial infarction	DiseaseOrPhenotypicFeature	10:58	12:60	0:2	D000244	ADP	ChemicalEntity	145	146	6	1:NR:2	L2R	CROSS	58-60	148-149	D009203	myocardial infarction|myocardial infarction	DiseaseOrPhenotypicFeature	10:58	12:60	0:2	D010100	oxygen	ChemicalEntity	148	149	6	1:NR:2	L2R	CROSS	91-92	145-146	D008055	lipid	ChemicalEntity	91	92	3	D000244	ADP	ChemicalEntity	145	146	6	1:NR:2	L2R	CROSS	91-92	148-149	D008055	lipid	ChemicalEntity	91	92	3	D010100	oxygen	ChemicalEntity	148	149	6	1:Positive_Correlation:2	L2R	NON-CROSS	145-146	148-149	D000244	ADP	ChemicalEntity	145	146	6	D010100	oxygen	ChemicalEntity	148	149	6
17059986	A novel splicing mutation in SLC12A3 associated with Gitelman syndrome and idiopathic intracranial hypertension .|We report a case of Gitelman syndrome ( GS ) in a dizygotic twin who presented at 12 years of age with growth delay , metabolic alkalosis , hypomagnesemia and hypokalemia with inappropriate kaliuresis , and idiopathic intracranial hypertension with bilateral papilledema ( pseudotumor cerebri ) .|The patient , her twin sister , and her mother also presented with cerebral cavernous malformations .|Based on the early onset and normocalciuria , Bartter syndrome was diagnosed first .|However , mutation analysis showed that the proband is a compound heterozygote for 2 mutations in SLC12A3 : a substitution of serine by leucine at amino acid position 555 ( p . Ser555Leu ) and a novel guanine to cytosine transition at the 5 ' splice site of intron 22 ( c . 2633 + 1G > C ) , providing the molecular diagnosis of GS .|These mutations were not detected in 200 normal chromosomes and cosegregated within the family .|Analysis of complementary DNA showed that the heterozygous nucleotide change c . 2633 + 1G > C caused the appearance of 2 RNA molecules , 1 normal transcript and 1 skipping the entire exon 22 ( r . 2521_2634del ) .|Supplementation with potassium and magnesium improved clinical symptoms and resulted in catch - up growth , but vision remained impaired .|Three similar associations of Bartter syndrome / GS with pseudotumor cerebri were found in the literature , suggesting that electrolyte abnormalities and secondary aldosteronism may have a role in idiopathic intracranial hypertension .|This study provides further evidence for the phenotypical heterogeneity of GS and its association with severe manifestations in children .|It also shows the independent segregation of familial cavernomatosis and GS .	1:Association:2	L2R	NON-CROSS	5-6	8-10	6559	SLC12A3|SLC12A3	GeneOrGeneProduct	5:109	6:110	0:4	D053579	Gitelman syndrome|Gitelman syndrome|GS|GS|GS|GS|GS	DiseaseOrPhenotypicFeature	8:20:23:158:244:280:300	10:22:24:159:245:281:301	0:1:1:4:8:9:10	1:Association:2	L2R	NON-CROSS	5-6	11-14	6559	SLC12A3|SLC12A3	GeneOrGeneProduct	5:109	6:110	0:4	D011559	idiopathic intracranial hypertension|idiopathic intracranial hypertension|pseudotumor cerebri|pseudotumor cerebri|idiopathic intracranial hypertension	DiseaseOrPhenotypicFeature	11:51:58:246:266	14:54:60:248:269	0:1:1:8:8	1:NR:2	L2R	CROSS	5-6	37-39	6559	SLC12A3|SLC12A3	GeneOrGeneProduct	5:109	6:110	0:4	D006130	growth delay	DiseaseOrPhenotypicFeature	37	39	1	1:NR:2	L2R	CROSS	5-6	40-42	6559	SLC12A3|SLC12A3	GeneOrGeneProduct	5:109	6:110	0:4	D000471	metabolic alkalosis	DiseaseOrPhenotypicFeature	40	42	1	1:NR:2	L2R	CROSS	5-6	43-44	6559	SLC12A3|SLC12A3	GeneOrGeneProduct	5:109	6:110	0:4	C537153	hypomagnesemia	DiseaseOrPhenotypicFeature	43	44	1	1:NR:2	L2R	CROSS	5-6	45-46	6559	SLC12A3|SLC12A3	GeneOrGeneProduct	5:109	6:110	0:4	D007008	hypokalemia	DiseaseOrPhenotypicFeature	45	46	1	1:NR:2	L2R	CROSS	5-6	55-57	6559	SLC12A3|SLC12A3	GeneOrGeneProduct	5:109	6:110	0:4	D010211	bilateral papilledema	DiseaseOrPhenotypicFeature	55	57	1	1:NR:2	L2R	CROSS	75-78	109-110	6559	SLC12A3|SLC12A3	GeneOrGeneProduct	5:109	6:110	0:4	D002543	cerebral cavernous malformations	DiseaseOrPhenotypicFeature	75	78	2	1:NR:2	L2R	CROSS	87-89	109-110	6559	SLC12A3|SLC12A3	GeneOrGeneProduct	5:109	6:110	0:4	D001477	Bartter syndrome|Bartter syndrome|secondary aldosteronism	DiseaseOrPhenotypicFeature	87:241:259	89:243:261	3:8:8	1:NR:2	L2R	CROSS	109-110	218-219	6559	SLC12A3|SLC12A3	GeneOrGeneProduct	5:109	6:110	0:4	D011188	potassium	ChemicalEntity	218	219	7	1:NR:2	L2R	CROSS	109-110	220-221	6559	SLC12A3|SLC12A3	GeneOrGeneProduct	5:109	6:110	0:4	D008274	magnesium	ChemicalEntity	220	221	7	1:NR:2	L2R	CROSS	109-110	256-258	6559	SLC12A3|SLC12A3	GeneOrGeneProduct	5:109	6:110	0:4	D014883	electrolyte abnormalities	DiseaseOrPhenotypicFeature	256	258	8	1:NR:2	L2R	CROSS	109-110	297-299	6559	SLC12A3|SLC12A3	GeneOrGeneProduct	5:109	6:110	0:4	D006392	familial cavernomatosis	DiseaseOrPhenotypicFeature	297	299	10	1:Association:2	R2L	NON-CROSS	158-159	123-126	rs148038173	serine by leucine at amino acid position 555|p . Ser555Leu	SequenceVariant	114:123	122:126	4:4	D053579	Gitelman syndrome|Gitelman syndrome|GS|GS|GS|GS|GS	DiseaseOrPhenotypicFeature	8:20:23:158:244:280:300	10:22:24:159:245:281:301	0:1:1:4:8:9:10	1:Association:2	R2L	NON-CROSS	158-159	130-133	c|SUB|G||C	guanine to cytosine	SequenceVariant	130	133	4	D053579	Gitelman syndrome|Gitelman syndrome|GS|GS|GS|GS|GS	DiseaseOrPhenotypicFeature	8:20:23:158:244:280:300	10:22:24:159:245:281:301	0:1:1:4:8:9:10	1:Association:2	R2L	NON-CROSS	158-159	144-151	c|SUB|G|2633+1|C	c . 2633 + 1G > C|c . 2633 + 1G > C	SequenceVariant	144:185	151:192	4:6	D053579	Gitelman syndrome|Gitelman syndrome|GS|GS|GS|GS|GS	DiseaseOrPhenotypicFeature	8:20:23:158:244:280:300	10:22:24:159:245:281:301	0:1:1:4:8:9:10	1:NR:2	L2R	CROSS	211-214	244-245	D053579	Gitelman syndrome|Gitelman syndrome|GS|GS|GS|GS|GS	DiseaseOrPhenotypicFeature	8:20:23:158:244:280:300	10:22:24:159:245:281:301	0:1:1:4:8:9:10	r|DEL|2521_2634|	r . 2521_2634del	SequenceVariant	211	214	6	1:Negative_Correlation:2	L2R	CROSS	218-219	244-245	D053579	Gitelman syndrome|Gitelman syndrome|GS|GS|GS|GS|GS	DiseaseOrPhenotypicFeature	8:20:23:158:244:280:300	10:22:24:159:245:281:301	0:1:1:4:8:9:10	D011188	potassium	ChemicalEntity	218	219	7	1:Negative_Correlation:2	L2R	CROSS	220-221	244-245	D053579	Gitelman syndrome|Gitelman syndrome|GS|GS|GS|GS|GS	DiseaseOrPhenotypicFeature	8:20:23:158:244:280:300	10:22:24:159:245:281:301	0:1:1:4:8:9:10	D008274	magnesium	ChemicalEntity	220	221	7	1:Association:2	L2R	CROSS	58-60	114-122	D011559	idiopathic intracranial hypertension|idiopathic intracranial hypertension|pseudotumor cerebri|pseudotumor cerebri|idiopathic intracranial hypertension	DiseaseOrPhenotypicFeature	11:51:58:246:266	14:54:60:248:269	0:1:1:8:8	rs148038173	serine by leucine at amino acid position 555|p . Ser555Leu	SequenceVariant	114:123	122:126	4:4	1:Association:2	R2L	CROSS	130-133	58-60	c|SUB|G||C	guanine to cytosine	SequenceVariant	130	133	4	D011559	idiopathic intracranial hypertension|idiopathic intracranial hypertension|pseudotumor cerebri|pseudotumor cerebri|idiopathic intracranial hypertension	DiseaseOrPhenotypicFeature	11:51:58:246:266	14:54:60:248:269	0:1:1:8:8	1:Association:2	R2L	CROSS	246-248	185-192	c|SUB|G|2633+1|C	c . 2633 + 1G > C|c . 2633 + 1G > C	SequenceVariant	144:185	151:192	4:6	D011559	idiopathic intracranial hypertension|idiopathic intracranial hypertension|pseudotumor cerebri|pseudotumor cerebri|idiopathic intracranial hypertension	DiseaseOrPhenotypicFeature	11:51:58:246:266	14:54:60:248:269	0:1:1:8:8	1:NR:2	L2R	CROSS	211-214	246-248	D011559	idiopathic intracranial hypertension|idiopathic intracranial hypertension|pseudotumor cerebri|pseudotumor cerebri|idiopathic intracranial hypertension	DiseaseOrPhenotypicFeature	11:51:58:246:266	14:54:60:248:269	0:1:1:8:8	r|DEL|2521_2634|	r . 2521_2634del	SequenceVariant	211	214	6	1:NR:2	L2R	CROSS	218-219	246-248	D011559	idiopathic intracranial hypertension|idiopathic intracranial hypertension|pseudotumor cerebri|pseudotumor cerebri|idiopathic intracranial hypertension	DiseaseOrPhenotypicFeature	11:51:58:246:266	14:54:60:248:269	0:1:1:8:8	D011188	potassium	ChemicalEntity	218	219	7	1:NR:2	L2R	CROSS	220-221	246-248	D011559	idiopathic intracranial hypertension|idiopathic intracranial hypertension|pseudotumor cerebri|pseudotumor cerebri|idiopathic intracranial hypertension	DiseaseOrPhenotypicFeature	11:51:58:246:266	14:54:60:248:269	0:1:1:8:8	D008274	magnesium	ChemicalEntity	220	221	7	1:NR:2	L2R	CROSS	37-39	114-122	D006130	growth delay	DiseaseOrPhenotypicFeature	37	39	1	rs148038173	serine by leucine at amino acid position 555|p . Ser555Leu	SequenceVariant	114:123	122:126	4:4	1:NR:2	L2R	CROSS	37-39	130-133	D006130	growth delay	DiseaseOrPhenotypicFeature	37	39	1	c|SUB|G||C	guanine to cytosine	SequenceVariant	130	133	4	1:NR:2	L2R	CROSS	37-39	144-151	D006130	growth delay	DiseaseOrPhenotypicFeature	37	39	1	c|SUB|G|2633+1|C	c . 2633 + 1G > C|c . 2633 + 1G > C	SequenceVariant	144:185	151:192	4:6	1:NR:2	L2R	CROSS	37-39	211-214	D006130	growth delay	DiseaseOrPhenotypicFeature	37	39	1	r|DEL|2521_2634|	r . 2521_2634del	SequenceVariant	211	214	6	1:NR:2	L2R	CROSS	37-39	218-219	D006130	growth delay	DiseaseOrPhenotypicFeature	37	39	1	D011188	potassium	ChemicalEntity	218	219	7	1:NR:2	L2R	CROSS	37-39	220-221	D006130	growth delay	DiseaseOrPhenotypicFeature	37	39	1	D008274	magnesium	ChemicalEntity	220	221	7	1:NR:2	L2R	CROSS	40-42	114-122	D000471	metabolic alkalosis	DiseaseOrPhenotypicFeature	40	42	1	rs148038173	serine by leucine at amino acid position 555|p . Ser555Leu	SequenceVariant	114:123	122:126	4:4	1:NR:2	L2R	CROSS	40-42	130-133	D000471	metabolic alkalosis	DiseaseOrPhenotypicFeature	40	42	1	c|SUB|G||C	guanine to cytosine	SequenceVariant	130	133	4	1:NR:2	L2R	CROSS	40-42	144-151	D000471	metabolic alkalosis	DiseaseOrPhenotypicFeature	40	42	1	c|SUB|G|2633+1|C	c . 2633 + 1G > C|c . 2633 + 1G > C	SequenceVariant	144:185	151:192	4:6	1:NR:2	L2R	CROSS	40-42	211-214	D000471	metabolic alkalosis	DiseaseOrPhenotypicFeature	40	42	1	r|DEL|2521_2634|	r . 2521_2634del	SequenceVariant	211	214	6	1:NR:2	L2R	CROSS	40-42	218-219	D000471	metabolic alkalosis	DiseaseOrPhenotypicFeature	40	42	1	D011188	potassium	ChemicalEntity	218	219	7	1:NR:2	L2R	CROSS	40-42	220-221	D000471	metabolic alkalosis	DiseaseOrPhenotypicFeature	40	42	1	D008274	magnesium	ChemicalEntity	220	221	7	1:NR:2	L2R	CROSS	43-44	114-122	C537153	hypomagnesemia	DiseaseOrPhenotypicFeature	43	44	1	rs148038173	serine by leucine at amino acid position 555|p . Ser555Leu	SequenceVariant	114:123	122:126	4:4	1:NR:2	L2R	CROSS	43-44	130-133	C537153	hypomagnesemia	DiseaseOrPhenotypicFeature	43	44	1	c|SUB|G||C	guanine to cytosine	SequenceVariant	130	133	4	1:NR:2	L2R	CROSS	43-44	144-151	C537153	hypomagnesemia	DiseaseOrPhenotypicFeature	43	44	1	c|SUB|G|2633+1|C	c . 2633 + 1G > C|c . 2633 + 1G > C	SequenceVariant	144:185	151:192	4:6	1:NR:2	L2R	CROSS	43-44	211-214	C537153	hypomagnesemia	DiseaseOrPhenotypicFeature	43	44	1	r|DEL|2521_2634|	r . 2521_2634del	SequenceVariant	211	214	6	1:NR:2	L2R	CROSS	43-44	218-219	C537153	hypomagnesemia	DiseaseOrPhenotypicFeature	43	44	1	D011188	potassium	ChemicalEntity	218	219	7	1:NR:2	L2R	CROSS	43-44	220-221	C537153	hypomagnesemia	DiseaseOrPhenotypicFeature	43	44	1	D008274	magnesium	ChemicalEntity	220	221	7	1:NR:2	L2R	CROSS	45-46	114-122	D007008	hypokalemia	DiseaseOrPhenotypicFeature	45	46	1	rs148038173	serine by leucine at amino acid position 555|p . Ser555Leu	SequenceVariant	114:123	122:126	4:4	1:NR:2	L2R	CROSS	45-46	130-133	D007008	hypokalemia	DiseaseOrPhenotypicFeature	45	46	1	c|SUB|G||C	guanine to cytosine	SequenceVariant	130	133	4	1:NR:2	L2R	CROSS	45-46	144-151	D007008	hypokalemia	DiseaseOrPhenotypicFeature	45	46	1	c|SUB|G|2633+1|C	c . 2633 + 1G > C|c . 2633 + 1G > C	SequenceVariant	144:185	151:192	4:6	1:NR:2	L2R	CROSS	45-46	211-214	D007008	hypokalemia	DiseaseOrPhenotypicFeature	45	46	1	r|DEL|2521_2634|	r . 2521_2634del	SequenceVariant	211	214	6	1:NR:2	L2R	CROSS	45-46	218-219	D007008	hypokalemia	DiseaseOrPhenotypicFeature	45	46	1	D011188	potassium	ChemicalEntity	218	219	7	1:NR:2	L2R	CROSS	45-46	220-221	D007008	hypokalemia	DiseaseOrPhenotypicFeature	45	46	1	D008274	magnesium	ChemicalEntity	220	221	7	1:NR:2	L2R	CROSS	55-57	114-122	D010211	bilateral papilledema	DiseaseOrPhenotypicFeature	55	57	1	rs148038173	serine by leucine at amino acid position 555|p . Ser555Leu	SequenceVariant	114:123	122:126	4:4	1:NR:2	L2R	CROSS	55-57	130-133	D010211	bilateral papilledema	DiseaseOrPhenotypicFeature	55	57	1	c|SUB|G||C	guanine to cytosine	SequenceVariant	130	133	4	1:NR:2	L2R	CROSS	55-57	144-151	D010211	bilateral papilledema	DiseaseOrPhenotypicFeature	55	57	1	c|SUB|G|2633+1|C	c . 2633 + 1G > C|c . 2633 + 1G > C	SequenceVariant	144:185	151:192	4:6	1:NR:2	L2R	CROSS	55-57	211-214	D010211	bilateral papilledema	DiseaseOrPhenotypicFeature	55	57	1	r|DEL|2521_2634|	r . 2521_2634del	SequenceVariant	211	214	6	1:NR:2	L2R	CROSS	55-57	218-219	D010211	bilateral papilledema	DiseaseOrPhenotypicFeature	55	57	1	D011188	potassium	ChemicalEntity	218	219	7	1:NR:2	L2R	CROSS	55-57	220-221	D010211	bilateral papilledema	DiseaseOrPhenotypicFeature	55	57	1	D008274	magnesium	ChemicalEntity	220	221	7	1:NR:2	L2R	CROSS	75-78	114-122	D002543	cerebral cavernous malformations	DiseaseOrPhenotypicFeature	75	78	2	rs148038173	serine by leucine at amino acid position 555|p . Ser555Leu	SequenceVariant	114:123	122:126	4:4	1:NR:2	L2R	CROSS	75-78	130-133	D002543	cerebral cavernous malformations	DiseaseOrPhenotypicFeature	75	78	2	c|SUB|G||C	guanine to cytosine	SequenceVariant	130	133	4	1:NR:2	L2R	CROSS	75-78	144-151	D002543	cerebral cavernous malformations	DiseaseOrPhenotypicFeature	75	78	2	c|SUB|G|2633+1|C	c . 2633 + 1G > C|c . 2633 + 1G > C	SequenceVariant	144:185	151:192	4:6	1:NR:2	L2R	CROSS	75-78	211-214	D002543	cerebral cavernous malformations	DiseaseOrPhenotypicFeature	75	78	2	r|DEL|2521_2634|	r . 2521_2634del	SequenceVariant	211	214	6	1:NR:2	L2R	CROSS	75-78	218-219	D002543	cerebral cavernous malformations	DiseaseOrPhenotypicFeature	75	78	2	D011188	potassium	ChemicalEntity	218	219	7	1:NR:2	L2R	CROSS	75-78	220-221	D002543	cerebral cavernous malformations	DiseaseOrPhenotypicFeature	75	78	2	D008274	magnesium	ChemicalEntity	220	221	7	1:NR:2	L2R	CROSS	87-89	114-122	D001477	Bartter syndrome|Bartter syndrome|secondary aldosteronism	DiseaseOrPhenotypicFeature	87:241:259	89:243:261	3:8:8	rs148038173	serine by leucine at amino acid position 555|p . Ser555Leu	SequenceVariant	114:123	122:126	4:4	1:NR:2	L2R	CROSS	87-89	130-133	D001477	Bartter syndrome|Bartter syndrome|secondary aldosteronism	DiseaseOrPhenotypicFeature	87:241:259	89:243:261	3:8:8	c|SUB|G||C	guanine to cytosine	SequenceVariant	130	133	4	1:NR:2	L2R	CROSS	185-192	241-243	D001477	Bartter syndrome|Bartter syndrome|secondary aldosteronism	DiseaseOrPhenotypicFeature	87:241:259	89:243:261	3:8:8	c|SUB|G|2633+1|C	c . 2633 + 1G > C|c . 2633 + 1G > C	SequenceVariant	144:185	151:192	4:6	1:NR:2	L2R	CROSS	211-214	241-243	D001477	Bartter syndrome|Bartter syndrome|secondary aldosteronism	DiseaseOrPhenotypicFeature	87:241:259	89:243:261	3:8:8	r|DEL|2521_2634|	r . 2521_2634del	SequenceVariant	211	214	6	1:NR:2	L2R	CROSS	218-219	241-243	D001477	Bartter syndrome|Bartter syndrome|secondary aldosteronism	DiseaseOrPhenotypicFeature	87:241:259	89:243:261	3:8:8	D011188	potassium	ChemicalEntity	218	219	7	1:NR:2	L2R	CROSS	220-221	241-243	D001477	Bartter syndrome|Bartter syndrome|secondary aldosteronism	DiseaseOrPhenotypicFeature	87:241:259	89:243:261	3:8:8	D008274	magnesium	ChemicalEntity	220	221	7	1:NR:2	L2R	CROSS	123-126	218-219	rs148038173	serine by leucine at amino acid position 555|p . Ser555Leu	SequenceVariant	114:123	122:126	4:4	D011188	potassium	ChemicalEntity	218	219	7	1:NR:2	L2R	CROSS	123-126	220-221	rs148038173	serine by leucine at amino acid position 555|p . Ser555Leu	SequenceVariant	114:123	122:126	4:4	D008274	magnesium	ChemicalEntity	220	221	7	1:NR:2	L2R	CROSS	123-126	256-258	rs148038173	serine by leucine at amino acid position 555|p . Ser555Leu	SequenceVariant	114:123	122:126	4:4	D014883	electrolyte abnormalities	DiseaseOrPhenotypicFeature	256	258	8	1:NR:2	L2R	CROSS	123-126	297-299	rs148038173	serine by leucine at amino acid position 555|p . Ser555Leu	SequenceVariant	114:123	122:126	4:4	D006392	familial cavernomatosis	DiseaseOrPhenotypicFeature	297	299	10	1:NR:2	L2R	CROSS	130-133	218-219	c|SUB|G||C	guanine to cytosine	SequenceVariant	130	133	4	D011188	potassium	ChemicalEntity	218	219	7	1:NR:2	L2R	CROSS	130-133	220-221	c|SUB|G||C	guanine to cytosine	SequenceVariant	130	133	4	D008274	magnesium	ChemicalEntity	220	221	7	1:NR:2	L2R	CROSS	130-133	256-258	c|SUB|G||C	guanine to cytosine	SequenceVariant	130	133	4	D014883	electrolyte abnormalities	DiseaseOrPhenotypicFeature	256	258	8	1:NR:2	L2R	CROSS	130-133	297-299	c|SUB|G||C	guanine to cytosine	SequenceVariant	130	133	4	D006392	familial cavernomatosis	DiseaseOrPhenotypicFeature	297	299	10	1:NR:2	L2R	CROSS	185-192	218-219	c|SUB|G|2633+1|C	c . 2633 + 1G > C|c . 2633 + 1G > C	SequenceVariant	144:185	151:192	4:6	D011188	potassium	ChemicalEntity	218	219	7	1:NR:2	L2R	CROSS	185-192	220-221	c|SUB|G|2633+1|C	c . 2633 + 1G > C|c . 2633 + 1G > C	SequenceVariant	144:185	151:192	4:6	D008274	magnesium	ChemicalEntity	220	221	7	1:NR:2	L2R	CROSS	185-192	256-258	c|SUB|G|2633+1|C	c . 2633 + 1G > C|c . 2633 + 1G > C	SequenceVariant	144:185	151:192	4:6	D014883	electrolyte abnormalities	DiseaseOrPhenotypicFeature	256	258	8	1:NR:2	L2R	CROSS	185-192	297-299	c|SUB|G|2633+1|C	c . 2633 + 1G > C|c . 2633 + 1G > C	SequenceVariant	144:185	151:192	4:6	D006392	familial cavernomatosis	DiseaseOrPhenotypicFeature	297	299	10	1:NR:2	L2R	CROSS	211-214	218-219	r|DEL|2521_2634|	r . 2521_2634del	SequenceVariant	211	214	6	D011188	potassium	ChemicalEntity	218	219	7	1:NR:2	L2R	CROSS	211-214	220-221	r|DEL|2521_2634|	r . 2521_2634del	SequenceVariant	211	214	6	D008274	magnesium	ChemicalEntity	220	221	7	1:NR:2	L2R	CROSS	211-214	256-258	r|DEL|2521_2634|	r . 2521_2634del	SequenceVariant	211	214	6	D014883	electrolyte abnormalities	DiseaseOrPhenotypicFeature	256	258	8	1:NR:2	L2R	CROSS	211-214	297-299	r|DEL|2521_2634|	r . 2521_2634del	SequenceVariant	211	214	6	D006392	familial cavernomatosis	DiseaseOrPhenotypicFeature	297	299	10	1:Cotreatment:2	L2R	NON-CROSS	218-219	220-221	D011188	potassium	ChemicalEntity	218	219	7	D008274	magnesium	ChemicalEntity	220	221	7	1:NR:2	L2R	CROSS	218-219	256-258	D011188	potassium	ChemicalEntity	218	219	7	D014883	electrolyte abnormalities	DiseaseOrPhenotypicFeature	256	258	8	1:NR:2	L2R	CROSS	218-219	297-299	D011188	potassium	ChemicalEntity	218	219	7	D006392	familial cavernomatosis	DiseaseOrPhenotypicFeature	297	299	10	1:NR:2	L2R	CROSS	220-221	256-258	D008274	magnesium	ChemicalEntity	220	221	7	D014883	electrolyte abnormalities	DiseaseOrPhenotypicFeature	256	258	8	1:NR:2	L2R	CROSS	220-221	297-299	D008274	magnesium	ChemicalEntity	220	221	7	D006392	familial cavernomatosis	DiseaseOrPhenotypicFeature	297	299	10
18991055	Association between polymorphisms in SLC30A8 , HHEX , CDKN2A / B , IGF2BP2 , FTO , WFS1 , CDKAL1 , KCNQ1 and type 2 diabetes in the Korean population .|According to recent genome - wide association studies , a number of single nucleotide polymorphisms ( SNPs ) are reported to be associated with type 2 diabetes mellitus ( T2DM ) .|The aim of the present study was to investigate the association among the polymorphisms of SLC30A8 , HHEX , CDKN2A / B , IGF2BP2 , FTO , WFS1 , CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population .|This study was based on a multicenter case - control study , including 908 patients with T2DM and 502 non - diabetic controls .|We genotyped rs13266634 , rs1111875 , rs10811661 , rs4402960 , rs8050136 , rs734312 , rs7754840 and rs2237892 and measured the body weight , body mass index and fasting plasma glucose in all patients and controls .|The strongest association was found in a variant of CDKAL1 [ rs7754840 , odds ratio ( OR ) = 1 . 77 , 95 % CI = 1 . 50 - 2 . 10 , p = 5 . 0 x 10 ( - 11 ) ] .|The G allele of rs1111875 ( OR = 1 . 43 , 95 % CI = 1 . 18 - 1 . 72 , p = 1 . 8 x 10 ( - 4 ) ) in HHEX ) , the T allele of rs10811661 ( OR = 1 . 47 , 95 % CI = 1 . 23 - 1 . 75 , p = 2 . 1 x 10 ( - 5 ) ) in CDKN2A / B ) and the C allele of rs2237892 ( OR = 1 . 31 , 95 % CI = 1 . 10 - 1 . 56 , p = 0 . 003 ) in KCNQ1 showed significant associations with T2DM .|Rs13266634 ( OR = 1 . 19 , 95 % CI = 1 . 00 - 1 . 42 , p = 0 . 045 ) in SLC30A8 showed a nominal association with the risk of T2DM , whereas SNPs in IGF2BP2 , FTO and WFS1 were not associated .|In conclusion , we have shown that SNPs in HHEX , CDKN2A / B , CDKAL1 , KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population .	1:NR:2	L2R	NON-CROSS	4-5	6-7	169026	SLC30A8|SLC30A8|SLC30A8|SLC30A8	GeneOrGeneProduct	4:77:359:401	5:78:360:402	0:2:7:8	3087	HHEX|HHEX|HHEX|HHEX	GeneOrGeneProduct	6:79:249:391	7:80:250:392	0:2:6:8	1:NR:2	L2R	NON-CROSS	4-5	8-11	169026	SLC30A8|SLC30A8|SLC30A8|SLC30A8	GeneOrGeneProduct	4:77:359:401	5:78:360:402	0:2:7:8	1029,1030	CDKN2A / B|CDKN2A / B|CDKN2A / B|CDKN2A / B	GeneOrGeneProduct	8:81:289:393	11:84:292:396	0:2:6:8	1:NR:2	L2R	NON-CROSS	4-5	12-13	169026	SLC30A8|SLC30A8|SLC30A8|SLC30A8	GeneOrGeneProduct	4:77:359:401	5:78:360:402	0:2:7:8	10644	IGF2BP2|IGF2BP2|IGF2BP2	GeneOrGeneProduct	12:85:373	13:86:374	0:2:7	1:NR:2	L2R	NON-CROSS	4-5	14-15	169026	SLC30A8|SLC30A8|SLC30A8|SLC30A8	GeneOrGeneProduct	4:77:359:401	5:78:360:402	0:2:7:8	79068	FTO|FTO|FTO	GeneOrGeneProduct	14:87:375	15:88:376	0:2:7	1:NR:2	L2R	NON-CROSS	4-5	16-17	169026	SLC30A8|SLC30A8|SLC30A8|SLC30A8	GeneOrGeneProduct	4:77:359:401	5:78:360:402	0:2:7:8	7466	WFS1|WFS1|WFS1	GeneOrGeneProduct	16:89:377	17:90:378	0:2:7	1:NR:2	L2R	NON-CROSS	397-398	401-402	169026	SLC30A8|SLC30A8|SLC30A8|SLC30A8	GeneOrGeneProduct	4:77:359:401	5:78:360:402	0:2:7:8	54901	CDKAL1|CDKAL1|CDKAL1|CDKAL1	GeneOrGeneProduct	18:91:173:397	19:92:174:398	0:2:5:8	1:NR:2	L2R	NON-CROSS	399-400	401-402	169026	SLC30A8|SLC30A8|SLC30A8|SLC30A8	GeneOrGeneProduct	4:77:359:401	5:78:360:402	0:2:7:8	3784	KCNQ1|KCNQ1|KCNQ1|KCNQ1	GeneOrGeneProduct	20:93:325:399	21:94:326:400	0:2:6:8	1:Association:2	R2L	NON-CROSS	406-407	401-402	D003924	type 2 diabetes|type 2 diabetes mellitus|T2DM|T2DM|T2DM|T2DM|T2DM|T2DM	DiseaseOrPhenotypicFeature	22:54:59:98:120:330:368:406	25:58:60:99:121:331:369:407	0:1:1:2:3:6:7:8	169026	SLC30A8|SLC30A8|SLC30A8|SLC30A8	GeneOrGeneProduct	4:77:359:401	5:78:360:402	0:2:7:8	1:NR:2	L2R	CROSS	77-78	125-126	169026	SLC30A8|SLC30A8|SLC30A8|SLC30A8	GeneOrGeneProduct	4:77:359:401	5:78:360:402	0:2:7:8	D003920	diabetic	DiseaseOrPhenotypicFeature	125	126	3	1:NR:2	L2R	CROSS	77-78	157-158	169026	SLC30A8|SLC30A8|SLC30A8|SLC30A8	GeneOrGeneProduct	4:77:359:401	5:78:360:402	0:2:7:8	D005947	glucose	ChemicalEntity	157	158	4	1:NR:2	L2R	NON-CROSS	6-7	8-11	3087	HHEX|HHEX|HHEX|HHEX	GeneOrGeneProduct	6:79:249:391	7:80:250:392	0:2:6:8	1029,1030	CDKN2A / B|CDKN2A / B|CDKN2A / B|CDKN2A / B	GeneOrGeneProduct	8:81:289:393	11:84:292:396	0:2:6:8	1:NR:2	L2R	NON-CROSS	6-7	12-13	3087	HHEX|HHEX|HHEX|HHEX	GeneOrGeneProduct	6:79:249:391	7:80:250:392	0:2:6:8	10644	IGF2BP2|IGF2BP2|IGF2BP2	GeneOrGeneProduct	12:85:373	13:86:374	0:2:7	1:NR:2	L2R	NON-CROSS	6-7	14-15	3087	HHEX|HHEX|HHEX|HHEX	GeneOrGeneProduct	6:79:249:391	7:80:250:392	0:2:6:8	79068	FTO|FTO|FTO	GeneOrGeneProduct	14:87:375	15:88:376	0:2:7	1:NR:2	L2R	NON-CROSS	6-7	16-17	3087	HHEX|HHEX|HHEX|HHEX	GeneOrGeneProduct	6:79:249:391	7:80:250:392	0:2:6:8	7466	WFS1|WFS1|WFS1	GeneOrGeneProduct	16:89:377	17:90:378	0:2:7	1:NR:2	L2R	NON-CROSS	391-392	397-398	3087	HHEX|HHEX|HHEX|HHEX	GeneOrGeneProduct	6:79:249:391	7:80:250:392	0:2:6:8	54901	CDKAL1|CDKAL1|CDKAL1|CDKAL1	GeneOrGeneProduct	18:91:173:397	19:92:174:398	0:2:5:8	1:NR:2	L2R	NON-CROSS	391-392	399-400	3087	HHEX|HHEX|HHEX|HHEX	GeneOrGeneProduct	6:79:249:391	7:80:250:392	0:2:6:8	3784	KCNQ1|KCNQ1|KCNQ1|KCNQ1	GeneOrGeneProduct	20:93:325:399	21:94:326:400	0:2:6:8	1:Association:2	R2L	NON-CROSS	406-407	391-392	D003924	type 2 diabetes|type 2 diabetes mellitus|T2DM|T2DM|T2DM|T2DM|T2DM|T2DM	DiseaseOrPhenotypicFeature	22:54:59:98:120:330:368:406	25:58:60:99:121:331:369:407	0:1:1:2:3:6:7:8	3087	HHEX|HHEX|HHEX|HHEX	GeneOrGeneProduct	6:79:249:391	7:80:250:392	0:2:6:8	1:NR:2	L2R	CROSS	79-80	125-126	3087	HHEX|HHEX|HHEX|HHEX	GeneOrGeneProduct	6:79:249:391	7:80:250:392	0:2:6:8	D003920	diabetic	DiseaseOrPhenotypicFeature	125	126	3	1:NR:2	L2R	CROSS	79-80	157-158	3087	HHEX|HHEX|HHEX|HHEX	GeneOrGeneProduct	6:79:249:391	7:80:250:392	0:2:6:8	D005947	glucose	ChemicalEntity	157	158	4	1:NR:2	L2R	NON-CROSS	8-11	12-13	1029,1030	CDKN2A / B|CDKN2A / B|CDKN2A / B|CDKN2A / B	GeneOrGeneProduct	8:81:289:393	11:84:292:396	0:2:6:8	10644	IGF2BP2|IGF2BP2|IGF2BP2	GeneOrGeneProduct	12:85:373	13:86:374	0:2:7	1:NR:2	L2R	NON-CROSS	8-11	14-15	1029,1030	CDKN2A / B|CDKN2A / B|CDKN2A / B|CDKN2A / B	GeneOrGeneProduct	8:81:289:393	11:84:292:396	0:2:6:8	79068	FTO|FTO|FTO	GeneOrGeneProduct	14:87:375	15:88:376	0:2:7	1:NR:2	L2R	NON-CROSS	8-11	16-17	1029,1030	CDKN2A / B|CDKN2A / B|CDKN2A / B|CDKN2A / B	GeneOrGeneProduct	8:81:289:393	11:84:292:396	0:2:6:8	7466	WFS1|WFS1|WFS1	GeneOrGeneProduct	16:89:377	17:90:378	0:2:7	1:NR:2	L2R	NON-CROSS	393-396	397-398	1029,1030	CDKN2A / B|CDKN2A / B|CDKN2A / B|CDKN2A / B	GeneOrGeneProduct	8:81:289:393	11:84:292:396	0:2:6:8	54901	CDKAL1|CDKAL1|CDKAL1|CDKAL1	GeneOrGeneProduct	18:91:173:397	19:92:174:398	0:2:5:8	1:NR:2	L2R	NON-CROSS	393-396	399-400	1029,1030	CDKN2A / B|CDKN2A / B|CDKN2A / B|CDKN2A / B	GeneOrGeneProduct	8:81:289:393	11:84:292:396	0:2:6:8	3784	KCNQ1|KCNQ1|KCNQ1|KCNQ1	GeneOrGeneProduct	20:93:325:399	21:94:326:400	0:2:6:8	1:NR:2	L2R	NON-CROSS	393-396	406-407	1029,1030	CDKN2A / B|CDKN2A / B|CDKN2A / B|CDKN2A / B	GeneOrGeneProduct	8:81:289:393	11:84:292:396	0:2:6:8	D003924	type 2 diabetes|type 2 diabetes mellitus|T2DM|T2DM|T2DM|T2DM|T2DM|T2DM	DiseaseOrPhenotypicFeature	22:54:59:98:120:330:368:406	25:58:60:99:121:331:369:407	0:1:1:2:3:6:7:8	1:NR:2	L2R	CROSS	81-84	125-126	1029,1030	CDKN2A / B|CDKN2A / B|CDKN2A / B|CDKN2A / B	GeneOrGeneProduct	8:81:289:393	11:84:292:396	0:2:6:8	D003920	diabetic	DiseaseOrPhenotypicFeature	125	126	3	1:NR:2	L2R	CROSS	81-84	157-158	1029,1030	CDKN2A / B|CDKN2A / B|CDKN2A / B|CDKN2A / B	GeneOrGeneProduct	8:81:289:393	11:84:292:396	0:2:6:8	D005947	glucose	ChemicalEntity	157	158	4	1:NR:2	L2R	NON-CROSS	12-13	14-15	10644	IGF2BP2|IGF2BP2|IGF2BP2	GeneOrGeneProduct	12:85:373	13:86:374	0:2:7	79068	FTO|FTO|FTO	GeneOrGeneProduct	14:87:375	15:88:376	0:2:7	1:NR:2	L2R	NON-CROSS	12-13	16-17	10644	IGF2BP2|IGF2BP2|IGF2BP2	GeneOrGeneProduct	12:85:373	13:86:374	0:2:7	7466	WFS1|WFS1|WFS1	GeneOrGeneProduct	16:89:377	17:90:378	0:2:7	1:NR:2	L2R	NON-CROSS	12-13	18-19	10644	IGF2BP2|IGF2BP2|IGF2BP2	GeneOrGeneProduct	12:85:373	13:86:374	0:2:7	54901	CDKAL1|CDKAL1|CDKAL1|CDKAL1	GeneOrGeneProduct	18:91:173:397	19:92:174:398	0:2:5:8	1:NR:2	L2R	NON-CROSS	12-13	20-21	10644	IGF2BP2|IGF2BP2|IGF2BP2	GeneOrGeneProduct	12:85:373	13:86:374	0:2:7	3784	KCNQ1|KCNQ1|KCNQ1|KCNQ1	GeneOrGeneProduct	20:93:325:399	21:94:326:400	0:2:6:8	1:NR:2	L2R	NON-CROSS	368-369	373-374	10644	IGF2BP2|IGF2BP2|IGF2BP2	GeneOrGeneProduct	12:85:373	13:86:374	0:2:7	D003924	type 2 diabetes|type 2 diabetes mellitus|T2DM|T2DM|T2DM|T2DM|T2DM|T2DM	DiseaseOrPhenotypicFeature	22:54:59:98:120:330:368:406	25:58:60:99:121:331:369:407	0:1:1:2:3:6:7:8	1:NR:2	L2R	CROSS	85-86	125-126	10644	IGF2BP2|IGF2BP2|IGF2BP2	GeneOrGeneProduct	12:85:373	13:86:374	0:2:7	D003920	diabetic	DiseaseOrPhenotypicFeature	125	126	3	1:NR:2	L2R	CROSS	85-86	157-158	10644	IGF2BP2|IGF2BP2|IGF2BP2	GeneOrGeneProduct	12:85:373	13:86:374	0:2:7	D005947	glucose	ChemicalEntity	157	158	4	1:NR:2	L2R	NON-CROSS	14-15	16-17	79068	FTO|FTO|FTO	GeneOrGeneProduct	14:87:375	15:88:376	0:2:7	7466	WFS1|WFS1|WFS1	GeneOrGeneProduct	16:89:377	17:90:378	0:2:7	1:NR:2	L2R	NON-CROSS	14-15	18-19	79068	FTO|FTO|FTO	GeneOrGeneProduct	14:87:375	15:88:376	0:2:7	54901	CDKAL1|CDKAL1|CDKAL1|CDKAL1	GeneOrGeneProduct	18:91:173:397	19:92:174:398	0:2:5:8	1:NR:2	L2R	NON-CROSS	14-15	20-21	79068	FTO|FTO|FTO	GeneOrGeneProduct	14:87:375	15:88:376	0:2:7	3784	KCNQ1|KCNQ1|KCNQ1|KCNQ1	GeneOrGeneProduct	20:93:325:399	21:94:326:400	0:2:6:8	1:NR:2	L2R	NON-CROSS	368-369	375-376	79068	FTO|FTO|FTO	GeneOrGeneProduct	14:87:375	15:88:376	0:2:7	D003924	type 2 diabetes|type 2 diabetes mellitus|T2DM|T2DM|T2DM|T2DM|T2DM|T2DM	DiseaseOrPhenotypicFeature	22:54:59:98:120:330:368:406	25:58:60:99:121:331:369:407	0:1:1:2:3:6:7:8	1:NR:2	L2R	CROSS	87-88	125-126	79068	FTO|FTO|FTO	GeneOrGeneProduct	14:87:375	15:88:376	0:2:7	D003920	diabetic	DiseaseOrPhenotypicFeature	125	126	3	1:NR:2	L2R	CROSS	87-88	157-158	79068	FTO|FTO|FTO	GeneOrGeneProduct	14:87:375	15:88:376	0:2:7	D005947	glucose	ChemicalEntity	157	158	4	1:NR:2	L2R	NON-CROSS	16-17	18-19	7466	WFS1|WFS1|WFS1	GeneOrGeneProduct	16:89:377	17:90:378	0:2:7	54901	CDKAL1|CDKAL1|CDKAL1|CDKAL1	GeneOrGeneProduct	18:91:173:397	19:92:174:398	0:2:5:8	1:NR:2	L2R	NON-CROSS	16-17	20-21	7466	WFS1|WFS1|WFS1	GeneOrGeneProduct	16:89:377	17:90:378	0:2:7	3784	KCNQ1|KCNQ1|KCNQ1|KCNQ1	GeneOrGeneProduct	20:93:325:399	21:94:326:400	0:2:6:8	1:NR:2	L2R	NON-CROSS	16-17	22-25	7466	WFS1|WFS1|WFS1	GeneOrGeneProduct	16:89:377	17:90:378	0:2:7	D003924	type 2 diabetes|type 2 diabetes mellitus|T2DM|T2DM|T2DM|T2DM|T2DM|T2DM	DiseaseOrPhenotypicFeature	22:54:59:98:120:330:368:406	25:58:60:99:121:331:369:407	0:1:1:2:3:6:7:8	1:NR:2	L2R	CROSS	89-90	125-126	7466	WFS1|WFS1|WFS1	GeneOrGeneProduct	16:89:377	17:90:378	0:2:7	D003920	diabetic	DiseaseOrPhenotypicFeature	125	126	3	1:NR:2	L2R	CROSS	89-90	157-158	7466	WFS1|WFS1|WFS1	GeneOrGeneProduct	16:89:377	17:90:378	0:2:7	D005947	glucose	ChemicalEntity	157	158	4	1:NR:2	L2R	NON-CROSS	18-19	20-21	54901	CDKAL1|CDKAL1|CDKAL1|CDKAL1	GeneOrGeneProduct	18:91:173:397	19:92:174:398	0:2:5:8	3784	KCNQ1|KCNQ1|KCNQ1|KCNQ1	GeneOrGeneProduct	20:93:325:399	21:94:326:400	0:2:6:8	1:Association:2	R2L	NON-CROSS	22-25	18-19	D003924	type 2 diabetes|type 2 diabetes mellitus|T2DM|T2DM|T2DM|T2DM|T2DM|T2DM	DiseaseOrPhenotypicFeature	22:54:59:98:120:330:368:406	25:58:60:99:121:331:369:407	0:1:1:2:3:6:7:8	54901	CDKAL1|CDKAL1|CDKAL1|CDKAL1	GeneOrGeneProduct	18:91:173:397	19:92:174:398	0:2:5:8	1:NR:2	L2R	CROSS	91-92	125-126	54901	CDKAL1|CDKAL1|CDKAL1|CDKAL1	GeneOrGeneProduct	18:91:173:397	19:92:174:398	0:2:5:8	D003920	diabetic	DiseaseOrPhenotypicFeature	125	126	3	1:NR:2	L2R	CROSS	157-158	173-174	54901	CDKAL1|CDKAL1|CDKAL1|CDKAL1	GeneOrGeneProduct	18:91:173:397	19:92:174:398	0:2:5:8	D005947	glucose	ChemicalEntity	157	158	4	1:Association:2	R2L	NON-CROSS	22-25	20-21	D003924	type 2 diabetes|type 2 diabetes mellitus|T2DM|T2DM|T2DM|T2DM|T2DM|T2DM	DiseaseOrPhenotypicFeature	22:54:59:98:120:330:368:406	25:58:60:99:121:331:369:407	0:1:1:2:3:6:7:8	3784	KCNQ1|KCNQ1|KCNQ1|KCNQ1	GeneOrGeneProduct	20:93:325:399	21:94:326:400	0:2:6:8	1:NR:2	L2R	CROSS	93-94	125-126	3784	KCNQ1|KCNQ1|KCNQ1|KCNQ1	GeneOrGeneProduct	20:93:325:399	21:94:326:400	0:2:6:8	D003920	diabetic	DiseaseOrPhenotypicFeature	125	126	3	1:NR:2	L2R	CROSS	93-94	157-158	3784	KCNQ1|KCNQ1|KCNQ1|KCNQ1	GeneOrGeneProduct	20:93:325:399	21:94:326:400	0:2:6:8	D005947	glucose	ChemicalEntity	157	158	4	1:Positive_Correlation:2	R2L	NON-CROSS	332-333	330-331	rs13266634	rs13266634|Rs13266634	SequenceVariant	130:332	131:333	4:7	D003924	type 2 diabetes|type 2 diabetes mellitus|T2DM|T2DM|T2DM|T2DM|T2DM|T2DM	DiseaseOrPhenotypicFeature	22:54:59:98:120:330:368:406	25:58:60:99:121:331:369:407	0:1:1:2:3:6:7:8	1:Positive_Correlation:2	R2L	NON-CROSS	132-133	120-121	rs1111875	rs1111875|rs1111875	SequenceVariant	132:216	133:217	4:6	D003924	type 2 diabetes|type 2 diabetes mellitus|T2DM|T2DM|T2DM|T2DM|T2DM|T2DM	DiseaseOrPhenotypicFeature	22:54:59:98:120:330:368:406	25:58:60:99:121:331:369:407	0:1:1:2:3:6:7:8	1:Positive_Correlation:2	R2L	NON-CROSS	134-135	120-121	rs10811661	rs10811661|rs10811661	SequenceVariant	134:256	135:257	4:6	D003924	type 2 diabetes|type 2 diabetes mellitus|T2DM|T2DM|T2DM|T2DM|T2DM|T2DM	DiseaseOrPhenotypicFeature	22:54:59:98:120:330:368:406	25:58:60:99:121:331:369:407	0:1:1:2:3:6:7:8	1:NR:2	L2R	CROSS	120-121	136-137	D003924	type 2 diabetes|type 2 diabetes mellitus|T2DM|T2DM|T2DM|T2DM|T2DM|T2DM	DiseaseOrPhenotypicFeature	22:54:59:98:120:330:368:406	25:58:60:99:121:331:369:407	0:1:1:2:3:6:7:8	rs4402960	rs4402960	SequenceVariant	136	137	4	1:NR:2	L2R	CROSS	120-121	138-139	D003924	type 2 diabetes|type 2 diabetes mellitus|T2DM|T2DM|T2DM|T2DM|T2DM|T2DM	DiseaseOrPhenotypicFeature	22:54:59:98:120:330:368:406	25:58:60:99:121:331:369:407	0:1:1:2:3:6:7:8	rs8050136	rs8050136	SequenceVariant	138	139	4	1:NR:2	L2R	CROSS	120-121	140-141	D003924	type 2 diabetes|type 2 diabetes mellitus|T2DM|T2DM|T2DM|T2DM|T2DM|T2DM	DiseaseOrPhenotypicFeature	22:54:59:98:120:330:368:406	25:58:60:99:121:331:369:407	0:1:1:2:3:6:7:8	rs734312	rs734312	SequenceVariant	140	141	4	1:Positive_Correlation:2	R2L	CROSS	142-143	120-121	rs7754840	rs7754840|rs7754840	SequenceVariant	142:175	143:176	4:5	D003924	type 2 diabetes|type 2 diabetes mellitus|T2DM|T2DM|T2DM|T2DM|T2DM|T2DM	DiseaseOrPhenotypicFeature	22:54:59:98:120:330:368:406	25:58:60:99:121:331:369:407	0:1:1:2:3:6:7:8	1:Positive_Correlation:2	R2L	NON-CROSS	144-145	120-121	rs2237892	rs2237892|rs2237892	SequenceVariant	144:298	145:299	4:6	D003924	type 2 diabetes|type 2 diabetes mellitus|T2DM|T2DM|T2DM|T2DM|T2DM|T2DM	DiseaseOrPhenotypicFeature	22:54:59:98:120:330:368:406	25:58:60:99:121:331:369:407	0:1:1:2:3:6:7:8	1:NR:2	L2R	CROSS	120-121	157-158	D003924	type 2 diabetes|type 2 diabetes mellitus|T2DM|T2DM|T2DM|T2DM|T2DM|T2DM	DiseaseOrPhenotypicFeature	22:54:59:98:120:330:368:406	25:58:60:99:121:331:369:407	0:1:1:2:3:6:7:8	D005947	glucose	ChemicalEntity	157	158	4	1:NR:2	L2R	CROSS	125-126	130-131	D003920	diabetic	DiseaseOrPhenotypicFeature	125	126	3	rs13266634	rs13266634|Rs13266634	SequenceVariant	130:332	131:333	4:7	1:NR:2	L2R	CROSS	125-126	132-133	D003920	diabetic	DiseaseOrPhenotypicFeature	125	126	3	rs1111875	rs1111875|rs1111875	SequenceVariant	132:216	133:217	4:6	1:NR:2	L2R	CROSS	125-126	134-135	D003920	diabetic	DiseaseOrPhenotypicFeature	125	126	3	rs10811661	rs10811661|rs10811661	SequenceVariant	134:256	135:257	4:6	1:NR:2	L2R	CROSS	125-126	136-137	D003920	diabetic	DiseaseOrPhenotypicFeature	125	126	3	rs4402960	rs4402960	SequenceVariant	136	137	4	1:NR:2	L2R	CROSS	125-126	138-139	D003920	diabetic	DiseaseOrPhenotypicFeature	125	126	3	rs8050136	rs8050136	SequenceVariant	138	139	4	1:NR:2	L2R	CROSS	125-126	140-141	D003920	diabetic	DiseaseOrPhenotypicFeature	125	126	3	rs734312	rs734312	SequenceVariant	140	141	4	1:NR:2	L2R	CROSS	125-126	142-143	D003920	diabetic	DiseaseOrPhenotypicFeature	125	126	3	rs7754840	rs7754840|rs7754840	SequenceVariant	142:175	143:176	4:5	1:NR:2	L2R	CROSS	125-126	144-145	D003920	diabetic	DiseaseOrPhenotypicFeature	125	126	3	rs2237892	rs2237892|rs2237892	SequenceVariant	144:298	145:299	4:6	1:NR:2	L2R	CROSS	125-126	157-158	D003920	diabetic	DiseaseOrPhenotypicFeature	125	126	3	D005947	glucose	ChemicalEntity	157	158	4	1:NR:2	L2R	NON-CROSS	130-131	157-158	rs13266634	rs13266634|Rs13266634	SequenceVariant	130:332	131:333	4:7	D005947	glucose	ChemicalEntity	157	158	4	1:NR:2	L2R	NON-CROSS	132-133	157-158	rs1111875	rs1111875|rs1111875	SequenceVariant	132:216	133:217	4:6	D005947	glucose	ChemicalEntity	157	158	4	1:NR:2	L2R	NON-CROSS	134-135	157-158	rs10811661	rs10811661|rs10811661	SequenceVariant	134:256	135:257	4:6	D005947	glucose	ChemicalEntity	157	158	4	1:NR:2	L2R	NON-CROSS	136-137	157-158	rs4402960	rs4402960	SequenceVariant	136	137	4	D005947	glucose	ChemicalEntity	157	158	4	1:NR:2	L2R	NON-CROSS	138-139	157-158	rs8050136	rs8050136	SequenceVariant	138	139	4	D005947	glucose	ChemicalEntity	157	158	4	1:NR:2	L2R	NON-CROSS	140-141	157-158	rs734312	rs734312	SequenceVariant	140	141	4	D005947	glucose	ChemicalEntity	157	158	4	1:NR:2	L2R	NON-CROSS	142-143	157-158	rs7754840	rs7754840|rs7754840	SequenceVariant	142:175	143:176	4:5	D005947	glucose	ChemicalEntity	157	158	4	1:NR:2	L2R	NON-CROSS	144-145	157-158	rs2237892	rs2237892|rs2237892	SequenceVariant	144:298	145:299	4:6	D005947	glucose	ChemicalEntity	157	158	4
20705401	Serotonin 6 receptor gene is associated with methamphetamine - induced psychosis in a Japanese population .|BACKGROUND : Altered serotonergic neural transmission is hypothesized to be a susceptibility factor for psychotic disorders such as schizophrenia .|The serotonin 6 ( 5 - HT6 ) receptor is therapeutically targeted by several second generation antipsychotics , such as clozapine and olanzapine , and d - amphetamine - induced hyperactivity in rats is corrected with the use of a selective 5 - HT6 receptor antagonist .|In addition , the disrupted prepulse inhibition induced by d - amphetamine or phencyclidine was restored by 5 - HT6 receptor antagonist in an animal study using rats .|These animal models were considered to reflect the positive symptoms of schizophrenia , and the above evidence suggests that altered 5 - HT6 receptors are involved in the pathophysiology of psychotic disorders .|The symptoms of methamphetamine ( METH ) - induced psychosis are similar to those of paranoid type schizophrenia .|Therefore , we conducted an analysis of the association of the 5 - HT6 gene ( HTR6 ) with METH - induced psychosis .|METHOD : Using five tagging SNPs ( rs6693503 , rs1805054 , rs4912138 , rs3790757 and rs9659997 ) , we conducted a genetic association analysis of case - control samples ( 197 METH - induced psychosis patients and 337 controls ) in the Japanese population .|The age and sex of the control subjects did not differ from those of the methamphetamine dependence patients .|RESULTS : rs6693503 was associated with METH - induced psychosis patients in the allele / genotype - wise analysis .|Moreover , this association remained significant after Bonferroni correction .|In the haplotype - wise analysis , we detected an association between two markers ( rs6693503 and rs1805054 ) and three markers ( rs6693503 , rs1805054 and rs4912138 ) in HTR6 and METH - induced psychosis patients , respectively .|CONCLUSION : HTR6 may play an important role in the pathophysiology of METH - induced psychosis in the Japanese population .	1:Association:2	L2R	NON-CROSS	312-313	314-315	3362	Serotonin 6 receptor|serotonin 6 ( 5 - HT6 ) receptor|5 - HT6 receptors|5 - HT6|HTR6|HTR6|HTR6	GeneOrGeneProduct	0:37:132:175:180:312:324	3:45:136:178:181:313:325	0:2:4:6:6:11:12	D008694	methamphetamine|methamphetamine|METH|METH|METH|methamphetamine|METH|METH|METH	ChemicalEntity	7:148:150:183:219:248:258:314:334	8:149:151:184:220:249:259:315:335	0:5:5:6:7:8:9:11:12	1:Association:2	L2R	NON-CROSS	312-313	317-318	3362	Serotonin 6 receptor|serotonin 6 ( 5 - HT6 ) receptor|5 - HT6 receptors|5 - HT6|HTR6|HTR6|HTR6	GeneOrGeneProduct	0:37:132:175:180:312:324	3:45:136:178:181:313:325	0:2:4:6:6:11:12	D011605	psychosis|psychotic disorders|psychotic disorders|psychosis|psychosis|psychosis|psychosis|psychosis|psychosis	DiseaseOrPhenotypicFeature	10:30:142:154:186:222:261:317:337	11:32:144:155:187:223:262:318:338	0:1:4:5:6:7:9:11:12	1:NR:2	L2R	NON-CROSS	123-124	132-136	3362	Serotonin 6 receptor|serotonin 6 ( 5 - HT6 ) receptor|5 - HT6 receptors|5 - HT6|HTR6|HTR6|HTR6	GeneOrGeneProduct	0:37:132:175:180:312:324	3:45:136:178:181:313:325	0:2:4:6:6:11:12	D012559	schizophrenia|schizophrenia	DiseaseOrPhenotypicFeature	34:123	35:124	1:4	1:Association:2	L2R	NON-CROSS	37-45	52-53	3362	Serotonin 6 receptor|serotonin 6 ( 5 - HT6 ) receptor|5 - HT6 receptors|5 - HT6|HTR6|HTR6|HTR6	GeneOrGeneProduct	0:37:132:175:180:312:324	3:45:136:178:181:313:325	0:2:4:6:6:11:12	D014150	antipsychotics	ChemicalEntity	52	53	2	1:Association:2	L2R	NON-CROSS	37-45	56-57	3362	Serotonin 6 receptor|serotonin 6 ( 5 - HT6 ) receptor|5 - HT6 receptors|5 - HT6|HTR6|HTR6|HTR6	GeneOrGeneProduct	0:37:132:175:180:312:324	3:45:136:178:181:313:325	0:2:4:6:6:11:12	D003024	clozapine	ChemicalEntity	56	57	2	1:Association:2	L2R	NON-CROSS	37-45	58-59	3362	Serotonin 6 receptor|serotonin 6 ( 5 - HT6 ) receptor|5 - HT6 receptors|5 - HT6|HTR6|HTR6|HTR6	GeneOrGeneProduct	0:37:132:175:180:312:324	3:45:136:178:181:313:325	0:2:4:6:6:11:12	D000077152	olanzapine	ChemicalEntity	58	59	2	1:NR:2	L2R	NON-CROSS	37-45	61-64	3362	Serotonin 6 receptor|serotonin 6 ( 5 - HT6 ) receptor|5 - HT6 receptors|5 - HT6|HTR6|HTR6|HTR6	GeneOrGeneProduct	0:37:132:175:180:312:324	3:45:136:178:181:313:325	0:2:4:6:6:11:12	D003913	d - amphetamine|d - amphetamine	ChemicalEntity	61:92	64:95	2:3	1:Association:2	L2R	NON-CROSS	37-45	66-67	3362	Serotonin 6 receptor|serotonin 6 ( 5 - HT6 ) receptor|5 - HT6 receptors|5 - HT6|HTR6|HTR6|HTR6	GeneOrGeneProduct	0:37:132:175:180:312:324	3:45:136:178:181:313:325	0:2:4:6:6:11:12	D006948	hyperactivity	DiseaseOrPhenotypicFeature	66	67	2	1:NR:2	L2R	NON-CROSS	100-105	132-136	3362	Serotonin 6 receptor|serotonin 6 ( 5 - HT6 ) receptor|5 - HT6 receptors|5 - HT6|HTR6|HTR6|HTR6	GeneOrGeneProduct	0:37:132:175:180:312:324	3:45:136:178:181:313:325	0:2:4:6:6:11:12	D012702	5 - HT6 receptor antagonist|5 - HT6 receptor antagonist	ChemicalEntity	77:100	82:105	2:3	1:NR:2	L2R	CROSS	96-97	132-136	3362	Serotonin 6 receptor|serotonin 6 ( 5 - HT6 ) receptor|5 - HT6 receptors|5 - HT6|HTR6|HTR6|HTR6	GeneOrGeneProduct	0:37:132:175:180:312:324	3:45:136:178:181:313:325	0:2:4:6:6:11:12	D010622	phencyclidine	ChemicalEntity	96	97	3	1:NR:2	L2R	CROSS	160-163	175-178	3362	Serotonin 6 receptor|serotonin 6 ( 5 - HT6 ) receptor|5 - HT6 receptors|5 - HT6|HTR6|HTR6|HTR6	GeneOrGeneProduct	0:37:132:175:180:312:324	3:45:136:178:181:313:325	0:2:4:6:6:11:12	D012563	paranoid type schizophrenia	DiseaseOrPhenotypicFeature	160	163	5	1:Positive_Correlation:2	L2R	NON-CROSS	7-8	10-11	D008694	methamphetamine|methamphetamine|METH|METH|METH|methamphetamine|METH|METH|METH	ChemicalEntity	7:148:150:183:219:248:258:314:334	8:149:151:184:220:249:259:315:335	0:5:5:6:7:8:9:11:12	D011605	psychosis|psychotic disorders|psychotic disorders|psychosis|psychosis|psychosis|psychosis|psychosis|psychosis	DiseaseOrPhenotypicFeature	10:30:142:154:186:222:261:317:337	11:32:144:155:187:223:262:318:338	0:1:4:5:6:7:9:11:12	1:NR:2	L2R	CROSS	123-124	148-149	D008694	methamphetamine|methamphetamine|METH|METH|METH|methamphetamine|METH|METH|METH	ChemicalEntity	7:148:150:183:219:248:258:314:334	8:149:151:184:220:249:259:315:335	0:5:5:6:7:8:9:11:12	D012559	schizophrenia|schizophrenia	DiseaseOrPhenotypicFeature	34:123	35:124	1:4	1:NR:2	L2R	CROSS	7-8	52-53	D008694	methamphetamine|methamphetamine|METH|METH|METH|methamphetamine|METH|METH|METH	ChemicalEntity	7:148:150:183:219:248:258:314:334	8:149:151:184:220:249:259:315:335	0:5:5:6:7:8:9:11:12	D014150	antipsychotics	ChemicalEntity	52	53	2	1:NR:2	L2R	CROSS	7-8	56-57	D008694	methamphetamine|methamphetamine|METH|METH|METH|methamphetamine|METH|METH|METH	ChemicalEntity	7:148:150:183:219:248:258:314:334	8:149:151:184:220:249:259:315:335	0:5:5:6:7:8:9:11:12	D003024	clozapine	ChemicalEntity	56	57	2	1:NR:2	L2R	CROSS	7-8	58-59	D008694	methamphetamine|methamphetamine|METH|METH|METH|methamphetamine|METH|METH|METH	ChemicalEntity	7:148:150:183:219:248:258:314:334	8:149:151:184:220:249:259:315:335	0:5:5:6:7:8:9:11:12	D000077152	olanzapine	ChemicalEntity	58	59	2	1:NR:2	L2R	CROSS	7-8	61-64	D008694	methamphetamine|methamphetamine|METH|METH|METH|methamphetamine|METH|METH|METH	ChemicalEntity	7:148:150:183:219:248:258:314:334	8:149:151:184:220:249:259:315:335	0:5:5:6:7:8:9:11:12	D003913	d - amphetamine|d - amphetamine	ChemicalEntity	61:92	64:95	2:3	1:NR:2	L2R	CROSS	7-8	66-67	D008694	methamphetamine|methamphetamine|METH|METH|METH|methamphetamine|METH|METH|METH	ChemicalEntity	7:148:150:183:219:248:258:314:334	8:149:151:184:220:249:259:315:335	0:5:5:6:7:8:9:11:12	D006948	hyperactivity	DiseaseOrPhenotypicFeature	66	67	2	1:NR:2	L2R	CROSS	100-105	150-151	D008694	methamphetamine|methamphetamine|METH|METH|METH|methamphetamine|METH|METH|METH	ChemicalEntity	7:148:150:183:219:248:258:314:334	8:149:151:184:220:249:259:315:335	0:5:5:6:7:8:9:11:12	D012702	5 - HT6 receptor antagonist|5 - HT6 receptor antagonist	ChemicalEntity	77:100	82:105	2:3	1:NR:2	L2R	CROSS	96-97	148-149	D008694	methamphetamine|methamphetamine|METH|METH|METH|methamphetamine|METH|METH|METH	ChemicalEntity	7:148:150:183:219:248:258:314:334	8:149:151:184:220:249:259:315:335	0:5:5:6:7:8:9:11:12	D010622	phencyclidine	ChemicalEntity	96	97	3	1:NR:2	L2R	NON-CROSS	150-151	160-163	D008694	methamphetamine|methamphetamine|METH|METH|METH|methamphetamine|METH|METH|METH	ChemicalEntity	7:148:150:183:219:248:258:314:334	8:149:151:184:220:249:259:315:335	0:5:5:6:7:8:9:11:12	D012563	paranoid type schizophrenia	DiseaseOrPhenotypicFeature	160	163	5	1:Association:2	R2L	NON-CROSS	258-259	254-255	rs6693503	rs6693503|rs6693503|rs6693503|rs6693503	SequenceVariant	195:254:297:305	196:255:298:306	7:9:11:11	D008694	methamphetamine|methamphetamine|METH|METH|METH|methamphetamine|METH|METH|METH	ChemicalEntity	7:148:150:183:219:248:258:314:334	8:149:151:184:220:249:259:315:335	0:5:5:6:7:8:9:11:12	1:Association:2	R2L	NON-CROSS	314-315	307-308	rs1805054	rs1805054|rs1805054|rs1805054	SequenceVariant	197:299:307	198:300:308	7:11:11	D008694	methamphetamine|methamphetamine|METH|METH|METH|methamphetamine|METH|METH|METH	ChemicalEntity	7:148:150:183:219:248:258:314:334	8:149:151:184:220:249:259:315:335	0:5:5:6:7:8:9:11:12	1:Association:2	R2L	NON-CROSS	314-315	309-310	rs4912138	rs4912138|rs4912138	SequenceVariant	199:309	200:310	7:11	D008694	methamphetamine|methamphetamine|METH|METH|METH|methamphetamine|METH|METH|METH	ChemicalEntity	7:148:150:183:219:248:258:314:334	8:149:151:184:220:249:259:315:335	0:5:5:6:7:8:9:11:12	1:NR:2	L2R	NON-CROSS	183-184	201-202	D008694	methamphetamine|methamphetamine|METH|METH|METH|methamphetamine|METH|METH|METH	ChemicalEntity	7:148:150:183:219:248:258:314:334	8:149:151:184:220:249:259:315:335	0:5:5:6:7:8:9:11:12	rs3790757	rs3790757	SequenceVariant	201	202	7	1:NR:2	L2R	NON-CROSS	203-204	219-220	D008694	methamphetamine|methamphetamine|METH|METH|METH|methamphetamine|METH|METH|METH	ChemicalEntity	7:148:150:183:219:248:258:314:334	8:149:151:184:220:249:259:315:335	0:5:5:6:7:8:9:11:12	rs9659997	rs9659997	SequenceVariant	203	204	7	1:NR:2	L2R	CROSS	30-32	52-53	D011605	psychosis|psychotic disorders|psychotic disorders|psychosis|psychosis|psychosis|psychosis|psychosis|psychosis	DiseaseOrPhenotypicFeature	10:30:142:154:186:222:261:317:337	11:32:144:155:187:223:262:318:338	0:1:4:5:6:7:9:11:12	D014150	antipsychotics	ChemicalEntity	52	53	2	1:Negative_Correlation:2	L2R	CROSS	30-32	56-57	D011605	psychosis|psychotic disorders|psychotic disorders|psychosis|psychosis|psychosis|psychosis|psychosis|psychosis	DiseaseOrPhenotypicFeature	10:30:142:154:186:222:261:317:337	11:32:144:155:187:223:262:318:338	0:1:4:5:6:7:9:11:12	D003024	clozapine	ChemicalEntity	56	57	2	1:Negative_Correlation:2	L2R	CROSS	30-32	58-59	D011605	psychosis|psychotic disorders|psychotic disorders|psychosis|psychosis|psychosis|psychosis|psychosis|psychosis	DiseaseOrPhenotypicFeature	10:30:142:154:186:222:261:317:337	11:32:144:155:187:223:262:318:338	0:1:4:5:6:7:9:11:12	D000077152	olanzapine	ChemicalEntity	58	59	2	1:NR:2	L2R	CROSS	30-32	61-64	D011605	psychosis|psychotic disorders|psychotic disorders|psychosis|psychosis|psychosis|psychosis|psychosis|psychosis	DiseaseOrPhenotypicFeature	10:30:142:154:186:222:261:317:337	11:32:144:155:187:223:262:318:338	0:1:4:5:6:7:9:11:12	D003913	d - amphetamine|d - amphetamine	ChemicalEntity	61:92	64:95	2:3	1:NR:2	L2R	CROSS	100-105	142-144	D011605	psychosis|psychotic disorders|psychotic disorders|psychosis|psychosis|psychosis|psychosis|psychosis|psychosis	DiseaseOrPhenotypicFeature	10:30:142:154:186:222:261:317:337	11:32:144:155:187:223:262:318:338	0:1:4:5:6:7:9:11:12	D012702	5 - HT6 receptor antagonist|5 - HT6 receptor antagonist	ChemicalEntity	77:100	82:105	2:3	1:NR:2	L2R	CROSS	96-97	142-144	D011605	psychosis|psychotic disorders|psychotic disorders|psychosis|psychosis|psychosis|psychosis|psychosis|psychosis	DiseaseOrPhenotypicFeature	10:30:142:154:186:222:261:317:337	11:32:144:155:187:223:262:318:338	0:1:4:5:6:7:9:11:12	D010622	phencyclidine	ChemicalEntity	96	97	3	1:Association:2	R2L	NON-CROSS	261-262	254-255	rs6693503	rs6693503|rs6693503|rs6693503|rs6693503	SequenceVariant	195:254:297:305	196:255:298:306	7:9:11:11	D011605	psychosis|psychotic disorders|psychotic disorders|psychosis|psychosis|psychosis|psychosis|psychosis|psychosis	DiseaseOrPhenotypicFeature	10:30:142:154:186:222:261:317:337	11:32:144:155:187:223:262:318:338	0:1:4:5:6:7:9:11:12	1:Association:2	R2L	NON-CROSS	317-318	307-308	rs1805054	rs1805054|rs1805054|rs1805054	SequenceVariant	197:299:307	198:300:308	7:11:11	D011605	psychosis|psychotic disorders|psychotic disorders|psychosis|psychosis|psychosis|psychosis|psychosis|psychosis	DiseaseOrPhenotypicFeature	10:30:142:154:186:222:261:317:337	11:32:144:155:187:223:262:318:338	0:1:4:5:6:7:9:11:12	1:Association:2	R2L	NON-CROSS	317-318	309-310	rs4912138	rs4912138|rs4912138	SequenceVariant	199:309	200:310	7:11	D011605	psychosis|psychotic disorders|psychotic disorders|psychosis|psychosis|psychosis|psychosis|psychosis|psychosis	DiseaseOrPhenotypicFeature	10:30:142:154:186:222:261:317:337	11:32:144:155:187:223:262:318:338	0:1:4:5:6:7:9:11:12	1:NR:2	L2R	NON-CROSS	186-187	201-202	D011605	psychosis|psychotic disorders|psychotic disorders|psychosis|psychosis|psychosis|psychosis|psychosis|psychosis	DiseaseOrPhenotypicFeature	10:30:142:154:186:222:261:317:337	11:32:144:155:187:223:262:318:338	0:1:4:5:6:7:9:11:12	rs3790757	rs3790757	SequenceVariant	201	202	7	1:NR:2	L2R	NON-CROSS	186-187	203-204	D011605	psychosis|psychotic disorders|psychotic disorders|psychosis|psychosis|psychosis|psychosis|psychosis|psychosis	DiseaseOrPhenotypicFeature	10:30:142:154:186:222:261:317:337	11:32:144:155:187:223:262:318:338	0:1:4:5:6:7:9:11:12	rs9659997	rs9659997	SequenceVariant	203	204	7	1:NR:2	L2R	CROSS	34-35	52-53	D012559	schizophrenia|schizophrenia	DiseaseOrPhenotypicFeature	34:123	35:124	1:4	D014150	antipsychotics	ChemicalEntity	52	53	2	1:NR:2	L2R	CROSS	34-35	56-57	D012559	schizophrenia|schizophrenia	DiseaseOrPhenotypicFeature	34:123	35:124	1:4	D003024	clozapine	ChemicalEntity	56	57	2	1:NR:2	L2R	CROSS	34-35	58-59	D012559	schizophrenia|schizophrenia	DiseaseOrPhenotypicFeature	34:123	35:124	1:4	D000077152	olanzapine	ChemicalEntity	58	59	2	1:NR:2	L2R	CROSS	34-35	61-64	D012559	schizophrenia|schizophrenia	DiseaseOrPhenotypicFeature	34:123	35:124	1:4	D003913	d - amphetamine|d - amphetamine	ChemicalEntity	61:92	64:95	2:3	1:Association:2	R2L	CROSS	123-124	100-105	D012702	5 - HT6 receptor antagonist|5 - HT6 receptor antagonist	ChemicalEntity	77:100	82:105	2:3	D012559	schizophrenia|schizophrenia	DiseaseOrPhenotypicFeature	34:123	35:124	1:4	1:NR:2	L2R	CROSS	96-97	123-124	D012559	schizophrenia|schizophrenia	DiseaseOrPhenotypicFeature	34:123	35:124	1:4	D010622	phencyclidine	ChemicalEntity	96	97	3	1:NR:2	L2R	CROSS	123-124	195-196	D012559	schizophrenia|schizophrenia	DiseaseOrPhenotypicFeature	34:123	35:124	1:4	rs6693503	rs6693503|rs6693503|rs6693503|rs6693503	SequenceVariant	195:254:297:305	196:255:298:306	7:9:11:11	1:NR:2	L2R	CROSS	123-124	197-198	D012559	schizophrenia|schizophrenia	DiseaseOrPhenotypicFeature	34:123	35:124	1:4	rs1805054	rs1805054|rs1805054|rs1805054	SequenceVariant	197:299:307	198:300:308	7:11:11	1:NR:2	L2R	CROSS	123-124	199-200	D012559	schizophrenia|schizophrenia	DiseaseOrPhenotypicFeature	34:123	35:124	1:4	rs4912138	rs4912138|rs4912138	SequenceVariant	199:309	200:310	7:11	1:NR:2	L2R	CROSS	123-124	201-202	D012559	schizophrenia|schizophrenia	DiseaseOrPhenotypicFeature	34:123	35:124	1:4	rs3790757	rs3790757	SequenceVariant	201	202	7	1:NR:2	L2R	CROSS	123-124	203-204	D012559	schizophrenia|schizophrenia	DiseaseOrPhenotypicFeature	34:123	35:124	1:4	rs9659997	rs9659997	SequenceVariant	203	204	7	1:NR:2	L2R	NON-CROSS	52-53	56-57	D014150	antipsychotics	ChemicalEntity	52	53	2	D003024	clozapine	ChemicalEntity	56	57	2	1:NR:2	L2R	NON-CROSS	52-53	58-59	D014150	antipsychotics	ChemicalEntity	52	53	2	D000077152	olanzapine	ChemicalEntity	58	59	2	1:NR:2	L2R	NON-CROSS	52-53	61-64	D014150	antipsychotics	ChemicalEntity	52	53	2	D003913	d - amphetamine|d - amphetamine	ChemicalEntity	61:92	64:95	2:3	1:NR:2	L2R	NON-CROSS	52-53	66-67	D014150	antipsychotics	ChemicalEntity	52	53	2	D006948	hyperactivity	DiseaseOrPhenotypicFeature	66	67	2	1:NR:2	L2R	NON-CROSS	52-53	77-82	D014150	antipsychotics	ChemicalEntity	52	53	2	D012702	5 - HT6 receptor antagonist|5 - HT6 receptor antagonist	ChemicalEntity	77:100	82:105	2:3	1:NR:2	L2R	CROSS	52-53	96-97	D014150	antipsychotics	ChemicalEntity	52	53	2	D010622	phencyclidine	ChemicalEntity	96	97	3	1:NR:2	L2R	CROSS	52-53	160-163	D014150	antipsychotics	ChemicalEntity	52	53	2	D012563	paranoid type schizophrenia	DiseaseOrPhenotypicFeature	160	163	5	1:NR:2	L2R	CROSS	52-53	195-196	D014150	antipsychotics	ChemicalEntity	52	53	2	rs6693503	rs6693503|rs6693503|rs6693503|rs6693503	SequenceVariant	195:254:297:305	196:255:298:306	7:9:11:11	1:NR:2	L2R	CROSS	52-53	197-198	D014150	antipsychotics	ChemicalEntity	52	53	2	rs1805054	rs1805054|rs1805054|rs1805054	SequenceVariant	197:299:307	198:300:308	7:11:11	1:NR:2	L2R	CROSS	52-53	199-200	D014150	antipsychotics	ChemicalEntity	52	53	2	rs4912138	rs4912138|rs4912138	SequenceVariant	199:309	200:310	7:11	1:NR:2	L2R	CROSS	52-53	201-202	D014150	antipsychotics	ChemicalEntity	52	53	2	rs3790757	rs3790757	SequenceVariant	201	202	7	1:NR:2	L2R	CROSS	52-53	203-204	D014150	antipsychotics	ChemicalEntity	52	53	2	rs9659997	rs9659997	SequenceVariant	203	204	7	1:NR:2	L2R	NON-CROSS	56-57	58-59	D003024	clozapine	ChemicalEntity	56	57	2	D000077152	olanzapine	ChemicalEntity	58	59	2	1:NR:2	L2R	NON-CROSS	56-57	61-64	D003024	clozapine	ChemicalEntity	56	57	2	D003913	d - amphetamine|d - amphetamine	ChemicalEntity	61:92	64:95	2:3	1:NR:2	L2R	NON-CROSS	56-57	66-67	D003024	clozapine	ChemicalEntity	56	57	2	D006948	hyperactivity	DiseaseOrPhenotypicFeature	66	67	2	1:NR:2	L2R	NON-CROSS	56-57	77-82	D003024	clozapine	ChemicalEntity	56	57	2	D012702	5 - HT6 receptor antagonist|5 - HT6 receptor antagonist	ChemicalEntity	77:100	82:105	2:3	1:NR:2	L2R	CROSS	56-57	96-97	D003024	clozapine	ChemicalEntity	56	57	2	D010622	phencyclidine	ChemicalEntity	96	97	3	1:NR:2	L2R	CROSS	56-57	160-163	D003024	clozapine	ChemicalEntity	56	57	2	D012563	paranoid type schizophrenia	DiseaseOrPhenotypicFeature	160	163	5	1:NR:2	L2R	CROSS	56-57	195-196	D003024	clozapine	ChemicalEntity	56	57	2	rs6693503	rs6693503|rs6693503|rs6693503|rs6693503	SequenceVariant	195:254:297:305	196:255:298:306	7:9:11:11	1:NR:2	L2R	CROSS	56-57	197-198	D003024	clozapine	ChemicalEntity	56	57	2	rs1805054	rs1805054|rs1805054|rs1805054	SequenceVariant	197:299:307	198:300:308	7:11:11	1:NR:2	L2R	CROSS	56-57	199-200	D003024	clozapine	ChemicalEntity	56	57	2	rs4912138	rs4912138|rs4912138	SequenceVariant	199:309	200:310	7:11	1:NR:2	L2R	CROSS	56-57	201-202	D003024	clozapine	ChemicalEntity	56	57	2	rs3790757	rs3790757	SequenceVariant	201	202	7	1:NR:2	L2R	CROSS	56-57	203-204	D003024	clozapine	ChemicalEntity	56	57	2	rs9659997	rs9659997	SequenceVariant	203	204	7	1:NR:2	L2R	NON-CROSS	58-59	61-64	D000077152	olanzapine	ChemicalEntity	58	59	2	D003913	d - amphetamine|d - amphetamine	ChemicalEntity	61:92	64:95	2:3	1:NR:2	L2R	NON-CROSS	58-59	66-67	D000077152	olanzapine	ChemicalEntity	58	59	2	D006948	hyperactivity	DiseaseOrPhenotypicFeature	66	67	2	1:NR:2	L2R	NON-CROSS	58-59	77-82	D000077152	olanzapine	ChemicalEntity	58	59	2	D012702	5 - HT6 receptor antagonist|5 - HT6 receptor antagonist	ChemicalEntity	77:100	82:105	2:3	1:NR:2	L2R	CROSS	58-59	96-97	D000077152	olanzapine	ChemicalEntity	58	59	2	D010622	phencyclidine	ChemicalEntity	96	97	3	1:NR:2	L2R	CROSS	58-59	160-163	D000077152	olanzapine	ChemicalEntity	58	59	2	D012563	paranoid type schizophrenia	DiseaseOrPhenotypicFeature	160	163	5	1:NR:2	L2R	CROSS	58-59	195-196	D000077152	olanzapine	ChemicalEntity	58	59	2	rs6693503	rs6693503|rs6693503|rs6693503|rs6693503	SequenceVariant	195:254:297:305	196:255:298:306	7:9:11:11	1:NR:2	L2R	CROSS	58-59	197-198	D000077152	olanzapine	ChemicalEntity	58	59	2	rs1805054	rs1805054|rs1805054|rs1805054	SequenceVariant	197:299:307	198:300:308	7:11:11	1:NR:2	L2R	CROSS	58-59	199-200	D000077152	olanzapine	ChemicalEntity	58	59	2	rs4912138	rs4912138|rs4912138	SequenceVariant	199:309	200:310	7:11	1:NR:2	L2R	CROSS	58-59	201-202	D000077152	olanzapine	ChemicalEntity	58	59	2	rs3790757	rs3790757	SequenceVariant	201	202	7	1:NR:2	L2R	CROSS	58-59	203-204	D000077152	olanzapine	ChemicalEntity	58	59	2	rs9659997	rs9659997	SequenceVariant	203	204	7	1:Positive_Correlation:2	L2R	NON-CROSS	61-64	66-67	D003913	d - amphetamine|d - amphetamine	ChemicalEntity	61:92	64:95	2:3	D006948	hyperactivity	DiseaseOrPhenotypicFeature	66	67	2	1:Association:2	L2R	NON-CROSS	92-95	100-105	D003913	d - amphetamine|d - amphetamine	ChemicalEntity	61:92	64:95	2:3	D012702	5 - HT6 receptor antagonist|5 - HT6 receptor antagonist	ChemicalEntity	77:100	82:105	2:3	1:NR:2	L2R	NON-CROSS	92-95	96-97	D003913	d - amphetamine|d - amphetamine	ChemicalEntity	61:92	64:95	2:3	D010622	phencyclidine	ChemicalEntity	96	97	3	1:NR:2	L2R	CROSS	92-95	160-163	D003913	d - amphetamine|d - amphetamine	ChemicalEntity	61:92	64:95	2:3	D012563	paranoid type schizophrenia	DiseaseOrPhenotypicFeature	160	163	5	1:NR:2	L2R	CROSS	92-95	195-196	D003913	d - amphetamine|d - amphetamine	ChemicalEntity	61:92	64:95	2:3	rs6693503	rs6693503|rs6693503|rs6693503|rs6693503	SequenceVariant	195:254:297:305	196:255:298:306	7:9:11:11	1:NR:2	L2R	CROSS	92-95	197-198	D003913	d - amphetamine|d - amphetamine	ChemicalEntity	61:92	64:95	2:3	rs1805054	rs1805054|rs1805054|rs1805054	SequenceVariant	197:299:307	198:300:308	7:11:11	1:NR:2	L2R	CROSS	92-95	199-200	D003913	d - amphetamine|d - amphetamine	ChemicalEntity	61:92	64:95	2:3	rs4912138	rs4912138|rs4912138	SequenceVariant	199:309	200:310	7:11	1:NR:2	L2R	CROSS	92-95	201-202	D003913	d - amphetamine|d - amphetamine	ChemicalEntity	61:92	64:95	2:3	rs3790757	rs3790757	SequenceVariant	201	202	7	1:NR:2	L2R	CROSS	92-95	203-204	D003913	d - amphetamine|d - amphetamine	ChemicalEntity	61:92	64:95	2:3	rs9659997	rs9659997	SequenceVariant	203	204	7	1:NR:2	L2R	NON-CROSS	66-67	77-82	D006948	hyperactivity	DiseaseOrPhenotypicFeature	66	67	2	D012702	5 - HT6 receptor antagonist|5 - HT6 receptor antagonist	ChemicalEntity	77:100	82:105	2:3	1:NR:2	L2R	CROSS	66-67	96-97	D006948	hyperactivity	DiseaseOrPhenotypicFeature	66	67	2	D010622	phencyclidine	ChemicalEntity	96	97	3	1:NR:2	L2R	CROSS	66-67	195-196	D006948	hyperactivity	DiseaseOrPhenotypicFeature	66	67	2	rs6693503	rs6693503|rs6693503|rs6693503|rs6693503	SequenceVariant	195:254:297:305	196:255:298:306	7:9:11:11	1:NR:2	L2R	CROSS	66-67	197-198	D006948	hyperactivity	DiseaseOrPhenotypicFeature	66	67	2	rs1805054	rs1805054|rs1805054|rs1805054	SequenceVariant	197:299:307	198:300:308	7:11:11	1:NR:2	L2R	CROSS	66-67	199-200	D006948	hyperactivity	DiseaseOrPhenotypicFeature	66	67	2	rs4912138	rs4912138|rs4912138	SequenceVariant	199:309	200:310	7:11	1:NR:2	L2R	CROSS	66-67	201-202	D006948	hyperactivity	DiseaseOrPhenotypicFeature	66	67	2	rs3790757	rs3790757	SequenceVariant	201	202	7	1:NR:2	L2R	CROSS	66-67	203-204	D006948	hyperactivity	DiseaseOrPhenotypicFeature	66	67	2	rs9659997	rs9659997	SequenceVariant	203	204	7	1:Association:2	R2L	NON-CROSS	100-105	96-97	D010622	phencyclidine	ChemicalEntity	96	97	3	D012702	5 - HT6 receptor antagonist|5 - HT6 receptor antagonist	ChemicalEntity	77:100	82:105	2:3	1:NR:2	L2R	CROSS	100-105	160-163	D012702	5 - HT6 receptor antagonist|5 - HT6 receptor antagonist	ChemicalEntity	77:100	82:105	2:3	D012563	paranoid type schizophrenia	DiseaseOrPhenotypicFeature	160	163	5	1:NR:2	L2R	CROSS	100-105	195-196	D012702	5 - HT6 receptor antagonist|5 - HT6 receptor antagonist	ChemicalEntity	77:100	82:105	2:3	rs6693503	rs6693503|rs6693503|rs6693503|rs6693503	SequenceVariant	195:254:297:305	196:255:298:306	7:9:11:11	1:NR:2	L2R	CROSS	100-105	197-198	D012702	5 - HT6 receptor antagonist|5 - HT6 receptor antagonist	ChemicalEntity	77:100	82:105	2:3	rs1805054	rs1805054|rs1805054|rs1805054	SequenceVariant	197:299:307	198:300:308	7:11:11	1:NR:2	L2R	CROSS	100-105	199-200	D012702	5 - HT6 receptor antagonist|5 - HT6 receptor antagonist	ChemicalEntity	77:100	82:105	2:3	rs4912138	rs4912138|rs4912138	SequenceVariant	199:309	200:310	7:11	1:NR:2	L2R	CROSS	100-105	201-202	D012702	5 - HT6 receptor antagonist|5 - HT6 receptor antagonist	ChemicalEntity	77:100	82:105	2:3	rs3790757	rs3790757	SequenceVariant	201	202	7	1:NR:2	L2R	CROSS	100-105	203-204	D012702	5 - HT6 receptor antagonist|5 - HT6 receptor antagonist	ChemicalEntity	77:100	82:105	2:3	rs9659997	rs9659997	SequenceVariant	203	204	7	1:NR:2	L2R	CROSS	96-97	160-163	D010622	phencyclidine	ChemicalEntity	96	97	3	D012563	paranoid type schizophrenia	DiseaseOrPhenotypicFeature	160	163	5	1:NR:2	L2R	CROSS	96-97	195-196	D010622	phencyclidine	ChemicalEntity	96	97	3	rs6693503	rs6693503|rs6693503|rs6693503|rs6693503	SequenceVariant	195:254:297:305	196:255:298:306	7:9:11:11	1:NR:2	L2R	CROSS	96-97	197-198	D010622	phencyclidine	ChemicalEntity	96	97	3	rs1805054	rs1805054|rs1805054|rs1805054	SequenceVariant	197:299:307	198:300:308	7:11:11	1:NR:2	L2R	CROSS	96-97	199-200	D010622	phencyclidine	ChemicalEntity	96	97	3	rs4912138	rs4912138|rs4912138	SequenceVariant	199:309	200:310	7:11	1:NR:2	L2R	CROSS	96-97	201-202	D010622	phencyclidine	ChemicalEntity	96	97	3	rs3790757	rs3790757	SequenceVariant	201	202	7	1:NR:2	L2R	CROSS	96-97	203-204	D010622	phencyclidine	ChemicalEntity	96	97	3	rs9659997	rs9659997	SequenceVariant	203	204	7	1:NR:2	L2R	CROSS	160-163	195-196	D012563	paranoid type schizophrenia	DiseaseOrPhenotypicFeature	160	163	5	rs6693503	rs6693503|rs6693503|rs6693503|rs6693503	SequenceVariant	195:254:297:305	196:255:298:306	7:9:11:11	1:NR:2	L2R	CROSS	160-163	197-198	D012563	paranoid type schizophrenia	DiseaseOrPhenotypicFeature	160	163	5	rs1805054	rs1805054|rs1805054|rs1805054	SequenceVariant	197:299:307	198:300:308	7:11:11	1:NR:2	L2R	CROSS	160-163	199-200	D012563	paranoid type schizophrenia	DiseaseOrPhenotypicFeature	160	163	5	rs4912138	rs4912138|rs4912138	SequenceVariant	199:309	200:310	7:11	1:NR:2	L2R	CROSS	160-163	201-202	D012563	paranoid type schizophrenia	DiseaseOrPhenotypicFeature	160	163	5	rs3790757	rs3790757	SequenceVariant	201	202	7	1:NR:2	L2R	CROSS	160-163	203-204	D012563	paranoid type schizophrenia	DiseaseOrPhenotypicFeature	160	163	5	rs9659997	rs9659997	SequenceVariant	203	204	7
22369755	Reciprocal effects of NNK and SLURP - 1 on oncogene expression in target epithelial cells .|AIMS : To elucidate how the nicotinic acetylcholine receptors expressed on bronchial and oral epithelial cells targeted by the tobacco nitrosamine ( 4 - ( methylnitrosamino ) - 1 - ( 3 - pyridyl ) - 1 - butanone ) ( NNK ) facilitate carcinogenic transformation .|MAIN METHODS : Since NNK - dependent transformation can be abolished by the nicotinergic secreted mammalian Ly - 6 / urokinase plasminogen activator receptor related protein - 1 ( SLURP - 1 ) , we compared effects of NNK and recombinant ( r ) SLURP - 1 on the expression of genes related to tumorigenesis in human immortalized bronchial and oral epithelial cell lines BEP2D and Het - 1A , respectively .|KEY FINDINGS : NNK stimulated expression of oncogenic genes , including MYB and PIK3CA in BEP2D , ETS1 , NRAS and SRC in Het - 1A , and AKT1 , KIT and RB1 in both cell types , which could be abolished in the presence of rSLURP - 1 .|Other cancer - related genes whose upregulation by NNK was abolishable by rSLURP - 1 were the growth factors EGF in BEP2D cells and HGF in Het - 1A cells , and the transcription factors CDKN2A and STAT3 ( Het - 1A only ) .|NNK also upregulated the anti - apoptotic BCL2 ( Het - 1A ) and downregulated the pro - apoptotic TNF ( Het - 1A ) , BAX and CASP8 ( BEP2D ) , all of which could be abolished , in part , by rSLURP - 1 .|NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta - catenin ( BEP2D ) , as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het - 1A cells .|These pro - oncogenic effects of NNK were abolished by rSLURP - 1 that also upregulated RUNX3 .|SIGNIFICANCE : The obtained results identified target genes for both NNK and SLURP - 1 and shed light on the molecular mechanism of their reciprocal effects on tumorigenic transformation of bronchial and oral epithelial cells .	1:Negative_Correlation:2	L2R	NON-CROSS	3-4	5-8	C016583	NNK|4 - ( methylnitrosamino ) - 1 - ( 3 - pyridyl ) - 1 - butanone|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK	ChemicalEntity	3:38:57:67:101:138:193:230:278:322:344	4:55:58:68:102:139:194:231:279:323:345	0:1:1:2:2:3:4:5:6:7:8	57152	SLURP - 1|Ly - 6 / urokinase plasminogen activator receptor related protein - 1|SLURP - 1|SLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|SLURP - 1	GeneOrGeneProduct	5:79:92:107:181:197:274:326:346	8:91:95:110:184:200:277:329:349	0:2:2:2:3:4:5:7:8	1:NR:2	L2R	NON-CROSS	22-25	38-55	C016583	NNK|4 - ( methylnitrosamino ) - 1 - ( 3 - pyridyl ) - 1 - butanone|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK	ChemicalEntity	3:38:57:67:101:138:193:230:278:322:344	4:55:58:68:102:139:194:231:279:323:345	0:1:1:2:2:3:4:5:6:7:8	1136	nicotinic acetylcholine receptors	GeneOrGeneProduct	22	25	1	1:NR:2	L2R	NON-CROSS	36-37	38-55	C016583	NNK|4 - ( methylnitrosamino ) - 1 - ( 3 - pyridyl ) - 1 - butanone|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK	ChemicalEntity	3:38:57:67:101:138:193:230:278:322:344	4:55:58:68:102:139:194:231:279:323:345	0:1:1:2:2:3:4:5:6:7:8	D009602	nitrosamine	ChemicalEntity	36	37	1	1:Association:2	L2R	NON-CROSS	57-58	60-61	C016583	NNK|4 - ( methylnitrosamino ) - 1 - ( 3 - pyridyl ) - 1 - butanone|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK	ChemicalEntity	3:38:57:67:101:138:193:230:278:322:344	4:55:58:68:102:139:194:231:279:323:345	0:1:1:2:2:3:4:5:6:7:8	D009369	carcinogenic|tumorigenesis|cancer|tumor|tumorigenic	DiseaseOrPhenotypicFeature	60:117:186:300:361	61:118:187:301:362	1:2:4:6:8	1:Positive_Correlation:2	L2R	NON-CROSS	138-139	146-147	C016583	NNK|4 - ( methylnitrosamino ) - 1 - ( 3 - pyridyl ) - 1 - butanone|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK	ChemicalEntity	3:38:57:67:101:138:193:230:278:322:344	4:55:58:68:102:139:194:231:279:323:345	0:1:1:2:2:3:4:5:6:7:8	4602	MYB	GeneOrGeneProduct	146	147	3	1:Positive_Correlation:2	L2R	NON-CROSS	138-139	148-149	C016583	NNK|4 - ( methylnitrosamino ) - 1 - ( 3 - pyridyl ) - 1 - butanone|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK	ChemicalEntity	3:38:57:67:101:138:193:230:278:322:344	4:55:58:68:102:139:194:231:279:323:345	0:1:1:2:2:3:4:5:6:7:8	5290	PIK3CA	GeneOrGeneProduct	148	149	3	1:Positive_Correlation:2	R2L	NON-CROSS	152-153	138-139	2113	ETS1	GeneOrGeneProduct	152	153	3	C016583	NNK|4 - ( methylnitrosamino ) - 1 - ( 3 - pyridyl ) - 1 - butanone|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK	ChemicalEntity	3:38:57:67:101:138:193:230:278:322:344	4:55:58:68:102:139:194:231:279:323:345	0:1:1:2:2:3:4:5:6:7:8	1:Positive_Correlation:2	R2L	NON-CROSS	154-155	138-139	4893	NRAS	GeneOrGeneProduct	154	155	3	C016583	NNK|4 - ( methylnitrosamino ) - 1 - ( 3 - pyridyl ) - 1 - butanone|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK	ChemicalEntity	3:38:57:67:101:138:193:230:278:322:344	4:55:58:68:102:139:194:231:279:323:345	0:1:1:2:2:3:4:5:6:7:8	1:Positive_Correlation:2	R2L	NON-CROSS	156-157	138-139	6714	SRC	GeneOrGeneProduct	156	157	3	C016583	NNK|4 - ( methylnitrosamino ) - 1 - ( 3 - pyridyl ) - 1 - butanone|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK	ChemicalEntity	3:38:57:67:101:138:193:230:278:322:344	4:55:58:68:102:139:194:231:279:323:345	0:1:1:2:2:3:4:5:6:7:8	1:Positive_Correlation:2	R2L	NON-CROSS	163-164	138-139	207	AKT1	GeneOrGeneProduct	163	164	3	C016583	NNK|4 - ( methylnitrosamino ) - 1 - ( 3 - pyridyl ) - 1 - butanone|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK	ChemicalEntity	3:38:57:67:101:138:193:230:278:322:344	4:55:58:68:102:139:194:231:279:323:345	0:1:1:2:2:3:4:5:6:7:8	1:Positive_Correlation:2	R2L	NON-CROSS	165-166	138-139	3815	KIT	GeneOrGeneProduct	165	166	3	C016583	NNK|4 - ( methylnitrosamino ) - 1 - ( 3 - pyridyl ) - 1 - butanone|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK	ChemicalEntity	3:38:57:67:101:138:193:230:278:322:344	4:55:58:68:102:139:194:231:279:323:345	0:1:1:2:2:3:4:5:6:7:8	1:Positive_Correlation:2	R2L	NON-CROSS	193-194	167-168	5925	RB1	GeneOrGeneProduct	167	168	3	C016583	NNK|4 - ( methylnitrosamino ) - 1 - ( 3 - pyridyl ) - 1 - butanone|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK	ChemicalEntity	3:38:57:67:101:138:193:230:278:322:344	4:55:58:68:102:139:194:231:279:323:345	0:1:1:2:2:3:4:5:6:7:8	1:Positive_Correlation:2	L2R	NON-CROSS	193-194	204-205	C016583	NNK|4 - ( methylnitrosamino ) - 1 - ( 3 - pyridyl ) - 1 - butanone|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK	ChemicalEntity	3:38:57:67:101:138:193:230:278:322:344	4:55:58:68:102:139:194:231:279:323:345	0:1:1:2:2:3:4:5:6:7:8	1950	EGF	GeneOrGeneProduct	204	205	4	1:Positive_Correlation:2	L2R	NON-CROSS	193-194	209-210	C016583	NNK|4 - ( methylnitrosamino ) - 1 - ( 3 - pyridyl ) - 1 - butanone|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK	ChemicalEntity	3:38:57:67:101:138:193:230:278:322:344	4:55:58:68:102:139:194:231:279:323:345	0:1:1:2:2:3:4:5:6:7:8	3082	HGF	GeneOrGeneProduct	209	210	4	1:Positive_Correlation:2	L2R	NON-CROSS	220-221	230-231	C016583	NNK|4 - ( methylnitrosamino ) - 1 - ( 3 - pyridyl ) - 1 - butanone|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK	ChemicalEntity	3:38:57:67:101:138:193:230:278:322:344	4:55:58:68:102:139:194:231:279:323:345	0:1:1:2:2:3:4:5:6:7:8	1029	CDKN2A	GeneOrGeneProduct	220	221	4	1:Positive_Correlation:2	L2R	NON-CROSS	222-223	230-231	C016583	NNK|4 - ( methylnitrosamino ) - 1 - ( 3 - pyridyl ) - 1 - butanone|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK	ChemicalEntity	3:38:57:67:101:138:193:230:278:322:344	4:55:58:68:102:139:194:231:279:323:345	0:1:1:2:2:3:4:5:6:7:8	6774	STAT3	GeneOrGeneProduct	222	223	4	1:Positive_Correlation:2	L2R	NON-CROSS	230-231	237-238	C016583	NNK|4 - ( methylnitrosamino ) - 1 - ( 3 - pyridyl ) - 1 - butanone|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK	ChemicalEntity	3:38:57:67:101:138:193:230:278:322:344	4:55:58:68:102:139:194:231:279:323:345	0:1:1:2:2:3:4:5:6:7:8	596	BCL2	GeneOrGeneProduct	237	238	5	1:Negative_Correlation:2	L2R	NON-CROSS	230-231	249-250	C016583	NNK|4 - ( methylnitrosamino ) - 1 - ( 3 - pyridyl ) - 1 - butanone|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK	ChemicalEntity	3:38:57:67:101:138:193:230:278:322:344	4:55:58:68:102:139:194:231:279:323:345	0:1:1:2:2:3:4:5:6:7:8	7124	TNF	GeneOrGeneProduct	249	250	5	1:Negative_Correlation:2	L2R	NON-CROSS	256-257	278-279	C016583	NNK|4 - ( methylnitrosamino ) - 1 - ( 3 - pyridyl ) - 1 - butanone|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK	ChemicalEntity	3:38:57:67:101:138:193:230:278:322:344	4:55:58:68:102:139:194:231:279:323:345	0:1:1:2:2:3:4:5:6:7:8	581	BAX	GeneOrGeneProduct	256	257	5	1:Negative_Correlation:2	L2R	NON-CROSS	258-259	278-279	C016583	NNK|4 - ( methylnitrosamino ) - 1 - ( 3 - pyridyl ) - 1 - butanone|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK	ChemicalEntity	3:38:57:67:101:138:193:230:278:322:344	4:55:58:68:102:139:194:231:279:323:345	0:1:1:2:2:3:4:5:6:7:8	841	CASP8	GeneOrGeneProduct	258	259	5	1:Negative_Correlation:2	L2R	NON-CROSS	278-279	283-284	C016583	NNK|4 - ( methylnitrosamino ) - 1 - ( 3 - pyridyl ) - 1 - butanone|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK	ChemicalEntity	3:38:57:67:101:138:193:230:278:322:344	4:55:58:68:102:139:194:231:279:323:345	0:1:1:2:2:3:4:5:6:7:8	1499	CTNNB1|beta - catenin	GeneOrGeneProduct	283:290	284:293	6:6	1:Negative_Correlation:2	L2R	NON-CROSS	302-303	322-323	C016583	NNK|4 - ( methylnitrosamino ) - 1 - ( 3 - pyridyl ) - 1 - butanone|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK	ChemicalEntity	3:38:57:67:101:138:193:230:278:322:344	4:55:58:68:102:139:194:231:279:323:345	0:1:1:2:2:3:4:5:6:7:8	1033	CDKN3	GeneOrGeneProduct	302	303	6	1:Negative_Correlation:2	L2R	NON-CROSS	304-305	322-323	C016583	NNK|4 - ( methylnitrosamino ) - 1 - ( 3 - pyridyl ) - 1 - butanone|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK	ChemicalEntity	3:38:57:67:101:138:193:230:278:322:344	4:55:58:68:102:139:194:231:279:323:345	0:1:1:2:2:3:4:5:6:7:8	27022	FOXD3	GeneOrGeneProduct	304	305	6	1:Negative_Correlation:2	L2R	NON-CROSS	309-310	322-323	C016583	NNK|4 - ( methylnitrosamino ) - 1 - ( 3 - pyridyl ) - 1 - butanone|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK	ChemicalEntity	3:38:57:67:101:138:193:230:278:322:344	4:55:58:68:102:139:194:231:279:323:345	0:1:1:2:2:3:4:5:6:7:8	5268	SERPINB5	GeneOrGeneProduct	309	310	6	1:Positive_Correlation:2	L2R	NON-CROSS	322-323	332-333	C016583	NNK|4 - ( methylnitrosamino ) - 1 - ( 3 - pyridyl ) - 1 - butanone|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK|NNK	ChemicalEntity	3:38:57:67:101:138:193:230:278:322:344	4:55:58:68:102:139:194:231:279:323:345	0:1:1:2:2:3:4:5:6:7:8	864	RUNX3	GeneOrGeneProduct	332	333	7	1:NR:2	L2R	CROSS	5-8	22-25	57152	SLURP - 1|Ly - 6 / urokinase plasminogen activator receptor related protein - 1|SLURP - 1|SLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|SLURP - 1	GeneOrGeneProduct	5:79:92:107:181:197:274:326:346	8:91:95:110:184:200:277:329:349	0:2:2:2:3:4:5:7:8	1136	nicotinic acetylcholine receptors	GeneOrGeneProduct	22	25	1	1:NR:2	L2R	CROSS	5-8	36-37	57152	SLURP - 1|Ly - 6 / urokinase plasminogen activator receptor related protein - 1|SLURP - 1|SLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|SLURP - 1	GeneOrGeneProduct	5:79:92:107:181:197:274:326:346	8:91:95:110:184:200:277:329:349	0:2:2:2:3:4:5:7:8	D009602	nitrosamine	ChemicalEntity	36	37	1	1:Association:2	L2R	NON-CROSS	181-184	186-187	57152	SLURP - 1|Ly - 6 / urokinase plasminogen activator receptor related protein - 1|SLURP - 1|SLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|SLURP - 1	GeneOrGeneProduct	5:79:92:107:181:197:274:326:346	8:91:95:110:184:200:277:329:349	0:2:2:2:3:4:5:7:8	D009369	carcinogenic|tumorigenesis|cancer|tumor|tumorigenic	DiseaseOrPhenotypicFeature	60:117:186:300:361	61:118:187:301:362	1:2:4:6:8	1:NR:2	L2R	NON-CROSS	146-147	181-184	57152	SLURP - 1|Ly - 6 / urokinase plasminogen activator receptor related protein - 1|SLURP - 1|SLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|SLURP - 1	GeneOrGeneProduct	5:79:92:107:181:197:274:326:346	8:91:95:110:184:200:277:329:349	0:2:2:2:3:4:5:7:8	4602	MYB	GeneOrGeneProduct	146	147	3	1:NR:2	L2R	NON-CROSS	148-149	181-184	57152	SLURP - 1|Ly - 6 / urokinase plasminogen activator receptor related protein - 1|SLURP - 1|SLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|SLURP - 1	GeneOrGeneProduct	5:79:92:107:181:197:274:326:346	8:91:95:110:184:200:277:329:349	0:2:2:2:3:4:5:7:8	5290	PIK3CA	GeneOrGeneProduct	148	149	3	1:NR:2	L2R	NON-CROSS	152-153	181-184	57152	SLURP - 1|Ly - 6 / urokinase plasminogen activator receptor related protein - 1|SLURP - 1|SLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|SLURP - 1	GeneOrGeneProduct	5:79:92:107:181:197:274:326:346	8:91:95:110:184:200:277:329:349	0:2:2:2:3:4:5:7:8	2113	ETS1	GeneOrGeneProduct	152	153	3	1:NR:2	L2R	NON-CROSS	154-155	181-184	57152	SLURP - 1|Ly - 6 / urokinase plasminogen activator receptor related protein - 1|SLURP - 1|SLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|SLURP - 1	GeneOrGeneProduct	5:79:92:107:181:197:274:326:346	8:91:95:110:184:200:277:329:349	0:2:2:2:3:4:5:7:8	4893	NRAS	GeneOrGeneProduct	154	155	3	1:NR:2	L2R	NON-CROSS	156-157	181-184	57152	SLURP - 1|Ly - 6 / urokinase plasminogen activator receptor related protein - 1|SLURP - 1|SLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|SLURP - 1	GeneOrGeneProduct	5:79:92:107:181:197:274:326:346	8:91:95:110:184:200:277:329:349	0:2:2:2:3:4:5:7:8	6714	SRC	GeneOrGeneProduct	156	157	3	1:NR:2	L2R	NON-CROSS	163-164	181-184	57152	SLURP - 1|Ly - 6 / urokinase plasminogen activator receptor related protein - 1|SLURP - 1|SLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|SLURP - 1	GeneOrGeneProduct	5:79:92:107:181:197:274:326:346	8:91:95:110:184:200:277:329:349	0:2:2:2:3:4:5:7:8	207	AKT1	GeneOrGeneProduct	163	164	3	1:NR:2	L2R	NON-CROSS	165-166	181-184	57152	SLURP - 1|Ly - 6 / urokinase plasminogen activator receptor related protein - 1|SLURP - 1|SLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|SLURP - 1	GeneOrGeneProduct	5:79:92:107:181:197:274:326:346	8:91:95:110:184:200:277:329:349	0:2:2:2:3:4:5:7:8	3815	KIT	GeneOrGeneProduct	165	166	3	1:NR:2	L2R	NON-CROSS	167-168	181-184	57152	SLURP - 1|Ly - 6 / urokinase plasminogen activator receptor related protein - 1|SLURP - 1|SLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|SLURP - 1	GeneOrGeneProduct	5:79:92:107:181:197:274:326:346	8:91:95:110:184:200:277:329:349	0:2:2:2:3:4:5:7:8	5925	RB1	GeneOrGeneProduct	167	168	3	1:NR:2	L2R	NON-CROSS	197-200	204-205	57152	SLURP - 1|Ly - 6 / urokinase plasminogen activator receptor related protein - 1|SLURP - 1|SLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|SLURP - 1	GeneOrGeneProduct	5:79:92:107:181:197:274:326:346	8:91:95:110:184:200:277:329:349	0:2:2:2:3:4:5:7:8	1950	EGF	GeneOrGeneProduct	204	205	4	1:NR:2	L2R	NON-CROSS	197-200	209-210	57152	SLURP - 1|Ly - 6 / urokinase plasminogen activator receptor related protein - 1|SLURP - 1|SLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|SLURP - 1	GeneOrGeneProduct	5:79:92:107:181:197:274:326:346	8:91:95:110:184:200:277:329:349	0:2:2:2:3:4:5:7:8	3082	HGF	GeneOrGeneProduct	209	210	4	1:NR:2	L2R	NON-CROSS	197-200	220-221	57152	SLURP - 1|Ly - 6 / urokinase plasminogen activator receptor related protein - 1|SLURP - 1|SLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|SLURP - 1	GeneOrGeneProduct	5:79:92:107:181:197:274:326:346	8:91:95:110:184:200:277:329:349	0:2:2:2:3:4:5:7:8	1029	CDKN2A	GeneOrGeneProduct	220	221	4	1:NR:2	L2R	NON-CROSS	197-200	222-223	57152	SLURP - 1|Ly - 6 / urokinase plasminogen activator receptor related protein - 1|SLURP - 1|SLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|SLURP - 1	GeneOrGeneProduct	5:79:92:107:181:197:274:326:346	8:91:95:110:184:200:277:329:349	0:2:2:2:3:4:5:7:8	6774	STAT3	GeneOrGeneProduct	222	223	4	1:NR:2	L2R	NON-CROSS	237-238	274-277	57152	SLURP - 1|Ly - 6 / urokinase plasminogen activator receptor related protein - 1|SLURP - 1|SLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|SLURP - 1	GeneOrGeneProduct	5:79:92:107:181:197:274:326:346	8:91:95:110:184:200:277:329:349	0:2:2:2:3:4:5:7:8	596	BCL2	GeneOrGeneProduct	237	238	5	1:NR:2	L2R	NON-CROSS	249-250	274-277	57152	SLURP - 1|Ly - 6 / urokinase plasminogen activator receptor related protein - 1|SLURP - 1|SLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|SLURP - 1	GeneOrGeneProduct	5:79:92:107:181:197:274:326:346	8:91:95:110:184:200:277:329:349	0:2:2:2:3:4:5:7:8	7124	TNF	GeneOrGeneProduct	249	250	5	1:NR:2	L2R	NON-CROSS	256-257	274-277	57152	SLURP - 1|Ly - 6 / urokinase plasminogen activator receptor related protein - 1|SLURP - 1|SLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|SLURP - 1	GeneOrGeneProduct	5:79:92:107:181:197:274:326:346	8:91:95:110:184:200:277:329:349	0:2:2:2:3:4:5:7:8	581	BAX	GeneOrGeneProduct	256	257	5	1:NR:2	L2R	NON-CROSS	258-259	274-277	57152	SLURP - 1|Ly - 6 / urokinase plasminogen activator receptor related protein - 1|SLURP - 1|SLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|SLURP - 1	GeneOrGeneProduct	5:79:92:107:181:197:274:326:346	8:91:95:110:184:200:277:329:349	0:2:2:2:3:4:5:7:8	841	CASP8	GeneOrGeneProduct	258	259	5	1:NR:2	L2R	CROSS	274-277	283-284	57152	SLURP - 1|Ly - 6 / urokinase plasminogen activator receptor related protein - 1|SLURP - 1|SLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|SLURP - 1	GeneOrGeneProduct	5:79:92:107:181:197:274:326:346	8:91:95:110:184:200:277:329:349	0:2:2:2:3:4:5:7:8	1499	CTNNB1|beta - catenin	GeneOrGeneProduct	283:290	284:293	6:6	1:NR:2	L2R	CROSS	302-303	326-329	57152	SLURP - 1|Ly - 6 / urokinase plasminogen activator receptor related protein - 1|SLURP - 1|SLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|SLURP - 1	GeneOrGeneProduct	5:79:92:107:181:197:274:326:346	8:91:95:110:184:200:277:329:349	0:2:2:2:3:4:5:7:8	1033	CDKN3	GeneOrGeneProduct	302	303	6	1:NR:2	L2R	CROSS	304-305	326-329	57152	SLURP - 1|Ly - 6 / urokinase plasminogen activator receptor related protein - 1|SLURP - 1|SLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|SLURP - 1	GeneOrGeneProduct	5:79:92:107:181:197:274:326:346	8:91:95:110:184:200:277:329:349	0:2:2:2:3:4:5:7:8	27022	FOXD3	GeneOrGeneProduct	304	305	6	1:NR:2	L2R	CROSS	309-310	326-329	57152	SLURP - 1|Ly - 6 / urokinase plasminogen activator receptor related protein - 1|SLURP - 1|SLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|SLURP - 1	GeneOrGeneProduct	5:79:92:107:181:197:274:326:346	8:91:95:110:184:200:277:329:349	0:2:2:2:3:4:5:7:8	5268	SERPINB5	GeneOrGeneProduct	309	310	6	1:Positive_Correlation:2	L2R	NON-CROSS	326-329	332-333	57152	SLURP - 1|Ly - 6 / urokinase plasminogen activator receptor related protein - 1|SLURP - 1|SLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|rSLURP - 1|SLURP - 1	GeneOrGeneProduct	5:79:92:107:181:197:274:326:346	8:91:95:110:184:200:277:329:349	0:2:2:2:3:4:5:7:8	864	RUNX3	GeneOrGeneProduct	332	333	7	1:NR:2	L2R	NON-CROSS	22-25	36-37	1136	nicotinic acetylcholine receptors	GeneOrGeneProduct	22	25	1	D009602	nitrosamine	ChemicalEntity	36	37	1	1:NR:2	L2R	NON-CROSS	22-25	60-61	1136	nicotinic acetylcholine receptors	GeneOrGeneProduct	22	25	1	D009369	carcinogenic|tumorigenesis|cancer|tumor|tumorigenic	DiseaseOrPhenotypicFeature	60:117:186:300:361	61:118:187:301:362	1:2:4:6:8	1:NR:2	L2R	CROSS	22-25	146-147	1136	nicotinic acetylcholine receptors	GeneOrGeneProduct	22	25	1	4602	MYB	GeneOrGeneProduct	146	147	3	1:NR:2	L2R	CROSS	22-25	148-149	1136	nicotinic acetylcholine receptors	GeneOrGeneProduct	22	25	1	5290	PIK3CA	GeneOrGeneProduct	148	149	3	1:NR:2	L2R	CROSS	22-25	152-153	1136	nicotinic acetylcholine receptors	GeneOrGeneProduct	22	25	1	2113	ETS1	GeneOrGeneProduct	152	153	3	1:NR:2	L2R	CROSS	22-25	154-155	1136	nicotinic acetylcholine receptors	GeneOrGeneProduct	22	25	1	4893	NRAS	GeneOrGeneProduct	154	155	3	1:NR:2	L2R	CROSS	22-25	156-157	1136	nicotinic acetylcholine receptors	GeneOrGeneProduct	22	25	1	6714	SRC	GeneOrGeneProduct	156	157	3	1:NR:2	L2R	CROSS	22-25	163-164	1136	nicotinic acetylcholine receptors	GeneOrGeneProduct	22	25	1	207	AKT1	GeneOrGeneProduct	163	164	3	1:NR:2	L2R	CROSS	22-25	165-166	1136	nicotinic acetylcholine receptors	GeneOrGeneProduct	22	25	1	3815	KIT	GeneOrGeneProduct	165	166	3	1:NR:2	L2R	CROSS	22-25	167-168	1136	nicotinic acetylcholine receptors	GeneOrGeneProduct	22	25	1	5925	RB1	GeneOrGeneProduct	167	168	3	1:NR:2	L2R	CROSS	22-25	204-205	1136	nicotinic acetylcholine receptors	GeneOrGeneProduct	22	25	1	1950	EGF	GeneOrGeneProduct	204	205	4	1:NR:2	L2R	CROSS	22-25	209-210	1136	nicotinic acetylcholine receptors	GeneOrGeneProduct	22	25	1	3082	HGF	GeneOrGeneProduct	209	210	4	1:NR:2	L2R	CROSS	22-25	220-221	1136	nicotinic acetylcholine receptors	GeneOrGeneProduct	22	25	1	1029	CDKN2A	GeneOrGeneProduct	220	221	4	1:NR:2	L2R	CROSS	22-25	222-223	1136	nicotinic acetylcholine receptors	GeneOrGeneProduct	22	25	1	6774	STAT3	GeneOrGeneProduct	222	223	4	1:NR:2	L2R	CROSS	22-25	237-238	1136	nicotinic acetylcholine receptors	GeneOrGeneProduct	22	25	1	596	BCL2	GeneOrGeneProduct	237	238	5	1:NR:2	L2R	CROSS	22-25	249-250	1136	nicotinic acetylcholine receptors	GeneOrGeneProduct	22	25	1	7124	TNF	GeneOrGeneProduct	249	250	5	1:NR:2	L2R	CROSS	22-25	256-257	1136	nicotinic acetylcholine receptors	GeneOrGeneProduct	22	25	1	581	BAX	GeneOrGeneProduct	256	257	5	1:NR:2	L2R	CROSS	22-25	258-259	1136	nicotinic acetylcholine receptors	GeneOrGeneProduct	22	25	1	841	CASP8	GeneOrGeneProduct	258	259	5	1:NR:2	L2R	CROSS	22-25	283-284	1136	nicotinic acetylcholine receptors	GeneOrGeneProduct	22	25	1	1499	CTNNB1|beta - catenin	GeneOrGeneProduct	283:290	284:293	6:6	1:NR:2	L2R	CROSS	22-25	302-303	1136	nicotinic acetylcholine receptors	GeneOrGeneProduct	22	25	1	1033	CDKN3	GeneOrGeneProduct	302	303	6	1:NR:2	L2R	CROSS	22-25	304-305	1136	nicotinic acetylcholine receptors	GeneOrGeneProduct	22	25	1	27022	FOXD3	GeneOrGeneProduct	304	305	6	1:NR:2	L2R	CROSS	22-25	309-310	1136	nicotinic acetylcholine receptors	GeneOrGeneProduct	22	25	1	5268	SERPINB5	GeneOrGeneProduct	309	310	6	1:NR:2	L2R	CROSS	22-25	332-333	1136	nicotinic acetylcholine receptors	GeneOrGeneProduct	22	25	1	864	RUNX3	GeneOrGeneProduct	332	333	7	1:NR:2	L2R	NON-CROSS	36-37	60-61	D009602	nitrosamine	ChemicalEntity	36	37	1	D009369	carcinogenic|tumorigenesis|cancer|tumor|tumorigenic	DiseaseOrPhenotypicFeature	60:117:186:300:361	61:118:187:301:362	1:2:4:6:8	1:NR:2	L2R	CROSS	36-37	146-147	D009602	nitrosamine	ChemicalEntity	36	37	1	4602	MYB	GeneOrGeneProduct	146	147	3	1:NR:2	L2R	CROSS	36-37	148-149	D009602	nitrosamine	ChemicalEntity	36	37	1	5290	PIK3CA	GeneOrGeneProduct	148	149	3	1:NR:2	L2R	CROSS	36-37	152-153	D009602	nitrosamine	ChemicalEntity	36	37	1	2113	ETS1	GeneOrGeneProduct	152	153	3	1:NR:2	L2R	CROSS	36-37	154-155	D009602	nitrosamine	ChemicalEntity	36	37	1	4893	NRAS	GeneOrGeneProduct	154	155	3	1:NR:2	L2R	CROSS	36-37	156-157	D009602	nitrosamine	ChemicalEntity	36	37	1	6714	SRC	GeneOrGeneProduct	156	157	3	1:NR:2	L2R	CROSS	36-37	163-164	D009602	nitrosamine	ChemicalEntity	36	37	1	207	AKT1	GeneOrGeneProduct	163	164	3	1:NR:2	L2R	CROSS	36-37	165-166	D009602	nitrosamine	ChemicalEntity	36	37	1	3815	KIT	GeneOrGeneProduct	165	166	3	1:NR:2	L2R	CROSS	36-37	167-168	D009602	nitrosamine	ChemicalEntity	36	37	1	5925	RB1	GeneOrGeneProduct	167	168	3	1:NR:2	L2R	CROSS	36-37	204-205	D009602	nitrosamine	ChemicalEntity	36	37	1	1950	EGF	GeneOrGeneProduct	204	205	4	1:NR:2	L2R	CROSS	36-37	209-210	D009602	nitrosamine	ChemicalEntity	36	37	1	3082	HGF	GeneOrGeneProduct	209	210	4	1:NR:2	L2R	CROSS	36-37	220-221	D009602	nitrosamine	ChemicalEntity	36	37	1	1029	CDKN2A	GeneOrGeneProduct	220	221	4	1:NR:2	L2R	CROSS	36-37	222-223	D009602	nitrosamine	ChemicalEntity	36	37	1	6774	STAT3	GeneOrGeneProduct	222	223	4	1:NR:2	L2R	CROSS	36-37	237-238	D009602	nitrosamine	ChemicalEntity	36	37	1	596	BCL2	GeneOrGeneProduct	237	238	5	1:NR:2	L2R	CROSS	36-37	249-250	D009602	nitrosamine	ChemicalEntity	36	37	1	7124	TNF	GeneOrGeneProduct	249	250	5	1:NR:2	L2R	CROSS	36-37	256-257	D009602	nitrosamine	ChemicalEntity	36	37	1	581	BAX	GeneOrGeneProduct	256	257	5	1:NR:2	L2R	CROSS	36-37	258-259	D009602	nitrosamine	ChemicalEntity	36	37	1	841	CASP8	GeneOrGeneProduct	258	259	5	1:NR:2	L2R	CROSS	36-37	283-284	D009602	nitrosamine	ChemicalEntity	36	37	1	1499	CTNNB1|beta - catenin	GeneOrGeneProduct	283:290	284:293	6:6	1:NR:2	L2R	CROSS	36-37	302-303	D009602	nitrosamine	ChemicalEntity	36	37	1	1033	CDKN3	GeneOrGeneProduct	302	303	6	1:NR:2	L2R	CROSS	36-37	304-305	D009602	nitrosamine	ChemicalEntity	36	37	1	27022	FOXD3	GeneOrGeneProduct	304	305	6	1:NR:2	L2R	CROSS	36-37	309-310	D009602	nitrosamine	ChemicalEntity	36	37	1	5268	SERPINB5	GeneOrGeneProduct	309	310	6	1:NR:2	L2R	CROSS	36-37	332-333	D009602	nitrosamine	ChemicalEntity	36	37	1	864	RUNX3	GeneOrGeneProduct	332	333	7	1:NR:2	L2R	CROSS	117-118	146-147	D009369	carcinogenic|tumorigenesis|cancer|tumor|tumorigenic	DiseaseOrPhenotypicFeature	60:117:186:300:361	61:118:187:301:362	1:2:4:6:8	4602	MYB	GeneOrGeneProduct	146	147	3	1:NR:2	L2R	CROSS	117-118	148-149	D009369	carcinogenic|tumorigenesis|cancer|tumor|tumorigenic	DiseaseOrPhenotypicFeature	60:117:186:300:361	61:118:187:301:362	1:2:4:6:8	5290	PIK3CA	GeneOrGeneProduct	148	149	3	1:NR:2	L2R	CROSS	152-153	186-187	D009369	carcinogenic|tumorigenesis|cancer|tumor|tumorigenic	DiseaseOrPhenotypicFeature	60:117:186:300:361	61:118:187:301:362	1:2:4:6:8	2113	ETS1	GeneOrGeneProduct	152	153	3	1:NR:2	L2R	CROSS	154-155	186-187	D009369	carcinogenic|tumorigenesis|cancer|tumor|tumorigenic	DiseaseOrPhenotypicFeature	60:117:186:300:361	61:118:187:301:362	1:2:4:6:8	4893	NRAS	GeneOrGeneProduct	154	155	3	1:NR:2	L2R	CROSS	156-157	186-187	D009369	carcinogenic|tumorigenesis|cancer|tumor|tumorigenic	DiseaseOrPhenotypicFeature	60:117:186:300:361	61:118:187:301:362	1:2:4:6:8	6714	SRC	GeneOrGeneProduct	156	157	3	1:NR:2	L2R	CROSS	163-164	186-187	D009369	carcinogenic|tumorigenesis|cancer|tumor|tumorigenic	DiseaseOrPhenotypicFeature	60:117:186:300:361	61:118:187:301:362	1:2:4:6:8	207	AKT1	GeneOrGeneProduct	163	164	3	1:NR:2	L2R	CROSS	165-166	186-187	D009369	carcinogenic|tumorigenesis|cancer|tumor|tumorigenic	DiseaseOrPhenotypicFeature	60:117:186:300:361	61:118:187:301:362	1:2:4:6:8	3815	KIT	GeneOrGeneProduct	165	166	3	1:NR:2	L2R	CROSS	167-168	186-187	D009369	carcinogenic|tumorigenesis|cancer|tumor|tumorigenic	DiseaseOrPhenotypicFeature	60:117:186:300:361	61:118:187:301:362	1:2:4:6:8	5925	RB1	GeneOrGeneProduct	167	168	3	1:Association:2	L2R	NON-CROSS	186-187	204-205	D009369	carcinogenic|tumorigenesis|cancer|tumor|tumorigenic	DiseaseOrPhenotypicFeature	60:117:186:300:361	61:118:187:301:362	1:2:4:6:8	1950	EGF	GeneOrGeneProduct	204	205	4	1:Association:2	L2R	NON-CROSS	186-187	209-210	D009369	carcinogenic|tumorigenesis|cancer|tumor|tumorigenic	DiseaseOrPhenotypicFeature	60:117:186:300:361	61:118:187:301:362	1:2:4:6:8	3082	HGF	GeneOrGeneProduct	209	210	4	1:Association:2	L2R	NON-CROSS	186-187	220-221	D009369	carcinogenic|tumorigenesis|cancer|tumor|tumorigenic	DiseaseOrPhenotypicFeature	60:117:186:300:361	61:118:187:301:362	1:2:4:6:8	1029	CDKN2A	GeneOrGeneProduct	220	221	4	1:Association:2	L2R	NON-CROSS	186-187	222-223	D009369	carcinogenic|tumorigenesis|cancer|tumor|tumorigenic	DiseaseOrPhenotypicFeature	60:117:186:300:361	61:118:187:301:362	1:2:4:6:8	6774	STAT3	GeneOrGeneProduct	222	223	4	1:NR:2	L2R	CROSS	186-187	237-238	D009369	carcinogenic|tumorigenesis|cancer|tumor|tumorigenic	DiseaseOrPhenotypicFeature	60:117:186:300:361	61:118:187:301:362	1:2:4:6:8	596	BCL2	GeneOrGeneProduct	237	238	5	1:NR:2	L2R	CROSS	249-250	300-301	D009369	carcinogenic|tumorigenesis|cancer|tumor|tumorigenic	DiseaseOrPhenotypicFeature	60:117:186:300:361	61:118:187:301:362	1:2:4:6:8	7124	TNF	GeneOrGeneProduct	249	250	5	1:NR:2	L2R	CROSS	256-257	300-301	D009369	carcinogenic|tumorigenesis|cancer|tumor|tumorigenic	DiseaseOrPhenotypicFeature	60:117:186:300:361	61:118:187:301:362	1:2:4:6:8	581	BAX	GeneOrGeneProduct	256	257	5	1:NR:2	L2R	CROSS	258-259	300-301	D009369	carcinogenic|tumorigenesis|cancer|tumor|tumorigenic	DiseaseOrPhenotypicFeature	60:117:186:300:361	61:118:187:301:362	1:2:4:6:8	841	CASP8	GeneOrGeneProduct	258	259	5	1:NR:2	L2R	NON-CROSS	290-293	300-301	D009369	carcinogenic|tumorigenesis|cancer|tumor|tumorigenic	DiseaseOrPhenotypicFeature	60:117:186:300:361	61:118:187:301:362	1:2:4:6:8	1499	CTNNB1|beta - catenin	GeneOrGeneProduct	283:290	284:293	6:6	1:Association:2	R2L	NON-CROSS	302-303	300-301	1033	CDKN3	GeneOrGeneProduct	302	303	6	D009369	carcinogenic|tumorigenesis|cancer|tumor|tumorigenic	DiseaseOrPhenotypicFeature	60:117:186:300:361	61:118:187:301:362	1:2:4:6:8	1:Association:2	R2L	NON-CROSS	304-305	300-301	27022	FOXD3	GeneOrGeneProduct	304	305	6	D009369	carcinogenic|tumorigenesis|cancer|tumor|tumorigenic	DiseaseOrPhenotypicFeature	60:117:186:300:361	61:118:187:301:362	1:2:4:6:8	1:Association:2	R2L	NON-CROSS	309-310	300-301	5268	SERPINB5	GeneOrGeneProduct	309	310	6	D009369	carcinogenic|tumorigenesis|cancer|tumor|tumorigenic	DiseaseOrPhenotypicFeature	60:117:186:300:361	61:118:187:301:362	1:2:4:6:8	1:NR:2	L2R	CROSS	332-333	361-362	D009369	carcinogenic|tumorigenesis|cancer|tumor|tumorigenic	DiseaseOrPhenotypicFeature	60:117:186:300:361	61:118:187:301:362	1:2:4:6:8	864	RUNX3	GeneOrGeneProduct	332	333	7	1:NR:2	L2R	NON-CROSS	146-147	148-149	4602	MYB	GeneOrGeneProduct	146	147	3	5290	PIK3CA	GeneOrGeneProduct	148	149	3	1:NR:2	L2R	NON-CROSS	146-147	152-153	4602	MYB	GeneOrGeneProduct	146	147	3	2113	ETS1	GeneOrGeneProduct	152	153	3	1:NR:2	L2R	NON-CROSS	146-147	154-155	4602	MYB	GeneOrGeneProduct	146	147	3	4893	NRAS	GeneOrGeneProduct	154	155	3	1:NR:2	L2R	NON-CROSS	146-147	156-157	4602	MYB	GeneOrGeneProduct	146	147	3	6714	SRC	GeneOrGeneProduct	156	157	3	1:NR:2	L2R	NON-CROSS	146-147	163-164	4602	MYB	GeneOrGeneProduct	146	147	3	207	AKT1	GeneOrGeneProduct	163	164	3	1:NR:2	L2R	NON-CROSS	146-147	165-166	4602	MYB	GeneOrGeneProduct	146	147	3	3815	KIT	GeneOrGeneProduct	165	166	3	1:NR:2	L2R	NON-CROSS	146-147	167-168	4602	MYB	GeneOrGeneProduct	146	147	3	5925	RB1	GeneOrGeneProduct	167	168	3	1:NR:2	L2R	CROSS	146-147	204-205	4602	MYB	GeneOrGeneProduct	146	147	3	1950	EGF	GeneOrGeneProduct	204	205	4	1:NR:2	L2R	CROSS	146-147	209-210	4602	MYB	GeneOrGeneProduct	146	147	3	3082	HGF	GeneOrGeneProduct	209	210	4	1:NR:2	L2R	CROSS	146-147	220-221	4602	MYB	GeneOrGeneProduct	146	147	3	1029	CDKN2A	GeneOrGeneProduct	220	221	4	1:NR:2	L2R	CROSS	146-147	222-223	4602	MYB	GeneOrGeneProduct	146	147	3	6774	STAT3	GeneOrGeneProduct	222	223	4	1:NR:2	L2R	CROSS	146-147	237-238	4602	MYB	GeneOrGeneProduct	146	147	3	596	BCL2	GeneOrGeneProduct	237	238	5	1:NR:2	L2R	CROSS	146-147	249-250	4602	MYB	GeneOrGeneProduct	146	147	3	7124	TNF	GeneOrGeneProduct	249	250	5	1:NR:2	L2R	CROSS	146-147	256-257	4602	MYB	GeneOrGeneProduct	146	147	3	581	BAX	GeneOrGeneProduct	256	257	5	1:NR:2	L2R	CROSS	146-147	258-259	4602	MYB	GeneOrGeneProduct	146	147	3	841	CASP8	GeneOrGeneProduct	258	259	5	1:NR:2	L2R	CROSS	146-147	283-284	4602	MYB	GeneOrGeneProduct	146	147	3	1499	CTNNB1|beta - catenin	GeneOrGeneProduct	283:290	284:293	6:6	1:NR:2	L2R	CROSS	146-147	302-303	4602	MYB	GeneOrGeneProduct	146	147	3	1033	CDKN3	GeneOrGeneProduct	302	303	6	1:NR:2	L2R	CROSS	146-147	304-305	4602	MYB	GeneOrGeneProduct	146	147	3	27022	FOXD3	GeneOrGeneProduct	304	305	6	1:NR:2	L2R	CROSS	146-147	309-310	4602	MYB	GeneOrGeneProduct	146	147	3	5268	SERPINB5	GeneOrGeneProduct	309	310	6	1:NR:2	L2R	CROSS	146-147	332-333	4602	MYB	GeneOrGeneProduct	146	147	3	864	RUNX3	GeneOrGeneProduct	332	333	7	1:NR:2	L2R	NON-CROSS	148-149	152-153	5290	PIK3CA	GeneOrGeneProduct	148	149	3	2113	ETS1	GeneOrGeneProduct	152	153	3	1:NR:2	L2R	NON-CROSS	148-149	154-155	5290	PIK3CA	GeneOrGeneProduct	148	149	3	4893	NRAS	GeneOrGeneProduct	154	155	3	1:NR:2	L2R	NON-CROSS	148-149	156-157	5290	PIK3CA	GeneOrGeneProduct	148	149	3	6714	SRC	GeneOrGeneProduct	156	157	3	1:NR:2	L2R	NON-CROSS	148-149	163-164	5290	PIK3CA	GeneOrGeneProduct	148	149	3	207	AKT1	GeneOrGeneProduct	163	164	3	1:NR:2	L2R	NON-CROSS	148-149	165-166	5290	PIK3CA	GeneOrGeneProduct	148	149	3	3815	KIT	GeneOrGeneProduct	165	166	3	1:NR:2	L2R	NON-CROSS	148-149	167-168	5290	PIK3CA	GeneOrGeneProduct	148	149	3	5925	RB1	GeneOrGeneProduct	167	168	3	1:NR:2	L2R	CROSS	148-149	204-205	5290	PIK3CA	GeneOrGeneProduct	148	149	3	1950	EGF	GeneOrGeneProduct	204	205	4	1:NR:2	L2R	CROSS	148-149	209-210	5290	PIK3CA	GeneOrGeneProduct	148	149	3	3082	HGF	GeneOrGeneProduct	209	210	4	1:NR:2	L2R	CROSS	148-149	220-221	5290	PIK3CA	GeneOrGeneProduct	148	149	3	1029	CDKN2A	GeneOrGeneProduct	220	221	4	1:NR:2	L2R	CROSS	148-149	222-223	5290	PIK3CA	GeneOrGeneProduct	148	149	3	6774	STAT3	GeneOrGeneProduct	222	223	4	1:NR:2	L2R	CROSS	148-149	237-238	5290	PIK3CA	GeneOrGeneProduct	148	149	3	596	BCL2	GeneOrGeneProduct	237	238	5	1:NR:2	L2R	CROSS	148-149	249-250	5290	PIK3CA	GeneOrGeneProduct	148	149	3	7124	TNF	GeneOrGeneProduct	249	250	5	1:NR:2	L2R	CROSS	148-149	256-257	5290	PIK3CA	GeneOrGeneProduct	148	149	3	581	BAX	GeneOrGeneProduct	256	257	5	1:NR:2	L2R	CROSS	148-149	258-259	5290	PIK3CA	GeneOrGeneProduct	148	149	3	841	CASP8	GeneOrGeneProduct	258	259	5	1:NR:2	L2R	CROSS	148-149	283-284	5290	PIK3CA	GeneOrGeneProduct	148	149	3	1499	CTNNB1|beta - catenin	GeneOrGeneProduct	283:290	284:293	6:6	1:NR:2	L2R	CROSS	148-149	302-303	5290	PIK3CA	GeneOrGeneProduct	148	149	3	1033	CDKN3	GeneOrGeneProduct	302	303	6	1:NR:2	L2R	CROSS	148-149	304-305	5290	PIK3CA	GeneOrGeneProduct	148	149	3	27022	FOXD3	GeneOrGeneProduct	304	305	6	1:NR:2	L2R	CROSS	148-149	309-310	5290	PIK3CA	GeneOrGeneProduct	148	149	3	5268	SERPINB5	GeneOrGeneProduct	309	310	6	1:NR:2	L2R	CROSS	148-149	332-333	5290	PIK3CA	GeneOrGeneProduct	148	149	3	864	RUNX3	GeneOrGeneProduct	332	333	7	1:NR:2	L2R	NON-CROSS	152-153	154-155	2113	ETS1	GeneOrGeneProduct	152	153	3	4893	NRAS	GeneOrGeneProduct	154	155	3	1:NR:2	L2R	NON-CROSS	152-153	156-157	2113	ETS1	GeneOrGeneProduct	152	153	3	6714	SRC	GeneOrGeneProduct	156	157	3	1:NR:2	L2R	NON-CROSS	152-153	163-164	2113	ETS1	GeneOrGeneProduct	152	153	3	207	AKT1	GeneOrGeneProduct	163	164	3	1:NR:2	L2R	NON-CROSS	152-153	165-166	2113	ETS1	GeneOrGeneProduct	152	153	3	3815	KIT	GeneOrGeneProduct	165	166	3	1:NR:2	L2R	NON-CROSS	152-153	167-168	2113	ETS1	GeneOrGeneProduct	152	153	3	5925	RB1	GeneOrGeneProduct	167	168	3	1:NR:2	L2R	CROSS	152-153	204-205	2113	ETS1	GeneOrGeneProduct	152	153	3	1950	EGF	GeneOrGeneProduct	204	205	4	1:NR:2	L2R	CROSS	152-153	209-210	2113	ETS1	GeneOrGeneProduct	152	153	3	3082	HGF	GeneOrGeneProduct	209	210	4	1:NR:2	L2R	CROSS	152-153	220-221	2113	ETS1	GeneOrGeneProduct	152	153	3	1029	CDKN2A	GeneOrGeneProduct	220	221	4	1:NR:2	L2R	CROSS	152-153	222-223	2113	ETS1	GeneOrGeneProduct	152	153	3	6774	STAT3	GeneOrGeneProduct	222	223	4	1:NR:2	L2R	CROSS	152-153	237-238	2113	ETS1	GeneOrGeneProduct	152	153	3	596	BCL2	GeneOrGeneProduct	237	238	5	1:NR:2	L2R	CROSS	152-153	249-250	2113	ETS1	GeneOrGeneProduct	152	153	3	7124	TNF	GeneOrGeneProduct	249	250	5	1:NR:2	L2R	CROSS	152-153	256-257	2113	ETS1	GeneOrGeneProduct	152	153	3	581	BAX	GeneOrGeneProduct	256	257	5	1:NR:2	L2R	CROSS	152-153	258-259	2113	ETS1	GeneOrGeneProduct	152	153	3	841	CASP8	GeneOrGeneProduct	258	259	5	1:NR:2	L2R	CROSS	152-153	283-284	2113	ETS1	GeneOrGeneProduct	152	153	3	1499	CTNNB1|beta - catenin	GeneOrGeneProduct	283:290	284:293	6:6	1:NR:2	L2R	CROSS	152-153	302-303	2113	ETS1	GeneOrGeneProduct	152	153	3	1033	CDKN3	GeneOrGeneProduct	302	303	6	1:NR:2	L2R	CROSS	152-153	304-305	2113	ETS1	GeneOrGeneProduct	152	153	3	27022	FOXD3	GeneOrGeneProduct	304	305	6	1:NR:2	L2R	CROSS	152-153	309-310	2113	ETS1	GeneOrGeneProduct	152	153	3	5268	SERPINB5	GeneOrGeneProduct	309	310	6	1:NR:2	L2R	CROSS	152-153	332-333	2113	ETS1	GeneOrGeneProduct	152	153	3	864	RUNX3	GeneOrGeneProduct	332	333	7	1:NR:2	L2R	NON-CROSS	154-155	156-157	4893	NRAS	GeneOrGeneProduct	154	155	3	6714	SRC	GeneOrGeneProduct	156	157	3	1:NR:2	L2R	NON-CROSS	154-155	163-164	4893	NRAS	GeneOrGeneProduct	154	155	3	207	AKT1	GeneOrGeneProduct	163	164	3	1:NR:2	L2R	NON-CROSS	154-155	165-166	4893	NRAS	GeneOrGeneProduct	154	155	3	3815	KIT	GeneOrGeneProduct	165	166	3	1:NR:2	L2R	NON-CROSS	154-155	167-168	4893	NRAS	GeneOrGeneProduct	154	155	3	5925	RB1	GeneOrGeneProduct	167	168	3	1:NR:2	L2R	CROSS	154-155	204-205	4893	NRAS	GeneOrGeneProduct	154	155	3	1950	EGF	GeneOrGeneProduct	204	205	4	1:NR:2	L2R	CROSS	154-155	209-210	4893	NRAS	GeneOrGeneProduct	154	155	3	3082	HGF	GeneOrGeneProduct	209	210	4	1:NR:2	L2R	CROSS	154-155	220-221	4893	NRAS	GeneOrGeneProduct	154	155	3	1029	CDKN2A	GeneOrGeneProduct	220	221	4	1:NR:2	L2R	CROSS	154-155	222-223	4893	NRAS	GeneOrGeneProduct	154	155	3	6774	STAT3	GeneOrGeneProduct	222	223	4	1:NR:2	L2R	CROSS	154-155	237-238	4893	NRAS	GeneOrGeneProduct	154	155	3	596	BCL2	GeneOrGeneProduct	237	238	5	1:NR:2	L2R	CROSS	154-155	249-250	4893	NRAS	GeneOrGeneProduct	154	155	3	7124	TNF	GeneOrGeneProduct	249	250	5	1:NR:2	L2R	CROSS	154-155	256-257	4893	NRAS	GeneOrGeneProduct	154	155	3	581	BAX	GeneOrGeneProduct	256	257	5	1:NR:2	L2R	CROSS	154-155	258-259	4893	NRAS	GeneOrGeneProduct	154	155	3	841	CASP8	GeneOrGeneProduct	258	259	5	1:NR:2	L2R	CROSS	154-155	283-284	4893	NRAS	GeneOrGeneProduct	154	155	3	1499	CTNNB1|beta - catenin	GeneOrGeneProduct	283:290	284:293	6:6	1:NR:2	L2R	CROSS	154-155	302-303	4893	NRAS	GeneOrGeneProduct	154	155	3	1033	CDKN3	GeneOrGeneProduct	302	303	6	1:NR:2	L2R	CROSS	154-155	304-305	4893	NRAS	GeneOrGeneProduct	154	155	3	27022	FOXD3	GeneOrGeneProduct	304	305	6	1:NR:2	L2R	CROSS	154-155	309-310	4893	NRAS	GeneOrGeneProduct	154	155	3	5268	SERPINB5	GeneOrGeneProduct	309	310	6	1:NR:2	L2R	CROSS	154-155	332-333	4893	NRAS	GeneOrGeneProduct	154	155	3	864	RUNX3	GeneOrGeneProduct	332	333	7	1:NR:2	L2R	NON-CROSS	156-157	163-164	6714	SRC	GeneOrGeneProduct	156	157	3	207	AKT1	GeneOrGeneProduct	163	164	3	1:NR:2	L2R	NON-CROSS	156-157	165-166	6714	SRC	GeneOrGeneProduct	156	157	3	3815	KIT	GeneOrGeneProduct	165	166	3	1:NR:2	L2R	NON-CROSS	156-157	167-168	6714	SRC	GeneOrGeneProduct	156	157	3	5925	RB1	GeneOrGeneProduct	167	168	3	1:NR:2	L2R	CROSS	156-157	204-205	6714	SRC	GeneOrGeneProduct	156	157	3	1950	EGF	GeneOrGeneProduct	204	205	4	1:NR:2	L2R	CROSS	156-157	209-210	6714	SRC	GeneOrGeneProduct	156	157	3	3082	HGF	GeneOrGeneProduct	209	210	4	1:NR:2	L2R	CROSS	156-157	220-221	6714	SRC	GeneOrGeneProduct	156	157	3	1029	CDKN2A	GeneOrGeneProduct	220	221	4	1:NR:2	L2R	CROSS	156-157	222-223	6714	SRC	GeneOrGeneProduct	156	157	3	6774	STAT3	GeneOrGeneProduct	222	223	4	1:NR:2	L2R	CROSS	156-157	237-238	6714	SRC	GeneOrGeneProduct	156	157	3	596	BCL2	GeneOrGeneProduct	237	238	5	1:NR:2	L2R	CROSS	156-157	249-250	6714	SRC	GeneOrGeneProduct	156	157	3	7124	TNF	GeneOrGeneProduct	249	250	5	1:NR:2	L2R	CROSS	156-157	256-257	6714	SRC	GeneOrGeneProduct	156	157	3	581	BAX	GeneOrGeneProduct	256	257	5	1:NR:2	L2R	CROSS	156-157	258-259	6714	SRC	GeneOrGeneProduct	156	157	3	841	CASP8	GeneOrGeneProduct	258	259	5	1:NR:2	L2R	CROSS	156-157	283-284	6714	SRC	GeneOrGeneProduct	156	157	3	1499	CTNNB1|beta - catenin	GeneOrGeneProduct	283:290	284:293	6:6	1:NR:2	L2R	CROSS	156-157	302-303	6714	SRC	GeneOrGeneProduct	156	157	3	1033	CDKN3	GeneOrGeneProduct	302	303	6	1:NR:2	L2R	CROSS	156-157	304-305	6714	SRC	GeneOrGeneProduct	156	157	3	27022	FOXD3	GeneOrGeneProduct	304	305	6	1:NR:2	L2R	CROSS	156-157	309-310	6714	SRC	GeneOrGeneProduct	156	157	3	5268	SERPINB5	GeneOrGeneProduct	309	310	6	1:NR:2	L2R	CROSS	156-157	332-333	6714	SRC	GeneOrGeneProduct	156	157	3	864	RUNX3	GeneOrGeneProduct	332	333	7	1:NR:2	L2R	NON-CROSS	163-164	165-166	207	AKT1	GeneOrGeneProduct	163	164	3	3815	KIT	GeneOrGeneProduct	165	166	3	1:NR:2	L2R	NON-CROSS	163-164	167-168	207	AKT1	GeneOrGeneProduct	163	164	3	5925	RB1	GeneOrGeneProduct	167	168	3	1:NR:2	L2R	CROSS	163-164	204-205	207	AKT1	GeneOrGeneProduct	163	164	3	1950	EGF	GeneOrGeneProduct	204	205	4	1:NR:2	L2R	CROSS	163-164	209-210	207	AKT1	GeneOrGeneProduct	163	164	3	3082	HGF	GeneOrGeneProduct	209	210	4	1:NR:2	L2R	CROSS	163-164	220-221	207	AKT1	GeneOrGeneProduct	163	164	3	1029	CDKN2A	GeneOrGeneProduct	220	221	4	1:NR:2	L2R	CROSS	163-164	222-223	207	AKT1	GeneOrGeneProduct	163	164	3	6774	STAT3	GeneOrGeneProduct	222	223	4	1:NR:2	L2R	CROSS	163-164	237-238	207	AKT1	GeneOrGeneProduct	163	164	3	596	BCL2	GeneOrGeneProduct	237	238	5	1:NR:2	L2R	CROSS	163-164	249-250	207	AKT1	GeneOrGeneProduct	163	164	3	7124	TNF	GeneOrGeneProduct	249	250	5	1:NR:2	L2R	CROSS	163-164	256-257	207	AKT1	GeneOrGeneProduct	163	164	3	581	BAX	GeneOrGeneProduct	256	257	5	1:NR:2	L2R	CROSS	163-164	258-259	207	AKT1	GeneOrGeneProduct	163	164	3	841	CASP8	GeneOrGeneProduct	258	259	5	1:NR:2	L2R	CROSS	163-164	283-284	207	AKT1	GeneOrGeneProduct	163	164	3	1499	CTNNB1|beta - catenin	GeneOrGeneProduct	283:290	284:293	6:6	1:NR:2	L2R	CROSS	163-164	302-303	207	AKT1	GeneOrGeneProduct	163	164	3	1033	CDKN3	GeneOrGeneProduct	302	303	6	1:NR:2	L2R	CROSS	163-164	304-305	207	AKT1	GeneOrGeneProduct	163	164	3	27022	FOXD3	GeneOrGeneProduct	304	305	6	1:NR:2	L2R	CROSS	163-164	309-310	207	AKT1	GeneOrGeneProduct	163	164	3	5268	SERPINB5	GeneOrGeneProduct	309	310	6	1:NR:2	L2R	CROSS	163-164	332-333	207	AKT1	GeneOrGeneProduct	163	164	3	864	RUNX3	GeneOrGeneProduct	332	333	7	1:NR:2	L2R	NON-CROSS	165-166	167-168	3815	KIT	GeneOrGeneProduct	165	166	3	5925	RB1	GeneOrGeneProduct	167	168	3	1:NR:2	L2R	CROSS	165-166	204-205	3815	KIT	GeneOrGeneProduct	165	166	3	1950	EGF	GeneOrGeneProduct	204	205	4	1:NR:2	L2R	CROSS	165-166	209-210	3815	KIT	GeneOrGeneProduct	165	166	3	3082	HGF	GeneOrGeneProduct	209	210	4	1:NR:2	L2R	CROSS	165-166	220-221	3815	KIT	GeneOrGeneProduct	165	166	3	1029	CDKN2A	GeneOrGeneProduct	220	221	4	1:NR:2	L2R	CROSS	165-166	222-223	3815	KIT	GeneOrGeneProduct	165	166	3	6774	STAT3	GeneOrGeneProduct	222	223	4	1:NR:2	L2R	CROSS	165-166	237-238	3815	KIT	GeneOrGeneProduct	165	166	3	596	BCL2	GeneOrGeneProduct	237	238	5	1:NR:2	L2R	CROSS	165-166	249-250	3815	KIT	GeneOrGeneProduct	165	166	3	7124	TNF	GeneOrGeneProduct	249	250	5	1:NR:2	L2R	CROSS	165-166	256-257	3815	KIT	GeneOrGeneProduct	165	166	3	581	BAX	GeneOrGeneProduct	256	257	5	1:NR:2	L2R	CROSS	165-166	258-259	3815	KIT	GeneOrGeneProduct	165	166	3	841	CASP8	GeneOrGeneProduct	258	259	5	1:NR:2	L2R	CROSS	165-166	283-284	3815	KIT	GeneOrGeneProduct	165	166	3	1499	CTNNB1|beta - catenin	GeneOrGeneProduct	283:290	284:293	6:6	1:NR:2	L2R	CROSS	165-166	302-303	3815	KIT	GeneOrGeneProduct	165	166	3	1033	CDKN3	GeneOrGeneProduct	302	303	6	1:NR:2	L2R	CROSS	165-166	304-305	3815	KIT	GeneOrGeneProduct	165	166	3	27022	FOXD3	GeneOrGeneProduct	304	305	6	1:NR:2	L2R	CROSS	165-166	309-310	3815	KIT	GeneOrGeneProduct	165	166	3	5268	SERPINB5	GeneOrGeneProduct	309	310	6	1:NR:2	L2R	CROSS	165-166	332-333	3815	KIT	GeneOrGeneProduct	165	166	3	864	RUNX3	GeneOrGeneProduct	332	333	7	1:NR:2	L2R	CROSS	167-168	204-205	5925	RB1	GeneOrGeneProduct	167	168	3	1950	EGF	GeneOrGeneProduct	204	205	4	1:NR:2	L2R	CROSS	167-168	209-210	5925	RB1	GeneOrGeneProduct	167	168	3	3082	HGF	GeneOrGeneProduct	209	210	4	1:NR:2	L2R	CROSS	167-168	220-221	5925	RB1	GeneOrGeneProduct	167	168	3	1029	CDKN2A	GeneOrGeneProduct	220	221	4	1:NR:2	L2R	CROSS	167-168	222-223	5925	RB1	GeneOrGeneProduct	167	168	3	6774	STAT3	GeneOrGeneProduct	222	223	4	1:NR:2	L2R	CROSS	167-168	237-238	5925	RB1	GeneOrGeneProduct	167	168	3	596	BCL2	GeneOrGeneProduct	237	238	5	1:NR:2	L2R	CROSS	167-168	249-250	5925	RB1	GeneOrGeneProduct	167	168	3	7124	TNF	GeneOrGeneProduct	249	250	5	1:NR:2	L2R	CROSS	167-168	256-257	5925	RB1	GeneOrGeneProduct	167	168	3	581	BAX	GeneOrGeneProduct	256	257	5	1:NR:2	L2R	CROSS	167-168	258-259	5925	RB1	GeneOrGeneProduct	167	168	3	841	CASP8	GeneOrGeneProduct	258	259	5	1:NR:2	L2R	CROSS	167-168	283-284	5925	RB1	GeneOrGeneProduct	167	168	3	1499	CTNNB1|beta - catenin	GeneOrGeneProduct	283:290	284:293	6:6	1:NR:2	L2R	CROSS	167-168	302-303	5925	RB1	GeneOrGeneProduct	167	168	3	1033	CDKN3	GeneOrGeneProduct	302	303	6	1:NR:2	L2R	CROSS	167-168	304-305	5925	RB1	GeneOrGeneProduct	167	168	3	27022	FOXD3	GeneOrGeneProduct	304	305	6	1:NR:2	L2R	CROSS	167-168	309-310	5925	RB1	GeneOrGeneProduct	167	168	3	5268	SERPINB5	GeneOrGeneProduct	309	310	6	1:NR:2	L2R	CROSS	167-168	332-333	5925	RB1	GeneOrGeneProduct	167	168	3	864	RUNX3	GeneOrGeneProduct	332	333	7	1:NR:2	L2R	NON-CROSS	204-205	209-210	1950	EGF	GeneOrGeneProduct	204	205	4	3082	HGF	GeneOrGeneProduct	209	210	4	1:NR:2	L2R	NON-CROSS	204-205	220-221	1950	EGF	GeneOrGeneProduct	204	205	4	1029	CDKN2A	GeneOrGeneProduct	220	221	4	1:NR:2	L2R	NON-CROSS	204-205	222-223	1950	EGF	GeneOrGeneProduct	204	205	4	6774	STAT3	GeneOrGeneProduct	222	223	4	1:NR:2	L2R	CROSS	204-205	237-238	1950	EGF	GeneOrGeneProduct	204	205	4	596	BCL2	GeneOrGeneProduct	237	238	5	1:NR:2	L2R	CROSS	204-205	249-250	1950	EGF	GeneOrGeneProduct	204	205	4	7124	TNF	GeneOrGeneProduct	249	250	5	1:NR:2	L2R	CROSS	204-205	256-257	1950	EGF	GeneOrGeneProduct	204	205	4	581	BAX	GeneOrGeneProduct	256	257	5	1:NR:2	L2R	CROSS	204-205	258-259	1950	EGF	GeneOrGeneProduct	204	205	4	841	CASP8	GeneOrGeneProduct	258	259	5	1:NR:2	L2R	CROSS	204-205	283-284	1950	EGF	GeneOrGeneProduct	204	205	4	1499	CTNNB1|beta - catenin	GeneOrGeneProduct	283:290	284:293	6:6	1:NR:2	L2R	CROSS	204-205	302-303	1950	EGF	GeneOrGeneProduct	204	205	4	1033	CDKN3	GeneOrGeneProduct	302	303	6	1:NR:2	L2R	CROSS	204-205	304-305	1950	EGF	GeneOrGeneProduct	204	205	4	27022	FOXD3	GeneOrGeneProduct	304	305	6	1:NR:2	L2R	CROSS	204-205	309-310	1950	EGF	GeneOrGeneProduct	204	205	4	5268	SERPINB5	GeneOrGeneProduct	309	310	6	1:NR:2	L2R	CROSS	204-205	332-333	1950	EGF	GeneOrGeneProduct	204	205	4	864	RUNX3	GeneOrGeneProduct	332	333	7	1:NR:2	L2R	NON-CROSS	209-210	220-221	3082	HGF	GeneOrGeneProduct	209	210	4	1029	CDKN2A	GeneOrGeneProduct	220	221	4	1:NR:2	L2R	NON-CROSS	209-210	222-223	3082	HGF	GeneOrGeneProduct	209	210	4	6774	STAT3	GeneOrGeneProduct	222	223	4	1:NR:2	L2R	CROSS	209-210	237-238	3082	HGF	GeneOrGeneProduct	209	210	4	596	BCL2	GeneOrGeneProduct	237	238	5	1:NR:2	L2R	CROSS	209-210	249-250	3082	HGF	GeneOrGeneProduct	209	210	4	7124	TNF	GeneOrGeneProduct	249	250	5	1:NR:2	L2R	CROSS	209-210	256-257	3082	HGF	GeneOrGeneProduct	209	210	4	581	BAX	GeneOrGeneProduct	256	257	5	1:NR:2	L2R	CROSS	209-210	258-259	3082	HGF	GeneOrGeneProduct	209	210	4	841	CASP8	GeneOrGeneProduct	258	259	5	1:NR:2	L2R	CROSS	209-210	283-284	3082	HGF	GeneOrGeneProduct	209	210	4	1499	CTNNB1|beta - catenin	GeneOrGeneProduct	283:290	284:293	6:6	1:NR:2	L2R	CROSS	209-210	302-303	3082	HGF	GeneOrGeneProduct	209	210	4	1033	CDKN3	GeneOrGeneProduct	302	303	6	1:NR:2	L2R	CROSS	209-210	304-305	3082	HGF	GeneOrGeneProduct	209	210	4	27022	FOXD3	GeneOrGeneProduct	304	305	6	1:NR:2	L2R	CROSS	209-210	309-310	3082	HGF	GeneOrGeneProduct	209	210	4	5268	SERPINB5	GeneOrGeneProduct	309	310	6	1:NR:2	L2R	CROSS	209-210	332-333	3082	HGF	GeneOrGeneProduct	209	210	4	864	RUNX3	GeneOrGeneProduct	332	333	7	1:NR:2	L2R	NON-CROSS	220-221	222-223	1029	CDKN2A	GeneOrGeneProduct	220	221	4	6774	STAT3	GeneOrGeneProduct	222	223	4	1:NR:2	L2R	CROSS	220-221	237-238	1029	CDKN2A	GeneOrGeneProduct	220	221	4	596	BCL2	GeneOrGeneProduct	237	238	5	1:NR:2	L2R	CROSS	220-221	249-250	1029	CDKN2A	GeneOrGeneProduct	220	221	4	7124	TNF	GeneOrGeneProduct	249	250	5	1:NR:2	L2R	CROSS	220-221	256-257	1029	CDKN2A	GeneOrGeneProduct	220	221	4	581	BAX	GeneOrGeneProduct	256	257	5	1:NR:2	L2R	CROSS	220-221	258-259	1029	CDKN2A	GeneOrGeneProduct	220	221	4	841	CASP8	GeneOrGeneProduct	258	259	5	1:NR:2	L2R	CROSS	220-221	283-284	1029	CDKN2A	GeneOrGeneProduct	220	221	4	1499	CTNNB1|beta - catenin	GeneOrGeneProduct	283:290	284:293	6:6	1:NR:2	L2R	CROSS	220-221	302-303	1029	CDKN2A	GeneOrGeneProduct	220	221	4	1033	CDKN3	GeneOrGeneProduct	302	303	6	1:NR:2	L2R	CROSS	220-221	304-305	1029	CDKN2A	GeneOrGeneProduct	220	221	4	27022	FOXD3	GeneOrGeneProduct	304	305	6	1:NR:2	L2R	CROSS	220-221	309-310	1029	CDKN2A	GeneOrGeneProduct	220	221	4	5268	SERPINB5	GeneOrGeneProduct	309	310	6	1:NR:2	L2R	CROSS	220-221	332-333	1029	CDKN2A	GeneOrGeneProduct	220	221	4	864	RUNX3	GeneOrGeneProduct	332	333	7	1:NR:2	L2R	CROSS	222-223	237-238	6774	STAT3	GeneOrGeneProduct	222	223	4	596	BCL2	GeneOrGeneProduct	237	238	5	1:NR:2	L2R	CROSS	222-223	249-250	6774	STAT3	GeneOrGeneProduct	222	223	4	7124	TNF	GeneOrGeneProduct	249	250	5	1:NR:2	L2R	CROSS	222-223	256-257	6774	STAT3	GeneOrGeneProduct	222	223	4	581	BAX	GeneOrGeneProduct	256	257	5	1:NR:2	L2R	CROSS	222-223	258-259	6774	STAT3	GeneOrGeneProduct	222	223	4	841	CASP8	GeneOrGeneProduct	258	259	5	1:NR:2	L2R	CROSS	222-223	283-284	6774	STAT3	GeneOrGeneProduct	222	223	4	1499	CTNNB1|beta - catenin	GeneOrGeneProduct	283:290	284:293	6:6	1:NR:2	L2R	CROSS	222-223	302-303	6774	STAT3	GeneOrGeneProduct	222	223	4	1033	CDKN3	GeneOrGeneProduct	302	303	6	1:NR:2	L2R	CROSS	222-223	304-305	6774	STAT3	GeneOrGeneProduct	222	223	4	27022	FOXD3	GeneOrGeneProduct	304	305	6	1:NR:2	L2R	CROSS	222-223	309-310	6774	STAT3	GeneOrGeneProduct	222	223	4	5268	SERPINB5	GeneOrGeneProduct	309	310	6	1:NR:2	L2R	CROSS	222-223	332-333	6774	STAT3	GeneOrGeneProduct	222	223	4	864	RUNX3	GeneOrGeneProduct	332	333	7	1:NR:2	L2R	NON-CROSS	237-238	249-250	596	BCL2	GeneOrGeneProduct	237	238	5	7124	TNF	GeneOrGeneProduct	249	250	5	1:NR:2	L2R	NON-CROSS	237-238	256-257	596	BCL2	GeneOrGeneProduct	237	238	5	581	BAX	GeneOrGeneProduct	256	257	5	1:NR:2	L2R	NON-CROSS	237-238	258-259	596	BCL2	GeneOrGeneProduct	237	238	5	841	CASP8	GeneOrGeneProduct	258	259	5	1:NR:2	L2R	CROSS	237-238	283-284	596	BCL2	GeneOrGeneProduct	237	238	5	1499	CTNNB1|beta - catenin	GeneOrGeneProduct	283:290	284:293	6:6	1:NR:2	L2R	CROSS	237-238	302-303	596	BCL2	GeneOrGeneProduct	237	238	5	1033	CDKN3	GeneOrGeneProduct	302	303	6	1:NR:2	L2R	CROSS	237-238	304-305	596	BCL2	GeneOrGeneProduct	237	238	5	27022	FOXD3	GeneOrGeneProduct	304	305	6	1:NR:2	L2R	CROSS	237-238	309-310	596	BCL2	GeneOrGeneProduct	237	238	5	5268	SERPINB5	GeneOrGeneProduct	309	310	6	1:NR:2	L2R	CROSS	237-238	332-333	596	BCL2	GeneOrGeneProduct	237	238	5	864	RUNX3	GeneOrGeneProduct	332	333	7	1:NR:2	L2R	NON-CROSS	249-250	256-257	7124	TNF	GeneOrGeneProduct	249	250	5	581	BAX	GeneOrGeneProduct	256	257	5	1:NR:2	L2R	NON-CROSS	249-250	258-259	7124	TNF	GeneOrGeneProduct	249	250	5	841	CASP8	GeneOrGeneProduct	258	259	5	1:NR:2	L2R	CROSS	249-250	283-284	7124	TNF	GeneOrGeneProduct	249	250	5	1499	CTNNB1|beta - catenin	GeneOrGeneProduct	283:290	284:293	6:6	1:NR:2	L2R	CROSS	249-250	302-303	7124	TNF	GeneOrGeneProduct	249	250	5	1033	CDKN3	GeneOrGeneProduct	302	303	6	1:NR:2	L2R	CROSS	249-250	304-305	7124	TNF	GeneOrGeneProduct	249	250	5	27022	FOXD3	GeneOrGeneProduct	304	305	6	1:NR:2	L2R	CROSS	249-250	309-310	7124	TNF	GeneOrGeneProduct	249	250	5	5268	SERPINB5	GeneOrGeneProduct	309	310	6	1:NR:2	L2R	CROSS	249-250	332-333	7124	TNF	GeneOrGeneProduct	249	250	5	864	RUNX3	GeneOrGeneProduct	332	333	7	1:NR:2	L2R	NON-CROSS	256-257	258-259	581	BAX	GeneOrGeneProduct	256	257	5	841	CASP8	GeneOrGeneProduct	258	259	5	1:NR:2	L2R	CROSS	256-257	283-284	581	BAX	GeneOrGeneProduct	256	257	5	1499	CTNNB1|beta - catenin	GeneOrGeneProduct	283:290	284:293	6:6	1:NR:2	L2R	CROSS	256-257	302-303	581	BAX	GeneOrGeneProduct	256	257	5	1033	CDKN3	GeneOrGeneProduct	302	303	6	1:NR:2	L2R	CROSS	256-257	304-305	581	BAX	GeneOrGeneProduct	256	257	5	27022	FOXD3	GeneOrGeneProduct	304	305	6	1:NR:2	L2R	CROSS	256-257	309-310	581	BAX	GeneOrGeneProduct	256	257	5	5268	SERPINB5	GeneOrGeneProduct	309	310	6	1:NR:2	L2R	CROSS	256-257	332-333	581	BAX	GeneOrGeneProduct	256	257	5	864	RUNX3	GeneOrGeneProduct	332	333	7	1:NR:2	L2R	CROSS	258-259	283-284	841	CASP8	GeneOrGeneProduct	258	259	5	1499	CTNNB1|beta - catenin	GeneOrGeneProduct	283:290	284:293	6:6	1:NR:2	L2R	CROSS	258-259	302-303	841	CASP8	GeneOrGeneProduct	258	259	5	1033	CDKN3	GeneOrGeneProduct	302	303	6	1:NR:2	L2R	CROSS	258-259	304-305	841	CASP8	GeneOrGeneProduct	258	259	5	27022	FOXD3	GeneOrGeneProduct	304	305	6	1:NR:2	L2R	CROSS	258-259	309-310	841	CASP8	GeneOrGeneProduct	258	259	5	5268	SERPINB5	GeneOrGeneProduct	309	310	6	1:NR:2	L2R	CROSS	258-259	332-333	841	CASP8	GeneOrGeneProduct	258	259	5	864	RUNX3	GeneOrGeneProduct	332	333	7	1:NR:2	L2R	NON-CROSS	290-293	302-303	1499	CTNNB1|beta - catenin	GeneOrGeneProduct	283:290	284:293	6:6	1033	CDKN3	GeneOrGeneProduct	302	303	6	1:NR:2	L2R	NON-CROSS	290-293	304-305	1499	CTNNB1|beta - catenin	GeneOrGeneProduct	283:290	284:293	6:6	27022	FOXD3	GeneOrGeneProduct	304	305	6	1:NR:2	L2R	NON-CROSS	290-293	309-310	1499	CTNNB1|beta - catenin	GeneOrGeneProduct	283:290	284:293	6:6	5268	SERPINB5	GeneOrGeneProduct	309	310	6	1:NR:2	L2R	CROSS	290-293	332-333	1499	CTNNB1|beta - catenin	GeneOrGeneProduct	283:290	284:293	6:6	864	RUNX3	GeneOrGeneProduct	332	333	7	1:NR:2	L2R	NON-CROSS	302-303	304-305	1033	CDKN3	GeneOrGeneProduct	302	303	6	27022	FOXD3	GeneOrGeneProduct	304	305	6	1:NR:2	L2R	NON-CROSS	302-303	309-310	1033	CDKN3	GeneOrGeneProduct	302	303	6	5268	SERPINB5	GeneOrGeneProduct	309	310	6	1:NR:2	L2R	CROSS	302-303	332-333	1033	CDKN3	GeneOrGeneProduct	302	303	6	864	RUNX3	GeneOrGeneProduct	332	333	7	1:NR:2	L2R	NON-CROSS	304-305	309-310	27022	FOXD3	GeneOrGeneProduct	304	305	6	5268	SERPINB5	GeneOrGeneProduct	309	310	6	1:NR:2	L2R	CROSS	304-305	332-333	27022	FOXD3	GeneOrGeneProduct	304	305	6	864	RUNX3	GeneOrGeneProduct	332	333	7	1:NR:2	L2R	CROSS	309-310	332-333	5268	SERPINB5	GeneOrGeneProduct	309	310	6	864	RUNX3	GeneOrGeneProduct	332	333	7
27959387	Long - term exposure of MCF - 7 breast cancer cells to ethanol stimulates oncogenic features .|Alcohol consumption is a risk factor for breast cancer .|Little is known regarding the mechanism , although it is assumed that acetaldehyde or estrogen mediated pathways play a role .|We previously showed that long - term exposure to 2 . 5 mM ethanol ( blood alcohol ~0 . 012 % ) of MCF - 12A , a human normal epithelial breast cell line , induced epithelial mesenchymal transition ( EMT ) and oncogenic transformation .|In this study , we investigated in the human breast cancer cell line MCF - 7 , whether a similar exposure to ethanol at concentrations ranging up to peak blood levels in heavy drinkers would increase malignant progression .|Short - term ( 1 - week ) incubation to ethanol at as low as 1 - 5 mM ( corresponding to blood alcohol concentration of ~0 . 0048 - 0 . 024 % ) upregulated the stem cell related proteins Oct4 and Nanog , but they were reduced after exposure at 25 mM .|Long - term ( 4 - week ) exposure to 25 mM ethanol upregulated the Oct4 and Nanog proteins , as well as the malignancy marker Ceacam6 .|DNA microarray analysis in cells exposed for 1 week showed upregulated expression of metallothionein genes , particularly MT1X .|Long - term exposure upregulated expression of some malignancy related genes ( STEAP4 , SERPINA3 , SAMD9 , GDF15 , KRT15 , ITGB6 , TP63 , and PGR , as well as the CEACAM , interferon related , and HLA gene families ) .|Some of these findings were validated by RT - PCR .|A similar treatment also modulated numerous microRNAs ( miRs ) including one regulator of Oct4 as well as miRs involved in oncogenesis and / or malignancy , with only a few estrogen - induced miRs .|Long - term 25 mM ethanol also induced a 5 . 6 - fold upregulation of anchorage - independent growth , an indicator of malignant - like features .|Exposure to acetaldehyde resulted in little or no effect comparable to that of ethanol .|The previously shown alcohol induction of oncogenic transformation of normal breast cells is now complemented by the current results suggesting alcohol 's potential involvement in malignant progression of breast cancer .	1:Positive_Correlation:2	R2L	NON-CROSS	12-13	8-10	D000431	ethanol|ethanol|ethanol|ethanol|ethanol|ethanol|ethanol	ChemicalEntity	12:61:116:143:200:331:368	13:62:117:144:201:332:369	0:3:4:5:6:11:12	D001943	breast cancer|breast cancer|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	8:24:103:398	10:26:105:400	0:1:4:13	1:Positive_Correlation:2	R2L	NON-CROSS	24-26	17-18	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	17:64:156:373:390	18:65:157:374:391	1:3:5:13:13	D001943	breast cancer|breast cancer|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	8:24:103:398	10:26:105:400	0:1:4:13	1:NR:2	L2R	CROSS	24-26	39-40	D001943	breast cancer|breast cancer|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	8:24:103:398	10:26:105:400	0:1:4:13	D000079	acetaldehyde|acetaldehyde	ChemicalEntity	39:357	40:358	2:12	1:NR:2	L2R	CROSS	24-26	41-42	D001943	breast cancer|breast cancer|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	8:24:103:398	10:26:105:400	0:1:4:13	D004967	estrogen|estrogen	ChemicalEntity	41:321	42:322	2:10	1:NR:2	L2R	CROSS	103-105	174-175	D001943	breast cancer|breast cancer|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	8:24:103:398	10:26:105:400	0:1:4:13	5460	Oct4|Oct4|Oct4	GeneOrGeneProduct	174:203:304	175:204:305	5:6:10	1:NR:2	L2R	CROSS	103-105	176-177	D001943	breast cancer|breast cancer|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	8:24:103:398	10:26:105:400	0:1:4:13	79923	Nanog|Nanog	GeneOrGeneProduct	176:205	177:206	5:6	1:NR:2	L2R	CROSS	103-105	214-215	D001943	breast cancer|breast cancer|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	8:24:103:398	10:26:105:400	0:1:4:13	4680	Ceacam6|CEACAM	GeneOrGeneProduct	214:268	215:269	6:8	1:NR:2	L2R	CROSS	103-105	229-230	D001943	breast cancer|breast cancer|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	8:24:103:398	10:26:105:400	0:1:4:13	4501	metallothionein|MT1X	GeneOrGeneProduct	229:233	230:234	7:7	1:NR:2	L2R	CROSS	103-105	247-248	D001943	breast cancer|breast cancer|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	8:24:103:398	10:26:105:400	0:1:4:13	79689	STEAP4	GeneOrGeneProduct	247	248	8	1:NR:2	L2R	CROSS	103-105	249-250	D001943	breast cancer|breast cancer|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	8:24:103:398	10:26:105:400	0:1:4:13	12	SERPINA3	GeneOrGeneProduct	249	250	8	1:NR:2	L2R	CROSS	103-105	251-252	D001943	breast cancer|breast cancer|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	8:24:103:398	10:26:105:400	0:1:4:13	54809	SAMD9	GeneOrGeneProduct	251	252	8	1:NR:2	L2R	CROSS	253-254	398-400	D001943	breast cancer|breast cancer|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	8:24:103:398	10:26:105:400	0:1:4:13	9518	GDF15	GeneOrGeneProduct	253	254	8	1:NR:2	L2R	CROSS	255-256	398-400	D001943	breast cancer|breast cancer|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	8:24:103:398	10:26:105:400	0:1:4:13	3866	KRT15	GeneOrGeneProduct	255	256	8	1:NR:2	L2R	CROSS	257-258	398-400	D001943	breast cancer|breast cancer|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	8:24:103:398	10:26:105:400	0:1:4:13	3694	ITGB6	GeneOrGeneProduct	257	258	8	1:NR:2	L2R	CROSS	259-260	398-400	D001943	breast cancer|breast cancer|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	8:24:103:398	10:26:105:400	0:1:4:13	8626	TP63	GeneOrGeneProduct	259	260	8	1:NR:2	L2R	CROSS	262-263	398-400	D001943	breast cancer|breast cancer|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	8:24:103:398	10:26:105:400	0:1:4:13	5241	PGR	GeneOrGeneProduct	262	263	8	1:NR:2	L2R	CROSS	270-271	398-400	D001943	breast cancer|breast cancer|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	8:24:103:398	10:26:105:400	0:1:4:13	282617	interferon	GeneOrGeneProduct	270	271	8	1:NR:2	L2R	CROSS	274-275	398-400	D001943	breast cancer|breast cancer|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	8:24:103:398	10:26:105:400	0:1:4:13	3123	HLA	GeneOrGeneProduct	274	275	8	1:Positive_Correlation:2	R2L	NON-CROSS	64-65	61-62	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	17:64:156:373:390	18:65:157:374:391	1:3:5:13:13	D000431	ethanol|ethanol|ethanol|ethanol|ethanol|ethanol|ethanol	ChemicalEntity	12:61:116:143:200:331:368	13:62:117:144:201:332:369	0:3:4:5:6:11:12	1:NR:2	L2R	NON-CROSS	357-358	368-369	D000431	ethanol|ethanol|ethanol|ethanol|ethanol|ethanol|ethanol	ChemicalEntity	12:61:116:143:200:331:368	13:62:117:144:201:332:369	0:3:4:5:6:11:12	D000079	acetaldehyde|acetaldehyde	ChemicalEntity	39:357	40:358	2:12	1:NR:2	L2R	CROSS	321-322	331-332	D000431	ethanol|ethanol|ethanol|ethanol|ethanol|ethanol|ethanol	ChemicalEntity	12:61:116:143:200:331:368	13:62:117:144:201:332:369	0:3:4:5:6:11:12	D004967	estrogen|estrogen	ChemicalEntity	41:321	42:322	2:10	1:Positive_Correlation:2	L2R	NON-CROSS	200-201	203-204	D000431	ethanol|ethanol|ethanol|ethanol|ethanol|ethanol|ethanol	ChemicalEntity	12:61:116:143:200:331:368	13:62:117:144:201:332:369	0:3:4:5:6:11:12	5460	Oct4|Oct4|Oct4	GeneOrGeneProduct	174:203:304	175:204:305	5:6:10	1:Positive_Correlation:2	L2R	NON-CROSS	200-201	205-206	D000431	ethanol|ethanol|ethanol|ethanol|ethanol|ethanol|ethanol	ChemicalEntity	12:61:116:143:200:331:368	13:62:117:144:201:332:369	0:3:4:5:6:11:12	79923	Nanog|Nanog	GeneOrGeneProduct	176:205	177:206	5:6	1:Association:2	L2R	NON-CROSS	200-201	212-213	D000431	ethanol|ethanol|ethanol|ethanol|ethanol|ethanol|ethanol	ChemicalEntity	12:61:116:143:200:331:368	13:62:117:144:201:332:369	0:3:4:5:6:11:12	D009369	malignancy|malignancy|malignancy	DiseaseOrPhenotypicFeature	212:243:315	213:244:316	6:8:10	1:Positive_Correlation:2	L2R	NON-CROSS	200-201	214-215	D000431	ethanol|ethanol|ethanol|ethanol|ethanol|ethanol|ethanol	ChemicalEntity	12:61:116:143:200:331:368	13:62:117:144:201:332:369	0:3:4:5:6:11:12	4680	Ceacam6|CEACAM	GeneOrGeneProduct	214:268	215:269	6:8	1:Positive_Correlation:2	L2R	CROSS	200-201	229-230	D000431	ethanol|ethanol|ethanol|ethanol|ethanol|ethanol|ethanol	ChemicalEntity	12:61:116:143:200:331:368	13:62:117:144:201:332:369	0:3:4:5:6:11:12	4501	metallothionein|MT1X	GeneOrGeneProduct	229:233	230:234	7:7	1:Positive_Correlation:2	R2L	CROSS	247-248	200-201	79689	STEAP4	GeneOrGeneProduct	247	248	8	D000431	ethanol|ethanol|ethanol|ethanol|ethanol|ethanol|ethanol	ChemicalEntity	12:61:116:143:200:331:368	13:62:117:144:201:332:369	0:3:4:5:6:11:12	1:Positive_Correlation:2	R2L	CROSS	249-250	200-201	12	SERPINA3	GeneOrGeneProduct	249	250	8	D000431	ethanol|ethanol|ethanol|ethanol|ethanol|ethanol|ethanol	ChemicalEntity	12:61:116:143:200:331:368	13:62:117:144:201:332:369	0:3:4:5:6:11:12	1:Positive_Correlation:2	R2L	CROSS	251-252	200-201	54809	SAMD9	GeneOrGeneProduct	251	252	8	D000431	ethanol|ethanol|ethanol|ethanol|ethanol|ethanol|ethanol	ChemicalEntity	12:61:116:143:200:331:368	13:62:117:144:201:332:369	0:3:4:5:6:11:12	1:Positive_Correlation:2	R2L	CROSS	253-254	200-201	9518	GDF15	GeneOrGeneProduct	253	254	8	D000431	ethanol|ethanol|ethanol|ethanol|ethanol|ethanol|ethanol	ChemicalEntity	12:61:116:143:200:331:368	13:62:117:144:201:332:369	0:3:4:5:6:11:12	1:Positive_Correlation:2	R2L	CROSS	255-256	200-201	3866	KRT15	GeneOrGeneProduct	255	256	8	D000431	ethanol|ethanol|ethanol|ethanol|ethanol|ethanol|ethanol	ChemicalEntity	12:61:116:143:200:331:368	13:62:117:144:201:332:369	0:3:4:5:6:11:12	1:Positive_Correlation:2	R2L	CROSS	257-258	200-201	3694	ITGB6	GeneOrGeneProduct	257	258	8	D000431	ethanol|ethanol|ethanol|ethanol|ethanol|ethanol|ethanol	ChemicalEntity	12:61:116:143:200:331:368	13:62:117:144:201:332:369	0:3:4:5:6:11:12	1:Positive_Correlation:2	R2L	CROSS	259-260	200-201	8626	TP63	GeneOrGeneProduct	259	260	8	D000431	ethanol|ethanol|ethanol|ethanol|ethanol|ethanol|ethanol	ChemicalEntity	12:61:116:143:200:331:368	13:62:117:144:201:332:369	0:3:4:5:6:11:12	1:Positive_Correlation:2	R2L	CROSS	262-263	200-201	5241	PGR	GeneOrGeneProduct	262	263	8	D000431	ethanol|ethanol|ethanol|ethanol|ethanol|ethanol|ethanol	ChemicalEntity	12:61:116:143:200:331:368	13:62:117:144:201:332:369	0:3:4:5:6:11:12	1:Positive_Correlation:2	R2L	CROSS	331-332	270-271	282617	interferon	GeneOrGeneProduct	270	271	8	D000431	ethanol|ethanol|ethanol|ethanol|ethanol|ethanol|ethanol	ChemicalEntity	12:61:116:143:200:331:368	13:62:117:144:201:332:369	0:3:4:5:6:11:12	1:Positive_Correlation:2	R2L	CROSS	331-332	274-275	3123	HLA	GeneOrGeneProduct	274	275	8	D000431	ethanol|ethanol|ethanol|ethanol|ethanol|ethanol|ethanol	ChemicalEntity	12:61:116:143:200:331:368	13:62:117:144:201:332:369	0:3:4:5:6:11:12	1:NR:2	L2R	CROSS	357-358	373-374	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	17:64:156:373:390	18:65:157:374:391	1:3:5:13:13	D000079	acetaldehyde|acetaldehyde	ChemicalEntity	39:357	40:358	2:12	1:NR:2	L2R	CROSS	41-42	64-65	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	17:64:156:373:390	18:65:157:374:391	1:3:5:13:13	D004967	estrogen|estrogen	ChemicalEntity	41:321	42:322	2:10	1:Positive_Correlation:2	R2L	NON-CROSS	174-175	156-157	5460	Oct4|Oct4|Oct4	GeneOrGeneProduct	174:203:304	175:204:305	5:6:10	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	17:64:156:373:390	18:65:157:374:391	1:3:5:13:13	1:Positive_Correlation:2	R2L	NON-CROSS	176-177	156-157	79923	Nanog|Nanog	GeneOrGeneProduct	176:205	177:206	5:6	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	17:64:156:373:390	18:65:157:374:391	1:3:5:13:13	1:NR:2	L2R	CROSS	156-157	212-213	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	17:64:156:373:390	18:65:157:374:391	1:3:5:13:13	D009369	malignancy|malignancy|malignancy	DiseaseOrPhenotypicFeature	212:243:315	213:244:316	6:8:10	1:NR:2	L2R	CROSS	156-157	214-215	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	17:64:156:373:390	18:65:157:374:391	1:3:5:13:13	4680	Ceacam6|CEACAM	GeneOrGeneProduct	214:268	215:269	6:8	1:NR:2	L2R	CROSS	156-157	229-230	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	17:64:156:373:390	18:65:157:374:391	1:3:5:13:13	4501	metallothionein|MT1X	GeneOrGeneProduct	229:233	230:234	7:7	1:NR:2	L2R	CROSS	156-157	247-248	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	17:64:156:373:390	18:65:157:374:391	1:3:5:13:13	79689	STEAP4	GeneOrGeneProduct	247	248	8	1:NR:2	L2R	CROSS	156-157	249-250	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	17:64:156:373:390	18:65:157:374:391	1:3:5:13:13	12	SERPINA3	GeneOrGeneProduct	249	250	8	1:NR:2	L2R	CROSS	156-157	251-252	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	17:64:156:373:390	18:65:157:374:391	1:3:5:13:13	54809	SAMD9	GeneOrGeneProduct	251	252	8	1:NR:2	L2R	CROSS	156-157	253-254	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	17:64:156:373:390	18:65:157:374:391	1:3:5:13:13	9518	GDF15	GeneOrGeneProduct	253	254	8	1:NR:2	L2R	CROSS	156-157	255-256	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	17:64:156:373:390	18:65:157:374:391	1:3:5:13:13	3866	KRT15	GeneOrGeneProduct	255	256	8	1:NR:2	L2R	CROSS	156-157	257-258	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	17:64:156:373:390	18:65:157:374:391	1:3:5:13:13	3694	ITGB6	GeneOrGeneProduct	257	258	8	1:NR:2	L2R	CROSS	156-157	259-260	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	17:64:156:373:390	18:65:157:374:391	1:3:5:13:13	8626	TP63	GeneOrGeneProduct	259	260	8	1:NR:2	L2R	CROSS	156-157	262-263	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	17:64:156:373:390	18:65:157:374:391	1:3:5:13:13	5241	PGR	GeneOrGeneProduct	262	263	8	1:NR:2	L2R	CROSS	270-271	373-374	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	17:64:156:373:390	18:65:157:374:391	1:3:5:13:13	282617	interferon	GeneOrGeneProduct	270	271	8	1:NR:2	L2R	CROSS	274-275	373-374	D000438	Alcohol|alcohol|alcohol|alcohol|alcohol	ChemicalEntity	17:64:156:373:390	18:65:157:374:391	1:3:5:13:13	3123	HLA	GeneOrGeneProduct	274	275	8	1:NR:2	L2R	NON-CROSS	39-40	41-42	D000079	acetaldehyde|acetaldehyde	ChemicalEntity	39:357	40:358	2:12	D004967	estrogen|estrogen	ChemicalEntity	41:321	42:322	2:10	1:NR:2	L2R	CROSS	304-305	357-358	D000079	acetaldehyde|acetaldehyde	ChemicalEntity	39:357	40:358	2:12	5460	Oct4|Oct4|Oct4	GeneOrGeneProduct	174:203:304	175:204:305	5:6:10	1:NR:2	L2R	CROSS	39-40	176-177	D000079	acetaldehyde|acetaldehyde	ChemicalEntity	39:357	40:358	2:12	79923	Nanog|Nanog	GeneOrGeneProduct	176:205	177:206	5:6	1:NR:2	L2R	CROSS	315-316	357-358	D000079	acetaldehyde|acetaldehyde	ChemicalEntity	39:357	40:358	2:12	D009369	malignancy|malignancy|malignancy	DiseaseOrPhenotypicFeature	212:243:315	213:244:316	6:8:10	1:NR:2	L2R	CROSS	268-269	357-358	D000079	acetaldehyde|acetaldehyde	ChemicalEntity	39:357	40:358	2:12	4680	Ceacam6|CEACAM	GeneOrGeneProduct	214:268	215:269	6:8	1:NR:2	L2R	CROSS	233-234	357-358	D000079	acetaldehyde|acetaldehyde	ChemicalEntity	39:357	40:358	2:12	4501	metallothionein|MT1X	GeneOrGeneProduct	229:233	230:234	7:7	1:NR:2	L2R	CROSS	247-248	357-358	D000079	acetaldehyde|acetaldehyde	ChemicalEntity	39:357	40:358	2:12	79689	STEAP4	GeneOrGeneProduct	247	248	8	1:NR:2	L2R	CROSS	249-250	357-358	D000079	acetaldehyde|acetaldehyde	ChemicalEntity	39:357	40:358	2:12	12	SERPINA3	GeneOrGeneProduct	249	250	8	1:NR:2	L2R	CROSS	251-252	357-358	D000079	acetaldehyde|acetaldehyde	ChemicalEntity	39:357	40:358	2:12	54809	SAMD9	GeneOrGeneProduct	251	252	8	1:NR:2	L2R	CROSS	253-254	357-358	D000079	acetaldehyde|acetaldehyde	ChemicalEntity	39:357	40:358	2:12	9518	GDF15	GeneOrGeneProduct	253	254	8	1:NR:2	L2R	CROSS	255-256	357-358	D000079	acetaldehyde|acetaldehyde	ChemicalEntity	39:357	40:358	2:12	3866	KRT15	GeneOrGeneProduct	255	256	8	1:NR:2	L2R	CROSS	257-258	357-358	D000079	acetaldehyde|acetaldehyde	ChemicalEntity	39:357	40:358	2:12	3694	ITGB6	GeneOrGeneProduct	257	258	8	1:NR:2	L2R	CROSS	259-260	357-358	D000079	acetaldehyde|acetaldehyde	ChemicalEntity	39:357	40:358	2:12	8626	TP63	GeneOrGeneProduct	259	260	8	1:NR:2	L2R	CROSS	262-263	357-358	D000079	acetaldehyde|acetaldehyde	ChemicalEntity	39:357	40:358	2:12	5241	PGR	GeneOrGeneProduct	262	263	8	1:NR:2	L2R	CROSS	270-271	357-358	D000079	acetaldehyde|acetaldehyde	ChemicalEntity	39:357	40:358	2:12	282617	interferon	GeneOrGeneProduct	270	271	8	1:NR:2	L2R	CROSS	274-275	357-358	D000079	acetaldehyde|acetaldehyde	ChemicalEntity	39:357	40:358	2:12	3123	HLA	GeneOrGeneProduct	274	275	8	1:NR:2	L2R	NON-CROSS	304-305	321-322	D004967	estrogen|estrogen	ChemicalEntity	41:321	42:322	2:10	5460	Oct4|Oct4|Oct4	GeneOrGeneProduct	174:203:304	175:204:305	5:6:10	1:NR:2	L2R	CROSS	205-206	321-322	D004967	estrogen|estrogen	ChemicalEntity	41:321	42:322	2:10	79923	Nanog|Nanog	GeneOrGeneProduct	176:205	177:206	5:6	1:NR:2	L2R	NON-CROSS	315-316	321-322	D004967	estrogen|estrogen	ChemicalEntity	41:321	42:322	2:10	D009369	malignancy|malignancy|malignancy	DiseaseOrPhenotypicFeature	212:243:315	213:244:316	6:8:10	1:NR:2	L2R	CROSS	268-269	321-322	D004967	estrogen|estrogen	ChemicalEntity	41:321	42:322	2:10	4680	Ceacam6|CEACAM	GeneOrGeneProduct	214:268	215:269	6:8	1:NR:2	L2R	CROSS	233-234	321-322	D004967	estrogen|estrogen	ChemicalEntity	41:321	42:322	2:10	4501	metallothionein|MT1X	GeneOrGeneProduct	229:233	230:234	7:7	1:NR:2	L2R	CROSS	247-248	321-322	D004967	estrogen|estrogen	ChemicalEntity	41:321	42:322	2:10	79689	STEAP4	GeneOrGeneProduct	247	248	8	1:NR:2	L2R	CROSS	249-250	321-322	D004967	estrogen|estrogen	ChemicalEntity	41:321	42:322	2:10	12	SERPINA3	GeneOrGeneProduct	249	250	8	1:NR:2	L2R	CROSS	251-252	321-322	D004967	estrogen|estrogen	ChemicalEntity	41:321	42:322	2:10	54809	SAMD9	GeneOrGeneProduct	251	252	8	1:NR:2	L2R	CROSS	253-254	321-322	D004967	estrogen|estrogen	ChemicalEntity	41:321	42:322	2:10	9518	GDF15	GeneOrGeneProduct	253	254	8	1:NR:2	L2R	CROSS	255-256	321-322	D004967	estrogen|estrogen	ChemicalEntity	41:321	42:322	2:10	3866	KRT15	GeneOrGeneProduct	255	256	8	1:NR:2	L2R	CROSS	257-258	321-322	D004967	estrogen|estrogen	ChemicalEntity	41:321	42:322	2:10	3694	ITGB6	GeneOrGeneProduct	257	258	8	1:NR:2	L2R	CROSS	259-260	321-322	D004967	estrogen|estrogen	ChemicalEntity	41:321	42:322	2:10	8626	TP63	GeneOrGeneProduct	259	260	8	1:NR:2	L2R	CROSS	262-263	321-322	D004967	estrogen|estrogen	ChemicalEntity	41:321	42:322	2:10	5241	PGR	GeneOrGeneProduct	262	263	8	1:NR:2	L2R	CROSS	270-271	321-322	D004967	estrogen|estrogen	ChemicalEntity	41:321	42:322	2:10	282617	interferon	GeneOrGeneProduct	270	271	8	1:NR:2	L2R	CROSS	274-275	321-322	D004967	estrogen|estrogen	ChemicalEntity	41:321	42:322	2:10	3123	HLA	GeneOrGeneProduct	274	275	8	1:NR:2	L2R	NON-CROSS	174-175	176-177	5460	Oct4|Oct4|Oct4	GeneOrGeneProduct	174:203:304	175:204:305	5:6:10	79923	Nanog|Nanog	GeneOrGeneProduct	176:205	177:206	5:6	1:NR:2	L2R	NON-CROSS	203-204	212-213	5460	Oct4|Oct4|Oct4	GeneOrGeneProduct	174:203:304	175:204:305	5:6:10	D009369	malignancy|malignancy|malignancy	DiseaseOrPhenotypicFeature	212:243:315	213:244:316	6:8:10	1:NR:2	L2R	NON-CROSS	203-204	214-215	5460	Oct4|Oct4|Oct4	GeneOrGeneProduct	174:203:304	175:204:305	5:6:10	4680	Ceacam6|CEACAM	GeneOrGeneProduct	214:268	215:269	6:8	1:NR:2	L2R	CROSS	203-204	229-230	5460	Oct4|Oct4|Oct4	GeneOrGeneProduct	174:203:304	175:204:305	5:6:10	4501	metallothionein|MT1X	GeneOrGeneProduct	229:233	230:234	7:7	1:NR:2	L2R	CROSS	203-204	247-248	5460	Oct4|Oct4|Oct4	GeneOrGeneProduct	174:203:304	175:204:305	5:6:10	79689	STEAP4	GeneOrGeneProduct	247	248	8	1:NR:2	L2R	CROSS	203-204	249-250	5460	Oct4|Oct4|Oct4	GeneOrGeneProduct	174:203:304	175:204:305	5:6:10	12	SERPINA3	GeneOrGeneProduct	249	250	8	1:NR:2	L2R	CROSS	203-204	251-252	5460	Oct4|Oct4|Oct4	GeneOrGeneProduct	174:203:304	175:204:305	5:6:10	54809	SAMD9	GeneOrGeneProduct	251	252	8	1:NR:2	L2R	CROSS	203-204	253-254	5460	Oct4|Oct4|Oct4	GeneOrGeneProduct	174:203:304	175:204:305	5:6:10	9518	GDF15	GeneOrGeneProduct	253	254	8	1:NR:2	L2R	CROSS	255-256	304-305	5460	Oct4|Oct4|Oct4	GeneOrGeneProduct	174:203:304	175:204:305	5:6:10	3866	KRT15	GeneOrGeneProduct	255	256	8	1:NR:2	L2R	CROSS	257-258	304-305	5460	Oct4|Oct4|Oct4	GeneOrGeneProduct	174:203:304	175:204:305	5:6:10	3694	ITGB6	GeneOrGeneProduct	257	258	8	1:NR:2	L2R	CROSS	259-260	304-305	5460	Oct4|Oct4|Oct4	GeneOrGeneProduct	174:203:304	175:204:305	5:6:10	8626	TP63	GeneOrGeneProduct	259	260	8	1:NR:2	L2R	CROSS	262-263	304-305	5460	Oct4|Oct4|Oct4	GeneOrGeneProduct	174:203:304	175:204:305	5:6:10	5241	PGR	GeneOrGeneProduct	262	263	8	1:NR:2	L2R	CROSS	270-271	304-305	5460	Oct4|Oct4|Oct4	GeneOrGeneProduct	174:203:304	175:204:305	5:6:10	282617	interferon	GeneOrGeneProduct	270	271	8	1:NR:2	L2R	CROSS	274-275	304-305	5460	Oct4|Oct4|Oct4	GeneOrGeneProduct	174:203:304	175:204:305	5:6:10	3123	HLA	GeneOrGeneProduct	274	275	8	1:NR:2	L2R	NON-CROSS	205-206	212-213	79923	Nanog|Nanog	GeneOrGeneProduct	176:205	177:206	5:6	D009369	malignancy|malignancy|malignancy	DiseaseOrPhenotypicFeature	212:243:315	213:244:316	6:8:10	1:NR:2	L2R	NON-CROSS	205-206	214-215	79923	Nanog|Nanog	GeneOrGeneProduct	176:205	177:206	5:6	4680	Ceacam6|CEACAM	GeneOrGeneProduct	214:268	215:269	6:8	1:NR:2	L2R	CROSS	205-206	229-230	79923	Nanog|Nanog	GeneOrGeneProduct	176:205	177:206	5:6	4501	metallothionein|MT1X	GeneOrGeneProduct	229:233	230:234	7:7	1:NR:2	L2R	CROSS	205-206	247-248	79923	Nanog|Nanog	GeneOrGeneProduct	176:205	177:206	5:6	79689	STEAP4	GeneOrGeneProduct	247	248	8	1:NR:2	L2R	CROSS	205-206	249-250	79923	Nanog|Nanog	GeneOrGeneProduct	176:205	177:206	5:6	12	SERPINA3	GeneOrGeneProduct	249	250	8	1:NR:2	L2R	CROSS	205-206	251-252	79923	Nanog|Nanog	GeneOrGeneProduct	176:205	177:206	5:6	54809	SAMD9	GeneOrGeneProduct	251	252	8	1:NR:2	L2R	CROSS	205-206	253-254	79923	Nanog|Nanog	GeneOrGeneProduct	176:205	177:206	5:6	9518	GDF15	GeneOrGeneProduct	253	254	8	1:NR:2	L2R	CROSS	205-206	255-256	79923	Nanog|Nanog	GeneOrGeneProduct	176:205	177:206	5:6	3866	KRT15	GeneOrGeneProduct	255	256	8	1:NR:2	L2R	CROSS	205-206	257-258	79923	Nanog|Nanog	GeneOrGeneProduct	176:205	177:206	5:6	3694	ITGB6	GeneOrGeneProduct	257	258	8	1:NR:2	L2R	CROSS	205-206	259-260	79923	Nanog|Nanog	GeneOrGeneProduct	176:205	177:206	5:6	8626	TP63	GeneOrGeneProduct	259	260	8	1:NR:2	L2R	CROSS	205-206	262-263	79923	Nanog|Nanog	GeneOrGeneProduct	176:205	177:206	5:6	5241	PGR	GeneOrGeneProduct	262	263	8	1:NR:2	L2R	CROSS	205-206	270-271	79923	Nanog|Nanog	GeneOrGeneProduct	176:205	177:206	5:6	282617	interferon	GeneOrGeneProduct	270	271	8	1:NR:2	L2R	CROSS	205-206	274-275	79923	Nanog|Nanog	GeneOrGeneProduct	176:205	177:206	5:6	3123	HLA	GeneOrGeneProduct	274	275	8	1:Association:2	L2R	NON-CROSS	212-213	214-215	D009369	malignancy|malignancy|malignancy	DiseaseOrPhenotypicFeature	212:243:315	213:244:316	6:8:10	4680	Ceacam6|CEACAM	GeneOrGeneProduct	214:268	215:269	6:8	1:NR:2	L2R	CROSS	233-234	243-244	D009369	malignancy|malignancy|malignancy	DiseaseOrPhenotypicFeature	212:243:315	213:244:316	6:8:10	4501	metallothionein|MT1X	GeneOrGeneProduct	229:233	230:234	7:7	1:Association:2	R2L	NON-CROSS	247-248	243-244	79689	STEAP4	GeneOrGeneProduct	247	248	8	D009369	malignancy|malignancy|malignancy	DiseaseOrPhenotypicFeature	212:243:315	213:244:316	6:8:10	1:Association:2	R2L	NON-CROSS	249-250	243-244	12	SERPINA3	GeneOrGeneProduct	249	250	8	D009369	malignancy|malignancy|malignancy	DiseaseOrPhenotypicFeature	212:243:315	213:244:316	6:8:10	1:Association:2	R2L	NON-CROSS	251-252	243-244	54809	SAMD9	GeneOrGeneProduct	251	252	8	D009369	malignancy|malignancy|malignancy	DiseaseOrPhenotypicFeature	212:243:315	213:244:316	6:8:10	1:Association:2	R2L	NON-CROSS	253-254	243-244	9518	GDF15	GeneOrGeneProduct	253	254	8	D009369	malignancy|malignancy|malignancy	DiseaseOrPhenotypicFeature	212:243:315	213:244:316	6:8:10	1:Association:2	R2L	NON-CROSS	255-256	243-244	3866	KRT15	GeneOrGeneProduct	255	256	8	D009369	malignancy|malignancy|malignancy	DiseaseOrPhenotypicFeature	212:243:315	213:244:316	6:8:10	1:Association:2	R2L	NON-CROSS	257-258	243-244	3694	ITGB6	GeneOrGeneProduct	257	258	8	D009369	malignancy|malignancy|malignancy	DiseaseOrPhenotypicFeature	212:243:315	213:244:316	6:8:10	1:Association:2	R2L	NON-CROSS	259-260	243-244	8626	TP63	GeneOrGeneProduct	259	260	8	D009369	malignancy|malignancy|malignancy	DiseaseOrPhenotypicFeature	212:243:315	213:244:316	6:8:10	1:Association:2	R2L	NON-CROSS	262-263	243-244	5241	PGR	GeneOrGeneProduct	262	263	8	D009369	malignancy|malignancy|malignancy	DiseaseOrPhenotypicFeature	212:243:315	213:244:316	6:8:10	1:Association:2	R2L	NON-CROSS	270-271	243-244	282617	interferon	GeneOrGeneProduct	270	271	8	D009369	malignancy|malignancy|malignancy	DiseaseOrPhenotypicFeature	212:243:315	213:244:316	6:8:10	1:Association:2	R2L	NON-CROSS	274-275	243-244	3123	HLA	GeneOrGeneProduct	274	275	8	D009369	malignancy|malignancy|malignancy	DiseaseOrPhenotypicFeature	212:243:315	213:244:316	6:8:10	1:NR:2	L2R	CROSS	214-215	229-230	4680	Ceacam6|CEACAM	GeneOrGeneProduct	214:268	215:269	6:8	4501	metallothionein|MT1X	GeneOrGeneProduct	229:233	230:234	7:7	1:NR:2	L2R	NON-CROSS	247-248	268-269	4680	Ceacam6|CEACAM	GeneOrGeneProduct	214:268	215:269	6:8	79689	STEAP4	GeneOrGeneProduct	247	248	8	1:NR:2	L2R	NON-CROSS	249-250	268-269	4680	Ceacam6|CEACAM	GeneOrGeneProduct	214:268	215:269	6:8	12	SERPINA3	GeneOrGeneProduct	249	250	8	1:NR:2	L2R	NON-CROSS	251-252	268-269	4680	Ceacam6|CEACAM	GeneOrGeneProduct	214:268	215:269	6:8	54809	SAMD9	GeneOrGeneProduct	251	252	8	1:NR:2	L2R	NON-CROSS	253-254	268-269	4680	Ceacam6|CEACAM	GeneOrGeneProduct	214:268	215:269	6:8	9518	GDF15	GeneOrGeneProduct	253	254	8	1:NR:2	L2R	NON-CROSS	255-256	268-269	4680	Ceacam6|CEACAM	GeneOrGeneProduct	214:268	215:269	6:8	3866	KRT15	GeneOrGeneProduct	255	256	8	1:NR:2	L2R	NON-CROSS	257-258	268-269	4680	Ceacam6|CEACAM	GeneOrGeneProduct	214:268	215:269	6:8	3694	ITGB6	GeneOrGeneProduct	257	258	8	1:NR:2	L2R	NON-CROSS	259-260	268-269	4680	Ceacam6|CEACAM	GeneOrGeneProduct	214:268	215:269	6:8	8626	TP63	GeneOrGeneProduct	259	260	8	1:NR:2	L2R	NON-CROSS	262-263	268-269	4680	Ceacam6|CEACAM	GeneOrGeneProduct	214:268	215:269	6:8	5241	PGR	GeneOrGeneProduct	262	263	8	1:NR:2	L2R	NON-CROSS	268-269	270-271	4680	Ceacam6|CEACAM	GeneOrGeneProduct	214:268	215:269	6:8	282617	interferon	GeneOrGeneProduct	270	271	8	1:NR:2	L2R	NON-CROSS	268-269	274-275	4680	Ceacam6|CEACAM	GeneOrGeneProduct	214:268	215:269	6:8	3123	HLA	GeneOrGeneProduct	274	275	8	1:NR:2	L2R	CROSS	233-234	247-248	4501	metallothionein|MT1X	GeneOrGeneProduct	229:233	230:234	7:7	79689	STEAP4	GeneOrGeneProduct	247	248	8	1:NR:2	L2R	CROSS	233-234	249-250	4501	metallothionein|MT1X	GeneOrGeneProduct	229:233	230:234	7:7	12	SERPINA3	GeneOrGeneProduct	249	250	8	1:NR:2	L2R	CROSS	233-234	251-252	4501	metallothionein|MT1X	GeneOrGeneProduct	229:233	230:234	7:7	54809	SAMD9	GeneOrGeneProduct	251	252	8	1:NR:2	L2R	CROSS	233-234	253-254	4501	metallothionein|MT1X	GeneOrGeneProduct	229:233	230:234	7:7	9518	GDF15	GeneOrGeneProduct	253	254	8	1:NR:2	L2R	CROSS	233-234	255-256	4501	metallothionein|MT1X	GeneOrGeneProduct	229:233	230:234	7:7	3866	KRT15	GeneOrGeneProduct	255	256	8	1:NR:2	L2R	CROSS	233-234	257-258	4501	metallothionein|MT1X	GeneOrGeneProduct	229:233	230:234	7:7	3694	ITGB6	GeneOrGeneProduct	257	258	8	1:NR:2	L2R	CROSS	233-234	259-260	4501	metallothionein|MT1X	GeneOrGeneProduct	229:233	230:234	7:7	8626	TP63	GeneOrGeneProduct	259	260	8	1:NR:2	L2R	CROSS	233-234	262-263	4501	metallothionein|MT1X	GeneOrGeneProduct	229:233	230:234	7:7	5241	PGR	GeneOrGeneProduct	262	263	8	1:NR:2	L2R	CROSS	233-234	270-271	4501	metallothionein|MT1X	GeneOrGeneProduct	229:233	230:234	7:7	282617	interferon	GeneOrGeneProduct	270	271	8	1:NR:2	L2R	CROSS	233-234	274-275	4501	metallothionein|MT1X	GeneOrGeneProduct	229:233	230:234	7:7	3123	HLA	GeneOrGeneProduct	274	275	8	1:NR:2	L2R	NON-CROSS	247-248	249-250	79689	STEAP4	GeneOrGeneProduct	247	248	8	12	SERPINA3	GeneOrGeneProduct	249	250	8	1:NR:2	L2R	NON-CROSS	247-248	251-252	79689	STEAP4	GeneOrGeneProduct	247	248	8	54809	SAMD9	GeneOrGeneProduct	251	252	8	1:NR:2	L2R	NON-CROSS	247-248	253-254	79689	STEAP4	GeneOrGeneProduct	247	248	8	9518	GDF15	GeneOrGeneProduct	253	254	8	1:NR:2	L2R	NON-CROSS	247-248	255-256	79689	STEAP4	GeneOrGeneProduct	247	248	8	3866	KRT15	GeneOrGeneProduct	255	256	8	1:NR:2	L2R	NON-CROSS	247-248	257-258	79689	STEAP4	GeneOrGeneProduct	247	248	8	3694	ITGB6	GeneOrGeneProduct	257	258	8	1:NR:2	L2R	NON-CROSS	247-248	259-260	79689	STEAP4	GeneOrGeneProduct	247	248	8	8626	TP63	GeneOrGeneProduct	259	260	8	1:NR:2	L2R	NON-CROSS	247-248	262-263	79689	STEAP4	GeneOrGeneProduct	247	248	8	5241	PGR	GeneOrGeneProduct	262	263	8	1:NR:2	L2R	NON-CROSS	247-248	270-271	79689	STEAP4	GeneOrGeneProduct	247	248	8	282617	interferon	GeneOrGeneProduct	270	271	8	1:NR:2	L2R	NON-CROSS	247-248	274-275	79689	STEAP4	GeneOrGeneProduct	247	248	8	3123	HLA	GeneOrGeneProduct	274	275	8	1:NR:2	L2R	NON-CROSS	249-250	251-252	12	SERPINA3	GeneOrGeneProduct	249	250	8	54809	SAMD9	GeneOrGeneProduct	251	252	8	1:NR:2	L2R	NON-CROSS	249-250	253-254	12	SERPINA3	GeneOrGeneProduct	249	250	8	9518	GDF15	GeneOrGeneProduct	253	254	8	1:NR:2	L2R	NON-CROSS	249-250	255-256	12	SERPINA3	GeneOrGeneProduct	249	250	8	3866	KRT15	GeneOrGeneProduct	255	256	8	1:NR:2	L2R	NON-CROSS	249-250	257-258	12	SERPINA3	GeneOrGeneProduct	249	250	8	3694	ITGB6	GeneOrGeneProduct	257	258	8	1:NR:2	L2R	NON-CROSS	249-250	259-260	12	SERPINA3	GeneOrGeneProduct	249	250	8	8626	TP63	GeneOrGeneProduct	259	260	8	1:NR:2	L2R	NON-CROSS	249-250	262-263	12	SERPINA3	GeneOrGeneProduct	249	250	8	5241	PGR	GeneOrGeneProduct	262	263	8	1:NR:2	L2R	NON-CROSS	249-250	270-271	12	SERPINA3	GeneOrGeneProduct	249	250	8	282617	interferon	GeneOrGeneProduct	270	271	8	1:NR:2	L2R	NON-CROSS	249-250	274-275	12	SERPINA3	GeneOrGeneProduct	249	250	8	3123	HLA	GeneOrGeneProduct	274	275	8	1:NR:2	L2R	NON-CROSS	251-252	253-254	54809	SAMD9	GeneOrGeneProduct	251	252	8	9518	GDF15	GeneOrGeneProduct	253	254	8	1:NR:2	L2R	NON-CROSS	251-252	255-256	54809	SAMD9	GeneOrGeneProduct	251	252	8	3866	KRT15	GeneOrGeneProduct	255	256	8	1:NR:2	L2R	NON-CROSS	251-252	257-258	54809	SAMD9	GeneOrGeneProduct	251	252	8	3694	ITGB6	GeneOrGeneProduct	257	258	8	1:NR:2	L2R	NON-CROSS	251-252	259-260	54809	SAMD9	GeneOrGeneProduct	251	252	8	8626	TP63	GeneOrGeneProduct	259	260	8	1:NR:2	L2R	NON-CROSS	251-252	262-263	54809	SAMD9	GeneOrGeneProduct	251	252	8	5241	PGR	GeneOrGeneProduct	262	263	8	1:NR:2	L2R	NON-CROSS	251-252	270-271	54809	SAMD9	GeneOrGeneProduct	251	252	8	282617	interferon	GeneOrGeneProduct	270	271	8	1:NR:2	L2R	NON-CROSS	251-252	274-275	54809	SAMD9	GeneOrGeneProduct	251	252	8	3123	HLA	GeneOrGeneProduct	274	275	8	1:NR:2	L2R	NON-CROSS	253-254	255-256	9518	GDF15	GeneOrGeneProduct	253	254	8	3866	KRT15	GeneOrGeneProduct	255	256	8	1:NR:2	L2R	NON-CROSS	253-254	257-258	9518	GDF15	GeneOrGeneProduct	253	254	8	3694	ITGB6	GeneOrGeneProduct	257	258	8	1:NR:2	L2R	NON-CROSS	253-254	259-260	9518	GDF15	GeneOrGeneProduct	253	254	8	8626	TP63	GeneOrGeneProduct	259	260	8	1:NR:2	L2R	NON-CROSS	253-254	262-263	9518	GDF15	GeneOrGeneProduct	253	254	8	5241	PGR	GeneOrGeneProduct	262	263	8	1:NR:2	L2R	NON-CROSS	253-254	270-271	9518	GDF15	GeneOrGeneProduct	253	254	8	282617	interferon	GeneOrGeneProduct	270	271	8	1:NR:2	L2R	NON-CROSS	253-254	274-275	9518	GDF15	GeneOrGeneProduct	253	254	8	3123	HLA	GeneOrGeneProduct	274	275	8	1:NR:2	L2R	NON-CROSS	255-256	257-258	3866	KRT15	GeneOrGeneProduct	255	256	8	3694	ITGB6	GeneOrGeneProduct	257	258	8	1:NR:2	L2R	NON-CROSS	255-256	259-260	3866	KRT15	GeneOrGeneProduct	255	256	8	8626	TP63	GeneOrGeneProduct	259	260	8	1:NR:2	L2R	NON-CROSS	255-256	262-263	3866	KRT15	GeneOrGeneProduct	255	256	8	5241	PGR	GeneOrGeneProduct	262	263	8	1:NR:2	L2R	NON-CROSS	255-256	270-271	3866	KRT15	GeneOrGeneProduct	255	256	8	282617	interferon	GeneOrGeneProduct	270	271	8	1:NR:2	L2R	NON-CROSS	255-256	274-275	3866	KRT15	GeneOrGeneProduct	255	256	8	3123	HLA	GeneOrGeneProduct	274	275	8	1:NR:2	L2R	NON-CROSS	257-258	259-260	3694	ITGB6	GeneOrGeneProduct	257	258	8	8626	TP63	GeneOrGeneProduct	259	260	8	1:NR:2	L2R	NON-CROSS	257-258	262-263	3694	ITGB6	GeneOrGeneProduct	257	258	8	5241	PGR	GeneOrGeneProduct	262	263	8	1:NR:2	L2R	NON-CROSS	257-258	270-271	3694	ITGB6	GeneOrGeneProduct	257	258	8	282617	interferon	GeneOrGeneProduct	270	271	8	1:NR:2	L2R	NON-CROSS	257-258	274-275	3694	ITGB6	GeneOrGeneProduct	257	258	8	3123	HLA	GeneOrGeneProduct	274	275	8	1:NR:2	L2R	NON-CROSS	259-260	262-263	8626	TP63	GeneOrGeneProduct	259	260	8	5241	PGR	GeneOrGeneProduct	262	263	8	1:NR:2	L2R	NON-CROSS	259-260	270-271	8626	TP63	GeneOrGeneProduct	259	260	8	282617	interferon	GeneOrGeneProduct	270	271	8	1:NR:2	L2R	NON-CROSS	259-260	274-275	8626	TP63	GeneOrGeneProduct	259	260	8	3123	HLA	GeneOrGeneProduct	274	275	8	1:NR:2	L2R	NON-CROSS	262-263	270-271	5241	PGR	GeneOrGeneProduct	262	263	8	282617	interferon	GeneOrGeneProduct	270	271	8	1:NR:2	L2R	NON-CROSS	262-263	274-275	5241	PGR	GeneOrGeneProduct	262	263	8	3123	HLA	GeneOrGeneProduct	274	275	8	1:NR:2	L2R	NON-CROSS	270-271	274-275	282617	interferon	GeneOrGeneProduct	270	271	8	3123	HLA	GeneOrGeneProduct	274	275	8
21684788	Large contiguous gene deletions in Sjogren - Larsson syndrome .|Sjogren - Larsson syndrome ( SLS ) is an autosomal recessive disorder characterized by ichthyosis , mental retardation , spasticity and mutations in the ALDH3A2 gene for fatty aldehyde dehydrogenase , an enzyme that catalyzes the oxidation of fatty aldehyde to fatty acid .|More than 70 mutations have been identified in SLS patients , including small deletions or insertions , missense mutations , splicing defects and complex nucleotide changes .|We now describe 2 SLS patients whose disease is caused by large contiguous gene deletions of the ALDH3A2 locus on 17p11 . 2 .|The deletions were defined using long distance inverse PCR and microarray - based comparative genomic hybridization .|A 24 - year - old SLS female was homozygous for a 352 - kb deletion involving ALDH3A2 and 4 contiguous genes including ALDH3A1 , which codes for the major soluble protein in cornea .|Although lacking corneal disease , she showed severe symptoms of SLS with uncommon deterioration in oral motor function and loss of ambulation .|The other 19 - month - old female patient was a compound heterozygote for a 1 . 44 - Mb contiguous gene deletion and a missense mutation ( c . 407C > T , P136L ) in ALDH3A2 .|These studies suggest that large gene deletions may account for up to 5 % of the mutant alleles in SLS .|Geneticists should consider the possibility of compound heterozygosity for large deletions in patients with SLS and other inborn errors of metabolism , which has implications for carrier testing and prenatal diagnosis .	1:Association:2	L2R	NON-CROSS	85-86	98-99	D016111	Sjogren - Larsson syndrome|Sjogren - Larsson syndrome|SLS|SLS|SLS|SLS|SLS|SLS|SLS	DiseaseOrPhenotypicFeature	5:10:15:62:85:128:167:238:254	9:14:16:63:86:129:168:239:255	0:1:1:2:3:5:6:8:9	224	ALDH3A2|fatty aldehyde dehydrogenase|ALDH3A2|ALDH3A2	GeneOrGeneProduct	34:37:98:217	35:40:99:218	1:1:3:7	1:NR:2	L2R	NON-CROSS	48-50	62-63	D016111	Sjogren - Larsson syndrome|Sjogren - Larsson syndrome|SLS|SLS|SLS|SLS|SLS|SLS|SLS	DiseaseOrPhenotypicFeature	5:10:15:62:85:128:167:238:254	9:14:16:63:86:129:168:239:255	0:1:1:2:3:5:6:8:9	C001634	fatty aldehyde	ChemicalEntity	48	50	1	1:NR:2	L2R	NON-CROSS	51-53	62-63	D016111	Sjogren - Larsson syndrome|Sjogren - Larsson syndrome|SLS|SLS|SLS|SLS|SLS|SLS|SLS	DiseaseOrPhenotypicFeature	5:10:15:62:85:128:167:238:254	9:14:16:63:86:129:168:239:255	0:1:1:2:3:5:6:8:9	D005227	fatty acid	ChemicalEntity	51	53	1	1:Association:2	R2L	NON-CROSS	134-138	128-129	c|DEL||352K	352 - kb deletion	SequenceVariant	134	138	5	D016111	Sjogren - Larsson syndrome|Sjogren - Larsson syndrome|SLS|SLS|SLS|SLS|SLS|SLS|SLS	DiseaseOrPhenotypicFeature	5:10:15:62:85:128:167:238:254	9:14:16:63:86:129:168:239:255	0:1:1:2:3:5:6:8:9	1:NR:2	L2R	NON-CROSS	128-129	139-142	D016111	Sjogren - Larsson syndrome|Sjogren - Larsson syndrome|SLS|SLS|SLS|SLS|SLS|SLS|SLS	DiseaseOrPhenotypicFeature	5:10:15:62:85:128:167:238:254	9:14:16:63:86:129:168:239:255	0:1:1:2:3:5:6:8:9	223,224	ALDH3A2 and 4	GeneOrGeneProduct	139	142	5	1:Association:2	R2L	NON-CROSS	145-146	128-129	218	ALDH3A1	GeneOrGeneProduct	145	146	5	D016111	Sjogren - Larsson syndrome|Sjogren - Larsson syndrome|SLS|SLS|SLS|SLS|SLS|SLS|SLS	DiseaseOrPhenotypicFeature	5:10:15:62:85:128:167:238:254	9:14:16:63:86:129:168:239:255	0:1:1:2:3:5:6:8:9	1:Positive_Correlation:2	R2L	CROSS	195-203	167-168	c|DEL||1.44M	1 . 44 - Mb contiguous gene deletion	SequenceVariant	195	203	7	D016111	Sjogren - Larsson syndrome|Sjogren - Larsson syndrome|SLS|SLS|SLS|SLS|SLS|SLS|SLS	DiseaseOrPhenotypicFeature	5:10:15:62:85:128:167:238:254	9:14:16:63:86:129:168:239:255	0:1:1:2:3:5:6:8:9	1:Association:2	R2L	CROSS	238-239	208-213	c|SUB|C|407|T	c . 407C > T	SequenceVariant	208	213	7	D016111	Sjogren - Larsson syndrome|Sjogren - Larsson syndrome|SLS|SLS|SLS|SLS|SLS|SLS|SLS	DiseaseOrPhenotypicFeature	5:10:15:62:85:128:167:238:254	9:14:16:63:86:129:168:239:255	0:1:1:2:3:5:6:8:9	1:Association:2	R2L	CROSS	238-239	214-215	p|SUB|P|136|L	P136L	SequenceVariant	214	215	7	D016111	Sjogren - Larsson syndrome|Sjogren - Larsson syndrome|SLS|SLS|SLS|SLS|SLS|SLS|SLS	DiseaseOrPhenotypicFeature	5:10:15:62:85:128:167:238:254	9:14:16:63:86:129:168:239:255	0:1:1:2:3:5:6:8:9	1:NR:2	L2R	NON-CROSS	19-22	34-35	D030342	autosomal recessive disorder	DiseaseOrPhenotypicFeature	19	22	1	224	ALDH3A2|fatty aldehyde dehydrogenase|ALDH3A2|ALDH3A2	GeneOrGeneProduct	34:37:98:217	35:40:99:218	1:1:3:7	1:NR:2	L2R	NON-CROSS	19-22	48-50	D030342	autosomal recessive disorder	DiseaseOrPhenotypicFeature	19	22	1	C001634	fatty aldehyde	ChemicalEntity	48	50	1	1:NR:2	L2R	NON-CROSS	19-22	51-53	D030342	autosomal recessive disorder	DiseaseOrPhenotypicFeature	19	22	1	D005227	fatty acid	ChemicalEntity	51	53	1	1:NR:2	L2R	CROSS	19-22	134-138	D030342	autosomal recessive disorder	DiseaseOrPhenotypicFeature	19	22	1	c|DEL||352K	352 - kb deletion	SequenceVariant	134	138	5	1:NR:2	L2R	CROSS	19-22	139-142	D030342	autosomal recessive disorder	DiseaseOrPhenotypicFeature	19	22	1	223,224	ALDH3A2 and 4	GeneOrGeneProduct	139	142	5	1:NR:2	L2R	CROSS	19-22	145-146	D030342	autosomal recessive disorder	DiseaseOrPhenotypicFeature	19	22	1	218	ALDH3A1	GeneOrGeneProduct	145	146	5	1:NR:2	L2R	CROSS	19-22	195-203	D030342	autosomal recessive disorder	DiseaseOrPhenotypicFeature	19	22	1	c|DEL||1.44M	1 . 44 - Mb contiguous gene deletion	SequenceVariant	195	203	7	1:NR:2	L2R	CROSS	19-22	208-213	D030342	autosomal recessive disorder	DiseaseOrPhenotypicFeature	19	22	1	c|SUB|C|407|T	c . 407C > T	SequenceVariant	208	213	7	1:NR:2	L2R	CROSS	19-22	214-215	D030342	autosomal recessive disorder	DiseaseOrPhenotypicFeature	19	22	1	p|SUB|P|136|L	P136L	SequenceVariant	214	215	7	1:NR:2	L2R	NON-CROSS	24-25	34-35	D007057	ichthyosis	DiseaseOrPhenotypicFeature	24	25	1	224	ALDH3A2|fatty aldehyde dehydrogenase|ALDH3A2|ALDH3A2	GeneOrGeneProduct	34:37:98:217	35:40:99:218	1:1:3:7	1:NR:2	L2R	NON-CROSS	24-25	48-50	D007057	ichthyosis	DiseaseOrPhenotypicFeature	24	25	1	C001634	fatty aldehyde	ChemicalEntity	48	50	1	1:NR:2	L2R	NON-CROSS	24-25	51-53	D007057	ichthyosis	DiseaseOrPhenotypicFeature	24	25	1	D005227	fatty acid	ChemicalEntity	51	53	1	1:NR:2	L2R	CROSS	24-25	134-138	D007057	ichthyosis	DiseaseOrPhenotypicFeature	24	25	1	c|DEL||352K	352 - kb deletion	SequenceVariant	134	138	5	1:NR:2	L2R	CROSS	24-25	139-142	D007057	ichthyosis	DiseaseOrPhenotypicFeature	24	25	1	223,224	ALDH3A2 and 4	GeneOrGeneProduct	139	142	5	1:NR:2	L2R	CROSS	24-25	145-146	D007057	ichthyosis	DiseaseOrPhenotypicFeature	24	25	1	218	ALDH3A1	GeneOrGeneProduct	145	146	5	1:NR:2	L2R	CROSS	24-25	195-203	D007057	ichthyosis	DiseaseOrPhenotypicFeature	24	25	1	c|DEL||1.44M	1 . 44 - Mb contiguous gene deletion	SequenceVariant	195	203	7	1:NR:2	L2R	CROSS	24-25	208-213	D007057	ichthyosis	DiseaseOrPhenotypicFeature	24	25	1	c|SUB|C|407|T	c . 407C > T	SequenceVariant	208	213	7	1:NR:2	L2R	CROSS	24-25	214-215	D007057	ichthyosis	DiseaseOrPhenotypicFeature	24	25	1	p|SUB|P|136|L	P136L	SequenceVariant	214	215	7	1:NR:2	L2R	NON-CROSS	26-28	34-35	D008607	mental retardation	DiseaseOrPhenotypicFeature	26	28	1	224	ALDH3A2|fatty aldehyde dehydrogenase|ALDH3A2|ALDH3A2	GeneOrGeneProduct	34:37:98:217	35:40:99:218	1:1:3:7	1:NR:2	L2R	NON-CROSS	26-28	48-50	D008607	mental retardation	DiseaseOrPhenotypicFeature	26	28	1	C001634	fatty aldehyde	ChemicalEntity	48	50	1	1:NR:2	L2R	NON-CROSS	26-28	51-53	D008607	mental retardation	DiseaseOrPhenotypicFeature	26	28	1	D005227	fatty acid	ChemicalEntity	51	53	1	1:NR:2	L2R	CROSS	26-28	134-138	D008607	mental retardation	DiseaseOrPhenotypicFeature	26	28	1	c|DEL||352K	352 - kb deletion	SequenceVariant	134	138	5	1:NR:2	L2R	CROSS	26-28	139-142	D008607	mental retardation	DiseaseOrPhenotypicFeature	26	28	1	223,224	ALDH3A2 and 4	GeneOrGeneProduct	139	142	5	1:NR:2	L2R	CROSS	26-28	145-146	D008607	mental retardation	DiseaseOrPhenotypicFeature	26	28	1	218	ALDH3A1	GeneOrGeneProduct	145	146	5	1:NR:2	L2R	CROSS	26-28	195-203	D008607	mental retardation	DiseaseOrPhenotypicFeature	26	28	1	c|DEL||1.44M	1 . 44 - Mb contiguous gene deletion	SequenceVariant	195	203	7	1:NR:2	L2R	CROSS	26-28	208-213	D008607	mental retardation	DiseaseOrPhenotypicFeature	26	28	1	c|SUB|C|407|T	c . 407C > T	SequenceVariant	208	213	7	1:NR:2	L2R	CROSS	26-28	214-215	D008607	mental retardation	DiseaseOrPhenotypicFeature	26	28	1	p|SUB|P|136|L	P136L	SequenceVariant	214	215	7	1:NR:2	L2R	NON-CROSS	29-30	34-35	D009128	spasticity	DiseaseOrPhenotypicFeature	29	30	1	224	ALDH3A2|fatty aldehyde dehydrogenase|ALDH3A2|ALDH3A2	GeneOrGeneProduct	34:37:98:217	35:40:99:218	1:1:3:7	1:NR:2	L2R	NON-CROSS	29-30	48-50	D009128	spasticity	DiseaseOrPhenotypicFeature	29	30	1	C001634	fatty aldehyde	ChemicalEntity	48	50	1	1:NR:2	L2R	NON-CROSS	29-30	51-53	D009128	spasticity	DiseaseOrPhenotypicFeature	29	30	1	D005227	fatty acid	ChemicalEntity	51	53	1	1:NR:2	L2R	CROSS	29-30	134-138	D009128	spasticity	DiseaseOrPhenotypicFeature	29	30	1	c|DEL||352K	352 - kb deletion	SequenceVariant	134	138	5	1:NR:2	L2R	CROSS	29-30	139-142	D009128	spasticity	DiseaseOrPhenotypicFeature	29	30	1	223,224	ALDH3A2 and 4	GeneOrGeneProduct	139	142	5	1:NR:2	L2R	CROSS	29-30	145-146	D009128	spasticity	DiseaseOrPhenotypicFeature	29	30	1	218	ALDH3A1	GeneOrGeneProduct	145	146	5	1:NR:2	L2R	CROSS	29-30	195-203	D009128	spasticity	DiseaseOrPhenotypicFeature	29	30	1	c|DEL||1.44M	1 . 44 - Mb contiguous gene deletion	SequenceVariant	195	203	7	1:NR:2	L2R	CROSS	29-30	208-213	D009128	spasticity	DiseaseOrPhenotypicFeature	29	30	1	c|SUB|C|407|T	c . 407C > T	SequenceVariant	208	213	7	1:NR:2	L2R	CROSS	29-30	214-215	D009128	spasticity	DiseaseOrPhenotypicFeature	29	30	1	p|SUB|P|136|L	P136L	SequenceVariant	214	215	7	1:Association:2	L2R	NON-CROSS	37-40	48-50	224	ALDH3A2|fatty aldehyde dehydrogenase|ALDH3A2|ALDH3A2	GeneOrGeneProduct	34:37:98:217	35:40:99:218	1:1:3:7	C001634	fatty aldehyde	ChemicalEntity	48	50	1	1:Association:2	L2R	NON-CROSS	37-40	51-53	224	ALDH3A2|fatty aldehyde dehydrogenase|ALDH3A2|ALDH3A2	GeneOrGeneProduct	34:37:98:217	35:40:99:218	1:1:3:7	D005227	fatty acid	ChemicalEntity	51	53	1	1:NR:2	L2R	CROSS	98-99	139-142	224	ALDH3A2|fatty aldehyde dehydrogenase|ALDH3A2|ALDH3A2	GeneOrGeneProduct	34:37:98:217	35:40:99:218	1:1:3:7	223,224	ALDH3A2 and 4	GeneOrGeneProduct	139	142	5	1:NR:2	L2R	CROSS	98-99	145-146	224	ALDH3A2|fatty aldehyde dehydrogenase|ALDH3A2|ALDH3A2	GeneOrGeneProduct	34:37:98:217	35:40:99:218	1:1:3:7	218	ALDH3A1	GeneOrGeneProduct	145	146	5	1:NR:2	L2R	CROSS	159-161	217-218	224	ALDH3A2|fatty aldehyde dehydrogenase|ALDH3A2|ALDH3A2	GeneOrGeneProduct	34:37:98:217	35:40:99:218	1:1:3:7	D003316	corneal disease	DiseaseOrPhenotypicFeature	159	161	6	1:NR:2	L2R	CROSS	217-218	257-261	224	ALDH3A2|fatty aldehyde dehydrogenase|ALDH3A2|ALDH3A2	GeneOrGeneProduct	34:37:98:217	35:40:99:218	1:1:3:7	D008661	inborn errors of metabolism	DiseaseOrPhenotypicFeature	257	261	9	1:NR:2	L2R	NON-CROSS	48-50	51-53	C001634	fatty aldehyde	ChemicalEntity	48	50	1	D005227	fatty acid	ChemicalEntity	51	53	1	1:NR:2	L2R	CROSS	48-50	134-138	C001634	fatty aldehyde	ChemicalEntity	48	50	1	c|DEL||352K	352 - kb deletion	SequenceVariant	134	138	5	1:NR:2	L2R	CROSS	48-50	139-142	C001634	fatty aldehyde	ChemicalEntity	48	50	1	223,224	ALDH3A2 and 4	GeneOrGeneProduct	139	142	5	1:NR:2	L2R	CROSS	48-50	145-146	C001634	fatty aldehyde	ChemicalEntity	48	50	1	218	ALDH3A1	GeneOrGeneProduct	145	146	5	1:NR:2	L2R	CROSS	48-50	159-161	C001634	fatty aldehyde	ChemicalEntity	48	50	1	D003316	corneal disease	DiseaseOrPhenotypicFeature	159	161	6	1:NR:2	L2R	CROSS	48-50	195-203	C001634	fatty aldehyde	ChemicalEntity	48	50	1	c|DEL||1.44M	1 . 44 - Mb contiguous gene deletion	SequenceVariant	195	203	7	1:NR:2	L2R	CROSS	48-50	208-213	C001634	fatty aldehyde	ChemicalEntity	48	50	1	c|SUB|C|407|T	c . 407C > T	SequenceVariant	208	213	7	1:NR:2	L2R	CROSS	48-50	214-215	C001634	fatty aldehyde	ChemicalEntity	48	50	1	p|SUB|P|136|L	P136L	SequenceVariant	214	215	7	1:NR:2	L2R	CROSS	48-50	257-261	C001634	fatty aldehyde	ChemicalEntity	48	50	1	D008661	inborn errors of metabolism	DiseaseOrPhenotypicFeature	257	261	9	1:NR:2	L2R	CROSS	51-53	134-138	D005227	fatty acid	ChemicalEntity	51	53	1	c|DEL||352K	352 - kb deletion	SequenceVariant	134	138	5	1:NR:2	L2R	CROSS	51-53	139-142	D005227	fatty acid	ChemicalEntity	51	53	1	223,224	ALDH3A2 and 4	GeneOrGeneProduct	139	142	5	1:NR:2	L2R	CROSS	51-53	145-146	D005227	fatty acid	ChemicalEntity	51	53	1	218	ALDH3A1	GeneOrGeneProduct	145	146	5	1:NR:2	L2R	CROSS	51-53	159-161	D005227	fatty acid	ChemicalEntity	51	53	1	D003316	corneal disease	DiseaseOrPhenotypicFeature	159	161	6	1:NR:2	L2R	CROSS	51-53	195-203	D005227	fatty acid	ChemicalEntity	51	53	1	c|DEL||1.44M	1 . 44 - Mb contiguous gene deletion	SequenceVariant	195	203	7	1:NR:2	L2R	CROSS	51-53	208-213	D005227	fatty acid	ChemicalEntity	51	53	1	c|SUB|C|407|T	c . 407C > T	SequenceVariant	208	213	7	1:NR:2	L2R	CROSS	51-53	214-215	D005227	fatty acid	ChemicalEntity	51	53	1	p|SUB|P|136|L	P136L	SequenceVariant	214	215	7	1:NR:2	L2R	CROSS	51-53	257-261	D005227	fatty acid	ChemicalEntity	51	53	1	D008661	inborn errors of metabolism	DiseaseOrPhenotypicFeature	257	261	9	1:NR:2	L2R	CROSS	134-138	159-161	c|DEL||352K	352 - kb deletion	SequenceVariant	134	138	5	D003316	corneal disease	DiseaseOrPhenotypicFeature	159	161	6	1:NR:2	L2R	CROSS	134-138	257-261	c|DEL||352K	352 - kb deletion	SequenceVariant	134	138	5	D008661	inborn errors of metabolism	DiseaseOrPhenotypicFeature	257	261	9	1:NR:2	L2R	NON-CROSS	139-142	145-146	223,224	ALDH3A2 and 4	GeneOrGeneProduct	139	142	5	218	ALDH3A1	GeneOrGeneProduct	145	146	5	1:NR:2	L2R	CROSS	139-142	159-161	223,224	ALDH3A2 and 4	GeneOrGeneProduct	139	142	5	D003316	corneal disease	DiseaseOrPhenotypicFeature	159	161	6	1:NR:2	L2R	CROSS	139-142	257-261	223,224	ALDH3A2 and 4	GeneOrGeneProduct	139	142	5	D008661	inborn errors of metabolism	DiseaseOrPhenotypicFeature	257	261	9	1:NR:2	L2R	CROSS	145-146	159-161	218	ALDH3A1	GeneOrGeneProduct	145	146	5	D003316	corneal disease	DiseaseOrPhenotypicFeature	159	161	6	1:NR:2	L2R	CROSS	145-146	257-261	218	ALDH3A1	GeneOrGeneProduct	145	146	5	D008661	inborn errors of metabolism	DiseaseOrPhenotypicFeature	257	261	9	1:NR:2	L2R	CROSS	159-161	195-203	D003316	corneal disease	DiseaseOrPhenotypicFeature	159	161	6	c|DEL||1.44M	1 . 44 - Mb contiguous gene deletion	SequenceVariant	195	203	7	1:NR:2	L2R	CROSS	159-161	208-213	D003316	corneal disease	DiseaseOrPhenotypicFeature	159	161	6	c|SUB|C|407|T	c . 407C > T	SequenceVariant	208	213	7	1:NR:2	L2R	CROSS	159-161	214-215	D003316	corneal disease	DiseaseOrPhenotypicFeature	159	161	6	p|SUB|P|136|L	P136L	SequenceVariant	214	215	7	1:NR:2	L2R	CROSS	195-203	257-261	c|DEL||1.44M	1 . 44 - Mb contiguous gene deletion	SequenceVariant	195	203	7	D008661	inborn errors of metabolism	DiseaseOrPhenotypicFeature	257	261	9	1:NR:2	L2R	CROSS	208-213	257-261	c|SUB|C|407|T	c . 407C > T	SequenceVariant	208	213	7	D008661	inborn errors of metabolism	DiseaseOrPhenotypicFeature	257	261	9	1:NR:2	L2R	CROSS	214-215	257-261	p|SUB|P|136|L	P136L	SequenceVariant	214	215	7	D008661	inborn errors of metabolism	DiseaseOrPhenotypicFeature	257	261	9
26937641	Serum Amyloid A Induces Inflammation , Proliferation and Cell Death in Activated Hepatic Stellate Cells .|Serum amyloid A ( SAA ) is an evolutionary highly conserved acute phase protein that is predominantly secreted by hepatocytes .|However , its role in liver injury and fibrogenesis has not been elucidated so far .|In this study , we determined the effects of SAA on hepatic stellate cells ( HSCs ) , the main fibrogenic cell type of the liver .|Serum amyloid A potently activated IkappaB kinase , c - Jun N - terminal kinase ( JNK ) , Erk and Akt and enhanced NF - kappaB - dependent luciferase activity in primary human and rat HSCs .|Serum amyloid A induced the transcription of MCP - 1 , RANTES and MMP9 in an NF - kappaB - and JNK - dependent manner .|Blockade of NF - kappaB revealed cytotoxic effects of SAA in primary HSCs with signs of apoptosis such as caspase 3 and PARP cleavage and Annexin V staining .|Serum amyloid A induced HSC proliferation , which depended on JNK , Erk and Akt activity .|In primary hepatocytes , SAA also activated MAP kinases , but did not induce relevant cell death after NF - kappaB inhibition .|In two models of hepatic fibrogenesis , CCl4 treatment and bile duct ligation , hepatic mRNA levels of SAA1 and SAA3 were strongly increased .|In conclusion , SAA may modulate fibrogenic responses in the liver in a positive and negative fashion by inducing inflammation , proliferation and cell death in HSCs .	1:NR:2	L2R	CROSS	42-46	62-63	20208,20210,6288	Serum Amyloid A|Serum amyloid A|SAA|SAA|Serum amyloid A|Serum amyloid A|SAA|Serum amyloid A|SAA|SAA	GeneOrGeneProduct	0:16:20:62:80:118:153:173:194:241	3:19:21:63:83:121:154:176:195:242	0:1:1:3:4:5:6:7:8:10	D008107	liver injury and fibrogenesis|hepatic fibrogenesis	DiseaseOrPhenotypicFeature	42:217	46:219	2:9	1:NR:2	L2R	NON-CROSS	80-83	85-87	20208,20210,6288	Serum Amyloid A|Serum amyloid A|SAA|SAA|Serum amyloid A|Serum amyloid A|SAA|Serum amyloid A|SAA|SAA	GeneOrGeneProduct	0:16:20:62:80:118:153:173:194:241	3:19:21:63:83:121:154:176:195:242	0:1:1:3:4:5:6:7:8:10	84351,9641	IkappaB kinase	GeneOrGeneProduct	85	87	4	1:NR:2	L2R	NON-CROSS	80-83	88-95	20208,20210,6288	Serum Amyloid A|Serum amyloid A|SAA|SAA|Serum amyloid A|Serum amyloid A|SAA|Serum amyloid A|SAA|SAA	GeneOrGeneProduct	0:16:20:62:80:118:153:173:194:241	3:19:21:63:83:121:154:176:195:242	0:1:1:3:4:5:6:7:8:10	116554,5599	c - Jun N - terminal kinase|JNK|JNK|JNK	GeneOrGeneProduct	88:96:139:183	95:97:140:184	4:4:5:7	1:NR:2	L2R	NON-CROSS	185-186	194-195	20208,20210,6288	Serum Amyloid A|Serum amyloid A|SAA|SAA|Serum amyloid A|Serum amyloid A|SAA|Serum amyloid A|SAA|SAA	GeneOrGeneProduct	0:16:20:62:80:118:153:173:194:241	3:19:21:63:83:121:154:176:195:242	0:1:1:3:4:5:6:7:8:10	116590,5594	Erk|Erk	GeneOrGeneProduct	99:185	100:186	4:7	1:NR:2	L2R	NON-CROSS	187-188	194-195	20208,20210,6288	Serum Amyloid A|Serum amyloid A|SAA|SAA|Serum amyloid A|Serum amyloid A|SAA|Serum amyloid A|SAA|SAA	GeneOrGeneProduct	0:16:20:62:80:118:153:173:194:241	3:19:21:63:83:121:154:176:195:242	0:1:1:3:4:5:6:7:8:10	207,24185	Akt|Akt	GeneOrGeneProduct	101:187	102:188	4:7	1:NR:2	L2R	NON-CROSS	146-149	153-154	20208,20210,6288	Serum Amyloid A|Serum amyloid A|SAA|SAA|Serum amyloid A|Serum amyloid A|SAA|Serum amyloid A|SAA|SAA	GeneOrGeneProduct	0:16:20:62:80:118:153:173:194:241	3:19:21:63:83:121:154:176:195:242	0:1:1:3:4:5:6:7:8:10	4790,81736	NF - kappaB|NF - kappaB|NF - kappaB|NF - kappaB	GeneOrGeneProduct	104:134:146:208	107:137:149:211	4:5:6:8	1:NR:2	L2R	NON-CROSS	118-121	125-128	20208,20210,6288	Serum Amyloid A|Serum amyloid A|SAA|SAA|Serum amyloid A|Serum amyloid A|SAA|Serum amyloid A|SAA|SAA	GeneOrGeneProduct	0:16:20:62:80:118:153:173:194:241	3:19:21:63:83:121:154:176:195:242	0:1:1:3:4:5:6:7:8:10	24770,6347	MCP - 1	GeneOrGeneProduct	125	128	5	1:NR:2	L2R	NON-CROSS	118-121	129-130	20208,20210,6288	Serum Amyloid A|Serum amyloid A|SAA|SAA|Serum amyloid A|Serum amyloid A|SAA|Serum amyloid A|SAA|SAA	GeneOrGeneProduct	0:16:20:62:80:118:153:173:194:241	3:19:21:63:83:121:154:176:195:242	0:1:1:3:4:5:6:7:8:10	6352,81780	RANTES	GeneOrGeneProduct	129	130	5	1:NR:2	L2R	NON-CROSS	118-121	131-132	20208,20210,6288	Serum Amyloid A|Serum amyloid A|SAA|SAA|Serum amyloid A|Serum amyloid A|SAA|Serum amyloid A|SAA|SAA	GeneOrGeneProduct	0:16:20:62:80:118:153:173:194:241	3:19:21:63:83:121:154:176:195:242	0:1:1:3:4:5:6:7:8:10	4318,81687	MMP9	GeneOrGeneProduct	131	132	5	1:NR:2	L2R	NON-CROSS	150-151	153-154	20208,20210,6288	Serum Amyloid A|Serum amyloid A|SAA|SAA|Serum amyloid A|Serum amyloid A|SAA|Serum amyloid A|SAA|SAA	GeneOrGeneProduct	0:16:20:62:80:118:153:173:194:241	3:19:21:63:83:121:154:176:195:242	0:1:1:3:4:5:6:7:8:10	D064420	cytotoxic	DiseaseOrPhenotypicFeature	150	151	6	1:NR:2	L2R	NON-CROSS	163-165	173-176	20208,20210,6288	Serum Amyloid A|Serum amyloid A|SAA|SAA|Serum amyloid A|Serum amyloid A|SAA|Serum amyloid A|SAA|SAA	GeneOrGeneProduct	0:16:20:62:80:118:153:173:194:241	3:19:21:63:83:121:154:176:195:242	0:1:1:3:4:5:6:7:8:10	25402,836	caspase 3	GeneOrGeneProduct	163	165	6	1:NR:2	L2R	NON-CROSS	166-167	173-176	20208,20210,6288	Serum Amyloid A|Serum amyloid A|SAA|SAA|Serum amyloid A|Serum amyloid A|SAA|Serum amyloid A|SAA|SAA	GeneOrGeneProduct	0:16:20:62:80:118:153:173:194:241	3:19:21:63:83:121:154:176:195:242	0:1:1:3:4:5:6:7:8:10	142,25591	PARP	GeneOrGeneProduct	166	167	6	1:NR:2	L2R	NON-CROSS	169-171	173-176	20208,20210,6288	Serum Amyloid A|Serum amyloid A|SAA|SAA|Serum amyloid A|Serum amyloid A|SAA|Serum amyloid A|SAA|SAA	GeneOrGeneProduct	0:16:20:62:80:118:153:173:194:241	3:19:21:63:83:121:154:176:195:242	0:1:1:3:4:5:6:7:8:10	25673,308	Annexin V	GeneOrGeneProduct	169	171	6	1:NR:2	L2R	NON-CROSS	194-195	197-199	20208,20210,6288	Serum Amyloid A|Serum amyloid A|SAA|SAA|Serum amyloid A|Serum amyloid A|SAA|Serum amyloid A|SAA|SAA	GeneOrGeneProduct	0:16:20:62:80:118:153:173:194:241	3:19:21:63:83:121:154:176:195:242	0:1:1:3:4:5:6:7:8:10	116554,116590,207,24185,5594,5599	MAP kinases	GeneOrGeneProduct	197	199	8	1:NR:2	L2R	CROSS	220-221	241-242	20208,20210,6288	Serum Amyloid A|Serum amyloid A|SAA|SAA|Serum amyloid A|Serum amyloid A|SAA|Serum amyloid A|SAA|SAA	GeneOrGeneProduct	0:16:20:62:80:118:153:173:194:241	3:19:21:63:83:121:154:176:195:242	0:1:1:3:4:5:6:7:8:10	6351	CCl4	GeneOrGeneProduct	220	221	9	1:NR:2	L2R	CROSS	231-232	241-242	20208,20210,6288	Serum Amyloid A|Serum amyloid A|SAA|SAA|Serum amyloid A|Serum amyloid A|SAA|Serum amyloid A|SAA|SAA	GeneOrGeneProduct	0:16:20:62:80:118:153:173:194:241	3:19:21:63:83:121:154:176:195:242	0:1:1:3:4:5:6:7:8:10	20208	SAA1	GeneOrGeneProduct	231	232	9	1:NR:2	L2R	CROSS	233-234	241-242	20208,20210,6288	Serum Amyloid A|Serum amyloid A|SAA|SAA|Serum amyloid A|Serum amyloid A|SAA|Serum amyloid A|SAA|SAA	GeneOrGeneProduct	0:16:20:62:80:118:153:173:194:241	3:19:21:63:83:121:154:176:195:242	0:1:1:3:4:5:6:7:8:10	20210	SAA3	GeneOrGeneProduct	233	234	9	1:NR:2	L2R	CROSS	42-46	85-87	D008107	liver injury and fibrogenesis|hepatic fibrogenesis	DiseaseOrPhenotypicFeature	42:217	46:219	2:9	84351,9641	IkappaB kinase	GeneOrGeneProduct	85	87	4	1:NR:2	L2R	CROSS	183-184	217-219	D008107	liver injury and fibrogenesis|hepatic fibrogenesis	DiseaseOrPhenotypicFeature	42:217	46:219	2:9	116554,5599	c - Jun N - terminal kinase|JNK|JNK|JNK	GeneOrGeneProduct	88:96:139:183	95:97:140:184	4:4:5:7	1:NR:2	L2R	CROSS	185-186	217-219	D008107	liver injury and fibrogenesis|hepatic fibrogenesis	DiseaseOrPhenotypicFeature	42:217	46:219	2:9	116590,5594	Erk|Erk	GeneOrGeneProduct	99:185	100:186	4:7	1:NR:2	L2R	CROSS	187-188	217-219	D008107	liver injury and fibrogenesis|hepatic fibrogenesis	DiseaseOrPhenotypicFeature	42:217	46:219	2:9	207,24185	Akt|Akt	GeneOrGeneProduct	101:187	102:188	4:7	1:NR:2	L2R	CROSS	208-211	217-219	D008107	liver injury and fibrogenesis|hepatic fibrogenesis	DiseaseOrPhenotypicFeature	42:217	46:219	2:9	4790,81736	NF - kappaB|NF - kappaB|NF - kappaB|NF - kappaB	GeneOrGeneProduct	104:134:146:208	107:137:149:211	4:5:6:8	1:NR:2	L2R	CROSS	42-46	125-128	D008107	liver injury and fibrogenesis|hepatic fibrogenesis	DiseaseOrPhenotypicFeature	42:217	46:219	2:9	24770,6347	MCP - 1	GeneOrGeneProduct	125	128	5	1:NR:2	L2R	CROSS	42-46	129-130	D008107	liver injury and fibrogenesis|hepatic fibrogenesis	DiseaseOrPhenotypicFeature	42:217	46:219	2:9	6352,81780	RANTES	GeneOrGeneProduct	129	130	5	1:NR:2	L2R	CROSS	42-46	131-132	D008107	liver injury and fibrogenesis|hepatic fibrogenesis	DiseaseOrPhenotypicFeature	42:217	46:219	2:9	4318,81687	MMP9	GeneOrGeneProduct	131	132	5	1:NR:2	L2R	CROSS	163-165	217-219	D008107	liver injury and fibrogenesis|hepatic fibrogenesis	DiseaseOrPhenotypicFeature	42:217	46:219	2:9	25402,836	caspase 3	GeneOrGeneProduct	163	165	6	1:NR:2	L2R	CROSS	166-167	217-219	D008107	liver injury and fibrogenesis|hepatic fibrogenesis	DiseaseOrPhenotypicFeature	42:217	46:219	2:9	142,25591	PARP	GeneOrGeneProduct	166	167	6	1:NR:2	L2R	CROSS	169-171	217-219	D008107	liver injury and fibrogenesis|hepatic fibrogenesis	DiseaseOrPhenotypicFeature	42:217	46:219	2:9	25673,308	Annexin V	GeneOrGeneProduct	169	171	6	1:NR:2	L2R	CROSS	197-199	217-219	D008107	liver injury and fibrogenesis|hepatic fibrogenesis	DiseaseOrPhenotypicFeature	42:217	46:219	2:9	116554,116590,207,24185,5594,5599	MAP kinases	GeneOrGeneProduct	197	199	8	1:Association:2	R2L	NON-CROSS	220-221	217-219	6351	CCl4	GeneOrGeneProduct	220	221	9	D008107	liver injury and fibrogenesis|hepatic fibrogenesis	DiseaseOrPhenotypicFeature	42:217	46:219	2:9	1:Association:2	L2R	NON-CROSS	217-219	231-232	D008107	liver injury and fibrogenesis|hepatic fibrogenesis	DiseaseOrPhenotypicFeature	42:217	46:219	2:9	20208	SAA1	GeneOrGeneProduct	231	232	9	1:Association:2	L2R	NON-CROSS	217-219	233-234	D008107	liver injury and fibrogenesis|hepatic fibrogenesis	DiseaseOrPhenotypicFeature	42:217	46:219	2:9	20210	SAA3	GeneOrGeneProduct	233	234	9	1:NR:2	L2R	NON-CROSS	85-87	88-95	84351,9641	IkappaB kinase	GeneOrGeneProduct	85	87	4	116554,5599	c - Jun N - terminal kinase|JNK|JNK|JNK	GeneOrGeneProduct	88:96:139:183	95:97:140:184	4:4:5:7	1:NR:2	L2R	NON-CROSS	85-87	99-100	84351,9641	IkappaB kinase	GeneOrGeneProduct	85	87	4	116590,5594	Erk|Erk	GeneOrGeneProduct	99:185	100:186	4:7	1:NR:2	L2R	NON-CROSS	85-87	101-102	84351,9641	IkappaB kinase	GeneOrGeneProduct	85	87	4	207,24185	Akt|Akt	GeneOrGeneProduct	101:187	102:188	4:7	1:NR:2	L2R	NON-CROSS	85-87	104-107	84351,9641	IkappaB kinase	GeneOrGeneProduct	85	87	4	4790,81736	NF - kappaB|NF - kappaB|NF - kappaB|NF - kappaB	GeneOrGeneProduct	104:134:146:208	107:137:149:211	4:5:6:8	1:NR:2	L2R	CROSS	85-87	125-128	84351,9641	IkappaB kinase	GeneOrGeneProduct	85	87	4	24770,6347	MCP - 1	GeneOrGeneProduct	125	128	5	1:NR:2	L2R	CROSS	85-87	129-130	84351,9641	IkappaB kinase	GeneOrGeneProduct	85	87	4	6352,81780	RANTES	GeneOrGeneProduct	129	130	5	1:NR:2	L2R	CROSS	85-87	131-132	84351,9641	IkappaB kinase	GeneOrGeneProduct	85	87	4	4318,81687	MMP9	GeneOrGeneProduct	131	132	5	1:NR:2	L2R	CROSS	85-87	150-151	84351,9641	IkappaB kinase	GeneOrGeneProduct	85	87	4	D064420	cytotoxic	DiseaseOrPhenotypicFeature	150	151	6	1:NR:2	L2R	CROSS	85-87	163-165	84351,9641	IkappaB kinase	GeneOrGeneProduct	85	87	4	25402,836	caspase 3	GeneOrGeneProduct	163	165	6	1:NR:2	L2R	CROSS	85-87	166-167	84351,9641	IkappaB kinase	GeneOrGeneProduct	85	87	4	142,25591	PARP	GeneOrGeneProduct	166	167	6	1:NR:2	L2R	CROSS	85-87	169-171	84351,9641	IkappaB kinase	GeneOrGeneProduct	85	87	4	25673,308	Annexin V	GeneOrGeneProduct	169	171	6	1:NR:2	L2R	CROSS	85-87	197-199	84351,9641	IkappaB kinase	GeneOrGeneProduct	85	87	4	116554,116590,207,24185,5594,5599	MAP kinases	GeneOrGeneProduct	197	199	8	1:NR:2	L2R	CROSS	85-87	220-221	84351,9641	IkappaB kinase	GeneOrGeneProduct	85	87	4	6351	CCl4	GeneOrGeneProduct	220	221	9	1:NR:2	L2R	CROSS	85-87	231-232	84351,9641	IkappaB kinase	GeneOrGeneProduct	85	87	4	20208	SAA1	GeneOrGeneProduct	231	232	9	1:NR:2	L2R	CROSS	85-87	233-234	84351,9641	IkappaB kinase	GeneOrGeneProduct	85	87	4	20210	SAA3	GeneOrGeneProduct	233	234	9	1:NR:2	L2R	NON-CROSS	183-184	185-186	116554,5599	c - Jun N - terminal kinase|JNK|JNK|JNK	GeneOrGeneProduct	88:96:139:183	95:97:140:184	4:4:5:7	116590,5594	Erk|Erk	GeneOrGeneProduct	99:185	100:186	4:7	1:NR:2	L2R	NON-CROSS	183-184	187-188	116554,5599	c - Jun N - terminal kinase|JNK|JNK|JNK	GeneOrGeneProduct	88:96:139:183	95:97:140:184	4:4:5:7	207,24185	Akt|Akt	GeneOrGeneProduct	101:187	102:188	4:7	1:NR:2	L2R	NON-CROSS	134-137	139-140	116554,5599	c - Jun N - terminal kinase|JNK|JNK|JNK	GeneOrGeneProduct	88:96:139:183	95:97:140:184	4:4:5:7	4790,81736	NF - kappaB|NF - kappaB|NF - kappaB|NF - kappaB	GeneOrGeneProduct	104:134:146:208	107:137:149:211	4:5:6:8	1:NR:2	L2R	NON-CROSS	125-128	139-140	116554,5599	c - Jun N - terminal kinase|JNK|JNK|JNK	GeneOrGeneProduct	88:96:139:183	95:97:140:184	4:4:5:7	24770,6347	MCP - 1	GeneOrGeneProduct	125	128	5	1:NR:2	L2R	NON-CROSS	129-130	139-140	116554,5599	c - Jun N - terminal kinase|JNK|JNK|JNK	GeneOrGeneProduct	88:96:139:183	95:97:140:184	4:4:5:7	6352,81780	RANTES	GeneOrGeneProduct	129	130	5	1:NR:2	L2R	NON-CROSS	131-132	139-140	116554,5599	c - Jun N - terminal kinase|JNK|JNK|JNK	GeneOrGeneProduct	88:96:139:183	95:97:140:184	4:4:5:7	4318,81687	MMP9	GeneOrGeneProduct	131	132	5	1:NR:2	L2R	CROSS	139-140	150-151	116554,5599	c - Jun N - terminal kinase|JNK|JNK|JNK	GeneOrGeneProduct	88:96:139:183	95:97:140:184	4:4:5:7	D064420	cytotoxic	DiseaseOrPhenotypicFeature	150	151	6	1:NR:2	L2R	CROSS	163-165	183-184	116554,5599	c - Jun N - terminal kinase|JNK|JNK|JNK	GeneOrGeneProduct	88:96:139:183	95:97:140:184	4:4:5:7	25402,836	caspase 3	GeneOrGeneProduct	163	165	6	1:NR:2	L2R	CROSS	166-167	183-184	116554,5599	c - Jun N - terminal kinase|JNK|JNK|JNK	GeneOrGeneProduct	88:96:139:183	95:97:140:184	4:4:5:7	142,25591	PARP	GeneOrGeneProduct	166	167	6	1:NR:2	L2R	CROSS	169-171	183-184	116554,5599	c - Jun N - terminal kinase|JNK|JNK|JNK	GeneOrGeneProduct	88:96:139:183	95:97:140:184	4:4:5:7	25673,308	Annexin V	GeneOrGeneProduct	169	171	6	1:NR:2	L2R	CROSS	183-184	197-199	116554,5599	c - Jun N - terminal kinase|JNK|JNK|JNK	GeneOrGeneProduct	88:96:139:183	95:97:140:184	4:4:5:7	116554,116590,207,24185,5594,5599	MAP kinases	GeneOrGeneProduct	197	199	8	1:NR:2	L2R	CROSS	183-184	220-221	116554,5599	c - Jun N - terminal kinase|JNK|JNK|JNK	GeneOrGeneProduct	88:96:139:183	95:97:140:184	4:4:5:7	6351	CCl4	GeneOrGeneProduct	220	221	9	1:NR:2	L2R	CROSS	183-184	231-232	116554,5599	c - Jun N - terminal kinase|JNK|JNK|JNK	GeneOrGeneProduct	88:96:139:183	95:97:140:184	4:4:5:7	20208	SAA1	GeneOrGeneProduct	231	232	9	1:NR:2	L2R	CROSS	183-184	233-234	116554,5599	c - Jun N - terminal kinase|JNK|JNK|JNK	GeneOrGeneProduct	88:96:139:183	95:97:140:184	4:4:5:7	20210	SAA3	GeneOrGeneProduct	233	234	9	1:NR:2	L2R	NON-CROSS	99-100	101-102	116590,5594	Erk|Erk	GeneOrGeneProduct	99:185	100:186	4:7	207,24185	Akt|Akt	GeneOrGeneProduct	101:187	102:188	4:7	1:NR:2	L2R	NON-CROSS	99-100	104-107	116590,5594	Erk|Erk	GeneOrGeneProduct	99:185	100:186	4:7	4790,81736	NF - kappaB|NF - kappaB|NF - kappaB|NF - kappaB	GeneOrGeneProduct	104:134:146:208	107:137:149:211	4:5:6:8	1:NR:2	L2R	CROSS	99-100	125-128	116590,5594	Erk|Erk	GeneOrGeneProduct	99:185	100:186	4:7	24770,6347	MCP - 1	GeneOrGeneProduct	125	128	5	1:NR:2	L2R	CROSS	99-100	129-130	116590,5594	Erk|Erk	GeneOrGeneProduct	99:185	100:186	4:7	6352,81780	RANTES	GeneOrGeneProduct	129	130	5	1:NR:2	L2R	CROSS	99-100	131-132	116590,5594	Erk|Erk	GeneOrGeneProduct	99:185	100:186	4:7	4318,81687	MMP9	GeneOrGeneProduct	131	132	5	1:NR:2	L2R	CROSS	150-151	185-186	116590,5594	Erk|Erk	GeneOrGeneProduct	99:185	100:186	4:7	D064420	cytotoxic	DiseaseOrPhenotypicFeature	150	151	6	1:NR:2	L2R	CROSS	163-165	185-186	116590,5594	Erk|Erk	GeneOrGeneProduct	99:185	100:186	4:7	25402,836	caspase 3	GeneOrGeneProduct	163	165	6	1:NR:2	L2R	CROSS	166-167	185-186	116590,5594	Erk|Erk	GeneOrGeneProduct	99:185	100:186	4:7	142,25591	PARP	GeneOrGeneProduct	166	167	6	1:NR:2	L2R	CROSS	169-171	185-186	116590,5594	Erk|Erk	GeneOrGeneProduct	99:185	100:186	4:7	25673,308	Annexin V	GeneOrGeneProduct	169	171	6	1:NR:2	L2R	CROSS	185-186	197-199	116590,5594	Erk|Erk	GeneOrGeneProduct	99:185	100:186	4:7	116554,116590,207,24185,5594,5599	MAP kinases	GeneOrGeneProduct	197	199	8	1:NR:2	L2R	CROSS	185-186	220-221	116590,5594	Erk|Erk	GeneOrGeneProduct	99:185	100:186	4:7	6351	CCl4	GeneOrGeneProduct	220	221	9	1:NR:2	L2R	CROSS	185-186	231-232	116590,5594	Erk|Erk	GeneOrGeneProduct	99:185	100:186	4:7	20208	SAA1	GeneOrGeneProduct	231	232	9	1:NR:2	L2R	CROSS	185-186	233-234	116590,5594	Erk|Erk	GeneOrGeneProduct	99:185	100:186	4:7	20210	SAA3	GeneOrGeneProduct	233	234	9	1:NR:2	L2R	NON-CROSS	101-102	104-107	207,24185	Akt|Akt	GeneOrGeneProduct	101:187	102:188	4:7	4790,81736	NF - kappaB|NF - kappaB|NF - kappaB|NF - kappaB	GeneOrGeneProduct	104:134:146:208	107:137:149:211	4:5:6:8	1:NR:2	L2R	CROSS	101-102	125-128	207,24185	Akt|Akt	GeneOrGeneProduct	101:187	102:188	4:7	24770,6347	MCP - 1	GeneOrGeneProduct	125	128	5	1:NR:2	L2R	CROSS	101-102	129-130	207,24185	Akt|Akt	GeneOrGeneProduct	101:187	102:188	4:7	6352,81780	RANTES	GeneOrGeneProduct	129	130	5	1:NR:2	L2R	CROSS	101-102	131-132	207,24185	Akt|Akt	GeneOrGeneProduct	101:187	102:188	4:7	4318,81687	MMP9	GeneOrGeneProduct	131	132	5	1:NR:2	L2R	CROSS	150-151	187-188	207,24185	Akt|Akt	GeneOrGeneProduct	101:187	102:188	4:7	D064420	cytotoxic	DiseaseOrPhenotypicFeature	150	151	6	1:NR:2	L2R	CROSS	163-165	187-188	207,24185	Akt|Akt	GeneOrGeneProduct	101:187	102:188	4:7	25402,836	caspase 3	GeneOrGeneProduct	163	165	6	1:NR:2	L2R	CROSS	166-167	187-188	207,24185	Akt|Akt	GeneOrGeneProduct	101:187	102:188	4:7	142,25591	PARP	GeneOrGeneProduct	166	167	6	1:NR:2	L2R	CROSS	169-171	187-188	207,24185	Akt|Akt	GeneOrGeneProduct	101:187	102:188	4:7	25673,308	Annexin V	GeneOrGeneProduct	169	171	6	1:NR:2	L2R	CROSS	187-188	197-199	207,24185	Akt|Akt	GeneOrGeneProduct	101:187	102:188	4:7	116554,116590,207,24185,5594,5599	MAP kinases	GeneOrGeneProduct	197	199	8	1:NR:2	L2R	CROSS	187-188	220-221	207,24185	Akt|Akt	GeneOrGeneProduct	101:187	102:188	4:7	6351	CCl4	GeneOrGeneProduct	220	221	9	1:NR:2	L2R	CROSS	187-188	231-232	207,24185	Akt|Akt	GeneOrGeneProduct	101:187	102:188	4:7	20208	SAA1	GeneOrGeneProduct	231	232	9	1:NR:2	L2R	CROSS	187-188	233-234	207,24185	Akt|Akt	GeneOrGeneProduct	101:187	102:188	4:7	20210	SAA3	GeneOrGeneProduct	233	234	9	1:NR:2	L2R	NON-CROSS	125-128	134-137	4790,81736	NF - kappaB|NF - kappaB|NF - kappaB|NF - kappaB	GeneOrGeneProduct	104:134:146:208	107:137:149:211	4:5:6:8	24770,6347	MCP - 1	GeneOrGeneProduct	125	128	5	1:NR:2	L2R	NON-CROSS	129-130	134-137	4790,81736	NF - kappaB|NF - kappaB|NF - kappaB|NF - kappaB	GeneOrGeneProduct	104:134:146:208	107:137:149:211	4:5:6:8	6352,81780	RANTES	GeneOrGeneProduct	129	130	5	1:NR:2	L2R	NON-CROSS	131-132	134-137	4790,81736	NF - kappaB|NF - kappaB|NF - kappaB|NF - kappaB	GeneOrGeneProduct	104:134:146:208	107:137:149:211	4:5:6:8	4318,81687	MMP9	GeneOrGeneProduct	131	132	5	1:NR:2	L2R	NON-CROSS	146-149	150-151	4790,81736	NF - kappaB|NF - kappaB|NF - kappaB|NF - kappaB	GeneOrGeneProduct	104:134:146:208	107:137:149:211	4:5:6:8	D064420	cytotoxic	DiseaseOrPhenotypicFeature	150	151	6	1:NR:2	L2R	NON-CROSS	146-149	163-165	4790,81736	NF - kappaB|NF - kappaB|NF - kappaB|NF - kappaB	GeneOrGeneProduct	104:134:146:208	107:137:149:211	4:5:6:8	25402,836	caspase 3	GeneOrGeneProduct	163	165	6	1:NR:2	L2R	NON-CROSS	146-149	166-167	4790,81736	NF - kappaB|NF - kappaB|NF - kappaB|NF - kappaB	GeneOrGeneProduct	104:134:146:208	107:137:149:211	4:5:6:8	142,25591	PARP	GeneOrGeneProduct	166	167	6	1:NR:2	L2R	NON-CROSS	146-149	169-171	4790,81736	NF - kappaB|NF - kappaB|NF - kappaB|NF - kappaB	GeneOrGeneProduct	104:134:146:208	107:137:149:211	4:5:6:8	25673,308	Annexin V	GeneOrGeneProduct	169	171	6	1:NR:2	L2R	NON-CROSS	197-199	208-211	4790,81736	NF - kappaB|NF - kappaB|NF - kappaB|NF - kappaB	GeneOrGeneProduct	104:134:146:208	107:137:149:211	4:5:6:8	116554,116590,207,24185,5594,5599	MAP kinases	GeneOrGeneProduct	197	199	8	1:NR:2	L2R	CROSS	208-211	220-221	4790,81736	NF - kappaB|NF - kappaB|NF - kappaB|NF - kappaB	GeneOrGeneProduct	104:134:146:208	107:137:149:211	4:5:6:8	6351	CCl4	GeneOrGeneProduct	220	221	9	1:NR:2	L2R	CROSS	208-211	231-232	4790,81736	NF - kappaB|NF - kappaB|NF - kappaB|NF - kappaB	GeneOrGeneProduct	104:134:146:208	107:137:149:211	4:5:6:8	20208	SAA1	GeneOrGeneProduct	231	232	9	1:NR:2	L2R	CROSS	208-211	233-234	4790,81736	NF - kappaB|NF - kappaB|NF - kappaB|NF - kappaB	GeneOrGeneProduct	104:134:146:208	107:137:149:211	4:5:6:8	20210	SAA3	GeneOrGeneProduct	233	234	9	1:NR:2	L2R	NON-CROSS	125-128	129-130	24770,6347	MCP - 1	GeneOrGeneProduct	125	128	5	6352,81780	RANTES	GeneOrGeneProduct	129	130	5	1:NR:2	L2R	NON-CROSS	125-128	131-132	24770,6347	MCP - 1	GeneOrGeneProduct	125	128	5	4318,81687	MMP9	GeneOrGeneProduct	131	132	5	1:NR:2	L2R	CROSS	125-128	150-151	24770,6347	MCP - 1	GeneOrGeneProduct	125	128	5	D064420	cytotoxic	DiseaseOrPhenotypicFeature	150	151	6	1:NR:2	L2R	CROSS	125-128	163-165	24770,6347	MCP - 1	GeneOrGeneProduct	125	128	5	25402,836	caspase 3	GeneOrGeneProduct	163	165	6	1:NR:2	L2R	CROSS	125-128	166-167	24770,6347	MCP - 1	GeneOrGeneProduct	125	128	5	142,25591	PARP	GeneOrGeneProduct	166	167	6	1:NR:2	L2R	CROSS	125-128	169-171	24770,6347	MCP - 1	GeneOrGeneProduct	125	128	5	25673,308	Annexin V	GeneOrGeneProduct	169	171	6	1:NR:2	L2R	CROSS	125-128	197-199	24770,6347	MCP - 1	GeneOrGeneProduct	125	128	5	116554,116590,207,24185,5594,5599	MAP kinases	GeneOrGeneProduct	197	199	8	1:NR:2	L2R	CROSS	125-128	220-221	24770,6347	MCP - 1	GeneOrGeneProduct	125	128	5	6351	CCl4	GeneOrGeneProduct	220	221	9	1:NR:2	L2R	CROSS	125-128	231-232	24770,6347	MCP - 1	GeneOrGeneProduct	125	128	5	20208	SAA1	GeneOrGeneProduct	231	232	9	1:NR:2	L2R	CROSS	125-128	233-234	24770,6347	MCP - 1	GeneOrGeneProduct	125	128	5	20210	SAA3	GeneOrGeneProduct	233	234	9	1:NR:2	L2R	NON-CROSS	129-130	131-132	6352,81780	RANTES	GeneOrGeneProduct	129	130	5	4318,81687	MMP9	GeneOrGeneProduct	131	132	5	1:NR:2	L2R	CROSS	129-130	150-151	6352,81780	RANTES	GeneOrGeneProduct	129	130	5	D064420	cytotoxic	DiseaseOrPhenotypicFeature	150	151	6	1:NR:2	L2R	CROSS	129-130	163-165	6352,81780	RANTES	GeneOrGeneProduct	129	130	5	25402,836	caspase 3	GeneOrGeneProduct	163	165	6	1:NR:2	L2R	CROSS	129-130	166-167	6352,81780	RANTES	GeneOrGeneProduct	129	130	5	142,25591	PARP	GeneOrGeneProduct	166	167	6	1:NR:2	L2R	CROSS	129-130	169-171	6352,81780	RANTES	GeneOrGeneProduct	129	130	5	25673,308	Annexin V	GeneOrGeneProduct	169	171	6	1:NR:2	L2R	CROSS	129-130	197-199	6352,81780	RANTES	GeneOrGeneProduct	129	130	5	116554,116590,207,24185,5594,5599	MAP kinases	GeneOrGeneProduct	197	199	8	1:NR:2	L2R	CROSS	129-130	220-221	6352,81780	RANTES	GeneOrGeneProduct	129	130	5	6351	CCl4	GeneOrGeneProduct	220	221	9	1:NR:2	L2R	CROSS	129-130	231-232	6352,81780	RANTES	GeneOrGeneProduct	129	130	5	20208	SAA1	GeneOrGeneProduct	231	232	9	1:NR:2	L2R	CROSS	129-130	233-234	6352,81780	RANTES	GeneOrGeneProduct	129	130	5	20210	SAA3	GeneOrGeneProduct	233	234	9	1:NR:2	L2R	CROSS	131-132	150-151	4318,81687	MMP9	GeneOrGeneProduct	131	132	5	D064420	cytotoxic	DiseaseOrPhenotypicFeature	150	151	6	1:NR:2	L2R	CROSS	131-132	163-165	4318,81687	MMP9	GeneOrGeneProduct	131	132	5	25402,836	caspase 3	GeneOrGeneProduct	163	165	6	1:NR:2	L2R	CROSS	131-132	166-167	4318,81687	MMP9	GeneOrGeneProduct	131	132	5	142,25591	PARP	GeneOrGeneProduct	166	167	6	1:NR:2	L2R	CROSS	131-132	169-171	4318,81687	MMP9	GeneOrGeneProduct	131	132	5	25673,308	Annexin V	GeneOrGeneProduct	169	171	6	1:NR:2	L2R	CROSS	131-132	197-199	4318,81687	MMP9	GeneOrGeneProduct	131	132	5	116554,116590,207,24185,5594,5599	MAP kinases	GeneOrGeneProduct	197	199	8	1:NR:2	L2R	CROSS	131-132	220-221	4318,81687	MMP9	GeneOrGeneProduct	131	132	5	6351	CCl4	GeneOrGeneProduct	220	221	9	1:NR:2	L2R	CROSS	131-132	231-232	4318,81687	MMP9	GeneOrGeneProduct	131	132	5	20208	SAA1	GeneOrGeneProduct	231	232	9	1:NR:2	L2R	CROSS	131-132	233-234	4318,81687	MMP9	GeneOrGeneProduct	131	132	5	20210	SAA3	GeneOrGeneProduct	233	234	9	1:NR:2	L2R	NON-CROSS	150-151	163-165	D064420	cytotoxic	DiseaseOrPhenotypicFeature	150	151	6	25402,836	caspase 3	GeneOrGeneProduct	163	165	6	1:NR:2	L2R	NON-CROSS	150-151	166-167	D064420	cytotoxic	DiseaseOrPhenotypicFeature	150	151	6	142,25591	PARP	GeneOrGeneProduct	166	167	6	1:NR:2	L2R	NON-CROSS	150-151	169-171	D064420	cytotoxic	DiseaseOrPhenotypicFeature	150	151	6	25673,308	Annexin V	GeneOrGeneProduct	169	171	6	1:NR:2	L2R	CROSS	150-151	197-199	D064420	cytotoxic	DiseaseOrPhenotypicFeature	150	151	6	116554,116590,207,24185,5594,5599	MAP kinases	GeneOrGeneProduct	197	199	8	1:NR:2	L2R	CROSS	150-151	220-221	D064420	cytotoxic	DiseaseOrPhenotypicFeature	150	151	6	6351	CCl4	GeneOrGeneProduct	220	221	9	1:NR:2	L2R	CROSS	150-151	231-232	D064420	cytotoxic	DiseaseOrPhenotypicFeature	150	151	6	20208	SAA1	GeneOrGeneProduct	231	232	9	1:NR:2	L2R	CROSS	150-151	233-234	D064420	cytotoxic	DiseaseOrPhenotypicFeature	150	151	6	20210	SAA3	GeneOrGeneProduct	233	234	9	1:NR:2	L2R	NON-CROSS	163-165	166-167	25402,836	caspase 3	GeneOrGeneProduct	163	165	6	142,25591	PARP	GeneOrGeneProduct	166	167	6	1:NR:2	L2R	NON-CROSS	163-165	169-171	25402,836	caspase 3	GeneOrGeneProduct	163	165	6	25673,308	Annexin V	GeneOrGeneProduct	169	171	6	1:NR:2	L2R	CROSS	163-165	197-199	25402,836	caspase 3	GeneOrGeneProduct	163	165	6	116554,116590,207,24185,5594,5599	MAP kinases	GeneOrGeneProduct	197	199	8	1:NR:2	L2R	CROSS	163-165	220-221	25402,836	caspase 3	GeneOrGeneProduct	163	165	6	6351	CCl4	GeneOrGeneProduct	220	221	9	1:NR:2	L2R	CROSS	163-165	231-232	25402,836	caspase 3	GeneOrGeneProduct	163	165	6	20208	SAA1	GeneOrGeneProduct	231	232	9	1:NR:2	L2R	CROSS	163-165	233-234	25402,836	caspase 3	GeneOrGeneProduct	163	165	6	20210	SAA3	GeneOrGeneProduct	233	234	9	1:NR:2	L2R	NON-CROSS	166-167	169-171	142,25591	PARP	GeneOrGeneProduct	166	167	6	25673,308	Annexin V	GeneOrGeneProduct	169	171	6	1:NR:2	L2R	CROSS	166-167	197-199	142,25591	PARP	GeneOrGeneProduct	166	167	6	116554,116590,207,24185,5594,5599	MAP kinases	GeneOrGeneProduct	197	199	8	1:NR:2	L2R	CROSS	166-167	220-221	142,25591	PARP	GeneOrGeneProduct	166	167	6	6351	CCl4	GeneOrGeneProduct	220	221	9	1:NR:2	L2R	CROSS	166-167	231-232	142,25591	PARP	GeneOrGeneProduct	166	167	6	20208	SAA1	GeneOrGeneProduct	231	232	9	1:NR:2	L2R	CROSS	166-167	233-234	142,25591	PARP	GeneOrGeneProduct	166	167	6	20210	SAA3	GeneOrGeneProduct	233	234	9	1:NR:2	L2R	CROSS	169-171	197-199	25673,308	Annexin V	GeneOrGeneProduct	169	171	6	116554,116590,207,24185,5594,5599	MAP kinases	GeneOrGeneProduct	197	199	8	1:NR:2	L2R	CROSS	169-171	220-221	25673,308	Annexin V	GeneOrGeneProduct	169	171	6	6351	CCl4	GeneOrGeneProduct	220	221	9	1:NR:2	L2R	CROSS	169-171	231-232	25673,308	Annexin V	GeneOrGeneProduct	169	171	6	20208	SAA1	GeneOrGeneProduct	231	232	9	1:NR:2	L2R	CROSS	169-171	233-234	25673,308	Annexin V	GeneOrGeneProduct	169	171	6	20210	SAA3	GeneOrGeneProduct	233	234	9	1:NR:2	L2R	CROSS	197-199	220-221	116554,116590,207,24185,5594,5599	MAP kinases	GeneOrGeneProduct	197	199	8	6351	CCl4	GeneOrGeneProduct	220	221	9	1:NR:2	L2R	CROSS	197-199	231-232	116554,116590,207,24185,5594,5599	MAP kinases	GeneOrGeneProduct	197	199	8	20208	SAA1	GeneOrGeneProduct	231	232	9	1:NR:2	L2R	CROSS	197-199	233-234	116554,116590,207,24185,5594,5599	MAP kinases	GeneOrGeneProduct	197	199	8	20210	SAA3	GeneOrGeneProduct	233	234	9	1:Positive_Correlation:2	L2R	NON-CROSS	220-221	231-232	6351	CCl4	GeneOrGeneProduct	220	221	9	20208	SAA1	GeneOrGeneProduct	231	232	9	1:Positive_Correlation:2	L2R	NON-CROSS	220-221	233-234	6351	CCl4	GeneOrGeneProduct	220	221	9	20210	SAA3	GeneOrGeneProduct	233	234	9	1:NR:2	L2R	NON-CROSS	231-232	233-234	20208	SAA1	GeneOrGeneProduct	231	232	9	20210	SAA3	GeneOrGeneProduct	233	234	9
15464247	Influence of interleukin 12B ( IL12B ) polymorphisms on spontaneous and treatment - induced recovery from hepatitis C virus infection .|BACKGROUND / AIMS : Interleukin - 12 ( IL - 12 ) governs the Th1 - type immune response , affecting the spontaneous and treatment - induced recovery from HCV - infection .|We investigated whether the IL12B polymorphisms within the promoter region ( 4 bp insertion / deletion ) and the 3 ' - UTR ( 1188 - A / C ) , which have been reported to influence IL - 12 synthesis , are associated with the outcome of HCV infection .|METHODS : We analyzed 186 individuals with spontaneous HCV clearance , 501 chronically HCV infected patients , and 217 healthy controls .|IL12B 3 ' - UTR and promoter genotyping was performed by Taqman - based assays with allele - specific oligonucleotide probes and PCR - based allele - specific DNA - amplification , respectively .|RESULTS : The proportion of IL12B promoter and 3 ' - UTR genotypes did not differ significantly between the different cohorts .|However , HCV genotype 1 - infected patients with high baseline viremia carrying the IL12B 3 ' - UTR 1188 - C - allele showed significantly higher sustained virologic response ( SVR ) rates ( 25 . 3 % vs . 46 % vs . 54 . 5 % for A / A , A / C and C / C ) due to reduced relapse rates ( 24 . 2 % vs . 12 % vs . zero % for A / A , A / C and C / C ) .|CONCLUSIONS : IL12B 3 ' - UTR 1188 - C - allele carriers appear to be capable of responding more efficiently to antiviral combination therapy as a consequence of a reduced relapse rate .|No association of IL12B polymorphisms and self - limited HCV infection could be demonstrated .	1:NR:2	L2R	NON-CROSS	314-315	320-322	3593	interleukin 12B|IL12B|Interleukin - 12|IL - 12|IL12B|IL - 12|IL12B|IL12B|IL12B|IL12B|IL12B	GeneOrGeneProduct	2:5:25:29:58:91:127:166:197:279:314	4:6:28:32:59:94:128:167:198:280:315	0:0:1:1:2:2:4:5:6:7:8	D006526	hepatitis C virus infection|HCV - infection|HCV infection|HCV infected|HCV genotype 1 - infected|HCV infection	DiseaseOrPhenotypicFeature	16:50:102:118:185:320	20:53:104:120:190:322	0:1:2:3:6:8	1:NR:2	L2R	NON-CROSS	127-128	146-147	3593	interleukin 12B|IL12B|Interleukin - 12|IL - 12|IL12B|IL - 12|IL12B|IL12B|IL12B|IL12B|IL12B	GeneOrGeneProduct	2:5:25:29:58:91:127:166:197:279:314	4:6:28:32:59:94:128:167:198:280:315	0:0:1:1:2:2:4:5:6:7:8	D009841	oligonucleotide	ChemicalEntity	146	147	4	1:Association:2	R2L	NON-CROSS	197-198	194-195	D014766	viremia	DiseaseOrPhenotypicFeature	194	195	6	3593	interleukin 12B|IL12B|Interleukin - 12|IL - 12|IL12B|IL - 12|IL12B|IL12B|IL12B|IL12B|IL12B	GeneOrGeneProduct	2:5:25:29:58:91:127:166:197:279:314	4:6:28:32:59:94:128:167:198:280:315	0:0:1:1:2:2:4:5:6:7:8	1:NR:2	L2R	NON-CROSS	50-53	65-70	D006526	hepatitis C virus infection|HCV - infection|HCV infection|HCV infected|HCV genotype 1 - infected|HCV infection	DiseaseOrPhenotypicFeature	16:50:102:118:185:320	20:53:104:120:190:322	0:1:2:3:6:8	c|INDEL||4	4 bp insertion / deletion	SequenceVariant	65	70	2	1:NR:2	L2R	NON-CROSS	78-83	102-104	D006526	hepatitis C virus infection|HCV - infection|HCV infection|HCV infected|HCV genotype 1 - infected|HCV infection	DiseaseOrPhenotypicFeature	16:50:102:118:185:320	20:53:104:120:190:322	0:1:2:3:6:8	c|SUB|A|1188|C	1188 - A / C	SequenceVariant	78	83	2	1:NR:2	L2R	CROSS	118-120	146-147	D006526	hepatitis C virus infection|HCV - infection|HCV infection|HCV infected|HCV genotype 1 - infected|HCV infection	DiseaseOrPhenotypicFeature	16:50:102:118:185:320	20:53:104:120:190:322	0:1:2:3:6:8	D009841	oligonucleotide	ChemicalEntity	146	147	4	1:NR:2	L2R	NON-CROSS	185-190	202-205	D006526	hepatitis C virus infection|HCV - infection|HCV infection|HCV infected|HCV genotype 1 - infected|HCV infection	DiseaseOrPhenotypicFeature	16:50:102:118:185:320	20:53:104:120:190:322	0:1:2:3:6:8	c|Allele|C|1188	1188 - C|1188 - C	SequenceVariant	202:284	205:287	6:7	1:NR:2	L2R	CROSS	65-70	146-147	c|INDEL||4	4 bp insertion / deletion	SequenceVariant	65	70	2	D009841	oligonucleotide	ChemicalEntity	146	147	4	1:NR:2	L2R	CROSS	65-70	194-195	c|INDEL||4	4 bp insertion / deletion	SequenceVariant	65	70	2	D014766	viremia	DiseaseOrPhenotypicFeature	194	195	6	1:NR:2	L2R	CROSS	78-83	146-147	c|SUB|A|1188|C	1188 - A / C	SequenceVariant	78	83	2	D009841	oligonucleotide	ChemicalEntity	146	147	4	1:NR:2	L2R	CROSS	78-83	194-195	c|SUB|A|1188|C	1188 - A / C	SequenceVariant	78	83	2	D014766	viremia	DiseaseOrPhenotypicFeature	194	195	6	1:NR:2	L2R	CROSS	146-147	194-195	D009841	oligonucleotide	ChemicalEntity	146	147	4	D014766	viremia	DiseaseOrPhenotypicFeature	194	195	6	1:NR:2	L2R	CROSS	146-147	202-205	D009841	oligonucleotide	ChemicalEntity	146	147	4	c|Allele|C|1188	1188 - C|1188 - C	SequenceVariant	202:284	205:287	6:7	1:Association:2	L2R	NON-CROSS	194-195	202-205	D014766	viremia	DiseaseOrPhenotypicFeature	194	195	6	c|Allele|C|1188	1188 - C|1188 - C	SequenceVariant	202:284	205:287	6:7
15824163	No Evidence for BRAF as a melanoma / nevus susceptibility gene .|Somatic mutations of BRAF have been identified in both melanoma tumors and benign nevi .|Germ line mutations in BRAF have not been identified as causal in families predisposed to melanoma .|However , a recent study suggested that a BRAF haplotype was associated with risk of sporadic melanoma in men .|Polymorphisms or other variants in the BRAF gene may therefore act as candidate low - penetrance genes for nevus / melanoma susceptibility .|We hypothesized that promoter variants would be the most likely candidates for determinants of risk .|Using denaturing high - pressure liquid chromatography and sequencing , we screened peripheral blood DNA from 184 familial melanoma cases for BRAF promoter variants .|We identified a promoter insertion / deletion in linkage disequilibrium with the previously described BRAF polymorphism in intron 11 ( rs1639679 ) reported to be associated with melanoma susceptibility in males .|We therefore investigated the contribution of this BRAF polymorphism to melanoma susceptibility in 581 consecutively recruited incident cases , 258 incident cases in a study of late relapse , 673 female general practitioner controls , and the 184 familial cases .|We found no statistically significant difference in either genotype or allele frequencies between cases and controls overall or between male and female cases for the BRAF polymorphism in the two incident case series .|Our results therefore suggest that the BRAF polymorphism is not significantly associated with melanoma and the promoter insertion / deletion linked with the polymorphism is not a causal variant .|In addition , we found that there was no association between the BRAF genotype and mean total number of banal or atypical nevi in either the cases or controls .	1:Association:2	R2L	NON-CROSS	6-7	3-4	D008545	melanoma|melanoma tumors|melanoma|sporadic melanoma|melanoma|familial melanoma|melanoma|melanoma|melanoma	DiseaseOrPhenotypicFeature	6:21:42:59:84:120:155:170:248	7:23:43:61:85:122:156:171:249	0:1:2:3:4:6:7:8:10	673	BRAF|BRAF|BRAF|BRAF|BRAF|BRAF|BRAF|BRAF|BRAF|BRAF|BRAF	GeneOrGeneProduct	3:15:31:52:70:124:142:167:226:241:277	4:16:32:53:71:125:143:168:227:242:278	0:1:2:3:4:6:7:8:9:10:11	1:NR:2	L2R	NON-CROSS	3-4	8-9	673	BRAF|BRAF|BRAF|BRAF|BRAF|BRAF|BRAF|BRAF|BRAF|BRAF|BRAF	GeneOrGeneProduct	3:15:31:52:70:124:142:167:226:241:277	4:16:32:53:71:125:143:168:227:242:278	0:1:2:3:4:6:7:8:9:10:11	D009506	nevus|nevi|nevus|nevi	DiseaseOrPhenotypicFeature	8:25:82:287	9:26:83:288	0:1:4:11	1:NR:2	L2R	NON-CROSS	148-149	155-156	D008545	melanoma|melanoma tumors|melanoma|sporadic melanoma|melanoma|familial melanoma|melanoma|melanoma|melanoma	DiseaseOrPhenotypicFeature	6:21:42:59:84:120:155:170:248	7:23:43:61:85:122:156:171:249	0:1:2:3:4:6:7:8:10	rs1639679	rs1639679	SequenceVariant	148	149	7	1:NR:2	L2R	CROSS	82-83	148-149	D009506	nevus|nevi|nevus|nevi	DiseaseOrPhenotypicFeature	8:25:82:287	9:26:83:288	0:1:4:11	rs1639679	rs1639679	SequenceVariant	148	149	7
26900322	CFI - rs7356506 polymorphisms associated with Vogt - Koyanagi - Harada syndrome .|PURPOSE : Complement factor I ( CFI ) plays an important role in complement activation pathways and is known to affect the development of uveitis .|The present study was performed to investigate the existence of an association between CFI genetic polymorphisms and Vogt - Koyanagi - Harada ( VKH ) syndrome .|METHODS : A total of 100 patients diagnosed with VKH syndrome and 300 healthy controls were recruited for the study .|Two milliliters of peripheral blood were collected in a sterile anticoagulative tube .|CFI - rs7356506 polymorphisms were genotyped using Sequenom MassARRAY technology .|Allele and genotype frequencies were compared between patients and controls using a X ( 2 ) test .|The analyses were stratified for recurrent status , complicated cataract status , and steroid - sensitive status .|RESULTS : No significant association was found between CFI - rs7356506 polymorphisms and VKH syndrome .|However , patients with recurrent VKH syndrome had lower frequencies of the G allele and GG homozygosity in CFI - rs7356506 when compared to the controls ( p = 0 . 016 , odds ratio [ OR ] = 0 . 429 , 95 % confidence interval [ CI ] = 0 . 212 - 0 . 871 ; p = 0 . 014 , OR = 0 . 364 , 95 % CI = 0 . 158 - 0 . 837 , respectively ) .|Furthermore , there were significant decreases in the frequencies of the G allele and GG homozygosity in CFI - rs7356506 in patients with VKH syndrome with complicated cataract compared to the controls ( p < 0 . 001 , OR = 0 . 357 , 95 % CI = 0 . 197 - 0 . 648 ; p < 0 . 001 , OR = 0 . 273 , 95 % CI = 0 . 135 - 0 . 551 , respectively ) .|Nevertheless , no significant association with patients with VKH syndrome in steroid - sensitive statuses was detected for CFI - rs7356506 polymorphisms .|CONCLUSIONS : Our results indicate that CFI polymorphisms are not significantly associated with VKH syndrome ; nevertheless , we identified a trend for the association of CFI - 7356506 with VKH syndrome that depends on the recurrent status and the complicated cataract status but not on the steroid - sensitive status .	1:Association:2	L2R	NON-CROSS	52-53	56-65	3426	CFI|Complement factor I|CFI|CFI|CFI|CFI|CFI|CFI|CFI|CFI|CFI	GeneOrGeneProduct	0:15:19:52:100:155:181:266:351:362:382	1:18:20:53:101:156:182:267:352:363:383	0:1:1:2:5:8:9:10:11:12:12	D014607	Vogt - Koyanagi - Harada syndrome|Vogt - Koyanagi - Harada ( VKH ) syndrome|VKH syndrome|VKH syndrome|VKH syndrome|VKH syndrome|VKH syndrome|VKH syndrome|VKH syndrome	DiseaseOrPhenotypicFeature	6:56:75:160:168:272:341:369:386	12:65:77:162:170:274:343:371:388	0:2:3:8:9:10:11:12:12	1:Association:2	L2R	NON-CROSS	37-38	52-53	3426	CFI|Complement factor I|CFI|CFI|CFI|CFI|CFI|CFI|CFI|CFI|CFI	GeneOrGeneProduct	0:15:19:52:100:155:181:266:351:362:382	1:18:20:53:101:156:182:267:352:363:383	0:1:1:2:5:8:9:10:11:12:12	D014605	uveitis	DiseaseOrPhenotypicFeature	37	38	1	1:Association:2	L2R	NON-CROSS	266-267	276-277	3426	CFI|Complement factor I|CFI|CFI|CFI|CFI|CFI|CFI|CFI|CFI|CFI	GeneOrGeneProduct	0:15:19:52:100:155:181:266:351:362:382	1:18:20:53:101:156:182:267:352:363:383	0:1:1:2:5:8:9:10:11:12:12	D002386	cataract|cataract|cataract	DiseaseOrPhenotypicFeature	138:276:397	139:277:398	7:10:12	1:NR:2	L2R	NON-CROSS	344-345	351-352	3426	CFI|Complement factor I|CFI|CFI|CFI|CFI|CFI|CFI|CFI|CFI|CFI	GeneOrGeneProduct	0:15:19:52:100:155:181:266:351:362:382	1:18:20:53:101:156:182:267:352:363:383	0:1:1:2:5:8:9:10:11:12:12	D013256	steroid|steroid|steroid	ChemicalEntity	142:344:403	143:345:404	7:11:12	1:Association:2	L2R	NON-CROSS	384-385	386-388	rs7356506	rs7356506|rs7356506|rs7356506|rs7356506|rs7356506|rs7356506|7356506	SequenceVariant	2:102:157:183:268:353:384	3:103:158:184:269:354:385	0:5:8:9:10:11:12	D014607	Vogt - Koyanagi - Harada syndrome|Vogt - Koyanagi - Harada ( VKH ) syndrome|VKH syndrome|VKH syndrome|VKH syndrome|VKH syndrome|VKH syndrome|VKH syndrome|VKH syndrome	DiseaseOrPhenotypicFeature	6:56:75:160:168:272:341:369:386	12:65:77:162:170:274:343:371:388	0:2:3:8:9:10:11:12:12	1:NR:2	L2R	CROSS	2-3	37-38	rs7356506	rs7356506|rs7356506|rs7356506|rs7356506|rs7356506|rs7356506|7356506	SequenceVariant	2:102:157:183:268:353:384	3:103:158:184:269:354:385	0:5:8:9:10:11:12	D014605	uveitis	DiseaseOrPhenotypicFeature	37	38	1	1:Association:2	L2R	NON-CROSS	268-269	276-277	rs7356506	rs7356506|rs7356506|rs7356506|rs7356506|rs7356506|rs7356506|7356506	SequenceVariant	2:102:157:183:268:353:384	3:103:158:184:269:354:385	0:5:8:9:10:11:12	D002386	cataract|cataract|cataract	DiseaseOrPhenotypicFeature	138:276:397	139:277:398	7:10:12	1:NR:2	L2R	NON-CROSS	344-345	353-354	rs7356506	rs7356506|rs7356506|rs7356506|rs7356506|rs7356506|rs7356506|7356506	SequenceVariant	2:102:157:183:268:353:384	3:103:158:184:269:354:385	0:5:8:9:10:11:12	D013256	steroid|steroid|steroid	ChemicalEntity	142:344:403	143:345:404	7:11:12	1:NR:2	L2R	NON-CROSS	341-343	344-345	D014607	Vogt - Koyanagi - Harada syndrome|Vogt - Koyanagi - Harada ( VKH ) syndrome|VKH syndrome|VKH syndrome|VKH syndrome|VKH syndrome|VKH syndrome|VKH syndrome|VKH syndrome	DiseaseOrPhenotypicFeature	6:56:75:160:168:272:341:369:386	12:65:77:162:170:274:343:371:388	0:2:3:8:9:10:11:12:12	D013256	steroid|steroid|steroid	ChemicalEntity	142:344:403	143:345:404	7:11:12	1:NR:2	L2R	CROSS	37-38	142-143	D014605	uveitis	DiseaseOrPhenotypicFeature	37	38	1	D013256	steroid|steroid|steroid	ChemicalEntity	142:344:403	143:345:404	7:11:12	1:NR:2	L2R	NON-CROSS	138-139	142-143	D002386	cataract|cataract|cataract	DiseaseOrPhenotypicFeature	138:276:397	139:277:398	7:10:12	D013256	steroid|steroid|steroid	ChemicalEntity	142:344:403	143:345:404	7:11:12
16840830	Two novel mutations in the MEN1 gene in subjects with multiple endocrine neoplasia - 1 .|Multiple endocrine neoplasia type 1 ( MEN1 ) is characterized by parathyroid , enteropancreatic endocrine and pituitary adenomas as well as germline mutation of the MEN1 gene .|We describe 2 families with MEN1 with novel mutations in the MEN1 gene .|One family was of Turkish origin , and the index patient had primary hyperparathyroidism ( PHPT ) plus a prolactinoma ; three relatives had PHPT only .|The index patient in the second family was a 46 - yr - old woman of Chinese origin living in Taiwan .|This patient presented with a complaint of epigastric pain and watery diarrhea over the past 3 months , and had undergone subtotal parathyroidectomy and enucleation of pancreatic islet cell tumor about 10 yr before .|There was also a prolactinoma .|Sequence analysis of the MEN1 gene from leukocyte genomic DNA revealed heterozygous mutations in both probands .|The Turkish patient and her affected relatives all had a heterozygous A to G transition at codon 557 ( AAG - - > GAG ) of exon 10 of MEN1 that results in a replacement of lysine by glutamic acid .|The Chinese index patient and one of her siblings had a heterozygous mutation at codon 418 of exon 9 ( GAC - - > TAT ) that results in a substitution of aspartic acid by tyrosine .|In conclusion , we have identified 2 novel missense mutations in the MEN1 gene .	1:Association:2	L2R	NON-CROSS	5-6	10-15	4221	MEN1|MEN1|MEN1|MEN1|MEN1|MEN1|MEN1	GeneOrGeneProduct	5:41:49:55:152:194:255	6:42:50:56:153:195:256	0:1:2:2:7:8:10	D018761	multiple endocrine neoplasia - 1|Multiple endocrine neoplasia type 1|MEN1	DiseaseOrPhenotypicFeature	10:16:22	15:21:23	0:1:1	1:NR:2	L2R	NON-CROSS	29-34	41-42	4221	MEN1|MEN1|MEN1|MEN1|MEN1|MEN1|MEN1	GeneOrGeneProduct	5:41:49:55:152:194:255	6:42:50:56:153:195:256	0:1:2:2:7:8:10	C535650,D010911	enteropancreatic endocrine and pituitary adenomas	DiseaseOrPhenotypicFeature	29	34	1	1:NR:2	L2R	CROSS	55-56	70-72	4221	MEN1|MEN1|MEN1|MEN1|MEN1|MEN1|MEN1	GeneOrGeneProduct	5:41:49:55:152:194:255	6:42:50:56:153:195:256	0:1:2:2:7:8:10	D049950	primary hyperparathyroidism|PHPT|PHPT	DiseaseOrPhenotypicFeature	70:73:82	72:74:83	3:3:3	1:NR:2	L2R	CROSS	146-147	152-153	4221	MEN1|MEN1|MEN1|MEN1|MEN1|MEN1|MEN1	GeneOrGeneProduct	5:41:49:55:152:194:255	6:42:50:56:153:195:256	0:1:2:2:7:8:10	D015175	prolactinoma|prolactinoma	DiseaseOrPhenotypicFeature	77:146	78:147	3:6	1:NR:2	L2R	CROSS	115-116	152-153	4221	MEN1|MEN1|MEN1|MEN1|MEN1|MEN1|MEN1	GeneOrGeneProduct	5:41:49:55:152:194:255	6:42:50:56:153:195:256	0:1:2:2:7:8:10	D010146	pain	DiseaseOrPhenotypicFeature	115	116	5	1:NR:2	L2R	CROSS	118-119	152-153	4221	MEN1|MEN1|MEN1|MEN1|MEN1|MEN1|MEN1	GeneOrGeneProduct	5:41:49:55:152:194:255	6:42:50:56:153:195:256	0:1:2:2:7:8:10	D003967	diarrhea	DiseaseOrPhenotypicFeature	118	119	5	1:NR:2	L2R	CROSS	133-137	152-153	4221	MEN1|MEN1|MEN1|MEN1|MEN1|MEN1|MEN1	GeneOrGeneProduct	5:41:49:55:152:194:255	6:42:50:56:153:195:256	0:1:2:2:7:8:10	D007516	pancreatic islet cell tumor	DiseaseOrPhenotypicFeature	133	137	5	1:Association:2	L2R	CROSS	22-23	176-190	D018761	multiple endocrine neoplasia - 1|Multiple endocrine neoplasia type 1|MEN1	DiseaseOrPhenotypicFeature	10:16:22	15:21:23	0:1:1	p|SUB|K|557|E	A to G transition at codon 557 ( AAG - - > GAG )	SequenceVariant	176	190	8	1:Association:2	L2R	CROSS	22-23	201-205	D018761	multiple endocrine neoplasia - 1|Multiple endocrine neoplasia type 1|MEN1	DiseaseOrPhenotypicFeature	10:16:22	15:21:23	0:1:1	p|SUB|K||E	lysine by glutamic acid	SequenceVariant	201	205	8	1:Association:2	L2R	CROSS	22-23	218-232	D018761	multiple endocrine neoplasia - 1|Multiple endocrine neoplasia type 1|MEN1	DiseaseOrPhenotypicFeature	10:16:22	15:21:23	0:1:1	p|SUB|D|418|Y	mutation at codon 418 of exon 9 ( GAC - - > TAT )	SequenceVariant	218	232	9	1:Association:2	L2R	CROSS	22-23	238-242	D018761	multiple endocrine neoplasia - 1|Multiple endocrine neoplasia type 1|MEN1	DiseaseOrPhenotypicFeature	10:16:22	15:21:23	0:1:1	p|SUB|D||Y	aspartic acid by tyrosine	SequenceVariant	238	242	9	1:NR:2	L2R	CROSS	29-34	176-190	C535650,D010911	enteropancreatic endocrine and pituitary adenomas	DiseaseOrPhenotypicFeature	29	34	1	p|SUB|K|557|E	A to G transition at codon 557 ( AAG - - > GAG )	SequenceVariant	176	190	8	1:NR:2	L2R	CROSS	29-34	201-205	C535650,D010911	enteropancreatic endocrine and pituitary adenomas	DiseaseOrPhenotypicFeature	29	34	1	p|SUB|K||E	lysine by glutamic acid	SequenceVariant	201	205	8	1:NR:2	L2R	CROSS	29-34	218-232	C535650,D010911	enteropancreatic endocrine and pituitary adenomas	DiseaseOrPhenotypicFeature	29	34	1	p|SUB|D|418|Y	mutation at codon 418 of exon 9 ( GAC - - > TAT )	SequenceVariant	218	232	9	1:NR:2	L2R	CROSS	29-34	238-242	C535650,D010911	enteropancreatic endocrine and pituitary adenomas	DiseaseOrPhenotypicFeature	29	34	1	p|SUB|D||Y	aspartic acid by tyrosine	SequenceVariant	238	242	9	1:NR:2	L2R	CROSS	82-83	176-190	D049950	primary hyperparathyroidism|PHPT|PHPT	DiseaseOrPhenotypicFeature	70:73:82	72:74:83	3:3:3	p|SUB|K|557|E	A to G transition at codon 557 ( AAG - - > GAG )	SequenceVariant	176	190	8	1:NR:2	L2R	CROSS	82-83	201-205	D049950	primary hyperparathyroidism|PHPT|PHPT	DiseaseOrPhenotypicFeature	70:73:82	72:74:83	3:3:3	p|SUB|K||E	lysine by glutamic acid	SequenceVariant	201	205	8	1:NR:2	L2R	CROSS	82-83	218-232	D049950	primary hyperparathyroidism|PHPT|PHPT	DiseaseOrPhenotypicFeature	70:73:82	72:74:83	3:3:3	p|SUB|D|418|Y	mutation at codon 418 of exon 9 ( GAC - - > TAT )	SequenceVariant	218	232	9	1:NR:2	L2R	CROSS	82-83	238-242	D049950	primary hyperparathyroidism|PHPT|PHPT	DiseaseOrPhenotypicFeature	70:73:82	72:74:83	3:3:3	p|SUB|D||Y	aspartic acid by tyrosine	SequenceVariant	238	242	9	1:NR:2	L2R	CROSS	146-147	176-190	D015175	prolactinoma|prolactinoma	DiseaseOrPhenotypicFeature	77:146	78:147	3:6	p|SUB|K|557|E	A to G transition at codon 557 ( AAG - - > GAG )	SequenceVariant	176	190	8	1:NR:2	L2R	CROSS	146-147	201-205	D015175	prolactinoma|prolactinoma	DiseaseOrPhenotypicFeature	77:146	78:147	3:6	p|SUB|K||E	lysine by glutamic acid	SequenceVariant	201	205	8	1:NR:2	L2R	CROSS	146-147	218-232	D015175	prolactinoma|prolactinoma	DiseaseOrPhenotypicFeature	77:146	78:147	3:6	p|SUB|D|418|Y	mutation at codon 418 of exon 9 ( GAC - - > TAT )	SequenceVariant	218	232	9	1:NR:2	L2R	CROSS	146-147	238-242	D015175	prolactinoma|prolactinoma	DiseaseOrPhenotypicFeature	77:146	78:147	3:6	p|SUB|D||Y	aspartic acid by tyrosine	SequenceVariant	238	242	9	1:NR:2	L2R	CROSS	115-116	176-190	D010146	pain	DiseaseOrPhenotypicFeature	115	116	5	p|SUB|K|557|E	A to G transition at codon 557 ( AAG - - > GAG )	SequenceVariant	176	190	8	1:NR:2	L2R	CROSS	115-116	201-205	D010146	pain	DiseaseOrPhenotypicFeature	115	116	5	p|SUB|K||E	lysine by glutamic acid	SequenceVariant	201	205	8	1:NR:2	L2R	CROSS	115-116	218-232	D010146	pain	DiseaseOrPhenotypicFeature	115	116	5	p|SUB|D|418|Y	mutation at codon 418 of exon 9 ( GAC - - > TAT )	SequenceVariant	218	232	9	1:NR:2	L2R	CROSS	115-116	238-242	D010146	pain	DiseaseOrPhenotypicFeature	115	116	5	p|SUB|D||Y	aspartic acid by tyrosine	SequenceVariant	238	242	9	1:NR:2	L2R	CROSS	118-119	176-190	D003967	diarrhea	DiseaseOrPhenotypicFeature	118	119	5	p|SUB|K|557|E	A to G transition at codon 557 ( AAG - - > GAG )	SequenceVariant	176	190	8	1:NR:2	L2R	CROSS	118-119	201-205	D003967	diarrhea	DiseaseOrPhenotypicFeature	118	119	5	p|SUB|K||E	lysine by glutamic acid	SequenceVariant	201	205	8	1:NR:2	L2R	CROSS	118-119	218-232	D003967	diarrhea	DiseaseOrPhenotypicFeature	118	119	5	p|SUB|D|418|Y	mutation at codon 418 of exon 9 ( GAC - - > TAT )	SequenceVariant	218	232	9	1:NR:2	L2R	CROSS	118-119	238-242	D003967	diarrhea	DiseaseOrPhenotypicFeature	118	119	5	p|SUB|D||Y	aspartic acid by tyrosine	SequenceVariant	238	242	9	1:NR:2	L2R	CROSS	133-137	176-190	D007516	pancreatic islet cell tumor	DiseaseOrPhenotypicFeature	133	137	5	p|SUB|K|557|E	A to G transition at codon 557 ( AAG - - > GAG )	SequenceVariant	176	190	8	1:NR:2	L2R	CROSS	133-137	201-205	D007516	pancreatic islet cell tumor	DiseaseOrPhenotypicFeature	133	137	5	p|SUB|K||E	lysine by glutamic acid	SequenceVariant	201	205	8	1:NR:2	L2R	CROSS	133-137	218-232	D007516	pancreatic islet cell tumor	DiseaseOrPhenotypicFeature	133	137	5	p|SUB|D|418|Y	mutation at codon 418 of exon 9 ( GAC - - > TAT )	SequenceVariant	218	232	9	1:NR:2	L2R	CROSS	133-137	238-242	D007516	pancreatic islet cell tumor	DiseaseOrPhenotypicFeature	133	137	5	p|SUB|D||Y	aspartic acid by tyrosine	SequenceVariant	238	242	9
15668505	Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers .|The HH genotype of the nonconservative amino acid substitution polymorphism N372H in the BRCA2 gene was reported to be associated with a 1 . 3 - to 1 . 5 - fold increase in risk of both breast and ovarian cancer .|As these studies concerned sporadic cancer cases , we investigated whether N372H and another common variant located in the 5 ' - untranslated region ( 203G > A ) of the BRCA2 gene modify breast or ovarian cancer risk in BRCA1 mutation carriers .|The study includes 778 women carrying a BRCA1 germ - line mutation belonging to 403 families .|The two BRCA2 variants were analyzed by the TaqMan allelic discrimination technique .|Genotypes were analyzed by disease - free survival analysis using a Cox proportional hazards model .|We found no evidence of a significant modification of breast cancer penetrance in BRCA1 mutation carriers by either polymorphism .|In respect of ovarian cancer risk , we also saw no effect with the N372H variant but we did observe a borderline association with the 5 ' - untranslated region 203A allele ( hazard ratio , 1 . 43 ; CI , 1 . 01 - 2 . 00 ) .|In contrast to the result of Healey et al . on newborn females and adult female controls , we found no departure from Hardy - Weinberg equilibrium in the distribution of N372H alleles for our female BRCA1 carriers .|We conclude that if these single - nucleotide polymorphisms do modify the risk of cancer in BRCA1 mutation carriers , their effects are not significantly larger than that of N372H previously observed in the general population .	1:NR:2	L2R	NON-CROSS	89-90	92-96	675	BRCA2|BRCA2|BRCA2|BRCA2	GeneOrGeneProduct	1:29:89:121	2:30:90:122	0:1:2:4	D001943,D010051	breast and ovarian cancer|breast and ovarian cancer|breast or ovarian cancer	DiseaseOrPhenotypicFeature	6:53:92	10:57:96	0:1:2	1:NR:2	L2R	NON-CROSS	89-90	98-99	675	BRCA2|BRCA2|BRCA2|BRCA2	GeneOrGeneProduct	1:29:89:121	2:30:90:122	0:1:2:4	672	BRCA1|BRCA1|BRCA1|BRCA1|BRCA1|BRCA1	GeneOrGeneProduct	12:98:109:161:255:274	13:99:110:162:256:275	0:2:3:6:8:9	1:NR:2	L2R	NON-CROSS	63-64	89-90	675	BRCA2|BRCA2|BRCA2|BRCA2	GeneOrGeneProduct	1:29:89:121	2:30:90:122	0:1:2:4	D009369	cancer|cancer	DiseaseOrPhenotypicFeature	63:272	64:273	2:9	1:Association:2	L2R	CROSS	121-122	157-159	675	BRCA2|BRCA2|BRCA2|BRCA2	GeneOrGeneProduct	1:29:89:121	2:30:90:122	0:1:2:4	D001943	breast cancer	DiseaseOrPhenotypicFeature	157	159	6	1:Association:2	L2R	CROSS	121-122	171-173	675	BRCA2|BRCA2|BRCA2|BRCA2	GeneOrGeneProduct	1:29:89:121	2:30:90:122	0:1:2:4	D010051	ovarian cancer	DiseaseOrPhenotypicFeature	171	173	7	1:NR:2	L2R	NON-CROSS	6-10	12-13	D001943,D010051	breast and ovarian cancer|breast and ovarian cancer|breast or ovarian cancer	DiseaseOrPhenotypicFeature	6:53:92	10:57:96	0:1:2	672	BRCA1|BRCA1|BRCA1|BRCA1|BRCA1|BRCA1	GeneOrGeneProduct	12:98:109:161:255:274	13:99:110:162:256:275	0:2:3:6:8:9	1:NR:2	L2R	NON-CROSS	53-57	69-70	D001943,D010051	breast and ovarian cancer|breast and ovarian cancer|breast or ovarian cancer	DiseaseOrPhenotypicFeature	6:53:92	10:57:96	0:1:2	rs144848	N372H|N372H|N372H|N372H|N372H	SequenceVariant	26:69:182:250:287	27:70:183:251:288	1:2:7:8:9	1:NR:2	L2R	NON-CROSS	83-86	92-96	D001943,D010051	breast and ovarian cancer|breast and ovarian cancer|breast or ovarian cancer	DiseaseOrPhenotypicFeature	6:53:92	10:57:96	0:1:2	g|SUB|G|203|A	203G > A	SequenceVariant	83	86	2	1:NR:2	L2R	CROSS	92-96	198-199	D001943,D010051	breast and ovarian cancer|breast and ovarian cancer|breast or ovarian cancer	DiseaseOrPhenotypicFeature	6:53:92	10:57:96	0:1:2	g|Allele|A|203	203A	SequenceVariant	198	199	7	1:NR:2	L2R	NON-CROSS	272-273	274-275	672	BRCA1|BRCA1|BRCA1|BRCA1|BRCA1|BRCA1	GeneOrGeneProduct	12:98:109:161:255:274	13:99:110:162:256:275	0:2:3:6:8:9	D009369	cancer|cancer	DiseaseOrPhenotypicFeature	63:272	64:273	2:9	1:Association:2	L2R	NON-CROSS	157-159	161-162	672	BRCA1|BRCA1|BRCA1|BRCA1|BRCA1|BRCA1	GeneOrGeneProduct	12:98:109:161:255:274	13:99:110:162:256:275	0:2:3:6:8:9	D001943	breast cancer	DiseaseOrPhenotypicFeature	157	159	6	1:Association:2	L2R	CROSS	161-162	171-173	672	BRCA1|BRCA1|BRCA1|BRCA1|BRCA1|BRCA1	GeneOrGeneProduct	12:98:109:161:255:274	13:99:110:162:256:275	0:2:3:6:8:9	D010051	ovarian cancer	DiseaseOrPhenotypicFeature	171	173	7	1:NR:2	L2R	NON-CROSS	63-64	69-70	rs144848	N372H|N372H|N372H|N372H|N372H	SequenceVariant	26:69:182:250:287	27:70:183:251:288	1:2:7:8:9	D009369	cancer|cancer	DiseaseOrPhenotypicFeature	63:272	64:273	2:9	1:Positive_Correlation:2	L2R	CROSS	157-159	182-183	rs144848	N372H|N372H|N372H|N372H|N372H	SequenceVariant	26:69:182:250:287	27:70:183:251:288	1:2:7:8:9	D001943	breast cancer	DiseaseOrPhenotypicFeature	157	159	6	1:Positive_Correlation:2	L2R	NON-CROSS	171-173	182-183	rs144848	N372H|N372H|N372H|N372H|N372H	SequenceVariant	26:69:182:250:287	27:70:183:251:288	1:2:7:8:9	D010051	ovarian cancer	DiseaseOrPhenotypicFeature	171	173	7	1:NR:2	L2R	NON-CROSS	63-64	83-86	D009369	cancer|cancer	DiseaseOrPhenotypicFeature	63:272	64:273	2:9	g|SUB|G|203|A	203G > A	SequenceVariant	83	86	2	1:NR:2	L2R	CROSS	198-199	272-273	D009369	cancer|cancer	DiseaseOrPhenotypicFeature	63:272	64:273	2:9	g|Allele|A|203	203A	SequenceVariant	198	199	7	1:NR:2	L2R	CROSS	83-86	157-159	g|SUB|G|203|A	203G > A	SequenceVariant	83	86	2	D001943	breast cancer	DiseaseOrPhenotypicFeature	157	159	6	1:NR:2	L2R	CROSS	83-86	171-173	g|SUB|G|203|A	203G > A	SequenceVariant	83	86	2	D010051	ovarian cancer	DiseaseOrPhenotypicFeature	171	173	7	1:NR:2	L2R	CROSS	157-159	198-199	D001943	breast cancer	DiseaseOrPhenotypicFeature	157	159	6	g|Allele|A|203	203A	SequenceVariant	198	199	7	1:Association:2	L2R	NON-CROSS	171-173	198-199	D010051	ovarian cancer	DiseaseOrPhenotypicFeature	171	173	7	g|Allele|A|203	203A	SequenceVariant	198	199	7
26847345	Transgelin increases metastatic potential of colorectal cancer cells in vivo and alters expression of genes involved in cell motility .|BACKGROUND : Transgelin is an actin - binding protein that promotes motility in normal cells .|Although the role of transgelin in cancer is controversial , a number of studies have shown that elevated levels correlate with aggressive tumor behavior , advanced stage , and poor prognosis .|Here we sought to determine the role of transgelin more directly by determining whether experimental manipulation of transgelin levels in colorectal cancer ( CRC ) cells led to changes in metastatic potential in vivo .|METHODS : Isogenic CRC cell lines that differ in transgelin expression were characterized using in vitro assays of growth and invasiveness and a mouse tail vein assay of experimental metastasis .|Downstream effects of transgelin overexpression were investigated by gene expression profiling and quantitative PCR .|RESULTS : Stable overexpression of transgelin in RKO cells , which have low endogenous levels , led to increased invasiveness , growth at low density , and growth in soft agar .|Overexpression also led to an increase in the number and size of lung metastases in the mouse tail vein injection model .|Similarly , attenuation of transgelin expression in HCT116 cells , which have high endogenous levels , decreased metastases in the same model .|Investigation of mRNA expression patterns showed that transgelin overexpression altered the levels of approximately 250 other transcripts , with over - representation of genes that affect function of actin or other cytoskeletal proteins .|Changes included increases in HOOK1 , SDCCAG8 , ENAH / Mena , and TNS1 and decreases in EMB , BCL11B , and PTPRD .|CONCLUSIONS : Increases or decreases in transgelin levels have reciprocal effects on tumor cell behavior , with higher expression promoting metastasis .|Chronic overexpression influences steady - state levels of mRNAs for metastasis - related genes .	1:Association:2	L2R	NON-CROSS	85-86	88-90	6876	Transgelin|Transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin	GeneOrGeneProduct	0:22:40:76:85:112:137:154:207:233:290	1:23:41:77:86:113:138:155:208:234:291	0:1:2:3:3:4:5:6:8:9:11	D015179	colorectal cancer|colorectal cancer|CRC|CRC	DiseaseOrPhenotypicFeature	5:88:91:106	7:90:92:107	0:3:3:4	1:NR:2	L2R	NON-CROSS	22-23	25-29	6876	Transgelin|Transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin	GeneOrGeneProduct	0:22:40:76:85:112:137:154:207:233:290	1:23:41:77:86:113:138:155:208:234:291	0:1:2:3:3:4:5:6:8:9:11	21345,6876	actin - binding protein	GeneOrGeneProduct	25	29	1	1:Association:2	L2R	NON-CROSS	40-41	42-43	6876	Transgelin|Transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin	GeneOrGeneProduct	0:22:40:76:85:112:137:154:207:233:290	1:23:41:77:86:113:138:155:208:234:291	0:1:2:3:3:4:5:6:8:9:11	D009369	cancer|tumor|tumor	DiseaseOrPhenotypicFeature	42:58:296	43:59:297	2:2:11	1:Association:2	L2R	CROSS	193-195	207-208	6876	Transgelin|Transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin	GeneOrGeneProduct	0:22:40:76:85:112:137:154:207:233:290	1:23:41:77:86:113:138:155:208:234:291	0:1:2:3:3:4:5:6:8:9:11	D008175	lung metastases	DiseaseOrPhenotypicFeature	193	195	7	1:NR:2	L2R	NON-CROSS	207-208	220-221	6876	Transgelin|Transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin	GeneOrGeneProduct	0:22:40:76:85:112:137:154:207:233:290	1:23:41:77:86:113:138:155:208:234:291	0:1:2:3:3:4:5:6:8:9:11	D009362	metastases	DiseaseOrPhenotypicFeature	220	221	8	1:Association:2	L2R	NON-CROSS	233-234	254-255	6876	Transgelin|Transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin	GeneOrGeneProduct	0:22:40:76:85:112:137:154:207:233:290	1:23:41:77:86:113:138:155:208:234:291	0:1:2:3:3:4:5:6:8:9:11	60	actin	GeneOrGeneProduct	254	255	9	1:NR:2	L2R	NON-CROSS	233-234	257-259	6876	Transgelin|Transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin	GeneOrGeneProduct	0:22:40:76:85:112:137:154:207:233:290	1:23:41:77:86:113:138:155:208:234:291	0:1:2:3:3:4:5:6:8:9:11	51361,55740,7145	cytoskeletal proteins	GeneOrGeneProduct	257	259	9	1:Positive_Correlation:2	L2R	CROSS	264-265	290-291	6876	Transgelin|Transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin	GeneOrGeneProduct	0:22:40:76:85:112:137:154:207:233:290	1:23:41:77:86:113:138:155:208:234:291	0:1:2:3:3:4:5:6:8:9:11	51361	HOOK1	GeneOrGeneProduct	264	265	10	1:Positive_Correlation:2	L2R	CROSS	266-267	290-291	6876	Transgelin|Transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin	GeneOrGeneProduct	0:22:40:76:85:112:137:154:207:233:290	1:23:41:77:86:113:138:155:208:234:291	0:1:2:3:3:4:5:6:8:9:11	10806	SDCCAG8	GeneOrGeneProduct	266	267	10	1:Positive_Correlation:2	L2R	CROSS	270-271	290-291	6876	Transgelin|Transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin	GeneOrGeneProduct	0:22:40:76:85:112:137:154:207:233:290	1:23:41:77:86:113:138:155:208:234:291	0:1:2:3:3:4:5:6:8:9:11	55740	ENAH|Mena	GeneOrGeneProduct	268:270	269:271	10:10	1:Positive_Correlation:2	L2R	CROSS	273-274	290-291	6876	Transgelin|Transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin	GeneOrGeneProduct	0:22:40:76:85:112:137:154:207:233:290	1:23:41:77:86:113:138:155:208:234:291	0:1:2:3:3:4:5:6:8:9:11	7145	TNS1	GeneOrGeneProduct	273	274	10	1:Negative_Correlation:2	L2R	CROSS	277-278	290-291	6876	Transgelin|Transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin	GeneOrGeneProduct	0:22:40:76:85:112:137:154:207:233:290	1:23:41:77:86:113:138:155:208:234:291	0:1:2:3:3:4:5:6:8:9:11	133418	EMB	GeneOrGeneProduct	277	278	10	1:Negative_Correlation:2	L2R	CROSS	279-280	290-291	6876	Transgelin|Transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin	GeneOrGeneProduct	0:22:40:76:85:112:137:154:207:233:290	1:23:41:77:86:113:138:155:208:234:291	0:1:2:3:3:4:5:6:8:9:11	64919	BCL11B	GeneOrGeneProduct	279	280	10	1:Negative_Correlation:2	L2R	CROSS	282-283	290-291	6876	Transgelin|Transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin|transgelin	GeneOrGeneProduct	0:22:40:76:85:112:137:154:207:233:290	1:23:41:77:86:113:138:155:208:234:291	0:1:2:3:3:4:5:6:8:9:11	5789	PTPRD	GeneOrGeneProduct	282	283	10	1:NR:2	L2R	CROSS	5-7	25-29	D015179	colorectal cancer|colorectal cancer|CRC|CRC	DiseaseOrPhenotypicFeature	5:88:91:106	7:90:92:107	0:3:3:4	21345,6876	actin - binding protein	GeneOrGeneProduct	25	29	1	1:NR:2	L2R	CROSS	106-107	254-255	D015179	colorectal cancer|colorectal cancer|CRC|CRC	DiseaseOrPhenotypicFeature	5:88:91:106	7:90:92:107	0:3:3:4	60	actin	GeneOrGeneProduct	254	255	9	1:NR:2	L2R	CROSS	106-107	257-259	D015179	colorectal cancer|colorectal cancer|CRC|CRC	DiseaseOrPhenotypicFeature	5:88:91:106	7:90:92:107	0:3:3:4	51361,55740,7145	cytoskeletal proteins	GeneOrGeneProduct	257	259	9	1:NR:2	L2R	CROSS	106-107	264-265	D015179	colorectal cancer|colorectal cancer|CRC|CRC	DiseaseOrPhenotypicFeature	5:88:91:106	7:90:92:107	0:3:3:4	51361	HOOK1	GeneOrGeneProduct	264	265	10	1:NR:2	L2R	CROSS	106-107	266-267	D015179	colorectal cancer|colorectal cancer|CRC|CRC	DiseaseOrPhenotypicFeature	5:88:91:106	7:90:92:107	0:3:3:4	10806	SDCCAG8	GeneOrGeneProduct	266	267	10	1:NR:2	L2R	CROSS	106-107	268-269	D015179	colorectal cancer|colorectal cancer|CRC|CRC	DiseaseOrPhenotypicFeature	5:88:91:106	7:90:92:107	0:3:3:4	55740	ENAH|Mena	GeneOrGeneProduct	268:270	269:271	10:10	1:NR:2	L2R	CROSS	106-107	273-274	D015179	colorectal cancer|colorectal cancer|CRC|CRC	DiseaseOrPhenotypicFeature	5:88:91:106	7:90:92:107	0:3:3:4	7145	TNS1	GeneOrGeneProduct	273	274	10	1:NR:2	L2R	CROSS	106-107	277-278	D015179	colorectal cancer|colorectal cancer|CRC|CRC	DiseaseOrPhenotypicFeature	5:88:91:106	7:90:92:107	0:3:3:4	133418	EMB	GeneOrGeneProduct	277	278	10	1:NR:2	L2R	CROSS	106-107	279-280	D015179	colorectal cancer|colorectal cancer|CRC|CRC	DiseaseOrPhenotypicFeature	5:88:91:106	7:90:92:107	0:3:3:4	64919	BCL11B	GeneOrGeneProduct	279	280	10	1:NR:2	L2R	CROSS	106-107	282-283	D015179	colorectal cancer|colorectal cancer|CRC|CRC	DiseaseOrPhenotypicFeature	5:88:91:106	7:90:92:107	0:3:3:4	5789	PTPRD	GeneOrGeneProduct	282	283	10	1:NR:2	L2R	CROSS	25-29	42-43	21345,6876	actin - binding protein	GeneOrGeneProduct	25	29	1	D009369	cancer|tumor|tumor	DiseaseOrPhenotypicFeature	42:58:296	43:59:297	2:2:11	1:NR:2	L2R	CROSS	25-29	193-195	21345,6876	actin - binding protein	GeneOrGeneProduct	25	29	1	D008175	lung metastases	DiseaseOrPhenotypicFeature	193	195	7	1:NR:2	L2R	CROSS	25-29	220-221	21345,6876	actin - binding protein	GeneOrGeneProduct	25	29	1	D009362	metastases	DiseaseOrPhenotypicFeature	220	221	8	1:NR:2	L2R	CROSS	25-29	254-255	21345,6876	actin - binding protein	GeneOrGeneProduct	25	29	1	60	actin	GeneOrGeneProduct	254	255	9	1:NR:2	L2R	CROSS	25-29	257-259	21345,6876	actin - binding protein	GeneOrGeneProduct	25	29	1	51361,55740,7145	cytoskeletal proteins	GeneOrGeneProduct	257	259	9	1:NR:2	L2R	CROSS	25-29	264-265	21345,6876	actin - binding protein	GeneOrGeneProduct	25	29	1	51361	HOOK1	GeneOrGeneProduct	264	265	10	1:NR:2	L2R	CROSS	25-29	266-267	21345,6876	actin - binding protein	GeneOrGeneProduct	25	29	1	10806	SDCCAG8	GeneOrGeneProduct	266	267	10	1:NR:2	L2R	CROSS	25-29	268-269	21345,6876	actin - binding protein	GeneOrGeneProduct	25	29	1	55740	ENAH|Mena	GeneOrGeneProduct	268:270	269:271	10:10	1:NR:2	L2R	CROSS	25-29	273-274	21345,6876	actin - binding protein	GeneOrGeneProduct	25	29	1	7145	TNS1	GeneOrGeneProduct	273	274	10	1:NR:2	L2R	CROSS	25-29	277-278	21345,6876	actin - binding protein	GeneOrGeneProduct	25	29	1	133418	EMB	GeneOrGeneProduct	277	278	10	1:NR:2	L2R	CROSS	25-29	279-280	21345,6876	actin - binding protein	GeneOrGeneProduct	25	29	1	64919	BCL11B	GeneOrGeneProduct	279	280	10	1:NR:2	L2R	CROSS	25-29	282-283	21345,6876	actin - binding protein	GeneOrGeneProduct	25	29	1	5789	PTPRD	GeneOrGeneProduct	282	283	10	1:NR:2	L2R	CROSS	254-255	296-297	D009369	cancer|tumor|tumor	DiseaseOrPhenotypicFeature	42:58:296	43:59:297	2:2:11	60	actin	GeneOrGeneProduct	254	255	9	1:NR:2	L2R	CROSS	257-259	296-297	D009369	cancer|tumor|tumor	DiseaseOrPhenotypicFeature	42:58:296	43:59:297	2:2:11	51361,55740,7145	cytoskeletal proteins	GeneOrGeneProduct	257	259	9	1:NR:2	L2R	CROSS	264-265	296-297	D009369	cancer|tumor|tumor	DiseaseOrPhenotypicFeature	42:58:296	43:59:297	2:2:11	51361	HOOK1	GeneOrGeneProduct	264	265	10	1:NR:2	L2R	CROSS	266-267	296-297	D009369	cancer|tumor|tumor	DiseaseOrPhenotypicFeature	42:58:296	43:59:297	2:2:11	10806	SDCCAG8	GeneOrGeneProduct	266	267	10	1:NR:2	L2R	CROSS	270-271	296-297	D009369	cancer|tumor|tumor	DiseaseOrPhenotypicFeature	42:58:296	43:59:297	2:2:11	55740	ENAH|Mena	GeneOrGeneProduct	268:270	269:271	10:10	1:NR:2	L2R	CROSS	273-274	296-297	D009369	cancer|tumor|tumor	DiseaseOrPhenotypicFeature	42:58:296	43:59:297	2:2:11	7145	TNS1	GeneOrGeneProduct	273	274	10	1:NR:2	L2R	CROSS	277-278	296-297	D009369	cancer|tumor|tumor	DiseaseOrPhenotypicFeature	42:58:296	43:59:297	2:2:11	133418	EMB	GeneOrGeneProduct	277	278	10	1:NR:2	L2R	CROSS	279-280	296-297	D009369	cancer|tumor|tumor	DiseaseOrPhenotypicFeature	42:58:296	43:59:297	2:2:11	64919	BCL11B	GeneOrGeneProduct	279	280	10	1:NR:2	L2R	CROSS	282-283	296-297	D009369	cancer|tumor|tumor	DiseaseOrPhenotypicFeature	42:58:296	43:59:297	2:2:11	5789	PTPRD	GeneOrGeneProduct	282	283	10	1:NR:2	L2R	CROSS	193-195	254-255	D008175	lung metastases	DiseaseOrPhenotypicFeature	193	195	7	60	actin	GeneOrGeneProduct	254	255	9	1:NR:2	L2R	CROSS	193-195	257-259	D008175	lung metastases	DiseaseOrPhenotypicFeature	193	195	7	51361,55740,7145	cytoskeletal proteins	GeneOrGeneProduct	257	259	9	1:NR:2	L2R	CROSS	193-195	264-265	D008175	lung metastases	DiseaseOrPhenotypicFeature	193	195	7	51361	HOOK1	GeneOrGeneProduct	264	265	10	1:NR:2	L2R	CROSS	193-195	266-267	D008175	lung metastases	DiseaseOrPhenotypicFeature	193	195	7	10806	SDCCAG8	GeneOrGeneProduct	266	267	10	1:NR:2	L2R	CROSS	193-195	268-269	D008175	lung metastases	DiseaseOrPhenotypicFeature	193	195	7	55740	ENAH|Mena	GeneOrGeneProduct	268:270	269:271	10:10	1:NR:2	L2R	CROSS	193-195	273-274	D008175	lung metastases	DiseaseOrPhenotypicFeature	193	195	7	7145	TNS1	GeneOrGeneProduct	273	274	10	1:NR:2	L2R	CROSS	193-195	277-278	D008175	lung metastases	DiseaseOrPhenotypicFeature	193	195	7	133418	EMB	GeneOrGeneProduct	277	278	10	1:NR:2	L2R	CROSS	193-195	279-280	D008175	lung metastases	DiseaseOrPhenotypicFeature	193	195	7	64919	BCL11B	GeneOrGeneProduct	279	280	10	1:NR:2	L2R	CROSS	193-195	282-283	D008175	lung metastases	DiseaseOrPhenotypicFeature	193	195	7	5789	PTPRD	GeneOrGeneProduct	282	283	10	1:NR:2	L2R	CROSS	220-221	254-255	D009362	metastases	DiseaseOrPhenotypicFeature	220	221	8	60	actin	GeneOrGeneProduct	254	255	9	1:NR:2	L2R	CROSS	220-221	257-259	D009362	metastases	DiseaseOrPhenotypicFeature	220	221	8	51361,55740,7145	cytoskeletal proteins	GeneOrGeneProduct	257	259	9	1:NR:2	L2R	CROSS	220-221	264-265	D009362	metastases	DiseaseOrPhenotypicFeature	220	221	8	51361	HOOK1	GeneOrGeneProduct	264	265	10	1:NR:2	L2R	CROSS	220-221	266-267	D009362	metastases	DiseaseOrPhenotypicFeature	220	221	8	10806	SDCCAG8	GeneOrGeneProduct	266	267	10	1:NR:2	L2R	CROSS	220-221	268-269	D009362	metastases	DiseaseOrPhenotypicFeature	220	221	8	55740	ENAH|Mena	GeneOrGeneProduct	268:270	269:271	10:10	1:NR:2	L2R	CROSS	220-221	273-274	D009362	metastases	DiseaseOrPhenotypicFeature	220	221	8	7145	TNS1	GeneOrGeneProduct	273	274	10	1:NR:2	L2R	CROSS	220-221	277-278	D009362	metastases	DiseaseOrPhenotypicFeature	220	221	8	133418	EMB	GeneOrGeneProduct	277	278	10	1:NR:2	L2R	CROSS	220-221	279-280	D009362	metastases	DiseaseOrPhenotypicFeature	220	221	8	64919	BCL11B	GeneOrGeneProduct	279	280	10	1:NR:2	L2R	CROSS	220-221	282-283	D009362	metastases	DiseaseOrPhenotypicFeature	220	221	8	5789	PTPRD	GeneOrGeneProduct	282	283	10	1:NR:2	L2R	NON-CROSS	254-255	257-259	60	actin	GeneOrGeneProduct	254	255	9	51361,55740,7145	cytoskeletal proteins	GeneOrGeneProduct	257	259	9	1:NR:2	L2R	CROSS	254-255	264-265	60	actin	GeneOrGeneProduct	254	255	9	51361	HOOK1	GeneOrGeneProduct	264	265	10	1:NR:2	L2R	CROSS	254-255	266-267	60	actin	GeneOrGeneProduct	254	255	9	10806	SDCCAG8	GeneOrGeneProduct	266	267	10	1:NR:2	L2R	CROSS	254-255	268-269	60	actin	GeneOrGeneProduct	254	255	9	55740	ENAH|Mena	GeneOrGeneProduct	268:270	269:271	10:10	1:NR:2	L2R	CROSS	254-255	273-274	60	actin	GeneOrGeneProduct	254	255	9	7145	TNS1	GeneOrGeneProduct	273	274	10	1:NR:2	L2R	CROSS	254-255	277-278	60	actin	GeneOrGeneProduct	254	255	9	133418	EMB	GeneOrGeneProduct	277	278	10	1:NR:2	L2R	CROSS	254-255	279-280	60	actin	GeneOrGeneProduct	254	255	9	64919	BCL11B	GeneOrGeneProduct	279	280	10	1:NR:2	L2R	CROSS	254-255	282-283	60	actin	GeneOrGeneProduct	254	255	9	5789	PTPRD	GeneOrGeneProduct	282	283	10	1:NR:2	L2R	CROSS	257-259	264-265	51361,55740,7145	cytoskeletal proteins	GeneOrGeneProduct	257	259	9	51361	HOOK1	GeneOrGeneProduct	264	265	10	1:NR:2	L2R	CROSS	257-259	266-267	51361,55740,7145	cytoskeletal proteins	GeneOrGeneProduct	257	259	9	10806	SDCCAG8	GeneOrGeneProduct	266	267	10	1:NR:2	L2R	CROSS	257-259	268-269	51361,55740,7145	cytoskeletal proteins	GeneOrGeneProduct	257	259	9	55740	ENAH|Mena	GeneOrGeneProduct	268:270	269:271	10:10	1:NR:2	L2R	CROSS	257-259	273-274	51361,55740,7145	cytoskeletal proteins	GeneOrGeneProduct	257	259	9	7145	TNS1	GeneOrGeneProduct	273	274	10	1:NR:2	L2R	CROSS	257-259	277-278	51361,55740,7145	cytoskeletal proteins	GeneOrGeneProduct	257	259	9	133418	EMB	GeneOrGeneProduct	277	278	10	1:NR:2	L2R	CROSS	257-259	279-280	51361,55740,7145	cytoskeletal proteins	GeneOrGeneProduct	257	259	9	64919	BCL11B	GeneOrGeneProduct	279	280	10	1:NR:2	L2R	CROSS	257-259	282-283	51361,55740,7145	cytoskeletal proteins	GeneOrGeneProduct	257	259	9	5789	PTPRD	GeneOrGeneProduct	282	283	10	1:NR:2	L2R	NON-CROSS	264-265	266-267	51361	HOOK1	GeneOrGeneProduct	264	265	10	10806	SDCCAG8	GeneOrGeneProduct	266	267	10	1:NR:2	L2R	NON-CROSS	264-265	268-269	51361	HOOK1	GeneOrGeneProduct	264	265	10	55740	ENAH|Mena	GeneOrGeneProduct	268:270	269:271	10:10	1:NR:2	L2R	NON-CROSS	264-265	273-274	51361	HOOK1	GeneOrGeneProduct	264	265	10	7145	TNS1	GeneOrGeneProduct	273	274	10	1:NR:2	L2R	NON-CROSS	264-265	277-278	51361	HOOK1	GeneOrGeneProduct	264	265	10	133418	EMB	GeneOrGeneProduct	277	278	10	1:NR:2	L2R	NON-CROSS	264-265	279-280	51361	HOOK1	GeneOrGeneProduct	264	265	10	64919	BCL11B	GeneOrGeneProduct	279	280	10	1:NR:2	L2R	NON-CROSS	264-265	282-283	51361	HOOK1	GeneOrGeneProduct	264	265	10	5789	PTPRD	GeneOrGeneProduct	282	283	10	1:NR:2	L2R	NON-CROSS	266-267	268-269	10806	SDCCAG8	GeneOrGeneProduct	266	267	10	55740	ENAH|Mena	GeneOrGeneProduct	268:270	269:271	10:10	1:NR:2	L2R	NON-CROSS	266-267	273-274	10806	SDCCAG8	GeneOrGeneProduct	266	267	10	7145	TNS1	GeneOrGeneProduct	273	274	10	1:NR:2	L2R	NON-CROSS	266-267	277-278	10806	SDCCAG8	GeneOrGeneProduct	266	267	10	133418	EMB	GeneOrGeneProduct	277	278	10	1:NR:2	L2R	NON-CROSS	266-267	279-280	10806	SDCCAG8	GeneOrGeneProduct	266	267	10	64919	BCL11B	GeneOrGeneProduct	279	280	10	1:NR:2	L2R	NON-CROSS	266-267	282-283	10806	SDCCAG8	GeneOrGeneProduct	266	267	10	5789	PTPRD	GeneOrGeneProduct	282	283	10	1:NR:2	L2R	NON-CROSS	270-271	273-274	55740	ENAH|Mena	GeneOrGeneProduct	268:270	269:271	10:10	7145	TNS1	GeneOrGeneProduct	273	274	10	1:NR:2	L2R	NON-CROSS	270-271	277-278	55740	ENAH|Mena	GeneOrGeneProduct	268:270	269:271	10:10	133418	EMB	GeneOrGeneProduct	277	278	10	1:NR:2	L2R	NON-CROSS	270-271	279-280	55740	ENAH|Mena	GeneOrGeneProduct	268:270	269:271	10:10	64919	BCL11B	GeneOrGeneProduct	279	280	10	1:NR:2	L2R	NON-CROSS	270-271	282-283	55740	ENAH|Mena	GeneOrGeneProduct	268:270	269:271	10:10	5789	PTPRD	GeneOrGeneProduct	282	283	10	1:NR:2	L2R	NON-CROSS	273-274	277-278	7145	TNS1	GeneOrGeneProduct	273	274	10	133418	EMB	GeneOrGeneProduct	277	278	10	1:NR:2	L2R	NON-CROSS	273-274	279-280	7145	TNS1	GeneOrGeneProduct	273	274	10	64919	BCL11B	GeneOrGeneProduct	279	280	10	1:NR:2	L2R	NON-CROSS	273-274	282-283	7145	TNS1	GeneOrGeneProduct	273	274	10	5789	PTPRD	GeneOrGeneProduct	282	283	10	1:NR:2	L2R	NON-CROSS	277-278	279-280	133418	EMB	GeneOrGeneProduct	277	278	10	64919	BCL11B	GeneOrGeneProduct	279	280	10	1:NR:2	L2R	NON-CROSS	277-278	282-283	133418	EMB	GeneOrGeneProduct	277	278	10	5789	PTPRD	GeneOrGeneProduct	282	283	10	1:NR:2	L2R	NON-CROSS	279-280	282-283	64919	BCL11B	GeneOrGeneProduct	279	280	10	5789	PTPRD	GeneOrGeneProduct	282	283	10
15818664	Association of sporadic chondrocalcinosis with a - 4 - basepair G - to - A transition in the 5 ' - untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate .|OBJECTIVE : Certain mutations in ANKH , which encodes a multiple - pass transmembrane protein that regulates inorganic pyrophosphate ( PPi ) transport , are linked to autosomal - dominant familial chondrocalcinosis .|This study investigated the potential for ANKH sequence variants to promote sporadic chondrocalcinosis .|METHODS : ANKH variants identified by genomic sequencing were screened for association with chondrocalcinosis in 128 patients with severe sporadic chondrocalcinosis or pseudogout and in ethnically matched healthy controls .|The effects of specific variants on expression of common markers were evaluated by in vitro transcription / translation .|The function of these variants was studied in transfected human immortalized CH - 8 articular chondrocytes .|RESULTS : Sporadic chondrocalcinosis was associated with a G - to - A transition in the ANKH 5 ' - untranslated region ( 5 ' - UTR ) at 4 bp upstream of the start codon ( in homozygotes of the minor allele , genotype relative risk 6 . 0 , P = 0 . 0006 ; overall genotype association P = 0 . 02 ) .|This - 4 - bp transition , as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis ( + 14 bp C - to - T and C - terminal GAG deletion , respectively ) , but not the French familial chondrocalcinosis kindred 143 - bp T - to - C mutation , increased reticulocyte ANKH transcription / ANKH translation in vitro .|Transfection of complementary DNA for both the wild - type ANKH and the - 4 - bp ANKH protein variant promoted increased extracellular PPi in CH - 8 cells , but unexpectedly , these ANKH mutants had divergent effects on the expression of extracellular PPi and the chondrocyte hypertrophy marker , type X collagen .|CONCLUSION : A subset of sporadic chondrocalcinosis appears to be heritable via a - 4 - bp G - to - A ANKH 5 ' - UTR transition that up - regulates expression of ANKH and extracellular PPi in chondrocyte cells .|Distinct ANKH mutations associated with heritable chondrocalcinosis may promote disease by divergent effects on extracellular PPi and chondrocyte hypertrophy , which is likely to mediate differences in the clinical phenotypes and severity of the disease .	1:Positive_Correlation:2	L2R	NON-CROSS	2-4	6-15	D002805	sporadic chondrocalcinosis|autosomal - dominant familial chondrocalcinosis|chondrocalcinosis|chondrocalcinosis|chondrocalcinosis|pseudogout|Sporadic chondrocalcinosis|familial and sporadic chondrocalcinosis|familial chondrocalcinosis|sporadic chondrocalcinosis|chondrocalcinosis	DiseaseOrPhenotypicFeature	2:67:85:100:107:109:155:235:262:345:388	4:72:86:101:108:110:157:239:264:347:389	0:1:2:3:3:3:6:7:7:9:10	c|SUB|G|-4|A	- 4 - basepair G - to - A|- 4 - bp G - to - A	SequenceVariant	6:353	15:362	0:9	1:Association:2	R2L	NON-CROSS	89-90	85-86	56172	ANKH|ANKH|ANKH|ANKH|ANKH|ANKH|ANKH|ANKH|ANKH|ANKH|ANKH|ANKH|ANKH|ANKH	GeneOrGeneProduct	24:30:45:79:89:169:277:280:295:302:319:362:374:383	25:31:46:80:90:170:278:281:296:303:320:363:375:384	0:0:1:2:3:6:7:7:8:8:8:9:9:10	D002805	sporadic chondrocalcinosis|autosomal - dominant familial chondrocalcinosis|chondrocalcinosis|chondrocalcinosis|chondrocalcinosis|pseudogout|Sporadic chondrocalcinosis|familial and sporadic chondrocalcinosis|familial chondrocalcinosis|sporadic chondrocalcinosis|chondrocalcinosis	DiseaseOrPhenotypicFeature	2:67:85:100:107:109:155:235:262:345:388	4:72:86:101:108:110:157:239:264:347:389	0:1:2:3:3:3:6:7:7:9:10	1:Association:2	L2R	NON-CROSS	388-389	397-398	D002805	sporadic chondrocalcinosis|autosomal - dominant familial chondrocalcinosis|chondrocalcinosis|chondrocalcinosis|chondrocalcinosis|pseudogout|Sporadic chondrocalcinosis|familial and sporadic chondrocalcinosis|familial chondrocalcinosis|sporadic chondrocalcinosis|chondrocalcinosis	DiseaseOrPhenotypicFeature	2:67:85:100:107:109:155:235:262:345:388	4:72:86:101:108:110:157:239:264:347:389	0:1:2:3:3:3:6:7:7:9:10	D043564	inorganic pyrophosphate|inorganic pyrophosphate|PPi|PPi|PPi|PPi|PPi	ChemicalEntity	37:57:60:308:329:377:397	39:59:61:309:330:378:398	0:1:1:8:8:9:10	1:Association:2	L2R	NON-CROSS	155-157	161-166	D002805	sporadic chondrocalcinosis|autosomal - dominant familial chondrocalcinosis|chondrocalcinosis|chondrocalcinosis|chondrocalcinosis|pseudogout|Sporadic chondrocalcinosis|familial and sporadic chondrocalcinosis|familial chondrocalcinosis|sporadic chondrocalcinosis|chondrocalcinosis	DiseaseOrPhenotypicFeature	2:67:85:100:107:109:155:235:262:345:388	4:72:86:101:108:110:157:239:264:347:389	0:1:2:3:3:3:6:7:7:9:10	c|SUB|G||A	G - to - A	SequenceVariant	161	166	6	1:Association:2	L2R	NON-CROSS	235-239	240-248	D002805	sporadic chondrocalcinosis|autosomal - dominant familial chondrocalcinosis|chondrocalcinosis|chondrocalcinosis|chondrocalcinosis|pseudogout|Sporadic chondrocalcinosis|familial and sporadic chondrocalcinosis|familial chondrocalcinosis|sporadic chondrocalcinosis|chondrocalcinosis	DiseaseOrPhenotypicFeature	2:67:85:100:107:109:155:235:262:345:388	4:72:86:101:108:110:157:239:264:347:389	0:1:2:3:3:3:6:7:7:9:10	c|SUB|C|14|T	+ 14 bp C - to - T	SequenceVariant	240	248	7	1:Association:2	L2R	NON-CROSS	252-254	262-264	D002805	sporadic chondrocalcinosis|autosomal - dominant familial chondrocalcinosis|chondrocalcinosis|chondrocalcinosis|chondrocalcinosis|pseudogout|Sporadic chondrocalcinosis|familial and sporadic chondrocalcinosis|familial chondrocalcinosis|sporadic chondrocalcinosis|chondrocalcinosis	DiseaseOrPhenotypicFeature	2:67:85:100:107:109:155:235:262:345:388	4:72:86:101:108:110:157:239:264:347:389	0:1:2:3:3:3:6:7:7:9:10	c|DEL||GAG	GAG deletion	SequenceVariant	252	254	7	1:NR:2	L2R	NON-CROSS	262-264	265-273	D002805	sporadic chondrocalcinosis|autosomal - dominant familial chondrocalcinosis|chondrocalcinosis|chondrocalcinosis|chondrocalcinosis|pseudogout|Sporadic chondrocalcinosis|familial and sporadic chondrocalcinosis|familial chondrocalcinosis|sporadic chondrocalcinosis|chondrocalcinosis	DiseaseOrPhenotypicFeature	2:67:85:100:107:109:155:235:262:345:388	4:72:86:101:108:110:157:239:264:347:389	0:1:2:3:3:3:6:7:7:9:10	c|SUB|T|143|C	143 - bp T - to - C	SequenceVariant	265	273	7	1:NR:2	L2R	CROSS	336-339	345-347	D002805	sporadic chondrocalcinosis|autosomal - dominant familial chondrocalcinosis|chondrocalcinosis|chondrocalcinosis|chondrocalcinosis|pseudogout|Sporadic chondrocalcinosis|familial and sporadic chondrocalcinosis|familial chondrocalcinosis|sporadic chondrocalcinosis|chondrocalcinosis	DiseaseOrPhenotypicFeature	2:67:85:100:107:109:155:235:262:345:388	4:72:86:101:108:110:157:239:264:347:389	0:1:2:3:3:3:6:7:7:9:10	1300	type X collagen	GeneOrGeneProduct	336	339	8	1:Positive_Correlation:2	L2R	NON-CROSS	353-362	377-378	c|SUB|G|-4|A	- 4 - basepair G - to - A|- 4 - bp G - to - A	SequenceVariant	6:353	15:362	0:9	D043564	inorganic pyrophosphate|inorganic pyrophosphate|PPi|PPi|PPi|PPi|PPi	ChemicalEntity	37:57:60:308:329:377:397	39:59:61:309:330:378:398	0:1:1:8:8:9:10	1:Association:2	L2R	CROSS	333-334	353-362	c|SUB|G|-4|A	- 4 - basepair G - to - A|- 4 - bp G - to - A	SequenceVariant	6:353	15:362	0:9	D006984	hypertrophy|hypertrophy	DiseaseOrPhenotypicFeature	333:400	334:401	8:10	1:Association:2	L2R	NON-CROSS	374-375	377-378	56172	ANKH|ANKH|ANKH|ANKH|ANKH|ANKH|ANKH|ANKH|ANKH|ANKH|ANKH|ANKH|ANKH|ANKH	GeneOrGeneProduct	24:30:45:79:89:169:277:280:295:302:319:362:374:383	25:31:46:80:90:170:278:281:296:303:320:363:375:384	0:0:1:2:3:6:7:7:8:8:8:9:9:10	D043564	inorganic pyrophosphate|inorganic pyrophosphate|PPi|PPi|PPi|PPi|PPi	ChemicalEntity	37:57:60:308:329:377:397	39:59:61:309:330:378:398	0:1:1:8:8:9:10	1:Association:2	L2R	NON-CROSS	319-320	333-334	56172	ANKH|ANKH|ANKH|ANKH|ANKH|ANKH|ANKH|ANKH|ANKH|ANKH|ANKH|ANKH|ANKH|ANKH	GeneOrGeneProduct	24:30:45:79:89:169:277:280:295:302:319:362:374:383	25:31:46:80:90:170:278:281:296:303:320:363:375:384	0:0:1:2:3:6:7:7:8:8:8:9:9:10	D006984	hypertrophy|hypertrophy	DiseaseOrPhenotypicFeature	333:400	334:401	8:10	1:NR:2	L2R	NON-CROSS	319-320	336-339	56172	ANKH|ANKH|ANKH|ANKH|ANKH|ANKH|ANKH|ANKH|ANKH|ANKH|ANKH|ANKH|ANKH|ANKH	GeneOrGeneProduct	24:30:45:79:89:169:277:280:295:302:319:362:374:383	25:31:46:80:90:170:278:281:296:303:320:363:375:384	0:0:1:2:3:6:7:7:8:8:8:9:9:10	1300	type X collagen	GeneOrGeneProduct	336	339	8	1:NR:2	L2R	CROSS	60-61	161-166	D043564	inorganic pyrophosphate|inorganic pyrophosphate|PPi|PPi|PPi|PPi|PPi	ChemicalEntity	37:57:60:308:329:377:397	39:59:61:309:330:378:398	0:1:1:8:8:9:10	c|SUB|G||A	G - to - A	SequenceVariant	161	166	6	1:NR:2	L2R	CROSS	240-248	308-309	D043564	inorganic pyrophosphate|inorganic pyrophosphate|PPi|PPi|PPi|PPi|PPi	ChemicalEntity	37:57:60:308:329:377:397	39:59:61:309:330:378:398	0:1:1:8:8:9:10	c|SUB|C|14|T	+ 14 bp C - to - T	SequenceVariant	240	248	7	1:NR:2	L2R	CROSS	252-254	308-309	D043564	inorganic pyrophosphate|inorganic pyrophosphate|PPi|PPi|PPi|PPi|PPi	ChemicalEntity	37:57:60:308:329:377:397	39:59:61:309:330:378:398	0:1:1:8:8:9:10	c|DEL||GAG	GAG deletion	SequenceVariant	252	254	7	1:NR:2	L2R	CROSS	265-273	308-309	D043564	inorganic pyrophosphate|inorganic pyrophosphate|PPi|PPi|PPi|PPi|PPi	ChemicalEntity	37:57:60:308:329:377:397	39:59:61:309:330:378:398	0:1:1:8:8:9:10	c|SUB|T|143|C	143 - bp T - to - C	SequenceVariant	265	273	7	1:NR:2	L2R	NON-CROSS	397-398	400-401	D043564	inorganic pyrophosphate|inorganic pyrophosphate|PPi|PPi|PPi|PPi|PPi	ChemicalEntity	37:57:60:308:329:377:397	39:59:61:309:330:378:398	0:1:1:8:8:9:10	D006984	hypertrophy|hypertrophy	DiseaseOrPhenotypicFeature	333:400	334:401	8:10	1:NR:2	L2R	NON-CROSS	329-330	336-339	D043564	inorganic pyrophosphate|inorganic pyrophosphate|PPi|PPi|PPi|PPi|PPi	ChemicalEntity	37:57:60:308:329:377:397	39:59:61:309:330:378:398	0:1:1:8:8:9:10	1300	type X collagen	GeneOrGeneProduct	336	339	8	1:NR:2	L2R	CROSS	161-166	333-334	c|SUB|G||A	G - to - A	SequenceVariant	161	166	6	D006984	hypertrophy|hypertrophy	DiseaseOrPhenotypicFeature	333:400	334:401	8:10	1:NR:2	L2R	CROSS	240-248	333-334	c|SUB|C|14|T	+ 14 bp C - to - T	SequenceVariant	240	248	7	D006984	hypertrophy|hypertrophy	DiseaseOrPhenotypicFeature	333:400	334:401	8:10	1:NR:2	L2R	CROSS	252-254	333-334	c|DEL||GAG	GAG deletion	SequenceVariant	252	254	7	D006984	hypertrophy|hypertrophy	DiseaseOrPhenotypicFeature	333:400	334:401	8:10	1:NR:2	L2R	CROSS	265-273	333-334	c|SUB|T|143|C	143 - bp T - to - C	SequenceVariant	265	273	7	D006984	hypertrophy|hypertrophy	DiseaseOrPhenotypicFeature	333:400	334:401	8:10	1:NR:2	L2R	NON-CROSS	333-334	336-339	D006984	hypertrophy|hypertrophy	DiseaseOrPhenotypicFeature	333:400	334:401	8:10	1300	type X collagen	GeneOrGeneProduct	336	339	8
22729903	Contribution of STAT4 gene single - nucleotide polymorphism to systemic lupus erythematosus in the Polish population .|The STAT4 has been found to be a susceptible gene in the development of systemic lupus erythematosus ( SLE ) in various populations .|There are evident population differences in the context of clinical manifestations of SLE , therefore we investigated the prevalence of the STAT4 G > C ( rs7582694 ) polymorphism in patients with SLE ( n = 253 ) and controls ( n = 521 ) in a sample of the Polish population .|We found that patients with the STAT4 C / G and CC genotypes exhibited a 1 . 583 - fold increased risk of SLE incidence ( 95 % CI = 1 . 168 - 2 . 145 , p = 0 . 003 ) , with OR for the C / C versus C / G and G / G genotypes was 1 . 967 ( 95 % CI = 1 . 152 - 3 . 358 , p = 0 . 0119 ) .|The OR for the STAT4 C allele frequency showed a 1 . 539 - fold increased risk of SLE ( 95 % CI = 1 . 209 - 1 . 959 , p = 0 . 0004 ) .|We also observed an increased frequency of STAT4 C / C and C / G genotypes in SLE patients with renal symptoms OR = 2 . 259 ( 1 . 365 - 3 . 738 , p = 0 . 0014 ) , ( p ( corr ) = 0 . 0238 ) and in SLE patients with neurologic manifestations OR = 2 . 867 ( 1 . 467 - 5 . 604 , p = 0 . 0016 ) , ( p ( corr ) = 0 . 0272 ) .|Moreover , we found a contribution of STAT4 C / C and C / G genotypes to the presence of the anti - snRNP Ab OR = 3 . 237 ( 1 . 667 - 6 . 288 , p = 0 . 0003 ) , ( p ( corr ) = 0 . 0051 ) and the presence of the anti - Scl - 70 Ab OR = 2 . 665 ( 1 . 380 - 5 . 147 , p = 0 . 0028 ) , ( p ( corr ) = 0 . 0476 ) .|Our studies confirmed an association of the STAT4 C ( rs7582694 ) variant with the development of SLE and occurrence of some clinical manifestations of the disease .	1:Association:2	R2L	NON-CROSS	9-12	2-3	D008180	systemic lupus erythematosus|systemic lupus erythematosus|SLE|SLE|SLE|SLE|SLE|SLE|SLE|SLE	DiseaseOrPhenotypicFeature	9:31:35:53:73:117:197:235:273:426	12:34:36:54:74:118:198:236:274:427	0:1:1:2:2:3:4:5:5:7	6775	STAT4|STAT4|STAT4|STAT4|STAT4|STAT4|STAT4|STAT4	GeneOrGeneProduct	2:18:62:100:183:225:317:416	3:19:63:101:184:226:318:417	0:1:2:3:4:5:6:7	1:Association:2	L2R	NON-CROSS	225-226	238-240	6775	STAT4|STAT4|STAT4|STAT4|STAT4|STAT4|STAT4|STAT4	GeneOrGeneProduct	2:18:62:100:183:225:317:416	3:19:63:101:184:226:318:417	0:1:2:3:4:5:6:7	D007674	renal symptoms	DiseaseOrPhenotypicFeature	238	240	5	1:Association:2	L2R	NON-CROSS	317-318	333-334	6775	STAT4|STAT4|STAT4|STAT4|STAT4|STAT4|STAT4|STAT4	GeneOrGeneProduct	2:18:62:100:183:225:317:416	3:19:63:101:184:226:318:417	0:1:2:3:4:5:6:7	57819	snRNP	GeneOrGeneProduct	333	334	6	1:Association:2	R2L	NON-CROSS	416-417	373-376	7150	Scl - 70	GeneOrGeneProduct	373	376	6	6775	STAT4|STAT4|STAT4|STAT4|STAT4|STAT4|STAT4|STAT4	GeneOrGeneProduct	2:18:62:100:183:225:317:416	3:19:63:101:184:226:318:417	0:1:2:3:4:5:6:7	1:Positive_Correlation:2	L2R	NON-CROSS	67-68	73-74	D008180	systemic lupus erythematosus|systemic lupus erythematosus|SLE|SLE|SLE|SLE|SLE|SLE|SLE|SLE	DiseaseOrPhenotypicFeature	9:31:35:53:73:117:197:235:273:426	12:34:36:54:74:118:198:236:274:427	0:1:1:2:2:3:4:5:5:7	rs7582694	G > C|rs7582694|rs7582694	SequenceVariant	63:67:419	66:68:420	2:2:7	1:NR:2	L2R	CROSS	273-274	333-334	D008180	systemic lupus erythematosus|systemic lupus erythematosus|SLE|SLE|SLE|SLE|SLE|SLE|SLE|SLE	DiseaseOrPhenotypicFeature	9:31:35:53:73:117:197:235:273:426	12:34:36:54:74:118:198:236:274:427	0:1:1:2:2:3:4:5:5:7	57819	snRNP	GeneOrGeneProduct	333	334	6	1:NR:2	L2R	CROSS	373-376	426-427	D008180	systemic lupus erythematosus|systemic lupus erythematosus|SLE|SLE|SLE|SLE|SLE|SLE|SLE|SLE	DiseaseOrPhenotypicFeature	9:31:35:53:73:117:197:235:273:426	12:34:36:54:74:118:198:236:274:427	0:1:1:2:2:3:4:5:5:7	7150	Scl - 70	GeneOrGeneProduct	373	376	6	1:Positive_Correlation:2	L2R	CROSS	67-68	238-240	rs7582694	G > C|rs7582694|rs7582694	SequenceVariant	63:67:419	66:68:420	2:2:7	D007674	renal symptoms	DiseaseOrPhenotypicFeature	238	240	5	1:NR:2	L2R	CROSS	238-240	333-334	D007674	renal symptoms	DiseaseOrPhenotypicFeature	238	240	5	57819	snRNP	GeneOrGeneProduct	333	334	6	1:NR:2	L2R	CROSS	238-240	373-376	D007674	renal symptoms	DiseaseOrPhenotypicFeature	238	240	5	7150	Scl - 70	GeneOrGeneProduct	373	376	6	1:NR:2	L2R	NON-CROSS	333-334	373-376	57819	snRNP	GeneOrGeneProduct	333	334	6	7150	Scl - 70	GeneOrGeneProduct	373	376	6
25277705	Leukemia inhibitory factor protects the lung during respiratory syncytial viral infection .|BACKGROUND : Respiratory syncytial virus ( RSV ) infects the lung epithelium where it stimulates the production of numerous host cytokines that are associated with disease burden and acute lung injury .|Characterizing the host cytokine response to RSV infection , the regulation of host cytokines and the impact of neutralizing an RSV - inducible cytokine during infection were undertaken in this study .|METHODS : A549 , primary human small airway epithelial ( SAE ) cells and wild - type , TIR - domain - containing adapter - inducing interferon - b ( Trif ) and mitochondrial antiviral - signaling protein ( Mavs ) knockout ( KO ) mice were infected with RSV and cytokine responses were investigated by ELISA , multiplex analysis and qPCR .|Neutralizing anti - leukemia inhibitory factor ( LIF ) IgG or control IgG was administered to a group of wild - type animals prior to RSV infection .|RESULTS AND DISCUSSION : RSV - infected A549 and SAE cells release a network of cytokines , including newly identified RSV - inducible cytokines LIF , migration inhibitory factor ( MIF ) , stem cell factor ( SCF ) , CCL27 , CXCL12 and stem cell growth factor beta ( SCGF - b ) .|These RSV - inducible cytokines were also observed in the airways of mice during an infection .|To identify the regulation of RSV inducible cytokines , Mavs and Trif deficient animals were infected with RSV .|In vivo induction of airway IL - 1b , IL - 4 , IL - 5 , IL - 6 , IL - 12 ( p40 ) , IFN - g , CCL2 , CCL5 , CCL3 , CXCL1 , IP - 10 / CXCL10 , IL - 22 , MIG / CXCL9 and MIF were dependent on Mavs expression in mice .|Loss of Trif expression in mice altered the RSV induction of IL - 1b , IL - 5 , CXCL12 , MIF , LIF , CXCL12 and IFN - g .|Silencing of retinoic acid - inducible gene - 1 ( RIG - I ) expression in A549 cells had a greater impact on RSV - inducible cytokines than melanoma differentiation - associated protein 5 ( MDA5 ) and laboratory of genetics and physiology 2 ( LGP2 ) , and Trif expression .|To evaluate the role of LIF in the airways during RSV infection , animals were treated with neutralizing anti - LIF IgG , which enhanced RSV pathology observed with increased airspace protein content , apoptosis and airway hyperresponsiveness compared to control IgG treatment .|CONCLUSIONS : RSV infection in the epithelium induces a network of immune factors to counter infection , primarily in a RIG - I dependent manner .|Expression of LIF protects the lung from lung injury and enhanced pathology during RSV infection .	1:NR:2	L2R	NON-CROSS	0-3	7-11	16878,3976	Leukemia inhibitory factor|LIF	GeneOrGeneProduct	0:476	3:477	0:13	D018357	respiratory syncytial viral infection|RSV infection|RSV infection|RSV - infected|RSV infection|RSV infection|RSV infection	DiseaseOrPhenotypicFeature	7:50:164:171:414:450:487	11:52:166:174:416:452:489	0:2:4:5:11:12:13	1:NR:2	L2R	CROSS	0-3	40-43	16878,3976	Leukemia inhibitory factor|LIF	GeneOrGeneProduct	0:476	3:477	0:13	D055371	acute lung injury	DiseaseOrPhenotypicFeature	40	43	1	1:NR:2	L2R	CROSS	463-464	476-477	16878,3976	Leukemia inhibitory factor|LIF	GeneOrGeneProduct	0:476	3:477	0:13	D007239	infection|infection|infection	DiseaseOrPhenotypicFeature	69:237:463	70:238:464	2:6:12	1:NR:2	L2R	CROSS	0-3	94-105	16878,3976	Leukemia inhibitory factor|LIF	GeneOrGeneProduct	0:476	3:477	0:13	106759	TIR - domain - containing adapter - inducing interferon - b|Trif|Trif|Trif	GeneOrGeneProduct	94:106:250:323	105:107:251:324	3:3:7:9	1:NR:2	L2R	CROSS	0-3	109-114	16878,3976	Leukemia inhibitory factor|LIF	GeneOrGeneProduct	0:476	3:477	0:13	228607	mitochondrial antiviral - signaling protein|Mavs|Mavs|Mavs	GeneOrGeneProduct	109:115:248:316	114:116:249:317	3:3:7:8	1:NR:2	L2R	CROSS	0-3	142-145	16878,3976	Leukemia inhibitory factor|LIF	GeneOrGeneProduct	0:476	3:477	0:13	3976	leukemia inhibitory factor|LIF|LIF	GeneOrGeneProduct	142:146:191	145:147:192	4:4:5	1:NR:2	L2R	CROSS	0-3	193-196	16878,3976	Leukemia inhibitory factor|LIF	GeneOrGeneProduct	0:476	3:477	0:13	4282	migration inhibitory factor|MIF	GeneOrGeneProduct	193:197	196:198	5:5	1:NR:2	L2R	CROSS	0-3	200-203	16878,3976	Leukemia inhibitory factor|LIF	GeneOrGeneProduct	0:476	3:477	0:13	4254	stem cell factor|SCF	GeneOrGeneProduct	200:204	203:205	5:5	1:NR:2	L2R	CROSS	0-3	207-208	16878,3976	Leukemia inhibitory factor|LIF	GeneOrGeneProduct	0:476	3:477	0:13	10850	CCL27	GeneOrGeneProduct	207	208	5	1:NR:2	L2R	CROSS	0-3	209-210	16878,3976	Leukemia inhibitory factor|LIF	GeneOrGeneProduct	0:476	3:477	0:13	6387	CXCL12	GeneOrGeneProduct	209	210	5	1:NR:2	L2R	CROSS	0-3	211-216	16878,3976	Leukemia inhibitory factor|LIF	GeneOrGeneProduct	0:476	3:477	0:13	6320	stem cell growth factor beta|SCGF - b	GeneOrGeneProduct	211:217	216:220	5:5	1:NR:2	L2R	CROSS	332-335	476-477	16878,3976	Leukemia inhibitory factor|LIF	GeneOrGeneProduct	0:476	3:477	0:13	16176	IL - 1b|IL - 1b	GeneOrGeneProduct	263:332	266:335	8:9	1:NR:2	L2R	CROSS	267-270	476-477	16878,3976	Leukemia inhibitory factor|LIF	GeneOrGeneProduct	0:476	3:477	0:13	16189	IL - 4	GeneOrGeneProduct	267	270	8	1:NR:2	L2R	CROSS	336-339	476-477	16878,3976	Leukemia inhibitory factor|LIF	GeneOrGeneProduct	0:476	3:477	0:13	16191	IL - 5|IL - 5	GeneOrGeneProduct	271:336	274:339	8:9	1:NR:2	L2R	CROSS	275-278	476-477	16878,3976	Leukemia inhibitory factor|LIF	GeneOrGeneProduct	0:476	3:477	0:13	16193	IL - 6	GeneOrGeneProduct	275	278	8	1:NR:2	L2R	CROSS	283-284	476-477	16878,3976	Leukemia inhibitory factor|LIF	GeneOrGeneProduct	0:476	3:477	0:13	16160	IL - 12|p40	GeneOrGeneProduct	279:283	282:284	8:8	1:NR:2	L2R	CROSS	348-351	476-477	16878,3976	Leukemia inhibitory factor|LIF	GeneOrGeneProduct	0:476	3:477	0:13	15978	IFN - g|IFN - g	GeneOrGeneProduct	286:348	289:351	8:9	1:NR:2	L2R	CROSS	290-291	476-477	16878,3976	Leukemia inhibitory factor|LIF	GeneOrGeneProduct	0:476	3:477	0:13	20296	CCL2	GeneOrGeneProduct	290	291	8	1:NR:2	L2R	CROSS	292-293	476-477	16878,3976	Leukemia inhibitory factor|LIF	GeneOrGeneProduct	0:476	3:477	0:13	20304	CCL5	GeneOrGeneProduct	292	293	8	1:NR:2	L2R	CROSS	294-295	476-477	16878,3976	Leukemia inhibitory factor|LIF	GeneOrGeneProduct	0:476	3:477	0:13	20302	CCL3	GeneOrGeneProduct	294	295	8	1:NR:2	L2R	CROSS	296-297	476-477	16878,3976	Leukemia inhibitory factor|LIF	GeneOrGeneProduct	0:476	3:477	0:13	14825	CXCL1	GeneOrGeneProduct	296	297	8	1:NR:2	L2R	CROSS	302-303	476-477	16878,3976	Leukemia inhibitory factor|LIF	GeneOrGeneProduct	0:476	3:477	0:13	15945	IP - 10|CXCL10	GeneOrGeneProduct	298:302	301:303	8:8	1:NR:2	L2R	CROSS	304-307	476-477	16878,3976	Leukemia inhibitory factor|LIF	GeneOrGeneProduct	0:476	3:477	0:13	50929	IL - 22	GeneOrGeneProduct	304	307	8	1:NR:2	L2R	CROSS	310-311	476-477	16878,3976	Leukemia inhibitory factor|LIF	GeneOrGeneProduct	0:476	3:477	0:13	17329	MIG|CXCL9	GeneOrGeneProduct	308:310	309:311	8:8	1:NR:2	L2R	CROSS	342-343	476-477	16878,3976	Leukemia inhibitory factor|LIF	GeneOrGeneProduct	0:476	3:477	0:13	17319	MIF|MIF	GeneOrGeneProduct	312:342	313:343	8:9	1:NR:2	L2R	CROSS	346-347	476-477	16878,3976	Leukemia inhibitory factor|LIF	GeneOrGeneProduct	0:476	3:477	0:13	20315	CXCL12|CXCL12	GeneOrGeneProduct	340:346	341:347	9:9	1:NR:2	L2R	CROSS	424-425	476-477	16878,3976	Leukemia inhibitory factor|LIF	GeneOrGeneProduct	0:476	3:477	0:13	16878	LIF|LIF|LIF	GeneOrGeneProduct	344:409:424	345:410:425	9:11:11	1:NR:2	L2R	CROSS	468-471	476-477	16878,3976	Leukemia inhibitory factor|LIF	GeneOrGeneProduct	0:476	3:477	0:13	23586	retinoic acid - inducible gene - 1|RIG - I|RIG - I	GeneOrGeneProduct	354:362:468	361:365:471	10:10:12	1:NR:2	L2R	CROSS	387-388	476-477	16878,3976	Leukemia inhibitory factor|LIF	GeneOrGeneProduct	0:476	3:477	0:13	64135	melanoma differentiation - associated protein 5|MDA5	GeneOrGeneProduct	380:387	386:388	10:10	1:NR:2	L2R	CROSS	397-398	476-477	16878,3976	Leukemia inhibitory factor|LIF	GeneOrGeneProduct	0:476	3:477	0:13	79132	laboratory of genetics and physiology 2|LGP2	GeneOrGeneProduct	390:397	396:398	10:10	1:NR:2	L2R	CROSS	401-402	476-477	16878,3976	Leukemia inhibitory factor|LIF	GeneOrGeneProduct	0:476	3:477	0:13	148022	Trif	GeneOrGeneProduct	401	402	10	1:NR:2	L2R	NON-CROSS	476-477	481-483	16878,3976	Leukemia inhibitory factor|LIF	GeneOrGeneProduct	0:476	3:477	0:13	D055370	lung injury	DiseaseOrPhenotypicFeature	481	483	13	1:Positive_Correlation:2	L2R	CROSS	50-52	94-105	D018357	respiratory syncytial viral infection|RSV infection|RSV infection|RSV - infected|RSV infection|RSV infection|RSV infection	DiseaseOrPhenotypicFeature	7:50:164:171:414:450:487	11:52:166:174:416:452:489	0:2:4:5:11:12:13	106759	TIR - domain - containing adapter - inducing interferon - b|Trif|Trif|Trif	GeneOrGeneProduct	94:106:250:323	105:107:251:324	3:3:7:9	1:Positive_Correlation:2	L2R	CROSS	115-116	164-166	D018357	respiratory syncytial viral infection|RSV infection|RSV infection|RSV - infected|RSV infection|RSV infection|RSV infection	DiseaseOrPhenotypicFeature	7:50:164:171:414:450:487	11:52:166:174:416:452:489	0:2:4:5:11:12:13	228607	mitochondrial antiviral - signaling protein|Mavs|Mavs|Mavs	GeneOrGeneProduct	109:115:248:316	114:116:249:317	3:3:7:8	1:Positive_Correlation:2	R2L	NON-CROSS	191-192	171-174	3976	leukemia inhibitory factor|LIF|LIF	GeneOrGeneProduct	142:146:191	145:147:192	4:4:5	D018357	respiratory syncytial viral infection|RSV infection|RSV infection|RSV - infected|RSV infection|RSV infection|RSV infection	DiseaseOrPhenotypicFeature	7:50:164:171:414:450:487	11:52:166:174:416:452:489	0:2:4:5:11:12:13	1:Positive_Correlation:2	L2R	NON-CROSS	171-174	193-196	D018357	respiratory syncytial viral infection|RSV infection|RSV infection|RSV - infected|RSV infection|RSV infection|RSV infection	DiseaseOrPhenotypicFeature	7:50:164:171:414:450:487	11:52:166:174:416:452:489	0:2:4:5:11:12:13	4282	migration inhibitory factor|MIF	GeneOrGeneProduct	193:197	196:198	5:5	1:Positive_Correlation:2	L2R	NON-CROSS	171-174	200-203	D018357	respiratory syncytial viral infection|RSV infection|RSV infection|RSV - infected|RSV infection|RSV infection|RSV infection	DiseaseOrPhenotypicFeature	7:50:164:171:414:450:487	11:52:166:174:416:452:489	0:2:4:5:11:12:13	4254	stem cell factor|SCF	GeneOrGeneProduct	200:204	203:205	5:5	1:Positive_Correlation:2	L2R	NON-CROSS	171-174	207-208	D018357	respiratory syncytial viral infection|RSV infection|RSV infection|RSV - infected|RSV infection|RSV infection|RSV infection	DiseaseOrPhenotypicFeature	7:50:164:171:414:450:487	11:52:166:174:416:452:489	0:2:4:5:11:12:13	10850	CCL27	GeneOrGeneProduct	207	208	5	1:Positive_Correlation:2	L2R	NON-CROSS	171-174	209-210	D018357	respiratory syncytial viral infection|RSV infection|RSV infection|RSV - infected|RSV infection|RSV infection|RSV infection	DiseaseOrPhenotypicFeature	7:50:164:171:414:450:487	11:52:166:174:416:452:489	0:2:4:5:11:12:13	6387	CXCL12	GeneOrGeneProduct	209	210	5	1:Positive_Correlation:2	L2R	NON-CROSS	171-174	211-216	D018357	respiratory syncytial viral infection|RSV infection|RSV infection|RSV - infected|RSV infection|RSV infection|RSV infection	DiseaseOrPhenotypicFeature	7:50:164:171:414:450:487	11:52:166:174:416:452:489	0:2:4:5:11:12:13	6320	stem cell growth factor beta|SCGF - b	GeneOrGeneProduct	211:217	216:220	5:5	1:NR:2	L2R	CROSS	332-335	414-416	D018357	respiratory syncytial viral infection|RSV infection|RSV infection|RSV - infected|RSV infection|RSV infection|RSV infection	DiseaseOrPhenotypicFeature	7:50:164:171:414:450:487	11:52:166:174:416:452:489	0:2:4:5:11:12:13	16176	IL - 1b|IL - 1b	GeneOrGeneProduct	263:332	266:335	8:9	1:NR:2	L2R	CROSS	171-174	267-270	D018357	respiratory syncytial viral infection|RSV infection|RSV infection|RSV - infected|RSV infection|RSV infection|RSV infection	DiseaseOrPhenotypicFeature	7:50:164:171:414:450:487	11:52:166:174:416:452:489	0:2:4:5:11:12:13	16189	IL - 4	GeneOrGeneProduct	267	270	8	1:NR:2	L2R	CROSS	336-339	414-416	D018357	respiratory syncytial viral infection|RSV infection|RSV infection|RSV - infected|RSV infection|RSV infection|RSV infection	DiseaseOrPhenotypicFeature	7:50:164:171:414:450:487	11:52:166:174:416:452:489	0:2:4:5:11:12:13	16191	IL - 5|IL - 5	GeneOrGeneProduct	271:336	274:339	8:9	1:NR:2	L2R	CROSS	171-174	275-278	D018357	respiratory syncytial viral infection|RSV infection|RSV infection|RSV - infected|RSV infection|RSV infection|RSV infection	DiseaseOrPhenotypicFeature	7:50:164:171:414:450:487	11:52:166:174:416:452:489	0:2:4:5:11:12:13	16193	IL - 6	GeneOrGeneProduct	275	278	8	1:NR:2	L2R	CROSS	171-174	279-282	D018357	respiratory syncytial viral infection|RSV infection|RSV infection|RSV - infected|RSV infection|RSV infection|RSV infection	DiseaseOrPhenotypicFeature	7:50:164:171:414:450:487	11:52:166:174:416:452:489	0:2:4:5:11:12:13	16160	IL - 12|p40	GeneOrGeneProduct	279:283	282:284	8:8	1:NR:2	L2R	CROSS	348-351	414-416	D018357	respiratory syncytial viral infection|RSV infection|RSV infection|RSV - infected|RSV infection|RSV infection|RSV infection	DiseaseOrPhenotypicFeature	7:50:164:171:414:450:487	11:52:166:174:416:452:489	0:2:4:5:11:12:13	15978	IFN - g|IFN - g	GeneOrGeneProduct	286:348	289:351	8:9	1:NR:2	L2R	CROSS	171-174	290-291	D018357	respiratory syncytial viral infection|RSV infection|RSV infection|RSV - infected|RSV infection|RSV infection|RSV infection	DiseaseOrPhenotypicFeature	7:50:164:171:414:450:487	11:52:166:174:416:452:489	0:2:4:5:11:12:13	20296	CCL2	GeneOrGeneProduct	290	291	8	1:NR:2	L2R	CROSS	171-174	292-293	D018357	respiratory syncytial viral infection|RSV infection|RSV infection|RSV - infected|RSV infection|RSV infection|RSV infection	DiseaseOrPhenotypicFeature	7:50:164:171:414:450:487	11:52:166:174:416:452:489	0:2:4:5:11:12:13	20304	CCL5	GeneOrGeneProduct	292	293	8	1:NR:2	L2R	CROSS	294-295	414-416	D018357	respiratory syncytial viral infection|RSV infection|RSV infection|RSV - infected|RSV infection|RSV infection|RSV infection	DiseaseOrPhenotypicFeature	7:50:164:171:414:450:487	11:52:166:174:416:452:489	0:2:4:5:11:12:13	20302	CCL3	GeneOrGeneProduct	294	295	8	1:NR:2	L2R	CROSS	296-297	414-416	D018357	respiratory syncytial viral infection|RSV infection|RSV infection|RSV - infected|RSV infection|RSV infection|RSV infection	DiseaseOrPhenotypicFeature	7:50:164:171:414:450:487	11:52:166:174:416:452:489	0:2:4:5:11:12:13	14825	CXCL1	GeneOrGeneProduct	296	297	8	1:NR:2	L2R	CROSS	302-303	414-416	D018357	respiratory syncytial viral infection|RSV infection|RSV infection|RSV - infected|RSV infection|RSV infection|RSV infection	DiseaseOrPhenotypicFeature	7:50:164:171:414:450:487	11:52:166:174:416:452:489	0:2:4:5:11:12:13	15945	IP - 10|CXCL10	GeneOrGeneProduct	298:302	301:303	8:8	1:NR:2	L2R	CROSS	304-307	414-416	D018357	respiratory syncytial viral infection|RSV infection|RSV infection|RSV - infected|RSV infection|RSV infection|RSV infection	DiseaseOrPhenotypicFeature	7:50:164:171:414:450:487	11:52:166:174:416:452:489	0:2:4:5:11:12:13	50929	IL - 22	GeneOrGeneProduct	304	307	8	1:NR:2	L2R	CROSS	310-311	414-416	D018357	respiratory syncytial viral infection|RSV infection|RSV infection|RSV - infected|RSV infection|RSV infection|RSV infection	DiseaseOrPhenotypicFeature	7:50:164:171:414:450:487	11:52:166:174:416:452:489	0:2:4:5:11:12:13	17329	MIG|CXCL9	GeneOrGeneProduct	308:310	309:311	8:8	1:NR:2	L2R	CROSS	342-343	414-416	D018357	respiratory syncytial viral infection|RSV infection|RSV infection|RSV - infected|RSV infection|RSV infection|RSV infection	DiseaseOrPhenotypicFeature	7:50:164:171:414:450:487	11:52:166:174:416:452:489	0:2:4:5:11:12:13	17319	MIF|MIF	GeneOrGeneProduct	312:342	313:343	8:9	1:NR:2	L2R	CROSS	346-347	414-416	D018357	respiratory syncytial viral infection|RSV infection|RSV infection|RSV - infected|RSV infection|RSV infection|RSV infection	DiseaseOrPhenotypicFeature	7:50:164:171:414:450:487	11:52:166:174:416:452:489	0:2:4:5:11:12:13	20315	CXCL12|CXCL12	GeneOrGeneProduct	340:346	341:347	9:9	1:Association:2	R2L	NON-CROSS	414-416	409-410	16878	LIF|LIF|LIF	GeneOrGeneProduct	344:409:424	345:410:425	9:11:11	D018357	respiratory syncytial viral infection|RSV infection|RSV infection|RSV - infected|RSV infection|RSV infection|RSV infection	DiseaseOrPhenotypicFeature	7:50:164:171:414:450:487	11:52:166:174:416:452:489	0:2:4:5:11:12:13	1:Association:2	L2R	NON-CROSS	450-452	468-471	D018357	respiratory syncytial viral infection|RSV infection|RSV infection|RSV - infected|RSV infection|RSV infection|RSV infection	DiseaseOrPhenotypicFeature	7:50:164:171:414:450:487	11:52:166:174:416:452:489	0:2:4:5:11:12:13	23586	retinoic acid - inducible gene - 1|RIG - I|RIG - I	GeneOrGeneProduct	354:362:468	361:365:471	10:10:12	1:NR:2	L2R	CROSS	387-388	414-416	D018357	respiratory syncytial viral infection|RSV infection|RSV infection|RSV - infected|RSV infection|RSV infection|RSV infection	DiseaseOrPhenotypicFeature	7:50:164:171:414:450:487	11:52:166:174:416:452:489	0:2:4:5:11:12:13	64135	melanoma differentiation - associated protein 5|MDA5	GeneOrGeneProduct	380:387	386:388	10:10	1:NR:2	L2R	CROSS	397-398	414-416	D018357	respiratory syncytial viral infection|RSV infection|RSV infection|RSV - infected|RSV infection|RSV infection|RSV infection	DiseaseOrPhenotypicFeature	7:50:164:171:414:450:487	11:52:166:174:416:452:489	0:2:4:5:11:12:13	79132	laboratory of genetics and physiology 2|LGP2	GeneOrGeneProduct	390:397	396:398	10:10	1:NR:2	L2R	CROSS	401-402	414-416	D018357	respiratory syncytial viral infection|RSV infection|RSV infection|RSV - infected|RSV infection|RSV infection|RSV infection	DiseaseOrPhenotypicFeature	7:50:164:171:414:450:487	11:52:166:174:416:452:489	0:2:4:5:11:12:13	148022	Trif	GeneOrGeneProduct	401	402	10	1:NR:2	L2R	CROSS	40-43	94-105	D055371	acute lung injury	DiseaseOrPhenotypicFeature	40	43	1	106759	TIR - domain - containing adapter - inducing interferon - b|Trif|Trif|Trif	GeneOrGeneProduct	94:106:250:323	105:107:251:324	3:3:7:9	1:NR:2	L2R	CROSS	40-43	109-114	D055371	acute lung injury	DiseaseOrPhenotypicFeature	40	43	1	228607	mitochondrial antiviral - signaling protein|Mavs|Mavs|Mavs	GeneOrGeneProduct	109:115:248:316	114:116:249:317	3:3:7:8	1:NR:2	L2R	CROSS	40-43	142-145	D055371	acute lung injury	DiseaseOrPhenotypicFeature	40	43	1	3976	leukemia inhibitory factor|LIF|LIF	GeneOrGeneProduct	142:146:191	145:147:192	4:4:5	1:NR:2	L2R	CROSS	40-43	193-196	D055371	acute lung injury	DiseaseOrPhenotypicFeature	40	43	1	4282	migration inhibitory factor|MIF	GeneOrGeneProduct	193:197	196:198	5:5	1:NR:2	L2R	CROSS	40-43	200-203	D055371	acute lung injury	DiseaseOrPhenotypicFeature	40	43	1	4254	stem cell factor|SCF	GeneOrGeneProduct	200:204	203:205	5:5	1:NR:2	L2R	CROSS	40-43	207-208	D055371	acute lung injury	DiseaseOrPhenotypicFeature	40	43	1	10850	CCL27	GeneOrGeneProduct	207	208	5	1:NR:2	L2R	CROSS	40-43	209-210	D055371	acute lung injury	DiseaseOrPhenotypicFeature	40	43	1	6387	CXCL12	GeneOrGeneProduct	209	210	5	1:NR:2	L2R	CROSS	40-43	211-216	D055371	acute lung injury	DiseaseOrPhenotypicFeature	40	43	1	6320	stem cell growth factor beta|SCGF - b	GeneOrGeneProduct	211:217	216:220	5:5	1:NR:2	L2R	CROSS	40-43	263-266	D055371	acute lung injury	DiseaseOrPhenotypicFeature	40	43	1	16176	IL - 1b|IL - 1b	GeneOrGeneProduct	263:332	266:335	8:9	1:NR:2	L2R	CROSS	40-43	267-270	D055371	acute lung injury	DiseaseOrPhenotypicFeature	40	43	1	16189	IL - 4	GeneOrGeneProduct	267	270	8	1:NR:2	L2R	CROSS	40-43	271-274	D055371	acute lung injury	DiseaseOrPhenotypicFeature	40	43	1	16191	IL - 5|IL - 5	GeneOrGeneProduct	271:336	274:339	8:9	1:NR:2	L2R	CROSS	40-43	275-278	D055371	acute lung injury	DiseaseOrPhenotypicFeature	40	43	1	16193	IL - 6	GeneOrGeneProduct	275	278	8	1:NR:2	L2R	CROSS	40-43	279-282	D055371	acute lung injury	DiseaseOrPhenotypicFeature	40	43	1	16160	IL - 12|p40	GeneOrGeneProduct	279:283	282:284	8:8	1:NR:2	L2R	CROSS	40-43	286-289	D055371	acute lung injury	DiseaseOrPhenotypicFeature	40	43	1	15978	IFN - g|IFN - g	GeneOrGeneProduct	286:348	289:351	8:9	1:NR:2	L2R	CROSS	40-43	290-291	D055371	acute lung injury	DiseaseOrPhenotypicFeature	40	43	1	20296	CCL2	GeneOrGeneProduct	290	291	8	1:NR:2	L2R	CROSS	40-43	292-293	D055371	acute lung injury	DiseaseOrPhenotypicFeature	40	43	1	20304	CCL5	GeneOrGeneProduct	292	293	8	1:NR:2	L2R	CROSS	40-43	294-295	D055371	acute lung injury	DiseaseOrPhenotypicFeature	40	43	1	20302	CCL3	GeneOrGeneProduct	294	295	8	1:NR:2	L2R	CROSS	40-43	296-297	D055371	acute lung injury	DiseaseOrPhenotypicFeature	40	43	1	14825	CXCL1	GeneOrGeneProduct	296	297	8	1:NR:2	L2R	CROSS	40-43	298-301	D055371	acute lung injury	DiseaseOrPhenotypicFeature	40	43	1	15945	IP - 10|CXCL10	GeneOrGeneProduct	298:302	301:303	8:8	1:NR:2	L2R	CROSS	40-43	304-307	D055371	acute lung injury	DiseaseOrPhenotypicFeature	40	43	1	50929	IL - 22	GeneOrGeneProduct	304	307	8	1:NR:2	L2R	CROSS	40-43	308-309	D055371	acute lung injury	DiseaseOrPhenotypicFeature	40	43	1	17329	MIG|CXCL9	GeneOrGeneProduct	308:310	309:311	8:8	1:NR:2	L2R	CROSS	40-43	312-313	D055371	acute lung injury	DiseaseOrPhenotypicFeature	40	43	1	17319	MIF|MIF	GeneOrGeneProduct	312:342	313:343	8:9	1:NR:2	L2R	CROSS	40-43	340-341	D055371	acute lung injury	DiseaseOrPhenotypicFeature	40	43	1	20315	CXCL12|CXCL12	GeneOrGeneProduct	340:346	341:347	9:9	1:NR:2	L2R	CROSS	40-43	344-345	D055371	acute lung injury	DiseaseOrPhenotypicFeature	40	43	1	16878	LIF|LIF|LIF	GeneOrGeneProduct	344:409:424	345:410:425	9:11:11	1:NR:2	L2R	CROSS	40-43	354-361	D055371	acute lung injury	DiseaseOrPhenotypicFeature	40	43	1	23586	retinoic acid - inducible gene - 1|RIG - I|RIG - I	GeneOrGeneProduct	354:362:468	361:365:471	10:10:12	1:NR:2	L2R	CROSS	40-43	380-386	D055371	acute lung injury	DiseaseOrPhenotypicFeature	40	43	1	64135	melanoma differentiation - associated protein 5|MDA5	GeneOrGeneProduct	380:387	386:388	10:10	1:NR:2	L2R	CROSS	40-43	390-396	D055371	acute lung injury	DiseaseOrPhenotypicFeature	40	43	1	79132	laboratory of genetics and physiology 2|LGP2	GeneOrGeneProduct	390:397	396:398	10:10	1:NR:2	L2R	CROSS	40-43	401-402	D055371	acute lung injury	DiseaseOrPhenotypicFeature	40	43	1	148022	Trif	GeneOrGeneProduct	401	402	10	1:NR:2	L2R	CROSS	237-238	250-251	D007239	infection|infection|infection	DiseaseOrPhenotypicFeature	69:237:463	70:238:464	2:6:12	106759	TIR - domain - containing adapter - inducing interferon - b|Trif|Trif|Trif	GeneOrGeneProduct	94:106:250:323	105:107:251:324	3:3:7:9	1:NR:2	L2R	CROSS	237-238	248-249	D007239	infection|infection|infection	DiseaseOrPhenotypicFeature	69:237:463	70:238:464	2:6:12	228607	mitochondrial antiviral - signaling protein|Mavs|Mavs|Mavs	GeneOrGeneProduct	109:115:248:316	114:116:249:317	3:3:7:8	1:Association:2	R2L	CROSS	237-238	191-192	3976	leukemia inhibitory factor|LIF|LIF	GeneOrGeneProduct	142:146:191	145:147:192	4:4:5	D007239	infection|infection|infection	DiseaseOrPhenotypicFeature	69:237:463	70:238:464	2:6:12	1:Association:2	R2L	CROSS	237-238	197-198	4282	migration inhibitory factor|MIF	GeneOrGeneProduct	193:197	196:198	5:5	D007239	infection|infection|infection	DiseaseOrPhenotypicFeature	69:237:463	70:238:464	2:6:12	1:Association:2	R2L	CROSS	237-238	204-205	4254	stem cell factor|SCF	GeneOrGeneProduct	200:204	203:205	5:5	D007239	infection|infection|infection	DiseaseOrPhenotypicFeature	69:237:463	70:238:464	2:6:12	1:Association:2	R2L	CROSS	237-238	207-208	10850	CCL27	GeneOrGeneProduct	207	208	5	D007239	infection|infection|infection	DiseaseOrPhenotypicFeature	69:237:463	70:238:464	2:6:12	1:Association:2	R2L	CROSS	237-238	209-210	6387	CXCL12	GeneOrGeneProduct	209	210	5	D007239	infection|infection|infection	DiseaseOrPhenotypicFeature	69:237:463	70:238:464	2:6:12	1:Association:2	R2L	CROSS	237-238	217-220	6320	stem cell growth factor beta|SCGF - b	GeneOrGeneProduct	211:217	216:220	5:5	D007239	infection|infection|infection	DiseaseOrPhenotypicFeature	69:237:463	70:238:464	2:6:12	1:NR:2	L2R	CROSS	237-238	263-266	D007239	infection|infection|infection	DiseaseOrPhenotypicFeature	69:237:463	70:238:464	2:6:12	16176	IL - 1b|IL - 1b	GeneOrGeneProduct	263:332	266:335	8:9	1:NR:2	L2R	CROSS	237-238	267-270	D007239	infection|infection|infection	DiseaseOrPhenotypicFeature	69:237:463	70:238:464	2:6:12	16189	IL - 4	GeneOrGeneProduct	267	270	8	1:NR:2	L2R	CROSS	237-238	271-274	D007239	infection|infection|infection	DiseaseOrPhenotypicFeature	69:237:463	70:238:464	2:6:12	16191	IL - 5|IL - 5	GeneOrGeneProduct	271:336	274:339	8:9	1:NR:2	L2R	CROSS	237-238	275-278	D007239	infection|infection|infection	DiseaseOrPhenotypicFeature	69:237:463	70:238:464	2:6:12	16193	IL - 6	GeneOrGeneProduct	275	278	8	1:NR:2	L2R	CROSS	237-238	279-282	D007239	infection|infection|infection	DiseaseOrPhenotypicFeature	69:237:463	70:238:464	2:6:12	16160	IL - 12|p40	GeneOrGeneProduct	279:283	282:284	8:8	1:NR:2	L2R	CROSS	237-238	286-289	D007239	infection|infection|infection	DiseaseOrPhenotypicFeature	69:237:463	70:238:464	2:6:12	15978	IFN - g|IFN - g	GeneOrGeneProduct	286:348	289:351	8:9	1:NR:2	L2R	CROSS	237-238	290-291	D007239	infection|infection|infection	DiseaseOrPhenotypicFeature	69:237:463	70:238:464	2:6:12	20296	CCL2	GeneOrGeneProduct	290	291	8	1:NR:2	L2R	CROSS	237-238	292-293	D007239	infection|infection|infection	DiseaseOrPhenotypicFeature	69:237:463	70:238:464	2:6:12	20304	CCL5	GeneOrGeneProduct	292	293	8	1:NR:2	L2R	CROSS	237-238	294-295	D007239	infection|infection|infection	DiseaseOrPhenotypicFeature	69:237:463	70:238:464	2:6:12	20302	CCL3	GeneOrGeneProduct	294	295	8	1:NR:2	L2R	CROSS	237-238	296-297	D007239	infection|infection|infection	DiseaseOrPhenotypicFeature	69:237:463	70:238:464	2:6:12	14825	CXCL1	GeneOrGeneProduct	296	297	8	1:NR:2	L2R	CROSS	237-238	298-301	D007239	infection|infection|infection	DiseaseOrPhenotypicFeature	69:237:463	70:238:464	2:6:12	15945	IP - 10|CXCL10	GeneOrGeneProduct	298:302	301:303	8:8	1:NR:2	L2R	CROSS	237-238	304-307	D007239	infection|infection|infection	DiseaseOrPhenotypicFeature	69:237:463	70:238:464	2:6:12	50929	IL - 22	GeneOrGeneProduct	304	307	8	1:NR:2	L2R	CROSS	237-238	308-309	D007239	infection|infection|infection	DiseaseOrPhenotypicFeature	69:237:463	70:238:464	2:6:12	17329	MIG|CXCL9	GeneOrGeneProduct	308:310	309:311	8:8	1:NR:2	L2R	CROSS	237-238	312-313	D007239	infection|infection|infection	DiseaseOrPhenotypicFeature	69:237:463	70:238:464	2:6:12	17319	MIF|MIF	GeneOrGeneProduct	312:342	313:343	8:9	1:NR:2	L2R	CROSS	237-238	340-341	D007239	infection|infection|infection	DiseaseOrPhenotypicFeature	69:237:463	70:238:464	2:6:12	20315	CXCL12|CXCL12	GeneOrGeneProduct	340:346	341:347	9:9	1:NR:2	L2R	CROSS	424-425	463-464	D007239	infection|infection|infection	DiseaseOrPhenotypicFeature	69:237:463	70:238:464	2:6:12	16878	LIF|LIF|LIF	GeneOrGeneProduct	344:409:424	345:410:425	9:11:11	1:Association:2	R2L	NON-CROSS	468-471	463-464	23586	retinoic acid - inducible gene - 1|RIG - I|RIG - I	GeneOrGeneProduct	354:362:468	361:365:471	10:10:12	D007239	infection|infection|infection	DiseaseOrPhenotypicFeature	69:237:463	70:238:464	2:6:12	1:NR:2	L2R	CROSS	387-388	463-464	D007239	infection|infection|infection	DiseaseOrPhenotypicFeature	69:237:463	70:238:464	2:6:12	64135	melanoma differentiation - associated protein 5|MDA5	GeneOrGeneProduct	380:387	386:388	10:10	1:NR:2	L2R	CROSS	397-398	463-464	D007239	infection|infection|infection	DiseaseOrPhenotypicFeature	69:237:463	70:238:464	2:6:12	79132	laboratory of genetics and physiology 2|LGP2	GeneOrGeneProduct	390:397	396:398	10:10	1:NR:2	L2R	CROSS	401-402	463-464	D007239	infection|infection|infection	DiseaseOrPhenotypicFeature	69:237:463	70:238:464	2:6:12	148022	Trif	GeneOrGeneProduct	401	402	10	1:NR:2	L2R	NON-CROSS	248-249	250-251	106759	TIR - domain - containing adapter - inducing interferon - b|Trif|Trif|Trif	GeneOrGeneProduct	94:106:250:323	105:107:251:324	3:3:7:9	228607	mitochondrial antiviral - signaling protein|Mavs|Mavs|Mavs	GeneOrGeneProduct	109:115:248:316	114:116:249:317	3:3:7:8	1:NR:2	L2R	CROSS	106-107	142-145	106759	TIR - domain - containing adapter - inducing interferon - b|Trif|Trif|Trif	GeneOrGeneProduct	94:106:250:323	105:107:251:324	3:3:7:9	3976	leukemia inhibitory factor|LIF|LIF	GeneOrGeneProduct	142:146:191	145:147:192	4:4:5	1:NR:2	L2R	CROSS	197-198	250-251	106759	TIR - domain - containing adapter - inducing interferon - b|Trif|Trif|Trif	GeneOrGeneProduct	94:106:250:323	105:107:251:324	3:3:7:9	4282	migration inhibitory factor|MIF	GeneOrGeneProduct	193:197	196:198	5:5	1:NR:2	L2R	CROSS	204-205	250-251	106759	TIR - domain - containing adapter - inducing interferon - b|Trif|Trif|Trif	GeneOrGeneProduct	94:106:250:323	105:107:251:324	3:3:7:9	4254	stem cell factor|SCF	GeneOrGeneProduct	200:204	203:205	5:5	1:NR:2	L2R	CROSS	207-208	250-251	106759	TIR - domain - containing adapter - inducing interferon - b|Trif|Trif|Trif	GeneOrGeneProduct	94:106:250:323	105:107:251:324	3:3:7:9	10850	CCL27	GeneOrGeneProduct	207	208	5	1:NR:2	L2R	CROSS	209-210	250-251	106759	TIR - domain - containing adapter - inducing interferon - b|Trif|Trif|Trif	GeneOrGeneProduct	94:106:250:323	105:107:251:324	3:3:7:9	6387	CXCL12	GeneOrGeneProduct	209	210	5	1:NR:2	L2R	CROSS	217-220	250-251	106759	TIR - domain - containing adapter - inducing interferon - b|Trif|Trif|Trif	GeneOrGeneProduct	94:106:250:323	105:107:251:324	3:3:7:9	6320	stem cell growth factor beta|SCGF - b	GeneOrGeneProduct	211:217	216:220	5:5	1:Association:2	L2R	NON-CROSS	323-324	332-335	106759	TIR - domain - containing adapter - inducing interferon - b|Trif|Trif|Trif	GeneOrGeneProduct	94:106:250:323	105:107:251:324	3:3:7:9	16176	IL - 1b|IL - 1b	GeneOrGeneProduct	263:332	266:335	8:9	1:NR:2	L2R	CROSS	250-251	267-270	106759	TIR - domain - containing adapter - inducing interferon - b|Trif|Trif|Trif	GeneOrGeneProduct	94:106:250:323	105:107:251:324	3:3:7:9	16189	IL - 4	GeneOrGeneProduct	267	270	8	1:Association:2	L2R	NON-CROSS	323-324	336-339	106759	TIR - domain - containing adapter - inducing interferon - b|Trif|Trif|Trif	GeneOrGeneProduct	94:106:250:323	105:107:251:324	3:3:7:9	16191	IL - 5|IL - 5	GeneOrGeneProduct	271:336	274:339	8:9	1:NR:2	L2R	CROSS	250-251	275-278	106759	TIR - domain - containing adapter - inducing interferon - b|Trif|Trif|Trif	GeneOrGeneProduct	94:106:250:323	105:107:251:324	3:3:7:9	16193	IL - 6	GeneOrGeneProduct	275	278	8	1:NR:2	L2R	CROSS	250-251	279-282	106759	TIR - domain - containing adapter - inducing interferon - b|Trif|Trif|Trif	GeneOrGeneProduct	94:106:250:323	105:107:251:324	3:3:7:9	16160	IL - 12|p40	GeneOrGeneProduct	279:283	282:284	8:8	1:Association:2	L2R	NON-CROSS	323-324	348-351	106759	TIR - domain - containing adapter - inducing interferon - b|Trif|Trif|Trif	GeneOrGeneProduct	94:106:250:323	105:107:251:324	3:3:7:9	15978	IFN - g|IFN - g	GeneOrGeneProduct	286:348	289:351	8:9	1:NR:2	L2R	CROSS	290-291	323-324	106759	TIR - domain - containing adapter - inducing interferon - b|Trif|Trif|Trif	GeneOrGeneProduct	94:106:250:323	105:107:251:324	3:3:7:9	20296	CCL2	GeneOrGeneProduct	290	291	8	1:NR:2	L2R	CROSS	292-293	323-324	106759	TIR - domain - containing adapter - inducing interferon - b|Trif|Trif|Trif	GeneOrGeneProduct	94:106:250:323	105:107:251:324	3:3:7:9	20304	CCL5	GeneOrGeneProduct	292	293	8	1:NR:2	L2R	CROSS	294-295	323-324	106759	TIR - domain - containing adapter - inducing interferon - b|Trif|Trif|Trif	GeneOrGeneProduct	94:106:250:323	105:107:251:324	3:3:7:9	20302	CCL3	GeneOrGeneProduct	294	295	8	1:NR:2	L2R	CROSS	296-297	323-324	106759	TIR - domain - containing adapter - inducing interferon - b|Trif|Trif|Trif	GeneOrGeneProduct	94:106:250:323	105:107:251:324	3:3:7:9	14825	CXCL1	GeneOrGeneProduct	296	297	8	1:NR:2	L2R	CROSS	302-303	323-324	106759	TIR - domain - containing adapter - inducing interferon - b|Trif|Trif|Trif	GeneOrGeneProduct	94:106:250:323	105:107:251:324	3:3:7:9	15945	IP - 10|CXCL10	GeneOrGeneProduct	298:302	301:303	8:8	1:NR:2	L2R	CROSS	304-307	323-324	106759	TIR - domain - containing adapter - inducing interferon - b|Trif|Trif|Trif	GeneOrGeneProduct	94:106:250:323	105:107:251:324	3:3:7:9	50929	IL - 22	GeneOrGeneProduct	304	307	8	1:NR:2	L2R	CROSS	310-311	323-324	106759	TIR - domain - containing adapter - inducing interferon - b|Trif|Trif|Trif	GeneOrGeneProduct	94:106:250:323	105:107:251:324	3:3:7:9	17329	MIG|CXCL9	GeneOrGeneProduct	308:310	309:311	8:8	1:Association:2	L2R	NON-CROSS	312-313	323-324	106759	TIR - domain - containing adapter - inducing interferon - b|Trif|Trif|Trif	GeneOrGeneProduct	94:106:250:323	105:107:251:324	3:3:7:9	17319	MIF|MIF	GeneOrGeneProduct	312:342	313:343	8:9	1:Association:2	L2R	NON-CROSS	323-324	340-341	106759	TIR - domain - containing adapter - inducing interferon - b|Trif|Trif|Trif	GeneOrGeneProduct	94:106:250:323	105:107:251:324	3:3:7:9	20315	CXCL12|CXCL12	GeneOrGeneProduct	340:346	341:347	9:9	1:Association:2	L2R	NON-CROSS	323-324	344-345	106759	TIR - domain - containing adapter - inducing interferon - b|Trif|Trif|Trif	GeneOrGeneProduct	94:106:250:323	105:107:251:324	3:3:7:9	16878	LIF|LIF|LIF	GeneOrGeneProduct	344:409:424	345:410:425	9:11:11	1:NR:2	L2R	CROSS	323-324	354-361	106759	TIR - domain - containing adapter - inducing interferon - b|Trif|Trif|Trif	GeneOrGeneProduct	94:106:250:323	105:107:251:324	3:3:7:9	23586	retinoic acid - inducible gene - 1|RIG - I|RIG - I	GeneOrGeneProduct	354:362:468	361:365:471	10:10:12	1:NR:2	L2R	CROSS	323-324	380-386	106759	TIR - domain - containing adapter - inducing interferon - b|Trif|Trif|Trif	GeneOrGeneProduct	94:106:250:323	105:107:251:324	3:3:7:9	64135	melanoma differentiation - associated protein 5|MDA5	GeneOrGeneProduct	380:387	386:388	10:10	1:NR:2	L2R	CROSS	323-324	390-396	106759	TIR - domain - containing adapter - inducing interferon - b|Trif|Trif|Trif	GeneOrGeneProduct	94:106:250:323	105:107:251:324	3:3:7:9	79132	laboratory of genetics and physiology 2|LGP2	GeneOrGeneProduct	390:397	396:398	10:10	1:NR:2	L2R	CROSS	323-324	401-402	106759	TIR - domain - containing adapter - inducing interferon - b|Trif|Trif|Trif	GeneOrGeneProduct	94:106:250:323	105:107:251:324	3:3:7:9	148022	Trif	GeneOrGeneProduct	401	402	10	1:NR:2	L2R	CROSS	323-324	481-483	106759	TIR - domain - containing adapter - inducing interferon - b|Trif|Trif|Trif	GeneOrGeneProduct	94:106:250:323	105:107:251:324	3:3:7:9	D055370	lung injury	DiseaseOrPhenotypicFeature	481	483	13	1:NR:2	L2R	CROSS	115-116	142-145	228607	mitochondrial antiviral - signaling protein|Mavs|Mavs|Mavs	GeneOrGeneProduct	109:115:248:316	114:116:249:317	3:3:7:8	3976	leukemia inhibitory factor|LIF|LIF	GeneOrGeneProduct	142:146:191	145:147:192	4:4:5	1:NR:2	L2R	CROSS	197-198	248-249	228607	mitochondrial antiviral - signaling protein|Mavs|Mavs|Mavs	GeneOrGeneProduct	109:115:248:316	114:116:249:317	3:3:7:8	4282	migration inhibitory factor|MIF	GeneOrGeneProduct	193:197	196:198	5:5	1:NR:2	L2R	CROSS	204-205	248-249	228607	mitochondrial antiviral - signaling protein|Mavs|Mavs|Mavs	GeneOrGeneProduct	109:115:248:316	114:116:249:317	3:3:7:8	4254	stem cell factor|SCF	GeneOrGeneProduct	200:204	203:205	5:5	1:NR:2	L2R	CROSS	207-208	248-249	228607	mitochondrial antiviral - signaling protein|Mavs|Mavs|Mavs	GeneOrGeneProduct	109:115:248:316	114:116:249:317	3:3:7:8	10850	CCL27	GeneOrGeneProduct	207	208	5	1:NR:2	L2R	CROSS	209-210	248-249	228607	mitochondrial antiviral - signaling protein|Mavs|Mavs|Mavs	GeneOrGeneProduct	109:115:248:316	114:116:249:317	3:3:7:8	6387	CXCL12	GeneOrGeneProduct	209	210	5	1:NR:2	L2R	CROSS	217-220	248-249	228607	mitochondrial antiviral - signaling protein|Mavs|Mavs|Mavs	GeneOrGeneProduct	109:115:248:316	114:116:249:317	3:3:7:8	6320	stem cell growth factor beta|SCGF - b	GeneOrGeneProduct	211:217	216:220	5:5	1:Association:2	R2L	NON-CROSS	263-266	248-249	16176	IL - 1b|IL - 1b	GeneOrGeneProduct	263:332	266:335	8:9	228607	mitochondrial antiviral - signaling protein|Mavs|Mavs|Mavs	GeneOrGeneProduct	109:115:248:316	114:116:249:317	3:3:7:8	1:Association:2	R2L	NON-CROSS	267-270	248-249	16189	IL - 4	GeneOrGeneProduct	267	270	8	228607	mitochondrial antiviral - signaling protein|Mavs|Mavs|Mavs	GeneOrGeneProduct	109:115:248:316	114:116:249:317	3:3:7:8	1:Association:2	R2L	NON-CROSS	336-339	316-317	16191	IL - 5|IL - 5	GeneOrGeneProduct	271:336	274:339	8:9	228607	mitochondrial antiviral - signaling protein|Mavs|Mavs|Mavs	GeneOrGeneProduct	109:115:248:316	114:116:249:317	3:3:7:8	1:Association:2	R2L	NON-CROSS	275-278	248-249	16193	IL - 6	GeneOrGeneProduct	275	278	8	228607	mitochondrial antiviral - signaling protein|Mavs|Mavs|Mavs	GeneOrGeneProduct	109:115:248:316	114:116:249:317	3:3:7:8	1:Association:2	R2L	NON-CROSS	279-282	248-249	16160	IL - 12|p40	GeneOrGeneProduct	279:283	282:284	8:8	228607	mitochondrial antiviral - signaling protein|Mavs|Mavs|Mavs	GeneOrGeneProduct	109:115:248:316	114:116:249:317	3:3:7:8	1:Association:2	R2L	NON-CROSS	316-317	286-289	15978	IFN - g|IFN - g	GeneOrGeneProduct	286:348	289:351	8:9	228607	mitochondrial antiviral - signaling protein|Mavs|Mavs|Mavs	GeneOrGeneProduct	109:115:248:316	114:116:249:317	3:3:7:8	1:Association:2	R2L	NON-CROSS	316-317	290-291	20296	CCL2	GeneOrGeneProduct	290	291	8	228607	mitochondrial antiviral - signaling protein|Mavs|Mavs|Mavs	GeneOrGeneProduct	109:115:248:316	114:116:249:317	3:3:7:8	1:Association:2	R2L	NON-CROSS	316-317	292-293	20304	CCL5	GeneOrGeneProduct	292	293	8	228607	mitochondrial antiviral - signaling protein|Mavs|Mavs|Mavs	GeneOrGeneProduct	109:115:248:316	114:116:249:317	3:3:7:8	1:Association:2	R2L	NON-CROSS	316-317	294-295	20302	CCL3	GeneOrGeneProduct	294	295	8	228607	mitochondrial antiviral - signaling protein|Mavs|Mavs|Mavs	GeneOrGeneProduct	109:115:248:316	114:116:249:317	3:3:7:8	1:Association:2	R2L	NON-CROSS	316-317	296-297	14825	CXCL1	GeneOrGeneProduct	296	297	8	228607	mitochondrial antiviral - signaling protein|Mavs|Mavs|Mavs	GeneOrGeneProduct	109:115:248:316	114:116:249:317	3:3:7:8	1:Association:2	R2L	NON-CROSS	316-317	302-303	15945	IP - 10|CXCL10	GeneOrGeneProduct	298:302	301:303	8:8	228607	mitochondrial antiviral - signaling protein|Mavs|Mavs|Mavs	GeneOrGeneProduct	109:115:248:316	114:116:249:317	3:3:7:8	1:Association:2	R2L	NON-CROSS	316-317	304-307	50929	IL - 22	GeneOrGeneProduct	304	307	8	228607	mitochondrial antiviral - signaling protein|Mavs|Mavs|Mavs	GeneOrGeneProduct	109:115:248:316	114:116:249:317	3:3:7:8	1:Association:2	R2L	NON-CROSS	316-317	310-311	17329	MIG|CXCL9	GeneOrGeneProduct	308:310	309:311	8:8	228607	mitochondrial antiviral - signaling protein|Mavs|Mavs|Mavs	GeneOrGeneProduct	109:115:248:316	114:116:249:317	3:3:7:8	1:Association:2	R2L	NON-CROSS	316-317	312-313	17319	MIF|MIF	GeneOrGeneProduct	312:342	313:343	8:9	228607	mitochondrial antiviral - signaling protein|Mavs|Mavs|Mavs	GeneOrGeneProduct	109:115:248:316	114:116:249:317	3:3:7:8	1:NR:2	L2R	CROSS	316-317	340-341	228607	mitochondrial antiviral - signaling protein|Mavs|Mavs|Mavs	GeneOrGeneProduct	109:115:248:316	114:116:249:317	3:3:7:8	20315	CXCL12|CXCL12	GeneOrGeneProduct	340:346	341:347	9:9	1:NR:2	L2R	CROSS	316-317	344-345	228607	mitochondrial antiviral - signaling protein|Mavs|Mavs|Mavs	GeneOrGeneProduct	109:115:248:316	114:116:249:317	3:3:7:8	16878	LIF|LIF|LIF	GeneOrGeneProduct	344:409:424	345:410:425	9:11:11	1:NR:2	L2R	CROSS	316-317	354-361	228607	mitochondrial antiviral - signaling protein|Mavs|Mavs|Mavs	GeneOrGeneProduct	109:115:248:316	114:116:249:317	3:3:7:8	23586	retinoic acid - inducible gene - 1|RIG - I|RIG - I	GeneOrGeneProduct	354:362:468	361:365:471	10:10:12	1:NR:2	L2R	CROSS	316-317	380-386	228607	mitochondrial antiviral - signaling protein|Mavs|Mavs|Mavs	GeneOrGeneProduct	109:115:248:316	114:116:249:317	3:3:7:8	64135	melanoma differentiation - associated protein 5|MDA5	GeneOrGeneProduct	380:387	386:388	10:10	1:NR:2	L2R	CROSS	316-317	390-396	228607	mitochondrial antiviral - signaling protein|Mavs|Mavs|Mavs	GeneOrGeneProduct	109:115:248:316	114:116:249:317	3:3:7:8	79132	laboratory of genetics and physiology 2|LGP2	GeneOrGeneProduct	390:397	396:398	10:10	1:NR:2	L2R	CROSS	316-317	401-402	228607	mitochondrial antiviral - signaling protein|Mavs|Mavs|Mavs	GeneOrGeneProduct	109:115:248:316	114:116:249:317	3:3:7:8	148022	Trif	GeneOrGeneProduct	401	402	10	1:NR:2	L2R	CROSS	316-317	481-483	228607	mitochondrial antiviral - signaling protein|Mavs|Mavs|Mavs	GeneOrGeneProduct	109:115:248:316	114:116:249:317	3:3:7:8	D055370	lung injury	DiseaseOrPhenotypicFeature	481	483	13	1:NR:2	L2R	NON-CROSS	191-192	193-196	3976	leukemia inhibitory factor|LIF|LIF	GeneOrGeneProduct	142:146:191	145:147:192	4:4:5	4282	migration inhibitory factor|MIF	GeneOrGeneProduct	193:197	196:198	5:5	1:NR:2	L2R	NON-CROSS	191-192	200-203	3976	leukemia inhibitory factor|LIF|LIF	GeneOrGeneProduct	142:146:191	145:147:192	4:4:5	4254	stem cell factor|SCF	GeneOrGeneProduct	200:204	203:205	5:5	1:NR:2	L2R	NON-CROSS	191-192	207-208	3976	leukemia inhibitory factor|LIF|LIF	GeneOrGeneProduct	142:146:191	145:147:192	4:4:5	10850	CCL27	GeneOrGeneProduct	207	208	5	1:NR:2	L2R	NON-CROSS	191-192	209-210	3976	leukemia inhibitory factor|LIF|LIF	GeneOrGeneProduct	142:146:191	145:147:192	4:4:5	6387	CXCL12	GeneOrGeneProduct	209	210	5	1:NR:2	L2R	NON-CROSS	191-192	211-216	3976	leukemia inhibitory factor|LIF|LIF	GeneOrGeneProduct	142:146:191	145:147:192	4:4:5	6320	stem cell growth factor beta|SCGF - b	GeneOrGeneProduct	211:217	216:220	5:5	1:NR:2	L2R	CROSS	191-192	263-266	3976	leukemia inhibitory factor|LIF|LIF	GeneOrGeneProduct	142:146:191	145:147:192	4:4:5	16176	IL - 1b|IL - 1b	GeneOrGeneProduct	263:332	266:335	8:9	1:NR:2	L2R	CROSS	191-192	267-270	3976	leukemia inhibitory factor|LIF|LIF	GeneOrGeneProduct	142:146:191	145:147:192	4:4:5	16189	IL - 4	GeneOrGeneProduct	267	270	8	1:NR:2	L2R	CROSS	191-192	271-274	3976	leukemia inhibitory factor|LIF|LIF	GeneOrGeneProduct	142:146:191	145:147:192	4:4:5	16191	IL - 5|IL - 5	GeneOrGeneProduct	271:336	274:339	8:9	1:NR:2	L2R	CROSS	191-192	275-278	3976	leukemia inhibitory factor|LIF|LIF	GeneOrGeneProduct	142:146:191	145:147:192	4:4:5	16193	IL - 6	GeneOrGeneProduct	275	278	8	1:NR:2	L2R	CROSS	191-192	279-282	3976	leukemia inhibitory factor|LIF|LIF	GeneOrGeneProduct	142:146:191	145:147:192	4:4:5	16160	IL - 12|p40	GeneOrGeneProduct	279:283	282:284	8:8	1:NR:2	L2R	CROSS	191-192	286-289	3976	leukemia inhibitory factor|LIF|LIF	GeneOrGeneProduct	142:146:191	145:147:192	4:4:5	15978	IFN - g|IFN - g	GeneOrGeneProduct	286:348	289:351	8:9	1:NR:2	L2R	CROSS	191-192	290-291	3976	leukemia inhibitory factor|LIF|LIF	GeneOrGeneProduct	142:146:191	145:147:192	4:4:5	20296	CCL2	GeneOrGeneProduct	290	291	8	1:NR:2	L2R	CROSS	191-192	292-293	3976	leukemia inhibitory factor|LIF|LIF	GeneOrGeneProduct	142:146:191	145:147:192	4:4:5	20304	CCL5	GeneOrGeneProduct	292	293	8	1:NR:2	L2R	CROSS	191-192	294-295	3976	leukemia inhibitory factor|LIF|LIF	GeneOrGeneProduct	142:146:191	145:147:192	4:4:5	20302	CCL3	GeneOrGeneProduct	294	295	8	1:NR:2	L2R	CROSS	191-192	296-297	3976	leukemia inhibitory factor|LIF|LIF	GeneOrGeneProduct	142:146:191	145:147:192	4:4:5	14825	CXCL1	GeneOrGeneProduct	296	297	8	1:NR:2	L2R	CROSS	191-192	298-301	3976	leukemia inhibitory factor|LIF|LIF	GeneOrGeneProduct	142:146:191	145:147:192	4:4:5	15945	IP - 10|CXCL10	GeneOrGeneProduct	298:302	301:303	8:8	1:NR:2	L2R	CROSS	191-192	304-307	3976	leukemia inhibitory factor|LIF|LIF	GeneOrGeneProduct	142:146:191	145:147:192	4:4:5	50929	IL - 22	GeneOrGeneProduct	304	307	8	1:NR:2	L2R	CROSS	191-192	308-309	3976	leukemia inhibitory factor|LIF|LIF	GeneOrGeneProduct	142:146:191	145:147:192	4:4:5	17329	MIG|CXCL9	GeneOrGeneProduct	308:310	309:311	8:8	1:NR:2	L2R	CROSS	191-192	312-313	3976	leukemia inhibitory factor|LIF|LIF	GeneOrGeneProduct	142:146:191	145:147:192	4:4:5	17319	MIF|MIF	GeneOrGeneProduct	312:342	313:343	8:9	1:NR:2	L2R	CROSS	191-192	340-341	3976	leukemia inhibitory factor|LIF|LIF	GeneOrGeneProduct	142:146:191	145:147:192	4:4:5	20315	CXCL12|CXCL12	GeneOrGeneProduct	340:346	341:347	9:9	1:NR:2	L2R	CROSS	191-192	344-345	3976	leukemia inhibitory factor|LIF|LIF	GeneOrGeneProduct	142:146:191	145:147:192	4:4:5	16878	LIF|LIF|LIF	GeneOrGeneProduct	344:409:424	345:410:425	9:11:11	1:Association:2	R2L	CROSS	354-361	191-192	23586	retinoic acid - inducible gene - 1|RIG - I|RIG - I	GeneOrGeneProduct	354:362:468	361:365:471	10:10:12	3976	leukemia inhibitory factor|LIF|LIF	GeneOrGeneProduct	142:146:191	145:147:192	4:4:5	1:NR:2	L2R	CROSS	191-192	380-386	3976	leukemia inhibitory factor|LIF|LIF	GeneOrGeneProduct	142:146:191	145:147:192	4:4:5	64135	melanoma differentiation - associated protein 5|MDA5	GeneOrGeneProduct	380:387	386:388	10:10	1:NR:2	L2R	CROSS	191-192	390-396	3976	leukemia inhibitory factor|LIF|LIF	GeneOrGeneProduct	142:146:191	145:147:192	4:4:5	79132	laboratory of genetics and physiology 2|LGP2	GeneOrGeneProduct	390:397	396:398	10:10	1:NR:2	L2R	CROSS	191-192	401-402	3976	leukemia inhibitory factor|LIF|LIF	GeneOrGeneProduct	142:146:191	145:147:192	4:4:5	148022	Trif	GeneOrGeneProduct	401	402	10	1:Negative_Correlation:2	L2R	CROSS	191-192	481-483	3976	leukemia inhibitory factor|LIF|LIF	GeneOrGeneProduct	142:146:191	145:147:192	4:4:5	D055370	lung injury	DiseaseOrPhenotypicFeature	481	483	13	1:NR:2	L2R	NON-CROSS	197-198	200-203	4282	migration inhibitory factor|MIF	GeneOrGeneProduct	193:197	196:198	5:5	4254	stem cell factor|SCF	GeneOrGeneProduct	200:204	203:205	5:5	1:NR:2	L2R	NON-CROSS	197-198	207-208	4282	migration inhibitory factor|MIF	GeneOrGeneProduct	193:197	196:198	5:5	10850	CCL27	GeneOrGeneProduct	207	208	5	1:NR:2	L2R	NON-CROSS	197-198	209-210	4282	migration inhibitory factor|MIF	GeneOrGeneProduct	193:197	196:198	5:5	6387	CXCL12	GeneOrGeneProduct	209	210	5	1:NR:2	L2R	NON-CROSS	197-198	211-216	4282	migration inhibitory factor|MIF	GeneOrGeneProduct	193:197	196:198	5:5	6320	stem cell growth factor beta|SCGF - b	GeneOrGeneProduct	211:217	216:220	5:5	1:NR:2	L2R	CROSS	197-198	263-266	4282	migration inhibitory factor|MIF	GeneOrGeneProduct	193:197	196:198	5:5	16176	IL - 1b|IL - 1b	GeneOrGeneProduct	263:332	266:335	8:9	1:NR:2	L2R	CROSS	197-198	267-270	4282	migration inhibitory factor|MIF	GeneOrGeneProduct	193:197	196:198	5:5	16189	IL - 4	GeneOrGeneProduct	267	270	8	1:NR:2	L2R	CROSS	197-198	271-274	4282	migration inhibitory factor|MIF	GeneOrGeneProduct	193:197	196:198	5:5	16191	IL - 5|IL - 5	GeneOrGeneProduct	271:336	274:339	8:9	1:NR:2	L2R	CROSS	197-198	275-278	4282	migration inhibitory factor|MIF	GeneOrGeneProduct	193:197	196:198	5:5	16193	IL - 6	GeneOrGeneProduct	275	278	8	1:NR:2	L2R	CROSS	197-198	279-282	4282	migration inhibitory factor|MIF	GeneOrGeneProduct	193:197	196:198	5:5	16160	IL - 12|p40	GeneOrGeneProduct	279:283	282:284	8:8	1:NR:2	L2R	CROSS	197-198	286-289	4282	migration inhibitory factor|MIF	GeneOrGeneProduct	193:197	196:198	5:5	15978	IFN - g|IFN - g	GeneOrGeneProduct	286:348	289:351	8:9	1:NR:2	L2R	CROSS	197-198	290-291	4282	migration inhibitory factor|MIF	GeneOrGeneProduct	193:197	196:198	5:5	20296	CCL2	GeneOrGeneProduct	290	291	8	1:NR:2	L2R	CROSS	197-198	292-293	4282	migration inhibitory factor|MIF	GeneOrGeneProduct	193:197	196:198	5:5	20304	CCL5	GeneOrGeneProduct	292	293	8	1:NR:2	L2R	CROSS	197-198	294-295	4282	migration inhibitory factor|MIF	GeneOrGeneProduct	193:197	196:198	5:5	20302	CCL3	GeneOrGeneProduct	294	295	8	1:NR:2	L2R	CROSS	197-198	296-297	4282	migration inhibitory factor|MIF	GeneOrGeneProduct	193:197	196:198	5:5	14825	CXCL1	GeneOrGeneProduct	296	297	8	1:NR:2	L2R	CROSS	197-198	298-301	4282	migration inhibitory factor|MIF	GeneOrGeneProduct	193:197	196:198	5:5	15945	IP - 10|CXCL10	GeneOrGeneProduct	298:302	301:303	8:8	1:NR:2	L2R	CROSS	197-198	304-307	4282	migration inhibitory factor|MIF	GeneOrGeneProduct	193:197	196:198	5:5	50929	IL - 22	GeneOrGeneProduct	304	307	8	1:NR:2	L2R	CROSS	197-198	308-309	4282	migration inhibitory factor|MIF	GeneOrGeneProduct	193:197	196:198	5:5	17329	MIG|CXCL9	GeneOrGeneProduct	308:310	309:311	8:8	1:NR:2	L2R	CROSS	197-198	312-313	4282	migration inhibitory factor|MIF	GeneOrGeneProduct	193:197	196:198	5:5	17319	MIF|MIF	GeneOrGeneProduct	312:342	313:343	8:9	1:NR:2	L2R	CROSS	197-198	340-341	4282	migration inhibitory factor|MIF	GeneOrGeneProduct	193:197	196:198	5:5	20315	CXCL12|CXCL12	GeneOrGeneProduct	340:346	341:347	9:9	1:NR:2	L2R	CROSS	197-198	344-345	4282	migration inhibitory factor|MIF	GeneOrGeneProduct	193:197	196:198	5:5	16878	LIF|LIF|LIF	GeneOrGeneProduct	344:409:424	345:410:425	9:11:11	1:Association:2	R2L	CROSS	354-361	197-198	23586	retinoic acid - inducible gene - 1|RIG - I|RIG - I	GeneOrGeneProduct	354:362:468	361:365:471	10:10:12	4282	migration inhibitory factor|MIF	GeneOrGeneProduct	193:197	196:198	5:5	1:NR:2	L2R	CROSS	197-198	380-386	4282	migration inhibitory factor|MIF	GeneOrGeneProduct	193:197	196:198	5:5	64135	melanoma differentiation - associated protein 5|MDA5	GeneOrGeneProduct	380:387	386:388	10:10	1:NR:2	L2R	CROSS	197-198	390-396	4282	migration inhibitory factor|MIF	GeneOrGeneProduct	193:197	196:198	5:5	79132	laboratory of genetics and physiology 2|LGP2	GeneOrGeneProduct	390:397	396:398	10:10	1:NR:2	L2R	CROSS	197-198	401-402	4282	migration inhibitory factor|MIF	GeneOrGeneProduct	193:197	196:198	5:5	148022	Trif	GeneOrGeneProduct	401	402	10	1:NR:2	L2R	CROSS	197-198	481-483	4282	migration inhibitory factor|MIF	GeneOrGeneProduct	193:197	196:198	5:5	D055370	lung injury	DiseaseOrPhenotypicFeature	481	483	13	1:NR:2	L2R	NON-CROSS	204-205	207-208	4254	stem cell factor|SCF	GeneOrGeneProduct	200:204	203:205	5:5	10850	CCL27	GeneOrGeneProduct	207	208	5	1:NR:2	L2R	NON-CROSS	204-205	209-210	4254	stem cell factor|SCF	GeneOrGeneProduct	200:204	203:205	5:5	6387	CXCL12	GeneOrGeneProduct	209	210	5	1:NR:2	L2R	NON-CROSS	204-205	211-216	4254	stem cell factor|SCF	GeneOrGeneProduct	200:204	203:205	5:5	6320	stem cell growth factor beta|SCGF - b	GeneOrGeneProduct	211:217	216:220	5:5	1:NR:2	L2R	CROSS	204-205	263-266	4254	stem cell factor|SCF	GeneOrGeneProduct	200:204	203:205	5:5	16176	IL - 1b|IL - 1b	GeneOrGeneProduct	263:332	266:335	8:9	1:NR:2	L2R	CROSS	204-205	267-270	4254	stem cell factor|SCF	GeneOrGeneProduct	200:204	203:205	5:5	16189	IL - 4	GeneOrGeneProduct	267	270	8	1:NR:2	L2R	CROSS	204-205	271-274	4254	stem cell factor|SCF	GeneOrGeneProduct	200:204	203:205	5:5	16191	IL - 5|IL - 5	GeneOrGeneProduct	271:336	274:339	8:9	1:NR:2	L2R	CROSS	204-205	275-278	4254	stem cell factor|SCF	GeneOrGeneProduct	200:204	203:205	5:5	16193	IL - 6	GeneOrGeneProduct	275	278	8	1:NR:2	L2R	CROSS	204-205	279-282	4254	stem cell factor|SCF	GeneOrGeneProduct	200:204	203:205	5:5	16160	IL - 12|p40	GeneOrGeneProduct	279:283	282:284	8:8	1:NR:2	L2R	CROSS	204-205	286-289	4254	stem cell factor|SCF	GeneOrGeneProduct	200:204	203:205	5:5	15978	IFN - g|IFN - g	GeneOrGeneProduct	286:348	289:351	8:9	1:NR:2	L2R	CROSS	204-205	290-291	4254	stem cell factor|SCF	GeneOrGeneProduct	200:204	203:205	5:5	20296	CCL2	GeneOrGeneProduct	290	291	8	1:NR:2	L2R	CROSS	204-205	292-293	4254	stem cell factor|SCF	GeneOrGeneProduct	200:204	203:205	5:5	20304	CCL5	GeneOrGeneProduct	292	293	8	1:NR:2	L2R	CROSS	204-205	294-295	4254	stem cell factor|SCF	GeneOrGeneProduct	200:204	203:205	5:5	20302	CCL3	GeneOrGeneProduct	294	295	8	1:NR:2	L2R	CROSS	204-205	296-297	4254	stem cell factor|SCF	GeneOrGeneProduct	200:204	203:205	5:5	14825	CXCL1	GeneOrGeneProduct	296	297	8	1:NR:2	L2R	CROSS	204-205	298-301	4254	stem cell factor|SCF	GeneOrGeneProduct	200:204	203:205	5:5	15945	IP - 10|CXCL10	GeneOrGeneProduct	298:302	301:303	8:8	1:NR:2	L2R	CROSS	204-205	304-307	4254	stem cell factor|SCF	GeneOrGeneProduct	200:204	203:205	5:5	50929	IL - 22	GeneOrGeneProduct	304	307	8	1:NR:2	L2R	CROSS	204-205	308-309	4254	stem cell factor|SCF	GeneOrGeneProduct	200:204	203:205	5:5	17329	MIG|CXCL9	GeneOrGeneProduct	308:310	309:311	8:8	1:NR:2	L2R	CROSS	204-205	312-313	4254	stem cell factor|SCF	GeneOrGeneProduct	200:204	203:205	5:5	17319	MIF|MIF	GeneOrGeneProduct	312:342	313:343	8:9	1:NR:2	L2R	CROSS	204-205	340-341	4254	stem cell factor|SCF	GeneOrGeneProduct	200:204	203:205	5:5	20315	CXCL12|CXCL12	GeneOrGeneProduct	340:346	341:347	9:9	1:NR:2	L2R	CROSS	204-205	344-345	4254	stem cell factor|SCF	GeneOrGeneProduct	200:204	203:205	5:5	16878	LIF|LIF|LIF	GeneOrGeneProduct	344:409:424	345:410:425	9:11:11	1:Association:2	R2L	CROSS	354-361	204-205	23586	retinoic acid - inducible gene - 1|RIG - I|RIG - I	GeneOrGeneProduct	354:362:468	361:365:471	10:10:12	4254	stem cell factor|SCF	GeneOrGeneProduct	200:204	203:205	5:5	1:NR:2	L2R	CROSS	204-205	380-386	4254	stem cell factor|SCF	GeneOrGeneProduct	200:204	203:205	5:5	64135	melanoma differentiation - associated protein 5|MDA5	GeneOrGeneProduct	380:387	386:388	10:10	1:NR:2	L2R	CROSS	204-205	390-396	4254	stem cell factor|SCF	GeneOrGeneProduct	200:204	203:205	5:5	79132	laboratory of genetics and physiology 2|LGP2	GeneOrGeneProduct	390:397	396:398	10:10	1:NR:2	L2R	CROSS	204-205	401-402	4254	stem cell factor|SCF	GeneOrGeneProduct	200:204	203:205	5:5	148022	Trif	GeneOrGeneProduct	401	402	10	1:NR:2	L2R	CROSS	204-205	481-483	4254	stem cell factor|SCF	GeneOrGeneProduct	200:204	203:205	5:5	D055370	lung injury	DiseaseOrPhenotypicFeature	481	483	13	1:NR:2	L2R	NON-CROSS	207-208	209-210	10850	CCL27	GeneOrGeneProduct	207	208	5	6387	CXCL12	GeneOrGeneProduct	209	210	5	1:NR:2	L2R	NON-CROSS	207-208	211-216	10850	CCL27	GeneOrGeneProduct	207	208	5	6320	stem cell growth factor beta|SCGF - b	GeneOrGeneProduct	211:217	216:220	5:5	1:NR:2	L2R	CROSS	207-208	263-266	10850	CCL27	GeneOrGeneProduct	207	208	5	16176	IL - 1b|IL - 1b	GeneOrGeneProduct	263:332	266:335	8:9	1:NR:2	L2R	CROSS	207-208	267-270	10850	CCL27	GeneOrGeneProduct	207	208	5	16189	IL - 4	GeneOrGeneProduct	267	270	8	1:NR:2	L2R	CROSS	207-208	271-274	10850	CCL27	GeneOrGeneProduct	207	208	5	16191	IL - 5|IL - 5	GeneOrGeneProduct	271:336	274:339	8:9	1:NR:2	L2R	CROSS	207-208	275-278	10850	CCL27	GeneOrGeneProduct	207	208	5	16193	IL - 6	GeneOrGeneProduct	275	278	8	1:NR:2	L2R	CROSS	207-208	279-282	10850	CCL27	GeneOrGeneProduct	207	208	5	16160	IL - 12|p40	GeneOrGeneProduct	279:283	282:284	8:8	1:NR:2	L2R	CROSS	207-208	286-289	10850	CCL27	GeneOrGeneProduct	207	208	5	15978	IFN - g|IFN - g	GeneOrGeneProduct	286:348	289:351	8:9	1:NR:2	L2R	CROSS	207-208	290-291	10850	CCL27	GeneOrGeneProduct	207	208	5	20296	CCL2	GeneOrGeneProduct	290	291	8	1:NR:2	L2R	CROSS	207-208	292-293	10850	CCL27	GeneOrGeneProduct	207	208	5	20304	CCL5	GeneOrGeneProduct	292	293	8	1:NR:2	L2R	CROSS	207-208	294-295	10850	CCL27	GeneOrGeneProduct	207	208	5	20302	CCL3	GeneOrGeneProduct	294	295	8	1:NR:2	L2R	CROSS	207-208	296-297	10850	CCL27	GeneOrGeneProduct	207	208	5	14825	CXCL1	GeneOrGeneProduct	296	297	8	1:NR:2	L2R	CROSS	207-208	298-301	10850	CCL27	GeneOrGeneProduct	207	208	5	15945	IP - 10|CXCL10	GeneOrGeneProduct	298:302	301:303	8:8	1:NR:2	L2R	CROSS	207-208	304-307	10850	CCL27	GeneOrGeneProduct	207	208	5	50929	IL - 22	GeneOrGeneProduct	304	307	8	1:NR:2	L2R	CROSS	207-208	308-309	10850	CCL27	GeneOrGeneProduct	207	208	5	17329	MIG|CXCL9	GeneOrGeneProduct	308:310	309:311	8:8	1:NR:2	L2R	CROSS	207-208	312-313	10850	CCL27	GeneOrGeneProduct	207	208	5	17319	MIF|MIF	GeneOrGeneProduct	312:342	313:343	8:9	1:NR:2	L2R	CROSS	207-208	340-341	10850	CCL27	GeneOrGeneProduct	207	208	5	20315	CXCL12|CXCL12	GeneOrGeneProduct	340:346	341:347	9:9	1:NR:2	L2R	CROSS	207-208	344-345	10850	CCL27	GeneOrGeneProduct	207	208	5	16878	LIF|LIF|LIF	GeneOrGeneProduct	344:409:424	345:410:425	9:11:11	1:Association:2	R2L	CROSS	354-361	207-208	23586	retinoic acid - inducible gene - 1|RIG - I|RIG - I	GeneOrGeneProduct	354:362:468	361:365:471	10:10:12	10850	CCL27	GeneOrGeneProduct	207	208	5	1:NR:2	L2R	CROSS	207-208	380-386	10850	CCL27	GeneOrGeneProduct	207	208	5	64135	melanoma differentiation - associated protein 5|MDA5	GeneOrGeneProduct	380:387	386:388	10:10	1:NR:2	L2R	CROSS	207-208	390-396	10850	CCL27	GeneOrGeneProduct	207	208	5	79132	laboratory of genetics and physiology 2|LGP2	GeneOrGeneProduct	390:397	396:398	10:10	1:NR:2	L2R	CROSS	207-208	401-402	10850	CCL27	GeneOrGeneProduct	207	208	5	148022	Trif	GeneOrGeneProduct	401	402	10	1:NR:2	L2R	CROSS	207-208	481-483	10850	CCL27	GeneOrGeneProduct	207	208	5	D055370	lung injury	DiseaseOrPhenotypicFeature	481	483	13	1:NR:2	L2R	NON-CROSS	209-210	211-216	6387	CXCL12	GeneOrGeneProduct	209	210	5	6320	stem cell growth factor beta|SCGF - b	GeneOrGeneProduct	211:217	216:220	5:5	1:NR:2	L2R	CROSS	209-210	263-266	6387	CXCL12	GeneOrGeneProduct	209	210	5	16176	IL - 1b|IL - 1b	GeneOrGeneProduct	263:332	266:335	8:9	1:NR:2	L2R	CROSS	209-210	267-270	6387	CXCL12	GeneOrGeneProduct	209	210	5	16189	IL - 4	GeneOrGeneProduct	267	270	8	1:NR:2	L2R	CROSS	209-210	271-274	6387	CXCL12	GeneOrGeneProduct	209	210	5	16191	IL - 5|IL - 5	GeneOrGeneProduct	271:336	274:339	8:9	1:NR:2	L2R	CROSS	209-210	275-278	6387	CXCL12	GeneOrGeneProduct	209	210	5	16193	IL - 6	GeneOrGeneProduct	275	278	8	1:NR:2	L2R	CROSS	209-210	279-282	6387	CXCL12	GeneOrGeneProduct	209	210	5	16160	IL - 12|p40	GeneOrGeneProduct	279:283	282:284	8:8	1:NR:2	L2R	CROSS	209-210	286-289	6387	CXCL12	GeneOrGeneProduct	209	210	5	15978	IFN - g|IFN - g	GeneOrGeneProduct	286:348	289:351	8:9	1:NR:2	L2R	CROSS	209-210	290-291	6387	CXCL12	GeneOrGeneProduct	209	210	5	20296	CCL2	GeneOrGeneProduct	290	291	8	1:NR:2	L2R	CROSS	209-210	292-293	6387	CXCL12	GeneOrGeneProduct	209	210	5	20304	CCL5	GeneOrGeneProduct	292	293	8	1:NR:2	L2R	CROSS	209-210	294-295	6387	CXCL12	GeneOrGeneProduct	209	210	5	20302	CCL3	GeneOrGeneProduct	294	295	8	1:NR:2	L2R	CROSS	209-210	296-297	6387	CXCL12	GeneOrGeneProduct	209	210	5	14825	CXCL1	GeneOrGeneProduct	296	297	8	1:NR:2	L2R	CROSS	209-210	298-301	6387	CXCL12	GeneOrGeneProduct	209	210	5	15945	IP - 10|CXCL10	GeneOrGeneProduct	298:302	301:303	8:8	1:NR:2	L2R	CROSS	209-210	304-307	6387	CXCL12	GeneOrGeneProduct	209	210	5	50929	IL - 22	GeneOrGeneProduct	304	307	8	1:NR:2	L2R	CROSS	209-210	308-309	6387	CXCL12	GeneOrGeneProduct	209	210	5	17329	MIG|CXCL9	GeneOrGeneProduct	308:310	309:311	8:8	1:NR:2	L2R	CROSS	209-210	312-313	6387	CXCL12	GeneOrGeneProduct	209	210	5	17319	MIF|MIF	GeneOrGeneProduct	312:342	313:343	8:9	1:NR:2	L2R	CROSS	209-210	340-341	6387	CXCL12	GeneOrGeneProduct	209	210	5	20315	CXCL12|CXCL12	GeneOrGeneProduct	340:346	341:347	9:9	1:NR:2	L2R	CROSS	209-210	344-345	6387	CXCL12	GeneOrGeneProduct	209	210	5	16878	LIF|LIF|LIF	GeneOrGeneProduct	344:409:424	345:410:425	9:11:11	1:Association:2	R2L	CROSS	354-361	209-210	23586	retinoic acid - inducible gene - 1|RIG - I|RIG - I	GeneOrGeneProduct	354:362:468	361:365:471	10:10:12	6387	CXCL12	GeneOrGeneProduct	209	210	5	1:NR:2	L2R	CROSS	209-210	380-386	6387	CXCL12	GeneOrGeneProduct	209	210	5	64135	melanoma differentiation - associated protein 5|MDA5	GeneOrGeneProduct	380:387	386:388	10:10	1:NR:2	L2R	CROSS	209-210	390-396	6387	CXCL12	GeneOrGeneProduct	209	210	5	79132	laboratory of genetics and physiology 2|LGP2	GeneOrGeneProduct	390:397	396:398	10:10	1:NR:2	L2R	CROSS	209-210	401-402	6387	CXCL12	GeneOrGeneProduct	209	210	5	148022	Trif	GeneOrGeneProduct	401	402	10	1:NR:2	L2R	CROSS	209-210	481-483	6387	CXCL12	GeneOrGeneProduct	209	210	5	D055370	lung injury	DiseaseOrPhenotypicFeature	481	483	13	1:NR:2	L2R	CROSS	217-220	263-266	6320	stem cell growth factor beta|SCGF - b	GeneOrGeneProduct	211:217	216:220	5:5	16176	IL - 1b|IL - 1b	GeneOrGeneProduct	263:332	266:335	8:9	1:NR:2	L2R	CROSS	217-220	267-270	6320	stem cell growth factor beta|SCGF - b	GeneOrGeneProduct	211:217	216:220	5:5	16189	IL - 4	GeneOrGeneProduct	267	270	8	1:NR:2	L2R	CROSS	217-220	271-274	6320	stem cell growth factor beta|SCGF - b	GeneOrGeneProduct	211:217	216:220	5:5	16191	IL - 5|IL - 5	GeneOrGeneProduct	271:336	274:339	8:9	1:NR:2	L2R	CROSS	217-220	275-278	6320	stem cell growth factor beta|SCGF - b	GeneOrGeneProduct	211:217	216:220	5:5	16193	IL - 6	GeneOrGeneProduct	275	278	8	1:NR:2	L2R	CROSS	217-220	279-282	6320	stem cell growth factor beta|SCGF - b	GeneOrGeneProduct	211:217	216:220	5:5	16160	IL - 12|p40	GeneOrGeneProduct	279:283	282:284	8:8	1:NR:2	L2R	CROSS	217-220	286-289	6320	stem cell growth factor beta|SCGF - b	GeneOrGeneProduct	211:217	216:220	5:5	15978	IFN - g|IFN - g	GeneOrGeneProduct	286:348	289:351	8:9	1:NR:2	L2R	CROSS	217-220	290-291	6320	stem cell growth factor beta|SCGF - b	GeneOrGeneProduct	211:217	216:220	5:5	20296	CCL2	GeneOrGeneProduct	290	291	8	1:NR:2	L2R	CROSS	217-220	292-293	6320	stem cell growth factor beta|SCGF - b	GeneOrGeneProduct	211:217	216:220	5:5	20304	CCL5	GeneOrGeneProduct	292	293	8	1:NR:2	L2R	CROSS	217-220	294-295	6320	stem cell growth factor beta|SCGF - b	GeneOrGeneProduct	211:217	216:220	5:5	20302	CCL3	GeneOrGeneProduct	294	295	8	1:NR:2	L2R	CROSS	217-220	296-297	6320	stem cell growth factor beta|SCGF - b	GeneOrGeneProduct	211:217	216:220	5:5	14825	CXCL1	GeneOrGeneProduct	296	297	8	1:NR:2	L2R	CROSS	217-220	298-301	6320	stem cell growth factor beta|SCGF - b	GeneOrGeneProduct	211:217	216:220	5:5	15945	IP - 10|CXCL10	GeneOrGeneProduct	298:302	301:303	8:8	1:NR:2	L2R	CROSS	217-220	304-307	6320	stem cell growth factor beta|SCGF - b	GeneOrGeneProduct	211:217	216:220	5:5	50929	IL - 22	GeneOrGeneProduct	304	307	8	1:NR:2	L2R	CROSS	217-220	308-309	6320	stem cell growth factor beta|SCGF - b	GeneOrGeneProduct	211:217	216:220	5:5	17329	MIG|CXCL9	GeneOrGeneProduct	308:310	309:311	8:8	1:NR:2	L2R	CROSS	217-220	312-313	6320	stem cell growth factor beta|SCGF - b	GeneOrGeneProduct	211:217	216:220	5:5	17319	MIF|MIF	GeneOrGeneProduct	312:342	313:343	8:9	1:NR:2	L2R	CROSS	217-220	340-341	6320	stem cell growth factor beta|SCGF - b	GeneOrGeneProduct	211:217	216:220	5:5	20315	CXCL12|CXCL12	GeneOrGeneProduct	340:346	341:347	9:9	1:NR:2	L2R	CROSS	217-220	344-345	6320	stem cell growth factor beta|SCGF - b	GeneOrGeneProduct	211:217	216:220	5:5	16878	LIF|LIF|LIF	GeneOrGeneProduct	344:409:424	345:410:425	9:11:11	1:Association:2	R2L	CROSS	354-361	217-220	23586	retinoic acid - inducible gene - 1|RIG - I|RIG - I	GeneOrGeneProduct	354:362:468	361:365:471	10:10:12	6320	stem cell growth factor beta|SCGF - b	GeneOrGeneProduct	211:217	216:220	5:5	1:NR:2	L2R	CROSS	217-220	380-386	6320	stem cell growth factor beta|SCGF - b	GeneOrGeneProduct	211:217	216:220	5:5	64135	melanoma differentiation - associated protein 5|MDA5	GeneOrGeneProduct	380:387	386:388	10:10	1:NR:2	L2R	CROSS	217-220	390-396	6320	stem cell growth factor beta|SCGF - b	GeneOrGeneProduct	211:217	216:220	5:5	79132	laboratory of genetics and physiology 2|LGP2	GeneOrGeneProduct	390:397	396:398	10:10	1:NR:2	L2R	CROSS	217-220	401-402	6320	stem cell growth factor beta|SCGF - b	GeneOrGeneProduct	211:217	216:220	5:5	148022	Trif	GeneOrGeneProduct	401	402	10	1:NR:2	L2R	CROSS	217-220	481-483	6320	stem cell growth factor beta|SCGF - b	GeneOrGeneProduct	211:217	216:220	5:5	D055370	lung injury	DiseaseOrPhenotypicFeature	481	483	13	1:NR:2	L2R	NON-CROSS	263-266	267-270	16176	IL - 1b|IL - 1b	GeneOrGeneProduct	263:332	266:335	8:9	16189	IL - 4	GeneOrGeneProduct	267	270	8	1:NR:2	L2R	NON-CROSS	332-335	336-339	16176	IL - 1b|IL - 1b	GeneOrGeneProduct	263:332	266:335	8:9	16191	IL - 5|IL - 5	GeneOrGeneProduct	271:336	274:339	8:9	1:NR:2	L2R	NON-CROSS	263-266	275-278	16176	IL - 1b|IL - 1b	GeneOrGeneProduct	263:332	266:335	8:9	16193	IL - 6	GeneOrGeneProduct	275	278	8	1:NR:2	L2R	NON-CROSS	263-266	279-282	16176	IL - 1b|IL - 1b	GeneOrGeneProduct	263:332	266:335	8:9	16160	IL - 12|p40	GeneOrGeneProduct	279:283	282:284	8:8	1:NR:2	L2R	NON-CROSS	332-335	348-351	16176	IL - 1b|IL - 1b	GeneOrGeneProduct	263:332	266:335	8:9	15978	IFN - g|IFN - g	GeneOrGeneProduct	286:348	289:351	8:9	1:NR:2	L2R	NON-CROSS	263-266	290-291	16176	IL - 1b|IL - 1b	GeneOrGeneProduct	263:332	266:335	8:9	20296	CCL2	GeneOrGeneProduct	290	291	8	1:NR:2	L2R	NON-CROSS	263-266	292-293	16176	IL - 1b|IL - 1b	GeneOrGeneProduct	263:332	266:335	8:9	20304	CCL5	GeneOrGeneProduct	292	293	8	1:NR:2	L2R	NON-CROSS	263-266	294-295	16176	IL - 1b|IL - 1b	GeneOrGeneProduct	263:332	266:335	8:9	20302	CCL3	GeneOrGeneProduct	294	295	8	1:NR:2	L2R	NON-CROSS	263-266	296-297	16176	IL - 1b|IL - 1b	GeneOrGeneProduct	263:332	266:335	8:9	14825	CXCL1	GeneOrGeneProduct	296	297	8	1:NR:2	L2R	NON-CROSS	302-303	332-335	16176	IL - 1b|IL - 1b	GeneOrGeneProduct	263:332	266:335	8:9	15945	IP - 10|CXCL10	GeneOrGeneProduct	298:302	301:303	8:8	1:NR:2	L2R	NON-CROSS	304-307	332-335	16176	IL - 1b|IL - 1b	GeneOrGeneProduct	263:332	266:335	8:9	50929	IL - 22	GeneOrGeneProduct	304	307	8	1:NR:2	L2R	NON-CROSS	310-311	332-335	16176	IL - 1b|IL - 1b	GeneOrGeneProduct	263:332	266:335	8:9	17329	MIG|CXCL9	GeneOrGeneProduct	308:310	309:311	8:8	1:NR:2	L2R	NON-CROSS	332-335	342-343	16176	IL - 1b|IL - 1b	GeneOrGeneProduct	263:332	266:335	8:9	17319	MIF|MIF	GeneOrGeneProduct	312:342	313:343	8:9	1:NR:2	L2R	NON-CROSS	332-335	340-341	16176	IL - 1b|IL - 1b	GeneOrGeneProduct	263:332	266:335	8:9	20315	CXCL12|CXCL12	GeneOrGeneProduct	340:346	341:347	9:9	1:NR:2	L2R	NON-CROSS	332-335	344-345	16176	IL - 1b|IL - 1b	GeneOrGeneProduct	263:332	266:335	8:9	16878	LIF|LIF|LIF	GeneOrGeneProduct	344:409:424	345:410:425	9:11:11	1:NR:2	L2R	CROSS	332-335	354-361	16176	IL - 1b|IL - 1b	GeneOrGeneProduct	263:332	266:335	8:9	23586	retinoic acid - inducible gene - 1|RIG - I|RIG - I	GeneOrGeneProduct	354:362:468	361:365:471	10:10:12	1:NR:2	L2R	CROSS	332-335	380-386	16176	IL - 1b|IL - 1b	GeneOrGeneProduct	263:332	266:335	8:9	64135	melanoma differentiation - associated protein 5|MDA5	GeneOrGeneProduct	380:387	386:388	10:10	1:NR:2	L2R	CROSS	332-335	390-396	16176	IL - 1b|IL - 1b	GeneOrGeneProduct	263:332	266:335	8:9	79132	laboratory of genetics and physiology 2|LGP2	GeneOrGeneProduct	390:397	396:398	10:10	1:NR:2	L2R	CROSS	332-335	401-402	16176	IL - 1b|IL - 1b	GeneOrGeneProduct	263:332	266:335	8:9	148022	Trif	GeneOrGeneProduct	401	402	10	1:NR:2	L2R	CROSS	332-335	481-483	16176	IL - 1b|IL - 1b	GeneOrGeneProduct	263:332	266:335	8:9	D055370	lung injury	DiseaseOrPhenotypicFeature	481	483	13	1:NR:2	L2R	NON-CROSS	267-270	271-274	16189	IL - 4	GeneOrGeneProduct	267	270	8	16191	IL - 5|IL - 5	GeneOrGeneProduct	271:336	274:339	8:9	1:NR:2	L2R	NON-CROSS	267-270	275-278	16189	IL - 4	GeneOrGeneProduct	267	270	8	16193	IL - 6	GeneOrGeneProduct	275	278	8	1:NR:2	L2R	NON-CROSS	267-270	279-282	16189	IL - 4	GeneOrGeneProduct	267	270	8	16160	IL - 12|p40	GeneOrGeneProduct	279:283	282:284	8:8	1:NR:2	L2R	NON-CROSS	267-270	286-289	16189	IL - 4	GeneOrGeneProduct	267	270	8	15978	IFN - g|IFN - g	GeneOrGeneProduct	286:348	289:351	8:9	1:NR:2	L2R	NON-CROSS	267-270	290-291	16189	IL - 4	GeneOrGeneProduct	267	270	8	20296	CCL2	GeneOrGeneProduct	290	291	8	1:NR:2	L2R	NON-CROSS	267-270	292-293	16189	IL - 4	GeneOrGeneProduct	267	270	8	20304	CCL5	GeneOrGeneProduct	292	293	8	1:NR:2	L2R	NON-CROSS	267-270	294-295	16189	IL - 4	GeneOrGeneProduct	267	270	8	20302	CCL3	GeneOrGeneProduct	294	295	8	1:NR:2	L2R	NON-CROSS	267-270	296-297	16189	IL - 4	GeneOrGeneProduct	267	270	8	14825	CXCL1	GeneOrGeneProduct	296	297	8	1:NR:2	L2R	NON-CROSS	267-270	298-301	16189	IL - 4	GeneOrGeneProduct	267	270	8	15945	IP - 10|CXCL10	GeneOrGeneProduct	298:302	301:303	8:8	1:NR:2	L2R	NON-CROSS	267-270	304-307	16189	IL - 4	GeneOrGeneProduct	267	270	8	50929	IL - 22	GeneOrGeneProduct	304	307	8	1:NR:2	L2R	NON-CROSS	267-270	308-309	16189	IL - 4	GeneOrGeneProduct	267	270	8	17329	MIG|CXCL9	GeneOrGeneProduct	308:310	309:311	8:8	1:NR:2	L2R	NON-CROSS	267-270	312-313	16189	IL - 4	GeneOrGeneProduct	267	270	8	17319	MIF|MIF	GeneOrGeneProduct	312:342	313:343	8:9	1:NR:2	L2R	CROSS	267-270	340-341	16189	IL - 4	GeneOrGeneProduct	267	270	8	20315	CXCL12|CXCL12	GeneOrGeneProduct	340:346	341:347	9:9	1:NR:2	L2R	CROSS	267-270	344-345	16189	IL - 4	GeneOrGeneProduct	267	270	8	16878	LIF|LIF|LIF	GeneOrGeneProduct	344:409:424	345:410:425	9:11:11	1:NR:2	L2R	CROSS	267-270	354-361	16189	IL - 4	GeneOrGeneProduct	267	270	8	23586	retinoic acid - inducible gene - 1|RIG - I|RIG - I	GeneOrGeneProduct	354:362:468	361:365:471	10:10:12	1:NR:2	L2R	CROSS	267-270	380-386	16189	IL - 4	GeneOrGeneProduct	267	270	8	64135	melanoma differentiation - associated protein 5|MDA5	GeneOrGeneProduct	380:387	386:388	10:10	1:NR:2	L2R	CROSS	267-270	390-396	16189	IL - 4	GeneOrGeneProduct	267	270	8	79132	laboratory of genetics and physiology 2|LGP2	GeneOrGeneProduct	390:397	396:398	10:10	1:NR:2	L2R	CROSS	267-270	401-402	16189	IL - 4	GeneOrGeneProduct	267	270	8	148022	Trif	GeneOrGeneProduct	401	402	10	1:NR:2	L2R	CROSS	267-270	481-483	16189	IL - 4	GeneOrGeneProduct	267	270	8	D055370	lung injury	DiseaseOrPhenotypicFeature	481	483	13	1:NR:2	L2R	NON-CROSS	271-274	275-278	16191	IL - 5|IL - 5	GeneOrGeneProduct	271:336	274:339	8:9	16193	IL - 6	GeneOrGeneProduct	275	278	8	1:NR:2	L2R	NON-CROSS	271-274	279-282	16191	IL - 5|IL - 5	GeneOrGeneProduct	271:336	274:339	8:9	16160	IL - 12|p40	GeneOrGeneProduct	279:283	282:284	8:8	1:NR:2	L2R	NON-CROSS	336-339	348-351	16191	IL - 5|IL - 5	GeneOrGeneProduct	271:336	274:339	8:9	15978	IFN - g|IFN - g	GeneOrGeneProduct	286:348	289:351	8:9	1:NR:2	L2R	NON-CROSS	271-274	290-291	16191	IL - 5|IL - 5	GeneOrGeneProduct	271:336	274:339	8:9	20296	CCL2	GeneOrGeneProduct	290	291	8	1:NR:2	L2R	NON-CROSS	271-274	292-293	16191	IL - 5|IL - 5	GeneOrGeneProduct	271:336	274:339	8:9	20304	CCL5	GeneOrGeneProduct	292	293	8	1:NR:2	L2R	NON-CROSS	271-274	294-295	16191	IL - 5|IL - 5	GeneOrGeneProduct	271:336	274:339	8:9	20302	CCL3	GeneOrGeneProduct	294	295	8	1:NR:2	L2R	NON-CROSS	271-274	296-297	16191	IL - 5|IL - 5	GeneOrGeneProduct	271:336	274:339	8:9	14825	CXCL1	GeneOrGeneProduct	296	297	8	1:NR:2	L2R	NON-CROSS	271-274	298-301	16191	IL - 5|IL - 5	GeneOrGeneProduct	271:336	274:339	8:9	15945	IP - 10|CXCL10	GeneOrGeneProduct	298:302	301:303	8:8	1:NR:2	L2R	NON-CROSS	304-307	336-339	16191	IL - 5|IL - 5	GeneOrGeneProduct	271:336	274:339	8:9	50929	IL - 22	GeneOrGeneProduct	304	307	8	1:NR:2	L2R	NON-CROSS	310-311	336-339	16191	IL - 5|IL - 5	GeneOrGeneProduct	271:336	274:339	8:9	17329	MIG|CXCL9	GeneOrGeneProduct	308:310	309:311	8:8	1:NR:2	L2R	NON-CROSS	336-339	342-343	16191	IL - 5|IL - 5	GeneOrGeneProduct	271:336	274:339	8:9	17319	MIF|MIF	GeneOrGeneProduct	312:342	313:343	8:9	1:NR:2	L2R	NON-CROSS	336-339	340-341	16191	IL - 5|IL - 5	GeneOrGeneProduct	271:336	274:339	8:9	20315	CXCL12|CXCL12	GeneOrGeneProduct	340:346	341:347	9:9	1:NR:2	L2R	NON-CROSS	336-339	344-345	16191	IL - 5|IL - 5	GeneOrGeneProduct	271:336	274:339	8:9	16878	LIF|LIF|LIF	GeneOrGeneProduct	344:409:424	345:410:425	9:11:11	1:NR:2	L2R	CROSS	336-339	354-361	16191	IL - 5|IL - 5	GeneOrGeneProduct	271:336	274:339	8:9	23586	retinoic acid - inducible gene - 1|RIG - I|RIG - I	GeneOrGeneProduct	354:362:468	361:365:471	10:10:12	1:NR:2	L2R	CROSS	336-339	380-386	16191	IL - 5|IL - 5	GeneOrGeneProduct	271:336	274:339	8:9	64135	melanoma differentiation - associated protein 5|MDA5	GeneOrGeneProduct	380:387	386:388	10:10	1:NR:2	L2R	CROSS	336-339	390-396	16191	IL - 5|IL - 5	GeneOrGeneProduct	271:336	274:339	8:9	79132	laboratory of genetics and physiology 2|LGP2	GeneOrGeneProduct	390:397	396:398	10:10	1:NR:2	L2R	CROSS	336-339	401-402	16191	IL - 5|IL - 5	GeneOrGeneProduct	271:336	274:339	8:9	148022	Trif	GeneOrGeneProduct	401	402	10	1:NR:2	L2R	CROSS	336-339	481-483	16191	IL - 5|IL - 5	GeneOrGeneProduct	271:336	274:339	8:9	D055370	lung injury	DiseaseOrPhenotypicFeature	481	483	13	1:NR:2	L2R	NON-CROSS	275-278	279-282	16193	IL - 6	GeneOrGeneProduct	275	278	8	16160	IL - 12|p40	GeneOrGeneProduct	279:283	282:284	8:8	1:NR:2	L2R	NON-CROSS	275-278	286-289	16193	IL - 6	GeneOrGeneProduct	275	278	8	15978	IFN - g|IFN - g	GeneOrGeneProduct	286:348	289:351	8:9	1:NR:2	L2R	NON-CROSS	275-278	290-291	16193	IL - 6	GeneOrGeneProduct	275	278	8	20296	CCL2	GeneOrGeneProduct	290	291	8	1:NR:2	L2R	NON-CROSS	275-278	292-293	16193	IL - 6	GeneOrGeneProduct	275	278	8	20304	CCL5	GeneOrGeneProduct	292	293	8	1:NR:2	L2R	NON-CROSS	275-278	294-295	16193	IL - 6	GeneOrGeneProduct	275	278	8	20302	CCL3	GeneOrGeneProduct	294	295	8	1:NR:2	L2R	NON-CROSS	275-278	296-297	16193	IL - 6	GeneOrGeneProduct	275	278	8	14825	CXCL1	GeneOrGeneProduct	296	297	8	1:NR:2	L2R	NON-CROSS	275-278	298-301	16193	IL - 6	GeneOrGeneProduct	275	278	8	15945	IP - 10|CXCL10	GeneOrGeneProduct	298:302	301:303	8:8	1:NR:2	L2R	NON-CROSS	275-278	304-307	16193	IL - 6	GeneOrGeneProduct	275	278	8	50929	IL - 22	GeneOrGeneProduct	304	307	8	1:NR:2	L2R	NON-CROSS	275-278	308-309	16193	IL - 6	GeneOrGeneProduct	275	278	8	17329	MIG|CXCL9	GeneOrGeneProduct	308:310	309:311	8:8	1:NR:2	L2R	NON-CROSS	275-278	312-313	16193	IL - 6	GeneOrGeneProduct	275	278	8	17319	MIF|MIF	GeneOrGeneProduct	312:342	313:343	8:9	1:NR:2	L2R	CROSS	275-278	340-341	16193	IL - 6	GeneOrGeneProduct	275	278	8	20315	CXCL12|CXCL12	GeneOrGeneProduct	340:346	341:347	9:9	1:NR:2	L2R	CROSS	275-278	344-345	16193	IL - 6	GeneOrGeneProduct	275	278	8	16878	LIF|LIF|LIF	GeneOrGeneProduct	344:409:424	345:410:425	9:11:11	1:NR:2	L2R	CROSS	275-278	354-361	16193	IL - 6	GeneOrGeneProduct	275	278	8	23586	retinoic acid - inducible gene - 1|RIG - I|RIG - I	GeneOrGeneProduct	354:362:468	361:365:471	10:10:12	1:NR:2	L2R	CROSS	275-278	380-386	16193	IL - 6	GeneOrGeneProduct	275	278	8	64135	melanoma differentiation - associated protein 5|MDA5	GeneOrGeneProduct	380:387	386:388	10:10	1:NR:2	L2R	CROSS	275-278	390-396	16193	IL - 6	GeneOrGeneProduct	275	278	8	79132	laboratory of genetics and physiology 2|LGP2	GeneOrGeneProduct	390:397	396:398	10:10	1:NR:2	L2R	CROSS	275-278	401-402	16193	IL - 6	GeneOrGeneProduct	275	278	8	148022	Trif	GeneOrGeneProduct	401	402	10	1:NR:2	L2R	CROSS	275-278	481-483	16193	IL - 6	GeneOrGeneProduct	275	278	8	D055370	lung injury	DiseaseOrPhenotypicFeature	481	483	13	1:NR:2	L2R	NON-CROSS	283-284	286-289	16160	IL - 12|p40	GeneOrGeneProduct	279:283	282:284	8:8	15978	IFN - g|IFN - g	GeneOrGeneProduct	286:348	289:351	8:9	1:NR:2	L2R	NON-CROSS	283-284	290-291	16160	IL - 12|p40	GeneOrGeneProduct	279:283	282:284	8:8	20296	CCL2	GeneOrGeneProduct	290	291	8	1:NR:2	L2R	NON-CROSS	283-284	292-293	16160	IL - 12|p40	GeneOrGeneProduct	279:283	282:284	8:8	20304	CCL5	GeneOrGeneProduct	292	293	8	1:NR:2	L2R	NON-CROSS	283-284	294-295	16160	IL - 12|p40	GeneOrGeneProduct	279:283	282:284	8:8	20302	CCL3	GeneOrGeneProduct	294	295	8	1:NR:2	L2R	NON-CROSS	283-284	296-297	16160	IL - 12|p40	GeneOrGeneProduct	279:283	282:284	8:8	14825	CXCL1	GeneOrGeneProduct	296	297	8	1:NR:2	L2R	NON-CROSS	283-284	298-301	16160	IL - 12|p40	GeneOrGeneProduct	279:283	282:284	8:8	15945	IP - 10|CXCL10	GeneOrGeneProduct	298:302	301:303	8:8	1:NR:2	L2R	NON-CROSS	283-284	304-307	16160	IL - 12|p40	GeneOrGeneProduct	279:283	282:284	8:8	50929	IL - 22	GeneOrGeneProduct	304	307	8	1:NR:2	L2R	NON-CROSS	283-284	308-309	16160	IL - 12|p40	GeneOrGeneProduct	279:283	282:284	8:8	17329	MIG|CXCL9	GeneOrGeneProduct	308:310	309:311	8:8	1:NR:2	L2R	NON-CROSS	283-284	312-313	16160	IL - 12|p40	GeneOrGeneProduct	279:283	282:284	8:8	17319	MIF|MIF	GeneOrGeneProduct	312:342	313:343	8:9	1:NR:2	L2R	CROSS	283-284	340-341	16160	IL - 12|p40	GeneOrGeneProduct	279:283	282:284	8:8	20315	CXCL12|CXCL12	GeneOrGeneProduct	340:346	341:347	9:9	1:NR:2	L2R	CROSS	283-284	344-345	16160	IL - 12|p40	GeneOrGeneProduct	279:283	282:284	8:8	16878	LIF|LIF|LIF	GeneOrGeneProduct	344:409:424	345:410:425	9:11:11	1:NR:2	L2R	CROSS	283-284	354-361	16160	IL - 12|p40	GeneOrGeneProduct	279:283	282:284	8:8	23586	retinoic acid - inducible gene - 1|RIG - I|RIG - I	GeneOrGeneProduct	354:362:468	361:365:471	10:10:12	1:NR:2	L2R	CROSS	283-284	380-386	16160	IL - 12|p40	GeneOrGeneProduct	279:283	282:284	8:8	64135	melanoma differentiation - associated protein 5|MDA5	GeneOrGeneProduct	380:387	386:388	10:10	1:NR:2	L2R	CROSS	283-284	390-396	16160	IL - 12|p40	GeneOrGeneProduct	279:283	282:284	8:8	79132	laboratory of genetics and physiology 2|LGP2	GeneOrGeneProduct	390:397	396:398	10:10	1:NR:2	L2R	CROSS	283-284	401-402	16160	IL - 12|p40	GeneOrGeneProduct	279:283	282:284	8:8	148022	Trif	GeneOrGeneProduct	401	402	10	1:NR:2	L2R	CROSS	283-284	481-483	16160	IL - 12|p40	GeneOrGeneProduct	279:283	282:284	8:8	D055370	lung injury	DiseaseOrPhenotypicFeature	481	483	13	1:NR:2	L2R	NON-CROSS	286-289	290-291	15978	IFN - g|IFN - g	GeneOrGeneProduct	286:348	289:351	8:9	20296	CCL2	GeneOrGeneProduct	290	291	8	1:NR:2	L2R	NON-CROSS	286-289	292-293	15978	IFN - g|IFN - g	GeneOrGeneProduct	286:348	289:351	8:9	20304	CCL5	GeneOrGeneProduct	292	293	8	1:NR:2	L2R	NON-CROSS	286-289	294-295	15978	IFN - g|IFN - g	GeneOrGeneProduct	286:348	289:351	8:9	20302	CCL3	GeneOrGeneProduct	294	295	8	1:NR:2	L2R	NON-CROSS	286-289	296-297	15978	IFN - g|IFN - g	GeneOrGeneProduct	286:348	289:351	8:9	14825	CXCL1	GeneOrGeneProduct	296	297	8	1:NR:2	L2R	NON-CROSS	286-289	298-301	15978	IFN - g|IFN - g	GeneOrGeneProduct	286:348	289:351	8:9	15945	IP - 10|CXCL10	GeneOrGeneProduct	298:302	301:303	8:8	1:NR:2	L2R	NON-CROSS	286-289	304-307	15978	IFN - g|IFN - g	GeneOrGeneProduct	286:348	289:351	8:9	50929	IL - 22	GeneOrGeneProduct	304	307	8	1:NR:2	L2R	NON-CROSS	286-289	308-309	15978	IFN - g|IFN - g	GeneOrGeneProduct	286:348	289:351	8:9	17329	MIG|CXCL9	GeneOrGeneProduct	308:310	309:311	8:8	1:NR:2	L2R	NON-CROSS	342-343	348-351	15978	IFN - g|IFN - g	GeneOrGeneProduct	286:348	289:351	8:9	17319	MIF|MIF	GeneOrGeneProduct	312:342	313:343	8:9	1:NR:2	L2R	NON-CROSS	346-347	348-351	15978	IFN - g|IFN - g	GeneOrGeneProduct	286:348	289:351	8:9	20315	CXCL12|CXCL12	GeneOrGeneProduct	340:346	341:347	9:9	1:NR:2	L2R	NON-CROSS	344-345	348-351	15978	IFN - g|IFN - g	GeneOrGeneProduct	286:348	289:351	8:9	16878	LIF|LIF|LIF	GeneOrGeneProduct	344:409:424	345:410:425	9:11:11	1:NR:2	L2R	CROSS	348-351	354-361	15978	IFN - g|IFN - g	GeneOrGeneProduct	286:348	289:351	8:9	23586	retinoic acid - inducible gene - 1|RIG - I|RIG - I	GeneOrGeneProduct	354:362:468	361:365:471	10:10:12	1:NR:2	L2R	CROSS	348-351	380-386	15978	IFN - g|IFN - g	GeneOrGeneProduct	286:348	289:351	8:9	64135	melanoma differentiation - associated protein 5|MDA5	GeneOrGeneProduct	380:387	386:388	10:10	1:NR:2	L2R	CROSS	348-351	390-396	15978	IFN - g|IFN - g	GeneOrGeneProduct	286:348	289:351	8:9	79132	laboratory of genetics and physiology 2|LGP2	GeneOrGeneProduct	390:397	396:398	10:10	1:NR:2	L2R	CROSS	348-351	401-402	15978	IFN - g|IFN - g	GeneOrGeneProduct	286:348	289:351	8:9	148022	Trif	GeneOrGeneProduct	401	402	10	1:NR:2	L2R	CROSS	348-351	481-483	15978	IFN - g|IFN - g	GeneOrGeneProduct	286:348	289:351	8:9	D055370	lung injury	DiseaseOrPhenotypicFeature	481	483	13	1:NR:2	L2R	NON-CROSS	290-291	292-293	20296	CCL2	GeneOrGeneProduct	290	291	8	20304	CCL5	GeneOrGeneProduct	292	293	8	1:NR:2	L2R	NON-CROSS	290-291	294-295	20296	CCL2	GeneOrGeneProduct	290	291	8	20302	CCL3	GeneOrGeneProduct	294	295	8	1:NR:2	L2R	NON-CROSS	290-291	296-297	20296	CCL2	GeneOrGeneProduct	290	291	8	14825	CXCL1	GeneOrGeneProduct	296	297	8	1:NR:2	L2R	NON-CROSS	290-291	298-301	20296	CCL2	GeneOrGeneProduct	290	291	8	15945	IP - 10|CXCL10	GeneOrGeneProduct	298:302	301:303	8:8	1:NR:2	L2R	NON-CROSS	290-291	304-307	20296	CCL2	GeneOrGeneProduct	290	291	8	50929	IL - 22	GeneOrGeneProduct	304	307	8	1:NR:2	L2R	NON-CROSS	290-291	308-309	20296	CCL2	GeneOrGeneProduct	290	291	8	17329	MIG|CXCL9	GeneOrGeneProduct	308:310	309:311	8:8	1:NR:2	L2R	NON-CROSS	290-291	312-313	20296	CCL2	GeneOrGeneProduct	290	291	8	17319	MIF|MIF	GeneOrGeneProduct	312:342	313:343	8:9	1:NR:2	L2R	CROSS	290-291	340-341	20296	CCL2	GeneOrGeneProduct	290	291	8	20315	CXCL12|CXCL12	GeneOrGeneProduct	340:346	341:347	9:9	1:NR:2	L2R	CROSS	290-291	344-345	20296	CCL2	GeneOrGeneProduct	290	291	8	16878	LIF|LIF|LIF	GeneOrGeneProduct	344:409:424	345:410:425	9:11:11	1:NR:2	L2R	CROSS	290-291	354-361	20296	CCL2	GeneOrGeneProduct	290	291	8	23586	retinoic acid - inducible gene - 1|RIG - I|RIG - I	GeneOrGeneProduct	354:362:468	361:365:471	10:10:12	1:NR:2	L2R	CROSS	290-291	380-386	20296	CCL2	GeneOrGeneProduct	290	291	8	64135	melanoma differentiation - associated protein 5|MDA5	GeneOrGeneProduct	380:387	386:388	10:10	1:NR:2	L2R	CROSS	290-291	390-396	20296	CCL2	GeneOrGeneProduct	290	291	8	79132	laboratory of genetics and physiology 2|LGP2	GeneOrGeneProduct	390:397	396:398	10:10	1:NR:2	L2R	CROSS	290-291	401-402	20296	CCL2	GeneOrGeneProduct	290	291	8	148022	Trif	GeneOrGeneProduct	401	402	10	1:NR:2	L2R	CROSS	290-291	481-483	20296	CCL2	GeneOrGeneProduct	290	291	8	D055370	lung injury	DiseaseOrPhenotypicFeature	481	483	13	1:NR:2	L2R	NON-CROSS	292-293	294-295	20304	CCL5	GeneOrGeneProduct	292	293	8	20302	CCL3	GeneOrGeneProduct	294	295	8	1:NR:2	L2R	NON-CROSS	292-293	296-297	20304	CCL5	GeneOrGeneProduct	292	293	8	14825	CXCL1	GeneOrGeneProduct	296	297	8	1:NR:2	L2R	NON-CROSS	292-293	298-301	20304	CCL5	GeneOrGeneProduct	292	293	8	15945	IP - 10|CXCL10	GeneOrGeneProduct	298:302	301:303	8:8	1:NR:2	L2R	NON-CROSS	292-293	304-307	20304	CCL5	GeneOrGeneProduct	292	293	8	50929	IL - 22	GeneOrGeneProduct	304	307	8	1:NR:2	L2R	NON-CROSS	292-293	308-309	20304	CCL5	GeneOrGeneProduct	292	293	8	17329	MIG|CXCL9	GeneOrGeneProduct	308:310	309:311	8:8	1:NR:2	L2R	NON-CROSS	292-293	312-313	20304	CCL5	GeneOrGeneProduct	292	293	8	17319	MIF|MIF	GeneOrGeneProduct	312:342	313:343	8:9	1:NR:2	L2R	CROSS	292-293	340-341	20304	CCL5	GeneOrGeneProduct	292	293	8	20315	CXCL12|CXCL12	GeneOrGeneProduct	340:346	341:347	9:9	1:NR:2	L2R	CROSS	292-293	344-345	20304	CCL5	GeneOrGeneProduct	292	293	8	16878	LIF|LIF|LIF	GeneOrGeneProduct	344:409:424	345:410:425	9:11:11	1:NR:2	L2R	CROSS	292-293	354-361	20304	CCL5	GeneOrGeneProduct	292	293	8	23586	retinoic acid - inducible gene - 1|RIG - I|RIG - I	GeneOrGeneProduct	354:362:468	361:365:471	10:10:12	1:NR:2	L2R	CROSS	292-293	380-386	20304	CCL5	GeneOrGeneProduct	292	293	8	64135	melanoma differentiation - associated protein 5|MDA5	GeneOrGeneProduct	380:387	386:388	10:10	1:NR:2	L2R	CROSS	292-293	390-396	20304	CCL5	GeneOrGeneProduct	292	293	8	79132	laboratory of genetics and physiology 2|LGP2	GeneOrGeneProduct	390:397	396:398	10:10	1:NR:2	L2R	CROSS	292-293	401-402	20304	CCL5	GeneOrGeneProduct	292	293	8	148022	Trif	GeneOrGeneProduct	401	402	10	1:NR:2	L2R	CROSS	292-293	481-483	20304	CCL5	GeneOrGeneProduct	292	293	8	D055370	lung injury	DiseaseOrPhenotypicFeature	481	483	13	1:NR:2	L2R	NON-CROSS	294-295	296-297	20302	CCL3	GeneOrGeneProduct	294	295	8	14825	CXCL1	GeneOrGeneProduct	296	297	8	1:NR:2	L2R	NON-CROSS	294-295	298-301	20302	CCL3	GeneOrGeneProduct	294	295	8	15945	IP - 10|CXCL10	GeneOrGeneProduct	298:302	301:303	8:8	1:NR:2	L2R	NON-CROSS	294-295	304-307	20302	CCL3	GeneOrGeneProduct	294	295	8	50929	IL - 22	GeneOrGeneProduct	304	307	8	1:NR:2	L2R	NON-CROSS	294-295	308-309	20302	CCL3	GeneOrGeneProduct	294	295	8	17329	MIG|CXCL9	GeneOrGeneProduct	308:310	309:311	8:8	1:NR:2	L2R	NON-CROSS	294-295	312-313	20302	CCL3	GeneOrGeneProduct	294	295	8	17319	MIF|MIF	GeneOrGeneProduct	312:342	313:343	8:9	1:NR:2	L2R	CROSS	294-295	340-341	20302	CCL3	GeneOrGeneProduct	294	295	8	20315	CXCL12|CXCL12	GeneOrGeneProduct	340:346	341:347	9:9	1:NR:2	L2R	CROSS	294-295	344-345	20302	CCL3	GeneOrGeneProduct	294	295	8	16878	LIF|LIF|LIF	GeneOrGeneProduct	344:409:424	345:410:425	9:11:11	1:NR:2	L2R	CROSS	294-295	354-361	20302	CCL3	GeneOrGeneProduct	294	295	8	23586	retinoic acid - inducible gene - 1|RIG - I|RIG - I	GeneOrGeneProduct	354:362:468	361:365:471	10:10:12	1:NR:2	L2R	CROSS	294-295	380-386	20302	CCL3	GeneOrGeneProduct	294	295	8	64135	melanoma differentiation - associated protein 5|MDA5	GeneOrGeneProduct	380:387	386:388	10:10	1:NR:2	L2R	CROSS	294-295	390-396	20302	CCL3	GeneOrGeneProduct	294	295	8	79132	laboratory of genetics and physiology 2|LGP2	GeneOrGeneProduct	390:397	396:398	10:10	1:NR:2	L2R	CROSS	294-295	401-402	20302	CCL3	GeneOrGeneProduct	294	295	8	148022	Trif	GeneOrGeneProduct	401	402	10	1:NR:2	L2R	CROSS	294-295	481-483	20302	CCL3	GeneOrGeneProduct	294	295	8	D055370	lung injury	DiseaseOrPhenotypicFeature	481	483	13	1:NR:2	L2R	NON-CROSS	296-297	298-301	14825	CXCL1	GeneOrGeneProduct	296	297	8	15945	IP - 10|CXCL10	GeneOrGeneProduct	298:302	301:303	8:8	1:NR:2	L2R	NON-CROSS	296-297	304-307	14825	CXCL1	GeneOrGeneProduct	296	297	8	50929	IL - 22	GeneOrGeneProduct	304	307	8	1:NR:2	L2R	NON-CROSS	296-297	308-309	14825	CXCL1	GeneOrGeneProduct	296	297	8	17329	MIG|CXCL9	GeneOrGeneProduct	308:310	309:311	8:8	1:NR:2	L2R	NON-CROSS	296-297	312-313	14825	CXCL1	GeneOrGeneProduct	296	297	8	17319	MIF|MIF	GeneOrGeneProduct	312:342	313:343	8:9	1:NR:2	L2R	CROSS	296-297	340-341	14825	CXCL1	GeneOrGeneProduct	296	297	8	20315	CXCL12|CXCL12	GeneOrGeneProduct	340:346	341:347	9:9	1:NR:2	L2R	CROSS	296-297	344-345	14825	CXCL1	GeneOrGeneProduct	296	297	8	16878	LIF|LIF|LIF	GeneOrGeneProduct	344:409:424	345:410:425	9:11:11	1:NR:2	L2R	CROSS	296-297	354-361	14825	CXCL1	GeneOrGeneProduct	296	297	8	23586	retinoic acid - inducible gene - 1|RIG - I|RIG - I	GeneOrGeneProduct	354:362:468	361:365:471	10:10:12	1:NR:2	L2R	CROSS	296-297	380-386	14825	CXCL1	GeneOrGeneProduct	296	297	8	64135	melanoma differentiation - associated protein 5|MDA5	GeneOrGeneProduct	380:387	386:388	10:10	1:NR:2	L2R	CROSS	296-297	390-396	14825	CXCL1	GeneOrGeneProduct	296	297	8	79132	laboratory of genetics and physiology 2|LGP2	GeneOrGeneProduct	390:397	396:398	10:10	1:NR:2	L2R	CROSS	296-297	401-402	14825	CXCL1	GeneOrGeneProduct	296	297	8	148022	Trif	GeneOrGeneProduct	401	402	10	1:NR:2	L2R	CROSS	296-297	481-483	14825	CXCL1	GeneOrGeneProduct	296	297	8	D055370	lung injury	DiseaseOrPhenotypicFeature	481	483	13	1:NR:2	L2R	NON-CROSS	302-303	304-307	15945	IP - 10|CXCL10	GeneOrGeneProduct	298:302	301:303	8:8	50929	IL - 22	GeneOrGeneProduct	304	307	8	1:NR:2	L2R	NON-CROSS	302-303	308-309	15945	IP - 10|CXCL10	GeneOrGeneProduct	298:302	301:303	8:8	17329	MIG|CXCL9	GeneOrGeneProduct	308:310	309:311	8:8	1:NR:2	L2R	NON-CROSS	302-303	312-313	15945	IP - 10|CXCL10	GeneOrGeneProduct	298:302	301:303	8:8	17319	MIF|MIF	GeneOrGeneProduct	312:342	313:343	8:9	1:NR:2	L2R	CROSS	302-303	340-341	15945	IP - 10|CXCL10	GeneOrGeneProduct	298:302	301:303	8:8	20315	CXCL12|CXCL12	GeneOrGeneProduct	340:346	341:347	9:9	1:NR:2	L2R	CROSS	302-303	344-345	15945	IP - 10|CXCL10	GeneOrGeneProduct	298:302	301:303	8:8	16878	LIF|LIF|LIF	GeneOrGeneProduct	344:409:424	345:410:425	9:11:11	1:NR:2	L2R	CROSS	302-303	354-361	15945	IP - 10|CXCL10	GeneOrGeneProduct	298:302	301:303	8:8	23586	retinoic acid - inducible gene - 1|RIG - I|RIG - I	GeneOrGeneProduct	354:362:468	361:365:471	10:10:12	1:NR:2	L2R	CROSS	302-303	380-386	15945	IP - 10|CXCL10	GeneOrGeneProduct	298:302	301:303	8:8	64135	melanoma differentiation - associated protein 5|MDA5	GeneOrGeneProduct	380:387	386:388	10:10	1:NR:2	L2R	CROSS	302-303	390-396	15945	IP - 10|CXCL10	GeneOrGeneProduct	298:302	301:303	8:8	79132	laboratory of genetics and physiology 2|LGP2	GeneOrGeneProduct	390:397	396:398	10:10	1:NR:2	L2R	CROSS	302-303	401-402	15945	IP - 10|CXCL10	GeneOrGeneProduct	298:302	301:303	8:8	148022	Trif	GeneOrGeneProduct	401	402	10	1:NR:2	L2R	CROSS	302-303	481-483	15945	IP - 10|CXCL10	GeneOrGeneProduct	298:302	301:303	8:8	D055370	lung injury	DiseaseOrPhenotypicFeature	481	483	13	1:NR:2	L2R	NON-CROSS	304-307	308-309	50929	IL - 22	GeneOrGeneProduct	304	307	8	17329	MIG|CXCL9	GeneOrGeneProduct	308:310	309:311	8:8	1:NR:2	L2R	NON-CROSS	304-307	312-313	50929	IL - 22	GeneOrGeneProduct	304	307	8	17319	MIF|MIF	GeneOrGeneProduct	312:342	313:343	8:9	1:NR:2	L2R	CROSS	304-307	340-341	50929	IL - 22	GeneOrGeneProduct	304	307	8	20315	CXCL12|CXCL12	GeneOrGeneProduct	340:346	341:347	9:9	1:NR:2	L2R	CROSS	304-307	344-345	50929	IL - 22	GeneOrGeneProduct	304	307	8	16878	LIF|LIF|LIF	GeneOrGeneProduct	344:409:424	345:410:425	9:11:11	1:NR:2	L2R	CROSS	304-307	354-361	50929	IL - 22	GeneOrGeneProduct	304	307	8	23586	retinoic acid - inducible gene - 1|RIG - I|RIG - I	GeneOrGeneProduct	354:362:468	361:365:471	10:10:12	1:NR:2	L2R	CROSS	304-307	380-386	50929	IL - 22	GeneOrGeneProduct	304	307	8	64135	melanoma differentiation - associated protein 5|MDA5	GeneOrGeneProduct	380:387	386:388	10:10	1:NR:2	L2R	CROSS	304-307	390-396	50929	IL - 22	GeneOrGeneProduct	304	307	8	79132	laboratory of genetics and physiology 2|LGP2	GeneOrGeneProduct	390:397	396:398	10:10	1:NR:2	L2R	CROSS	304-307	401-402	50929	IL - 22	GeneOrGeneProduct	304	307	8	148022	Trif	GeneOrGeneProduct	401	402	10	1:NR:2	L2R	CROSS	304-307	481-483	50929	IL - 22	GeneOrGeneProduct	304	307	8	D055370	lung injury	DiseaseOrPhenotypicFeature	481	483	13	1:NR:2	L2R	NON-CROSS	310-311	312-313	17329	MIG|CXCL9	GeneOrGeneProduct	308:310	309:311	8:8	17319	MIF|MIF	GeneOrGeneProduct	312:342	313:343	8:9	1:NR:2	L2R	CROSS	310-311	340-341	17329	MIG|CXCL9	GeneOrGeneProduct	308:310	309:311	8:8	20315	CXCL12|CXCL12	GeneOrGeneProduct	340:346	341:347	9:9	1:NR:2	L2R	CROSS	310-311	344-345	17329	MIG|CXCL9	GeneOrGeneProduct	308:310	309:311	8:8	16878	LIF|LIF|LIF	GeneOrGeneProduct	344:409:424	345:410:425	9:11:11	1:NR:2	L2R	CROSS	310-311	354-361	17329	MIG|CXCL9	GeneOrGeneProduct	308:310	309:311	8:8	23586	retinoic acid - inducible gene - 1|RIG - I|RIG - I	GeneOrGeneProduct	354:362:468	361:365:471	10:10:12	1:NR:2	L2R	CROSS	310-311	380-386	17329	MIG|CXCL9	GeneOrGeneProduct	308:310	309:311	8:8	64135	melanoma differentiation - associated protein 5|MDA5	GeneOrGeneProduct	380:387	386:388	10:10	1:NR:2	L2R	CROSS	310-311	390-396	17329	MIG|CXCL9	GeneOrGeneProduct	308:310	309:311	8:8	79132	laboratory of genetics and physiology 2|LGP2	GeneOrGeneProduct	390:397	396:398	10:10	1:NR:2	L2R	CROSS	310-311	401-402	17329	MIG|CXCL9	GeneOrGeneProduct	308:310	309:311	8:8	148022	Trif	GeneOrGeneProduct	401	402	10	1:NR:2	L2R	CROSS	310-311	481-483	17329	MIG|CXCL9	GeneOrGeneProduct	308:310	309:311	8:8	D055370	lung injury	DiseaseOrPhenotypicFeature	481	483	13	1:NR:2	L2R	NON-CROSS	340-341	342-343	17319	MIF|MIF	GeneOrGeneProduct	312:342	313:343	8:9	20315	CXCL12|CXCL12	GeneOrGeneProduct	340:346	341:347	9:9	1:NR:2	L2R	NON-CROSS	342-343	344-345	17319	MIF|MIF	GeneOrGeneProduct	312:342	313:343	8:9	16878	LIF|LIF|LIF	GeneOrGeneProduct	344:409:424	345:410:425	9:11:11	1:NR:2	L2R	CROSS	342-343	354-361	17319	MIF|MIF	GeneOrGeneProduct	312:342	313:343	8:9	23586	retinoic acid - inducible gene - 1|RIG - I|RIG - I	GeneOrGeneProduct	354:362:468	361:365:471	10:10:12	1:NR:2	L2R	CROSS	342-343	380-386	17319	MIF|MIF	GeneOrGeneProduct	312:342	313:343	8:9	64135	melanoma differentiation - associated protein 5|MDA5	GeneOrGeneProduct	380:387	386:388	10:10	1:NR:2	L2R	CROSS	342-343	390-396	17319	MIF|MIF	GeneOrGeneProduct	312:342	313:343	8:9	79132	laboratory of genetics and physiology 2|LGP2	GeneOrGeneProduct	390:397	396:398	10:10	1:NR:2	L2R	CROSS	342-343	401-402	17319	MIF|MIF	GeneOrGeneProduct	312:342	313:343	8:9	148022	Trif	GeneOrGeneProduct	401	402	10	1:NR:2	L2R	CROSS	342-343	481-483	17319	MIF|MIF	GeneOrGeneProduct	312:342	313:343	8:9	D055370	lung injury	DiseaseOrPhenotypicFeature	481	483	13	1:NR:2	L2R	NON-CROSS	344-345	346-347	20315	CXCL12|CXCL12	GeneOrGeneProduct	340:346	341:347	9:9	16878	LIF|LIF|LIF	GeneOrGeneProduct	344:409:424	345:410:425	9:11:11	1:NR:2	L2R	CROSS	346-347	354-361	20315	CXCL12|CXCL12	GeneOrGeneProduct	340:346	341:347	9:9	23586	retinoic acid - inducible gene - 1|RIG - I|RIG - I	GeneOrGeneProduct	354:362:468	361:365:471	10:10:12	1:NR:2	L2R	CROSS	346-347	380-386	20315	CXCL12|CXCL12	GeneOrGeneProduct	340:346	341:347	9:9	64135	melanoma differentiation - associated protein 5|MDA5	GeneOrGeneProduct	380:387	386:388	10:10	1:NR:2	L2R	CROSS	346-347	390-396	20315	CXCL12|CXCL12	GeneOrGeneProduct	340:346	341:347	9:9	79132	laboratory of genetics and physiology 2|LGP2	GeneOrGeneProduct	390:397	396:398	10:10	1:NR:2	L2R	CROSS	346-347	401-402	20315	CXCL12|CXCL12	GeneOrGeneProduct	340:346	341:347	9:9	148022	Trif	GeneOrGeneProduct	401	402	10	1:NR:2	L2R	CROSS	346-347	481-483	20315	CXCL12|CXCL12	GeneOrGeneProduct	340:346	341:347	9:9	D055370	lung injury	DiseaseOrPhenotypicFeature	481	483	13	1:NR:2	L2R	CROSS	344-345	354-361	16878	LIF|LIF|LIF	GeneOrGeneProduct	344:409:424	345:410:425	9:11:11	23586	retinoic acid - inducible gene - 1|RIG - I|RIG - I	GeneOrGeneProduct	354:362:468	361:365:471	10:10:12	1:NR:2	L2R	CROSS	387-388	409-410	16878	LIF|LIF|LIF	GeneOrGeneProduct	344:409:424	345:410:425	9:11:11	64135	melanoma differentiation - associated protein 5|MDA5	GeneOrGeneProduct	380:387	386:388	10:10	1:NR:2	L2R	CROSS	397-398	409-410	16878	LIF|LIF|LIF	GeneOrGeneProduct	344:409:424	345:410:425	9:11:11	79132	laboratory of genetics and physiology 2|LGP2	GeneOrGeneProduct	390:397	396:398	10:10	1:NR:2	L2R	CROSS	401-402	409-410	16878	LIF|LIF|LIF	GeneOrGeneProduct	344:409:424	345:410:425	9:11:11	148022	Trif	GeneOrGeneProduct	401	402	10	1:Negative_Correlation:2	L2R	CROSS	424-425	481-483	16878	LIF|LIF|LIF	GeneOrGeneProduct	344:409:424	345:410:425	9:11:11	D055370	lung injury	DiseaseOrPhenotypicFeature	481	483	13	1:NR:2	L2R	NON-CROSS	362-365	380-386	23586	retinoic acid - inducible gene - 1|RIG - I|RIG - I	GeneOrGeneProduct	354:362:468	361:365:471	10:10:12	64135	melanoma differentiation - associated protein 5|MDA5	GeneOrGeneProduct	380:387	386:388	10:10	1:NR:2	L2R	NON-CROSS	362-365	390-396	23586	retinoic acid - inducible gene - 1|RIG - I|RIG - I	GeneOrGeneProduct	354:362:468	361:365:471	10:10:12	79132	laboratory of genetics and physiology 2|LGP2	GeneOrGeneProduct	390:397	396:398	10:10	1:NR:2	L2R	NON-CROSS	362-365	401-402	23586	retinoic acid - inducible gene - 1|RIG - I|RIG - I	GeneOrGeneProduct	354:362:468	361:365:471	10:10:12	148022	Trif	GeneOrGeneProduct	401	402	10	1:NR:2	L2R	CROSS	468-471	481-483	23586	retinoic acid - inducible gene - 1|RIG - I|RIG - I	GeneOrGeneProduct	354:362:468	361:365:471	10:10:12	D055370	lung injury	DiseaseOrPhenotypicFeature	481	483	13	1:NR:2	L2R	NON-CROSS	387-388	390-396	64135	melanoma differentiation - associated protein 5|MDA5	GeneOrGeneProduct	380:387	386:388	10:10	79132	laboratory of genetics and physiology 2|LGP2	GeneOrGeneProduct	390:397	396:398	10:10	1:NR:2	L2R	NON-CROSS	387-388	401-402	64135	melanoma differentiation - associated protein 5|MDA5	GeneOrGeneProduct	380:387	386:388	10:10	148022	Trif	GeneOrGeneProduct	401	402	10	1:NR:2	L2R	CROSS	387-388	481-483	64135	melanoma differentiation - associated protein 5|MDA5	GeneOrGeneProduct	380:387	386:388	10:10	D055370	lung injury	DiseaseOrPhenotypicFeature	481	483	13	1:NR:2	L2R	NON-CROSS	397-398	401-402	79132	laboratory of genetics and physiology 2|LGP2	GeneOrGeneProduct	390:397	396:398	10:10	148022	Trif	GeneOrGeneProduct	401	402	10	1:NR:2	L2R	CROSS	397-398	481-483	79132	laboratory of genetics and physiology 2|LGP2	GeneOrGeneProduct	390:397	396:398	10:10	D055370	lung injury	DiseaseOrPhenotypicFeature	481	483	13	1:NR:2	L2R	CROSS	401-402	481-483	148022	Trif	GeneOrGeneProduct	401	402	10	D055370	lung injury	DiseaseOrPhenotypicFeature	481	483	13
15130900	Urinary bladder cancer in Wegener 's granulomatosis : risks and relation to cyclophosphamide .|OBJECTIVE : To assess and characterise the risk of bladder cancer , and its relation to cyclophosphamide , in patients with Wegener 's granulomatosis .|METHODS : In the population based , nationwide Swedish Inpatient Register a cohort of 1065 patients with Wegener 's granulomatosis , 1969 - 95 , was identified .|Through linkage with the Swedish Cancer Register , all subjects in this cohort diagnosed with bladder cancer were identified .|Nested within the cohort , a matched case - control study was performed to estimate the association between cyclophosphamide and bladder cancer using odds ratios ( ORs ) as relative risk .|In the cohort the cumulative risk of bladder cancer after Wegener 's granulomatosis , and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener 's granulomatosis , were also estimated .|RESULTS : The median cumulative doses of cyclophosphamide among cases ( n = 11 ) and controls ( n = 25 ) were 113 g and 25 g , respectively .|The risk of bladder cancer doubled for every 10 g increment in cyclophosphamide ( OR = 2 . 0 , 95 % confidence interval ( CI ) 0 . 8 to 4 . 9 ) .|Treatment duration longer than 1 year was associated with an eightfold increased risk ( OR = 7 . 7 , 95 % CI 0 . 9 to 69 ) .|The absolute risk for bladder cancer in the cohort reached 10 % 16 years after diagnosis of Wegener 's granulomatosis , and a history of bladder cancer was ( non - significantly ) twice as common as expected at the time of diagnosis of Wegener 's granulomatosis .|CONCLUSION : The results indicate a dose - response relationship between cyclophosphamide and the risk of bladder cancer , high cumulative risks in the entire cohort , and also the possibility of risk factors operating even before Wegener 's granulomatosis .	1:Positive_Correlation:2	R2L	NON-CROSS	107-109	105-106	D003520	cyclophosphamide|cyclophosphamide|cyclophosphamide|cyclophosphamide|cyclophosphamide|cyclophosphamide	ChemicalEntity	12:30:105:164:200:313	13:31:106:165:201:314	0:1:4:6:7:10	D001749	Urinary bladder cancer|bladder cancer|bladder cancer|bladder cancer|bladder cancer|bladder cancer|bladder cancer|bladder cancer|bladder cancer|bladder cancer	DiseaseOrPhenotypicFeature	0:23:82:107:126:141:191:258:279:318	3:25:84:109:128:143:193:260:281:320	0:1:3:4:5:5:7:9:9:10	1:Association:2	R2L	NON-CROSS	35-38	30-31	D003520	cyclophosphamide|cyclophosphamide|cyclophosphamide|cyclophosphamide|cyclophosphamide|cyclophosphamide	ChemicalEntity	12:30:105:164:200:313	13:31:106:165:201:314	0:1:4:6:7:10	D014890	Wegener 's granulomatosis|Wegener 's granulomatosis|Wegener 's granulomatosis|Wegener 's granulomatosis|Wegener 's granulomatosis|Wegener 's granulomatosis|Wegener 's granulomatosis|Wegener 's granulomatosis	DiseaseOrPhenotypicFeature	4:35:56:129:149:271:298:339	7:38:59:132:152:274:301:342	0:1:2:5:5:9:9:10	1:NR:2	L2R	CROSS	72-73	105-106	D003520	cyclophosphamide|cyclophosphamide|cyclophosphamide|cyclophosphamide|cyclophosphamide|cyclophosphamide	ChemicalEntity	12:30:105:164:200:313	13:31:106:165:201:314	0:1:4:6:7:10	D009369	Cancer	DiseaseOrPhenotypicFeature	72	73	3
18257781	Co - inheritance of a PKD1 mutation and homozygous PKD2 variant : a potential modifier in autosomal dominant polycystic kidney disease .|BACKGROUND : Autosomal dominant polycystic kidney disease ( ADPKD ) , which is caused by mutations in polycystins 1 ( PC1 ) and 2 ( PC2 ) , is one of the most commonly inherited renal diseases , affecting ~1 : 1000 Caucasians .|MATERIALS AND METHODS : We screened Greek ADPKD patients with the denaturing gradient gel electrophoresis ( DGGE ) assay and direct sequencing .|RESULTS : We identified a patient homozygous for a nucleotide change c . 1445T > G , resulting in a novel homozygous substitution of the non - polar hydrophobic phenylalanine to the polar hydrophilic cysteine in exon 6 at codon 482 ( p . F482C ) of the PKD2 gene and a de - novo PKD1 splice - site variant IVS21 - 2delAG .|We did not find this PKD2 variant in a screen of 280 chromosomes of healthy subjects , supporting its pathogenicity .|The proband 's parents did not have the PKD1 mutation .|Real - time PCR of the PKD2 transcript from a skin biopsy revealed 20 - fold higher expression in the patient than in a healthy subject and was higher in the patient 's peripheral blood mononuclear cells ( PBMCs ) than in those of her heterozygote daughter and a healthy subject .|The greater gene expression was also supported by Western blotting .|Inner medullar collecting duct ( IMCD ) cells transfected with the mutant PKD2 mouse gene presented a perinuclear and diffuse cytoplasmic localization compared with the wild type ER localization .|Patch - clamping of PBMCs from the p . F482C homozygous and heterozygous subjects revealed lower polycystin - 2 channel function than in controls .|CONCLUSIONS : We report for the first time a patient with ADPKD who is heterozygous for a de novo PKD1 variant and homozygous for a novel PKD2 mutation .	1:NR:2	L2R	NON-CROSS	5-6	9-10	5310	PKD1|polycystins 1|PC1|PKD1|PKD1|PKD1	GeneOrGeneProduct	5:39:42:144:182:322	6:41:43:145:183:323	0:1:1:3:5:10	5311	PKD2|PC2|PKD2|PKD2|PKD2|polycystin - 2|PKD2	GeneOrGeneProduct	9:47:137:158:191:294:329	10:48:138:159:192:297:330	0:1:3:4:6:9:10	1:Association:2	R2L	NON-CROSS	322-323	314-315	D007690	autosomal dominant polycystic kidney disease|Autosomal dominant polycystic kidney disease|ADPKD|ADPKD|ADPKD	DiseaseOrPhenotypicFeature	16:24:30:73:314	21:29:31:74:315	0:1:1:2:10	5310	PKD1|polycystins 1|PC1|PKD1|PKD1|PKD1	GeneOrGeneProduct	5:39:42:144:182:322	6:41:43:145:183:323	0:1:1:3:5:10	1:NR:2	L2R	NON-CROSS	42-43	57-59	5310	PKD1|polycystins 1|PC1|PKD1|PKD1|PKD1	GeneOrGeneProduct	5:39:42:144:182:322	6:41:43:145:183:323	0:1:1:3:5:10	D007674	renal diseases	DiseaseOrPhenotypicFeature	57	59	1	1:NR:2	L2R	CROSS	260-261	322-323	5310	PKD1|polycystins 1|PC1|PKD1|PKD1|PKD1	GeneOrGeneProduct	5:39:42:144:182:322	6:41:43:145:183:323	0:1:1:3:5:10	18764	PKD2	GeneOrGeneProduct	260	261	8	1:Association:2	R2L	NON-CROSS	16-21	9-10	D007690	autosomal dominant polycystic kidney disease|Autosomal dominant polycystic kidney disease|ADPKD|ADPKD|ADPKD	DiseaseOrPhenotypicFeature	16:24:30:73:314	21:29:31:74:315	0:1:1:2:10	5311	PKD2|PC2|PKD2|PKD2|PKD2|polycystin - 2|PKD2	GeneOrGeneProduct	9:47:137:158:191:294:329	10:48:138:159:192:297:330	0:1:3:4:6:9:10	1:NR:2	L2R	NON-CROSS	47-48	57-59	5311	PKD2|PC2|PKD2|PKD2|PKD2|polycystin - 2|PKD2	GeneOrGeneProduct	9:47:137:158:191:294:329	10:48:138:159:192:297:330	0:1:3:4:6:9:10	D007674	renal diseases	DiseaseOrPhenotypicFeature	57	59	1	1:NR:2	L2R	CROSS	260-261	294-297	5311	PKD2|PC2|PKD2|PKD2|PKD2|polycystin - 2|PKD2	GeneOrGeneProduct	9:47:137:158:191:294:329	10:48:138:159:192:297:330	0:1:3:4:6:9:10	18764	PKD2	GeneOrGeneProduct	260	261	8	1:Positive_Correlation:2	R2L	CROSS	100-105	73-74	rs75762896	c . 1445T > G|phenylalanine to the polar hydrophilic cysteine in exon 6 at codon 482|p . F482C|p . F482C	SequenceVariant	100:118:131:285	105:130:134:288	3:3:3:9	D007690	autosomal dominant polycystic kidney disease|Autosomal dominant polycystic kidney disease|ADPKD|ADPKD|ADPKD	DiseaseOrPhenotypicFeature	16:24:30:73:314	21:29:31:74:315	0:1:1:2:10	1:Positive_Correlation:2	R2L	CROSS	149-152	73-74	c|DEL|IVS21-2|AG	IVS21 - 2delAG	SequenceVariant	149	152	3	D007690	autosomal dominant polycystic kidney disease|Autosomal dominant polycystic kidney disease|ADPKD|ADPKD|ADPKD	DiseaseOrPhenotypicFeature	16:24:30:73:314	21:29:31:74:315	0:1:1:2:10	1:NR:2	L2R	CROSS	260-261	314-315	D007690	autosomal dominant polycystic kidney disease|Autosomal dominant polycystic kidney disease|ADPKD|ADPKD|ADPKD	DiseaseOrPhenotypicFeature	16:24:30:73:314	21:29:31:74:315	0:1:1:2:10	18764	PKD2	GeneOrGeneProduct	260	261	8	1:NR:2	L2R	CROSS	57-59	100-105	D007674	renal diseases	DiseaseOrPhenotypicFeature	57	59	1	rs75762896	c . 1445T > G|phenylalanine to the polar hydrophilic cysteine in exon 6 at codon 482|p . F482C|p . F482C	SequenceVariant	100:118:131:285	105:130:134:288	3:3:3:9	1:NR:2	L2R	CROSS	57-59	149-152	D007674	renal diseases	DiseaseOrPhenotypicFeature	57	59	1	c|DEL|IVS21-2|AG	IVS21 - 2delAG	SequenceVariant	149	152	3	1:NR:2	L2R	CROSS	57-59	260-261	D007674	renal diseases	DiseaseOrPhenotypicFeature	57	59	1	18764	PKD2	GeneOrGeneProduct	260	261	8
20534762	Two novel mutations of the TSH - beta subunit gene underlying congenital central hypothyroidism undetectable in neonatal TSH screening .|CONTEXT : Patients with TSH - beta subunit defects and congenital hypothyroidism are missed by TSH - based neonatal screening .|OBJECTIVE : Our objective was to report the molecular consequences of a novel splice - junction mutation and a novel missense mutation in the TSH - beta subunit gene found in two patients with congenital central hypothyroidism and conventional treatment - resistant anemia .|RESULTS : Patient 1 had a homozygous G to A nucleotide change at the 5 ' donor splice site of exon / intron 2 .|This resulted in a silent change at codon 34 of the mature protein .|In vitro splicing assays showed that the mutant minigene dramatically affected pre - mRNA processing , causing exon 2 to be completely skipped .|The putative product from a new out - of - frame translational start point in exon 3 is expected to yield a nonsense 25 - amino - acid peptide .|In patient 2 , sequence analysis revealed a compound heterozygosis for the already reported 313delT ( C105Vfs114X ) mutation and for a second novel mutation in exon 3 , substituting G for A at cDNA nucleotide position 323 , resulting in a C88Y change .|This cysteine residue is conserved among all dimeric pituitary and placental glycoprotein hormone - beta subunits .|Data from in silico analysis confirmed that the C88Y mutation would affect subunit conformation .|Indeed , two different bioinformatics approaches , PolyPhen and SIFT analysis , predicted C88Y to be a damaging substitution .|CONCLUSIONS : In isolated TSH deficiency , the exact molecular diagnosis is mandatory for diagnosis of isolated pituitary deficiency , delineation of prognosis , and genetic counseling .|Moreover , diagnosis of central hypothyroidism should be considered in the face of severe infant anemia of uncertain etiology .	1:Association:2	R2L	NON-CROSS	11-14	5-8	D003409	congenital central hypothyroidism|congenital hypothyroidism|congenital central hypothyroidism	DiseaseOrPhenotypicFeature	11:30:75	14:32:78	0:1:2	7252	TSH - beta|TSH|TSH - beta|TSH|TSH - beta	GeneOrGeneProduct	5:17:24:35:65	8:18:27:36:68	0:0:1:1:2	1:Association:2	L2R	NON-CROSS	65-68	83-84	7252	TSH - beta|TSH|TSH - beta|TSH|TSH - beta	GeneOrGeneProduct	5:17:24:35:65	8:18:27:36:68	0:0:1:1:2	D000740	anemia|anemia	DiseaseOrPhenotypicFeature	83:318	84:319	2:12	1:NR:2	L2R	CROSS	65-68	234-239	7252	TSH - beta|TSH|TSH - beta|TSH|TSH - beta	GeneOrGeneProduct	5:17:24:35:65	8:18:27:36:68	0:0:1:1:2	122876	glycoprotein hormone - beta subunits	GeneOrGeneProduct	234	239	8	1:NR:2	L2R	CROSS	65-68	279-281	7252	TSH - beta|TSH|TSH - beta|TSH|TSH - beta	GeneOrGeneProduct	5:17:24:35:65	8:18:27:36:68	0:0:1:1:2	D007037	TSH deficiency|central hypothyroidism	DiseaseOrPhenotypicFeature	279:307	281:309	11:12	1:NR:2	L2R	CROSS	65-68	291-294	7252	TSH - beta|TSH|TSH - beta|TSH|TSH - beta	GeneOrGeneProduct	5:17:24:35:65	8:18:27:36:68	0:0:1:1:2	C566321	isolated pituitary deficiency	DiseaseOrPhenotypicFeature	291	294	11	1:Association:2	L2R	CROSS	75-78	92-95	D003409	congenital central hypothyroidism|congenital hypothyroidism|congenital central hypothyroidism	DiseaseOrPhenotypicFeature	11:30:75	14:32:78	0:1:2	c|SUB|G||A	G to A	SequenceVariant	92	95	3	1:Association:2	L2R	CROSS	75-78	192-193	D003409	congenital central hypothyroidism|congenital hypothyroidism|congenital central hypothyroidism	DiseaseOrPhenotypicFeature	11:30:75	14:32:78	0:1:2	c|DEL|313|T	313delT	SequenceVariant	192	193	7	1:Association:2	L2R	CROSS	75-78	194-195	D003409	congenital central hypothyroidism|congenital hypothyroidism|congenital central hypothyroidism	DiseaseOrPhenotypicFeature	11:30:75	14:32:78	0:1:2	p|FS|C|105|V|114	C105Vfs114X	SequenceVariant	194	195	7	1:Association:2	L2R	CROSS	75-78	208-216	D003409	congenital central hypothyroidism|congenital hypothyroidism|congenital central hypothyroidism	DiseaseOrPhenotypicFeature	11:30:75	14:32:78	0:1:2	c|SUB|G|323|A	G for A at cDNA nucleotide position 323	SequenceVariant	208	216	7	1:Association:2	L2R	CROSS	75-78	220-221	D003409	congenital central hypothyroidism|congenital hypothyroidism|congenital central hypothyroidism	DiseaseOrPhenotypicFeature	11:30:75	14:32:78	0:1:2	p|SUB|C|88|Y	C88Y|C88Y|C88Y	SequenceVariant	220:248:268	221:249:269	7:9:10	1:NR:2	L2R	CROSS	75-78	234-239	D003409	congenital central hypothyroidism|congenital hypothyroidism|congenital central hypothyroidism	DiseaseOrPhenotypicFeature	11:30:75	14:32:78	0:1:2	122876	glycoprotein hormone - beta subunits	GeneOrGeneProduct	234	239	8	1:Association:2	L2R	CROSS	83-84	92-95	D000740	anemia|anemia	DiseaseOrPhenotypicFeature	83:318	84:319	2:12	c|SUB|G||A	G to A	SequenceVariant	92	95	3	1:Association:2	L2R	CROSS	83-84	192-193	D000740	anemia|anemia	DiseaseOrPhenotypicFeature	83:318	84:319	2:12	c|DEL|313|T	313delT	SequenceVariant	192	193	7	1:Association:2	L2R	CROSS	83-84	194-195	D000740	anemia|anemia	DiseaseOrPhenotypicFeature	83:318	84:319	2:12	p|FS|C|105|V|114	C105Vfs114X	SequenceVariant	194	195	7	1:Association:2	L2R	CROSS	208-216	318-319	D000740	anemia|anemia	DiseaseOrPhenotypicFeature	83:318	84:319	2:12	c|SUB|G|323|A	G for A at cDNA nucleotide position 323	SequenceVariant	208	216	7	1:Association:2	L2R	CROSS	268-269	318-319	D000740	anemia|anemia	DiseaseOrPhenotypicFeature	83:318	84:319	2:12	p|SUB|C|88|Y	C88Y|C88Y|C88Y	SequenceVariant	220:248:268	221:249:269	7:9:10	1:NR:2	L2R	CROSS	234-239	318-319	D000740	anemia|anemia	DiseaseOrPhenotypicFeature	83:318	84:319	2:12	122876	glycoprotein hormone - beta subunits	GeneOrGeneProduct	234	239	8	1:NR:2	L2R	CROSS	92-95	279-281	c|SUB|G||A	G to A	SequenceVariant	92	95	3	D007037	TSH deficiency|central hypothyroidism	DiseaseOrPhenotypicFeature	279:307	281:309	11:12	1:NR:2	L2R	CROSS	92-95	291-294	c|SUB|G||A	G to A	SequenceVariant	92	95	3	C566321	isolated pituitary deficiency	DiseaseOrPhenotypicFeature	291	294	11	1:NR:2	L2R	CROSS	192-193	279-281	c|DEL|313|T	313delT	SequenceVariant	192	193	7	D007037	TSH deficiency|central hypothyroidism	DiseaseOrPhenotypicFeature	279:307	281:309	11:12	1:NR:2	L2R	CROSS	192-193	291-294	c|DEL|313|T	313delT	SequenceVariant	192	193	7	C566321	isolated pituitary deficiency	DiseaseOrPhenotypicFeature	291	294	11	1:NR:2	L2R	CROSS	194-195	279-281	p|FS|C|105|V|114	C105Vfs114X	SequenceVariant	194	195	7	D007037	TSH deficiency|central hypothyroidism	DiseaseOrPhenotypicFeature	279:307	281:309	11:12	1:NR:2	L2R	CROSS	194-195	291-294	p|FS|C|105|V|114	C105Vfs114X	SequenceVariant	194	195	7	C566321	isolated pituitary deficiency	DiseaseOrPhenotypicFeature	291	294	11	1:NR:2	L2R	CROSS	208-216	279-281	c|SUB|G|323|A	G for A at cDNA nucleotide position 323	SequenceVariant	208	216	7	D007037	TSH deficiency|central hypothyroidism	DiseaseOrPhenotypicFeature	279:307	281:309	11:12	1:NR:2	L2R	CROSS	208-216	291-294	c|SUB|G|323|A	G for A at cDNA nucleotide position 323	SequenceVariant	208	216	7	C566321	isolated pituitary deficiency	DiseaseOrPhenotypicFeature	291	294	11	1:NR:2	L2R	CROSS	268-269	279-281	p|SUB|C|88|Y	C88Y|C88Y|C88Y	SequenceVariant	220:248:268	221:249:269	7:9:10	D007037	TSH deficiency|central hypothyroidism	DiseaseOrPhenotypicFeature	279:307	281:309	11:12	1:NR:2	L2R	CROSS	268-269	291-294	p|SUB|C|88|Y	C88Y|C88Y|C88Y	SequenceVariant	220:248:268	221:249:269	7:9:10	C566321	isolated pituitary deficiency	DiseaseOrPhenotypicFeature	291	294	11	1:NR:2	L2R	CROSS	234-239	279-281	122876	glycoprotein hormone - beta subunits	GeneOrGeneProduct	234	239	8	D007037	TSH deficiency|central hypothyroidism	DiseaseOrPhenotypicFeature	279:307	281:309	11:12	1:NR:2	L2R	CROSS	234-239	291-294	122876	glycoprotein hormone - beta subunits	GeneOrGeneProduct	234	239	8	C566321	isolated pituitary deficiency	DiseaseOrPhenotypicFeature	291	294	11
16970763	Mutations in the NDP gene : contribution to Norrie disease , familial exudative vitreoretinopathy and retinopathy of prematurity .|BACKGROUND : To examine the contribution of mutations within the Norrie disease ( NDP ) gene to the clinically similar retinal diseases Norrie disease , X - linked familial exudative vitreoretinopathy ( FEVR ) , Coat 's disease and retinopathy of prematurity ( ROP ) .|METHODS : A dataset comprising 13 Norrie - FEVR , one Coat 's disease , 31 ROP patients and 90 ex - premature babies of < 32 weeks ' gestation underwent an ophthalmologic examination and were screened for mutations within the NDP gene by direct DNA sequencing , denaturing high - performance liquid chromatography or gel electrophoresis .|Controls were only screened using denaturing high - performance liquid chromatography and gel electrophoresis .|Confirmation of mutations identified was obtained by DNA sequencing .|RESULTS : Evidence for two novel mutations in the NDP gene was presented : Leu103Val in one FEVR patient and His43Arg in monozygotic twin Norrie disease patients .|Furthermore , a previously described 14 - bp deletion located in the 5 ' unstranslated region of the NDP gene was detected in three cases of regressed ROP .|A second heterozygotic 14 - bp deletion was detected in an unaffected ex - premature girl .|Only two of the 13 Norrie - FEVR index cases had the full features of Norrie disease with deafness and mental retardation .|CONCLUSION : Two novel mutations within the coding region of the NDP gene were found , one associated with a severe disease phenotypes of Norrie disease and the other with FEVR .|A deletion within the non - coding region was associated with only mild - regressed ROP , despite the presence of low birthweight , prematurity and exposure to oxygen .|In full - term children with retinal detachment only 15 % appear to have the full features of Norrie disease and this is important for counselling parents on the possible long - term outcome .	1:Association:2	L2R	NON-CROSS	29-31	32-33	4693	NDP|NDP|NDP|NDP|NDP|NDP	GeneOrGeneProduct	3:32:106:157:194:256	4:33:107:158:195:257	0:1:2:5:6:9	C537849	Norrie disease|Norrie disease|retinal diseases Norrie disease|Norrie - FEVR|Norrie disease|Norrie - FEVR|Norrie disease|Norrie disease|Norrie disease	DiseaseOrPhenotypicFeature	8:29:39:71:172:227:237:269:325	10:31:43:74:174:230:239:271:327	0:1:1:2:5:8:8:9:11	1:Association:2	L2R	NON-CROSS	3-4	11-14	4693	NDP|NDP|NDP|NDP|NDP|NDP	GeneOrGeneProduct	3:32:106:157:194:256	4:33:107:158:195:257	0:1:2:5:6:9	D000080345	familial exudative vitreoretinopathy|X - linked familial exudative vitreoretinopathy|FEVR|FEVR|FEVR	DiseaseOrPhenotypicFeature	11:44:51:165:275	14:50:52:166:276	0:1:1:5:9	1:Association:2	L2R	NON-CROSS	194-195	203-204	4693	NDP|NDP|NDP|NDP|NDP|NDP	GeneOrGeneProduct	3:32:106:157:194:256	4:33:107:158:195:257	0:1:2:5:6:9	D012178	retinopathy of prematurity|retinopathy of prematurity|ROP|ROP|ROP|ROP	DiseaseOrPhenotypicFeature	15:58:62:81:203:292	18:61:63:82:204:293	0:1:1:2:6:10	1:NR:2	L2R	NON-CROSS	32-33	54-57	4693	NDP|NDP|NDP|NDP|NDP|NDP	GeneOrGeneProduct	3:32:106:157:194:256	4:33:107:158:195:257	0:1:2:5:6:9	D058456	Coat 's disease|Coat 's disease	DiseaseOrPhenotypicFeature	54:76	57:79	1:2	1:NR:2	L2R	CROSS	240-241	256-257	4693	NDP|NDP|NDP|NDP|NDP|NDP	GeneOrGeneProduct	3:32:106:157:194:256	4:33:107:158:195:257	0:1:2:5:6:9	D003638	deafness	DiseaseOrPhenotypicFeature	240	241	8	1:NR:2	L2R	CROSS	242-244	256-257	4693	NDP|NDP|NDP|NDP|NDP|NDP	GeneOrGeneProduct	3:32:106:157:194:256	4:33:107:158:195:257	0:1:2:5:6:9	D008607	mental retardation	DiseaseOrPhenotypicFeature	242	244	8	1:NR:2	L2R	CROSS	256-257	301-302	4693	NDP|NDP|NDP|NDP|NDP|NDP	GeneOrGeneProduct	3:32:106:157:194:256	4:33:107:158:195:257	0:1:2:5:6:9	D007235	prematurity	DiseaseOrPhenotypicFeature	301	302	10	1:NR:2	L2R	CROSS	256-257	305-306	4693	NDP|NDP|NDP|NDP|NDP|NDP	GeneOrGeneProduct	3:32:106:157:194:256	4:33:107:158:195:257	0:1:2:5:6:9	D010100	oxygen	ChemicalEntity	305	306	10	1:NR:2	L2R	CROSS	256-257	313-315	4693	NDP|NDP|NDP|NDP|NDP|NDP	GeneOrGeneProduct	3:32:106:157:194:256	4:33:107:158:195:257	0:1:2:5:6:9	D012163	retinal detachment	DiseaseOrPhenotypicFeature	313	315	11	1:NR:2	L2R	NON-CROSS	162-163	172-174	C537849	Norrie disease|Norrie disease|retinal diseases Norrie disease|Norrie - FEVR|Norrie disease|Norrie - FEVR|Norrie disease|Norrie disease|Norrie disease	DiseaseOrPhenotypicFeature	8:29:39:71:172:227:237:269:325	10:31:43:74:174:230:239:271:327	0:1:1:2:5:8:8:9:11	p|SUB|L|103|V	Leu103Val	SequenceVariant	162	163	5	1:Association:2	R2L	NON-CROSS	172-174	168-169	p|SUB|H|43|R	His43Arg	SequenceVariant	168	169	5	C537849	Norrie disease|Norrie disease|retinal diseases Norrie disease|Norrie - FEVR|Norrie disease|Norrie - FEVR|Norrie disease|Norrie disease|Norrie disease	DiseaseOrPhenotypicFeature	8:29:39:71:172:227:237:269:325	10:31:43:74:174:230:239:271:327	0:1:1:2:5:8:8:9:11	1:NR:2	L2R	CROSS	172-174	181-185	C537849	Norrie disease|Norrie disease|retinal diseases Norrie disease|Norrie - FEVR|Norrie disease|Norrie - FEVR|Norrie disease|Norrie disease|Norrie disease	DiseaseOrPhenotypicFeature	8:29:39:71:172:227:237:269:325	10:31:43:74:174:230:239:271:327	0:1:1:2:5:8:8:9:11	c|DEL||14	14 - bp deletion|14 - bp deletion	SequenceVariant	181:208	185:212	6:7	1:NR:2	L2R	CROSS	305-306	325-327	C537849	Norrie disease|Norrie disease|retinal diseases Norrie disease|Norrie - FEVR|Norrie disease|Norrie - FEVR|Norrie disease|Norrie disease|Norrie disease	DiseaseOrPhenotypicFeature	8:29:39:71:172:227:237:269:325	10:31:43:74:174:230:239:271:327	0:1:1:2:5:8:8:9:11	D010100	oxygen	ChemicalEntity	305	306	10	1:Association:2	R2L	NON-CROSS	165-166	162-163	p|SUB|L|103|V	Leu103Val	SequenceVariant	162	163	5	D000080345	familial exudative vitreoretinopathy|X - linked familial exudative vitreoretinopathy|FEVR|FEVR|FEVR	DiseaseOrPhenotypicFeature	11:44:51:165:275	14:50:52:166:276	0:1:1:5:9	1:NR:2	L2R	NON-CROSS	165-166	168-169	D000080345	familial exudative vitreoretinopathy|X - linked familial exudative vitreoretinopathy|FEVR|FEVR|FEVR	DiseaseOrPhenotypicFeature	11:44:51:165:275	14:50:52:166:276	0:1:1:5:9	p|SUB|H|43|R	His43Arg	SequenceVariant	168	169	5	1:NR:2	L2R	CROSS	165-166	181-185	D000080345	familial exudative vitreoretinopathy|X - linked familial exudative vitreoretinopathy|FEVR|FEVR|FEVR	DiseaseOrPhenotypicFeature	11:44:51:165:275	14:50:52:166:276	0:1:1:5:9	c|DEL||14	14 - bp deletion|14 - bp deletion	SequenceVariant	181:208	185:212	6:7	1:NR:2	L2R	CROSS	275-276	305-306	D000080345	familial exudative vitreoretinopathy|X - linked familial exudative vitreoretinopathy|FEVR|FEVR|FEVR	DiseaseOrPhenotypicFeature	11:44:51:165:275	14:50:52:166:276	0:1:1:5:9	D010100	oxygen	ChemicalEntity	305	306	10	1:NR:2	L2R	CROSS	162-163	203-204	D012178	retinopathy of prematurity|retinopathy of prematurity|ROP|ROP|ROP|ROP	DiseaseOrPhenotypicFeature	15:58:62:81:203:292	18:61:63:82:204:293	0:1:1:2:6:10	p|SUB|L|103|V	Leu103Val	SequenceVariant	162	163	5	1:NR:2	L2R	CROSS	168-169	203-204	D012178	retinopathy of prematurity|retinopathy of prematurity|ROP|ROP|ROP|ROP	DiseaseOrPhenotypicFeature	15:58:62:81:203:292	18:61:63:82:204:293	0:1:1:2:6:10	p|SUB|H|43|R	His43Arg	SequenceVariant	168	169	5	1:Association:2	R2L	NON-CROSS	208-212	203-204	c|DEL||14	14 - bp deletion|14 - bp deletion	SequenceVariant	181:208	185:212	6:7	D012178	retinopathy of prematurity|retinopathy of prematurity|ROP|ROP|ROP|ROP	DiseaseOrPhenotypicFeature	15:58:62:81:203:292	18:61:63:82:204:293	0:1:1:2:6:10	1:NR:2	L2R	NON-CROSS	292-293	305-306	D012178	retinopathy of prematurity|retinopathy of prematurity|ROP|ROP|ROP|ROP	DiseaseOrPhenotypicFeature	15:58:62:81:203:292	18:61:63:82:204:293	0:1:1:2:6:10	D010100	oxygen	ChemicalEntity	305	306	10	1:NR:2	L2R	CROSS	76-79	162-163	D058456	Coat 's disease|Coat 's disease	DiseaseOrPhenotypicFeature	54:76	57:79	1:2	p|SUB|L|103|V	Leu103Val	SequenceVariant	162	163	5	1:NR:2	L2R	CROSS	76-79	168-169	D058456	Coat 's disease|Coat 's disease	DiseaseOrPhenotypicFeature	54:76	57:79	1:2	p|SUB|H|43|R	His43Arg	SequenceVariant	168	169	5	1:NR:2	L2R	CROSS	76-79	181-185	D058456	Coat 's disease|Coat 's disease	DiseaseOrPhenotypicFeature	54:76	57:79	1:2	c|DEL||14	14 - bp deletion|14 - bp deletion	SequenceVariant	181:208	185:212	6:7	1:NR:2	L2R	CROSS	76-79	305-306	D058456	Coat 's disease|Coat 's disease	DiseaseOrPhenotypicFeature	54:76	57:79	1:2	D010100	oxygen	ChemicalEntity	305	306	10	1:NR:2	L2R	CROSS	162-163	240-241	p|SUB|L|103|V	Leu103Val	SequenceVariant	162	163	5	D003638	deafness	DiseaseOrPhenotypicFeature	240	241	8	1:NR:2	L2R	CROSS	162-163	242-244	p|SUB|L|103|V	Leu103Val	SequenceVariant	162	163	5	D008607	mental retardation	DiseaseOrPhenotypicFeature	242	244	8	1:NR:2	L2R	CROSS	162-163	301-302	p|SUB|L|103|V	Leu103Val	SequenceVariant	162	163	5	D007235	prematurity	DiseaseOrPhenotypicFeature	301	302	10	1:NR:2	L2R	CROSS	162-163	305-306	p|SUB|L|103|V	Leu103Val	SequenceVariant	162	163	5	D010100	oxygen	ChemicalEntity	305	306	10	1:NR:2	L2R	CROSS	162-163	313-315	p|SUB|L|103|V	Leu103Val	SequenceVariant	162	163	5	D012163	retinal detachment	DiseaseOrPhenotypicFeature	313	315	11	1:NR:2	L2R	CROSS	168-169	240-241	p|SUB|H|43|R	His43Arg	SequenceVariant	168	169	5	D003638	deafness	DiseaseOrPhenotypicFeature	240	241	8	1:NR:2	L2R	CROSS	168-169	242-244	p|SUB|H|43|R	His43Arg	SequenceVariant	168	169	5	D008607	mental retardation	DiseaseOrPhenotypicFeature	242	244	8	1:NR:2	L2R	CROSS	168-169	301-302	p|SUB|H|43|R	His43Arg	SequenceVariant	168	169	5	D007235	prematurity	DiseaseOrPhenotypicFeature	301	302	10	1:NR:2	L2R	CROSS	168-169	305-306	p|SUB|H|43|R	His43Arg	SequenceVariant	168	169	5	D010100	oxygen	ChemicalEntity	305	306	10	1:NR:2	L2R	CROSS	168-169	313-315	p|SUB|H|43|R	His43Arg	SequenceVariant	168	169	5	D012163	retinal detachment	DiseaseOrPhenotypicFeature	313	315	11	1:NR:2	L2R	CROSS	208-212	240-241	c|DEL||14	14 - bp deletion|14 - bp deletion	SequenceVariant	181:208	185:212	6:7	D003638	deafness	DiseaseOrPhenotypicFeature	240	241	8	1:NR:2	L2R	CROSS	208-212	242-244	c|DEL||14	14 - bp deletion|14 - bp deletion	SequenceVariant	181:208	185:212	6:7	D008607	mental retardation	DiseaseOrPhenotypicFeature	242	244	8	1:NR:2	L2R	CROSS	208-212	301-302	c|DEL||14	14 - bp deletion|14 - bp deletion	SequenceVariant	181:208	185:212	6:7	D007235	prematurity	DiseaseOrPhenotypicFeature	301	302	10	1:NR:2	L2R	CROSS	208-212	305-306	c|DEL||14	14 - bp deletion|14 - bp deletion	SequenceVariant	181:208	185:212	6:7	D010100	oxygen	ChemicalEntity	305	306	10	1:NR:2	L2R	CROSS	208-212	313-315	c|DEL||14	14 - bp deletion|14 - bp deletion	SequenceVariant	181:208	185:212	6:7	D012163	retinal detachment	DiseaseOrPhenotypicFeature	313	315	11	1:NR:2	L2R	CROSS	240-241	305-306	D003638	deafness	DiseaseOrPhenotypicFeature	240	241	8	D010100	oxygen	ChemicalEntity	305	306	10	1:NR:2	L2R	CROSS	242-244	305-306	D008607	mental retardation	DiseaseOrPhenotypicFeature	242	244	8	D010100	oxygen	ChemicalEntity	305	306	10	1:NR:2	L2R	NON-CROSS	301-302	305-306	D007235	prematurity	DiseaseOrPhenotypicFeature	301	302	10	D010100	oxygen	ChemicalEntity	305	306	10	1:NR:2	L2R	CROSS	305-306	313-315	D010100	oxygen	ChemicalEntity	305	306	10	D012163	retinal detachment	DiseaseOrPhenotypicFeature	313	315	11
19207031	Growth hormone dose in growth hormone - deficient adults is not associated with IGF - 1 gene polymorphisms .|AIMS : Several SNPs and a microsatellite cytosine - adenine repeat promoter polymorphism of the IGF - 1 gene have been reported to be associated with circulating IGF - 1 serum concentrations .|Variance in IGF - 1 concentrations due to genetic variations may affect different response to growth hormone ( GH ) treatment , resulting in different individually required GH - doses in GH - deficient patients .|The aim of this study was to test if the IGF - 1 gene polymorphisms are associated with the GH - dose of GH - deficient adults .|MATERIALS & METHODS : A total of nine tagging SNPs , five additionally selected SNPs and a cytosine - adenine repeat polymorphism were determined in 133 German adult patients ( 66 men , 67 women ; mean age 45 . 4 years + / - 13 . 1 standard deviation ; majority Caucasian ) with GH - deficiency ( GHD ) of different origin , derived from the prospective Pfizer International Metabolic Study ( KIMS ) Pharmacogenetics Study .|Patients received GH - treatment for 12 months with finished dose - titration of GH and centralized IGF - 1 measurements .|GH - dose after 1 year of treatment , IGF - 1 concentrations , IGF - 1 - standard deviation score ( SDS ) , the IGF - 1 : GH ratio and anthropometric data were analyzed by genotype .|RESULTS : Except for rs1019731 , which showed a significant difference of IGF - 1 - SDS by genotypes ( p = 0 . 02 ) , all polymorphisms showed no associations with the GH - doses , IGF - 1 concentrations , IGF - 1 - SDS and IGF - 1 : GH ratio after adjusting for the confounding variables gender , age and BMI .|CONCLUSION : IGF - 1 gene polymorphisms were not associated with the responsiveness to exogenous GH in GHD .|Therefore , genetic variations of the IGF - 1 gene seem not to be major influencing factors of the GH - IGF - axis causing variable response to exogenous GH - treatment .	1:Negative_Correlation:2	L2R	NON-CROSS	339-340	341-342	2688	Growth hormone|growth hormone|GH|GH|GH|GH|GH|GH|GH|GH|GH|GH|GH|GH	GeneOrGeneProduct	0:67:70:79:107:197:209:217:247:291:310:339:362:372	2:69:71:80:108:198:210:218:248:292:311:340:363:373	0:2:2:2:3:5:5:6:6:7:7:8:9:9	D004393	growth hormone - deficient|GH - deficient|GH - deficient|GH - deficiency|GHD|GHD	DiseaseOrPhenotypicFeature	4:83:111:171:175:341	8:86:114:174:176:342	0:2:3:4:4:8	1:Association:2	R2L	NON-CROSS	364-365	362-363	3479	IGF - 1|IGF - 1|IGF - 1|IGF - 1|IGF - 1|IGF - 1|IGF - 1|IGF - 1|IGF - 1|IGF - 1|IGF - 1|IGF - 1|IGF - 1|IGF - 1|IGF - 1|IGF	GeneOrGeneProduct	13:34:46:54:98:212:226:231:243:269:295:300:306:326:349:364	16:37:49:57:101:215:229:234:246:272:298:303:309:329:352:365	0:1:1:2:3:5:6:6:6:7:7:7:7:8:9:9	2688	Growth hormone|growth hormone|GH|GH|GH|GH|GH|GH|GH|GH|GH|GH|GH|GH	GeneOrGeneProduct	0:67:70:79:107:197:209:217:247:291:310:339:362:372	2:69:71:80:108:198:210:218:248:292:311:340:363:373	0:2:2:2:3:5:5:6:6:7:7:8:9:9	1:NR:2	L2R	NON-CROSS	4-8	13-16	D004393	growth hormone - deficient|GH - deficient|GH - deficient|GH - deficiency|GHD|GHD	DiseaseOrPhenotypicFeature	4:83:111:171:175:341	8:86:114:174:176:342	0:2:3:4:4:8	3479	IGF - 1|IGF - 1|IGF - 1|IGF - 1|IGF - 1|IGF - 1|IGF - 1|IGF - 1|IGF - 1|IGF - 1|IGF - 1|IGF - 1|IGF - 1|IGF - 1|IGF - 1|IGF	GeneOrGeneProduct	13:34:46:54:98:212:226:231:243:269:295:300:306:326:349:364	16:37:49:57:101:215:229:234:246:272:298:303:309:329:352:365	0:1:1:2:3:5:6:6:6:7:7:7:7:8:9:9	1:NR:2	L2R	CROSS	261-262	341-342	D004393	growth hormone - deficient|GH - deficient|GH - deficient|GH - deficiency|GHD|GHD	DiseaseOrPhenotypicFeature	4:83:111:171:175:341	8:86:114:174:176:342	0:2:3:4:4:8	rs1019731	rs1019731	SequenceVariant	261	262	7
19276632	Mutation analysis of FOXF2 in patients with disorders of sex development ( DSD ) in combination with cleft palate .|In contrast to disorders of sexual differentiation caused by lack of androgen production or inhibited androgen action , defects affecting development of the bipotent genital anlagen have rarely been investigated in humans .|We have previously documented that the transcription factor FOXF2 is highly expressed in human foreskin .|Moreover , Foxf2 knockout mice present with cleft palate in combination with hypoplasia of the genital tubercle .|We hypothesized that humans with disorders of sex development ( DSD ) in combination with cleft palate could have mutations in the FOXF2 gene .|Eighteen children with DSD and cleft palate were identified in the L beck DSD database ( about 1 , 500 entries ) .|Genomic DNA sequence analysis of the FOXF2 gene was performed and compared with 10 normal female and 10 normal male controls , respectively .|Two heterozygous DNA sequence variations were solely present in one single patient each but in none of the 20 normal controls : a duplication of GCC ( c . 97GCC [ 9 ] + [ 10 ] ) resulting in an extra alanine within exon 1 and a 25 * G > A substitution in the 3 ' - untranslated region .|Two patients carried a c . 262G > A sequence variation predicting for an Ala88Thr exchange which was also detected in 2 normal controls .|Two silent mutations , c . 1272C > T ( Ser424Ser ) and c . 1284T > C ( Tyr428Tyr ) , respectively , occurred in the coding region of exon 2 , again in both patients and normal controls .|In conclusion , the majority of the detected sequence alterations were polymorphisms without obvious functional relevance .|However , it can not be excluded that the 2 unique DNA sequence alterations could have affected FOXF2 on the mRNA or protein level thus contributing to the observed disturbances in genital and palate development .	1:Association:2	R2L	NON-CROSS	7-11	3-4	D012734	disorders of sex development|DSD|disorders of sexual differentiation|disorders of sex development|DSD|DSD|DSD	DiseaseOrPhenotypicFeature	7:12:23:92:97:115:125	11:13:27:96:98:116:126	0:0:1:4:4:5:5	2295	FOXF2|FOXF2|FOXF2|FOXF2|FOXF2	GeneOrGeneProduct	3:61:109:141:321	4:62:110:142:322	0:2:4:6:11	1:Association:2	R2L	NON-CROSS	109-110	102-104	D002972	cleft palate|cleft palate|cleft palate|cleft palate	DiseaseOrPhenotypicFeature	17:76:102:117	19:78:104:119	0:3:4:5	2295	FOXF2|FOXF2|FOXF2|FOXF2|FOXF2	GeneOrGeneProduct	3:61:109:141:321	4:62:110:142:322	0:2:4:6:11	1:NR:2	L2R	CROSS	35-36	61-62	2295	FOXF2|FOXF2|FOXF2|FOXF2|FOXF2	GeneOrGeneProduct	3:61:109:141:321	4:62:110:142:322	0:2:4:6:11	D000728	androgen|androgen	ChemicalEntity	31:35	32:36	1:1	1:NR:2	L2R	CROSS	61-62	71-72	2295	FOXF2|FOXF2|FOXF2|FOXF2|FOXF2	GeneOrGeneProduct	3:61:109:141:321	4:62:110:142:322	0:2:4:6:11	14238	Foxf2	GeneOrGeneProduct	71	72	3	1:NR:2	L2R	CROSS	61-62	81-86	2295	FOXF2|FOXF2|FOXF2|FOXF2|FOXF2	GeneOrGeneProduct	3:61:109:141:321	4:62:110:142:322	0:2:4:6:11	C537540	hypoplasia of the genital tubercle	DiseaseOrPhenotypicFeature	81	86	3	1:Negative_Correlation:2	L2R	NON-CROSS	23-27	31-32	D012734	disorders of sex development|DSD|disorders of sexual differentiation|disorders of sex development|DSD|DSD|DSD	DiseaseOrPhenotypicFeature	7:12:23:92:97:115:125	11:13:27:96:98:116:126	0:0:1:4:4:5:5	D000728	androgen|androgen	ChemicalEntity	31:35	32:36	1:1	1:NR:2	L2R	CROSS	71-72	92-96	D012734	disorders of sex development|DSD|disorders of sexual differentiation|disorders of sex development|DSD|DSD|DSD	DiseaseOrPhenotypicFeature	7:12:23:92:97:115:125	11:13:27:96:98:116:126	0:0:1:4:4:5:5	14238	Foxf2	GeneOrGeneProduct	71	72	3	1:Association:2	L2R	CROSS	125-126	182-185	D012734	disorders of sex development|DSD|disorders of sexual differentiation|disorders of sex development|DSD|DSD|DSD	DiseaseOrPhenotypicFeature	7:12:23:92:97:115:125	11:13:27:96:98:116:126	0:0:1:4:4:5:5	c|DUP||GCC|	duplication of GCC	SequenceVariant	182	185	7	1:Association:2	L2R	CROSS	125-126	186-196	D012734	disorders of sex development|DSD|disorders of sexual differentiation|disorders of sex development|DSD|DSD|DSD	DiseaseOrPhenotypicFeature	7:12:23:92:97:115:125	11:13:27:96:98:116:126	0:0:1:4:4:5:5	c|DUP|97|GCC|9-10	c . 97GCC [ 9 ] + [ 10 ]	SequenceVariant	186	196	7	1:Association:2	L2R	CROSS	125-126	207-212	D012734	disorders of sex development|DSD|disorders of sexual differentiation|disorders of sex development|DSD|DSD|DSD	DiseaseOrPhenotypicFeature	7:12:23:92:97:115:125	11:13:27:96:98:116:126	0:0:1:4:4:5:5	c|SUB|G|*25|A	25 * G > A	SequenceVariant	207	212	7	1:Association:2	R2L	CROSS	225-230	125-126	rs72667003	c . 262G > A|Ala88Thr	SequenceVariant	225:235	230:236	8:8	D012734	disorders of sex development|DSD|disorders of sexual differentiation|disorders of sex development|DSD|DSD|DSD	DiseaseOrPhenotypicFeature	7:12:23:92:97:115:125	11:13:27:96:98:116:126	0:0:1:4:4:5:5	1:Association:2	R2L	CROSS	250-255	125-126	rs61753348	c . 1272C > T|Ser424Ser	SequenceVariant	250:256	255:257	9:9	D012734	disorders of sex development|DSD|disorders of sexual differentiation|disorders of sex development|DSD|DSD|DSD	DiseaseOrPhenotypicFeature	7:12:23:92:97:115:125	11:13:27:96:98:116:126	0:0:1:4:4:5:5	1:Association:2	R2L	CROSS	259-264	125-126	rs2293783	c . 1284T > C|Tyr428Tyr	SequenceVariant	259:265	264:266	9:9	D012734	disorders of sex development|DSD|disorders of sexual differentiation|disorders of sex development|DSD|DSD|DSD	DiseaseOrPhenotypicFeature	7:12:23:92:97:115:125	11:13:27:96:98:116:126	0:0:1:4:4:5:5	1:NR:2	L2R	CROSS	17-19	31-32	D002972	cleft palate|cleft palate|cleft palate|cleft palate	DiseaseOrPhenotypicFeature	17:76:102:117	19:78:104:119	0:3:4:5	D000728	androgen|androgen	ChemicalEntity	31:35	32:36	1:1	1:Association:2	R2L	NON-CROSS	76-78	71-72	14238	Foxf2	GeneOrGeneProduct	71	72	3	D002972	cleft palate|cleft palate|cleft palate|cleft palate	DiseaseOrPhenotypicFeature	17:76:102:117	19:78:104:119	0:3:4:5	1:Association:2	L2R	CROSS	117-119	182-185	D002972	cleft palate|cleft palate|cleft palate|cleft palate	DiseaseOrPhenotypicFeature	17:76:102:117	19:78:104:119	0:3:4:5	c|DUP||GCC|	duplication of GCC	SequenceVariant	182	185	7	1:Association:2	L2R	CROSS	117-119	186-196	D002972	cleft palate|cleft palate|cleft palate|cleft palate	DiseaseOrPhenotypicFeature	17:76:102:117	19:78:104:119	0:3:4:5	c|DUP|97|GCC|9-10	c . 97GCC [ 9 ] + [ 10 ]	SequenceVariant	186	196	7	1:Association:2	L2R	CROSS	117-119	207-212	D002972	cleft palate|cleft palate|cleft palate|cleft palate	DiseaseOrPhenotypicFeature	17:76:102:117	19:78:104:119	0:3:4:5	c|SUB|G|*25|A	25 * G > A	SequenceVariant	207	212	7	1:Association:2	R2L	CROSS	225-230	117-119	rs72667003	c . 262G > A|Ala88Thr	SequenceVariant	225:235	230:236	8:8	D002972	cleft palate|cleft palate|cleft palate|cleft palate	DiseaseOrPhenotypicFeature	17:76:102:117	19:78:104:119	0:3:4:5	1:Association:2	R2L	CROSS	250-255	117-119	rs61753348	c . 1272C > T|Ser424Ser	SequenceVariant	250:256	255:257	9:9	D002972	cleft palate|cleft palate|cleft palate|cleft palate	DiseaseOrPhenotypicFeature	17:76:102:117	19:78:104:119	0:3:4:5	1:Association:2	R2L	CROSS	259-264	117-119	rs2293783	c . 1284T > C|Tyr428Tyr	SequenceVariant	259:265	264:266	9:9	D002972	cleft palate|cleft palate|cleft palate|cleft palate	DiseaseOrPhenotypicFeature	17:76:102:117	19:78:104:119	0:3:4:5	1:NR:2	L2R	CROSS	35-36	71-72	D000728	androgen|androgen	ChemicalEntity	31:35	32:36	1:1	14238	Foxf2	GeneOrGeneProduct	71	72	3	1:NR:2	L2R	CROSS	35-36	81-86	D000728	androgen|androgen	ChemicalEntity	31:35	32:36	1:1	C537540	hypoplasia of the genital tubercle	DiseaseOrPhenotypicFeature	81	86	3	1:NR:2	L2R	CROSS	35-36	182-185	D000728	androgen|androgen	ChemicalEntity	31:35	32:36	1:1	c|DUP||GCC|	duplication of GCC	SequenceVariant	182	185	7	1:NR:2	L2R	CROSS	35-36	186-196	D000728	androgen|androgen	ChemicalEntity	31:35	32:36	1:1	c|DUP|97|GCC|9-10	c . 97GCC [ 9 ] + [ 10 ]	SequenceVariant	186	196	7	1:NR:2	L2R	CROSS	35-36	207-212	D000728	androgen|androgen	ChemicalEntity	31:35	32:36	1:1	c|SUB|G|*25|A	25 * G > A	SequenceVariant	207	212	7	1:NR:2	L2R	CROSS	35-36	225-230	D000728	androgen|androgen	ChemicalEntity	31:35	32:36	1:1	rs72667003	c . 262G > A|Ala88Thr	SequenceVariant	225:235	230:236	8:8	1:NR:2	L2R	CROSS	35-36	250-255	D000728	androgen|androgen	ChemicalEntity	31:35	32:36	1:1	rs61753348	c . 1272C > T|Ser424Ser	SequenceVariant	250:256	255:257	9:9	1:NR:2	L2R	CROSS	35-36	259-264	D000728	androgen|androgen	ChemicalEntity	31:35	32:36	1:1	rs2293783	c . 1284T > C|Tyr428Tyr	SequenceVariant	259:265	264:266	9:9	1:Association:2	L2R	NON-CROSS	71-72	81-86	14238	Foxf2	GeneOrGeneProduct	71	72	3	C537540	hypoplasia of the genital tubercle	DiseaseOrPhenotypicFeature	81	86	3	1:NR:2	L2R	CROSS	81-86	182-185	C537540	hypoplasia of the genital tubercle	DiseaseOrPhenotypicFeature	81	86	3	c|DUP||GCC|	duplication of GCC	SequenceVariant	182	185	7	1:NR:2	L2R	CROSS	81-86	186-196	C537540	hypoplasia of the genital tubercle	DiseaseOrPhenotypicFeature	81	86	3	c|DUP|97|GCC|9-10	c . 97GCC [ 9 ] + [ 10 ]	SequenceVariant	186	196	7	1:NR:2	L2R	CROSS	81-86	207-212	C537540	hypoplasia of the genital tubercle	DiseaseOrPhenotypicFeature	81	86	3	c|SUB|G|*25|A	25 * G > A	SequenceVariant	207	212	7	1:NR:2	L2R	CROSS	81-86	225-230	C537540	hypoplasia of the genital tubercle	DiseaseOrPhenotypicFeature	81	86	3	rs72667003	c . 262G > A|Ala88Thr	SequenceVariant	225:235	230:236	8:8	1:NR:2	L2R	CROSS	81-86	250-255	C537540	hypoplasia of the genital tubercle	DiseaseOrPhenotypicFeature	81	86	3	rs61753348	c . 1272C > T|Ser424Ser	SequenceVariant	250:256	255:257	9:9	1:NR:2	L2R	CROSS	81-86	259-264	C537540	hypoplasia of the genital tubercle	DiseaseOrPhenotypicFeature	81	86	3	rs2293783	c . 1284T > C|Tyr428Tyr	SequenceVariant	259:265	264:266	9:9
21219851	A novel mutation screening system for Ehlers - Danlos Syndrome , vascular type by high - resolution melting curve analysis in combination with small amplicon genotyping using genomic DNA .|Ehlers - Danlos syndrome , vascular type ( vEDS ) ( MIM # 130050 ) is an autosomal dominant disorder caused by type III procollagen gene ( COL3A1 ) mutations .|Most COL3A1 mutations are detected by using total RNA from patient - derived fibroblasts , which requires an invasive skin biopsy .|High - resolution melting curve analysis ( hrMCA ) has recently been developed as a post - PCR mutation scanning method which enables simple , rapid , cost - effective , and highly sensitive mutation screening of large genes .|We established a hrMCA method to screen for COL3A1 mutations using genomic DNA .|PCR primers pairs for COL3A1 ( 52 amplicons ) were designed to cover all coding regions of the 52 exons , including the splicing sites .|We used 15 DNA samples ( 8 validation samples and 7 samples of clinically suspected vEDS patients ) in this study .|The eight known COL3A1 mutations in validation samples were all successfully detected by the hrMCA .|In addition , we identified five novel COL3A1 mutations , including one deletion ( c . 2187delA ) and one nonsense mutation ( c . 2992C > T ) that could not be determined by the conventional total RNA method .|Furthermore , we established a small amplicon genotyping ( SAG ) method for detecting three high frequency coding - region SNPs ( rs1800255 : G > A , rs1801184 : T > C , and rs2271683 : A > G ) in COL3A1 to differentiate mutations before sequencing .|The use of hrMCA in combination with SAG from genomic DNA enables rapid detection of COL3A1 mutations with high efficiency and specificity .|A better understanding of the genotype - phenotype correlation in COL3A1 using this method will lead to improve in diagnosis and treatment .	1:Association:2	L2R	NON-CROSS	41-44	52-55	D004535	Ehlers - Danlos Syndrome , vascular type|Ehlers - Danlos syndrome , vascular type|vEDS|MIM # 130050|vEDS	DiseaseOrPhenotypicFeature	6:30:38:41:178	13:37:39:44:179	0:1:1:1:6	1281	type III procollagen|COL3A1|COL3A1|COL3A1|COL3A1|COL3A1|COL3A1|COL3A1|COL3A1|COL3A1	GeneOrGeneProduct	52:57:62:131:141:188:208:284:306:324	55:58:63:132:142:189:209:285:307:325	1:1:2:4:5:7:8:9:10:11	1:Positive_Correlation:2	L2R	CROSS	178-179	215-218	D004535	Ehlers - Danlos Syndrome , vascular type|Ehlers - Danlos syndrome , vascular type|vEDS|MIM # 130050|vEDS	DiseaseOrPhenotypicFeature	6:30:38:41:178	13:37:39:44:179	0:1:1:1:6	c|DEL|2187|A	c . 2187delA	SequenceVariant	215	218	8	1:Positive_Correlation:2	L2R	CROSS	178-179	224-229	D004535	Ehlers - Danlos Syndrome , vascular type|Ehlers - Danlos syndrome , vascular type|vEDS|MIM # 130050|vEDS	DiseaseOrPhenotypicFeature	6:30:38:41:178	13:37:39:44:179	0:1:1:1:6	c|SUB|C|2992|T	c . 2992C > T	SequenceVariant	224	229	8	1:Positive_Correlation:2	L2R	CROSS	178-179	264-265	D004535	Ehlers - Danlos Syndrome , vascular type|Ehlers - Danlos syndrome , vascular type|vEDS|MIM # 130050|vEDS	DiseaseOrPhenotypicFeature	6:30:38:41:178	13:37:39:44:179	0:1:1:1:6	rs1800255	rs1800255|G > A	SequenceVariant	264:266	265:269	9:9	1:Positive_Correlation:2	L2R	CROSS	178-179	270-271	D004535	Ehlers - Danlos Syndrome , vascular type|Ehlers - Danlos syndrome , vascular type|vEDS|MIM # 130050|vEDS	DiseaseOrPhenotypicFeature	6:30:38:41:178	13:37:39:44:179	0:1:1:1:6	rs1801184	rs1801184|T > C	SequenceVariant	270:272	271:275	9:9	1:Positive_Correlation:2	L2R	CROSS	178-179	277-278	D004535	Ehlers - Danlos Syndrome , vascular type|Ehlers - Danlos syndrome , vascular type|vEDS|MIM # 130050|vEDS	DiseaseOrPhenotypicFeature	6:30:38:41:178	13:37:39:44:179	0:1:1:1:6	rs2271683	rs2271683|A > G	SequenceVariant	277:279	278:282	9:9	1:NR:2	L2R	NON-CROSS	47-50	52-55	D030342	autosomal dominant disorder	DiseaseOrPhenotypicFeature	47	50	1	1281	type III procollagen|COL3A1|COL3A1|COL3A1|COL3A1|COL3A1|COL3A1|COL3A1|COL3A1|COL3A1	GeneOrGeneProduct	52:57:62:131:141:188:208:284:306:324	55:58:63:132:142:189:209:285:307:325	1:1:2:4:5:7:8:9:10:11	1:NR:2	L2R	CROSS	47-50	215-218	D030342	autosomal dominant disorder	DiseaseOrPhenotypicFeature	47	50	1	c|DEL|2187|A	c . 2187delA	SequenceVariant	215	218	8	1:NR:2	L2R	CROSS	47-50	224-229	D030342	autosomal dominant disorder	DiseaseOrPhenotypicFeature	47	50	1	c|SUB|C|2992|T	c . 2992C > T	SequenceVariant	224	229	8	1:NR:2	L2R	CROSS	47-50	264-265	D030342	autosomal dominant disorder	DiseaseOrPhenotypicFeature	47	50	1	rs1800255	rs1800255|G > A	SequenceVariant	264:266	265:269	9:9	1:NR:2	L2R	CROSS	47-50	270-271	D030342	autosomal dominant disorder	DiseaseOrPhenotypicFeature	47	50	1	rs1801184	rs1801184|T > C	SequenceVariant	270:272	271:275	9:9	1:NR:2	L2R	CROSS	47-50	277-278	D030342	autosomal dominant disorder	DiseaseOrPhenotypicFeature	47	50	1	rs2271683	rs2271683|A > G	SequenceVariant	277:279	278:282	9:9
23069675	Critical role of neuronal pentraxin 1 in mitochondria - mediated hypoxic - ischemic neuronal injury .|Developing brain is highly susceptible to hypoxic - ischemic ( HI ) injury leading to severe neurological disabilities in surviving infants and children .|Previously , we have reported induction of neuronal pentraxin 1 ( NP1 ) , a novel neuronal protein of long - pentraxin family , following HI neuronal injury .|Here , we investigated how this specific signal is propagated to cause the HI neuronal death .|We used wild - type ( WT ) and NP1 knockout ( NP1 - KO ) mouse hippocampal cultures , modeled in vitro following exposure to oxygen glucose deprivation ( OGD ) , and in vivo neonatal ( P9 - 10 ) mouse model of HI brain injury .|Our results show induction of NP1 in primary hippocampal neurons following OGD exposure ( 4 - 8 h ) and in the ipsilateral hippocampal CA1 and CA3 regions at 24 - 48 h post - HI compared to the contralateral side .|We also found increased PTEN activity concurrent with OGD time - dependent ( 4 - 8 h ) dephosphorylation of Akt ( Ser473 ) and GSK - 3b ( Ser9 ) .|OGD also caused a time - dependent decrease in the phosphorylation of Bad ( Ser136 ) , and Bax protein levels .|Immunofluorescence staining and subcellular fractionation analyses revealed increased mitochondrial translocation of Bad and Bax proteins from cytoplasm following OGD ( 4 h ) and simultaneously increased release of Cyt C from mitochondria followed by activation of caspase - 3 .|NP1 protein was immunoprecipitated with Bad and Bax proteins ; OGD caused increased interactions of NP1 with Bad and Bax , thereby , facilitating their mitochondrial translocation and dissipation of mitochondrial membrane potential ( D ( m ) ) .|This NP1 induction preceded the increased mitochondrial release of cytochrome C ( Cyt C ) into the cytosol , activation of caspase - 3 and OGD time - dependent cell death in WT primary hippocampal neurons .|In contrast , in NP1 - KO neurons there was no translocation of Bad and Bax from cytosol to the mitochondria , and no evidence of D ( m ) loss , increased Cyt C release and caspase - 3 activation following OGD ; which resulted in significantly reduced neuronal death .|Our results indicate a regulatory role of NP1 in Bad / Bax - dependent mitochondrial release of Cyt C and caspase - 3 activation .|Together our findings demonstrate a novel mechanism by which NP1 regulates mitochondria - driven hippocampal cell death ; suggesting NP1 as a potential therapeutic target against HI brain injury in neonates .	1:Association:2	L2R	NON-CROSS	3-6	10-15	18164	neuronal pentraxin 1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1	GeneOrGeneProduct	3:95:98:140:271:286:312:352:407:434:444	6:96:99:141:272:287:313:353:408:435:445	0:4:4:5:9:9:10:11:12:13:13	D020925	hypoxic - ischemic neuronal injury|hypoxic - ischemic ( HI ) injury|HI neuronal injury|HI neuronal death|HI brain injury|HI brain injury	DiseaseOrPhenotypicFeature	10:22:65:82:131:451	15:29:68:85:134:454	0:1:2:3:4:13	1:NR:2	L2R	CROSS	3-6	32-34	18164	neuronal pentraxin 1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1	GeneOrGeneProduct	3:95:98:140:271:286:312:352:407:434:444	6:96:99:141:272:287:313:353:408:435:445	0:4:4:5:9:9:10:11:12:13:13	D009461	neurological disabilities	DiseaseOrPhenotypicFeature	32	34	1	1:NR:2	L2R	CROSS	3-6	47-50	18164	neuronal pentraxin 1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1	GeneOrGeneProduct	3:95:98:140:271:286:312:352:407:434:444	6:96:99:141:272:287:313:353:408:435:445	0:4:4:5:9:9:10:11:12:13:13	266777	neuronal pentraxin 1|NP1	GeneOrGeneProduct	47:51	50:52	2:2	1:NR:2	L2R	NON-CROSS	98-99	112-113	18164	neuronal pentraxin 1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1	GeneOrGeneProduct	3:95:98:140:271:286:312:352:407:434:444	6:96:99:141:272:287:313:353:408:435:445	0:4:4:5:9:9:10:11:12:13:13	D010100	oxygen	ChemicalEntity	112	113	4	1:NR:2	L2R	NON-CROSS	98-99	113-114	18164	neuronal pentraxin 1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1	GeneOrGeneProduct	3:95:98:140:271:286:312:352:407:434:444	6:96:99:141:272:287:313:353:408:435:445	0:4:4:5:9:9:10:11:12:13:13	D005947	glucose	ChemicalEntity	113	114	4	1:NR:2	L2R	NON-CROSS	140-141	159-160	18164	neuronal pentraxin 1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1	GeneOrGeneProduct	3:95:98:140:271:286:312:352:407:434:444	6:96:99:141:272:287:313:353:408:435:445	0:4:4:5:9:9:10:11:12:13:13	12346	CA1	GeneOrGeneProduct	159	160	5	1:NR:2	L2R	NON-CROSS	140-141	161-162	18164	neuronal pentraxin 1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1	GeneOrGeneProduct	3:95:98:140:271:286:312:352:407:434:444	6:96:99:141:272:287:313:353:408:435:445	0:4:4:5:9:9:10:11:12:13:13	12350	CA3	GeneOrGeneProduct	161	162	5	1:NR:2	L2R	CROSS	140-141	181-182	18164	neuronal pentraxin 1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1	GeneOrGeneProduct	3:95:98:140:271:286:312:352:407:434:444	6:96:99:141:272:287:313:353:408:435:445	0:4:4:5:9:9:10:11:12:13:13	19211	PTEN	GeneOrGeneProduct	181	182	6	1:NR:2	L2R	CROSS	140-141	197-198	18164	neuronal pentraxin 1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1	GeneOrGeneProduct	3:95:98:140:271:286:312:352:407:434:444	6:96:99:141:272:287:313:353:408:435:445	0:4:4:5:9:9:10:11:12:13:13	11651	Akt	GeneOrGeneProduct	197	198	6	1:NR:2	L2R	CROSS	140-141	202-205	18164	neuronal pentraxin 1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1	GeneOrGeneProduct	3:95:98:140:271:286:312:352:407:434:444	6:96:99:141:272:287:313:353:408:435:445	0:4:4:5:9:9:10:11:12:13:13	56637	GSK - 3b	GeneOrGeneProduct	202	205	6	1:Association:2	L2R	NON-CROSS	286-287	288-289	18164	neuronal pentraxin 1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1	GeneOrGeneProduct	3:95:98:140:271:286:312:352:407:434:444	6:96:99:141:272:287:313:353:408:435:445	0:4:4:5:9:9:10:11:12:13:13	12015	Bad|Bad|Bad|Bad|Bad|Bad	GeneOrGeneProduct	221:242:276:288:361:409	222:243:277:289:362:410	7:8:9:9:11:12	1:Association:2	L2R	NON-CROSS	286-287	290-291	18164	neuronal pentraxin 1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1	GeneOrGeneProduct	3:95:98:140:271:286:312:352:407:434:444	6:96:99:141:272:287:313:353:408:435:445	0:4:4:5:9:9:10:11:12:13:13	12028	Bax|Bax|Bax|Bax|Bax|Bax	GeneOrGeneProduct	227:244:278:290:363:411	228:245:279:291:364:412	7:8:9:9:11:12	1:NR:2	L2R	NON-CROSS	312-313	320-322	18164	neuronal pentraxin 1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1	GeneOrGeneProduct	3:95:98:140:271:286:312:352:407:434:444	6:96:99:141:272:287:313:353:408:435:445	0:4:4:5:9:9:10:11:12:13:13	13063	Cyt C|cytochrome C|Cyt C|Cyt C|Cyt C	GeneOrGeneProduct	259:320:323:381:417	261:322:325:383:419	8:10:10:11:12	1:NR:2	L2R	NON-CROSS	267-270	271-272	18164	neuronal pentraxin 1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1	GeneOrGeneProduct	3:95:98:140:271:286:312:352:407:434:444	6:96:99:141:272:287:313:353:408:435:445	0:4:4:5:9:9:10:11:12:13:13	12367	caspase - 3|caspase - 3|caspase - 3|caspase - 3	GeneOrGeneProduct	267:332:385:420	270:335:388:423	8:10:11:12	1:Association:2	L2R	NON-CROSS	397-399	407-408	18164	neuronal pentraxin 1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1|NP1	GeneOrGeneProduct	3:95:98:140:271:286:312:352:407:434:444	6:96:99:141:272:287:313:353:408:435:445	0:4:4:5:9:9:10:11:12:13:13	D009410	neuronal death	DiseaseOrPhenotypicFeature	397	399	11	1:Association:2	R2L	NON-CROSS	65-68	51-52	266777	neuronal pentraxin 1|NP1	GeneOrGeneProduct	47:51	50:52	2:2	D020925	hypoxic - ischemic neuronal injury|hypoxic - ischemic ( HI ) injury|HI neuronal injury|HI neuronal death|HI brain injury|HI brain injury	DiseaseOrPhenotypicFeature	10:22:65:82:131:451	15:29:68:85:134:454	0:1:2:3:4:13	1:NR:2	L2R	NON-CROSS	112-113	131-134	D020925	hypoxic - ischemic neuronal injury|hypoxic - ischemic ( HI ) injury|HI neuronal injury|HI neuronal death|HI brain injury|HI brain injury	DiseaseOrPhenotypicFeature	10:22:65:82:131:451	15:29:68:85:134:454	0:1:2:3:4:13	D010100	oxygen	ChemicalEntity	112	113	4	1:NR:2	L2R	NON-CROSS	113-114	131-134	D020925	hypoxic - ischemic neuronal injury|hypoxic - ischemic ( HI ) injury|HI neuronal injury|HI neuronal death|HI brain injury|HI brain injury	DiseaseOrPhenotypicFeature	10:22:65:82:131:451	15:29:68:85:134:454	0:1:2:3:4:13	D005947	glucose	ChemicalEntity	113	114	4	1:NR:2	L2R	CROSS	131-134	159-160	D020925	hypoxic - ischemic neuronal injury|hypoxic - ischemic ( HI ) injury|HI neuronal injury|HI neuronal death|HI brain injury|HI brain injury	DiseaseOrPhenotypicFeature	10:22:65:82:131:451	15:29:68:85:134:454	0:1:2:3:4:13	12346	CA1	GeneOrGeneProduct	159	160	5	1:NR:2	L2R	CROSS	131-134	161-162	D020925	hypoxic - ischemic neuronal injury|hypoxic - ischemic ( HI ) injury|HI neuronal injury|HI neuronal death|HI brain injury|HI brain injury	DiseaseOrPhenotypicFeature	10:22:65:82:131:451	15:29:68:85:134:454	0:1:2:3:4:13	12350	CA3	GeneOrGeneProduct	161	162	5	1:NR:2	L2R	CROSS	131-134	181-182	D020925	hypoxic - ischemic neuronal injury|hypoxic - ischemic ( HI ) injury|HI neuronal injury|HI neuronal death|HI brain injury|HI brain injury	DiseaseOrPhenotypicFeature	10:22:65:82:131:451	15:29:68:85:134:454	0:1:2:3:4:13	19211	PTEN	GeneOrGeneProduct	181	182	6	1:NR:2	L2R	CROSS	131-134	197-198	D020925	hypoxic - ischemic neuronal injury|hypoxic - ischemic ( HI ) injury|HI neuronal injury|HI neuronal death|HI brain injury|HI brain injury	DiseaseOrPhenotypicFeature	10:22:65:82:131:451	15:29:68:85:134:454	0:1:2:3:4:13	11651	Akt	GeneOrGeneProduct	197	198	6	1:NR:2	L2R	CROSS	131-134	199-200	D020925	hypoxic - ischemic neuronal injury|hypoxic - ischemic ( HI ) injury|HI neuronal injury|HI neuronal death|HI brain injury|HI brain injury	DiseaseOrPhenotypicFeature	10:22:65:82:131:451	15:29:68:85:134:454	0:1:2:3:4:13	p|AellelS|473	Ser473	SequenceVariant	199	200	6	1:NR:2	L2R	CROSS	131-134	202-205	D020925	hypoxic - ischemic neuronal injury|hypoxic - ischemic ( HI ) injury|HI neuronal injury|HI neuronal death|HI brain injury|HI brain injury	DiseaseOrPhenotypicFeature	10:22:65:82:131:451	15:29:68:85:134:454	0:1:2:3:4:13	56637	GSK - 3b	GeneOrGeneProduct	202	205	6	1:NR:2	L2R	CROSS	131-134	206-207	D020925	hypoxic - ischemic neuronal injury|hypoxic - ischemic ( HI ) injury|HI neuronal injury|HI neuronal death|HI brain injury|HI brain injury	DiseaseOrPhenotypicFeature	10:22:65:82:131:451	15:29:68:85:134:454	0:1:2:3:4:13	p|AellelS|9	Ser9	SequenceVariant	206	207	6	1:NR:2	L2R	CROSS	409-410	451-454	D020925	hypoxic - ischemic neuronal injury|hypoxic - ischemic ( HI ) injury|HI neuronal injury|HI neuronal death|HI brain injury|HI brain injury	DiseaseOrPhenotypicFeature	10:22:65:82:131:451	15:29:68:85:134:454	0:1:2:3:4:13	12015	Bad|Bad|Bad|Bad|Bad|Bad	GeneOrGeneProduct	221:242:276:288:361:409	222:243:277:289:362:410	7:8:9:9:11:12	1:NR:2	L2R	CROSS	131-134	223-224	D020925	hypoxic - ischemic neuronal injury|hypoxic - ischemic ( HI ) injury|HI neuronal injury|HI neuronal death|HI brain injury|HI brain injury	DiseaseOrPhenotypicFeature	10:22:65:82:131:451	15:29:68:85:134:454	0:1:2:3:4:13	p|AellelS|136	Ser136	SequenceVariant	223	224	7	1:NR:2	L2R	CROSS	411-412	451-454	D020925	hypoxic - ischemic neuronal injury|hypoxic - ischemic ( HI ) injury|HI neuronal injury|HI neuronal death|HI brain injury|HI brain injury	DiseaseOrPhenotypicFeature	10:22:65:82:131:451	15:29:68:85:134:454	0:1:2:3:4:13	12028	Bax|Bax|Bax|Bax|Bax|Bax	GeneOrGeneProduct	227:244:278:290:363:411	228:245:279:291:364:412	7:8:9:9:11:12	1:NR:2	L2R	CROSS	417-419	451-454	D020925	hypoxic - ischemic neuronal injury|hypoxic - ischemic ( HI ) injury|HI neuronal injury|HI neuronal death|HI brain injury|HI brain injury	DiseaseOrPhenotypicFeature	10:22:65:82:131:451	15:29:68:85:134:454	0:1:2:3:4:13	13063	Cyt C|cytochrome C|Cyt C|Cyt C|Cyt C	GeneOrGeneProduct	259:320:323:381:417	261:322:325:383:419	8:10:10:11:12	1:NR:2	L2R	CROSS	420-423	451-454	D020925	hypoxic - ischemic neuronal injury|hypoxic - ischemic ( HI ) injury|HI neuronal injury|HI neuronal death|HI brain injury|HI brain injury	DiseaseOrPhenotypicFeature	10:22:65:82:131:451	15:29:68:85:134:454	0:1:2:3:4:13	12367	caspase - 3|caspase - 3|caspase - 3|caspase - 3	GeneOrGeneProduct	267:332:385:420	270:335:388:423	8:10:11:12	1:NR:2	L2R	CROSS	32-34	47-50	D009461	neurological disabilities	DiseaseOrPhenotypicFeature	32	34	1	266777	neuronal pentraxin 1|NP1	GeneOrGeneProduct	47:51	50:52	2:2	1:NR:2	L2R	CROSS	32-34	112-113	D009461	neurological disabilities	DiseaseOrPhenotypicFeature	32	34	1	D010100	oxygen	ChemicalEntity	112	113	4	1:NR:2	L2R	CROSS	32-34	113-114	D009461	neurological disabilities	DiseaseOrPhenotypicFeature	32	34	1	D005947	glucose	ChemicalEntity	113	114	4	1:NR:2	L2R	CROSS	32-34	159-160	D009461	neurological disabilities	DiseaseOrPhenotypicFeature	32	34	1	12346	CA1	GeneOrGeneProduct	159	160	5	1:NR:2	L2R	CROSS	32-34	161-162	D009461	neurological disabilities	DiseaseOrPhenotypicFeature	32	34	1	12350	CA3	GeneOrGeneProduct	161	162	5	1:NR:2	L2R	CROSS	32-34	181-182	D009461	neurological disabilities	DiseaseOrPhenotypicFeature	32	34	1	19211	PTEN	GeneOrGeneProduct	181	182	6	1:NR:2	L2R	CROSS	32-34	197-198	D009461	neurological disabilities	DiseaseOrPhenotypicFeature	32	34	1	11651	Akt	GeneOrGeneProduct	197	198	6	1:NR:2	L2R	CROSS	32-34	199-200	D009461	neurological disabilities	DiseaseOrPhenotypicFeature	32	34	1	p|AellelS|473	Ser473	SequenceVariant	199	200	6	1:NR:2	L2R	CROSS	32-34	202-205	D009461	neurological disabilities	DiseaseOrPhenotypicFeature	32	34	1	56637	GSK - 3b	GeneOrGeneProduct	202	205	6	1:NR:2	L2R	CROSS	32-34	206-207	D009461	neurological disabilities	DiseaseOrPhenotypicFeature	32	34	1	p|AellelS|9	Ser9	SequenceVariant	206	207	6	1:NR:2	L2R	CROSS	32-34	221-222	D009461	neurological disabilities	DiseaseOrPhenotypicFeature	32	34	1	12015	Bad|Bad|Bad|Bad|Bad|Bad	GeneOrGeneProduct	221:242:276:288:361:409	222:243:277:289:362:410	7:8:9:9:11:12	1:NR:2	L2R	CROSS	32-34	223-224	D009461	neurological disabilities	DiseaseOrPhenotypicFeature	32	34	1	p|AellelS|136	Ser136	SequenceVariant	223	224	7	1:NR:2	L2R	CROSS	32-34	227-228	D009461	neurological disabilities	DiseaseOrPhenotypicFeature	32	34	1	12028	Bax|Bax|Bax|Bax|Bax|Bax	GeneOrGeneProduct	227:244:278:290:363:411	228:245:279:291:364:412	7:8:9:9:11:12	1:NR:2	L2R	CROSS	32-34	259-261	D009461	neurological disabilities	DiseaseOrPhenotypicFeature	32	34	1	13063	Cyt C|cytochrome C|Cyt C|Cyt C|Cyt C	GeneOrGeneProduct	259:320:323:381:417	261:322:325:383:419	8:10:10:11:12	1:NR:2	L2R	CROSS	32-34	267-270	D009461	neurological disabilities	DiseaseOrPhenotypicFeature	32	34	1	12367	caspase - 3|caspase - 3|caspase - 3|caspase - 3	GeneOrGeneProduct	267:332:385:420	270:335:388:423	8:10:11:12	1:NR:2	L2R	CROSS	51-52	112-113	266777	neuronal pentraxin 1|NP1	GeneOrGeneProduct	47:51	50:52	2:2	D010100	oxygen	ChemicalEntity	112	113	4	1:NR:2	L2R	CROSS	51-52	113-114	266777	neuronal pentraxin 1|NP1	GeneOrGeneProduct	47:51	50:52	2:2	D005947	glucose	ChemicalEntity	113	114	4	1:NR:2	L2R	CROSS	51-52	159-160	266777	neuronal pentraxin 1|NP1	GeneOrGeneProduct	47:51	50:52	2:2	12346	CA1	GeneOrGeneProduct	159	160	5	1:NR:2	L2R	CROSS	51-52	161-162	266777	neuronal pentraxin 1|NP1	GeneOrGeneProduct	47:51	50:52	2:2	12350	CA3	GeneOrGeneProduct	161	162	5	1:NR:2	L2R	CROSS	51-52	181-182	266777	neuronal pentraxin 1|NP1	GeneOrGeneProduct	47:51	50:52	2:2	19211	PTEN	GeneOrGeneProduct	181	182	6	1:NR:2	L2R	CROSS	51-52	197-198	266777	neuronal pentraxin 1|NP1	GeneOrGeneProduct	47:51	50:52	2:2	11651	Akt	GeneOrGeneProduct	197	198	6	1:NR:2	L2R	CROSS	51-52	202-205	266777	neuronal pentraxin 1|NP1	GeneOrGeneProduct	47:51	50:52	2:2	56637	GSK - 3b	GeneOrGeneProduct	202	205	6	1:NR:2	L2R	CROSS	51-52	221-222	266777	neuronal pentraxin 1|NP1	GeneOrGeneProduct	47:51	50:52	2:2	12015	Bad|Bad|Bad|Bad|Bad|Bad	GeneOrGeneProduct	221:242:276:288:361:409	222:243:277:289:362:410	7:8:9:9:11:12	1:NR:2	L2R	CROSS	51-52	227-228	266777	neuronal pentraxin 1|NP1	GeneOrGeneProduct	47:51	50:52	2:2	12028	Bax|Bax|Bax|Bax|Bax|Bax	GeneOrGeneProduct	227:244:278:290:363:411	228:245:279:291:364:412	7:8:9:9:11:12	1:NR:2	L2R	CROSS	51-52	259-261	266777	neuronal pentraxin 1|NP1	GeneOrGeneProduct	47:51	50:52	2:2	13063	Cyt C|cytochrome C|Cyt C|Cyt C|Cyt C	GeneOrGeneProduct	259:320:323:381:417	261:322:325:383:419	8:10:10:11:12	1:NR:2	L2R	CROSS	51-52	267-270	266777	neuronal pentraxin 1|NP1	GeneOrGeneProduct	47:51	50:52	2:2	12367	caspase - 3|caspase - 3|caspase - 3|caspase - 3	GeneOrGeneProduct	267:332:385:420	270:335:388:423	8:10:11:12	1:NR:2	L2R	CROSS	51-52	397-399	266777	neuronal pentraxin 1|NP1	GeneOrGeneProduct	47:51	50:52	2:2	D009410	neuronal death	DiseaseOrPhenotypicFeature	397	399	11	1:NR:2	L2R	NON-CROSS	112-113	113-114	D010100	oxygen	ChemicalEntity	112	113	4	D005947	glucose	ChemicalEntity	113	114	4	1:NR:2	L2R	CROSS	112-113	159-160	D010100	oxygen	ChemicalEntity	112	113	4	12346	CA1	GeneOrGeneProduct	159	160	5	1:NR:2	L2R	CROSS	112-113	161-162	D010100	oxygen	ChemicalEntity	112	113	4	12350	CA3	GeneOrGeneProduct	161	162	5	1:NR:2	L2R	CROSS	112-113	181-182	D010100	oxygen	ChemicalEntity	112	113	4	19211	PTEN	GeneOrGeneProduct	181	182	6	1:NR:2	L2R	CROSS	112-113	197-198	D010100	oxygen	ChemicalEntity	112	113	4	11651	Akt	GeneOrGeneProduct	197	198	6	1:NR:2	L2R	CROSS	112-113	199-200	D010100	oxygen	ChemicalEntity	112	113	4	p|AellelS|473	Ser473	SequenceVariant	199	200	6	1:NR:2	L2R	CROSS	112-113	202-205	D010100	oxygen	ChemicalEntity	112	113	4	56637	GSK - 3b	GeneOrGeneProduct	202	205	6	1:NR:2	L2R	CROSS	112-113	206-207	D010100	oxygen	ChemicalEntity	112	113	4	p|AellelS|9	Ser9	SequenceVariant	206	207	6	1:NR:2	L2R	CROSS	112-113	221-222	D010100	oxygen	ChemicalEntity	112	113	4	12015	Bad|Bad|Bad|Bad|Bad|Bad	GeneOrGeneProduct	221:242:276:288:361:409	222:243:277:289:362:410	7:8:9:9:11:12	1:NR:2	L2R	CROSS	112-113	223-224	D010100	oxygen	ChemicalEntity	112	113	4	p|AellelS|136	Ser136	SequenceVariant	223	224	7	1:NR:2	L2R	CROSS	112-113	227-228	D010100	oxygen	ChemicalEntity	112	113	4	12028	Bax|Bax|Bax|Bax|Bax|Bax	GeneOrGeneProduct	227:244:278:290:363:411	228:245:279:291:364:412	7:8:9:9:11:12	1:NR:2	L2R	CROSS	112-113	259-261	D010100	oxygen	ChemicalEntity	112	113	4	13063	Cyt C|cytochrome C|Cyt C|Cyt C|Cyt C	GeneOrGeneProduct	259:320:323:381:417	261:322:325:383:419	8:10:10:11:12	1:NR:2	L2R	CROSS	112-113	267-270	D010100	oxygen	ChemicalEntity	112	113	4	12367	caspase - 3|caspase - 3|caspase - 3|caspase - 3	GeneOrGeneProduct	267:332:385:420	270:335:388:423	8:10:11:12	1:NR:2	L2R	CROSS	112-113	397-399	D010100	oxygen	ChemicalEntity	112	113	4	D009410	neuronal death	DiseaseOrPhenotypicFeature	397	399	11	1:NR:2	L2R	CROSS	113-114	159-160	D005947	glucose	ChemicalEntity	113	114	4	12346	CA1	GeneOrGeneProduct	159	160	5	1:NR:2	L2R	CROSS	113-114	161-162	D005947	glucose	ChemicalEntity	113	114	4	12350	CA3	GeneOrGeneProduct	161	162	5	1:NR:2	L2R	CROSS	113-114	181-182	D005947	glucose	ChemicalEntity	113	114	4	19211	PTEN	GeneOrGeneProduct	181	182	6	1:NR:2	L2R	CROSS	113-114	197-198	D005947	glucose	ChemicalEntity	113	114	4	11651	Akt	GeneOrGeneProduct	197	198	6	1:NR:2	L2R	CROSS	113-114	199-200	D005947	glucose	ChemicalEntity	113	114	4	p|AellelS|473	Ser473	SequenceVariant	199	200	6	1:NR:2	L2R	CROSS	113-114	202-205	D005947	glucose	ChemicalEntity	113	114	4	56637	GSK - 3b	GeneOrGeneProduct	202	205	6	1:NR:2	L2R	CROSS	113-114	206-207	D005947	glucose	ChemicalEntity	113	114	4	p|AellelS|9	Ser9	SequenceVariant	206	207	6	1:NR:2	L2R	CROSS	113-114	221-222	D005947	glucose	ChemicalEntity	113	114	4	12015	Bad|Bad|Bad|Bad|Bad|Bad	GeneOrGeneProduct	221:242:276:288:361:409	222:243:277:289:362:410	7:8:9:9:11:12	1:NR:2	L2R	CROSS	113-114	223-224	D005947	glucose	ChemicalEntity	113	114	4	p|AellelS|136	Ser136	SequenceVariant	223	224	7	1:NR:2	L2R	CROSS	113-114	227-228	D005947	glucose	ChemicalEntity	113	114	4	12028	Bax|Bax|Bax|Bax|Bax|Bax	GeneOrGeneProduct	227:244:278:290:363:411	228:245:279:291:364:412	7:8:9:9:11:12	1:NR:2	L2R	CROSS	113-114	259-261	D005947	glucose	ChemicalEntity	113	114	4	13063	Cyt C|cytochrome C|Cyt C|Cyt C|Cyt C	GeneOrGeneProduct	259:320:323:381:417	261:322:325:383:419	8:10:10:11:12	1:NR:2	L2R	CROSS	113-114	267-270	D005947	glucose	ChemicalEntity	113	114	4	12367	caspase - 3|caspase - 3|caspase - 3|caspase - 3	GeneOrGeneProduct	267:332:385:420	270:335:388:423	8:10:11:12	1:NR:2	L2R	CROSS	113-114	397-399	D005947	glucose	ChemicalEntity	113	114	4	D009410	neuronal death	DiseaseOrPhenotypicFeature	397	399	11	1:NR:2	L2R	NON-CROSS	159-160	161-162	12346	CA1	GeneOrGeneProduct	159	160	5	12350	CA3	GeneOrGeneProduct	161	162	5	1:NR:2	L2R	CROSS	159-160	181-182	12346	CA1	GeneOrGeneProduct	159	160	5	19211	PTEN	GeneOrGeneProduct	181	182	6	1:NR:2	L2R	CROSS	159-160	197-198	12346	CA1	GeneOrGeneProduct	159	160	5	11651	Akt	GeneOrGeneProduct	197	198	6	1:NR:2	L2R	CROSS	159-160	202-205	12346	CA1	GeneOrGeneProduct	159	160	5	56637	GSK - 3b	GeneOrGeneProduct	202	205	6	1:NR:2	L2R	CROSS	159-160	221-222	12346	CA1	GeneOrGeneProduct	159	160	5	12015	Bad|Bad|Bad|Bad|Bad|Bad	GeneOrGeneProduct	221:242:276:288:361:409	222:243:277:289:362:410	7:8:9:9:11:12	1:NR:2	L2R	CROSS	159-160	227-228	12346	CA1	GeneOrGeneProduct	159	160	5	12028	Bax|Bax|Bax|Bax|Bax|Bax	GeneOrGeneProduct	227:244:278:290:363:411	228:245:279:291:364:412	7:8:9:9:11:12	1:NR:2	L2R	CROSS	159-160	259-261	12346	CA1	GeneOrGeneProduct	159	160	5	13063	Cyt C|cytochrome C|Cyt C|Cyt C|Cyt C	GeneOrGeneProduct	259:320:323:381:417	261:322:325:383:419	8:10:10:11:12	1:NR:2	L2R	CROSS	159-160	267-270	12346	CA1	GeneOrGeneProduct	159	160	5	12367	caspase - 3|caspase - 3|caspase - 3|caspase - 3	GeneOrGeneProduct	267:332:385:420	270:335:388:423	8:10:11:12	1:NR:2	L2R	CROSS	159-160	397-399	12346	CA1	GeneOrGeneProduct	159	160	5	D009410	neuronal death	DiseaseOrPhenotypicFeature	397	399	11	1:NR:2	L2R	CROSS	161-162	181-182	12350	CA3	GeneOrGeneProduct	161	162	5	19211	PTEN	GeneOrGeneProduct	181	182	6	1:NR:2	L2R	CROSS	161-162	197-198	12350	CA3	GeneOrGeneProduct	161	162	5	11651	Akt	GeneOrGeneProduct	197	198	6	1:NR:2	L2R	CROSS	161-162	202-205	12350	CA3	GeneOrGeneProduct	161	162	5	56637	GSK - 3b	GeneOrGeneProduct	202	205	6	1:NR:2	L2R	CROSS	161-162	221-222	12350	CA3	GeneOrGeneProduct	161	162	5	12015	Bad|Bad|Bad|Bad|Bad|Bad	GeneOrGeneProduct	221:242:276:288:361:409	222:243:277:289:362:410	7:8:9:9:11:12	1:NR:2	L2R	CROSS	161-162	227-228	12350	CA3	GeneOrGeneProduct	161	162	5	12028	Bax|Bax|Bax|Bax|Bax|Bax	GeneOrGeneProduct	227:244:278:290:363:411	228:245:279:291:364:412	7:8:9:9:11:12	1:NR:2	L2R	CROSS	161-162	259-261	12350	CA3	GeneOrGeneProduct	161	162	5	13063	Cyt C|cytochrome C|Cyt C|Cyt C|Cyt C	GeneOrGeneProduct	259:320:323:381:417	261:322:325:383:419	8:10:10:11:12	1:NR:2	L2R	CROSS	161-162	267-270	12350	CA3	GeneOrGeneProduct	161	162	5	12367	caspase - 3|caspase - 3|caspase - 3|caspase - 3	GeneOrGeneProduct	267:332:385:420	270:335:388:423	8:10:11:12	1:NR:2	L2R	CROSS	161-162	397-399	12350	CA3	GeneOrGeneProduct	161	162	5	D009410	neuronal death	DiseaseOrPhenotypicFeature	397	399	11	1:Association:2	L2R	NON-CROSS	181-182	197-198	19211	PTEN	GeneOrGeneProduct	181	182	6	11651	Akt	GeneOrGeneProduct	197	198	6	1:Association:2	L2R	NON-CROSS	181-182	202-205	19211	PTEN	GeneOrGeneProduct	181	182	6	56637	GSK - 3b	GeneOrGeneProduct	202	205	6	1:NR:2	L2R	CROSS	181-182	221-222	19211	PTEN	GeneOrGeneProduct	181	182	6	12015	Bad|Bad|Bad|Bad|Bad|Bad	GeneOrGeneProduct	221:242:276:288:361:409	222:243:277:289:362:410	7:8:9:9:11:12	1:NR:2	L2R	CROSS	181-182	227-228	19211	PTEN	GeneOrGeneProduct	181	182	6	12028	Bax|Bax|Bax|Bax|Bax|Bax	GeneOrGeneProduct	227:244:278:290:363:411	228:245:279:291:364:412	7:8:9:9:11:12	1:NR:2	L2R	CROSS	181-182	259-261	19211	PTEN	GeneOrGeneProduct	181	182	6	13063	Cyt C|cytochrome C|Cyt C|Cyt C|Cyt C	GeneOrGeneProduct	259:320:323:381:417	261:322:325:383:419	8:10:10:11:12	1:NR:2	L2R	CROSS	181-182	267-270	19211	PTEN	GeneOrGeneProduct	181	182	6	12367	caspase - 3|caspase - 3|caspase - 3|caspase - 3	GeneOrGeneProduct	267:332:385:420	270:335:388:423	8:10:11:12	1:NR:2	L2R	CROSS	181-182	397-399	19211	PTEN	GeneOrGeneProduct	181	182	6	D009410	neuronal death	DiseaseOrPhenotypicFeature	397	399	11	1:NR:2	L2R	NON-CROSS	197-198	202-205	11651	Akt	GeneOrGeneProduct	197	198	6	56637	GSK - 3b	GeneOrGeneProduct	202	205	6	1:NR:2	L2R	CROSS	197-198	221-222	11651	Akt	GeneOrGeneProduct	197	198	6	12015	Bad|Bad|Bad|Bad|Bad|Bad	GeneOrGeneProduct	221:242:276:288:361:409	222:243:277:289:362:410	7:8:9:9:11:12	1:NR:2	L2R	CROSS	197-198	227-228	11651	Akt	GeneOrGeneProduct	197	198	6	12028	Bax|Bax|Bax|Bax|Bax|Bax	GeneOrGeneProduct	227:244:278:290:363:411	228:245:279:291:364:412	7:8:9:9:11:12	1:NR:2	L2R	CROSS	197-198	259-261	11651	Akt	GeneOrGeneProduct	197	198	6	13063	Cyt C|cytochrome C|Cyt C|Cyt C|Cyt C	GeneOrGeneProduct	259:320:323:381:417	261:322:325:383:419	8:10:10:11:12	1:NR:2	L2R	CROSS	197-198	267-270	11651	Akt	GeneOrGeneProduct	197	198	6	12367	caspase - 3|caspase - 3|caspase - 3|caspase - 3	GeneOrGeneProduct	267:332:385:420	270:335:388:423	8:10:11:12	1:NR:2	L2R	CROSS	197-198	397-399	11651	Akt	GeneOrGeneProduct	197	198	6	D009410	neuronal death	DiseaseOrPhenotypicFeature	397	399	11	1:NR:2	L2R	CROSS	199-200	397-399	p|AellelS|473	Ser473	SequenceVariant	199	200	6	D009410	neuronal death	DiseaseOrPhenotypicFeature	397	399	11	1:NR:2	L2R	CROSS	202-205	221-222	56637	GSK - 3b	GeneOrGeneProduct	202	205	6	12015	Bad|Bad|Bad|Bad|Bad|Bad	GeneOrGeneProduct	221:242:276:288:361:409	222:243:277:289:362:410	7:8:9:9:11:12	1:NR:2	L2R	CROSS	202-205	227-228	56637	GSK - 3b	GeneOrGeneProduct	202	205	6	12028	Bax|Bax|Bax|Bax|Bax|Bax	GeneOrGeneProduct	227:244:278:290:363:411	228:245:279:291:364:412	7:8:9:9:11:12	1:NR:2	L2R	CROSS	202-205	259-261	56637	GSK - 3b	GeneOrGeneProduct	202	205	6	13063	Cyt C|cytochrome C|Cyt C|Cyt C|Cyt C	GeneOrGeneProduct	259:320:323:381:417	261:322:325:383:419	8:10:10:11:12	1:NR:2	L2R	CROSS	202-205	267-270	56637	GSK - 3b	GeneOrGeneProduct	202	205	6	12367	caspase - 3|caspase - 3|caspase - 3|caspase - 3	GeneOrGeneProduct	267:332:385:420	270:335:388:423	8:10:11:12	1:NR:2	L2R	CROSS	202-205	397-399	56637	GSK - 3b	GeneOrGeneProduct	202	205	6	D009410	neuronal death	DiseaseOrPhenotypicFeature	397	399	11	1:NR:2	L2R	CROSS	206-207	397-399	p|AellelS|9	Ser9	SequenceVariant	206	207	6	D009410	neuronal death	DiseaseOrPhenotypicFeature	397	399	11	1:NR:2	L2R	NON-CROSS	242-243	244-245	12015	Bad|Bad|Bad|Bad|Bad|Bad	GeneOrGeneProduct	221:242:276:288:361:409	222:243:277:289:362:410	7:8:9:9:11:12	12028	Bax|Bax|Bax|Bax|Bax|Bax	GeneOrGeneProduct	227:244:278:290:363:411	228:245:279:291:364:412	7:8:9:9:11:12	1:Association:2	L2R	NON-CROSS	409-410	417-419	12015	Bad|Bad|Bad|Bad|Bad|Bad	GeneOrGeneProduct	221:242:276:288:361:409	222:243:277:289:362:410	7:8:9:9:11:12	13063	Cyt C|cytochrome C|Cyt C|Cyt C|Cyt C	GeneOrGeneProduct	259:320:323:381:417	261:322:325:383:419	8:10:10:11:12	1:Association:2	L2R	NON-CROSS	267-270	276-277	12015	Bad|Bad|Bad|Bad|Bad|Bad	GeneOrGeneProduct	221:242:276:288:361:409	222:243:277:289:362:410	7:8:9:9:11:12	12367	caspase - 3|caspase - 3|caspase - 3|caspase - 3	GeneOrGeneProduct	267:332:385:420	270:335:388:423	8:10:11:12	1:Association:2	L2R	NON-CROSS	397-399	409-410	12015	Bad|Bad|Bad|Bad|Bad|Bad	GeneOrGeneProduct	221:242:276:288:361:409	222:243:277:289:362:410	7:8:9:9:11:12	D009410	neuronal death	DiseaseOrPhenotypicFeature	397	399	11	1:NR:2	L2R	CROSS	223-224	397-399	p|AellelS|136	Ser136	SequenceVariant	223	224	7	D009410	neuronal death	DiseaseOrPhenotypicFeature	397	399	11	1:Association:2	L2R	NON-CROSS	411-412	417-419	12028	Bax|Bax|Bax|Bax|Bax|Bax	GeneOrGeneProduct	227:244:278:290:363:411	228:245:279:291:364:412	7:8:9:9:11:12	13063	Cyt C|cytochrome C|Cyt C|Cyt C|Cyt C	GeneOrGeneProduct	259:320:323:381:417	261:322:325:383:419	8:10:10:11:12	1:Association:2	L2R	NON-CROSS	411-412	420-423	12028	Bax|Bax|Bax|Bax|Bax|Bax	GeneOrGeneProduct	227:244:278:290:363:411	228:245:279:291:364:412	7:8:9:9:11:12	12367	caspase - 3|caspase - 3|caspase - 3|caspase - 3	GeneOrGeneProduct	267:332:385:420	270:335:388:423	8:10:11:12	1:Association:2	L2R	NON-CROSS	397-399	411-412	12028	Bax|Bax|Bax|Bax|Bax|Bax	GeneOrGeneProduct	227:244:278:290:363:411	228:245:279:291:364:412	7:8:9:9:11:12	D009410	neuronal death	DiseaseOrPhenotypicFeature	397	399	11	1:NR:2	L2R	NON-CROSS	417-419	420-423	13063	Cyt C|cytochrome C|Cyt C|Cyt C|Cyt C	GeneOrGeneProduct	259:320:323:381:417	261:322:325:383:419	8:10:10:11:12	12367	caspase - 3|caspase - 3|caspase - 3|caspase - 3	GeneOrGeneProduct	267:332:385:420	270:335:388:423	8:10:11:12	1:Association:2	L2R	NON-CROSS	381-383	397-399	13063	Cyt C|cytochrome C|Cyt C|Cyt C|Cyt C	GeneOrGeneProduct	259:320:323:381:417	261:322:325:383:419	8:10:10:11:12	D009410	neuronal death	DiseaseOrPhenotypicFeature	397	399	11	1:Association:2	L2R	NON-CROSS	385-388	397-399	12367	caspase - 3|caspase - 3|caspase - 3|caspase - 3	GeneOrGeneProduct	267:332:385:420	270:335:388:423	8:10:11:12	D009410	neuronal death	DiseaseOrPhenotypicFeature	397	399	11
25874935	Neuroprotective effect of neuroserpin in oxygen - glucose deprivation - and reoxygenation - treated rat astrocytes in vitro .|Neuroserpin ( NSP ) reportedly exerts neuroprotective effects in cerebral ischemic animal models and patients ; however , the mechanism of protection is poorly understood .|We thus attempted to confirm neuroprotective effects of NSP on astrocytes in the ischemic state and then explored the relative mechanisms .|Astrocytes from neonatal rats were treated with oxygen - glucose deprivation ( OGD ) followed by reoxygenation ( OGD / R ) .|To confirm the neuroprotective effects of NSP , we measured the cell survival rate , relative lactate dehydrogenase ( LDH ) release ; we also performed morphological methods , namely Hoechst 33342 staining and Annexin V assay .|To explore the potential mechanisms of NSP , the release of nitric oxide ( NO ) and TNF - alpha related to NSP administration were measured by enzyme - linked immunosorbent assay .|The proteins related to the NF - kappaB , ERK1 / 2 , and PI3K / Akt pathways were investigated by Western blotting .|To verify the cause - and - effect relationship between neuroprotection and the NF - kappaB pathway , a NF - kappaB pathway inhibitor sc3060 was employed to observe the effects of NSP - induced neuroprotection .|We found that NSP significantly increased the cell survival rate and reduced LDH release in OGD / R - treated astrocytes .|It also reduced NO / TNF - alpha release .|Western blotting showed that the protein levels of p - IKKBalpha / beta and P65 were upregulated by the OGD / R treatment and such effects were significantly inhibited by NSP administration .|The NSP - induced inhibition could be significantly reversed by administration of the NF - kappaB pathway inhibitor sc3060 , whereas , expressions of p - ERK1 , p - ERK2 , and p - AKT were upregulated by the OGD / R treatment ; however , their levels were unchanged by NSP administration .|Our results thus verified the neuroprotective effects of NSP in ischemic astrocytes .|The potential mechanisms include inhibition of the release of NO / TNF - alpha and repression of the NF - kappaB signaling pathways .|Our data also indicated that NSP has little influence on the MAPK and PI3K / Akt pathways .	1:NR:2	L2R	NON-CROSS	3-4	5-6	116459	neuroserpin|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP	GeneOrGeneProduct	3:53:96:134:150:217:225:284:288:339:350:384	4:54:97:135:151:218:226:285:289:340:351:385	0:2:4:5:5:7:8:10:11:11:12:14	D010100	oxygen|oxygen	ChemicalEntity	5:74	6:75	0:3	1:NR:2	L2R	NON-CROSS	3-4	7-8	116459	neuroserpin|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP	GeneOrGeneProduct	3:53:96:134:150:217:225:284:288:339:350:384	4:54:97:135:151:218:226:285:289:340:351:385	0:2:4:5:5:7:8:10:11:11:12:14	D005947	glucose|glucose	ChemicalEntity	7:76	8:77	0:3	1:NR:2	L2R	CROSS	3-4	19-20	116459	neuroserpin|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP	GeneOrGeneProduct	3:53:96:134:150:217:225:284:288:339:350:384	4:54:97:135:151:218:226:285:289:340:351:385	0:2:4:5:5:7:8:10:11:11:12:14	116459,5274	Neuroserpin|NSP	GeneOrGeneProduct	19:21	20:22	1:1	1:Negative_Correlation:2	R2L	CROSS	53-54	28-30	D002545	cerebral ischemic	DiseaseOrPhenotypicFeature	28	30	1	116459	neuroserpin|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP	GeneOrGeneProduct	3:53:96:134:150:217:225:284:288:339:350:384	4:54:97:135:151:218:226:285:289:340:351:385	0:2:4:5:5:7:8:10:11:11:12:14	1:Negative_Correlation:2	L2R	NON-CROSS	350-351	352-353	116459	neuroserpin|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP	GeneOrGeneProduct	3:53:96:134:150:217:225:284:288:339:350:384	4:54:97:135:151:218:226:285:289:340:351:385	0:2:4:5:5:7:8:10:11:11:12:14	D007511	ischemic|ischemic	DiseaseOrPhenotypicFeature	58:352	59:353	2:12	1:Negative_Correlation:2	L2R	NON-CROSS	225-226	234-235	116459	neuroserpin|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP	GeneOrGeneProduct	3:53:96:134:150:217:225:284:288:339:350:384	4:54:97:135:151:218:226:285:289:340:351:385	0:2:4:5:5:7:8:10:11:11:12:14	24533	lactate dehydrogenase|LDH|LDH	GeneOrGeneProduct	106:109:234	108:110:235	4:4:8	1:NR:2	L2R	NON-CROSS	124-126	134-135	116459	neuroserpin|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP	GeneOrGeneProduct	3:53:96:134:150:217:225:284:288:339:350:384	4:54:97:135:151:218:226:285:289:340:351:385	0:2:4:5:5:7:8:10:11:11:12:14	25673	Annexin V	GeneOrGeneProduct	124	126	4	1:Negative_Correlation:2	R2L	NON-CROSS	139-141	134-135	D009569	nitric oxide|NO|NO|NO	ChemicalEntity	139:142:247:364	141:143:248:365	5:5:9:13	116459	neuroserpin|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP	GeneOrGeneProduct	3:53:96:134:150:217:225:284:288:339:350:384	4:54:97:135:151:218:226:285:289:340:351:385	0:2:4:5:5:7:8:10:11:11:12:14	1:Negative_Correlation:2	R2L	NON-CROSS	150-151	145-148	24835	TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	145:249:366	148:252:369	5:9:13	116459	neuroserpin|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP	GeneOrGeneProduct	3:53:96:134:150:217:225:284:288:339:350:384	4:54:97:135:151:218:226:285:289:340:351:385	0:2:4:5:5:7:8:10:11:11:12:14	1:NR:2	L2R	NON-CROSS	373-376	384-385	116459	neuroserpin|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP	GeneOrGeneProduct	3:53:96:134:150:217:225:284:288:339:350:384	4:54:97:135:151:218:226:285:289:340:351:385	0:2:4:5:5:7:8:10:11:11:12:14	309165	NF - kappaB|NF - kappaB|NF - kappaB|P65|NF - kappaB|NF - kappaB	GeneOrGeneProduct	166:198:204:268:300:373	169:201:207:269:303:376	6:7:7:10:11:13	1:NR:2	L2R	CROSS	150-151	170-173	116459	neuroserpin|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP	GeneOrGeneProduct	3:53:96:134:150:217:225:284:288:339:350:384	4:54:97:135:151:218:226:285:289:340:351:385	0:2:4:5:5:7:8:10:11:11:12:14	5594,5595	ERK1 / 2	GeneOrGeneProduct	170	173	6	1:NR:2	L2R	NON-CROSS	384-385	392-393	116459	neuroserpin|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP	GeneOrGeneProduct	3:53:96:134:150:217:225:284:288:339:350:384	4:54:97:135:151:218:226:285:289:340:351:385	0:2:4:5:5:7:8:10:11:11:12:14	298947	PI3K|PI3K	GeneOrGeneProduct	175:392	176:393	6:14	1:NR:2	L2R	NON-CROSS	384-385	394-395	116459	neuroserpin|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP	GeneOrGeneProduct	3:53:96:134:150:217:225:284:288:339:350:384	4:54:97:135:151:218:226:285:289:340:351:385	0:2:4:5:5:7:8:10:11:11:12:14	24185	Akt|AKT|Akt	GeneOrGeneProduct	177:322:394	178:323:395	6:11:14	1:Positive_Correlation:2	R2L	NON-CROSS	217-218	209-210	C118258	sc3060|sc3060	ChemicalEntity	209:305	210:306	7:11	116459	neuroserpin|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP	GeneOrGeneProduct	3:53:96:134:150:217:225:284:288:339:350:384	4:54:97:135:151:218:226:285:289:340:351:385	0:2:4:5:5:7:8:10:11:11:12:14	1:NR:2	L2R	NON-CROSS	264-267	284-285	116459	neuroserpin|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP	GeneOrGeneProduct	3:53:96:134:150:217:225:284:288:339:350:384	4:54:97:135:151:218:226:285:289:340:351:385	0:2:4:5:5:7:8:10:11:11:12:14	309361,84351	IKKBalpha / beta	GeneOrGeneProduct	264	267	10	1:NR:2	L2R	NON-CROSS	288-289	313-314	116459	neuroserpin|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP	GeneOrGeneProduct	3:53:96:134:150:217:225:284:288:339:350:384	4:54:97:135:151:218:226:285:289:340:351:385	0:2:4:5:5:7:8:10:11:11:12:14	50689	ERK1	GeneOrGeneProduct	313	314	11	1:NR:2	L2R	NON-CROSS	317-318	339-340	116459	neuroserpin|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP	GeneOrGeneProduct	3:53:96:134:150:217:225:284:288:339:350:384	4:54:97:135:151:218:226:285:289:340:351:385	0:2:4:5:5:7:8:10:11:11:12:14	116590	ERK2	GeneOrGeneProduct	317	318	11	1:NR:2	L2R	NON-CROSS	384-385	390-391	116459	neuroserpin|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP|NSP	GeneOrGeneProduct	3:53:96:134:150:217:225:284:288:339:350:384	4:54:97:135:151:218:226:285:289:340:351:385	0:2:4:5:5:7:8:10:11:11:12:14	116590,50689	MAPK	GeneOrGeneProduct	390	391	14	1:NR:2	L2R	NON-CROSS	5-6	7-8	D010100	oxygen|oxygen	ChemicalEntity	5:74	6:75	0:3	D005947	glucose|glucose	ChemicalEntity	7:76	8:77	0:3	1:NR:2	L2R	CROSS	5-6	19-20	D010100	oxygen|oxygen	ChemicalEntity	5:74	6:75	0:3	116459,5274	Neuroserpin|NSP	GeneOrGeneProduct	19:21	20:22	1:1	1:NR:2	L2R	CROSS	5-6	28-30	D010100	oxygen|oxygen	ChemicalEntity	5:74	6:75	0:3	D002545	cerebral ischemic	DiseaseOrPhenotypicFeature	28	30	1	1:NR:2	L2R	CROSS	58-59	74-75	D010100	oxygen|oxygen	ChemicalEntity	5:74	6:75	0:3	D007511	ischemic|ischemic	DiseaseOrPhenotypicFeature	58:352	59:353	2:12	1:NR:2	L2R	CROSS	74-75	106-108	D010100	oxygen|oxygen	ChemicalEntity	5:74	6:75	0:3	24533	lactate dehydrogenase|LDH|LDH	GeneOrGeneProduct	106:109:234	108:110:235	4:4:8	1:NR:2	L2R	CROSS	74-75	124-126	D010100	oxygen|oxygen	ChemicalEntity	5:74	6:75	0:3	25673	Annexin V	GeneOrGeneProduct	124	126	4	1:NR:2	L2R	CROSS	74-75	139-141	D010100	oxygen|oxygen	ChemicalEntity	5:74	6:75	0:3	D009569	nitric oxide|NO|NO|NO	ChemicalEntity	139:142:247:364	141:143:248:365	5:5:9:13	1:NR:2	L2R	CROSS	74-75	145-148	D010100	oxygen|oxygen	ChemicalEntity	5:74	6:75	0:3	24835	TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	145:249:366	148:252:369	5:9:13	1:NR:2	L2R	CROSS	74-75	166-169	D010100	oxygen|oxygen	ChemicalEntity	5:74	6:75	0:3	309165	NF - kappaB|NF - kappaB|NF - kappaB|P65|NF - kappaB|NF - kappaB	GeneOrGeneProduct	166:198:204:268:300:373	169:201:207:269:303:376	6:7:7:10:11:13	1:NR:2	L2R	CROSS	74-75	170-173	D010100	oxygen|oxygen	ChemicalEntity	5:74	6:75	0:3	5594,5595	ERK1 / 2	GeneOrGeneProduct	170	173	6	1:NR:2	L2R	CROSS	74-75	175-176	D010100	oxygen|oxygen	ChemicalEntity	5:74	6:75	0:3	298947	PI3K|PI3K	GeneOrGeneProduct	175:392	176:393	6:14	1:NR:2	L2R	CROSS	74-75	177-178	D010100	oxygen|oxygen	ChemicalEntity	5:74	6:75	0:3	24185	Akt|AKT|Akt	GeneOrGeneProduct	177:322:394	178:323:395	6:11:14	1:NR:2	L2R	CROSS	74-75	209-210	D010100	oxygen|oxygen	ChemicalEntity	5:74	6:75	0:3	C118258	sc3060|sc3060	ChemicalEntity	209:305	210:306	7:11	1:NR:2	L2R	CROSS	74-75	264-267	D010100	oxygen|oxygen	ChemicalEntity	5:74	6:75	0:3	309361,84351	IKKBalpha / beta	GeneOrGeneProduct	264	267	10	1:NR:2	L2R	CROSS	74-75	313-314	D010100	oxygen|oxygen	ChemicalEntity	5:74	6:75	0:3	50689	ERK1	GeneOrGeneProduct	313	314	11	1:NR:2	L2R	CROSS	74-75	317-318	D010100	oxygen|oxygen	ChemicalEntity	5:74	6:75	0:3	116590	ERK2	GeneOrGeneProduct	317	318	11	1:NR:2	L2R	CROSS	74-75	390-391	D010100	oxygen|oxygen	ChemicalEntity	5:74	6:75	0:3	116590,50689	MAPK	GeneOrGeneProduct	390	391	14	1:NR:2	L2R	CROSS	7-8	19-20	D005947	glucose|glucose	ChemicalEntity	7:76	8:77	0:3	116459,5274	Neuroserpin|NSP	GeneOrGeneProduct	19:21	20:22	1:1	1:NR:2	L2R	CROSS	7-8	28-30	D005947	glucose|glucose	ChemicalEntity	7:76	8:77	0:3	D002545	cerebral ischemic	DiseaseOrPhenotypicFeature	28	30	1	1:NR:2	L2R	CROSS	58-59	76-77	D005947	glucose|glucose	ChemicalEntity	7:76	8:77	0:3	D007511	ischemic|ischemic	DiseaseOrPhenotypicFeature	58:352	59:353	2:12	1:NR:2	L2R	CROSS	76-77	106-108	D005947	glucose|glucose	ChemicalEntity	7:76	8:77	0:3	24533	lactate dehydrogenase|LDH|LDH	GeneOrGeneProduct	106:109:234	108:110:235	4:4:8	1:NR:2	L2R	CROSS	76-77	124-126	D005947	glucose|glucose	ChemicalEntity	7:76	8:77	0:3	25673	Annexin V	GeneOrGeneProduct	124	126	4	1:NR:2	L2R	CROSS	76-77	139-141	D005947	glucose|glucose	ChemicalEntity	7:76	8:77	0:3	D009569	nitric oxide|NO|NO|NO	ChemicalEntity	139:142:247:364	141:143:248:365	5:5:9:13	1:NR:2	L2R	CROSS	76-77	145-148	D005947	glucose|glucose	ChemicalEntity	7:76	8:77	0:3	24835	TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	145:249:366	148:252:369	5:9:13	1:NR:2	L2R	CROSS	76-77	166-169	D005947	glucose|glucose	ChemicalEntity	7:76	8:77	0:3	309165	NF - kappaB|NF - kappaB|NF - kappaB|P65|NF - kappaB|NF - kappaB	GeneOrGeneProduct	166:198:204:268:300:373	169:201:207:269:303:376	6:7:7:10:11:13	1:NR:2	L2R	CROSS	76-77	170-173	D005947	glucose|glucose	ChemicalEntity	7:76	8:77	0:3	5594,5595	ERK1 / 2	GeneOrGeneProduct	170	173	6	1:NR:2	L2R	CROSS	76-77	175-176	D005947	glucose|glucose	ChemicalEntity	7:76	8:77	0:3	298947	PI3K|PI3K	GeneOrGeneProduct	175:392	176:393	6:14	1:NR:2	L2R	CROSS	76-77	177-178	D005947	glucose|glucose	ChemicalEntity	7:76	8:77	0:3	24185	Akt|AKT|Akt	GeneOrGeneProduct	177:322:394	178:323:395	6:11:14	1:NR:2	L2R	CROSS	76-77	209-210	D005947	glucose|glucose	ChemicalEntity	7:76	8:77	0:3	C118258	sc3060|sc3060	ChemicalEntity	209:305	210:306	7:11	1:NR:2	L2R	CROSS	76-77	264-267	D005947	glucose|glucose	ChemicalEntity	7:76	8:77	0:3	309361,84351	IKKBalpha / beta	GeneOrGeneProduct	264	267	10	1:NR:2	L2R	CROSS	76-77	313-314	D005947	glucose|glucose	ChemicalEntity	7:76	8:77	0:3	50689	ERK1	GeneOrGeneProduct	313	314	11	1:NR:2	L2R	CROSS	76-77	317-318	D005947	glucose|glucose	ChemicalEntity	7:76	8:77	0:3	116590	ERK2	GeneOrGeneProduct	317	318	11	1:NR:2	L2R	CROSS	76-77	390-391	D005947	glucose|glucose	ChemicalEntity	7:76	8:77	0:3	116590,50689	MAPK	GeneOrGeneProduct	390	391	14	1:NR:2	L2R	NON-CROSS	21-22	28-30	116459,5274	Neuroserpin|NSP	GeneOrGeneProduct	19:21	20:22	1:1	D002545	cerebral ischemic	DiseaseOrPhenotypicFeature	28	30	1	1:NR:2	L2R	CROSS	21-22	58-59	116459,5274	Neuroserpin|NSP	GeneOrGeneProduct	19:21	20:22	1:1	D007511	ischemic|ischemic	DiseaseOrPhenotypicFeature	58:352	59:353	2:12	1:NR:2	L2R	CROSS	21-22	106-108	116459,5274	Neuroserpin|NSP	GeneOrGeneProduct	19:21	20:22	1:1	24533	lactate dehydrogenase|LDH|LDH	GeneOrGeneProduct	106:109:234	108:110:235	4:4:8	1:NR:2	L2R	CROSS	21-22	124-126	116459,5274	Neuroserpin|NSP	GeneOrGeneProduct	19:21	20:22	1:1	25673	Annexin V	GeneOrGeneProduct	124	126	4	1:NR:2	L2R	CROSS	21-22	139-141	116459,5274	Neuroserpin|NSP	GeneOrGeneProduct	19:21	20:22	1:1	D009569	nitric oxide|NO|NO|NO	ChemicalEntity	139:142:247:364	141:143:248:365	5:5:9:13	1:NR:2	L2R	CROSS	21-22	145-148	116459,5274	Neuroserpin|NSP	GeneOrGeneProduct	19:21	20:22	1:1	24835	TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	145:249:366	148:252:369	5:9:13	1:NR:2	L2R	CROSS	21-22	166-169	116459,5274	Neuroserpin|NSP	GeneOrGeneProduct	19:21	20:22	1:1	309165	NF - kappaB|NF - kappaB|NF - kappaB|P65|NF - kappaB|NF - kappaB	GeneOrGeneProduct	166:198:204:268:300:373	169:201:207:269:303:376	6:7:7:10:11:13	1:NR:2	L2R	CROSS	21-22	170-173	116459,5274	Neuroserpin|NSP	GeneOrGeneProduct	19:21	20:22	1:1	5594,5595	ERK1 / 2	GeneOrGeneProduct	170	173	6	1:NR:2	L2R	CROSS	21-22	175-176	116459,5274	Neuroserpin|NSP	GeneOrGeneProduct	19:21	20:22	1:1	298947	PI3K|PI3K	GeneOrGeneProduct	175:392	176:393	6:14	1:NR:2	L2R	CROSS	21-22	177-178	116459,5274	Neuroserpin|NSP	GeneOrGeneProduct	19:21	20:22	1:1	24185	Akt|AKT|Akt	GeneOrGeneProduct	177:322:394	178:323:395	6:11:14	1:NR:2	L2R	CROSS	21-22	209-210	116459,5274	Neuroserpin|NSP	GeneOrGeneProduct	19:21	20:22	1:1	C118258	sc3060|sc3060	ChemicalEntity	209:305	210:306	7:11	1:NR:2	L2R	CROSS	21-22	264-267	116459,5274	Neuroserpin|NSP	GeneOrGeneProduct	19:21	20:22	1:1	309361,84351	IKKBalpha / beta	GeneOrGeneProduct	264	267	10	1:NR:2	L2R	CROSS	21-22	313-314	116459,5274	Neuroserpin|NSP	GeneOrGeneProduct	19:21	20:22	1:1	50689	ERK1	GeneOrGeneProduct	313	314	11	1:NR:2	L2R	CROSS	21-22	317-318	116459,5274	Neuroserpin|NSP	GeneOrGeneProduct	19:21	20:22	1:1	116590	ERK2	GeneOrGeneProduct	317	318	11	1:NR:2	L2R	CROSS	21-22	390-391	116459,5274	Neuroserpin|NSP	GeneOrGeneProduct	19:21	20:22	1:1	116590,50689	MAPK	GeneOrGeneProduct	390	391	14	1:NR:2	L2R	CROSS	28-30	106-108	D002545	cerebral ischemic	DiseaseOrPhenotypicFeature	28	30	1	24533	lactate dehydrogenase|LDH|LDH	GeneOrGeneProduct	106:109:234	108:110:235	4:4:8	1:NR:2	L2R	CROSS	28-30	124-126	D002545	cerebral ischemic	DiseaseOrPhenotypicFeature	28	30	1	25673	Annexin V	GeneOrGeneProduct	124	126	4	1:NR:2	L2R	CROSS	28-30	139-141	D002545	cerebral ischemic	DiseaseOrPhenotypicFeature	28	30	1	D009569	nitric oxide|NO|NO|NO	ChemicalEntity	139:142:247:364	141:143:248:365	5:5:9:13	1:NR:2	L2R	CROSS	28-30	145-148	D002545	cerebral ischemic	DiseaseOrPhenotypicFeature	28	30	1	24835	TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	145:249:366	148:252:369	5:9:13	1:NR:2	L2R	CROSS	28-30	166-169	D002545	cerebral ischemic	DiseaseOrPhenotypicFeature	28	30	1	309165	NF - kappaB|NF - kappaB|NF - kappaB|P65|NF - kappaB|NF - kappaB	GeneOrGeneProduct	166:198:204:268:300:373	169:201:207:269:303:376	6:7:7:10:11:13	1:NR:2	L2R	CROSS	28-30	170-173	D002545	cerebral ischemic	DiseaseOrPhenotypicFeature	28	30	1	5594,5595	ERK1 / 2	GeneOrGeneProduct	170	173	6	1:NR:2	L2R	CROSS	28-30	175-176	D002545	cerebral ischemic	DiseaseOrPhenotypicFeature	28	30	1	298947	PI3K|PI3K	GeneOrGeneProduct	175:392	176:393	6:14	1:NR:2	L2R	CROSS	28-30	177-178	D002545	cerebral ischemic	DiseaseOrPhenotypicFeature	28	30	1	24185	Akt|AKT|Akt	GeneOrGeneProduct	177:322:394	178:323:395	6:11:14	1:NR:2	L2R	CROSS	28-30	209-210	D002545	cerebral ischemic	DiseaseOrPhenotypicFeature	28	30	1	C118258	sc3060|sc3060	ChemicalEntity	209:305	210:306	7:11	1:NR:2	L2R	CROSS	28-30	264-267	D002545	cerebral ischemic	DiseaseOrPhenotypicFeature	28	30	1	309361,84351	IKKBalpha / beta	GeneOrGeneProduct	264	267	10	1:NR:2	L2R	CROSS	28-30	313-314	D002545	cerebral ischemic	DiseaseOrPhenotypicFeature	28	30	1	50689	ERK1	GeneOrGeneProduct	313	314	11	1:NR:2	L2R	CROSS	28-30	317-318	D002545	cerebral ischemic	DiseaseOrPhenotypicFeature	28	30	1	116590	ERK2	GeneOrGeneProduct	317	318	11	1:NR:2	L2R	CROSS	28-30	390-391	D002545	cerebral ischemic	DiseaseOrPhenotypicFeature	28	30	1	116590,50689	MAPK	GeneOrGeneProduct	390	391	14	1:NR:2	L2R	CROSS	58-59	106-108	D007511	ischemic|ischemic	DiseaseOrPhenotypicFeature	58:352	59:353	2:12	24533	lactate dehydrogenase|LDH|LDH	GeneOrGeneProduct	106:109:234	108:110:235	4:4:8	1:NR:2	L2R	CROSS	58-59	124-126	D007511	ischemic|ischemic	DiseaseOrPhenotypicFeature	58:352	59:353	2:12	25673	Annexin V	GeneOrGeneProduct	124	126	4	1:NR:2	L2R	CROSS	352-353	364-365	D007511	ischemic|ischemic	DiseaseOrPhenotypicFeature	58:352	59:353	2:12	D009569	nitric oxide|NO|NO|NO	ChemicalEntity	139:142:247:364	141:143:248:365	5:5:9:13	1:NR:2	L2R	CROSS	352-353	366-369	D007511	ischemic|ischemic	DiseaseOrPhenotypicFeature	58:352	59:353	2:12	24835	TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	145:249:366	148:252:369	5:9:13	1:NR:2	L2R	CROSS	352-353	373-376	D007511	ischemic|ischemic	DiseaseOrPhenotypicFeature	58:352	59:353	2:12	309165	NF - kappaB|NF - kappaB|NF - kappaB|P65|NF - kappaB|NF - kappaB	GeneOrGeneProduct	166:198:204:268:300:373	169:201:207:269:303:376	6:7:7:10:11:13	1:NR:2	L2R	CROSS	58-59	170-173	D007511	ischemic|ischemic	DiseaseOrPhenotypicFeature	58:352	59:353	2:12	5594,5595	ERK1 / 2	GeneOrGeneProduct	170	173	6	1:NR:2	L2R	CROSS	352-353	392-393	D007511	ischemic|ischemic	DiseaseOrPhenotypicFeature	58:352	59:353	2:12	298947	PI3K|PI3K	GeneOrGeneProduct	175:392	176:393	6:14	1:NR:2	L2R	CROSS	322-323	352-353	D007511	ischemic|ischemic	DiseaseOrPhenotypicFeature	58:352	59:353	2:12	24185	Akt|AKT|Akt	GeneOrGeneProduct	177:322:394	178:323:395	6:11:14	1:NR:2	L2R	CROSS	305-306	352-353	D007511	ischemic|ischemic	DiseaseOrPhenotypicFeature	58:352	59:353	2:12	C118258	sc3060|sc3060	ChemicalEntity	209:305	210:306	7:11	1:NR:2	L2R	CROSS	264-267	352-353	D007511	ischemic|ischemic	DiseaseOrPhenotypicFeature	58:352	59:353	2:12	309361,84351	IKKBalpha / beta	GeneOrGeneProduct	264	267	10	1:NR:2	L2R	CROSS	313-314	352-353	D007511	ischemic|ischemic	DiseaseOrPhenotypicFeature	58:352	59:353	2:12	50689	ERK1	GeneOrGeneProduct	313	314	11	1:NR:2	L2R	CROSS	317-318	352-353	D007511	ischemic|ischemic	DiseaseOrPhenotypicFeature	58:352	59:353	2:12	116590	ERK2	GeneOrGeneProduct	317	318	11	1:NR:2	L2R	CROSS	352-353	390-391	D007511	ischemic|ischemic	DiseaseOrPhenotypicFeature	58:352	59:353	2:12	116590,50689	MAPK	GeneOrGeneProduct	390	391	14	1:NR:2	L2R	NON-CROSS	109-110	124-126	24533	lactate dehydrogenase|LDH|LDH	GeneOrGeneProduct	106:109:234	108:110:235	4:4:8	25673	Annexin V	GeneOrGeneProduct	124	126	4	1:NR:2	L2R	CROSS	234-235	247-248	24533	lactate dehydrogenase|LDH|LDH	GeneOrGeneProduct	106:109:234	108:110:235	4:4:8	D009569	nitric oxide|NO|NO|NO	ChemicalEntity	139:142:247:364	141:143:248:365	5:5:9:13	1:NR:2	L2R	CROSS	234-235	249-252	24533	lactate dehydrogenase|LDH|LDH	GeneOrGeneProduct	106:109:234	108:110:235	4:4:8	24835	TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	145:249:366	148:252:369	5:9:13	1:NR:2	L2R	CROSS	204-207	234-235	24533	lactate dehydrogenase|LDH|LDH	GeneOrGeneProduct	106:109:234	108:110:235	4:4:8	309165	NF - kappaB|NF - kappaB|NF - kappaB|P65|NF - kappaB|NF - kappaB	GeneOrGeneProduct	166:198:204:268:300:373	169:201:207:269:303:376	6:7:7:10:11:13	1:NR:2	L2R	CROSS	109-110	170-173	24533	lactate dehydrogenase|LDH|LDH	GeneOrGeneProduct	106:109:234	108:110:235	4:4:8	5594,5595	ERK1 / 2	GeneOrGeneProduct	170	173	6	1:NR:2	L2R	CROSS	175-176	234-235	24533	lactate dehydrogenase|LDH|LDH	GeneOrGeneProduct	106:109:234	108:110:235	4:4:8	298947	PI3K|PI3K	GeneOrGeneProduct	175:392	176:393	6:14	1:NR:2	L2R	CROSS	177-178	234-235	24533	lactate dehydrogenase|LDH|LDH	GeneOrGeneProduct	106:109:234	108:110:235	4:4:8	24185	Akt|AKT|Akt	GeneOrGeneProduct	177:322:394	178:323:395	6:11:14	1:NR:2	L2R	CROSS	209-210	234-235	24533	lactate dehydrogenase|LDH|LDH	GeneOrGeneProduct	106:109:234	108:110:235	4:4:8	C118258	sc3060|sc3060	ChemicalEntity	209:305	210:306	7:11	1:NR:2	L2R	CROSS	234-235	264-267	24533	lactate dehydrogenase|LDH|LDH	GeneOrGeneProduct	106:109:234	108:110:235	4:4:8	309361,84351	IKKBalpha / beta	GeneOrGeneProduct	264	267	10	1:NR:2	L2R	CROSS	234-235	313-314	24533	lactate dehydrogenase|LDH|LDH	GeneOrGeneProduct	106:109:234	108:110:235	4:4:8	50689	ERK1	GeneOrGeneProduct	313	314	11	1:NR:2	L2R	CROSS	234-235	317-318	24533	lactate dehydrogenase|LDH|LDH	GeneOrGeneProduct	106:109:234	108:110:235	4:4:8	116590	ERK2	GeneOrGeneProduct	317	318	11	1:NR:2	L2R	CROSS	234-235	390-391	24533	lactate dehydrogenase|LDH|LDH	GeneOrGeneProduct	106:109:234	108:110:235	4:4:8	116590,50689	MAPK	GeneOrGeneProduct	390	391	14	1:NR:2	L2R	CROSS	124-126	139-141	25673	Annexin V	GeneOrGeneProduct	124	126	4	D009569	nitric oxide|NO|NO|NO	ChemicalEntity	139:142:247:364	141:143:248:365	5:5:9:13	1:NR:2	L2R	CROSS	124-126	145-148	25673	Annexin V	GeneOrGeneProduct	124	126	4	24835	TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	145:249:366	148:252:369	5:9:13	1:NR:2	L2R	CROSS	124-126	166-169	25673	Annexin V	GeneOrGeneProduct	124	126	4	309165	NF - kappaB|NF - kappaB|NF - kappaB|P65|NF - kappaB|NF - kappaB	GeneOrGeneProduct	166:198:204:268:300:373	169:201:207:269:303:376	6:7:7:10:11:13	1:NR:2	L2R	CROSS	124-126	170-173	25673	Annexin V	GeneOrGeneProduct	124	126	4	5594,5595	ERK1 / 2	GeneOrGeneProduct	170	173	6	1:NR:2	L2R	CROSS	124-126	175-176	25673	Annexin V	GeneOrGeneProduct	124	126	4	298947	PI3K|PI3K	GeneOrGeneProduct	175:392	176:393	6:14	1:NR:2	L2R	CROSS	124-126	177-178	25673	Annexin V	GeneOrGeneProduct	124	126	4	24185	Akt|AKT|Akt	GeneOrGeneProduct	177:322:394	178:323:395	6:11:14	1:NR:2	L2R	CROSS	124-126	209-210	25673	Annexin V	GeneOrGeneProduct	124	126	4	C118258	sc3060|sc3060	ChemicalEntity	209:305	210:306	7:11	1:NR:2	L2R	CROSS	124-126	264-267	25673	Annexin V	GeneOrGeneProduct	124	126	4	309361,84351	IKKBalpha / beta	GeneOrGeneProduct	264	267	10	1:NR:2	L2R	CROSS	124-126	313-314	25673	Annexin V	GeneOrGeneProduct	124	126	4	50689	ERK1	GeneOrGeneProduct	313	314	11	1:NR:2	L2R	CROSS	124-126	317-318	25673	Annexin V	GeneOrGeneProduct	124	126	4	116590	ERK2	GeneOrGeneProduct	317	318	11	1:NR:2	L2R	CROSS	124-126	390-391	25673	Annexin V	GeneOrGeneProduct	124	126	4	116590,50689	MAPK	GeneOrGeneProduct	390	391	14	1:NR:2	L2R	NON-CROSS	247-248	249-252	D009569	nitric oxide|NO|NO|NO	ChemicalEntity	139:142:247:364	141:143:248:365	5:5:9:13	24835	TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	145:249:366	148:252:369	5:9:13	1:NR:2	L2R	NON-CROSS	364-365	373-376	D009569	nitric oxide|NO|NO|NO	ChemicalEntity	139:142:247:364	141:143:248:365	5:5:9:13	309165	NF - kappaB|NF - kappaB|NF - kappaB|P65|NF - kappaB|NF - kappaB	GeneOrGeneProduct	166:198:204:268:300:373	169:201:207:269:303:376	6:7:7:10:11:13	1:NR:2	L2R	CROSS	142-143	170-173	D009569	nitric oxide|NO|NO|NO	ChemicalEntity	139:142:247:364	141:143:248:365	5:5:9:13	5594,5595	ERK1 / 2	GeneOrGeneProduct	170	173	6	1:NR:2	L2R	CROSS	364-365	392-393	D009569	nitric oxide|NO|NO|NO	ChemicalEntity	139:142:247:364	141:143:248:365	5:5:9:13	298947	PI3K|PI3K	GeneOrGeneProduct	175:392	176:393	6:14	1:NR:2	L2R	CROSS	364-365	394-395	D009569	nitric oxide|NO|NO|NO	ChemicalEntity	139:142:247:364	141:143:248:365	5:5:9:13	24185	Akt|AKT|Akt	GeneOrGeneProduct	177:322:394	178:323:395	6:11:14	1:NR:2	L2R	CROSS	209-210	247-248	D009569	nitric oxide|NO|NO|NO	ChemicalEntity	139:142:247:364	141:143:248:365	5:5:9:13	C118258	sc3060|sc3060	ChemicalEntity	209:305	210:306	7:11	1:NR:2	L2R	CROSS	247-248	264-267	D009569	nitric oxide|NO|NO|NO	ChemicalEntity	139:142:247:364	141:143:248:365	5:5:9:13	309361,84351	IKKBalpha / beta	GeneOrGeneProduct	264	267	10	1:NR:2	L2R	CROSS	313-314	364-365	D009569	nitric oxide|NO|NO|NO	ChemicalEntity	139:142:247:364	141:143:248:365	5:5:9:13	50689	ERK1	GeneOrGeneProduct	313	314	11	1:NR:2	L2R	CROSS	317-318	364-365	D009569	nitric oxide|NO|NO|NO	ChemicalEntity	139:142:247:364	141:143:248:365	5:5:9:13	116590	ERK2	GeneOrGeneProduct	317	318	11	1:NR:2	L2R	CROSS	364-365	390-391	D009569	nitric oxide|NO|NO|NO	ChemicalEntity	139:142:247:364	141:143:248:365	5:5:9:13	116590,50689	MAPK	GeneOrGeneProduct	390	391	14	1:NR:2	L2R	NON-CROSS	366-369	373-376	24835	TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	145:249:366	148:252:369	5:9:13	309165	NF - kappaB|NF - kappaB|NF - kappaB|P65|NF - kappaB|NF - kappaB	GeneOrGeneProduct	166:198:204:268:300:373	169:201:207:269:303:376	6:7:7:10:11:13	1:NR:2	L2R	CROSS	145-148	170-173	24835	TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	145:249:366	148:252:369	5:9:13	5594,5595	ERK1 / 2	GeneOrGeneProduct	170	173	6	1:NR:2	L2R	CROSS	366-369	392-393	24835	TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	145:249:366	148:252:369	5:9:13	298947	PI3K|PI3K	GeneOrGeneProduct	175:392	176:393	6:14	1:NR:2	L2R	CROSS	366-369	394-395	24835	TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	145:249:366	148:252:369	5:9:13	24185	Akt|AKT|Akt	GeneOrGeneProduct	177:322:394	178:323:395	6:11:14	1:NR:2	L2R	CROSS	209-210	249-252	24835	TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	145:249:366	148:252:369	5:9:13	C118258	sc3060|sc3060	ChemicalEntity	209:305	210:306	7:11	1:NR:2	L2R	CROSS	249-252	264-267	24835	TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	145:249:366	148:252:369	5:9:13	309361,84351	IKKBalpha / beta	GeneOrGeneProduct	264	267	10	1:NR:2	L2R	CROSS	313-314	366-369	24835	TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	145:249:366	148:252:369	5:9:13	50689	ERK1	GeneOrGeneProduct	313	314	11	1:NR:2	L2R	CROSS	317-318	366-369	24835	TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	145:249:366	148:252:369	5:9:13	116590	ERK2	GeneOrGeneProduct	317	318	11	1:NR:2	L2R	CROSS	366-369	390-391	24835	TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	145:249:366	148:252:369	5:9:13	116590,50689	MAPK	GeneOrGeneProduct	390	391	14	1:NR:2	L2R	NON-CROSS	166-169	170-173	309165	NF - kappaB|NF - kappaB|NF - kappaB|P65|NF - kappaB|NF - kappaB	GeneOrGeneProduct	166:198:204:268:300:373	169:201:207:269:303:376	6:7:7:10:11:13	5594,5595	ERK1 / 2	GeneOrGeneProduct	170	173	6	1:NR:2	L2R	NON-CROSS	166-169	175-176	309165	NF - kappaB|NF - kappaB|NF - kappaB|P65|NF - kappaB|NF - kappaB	GeneOrGeneProduct	166:198:204:268:300:373	169:201:207:269:303:376	6:7:7:10:11:13	298947	PI3K|PI3K	GeneOrGeneProduct	175:392	176:393	6:14	1:NR:2	L2R	NON-CROSS	166-169	177-178	309165	NF - kappaB|NF - kappaB|NF - kappaB|P65|NF - kappaB|NF - kappaB	GeneOrGeneProduct	166:198:204:268:300:373	169:201:207:269:303:376	6:7:7:10:11:13	24185	Akt|AKT|Akt	GeneOrGeneProduct	177:322:394	178:323:395	6:11:14	1:Negative_Correlation:2	L2R	NON-CROSS	204-207	209-210	309165	NF - kappaB|NF - kappaB|NF - kappaB|P65|NF - kappaB|NF - kappaB	GeneOrGeneProduct	166:198:204:268:300:373	169:201:207:269:303:376	6:7:7:10:11:13	C118258	sc3060|sc3060	ChemicalEntity	209:305	210:306	7:11	1:NR:2	L2R	NON-CROSS	264-267	268-269	309165	NF - kappaB|NF - kappaB|NF - kappaB|P65|NF - kappaB|NF - kappaB	GeneOrGeneProduct	166:198:204:268:300:373	169:201:207:269:303:376	6:7:7:10:11:13	309361,84351	IKKBalpha / beta	GeneOrGeneProduct	264	267	10	1:NR:2	L2R	NON-CROSS	300-303	313-314	309165	NF - kappaB|NF - kappaB|NF - kappaB|P65|NF - kappaB|NF - kappaB	GeneOrGeneProduct	166:198:204:268:300:373	169:201:207:269:303:376	6:7:7:10:11:13	50689	ERK1	GeneOrGeneProduct	313	314	11	1:NR:2	L2R	NON-CROSS	300-303	317-318	309165	NF - kappaB|NF - kappaB|NF - kappaB|P65|NF - kappaB|NF - kappaB	GeneOrGeneProduct	166:198:204:268:300:373	169:201:207:269:303:376	6:7:7:10:11:13	116590	ERK2	GeneOrGeneProduct	317	318	11	1:NR:2	L2R	CROSS	373-376	390-391	309165	NF - kappaB|NF - kappaB|NF - kappaB|P65|NF - kappaB|NF - kappaB	GeneOrGeneProduct	166:198:204:268:300:373	169:201:207:269:303:376	6:7:7:10:11:13	116590,50689	MAPK	GeneOrGeneProduct	390	391	14	1:NR:2	L2R	NON-CROSS	170-173	175-176	5594,5595	ERK1 / 2	GeneOrGeneProduct	170	173	6	298947	PI3K|PI3K	GeneOrGeneProduct	175:392	176:393	6:14	1:NR:2	L2R	NON-CROSS	170-173	177-178	5594,5595	ERK1 / 2	GeneOrGeneProduct	170	173	6	24185	Akt|AKT|Akt	GeneOrGeneProduct	177:322:394	178:323:395	6:11:14	1:NR:2	L2R	CROSS	170-173	209-210	5594,5595	ERK1 / 2	GeneOrGeneProduct	170	173	6	C118258	sc3060|sc3060	ChemicalEntity	209:305	210:306	7:11	1:NR:2	L2R	CROSS	170-173	264-267	5594,5595	ERK1 / 2	GeneOrGeneProduct	170	173	6	309361,84351	IKKBalpha / beta	GeneOrGeneProduct	264	267	10	1:NR:2	L2R	CROSS	170-173	313-314	5594,5595	ERK1 / 2	GeneOrGeneProduct	170	173	6	50689	ERK1	GeneOrGeneProduct	313	314	11	1:NR:2	L2R	CROSS	170-173	317-318	5594,5595	ERK1 / 2	GeneOrGeneProduct	170	173	6	116590	ERK2	GeneOrGeneProduct	317	318	11	1:NR:2	L2R	CROSS	170-173	390-391	5594,5595	ERK1 / 2	GeneOrGeneProduct	170	173	6	116590,50689	MAPK	GeneOrGeneProduct	390	391	14	1:NR:2	L2R	NON-CROSS	175-176	177-178	298947	PI3K|PI3K	GeneOrGeneProduct	175:392	176:393	6:14	24185	Akt|AKT|Akt	GeneOrGeneProduct	177:322:394	178:323:395	6:11:14	1:NR:2	L2R	CROSS	175-176	209-210	298947	PI3K|PI3K	GeneOrGeneProduct	175:392	176:393	6:14	C118258	sc3060|sc3060	ChemicalEntity	209:305	210:306	7:11	1:NR:2	L2R	CROSS	175-176	264-267	298947	PI3K|PI3K	GeneOrGeneProduct	175:392	176:393	6:14	309361,84351	IKKBalpha / beta	GeneOrGeneProduct	264	267	10	1:NR:2	L2R	CROSS	313-314	392-393	298947	PI3K|PI3K	GeneOrGeneProduct	175:392	176:393	6:14	50689	ERK1	GeneOrGeneProduct	313	314	11	1:NR:2	L2R	CROSS	317-318	392-393	298947	PI3K|PI3K	GeneOrGeneProduct	175:392	176:393	6:14	116590	ERK2	GeneOrGeneProduct	317	318	11	1:NR:2	L2R	NON-CROSS	390-391	392-393	298947	PI3K|PI3K	GeneOrGeneProduct	175:392	176:393	6:14	116590,50689	MAPK	GeneOrGeneProduct	390	391	14	1:NR:2	L2R	NON-CROSS	305-306	322-323	24185	Akt|AKT|Akt	GeneOrGeneProduct	177:322:394	178:323:395	6:11:14	C118258	sc3060|sc3060	ChemicalEntity	209:305	210:306	7:11	1:NR:2	L2R	CROSS	264-267	322-323	24185	Akt|AKT|Akt	GeneOrGeneProduct	177:322:394	178:323:395	6:11:14	309361,84351	IKKBalpha / beta	GeneOrGeneProduct	264	267	10	1:NR:2	L2R	NON-CROSS	313-314	322-323	24185	Akt|AKT|Akt	GeneOrGeneProduct	177:322:394	178:323:395	6:11:14	50689	ERK1	GeneOrGeneProduct	313	314	11	1:NR:2	L2R	NON-CROSS	317-318	322-323	24185	Akt|AKT|Akt	GeneOrGeneProduct	177:322:394	178:323:395	6:11:14	116590	ERK2	GeneOrGeneProduct	317	318	11	1:NR:2	L2R	NON-CROSS	390-391	394-395	24185	Akt|AKT|Akt	GeneOrGeneProduct	177:322:394	178:323:395	6:11:14	116590,50689	MAPK	GeneOrGeneProduct	390	391	14	1:NR:2	L2R	CROSS	264-267	305-306	C118258	sc3060|sc3060	ChemicalEntity	209:305	210:306	7:11	309361,84351	IKKBalpha / beta	GeneOrGeneProduct	264	267	10	1:NR:2	L2R	NON-CROSS	305-306	313-314	C118258	sc3060|sc3060	ChemicalEntity	209:305	210:306	7:11	50689	ERK1	GeneOrGeneProduct	313	314	11	1:NR:2	L2R	NON-CROSS	305-306	317-318	C118258	sc3060|sc3060	ChemicalEntity	209:305	210:306	7:11	116590	ERK2	GeneOrGeneProduct	317	318	11	1:NR:2	L2R	CROSS	305-306	390-391	C118258	sc3060|sc3060	ChemicalEntity	209:305	210:306	7:11	116590,50689	MAPK	GeneOrGeneProduct	390	391	14	1:NR:2	L2R	CROSS	264-267	313-314	309361,84351	IKKBalpha / beta	GeneOrGeneProduct	264	267	10	50689	ERK1	GeneOrGeneProduct	313	314	11	1:NR:2	L2R	CROSS	264-267	317-318	309361,84351	IKKBalpha / beta	GeneOrGeneProduct	264	267	10	116590	ERK2	GeneOrGeneProduct	317	318	11	1:NR:2	L2R	CROSS	264-267	390-391	309361,84351	IKKBalpha / beta	GeneOrGeneProduct	264	267	10	116590,50689	MAPK	GeneOrGeneProduct	390	391	14	1:NR:2	L2R	NON-CROSS	313-314	317-318	50689	ERK1	GeneOrGeneProduct	313	314	11	116590	ERK2	GeneOrGeneProduct	317	318	11	1:NR:2	L2R	CROSS	313-314	390-391	50689	ERK1	GeneOrGeneProduct	313	314	11	116590,50689	MAPK	GeneOrGeneProduct	390	391	14	1:NR:2	L2R	CROSS	317-318	390-391	116590	ERK2	GeneOrGeneProduct	317	318	11	116590,50689	MAPK	GeneOrGeneProduct	390	391	14
28846666	Interleukin 6 ( IL - 6 ) and Tumor Necrosis Factor alpha ( TNF - alpha ) Single Nucleotide Polymorphisms ( SNPs ) , Inflammation and Metabolism in Gestational Diabetes Mellitus in Inner Mongolia .|BACKGROUND Gestational diabetes mellitus ( GDM ) is common all over the world .|GDM women are with inflammatory and metabolisms abnormalities .|However , few studies have focused on the association of IL - 65 - 72C / G and TNF - alpha - 857C / T single nucleotide polymorphisms ( SNPs ) , inflammatory biomarkers , and metabolic indexes in women with GDM , especially in the Inner Mongolia population .|The aim of this study was to investigate the associations of IL - 65 - 72C / G and TNF - alpha - 857C / T SNPs , and inflammation and metabolic biomarkers in women with GDM pregnancies .|MATERIAL AND METHODS Blood samples and placentas from 140 women with GDM and 140 women with healthy pregnancies were collected .|Matrix - assisted laser desorption ionization time of flight mass spectrometry ( MALDI - TOF - MS ) and MassARRAY - IPLEX were performed to analyze IL - 65 - 72C / G and TNF - alpha - 857C / T SNPs .|Enzyme linked immunosorbent assay ( ELISA ) was performed to analyze inflammatory biomarkers and adipokines .|RESULTS Distribution frequency of TNF - alpha - 857CT ( OR = 3 . 316 , 95 % CI = 1 . 092 - 8 . 304 , p = 0 . 025 ) in women with GDM pregnancies were obviously higher than that in women with healthy pregnancies .|Women with GDM were of older maternal age , had higher BMI , were more nulliparous , and had T2DM and GDM history , compared to women with healthy pregnancies ( p < 0 . 05 ) .|Inflammatory biomarkers in serum ( hs - CRP , IL - 6 , IL - 8 , IL - 6 / IL - 10 ratio ) and placental ( NF - kappaB , IL - 6 , IL - 8 , IL - 6 / IL - 10 ratio , IL - 1b , TNF - alpha ) were significantly different ( p < 0 . 05 ) between women with GDM and women with healthy pregnancies .|Differences were found for serum FBG , FINS , HOMA - IR , and HOMA - beta , and placental IRS - 1 , IRS - 2 , leptin , adiponectin , visfatin , RBP - 4 , chemerin , nesfatin - 1 , FATP - 4 , EL , LPL , FABP - 1 , FABP - 3 , FABP - 4 , and FABP - 5 .|CONCLUSIONS TNF - alpha - 857C / T SNP , hs - CRP , IL - 6 , IL - 8 , and IL - 6 / IL - 10 were associated with GDM in women from Inner Mongolia , as was serious inflammation and disordered lipid and glucose metabolisms .	1:NR:2	L2R	NON-CROSS	3-6	8-12	3569	Interleukin 6|IL - 6|IL - 65|IL - 65|IL - 65|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6	GeneOrGeneProduct	0:3:68:119:194:324:332:348:356:476:485	2:6:71:122:197:327:335:351:359:479:488	0:0:3:4:6:10:10:10:10:12:12	7124	Tumor Necrosis Factor alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	8:13:76:127:202:231:369:463	12:16:79:130:205:234:372:466	0:0:3:4:6:8:10:12	1:Association:2	R2L	NON-CROSS	324-327	315-316	D007249	Inflammation|inflammatory|inflammatory|inflammation|inflammatory|Inflammatory|inflammation	DiseaseOrPhenotypicFeature	24:53:90:137:222:315:505	25:54:91:138:223:316:506	0:2:3:4:7:10:12	3569	Interleukin 6|IL - 6|IL - 65|IL - 65|IL - 65|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6	GeneOrGeneProduct	0:3:68:119:194:324:332:348:356:476:485	2:6:71:122:197:327:335:351:359:479:488	0:0:3:4:6:10:10:10:10:12:12	1:Association:2	L2R	NON-CROSS	485-488	495-496	3569	Interleukin 6|IL - 6|IL - 65|IL - 65|IL - 65|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6	GeneOrGeneProduct	0:3:68:119:194:324:332:348:356:476:485	2:6:71:122:197:327:335:351:359:479:488	0:0:3:4:6:10:10:10:10:12:12	D016640	Gestational Diabetes Mellitus|Gestational diabetes mellitus|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM	DiseaseOrPhenotypicFeature	28:36:40:49:99:144:158:264:279:298:386:495	31:39:41:50:100:145:159:265:280:299:387:496	0:1:1:2:3:4:5:8:9:9:10:12	1:NR:2	L2R	CROSS	55-57	68-71	3569	Interleukin 6|IL - 6|IL - 65|IL - 65|IL - 65|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6	GeneOrGeneProduct	0:3:68:119:194:324:332:348:356:476:485	2:6:71:122:197:327:335:351:359:479:488	0:0:3:4:6:10:10:10:10:12:12	D008659	metabolisms abnormalities	DiseaseOrPhenotypicFeature	55	57	2	1:NR:2	L2R	CROSS	194-197	225-226	3569	Interleukin 6|IL - 6|IL - 65|IL - 65|IL - 65|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6	GeneOrGeneProduct	0:3:68:119:194:324:332:348:356:476:485	2:6:71:122:197:327:335:351:359:479:488	0:0:3:4:6:10:10:10:10:12:12	3952,9370	adipokines	GeneOrGeneProduct	225	226	7	1:NR:2	L2R	CROSS	296-297	324-327	3569	Interleukin 6|IL - 6|IL - 65|IL - 65|IL - 65|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6	GeneOrGeneProduct	0:3:68:119:194:324:332:348:356:476:485	2:6:71:122:197:327:335:351:359:479:488	0:0:3:4:6:10:10:10:10:12:12	D003924	T2DM	DiseaseOrPhenotypicFeature	296	297	9	1:NR:2	L2R	NON-CROSS	474-475	476-479	3569	Interleukin 6|IL - 6|IL - 65|IL - 65|IL - 65|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6	GeneOrGeneProduct	0:3:68:119:194:324:332:348:356:476:485	2:6:71:122:197:327:335:351:359:479:488	0:0:3:4:6:10:10:10:10:12:12	1401	CRP|CRP	GeneOrGeneProduct	322:474	323:475	10:12	1:NR:2	L2R	NON-CROSS	324-327	328-331	3569	Interleukin 6|IL - 6|IL - 65|IL - 65|IL - 65|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6	GeneOrGeneProduct	0:3:68:119:194:324:332:348:356:476:485	2:6:71:122:197:327:335:351:359:479:488	0:0:3:4:6:10:10:10:10:12:12	3576	IL - 8|IL - 8|IL - 8	GeneOrGeneProduct	328:352:480	331:355:483	10:10:12	1:NR:2	L2R	NON-CROSS	332-335	336-339	3569	Interleukin 6|IL - 6|IL - 65|IL - 65|IL - 65|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6	GeneOrGeneProduct	0:3:68:119:194:324:332:348:356:476:485	2:6:71:122:197:327:335:351:359:479:488	0:0:3:4:6:10:10:10:10:12:12	3586	IL - 10|IL - 10|IL - 10	GeneOrGeneProduct	336:360:489	339:363:492	10:10:12	1:NR:2	L2R	NON-CROSS	344-347	348-351	3569	Interleukin 6|IL - 6|IL - 65|IL - 65|IL - 65|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6	GeneOrGeneProduct	0:3:68:119:194:324:332:348:356:476:485	2:6:71:122:197:327:335:351:359:479:488	0:0:3:4:6:10:10:10:10:12:12	4790	NF - kappaB	GeneOrGeneProduct	344	347	10	1:NR:2	L2R	NON-CROSS	356-359	365-368	3569	Interleukin 6|IL - 6|IL - 65|IL - 65|IL - 65|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6	GeneOrGeneProduct	0:3:68:119:194:324:332:348:356:476:485	2:6:71:122:197:327:335:351:359:479:488	0:0:3:4:6:10:10:10:10:12:12	3553	IL - 1b	GeneOrGeneProduct	365	368	10	1:NR:2	L2R	CROSS	356-359	413-416	3569	Interleukin 6|IL - 6|IL - 65|IL - 65|IL - 65|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6	GeneOrGeneProduct	0:3:68:119:194:324:332:348:356:476:485	2:6:71:122:197:327:335:351:359:479:488	0:0:3:4:6:10:10:10:10:12:12	3667	IRS - 1	GeneOrGeneProduct	413	416	11	1:NR:2	L2R	CROSS	417-420	476-479	3569	Interleukin 6|IL - 6|IL - 65|IL - 65|IL - 65|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6	GeneOrGeneProduct	0:3:68:119:194:324:332:348:356:476:485	2:6:71:122:197:327:335:351:359:479:488	0:0:3:4:6:10:10:10:10:12:12	8660	IRS - 2	GeneOrGeneProduct	417	420	11	1:NR:2	L2R	CROSS	421-422	476-479	3569	Interleukin 6|IL - 6|IL - 65|IL - 65|IL - 65|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6	GeneOrGeneProduct	0:3:68:119:194:324:332:348:356:476:485	2:6:71:122:197:327:335:351:359:479:488	0:0:3:4:6:10:10:10:10:12:12	3952	leptin	GeneOrGeneProduct	421	422	11	1:NR:2	L2R	CROSS	423-424	476-479	3569	Interleukin 6|IL - 6|IL - 65|IL - 65|IL - 65|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6	GeneOrGeneProduct	0:3:68:119:194:324:332:348:356:476:485	2:6:71:122:197:327:335:351:359:479:488	0:0:3:4:6:10:10:10:10:12:12	9370	adiponectin	GeneOrGeneProduct	423	424	11	1:NR:2	L2R	CROSS	425-426	476-479	3569	Interleukin 6|IL - 6|IL - 65|IL - 65|IL - 65|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6	GeneOrGeneProduct	0:3:68:119:194:324:332:348:356:476:485	2:6:71:122:197:327:335:351:359:479:488	0:0:3:4:6:10:10:10:10:12:12	10135	visfatin	GeneOrGeneProduct	425	426	11	1:NR:2	L2R	CROSS	427-430	476-479	3569	Interleukin 6|IL - 6|IL - 65|IL - 65|IL - 65|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6	GeneOrGeneProduct	0:3:68:119:194:324:332:348:356:476:485	2:6:71:122:197:327:335:351:359:479:488	0:0:3:4:6:10:10:10:10:12:12	5950	RBP - 4	GeneOrGeneProduct	427	430	11	1:NR:2	L2R	CROSS	431-432	476-479	3569	Interleukin 6|IL - 6|IL - 65|IL - 65|IL - 65|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6	GeneOrGeneProduct	0:3:68:119:194:324:332:348:356:476:485	2:6:71:122:197:327:335:351:359:479:488	0:0:3:4:6:10:10:10:10:12:12	5919	chemerin	GeneOrGeneProduct	431	432	11	1:NR:2	L2R	CROSS	433-436	476-479	3569	Interleukin 6|IL - 6|IL - 65|IL - 65|IL - 65|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6	GeneOrGeneProduct	0:3:68:119:194:324:332:348:356:476:485	2:6:71:122:197:327:335:351:359:479:488	0:0:3:4:6:10:10:10:10:12:12	4925	nesfatin - 1	GeneOrGeneProduct	433	436	11	1:NR:2	L2R	CROSS	437-440	476-479	3569	Interleukin 6|IL - 6|IL - 65|IL - 65|IL - 65|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6	GeneOrGeneProduct	0:3:68:119:194:324:332:348:356:476:485	2:6:71:122:197:327:335:351:359:479:488	0:0:3:4:6:10:10:10:10:12:12	10999	FATP - 4	GeneOrGeneProduct	437	440	11	1:NR:2	L2R	CROSS	441-442	476-479	3569	Interleukin 6|IL - 6|IL - 65|IL - 65|IL - 65|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6	GeneOrGeneProduct	0:3:68:119:194:324:332:348:356:476:485	2:6:71:122:197:327:335:351:359:479:488	0:0:3:4:6:10:10:10:10:12:12	9388	EL	GeneOrGeneProduct	441	442	11	1:NR:2	L2R	CROSS	443-444	476-479	3569	Interleukin 6|IL - 6|IL - 65|IL - 65|IL - 65|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6	GeneOrGeneProduct	0:3:68:119:194:324:332:348:356:476:485	2:6:71:122:197:327:335:351:359:479:488	0:0:3:4:6:10:10:10:10:12:12	4023	LPL	GeneOrGeneProduct	443	444	11	1:NR:2	L2R	CROSS	445-448	476-479	3569	Interleukin 6|IL - 6|IL - 65|IL - 65|IL - 65|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6	GeneOrGeneProduct	0:3:68:119:194:324:332:348:356:476:485	2:6:71:122:197:327:335:351:359:479:488	0:0:3:4:6:10:10:10:10:12:12	2168	FABP - 1	GeneOrGeneProduct	445	448	11	1:NR:2	L2R	CROSS	449-452	476-479	3569	Interleukin 6|IL - 6|IL - 65|IL - 65|IL - 65|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6	GeneOrGeneProduct	0:3:68:119:194:324:332:348:356:476:485	2:6:71:122:197:327:335:351:359:479:488	0:0:3:4:6:10:10:10:10:12:12	2170	FABP - 3	GeneOrGeneProduct	449	452	11	1:NR:2	L2R	CROSS	453-456	476-479	3569	Interleukin 6|IL - 6|IL - 65|IL - 65|IL - 65|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6	GeneOrGeneProduct	0:3:68:119:194:324:332:348:356:476:485	2:6:71:122:197:327:335:351:359:479:488	0:0:3:4:6:10:10:10:10:12:12	2167	FABP - 4	GeneOrGeneProduct	453	456	11	1:NR:2	L2R	CROSS	458-461	476-479	3569	Interleukin 6|IL - 6|IL - 65|IL - 65|IL - 65|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6	GeneOrGeneProduct	0:3:68:119:194:324:332:348:356:476:485	2:6:71:122:197:327:335:351:359:479:488	0:0:3:4:6:10:10:10:10:12:12	2171	FABP - 5	GeneOrGeneProduct	458	461	11	1:NR:2	L2R	NON-CROSS	485-488	507-512	3569	Interleukin 6|IL - 6|IL - 65|IL - 65|IL - 65|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6|IL - 6	GeneOrGeneProduct	0:3:68:119:194:324:332:348:356:476:485	2:6:71:122:197:327:335:351:359:479:488	0:0:3:4:6:10:10:10:10:12:12	D044882,D052439	disordered lipid and glucose metabolisms	DiseaseOrPhenotypicFeature	507	512	12	1:Association:2	R2L	NON-CROSS	137-138	127-130	D007249	Inflammation|inflammatory|inflammatory|inflammation|inflammatory|Inflammatory|inflammation	DiseaseOrPhenotypicFeature	24:53:90:137:222:315:505	25:54:91:138:223:316:506	0:2:3:4:7:10:12	7124	Tumor Necrosis Factor alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	8:13:76:127:202:231:369:463	12:16:79:130:205:234:372:466	0:0:3:4:6:8:10:12	1:Association:2	L2R	NON-CROSS	13-16	28-31	7124	Tumor Necrosis Factor alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	8:13:76:127:202:231:369:463	12:16:79:130:205:234:372:466	0:0:3:4:6:8:10:12	D016640	Gestational Diabetes Mellitus|Gestational diabetes mellitus|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM	DiseaseOrPhenotypicFeature	28:36:40:49:99:144:158:264:279:298:386:495	31:39:41:50:100:145:159:265:280:299:387:496	0:1:1:2:3:4:5:8:9:9:10:12	1:NR:2	L2R	CROSS	55-57	76-79	7124	Tumor Necrosis Factor alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	8:13:76:127:202:231:369:463	12:16:79:130:205:234:372:466	0:0:3:4:6:8:10:12	D008659	metabolisms abnormalities	DiseaseOrPhenotypicFeature	55	57	2	1:NR:2	L2R	CROSS	225-226	231-234	7124	Tumor Necrosis Factor alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	8:13:76:127:202:231:369:463	12:16:79:130:205:234:372:466	0:0:3:4:6:8:10:12	3952,9370	adipokines	GeneOrGeneProduct	225	226	7	1:NR:2	L2R	CROSS	231-234	296-297	7124	Tumor Necrosis Factor alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	8:13:76:127:202:231:369:463	12:16:79:130:205:234:372:466	0:0:3:4:6:8:10:12	D003924	T2DM	DiseaseOrPhenotypicFeature	296	297	9	1:NR:2	L2R	NON-CROSS	463-466	474-475	7124	Tumor Necrosis Factor alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	8:13:76:127:202:231:369:463	12:16:79:130:205:234:372:466	0:0:3:4:6:8:10:12	1401	CRP|CRP	GeneOrGeneProduct	322:474	323:475	10:12	1:NR:2	L2R	NON-CROSS	463-466	480-483	7124	Tumor Necrosis Factor alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	8:13:76:127:202:231:369:463	12:16:79:130:205:234:372:466	0:0:3:4:6:8:10:12	3576	IL - 8|IL - 8|IL - 8	GeneOrGeneProduct	328:352:480	331:355:483	10:10:12	1:NR:2	L2R	NON-CROSS	360-363	369-372	7124	Tumor Necrosis Factor alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	8:13:76:127:202:231:369:463	12:16:79:130:205:234:372:466	0:0:3:4:6:8:10:12	3586	IL - 10|IL - 10|IL - 10	GeneOrGeneProduct	336:360:489	339:363:492	10:10:12	1:NR:2	L2R	NON-CROSS	344-347	369-372	7124	Tumor Necrosis Factor alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	8:13:76:127:202:231:369:463	12:16:79:130:205:234:372:466	0:0:3:4:6:8:10:12	4790	NF - kappaB	GeneOrGeneProduct	344	347	10	1:NR:2	L2R	NON-CROSS	365-368	369-372	7124	Tumor Necrosis Factor alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	8:13:76:127:202:231:369:463	12:16:79:130:205:234:372:466	0:0:3:4:6:8:10:12	3553	IL - 1b	GeneOrGeneProduct	365	368	10	1:NR:2	L2R	CROSS	369-372	413-416	7124	Tumor Necrosis Factor alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	8:13:76:127:202:231:369:463	12:16:79:130:205:234:372:466	0:0:3:4:6:8:10:12	3667	IRS - 1	GeneOrGeneProduct	413	416	11	1:NR:2	L2R	CROSS	417-420	463-466	7124	Tumor Necrosis Factor alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	8:13:76:127:202:231:369:463	12:16:79:130:205:234:372:466	0:0:3:4:6:8:10:12	8660	IRS - 2	GeneOrGeneProduct	417	420	11	1:NR:2	L2R	CROSS	421-422	463-466	7124	Tumor Necrosis Factor alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	8:13:76:127:202:231:369:463	12:16:79:130:205:234:372:466	0:0:3:4:6:8:10:12	3952	leptin	GeneOrGeneProduct	421	422	11	1:NR:2	L2R	CROSS	423-424	463-466	7124	Tumor Necrosis Factor alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	8:13:76:127:202:231:369:463	12:16:79:130:205:234:372:466	0:0:3:4:6:8:10:12	9370	adiponectin	GeneOrGeneProduct	423	424	11	1:NR:2	L2R	CROSS	425-426	463-466	7124	Tumor Necrosis Factor alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	8:13:76:127:202:231:369:463	12:16:79:130:205:234:372:466	0:0:3:4:6:8:10:12	10135	visfatin	GeneOrGeneProduct	425	426	11	1:NR:2	L2R	CROSS	427-430	463-466	7124	Tumor Necrosis Factor alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	8:13:76:127:202:231:369:463	12:16:79:130:205:234:372:466	0:0:3:4:6:8:10:12	5950	RBP - 4	GeneOrGeneProduct	427	430	11	1:NR:2	L2R	CROSS	431-432	463-466	7124	Tumor Necrosis Factor alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	8:13:76:127:202:231:369:463	12:16:79:130:205:234:372:466	0:0:3:4:6:8:10:12	5919	chemerin	GeneOrGeneProduct	431	432	11	1:NR:2	L2R	CROSS	433-436	463-466	7124	Tumor Necrosis Factor alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	8:13:76:127:202:231:369:463	12:16:79:130:205:234:372:466	0:0:3:4:6:8:10:12	4925	nesfatin - 1	GeneOrGeneProduct	433	436	11	1:NR:2	L2R	CROSS	437-440	463-466	7124	Tumor Necrosis Factor alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	8:13:76:127:202:231:369:463	12:16:79:130:205:234:372:466	0:0:3:4:6:8:10:12	10999	FATP - 4	GeneOrGeneProduct	437	440	11	1:NR:2	L2R	CROSS	441-442	463-466	7124	Tumor Necrosis Factor alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	8:13:76:127:202:231:369:463	12:16:79:130:205:234:372:466	0:0:3:4:6:8:10:12	9388	EL	GeneOrGeneProduct	441	442	11	1:NR:2	L2R	CROSS	443-444	463-466	7124	Tumor Necrosis Factor alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	8:13:76:127:202:231:369:463	12:16:79:130:205:234:372:466	0:0:3:4:6:8:10:12	4023	LPL	GeneOrGeneProduct	443	444	11	1:NR:2	L2R	CROSS	445-448	463-466	7124	Tumor Necrosis Factor alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	8:13:76:127:202:231:369:463	12:16:79:130:205:234:372:466	0:0:3:4:6:8:10:12	2168	FABP - 1	GeneOrGeneProduct	445	448	11	1:NR:2	L2R	CROSS	449-452	463-466	7124	Tumor Necrosis Factor alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	8:13:76:127:202:231:369:463	12:16:79:130:205:234:372:466	0:0:3:4:6:8:10:12	2170	FABP - 3	GeneOrGeneProduct	449	452	11	1:NR:2	L2R	CROSS	453-456	463-466	7124	Tumor Necrosis Factor alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	8:13:76:127:202:231:369:463	12:16:79:130:205:234:372:466	0:0:3:4:6:8:10:12	2167	FABP - 4	GeneOrGeneProduct	453	456	11	1:NR:2	L2R	CROSS	458-461	463-466	7124	Tumor Necrosis Factor alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	8:13:76:127:202:231:369:463	12:16:79:130:205:234:372:466	0:0:3:4:6:8:10:12	2171	FABP - 5	GeneOrGeneProduct	458	461	11	1:NR:2	L2R	NON-CROSS	463-466	507-512	7124	Tumor Necrosis Factor alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha|TNF - alpha	GeneOrGeneProduct	8:13:76:127:202:231:369:463	12:16:79:130:205:234:372:466	0:0:3:4:6:8:10:12	D044882,D052439	disordered lipid and glucose metabolisms	DiseaseOrPhenotypicFeature	507	512	12	1:NR:2	L2R	NON-CROSS	122-126	137-138	D007249	Inflammation|inflammatory|inflammatory|inflammation|inflammatory|Inflammatory|inflammation	DiseaseOrPhenotypicFeature	24:53:90:137:222:315:505	25:54:91:138:223:316:506	0:2:3:4:7:10:12	rs1800796	- 72C / G|- 72C / G|- 72C / G	SequenceVariant	71:122:197	75:126:201	3:4:6	1:Association:2	R2L	NON-CROSS	137-138	130-134	rs1799724	- 857C / T|- 857C / T|- 857C / T|- 857CT|- 857C / T	SequenceVariant	79:130:205:234:466	83:134:209:236:470	3:4:6:8:12	D007249	Inflammation|inflammatory|inflammatory|inflammation|inflammatory|Inflammatory|inflammation	DiseaseOrPhenotypicFeature	24:53:90:137:222:315:505	25:54:91:138:223:316:506	0:2:3:4:7:10:12	1:NR:2	L2R	NON-CROSS	222-223	225-226	D007249	Inflammation|inflammatory|inflammatory|inflammation|inflammatory|Inflammatory|inflammation	DiseaseOrPhenotypicFeature	24:53:90:137:222:315:505	25:54:91:138:223:316:506	0:2:3:4:7:10:12	3952,9370	adipokines	GeneOrGeneProduct	225	226	7	1:Association:2	L2R	NON-CROSS	315-316	322-323	D007249	Inflammation|inflammatory|inflammatory|inflammation|inflammatory|Inflammatory|inflammation	DiseaseOrPhenotypicFeature	24:53:90:137:222:315:505	25:54:91:138:223:316:506	0:2:3:4:7:10:12	1401	CRP|CRP	GeneOrGeneProduct	322:474	323:475	10:12	1:Association:2	L2R	NON-CROSS	315-316	328-331	D007249	Inflammation|inflammatory|inflammatory|inflammation|inflammatory|Inflammatory|inflammation	DiseaseOrPhenotypicFeature	24:53:90:137:222:315:505	25:54:91:138:223:316:506	0:2:3:4:7:10:12	3576	IL - 8|IL - 8|IL - 8	GeneOrGeneProduct	328:352:480	331:355:483	10:10:12	1:Association:2	L2R	NON-CROSS	489-492	505-506	D007249	Inflammation|inflammatory|inflammatory|inflammation|inflammatory|Inflammatory|inflammation	DiseaseOrPhenotypicFeature	24:53:90:137:222:315:505	25:54:91:138:223:316:506	0:2:3:4:7:10:12	3586	IL - 10|IL - 10|IL - 10	GeneOrGeneProduct	336:360:489	339:363:492	10:10:12	1:Association:2	L2R	NON-CROSS	315-316	344-347	D007249	Inflammation|inflammatory|inflammatory|inflammation|inflammatory|Inflammatory|inflammation	DiseaseOrPhenotypicFeature	24:53:90:137:222:315:505	25:54:91:138:223:316:506	0:2:3:4:7:10:12	4790	NF - kappaB	GeneOrGeneProduct	344	347	10	1:Association:2	L2R	NON-CROSS	315-316	365-368	D007249	Inflammation|inflammatory|inflammatory|inflammation|inflammatory|Inflammatory|inflammation	DiseaseOrPhenotypicFeature	24:53:90:137:222:315:505	25:54:91:138:223:316:506	0:2:3:4:7:10:12	3553	IL - 1b	GeneOrGeneProduct	365	368	10	1:NR:2	L2R	CROSS	413-416	505-506	D007249	Inflammation|inflammatory|inflammatory|inflammation|inflammatory|Inflammatory|inflammation	DiseaseOrPhenotypicFeature	24:53:90:137:222:315:505	25:54:91:138:223:316:506	0:2:3:4:7:10:12	3667	IRS - 1	GeneOrGeneProduct	413	416	11	1:NR:2	L2R	CROSS	417-420	505-506	D007249	Inflammation|inflammatory|inflammatory|inflammation|inflammatory|Inflammatory|inflammation	DiseaseOrPhenotypicFeature	24:53:90:137:222:315:505	25:54:91:138:223:316:506	0:2:3:4:7:10:12	8660	IRS - 2	GeneOrGeneProduct	417	420	11	1:NR:2	L2R	CROSS	421-422	505-506	D007249	Inflammation|inflammatory|inflammatory|inflammation|inflammatory|Inflammatory|inflammation	DiseaseOrPhenotypicFeature	24:53:90:137:222:315:505	25:54:91:138:223:316:506	0:2:3:4:7:10:12	3952	leptin	GeneOrGeneProduct	421	422	11	1:NR:2	L2R	CROSS	423-424	505-506	D007249	Inflammation|inflammatory|inflammatory|inflammation|inflammatory|Inflammatory|inflammation	DiseaseOrPhenotypicFeature	24:53:90:137:222:315:505	25:54:91:138:223:316:506	0:2:3:4:7:10:12	9370	adiponectin	GeneOrGeneProduct	423	424	11	1:NR:2	L2R	CROSS	425-426	505-506	D007249	Inflammation|inflammatory|inflammatory|inflammation|inflammatory|Inflammatory|inflammation	DiseaseOrPhenotypicFeature	24:53:90:137:222:315:505	25:54:91:138:223:316:506	0:2:3:4:7:10:12	10135	visfatin	GeneOrGeneProduct	425	426	11	1:NR:2	L2R	CROSS	427-430	505-506	D007249	Inflammation|inflammatory|inflammatory|inflammation|inflammatory|Inflammatory|inflammation	DiseaseOrPhenotypicFeature	24:53:90:137:222:315:505	25:54:91:138:223:316:506	0:2:3:4:7:10:12	5950	RBP - 4	GeneOrGeneProduct	427	430	11	1:NR:2	L2R	CROSS	431-432	505-506	D007249	Inflammation|inflammatory|inflammatory|inflammation|inflammatory|Inflammatory|inflammation	DiseaseOrPhenotypicFeature	24:53:90:137:222:315:505	25:54:91:138:223:316:506	0:2:3:4:7:10:12	5919	chemerin	GeneOrGeneProduct	431	432	11	1:NR:2	L2R	CROSS	433-436	505-506	D007249	Inflammation|inflammatory|inflammatory|inflammation|inflammatory|Inflammatory|inflammation	DiseaseOrPhenotypicFeature	24:53:90:137:222:315:505	25:54:91:138:223:316:506	0:2:3:4:7:10:12	4925	nesfatin - 1	GeneOrGeneProduct	433	436	11	1:NR:2	L2R	CROSS	437-440	505-506	D007249	Inflammation|inflammatory|inflammatory|inflammation|inflammatory|Inflammatory|inflammation	DiseaseOrPhenotypicFeature	24:53:90:137:222:315:505	25:54:91:138:223:316:506	0:2:3:4:7:10:12	10999	FATP - 4	GeneOrGeneProduct	437	440	11	1:NR:2	L2R	CROSS	441-442	505-506	D007249	Inflammation|inflammatory|inflammatory|inflammation|inflammatory|Inflammatory|inflammation	DiseaseOrPhenotypicFeature	24:53:90:137:222:315:505	25:54:91:138:223:316:506	0:2:3:4:7:10:12	9388	EL	GeneOrGeneProduct	441	442	11	1:NR:2	L2R	CROSS	443-444	505-506	D007249	Inflammation|inflammatory|inflammatory|inflammation|inflammatory|Inflammatory|inflammation	DiseaseOrPhenotypicFeature	24:53:90:137:222:315:505	25:54:91:138:223:316:506	0:2:3:4:7:10:12	4023	LPL	GeneOrGeneProduct	443	444	11	1:NR:2	L2R	CROSS	445-448	505-506	D007249	Inflammation|inflammatory|inflammatory|inflammation|inflammatory|Inflammatory|inflammation	DiseaseOrPhenotypicFeature	24:53:90:137:222:315:505	25:54:91:138:223:316:506	0:2:3:4:7:10:12	2168	FABP - 1	GeneOrGeneProduct	445	448	11	1:NR:2	L2R	CROSS	449-452	505-506	D007249	Inflammation|inflammatory|inflammatory|inflammation|inflammatory|Inflammatory|inflammation	DiseaseOrPhenotypicFeature	24:53:90:137:222:315:505	25:54:91:138:223:316:506	0:2:3:4:7:10:12	2170	FABP - 3	GeneOrGeneProduct	449	452	11	1:NR:2	L2R	CROSS	453-456	505-506	D007249	Inflammation|inflammatory|inflammatory|inflammation|inflammatory|Inflammatory|inflammation	DiseaseOrPhenotypicFeature	24:53:90:137:222:315:505	25:54:91:138:223:316:506	0:2:3:4:7:10:12	2167	FABP - 4	GeneOrGeneProduct	453	456	11	1:NR:2	L2R	CROSS	458-461	505-506	D007249	Inflammation|inflammatory|inflammatory|inflammation|inflammatory|Inflammatory|inflammation	DiseaseOrPhenotypicFeature	24:53:90:137:222:315:505	25:54:91:138:223:316:506	0:2:3:4:7:10:12	2171	FABP - 5	GeneOrGeneProduct	458	461	11	1:NR:2	L2R	NON-CROSS	122-126	144-145	D016640	Gestational Diabetes Mellitus|Gestational diabetes mellitus|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM	DiseaseOrPhenotypicFeature	28:36:40:49:99:144:158:264:279:298:386:495	31:39:41:50:100:145:159:265:280:299:387:496	0:1:1:2:3:4:5:8:9:9:10:12	rs1800796	- 72C / G|- 72C / G|- 72C / G	SequenceVariant	71:122:197	75:126:201	3:4:6	1:Positive_Correlation:2	R2L	NON-CROSS	144-145	130-134	rs1799724	- 857C / T|- 857C / T|- 857C / T|- 857CT|- 857C / T	SequenceVariant	79:130:205:234:466	83:134:209:236:470	3:4:6:8:12	D016640	Gestational Diabetes Mellitus|Gestational diabetes mellitus|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM	DiseaseOrPhenotypicFeature	28:36:40:49:99:144:158:264:279:298:386:495	31:39:41:50:100:145:159:265:280:299:387:496	0:1:1:2:3:4:5:8:9:9:10:12	1:NR:2	L2R	CROSS	225-226	264-265	D016640	Gestational Diabetes Mellitus|Gestational diabetes mellitus|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM	DiseaseOrPhenotypicFeature	28:36:40:49:99:144:158:264:279:298:386:495	31:39:41:50:100:145:159:265:280:299:387:496	0:1:1:2:3:4:5:8:9:9:10:12	3952,9370	adipokines	GeneOrGeneProduct	225	226	7	1:Association:2	R2L	NON-CROSS	495-496	474-475	1401	CRP|CRP	GeneOrGeneProduct	322:474	323:475	10:12	D016640	Gestational Diabetes Mellitus|Gestational diabetes mellitus|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM	DiseaseOrPhenotypicFeature	28:36:40:49:99:144:158:264:279:298:386:495	31:39:41:50:100:145:159:265:280:299:387:496	0:1:1:2:3:4:5:8:9:9:10:12	1:Association:2	R2L	NON-CROSS	495-496	480-483	3576	IL - 8|IL - 8|IL - 8	GeneOrGeneProduct	328:352:480	331:355:483	10:10:12	D016640	Gestational Diabetes Mellitus|Gestational diabetes mellitus|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM	DiseaseOrPhenotypicFeature	28:36:40:49:99:144:158:264:279:298:386:495	31:39:41:50:100:145:159:265:280:299:387:496	0:1:1:2:3:4:5:8:9:9:10:12	1:Association:2	R2L	NON-CROSS	495-496	489-492	3586	IL - 10|IL - 10|IL - 10	GeneOrGeneProduct	336:360:489	339:363:492	10:10:12	D016640	Gestational Diabetes Mellitus|Gestational diabetes mellitus|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM	DiseaseOrPhenotypicFeature	28:36:40:49:99:144:158:264:279:298:386:495	31:39:41:50:100:145:159:265:280:299:387:496	0:1:1:2:3:4:5:8:9:9:10:12	1:Association:2	R2L	NON-CROSS	386-387	344-347	4790	NF - kappaB	GeneOrGeneProduct	344	347	10	D016640	Gestational Diabetes Mellitus|Gestational diabetes mellitus|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM	DiseaseOrPhenotypicFeature	28:36:40:49:99:144:158:264:279:298:386:495	31:39:41:50:100:145:159:265:280:299:387:496	0:1:1:2:3:4:5:8:9:9:10:12	1:Association:2	L2R	NON-CROSS	365-368	386-387	D016640	Gestational Diabetes Mellitus|Gestational diabetes mellitus|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM	DiseaseOrPhenotypicFeature	28:36:40:49:99:144:158:264:279:298:386:495	31:39:41:50:100:145:159:265:280:299:387:496	0:1:1:2:3:4:5:8:9:9:10:12	3553	IL - 1b	GeneOrGeneProduct	365	368	10	1:Association:2	L2R	CROSS	386-387	413-416	D016640	Gestational Diabetes Mellitus|Gestational diabetes mellitus|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM	DiseaseOrPhenotypicFeature	28:36:40:49:99:144:158:264:279:298:386:495	31:39:41:50:100:145:159:265:280:299:387:496	0:1:1:2:3:4:5:8:9:9:10:12	3667	IRS - 1	GeneOrGeneProduct	413	416	11	1:Association:2	L2R	CROSS	386-387	417-420	D016640	Gestational Diabetes Mellitus|Gestational diabetes mellitus|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM	DiseaseOrPhenotypicFeature	28:36:40:49:99:144:158:264:279:298:386:495	31:39:41:50:100:145:159:265:280:299:387:496	0:1:1:2:3:4:5:8:9:9:10:12	8660	IRS - 2	GeneOrGeneProduct	417	420	11	1:Association:2	L2R	CROSS	386-387	421-422	D016640	Gestational Diabetes Mellitus|Gestational diabetes mellitus|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM	DiseaseOrPhenotypicFeature	28:36:40:49:99:144:158:264:279:298:386:495	31:39:41:50:100:145:159:265:280:299:387:496	0:1:1:2:3:4:5:8:9:9:10:12	3952	leptin	GeneOrGeneProduct	421	422	11	1:Association:2	L2R	CROSS	386-387	423-424	D016640	Gestational Diabetes Mellitus|Gestational diabetes mellitus|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM	DiseaseOrPhenotypicFeature	28:36:40:49:99:144:158:264:279:298:386:495	31:39:41:50:100:145:159:265:280:299:387:496	0:1:1:2:3:4:5:8:9:9:10:12	9370	adiponectin	GeneOrGeneProduct	423	424	11	1:Association:2	L2R	CROSS	386-387	425-426	D016640	Gestational Diabetes Mellitus|Gestational diabetes mellitus|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM	DiseaseOrPhenotypicFeature	28:36:40:49:99:144:158:264:279:298:386:495	31:39:41:50:100:145:159:265:280:299:387:496	0:1:1:2:3:4:5:8:9:9:10:12	10135	visfatin	GeneOrGeneProduct	425	426	11	1:Association:2	L2R	CROSS	386-387	427-430	D016640	Gestational Diabetes Mellitus|Gestational diabetes mellitus|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM	DiseaseOrPhenotypicFeature	28:36:40:49:99:144:158:264:279:298:386:495	31:39:41:50:100:145:159:265:280:299:387:496	0:1:1:2:3:4:5:8:9:9:10:12	5950	RBP - 4	GeneOrGeneProduct	427	430	11	1:Association:2	L2R	CROSS	386-387	431-432	D016640	Gestational Diabetes Mellitus|Gestational diabetes mellitus|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM	DiseaseOrPhenotypicFeature	28:36:40:49:99:144:158:264:279:298:386:495	31:39:41:50:100:145:159:265:280:299:387:496	0:1:1:2:3:4:5:8:9:9:10:12	5919	chemerin	GeneOrGeneProduct	431	432	11	1:Association:2	L2R	CROSS	386-387	433-436	D016640	Gestational Diabetes Mellitus|Gestational diabetes mellitus|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM	DiseaseOrPhenotypicFeature	28:36:40:49:99:144:158:264:279:298:386:495	31:39:41:50:100:145:159:265:280:299:387:496	0:1:1:2:3:4:5:8:9:9:10:12	4925	nesfatin - 1	GeneOrGeneProduct	433	436	11	1:Association:2	L2R	CROSS	386-387	437-440	D016640	Gestational Diabetes Mellitus|Gestational diabetes mellitus|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM	DiseaseOrPhenotypicFeature	28:36:40:49:99:144:158:264:279:298:386:495	31:39:41:50:100:145:159:265:280:299:387:496	0:1:1:2:3:4:5:8:9:9:10:12	10999	FATP - 4	GeneOrGeneProduct	437	440	11	1:Association:2	L2R	CROSS	441-442	495-496	D016640	Gestational Diabetes Mellitus|Gestational diabetes mellitus|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM	DiseaseOrPhenotypicFeature	28:36:40:49:99:144:158:264:279:298:386:495	31:39:41:50:100:145:159:265:280:299:387:496	0:1:1:2:3:4:5:8:9:9:10:12	9388	EL	GeneOrGeneProduct	441	442	11	1:Association:2	L2R	CROSS	443-444	495-496	D016640	Gestational Diabetes Mellitus|Gestational diabetes mellitus|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM	DiseaseOrPhenotypicFeature	28:36:40:49:99:144:158:264:279:298:386:495	31:39:41:50:100:145:159:265:280:299:387:496	0:1:1:2:3:4:5:8:9:9:10:12	4023	LPL	GeneOrGeneProduct	443	444	11	1:Association:2	L2R	CROSS	445-448	495-496	D016640	Gestational Diabetes Mellitus|Gestational diabetes mellitus|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM	DiseaseOrPhenotypicFeature	28:36:40:49:99:144:158:264:279:298:386:495	31:39:41:50:100:145:159:265:280:299:387:496	0:1:1:2:3:4:5:8:9:9:10:12	2168	FABP - 1	GeneOrGeneProduct	445	448	11	1:Association:2	L2R	CROSS	449-452	495-496	D016640	Gestational Diabetes Mellitus|Gestational diabetes mellitus|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM	DiseaseOrPhenotypicFeature	28:36:40:49:99:144:158:264:279:298:386:495	31:39:41:50:100:145:159:265:280:299:387:496	0:1:1:2:3:4:5:8:9:9:10:12	2170	FABP - 3	GeneOrGeneProduct	449	452	11	1:Association:2	L2R	CROSS	453-456	495-496	D016640	Gestational Diabetes Mellitus|Gestational diabetes mellitus|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM	DiseaseOrPhenotypicFeature	28:36:40:49:99:144:158:264:279:298:386:495	31:39:41:50:100:145:159:265:280:299:387:496	0:1:1:2:3:4:5:8:9:9:10:12	2167	FABP - 4	GeneOrGeneProduct	453	456	11	1:Association:2	L2R	CROSS	458-461	495-496	D016640	Gestational Diabetes Mellitus|Gestational diabetes mellitus|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM|GDM	DiseaseOrPhenotypicFeature	28:36:40:49:99:144:158:264:279:298:386:495	31:39:41:50:100:145:159:265:280:299:387:496	0:1:1:2:3:4:5:8:9:9:10:12	2171	FABP - 5	GeneOrGeneProduct	458	461	11	1:NR:2	L2R	CROSS	55-57	71-75	D008659	metabolisms abnormalities	DiseaseOrPhenotypicFeature	55	57	2	rs1800796	- 72C / G|- 72C / G|- 72C / G	SequenceVariant	71:122:197	75:126:201	3:4:6	1:NR:2	L2R	CROSS	55-57	79-83	D008659	metabolisms abnormalities	DiseaseOrPhenotypicFeature	55	57	2	rs1799724	- 857C / T|- 857C / T|- 857C / T|- 857CT|- 857C / T	SequenceVariant	79:130:205:234:466	83:134:209:236:470	3:4:6:8:12	1:NR:2	L2R	CROSS	55-57	225-226	D008659	metabolisms abnormalities	DiseaseOrPhenotypicFeature	55	57	2	3952,9370	adipokines	GeneOrGeneProduct	225	226	7	1:NR:2	L2R	CROSS	55-57	322-323	D008659	metabolisms abnormalities	DiseaseOrPhenotypicFeature	55	57	2	1401	CRP|CRP	GeneOrGeneProduct	322:474	323:475	10:12	1:NR:2	L2R	CROSS	55-57	328-331	D008659	metabolisms abnormalities	DiseaseOrPhenotypicFeature	55	57	2	3576	IL - 8|IL - 8|IL - 8	GeneOrGeneProduct	328:352:480	331:355:483	10:10:12	1:NR:2	L2R	CROSS	55-57	336-339	D008659	metabolisms abnormalities	DiseaseOrPhenotypicFeature	55	57	2	3586	IL - 10|IL - 10|IL - 10	GeneOrGeneProduct	336:360:489	339:363:492	10:10:12	1:NR:2	L2R	CROSS	55-57	344-347	D008659	metabolisms abnormalities	DiseaseOrPhenotypicFeature	55	57	2	4790	NF - kappaB	GeneOrGeneProduct	344	347	10	1:NR:2	L2R	CROSS	55-57	365-368	D008659	metabolisms abnormalities	DiseaseOrPhenotypicFeature	55	57	2	3553	IL - 1b	GeneOrGeneProduct	365	368	10	1:NR:2	L2R	CROSS	55-57	413-416	D008659	metabolisms abnormalities	DiseaseOrPhenotypicFeature	55	57	2	3667	IRS - 1	GeneOrGeneProduct	413	416	11	1:NR:2	L2R	CROSS	55-57	417-420	D008659	metabolisms abnormalities	DiseaseOrPhenotypicFeature	55	57	2	8660	IRS - 2	GeneOrGeneProduct	417	420	11	1:NR:2	L2R	CROSS	55-57	421-422	D008659	metabolisms abnormalities	DiseaseOrPhenotypicFeature	55	57	2	3952	leptin	GeneOrGeneProduct	421	422	11	1:NR:2	L2R	CROSS	55-57	423-424	D008659	metabolisms abnormalities	DiseaseOrPhenotypicFeature	55	57	2	9370	adiponectin	GeneOrGeneProduct	423	424	11	1:NR:2	L2R	CROSS	55-57	425-426	D008659	metabolisms abnormalities	DiseaseOrPhenotypicFeature	55	57	2	10135	visfatin	GeneOrGeneProduct	425	426	11	1:NR:2	L2R	CROSS	55-57	427-430	D008659	metabolisms abnormalities	DiseaseOrPhenotypicFeature	55	57	2	5950	RBP - 4	GeneOrGeneProduct	427	430	11	1:NR:2	L2R	CROSS	55-57	431-432	D008659	metabolisms abnormalities	DiseaseOrPhenotypicFeature	55	57	2	5919	chemerin	GeneOrGeneProduct	431	432	11	1:NR:2	L2R	CROSS	55-57	433-436	D008659	metabolisms abnormalities	DiseaseOrPhenotypicFeature	55	57	2	4925	nesfatin - 1	GeneOrGeneProduct	433	436	11	1:NR:2	L2R	CROSS	55-57	437-440	D008659	metabolisms abnormalities	DiseaseOrPhenotypicFeature	55	57	2	10999	FATP - 4	GeneOrGeneProduct	437	440	11	1:NR:2	L2R	CROSS	55-57	441-442	D008659	metabolisms abnormalities	DiseaseOrPhenotypicFeature	55	57	2	9388	EL	GeneOrGeneProduct	441	442	11	1:NR:2	L2R	CROSS	55-57	443-444	D008659	metabolisms abnormalities	DiseaseOrPhenotypicFeature	55	57	2	4023	LPL	GeneOrGeneProduct	443	444	11	1:NR:2	L2R	CROSS	55-57	445-448	D008659	metabolisms abnormalities	DiseaseOrPhenotypicFeature	55	57	2	2168	FABP - 1	GeneOrGeneProduct	445	448	11	1:NR:2	L2R	CROSS	55-57	449-452	D008659	metabolisms abnormalities	DiseaseOrPhenotypicFeature	55	57	2	2170	FABP - 3	GeneOrGeneProduct	449	452	11	1:NR:2	L2R	CROSS	55-57	453-456	D008659	metabolisms abnormalities	DiseaseOrPhenotypicFeature	55	57	2	2167	FABP - 4	GeneOrGeneProduct	453	456	11	1:NR:2	L2R	CROSS	55-57	458-461	D008659	metabolisms abnormalities	DiseaseOrPhenotypicFeature	55	57	2	2171	FABP - 5	GeneOrGeneProduct	458	461	11	1:NR:2	L2R	CROSS	197-201	296-297	rs1800796	- 72C / G|- 72C / G|- 72C / G	SequenceVariant	71:122:197	75:126:201	3:4:6	D003924	T2DM	DiseaseOrPhenotypicFeature	296	297	9	1:NR:2	L2R	CROSS	197-201	507-512	rs1800796	- 72C / G|- 72C / G|- 72C / G	SequenceVariant	71:122:197	75:126:201	3:4:6	D044882,D052439	disordered lipid and glucose metabolisms	DiseaseOrPhenotypicFeature	507	512	12	1:NR:2	L2R	CROSS	234-236	296-297	rs1799724	- 857C / T|- 857C / T|- 857C / T|- 857CT|- 857C / T	SequenceVariant	79:130:205:234:466	83:134:209:236:470	3:4:6:8:12	D003924	T2DM	DiseaseOrPhenotypicFeature	296	297	9	1:NR:2	L2R	NON-CROSS	466-470	507-512	rs1799724	- 857C / T|- 857C / T|- 857C / T|- 857CT|- 857C / T	SequenceVariant	79:130:205:234:466	83:134:209:236:470	3:4:6:8:12	D044882,D052439	disordered lipid and glucose metabolisms	DiseaseOrPhenotypicFeature	507	512	12	1:NR:2	L2R	CROSS	225-226	296-297	3952,9370	adipokines	GeneOrGeneProduct	225	226	7	D003924	T2DM	DiseaseOrPhenotypicFeature	296	297	9	1:NR:2	L2R	CROSS	225-226	322-323	3952,9370	adipokines	GeneOrGeneProduct	225	226	7	1401	CRP|CRP	GeneOrGeneProduct	322:474	323:475	10:12	1:NR:2	L2R	CROSS	225-226	328-331	3952,9370	adipokines	GeneOrGeneProduct	225	226	7	3576	IL - 8|IL - 8|IL - 8	GeneOrGeneProduct	328:352:480	331:355:483	10:10:12	1:NR:2	L2R	CROSS	225-226	336-339	3952,9370	adipokines	GeneOrGeneProduct	225	226	7	3586	IL - 10|IL - 10|IL - 10	GeneOrGeneProduct	336:360:489	339:363:492	10:10:12	1:NR:2	L2R	CROSS	225-226	344-347	3952,9370	adipokines	GeneOrGeneProduct	225	226	7	4790	NF - kappaB	GeneOrGeneProduct	344	347	10	1:NR:2	L2R	CROSS	225-226	365-368	3952,9370	adipokines	GeneOrGeneProduct	225	226	7	3553	IL - 1b	GeneOrGeneProduct	365	368	10	1:NR:2	L2R	CROSS	225-226	413-416	3952,9370	adipokines	GeneOrGeneProduct	225	226	7	3667	IRS - 1	GeneOrGeneProduct	413	416	11	1:NR:2	L2R	CROSS	225-226	417-420	3952,9370	adipokines	GeneOrGeneProduct	225	226	7	8660	IRS - 2	GeneOrGeneProduct	417	420	11	1:NR:2	L2R	CROSS	225-226	421-422	3952,9370	adipokines	GeneOrGeneProduct	225	226	7	3952	leptin	GeneOrGeneProduct	421	422	11	1:NR:2	L2R	CROSS	225-226	423-424	3952,9370	adipokines	GeneOrGeneProduct	225	226	7	9370	adiponectin	GeneOrGeneProduct	423	424	11	1:NR:2	L2R	CROSS	225-226	425-426	3952,9370	adipokines	GeneOrGeneProduct	225	226	7	10135	visfatin	GeneOrGeneProduct	425	426	11	1:NR:2	L2R	CROSS	225-226	427-430	3952,9370	adipokines	GeneOrGeneProduct	225	226	7	5950	RBP - 4	GeneOrGeneProduct	427	430	11	1:NR:2	L2R	CROSS	225-226	431-432	3952,9370	adipokines	GeneOrGeneProduct	225	226	7	5919	chemerin	GeneOrGeneProduct	431	432	11	1:NR:2	L2R	CROSS	225-226	433-436	3952,9370	adipokines	GeneOrGeneProduct	225	226	7	4925	nesfatin - 1	GeneOrGeneProduct	433	436	11	1:NR:2	L2R	CROSS	225-226	437-440	3952,9370	adipokines	GeneOrGeneProduct	225	226	7	10999	FATP - 4	GeneOrGeneProduct	437	440	11	1:NR:2	L2R	CROSS	225-226	441-442	3952,9370	adipokines	GeneOrGeneProduct	225	226	7	9388	EL	GeneOrGeneProduct	441	442	11	1:NR:2	L2R	CROSS	225-226	443-444	3952,9370	adipokines	GeneOrGeneProduct	225	226	7	4023	LPL	GeneOrGeneProduct	443	444	11	1:NR:2	L2R	CROSS	225-226	445-448	3952,9370	adipokines	GeneOrGeneProduct	225	226	7	2168	FABP - 1	GeneOrGeneProduct	445	448	11	1:NR:2	L2R	CROSS	225-226	449-452	3952,9370	adipokines	GeneOrGeneProduct	225	226	7	2170	FABP - 3	GeneOrGeneProduct	449	452	11	1:NR:2	L2R	CROSS	225-226	453-456	3952,9370	adipokines	GeneOrGeneProduct	225	226	7	2167	FABP - 4	GeneOrGeneProduct	453	456	11	1:NR:2	L2R	CROSS	225-226	458-461	3952,9370	adipokines	GeneOrGeneProduct	225	226	7	2171	FABP - 5	GeneOrGeneProduct	458	461	11	1:NR:2	L2R	CROSS	225-226	507-512	3952,9370	adipokines	GeneOrGeneProduct	225	226	7	D044882,D052439	disordered lipid and glucose metabolisms	DiseaseOrPhenotypicFeature	507	512	12	1:NR:2	L2R	CROSS	296-297	322-323	D003924	T2DM	DiseaseOrPhenotypicFeature	296	297	9	1401	CRP|CRP	GeneOrGeneProduct	322:474	323:475	10:12	1:NR:2	L2R	CROSS	296-297	328-331	D003924	T2DM	DiseaseOrPhenotypicFeature	296	297	9	3576	IL - 8|IL - 8|IL - 8	GeneOrGeneProduct	328:352:480	331:355:483	10:10:12	1:NR:2	L2R	CROSS	296-297	336-339	D003924	T2DM	DiseaseOrPhenotypicFeature	296	297	9	3586	IL - 10|IL - 10|IL - 10	GeneOrGeneProduct	336:360:489	339:363:492	10:10:12	1:NR:2	L2R	CROSS	296-297	344-347	D003924	T2DM	DiseaseOrPhenotypicFeature	296	297	9	4790	NF - kappaB	GeneOrGeneProduct	344	347	10	1:NR:2	L2R	CROSS	296-297	365-368	D003924	T2DM	DiseaseOrPhenotypicFeature	296	297	9	3553	IL - 1b	GeneOrGeneProduct	365	368	10	1:NR:2	L2R	CROSS	296-297	413-416	D003924	T2DM	DiseaseOrPhenotypicFeature	296	297	9	3667	IRS - 1	GeneOrGeneProduct	413	416	11	1:NR:2	L2R	CROSS	296-297	417-420	D003924	T2DM	DiseaseOrPhenotypicFeature	296	297	9	8660	IRS - 2	GeneOrGeneProduct	417	420	11	1:NR:2	L2R	CROSS	296-297	421-422	D003924	T2DM	DiseaseOrPhenotypicFeature	296	297	9	3952	leptin	GeneOrGeneProduct	421	422	11	1:NR:2	L2R	CROSS	296-297	423-424	D003924	T2DM	DiseaseOrPhenotypicFeature	296	297	9	9370	adiponectin	GeneOrGeneProduct	423	424	11	1:NR:2	L2R	CROSS	296-297	425-426	D003924	T2DM	DiseaseOrPhenotypicFeature	296	297	9	10135	visfatin	GeneOrGeneProduct	425	426	11	1:NR:2	L2R	CROSS	296-297	427-430	D003924	T2DM	DiseaseOrPhenotypicFeature	296	297	9	5950	RBP - 4	GeneOrGeneProduct	427	430	11	1:NR:2	L2R	CROSS	296-297	431-432	D003924	T2DM	DiseaseOrPhenotypicFeature	296	297	9	5919	chemerin	GeneOrGeneProduct	431	432	11	1:NR:2	L2R	CROSS	296-297	433-436	D003924	T2DM	DiseaseOrPhenotypicFeature	296	297	9	4925	nesfatin - 1	GeneOrGeneProduct	433	436	11	1:NR:2	L2R	CROSS	296-297	437-440	D003924	T2DM	DiseaseOrPhenotypicFeature	296	297	9	10999	FATP - 4	GeneOrGeneProduct	437	440	11	1:NR:2	L2R	CROSS	296-297	441-442	D003924	T2DM	DiseaseOrPhenotypicFeature	296	297	9	9388	EL	GeneOrGeneProduct	441	442	11	1:NR:2	L2R	CROSS	296-297	443-444	D003924	T2DM	DiseaseOrPhenotypicFeature	296	297	9	4023	LPL	GeneOrGeneProduct	443	444	11	1:NR:2	L2R	CROSS	296-297	445-448	D003924	T2DM	DiseaseOrPhenotypicFeature	296	297	9	2168	FABP - 1	GeneOrGeneProduct	445	448	11	1:NR:2	L2R	CROSS	296-297	449-452	D003924	T2DM	DiseaseOrPhenotypicFeature	296	297	9	2170	FABP - 3	GeneOrGeneProduct	449	452	11	1:NR:2	L2R	CROSS	296-297	453-456	D003924	T2DM	DiseaseOrPhenotypicFeature	296	297	9	2167	FABP - 4	GeneOrGeneProduct	453	456	11	1:NR:2	L2R	CROSS	296-297	458-461	D003924	T2DM	DiseaseOrPhenotypicFeature	296	297	9	2171	FABP - 5	GeneOrGeneProduct	458	461	11	1:NR:2	L2R	NON-CROSS	322-323	328-331	1401	CRP|CRP	GeneOrGeneProduct	322:474	323:475	10:12	3576	IL - 8|IL - 8|IL - 8	GeneOrGeneProduct	328:352:480	331:355:483	10:10:12	1:NR:2	L2R	NON-CROSS	322-323	336-339	1401	CRP|CRP	GeneOrGeneProduct	322:474	323:475	10:12	3586	IL - 10|IL - 10|IL - 10	GeneOrGeneProduct	336:360:489	339:363:492	10:10:12	1:NR:2	L2R	NON-CROSS	322-323	344-347	1401	CRP|CRP	GeneOrGeneProduct	322:474	323:475	10:12	4790	NF - kappaB	GeneOrGeneProduct	344	347	10	1:NR:2	L2R	NON-CROSS	322-323	365-368	1401	CRP|CRP	GeneOrGeneProduct	322:474	323:475	10:12	3553	IL - 1b	GeneOrGeneProduct	365	368	10	1:NR:2	L2R	CROSS	413-416	474-475	1401	CRP|CRP	GeneOrGeneProduct	322:474	323:475	10:12	3667	IRS - 1	GeneOrGeneProduct	413	416	11	1:NR:2	L2R	CROSS	417-420	474-475	1401	CRP|CRP	GeneOrGeneProduct	322:474	323:475	10:12	8660	IRS - 2	GeneOrGeneProduct	417	420	11	1:NR:2	L2R	CROSS	421-422	474-475	1401	CRP|CRP	GeneOrGeneProduct	322:474	323:475	10:12	3952	leptin	GeneOrGeneProduct	421	422	11	1:NR:2	L2R	CROSS	423-424	474-475	1401	CRP|CRP	GeneOrGeneProduct	322:474	323:475	10:12	9370	adiponectin	GeneOrGeneProduct	423	424	11	1:NR:2	L2R	CROSS	425-426	474-475	1401	CRP|CRP	GeneOrGeneProduct	322:474	323:475	10:12	10135	visfatin	GeneOrGeneProduct	425	426	11	1:NR:2	L2R	CROSS	427-430	474-475	1401	CRP|CRP	GeneOrGeneProduct	322:474	323:475	10:12	5950	RBP - 4	GeneOrGeneProduct	427	430	11	1:NR:2	L2R	CROSS	431-432	474-475	1401	CRP|CRP	GeneOrGeneProduct	322:474	323:475	10:12	5919	chemerin	GeneOrGeneProduct	431	432	11	1:NR:2	L2R	CROSS	433-436	474-475	1401	CRP|CRP	GeneOrGeneProduct	322:474	323:475	10:12	4925	nesfatin - 1	GeneOrGeneProduct	433	436	11	1:NR:2	L2R	CROSS	437-440	474-475	1401	CRP|CRP	GeneOrGeneProduct	322:474	323:475	10:12	10999	FATP - 4	GeneOrGeneProduct	437	440	11	1:NR:2	L2R	CROSS	441-442	474-475	1401	CRP|CRP	GeneOrGeneProduct	322:474	323:475	10:12	9388	EL	GeneOrGeneProduct	441	442	11	1:NR:2	L2R	CROSS	443-444	474-475	1401	CRP|CRP	GeneOrGeneProduct	322:474	323:475	10:12	4023	LPL	GeneOrGeneProduct	443	444	11	1:NR:2	L2R	CROSS	445-448	474-475	1401	CRP|CRP	GeneOrGeneProduct	322:474	323:475	10:12	2168	FABP - 1	GeneOrGeneProduct	445	448	11	1:NR:2	L2R	CROSS	449-452	474-475	1401	CRP|CRP	GeneOrGeneProduct	322:474	323:475	10:12	2170	FABP - 3	GeneOrGeneProduct	449	452	11	1:NR:2	L2R	CROSS	453-456	474-475	1401	CRP|CRP	GeneOrGeneProduct	322:474	323:475	10:12	2167	FABP - 4	GeneOrGeneProduct	453	456	11	1:NR:2	L2R	CROSS	458-461	474-475	1401	CRP|CRP	GeneOrGeneProduct	322:474	323:475	10:12	2171	FABP - 5	GeneOrGeneProduct	458	461	11	1:NR:2	L2R	NON-CROSS	474-475	507-512	1401	CRP|CRP	GeneOrGeneProduct	322:474	323:475	10:12	D044882,D052439	disordered lipid and glucose metabolisms	DiseaseOrPhenotypicFeature	507	512	12	1:NR:2	L2R	NON-CROSS	328-331	336-339	3576	IL - 8|IL - 8|IL - 8	GeneOrGeneProduct	328:352:480	331:355:483	10:10:12	3586	IL - 10|IL - 10|IL - 10	GeneOrGeneProduct	336:360:489	339:363:492	10:10:12	1:NR:2	L2R	NON-CROSS	344-347	352-355	3576	IL - 8|IL - 8|IL - 8	GeneOrGeneProduct	328:352:480	331:355:483	10:10:12	4790	NF - kappaB	GeneOrGeneProduct	344	347	10	1:NR:2	L2R	NON-CROSS	352-355	365-368	3576	IL - 8|IL - 8|IL - 8	GeneOrGeneProduct	328:352:480	331:355:483	10:10:12	3553	IL - 1b	GeneOrGeneProduct	365	368	10	1:NR:2	L2R	CROSS	352-355	413-416	3576	IL - 8|IL - 8|IL - 8	GeneOrGeneProduct	328:352:480	331:355:483	10:10:12	3667	IRS - 1	GeneOrGeneProduct	413	416	11	1:NR:2	L2R	CROSS	417-420	480-483	3576	IL - 8|IL - 8|IL - 8	GeneOrGeneProduct	328:352:480	331:355:483	10:10:12	8660	IRS - 2	GeneOrGeneProduct	417	420	11	1:NR:2	L2R	CROSS	421-422	480-483	3576	IL - 8|IL - 8|IL - 8	GeneOrGeneProduct	328:352:480	331:355:483	10:10:12	3952	leptin	GeneOrGeneProduct	421	422	11	1:NR:2	L2R	CROSS	423-424	480-483	3576	IL - 8|IL - 8|IL - 8	GeneOrGeneProduct	328:352:480	331:355:483	10:10:12	9370	adiponectin	GeneOrGeneProduct	423	424	11	1:NR:2	L2R	CROSS	425-426	480-483	3576	IL - 8|IL - 8|IL - 8	GeneOrGeneProduct	328:352:480	331:355:483	10:10:12	10135	visfatin	GeneOrGeneProduct	425	426	11	1:NR:2	L2R	CROSS	427-430	480-483	3576	IL - 8|IL - 8|IL - 8	GeneOrGeneProduct	328:352:480	331:355:483	10:10:12	5950	RBP - 4	GeneOrGeneProduct	427	430	11	1:NR:2	L2R	CROSS	431-432	480-483	3576	IL - 8|IL - 8|IL - 8	GeneOrGeneProduct	328:352:480	331:355:483	10:10:12	5919	chemerin	GeneOrGeneProduct	431	432	11	1:NR:2	L2R	CROSS	433-436	480-483	3576	IL - 8|IL - 8|IL - 8	GeneOrGeneProduct	328:352:480	331:355:483	10:10:12	4925	nesfatin - 1	GeneOrGeneProduct	433	436	11	1:NR:2	L2R	CROSS	437-440	480-483	3576	IL - 8|IL - 8|IL - 8	GeneOrGeneProduct	328:352:480	331:355:483	10:10:12	10999	FATP - 4	GeneOrGeneProduct	437	440	11	1:NR:2	L2R	CROSS	441-442	480-483	3576	IL - 8|IL - 8|IL - 8	GeneOrGeneProduct	328:352:480	331:355:483	10:10:12	9388	EL	GeneOrGeneProduct	441	442	11	1:NR:2	L2R	CROSS	443-444	480-483	3576	IL - 8|IL - 8|IL - 8	GeneOrGeneProduct	328:352:480	331:355:483	10:10:12	4023	LPL	GeneOrGeneProduct	443	444	11	1:NR:2	L2R	CROSS	445-448	480-483	3576	IL - 8|IL - 8|IL - 8	GeneOrGeneProduct	328:352:480	331:355:483	10:10:12	2168	FABP - 1	GeneOrGeneProduct	445	448	11	1:NR:2	L2R	CROSS	449-452	480-483	3576	IL - 8|IL - 8|IL - 8	GeneOrGeneProduct	328:352:480	331:355:483	10:10:12	2170	FABP - 3	GeneOrGeneProduct	449	452	11	1:NR:2	L2R	CROSS	453-456	480-483	3576	IL - 8|IL - 8|IL - 8	GeneOrGeneProduct	328:352:480	331:355:483	10:10:12	2167	FABP - 4	GeneOrGeneProduct	453	456	11	1:NR:2	L2R	CROSS	458-461	480-483	3576	IL - 8|IL - 8|IL - 8	GeneOrGeneProduct	328:352:480	331:355:483	10:10:12	2171	FABP - 5	GeneOrGeneProduct	458	461	11	1:NR:2	L2R	NON-CROSS	480-483	507-512	3576	IL - 8|IL - 8|IL - 8	GeneOrGeneProduct	328:352:480	331:355:483	10:10:12	D044882,D052439	disordered lipid and glucose metabolisms	DiseaseOrPhenotypicFeature	507	512	12	1:NR:2	L2R	NON-CROSS	336-339	344-347	3586	IL - 10|IL - 10|IL - 10	GeneOrGeneProduct	336:360:489	339:363:492	10:10:12	4790	NF - kappaB	GeneOrGeneProduct	344	347	10	1:NR:2	L2R	NON-CROSS	360-363	365-368	3586	IL - 10|IL - 10|IL - 10	GeneOrGeneProduct	336:360:489	339:363:492	10:10:12	3553	IL - 1b	GeneOrGeneProduct	365	368	10	1:NR:2	L2R	CROSS	360-363	413-416	3586	IL - 10|IL - 10|IL - 10	GeneOrGeneProduct	336:360:489	339:363:492	10:10:12	3667	IRS - 1	GeneOrGeneProduct	413	416	11	1:NR:2	L2R	CROSS	360-363	417-420	3586	IL - 10|IL - 10|IL - 10	GeneOrGeneProduct	336:360:489	339:363:492	10:10:12	8660	IRS - 2	GeneOrGeneProduct	417	420	11	1:NR:2	L2R	CROSS	360-363	421-422	3586	IL - 10|IL - 10|IL - 10	GeneOrGeneProduct	336:360:489	339:363:492	10:10:12	3952	leptin	GeneOrGeneProduct	421	422	11	1:NR:2	L2R	CROSS	360-363	423-424	3586	IL - 10|IL - 10|IL - 10	GeneOrGeneProduct	336:360:489	339:363:492	10:10:12	9370	adiponectin	GeneOrGeneProduct	423	424	11	1:NR:2	L2R	CROSS	360-363	425-426	3586	IL - 10|IL - 10|IL - 10	GeneOrGeneProduct	336:360:489	339:363:492	10:10:12	10135	visfatin	GeneOrGeneProduct	425	426	11	1:NR:2	L2R	CROSS	427-430	489-492	3586	IL - 10|IL - 10|IL - 10	GeneOrGeneProduct	336:360:489	339:363:492	10:10:12	5950	RBP - 4	GeneOrGeneProduct	427	430	11	1:NR:2	L2R	CROSS	431-432	489-492	3586	IL - 10|IL - 10|IL - 10	GeneOrGeneProduct	336:360:489	339:363:492	10:10:12	5919	chemerin	GeneOrGeneProduct	431	432	11	1:NR:2	L2R	CROSS	433-436	489-492	3586	IL - 10|IL - 10|IL - 10	GeneOrGeneProduct	336:360:489	339:363:492	10:10:12	4925	nesfatin - 1	GeneOrGeneProduct	433	436	11	1:NR:2	L2R	CROSS	437-440	489-492	3586	IL - 10|IL - 10|IL - 10	GeneOrGeneProduct	336:360:489	339:363:492	10:10:12	10999	FATP - 4	GeneOrGeneProduct	437	440	11	1:NR:2	L2R	CROSS	441-442	489-492	3586	IL - 10|IL - 10|IL - 10	GeneOrGeneProduct	336:360:489	339:363:492	10:10:12	9388	EL	GeneOrGeneProduct	441	442	11	1:NR:2	L2R	CROSS	443-444	489-492	3586	IL - 10|IL - 10|IL - 10	GeneOrGeneProduct	336:360:489	339:363:492	10:10:12	4023	LPL	GeneOrGeneProduct	443	444	11	1:NR:2	L2R	CROSS	445-448	489-492	3586	IL - 10|IL - 10|IL - 10	GeneOrGeneProduct	336:360:489	339:363:492	10:10:12	2168	FABP - 1	GeneOrGeneProduct	445	448	11	1:NR:2	L2R	CROSS	449-452	489-492	3586	IL - 10|IL - 10|IL - 10	GeneOrGeneProduct	336:360:489	339:363:492	10:10:12	2170	FABP - 3	GeneOrGeneProduct	449	452	11	1:NR:2	L2R	CROSS	453-456	489-492	3586	IL - 10|IL - 10|IL - 10	GeneOrGeneProduct	336:360:489	339:363:492	10:10:12	2167	FABP - 4	GeneOrGeneProduct	453	456	11	1:NR:2	L2R	CROSS	458-461	489-492	3586	IL - 10|IL - 10|IL - 10	GeneOrGeneProduct	336:360:489	339:363:492	10:10:12	2171	FABP - 5	GeneOrGeneProduct	458	461	11	1:NR:2	L2R	NON-CROSS	489-492	507-512	3586	IL - 10|IL - 10|IL - 10	GeneOrGeneProduct	336:360:489	339:363:492	10:10:12	D044882,D052439	disordered lipid and glucose metabolisms	DiseaseOrPhenotypicFeature	507	512	12	1:NR:2	L2R	NON-CROSS	344-347	365-368	4790	NF - kappaB	GeneOrGeneProduct	344	347	10	3553	IL - 1b	GeneOrGeneProduct	365	368	10	1:NR:2	L2R	CROSS	344-347	413-416	4790	NF - kappaB	GeneOrGeneProduct	344	347	10	3667	IRS - 1	GeneOrGeneProduct	413	416	11	1:NR:2	L2R	CROSS	344-347	417-420	4790	NF - kappaB	GeneOrGeneProduct	344	347	10	8660	IRS - 2	GeneOrGeneProduct	417	420	11	1:NR:2	L2R	CROSS	344-347	421-422	4790	NF - kappaB	GeneOrGeneProduct	344	347	10	3952	leptin	GeneOrGeneProduct	421	422	11	1:NR:2	L2R	CROSS	344-347	423-424	4790	NF - kappaB	GeneOrGeneProduct	344	347	10	9370	adiponectin	GeneOrGeneProduct	423	424	11	1:NR:2	L2R	CROSS	344-347	425-426	4790	NF - kappaB	GeneOrGeneProduct	344	347	10	10135	visfatin	GeneOrGeneProduct	425	426	11	1:NR:2	L2R	CROSS	344-347	427-430	4790	NF - kappaB	GeneOrGeneProduct	344	347	10	5950	RBP - 4	GeneOrGeneProduct	427	430	11	1:NR:2	L2R	CROSS	344-347	431-432	4790	NF - kappaB	GeneOrGeneProduct	344	347	10	5919	chemerin	GeneOrGeneProduct	431	432	11	1:NR:2	L2R	CROSS	344-347	433-436	4790	NF - kappaB	GeneOrGeneProduct	344	347	10	4925	nesfatin - 1	GeneOrGeneProduct	433	436	11	1:NR:2	L2R	CROSS	344-347	437-440	4790	NF - kappaB	GeneOrGeneProduct	344	347	10	10999	FATP - 4	GeneOrGeneProduct	437	440	11	1:NR:2	L2R	CROSS	344-347	441-442	4790	NF - kappaB	GeneOrGeneProduct	344	347	10	9388	EL	GeneOrGeneProduct	441	442	11	1:NR:2	L2R	CROSS	344-347	443-444	4790	NF - kappaB	GeneOrGeneProduct	344	347	10	4023	LPL	GeneOrGeneProduct	443	444	11	1:NR:2	L2R	CROSS	344-347	445-448	4790	NF - kappaB	GeneOrGeneProduct	344	347	10	2168	FABP - 1	GeneOrGeneProduct	445	448	11	1:NR:2	L2R	CROSS	344-347	449-452	4790	NF - kappaB	GeneOrGeneProduct	344	347	10	2170	FABP - 3	GeneOrGeneProduct	449	452	11	1:NR:2	L2R	CROSS	344-347	453-456	4790	NF - kappaB	GeneOrGeneProduct	344	347	10	2167	FABP - 4	GeneOrGeneProduct	453	456	11	1:NR:2	L2R	CROSS	344-347	458-461	4790	NF - kappaB	GeneOrGeneProduct	344	347	10	2171	FABP - 5	GeneOrGeneProduct	458	461	11	1:NR:2	L2R	CROSS	344-347	507-512	4790	NF - kappaB	GeneOrGeneProduct	344	347	10	D044882,D052439	disordered lipid and glucose metabolisms	DiseaseOrPhenotypicFeature	507	512	12	1:NR:2	L2R	CROSS	365-368	413-416	3553	IL - 1b	GeneOrGeneProduct	365	368	10	3667	IRS - 1	GeneOrGeneProduct	413	416	11	1:NR:2	L2R	CROSS	365-368	417-420	3553	IL - 1b	GeneOrGeneProduct	365	368	10	8660	IRS - 2	GeneOrGeneProduct	417	420	11	1:NR:2	L2R	CROSS	365-368	421-422	3553	IL - 1b	GeneOrGeneProduct	365	368	10	3952	leptin	GeneOrGeneProduct	421	422	11	1:NR:2	L2R	CROSS	365-368	423-424	3553	IL - 1b	GeneOrGeneProduct	365	368	10	9370	adiponectin	GeneOrGeneProduct	423	424	11	1:NR:2	L2R	CROSS	365-368	425-426	3553	IL - 1b	GeneOrGeneProduct	365	368	10	10135	visfatin	GeneOrGeneProduct	425	426	11	1:NR:2	L2R	CROSS	365-368	427-430	3553	IL - 1b	GeneOrGeneProduct	365	368	10	5950	RBP - 4	GeneOrGeneProduct	427	430	11	1:NR:2	L2R	CROSS	365-368	431-432	3553	IL - 1b	GeneOrGeneProduct	365	368	10	5919	chemerin	GeneOrGeneProduct	431	432	11	1:NR:2	L2R	CROSS	365-368	433-436	3553	IL - 1b	GeneOrGeneProduct	365	368	10	4925	nesfatin - 1	GeneOrGeneProduct	433	436	11	1:NR:2	L2R	CROSS	365-368	437-440	3553	IL - 1b	GeneOrGeneProduct	365	368	10	10999	FATP - 4	GeneOrGeneProduct	437	440	11	1:NR:2	L2R	CROSS	365-368	441-442	3553	IL - 1b	GeneOrGeneProduct	365	368	10	9388	EL	GeneOrGeneProduct	441	442	11	1:NR:2	L2R	CROSS	365-368	443-444	3553	IL - 1b	GeneOrGeneProduct	365	368	10	4023	LPL	GeneOrGeneProduct	443	444	11	1:NR:2	L2R	CROSS	365-368	445-448	3553	IL - 1b	GeneOrGeneProduct	365	368	10	2168	FABP - 1	GeneOrGeneProduct	445	448	11	1:NR:2	L2R	CROSS	365-368	449-452	3553	IL - 1b	GeneOrGeneProduct	365	368	10	2170	FABP - 3	GeneOrGeneProduct	449	452	11	1:NR:2	L2R	CROSS	365-368	453-456	3553	IL - 1b	GeneOrGeneProduct	365	368	10	2167	FABP - 4	GeneOrGeneProduct	453	456	11	1:NR:2	L2R	CROSS	365-368	458-461	3553	IL - 1b	GeneOrGeneProduct	365	368	10	2171	FABP - 5	GeneOrGeneProduct	458	461	11	1:NR:2	L2R	CROSS	365-368	507-512	3553	IL - 1b	GeneOrGeneProduct	365	368	10	D044882,D052439	disordered lipid and glucose metabolisms	DiseaseOrPhenotypicFeature	507	512	12	1:NR:2	L2R	NON-CROSS	413-416	417-420	3667	IRS - 1	GeneOrGeneProduct	413	416	11	8660	IRS - 2	GeneOrGeneProduct	417	420	11	1:NR:2	L2R	NON-CROSS	413-416	421-422	3667	IRS - 1	GeneOrGeneProduct	413	416	11	3952	leptin	GeneOrGeneProduct	421	422	11	1:NR:2	L2R	NON-CROSS	413-416	423-424	3667	IRS - 1	GeneOrGeneProduct	413	416	11	9370	adiponectin	GeneOrGeneProduct	423	424	11	1:NR:2	L2R	NON-CROSS	413-416	425-426	3667	IRS - 1	GeneOrGeneProduct	413	416	11	10135	visfatin	GeneOrGeneProduct	425	426	11	1:NR:2	L2R	NON-CROSS	413-416	427-430	3667	IRS - 1	GeneOrGeneProduct	413	416	11	5950	RBP - 4	GeneOrGeneProduct	427	430	11	1:NR:2	L2R	NON-CROSS	413-416	431-432	3667	IRS - 1	GeneOrGeneProduct	413	416	11	5919	chemerin	GeneOrGeneProduct	431	432	11	1:NR:2	L2R	NON-CROSS	413-416	433-436	3667	IRS - 1	GeneOrGeneProduct	413	416	11	4925	nesfatin - 1	GeneOrGeneProduct	433	436	11	1:NR:2	L2R	NON-CROSS	413-416	437-440	3667	IRS - 1	GeneOrGeneProduct	413	416	11	10999	FATP - 4	GeneOrGeneProduct	437	440	11	1:NR:2	L2R	NON-CROSS	413-416	441-442	3667	IRS - 1	GeneOrGeneProduct	413	416	11	9388	EL	GeneOrGeneProduct	441	442	11	1:NR:2	L2R	NON-CROSS	413-416	443-444	3667	IRS - 1	GeneOrGeneProduct	413	416	11	4023	LPL	GeneOrGeneProduct	443	444	11	1:NR:2	L2R	NON-CROSS	413-416	445-448	3667	IRS - 1	GeneOrGeneProduct	413	416	11	2168	FABP - 1	GeneOrGeneProduct	445	448	11	1:NR:2	L2R	NON-CROSS	413-416	449-452	3667	IRS - 1	GeneOrGeneProduct	413	416	11	2170	FABP - 3	GeneOrGeneProduct	449	452	11	1:NR:2	L2R	NON-CROSS	413-416	453-456	3667	IRS - 1	GeneOrGeneProduct	413	416	11	2167	FABP - 4	GeneOrGeneProduct	453	456	11	1:NR:2	L2R	NON-CROSS	413-416	458-461	3667	IRS - 1	GeneOrGeneProduct	413	416	11	2171	FABP - 5	GeneOrGeneProduct	458	461	11	1:NR:2	L2R	CROSS	413-416	507-512	3667	IRS - 1	GeneOrGeneProduct	413	416	11	D044882,D052439	disordered lipid and glucose metabolisms	DiseaseOrPhenotypicFeature	507	512	12	1:NR:2	L2R	NON-CROSS	417-420	421-422	8660	IRS - 2	GeneOrGeneProduct	417	420	11	3952	leptin	GeneOrGeneProduct	421	422	11	1:NR:2	L2R	NON-CROSS	417-420	423-424	8660	IRS - 2	GeneOrGeneProduct	417	420	11	9370	adiponectin	GeneOrGeneProduct	423	424	11	1:NR:2	L2R	NON-CROSS	417-420	425-426	8660	IRS - 2	GeneOrGeneProduct	417	420	11	10135	visfatin	GeneOrGeneProduct	425	426	11	1:NR:2	L2R	NON-CROSS	417-420	427-430	8660	IRS - 2	GeneOrGeneProduct	417	420	11	5950	RBP - 4	GeneOrGeneProduct	427	430	11	1:NR:2	L2R	NON-CROSS	417-420	431-432	8660	IRS - 2	GeneOrGeneProduct	417	420	11	5919	chemerin	GeneOrGeneProduct	431	432	11	1:NR:2	L2R	NON-CROSS	417-420	433-436	8660	IRS - 2	GeneOrGeneProduct	417	420	11	4925	nesfatin - 1	GeneOrGeneProduct	433	436	11	1:NR:2	L2R	NON-CROSS	417-420	437-440	8660	IRS - 2	GeneOrGeneProduct	417	420	11	10999	FATP - 4	GeneOrGeneProduct	437	440	11	1:NR:2	L2R	NON-CROSS	417-420	441-442	8660	IRS - 2	GeneOrGeneProduct	417	420	11	9388	EL	GeneOrGeneProduct	441	442	11	1:NR:2	L2R	NON-CROSS	417-420	443-444	8660	IRS - 2	GeneOrGeneProduct	417	420	11	4023	LPL	GeneOrGeneProduct	443	444	11	1:NR:2	L2R	NON-CROSS	417-420	445-448	8660	IRS - 2	GeneOrGeneProduct	417	420	11	2168	FABP - 1	GeneOrGeneProduct	445	448	11	1:NR:2	L2R	NON-CROSS	417-420	449-452	8660	IRS - 2	GeneOrGeneProduct	417	420	11	2170	FABP - 3	GeneOrGeneProduct	449	452	11	1:NR:2	L2R	NON-CROSS	417-420	453-456	8660	IRS - 2	GeneOrGeneProduct	417	420	11	2167	FABP - 4	GeneOrGeneProduct	453	456	11	1:NR:2	L2R	NON-CROSS	417-420	458-461	8660	IRS - 2	GeneOrGeneProduct	417	420	11	2171	FABP - 5	GeneOrGeneProduct	458	461	11	1:NR:2	L2R	CROSS	417-420	507-512	8660	IRS - 2	GeneOrGeneProduct	417	420	11	D044882,D052439	disordered lipid and glucose metabolisms	DiseaseOrPhenotypicFeature	507	512	12	1:NR:2	L2R	NON-CROSS	421-422	423-424	3952	leptin	GeneOrGeneProduct	421	422	11	9370	adiponectin	GeneOrGeneProduct	423	424	11	1:NR:2	L2R	NON-CROSS	421-422	425-426	3952	leptin	GeneOrGeneProduct	421	422	11	10135	visfatin	GeneOrGeneProduct	425	426	11	1:NR:2	L2R	NON-CROSS	421-422	427-430	3952	leptin	GeneOrGeneProduct	421	422	11	5950	RBP - 4	GeneOrGeneProduct	427	430	11	1:NR:2	L2R	NON-CROSS	421-422	431-432	3952	leptin	GeneOrGeneProduct	421	422	11	5919	chemerin	GeneOrGeneProduct	431	432	11	1:NR:2	L2R	NON-CROSS	421-422	433-436	3952	leptin	GeneOrGeneProduct	421	422	11	4925	nesfatin - 1	GeneOrGeneProduct	433	436	11	1:NR:2	L2R	NON-CROSS	421-422	437-440	3952	leptin	GeneOrGeneProduct	421	422	11	10999	FATP - 4	GeneOrGeneProduct	437	440	11	1:NR:2	L2R	NON-CROSS	421-422	441-442	3952	leptin	GeneOrGeneProduct	421	422	11	9388	EL	GeneOrGeneProduct	441	442	11	1:NR:2	L2R	NON-CROSS	421-422	443-444	3952	leptin	GeneOrGeneProduct	421	422	11	4023	LPL	GeneOrGeneProduct	443	444	11	1:NR:2	L2R	NON-CROSS	421-422	445-448	3952	leptin	GeneOrGeneProduct	421	422	11	2168	FABP - 1	GeneOrGeneProduct	445	448	11	1:NR:2	L2R	NON-CROSS	421-422	449-452	3952	leptin	GeneOrGeneProduct	421	422	11	2170	FABP - 3	GeneOrGeneProduct	449	452	11	1:NR:2	L2R	NON-CROSS	421-422	453-456	3952	leptin	GeneOrGeneProduct	421	422	11	2167	FABP - 4	GeneOrGeneProduct	453	456	11	1:NR:2	L2R	NON-CROSS	421-422	458-461	3952	leptin	GeneOrGeneProduct	421	422	11	2171	FABP - 5	GeneOrGeneProduct	458	461	11	1:NR:2	L2R	CROSS	421-422	507-512	3952	leptin	GeneOrGeneProduct	421	422	11	D044882,D052439	disordered lipid and glucose metabolisms	DiseaseOrPhenotypicFeature	507	512	12	1:NR:2	L2R	NON-CROSS	423-424	425-426	9370	adiponectin	GeneOrGeneProduct	423	424	11	10135	visfatin	GeneOrGeneProduct	425	426	11	1:NR:2	L2R	NON-CROSS	423-424	427-430	9370	adiponectin	GeneOrGeneProduct	423	424	11	5950	RBP - 4	GeneOrGeneProduct	427	430	11	1:NR:2	L2R	NON-CROSS	423-424	431-432	9370	adiponectin	GeneOrGeneProduct	423	424	11	5919	chemerin	GeneOrGeneProduct	431	432	11	1:NR:2	L2R	NON-CROSS	423-424	433-436	9370	adiponectin	GeneOrGeneProduct	423	424	11	4925	nesfatin - 1	GeneOrGeneProduct	433	436	11	1:NR:2	L2R	NON-CROSS	423-424	437-440	9370	adiponectin	GeneOrGeneProduct	423	424	11	10999	FATP - 4	GeneOrGeneProduct	437	440	11	1:NR:2	L2R	NON-CROSS	423-424	441-442	9370	adiponectin	GeneOrGeneProduct	423	424	11	9388	EL	GeneOrGeneProduct	441	442	11	1:NR:2	L2R	NON-CROSS	423-424	443-444	9370	adiponectin	GeneOrGeneProduct	423	424	11	4023	LPL	GeneOrGeneProduct	443	444	11	1:NR:2	L2R	NON-CROSS	423-424	445-448	9370	adiponectin	GeneOrGeneProduct	423	424	11	2168	FABP - 1	GeneOrGeneProduct	445	448	11	1:NR:2	L2R	NON-CROSS	423-424	449-452	9370	adiponectin	GeneOrGeneProduct	423	424	11	2170	FABP - 3	GeneOrGeneProduct	449	452	11	1:NR:2	L2R	NON-CROSS	423-424	453-456	9370	adiponectin	GeneOrGeneProduct	423	424	11	2167	FABP - 4	GeneOrGeneProduct	453	456	11	1:NR:2	L2R	NON-CROSS	423-424	458-461	9370	adiponectin	GeneOrGeneProduct	423	424	11	2171	FABP - 5	GeneOrGeneProduct	458	461	11	1:NR:2	L2R	CROSS	423-424	507-512	9370	adiponectin	GeneOrGeneProduct	423	424	11	D044882,D052439	disordered lipid and glucose metabolisms	DiseaseOrPhenotypicFeature	507	512	12	1:NR:2	L2R	NON-CROSS	425-426	427-430	10135	visfatin	GeneOrGeneProduct	425	426	11	5950	RBP - 4	GeneOrGeneProduct	427	430	11	1:NR:2	L2R	NON-CROSS	425-426	431-432	10135	visfatin	GeneOrGeneProduct	425	426	11	5919	chemerin	GeneOrGeneProduct	431	432	11	1:NR:2	L2R	NON-CROSS	425-426	433-436	10135	visfatin	GeneOrGeneProduct	425	426	11	4925	nesfatin - 1	GeneOrGeneProduct	433	436	11	1:NR:2	L2R	NON-CROSS	425-426	437-440	10135	visfatin	GeneOrGeneProduct	425	426	11	10999	FATP - 4	GeneOrGeneProduct	437	440	11	1:NR:2	L2R	NON-CROSS	425-426	441-442	10135	visfatin	GeneOrGeneProduct	425	426	11	9388	EL	GeneOrGeneProduct	441	442	11	1:NR:2	L2R	NON-CROSS	425-426	443-444	10135	visfatin	GeneOrGeneProduct	425	426	11	4023	LPL	GeneOrGeneProduct	443	444	11	1:NR:2	L2R	NON-CROSS	425-426	445-448	10135	visfatin	GeneOrGeneProduct	425	426	11	2168	FABP - 1	GeneOrGeneProduct	445	448	11	1:NR:2	L2R	NON-CROSS	425-426	449-452	10135	visfatin	GeneOrGeneProduct	425	426	11	2170	FABP - 3	GeneOrGeneProduct	449	452	11	1:NR:2	L2R	NON-CROSS	425-426	453-456	10135	visfatin	GeneOrGeneProduct	425	426	11	2167	FABP - 4	GeneOrGeneProduct	453	456	11	1:NR:2	L2R	NON-CROSS	425-426	458-461	10135	visfatin	GeneOrGeneProduct	425	426	11	2171	FABP - 5	GeneOrGeneProduct	458	461	11	1:NR:2	L2R	CROSS	425-426	507-512	10135	visfatin	GeneOrGeneProduct	425	426	11	D044882,D052439	disordered lipid and glucose metabolisms	DiseaseOrPhenotypicFeature	507	512	12	1:NR:2	L2R	NON-CROSS	427-430	431-432	5950	RBP - 4	GeneOrGeneProduct	427	430	11	5919	chemerin	GeneOrGeneProduct	431	432	11	1:NR:2	L2R	NON-CROSS	427-430	433-436	5950	RBP - 4	GeneOrGeneProduct	427	430	11	4925	nesfatin - 1	GeneOrGeneProduct	433	436	11	1:NR:2	L2R	NON-CROSS	427-430	437-440	5950	RBP - 4	GeneOrGeneProduct	427	430	11	10999	FATP - 4	GeneOrGeneProduct	437	440	11	1:NR:2	L2R	NON-CROSS	427-430	441-442	5950	RBP - 4	GeneOrGeneProduct	427	430	11	9388	EL	GeneOrGeneProduct	441	442	11	1:NR:2	L2R	NON-CROSS	427-430	443-444	5950	RBP - 4	GeneOrGeneProduct	427	430	11	4023	LPL	GeneOrGeneProduct	443	444	11	1:NR:2	L2R	NON-CROSS	427-430	445-448	5950	RBP - 4	GeneOrGeneProduct	427	430	11	2168	FABP - 1	GeneOrGeneProduct	445	448	11	1:NR:2	L2R	NON-CROSS	427-430	449-452	5950	RBP - 4	GeneOrGeneProduct	427	430	11	2170	FABP - 3	GeneOrGeneProduct	449	452	11	1:NR:2	L2R	NON-CROSS	427-430	453-456	5950	RBP - 4	GeneOrGeneProduct	427	430	11	2167	FABP - 4	GeneOrGeneProduct	453	456	11	1:NR:2	L2R	NON-CROSS	427-430	458-461	5950	RBP - 4	GeneOrGeneProduct	427	430	11	2171	FABP - 5	GeneOrGeneProduct	458	461	11	1:NR:2	L2R	CROSS	427-430	507-512	5950	RBP - 4	GeneOrGeneProduct	427	430	11	D044882,D052439	disordered lipid and glucose metabolisms	DiseaseOrPhenotypicFeature	507	512	12	1:NR:2	L2R	NON-CROSS	431-432	433-436	5919	chemerin	GeneOrGeneProduct	431	432	11	4925	nesfatin - 1	GeneOrGeneProduct	433	436	11	1:NR:2	L2R	NON-CROSS	431-432	437-440	5919	chemerin	GeneOrGeneProduct	431	432	11	10999	FATP - 4	GeneOrGeneProduct	437	440	11	1:NR:2	L2R	NON-CROSS	431-432	441-442	5919	chemerin	GeneOrGeneProduct	431	432	11	9388	EL	GeneOrGeneProduct	441	442	11	1:NR:2	L2R	NON-CROSS	431-432	443-444	5919	chemerin	GeneOrGeneProduct	431	432	11	4023	LPL	GeneOrGeneProduct	443	444	11	1:NR:2	L2R	NON-CROSS	431-432	445-448	5919	chemerin	GeneOrGeneProduct	431	432	11	2168	FABP - 1	GeneOrGeneProduct	445	448	11	1:NR:2	L2R	NON-CROSS	431-432	449-452	5919	chemerin	GeneOrGeneProduct	431	432	11	2170	FABP - 3	GeneOrGeneProduct	449	452	11	1:NR:2	L2R	NON-CROSS	431-432	453-456	5919	chemerin	GeneOrGeneProduct	431	432	11	2167	FABP - 4	GeneOrGeneProduct	453	456	11	1:NR:2	L2R	NON-CROSS	431-432	458-461	5919	chemerin	GeneOrGeneProduct	431	432	11	2171	FABP - 5	GeneOrGeneProduct	458	461	11	1:NR:2	L2R	CROSS	431-432	507-512	5919	chemerin	GeneOrGeneProduct	431	432	11	D044882,D052439	disordered lipid and glucose metabolisms	DiseaseOrPhenotypicFeature	507	512	12	1:NR:2	L2R	NON-CROSS	433-436	437-440	4925	nesfatin - 1	GeneOrGeneProduct	433	436	11	10999	FATP - 4	GeneOrGeneProduct	437	440	11	1:NR:2	L2R	NON-CROSS	433-436	441-442	4925	nesfatin - 1	GeneOrGeneProduct	433	436	11	9388	EL	GeneOrGeneProduct	441	442	11	1:NR:2	L2R	NON-CROSS	433-436	443-444	4925	nesfatin - 1	GeneOrGeneProduct	433	436	11	4023	LPL	GeneOrGeneProduct	443	444	11	1:NR:2	L2R	NON-CROSS	433-436	445-448	4925	nesfatin - 1	GeneOrGeneProduct	433	436	11	2168	FABP - 1	GeneOrGeneProduct	445	448	11	1:NR:2	L2R	NON-CROSS	433-436	449-452	4925	nesfatin - 1	GeneOrGeneProduct	433	436	11	2170	FABP - 3	GeneOrGeneProduct	449	452	11	1:NR:2	L2R	NON-CROSS	433-436	453-456	4925	nesfatin - 1	GeneOrGeneProduct	433	436	11	2167	FABP - 4	GeneOrGeneProduct	453	456	11	1:NR:2	L2R	NON-CROSS	433-436	458-461	4925	nesfatin - 1	GeneOrGeneProduct	433	436	11	2171	FABP - 5	GeneOrGeneProduct	458	461	11	1:NR:2	L2R	CROSS	433-436	507-512	4925	nesfatin - 1	GeneOrGeneProduct	433	436	11	D044882,D052439	disordered lipid and glucose metabolisms	DiseaseOrPhenotypicFeature	507	512	12	1:NR:2	L2R	NON-CROSS	437-440	441-442	10999	FATP - 4	GeneOrGeneProduct	437	440	11	9388	EL	GeneOrGeneProduct	441	442	11	1:NR:2	L2R	NON-CROSS	437-440	443-444	10999	FATP - 4	GeneOrGeneProduct	437	440	11	4023	LPL	GeneOrGeneProduct	443	444	11	1:NR:2	L2R	NON-CROSS	437-440	445-448	10999	FATP - 4	GeneOrGeneProduct	437	440	11	2168	FABP - 1	GeneOrGeneProduct	445	448	11	1:NR:2	L2R	NON-CROSS	437-440	449-452	10999	FATP - 4	GeneOrGeneProduct	437	440	11	2170	FABP - 3	GeneOrGeneProduct	449	452	11	1:NR:2	L2R	NON-CROSS	437-440	453-456	10999	FATP - 4	GeneOrGeneProduct	437	440	11	2167	FABP - 4	GeneOrGeneProduct	453	456	11	1:NR:2	L2R	NON-CROSS	437-440	458-461	10999	FATP - 4	GeneOrGeneProduct	437	440	11	2171	FABP - 5	GeneOrGeneProduct	458	461	11	1:NR:2	L2R	CROSS	437-440	507-512	10999	FATP - 4	GeneOrGeneProduct	437	440	11	D044882,D052439	disordered lipid and glucose metabolisms	DiseaseOrPhenotypicFeature	507	512	12	1:NR:2	L2R	NON-CROSS	441-442	443-444	9388	EL	GeneOrGeneProduct	441	442	11	4023	LPL	GeneOrGeneProduct	443	444	11	1:NR:2	L2R	NON-CROSS	441-442	445-448	9388	EL	GeneOrGeneProduct	441	442	11	2168	FABP - 1	GeneOrGeneProduct	445	448	11	1:NR:2	L2R	NON-CROSS	441-442	449-452	9388	EL	GeneOrGeneProduct	441	442	11	2170	FABP - 3	GeneOrGeneProduct	449	452	11	1:NR:2	L2R	NON-CROSS	441-442	453-456	9388	EL	GeneOrGeneProduct	441	442	11	2167	FABP - 4	GeneOrGeneProduct	453	456	11	1:NR:2	L2R	NON-CROSS	441-442	458-461	9388	EL	GeneOrGeneProduct	441	442	11	2171	FABP - 5	GeneOrGeneProduct	458	461	11	1:NR:2	L2R	CROSS	441-442	507-512	9388	EL	GeneOrGeneProduct	441	442	11	D044882,D052439	disordered lipid and glucose metabolisms	DiseaseOrPhenotypicFeature	507	512	12	1:NR:2	L2R	NON-CROSS	443-444	445-448	4023	LPL	GeneOrGeneProduct	443	444	11	2168	FABP - 1	GeneOrGeneProduct	445	448	11	1:NR:2	L2R	NON-CROSS	443-444	449-452	4023	LPL	GeneOrGeneProduct	443	444	11	2170	FABP - 3	GeneOrGeneProduct	449	452	11	1:NR:2	L2R	NON-CROSS	443-444	453-456	4023	LPL	GeneOrGeneProduct	443	444	11	2167	FABP - 4	GeneOrGeneProduct	453	456	11	1:NR:2	L2R	NON-CROSS	443-444	458-461	4023	LPL	GeneOrGeneProduct	443	444	11	2171	FABP - 5	GeneOrGeneProduct	458	461	11	1:NR:2	L2R	CROSS	443-444	507-512	4023	LPL	GeneOrGeneProduct	443	444	11	D044882,D052439	disordered lipid and glucose metabolisms	DiseaseOrPhenotypicFeature	507	512	12	1:NR:2	L2R	NON-CROSS	445-448	449-452	2168	FABP - 1	GeneOrGeneProduct	445	448	11	2170	FABP - 3	GeneOrGeneProduct	449	452	11	1:NR:2	L2R	NON-CROSS	445-448	453-456	2168	FABP - 1	GeneOrGeneProduct	445	448	11	2167	FABP - 4	GeneOrGeneProduct	453	456	11	1:NR:2	L2R	NON-CROSS	445-448	458-461	2168	FABP - 1	GeneOrGeneProduct	445	448	11	2171	FABP - 5	GeneOrGeneProduct	458	461	11	1:NR:2	L2R	CROSS	445-448	507-512	2168	FABP - 1	GeneOrGeneProduct	445	448	11	D044882,D052439	disordered lipid and glucose metabolisms	DiseaseOrPhenotypicFeature	507	512	12	1:NR:2	L2R	NON-CROSS	449-452	453-456	2170	FABP - 3	GeneOrGeneProduct	449	452	11	2167	FABP - 4	GeneOrGeneProduct	453	456	11	1:NR:2	L2R	NON-CROSS	449-452	458-461	2170	FABP - 3	GeneOrGeneProduct	449	452	11	2171	FABP - 5	GeneOrGeneProduct	458	461	11	1:NR:2	L2R	CROSS	449-452	507-512	2170	FABP - 3	GeneOrGeneProduct	449	452	11	D044882,D052439	disordered lipid and glucose metabolisms	DiseaseOrPhenotypicFeature	507	512	12	1:NR:2	L2R	NON-CROSS	453-456	458-461	2167	FABP - 4	GeneOrGeneProduct	453	456	11	2171	FABP - 5	GeneOrGeneProduct	458	461	11	1:NR:2	L2R	CROSS	453-456	507-512	2167	FABP - 4	GeneOrGeneProduct	453	456	11	D044882,D052439	disordered lipid and glucose metabolisms	DiseaseOrPhenotypicFeature	507	512	12	1:NR:2	L2R	CROSS	458-461	507-512	2171	FABP - 5	GeneOrGeneProduct	458	461	11	D044882,D052439	disordered lipid and glucose metabolisms	DiseaseOrPhenotypicFeature	507	512	12
15459975	Fine mapping and identification of a candidate gene SSH1 in disseminated superficial actinic porokeratosis .|Disseminated superficial actinic porokeratosis ( DSAP ) is an uncommon autosomal dominant chronic keratinization disorder , characterized by multiple superficial keratotic lesions surrounded by a slightly raised keratotic border .|Thus far , although two loci for DSAP have been identified , the genetic basis and pathogenesis of this disorder have not been elucidated yet .|In this study , we performed a genome - wide linkage analysis in three Chinese affected families and localized the gene in an 8 . 0 cM interval defined by D12S330 and D12S354 on chromosome 12 .|Upon screening 30 candidate genes , we identified a missense mutation , p . Ser63Asn in SSH1 in one family , a frameshift mutation , p . Ser19CysfsX24 in an alternative variant ( isoform f ) of SSH1 in another family , and a frameshift mutation , p . Pro27ProfsX54 in the same alternative variant in one non - familial case with DSAP .|SSH1 encodes a phosphatase that plays a pivotal role in actin dynamics .|Our data suggested that cytoskeleton disorganization in epidermal cells is likely associated with the pathogenesis of DSAP .	1:Association:2	L2R	NON-CROSS	8-9	10-14	54434	SSH1|SSH1|SSH1|SSH1	GeneOrGeneProduct	8:124:145:172	9:125:146:173	0:4:4:5	D017499	disseminated superficial actinic porokeratosis|Disseminated superficial actinic porokeratosis|DSAP|DSAP|DSAP|DSAP	DiseaseOrPhenotypicFeature	10:15:20:52:170:201	14:19:21:53:171:202	0:1:1:2:4:6	1:NR:2	L2R	CROSS	8-9	28-30	54434	SSH1|SSH1|SSH1|SSH1	GeneOrGeneProduct	8:124:145:172	9:125:146:173	0:4:4:5	D007642	keratinization disorder|keratotic lesions	DiseaseOrPhenotypicFeature	28:35	30:37	1:1	1:Association:2	R2L	NON-CROSS	170-171	120-123	p|SUB|S|63|N	p . Ser63Asn	SequenceVariant	120	123	4	D017499	disseminated superficial actinic porokeratosis|Disseminated superficial actinic porokeratosis|DSAP|DSAP|DSAP|DSAP	DiseaseOrPhenotypicFeature	10:15:20:52:170:201	14:19:21:53:171:202	0:1:1:2:4:6	1:Association:2	R2L	NON-CROSS	170-171	133-136	p|FS|S|19|C|24	p . Ser19CysfsX24	SequenceVariant	133	136	4	D017499	disseminated superficial actinic porokeratosis|Disseminated superficial actinic porokeratosis|DSAP|DSAP|DSAP|DSAP	DiseaseOrPhenotypicFeature	10:15:20:52:170:201	14:19:21:53:171:202	0:1:1:2:4:6	1:Association:2	R2L	NON-CROSS	170-171	155-158	p|FS|P|63|P|54	p . Pro27ProfsX54	SequenceVariant	155	158	4	D017499	disseminated superficial actinic porokeratosis|Disseminated superficial actinic porokeratosis|DSAP|DSAP|DSAP|DSAP	DiseaseOrPhenotypicFeature	10:15:20:52:170:201	14:19:21:53:171:202	0:1:1:2:4:6	1:NR:2	L2R	CROSS	35-37	120-123	D007642	keratinization disorder|keratotic lesions	DiseaseOrPhenotypicFeature	28:35	30:37	1:1	p|SUB|S|63|N	p . Ser63Asn	SequenceVariant	120	123	4	1:NR:2	L2R	CROSS	35-37	133-136	D007642	keratinization disorder|keratotic lesions	DiseaseOrPhenotypicFeature	28:35	30:37	1:1	p|FS|S|19|C|24	p . Ser19CysfsX24	SequenceVariant	133	136	4	1:NR:2	L2R	CROSS	35-37	155-158	D007642	keratinization disorder|keratotic lesions	DiseaseOrPhenotypicFeature	28:35	30:37	1:1	p|FS|P|63|P|54	p . Pro27ProfsX54	SequenceVariant	155	158	4
16330669	Array - based comparative genomic hybridization analysis reveals recurrent chromosomal alterations and prognostic parameters in primary cutaneous large B - cell lymphoma .|PURPOSE : To evaluate the clinical relevance of genomic aberrations in primary cutaneous large B - cell lymphoma ( PCLBCL ) .|PATIENTS AND METHODS : Skin biopsy samples of 31 patients with a PCLBCL classified as either primary cutaneous follicle center lymphoma ( PCFCL ; n = 19 ) or PCLBCL , leg type ( n = 12 ) , according to the WHO - European Organisation for Research and Treatment of Cancer ( EORTC ) classification , were investigated using array - based comparative genomic hybridization , fluorescence in situ hybridization ( FISH ) , and examination of promoter hypermethylation .|RESULTS : The most recurrent alterations in PCFCL were high - level DNA amplifications at 2p16 . 1 ( 63 % ) and deletion of chromosome 14q32 . 33 ( 68 % ) .|FISH analysis confirmed c - REL amplification in patients with gains at 2p16 . 1 .|In PCLBCL , leg type , most prominent aberrations were a high - level DNA amplification of 18q21 . 31 - q21 . 33 ( 67 % ) , including the BCL - 2 and MALT1 genes as confirmed by FISH , and deletions of a small region within 9p21 . 3 containing the CDKN2A , CDKN2B , and NSG - x genes .|Homozygous deletion of 9p21 . 3 was detected in five of 12 patients with PCLBCL , leg type , but in zero of 19 patients with PCFCL .|Complete methylation of the promoter region of the CDKN2A gene was demonstrated in one PCLBCL , leg type , patient with hemizygous deletion , in one patient without deletion , but in zero of 19 patients with PCFCL .|Seven of seven PCLBCL , leg type , patients with deletion of 9p21 . 3 and / or complete methylation of CDKN2A died as a result of their lymphoma .|CONCLUSION : Our results demonstrate prominent differences in chromosomal alterations between PCFCL and PCLBCL , leg type , that support their classification as separate entities within the WHO - EORTC scheme .|Inactivation of CDKN2A by either deletion or methylation of its promoter could be an important prognostic parameter for the group of PCLBCL , leg type .	1:NR:2	L2R	CROSS	163-166	177-178	D016403	primary cutaneous large B - cell lymphoma|primary cutaneous large B - cell lymphoma|PCLBCL|PCLBCL|PCLBCL|PCLBCL|PCLBCL|PCLBCL|PCLBCL|PCLBCL|PCLBCL	DiseaseOrPhenotypicFeature	15:34:42:57:74:177:254:282:310:350:390	22:41:43:58:75:178:255:283:311:351:391	0:1:1:2:2:5:6:7:8:9:10	5966	c - REL	GeneOrGeneProduct	163	166	4	1:Association:2	L2R	NON-CROSS	177-178	207-210	D016403	primary cutaneous large B - cell lymphoma|primary cutaneous large B - cell lymphoma|PCLBCL|PCLBCL|PCLBCL|PCLBCL|PCLBCL|PCLBCL|PCLBCL|PCLBCL|PCLBCL	DiseaseOrPhenotypicFeature	15:34:42:57:74:177:254:282:310:350:390	22:41:43:58:75:178:255:283:311:351:391	0:1:1:2:2:5:6:7:8:9:10	596	BCL - 2	GeneOrGeneProduct	207	210	5	1:Association:2	L2R	NON-CROSS	177-178	211-212	D016403	primary cutaneous large B - cell lymphoma|primary cutaneous large B - cell lymphoma|PCLBCL|PCLBCL|PCLBCL|PCLBCL|PCLBCL|PCLBCL|PCLBCL|PCLBCL|PCLBCL	DiseaseOrPhenotypicFeature	15:34:42:57:74:177:254:282:310:350:390	22:41:43:58:75:178:255:283:311:351:391	0:1:1:2:2:5:6:7:8:9:10	10892	MALT1	GeneOrGeneProduct	211	212	5	1:Association:2	L2R	NON-CROSS	276-277	282-283	D016403	primary cutaneous large B - cell lymphoma|primary cutaneous large B - cell lymphoma|PCLBCL|PCLBCL|PCLBCL|PCLBCL|PCLBCL|PCLBCL|PCLBCL|PCLBCL|PCLBCL	DiseaseOrPhenotypicFeature	15:34:42:57:74:177:254:282:310:350:390	22:41:43:58:75:178:255:283:311:351:391	0:1:1:2:2:5:6:7:8:9:10	1029	CDKN2A|CDKN2A|CDKN2A|CDKN2A	GeneOrGeneProduct	230:276:328:371	231:277:329:372	5:7:8:10	1:Association:2	L2R	NON-CROSS	232-233	254-255	D016403	primary cutaneous large B - cell lymphoma|primary cutaneous large B - cell lymphoma|PCLBCL|PCLBCL|PCLBCL|PCLBCL|PCLBCL|PCLBCL|PCLBCL|PCLBCL|PCLBCL	DiseaseOrPhenotypicFeature	15:34:42:57:74:177:254:282:310:350:390	22:41:43:58:75:178:255:283:311:351:391	0:1:1:2:2:5:6:7:8:9:10	1030	CDKN2B	GeneOrGeneProduct	232	233	5	1:Association:2	L2R	NON-CROSS	235-238	254-255	D016403	primary cutaneous large B - cell lymphoma|primary cutaneous large B - cell lymphoma|PCLBCL|PCLBCL|PCLBCL|PCLBCL|PCLBCL|PCLBCL|PCLBCL|PCLBCL|PCLBCL	DiseaseOrPhenotypicFeature	15:34:42:57:74:177:254:282:310:350:390	22:41:43:58:75:178:255:283:311:351:391	0:1:1:2:2:5:6:7:8:9:10	27099	NSG - x	GeneOrGeneProduct	235	238	5	1:Association:2	L2R	CROSS	133-134	163-166	D008224	primary cutaneous follicle center lymphoma|PCFCL|PCFCL|PCFCL|PCFCL|PCFCL	DiseaseOrPhenotypicFeature	61:67:133:266:305:348	66:68:134:267:306:349	2:2:3:6:7:9	5966	c - REL	GeneOrGeneProduct	163	166	4	1:NR:2	L2R	CROSS	207-210	266-267	D008224	primary cutaneous follicle center lymphoma|PCFCL|PCFCL|PCFCL|PCFCL|PCFCL	DiseaseOrPhenotypicFeature	61:67:133:266:305:348	66:68:134:267:306:349	2:2:3:6:7:9	596	BCL - 2	GeneOrGeneProduct	207	210	5	1:NR:2	L2R	CROSS	211-212	266-267	D008224	primary cutaneous follicle center lymphoma|PCFCL|PCFCL|PCFCL|PCFCL|PCFCL	DiseaseOrPhenotypicFeature	61:67:133:266:305:348	66:68:134:267:306:349	2:2:3:6:7:9	10892	MALT1	GeneOrGeneProduct	211	212	5	1:NR:2	L2R	NON-CROSS	266-267	276-277	D008224	primary cutaneous follicle center lymphoma|PCFCL|PCFCL|PCFCL|PCFCL|PCFCL	DiseaseOrPhenotypicFeature	61:67:133:266:305:348	66:68:134:267:306:349	2:2:3:6:7:9	1029	CDKN2A|CDKN2A|CDKN2A|CDKN2A	GeneOrGeneProduct	230:276:328:371	231:277:329:372	5:7:8:10	1:NR:2	L2R	CROSS	232-233	266-267	D008224	primary cutaneous follicle center lymphoma|PCFCL|PCFCL|PCFCL|PCFCL|PCFCL	DiseaseOrPhenotypicFeature	61:67:133:266:305:348	66:68:134:267:306:349	2:2:3:6:7:9	1030	CDKN2B	GeneOrGeneProduct	232	233	5	1:NR:2	L2R	CROSS	235-238	266-267	D008224	primary cutaneous follicle center lymphoma|PCFCL|PCFCL|PCFCL|PCFCL|PCFCL	DiseaseOrPhenotypicFeature	61:67:133:266:305:348	66:68:134:267:306:349	2:2:3:6:7:9	27099	NSG - x	GeneOrGeneProduct	235	238	5	1:NR:2	L2R	CROSS	96-97	163-166	D009369	Cancer	DiseaseOrPhenotypicFeature	96	97	2	5966	c - REL	GeneOrGeneProduct	163	166	4	1:NR:2	L2R	CROSS	96-97	207-210	D009369	Cancer	DiseaseOrPhenotypicFeature	96	97	2	596	BCL - 2	GeneOrGeneProduct	207	210	5	1:NR:2	L2R	CROSS	96-97	211-212	D009369	Cancer	DiseaseOrPhenotypicFeature	96	97	2	10892	MALT1	GeneOrGeneProduct	211	212	5	1:NR:2	L2R	CROSS	96-97	230-231	D009369	Cancer	DiseaseOrPhenotypicFeature	96	97	2	1029	CDKN2A|CDKN2A|CDKN2A|CDKN2A	GeneOrGeneProduct	230:276:328:371	231:277:329:372	5:7:8:10	1:NR:2	L2R	CROSS	96-97	232-233	D009369	Cancer	DiseaseOrPhenotypicFeature	96	97	2	1030	CDKN2B	GeneOrGeneProduct	232	233	5	1:NR:2	L2R	CROSS	96-97	235-238	D009369	Cancer	DiseaseOrPhenotypicFeature	96	97	2	27099	NSG - x	GeneOrGeneProduct	235	238	5	1:NR:2	L2R	CROSS	163-166	207-210	5966	c - REL	GeneOrGeneProduct	163	166	4	596	BCL - 2	GeneOrGeneProduct	207	210	5	1:NR:2	L2R	CROSS	163-166	211-212	5966	c - REL	GeneOrGeneProduct	163	166	4	10892	MALT1	GeneOrGeneProduct	211	212	5	1:NR:2	L2R	CROSS	163-166	230-231	5966	c - REL	GeneOrGeneProduct	163	166	4	1029	CDKN2A|CDKN2A|CDKN2A|CDKN2A	GeneOrGeneProduct	230:276:328:371	231:277:329:372	5:7:8:10	1:NR:2	L2R	CROSS	163-166	232-233	5966	c - REL	GeneOrGeneProduct	163	166	4	1030	CDKN2B	GeneOrGeneProduct	232	233	5	1:NR:2	L2R	CROSS	163-166	235-238	5966	c - REL	GeneOrGeneProduct	163	166	4	27099	NSG - x	GeneOrGeneProduct	235	238	5	1:NR:2	L2R	CROSS	163-166	335-336	5966	c - REL	GeneOrGeneProduct	163	166	4	D008223	lymphoma	DiseaseOrPhenotypicFeature	335	336	8	1:NR:2	L2R	NON-CROSS	207-210	211-212	596	BCL - 2	GeneOrGeneProduct	207	210	5	10892	MALT1	GeneOrGeneProduct	211	212	5	1:NR:2	L2R	NON-CROSS	207-210	230-231	596	BCL - 2	GeneOrGeneProduct	207	210	5	1029	CDKN2A|CDKN2A|CDKN2A|CDKN2A	GeneOrGeneProduct	230:276:328:371	231:277:329:372	5:7:8:10	1:NR:2	L2R	NON-CROSS	207-210	232-233	596	BCL - 2	GeneOrGeneProduct	207	210	5	1030	CDKN2B	GeneOrGeneProduct	232	233	5	1:NR:2	L2R	NON-CROSS	207-210	235-238	596	BCL - 2	GeneOrGeneProduct	207	210	5	27099	NSG - x	GeneOrGeneProduct	235	238	5	1:NR:2	L2R	CROSS	207-210	335-336	596	BCL - 2	GeneOrGeneProduct	207	210	5	D008223	lymphoma	DiseaseOrPhenotypicFeature	335	336	8	1:NR:2	L2R	NON-CROSS	211-212	230-231	10892	MALT1	GeneOrGeneProduct	211	212	5	1029	CDKN2A|CDKN2A|CDKN2A|CDKN2A	GeneOrGeneProduct	230:276:328:371	231:277:329:372	5:7:8:10	1:NR:2	L2R	NON-CROSS	211-212	232-233	10892	MALT1	GeneOrGeneProduct	211	212	5	1030	CDKN2B	GeneOrGeneProduct	232	233	5	1:NR:2	L2R	NON-CROSS	211-212	235-238	10892	MALT1	GeneOrGeneProduct	211	212	5	27099	NSG - x	GeneOrGeneProduct	235	238	5	1:NR:2	L2R	CROSS	211-212	335-336	10892	MALT1	GeneOrGeneProduct	211	212	5	D008223	lymphoma	DiseaseOrPhenotypicFeature	335	336	8	1:NR:2	L2R	NON-CROSS	230-231	232-233	1029	CDKN2A|CDKN2A|CDKN2A|CDKN2A	GeneOrGeneProduct	230:276:328:371	231:277:329:372	5:7:8:10	1030	CDKN2B	GeneOrGeneProduct	232	233	5	1:NR:2	L2R	NON-CROSS	230-231	235-238	1029	CDKN2A|CDKN2A|CDKN2A|CDKN2A	GeneOrGeneProduct	230:276:328:371	231:277:329:372	5:7:8:10	27099	NSG - x	GeneOrGeneProduct	235	238	5	1:Association:2	L2R	NON-CROSS	328-329	335-336	1029	CDKN2A|CDKN2A|CDKN2A|CDKN2A	GeneOrGeneProduct	230:276:328:371	231:277:329:372	5:7:8:10	D008223	lymphoma	DiseaseOrPhenotypicFeature	335	336	8	1:NR:2	L2R	NON-CROSS	232-233	235-238	1030	CDKN2B	GeneOrGeneProduct	232	233	5	27099	NSG - x	GeneOrGeneProduct	235	238	5	1:NR:2	L2R	CROSS	232-233	335-336	1030	CDKN2B	GeneOrGeneProduct	232	233	5	D008223	lymphoma	DiseaseOrPhenotypicFeature	335	336	8	1:NR:2	L2R	CROSS	235-238	335-336	27099	NSG - x	GeneOrGeneProduct	235	238	5	D008223	lymphoma	DiseaseOrPhenotypicFeature	335	336	8
19208385	Osteogenesis imperfecta type III with intracranial hemorrhage and brachydactyly associated with mutations in exon 49 of COL1A2 .|Osteogenesis imperfecta ( OI ) is a heritable bone disorder characterized by fractures with minimal trauma .|Intracranial hemorrhage has been reported in a small number of OI patients .|Here we describe three patients , a boy ( aged 15 years ) and two girls ( aged 17 and 7 years ) with OI type III who suffered intracranial hemorrhage and in addition had brachydactyly and nail hypoplasia .|In all of these patients , OI was caused by glycine mutations affecting exon 49 of the COL1A2 gene , which codes for the most carboxy - terminal part of the triple - helical domain of the collagen type I alpha 2 chain .|These observations suggest that mutations in this region of the collagen type I alpha 2 chain carry a high risk of abnormal limb development and intracranial bleeding .	1:Association:2	R2L	NON-CROSS	16-17	0-4	1278	COL1A2|COL1A2|collagen type I alpha 2|collagen type I alpha 2	GeneOrGeneProduct	16:105:125:142	17:106:130:147	0:4:4:5	C536044	Osteogenesis imperfecta type III|OI type III	DiseaseOrPhenotypicFeature	0:72	4:75	0:3	1:Association:2	R2L	NON-CROSS	16-17	5-7	1278	COL1A2|COL1A2|collagen type I alpha 2|collagen type I alpha 2	GeneOrGeneProduct	16:105:125:142	17:106:130:147	0:4:4:5	D020300	intracranial hemorrhage|Intracranial hemorrhage|intracranial hemorrhage|intracranial bleeding	DiseaseOrPhenotypicFeature	5:35:77:157	7:37:79:159	0:2:3:5	1:Association:2	L2R	NON-CROSS	8-9	16-17	D059327	brachydactyly|brachydactyly	DiseaseOrPhenotypicFeature	8:83	9:84	0:3	1278	COL1A2|COL1A2|collagen type I alpha 2|collagen type I alpha 2	GeneOrGeneProduct	16:105:125:142	17:106:130:147	0:4:4:5	1:Association:2	L2R	NON-CROSS	16-17	18-20	1278	COL1A2|COL1A2|collagen type I alpha 2|collagen type I alpha 2	GeneOrGeneProduct	16:105:125:142	17:106:130:147	0:4:4:5	D010013	Osteogenesis imperfecta|OI|OI|OI	DiseaseOrPhenotypicFeature	18:21:45:94	20:22:46:95	1:1:2:4	1:NR:2	L2R	CROSS	16-17	26-28	1278	COL1A2|COL1A2|collagen type I alpha 2|collagen type I alpha 2	GeneOrGeneProduct	16:105:125:142	17:106:130:147	0:4:4:5	D001847	bone disorder	DiseaseOrPhenotypicFeature	26	28	1	1:NR:2	L2R	CROSS	16-17	30-31	1278	COL1A2|COL1A2|collagen type I alpha 2|collagen type I alpha 2	GeneOrGeneProduct	16:105:125:142	17:106:130:147	0:4:4:5	D050723	fractures	DiseaseOrPhenotypicFeature	30	31	1	1:NR:2	L2R	CROSS	16-17	33-34	1278	COL1A2|COL1A2|collagen type I alpha 2|collagen type I alpha 2	GeneOrGeneProduct	16:105:125:142	17:106:130:147	0:4:4:5	D014947	trauma	DiseaseOrPhenotypicFeature	33	34	1	1:NR:2	L2R	CROSS	85-87	105-106	1278	COL1A2|COL1A2|collagen type I alpha 2|collagen type I alpha 2	GeneOrGeneProduct	16:105:125:142	17:106:130:147	0:4:4:5	D009260	nail hypoplasia	DiseaseOrPhenotypicFeature	85	87	3	1:Association:2	L2R	NON-CROSS	142-147	153-156	1278	COL1A2|COL1A2|collagen type I alpha 2|collagen type I alpha 2	GeneOrGeneProduct	16:105:125:142	17:106:130:147	0:4:4:5	D009140	abnormal limb development	DiseaseOrPhenotypicFeature	153	156	5
19681452	Bilateral haemorrhagic infarction of the globus pallidus after cocaine and alcohol intoxication .|Cocaine is a risk factor for both ischemic and haemorrhagic stroke .|We present the case of a 31 - year - old man with bilateral ischemia of the globus pallidus after excessive alcohol and intranasal cocaine use .|Drug - related globus pallidus infarctions are most often associated with heroin .|Bilateral basal ganglia infarcts after the use of cocaine , without concurrent heroin use , have never been reported .|In our patient , transient cardiac arrhythmia or respiratory dysfunction related to cocaine and / or ethanol use were the most likely causes of cerebral hypoperfusion .	1:NR:2	L2R	NON-CROSS	1-7	8-9	D002543,D020520	haemorrhagic infarction of the globus pallidus	DiseaseOrPhenotypicFeature	1	7	0	D003042	cocaine|Cocaine|cocaine|cocaine|cocaine	ChemicalEntity	8:13:49:73:97	9:14:50:74:98	0:1:2:4:5	1:NR:2	L2R	NON-CROSS	1-7	10-11	D002543,D020520	haemorrhagic infarction of the globus pallidus	DiseaseOrPhenotypicFeature	1	7	0	D000431	alcohol|alcohol|ethanol	ChemicalEntity	10:46:101	11:47:102	0:2:5	1:NR:2	L2R	CROSS	1-7	63-64	D002543,D020520	haemorrhagic infarction of the globus pallidus	DiseaseOrPhenotypicFeature	1	7	0	D003932	heroin|heroin	ChemicalEntity	63:77	64:78	3:4	1:NR:2	L2R	NON-CROSS	8-9	10-11	D003042	cocaine|Cocaine|cocaine|cocaine|cocaine	ChemicalEntity	8:13:49:73:97	9:14:50:74:98	0:1:2:4:5	D000431	alcohol|alcohol|ethanol	ChemicalEntity	10:46:101	11:47:102	0:2:5	1:NR:2	L2R	NON-CROSS	13-14	20-24	D003042	cocaine|Cocaine|cocaine|cocaine|cocaine	ChemicalEntity	8:13:49:73:97	9:14:50:74:98	0:1:2:4:5	D002544,D020521	ischemic and haemorrhagic stroke	DiseaseOrPhenotypicFeature	20	24	1	1:Positive_Correlation:2	L2R	NON-CROSS	39-44	49-50	D003042	cocaine|Cocaine|cocaine|cocaine|cocaine	ChemicalEntity	8:13:49:73:97	9:14:50:74:98	0:1:2:4:5	D002545	ischemia of the globus pallidus|cerebral hypoperfusion	DiseaseOrPhenotypicFeature	39:109	44:111	2:5	1:Positive_Correlation:2	L2R	NON-CROSS	66-69	73-74	D003042	cocaine|Cocaine|cocaine|cocaine|cocaine	ChemicalEntity	8:13:49:73:97	9:14:50:74:98	0:1:2:4:5	D020520	globus pallidus infarctions|basal ganglia infarcts	DiseaseOrPhenotypicFeature	55:66	58:69	3:4	1:NR:2	L2R	NON-CROSS	73-74	77-78	D003042	cocaine|Cocaine|cocaine|cocaine|cocaine	ChemicalEntity	8:13:49:73:97	9:14:50:74:98	0:1:2:4:5	D003932	heroin|heroin	ChemicalEntity	63:77	64:78	3:4	1:Positive_Correlation:2	L2R	NON-CROSS	90-92	97-98	D003042	cocaine|Cocaine|cocaine|cocaine|cocaine	ChemicalEntity	8:13:49:73:97	9:14:50:74:98	0:1:2:4:5	D001145	cardiac arrhythmia	DiseaseOrPhenotypicFeature	90	92	5	1:Positive_Correlation:2	L2R	NON-CROSS	93-95	97-98	D003042	cocaine|Cocaine|cocaine|cocaine|cocaine	ChemicalEntity	8:13:49:73:97	9:14:50:74:98	0:1:2:4:5	D012131	respiratory dysfunction	DiseaseOrPhenotypicFeature	93	95	5	1:NR:2	L2R	CROSS	10-11	20-24	D000431	alcohol|alcohol|ethanol	ChemicalEntity	10:46:101	11:47:102	0:2:5	D002544,D020521	ischemic and haemorrhagic stroke	DiseaseOrPhenotypicFeature	20	24	1	1:Positive_Correlation:2	L2R	NON-CROSS	39-44	46-47	D000431	alcohol|alcohol|ethanol	ChemicalEntity	10:46:101	11:47:102	0:2:5	D002545	ischemia of the globus pallidus|cerebral hypoperfusion	DiseaseOrPhenotypicFeature	39:109	44:111	2:5	1:Positive_Correlation:2	L2R	CROSS	46-47	55-58	D000431	alcohol|alcohol|ethanol	ChemicalEntity	10:46:101	11:47:102	0:2:5	D020520	globus pallidus infarctions|basal ganglia infarcts	DiseaseOrPhenotypicFeature	55:66	58:69	3:4	1:NR:2	L2R	CROSS	46-47	63-64	D000431	alcohol|alcohol|ethanol	ChemicalEntity	10:46:101	11:47:102	0:2:5	D003932	heroin|heroin	ChemicalEntity	63:77	64:78	3:4	1:Positive_Correlation:2	L2R	NON-CROSS	90-92	101-102	D000431	alcohol|alcohol|ethanol	ChemicalEntity	10:46:101	11:47:102	0:2:5	D001145	cardiac arrhythmia	DiseaseOrPhenotypicFeature	90	92	5	1:Positive_Correlation:2	L2R	NON-CROSS	93-95	101-102	D000431	alcohol|alcohol|ethanol	ChemicalEntity	10:46:101	11:47:102	0:2:5	D012131	respiratory dysfunction	DiseaseOrPhenotypicFeature	93	95	5	1:NR:2	L2R	CROSS	20-24	63-64	D002544,D020521	ischemic and haemorrhagic stroke	DiseaseOrPhenotypicFeature	20	24	1	D003932	heroin|heroin	ChemicalEntity	63:77	64:78	3:4	1:NR:2	L2R	CROSS	39-44	63-64	D002545	ischemia of the globus pallidus|cerebral hypoperfusion	DiseaseOrPhenotypicFeature	39:109	44:111	2:5	D003932	heroin|heroin	ChemicalEntity	63:77	64:78	3:4	1:Positive_Correlation:2	L2R	NON-CROSS	63-64	66-69	D020520	globus pallidus infarctions|basal ganglia infarcts	DiseaseOrPhenotypicFeature	55:66	58:69	3:4	D003932	heroin|heroin	ChemicalEntity	63:77	64:78	3:4	1:NR:2	L2R	CROSS	77-78	90-92	D003932	heroin|heroin	ChemicalEntity	63:77	64:78	3:4	D001145	cardiac arrhythmia	DiseaseOrPhenotypicFeature	90	92	5	1:NR:2	L2R	CROSS	77-78	93-95	D003932	heroin|heroin	ChemicalEntity	63:77	64:78	3:4	D012131	respiratory dysfunction	DiseaseOrPhenotypicFeature	93	95	5
20709368	The fibrinogen gamma 10034C > T polymorphism is not associated with Peripheral Arterial Disease .|Conversion of fibrinogen to fibrin plays an essential role in hemostasis and results in stabilization of the fibrin clot .|Fibrinogen consists of three pairs of non - identical polypeptide chains , encoded by different genes ( fibrinogen alpha [ FGA ] , fibrinogen beta [ FGB ] and fibrinogen gamma [ FGG ] ) .|A functional single nucleotide polymorphism ( SNP ) in the 3 ' untranslated region of the FGG gene ( FGG 10034C > T , rs2066865 ) has been associated with deep venous thrombosis and myocardial infarction .|Aim of the present study was to analyze the role of this polymorphism in peripheral arterial disease ( PAD ) .|The study was designed as case - control study including 891 patients with documented PAD and 777 control subjects .|FGG genotypes were determined by exonuclease ( TaqMan ) assays .|FGG genotype frequencies were not significantly different between PAD patients ( CC : 57 . 3 % , CT : 36 . 7 % , TT : 5 . 8 % ) and control subjects ( CC : 60 . 9 % , CT : 33 . 5 % , TT 5 . 6 % ; p = 0 . 35 ) .|In a multivariate logistic regression analysis including age , sex , smoking , diabetes , arterial hypertension and hypercholesterolemia , the FGG 10034 T variant was not significantly associated with the presence of PAD ( Odds ratio 1 . 07 , 95 % confidence interval 0 . 84 - 1 . 37 ; p = 0 . 60 ) .|The FGG 10034C > T polymorphism was furthermore not associated with age at onset of PAD .|We conclude that the thrombophilic FGG 10034 T gene variant does not contribute to the genetic susceptibility to PAD .	1:NR:2	L2R	NON-CROSS	143-144	149-150	2266	fibrinogen gamma|fibrinogen gamma|FGG|FGG|FGG|FGG|FGG|FGG|FGG|FGG	GeneOrGeneProduct	1:64:67:87:90:149:160:244:284:305	3:66:68:88:91:150:161:245:285:306	0:2:2:3:3:6:7:8:9:10	D058729	Peripheral Arterial Disease|peripheral arterial disease|PAD|PAD|PAD|PAD|PAD|PAD	DiseaseOrPhenotypicFeature	11:122:126:143:168:256:298:318	14:125:127:144:169:257:299:319	0:4:4:5:7:8:9:10	1:NR:2	L2R	NON-CROSS	1-3	17-18	2266	fibrinogen gamma|fibrinogen gamma|FGG|FGG|FGG|FGG|FGG|FGG|FGG|FGG	GeneOrGeneProduct	1:64:67:87:90:149:160:244:284:305	3:66:68:88:91:150:161:245:285:306	0:2:2:3:3:6:7:8:9:10	2243,2244,2266	fibrinogen|fibrin|fibrin|Fibrinogen	GeneOrGeneProduct	17:19:32:35	18:20:33:36	1:1:1:2	1:NR:2	L2R	NON-CROSS	55-56	64-66	2266	fibrinogen gamma|fibrinogen gamma|FGG|FGG|FGG|FGG|FGG|FGG|FGG|FGG	GeneOrGeneProduct	1:64:67:87:90:149:160:244:284:305	3:66:68:88:91:150:161:245:285:306	0:2:2:3:3:6:7:8:9:10	2243	fibrinogen alpha|FGA	GeneOrGeneProduct	52:55	54:56	2:2	1:NR:2	L2R	NON-CROSS	61-62	64-66	2266	fibrinogen gamma|fibrinogen gamma|FGG|FGG|FGG|FGG|FGG|FGG|FGG|FGG	GeneOrGeneProduct	1:64:67:87:90:149:160:244:284:305	3:66:68:88:91:150:161:245:285:306	0:2:2:3:3:6:7:8:9:10	2244	fibrinogen beta|FGB	GeneOrGeneProduct	58:61	60:62	2:2	1:Association:2	L2R	NON-CROSS	90-91	101-104	2266	fibrinogen gamma|fibrinogen gamma|FGG|FGG|FGG|FGG|FGG|FGG|FGG|FGG	GeneOrGeneProduct	1:64:67:87:90:149:160:244:284:305	3:66:68:88:91:150:161:245:285:306	0:2:2:3:3:6:7:8:9:10	D020246	deep venous thrombosis	DiseaseOrPhenotypicFeature	101	104	3	1:Association:2	L2R	NON-CROSS	90-91	105-107	2266	fibrinogen gamma|fibrinogen gamma|FGG|FGG|FGG|FGG|FGG|FGG|FGG|FGG	GeneOrGeneProduct	1:64:67:87:90:149:160:244:284:305	3:66:68:88:91:150:161:245:285:306	0:2:2:3:3:6:7:8:9:10	D009203	myocardial infarction	DiseaseOrPhenotypicFeature	105	107	3	1:NR:2	L2R	NON-CROSS	236-237	244-245	2266	fibrinogen gamma|fibrinogen gamma|FGG|FGG|FGG|FGG|FGG|FGG|FGG|FGG	GeneOrGeneProduct	1:64:67:87:90:149:160:244:284:305	3:66:68:88:91:150:161:245:285:306	0:2:2:3:3:6:7:8:9:10	D003920	diabetes	DiseaseOrPhenotypicFeature	236	237	8	1:NR:2	L2R	NON-CROSS	239-240	244-245	2266	fibrinogen gamma|fibrinogen gamma|FGG|FGG|FGG|FGG|FGG|FGG|FGG|FGG	GeneOrGeneProduct	1:64:67:87:90:149:160:244:284:305	3:66:68:88:91:150:161:245:285:306	0:2:2:3:3:6:7:8:9:10	D006973	hypertension	DiseaseOrPhenotypicFeature	239	240	8	1:NR:2	L2R	NON-CROSS	241-242	244-245	2266	fibrinogen gamma|fibrinogen gamma|FGG|FGG|FGG|FGG|FGG|FGG|FGG|FGG	GeneOrGeneProduct	1:64:67:87:90:149:160:244:284:305	3:66:68:88:91:150:161:245:285:306	0:2:2:3:3:6:7:8:9:10	D006937	hypercholesterolemia	DiseaseOrPhenotypicFeature	241	242	8	1:NR:2	L2R	NON-CROSS	3-6	11-14	rs2066865	10034C > T|10034C > T|rs2066865|10034 T|10034C > T|10034 T	SequenceVariant	3:91:95:245:285:306	6:94:96:247:288:308	0:3:3:8:9:10	D058729	Peripheral Arterial Disease|peripheral arterial disease|PAD|PAD|PAD|PAD|PAD|PAD	DiseaseOrPhenotypicFeature	11:122:126:143:168:256:298:318	14:125:127:144:169:257:299:319	0:4:4:5:7:8:9:10	1:Association:2	L2R	NON-CROSS	95-96	101-104	rs2066865	10034C > T|10034C > T|rs2066865|10034 T|10034C > T|10034 T	SequenceVariant	3:91:95:245:285:306	6:94:96:247:288:308	0:3:3:8:9:10	D020246	deep venous thrombosis	DiseaseOrPhenotypicFeature	101	104	3	1:Association:2	L2R	NON-CROSS	95-96	105-107	rs2066865	10034C > T|10034C > T|rs2066865|10034 T|10034C > T|10034 T	SequenceVariant	3:91:95:245:285:306	6:94:96:247:288:308	0:3:3:8:9:10	D009203	myocardial infarction	DiseaseOrPhenotypicFeature	105	107	3	1:NR:2	L2R	NON-CROSS	236-237	245-247	rs2066865	10034C > T|10034C > T|rs2066865|10034 T|10034C > T|10034 T	SequenceVariant	3:91:95:245:285:306	6:94:96:247:288:308	0:3:3:8:9:10	D003920	diabetes	DiseaseOrPhenotypicFeature	236	237	8	1:NR:2	L2R	NON-CROSS	239-240	245-247	rs2066865	10034C > T|10034C > T|rs2066865|10034 T|10034C > T|10034 T	SequenceVariant	3:91:95:245:285:306	6:94:96:247:288:308	0:3:3:8:9:10	D006973	hypertension	DiseaseOrPhenotypicFeature	239	240	8	1:NR:2	L2R	NON-CROSS	241-242	245-247	rs2066865	10034C > T|10034C > T|rs2066865|10034 T|10034C > T|10034 T	SequenceVariant	3:91:95:245:285:306	6:94:96:247:288:308	0:3:3:8:9:10	D006937	hypercholesterolemia	DiseaseOrPhenotypicFeature	241	242	8	1:NR:2	L2R	CROSS	11-14	17-18	D058729	Peripheral Arterial Disease|peripheral arterial disease|PAD|PAD|PAD|PAD|PAD|PAD	DiseaseOrPhenotypicFeature	11:122:126:143:168:256:298:318	14:125:127:144:169:257:299:319	0:4:4:5:7:8:9:10	2243,2244,2266	fibrinogen|fibrin|fibrin|Fibrinogen	GeneOrGeneProduct	17:19:32:35	18:20:33:36	1:1:1:2	1:NR:2	L2R	CROSS	11-14	52-54	D058729	Peripheral Arterial Disease|peripheral arterial disease|PAD|PAD|PAD|PAD|PAD|PAD	DiseaseOrPhenotypicFeature	11:122:126:143:168:256:298:318	14:125:127:144:169:257:299:319	0:4:4:5:7:8:9:10	2243	fibrinogen alpha|FGA	GeneOrGeneProduct	52:55	54:56	2:2	1:NR:2	L2R	CROSS	11-14	58-60	D058729	Peripheral Arterial Disease|peripheral arterial disease|PAD|PAD|PAD|PAD|PAD|PAD	DiseaseOrPhenotypicFeature	11:122:126:143:168:256:298:318	14:125:127:144:169:257:299:319	0:4:4:5:7:8:9:10	2244	fibrinogen beta|FGB	GeneOrGeneProduct	58:61	60:62	2:2	1:NR:2	L2R	NON-CROSS	35-36	52-54	2243,2244,2266	fibrinogen|fibrin|fibrin|Fibrinogen	GeneOrGeneProduct	17:19:32:35	18:20:33:36	1:1:1:2	2243	fibrinogen alpha|FGA	GeneOrGeneProduct	52:55	54:56	2:2	1:NR:2	L2R	NON-CROSS	35-36	58-60	2243,2244,2266	fibrinogen|fibrin|fibrin|Fibrinogen	GeneOrGeneProduct	17:19:32:35	18:20:33:36	1:1:1:2	2244	fibrinogen beta|FGB	GeneOrGeneProduct	58:61	60:62	2:2	1:NR:2	L2R	CROSS	35-36	101-104	2243,2244,2266	fibrinogen|fibrin|fibrin|Fibrinogen	GeneOrGeneProduct	17:19:32:35	18:20:33:36	1:1:1:2	D020246	deep venous thrombosis	DiseaseOrPhenotypicFeature	101	104	3	1:NR:2	L2R	CROSS	35-36	105-107	2243,2244,2266	fibrinogen|fibrin|fibrin|Fibrinogen	GeneOrGeneProduct	17:19:32:35	18:20:33:36	1:1:1:2	D009203	myocardial infarction	DiseaseOrPhenotypicFeature	105	107	3	1:NR:2	L2R	CROSS	35-36	236-237	2243,2244,2266	fibrinogen|fibrin|fibrin|Fibrinogen	GeneOrGeneProduct	17:19:32:35	18:20:33:36	1:1:1:2	D003920	diabetes	DiseaseOrPhenotypicFeature	236	237	8	1:NR:2	L2R	CROSS	35-36	239-240	2243,2244,2266	fibrinogen|fibrin|fibrin|Fibrinogen	GeneOrGeneProduct	17:19:32:35	18:20:33:36	1:1:1:2	D006973	hypertension	DiseaseOrPhenotypicFeature	239	240	8	1:NR:2	L2R	CROSS	35-36	241-242	2243,2244,2266	fibrinogen|fibrin|fibrin|Fibrinogen	GeneOrGeneProduct	17:19:32:35	18:20:33:36	1:1:1:2	D006937	hypercholesterolemia	DiseaseOrPhenotypicFeature	241	242	8	1:NR:2	L2R	NON-CROSS	55-56	58-60	2243	fibrinogen alpha|FGA	GeneOrGeneProduct	52:55	54:56	2:2	2244	fibrinogen beta|FGB	GeneOrGeneProduct	58:61	60:62	2:2	1:NR:2	L2R	CROSS	55-56	101-104	2243	fibrinogen alpha|FGA	GeneOrGeneProduct	52:55	54:56	2:2	D020246	deep venous thrombosis	DiseaseOrPhenotypicFeature	101	104	3	1:NR:2	L2R	CROSS	55-56	105-107	2243	fibrinogen alpha|FGA	GeneOrGeneProduct	52:55	54:56	2:2	D009203	myocardial infarction	DiseaseOrPhenotypicFeature	105	107	3	1:NR:2	L2R	CROSS	55-56	236-237	2243	fibrinogen alpha|FGA	GeneOrGeneProduct	52:55	54:56	2:2	D003920	diabetes	DiseaseOrPhenotypicFeature	236	237	8	1:NR:2	L2R	CROSS	55-56	239-240	2243	fibrinogen alpha|FGA	GeneOrGeneProduct	52:55	54:56	2:2	D006973	hypertension	DiseaseOrPhenotypicFeature	239	240	8	1:NR:2	L2R	CROSS	55-56	241-242	2243	fibrinogen alpha|FGA	GeneOrGeneProduct	52:55	54:56	2:2	D006937	hypercholesterolemia	DiseaseOrPhenotypicFeature	241	242	8	1:NR:2	L2R	CROSS	61-62	101-104	2244	fibrinogen beta|FGB	GeneOrGeneProduct	58:61	60:62	2:2	D020246	deep venous thrombosis	DiseaseOrPhenotypicFeature	101	104	3	1:NR:2	L2R	CROSS	61-62	105-107	2244	fibrinogen beta|FGB	GeneOrGeneProduct	58:61	60:62	2:2	D009203	myocardial infarction	DiseaseOrPhenotypicFeature	105	107	3	1:NR:2	L2R	CROSS	61-62	236-237	2244	fibrinogen beta|FGB	GeneOrGeneProduct	58:61	60:62	2:2	D003920	diabetes	DiseaseOrPhenotypicFeature	236	237	8	1:NR:2	L2R	CROSS	61-62	239-240	2244	fibrinogen beta|FGB	GeneOrGeneProduct	58:61	60:62	2:2	D006973	hypertension	DiseaseOrPhenotypicFeature	239	240	8	1:NR:2	L2R	CROSS	61-62	241-242	2244	fibrinogen beta|FGB	GeneOrGeneProduct	58:61	60:62	2:2	D006937	hypercholesterolemia	DiseaseOrPhenotypicFeature	241	242	8
21879313	Genotype rs8099917 near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B - 100 concentration in chronic hepatitis C .|The life cycle of the hepatitis C virus ( HCV ) is closely related to host lipoprotein metabolism .|Serum levels of lipid are associated with the response to pegylated interferon plus ribavirin ( PEG - IFN / RBV ) therapy , while single nucleotide polymorphisms ( SNPs ) around the human interleukin 28B ( IL28B ) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG - IFN / RBV therapy in chronic hepatitis with HCV genotype 1b infection .|The aim of this study was to elucidate the relationship between serum lipid and factors that are able to predict the efficacy of PEG - IFN / RB therapy , with specific focus on apolipoprotein B - 100 ( apoB - 100 ) in 148 subjects with chronic HCV G1b infection .|Our results demonstrated that both the aa 70 substitution in the core region of the HCV and the rs8099917 SNP located proximal to the IL28B were independent factors in determining serum apoB - 100 and low - density lipoprotein ( LDL ) cholesterol levels .|A significant association was noted between higher levels of apoB - 100 ( P = 1 . 1 10 ( - 3 ) ) and LDL cholesterol ( P = 0 . 02 ) and the subjects having Arg70 .|A significant association was also observed between subjects carrying the rs8099917 TT responder genotype and higher levels of apoB - 100 ( P = 6 . 4 10 ( - 3 ) ) and LDL cholesterol ( P = 4 . 2 10 ( - 3 ) ) .|Our results suggest that apoB - 100 and LDL cholesterol are markers of impaired cellular lipoprotein pathways and / or host endogenous interferon response to HCV in chronic HCV infection .|In particular , serum apoB - 100 concentration might be an informative marker for judging changes in HCV - associated intracellular lipoprotein metabolism in patients carrying the rs8099917 responder genotype .	1:Association:2	R2L	NON-CROSS	32-35	1-2	D019698	chronic hepatitis C	DiseaseOrPhenotypicFeature	32	35	0	rs8099917	rs8099917|rs8099917|rs8099917|rs8099917	SequenceVariant	1:199:276:373	2:200:277:374	0:4:6:8	1:NR:2	L2R	CROSS	1-2	58-59	rs8099917	rs8099917|rs8099917|rs8099917|rs8099917	SequenceVariant	1:199:276:373	2:200:277:374	0:4:6:8	D008055	lipid|lipid	ChemicalEntity	58:141	59:142	2:3	1:NR:2	L2R	CROSS	156-157	199-200	rs8099917	rs8099917|rs8099917|rs8099917|rs8099917	SequenceVariant	1:199:276:373	2:200:277:374	0:4:6:8	D012254	ribavirin|RBV|RBV|RB	ChemicalEntity	68:74:118:156	69:75:119:157	2:2:2:3	1:NR:2	L2R	CROSS	121-123	199-200	rs8099917	rs8099917|rs8099917|rs8099917|rs8099917	SequenceVariant	1:199:276:373	2:200:277:374	0:4:6:8	D006521	chronic hepatitis	DiseaseOrPhenotypicFeature	121	123	2	1:Association:2	R2L	CROSS	199-200	177-180	D006526	HCV genotype 1b infection|HCV G1b infection|HCV infection	DiseaseOrPhenotypicFeature	124:177:343	128:180:345	2:3:7	rs8099917	rs8099917|rs8099917|rs8099917|rs8099917	SequenceVariant	1:199:276:373	2:200:277:374	0:4:6:8	1:Positive_Correlation:2	L2R	NON-CROSS	199-200	216-224	rs8099917	rs8099917|rs8099917|rs8099917|rs8099917	SequenceVariant	1:199:276:373	2:200:277:374	0:4:6:8	D008078	low - density lipoprotein ( LDL ) cholesterol|LDL cholesterol|LDL cholesterol|LDL cholesterol	ChemicalEntity	216:251:300:323	224:253:302:325	4:5:6:7	1:Association:2	L2R	NON-CROSS	205-206	212-215	282617	IL28B|interleukin 28B|IL28B|IL28B	GeneOrGeneProduct	4:88:91:205	5:90:92:206	0:2:2:4	338	apolipoprotein B - 100|apolipoprotein B - 100|apoB - 100|apoB - 100|apoB - 100|apoB - 100|apoB - 100|apoB - 100	GeneOrGeneProduct	26:163:168:212:235:284:319:350	30:167:171:215:238:287:322:353	0:3:3:4:5:6:7:8	1:Association:2	R2L	NON-CROSS	32-35	4-5	D019698	chronic hepatitis C	DiseaseOrPhenotypicFeature	32	35	0	282617	IL28B|interleukin 28B|IL28B|IL28B	GeneOrGeneProduct	4:88:91:205	5:90:92:206	0:2:2:4	1:NR:2	L2R	NON-CROSS	58-59	88-90	282617	IL28B|interleukin 28B|IL28B|IL28B	GeneOrGeneProduct	4:88:91:205	5:90:92:206	0:2:2:4	D008055	lipid|lipid	ChemicalEntity	58:141	59:142	2:3	1:Association:2	L2R	NON-CROSS	70-73	88-90	282617	IL28B|interleukin 28B|IL28B|IL28B	GeneOrGeneProduct	4:88:91:205	5:90:92:206	0:2:2:4	3439	pegylated interferon|PEG - IFN|PEG - IFN|PEG - IFN	GeneOrGeneProduct	65:70:114:152	67:73:117:155	2:2:2:3	1:Association:2	L2R	NON-CROSS	74-75	88-90	282617	IL28B|interleukin 28B|IL28B|IL28B	GeneOrGeneProduct	4:88:91:205	5:90:92:206	0:2:2:4	D012254	ribavirin|RBV|RBV|RB	ChemicalEntity	68:74:118:156	69:75:119:157	2:2:2:3	1:Association:2	L2R	NON-CROSS	91-92	121-123	282617	IL28B|interleukin 28B|IL28B|IL28B	GeneOrGeneProduct	4:88:91:205	5:90:92:206	0:2:2:4	D006521	chronic hepatitis	DiseaseOrPhenotypicFeature	121	123	2	1:Association:2	R2L	NON-CROSS	205-206	177-180	D006526	HCV genotype 1b infection|HCV G1b infection|HCV infection	DiseaseOrPhenotypicFeature	124:177:343	128:180:345	2:3:7	282617	IL28B|interleukin 28B|IL28B|IL28B	GeneOrGeneProduct	4:88:91:205	5:90:92:206	0:2:2:4	1:Association:2	L2R	NON-CROSS	205-206	216-224	282617	IL28B|interleukin 28B|IL28B|IL28B	GeneOrGeneProduct	4:88:91:205	5:90:92:206	0:2:2:4	D008078	low - density lipoprotein ( LDL ) cholesterol|LDL cholesterol|LDL cholesterol|LDL cholesterol	ChemicalEntity	216:251:300:323	224:253:302:325	4:5:6:7	1:Association:2	R2L	NON-CROSS	32-35	26-30	D019698	chronic hepatitis C	DiseaseOrPhenotypicFeature	32	35	0	338	apolipoprotein B - 100|apolipoprotein B - 100|apoB - 100|apoB - 100|apoB - 100|apoB - 100|apoB - 100|apoB - 100	GeneOrGeneProduct	26:163:168:212:235:284:319:350	30:167:171:215:238:287:322:353	0:3:3:4:5:6:7:8	1:NR:2	L2R	NON-CROSS	141-142	163-167	338	apolipoprotein B - 100|apolipoprotein B - 100|apoB - 100|apoB - 100|apoB - 100|apoB - 100|apoB - 100|apoB - 100	GeneOrGeneProduct	26:163:168:212:235:284:319:350	30:167:171:215:238:287:322:353	0:3:3:4:5:6:7:8	D008055	lipid|lipid	ChemicalEntity	58:141	59:142	2:3	1:NR:2	L2R	NON-CROSS	152-155	163-167	338	apolipoprotein B - 100|apolipoprotein B - 100|apoB - 100|apoB - 100|apoB - 100|apoB - 100|apoB - 100|apoB - 100	GeneOrGeneProduct	26:163:168:212:235:284:319:350	30:167:171:215:238:287:322:353	0:3:3:4:5:6:7:8	3439	pegylated interferon|PEG - IFN|PEG - IFN|PEG - IFN	GeneOrGeneProduct	65:70:114:152	67:73:117:155	2:2:2:3	1:NR:2	L2R	NON-CROSS	156-157	163-167	338	apolipoprotein B - 100|apolipoprotein B - 100|apoB - 100|apoB - 100|apoB - 100|apoB - 100|apoB - 100|apoB - 100	GeneOrGeneProduct	26:163:168:212:235:284:319:350	30:167:171:215:238:287:322:353	0:3:3:4:5:6:7:8	D012254	ribavirin|RBV|RBV|RB	ChemicalEntity	68:74:118:156	69:75:119:157	2:2:2:3	1:NR:2	L2R	CROSS	121-123	163-167	338	apolipoprotein B - 100|apolipoprotein B - 100|apoB - 100|apoB - 100|apoB - 100|apoB - 100|apoB - 100|apoB - 100	GeneOrGeneProduct	26:163:168:212:235:284:319:350	30:167:171:215:238:287:322:353	0:3:3:4:5:6:7:8	D006521	chronic hepatitis	DiseaseOrPhenotypicFeature	121	123	2	1:Association:2	R2L	NON-CROSS	350-353	343-345	D006526	HCV genotype 1b infection|HCV G1b infection|HCV infection	DiseaseOrPhenotypicFeature	124:177:343	128:180:345	2:3:7	338	apolipoprotein B - 100|apolipoprotein B - 100|apoB - 100|apoB - 100|apoB - 100|apoB - 100|apoB - 100|apoB - 100	GeneOrGeneProduct	26:163:168:212:235:284:319:350	30:167:171:215:238:287:322:353	0:3:3:4:5:6:7:8	1:Association:2	L2R	NON-CROSS	212-215	216-224	338	apolipoprotein B - 100|apolipoprotein B - 100|apoB - 100|apoB - 100|apoB - 100|apoB - 100|apoB - 100|apoB - 100	GeneOrGeneProduct	26:163:168:212:235:284:319:350	30:167:171:215:238:287:322:353	0:3:3:4:5:6:7:8	D008078	low - density lipoprotein ( LDL ) cholesterol|LDL cholesterol|LDL cholesterol|LDL cholesterol	ChemicalEntity	216:251:300:323	224:253:302:325	4:5:6:7	1:NR:2	L2R	CROSS	32-35	58-59	D019698	chronic hepatitis C	DiseaseOrPhenotypicFeature	32	35	0	D008055	lipid|lipid	ChemicalEntity	58:141	59:142	2:3	1:NR:2	L2R	CROSS	32-35	65-67	D019698	chronic hepatitis C	DiseaseOrPhenotypicFeature	32	35	0	3439	pegylated interferon|PEG - IFN|PEG - IFN|PEG - IFN	GeneOrGeneProduct	65:70:114:152	67:73:117:155	2:2:2:3	1:NR:2	L2R	CROSS	32-35	68-69	D019698	chronic hepatitis C	DiseaseOrPhenotypicFeature	32	35	0	D012254	ribavirin|RBV|RBV|RB	ChemicalEntity	68:74:118:156	69:75:119:157	2:2:2:3	1:NR:2	L2R	CROSS	32-35	216-224	D019698	chronic hepatitis C	DiseaseOrPhenotypicFeature	32	35	0	D008078	low - density lipoprotein ( LDL ) cholesterol|LDL cholesterol|LDL cholesterol|LDL cholesterol	ChemicalEntity	216:251:300:323	224:253:302:325	4:5:6:7	1:NR:2	L2R	CROSS	32-35	264-265	D019698	chronic hepatitis C	DiseaseOrPhenotypicFeature	32	35	0	p|Allele|R|70	Arg70	SequenceVariant	264	265	5	1:Association:2	L2R	NON-CROSS	58-59	65-67	D008055	lipid|lipid	ChemicalEntity	58:141	59:142	2:3	3439	pegylated interferon|PEG - IFN|PEG - IFN|PEG - IFN	GeneOrGeneProduct	65:70:114:152	67:73:117:155	2:2:2:3	1:Association:2	L2R	NON-CROSS	58-59	68-69	D008055	lipid|lipid	ChemicalEntity	58:141	59:142	2:3	D012254	ribavirin|RBV|RBV|RB	ChemicalEntity	68:74:118:156	69:75:119:157	2:2:2:3	1:NR:2	L2R	NON-CROSS	121-123	141-142	D008055	lipid|lipid	ChemicalEntity	58:141	59:142	2:3	D006521	chronic hepatitis	DiseaseOrPhenotypicFeature	121	123	2	1:NR:2	L2R	NON-CROSS	124-128	141-142	D008055	lipid|lipid	ChemicalEntity	58:141	59:142	2:3	D006526	HCV genotype 1b infection|HCV G1b infection|HCV infection	DiseaseOrPhenotypicFeature	124:177:343	128:180:345	2:3:7	1:NR:2	L2R	CROSS	141-142	216-224	D008055	lipid|lipid	ChemicalEntity	58:141	59:142	2:3	D008078	low - density lipoprotein ( LDL ) cholesterol|LDL cholesterol|LDL cholesterol|LDL cholesterol	ChemicalEntity	216:251:300:323	224:253:302:325	4:5:6:7	1:NR:2	L2R	CROSS	141-142	264-265	D008055	lipid|lipid	ChemicalEntity	58:141	59:142	2:3	p|Allele|R|70	Arg70	SequenceVariant	264	265	5	1:Cotreatment:2	L2R	NON-CROSS	65-67	68-69	3439	pegylated interferon|PEG - IFN|PEG - IFN|PEG - IFN	GeneOrGeneProduct	65:70:114:152	67:73:117:155	2:2:2:3	D012254	ribavirin|RBV|RBV|RB	ChemicalEntity	68:74:118:156	69:75:119:157	2:2:2:3	1:Negative_Correlation:2	L2R	NON-CROSS	114-117	121-123	3439	pegylated interferon|PEG - IFN|PEG - IFN|PEG - IFN	GeneOrGeneProduct	65:70:114:152	67:73:117:155	2:2:2:3	D006521	chronic hepatitis	DiseaseOrPhenotypicFeature	121	123	2	1:Negative_Correlation:2	L2R	NON-CROSS	114-117	124-128	3439	pegylated interferon|PEG - IFN|PEG - IFN|PEG - IFN	GeneOrGeneProduct	65:70:114:152	67:73:117:155	2:2:2:3	D006526	HCV genotype 1b infection|HCV G1b infection|HCV infection	DiseaseOrPhenotypicFeature	124:177:343	128:180:345	2:3:7	1:NR:2	L2R	CROSS	152-155	216-224	3439	pegylated interferon|PEG - IFN|PEG - IFN|PEG - IFN	GeneOrGeneProduct	65:70:114:152	67:73:117:155	2:2:2:3	D008078	low - density lipoprotein ( LDL ) cholesterol|LDL cholesterol|LDL cholesterol|LDL cholesterol	ChemicalEntity	216:251:300:323	224:253:302:325	4:5:6:7	1:Negative_Correlation:2	L2R	NON-CROSS	118-119	121-123	D012254	ribavirin|RBV|RBV|RB	ChemicalEntity	68:74:118:156	69:75:119:157	2:2:2:3	D006521	chronic hepatitis	DiseaseOrPhenotypicFeature	121	123	2	1:Negative_Correlation:2	L2R	NON-CROSS	118-119	124-128	D012254	ribavirin|RBV|RBV|RB	ChemicalEntity	68:74:118:156	69:75:119:157	2:2:2:3	D006526	HCV genotype 1b infection|HCV G1b infection|HCV infection	DiseaseOrPhenotypicFeature	124:177:343	128:180:345	2:3:7	1:NR:2	L2R	CROSS	156-157	216-224	D012254	ribavirin|RBV|RBV|RB	ChemicalEntity	68:74:118:156	69:75:119:157	2:2:2:3	D008078	low - density lipoprotein ( LDL ) cholesterol|LDL cholesterol|LDL cholesterol|LDL cholesterol	ChemicalEntity	216:251:300:323	224:253:302:325	4:5:6:7	1:NR:2	L2R	CROSS	156-157	264-265	D012254	ribavirin|RBV|RBV|RB	ChemicalEntity	68:74:118:156	69:75:119:157	2:2:2:3	p|Allele|R|70	Arg70	SequenceVariant	264	265	5	1:NR:2	L2R	CROSS	121-123	216-224	D006521	chronic hepatitis	DiseaseOrPhenotypicFeature	121	123	2	D008078	low - density lipoprotein ( LDL ) cholesterol|LDL cholesterol|LDL cholesterol|LDL cholesterol	ChemicalEntity	216:251:300:323	224:253:302:325	4:5:6:7	1:NR:2	L2R	CROSS	121-123	264-265	D006521	chronic hepatitis	DiseaseOrPhenotypicFeature	121	123	2	p|Allele|R|70	Arg70	SequenceVariant	264	265	5	1:Association:2	R2L	NON-CROSS	343-345	323-325	D008078	low - density lipoprotein ( LDL ) cholesterol|LDL cholesterol|LDL cholesterol|LDL cholesterol	ChemicalEntity	216:251:300:323	224:253:302:325	4:5:6:7	D006526	HCV genotype 1b infection|HCV G1b infection|HCV infection	DiseaseOrPhenotypicFeature	124:177:343	128:180:345	2:3:7	1:Association:2	L2R	CROSS	264-265	343-345	D006526	HCV genotype 1b infection|HCV G1b infection|HCV infection	DiseaseOrPhenotypicFeature	124:177:343	128:180:345	2:3:7	p|Allele|R|70	Arg70	SequenceVariant	264	265	5	1:Positive_Correlation:2	L2R	NON-CROSS	251-253	264-265	D008078	low - density lipoprotein ( LDL ) cholesterol|LDL cholesterol|LDL cholesterol|LDL cholesterol	ChemicalEntity	216:251:300:323	224:253:302:325	4:5:6:7	p|Allele|R|70	Arg70	SequenceVariant	264	265	5
27798239	Phosphatidylinositol 4 - kinase IIb negatively regulates invadopodia formation and suppresses an invasive cellular phenotype .|The type II phosphatidylinositol 4 - kinase ( PI4KII ) enzymes synthesize the lipid phosphatidylinositol 4 - phosphate ( PI ( 4 ) P ) , which has been detected at the Golgi complex and endosomal compartments and recruits clathrin adaptors .|Despite common mechanistic similarities between the isoforms , the extent of their redundancy is unclear .|We found that depletion of PI4KIIa and PI4KIIb using small interfering RNA led to actin remodeling .|Depletion of PI4KIIb also induced the formation of invadopodia containing membrane type I matrix metalloproteinase ( MT1 - MMP ) .|Depletion of PI4KII isoforms also differentially affected trans - Golgi network ( TGN ) pools of PI ( 4 ) P and post - TGN traffic .|PI4KIIb depletion caused increased MT1 - MMP trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of MT1 - MMP with membranes containing the endosomal markers Rab5 and Rab7 but increased localization with the exocytic Rab8 .|Depletion of PI4KIIb was sufficient to confer an aggressive invasive phenotype on minimally invasive HeLa and MCF - 7 cell lines .|Mining oncogenomic databases revealed that loss of the PI4K2B allele and underexpression of PI4KIIb mRNA are associated with human cancers .|This finding supports the cell data and suggests that PI4KIIb may be a clinically significant suppressor of invasion .|We propose that PI4KIIb synthesizes a pool of PI ( 4 ) P that maintains MT1 - MMP traffic in the degradative pathway and suppresses the formation of invadopodia .	1:NR:2	L2R	CROSS	0-5	17-23	55300	Phosphatidylinositol 4 - kinase IIb|PI4KIIb|PI4KIIb|PI4KIIb|PI4KIIb|PI4K2B|PI4KIIb|PI4KIIb|PI4KIIb	GeneOrGeneProduct	0:81:93:139:183:211:216:233:246	5:82:94:140:184:212:217:234:247	0:3:4:6:7:8:8:9:10	55300,55361	type II phosphatidylinositol 4 - kinase|PI4KII|PI4KII	GeneOrGeneProduct	17:24:114	23:25:115	1:1:5	1:Association:2	L2R	CROSS	0-5	29-30	55300	Phosphatidylinositol 4 - kinase IIb|PI4KIIb|PI4KIIb|PI4KIIb|PI4KIIb|PI4K2B|PI4KIIb|PI4KIIb|PI4KIIb	GeneOrGeneProduct	0:81:93:139:183:211:216:233:246	5:82:94:140:184:212:217:234:247	0:3:4:6:7:8:8:9:10	D008055	lipid	ChemicalEntity	29	30	1	1:Association:2	L2R	NON-CROSS	246-247	251-256	55300	Phosphatidylinositol 4 - kinase IIb|PI4KIIb|PI4KIIb|PI4KIIb|PI4KIIb|PI4K2B|PI4KIIb|PI4KIIb|PI4KIIb	GeneOrGeneProduct	0:81:93:139:183:211:216:233:246	5:82:94:140:184:212:217:234:247	0:3:4:6:7:8:8:9:10	C037178	phosphatidylinositol 4 - phosphate|PI ( 4 ) P|PI ( 4 ) P|PI ( 4 ) P	ChemicalEntity	30:35:128:251	34:40:133:256	1:1:5:10	1:Association:2	L2R	CROSS	55-56	81-82	55300	Phosphatidylinositol 4 - kinase IIb|PI4KIIb|PI4KIIb|PI4KIIb|PI4KIIb|PI4K2B|PI4KIIb|PI4KIIb|PI4KIIb	GeneOrGeneProduct	0:81:93:139:183:211:216:233:246	5:82:94:140:184:212:217:234:247	0:3:4:6:7:8:8:9:10	1213	clathrin	GeneOrGeneProduct	55	56	1	1:NR:2	L2R	NON-CROSS	79-80	81-82	55300	Phosphatidylinositol 4 - kinase IIb|PI4KIIb|PI4KIIb|PI4KIIb|PI4KIIb|PI4K2B|PI4KIIb|PI4KIIb|PI4KIIb	GeneOrGeneProduct	0:81:93:139:183:211:216:233:246	5:82:94:140:184:212:217:234:247	0:3:4:6:7:8:8:9:10	55361	PI4KIIa	GeneOrGeneProduct	79	80	3	1:Association:2	L2R	NON-CROSS	88-89	93-94	55300	Phosphatidylinositol 4 - kinase IIb|PI4KIIb|PI4KIIb|PI4KIIb|PI4KIIb|PI4K2B|PI4KIIb|PI4KIIb|PI4KIIb	GeneOrGeneProduct	0:81:93:139:183:211:216:233:246	5:82:94:140:184:212:217:234:247	0:3:4:6:7:8:8:9:10	60	actin	GeneOrGeneProduct	88	89	3	1:Association:2	L2R	NON-CROSS	139-140	143-146	55300	Phosphatidylinositol 4 - kinase IIb|PI4KIIb|PI4KIIb|PI4KIIb|PI4KIIb|PI4K2B|PI4KIIb|PI4KIIb|PI4KIIb	GeneOrGeneProduct	0:81:93:139:183:211:216:233:246	5:82:94:140:184:212:217:234:247	0:3:4:6:7:8:8:9:10	4323	membrane type I matrix metalloproteinase|MT1 - MMP|MT1 - MMP|MT1 - MMP|MT1 - MMP	GeneOrGeneProduct	101:107:143:161:258	106:110:146:164:261	4:4:6:6:10	1:NR:2	L2R	NON-CROSS	170-171	183-184	55300	Phosphatidylinositol 4 - kinase IIb|PI4KIIb|PI4KIIb|PI4KIIb|PI4KIIb|PI4K2B|PI4KIIb|PI4KIIb|PI4KIIb	GeneOrGeneProduct	0:81:93:139:183:211:216:233:246	5:82:94:140:184:212:217:234:247	0:3:4:6:7:8:8:9:10	5868	Rab5	GeneOrGeneProduct	170	171	6	1:NR:2	L2R	NON-CROSS	172-173	183-184	55300	Phosphatidylinositol 4 - kinase IIb|PI4KIIb|PI4KIIb|PI4KIIb|PI4KIIb|PI4K2B|PI4KIIb|PI4KIIb|PI4KIIb	GeneOrGeneProduct	0:81:93:139:183:211:216:233:246	5:82:94:140:184:212:217:234:247	0:3:4:6:7:8:8:9:10	338382	Rab7	GeneOrGeneProduct	172	173	6	1:Association:2	L2R	NON-CROSS	179-180	183-184	55300	Phosphatidylinositol 4 - kinase IIb|PI4KIIb|PI4KIIb|PI4KIIb|PI4KIIb|PI4K2B|PI4KIIb|PI4KIIb|PI4KIIb	GeneOrGeneProduct	0:81:93:139:183:211:216:233:246	5:82:94:140:184:212:217:234:247	0:3:4:6:7:8:8:9:10	4218	Rab8	GeneOrGeneProduct	179	180	6	1:Negative_Correlation:2	L2R	NON-CROSS	216-217	222-223	55300	Phosphatidylinositol 4 - kinase IIb|PI4KIIb|PI4KIIb|PI4KIIb|PI4KIIb|PI4K2B|PI4KIIb|PI4KIIb|PI4KIIb	GeneOrGeneProduct	0:81:93:139:183:211:216:233:246	5:82:94:140:184:212:217:234:247	0:3:4:6:7:8:8:9:10	D009369	cancers	DiseaseOrPhenotypicFeature	222	223	8	1:NR:2	L2R	NON-CROSS	24-25	29-30	55300,55361	type II phosphatidylinositol 4 - kinase|PI4KII|PI4KII	GeneOrGeneProduct	17:24:114	23:25:115	1:1:5	D008055	lipid	ChemicalEntity	29	30	1	1:NR:2	L2R	NON-CROSS	24-25	30-34	55300,55361	type II phosphatidylinositol 4 - kinase|PI4KII|PI4KII	GeneOrGeneProduct	17:24:114	23:25:115	1:1:5	C037178	phosphatidylinositol 4 - phosphate|PI ( 4 ) P|PI ( 4 ) P|PI ( 4 ) P	ChemicalEntity	30:35:128:251	34:40:133:256	1:1:5:10	1:NR:2	L2R	NON-CROSS	24-25	55-56	55300,55361	type II phosphatidylinositol 4 - kinase|PI4KII|PI4KII	GeneOrGeneProduct	17:24:114	23:25:115	1:1:5	1213	clathrin	GeneOrGeneProduct	55	56	1	1:NR:2	L2R	CROSS	79-80	114-115	55300,55361	type II phosphatidylinositol 4 - kinase|PI4KII|PI4KII	GeneOrGeneProduct	17:24:114	23:25:115	1:1:5	55361	PI4KIIa	GeneOrGeneProduct	79	80	3	1:NR:2	L2R	CROSS	88-89	114-115	55300,55361	type II phosphatidylinositol 4 - kinase|PI4KII|PI4KII	GeneOrGeneProduct	17:24:114	23:25:115	1:1:5	60	actin	GeneOrGeneProduct	88	89	3	1:NR:2	L2R	CROSS	107-110	114-115	55300,55361	type II phosphatidylinositol 4 - kinase|PI4KII|PI4KII	GeneOrGeneProduct	17:24:114	23:25:115	1:1:5	4323	membrane type I matrix metalloproteinase|MT1 - MMP|MT1 - MMP|MT1 - MMP|MT1 - MMP	GeneOrGeneProduct	101:107:143:161:258	106:110:146:164:261	4:4:6:6:10	1:NR:2	L2R	CROSS	114-115	170-171	55300,55361	type II phosphatidylinositol 4 - kinase|PI4KII|PI4KII	GeneOrGeneProduct	17:24:114	23:25:115	1:1:5	5868	Rab5	GeneOrGeneProduct	170	171	6	1:NR:2	L2R	CROSS	114-115	172-173	55300,55361	type II phosphatidylinositol 4 - kinase|PI4KII|PI4KII	GeneOrGeneProduct	17:24:114	23:25:115	1:1:5	338382	Rab7	GeneOrGeneProduct	172	173	6	1:NR:2	L2R	CROSS	114-115	179-180	55300,55361	type II phosphatidylinositol 4 - kinase|PI4KII|PI4KII	GeneOrGeneProduct	17:24:114	23:25:115	1:1:5	4218	Rab8	GeneOrGeneProduct	179	180	6	1:NR:2	L2R	CROSS	114-115	222-223	55300,55361	type II phosphatidylinositol 4 - kinase|PI4KII|PI4KII	GeneOrGeneProduct	17:24:114	23:25:115	1:1:5	D009369	cancers	DiseaseOrPhenotypicFeature	222	223	8	1:NR:2	L2R	NON-CROSS	29-30	30-34	D008055	lipid	ChemicalEntity	29	30	1	C037178	phosphatidylinositol 4 - phosphate|PI ( 4 ) P|PI ( 4 ) P|PI ( 4 ) P	ChemicalEntity	30:35:128:251	34:40:133:256	1:1:5:10	1:NR:2	L2R	NON-CROSS	29-30	55-56	D008055	lipid	ChemicalEntity	29	30	1	1213	clathrin	GeneOrGeneProduct	55	56	1	1:Association:2	R2L	CROSS	79-80	29-30	55361	PI4KIIa	GeneOrGeneProduct	79	80	3	D008055	lipid	ChemicalEntity	29	30	1	1:NR:2	L2R	CROSS	29-30	88-89	D008055	lipid	ChemicalEntity	29	30	1	60	actin	GeneOrGeneProduct	88	89	3	1:NR:2	L2R	CROSS	29-30	101-106	D008055	lipid	ChemicalEntity	29	30	1	4323	membrane type I matrix metalloproteinase|MT1 - MMP|MT1 - MMP|MT1 - MMP|MT1 - MMP	GeneOrGeneProduct	101:107:143:161:258	106:110:146:164:261	4:4:6:6:10	1:NR:2	L2R	CROSS	29-30	170-171	D008055	lipid	ChemicalEntity	29	30	1	5868	Rab5	GeneOrGeneProduct	170	171	6	1:NR:2	L2R	CROSS	29-30	172-173	D008055	lipid	ChemicalEntity	29	30	1	338382	Rab7	GeneOrGeneProduct	172	173	6	1:NR:2	L2R	CROSS	29-30	179-180	D008055	lipid	ChemicalEntity	29	30	1	4218	Rab8	GeneOrGeneProduct	179	180	6	1:NR:2	L2R	CROSS	29-30	222-223	D008055	lipid	ChemicalEntity	29	30	1	D009369	cancers	DiseaseOrPhenotypicFeature	222	223	8	1:NR:2	L2R	NON-CROSS	35-40	55-56	C037178	phosphatidylinositol 4 - phosphate|PI ( 4 ) P|PI ( 4 ) P|PI ( 4 ) P	ChemicalEntity	30:35:128:251	34:40:133:256	1:1:5:10	1213	clathrin	GeneOrGeneProduct	55	56	1	1:Association:2	R2L	CROSS	79-80	35-40	55361	PI4KIIa	GeneOrGeneProduct	79	80	3	C037178	phosphatidylinositol 4 - phosphate|PI ( 4 ) P|PI ( 4 ) P|PI ( 4 ) P	ChemicalEntity	30:35:128:251	34:40:133:256	1:1:5:10	1:NR:2	L2R	CROSS	88-89	128-133	C037178	phosphatidylinositol 4 - phosphate|PI ( 4 ) P|PI ( 4 ) P|PI ( 4 ) P	ChemicalEntity	30:35:128:251	34:40:133:256	1:1:5:10	60	actin	GeneOrGeneProduct	88	89	3	1:Association:2	L2R	NON-CROSS	251-256	258-261	C037178	phosphatidylinositol 4 - phosphate|PI ( 4 ) P|PI ( 4 ) P|PI ( 4 ) P	ChemicalEntity	30:35:128:251	34:40:133:256	1:1:5:10	4323	membrane type I matrix metalloproteinase|MT1 - MMP|MT1 - MMP|MT1 - MMP|MT1 - MMP	GeneOrGeneProduct	101:107:143:161:258	106:110:146:164:261	4:4:6:6:10	1:NR:2	L2R	CROSS	128-133	170-171	C037178	phosphatidylinositol 4 - phosphate|PI ( 4 ) P|PI ( 4 ) P|PI ( 4 ) P	ChemicalEntity	30:35:128:251	34:40:133:256	1:1:5:10	5868	Rab5	GeneOrGeneProduct	170	171	6	1:NR:2	L2R	CROSS	128-133	172-173	C037178	phosphatidylinositol 4 - phosphate|PI ( 4 ) P|PI ( 4 ) P|PI ( 4 ) P	ChemicalEntity	30:35:128:251	34:40:133:256	1:1:5:10	338382	Rab7	GeneOrGeneProduct	172	173	6	1:NR:2	L2R	CROSS	128-133	179-180	C037178	phosphatidylinositol 4 - phosphate|PI ( 4 ) P|PI ( 4 ) P|PI ( 4 ) P	ChemicalEntity	30:35:128:251	34:40:133:256	1:1:5:10	4218	Rab8	GeneOrGeneProduct	179	180	6	1:NR:2	L2R	CROSS	222-223	251-256	C037178	phosphatidylinositol 4 - phosphate|PI ( 4 ) P|PI ( 4 ) P|PI ( 4 ) P	ChemicalEntity	30:35:128:251	34:40:133:256	1:1:5:10	D009369	cancers	DiseaseOrPhenotypicFeature	222	223	8	1:Association:2	R2L	CROSS	79-80	55-56	55361	PI4KIIa	GeneOrGeneProduct	79	80	3	1213	clathrin	GeneOrGeneProduct	55	56	1	1:NR:2	L2R	CROSS	55-56	88-89	1213	clathrin	GeneOrGeneProduct	55	56	1	60	actin	GeneOrGeneProduct	88	89	3	1:NR:2	L2R	CROSS	55-56	101-106	1213	clathrin	GeneOrGeneProduct	55	56	1	4323	membrane type I matrix metalloproteinase|MT1 - MMP|MT1 - MMP|MT1 - MMP|MT1 - MMP	GeneOrGeneProduct	101:107:143:161:258	106:110:146:164:261	4:4:6:6:10	1:NR:2	L2R	CROSS	55-56	170-171	1213	clathrin	GeneOrGeneProduct	55	56	1	5868	Rab5	GeneOrGeneProduct	170	171	6	1:NR:2	L2R	CROSS	55-56	172-173	1213	clathrin	GeneOrGeneProduct	55	56	1	338382	Rab7	GeneOrGeneProduct	172	173	6	1:NR:2	L2R	CROSS	55-56	179-180	1213	clathrin	GeneOrGeneProduct	55	56	1	4218	Rab8	GeneOrGeneProduct	179	180	6	1:NR:2	L2R	CROSS	55-56	222-223	1213	clathrin	GeneOrGeneProduct	55	56	1	D009369	cancers	DiseaseOrPhenotypicFeature	222	223	8	1:Association:2	L2R	NON-CROSS	79-80	88-89	55361	PI4KIIa	GeneOrGeneProduct	79	80	3	60	actin	GeneOrGeneProduct	88	89	3	1:NR:2	L2R	CROSS	79-80	101-106	55361	PI4KIIa	GeneOrGeneProduct	79	80	3	4323	membrane type I matrix metalloproteinase|MT1 - MMP|MT1 - MMP|MT1 - MMP|MT1 - MMP	GeneOrGeneProduct	101:107:143:161:258	106:110:146:164:261	4:4:6:6:10	1:NR:2	L2R	CROSS	79-80	170-171	55361	PI4KIIa	GeneOrGeneProduct	79	80	3	5868	Rab5	GeneOrGeneProduct	170	171	6	1:NR:2	L2R	CROSS	79-80	172-173	55361	PI4KIIa	GeneOrGeneProduct	79	80	3	338382	Rab7	GeneOrGeneProduct	172	173	6	1:NR:2	L2R	CROSS	79-80	179-180	55361	PI4KIIa	GeneOrGeneProduct	79	80	3	4218	Rab8	GeneOrGeneProduct	179	180	6	1:NR:2	L2R	CROSS	79-80	222-223	55361	PI4KIIa	GeneOrGeneProduct	79	80	3	D009369	cancers	DiseaseOrPhenotypicFeature	222	223	8	1:NR:2	L2R	CROSS	88-89	101-106	60	actin	GeneOrGeneProduct	88	89	3	4323	membrane type I matrix metalloproteinase|MT1 - MMP|MT1 - MMP|MT1 - MMP|MT1 - MMP	GeneOrGeneProduct	101:107:143:161:258	106:110:146:164:261	4:4:6:6:10	1:NR:2	L2R	CROSS	88-89	170-171	60	actin	GeneOrGeneProduct	88	89	3	5868	Rab5	GeneOrGeneProduct	170	171	6	1:NR:2	L2R	CROSS	88-89	172-173	60	actin	GeneOrGeneProduct	88	89	3	338382	Rab7	GeneOrGeneProduct	172	173	6	1:NR:2	L2R	CROSS	88-89	179-180	60	actin	GeneOrGeneProduct	88	89	3	4218	Rab8	GeneOrGeneProduct	179	180	6	1:NR:2	L2R	CROSS	88-89	222-223	60	actin	GeneOrGeneProduct	88	89	3	D009369	cancers	DiseaseOrPhenotypicFeature	222	223	8	1:Association:2	L2R	NON-CROSS	161-164	170-171	4323	membrane type I matrix metalloproteinase|MT1 - MMP|MT1 - MMP|MT1 - MMP|MT1 - MMP	GeneOrGeneProduct	101:107:143:161:258	106:110:146:164:261	4:4:6:6:10	5868	Rab5	GeneOrGeneProduct	170	171	6	1:Association:2	L2R	NON-CROSS	161-164	172-173	4323	membrane type I matrix metalloproteinase|MT1 - MMP|MT1 - MMP|MT1 - MMP|MT1 - MMP	GeneOrGeneProduct	101:107:143:161:258	106:110:146:164:261	4:4:6:6:10	338382	Rab7	GeneOrGeneProduct	172	173	6	1:Association:2	L2R	NON-CROSS	161-164	179-180	4323	membrane type I matrix metalloproteinase|MT1 - MMP|MT1 - MMP|MT1 - MMP|MT1 - MMP	GeneOrGeneProduct	101:107:143:161:258	106:110:146:164:261	4:4:6:6:10	4218	Rab8	GeneOrGeneProduct	179	180	6	1:NR:2	L2R	CROSS	222-223	258-261	4323	membrane type I matrix metalloproteinase|MT1 - MMP|MT1 - MMP|MT1 - MMP|MT1 - MMP	GeneOrGeneProduct	101:107:143:161:258	106:110:146:164:261	4:4:6:6:10	D009369	cancers	DiseaseOrPhenotypicFeature	222	223	8	1:NR:2	L2R	NON-CROSS	170-171	172-173	5868	Rab5	GeneOrGeneProduct	170	171	6	338382	Rab7	GeneOrGeneProduct	172	173	6	1:NR:2	L2R	NON-CROSS	170-171	179-180	5868	Rab5	GeneOrGeneProduct	170	171	6	4218	Rab8	GeneOrGeneProduct	179	180	6	1:NR:2	L2R	CROSS	170-171	222-223	5868	Rab5	GeneOrGeneProduct	170	171	6	D009369	cancers	DiseaseOrPhenotypicFeature	222	223	8	1:NR:2	L2R	NON-CROSS	172-173	179-180	338382	Rab7	GeneOrGeneProduct	172	173	6	4218	Rab8	GeneOrGeneProduct	179	180	6	1:NR:2	L2R	CROSS	172-173	222-223	338382	Rab7	GeneOrGeneProduct	172	173	6	D009369	cancers	DiseaseOrPhenotypicFeature	222	223	8	1:NR:2	L2R	CROSS	179-180	222-223	4218	Rab8	GeneOrGeneProduct	179	180	6	D009369	cancers	DiseaseOrPhenotypicFeature	222	223	8
27993978	CenpH regulates meiotic G2 / M transition by modulating the APC / CCdh1 - cyclin B1 pathway in oocytes .|Meiotic resumption ( G2 / M transition ) and progression through meiosis I ( MI ) are two key stages for producing fertilization - competent eggs .|Here , we report that CenpH , a component of the kinetochore inner plate , is responsible for G2 / M transition in meiotic mouse oocytes .|Depletion of CenpH by morpholino injection decreased cyclin B1 levels , resulting in attenuation of maturation - promoting factor ( MPF ) activation , and severely compromised meiotic resumption .|CenpH protects cyclin B1 from destruction by competing with the action of APC / C ( Cdh1 ) Impaired G2 / M transition after CenpH depletion could be rescued by expression of exogenous cyclin B1 .|Unexpectedly , blocking CenpH did not affect spindle organization and meiotic cell cycle progression after germinal vesicle breakdown .|Our findings reveal a novel role of CenpH in regulating meiotic G2 / M transition by acting via the APC / C ( Cdh1 ) - cyclin B1 pathway .	1:Association:2	L2R	NON-CROSS	120-121	128-129	26886	CenpH|CenpH|CenpH|CenpH|CenpH|CenpH|CenpH	GeneOrGeneProduct	0:52:76:104:128:143:166	1:53:77:105:129:144:167	0:2:3:4:4:5:6	56371	APC / CCdh1|APC / C|Cdh1|APC / C|Cdh1	GeneOrGeneProduct	10:116:120:178:182	13:119:121:181:183	0:4:4:6:6	1:Positive_Correlation:2	L2R	NON-CROSS	104-105	106-108	26886	CenpH|CenpH|CenpH|CenpH|CenpH|CenpH|CenpH	GeneOrGeneProduct	0:52:76:104:128:143:166	1:53:77:105:129:144:167	0:2:3:4:4:5:6	268697	cyclin B1|cyclin B1|maturation - promoting factor|MPF|cyclin B1|cyclin B1|cyclin B1	GeneOrGeneProduct	14:81:89:94:106:137:185	16:83:93:95:108:139:187	0:3:3:3:4:4:6	1:Negative_Correlation:2	L2R	NON-CROSS	76-77	78-79	26886	CenpH|CenpH|CenpH|CenpH|CenpH|CenpH|CenpH	GeneOrGeneProduct	0:52:76:104:128:143:166	1:53:77:105:129:144:167	0:2:3:4:4:5:6	D060172	morpholino	ChemicalEntity	78	79	3	1:Association:2	R2L	NON-CROSS	14-16	10-13	268697	cyclin B1|cyclin B1|maturation - promoting factor|MPF|cyclin B1|cyclin B1|cyclin B1	GeneOrGeneProduct	14:81:89:94:106:137:185	16:83:93:95:108:139:187	0:3:3:3:4:4:6	56371	APC / CCdh1|APC / C|Cdh1|APC / C|Cdh1	GeneOrGeneProduct	10:116:120:178:182	13:119:121:181:183	0:4:4:6:6	1:NR:2	L2R	CROSS	78-79	116-119	56371	APC / CCdh1|APC / C|Cdh1|APC / C|Cdh1	GeneOrGeneProduct	10:116:120:178:182	13:119:121:181:183	0:4:4:6:6	D060172	morpholino	ChemicalEntity	78	79	3	1:Negative_Correlation:2	R2L	NON-CROSS	81-83	78-79	D060172	morpholino	ChemicalEntity	78	79	3	268697	cyclin B1|cyclin B1|maturation - promoting factor|MPF|cyclin B1|cyclin B1|cyclin B1	GeneOrGeneProduct	14:81:89:94:106:137:185	16:83:93:95:108:139:187	0:3:3:3:4:4:6
15111599	CRYBA3 / A1 gene mutation associated with suture - sparing autosomal dominant congenital nuclear cataract : a novel phenotype .|PURPOSE : To identify the genetic defect leading to the congenital nuclear cataract affecting a large five - generation Swiss family .|METHODS : Family history and clinical data were recorded .|The phenotype was documented by both slit lamp and Scheimpflug photography .|One cortical lens was evaluated by electron microscopy after cataract extraction .|Lenticular phenotyping and genotyping were performed independently with short tandem repeat polymorphism .|Linkage analysis was performed , and candidate genes were PCR amplified and screened for mutations on both strands using direct sequencing .|RESULTS : Affected individuals had a congenital nuclear lactescent cataract in both eyes .|Linkage was observed on chromosome 17 for DNA marker D17S1857 ( lod score : 3 . 44 at theta = 0 ) .|Direct sequencing of CRYBA3 / A1 , which maps to the vicinity , revealed an in - frame 3 - bp deletion in exon 4 ( 279delGAG ) .|This mutation involved a deletion of glycine - 91 , cosegregated in all affected individuals , and was not observed in unaffected individuals or in 250 normal control subjects from the same ethnic background .|Electron microscopy showed that cortical lens fiber morphology was normal .|CONCLUSIONS : The DeltaG91 mutation in CRYBA3 / A1 is associated with an autosomal dominant congenital nuclear lactescent cataract .|A splice mutation ( IVS3 + 1G / A ) in this gene has been reported in a zonular cataract with sutural opacities .|These results indicate phenotypic heterogeneity related to mutations in this gene .	1:Association:2	L2R	NON-CROSS	229-232	236-242	1411	CRYBA3 / A1|CRYBA3 / A1|CRYBA3 / A1	GeneOrGeneProduct	0:151:229	3:154:232	0:9:12	C565137	autosomal dominant congenital nuclear cataract|congenital nuclear cataract|congenital nuclear lactescent cataract|autosomal dominant congenital nuclear lactescent cataract	DiseaseOrPhenotypicFeature	10:30:117:236	15:33:121:242	0:1:7:12	1:NR:2	L2R	CROSS	0-3	25-27	1411	CRYBA3 / A1|CRYBA3 / A1|CRYBA3 / A1	GeneOrGeneProduct	0:151:229	3:154:232	0:9:12	D030342	genetic defect	DiseaseOrPhenotypicFeature	25	27	1	1:NR:2	L2R	CROSS	0-3	73-74	1411	CRYBA3 / A1|CRYBA3 / A1|CRYBA3 / A1	GeneOrGeneProduct	0:151:229	3:154:232	0:9:12	D002386	cataract	DiseaseOrPhenotypicFeature	73	74	4	1:Association:2	R2L	CROSS	261-263	229-232	C535342	zonular cataract	DiseaseOrPhenotypicFeature	261	263	13	1411	CRYBA3 / A1|CRYBA3 / A1|CRYBA3 / A1	GeneOrGeneProduct	0:151:229	3:154:232	0:9:12	1:Association:2	R2L	CROSS	166-170	117-121	c|DEL||3	3 - bp deletion	SequenceVariant	166	170	9	C565137	autosomal dominant congenital nuclear cataract|congenital nuclear cataract|congenital nuclear lactescent cataract|autosomal dominant congenital nuclear lactescent cataract	DiseaseOrPhenotypicFeature	10:30:117:236	15:33:121:242	0:1:7:12	1:Association:2	R2L	CROSS	174-175	117-121	c|DEL|279|GAG	279delGAG	SequenceVariant	174	175	9	C565137	autosomal dominant congenital nuclear cataract|congenital nuclear cataract|congenital nuclear lactescent cataract|autosomal dominant congenital nuclear lactescent cataract	DiseaseOrPhenotypicFeature	10:30:117:236	15:33:121:242	0:1:7:12	1:Association:2	R2L	NON-CROSS	236-242	226-227	p|DEL|91|G	deletion of glycine - 91|DeltaG91	SequenceVariant	181:226	186:227	10:12	C565137	autosomal dominant congenital nuclear cataract|congenital nuclear cataract|congenital nuclear lactescent cataract|autosomal dominant congenital nuclear lactescent cataract	DiseaseOrPhenotypicFeature	10:30:117:236	15:33:121:242	0:1:7:12	1:NR:2	L2R	CROSS	236-242	247-252	C565137	autosomal dominant congenital nuclear cataract|congenital nuclear cataract|congenital nuclear lactescent cataract|autosomal dominant congenital nuclear lactescent cataract	DiseaseOrPhenotypicFeature	10:30:117:236	15:33:121:242	0:1:7:12	c|SUB|G|IVS3+1|A	IVS3 + 1G / A	SequenceVariant	247	252	13	1:NR:2	L2R	CROSS	25-27	166-170	D030342	genetic defect	DiseaseOrPhenotypicFeature	25	27	1	c|DEL||3	3 - bp deletion	SequenceVariant	166	170	9	1:NR:2	L2R	CROSS	25-27	174-175	D030342	genetic defect	DiseaseOrPhenotypicFeature	25	27	1	c|DEL|279|GAG	279delGAG	SequenceVariant	174	175	9	1:NR:2	L2R	CROSS	25-27	181-186	D030342	genetic defect	DiseaseOrPhenotypicFeature	25	27	1	p|DEL|91|G	deletion of glycine - 91|DeltaG91	SequenceVariant	181:226	186:227	10:12	1:NR:2	L2R	CROSS	25-27	247-252	D030342	genetic defect	DiseaseOrPhenotypicFeature	25	27	1	c|SUB|G|IVS3+1|A	IVS3 + 1G / A	SequenceVariant	247	252	13	1:NR:2	L2R	CROSS	73-74	166-170	D002386	cataract	DiseaseOrPhenotypicFeature	73	74	4	c|DEL||3	3 - bp deletion	SequenceVariant	166	170	9	1:NR:2	L2R	CROSS	73-74	174-175	D002386	cataract	DiseaseOrPhenotypicFeature	73	74	4	c|DEL|279|GAG	279delGAG	SequenceVariant	174	175	9	1:NR:2	L2R	CROSS	73-74	181-186	D002386	cataract	DiseaseOrPhenotypicFeature	73	74	4	p|DEL|91|G	deletion of glycine - 91|DeltaG91	SequenceVariant	181:226	186:227	10:12	1:NR:2	L2R	CROSS	73-74	247-252	D002386	cataract	DiseaseOrPhenotypicFeature	73	74	4	c|SUB|G|IVS3+1|A	IVS3 + 1G / A	SequenceVariant	247	252	13	1:NR:2	L2R	CROSS	166-170	261-263	c|DEL||3	3 - bp deletion	SequenceVariant	166	170	9	C535342	zonular cataract	DiseaseOrPhenotypicFeature	261	263	13	1:NR:2	L2R	CROSS	174-175	261-263	c|DEL|279|GAG	279delGAG	SequenceVariant	174	175	9	C535342	zonular cataract	DiseaseOrPhenotypicFeature	261	263	13	1:NR:2	L2R	CROSS	226-227	261-263	p|DEL|91|G	deletion of glycine - 91|DeltaG91	SequenceVariant	181:226	186:227	10:12	C535342	zonular cataract	DiseaseOrPhenotypicFeature	261	263	13	1:Association:2	L2R	NON-CROSS	247-252	261-263	c|SUB|G|IVS3+1|A	IVS3 + 1G / A	SequenceVariant	247	252	13	C535342	zonular cataract	DiseaseOrPhenotypicFeature	261	263	13
15820770	Vitamin D - binding protein gene polymorphism association with IA - 2 autoantibodies in type 1 diabetes .|BACKGROUND : Vitamin D - binding protein ( DBP ) is the main systemic transporter of 1 . 25 ( OH ) 2D3 and is essential for its cellular endocytosis .|There are two known polymorphisms in exon 11 of the DBP gene resulting in amino acid variants : GAT - - > GAG substitution replaces aspartic acid by glutamic acid in codon 416 ; and ACG - - > AAG substitution in codon 420 leads to an exchange of threonine for lysine .|These DBP variants lead to differences in the affinity for 1 . 25 ( OH ) 2D3 .|Correlations between DBP alleles and type 1 diabetes have been described in different populations .|Therefore , we investigated the polymorphism in codon 416 of the DBP gene for an association with autoimmune markers of type 1 diabetes .|DESIGN AND METHODS : The present analysis was a case control study .|110 patients , 68 controls , and 115 first - degree relatives were genotyped for the DBP polymorphism in codon 416 .|DNA typing of DBP locus was performed by the PCR - restriction fragment length polymorphism method ( RFLP ) .|RESULTS : The frequencies of the Asp / Glu and Glu / Glu were significantly increased in diabetic subjects with detectable IA - 2 antibodies ( P < 0 . 01 ) .|On the contrary , the DBP Glu - containing genotype was not accompanied by differences in the prevalence of GAD65 antibodies .|These finding supports a role of the vitamin D endocrine system in the autoimmune process of type 1 diabetes .	1:Association:2	L2R	NON-CROSS	0-5	9-12	2638	Vitamin D - binding protein|Vitamin D - binding protein|DBP|DBP|DBP|DBP|DBP|DBP|DBP|DBP	GeneOrGeneProduct	0:20:26:59:103:122:146:188:197:252	5:25:27:60:104:123:147:189:198:253	0:1:1:2:3:4:5:7:8:10	5798	IA - 2|IA - 2	GeneOrGeneProduct	9:235	12:238	0:9	1:Association:2	L2R	NON-CROSS	122-123	125-128	2638	Vitamin D - binding protein|Vitamin D - binding protein|DBP|DBP|DBP|DBP|DBP|DBP|DBP|DBP	GeneOrGeneProduct	0:20:26:59:103:122:146:188:197:252	5:25:27:60:104:123:147:189:198:253	0:1:1:2:3:4:5:7:8:10	D003922	type 1 diabetes|type 1 diabetes|type 1 diabetes|type 1 diabetes	DiseaseOrPhenotypicFeature	14:125:155:285	17:128:158:288	0:4:5:11	1:Association:2	L2R	NON-CROSS	112-119	122-123	2638	Vitamin D - binding protein|Vitamin D - binding protein|DBP|DBP|DBP|DBP|DBP|DBP|DBP|DBP	GeneOrGeneProduct	0:20:26:59:103:122:146:188:197:252	5:25:27:60:104:123:147:189:198:253	0:1:1:2:3:4:5:7:8:10	D002117	1 . 25 ( OH ) 2D3|1 . 25 ( OH ) 2D3	ChemicalEntity	34:112	41:119	1:3	1:NR:2	L2R	CROSS	231-232	252-253	2638	Vitamin D - binding protein|Vitamin D - binding protein|DBP|DBP|DBP|DBP|DBP|DBP|DBP|DBP	GeneOrGeneProduct	0:20:26:59:103:122:146:188:197:252	5:25:27:60:104:123:147:189:198:253	0:1:1:2:3:4:5:7:8:10	D003920	diabetic	DiseaseOrPhenotypicFeature	231	232	9	1:NR:2	L2R	NON-CROSS	252-253	266-267	2638	Vitamin D - binding protein|Vitamin D - binding protein|DBP|DBP|DBP|DBP|DBP|DBP|DBP|DBP	GeneOrGeneProduct	0:20:26:59:103:122:146:188:197:252	5:25:27:60:104:123:147:189:198:253	0:1:1:2:3:4:5:7:8:10	2572	GAD65	GeneOrGeneProduct	266	267	10	1:NR:2	L2R	CROSS	252-253	276-278	2638	Vitamin D - binding protein|Vitamin D - binding protein|DBP|DBP|DBP|DBP|DBP|DBP|DBP|DBP	GeneOrGeneProduct	0:20:26:59:103:122:146:188:197:252	5:25:27:60:104:123:147:189:198:253	0:1:1:2:3:4:5:7:8:10	D014807	vitamin D	ChemicalEntity	276	278	11	1:Association:2	L2R	NON-CROSS	9-12	14-17	5798	IA - 2|IA - 2	GeneOrGeneProduct	9:235	12:238	0:9	D003922	type 1 diabetes|type 1 diabetes|type 1 diabetes|type 1 diabetes	DiseaseOrPhenotypicFeature	14:125:155:285	17:128:158:288	0:4:5:11	1:NR:2	L2R	CROSS	9-12	34-41	5798	IA - 2|IA - 2	GeneOrGeneProduct	9:235	12:238	0:9	D002117	1 . 25 ( OH ) 2D3|1 . 25 ( OH ) 2D3	ChemicalEntity	34:112	41:119	1:3	1:Association:2	L2R	NON-CROSS	231-232	235-238	5798	IA - 2|IA - 2	GeneOrGeneProduct	9:235	12:238	0:9	D003920	diabetic	DiseaseOrPhenotypicFeature	231	232	9	1:NR:2	L2R	CROSS	235-238	266-267	5798	IA - 2|IA - 2	GeneOrGeneProduct	9:235	12:238	0:9	2572	GAD65	GeneOrGeneProduct	266	267	10	1:NR:2	L2R	CROSS	235-238	276-278	5798	IA - 2|IA - 2	GeneOrGeneProduct	9:235	12:238	0:9	D014807	vitamin D	ChemicalEntity	276	278	11	1:NR:2	L2R	CROSS	112-119	125-128	D003922	type 1 diabetes|type 1 diabetes|type 1 diabetes|type 1 diabetes	DiseaseOrPhenotypicFeature	14:125:155:285	17:128:158:288	0:4:5:11	D002117	1 . 25 ( OH ) 2D3|1 . 25 ( OH ) 2D3	ChemicalEntity	34:112	41:119	1:3	1:NR:2	L2R	CROSS	67-82	125-128	D003922	type 1 diabetes|type 1 diabetes|type 1 diabetes|type 1 diabetes	DiseaseOrPhenotypicFeature	14:125:155:285	17:128:158:288	0:4:5:11	p|SUB|D|416|E	GAT - - > GAG substitution replaces aspartic acid by glutamic acid in codon 416	SequenceVariant	67	82	2	1:NR:2	L2R	CROSS	84-93	125-128	D003922	type 1 diabetes|type 1 diabetes|type 1 diabetes|type 1 diabetes	DiseaseOrPhenotypicFeature	14:125:155:285	17:128:158:288	0:4:5:11	p|SUB|T|420|K	ACG - - > AAG substitution in codon 420	SequenceVariant	84	93	2	1:NR:2	L2R	CROSS	98-101	125-128	D003922	type 1 diabetes|type 1 diabetes|type 1 diabetes|type 1 diabetes	DiseaseOrPhenotypicFeature	14:125:155:285	17:128:158:288	0:4:5:11	p|SUB|T||K	threonine for lysine	SequenceVariant	98	101	2	1:NR:2	L2R	CROSS	266-267	285-288	D003922	type 1 diabetes|type 1 diabetes|type 1 diabetes|type 1 diabetes	DiseaseOrPhenotypicFeature	14:125:155:285	17:128:158:288	0:4:5:11	2572	GAD65	GeneOrGeneProduct	266	267	10	1:Association:2	R2L	NON-CROSS	285-288	276-278	D014807	vitamin D	ChemicalEntity	276	278	11	D003922	type 1 diabetes|type 1 diabetes|type 1 diabetes|type 1 diabetes	DiseaseOrPhenotypicFeature	14:125:155:285	17:128:158:288	0:4:5:11	1:Association:2	R2L	CROSS	67-82	34-41	p|SUB|D|416|E	GAT - - > GAG substitution replaces aspartic acid by glutamic acid in codon 416	SequenceVariant	67	82	2	D002117	1 . 25 ( OH ) 2D3|1 . 25 ( OH ) 2D3	ChemicalEntity	34:112	41:119	1:3	1:Association:2	R2L	CROSS	112-119	84-93	p|SUB|T|420|K	ACG - - > AAG substitution in codon 420	SequenceVariant	84	93	2	D002117	1 . 25 ( OH ) 2D3|1 . 25 ( OH ) 2D3	ChemicalEntity	34:112	41:119	1:3	1:Association:2	R2L	CROSS	112-119	98-101	p|SUB|T||K	threonine for lysine	SequenceVariant	98	101	2	D002117	1 . 25 ( OH ) 2D3|1 . 25 ( OH ) 2D3	ChemicalEntity	34:112	41:119	1:3	1:NR:2	L2R	CROSS	112-119	231-232	D002117	1 . 25 ( OH ) 2D3|1 . 25 ( OH ) 2D3	ChemicalEntity	34:112	41:119	1:3	D003920	diabetic	DiseaseOrPhenotypicFeature	231	232	9	1:NR:2	L2R	CROSS	112-119	266-267	D002117	1 . 25 ( OH ) 2D3|1 . 25 ( OH ) 2D3	ChemicalEntity	34:112	41:119	1:3	2572	GAD65	GeneOrGeneProduct	266	267	10	1:NR:2	L2R	CROSS	112-119	276-278	D002117	1 . 25 ( OH ) 2D3|1 . 25 ( OH ) 2D3	ChemicalEntity	34:112	41:119	1:3	D014807	vitamin D	ChemicalEntity	276	278	11	1:NR:2	L2R	CROSS	67-82	231-232	p|SUB|D|416|E	GAT - - > GAG substitution replaces aspartic acid by glutamic acid in codon 416	SequenceVariant	67	82	2	D003920	diabetic	DiseaseOrPhenotypicFeature	231	232	9	1:NR:2	L2R	CROSS	67-82	276-278	p|SUB|D|416|E	GAT - - > GAG substitution replaces aspartic acid by glutamic acid in codon 416	SequenceVariant	67	82	2	D014807	vitamin D	ChemicalEntity	276	278	11	1:NR:2	L2R	CROSS	84-93	231-232	p|SUB|T|420|K	ACG - - > AAG substitution in codon 420	SequenceVariant	84	93	2	D003920	diabetic	DiseaseOrPhenotypicFeature	231	232	9	1:NR:2	L2R	CROSS	84-93	276-278	p|SUB|T|420|K	ACG - - > AAG substitution in codon 420	SequenceVariant	84	93	2	D014807	vitamin D	ChemicalEntity	276	278	11	1:NR:2	L2R	CROSS	98-101	231-232	p|SUB|T||K	threonine for lysine	SequenceVariant	98	101	2	D003920	diabetic	DiseaseOrPhenotypicFeature	231	232	9	1:NR:2	L2R	CROSS	98-101	276-278	p|SUB|T||K	threonine for lysine	SequenceVariant	98	101	2	D014807	vitamin D	ChemicalEntity	276	278	11	1:NR:2	L2R	CROSS	231-232	266-267	D003920	diabetic	DiseaseOrPhenotypicFeature	231	232	9	2572	GAD65	GeneOrGeneProduct	266	267	10	1:NR:2	L2R	CROSS	231-232	276-278	D003920	diabetic	DiseaseOrPhenotypicFeature	231	232	9	D014807	vitamin D	ChemicalEntity	276	278	11	1:NR:2	L2R	CROSS	266-267	276-278	2572	GAD65	GeneOrGeneProduct	266	267	10	D014807	vitamin D	ChemicalEntity	276	278	11
16186368	Characterization of Bietti crystalline dystrophy patients with CYP4V2 mutations .|PURPOSE : Mutations of the CYP4V2 gene , a novel family member of the cytochrome P450 genes on chromosome 4q35 , have recently been identified in patients with Bietti crystalline dystrophy ( BCD ) .|The aim of this study was to investigate the spectrum of mutations in this gene in BCD patients from Singapore , and to characterize their phenotype .|METHODS : Nine patients with BCD from six families were recruited into the study .|The 11 exons of the CYP4V2 gene were amplified from genomic DNA of patients by polymerase chain reaction and then sequenced .|Detailed characterization of the patients ' phenotype was performed with fundal photography , visual field testing , fundal fluorescein angiography , and electroretinography ( ERG ) .|RESULTS : Three pathogenic mutations were identified ; two mutations , S482X and K386T , were novel and found in three patients .|The third mutation , a previously identified 15 - bp deletion that included the 3 ' splice site for exon 7 , was found in all nine patients , with six patients carrying the deletion in the homozygous state .|Haplotype analysis in patients and controls indicated a founder effect for this deletion mutation in exon 7 .|Clinical heterogeneity was present in the patients .|Compound heterozygotes for the deletion in exon 7 seemed to have more severe disease compared to patients homozygous for the deletion .|There was good correlation between clinical stage of disease and ERG changes , but age did not correlate with disease severity .|CONCLUSIONS : This study identified novel mutations in the CYP4V2 gene as a cause of BCD .|A high carrier frequency for the 15 - bp deletion in exon 7 may exist in the Singapore population .|Phenotype characterization showed clinical heterogeneity , and age did not correlate with disease severity .	1:Association:2	L2R	NON-CROSS	2-5	7-8	C535440	Bietti crystalline dystrophy|Bietti crystalline dystrophy|BCD|BCD|BCD|BCD	DiseaseOrPhenotypicFeature	2:38:42:61:77:284	5:41:43:62:78:285	0:1:1:2:3:12	285440	CYP4V2|CYP4V2|cytochrome P450|CYP4V2|CYP4V2	GeneOrGeneProduct	7:15:24:92:278	8:16:26:93:279	0:1:1:4:12	1:Positive_Correlation:2	R2L	CROSS	147-148	77-78	rs146494374	S482X	SequenceVariant	147	148	6	C535440	Bietti crystalline dystrophy|Bietti crystalline dystrophy|BCD|BCD|BCD|BCD	DiseaseOrPhenotypicFeature	2:38:42:61:77:284	5:41:43:62:78:285	0:1:1:2:3:12	1:Positive_Correlation:2	R2L	CROSS	149-150	77-78	rs199476200	K386T	SequenceVariant	149	150	6	C535440	Bietti crystalline dystrophy|Bietti crystalline dystrophy|BCD|BCD|BCD|BCD	DiseaseOrPhenotypicFeature	2:38:42:61:77:284	5:41:43:62:78:285	0:1:1:2:3:12	1:Positive_Correlation:2	R2L	CROSS	292-296	284-285	c|DEL||15	15 - bp deletion|15 - bp deletion	SequenceVariant	166:292	170:296	7:13	C535440	Bietti crystalline dystrophy|Bietti crystalline dystrophy|BCD|BCD|BCD|BCD	DiseaseOrPhenotypicFeature	2:38:42:61:77:284	5:41:43:62:78:285	0:1:1:2:3:12
17511042	An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha - 2b and ribavirin treatment .|During treatment of chronic hepatitis C patients with interferon and ribavirin , a lot of side effects are described .|Twenty - three percent to 44 % of patients develop depression .|A minority of patients evolve to psychosis .|To the best of our knowledge , no cases of psychogenic parasitosis occurring during interferon therapy have been described in the literature .|We present a 49 - year - old woman who developed a delusional parasitosis during treatment with pegylated interferon alpha - 2b weekly and ribavirin .|She complained of seeing parasites and the larvae of fleas in her stools .|This could not be confirmed by any technical examination .|All the complaints disappeared after stopping pegylated interferon alpha - 2b and reappeared after restarting it .|She had a complete sustained viral response .	1:Positive_Correlation:2	L2R	NON-CROSS	73-75	77-78	D063726	delusional parasitosis|psychogenic parasitosis|delusional parasitosis	DiseaseOrPhenotypicFeature	5:73:98	7:75:100	0:4:5	3440	pegylated interferon alpha - 2b|interferon|interferon|pegylated interferon alpha - 2b|pegylated interferon alpha - 2b	GeneOrGeneProduct	14:31:77:103:142	19:32:78:108:147	0:1:4:5:8	1:NR:2	L2R	NON-CROSS	98-100	110-111	D063726	delusional parasitosis|psychogenic parasitosis|delusional parasitosis	DiseaseOrPhenotypicFeature	5:73:98	7:75:100	0:4:5	D012254	ribavirin|ribavirin|ribavirin	ChemicalEntity	20:33:110	21:34:111	0:1:5	1:Negative_Correlation:2	L2R	NON-CROSS	9-12	14-19	D019698	chronic hepatitis C|chronic hepatitis C	DiseaseOrPhenotypicFeature	9:26	12:29	0:1	3440	pegylated interferon alpha - 2b|interferon|interferon|pegylated interferon alpha - 2b|pegylated interferon alpha - 2b	GeneOrGeneProduct	14:31:77:103:142	19:32:78:108:147	0:1:4:5:8	1:Negative_Correlation:2	L2R	NON-CROSS	26-29	33-34	D019698	chronic hepatitis C|chronic hepatitis C	DiseaseOrPhenotypicFeature	9:26	12:29	0:1	D012254	ribavirin|ribavirin|ribavirin	ChemicalEntity	20:33:110	21:34:111	0:1:5	1:Cotreatment:2	L2R	NON-CROSS	14-19	20-21	3440	pegylated interferon alpha - 2b|interferon|interferon|pegylated interferon alpha - 2b|pegylated interferon alpha - 2b	GeneOrGeneProduct	14:31:77:103:142	19:32:78:108:147	0:1:4:5:8	D012254	ribavirin|ribavirin|ribavirin	ChemicalEntity	20:33:110	21:34:111	0:1:5	1:Positive_Correlation:2	L2R	CROSS	31-32	53-54	3440	pegylated interferon alpha - 2b|interferon|interferon|pegylated interferon alpha - 2b|pegylated interferon alpha - 2b	GeneOrGeneProduct	14:31:77:103:142	19:32:78:108:147	0:1:4:5:8	D003866	depression	DiseaseOrPhenotypicFeature	53	54	2	1:Positive_Correlation:2	R2L	CROSS	77-78	61-62	D011605	psychosis	DiseaseOrPhenotypicFeature	61	62	3	3440	pegylated interferon alpha - 2b|interferon|interferon|pegylated interferon alpha - 2b|pegylated interferon alpha - 2b	GeneOrGeneProduct	14:31:77:103:142	19:32:78:108:147	0:1:4:5:8	1:Positive_Correlation:2	L2R	CROSS	33-34	53-54	D012254	ribavirin|ribavirin|ribavirin	ChemicalEntity	20:33:110	21:34:111	0:1:5	D003866	depression	DiseaseOrPhenotypicFeature	53	54	2	1:NR:2	L2R	CROSS	33-34	61-62	D012254	ribavirin|ribavirin|ribavirin	ChemicalEntity	20:33:110	21:34:111	0:1:5	D011605	psychosis	DiseaseOrPhenotypicFeature	61	62	3
26110643	Protein - Trap Insertional Mutagenesis Uncovers New Genes Involved in Zebrafish Skin Development , Including a Neuregulin 2a - Based ErbB Signaling Pathway Required during Median Fin Fold Morphogenesis .|Skin disorders are widespread , but available treatments are limited .|A more comprehensive understanding of skin development mechanisms will drive identification of new treatment targets and modalities .|Here we report the Zebrafish Integument Project ( ZIP ) , an expression - driven platform for identifying new skin genes and phenotypes in the vertebrate model Danio rerio ( zebrafish ) .|In vivo selection for skin - specific expression of gene - break transposon ( GBT ) mutant lines identified eleven new , revertible GBT alleles of genes involved in skin development .|Eight genes - - fras1 , grip1 , hmcn1 , msxc , col4a4 , ahnak , capn12 , and nrg2a - - had been described in an integumentary context to varying degrees , while arhgef25b , fkbp10b , and megf6a emerged as novel skin genes .|Embryos homozygous for a GBT insertion within neuregulin 2a ( nrg2a ) revealed a novel requirement for a Neuregulin 2a ( Nrg2a ) - ErbB2 / 3 - AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold ( MFF ) morphogenesis .|In nrg2a mutant larvae , the basal keratinocytes within the apical MFF , known as ridge cells , displayed reduced pAKT levels as well as reduced apical domains and exaggerated basolateral domains .|Those defects compromised proper ridge cell elongation into a flattened epithelial morphology , resulting in thickened MFF edges .|Pharmacological inhibition verified that Nrg2a signals through the ErbB receptor tyrosine kinase network .|Moreover , knockdown of the epithelial polarity regulator and tumor suppressor lgl2 ameliorated the nrg2a mutant phenotype .|Identifying Lgl2 as an antagonist of Nrg2a - ErbB signaling revealed a significantly earlier role for Lgl2 during epidermal morphogenesis than has been described to date .|Furthermore , our findings demonstrated that successive , coordinated ridge cell shape changes drive apical MFF development , making MFF ridge cells a valuable model for investigating how the coordinated regulation of cell polarity and cell shape changes serves as a crucial mechanism of epithelial morphogenesis .	1:Association:2	L2R	NON-CROSS	2-3	16-18	436725	Trap	GeneOrGeneProduct	2	3	0	100006951	Neuregulin 2a|nrg2a|neuregulin 2a|nrg2a|Neuregulin 2a|Nrg2a|nrg2a|Nrg2a|nrg2a|Nrg2a	GeneOrGeneProduct	16:143:177:180:188:191:221:276:300:310	18:144:179:181:190:192:222:277:301:311	0:5:6:6:6:6:7:9:10:11	1:NR:2	L2R	NON-CROSS	2-3	20-21	436725	Trap	GeneOrGeneProduct	2	3	0	386635,386966	ErbB|ErbB2 / 3|ErbB receptor tyrosine kinase|ErbB	GeneOrGeneProduct	20:194:280:312	21:197:284:313	0:6:9:11	1:NR:2	L2R	CROSS	2-3	30-32	436725	Trap	GeneOrGeneProduct	2	3	0	D012871	Skin disorders	DiseaseOrPhenotypicFeature	30	32	1	1:NR:2	L2R	CROSS	2-3	128-129	436725	Trap	GeneOrGeneProduct	2	3	0	563428	fras1	GeneOrGeneProduct	128	129	5	1:NR:2	L2R	CROSS	2-3	130-131	436725	Trap	GeneOrGeneProduct	2	3	0	558006	grip1	GeneOrGeneProduct	130	131	5	1:NR:2	L2R	CROSS	2-3	132-133	436725	Trap	GeneOrGeneProduct	2	3	0	559150	hmcn1	GeneOrGeneProduct	132	133	5	1:NR:2	L2R	CROSS	2-3	134-135	436725	Trap	GeneOrGeneProduct	2	3	0	30526	msxc	GeneOrGeneProduct	134	135	5	1:NR:2	L2R	CROSS	2-3	136-137	436725	Trap	GeneOrGeneProduct	2	3	0	554270	col4a4	GeneOrGeneProduct	136	137	5	1:NR:2	L2R	CROSS	2-3	138-139	436725	Trap	GeneOrGeneProduct	2	3	0	559276	ahnak	GeneOrGeneProduct	138	139	5	1:NR:2	L2R	CROSS	2-3	140-141	436725	Trap	GeneOrGeneProduct	2	3	0	799247	capn12	GeneOrGeneProduct	140	141	5	1:NR:2	L2R	CROSS	2-3	158-159	436725	Trap	GeneOrGeneProduct	2	3	0	569561	arhgef25b	GeneOrGeneProduct	158	159	5	1:NR:2	L2R	CROSS	2-3	160-161	436725	Trap	GeneOrGeneProduct	2	3	0	324381	fkbp10b	GeneOrGeneProduct	160	161	5	1:NR:2	L2R	CROSS	2-3	163-164	436725	Trap	GeneOrGeneProduct	2	3	0	565108	megf6a	GeneOrGeneProduct	163	164	5	1:NR:2	L2R	CROSS	2-3	198-199	436725	Trap	GeneOrGeneProduct	2	3	0	101910198	AKT|AKT	GeneOrGeneProduct	198:240	199:241	6:7	1:NR:2	L2R	CROSS	2-3	295-296	436725	Trap	GeneOrGeneProduct	2	3	0	D009369	tumor	DiseaseOrPhenotypicFeature	295	296	10	1:NR:2	L2R	CROSS	2-3	297-298	436725	Trap	GeneOrGeneProduct	2	3	0	795670	lgl2|Lgl2|Lgl2	GeneOrGeneProduct	297:305:320	298:306:321	10:11:11	1:NR:2	L2R	NON-CROSS	310-311	312-313	100006951	Neuregulin 2a|nrg2a|neuregulin 2a|nrg2a|Neuregulin 2a|Nrg2a|nrg2a|Nrg2a|nrg2a|Nrg2a	GeneOrGeneProduct	16:143:177:180:188:191:221:276:300:310	18:144:179:181:190:192:222:277:301:311	0:5:6:6:6:6:7:9:10:11	386635,386966	ErbB|ErbB2 / 3|ErbB receptor tyrosine kinase|ErbB	GeneOrGeneProduct	20:194:280:312	21:197:284:313	0:6:9:11	1:Association:2	R2L	CROSS	30-32	16-18	D012871	Skin disorders	DiseaseOrPhenotypicFeature	30	32	1	100006951	Neuregulin 2a|nrg2a|neuregulin 2a|nrg2a|Neuregulin 2a|Nrg2a|nrg2a|Nrg2a|nrg2a|Nrg2a	GeneOrGeneProduct	16:143:177:180:188:191:221:276:300:310	18:144:179:181:190:192:222:277:301:311	0:5:6:6:6:6:7:9:10:11	1:NR:2	L2R	NON-CROSS	128-129	143-144	100006951	Neuregulin 2a|nrg2a|neuregulin 2a|nrg2a|Neuregulin 2a|Nrg2a|nrg2a|Nrg2a|nrg2a|Nrg2a	GeneOrGeneProduct	16:143:177:180:188:191:221:276:300:310	18:144:179:181:190:192:222:277:301:311	0:5:6:6:6:6:7:9:10:11	563428	fras1	GeneOrGeneProduct	128	129	5	1:NR:2	L2R	NON-CROSS	130-131	143-144	100006951	Neuregulin 2a|nrg2a|neuregulin 2a|nrg2a|Neuregulin 2a|Nrg2a|nrg2a|Nrg2a|nrg2a|Nrg2a	GeneOrGeneProduct	16:143:177:180:188:191:221:276:300:310	18:144:179:181:190:192:222:277:301:311	0:5:6:6:6:6:7:9:10:11	558006	grip1	GeneOrGeneProduct	130	131	5	1:NR:2	L2R	NON-CROSS	132-133	143-144	100006951	Neuregulin 2a|nrg2a|neuregulin 2a|nrg2a|Neuregulin 2a|Nrg2a|nrg2a|Nrg2a|nrg2a|Nrg2a	GeneOrGeneProduct	16:143:177:180:188:191:221:276:300:310	18:144:179:181:190:192:222:277:301:311	0:5:6:6:6:6:7:9:10:11	559150	hmcn1	GeneOrGeneProduct	132	133	5	1:NR:2	L2R	NON-CROSS	134-135	143-144	100006951	Neuregulin 2a|nrg2a|neuregulin 2a|nrg2a|Neuregulin 2a|Nrg2a|nrg2a|Nrg2a|nrg2a|Nrg2a	GeneOrGeneProduct	16:143:177:180:188:191:221:276:300:310	18:144:179:181:190:192:222:277:301:311	0:5:6:6:6:6:7:9:10:11	30526	msxc	GeneOrGeneProduct	134	135	5	1:NR:2	L2R	NON-CROSS	136-137	143-144	100006951	Neuregulin 2a|nrg2a|neuregulin 2a|nrg2a|Neuregulin 2a|Nrg2a|nrg2a|Nrg2a|nrg2a|Nrg2a	GeneOrGeneProduct	16:143:177:180:188:191:221:276:300:310	18:144:179:181:190:192:222:277:301:311	0:5:6:6:6:6:7:9:10:11	554270	col4a4	GeneOrGeneProduct	136	137	5	1:NR:2	L2R	NON-CROSS	138-139	143-144	100006951	Neuregulin 2a|nrg2a|neuregulin 2a|nrg2a|Neuregulin 2a|Nrg2a|nrg2a|Nrg2a|nrg2a|Nrg2a	GeneOrGeneProduct	16:143:177:180:188:191:221:276:300:310	18:144:179:181:190:192:222:277:301:311	0:5:6:6:6:6:7:9:10:11	559276	ahnak	GeneOrGeneProduct	138	139	5	1:NR:2	L2R	NON-CROSS	140-141	143-144	100006951	Neuregulin 2a|nrg2a|neuregulin 2a|nrg2a|Neuregulin 2a|Nrg2a|nrg2a|Nrg2a|nrg2a|Nrg2a	GeneOrGeneProduct	16:143:177:180:188:191:221:276:300:310	18:144:179:181:190:192:222:277:301:311	0:5:6:6:6:6:7:9:10:11	799247	capn12	GeneOrGeneProduct	140	141	5	1:NR:2	L2R	NON-CROSS	143-144	158-159	100006951	Neuregulin 2a|nrg2a|neuregulin 2a|nrg2a|Neuregulin 2a|Nrg2a|nrg2a|Nrg2a|nrg2a|Nrg2a	GeneOrGeneProduct	16:143:177:180:188:191:221:276:300:310	18:144:179:181:190:192:222:277:301:311	0:5:6:6:6:6:7:9:10:11	569561	arhgef25b	GeneOrGeneProduct	158	159	5	1:NR:2	L2R	NON-CROSS	143-144	160-161	100006951	Neuregulin 2a|nrg2a|neuregulin 2a|nrg2a|Neuregulin 2a|Nrg2a|nrg2a|Nrg2a|nrg2a|Nrg2a	GeneOrGeneProduct	16:143:177:180:188:191:221:276:300:310	18:144:179:181:190:192:222:277:301:311	0:5:6:6:6:6:7:9:10:11	324381	fkbp10b	GeneOrGeneProduct	160	161	5	1:NR:2	L2R	NON-CROSS	163-164	177-179	100006951	Neuregulin 2a|nrg2a|neuregulin 2a|nrg2a|Neuregulin 2a|Nrg2a|nrg2a|Nrg2a|nrg2a|Nrg2a	GeneOrGeneProduct	16:143:177:180:188:191:221:276:300:310	18:144:179:181:190:192:222:277:301:311	0:5:6:6:6:6:7:9:10:11	565108	megf6a	GeneOrGeneProduct	163	164	5	1:Association:2	L2R	NON-CROSS	191-192	198-199	100006951	Neuregulin 2a|nrg2a|neuregulin 2a|nrg2a|Neuregulin 2a|Nrg2a|nrg2a|Nrg2a|nrg2a|Nrg2a	GeneOrGeneProduct	16:143:177:180:188:191:221:276:300:310	18:144:179:181:190:192:222:277:301:311	0:5:6:6:6:6:7:9:10:11	101910198	AKT|AKT	GeneOrGeneProduct	198:240	199:241	6:7	1:NR:2	L2R	NON-CROSS	295-296	300-301	100006951	Neuregulin 2a|nrg2a|neuregulin 2a|nrg2a|Neuregulin 2a|Nrg2a|nrg2a|Nrg2a|nrg2a|Nrg2a	GeneOrGeneProduct	16:143:177:180:188:191:221:276:300:310	18:144:179:181:190:192:222:277:301:311	0:5:6:6:6:6:7:9:10:11	D009369	tumor	DiseaseOrPhenotypicFeature	295	296	10	1:Negative_Correlation:2	R2L	NON-CROSS	300-301	297-298	795670	lgl2|Lgl2|Lgl2	GeneOrGeneProduct	297:305:320	298:306:321	10:11:11	100006951	Neuregulin 2a|nrg2a|neuregulin 2a|nrg2a|Neuregulin 2a|Nrg2a|nrg2a|Nrg2a|nrg2a|Nrg2a	GeneOrGeneProduct	16:143:177:180:188:191:221:276:300:310	18:144:179:181:190:192:222:277:301:311	0:5:6:6:6:6:7:9:10:11	1:NR:2	L2R	CROSS	20-21	30-32	386635,386966	ErbB|ErbB2 / 3|ErbB receptor tyrosine kinase|ErbB	GeneOrGeneProduct	20:194:280:312	21:197:284:313	0:6:9:11	D012871	Skin disorders	DiseaseOrPhenotypicFeature	30	32	1	1:NR:2	L2R	CROSS	128-129	194-197	386635,386966	ErbB|ErbB2 / 3|ErbB receptor tyrosine kinase|ErbB	GeneOrGeneProduct	20:194:280:312	21:197:284:313	0:6:9:11	563428	fras1	GeneOrGeneProduct	128	129	5	1:NR:2	L2R	CROSS	130-131	194-197	386635,386966	ErbB|ErbB2 / 3|ErbB receptor tyrosine kinase|ErbB	GeneOrGeneProduct	20:194:280:312	21:197:284:313	0:6:9:11	558006	grip1	GeneOrGeneProduct	130	131	5	1:NR:2	L2R	CROSS	132-133	194-197	386635,386966	ErbB|ErbB2 / 3|ErbB receptor tyrosine kinase|ErbB	GeneOrGeneProduct	20:194:280:312	21:197:284:313	0:6:9:11	559150	hmcn1	GeneOrGeneProduct	132	133	5	1:NR:2	L2R	CROSS	134-135	194-197	386635,386966	ErbB|ErbB2 / 3|ErbB receptor tyrosine kinase|ErbB	GeneOrGeneProduct	20:194:280:312	21:197:284:313	0:6:9:11	30526	msxc	GeneOrGeneProduct	134	135	5	1:NR:2	L2R	CROSS	136-137	194-197	386635,386966	ErbB|ErbB2 / 3|ErbB receptor tyrosine kinase|ErbB	GeneOrGeneProduct	20:194:280:312	21:197:284:313	0:6:9:11	554270	col4a4	GeneOrGeneProduct	136	137	5	1:NR:2	L2R	CROSS	138-139	194-197	386635,386966	ErbB|ErbB2 / 3|ErbB receptor tyrosine kinase|ErbB	GeneOrGeneProduct	20:194:280:312	21:197:284:313	0:6:9:11	559276	ahnak	GeneOrGeneProduct	138	139	5	1:NR:2	L2R	CROSS	140-141	194-197	386635,386966	ErbB|ErbB2 / 3|ErbB receptor tyrosine kinase|ErbB	GeneOrGeneProduct	20:194:280:312	21:197:284:313	0:6:9:11	799247	capn12	GeneOrGeneProduct	140	141	5	1:NR:2	L2R	CROSS	158-159	194-197	386635,386966	ErbB|ErbB2 / 3|ErbB receptor tyrosine kinase|ErbB	GeneOrGeneProduct	20:194:280:312	21:197:284:313	0:6:9:11	569561	arhgef25b	GeneOrGeneProduct	158	159	5	1:NR:2	L2R	CROSS	160-161	194-197	386635,386966	ErbB|ErbB2 / 3|ErbB receptor tyrosine kinase|ErbB	GeneOrGeneProduct	20:194:280:312	21:197:284:313	0:6:9:11	324381	fkbp10b	GeneOrGeneProduct	160	161	5	1:NR:2	L2R	CROSS	163-164	194-197	386635,386966	ErbB|ErbB2 / 3|ErbB receptor tyrosine kinase|ErbB	GeneOrGeneProduct	20:194:280:312	21:197:284:313	0:6:9:11	565108	megf6a	GeneOrGeneProduct	163	164	5	1:NR:2	L2R	NON-CROSS	194-197	198-199	386635,386966	ErbB|ErbB2 / 3|ErbB receptor tyrosine kinase|ErbB	GeneOrGeneProduct	20:194:280:312	21:197:284:313	0:6:9:11	101910198	AKT|AKT	GeneOrGeneProduct	198:240	199:241	6:7	1:NR:2	L2R	CROSS	280-284	295-296	386635,386966	ErbB|ErbB2 / 3|ErbB receptor tyrosine kinase|ErbB	GeneOrGeneProduct	20:194:280:312	21:197:284:313	0:6:9:11	D009369	tumor	DiseaseOrPhenotypicFeature	295	296	10	1:NR:2	L2R	NON-CROSS	305-306	312-313	386635,386966	ErbB|ErbB2 / 3|ErbB receptor tyrosine kinase|ErbB	GeneOrGeneProduct	20:194:280:312	21:197:284:313	0:6:9:11	795670	lgl2|Lgl2|Lgl2	GeneOrGeneProduct	297:305:320	298:306:321	10:11:11	1:Association:2	L2R	CROSS	30-32	128-129	D012871	Skin disorders	DiseaseOrPhenotypicFeature	30	32	1	563428	fras1	GeneOrGeneProduct	128	129	5	1:Association:2	L2R	CROSS	30-32	130-131	D012871	Skin disorders	DiseaseOrPhenotypicFeature	30	32	1	558006	grip1	GeneOrGeneProduct	130	131	5	1:Association:2	L2R	CROSS	30-32	132-133	D012871	Skin disorders	DiseaseOrPhenotypicFeature	30	32	1	559150	hmcn1	GeneOrGeneProduct	132	133	5	1:Association:2	L2R	CROSS	30-32	134-135	D012871	Skin disorders	DiseaseOrPhenotypicFeature	30	32	1	30526	msxc	GeneOrGeneProduct	134	135	5	1:Association:2	L2R	CROSS	30-32	136-137	D012871	Skin disorders	DiseaseOrPhenotypicFeature	30	32	1	554270	col4a4	GeneOrGeneProduct	136	137	5	1:Association:2	L2R	CROSS	30-32	138-139	D012871	Skin disorders	DiseaseOrPhenotypicFeature	30	32	1	559276	ahnak	GeneOrGeneProduct	138	139	5	1:Association:2	L2R	CROSS	30-32	140-141	D012871	Skin disorders	DiseaseOrPhenotypicFeature	30	32	1	799247	capn12	GeneOrGeneProduct	140	141	5	1:Association:2	L2R	CROSS	30-32	158-159	D012871	Skin disorders	DiseaseOrPhenotypicFeature	30	32	1	569561	arhgef25b	GeneOrGeneProduct	158	159	5	1:Association:2	L2R	CROSS	30-32	160-161	D012871	Skin disorders	DiseaseOrPhenotypicFeature	30	32	1	324381	fkbp10b	GeneOrGeneProduct	160	161	5	1:Association:2	L2R	CROSS	30-32	163-164	D012871	Skin disorders	DiseaseOrPhenotypicFeature	30	32	1	565108	megf6a	GeneOrGeneProduct	163	164	5	1:NR:2	L2R	CROSS	30-32	198-199	D012871	Skin disorders	DiseaseOrPhenotypicFeature	30	32	1	101910198	AKT|AKT	GeneOrGeneProduct	198:240	199:241	6:7	1:NR:2	L2R	CROSS	30-32	297-298	D012871	Skin disorders	DiseaseOrPhenotypicFeature	30	32	1	795670	lgl2|Lgl2|Lgl2	GeneOrGeneProduct	297:305:320	298:306:321	10:11:11	1:NR:2	L2R	NON-CROSS	128-129	130-131	563428	fras1	GeneOrGeneProduct	128	129	5	558006	grip1	GeneOrGeneProduct	130	131	5	1:NR:2	L2R	NON-CROSS	128-129	132-133	563428	fras1	GeneOrGeneProduct	128	129	5	559150	hmcn1	GeneOrGeneProduct	132	133	5	1:NR:2	L2R	NON-CROSS	128-129	134-135	563428	fras1	GeneOrGeneProduct	128	129	5	30526	msxc	GeneOrGeneProduct	134	135	5	1:NR:2	L2R	NON-CROSS	128-129	136-137	563428	fras1	GeneOrGeneProduct	128	129	5	554270	col4a4	GeneOrGeneProduct	136	137	5	1:NR:2	L2R	NON-CROSS	128-129	138-139	563428	fras1	GeneOrGeneProduct	128	129	5	559276	ahnak	GeneOrGeneProduct	138	139	5	1:NR:2	L2R	NON-CROSS	128-129	140-141	563428	fras1	GeneOrGeneProduct	128	129	5	799247	capn12	GeneOrGeneProduct	140	141	5	1:NR:2	L2R	NON-CROSS	128-129	158-159	563428	fras1	GeneOrGeneProduct	128	129	5	569561	arhgef25b	GeneOrGeneProduct	158	159	5	1:NR:2	L2R	NON-CROSS	128-129	160-161	563428	fras1	GeneOrGeneProduct	128	129	5	324381	fkbp10b	GeneOrGeneProduct	160	161	5	1:NR:2	L2R	NON-CROSS	128-129	163-164	563428	fras1	GeneOrGeneProduct	128	129	5	565108	megf6a	GeneOrGeneProduct	163	164	5	1:NR:2	L2R	CROSS	128-129	198-199	563428	fras1	GeneOrGeneProduct	128	129	5	101910198	AKT|AKT	GeneOrGeneProduct	198:240	199:241	6:7	1:NR:2	L2R	CROSS	128-129	295-296	563428	fras1	GeneOrGeneProduct	128	129	5	D009369	tumor	DiseaseOrPhenotypicFeature	295	296	10	1:NR:2	L2R	CROSS	128-129	297-298	563428	fras1	GeneOrGeneProduct	128	129	5	795670	lgl2|Lgl2|Lgl2	GeneOrGeneProduct	297:305:320	298:306:321	10:11:11	1:NR:2	L2R	NON-CROSS	130-131	132-133	558006	grip1	GeneOrGeneProduct	130	131	5	559150	hmcn1	GeneOrGeneProduct	132	133	5	1:NR:2	L2R	NON-CROSS	130-131	134-135	558006	grip1	GeneOrGeneProduct	130	131	5	30526	msxc	GeneOrGeneProduct	134	135	5	1:NR:2	L2R	NON-CROSS	130-131	136-137	558006	grip1	GeneOrGeneProduct	130	131	5	554270	col4a4	GeneOrGeneProduct	136	137	5	1:NR:2	L2R	NON-CROSS	130-131	138-139	558006	grip1	GeneOrGeneProduct	130	131	5	559276	ahnak	GeneOrGeneProduct	138	139	5	1:NR:2	L2R	NON-CROSS	130-131	140-141	558006	grip1	GeneOrGeneProduct	130	131	5	799247	capn12	GeneOrGeneProduct	140	141	5	1:NR:2	L2R	NON-CROSS	130-131	158-159	558006	grip1	GeneOrGeneProduct	130	131	5	569561	arhgef25b	GeneOrGeneProduct	158	159	5	1:NR:2	L2R	NON-CROSS	130-131	160-161	558006	grip1	GeneOrGeneProduct	130	131	5	324381	fkbp10b	GeneOrGeneProduct	160	161	5	1:NR:2	L2R	NON-CROSS	130-131	163-164	558006	grip1	GeneOrGeneProduct	130	131	5	565108	megf6a	GeneOrGeneProduct	163	164	5	1:NR:2	L2R	CROSS	130-131	198-199	558006	grip1	GeneOrGeneProduct	130	131	5	101910198	AKT|AKT	GeneOrGeneProduct	198:240	199:241	6:7	1:NR:2	L2R	CROSS	130-131	295-296	558006	grip1	GeneOrGeneProduct	130	131	5	D009369	tumor	DiseaseOrPhenotypicFeature	295	296	10	1:NR:2	L2R	CROSS	130-131	297-298	558006	grip1	GeneOrGeneProduct	130	131	5	795670	lgl2|Lgl2|Lgl2	GeneOrGeneProduct	297:305:320	298:306:321	10:11:11	1:NR:2	L2R	NON-CROSS	132-133	134-135	559150	hmcn1	GeneOrGeneProduct	132	133	5	30526	msxc	GeneOrGeneProduct	134	135	5	1:NR:2	L2R	NON-CROSS	132-133	136-137	559150	hmcn1	GeneOrGeneProduct	132	133	5	554270	col4a4	GeneOrGeneProduct	136	137	5	1:NR:2	L2R	NON-CROSS	132-133	138-139	559150	hmcn1	GeneOrGeneProduct	132	133	5	559276	ahnak	GeneOrGeneProduct	138	139	5	1:NR:2	L2R	NON-CROSS	132-133	140-141	559150	hmcn1	GeneOrGeneProduct	132	133	5	799247	capn12	GeneOrGeneProduct	140	141	5	1:NR:2	L2R	NON-CROSS	132-133	158-159	559150	hmcn1	GeneOrGeneProduct	132	133	5	569561	arhgef25b	GeneOrGeneProduct	158	159	5	1:NR:2	L2R	NON-CROSS	132-133	160-161	559150	hmcn1	GeneOrGeneProduct	132	133	5	324381	fkbp10b	GeneOrGeneProduct	160	161	5	1:NR:2	L2R	NON-CROSS	132-133	163-164	559150	hmcn1	GeneOrGeneProduct	132	133	5	565108	megf6a	GeneOrGeneProduct	163	164	5	1:NR:2	L2R	CROSS	132-133	198-199	559150	hmcn1	GeneOrGeneProduct	132	133	5	101910198	AKT|AKT	GeneOrGeneProduct	198:240	199:241	6:7	1:NR:2	L2R	CROSS	132-133	295-296	559150	hmcn1	GeneOrGeneProduct	132	133	5	D009369	tumor	DiseaseOrPhenotypicFeature	295	296	10	1:NR:2	L2R	CROSS	132-133	297-298	559150	hmcn1	GeneOrGeneProduct	132	133	5	795670	lgl2|Lgl2|Lgl2	GeneOrGeneProduct	297:305:320	298:306:321	10:11:11	1:NR:2	L2R	NON-CROSS	134-135	136-137	30526	msxc	GeneOrGeneProduct	134	135	5	554270	col4a4	GeneOrGeneProduct	136	137	5	1:NR:2	L2R	NON-CROSS	134-135	138-139	30526	msxc	GeneOrGeneProduct	134	135	5	559276	ahnak	GeneOrGeneProduct	138	139	5	1:NR:2	L2R	NON-CROSS	134-135	140-141	30526	msxc	GeneOrGeneProduct	134	135	5	799247	capn12	GeneOrGeneProduct	140	141	5	1:NR:2	L2R	NON-CROSS	134-135	158-159	30526	msxc	GeneOrGeneProduct	134	135	5	569561	arhgef25b	GeneOrGeneProduct	158	159	5	1:NR:2	L2R	NON-CROSS	134-135	160-161	30526	msxc	GeneOrGeneProduct	134	135	5	324381	fkbp10b	GeneOrGeneProduct	160	161	5	1:NR:2	L2R	NON-CROSS	134-135	163-164	30526	msxc	GeneOrGeneProduct	134	135	5	565108	megf6a	GeneOrGeneProduct	163	164	5	1:NR:2	L2R	CROSS	134-135	198-199	30526	msxc	GeneOrGeneProduct	134	135	5	101910198	AKT|AKT	GeneOrGeneProduct	198:240	199:241	6:7	1:NR:2	L2R	CROSS	134-135	295-296	30526	msxc	GeneOrGeneProduct	134	135	5	D009369	tumor	DiseaseOrPhenotypicFeature	295	296	10	1:NR:2	L2R	CROSS	134-135	297-298	30526	msxc	GeneOrGeneProduct	134	135	5	795670	lgl2|Lgl2|Lgl2	GeneOrGeneProduct	297:305:320	298:306:321	10:11:11	1:NR:2	L2R	NON-CROSS	136-137	138-139	554270	col4a4	GeneOrGeneProduct	136	137	5	559276	ahnak	GeneOrGeneProduct	138	139	5	1:NR:2	L2R	NON-CROSS	136-137	140-141	554270	col4a4	GeneOrGeneProduct	136	137	5	799247	capn12	GeneOrGeneProduct	140	141	5	1:NR:2	L2R	NON-CROSS	136-137	158-159	554270	col4a4	GeneOrGeneProduct	136	137	5	569561	arhgef25b	GeneOrGeneProduct	158	159	5	1:NR:2	L2R	NON-CROSS	136-137	160-161	554270	col4a4	GeneOrGeneProduct	136	137	5	324381	fkbp10b	GeneOrGeneProduct	160	161	5	1:NR:2	L2R	NON-CROSS	136-137	163-164	554270	col4a4	GeneOrGeneProduct	136	137	5	565108	megf6a	GeneOrGeneProduct	163	164	5	1:NR:2	L2R	CROSS	136-137	198-199	554270	col4a4	GeneOrGeneProduct	136	137	5	101910198	AKT|AKT	GeneOrGeneProduct	198:240	199:241	6:7	1:NR:2	L2R	CROSS	136-137	295-296	554270	col4a4	GeneOrGeneProduct	136	137	5	D009369	tumor	DiseaseOrPhenotypicFeature	295	296	10	1:NR:2	L2R	CROSS	136-137	297-298	554270	col4a4	GeneOrGeneProduct	136	137	5	795670	lgl2|Lgl2|Lgl2	GeneOrGeneProduct	297:305:320	298:306:321	10:11:11	1:NR:2	L2R	NON-CROSS	138-139	140-141	559276	ahnak	GeneOrGeneProduct	138	139	5	799247	capn12	GeneOrGeneProduct	140	141	5	1:NR:2	L2R	NON-CROSS	138-139	158-159	559276	ahnak	GeneOrGeneProduct	138	139	5	569561	arhgef25b	GeneOrGeneProduct	158	159	5	1:NR:2	L2R	NON-CROSS	138-139	160-161	559276	ahnak	GeneOrGeneProduct	138	139	5	324381	fkbp10b	GeneOrGeneProduct	160	161	5	1:NR:2	L2R	NON-CROSS	138-139	163-164	559276	ahnak	GeneOrGeneProduct	138	139	5	565108	megf6a	GeneOrGeneProduct	163	164	5	1:NR:2	L2R	CROSS	138-139	198-199	559276	ahnak	GeneOrGeneProduct	138	139	5	101910198	AKT|AKT	GeneOrGeneProduct	198:240	199:241	6:7	1:NR:2	L2R	CROSS	138-139	295-296	559276	ahnak	GeneOrGeneProduct	138	139	5	D009369	tumor	DiseaseOrPhenotypicFeature	295	296	10	1:NR:2	L2R	CROSS	138-139	297-298	559276	ahnak	GeneOrGeneProduct	138	139	5	795670	lgl2|Lgl2|Lgl2	GeneOrGeneProduct	297:305:320	298:306:321	10:11:11	1:NR:2	L2R	NON-CROSS	140-141	158-159	799247	capn12	GeneOrGeneProduct	140	141	5	569561	arhgef25b	GeneOrGeneProduct	158	159	5	1:NR:2	L2R	NON-CROSS	140-141	160-161	799247	capn12	GeneOrGeneProduct	140	141	5	324381	fkbp10b	GeneOrGeneProduct	160	161	5	1:NR:2	L2R	NON-CROSS	140-141	163-164	799247	capn12	GeneOrGeneProduct	140	141	5	565108	megf6a	GeneOrGeneProduct	163	164	5	1:NR:2	L2R	CROSS	140-141	198-199	799247	capn12	GeneOrGeneProduct	140	141	5	101910198	AKT|AKT	GeneOrGeneProduct	198:240	199:241	6:7	1:NR:2	L2R	CROSS	140-141	295-296	799247	capn12	GeneOrGeneProduct	140	141	5	D009369	tumor	DiseaseOrPhenotypicFeature	295	296	10	1:NR:2	L2R	CROSS	140-141	297-298	799247	capn12	GeneOrGeneProduct	140	141	5	795670	lgl2|Lgl2|Lgl2	GeneOrGeneProduct	297:305:320	298:306:321	10:11:11	1:NR:2	L2R	NON-CROSS	158-159	160-161	569561	arhgef25b	GeneOrGeneProduct	158	159	5	324381	fkbp10b	GeneOrGeneProduct	160	161	5	1:NR:2	L2R	NON-CROSS	158-159	163-164	569561	arhgef25b	GeneOrGeneProduct	158	159	5	565108	megf6a	GeneOrGeneProduct	163	164	5	1:NR:2	L2R	CROSS	158-159	198-199	569561	arhgef25b	GeneOrGeneProduct	158	159	5	101910198	AKT|AKT	GeneOrGeneProduct	198:240	199:241	6:7	1:NR:2	L2R	CROSS	158-159	295-296	569561	arhgef25b	GeneOrGeneProduct	158	159	5	D009369	tumor	DiseaseOrPhenotypicFeature	295	296	10	1:NR:2	L2R	CROSS	158-159	297-298	569561	arhgef25b	GeneOrGeneProduct	158	159	5	795670	lgl2|Lgl2|Lgl2	GeneOrGeneProduct	297:305:320	298:306:321	10:11:11	1:NR:2	L2R	NON-CROSS	160-161	163-164	324381	fkbp10b	GeneOrGeneProduct	160	161	5	565108	megf6a	GeneOrGeneProduct	163	164	5	1:NR:2	L2R	CROSS	160-161	198-199	324381	fkbp10b	GeneOrGeneProduct	160	161	5	101910198	AKT|AKT	GeneOrGeneProduct	198:240	199:241	6:7	1:NR:2	L2R	CROSS	160-161	295-296	324381	fkbp10b	GeneOrGeneProduct	160	161	5	D009369	tumor	DiseaseOrPhenotypicFeature	295	296	10	1:NR:2	L2R	CROSS	160-161	297-298	324381	fkbp10b	GeneOrGeneProduct	160	161	5	795670	lgl2|Lgl2|Lgl2	GeneOrGeneProduct	297:305:320	298:306:321	10:11:11	1:NR:2	L2R	CROSS	163-164	198-199	565108	megf6a	GeneOrGeneProduct	163	164	5	101910198	AKT|AKT	GeneOrGeneProduct	198:240	199:241	6:7	1:NR:2	L2R	CROSS	163-164	295-296	565108	megf6a	GeneOrGeneProduct	163	164	5	D009369	tumor	DiseaseOrPhenotypicFeature	295	296	10	1:NR:2	L2R	CROSS	163-164	297-298	565108	megf6a	GeneOrGeneProduct	163	164	5	795670	lgl2|Lgl2|Lgl2	GeneOrGeneProduct	297:305:320	298:306:321	10:11:11	1:NR:2	L2R	CROSS	240-241	295-296	101910198	AKT|AKT	GeneOrGeneProduct	198:240	199:241	6:7	D009369	tumor	DiseaseOrPhenotypicFeature	295	296	10	1:NR:2	L2R	CROSS	240-241	297-298	101910198	AKT|AKT	GeneOrGeneProduct	198:240	199:241	6:7	795670	lgl2|Lgl2|Lgl2	GeneOrGeneProduct	297:305:320	298:306:321	10:11:11	1:Negative_Correlation:2	L2R	NON-CROSS	295-296	297-298	D009369	tumor	DiseaseOrPhenotypicFeature	295	296	10	795670	lgl2|Lgl2|Lgl2	GeneOrGeneProduct	297:305:320	298:306:321	10:11:11
18179903	Mutation analysis of CHRNA1 , CHRNB1 , CHRND , and RAPSN genes in multiple pterygium syndrome / fetal akinesia patients .|Multiple pterygium syndromes ( MPS ) comprise a group of multiple congenital anomaly disorders characterized by webbing ( pterygia ) of the neck , elbows , and / or knees and joint contractures ( arthrogryposis ) .|MPS are phenotypically and genetically heterogeneous but are traditionally divided into prenatally lethal and nonlethal ( Escobar ) types .|Previously , we and others reported that recessive mutations in the embryonal acetylcholine receptor g subunit ( CHRNG ) can cause both lethal and nonlethal MPS , thus demonstrating that pterygia resulted from fetal akinesia .|We hypothesized that mutations in acetylcholine receptor - related genes might also result in a MPS / fetal akinesia phenotype and so we analyzed 15 cases of lethal MPS / fetal akinesia without CHRNG mutations for mutations in the CHRNA1 , CHRNB1 , CHRND , and rapsyn ( RAPSN ) genes .|No CHRNA1 , CHRNB1 , or CHRND mutations were detected , but a homozygous RAPSN frameshift mutation , c . 1177 - 1178delAA , was identified in a family with three children affected with lethal fetal akinesia sequence .|Previously , RAPSN mutations have been reported in congenital myasthenia .|Functional studies were consistent with the hypothesis that whereas incomplete loss of rapsyn function may cause congenital myasthenia , more severe loss of function can result in a lethal fetal akinesia phenotype .	1:NR:2	L2R	NON-CROSS	3-4	5-6	1134	CHRNA1|CHRNA1|CHRNA1	GeneOrGeneProduct	3:153:167	4:154:168	0:4:5	1140	CHRNB1|CHRNB1|CHRNB1	GeneOrGeneProduct	5:155:169	6:156:170	0:4:5	1:NR:2	L2R	NON-CROSS	3-4	7-8	1134	CHRNA1|CHRNA1|CHRNA1	GeneOrGeneProduct	3:153:167	4:154:168	0:4:5	1144	CHRND|CHRND|CHRND	GeneOrGeneProduct	7:157:172	8:158:173	0:4:5	1:NR:2	L2R	NON-CROSS	162-163	167-168	1134	CHRNA1|CHRNA1|CHRNA1	GeneOrGeneProduct	3:153:167	4:154:168	0:4:5	5913	RAPSN|rapsyn|RAPSN|RAPSN|RAPSN|rapsyn	GeneOrGeneProduct	10:160:162:180:207:228	11:161:163:181:208:229	0:4:4:5:6:7	1:NR:2	L2R	NON-CROSS	3-4	13-16	1134	CHRNA1|CHRNA1|CHRNA1	GeneOrGeneProduct	3:153:167	4:154:168	0:4:5	C537377	multiple pterygium syndrome|Multiple pterygium syndromes|MPS|MPS|MPS|MPS|MPS	DiseaseOrPhenotypicFeature	13:21:25:58:103:129:142	16:24:26:59:104:130:143	0:1:1:2:3:4:4	1:NR:2	L2R	NON-CROSS	144-146	153-154	1134	CHRNA1|CHRNA1|CHRNA1	GeneOrGeneProduct	3:153:167	4:154:168	0:4:5	C536647	fetal akinesia|fetal akinesia|fetal akinesia|fetal akinesia|fetal akinesia sequence|fetal akinesia	DiseaseOrPhenotypicFeature	17:111:131:144:201:245	19:113:133:146:204:247	0:3:4:4:5:7	1:NR:2	L2R	CROSS	3-4	32-35	1134	CHRNA1|CHRNA1|CHRNA1	GeneOrGeneProduct	3:153:167	4:154:168	0:4:5	D000013	congenital anomaly disorders	DiseaseOrPhenotypicFeature	32	35	1	1:NR:2	L2R	CROSS	3-4	52-54	1134	CHRNA1|CHRNA1|CHRNA1	GeneOrGeneProduct	3:153:167	4:154:168	0:4:5	D003286	joint contractures	DiseaseOrPhenotypicFeature	52	54	1	1:NR:2	L2R	CROSS	3-4	55-56	1134	CHRNA1|CHRNA1|CHRNA1	GeneOrGeneProduct	3:153:167	4:154:168	0:4:5	D001176	arthrogryposis	DiseaseOrPhenotypicFeature	55	56	1	1:NR:2	L2R	NON-CROSS	147-148	153-154	1134	CHRNA1|CHRNA1|CHRNA1	GeneOrGeneProduct	3:153:167	4:154:168	0:4:5	1146	embryonal acetylcholine receptor g subunit|CHRNG|CHRNG	GeneOrGeneProduct	89:95:147	94:96:148	3:3:4	1:NR:2	L2R	CROSS	167-168	213-215	1134	CHRNA1|CHRNA1|CHRNA1	GeneOrGeneProduct	3:153:167	4:154:168	0:4:5	D020294	congenital myasthenia|congenital myasthenia	DiseaseOrPhenotypicFeature	213:232	215:234	6:7	1:NR:2	L2R	NON-CROSS	5-6	7-8	1140	CHRNB1|CHRNB1|CHRNB1	GeneOrGeneProduct	5:155:169	6:156:170	0:4:5	1144	CHRND|CHRND|CHRND	GeneOrGeneProduct	7:157:172	8:158:173	0:4:5	1:NR:2	L2R	NON-CROSS	5-6	10-11	1140	CHRNB1|CHRNB1|CHRNB1	GeneOrGeneProduct	5:155:169	6:156:170	0:4:5	5913	RAPSN|rapsyn|RAPSN|RAPSN|RAPSN|rapsyn	GeneOrGeneProduct	10:160:162:180:207:228	11:161:163:181:208:229	0:4:4:5:6:7	1:NR:2	L2R	NON-CROSS	5-6	13-16	1140	CHRNB1|CHRNB1|CHRNB1	GeneOrGeneProduct	5:155:169	6:156:170	0:4:5	C537377	multiple pterygium syndrome|Multiple pterygium syndromes|MPS|MPS|MPS|MPS|MPS	DiseaseOrPhenotypicFeature	13:21:25:58:103:129:142	16:24:26:59:104:130:143	0:1:1:2:3:4:4	1:NR:2	L2R	NON-CROSS	144-146	155-156	1140	CHRNB1|CHRNB1|CHRNB1	GeneOrGeneProduct	5:155:169	6:156:170	0:4:5	C536647	fetal akinesia|fetal akinesia|fetal akinesia|fetal akinesia|fetal akinesia sequence|fetal akinesia	DiseaseOrPhenotypicFeature	17:111:131:144:201:245	19:113:133:146:204:247	0:3:4:4:5:7	1:NR:2	L2R	CROSS	5-6	32-35	1140	CHRNB1|CHRNB1|CHRNB1	GeneOrGeneProduct	5:155:169	6:156:170	0:4:5	D000013	congenital anomaly disorders	DiseaseOrPhenotypicFeature	32	35	1	1:NR:2	L2R	CROSS	5-6	52-54	1140	CHRNB1|CHRNB1|CHRNB1	GeneOrGeneProduct	5:155:169	6:156:170	0:4:5	D003286	joint contractures	DiseaseOrPhenotypicFeature	52	54	1	1:NR:2	L2R	CROSS	5-6	55-56	1140	CHRNB1|CHRNB1|CHRNB1	GeneOrGeneProduct	5:155:169	6:156:170	0:4:5	D001176	arthrogryposis	DiseaseOrPhenotypicFeature	55	56	1	1:NR:2	L2R	NON-CROSS	147-148	155-156	1140	CHRNB1|CHRNB1|CHRNB1	GeneOrGeneProduct	5:155:169	6:156:170	0:4:5	1146	embryonal acetylcholine receptor g subunit|CHRNG|CHRNG	GeneOrGeneProduct	89:95:147	94:96:148	3:3:4	1:NR:2	L2R	CROSS	169-170	213-215	1140	CHRNB1|CHRNB1|CHRNB1	GeneOrGeneProduct	5:155:169	6:156:170	0:4:5	D020294	congenital myasthenia|congenital myasthenia	DiseaseOrPhenotypicFeature	213:232	215:234	6:7	1:NR:2	L2R	NON-CROSS	7-8	10-11	1144	CHRND|CHRND|CHRND	GeneOrGeneProduct	7:157:172	8:158:173	0:4:5	5913	RAPSN|rapsyn|RAPSN|RAPSN|RAPSN|rapsyn	GeneOrGeneProduct	10:160:162:180:207:228	11:161:163:181:208:229	0:4:4:5:6:7	1:NR:2	L2R	NON-CROSS	7-8	13-16	1144	CHRND|CHRND|CHRND	GeneOrGeneProduct	7:157:172	8:158:173	0:4:5	C537377	multiple pterygium syndrome|Multiple pterygium syndromes|MPS|MPS|MPS|MPS|MPS	DiseaseOrPhenotypicFeature	13:21:25:58:103:129:142	16:24:26:59:104:130:143	0:1:1:2:3:4:4	1:NR:2	L2R	NON-CROSS	7-8	17-19	1144	CHRND|CHRND|CHRND	GeneOrGeneProduct	7:157:172	8:158:173	0:4:5	C536647	fetal akinesia|fetal akinesia|fetal akinesia|fetal akinesia|fetal akinesia sequence|fetal akinesia	DiseaseOrPhenotypicFeature	17:111:131:144:201:245	19:113:133:146:204:247	0:3:4:4:5:7	1:NR:2	L2R	CROSS	7-8	32-35	1144	CHRND|CHRND|CHRND	GeneOrGeneProduct	7:157:172	8:158:173	0:4:5	D000013	congenital anomaly disorders	DiseaseOrPhenotypicFeature	32	35	1	1:NR:2	L2R	CROSS	7-8	52-54	1144	CHRND|CHRND|CHRND	GeneOrGeneProduct	7:157:172	8:158:173	0:4:5	D003286	joint contractures	DiseaseOrPhenotypicFeature	52	54	1	1:NR:2	L2R	CROSS	7-8	55-56	1144	CHRND|CHRND|CHRND	GeneOrGeneProduct	7:157:172	8:158:173	0:4:5	D001176	arthrogryposis	DiseaseOrPhenotypicFeature	55	56	1	1:NR:2	L2R	NON-CROSS	147-148	157-158	1144	CHRND|CHRND|CHRND	GeneOrGeneProduct	7:157:172	8:158:173	0:4:5	1146	embryonal acetylcholine receptor g subunit|CHRNG|CHRNG	GeneOrGeneProduct	89:95:147	94:96:148	3:3:4	1:NR:2	L2R	CROSS	172-173	213-215	1144	CHRND|CHRND|CHRND	GeneOrGeneProduct	7:157:172	8:158:173	0:4:5	D020294	congenital myasthenia|congenital myasthenia	DiseaseOrPhenotypicFeature	213:232	215:234	6:7	1:NR:2	L2R	NON-CROSS	10-11	13-16	5913	RAPSN|rapsyn|RAPSN|RAPSN|RAPSN|rapsyn	GeneOrGeneProduct	10:160:162:180:207:228	11:161:163:181:208:229	0:4:4:5:6:7	C537377	multiple pterygium syndrome|Multiple pterygium syndromes|MPS|MPS|MPS|MPS|MPS	DiseaseOrPhenotypicFeature	13:21:25:58:103:129:142	16:24:26:59:104:130:143	0:1:1:2:3:4:4	1:Negative_Correlation:2	L2R	NON-CROSS	201-204	207-208	5913	RAPSN|rapsyn|RAPSN|RAPSN|RAPSN|rapsyn	GeneOrGeneProduct	10:160:162:180:207:228	11:161:163:181:208:229	0:4:4:5:6:7	C536647	fetal akinesia|fetal akinesia|fetal akinesia|fetal akinesia|fetal akinesia sequence|fetal akinesia	DiseaseOrPhenotypicFeature	17:111:131:144:201:245	19:113:133:146:204:247	0:3:4:4:5:7	1:NR:2	L2R	CROSS	10-11	32-35	5913	RAPSN|rapsyn|RAPSN|RAPSN|RAPSN|rapsyn	GeneOrGeneProduct	10:160:162:180:207:228	11:161:163:181:208:229	0:4:4:5:6:7	D000013	congenital anomaly disorders	DiseaseOrPhenotypicFeature	32	35	1	1:NR:2	L2R	CROSS	10-11	52-54	5913	RAPSN|rapsyn|RAPSN|RAPSN|RAPSN|rapsyn	GeneOrGeneProduct	10:160:162:180:207:228	11:161:163:181:208:229	0:4:4:5:6:7	D003286	joint contractures	DiseaseOrPhenotypicFeature	52	54	1	1:NR:2	L2R	CROSS	10-11	55-56	5913	RAPSN|rapsyn|RAPSN|RAPSN|RAPSN|rapsyn	GeneOrGeneProduct	10:160:162:180:207:228	11:161:163:181:208:229	0:4:4:5:6:7	D001176	arthrogryposis	DiseaseOrPhenotypicFeature	55	56	1	1:NR:2	L2R	NON-CROSS	147-148	160-161	5913	RAPSN|rapsyn|RAPSN|RAPSN|RAPSN|rapsyn	GeneOrGeneProduct	10:160:162:180:207:228	11:161:163:181:208:229	0:4:4:5:6:7	1146	embryonal acetylcholine receptor g subunit|CHRNG|CHRNG	GeneOrGeneProduct	89:95:147	94:96:148	3:3:4	1:Negative_Correlation:2	L2R	NON-CROSS	228-229	232-234	5913	RAPSN|rapsyn|RAPSN|RAPSN|RAPSN|rapsyn	GeneOrGeneProduct	10:160:162:180:207:228	11:161:163:181:208:229	0:4:4:5:6:7	D020294	congenital myasthenia|congenital myasthenia	DiseaseOrPhenotypicFeature	213:232	215:234	6:7	1:Association:2	R2L	NON-CROSS	147-148	142-143	1146	embryonal acetylcholine receptor g subunit|CHRNG|CHRNG	GeneOrGeneProduct	89:95:147	94:96:148	3:3:4	C537377	multiple pterygium syndrome|Multiple pterygium syndromes|MPS|MPS|MPS|MPS|MPS	DiseaseOrPhenotypicFeature	13:21:25:58:103:129:142	16:24:26:59:104:130:143	0:1:1:2:3:4:4	1:NR:2	L2R	CROSS	142-143	184-189	C537377	multiple pterygium syndrome|Multiple pterygium syndromes|MPS|MPS|MPS|MPS|MPS	DiseaseOrPhenotypicFeature	13:21:25:58:103:129:142	16:24:26:59:104:130:143	0:1:1:2:3:4:4	c|DEL|1177_1178|AA	c . 1177 - 1178delAA	SequenceVariant	184	189	5	1:NR:2	L2R	NON-CROSS	144-146	147-148	C536647	fetal akinesia|fetal akinesia|fetal akinesia|fetal akinesia|fetal akinesia sequence|fetal akinesia	DiseaseOrPhenotypicFeature	17:111:131:144:201:245	19:113:133:146:204:247	0:3:4:4:5:7	1146	embryonal acetylcholine receptor g subunit|CHRNG|CHRNG	GeneOrGeneProduct	89:95:147	94:96:148	3:3:4	1:Positive_Correlation:2	R2L	NON-CROSS	201-204	184-189	c|DEL|1177_1178|AA	c . 1177 - 1178delAA	SequenceVariant	184	189	5	C536647	fetal akinesia|fetal akinesia|fetal akinesia|fetal akinesia|fetal akinesia sequence|fetal akinesia	DiseaseOrPhenotypicFeature	17:111:131:144:201:245	19:113:133:146:204:247	0:3:4:4:5:7	1:NR:2	L2R	CROSS	32-35	89-94	D000013	congenital anomaly disorders	DiseaseOrPhenotypicFeature	32	35	1	1146	embryonal acetylcholine receptor g subunit|CHRNG|CHRNG	GeneOrGeneProduct	89:95:147	94:96:148	3:3:4	1:NR:2	L2R	CROSS	32-35	184-189	D000013	congenital anomaly disorders	DiseaseOrPhenotypicFeature	32	35	1	c|DEL|1177_1178|AA	c . 1177 - 1178delAA	SequenceVariant	184	189	5	1:NR:2	L2R	CROSS	52-54	89-94	D003286	joint contractures	DiseaseOrPhenotypicFeature	52	54	1	1146	embryonal acetylcholine receptor g subunit|CHRNG|CHRNG	GeneOrGeneProduct	89:95:147	94:96:148	3:3:4	1:NR:2	L2R	CROSS	52-54	184-189	D003286	joint contractures	DiseaseOrPhenotypicFeature	52	54	1	c|DEL|1177_1178|AA	c . 1177 - 1178delAA	SequenceVariant	184	189	5	1:NR:2	L2R	CROSS	55-56	89-94	D001176	arthrogryposis	DiseaseOrPhenotypicFeature	55	56	1	1146	embryonal acetylcholine receptor g subunit|CHRNG|CHRNG	GeneOrGeneProduct	89:95:147	94:96:148	3:3:4	1:NR:2	L2R	CROSS	55-56	184-189	D001176	arthrogryposis	DiseaseOrPhenotypicFeature	55	56	1	c|DEL|1177_1178|AA	c . 1177 - 1178delAA	SequenceVariant	184	189	5	1:NR:2	L2R	CROSS	147-148	213-215	1146	embryonal acetylcholine receptor g subunit|CHRNG|CHRNG	GeneOrGeneProduct	89:95:147	94:96:148	3:3:4	D020294	congenital myasthenia|congenital myasthenia	DiseaseOrPhenotypicFeature	213:232	215:234	6:7	1:NR:2	L2R	CROSS	184-189	213-215	c|DEL|1177_1178|AA	c . 1177 - 1178delAA	SequenceVariant	184	189	5	D020294	congenital myasthenia|congenital myasthenia	DiseaseOrPhenotypicFeature	213:232	215:234	6:7
19353688	Pure monosomy and pure trisomy of 13q21 . 2 - 31 . 1 consequent to a familial insertional translocation : exclusion of PCDH9 as the responsible gene for autosomal dominant auditory neuropathy ( AUNA1 ) .|Insertional translocations ( IT ) are rare structural rearrangements .|Offspring of IT balanced carriers are at high risk to have either pure partial trisomy or monosomy for the inserted segment as manifested by " pure " phenotypes .|We describe an IT between chromosomes 3 and 13 segregating in a three - generation pedigree .|Short tandem repeat ( STR ) segregation analysis and array - comparative genomic hybridization were used to define the IT as a 25 . 1 Mb segment spanning 13q21 . 2 - q31 . 1 .|The phenotype of pure monosomy included deafness , duodenal stenosis , developmental and growth delay , vertebral anomalies , and facial dysmorphisms ; the trisomy was manifested by only minor dysmorphisms .|As the AUNA1 deafness locus on 13q14 - 21 overlaps the IT in the PCDH9 ( protocadherin - 9 ) gene region , PCDH9 was investigated as a candidate gene for deafness in both families .|Genotyping of STRs and single nucleotide polymorphisms defined the AUNA1 breakpoint as 35 kb 5 ' to PCDH9 , with a 2 . 4 Mb area of overlap with the IT .|DNA sequencing of coding regions in the AUNA1 family and in the retained homologue chromosome in the monosomic patient revealed no mutations .|We conclude that AUNA1 deafness does not share a common etiology with deafness associated with monosomy 13q21 . 2 - q31 . 3 ; deafness may result from monosomy of PCHD9 or another gene in the IT , as has been demonstrated in contiguous gene deletion syndromes .|Precise characterization of the breakpoints of the translocated region is useful to identify which genes may be contributing to the phenotype , either through haploinsufficiency or extra dosage effects , in order to define genotype - phenotype correlations .	1:Association:2	R2L	NON-CROSS	28-32	22-23	C563790	autosomal dominant auditory neuropathy|AUNA1|AUNA1|AUNA1|AUNA1|AUNA1	DiseaseOrPhenotypicFeature	28:33:162:205:235:254	32:34:163:206:236:255	0:0:6:7:8:9	5101	PCDH9|PCDH9|protocadherin - 9|PCDH9|PCDH9|PCHD9	GeneOrGeneProduct	22:174:176:183:213:281	23:175:179:184:214:282	0:6:6:6:7:9	1:Association:2	R2L	NON-CROSS	281-282	275-276	D003638	deafness|deafness|deafness|deafness|deafness|deafness	DiseaseOrPhenotypicFeature	134:163:191:255:263:275	135:164:192:256:264:276	5:6:6:9:9:9	5101	PCDH9|PCDH9|protocadherin - 9|PCDH9|PCDH9|PCHD9	GeneOrGeneProduct	22:174:176:183:213:281	23:175:179:184:214:282	0:6:6:6:7:9	1:NR:2	L2R	CROSS	136-138	174-175	5101	PCDH9|PCDH9|protocadherin - 9|PCDH9|PCDH9|PCHD9	GeneOrGeneProduct	22:174:176:183:213:281	23:175:179:184:214:282	0:6:6:6:7:9	C535720	duodenal stenosis	DiseaseOrPhenotypicFeature	136	138	5	1:NR:2	L2R	CROSS	139-143	176-179	5101	PCDH9|PCDH9|protocadherin - 9|PCDH9|PCDH9|PCHD9	GeneOrGeneProduct	22:174:176:183:213:281	23:175:179:184:214:282	0:6:6:6:7:9	D002658	developmental and growth delay	DiseaseOrPhenotypicFeature	139	143	5	1:NR:2	L2R	CROSS	144-146	174-175	5101	PCDH9|PCDH9|protocadherin - 9|PCDH9|PCDH9|PCHD9	GeneOrGeneProduct	22:174:176:183:213:281	23:175:179:184:214:282	0:6:6:6:7:9	C535781	vertebral anomalies	DiseaseOrPhenotypicFeature	144	146	5	1:NR:2	L2R	CROSS	158-159	174-175	5101	PCDH9|PCDH9|protocadherin - 9|PCDH9|PCDH9|PCHD9	GeneOrGeneProduct	22:174:176:183:213:281	23:175:179:184:214:282	0:6:6:6:7:9	D019465	facial dysmorphisms|dysmorphisms	DiseaseOrPhenotypicFeature	148:158	150:159	5:5
21126715	A Taiwanese boy with congenital generalized lipodystrophy caused by homozygous Ile262fs mutation in the BSCL2 gene .|Congenital generalized lipodystrophy ( CGL ) is a rare autosomal recessive disease that is characterized by a near - complete absence of adipose tissue from birth or early infancy .|Mutations in the BSCL2 gene are known to result in CGL2 , a more severe phenotype than CGL1 , with earlier onset , more extensive fat loss and biochemical changes , more severe intellectual impairment , and more severe cardiomyopathy .|We report a 3 - month - old Taiwanese boy with initial presentation of a lack of subcutaneous fat , prominent musculature , generalized eruptive xanthomas , and extreme hypertriglyceridemia .|Absence of mechanical adipose tissue in the orbits and scalp was revealed by head magnetic resonance imaging .|Hepatomegaly was noticed , and histological examination of a liver biopsy specimen suggested severe hepatic steatosis and periportal necrosis .|However , echocardiography indicated no sign of cardiomyopathy and he showed no distinct intellectual impairment that interfered with daily life .|About 1 year later , abdominal computed tomography revealed enlargement of kidneys .|He had a homozygous insertion of a nucleotide , 783insG ( Ile262fs mutation ) , in exon 7 of the BSCL2 gene .|We reviewed the genotype of CGL cases from Japan , India , China and Taiwan , and found that BSCL2 is a major causative gene for CGL in Asian .	1:Positive_Correlation:2	L2R	NON-CROSS	4-7	10-11	D052497	congenital generalized lipodystrophy|Congenital generalized lipodystrophy|CGL|CGL2|CGL1|CGL|CGL	DiseaseOrPhenotypicFeature	4:17:21:57:64:219:240	7:20:22:58:65:220:241	0:1:1:2:2:9:9	p|FS|I|262||	Ile262fs|Ile262fs	SequenceVariant	10:202	11:203	0:8	1:Association:2	L2R	NON-CROSS	14-15	17-20	D052497	congenital generalized lipodystrophy|Congenital generalized lipodystrophy|CGL|CGL2|CGL1|CGL|CGL	DiseaseOrPhenotypicFeature	4:17:21:57:64:219:240	7:20:22:58:65:220:241	0:1:1:2:2:9:9	26580	BSCL2|BSCL2|BSCL2|BSCL2	GeneOrGeneProduct	14:50:211:233	15:51:212:234	0:2:8:9	1:NR:2	L2R	CROSS	200-201	219-220	D052497	congenital generalized lipodystrophy|Congenital generalized lipodystrophy|CGL|CGL2|CGL1|CGL|CGL	DiseaseOrPhenotypicFeature	4:17:21:57:64:219:240	7:20:22:58:65:220:241	0:1:1:2:2:9:9	c|INS|783|G	783insG	SequenceVariant	200	201	8	1:NR:2	L2R	CROSS	10-11	26-29	p|FS|I|262||	Ile262fs|Ile262fs	SequenceVariant	10:202	11:203	0:8	D030342	autosomal recessive disease	DiseaseOrPhenotypicFeature	26	29	1	1:NR:2	L2R	CROSS	170-172	202-203	p|FS|I|262||	Ile262fs|Ile262fs	SequenceVariant	10:202	11:203	0:8	D008607	intellectual impairment|intellectual impairment	DiseaseOrPhenotypicFeature	80:170	82:172	2:6	1:NR:2	L2R	CROSS	164-165	202-203	p|FS|I|262||	Ile262fs|Ile262fs	SequenceVariant	10:202	11:203	0:8	D009202	cardiomyopathy|cardiomyopathy	DiseaseOrPhenotypicFeature	86:164	87:165	2:6	1:NR:2	L2R	CROSS	112-114	202-203	p|FS|I|262||	Ile262fs|Ile262fs	SequenceVariant	10:202	11:203	0:8	D014973	eruptive xanthomas	DiseaseOrPhenotypicFeature	112	114	3	1:NR:2	L2R	CROSS	117-118	202-203	p|FS|I|262||	Ile262fs|Ile262fs	SequenceVariant	10:202	11:203	0:8	D015228	hypertriglyceridemia	DiseaseOrPhenotypicFeature	117	118	3	1:NR:2	L2R	CROSS	137-138	202-203	p|FS|I|262||	Ile262fs|Ile262fs	SequenceVariant	10:202	11:203	0:8	D006529	Hepatomegaly	DiseaseOrPhenotypicFeature	137	138	5	1:NR:2	L2R	CROSS	151-153	202-203	p|FS|I|262||	Ile262fs|Ile262fs	SequenceVariant	10:202	11:203	0:8	D005234	hepatic steatosis	DiseaseOrPhenotypicFeature	151	153	5	1:NR:2	L2R	CROSS	155-156	202-203	p|FS|I|262||	Ile262fs|Ile262fs	SequenceVariant	10:202	11:203	0:8	D009336	necrosis	DiseaseOrPhenotypicFeature	155	156	5	1:Association:2	R2L	CROSS	202-203	187-190	D007674	enlargement of kidneys	DiseaseOrPhenotypicFeature	187	190	7	p|FS|I|262||	Ile262fs|Ile262fs	SequenceVariant	10:202	11:203	0:8	1:NR:2	L2R	CROSS	14-15	26-29	26580	BSCL2|BSCL2|BSCL2|BSCL2	GeneOrGeneProduct	14:50:211:233	15:51:212:234	0:2:8:9	D030342	autosomal recessive disease	DiseaseOrPhenotypicFeature	26	29	1	1:Association:2	L2R	NON-CROSS	50-51	80-82	26580	BSCL2|BSCL2|BSCL2|BSCL2	GeneOrGeneProduct	14:50:211:233	15:51:212:234	0:2:8:9	D008607	intellectual impairment|intellectual impairment	DiseaseOrPhenotypicFeature	80:170	82:172	2:6	1:Association:2	L2R	NON-CROSS	50-51	86-87	26580	BSCL2|BSCL2|BSCL2|BSCL2	GeneOrGeneProduct	14:50:211:233	15:51:212:234	0:2:8:9	D009202	cardiomyopathy|cardiomyopathy	DiseaseOrPhenotypicFeature	86:164	87:165	2:6	1:NR:2	L2R	CROSS	50-51	112-114	26580	BSCL2|BSCL2|BSCL2|BSCL2	GeneOrGeneProduct	14:50:211:233	15:51:212:234	0:2:8:9	D014973	eruptive xanthomas	DiseaseOrPhenotypicFeature	112	114	3	1:NR:2	L2R	CROSS	50-51	117-118	26580	BSCL2|BSCL2|BSCL2|BSCL2	GeneOrGeneProduct	14:50:211:233	15:51:212:234	0:2:8:9	D015228	hypertriglyceridemia	DiseaseOrPhenotypicFeature	117	118	3	1:NR:2	L2R	CROSS	137-138	211-212	26580	BSCL2|BSCL2|BSCL2|BSCL2	GeneOrGeneProduct	14:50:211:233	15:51:212:234	0:2:8:9	D006529	Hepatomegaly	DiseaseOrPhenotypicFeature	137	138	5	1:NR:2	L2R	CROSS	151-153	211-212	26580	BSCL2|BSCL2|BSCL2|BSCL2	GeneOrGeneProduct	14:50:211:233	15:51:212:234	0:2:8:9	D005234	hepatic steatosis	DiseaseOrPhenotypicFeature	151	153	5	1:NR:2	L2R	CROSS	155-156	211-212	26580	BSCL2|BSCL2|BSCL2|BSCL2	GeneOrGeneProduct	14:50:211:233	15:51:212:234	0:2:8:9	D009336	necrosis	DiseaseOrPhenotypicFeature	155	156	5	1:Association:2	R2L	CROSS	211-212	187-190	D007674	enlargement of kidneys	DiseaseOrPhenotypicFeature	187	190	7	26580	BSCL2|BSCL2|BSCL2|BSCL2	GeneOrGeneProduct	14:50:211:233	15:51:212:234	0:2:8:9	1:NR:2	L2R	CROSS	26-29	200-201	D030342	autosomal recessive disease	DiseaseOrPhenotypicFeature	26	29	1	c|INS|783|G	783insG	SequenceVariant	200	201	8	1:NR:2	L2R	CROSS	170-172	200-201	D008607	intellectual impairment|intellectual impairment	DiseaseOrPhenotypicFeature	80:170	82:172	2:6	c|INS|783|G	783insG	SequenceVariant	200	201	8	1:NR:2	L2R	CROSS	164-165	200-201	D009202	cardiomyopathy|cardiomyopathy	DiseaseOrPhenotypicFeature	86:164	87:165	2:6	c|INS|783|G	783insG	SequenceVariant	200	201	8	1:NR:2	L2R	CROSS	112-114	200-201	D014973	eruptive xanthomas	DiseaseOrPhenotypicFeature	112	114	3	c|INS|783|G	783insG	SequenceVariant	200	201	8	1:NR:2	L2R	CROSS	117-118	200-201	D015228	hypertriglyceridemia	DiseaseOrPhenotypicFeature	117	118	3	c|INS|783|G	783insG	SequenceVariant	200	201	8	1:NR:2	L2R	CROSS	137-138	200-201	D006529	Hepatomegaly	DiseaseOrPhenotypicFeature	137	138	5	c|INS|783|G	783insG	SequenceVariant	200	201	8	1:NR:2	L2R	CROSS	151-153	200-201	D005234	hepatic steatosis	DiseaseOrPhenotypicFeature	151	153	5	c|INS|783|G	783insG	SequenceVariant	200	201	8	1:NR:2	L2R	CROSS	155-156	200-201	D009336	necrosis	DiseaseOrPhenotypicFeature	155	156	5	c|INS|783|G	783insG	SequenceVariant	200	201	8	1:Association:2	L2R	CROSS	187-190	200-201	D007674	enlargement of kidneys	DiseaseOrPhenotypicFeature	187	190	7	c|INS|783|G	783insG	SequenceVariant	200	201	8
28068934	Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma .|BACKGROUND : PIK3CA mutations are expected to be potential therapeutic targets for esophageal squamous cell carcinoma ( ESCC ) .|We aimed to clarify the concordance between PIK3CA mutations detected in endoscopic biopsy specimens and corresponding surgically resected specimens .|METHODS : We examined five hotspot mutations in the PIK3CA gene ( E542K , E545K , E546K , H1047R , and H1047L ) in formalin - fixed and paraffin - embedded tissue sections of paired endoscopic biopsy and surgically resected specimens from 181 patients undergoing curative resection for ESCC between 2000 and 2011 using a Luminex technology - based multiplex gene mutation detection kit .|RESULTS : Mutation analyses were successfully performed for both endoscopic biopsy and surgically resected specimens in all the cases .|A PIK3CA mutation was detected in either type of specimen in 13 cases ( 7 . 2 % , 95 % confidence interval : 3 . 9 - 12 . 0 ) .|The overall concordance rate , positive predictive value , and negative predictive value were 98 . 3 % ( 178 / 181 ) , 90 . 9 % ( 10 / 11 ) , and 98 . 8 % ( 168 / 170 ) , respectively .|Among patients with a PIK3CA mutation detected in both types of specimens , the concordance between PIK3CA mutation genotypes was 100 % .|There were three cases with a discordant mutation status between the types of specimens ( PIK3CA mutation in surgically resected specimen and wild - type in biopsy specimen in two cases , and the opposite pattern in one case ) , suggesting possible intratumoral heterogeneity in the PIK3CA mutation status .|CONCLUSIONS : The PIK3CA mutation status was highly concordant between endoscopic biopsy and surgically resected specimens from the same patient , suggesting that endoscopic biopsy specimens can be clinically used to detect PIK3CA mutations in patients with ESCC .	1:Association:2	L2R	NON-CROSS	328-329	333-334	5290	PIK3CA|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PIK3CA	GeneOrGeneProduct	2:19:44:66:143:226:238:260:292:299:328	3:20:45:67:144:227:239:261:293:300:329	0:1:2:3:5:7:7:8:8:9:9	D000077277	esophageal squamous cell carcinoma|esophageal squamous cell carcinoma|ESCC|ESCC|ESCC	DiseaseOrPhenotypicFeature	12:29:34:105:333	16:33:35:106:334	0:1:1:3:9	1:NR:2	L2R	NON-CROSS	66-67	81-82	5290	PIK3CA|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PIK3CA	GeneOrGeneProduct	2:19:44:66:143:226:238:260:292:299:328	3:20:45:67:144:227:239:261:293:300:329	0:1:2:3:5:7:7:8:8:9:9	D005557	formalin	ChemicalEntity	81	82	3	1:NR:2	L2R	NON-CROSS	66-67	85-86	5290	PIK3CA|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PIK3CA	GeneOrGeneProduct	2:19:44:66:143:226:238:260:292:299:328	3:20:45:67:144:227:239:261:293:300:329	0:1:2:3:5:7:7:8:8:9:9	D010232	paraffin	ChemicalEntity	85	86	3	1:Association:2	R2L	NON-CROSS	69-70	34-35	rs121913273	E542K	SequenceVariant	69	70	3	D000077277	esophageal squamous cell carcinoma|esophageal squamous cell carcinoma|ESCC|ESCC|ESCC	DiseaseOrPhenotypicFeature	12:29:34:105:333	16:33:35:106:334	0:1:1:3:9	1:Association:2	R2L	NON-CROSS	105-106	71-72	rs104886003	E545K	SequenceVariant	71	72	3	D000077277	esophageal squamous cell carcinoma|esophageal squamous cell carcinoma|ESCC|ESCC|ESCC	DiseaseOrPhenotypicFeature	12:29:34:105:333	16:33:35:106:334	0:1:1:3:9	1:Association:2	R2L	NON-CROSS	105-106	73-74	p|SUB|E|546|K	E546K	SequenceVariant	73	74	3	D000077277	esophageal squamous cell carcinoma|esophageal squamous cell carcinoma|ESCC|ESCC|ESCC	DiseaseOrPhenotypicFeature	12:29:34:105:333	16:33:35:106:334	0:1:1:3:9	1:Association:2	R2L	NON-CROSS	105-106	78-79	rs121913279	H1047R|H1047L	SequenceVariant	75:78	76:79	3:3	D000077277	esophageal squamous cell carcinoma|esophageal squamous cell carcinoma|ESCC|ESCC|ESCC	DiseaseOrPhenotypicFeature	12:29:34:105:333	16:33:35:106:334	0:1:1:3:9	1:NR:2	L2R	NON-CROSS	81-82	105-106	D000077277	esophageal squamous cell carcinoma|esophageal squamous cell carcinoma|ESCC|ESCC|ESCC	DiseaseOrPhenotypicFeature	12:29:34:105:333	16:33:35:106:334	0:1:1:3:9	D005557	formalin	ChemicalEntity	81	82	3	1:NR:2	L2R	NON-CROSS	85-86	105-106	D000077277	esophageal squamous cell carcinoma|esophageal squamous cell carcinoma|ESCC|ESCC|ESCC	DiseaseOrPhenotypicFeature	12:29:34:105:333	16:33:35:106:334	0:1:1:3:9	D010232	paraffin	ChemicalEntity	85	86	3	1:NR:2	L2R	NON-CROSS	69-70	81-82	rs121913273	E542K	SequenceVariant	69	70	3	D005557	formalin	ChemicalEntity	81	82	3	1:NR:2	L2R	NON-CROSS	69-70	85-86	rs121913273	E542K	SequenceVariant	69	70	3	D010232	paraffin	ChemicalEntity	85	86	3	1:NR:2	L2R	NON-CROSS	71-72	81-82	rs104886003	E545K	SequenceVariant	71	72	3	D005557	formalin	ChemicalEntity	81	82	3	1:NR:2	L2R	NON-CROSS	71-72	85-86	rs104886003	E545K	SequenceVariant	71	72	3	D010232	paraffin	ChemicalEntity	85	86	3	1:NR:2	L2R	NON-CROSS	73-74	81-82	p|SUB|E|546|K	E546K	SequenceVariant	73	74	3	D005557	formalin	ChemicalEntity	81	82	3	1:NR:2	L2R	NON-CROSS	73-74	85-86	p|SUB|E|546|K	E546K	SequenceVariant	73	74	3	D010232	paraffin	ChemicalEntity	85	86	3	1:NR:2	L2R	NON-CROSS	78-79	81-82	rs121913279	H1047R|H1047L	SequenceVariant	75:78	76:79	3:3	D005557	formalin	ChemicalEntity	81	82	3	1:NR:2	L2R	NON-CROSS	78-79	85-86	rs121913279	H1047R|H1047L	SequenceVariant	75:78	76:79	3:3	D010232	paraffin	ChemicalEntity	85	86	3	1:NR:2	L2R	NON-CROSS	81-82	85-86	D005557	formalin	ChemicalEntity	81	82	3	D010232	paraffin	ChemicalEntity	85	86	3
16252083	Polymorphisms of the DNA mismatch repair gene HMSH2 in breast cancer occurence and progression .|The response of the cell to DNA damage and its ability to maintain genomic stability by DNA repair are crucial in preventing cancer initiation and progression .|Therefore , polymorphism of DNA repair genes may affect the process of carcinogenesis .|The importance of genetic variability of the components of mismatch repair ( MMR ) genes is well documented in colorectal cancer , but little is known about its role in breast cancer .|hMSH2 is one of the crucial proteins of MMR .|We performed a case - control study to test the association between two polymorphisms in the hMSH2 gene : an A - - > G transition at 127 position producing an Asn - - > Ser substitution at codon 127 ( the Asn127Ser polymorphism ) and a G - - > A transition at 1032 position resulting in a Gly - - > Asp change at codon 322 ( the Gly322Asp polymorphism ) and breast cancer risk and cancer progression .|Genotypes were determined in DNA from peripheral blood lymphocytes of 150 breast cancer patients and 150 age - matched women ( controls ) by restriction fragment length polymorphism and allele - specific PCR .|We did not observe any correlation between studied polymorphisms and breast cancer progression evaluated by node - metastasis , tumor size and Bloom - Richardson grading .|A strong association between breast cancer occurrence and the Gly / Gly phenotype of the Gly322Asp polymorphism ( odds ratio 8 . 39 ; 95 % confidence interval 1 . 44 - 48 . 8 ) was found .|Therefore , MMR may play a role in the breast carcinogenesis and the Gly322Asp polymorphism of the hMSH2 gene may be considered as a potential marker in breast cancer .	1:Association:2	L2R	NON-CROSS	7-8	9-11	4436	mismatch repair|HMSH2|mismatch repair|MMR|hMSH2|MMR|hMSH2|MMR|hMSH2	GeneOrGeneProduct	4:7:65:68:89:97:115:282:297	6:8:67:69:90:98:116:283:298	0:0:3:3:4:4:5:9:9	D001943	breast cancer|breast cancer|breast cancer|breast cancer|breast cancer|breast cancer|breast carcinogenesis|breast cancer	DiseaseOrPhenotypicFeature	9:86:173:191:224:245:289:307	11:88:175:193:226:247:291:309	0:3:5:6:7:8:9:9	1:Association:2	L2R	NON-CROSS	37-39	65-67	4436	mismatch repair|HMSH2|mismatch repair|MMR|hMSH2|MMR|hMSH2|MMR|hMSH2	GeneOrGeneProduct	4:7:65:68:89:97:115:282:297	6:8:67:69:90:98:116:283:298	0:0:3:3:4:4:5:9:9	D009369	cancer initiation|cancer|tumor	DiseaseOrPhenotypicFeature	37:177:233	39:178:234	1:5:7	1:NR:2	L2R	CROSS	54-55	65-67	4436	mismatch repair|HMSH2|mismatch repair|MMR|hMSH2|MMR|hMSH2|MMR|hMSH2	GeneOrGeneProduct	4:7:65:68:89:97:115:282:297	6:8:67:69:90:98:116:283:298	0:0:3:3:4:4:5:9:9	D063646	carcinogenesis	DiseaseOrPhenotypicFeature	54	55	2	1:Association:2	L2R	NON-CROSS	68-69	75-77	4436	mismatch repair|HMSH2|mismatch repair|MMR|hMSH2|MMR|hMSH2|MMR|hMSH2	GeneOrGeneProduct	4:7:65:68:89:97:115:282:297	6:8:67:69:90:98:116:283:298	0:0:3:3:4:4:5:9:9	D015179	colorectal cancer	DiseaseOrPhenotypicFeature	75	77	3	1:Association:2	R2L	NON-CROSS	119-128	86-88	rs17217772	A - - > G transition at 127 position|Asn - - > Ser substitution at codon 127|Asn127Ser	SequenceVariant	119:130:141	128:139:142	5:5:5	D001943	breast cancer|breast cancer|breast cancer|breast cancer|breast cancer|breast cancer|breast carcinogenesis|breast cancer	DiseaseOrPhenotypicFeature	9:86:173:191:224:245:289:307	11:88:175:193:226:247:291:309	0:3:5:6:7:8:9:9	1:Association:2	L2R	NON-CROSS	289-291	293-294	D001943	breast cancer|breast cancer|breast cancer|breast cancer|breast cancer|breast cancer|breast carcinogenesis|breast cancer	DiseaseOrPhenotypicFeature	9:86:173:191:224:245:289:307	11:88:175:193:226:247:291:309	0:3:5:6:7:8:9:9	rs4987188	G - - > A transition at 1032 position|Gly - - > Asp change at codon 322|Gly322Asp|Gly322Asp|Gly322Asp	SequenceVariant	146:158:169:256:293	155:167:170:257:294	5:5:5:8:9	1:Association:2	R2L	NON-CROSS	177-178	141-142	rs17217772	A - - > G transition at 127 position|Asn - - > Ser substitution at codon 127|Asn127Ser	SequenceVariant	119:130:141	128:139:142	5:5:5	D009369	cancer initiation|cancer|tumor	DiseaseOrPhenotypicFeature	37:177:233	39:178:234	1:5:7	1:NR:2	L2R	NON-CROSS	169-170	177-178	D009369	cancer initiation|cancer|tumor	DiseaseOrPhenotypicFeature	37:177:233	39:178:234	1:5:7	rs4987188	G - - > A transition at 1032 position|Gly - - > Asp change at codon 322|Gly322Asp|Gly322Asp|Gly322Asp	SequenceVariant	146:158:169:256:293	155:167:170:257:294	5:5:5:8:9	1:NR:2	L2R	CROSS	54-55	119-128	D063646	carcinogenesis	DiseaseOrPhenotypicFeature	54	55	2	rs17217772	A - - > G transition at 127 position|Asn - - > Ser substitution at codon 127|Asn127Ser	SequenceVariant	119:130:141	128:139:142	5:5:5	1:NR:2	L2R	CROSS	54-55	146-155	D063646	carcinogenesis	DiseaseOrPhenotypicFeature	54	55	2	rs4987188	G - - > A transition at 1032 position|Gly - - > Asp change at codon 322|Gly322Asp|Gly322Asp|Gly322Asp	SequenceVariant	146:158:169:256:293	155:167:170:257:294	5:5:5:8:9	1:NR:2	L2R	CROSS	75-77	119-128	D015179	colorectal cancer	DiseaseOrPhenotypicFeature	75	77	3	rs17217772	A - - > G transition at 127 position|Asn - - > Ser substitution at codon 127|Asn127Ser	SequenceVariant	119:130:141	128:139:142	5:5:5	1:NR:2	L2R	CROSS	75-77	146-155	D015179	colorectal cancer	DiseaseOrPhenotypicFeature	75	77	3	rs4987188	G - - > A transition at 1032 position|Gly - - > Asp change at codon 322|Gly322Asp|Gly322Asp|Gly322Asp	SequenceVariant	146:158:169:256:293	155:167:170:257:294	5:5:5:8:9
16820346	Atorvastatin prevented and reversed dexamethasone - induced hypertension in the rat .|To assess the antioxidant effects of atorvastatin ( atorva ) on dexamethasone ( dex ) - induced hypertension , 60 male Sprague - Dawley rats were treated with atorva 30 mg / kg / day or tap water for 15 days .|Dex increased systolic blood pressure ( SBP ) from 109 + / - 1 . 8 to 135 + / - 0 . 6 mmHg and plasma superoxide ( 5711 + / - 284 . 9 saline , 7931 + / - 392 . 8 U / ml dex , P < 0 . 001 ) .|In this prevention study , SBP in the atorva + dex group was increased from 115 + / - 0 . 4 to 124 + / - 1 . 5 mmHg , but this was significantly lower than in the dex - only group ( P ' < 0 . 05 ) .|Atorva reversed dex - induced hypertension ( 129 + / - 0 . 6 mmHg , vs . 135 + / - 0 . 6 mmHg P ' < 0 . 05 ) and decreased plasma superoxide ( 7931 + / - 392 . 8 dex , 1187 + / - 441 . 2 atorva + dex , P < 0 . 0001 ) .|Plasma nitrate / nitrite ( NOx ) was decreased in dex - treated rats compared to saline - treated rats ( 11 . 2 + / - 1 . 08 microm , 15 . 3 + / - 1 . 17 microm , respectively , P < 0 . 05 ) .|Atorva affected neither plasma NOx nor thymus weight .|Thus , atorvastatin prevented and reversed dexamethasone - induced hypertension in the rat .	1:Negative_Correlation:2	L2R	NON-CROSS	119-120	121-122	D000069059	Atorvastatin|atorvastatin|atorva|atorva|atorva|Atorva|atorva|Atorva|atorvastatin	ChemicalEntity	0:18:20:40:119:164:218:281:292	1:19:21:41:120:165:219:282:293	0:1:1:1:3:4:4:6:7	D003907	dexamethasone|dexamethasone|dex|Dex|dex|dex|dex|dex|dex|dex|dex|dexamethasone	ChemicalEntity	4:23:25:54:102:121:151:166:209:220:239:296	5:24:26:55:103:122:152:167:210:221:240:297	0:1:1:2:2:3:3:4:4:4:5:7	1:Negative_Correlation:2	L2R	NON-CROSS	164-165	169-170	D000069059	Atorvastatin|atorvastatin|atorva|atorva|atorva|Atorva|atorva|Atorva|atorvastatin	ChemicalEntity	0:18:20:40:119:164:218:281:292	1:19:21:41:120:165:219:282:293	0:1:1:1:3:4:4:6:7	D006973	hypertension|hypertension|hypertension|hypertension	DiseaseOrPhenotypicFeature	7:29:169:299	8:30:170:300	0:1:4:7	1:NR:2	L2R	NON-CROSS	15-16	18-19	D000069059	Atorvastatin|atorvastatin|atorva|atorva|atorva|Atorva|atorva|Atorva|atorvastatin	ChemicalEntity	0:18:20:40:119:164:218:281:292	1:19:21:41:120:165:219:282:293	0:1:1:1:3:4:4:6:7	D000975	antioxidant	ChemicalEntity	15	16	1	1:NR:2	L2R	NON-CROSS	200-201	218-219	D000069059	Atorvastatin|atorvastatin|atorva|atorva|atorva|Atorva|atorva|Atorva|atorvastatin	ChemicalEntity	0:18:20:40:119:164:218:281:292	1:19:21:41:120:165:219:282:293	0:1:1:1:3:4:4:6:7	D013481	superoxide|superoxide	ChemicalEntity	81:200	82:201	2:4	1:NR:2	L2R	CROSS	218-219	230-231	D000069059	Atorvastatin|atorvastatin|atorva|atorva|atorva|Atorva|atorva|Atorva|atorvastatin	ChemicalEntity	0:18:20:40:119:164:218:281:292	1:19:21:41:120:165:219:282:293	0:1:1:1:3:4:4:6:7	D009566	nitrate	ChemicalEntity	230	231	5	1:NR:2	L2R	CROSS	218-219	232-233	D000069059	Atorvastatin|atorvastatin|atorva|atorva|atorva|Atorva|atorva|Atorva|atorvastatin	ChemicalEntity	0:18:20:40:119:164:218:281:292	1:19:21:41:120:165:219:282:293	0:1:1:1:3:4:4:6:7	D009573	nitrite	ChemicalEntity	232	233	5	1:NR:2	L2R	NON-CROSS	281-282	285-286	D000069059	Atorvastatin|atorvastatin|atorva|atorva|atorva|Atorva|atorva|Atorva|atorvastatin	ChemicalEntity	0:18:20:40:119:164:218:281:292	1:19:21:41:120:165:219:282:293	0:1:1:1:3:4:4:6:7	D009589	NOx|NOx	ChemicalEntity	234:285	235:286	5:6	1:Positive_Correlation:2	L2R	NON-CROSS	4-5	7-8	D003907	dexamethasone|dexamethasone|dex|Dex|dex|dex|dex|dex|dex|dex|dex|dexamethasone	ChemicalEntity	4:23:25:54:102:121:151:166:209:220:239:296	5:24:26:55:103:122:152:167:210:221:240:297	0:1:1:2:2:3:3:4:4:4:5:7	D006973	hypertension|hypertension|hypertension|hypertension	DiseaseOrPhenotypicFeature	7:29:169:299	8:30:170:300	0:1:4:7	1:NR:2	L2R	NON-CROSS	15-16	23-24	D003907	dexamethasone|dexamethasone|dex|Dex|dex|dex|dex|dex|dex|dex|dex|dexamethasone	ChemicalEntity	4:23:25:54:102:121:151:166:209:220:239:296	5:24:26:55:103:122:152:167:210:221:240:297	0:1:1:2:2:3:3:4:4:4:5:7	D000975	antioxidant	ChemicalEntity	15	16	1	1:Positive_Correlation:2	L2R	NON-CROSS	200-201	209-210	D003907	dexamethasone|dexamethasone|dex|Dex|dex|dex|dex|dex|dex|dex|dex|dexamethasone	ChemicalEntity	4:23:25:54:102:121:151:166:209:220:239:296	5:24:26:55:103:122:152:167:210:221:240:297	0:1:1:2:2:3:3:4:4:4:5:7	D013481	superoxide|superoxide	ChemicalEntity	81:200	82:201	2:4	1:Negative_Correlation:2	R2L	NON-CROSS	239-240	230-231	D009566	nitrate	ChemicalEntity	230	231	5	D003907	dexamethasone|dexamethasone|dex|Dex|dex|dex|dex|dex|dex|dex|dex|dexamethasone	ChemicalEntity	4:23:25:54:102:121:151:166:209:220:239:296	5:24:26:55:103:122:152:167:210:221:240:297	0:1:1:2:2:3:3:4:4:4:5:7	1:Negative_Correlation:2	R2L	NON-CROSS	239-240	232-233	D009573	nitrite	ChemicalEntity	232	233	5	D003907	dexamethasone|dexamethasone|dex|Dex|dex|dex|dex|dex|dex|dex|dex|dexamethasone	ChemicalEntity	4:23:25:54:102:121:151:166:209:220:239:296	5:24:26:55:103:122:152:167:210:221:240:297	0:1:1:2:2:3:3:4:4:4:5:7	1:Negative_Correlation:2	R2L	NON-CROSS	239-240	234-235	D009589	NOx|NOx	ChemicalEntity	234:285	235:286	5:6	D003907	dexamethasone|dexamethasone|dex|Dex|dex|dex|dex|dex|dex|dex|dex|dexamethasone	ChemicalEntity	4:23:25:54:102:121:151:166:209:220:239:296	5:24:26:55:103:122:152:167:210:221:240:297	0:1:1:2:2:3:3:4:4:4:5:7	1:NR:2	L2R	NON-CROSS	7-8	15-16	D006973	hypertension|hypertension|hypertension|hypertension	DiseaseOrPhenotypicFeature	7:29:169:299	8:30:170:300	0:1:4:7	D000975	antioxidant	ChemicalEntity	15	16	1	1:NR:2	L2R	NON-CROSS	169-170	200-201	D006973	hypertension|hypertension|hypertension|hypertension	DiseaseOrPhenotypicFeature	7:29:169:299	8:30:170:300	0:1:4:7	D013481	superoxide|superoxide	ChemicalEntity	81:200	82:201	2:4	1:NR:2	L2R	CROSS	169-170	230-231	D006973	hypertension|hypertension|hypertension|hypertension	DiseaseOrPhenotypicFeature	7:29:169:299	8:30:170:300	0:1:4:7	D009566	nitrate	ChemicalEntity	230	231	5	1:NR:2	L2R	CROSS	169-170	232-233	D006973	hypertension|hypertension|hypertension|hypertension	DiseaseOrPhenotypicFeature	7:29:169:299	8:30:170:300	0:1:4:7	D009573	nitrite	ChemicalEntity	232	233	5	1:NR:2	L2R	CROSS	285-286	299-300	D006973	hypertension|hypertension|hypertension|hypertension	DiseaseOrPhenotypicFeature	7:29:169:299	8:30:170:300	0:1:4:7	D009589	NOx|NOx	ChemicalEntity	234:285	235:286	5:6	1:NR:2	L2R	CROSS	15-16	81-82	D000975	antioxidant	ChemicalEntity	15	16	1	D013481	superoxide|superoxide	ChemicalEntity	81:200	82:201	2:4	1:NR:2	L2R	CROSS	15-16	230-231	D000975	antioxidant	ChemicalEntity	15	16	1	D009566	nitrate	ChemicalEntity	230	231	5	1:NR:2	L2R	CROSS	15-16	232-233	D000975	antioxidant	ChemicalEntity	15	16	1	D009573	nitrite	ChemicalEntity	232	233	5	1:NR:2	L2R	CROSS	15-16	234-235	D000975	antioxidant	ChemicalEntity	15	16	1	D009589	NOx|NOx	ChemicalEntity	234:285	235:286	5:6	1:NR:2	L2R	CROSS	200-201	230-231	D013481	superoxide|superoxide	ChemicalEntity	81:200	82:201	2:4	D009566	nitrate	ChemicalEntity	230	231	5	1:NR:2	L2R	CROSS	200-201	232-233	D013481	superoxide|superoxide	ChemicalEntity	81:200	82:201	2:4	D009573	nitrite	ChemicalEntity	232	233	5	1:NR:2	L2R	CROSS	200-201	234-235	D013481	superoxide|superoxide	ChemicalEntity	81:200	82:201	2:4	D009589	NOx|NOx	ChemicalEntity	234:285	235:286	5:6	1:NR:2	L2R	NON-CROSS	230-231	232-233	D009566	nitrate	ChemicalEntity	230	231	5	D009573	nitrite	ChemicalEntity	232	233	5	1:NR:2	L2R	NON-CROSS	230-231	234-235	D009566	nitrate	ChemicalEntity	230	231	5	D009589	NOx|NOx	ChemicalEntity	234:285	235:286	5:6	1:NR:2	L2R	NON-CROSS	232-233	234-235	D009573	nitrite	ChemicalEntity	232	233	5	D009589	NOx|NOx	ChemicalEntity	234:285	235:286	5:6
17003923	Gene polymorphisms implicated in influencing susceptibility to venous and arterial thromboembolism : frequency distribution in a healthy German population .|Evolvement and progression of cardiovascular diseases affecting the venous and arterial system are influenced by a multitude of environmental and hereditary factors .|Many of these hereditary factors consist of defined gene polymorphisms , such as single nucleotide polymorphisms ( SNPs ) or insertion - deletion polymorphisms , which directly or indirectly affect the hemostatic system .|The frequencies of individual hemostatic gene polymorphisms in different normal populations are well defined .|However , descriptions of patterns of genetic variability of a larger extent of different factors of hereditary hypercoagulability in single populations are scarce .|The aim of this study was i ) to give a detailed description of the frequencies of factors of hereditary thrombophilia and their combinations in a German population ( n = 282 ) and ii ) to compare their distributions with those reported for other regions .|Variants of coagulation factors [ factor V 1691G > A ( factor V Leiden ) , factor V 4070A > G ( factor V HR2 haplotype ) , factor VII Arg353Gln , factor XIII Val34Leu , beta - fibrinogen - 455G > A , prothrombin 20210G > A ] , coagulation inhibitors [ tissue factor pathway inhibitor 536C > T , thrombomodulin 127G > A ] , fibrinolytic factors [ angiotensin converting enzyme intron 16 insertion / deletion , factor VII - activating protease 1601G > A ( FSAP Marburg I ) , plasminogen activator inhibitor 1 - 675 insertion / deletion ( 5G / 4G ) , tissue plasminogen activator intron h deletion / insertion ] , and other factors implicated in influencing susceptibility to thromboembolic diseases [ apolipoprotein E2 / E3 / E4 , glycoprotein Ia 807C > T , methylenetetrahydrofolate reductase 677C > T ] were included .|The distribution of glycoprotein Ia 807C > T deviated significantly from the Hardy - Weinberg equilibrium , and a comparison with previously published data indicates marked region and ethnicity dependent differences in the genotype distributions of some other factors .	1:Association:2	L2R	CROSS	7-11	168-170	D054556	venous and arterial thromboembolism	DiseaseOrPhenotypicFeature	7	11	0	2153	factor V|factor V Leiden|factor V|factor V	GeneOrGeneProduct	168:174:179:185	170:177:181:187	6:6:6:6	1:Association:2	L2R	CROSS	7-11	170-173	D054556	venous and arterial thromboembolism	DiseaseOrPhenotypicFeature	7	11	0	c|SUB|G|1691|A	1691G > A	SequenceVariant	170	173	6	1:Association:2	L2R	CROSS	7-11	181-184	D054556	venous and arterial thromboembolism	DiseaseOrPhenotypicFeature	7	11	0	c|SUB|A|4070|G	4070A > G	SequenceVariant	181	184	6	1:Association:2	L2R	CROSS	7-11	191-193	D054556	venous and arterial thromboembolism	DiseaseOrPhenotypicFeature	7	11	0	2155	factor VII	GeneOrGeneProduct	191	193	6	1:Association:2	L2R	CROSS	7-11	193-194	D054556	venous and arterial thromboembolism	DiseaseOrPhenotypicFeature	7	11	0	p|SUB|R|353|Q	Arg353Gln	SequenceVariant	193	194	6	1:Association:2	L2R	CROSS	7-11	195-197	D054556	venous and arterial thromboembolism	DiseaseOrPhenotypicFeature	7	11	0	2162	factor XIII	GeneOrGeneProduct	195	197	6	1:Association:2	L2R	CROSS	7-11	197-198	D054556	venous and arterial thromboembolism	DiseaseOrPhenotypicFeature	7	11	0	p|SUB|V|34|L	Val34Leu	SequenceVariant	197	198	6	1:Association:2	L2R	CROSS	7-11	199-202	D054556	venous and arterial thromboembolism	DiseaseOrPhenotypicFeature	7	11	0	2244	beta - fibrinogen	GeneOrGeneProduct	199	202	6	1:Association:2	L2R	CROSS	7-11	202-206	D054556	venous and arterial thromboembolism	DiseaseOrPhenotypicFeature	7	11	0	c|SUB|G|-455|A	- 455G > A	SequenceVariant	202	206	6	1:Association:2	L2R	CROSS	7-11	207-208	D054556	venous and arterial thromboembolism	DiseaseOrPhenotypicFeature	7	11	0	2147	prothrombin	GeneOrGeneProduct	207	208	6	1:Association:2	L2R	CROSS	7-11	208-211	D054556	venous and arterial thromboembolism	DiseaseOrPhenotypicFeature	7	11	0	c|SUB|G|20210|A	20210G > A	SequenceVariant	208	211	6	1:Association:2	L2R	CROSS	7-11	216-220	D054556	venous and arterial thromboembolism	DiseaseOrPhenotypicFeature	7	11	0	7035	tissue factor pathway inhibitor	GeneOrGeneProduct	216	220	6	1:Association:2	L2R	CROSS	7-11	220-223	D054556	venous and arterial thromboembolism	DiseaseOrPhenotypicFeature	7	11	0	c|SUB|C|536|T	536C > T	SequenceVariant	220	223	6	1:Association:2	L2R	CROSS	7-11	224-225	D054556	venous and arterial thromboembolism	DiseaseOrPhenotypicFeature	7	11	0	7056	thrombomodulin	GeneOrGeneProduct	224	225	6	1:Association:2	L2R	CROSS	7-11	225-228	D054556	venous and arterial thromboembolism	DiseaseOrPhenotypicFeature	7	11	0	c|SUB|G|127|A	127G > A	SequenceVariant	225	228	6	1:Association:2	R2L	CROSS	233-236	7-11	1636	angiotensin converting enzyme	GeneOrGeneProduct	233	236	6	D054556	venous and arterial thromboembolism	DiseaseOrPhenotypicFeature	7	11	0	1:Association:2	L2R	CROSS	7-11	242-247	D054556	venous and arterial thromboembolism	DiseaseOrPhenotypicFeature	7	11	0	3026	factor VII - activating protease|FSAP	GeneOrGeneProduct	242:251	247:252	6:6	1:Association:2	L2R	CROSS	7-11	247-250	D054556	venous and arterial thromboembolism	DiseaseOrPhenotypicFeature	7	11	0	c|SUB|G|1601|A	1601G > A	SequenceVariant	247	250	6	1:Association:2	L2R	CROSS	7-11	256-260	D054556	venous and arterial thromboembolism	DiseaseOrPhenotypicFeature	7	11	0	5054	plasminogen activator inhibitor 1	GeneOrGeneProduct	256	260	6	1:Association:2	L2R	CROSS	7-11	261-265	D054556	venous and arterial thromboembolism	DiseaseOrPhenotypicFeature	7	11	0	c|INDEL|675|	675 insertion / deletion	SequenceVariant	261	265	6	1:Association:2	R2L	CROSS	271-274	7-11	5327	tissue plasminogen activator	GeneOrGeneProduct	271	274	6	D054556	venous and arterial thromboembolism	DiseaseOrPhenotypicFeature	7	11	0	1:Association:2	L2R	CROSS	7-11	292-301	D054556	venous and arterial thromboembolism	DiseaseOrPhenotypicFeature	7	11	0	22915	apolipoprotein E2 / E3 / E4 , glycoprotein Ia|glycoprotein Ia	GeneOrGeneProduct	292:317	301:319	6:7	1:Association:2	L2R	CROSS	7-11	301-304	D054556	venous and arterial thromboembolism	DiseaseOrPhenotypicFeature	7	11	0	c|SUB|C|807|T	807C > T|807C > T	SequenceVariant	301:319	304:322	6:7	1:Association:2	L2R	CROSS	7-11	305-307	D054556	venous and arterial thromboembolism	DiseaseOrPhenotypicFeature	7	11	0	4524	methylenetetrahydrofolate reductase	GeneOrGeneProduct	305	307	6	1:Association:2	L2R	CROSS	7-11	307-310	D054556	venous and arterial thromboembolism	DiseaseOrPhenotypicFeature	7	11	0	c|SUB|C|677|T	677C > T	SequenceVariant	307	310	6	1:NR:2	L2R	CROSS	24-26	168-170	D002318	cardiovascular diseases	DiseaseOrPhenotypicFeature	24	26	1	2153	factor V|factor V Leiden|factor V|factor V	GeneOrGeneProduct	168:174:179:185	170:177:181:187	6:6:6:6	1:NR:2	L2R	CROSS	24-26	170-173	D002318	cardiovascular diseases	DiseaseOrPhenotypicFeature	24	26	1	c|SUB|G|1691|A	1691G > A	SequenceVariant	170	173	6	1:NR:2	L2R	CROSS	24-26	181-184	D002318	cardiovascular diseases	DiseaseOrPhenotypicFeature	24	26	1	c|SUB|A|4070|G	4070A > G	SequenceVariant	181	184	6	1:NR:2	L2R	CROSS	24-26	191-193	D002318	cardiovascular diseases	DiseaseOrPhenotypicFeature	24	26	1	2155	factor VII	GeneOrGeneProduct	191	193	6	1:NR:2	L2R	CROSS	24-26	193-194	D002318	cardiovascular diseases	DiseaseOrPhenotypicFeature	24	26	1	p|SUB|R|353|Q	Arg353Gln	SequenceVariant	193	194	6	1:NR:2	L2R	CROSS	24-26	195-197	D002318	cardiovascular diseases	DiseaseOrPhenotypicFeature	24	26	1	2162	factor XIII	GeneOrGeneProduct	195	197	6	1:NR:2	L2R	CROSS	24-26	197-198	D002318	cardiovascular diseases	DiseaseOrPhenotypicFeature	24	26	1	p|SUB|V|34|L	Val34Leu	SequenceVariant	197	198	6	1:NR:2	L2R	CROSS	24-26	199-202	D002318	cardiovascular diseases	DiseaseOrPhenotypicFeature	24	26	1	2244	beta - fibrinogen	GeneOrGeneProduct	199	202	6	1:NR:2	L2R	CROSS	24-26	202-206	D002318	cardiovascular diseases	DiseaseOrPhenotypicFeature	24	26	1	c|SUB|G|-455|A	- 455G > A	SequenceVariant	202	206	6	1:NR:2	L2R	CROSS	24-26	207-208	D002318	cardiovascular diseases	DiseaseOrPhenotypicFeature	24	26	1	2147	prothrombin	GeneOrGeneProduct	207	208	6	1:NR:2	L2R	CROSS	24-26	208-211	D002318	cardiovascular diseases	DiseaseOrPhenotypicFeature	24	26	1	c|SUB|G|20210|A	20210G > A	SequenceVariant	208	211	6	1:NR:2	L2R	CROSS	24-26	216-220	D002318	cardiovascular diseases	DiseaseOrPhenotypicFeature	24	26	1	7035	tissue factor pathway inhibitor	GeneOrGeneProduct	216	220	6	1:NR:2	L2R	CROSS	24-26	220-223	D002318	cardiovascular diseases	DiseaseOrPhenotypicFeature	24	26	1	c|SUB|C|536|T	536C > T	SequenceVariant	220	223	6	1:NR:2	L2R	CROSS	24-26	224-225	D002318	cardiovascular diseases	DiseaseOrPhenotypicFeature	24	26	1	7056	thrombomodulin	GeneOrGeneProduct	224	225	6	1:NR:2	L2R	CROSS	24-26	225-228	D002318	cardiovascular diseases	DiseaseOrPhenotypicFeature	24	26	1	c|SUB|G|127|A	127G > A	SequenceVariant	225	228	6	1:NR:2	L2R	CROSS	24-26	233-236	D002318	cardiovascular diseases	DiseaseOrPhenotypicFeature	24	26	1	1636	angiotensin converting enzyme	GeneOrGeneProduct	233	236	6	1:NR:2	L2R	CROSS	24-26	242-247	D002318	cardiovascular diseases	DiseaseOrPhenotypicFeature	24	26	1	3026	factor VII - activating protease|FSAP	GeneOrGeneProduct	242:251	247:252	6:6	1:NR:2	L2R	CROSS	24-26	247-250	D002318	cardiovascular diseases	DiseaseOrPhenotypicFeature	24	26	1	c|SUB|G|1601|A	1601G > A	SequenceVariant	247	250	6	1:NR:2	L2R	CROSS	24-26	256-260	D002318	cardiovascular diseases	DiseaseOrPhenotypicFeature	24	26	1	5054	plasminogen activator inhibitor 1	GeneOrGeneProduct	256	260	6	1:NR:2	L2R	CROSS	24-26	261-265	D002318	cardiovascular diseases	DiseaseOrPhenotypicFeature	24	26	1	c|INDEL|675|	675 insertion / deletion	SequenceVariant	261	265	6	1:NR:2	L2R	CROSS	24-26	271-274	D002318	cardiovascular diseases	DiseaseOrPhenotypicFeature	24	26	1	5327	tissue plasminogen activator	GeneOrGeneProduct	271	274	6	1:NR:2	L2R	CROSS	24-26	292-301	D002318	cardiovascular diseases	DiseaseOrPhenotypicFeature	24	26	1	22915	apolipoprotein E2 / E3 / E4 , glycoprotein Ia|glycoprotein Ia	GeneOrGeneProduct	292:317	301:319	6:7	1:NR:2	L2R	CROSS	24-26	301-304	D002318	cardiovascular diseases	DiseaseOrPhenotypicFeature	24	26	1	c|SUB|C|807|T	807C > T|807C > T	SequenceVariant	301:319	304:322	6:7	1:NR:2	L2R	CROSS	24-26	305-307	D002318	cardiovascular diseases	DiseaseOrPhenotypicFeature	24	26	1	4524	methylenetetrahydrofolate reductase	GeneOrGeneProduct	305	307	6	1:NR:2	L2R	CROSS	24-26	307-310	D002318	cardiovascular diseases	DiseaseOrPhenotypicFeature	24	26	1	c|SUB|C|677|T	677C > T	SequenceVariant	307	310	6	1:NR:2	L2R	CROSS	108-110	168-170	D019851	hereditary hypercoagulability	DiseaseOrPhenotypicFeature	108	110	4	2153	factor V|factor V Leiden|factor V|factor V	GeneOrGeneProduct	168:174:179:185	170:177:181:187	6:6:6:6	1:NR:2	L2R	CROSS	108-110	170-173	D019851	hereditary hypercoagulability	DiseaseOrPhenotypicFeature	108	110	4	c|SUB|G|1691|A	1691G > A	SequenceVariant	170	173	6	1:NR:2	L2R	CROSS	108-110	181-184	D019851	hereditary hypercoagulability	DiseaseOrPhenotypicFeature	108	110	4	c|SUB|A|4070|G	4070A > G	SequenceVariant	181	184	6	1:NR:2	L2R	CROSS	108-110	191-193	D019851	hereditary hypercoagulability	DiseaseOrPhenotypicFeature	108	110	4	2155	factor VII	GeneOrGeneProduct	191	193	6	1:NR:2	L2R	CROSS	108-110	193-194	D019851	hereditary hypercoagulability	DiseaseOrPhenotypicFeature	108	110	4	p|SUB|R|353|Q	Arg353Gln	SequenceVariant	193	194	6	1:NR:2	L2R	CROSS	108-110	195-197	D019851	hereditary hypercoagulability	DiseaseOrPhenotypicFeature	108	110	4	2162	factor XIII	GeneOrGeneProduct	195	197	6	1:NR:2	L2R	CROSS	108-110	197-198	D019851	hereditary hypercoagulability	DiseaseOrPhenotypicFeature	108	110	4	p|SUB|V|34|L	Val34Leu	SequenceVariant	197	198	6	1:NR:2	L2R	CROSS	108-110	199-202	D019851	hereditary hypercoagulability	DiseaseOrPhenotypicFeature	108	110	4	2244	beta - fibrinogen	GeneOrGeneProduct	199	202	6	1:NR:2	L2R	CROSS	108-110	202-206	D019851	hereditary hypercoagulability	DiseaseOrPhenotypicFeature	108	110	4	c|SUB|G|-455|A	- 455G > A	SequenceVariant	202	206	6	1:NR:2	L2R	CROSS	108-110	207-208	D019851	hereditary hypercoagulability	DiseaseOrPhenotypicFeature	108	110	4	2147	prothrombin	GeneOrGeneProduct	207	208	6	1:NR:2	L2R	CROSS	108-110	208-211	D019851	hereditary hypercoagulability	DiseaseOrPhenotypicFeature	108	110	4	c|SUB|G|20210|A	20210G > A	SequenceVariant	208	211	6	1:NR:2	L2R	CROSS	108-110	216-220	D019851	hereditary hypercoagulability	DiseaseOrPhenotypicFeature	108	110	4	7035	tissue factor pathway inhibitor	GeneOrGeneProduct	216	220	6	1:NR:2	L2R	CROSS	108-110	220-223	D019851	hereditary hypercoagulability	DiseaseOrPhenotypicFeature	108	110	4	c|SUB|C|536|T	536C > T	SequenceVariant	220	223	6	1:NR:2	L2R	CROSS	108-110	224-225	D019851	hereditary hypercoagulability	DiseaseOrPhenotypicFeature	108	110	4	7056	thrombomodulin	GeneOrGeneProduct	224	225	6	1:NR:2	L2R	CROSS	108-110	225-228	D019851	hereditary hypercoagulability	DiseaseOrPhenotypicFeature	108	110	4	c|SUB|G|127|A	127G > A	SequenceVariant	225	228	6	1:NR:2	L2R	CROSS	108-110	233-236	D019851	hereditary hypercoagulability	DiseaseOrPhenotypicFeature	108	110	4	1636	angiotensin converting enzyme	GeneOrGeneProduct	233	236	6	1:NR:2	L2R	CROSS	108-110	242-247	D019851	hereditary hypercoagulability	DiseaseOrPhenotypicFeature	108	110	4	3026	factor VII - activating protease|FSAP	GeneOrGeneProduct	242:251	247:252	6:6	1:NR:2	L2R	CROSS	108-110	247-250	D019851	hereditary hypercoagulability	DiseaseOrPhenotypicFeature	108	110	4	c|SUB|G|1601|A	1601G > A	SequenceVariant	247	250	6	1:NR:2	L2R	CROSS	108-110	256-260	D019851	hereditary hypercoagulability	DiseaseOrPhenotypicFeature	108	110	4	5054	plasminogen activator inhibitor 1	GeneOrGeneProduct	256	260	6	1:NR:2	L2R	CROSS	108-110	261-265	D019851	hereditary hypercoagulability	DiseaseOrPhenotypicFeature	108	110	4	c|INDEL|675|	675 insertion / deletion	SequenceVariant	261	265	6	1:NR:2	L2R	CROSS	108-110	271-274	D019851	hereditary hypercoagulability	DiseaseOrPhenotypicFeature	108	110	4	5327	tissue plasminogen activator	GeneOrGeneProduct	271	274	6	1:NR:2	L2R	CROSS	108-110	292-301	D019851	hereditary hypercoagulability	DiseaseOrPhenotypicFeature	108	110	4	22915	apolipoprotein E2 / E3 / E4 , glycoprotein Ia|glycoprotein Ia	GeneOrGeneProduct	292:317	301:319	6:7	1:NR:2	L2R	CROSS	108-110	301-304	D019851	hereditary hypercoagulability	DiseaseOrPhenotypicFeature	108	110	4	c|SUB|C|807|T	807C > T|807C > T	SequenceVariant	301:319	304:322	6:7	1:NR:2	L2R	CROSS	108-110	305-307	D019851	hereditary hypercoagulability	DiseaseOrPhenotypicFeature	108	110	4	4524	methylenetetrahydrofolate reductase	GeneOrGeneProduct	305	307	6	1:NR:2	L2R	CROSS	108-110	307-310	D019851	hereditary hypercoagulability	DiseaseOrPhenotypicFeature	108	110	4	c|SUB|C|677|T	677C > T	SequenceVariant	307	310	6	1:NR:2	L2R	CROSS	135-137	168-170	C540694	hereditary thrombophilia	DiseaseOrPhenotypicFeature	135	137	5	2153	factor V|factor V Leiden|factor V|factor V	GeneOrGeneProduct	168:174:179:185	170:177:181:187	6:6:6:6	1:NR:2	L2R	CROSS	135-137	170-173	C540694	hereditary thrombophilia	DiseaseOrPhenotypicFeature	135	137	5	c|SUB|G|1691|A	1691G > A	SequenceVariant	170	173	6	1:NR:2	L2R	CROSS	135-137	181-184	C540694	hereditary thrombophilia	DiseaseOrPhenotypicFeature	135	137	5	c|SUB|A|4070|G	4070A > G	SequenceVariant	181	184	6	1:NR:2	L2R	CROSS	135-137	191-193	C540694	hereditary thrombophilia	DiseaseOrPhenotypicFeature	135	137	5	2155	factor VII	GeneOrGeneProduct	191	193	6	1:NR:2	L2R	CROSS	135-137	193-194	C540694	hereditary thrombophilia	DiseaseOrPhenotypicFeature	135	137	5	p|SUB|R|353|Q	Arg353Gln	SequenceVariant	193	194	6	1:NR:2	L2R	CROSS	135-137	195-197	C540694	hereditary thrombophilia	DiseaseOrPhenotypicFeature	135	137	5	2162	factor XIII	GeneOrGeneProduct	195	197	6	1:NR:2	L2R	CROSS	135-137	197-198	C540694	hereditary thrombophilia	DiseaseOrPhenotypicFeature	135	137	5	p|SUB|V|34|L	Val34Leu	SequenceVariant	197	198	6	1:NR:2	L2R	CROSS	135-137	199-202	C540694	hereditary thrombophilia	DiseaseOrPhenotypicFeature	135	137	5	2244	beta - fibrinogen	GeneOrGeneProduct	199	202	6	1:NR:2	L2R	CROSS	135-137	202-206	C540694	hereditary thrombophilia	DiseaseOrPhenotypicFeature	135	137	5	c|SUB|G|-455|A	- 455G > A	SequenceVariant	202	206	6	1:NR:2	L2R	CROSS	135-137	207-208	C540694	hereditary thrombophilia	DiseaseOrPhenotypicFeature	135	137	5	2147	prothrombin	GeneOrGeneProduct	207	208	6	1:NR:2	L2R	CROSS	135-137	208-211	C540694	hereditary thrombophilia	DiseaseOrPhenotypicFeature	135	137	5	c|SUB|G|20210|A	20210G > A	SequenceVariant	208	211	6	1:NR:2	L2R	CROSS	135-137	216-220	C540694	hereditary thrombophilia	DiseaseOrPhenotypicFeature	135	137	5	7035	tissue factor pathway inhibitor	GeneOrGeneProduct	216	220	6	1:NR:2	L2R	CROSS	135-137	220-223	C540694	hereditary thrombophilia	DiseaseOrPhenotypicFeature	135	137	5	c|SUB|C|536|T	536C > T	SequenceVariant	220	223	6	1:NR:2	L2R	CROSS	135-137	224-225	C540694	hereditary thrombophilia	DiseaseOrPhenotypicFeature	135	137	5	7056	thrombomodulin	GeneOrGeneProduct	224	225	6	1:NR:2	L2R	CROSS	135-137	225-228	C540694	hereditary thrombophilia	DiseaseOrPhenotypicFeature	135	137	5	c|SUB|G|127|A	127G > A	SequenceVariant	225	228	6	1:NR:2	L2R	CROSS	135-137	233-236	C540694	hereditary thrombophilia	DiseaseOrPhenotypicFeature	135	137	5	1636	angiotensin converting enzyme	GeneOrGeneProduct	233	236	6	1:NR:2	L2R	CROSS	135-137	242-247	C540694	hereditary thrombophilia	DiseaseOrPhenotypicFeature	135	137	5	3026	factor VII - activating protease|FSAP	GeneOrGeneProduct	242:251	247:252	6:6	1:NR:2	L2R	CROSS	135-137	247-250	C540694	hereditary thrombophilia	DiseaseOrPhenotypicFeature	135	137	5	c|SUB|G|1601|A	1601G > A	SequenceVariant	247	250	6	1:NR:2	L2R	CROSS	135-137	256-260	C540694	hereditary thrombophilia	DiseaseOrPhenotypicFeature	135	137	5	5054	plasminogen activator inhibitor 1	GeneOrGeneProduct	256	260	6	1:NR:2	L2R	CROSS	135-137	261-265	C540694	hereditary thrombophilia	DiseaseOrPhenotypicFeature	135	137	5	c|INDEL|675|	675 insertion / deletion	SequenceVariant	261	265	6	1:NR:2	L2R	CROSS	135-137	271-274	C540694	hereditary thrombophilia	DiseaseOrPhenotypicFeature	135	137	5	5327	tissue plasminogen activator	GeneOrGeneProduct	271	274	6	1:NR:2	L2R	CROSS	135-137	292-301	C540694	hereditary thrombophilia	DiseaseOrPhenotypicFeature	135	137	5	22915	apolipoprotein E2 / E3 / E4 , glycoprotein Ia|glycoprotein Ia	GeneOrGeneProduct	292:317	301:319	6:7	1:NR:2	L2R	CROSS	135-137	301-304	C540694	hereditary thrombophilia	DiseaseOrPhenotypicFeature	135	137	5	c|SUB|C|807|T	807C > T|807C > T	SequenceVariant	301:319	304:322	6:7	1:NR:2	L2R	CROSS	135-137	305-307	C540694	hereditary thrombophilia	DiseaseOrPhenotypicFeature	135	137	5	4524	methylenetetrahydrofolate reductase	GeneOrGeneProduct	305	307	6	1:NR:2	L2R	CROSS	135-137	307-310	C540694	hereditary thrombophilia	DiseaseOrPhenotypicFeature	135	137	5	c|SUB|C|677|T	677C > T	SequenceVariant	307	310	6	1:NR:2	L2R	NON-CROSS	185-187	191-193	2153	factor V|factor V Leiden|factor V|factor V	GeneOrGeneProduct	168:174:179:185	170:177:181:187	6:6:6:6	2155	factor VII	GeneOrGeneProduct	191	193	6	1:NR:2	L2R	NON-CROSS	185-187	195-197	2153	factor V|factor V Leiden|factor V|factor V	GeneOrGeneProduct	168:174:179:185	170:177:181:187	6:6:6:6	2162	factor XIII	GeneOrGeneProduct	195	197	6	1:NR:2	L2R	NON-CROSS	185-187	199-202	2153	factor V|factor V Leiden|factor V|factor V	GeneOrGeneProduct	168:174:179:185	170:177:181:187	6:6:6:6	2244	beta - fibrinogen	GeneOrGeneProduct	199	202	6	1:NR:2	L2R	NON-CROSS	185-187	207-208	2153	factor V|factor V Leiden|factor V|factor V	GeneOrGeneProduct	168:174:179:185	170:177:181:187	6:6:6:6	2147	prothrombin	GeneOrGeneProduct	207	208	6	1:NR:2	L2R	NON-CROSS	185-187	216-220	2153	factor V|factor V Leiden|factor V|factor V	GeneOrGeneProduct	168:174:179:185	170:177:181:187	6:6:6:6	7035	tissue factor pathway inhibitor	GeneOrGeneProduct	216	220	6	1:NR:2	L2R	NON-CROSS	185-187	224-225	2153	factor V|factor V Leiden|factor V|factor V	GeneOrGeneProduct	168:174:179:185	170:177:181:187	6:6:6:6	7056	thrombomodulin	GeneOrGeneProduct	224	225	6	1:NR:2	L2R	NON-CROSS	185-187	233-236	2153	factor V|factor V Leiden|factor V|factor V	GeneOrGeneProduct	168:174:179:185	170:177:181:187	6:6:6:6	1636	angiotensin converting enzyme	GeneOrGeneProduct	233	236	6	1:NR:2	L2R	NON-CROSS	185-187	242-247	2153	factor V|factor V Leiden|factor V|factor V	GeneOrGeneProduct	168:174:179:185	170:177:181:187	6:6:6:6	3026	factor VII - activating protease|FSAP	GeneOrGeneProduct	242:251	247:252	6:6	1:NR:2	L2R	NON-CROSS	185-187	256-260	2153	factor V|factor V Leiden|factor V|factor V	GeneOrGeneProduct	168:174:179:185	170:177:181:187	6:6:6:6	5054	plasminogen activator inhibitor 1	GeneOrGeneProduct	256	260	6	1:NR:2	L2R	NON-CROSS	185-187	271-274	2153	factor V|factor V Leiden|factor V|factor V	GeneOrGeneProduct	168:174:179:185	170:177:181:187	6:6:6:6	5327	tissue plasminogen activator	GeneOrGeneProduct	271	274	6	1:NR:2	L2R	NON-CROSS	185-187	289-291	2153	factor V|factor V Leiden|factor V|factor V	GeneOrGeneProduct	168:174:179:185	170:177:181:187	6:6:6:6	D013923	thromboembolic diseases	DiseaseOrPhenotypicFeature	289	291	6	1:NR:2	L2R	NON-CROSS	185-187	292-301	2153	factor V|factor V Leiden|factor V|factor V	GeneOrGeneProduct	168:174:179:185	170:177:181:187	6:6:6:6	22915	apolipoprotein E2 / E3 / E4 , glycoprotein Ia|glycoprotein Ia	GeneOrGeneProduct	292:317	301:319	6:7	1:NR:2	L2R	NON-CROSS	185-187	305-307	2153	factor V|factor V Leiden|factor V|factor V	GeneOrGeneProduct	168:174:179:185	170:177:181:187	6:6:6:6	4524	methylenetetrahydrofolate reductase	GeneOrGeneProduct	305	307	6	1:NR:2	L2R	NON-CROSS	170-173	289-291	c|SUB|G|1691|A	1691G > A	SequenceVariant	170	173	6	D013923	thromboembolic diseases	DiseaseOrPhenotypicFeature	289	291	6	1:NR:2	L2R	NON-CROSS	181-184	289-291	c|SUB|A|4070|G	4070A > G	SequenceVariant	181	184	6	D013923	thromboembolic diseases	DiseaseOrPhenotypicFeature	289	291	6	1:NR:2	L2R	NON-CROSS	191-193	195-197	2155	factor VII	GeneOrGeneProduct	191	193	6	2162	factor XIII	GeneOrGeneProduct	195	197	6	1:NR:2	L2R	NON-CROSS	191-193	199-202	2155	factor VII	GeneOrGeneProduct	191	193	6	2244	beta - fibrinogen	GeneOrGeneProduct	199	202	6	1:NR:2	L2R	NON-CROSS	191-193	207-208	2155	factor VII	GeneOrGeneProduct	191	193	6	2147	prothrombin	GeneOrGeneProduct	207	208	6	1:NR:2	L2R	NON-CROSS	191-193	216-220	2155	factor VII	GeneOrGeneProduct	191	193	6	7035	tissue factor pathway inhibitor	GeneOrGeneProduct	216	220	6	1:NR:2	L2R	NON-CROSS	191-193	224-225	2155	factor VII	GeneOrGeneProduct	191	193	6	7056	thrombomodulin	GeneOrGeneProduct	224	225	6	1:NR:2	L2R	NON-CROSS	191-193	233-236	2155	factor VII	GeneOrGeneProduct	191	193	6	1636	angiotensin converting enzyme	GeneOrGeneProduct	233	236	6	1:NR:2	L2R	NON-CROSS	191-193	242-247	2155	factor VII	GeneOrGeneProduct	191	193	6	3026	factor VII - activating protease|FSAP	GeneOrGeneProduct	242:251	247:252	6:6	1:NR:2	L2R	NON-CROSS	191-193	256-260	2155	factor VII	GeneOrGeneProduct	191	193	6	5054	plasminogen activator inhibitor 1	GeneOrGeneProduct	256	260	6	1:NR:2	L2R	NON-CROSS	191-193	271-274	2155	factor VII	GeneOrGeneProduct	191	193	6	5327	tissue plasminogen activator	GeneOrGeneProduct	271	274	6	1:NR:2	L2R	NON-CROSS	191-193	289-291	2155	factor VII	GeneOrGeneProduct	191	193	6	D013923	thromboembolic diseases	DiseaseOrPhenotypicFeature	289	291	6	1:NR:2	L2R	NON-CROSS	191-193	292-301	2155	factor VII	GeneOrGeneProduct	191	193	6	22915	apolipoprotein E2 / E3 / E4 , glycoprotein Ia|glycoprotein Ia	GeneOrGeneProduct	292:317	301:319	6:7	1:NR:2	L2R	NON-CROSS	191-193	305-307	2155	factor VII	GeneOrGeneProduct	191	193	6	4524	methylenetetrahydrofolate reductase	GeneOrGeneProduct	305	307	6	1:NR:2	L2R	NON-CROSS	193-194	289-291	p|SUB|R|353|Q	Arg353Gln	SequenceVariant	193	194	6	D013923	thromboembolic diseases	DiseaseOrPhenotypicFeature	289	291	6	1:NR:2	L2R	NON-CROSS	195-197	199-202	2162	factor XIII	GeneOrGeneProduct	195	197	6	2244	beta - fibrinogen	GeneOrGeneProduct	199	202	6	1:NR:2	L2R	NON-CROSS	195-197	207-208	2162	factor XIII	GeneOrGeneProduct	195	197	6	2147	prothrombin	GeneOrGeneProduct	207	208	6	1:NR:2	L2R	NON-CROSS	195-197	216-220	2162	factor XIII	GeneOrGeneProduct	195	197	6	7035	tissue factor pathway inhibitor	GeneOrGeneProduct	216	220	6	1:NR:2	L2R	NON-CROSS	195-197	224-225	2162	factor XIII	GeneOrGeneProduct	195	197	6	7056	thrombomodulin	GeneOrGeneProduct	224	225	6	1:NR:2	L2R	NON-CROSS	195-197	233-236	2162	factor XIII	GeneOrGeneProduct	195	197	6	1636	angiotensin converting enzyme	GeneOrGeneProduct	233	236	6	1:NR:2	L2R	NON-CROSS	195-197	242-247	2162	factor XIII	GeneOrGeneProduct	195	197	6	3026	factor VII - activating protease|FSAP	GeneOrGeneProduct	242:251	247:252	6:6	1:NR:2	L2R	NON-CROSS	195-197	256-260	2162	factor XIII	GeneOrGeneProduct	195	197	6	5054	plasminogen activator inhibitor 1	GeneOrGeneProduct	256	260	6	1:NR:2	L2R	NON-CROSS	195-197	271-274	2162	factor XIII	GeneOrGeneProduct	195	197	6	5327	tissue plasminogen activator	GeneOrGeneProduct	271	274	6	1:NR:2	L2R	NON-CROSS	195-197	289-291	2162	factor XIII	GeneOrGeneProduct	195	197	6	D013923	thromboembolic diseases	DiseaseOrPhenotypicFeature	289	291	6	1:NR:2	L2R	NON-CROSS	195-197	292-301	2162	factor XIII	GeneOrGeneProduct	195	197	6	22915	apolipoprotein E2 / E3 / E4 , glycoprotein Ia|glycoprotein Ia	GeneOrGeneProduct	292:317	301:319	6:7	1:NR:2	L2R	NON-CROSS	195-197	305-307	2162	factor XIII	GeneOrGeneProduct	195	197	6	4524	methylenetetrahydrofolate reductase	GeneOrGeneProduct	305	307	6	1:NR:2	L2R	NON-CROSS	197-198	289-291	p|SUB|V|34|L	Val34Leu	SequenceVariant	197	198	6	D013923	thromboembolic diseases	DiseaseOrPhenotypicFeature	289	291	6	1:NR:2	L2R	NON-CROSS	199-202	207-208	2244	beta - fibrinogen	GeneOrGeneProduct	199	202	6	2147	prothrombin	GeneOrGeneProduct	207	208	6	1:NR:2	L2R	NON-CROSS	199-202	216-220	2244	beta - fibrinogen	GeneOrGeneProduct	199	202	6	7035	tissue factor pathway inhibitor	GeneOrGeneProduct	216	220	6	1:NR:2	L2R	NON-CROSS	199-202	224-225	2244	beta - fibrinogen	GeneOrGeneProduct	199	202	6	7056	thrombomodulin	GeneOrGeneProduct	224	225	6	1:NR:2	L2R	NON-CROSS	199-202	233-236	2244	beta - fibrinogen	GeneOrGeneProduct	199	202	6	1636	angiotensin converting enzyme	GeneOrGeneProduct	233	236	6	1:NR:2	L2R	NON-CROSS	199-202	242-247	2244	beta - fibrinogen	GeneOrGeneProduct	199	202	6	3026	factor VII - activating protease|FSAP	GeneOrGeneProduct	242:251	247:252	6:6	1:NR:2	L2R	NON-CROSS	199-202	256-260	2244	beta - fibrinogen	GeneOrGeneProduct	199	202	6	5054	plasminogen activator inhibitor 1	GeneOrGeneProduct	256	260	6	1:NR:2	L2R	NON-CROSS	199-202	271-274	2244	beta - fibrinogen	GeneOrGeneProduct	199	202	6	5327	tissue plasminogen activator	GeneOrGeneProduct	271	274	6	1:NR:2	L2R	NON-CROSS	199-202	289-291	2244	beta - fibrinogen	GeneOrGeneProduct	199	202	6	D013923	thromboembolic diseases	DiseaseOrPhenotypicFeature	289	291	6	1:NR:2	L2R	NON-CROSS	199-202	292-301	2244	beta - fibrinogen	GeneOrGeneProduct	199	202	6	22915	apolipoprotein E2 / E3 / E4 , glycoprotein Ia|glycoprotein Ia	GeneOrGeneProduct	292:317	301:319	6:7	1:NR:2	L2R	NON-CROSS	199-202	305-307	2244	beta - fibrinogen	GeneOrGeneProduct	199	202	6	4524	methylenetetrahydrofolate reductase	GeneOrGeneProduct	305	307	6	1:NR:2	L2R	NON-CROSS	202-206	289-291	c|SUB|G|-455|A	- 455G > A	SequenceVariant	202	206	6	D013923	thromboembolic diseases	DiseaseOrPhenotypicFeature	289	291	6	1:NR:2	L2R	NON-CROSS	207-208	216-220	2147	prothrombin	GeneOrGeneProduct	207	208	6	7035	tissue factor pathway inhibitor	GeneOrGeneProduct	216	220	6	1:NR:2	L2R	NON-CROSS	207-208	224-225	2147	prothrombin	GeneOrGeneProduct	207	208	6	7056	thrombomodulin	GeneOrGeneProduct	224	225	6	1:NR:2	L2R	NON-CROSS	207-208	233-236	2147	prothrombin	GeneOrGeneProduct	207	208	6	1636	angiotensin converting enzyme	GeneOrGeneProduct	233	236	6	1:NR:2	L2R	NON-CROSS	207-208	242-247	2147	prothrombin	GeneOrGeneProduct	207	208	6	3026	factor VII - activating protease|FSAP	GeneOrGeneProduct	242:251	247:252	6:6	1:NR:2	L2R	NON-CROSS	207-208	256-260	2147	prothrombin	GeneOrGeneProduct	207	208	6	5054	plasminogen activator inhibitor 1	GeneOrGeneProduct	256	260	6	1:NR:2	L2R	NON-CROSS	207-208	271-274	2147	prothrombin	GeneOrGeneProduct	207	208	6	5327	tissue plasminogen activator	GeneOrGeneProduct	271	274	6	1:NR:2	L2R	NON-CROSS	207-208	289-291	2147	prothrombin	GeneOrGeneProduct	207	208	6	D013923	thromboembolic diseases	DiseaseOrPhenotypicFeature	289	291	6	1:NR:2	L2R	NON-CROSS	207-208	292-301	2147	prothrombin	GeneOrGeneProduct	207	208	6	22915	apolipoprotein E2 / E3 / E4 , glycoprotein Ia|glycoprotein Ia	GeneOrGeneProduct	292:317	301:319	6:7	1:NR:2	L2R	NON-CROSS	207-208	305-307	2147	prothrombin	GeneOrGeneProduct	207	208	6	4524	methylenetetrahydrofolate reductase	GeneOrGeneProduct	305	307	6	1:NR:2	L2R	NON-CROSS	208-211	289-291	c|SUB|G|20210|A	20210G > A	SequenceVariant	208	211	6	D013923	thromboembolic diseases	DiseaseOrPhenotypicFeature	289	291	6	1:NR:2	L2R	NON-CROSS	216-220	224-225	7035	tissue factor pathway inhibitor	GeneOrGeneProduct	216	220	6	7056	thrombomodulin	GeneOrGeneProduct	224	225	6	1:NR:2	L2R	NON-CROSS	216-220	233-236	7035	tissue factor pathway inhibitor	GeneOrGeneProduct	216	220	6	1636	angiotensin converting enzyme	GeneOrGeneProduct	233	236	6	1:NR:2	L2R	NON-CROSS	216-220	242-247	7035	tissue factor pathway inhibitor	GeneOrGeneProduct	216	220	6	3026	factor VII - activating protease|FSAP	GeneOrGeneProduct	242:251	247:252	6:6	1:NR:2	L2R	NON-CROSS	216-220	256-260	7035	tissue factor pathway inhibitor	GeneOrGeneProduct	216	220	6	5054	plasminogen activator inhibitor 1	GeneOrGeneProduct	256	260	6	1:NR:2	L2R	NON-CROSS	216-220	271-274	7035	tissue factor pathway inhibitor	GeneOrGeneProduct	216	220	6	5327	tissue plasminogen activator	GeneOrGeneProduct	271	274	6	1:NR:2	L2R	NON-CROSS	216-220	289-291	7035	tissue factor pathway inhibitor	GeneOrGeneProduct	216	220	6	D013923	thromboembolic diseases	DiseaseOrPhenotypicFeature	289	291	6	1:NR:2	L2R	NON-CROSS	216-220	292-301	7035	tissue factor pathway inhibitor	GeneOrGeneProduct	216	220	6	22915	apolipoprotein E2 / E3 / E4 , glycoprotein Ia|glycoprotein Ia	GeneOrGeneProduct	292:317	301:319	6:7	1:NR:2	L2R	NON-CROSS	216-220	305-307	7035	tissue factor pathway inhibitor	GeneOrGeneProduct	216	220	6	4524	methylenetetrahydrofolate reductase	GeneOrGeneProduct	305	307	6	1:NR:2	L2R	NON-CROSS	220-223	289-291	c|SUB|C|536|T	536C > T	SequenceVariant	220	223	6	D013923	thromboembolic diseases	DiseaseOrPhenotypicFeature	289	291	6	1:NR:2	L2R	NON-CROSS	224-225	233-236	7056	thrombomodulin	GeneOrGeneProduct	224	225	6	1636	angiotensin converting enzyme	GeneOrGeneProduct	233	236	6	1:NR:2	L2R	NON-CROSS	224-225	242-247	7056	thrombomodulin	GeneOrGeneProduct	224	225	6	3026	factor VII - activating protease|FSAP	GeneOrGeneProduct	242:251	247:252	6:6	1:NR:2	L2R	NON-CROSS	224-225	256-260	7056	thrombomodulin	GeneOrGeneProduct	224	225	6	5054	plasminogen activator inhibitor 1	GeneOrGeneProduct	256	260	6	1:NR:2	L2R	NON-CROSS	224-225	271-274	7056	thrombomodulin	GeneOrGeneProduct	224	225	6	5327	tissue plasminogen activator	GeneOrGeneProduct	271	274	6	1:NR:2	L2R	NON-CROSS	224-225	289-291	7056	thrombomodulin	GeneOrGeneProduct	224	225	6	D013923	thromboembolic diseases	DiseaseOrPhenotypicFeature	289	291	6	1:NR:2	L2R	NON-CROSS	224-225	292-301	7056	thrombomodulin	GeneOrGeneProduct	224	225	6	22915	apolipoprotein E2 / E3 / E4 , glycoprotein Ia|glycoprotein Ia	GeneOrGeneProduct	292:317	301:319	6:7	1:NR:2	L2R	NON-CROSS	224-225	305-307	7056	thrombomodulin	GeneOrGeneProduct	224	225	6	4524	methylenetetrahydrofolate reductase	GeneOrGeneProduct	305	307	6	1:NR:2	L2R	NON-CROSS	225-228	289-291	c|SUB|G|127|A	127G > A	SequenceVariant	225	228	6	D013923	thromboembolic diseases	DiseaseOrPhenotypicFeature	289	291	6	1:NR:2	L2R	NON-CROSS	233-236	242-247	1636	angiotensin converting enzyme	GeneOrGeneProduct	233	236	6	3026	factor VII - activating protease|FSAP	GeneOrGeneProduct	242:251	247:252	6:6	1:NR:2	L2R	NON-CROSS	233-236	256-260	1636	angiotensin converting enzyme	GeneOrGeneProduct	233	236	6	5054	plasminogen activator inhibitor 1	GeneOrGeneProduct	256	260	6	1:NR:2	L2R	NON-CROSS	233-236	271-274	1636	angiotensin converting enzyme	GeneOrGeneProduct	233	236	6	5327	tissue plasminogen activator	GeneOrGeneProduct	271	274	6	1:NR:2	L2R	NON-CROSS	233-236	289-291	1636	angiotensin converting enzyme	GeneOrGeneProduct	233	236	6	D013923	thromboembolic diseases	DiseaseOrPhenotypicFeature	289	291	6	1:NR:2	L2R	NON-CROSS	233-236	292-301	1636	angiotensin converting enzyme	GeneOrGeneProduct	233	236	6	22915	apolipoprotein E2 / E3 / E4 , glycoprotein Ia|glycoprotein Ia	GeneOrGeneProduct	292:317	301:319	6:7	1:NR:2	L2R	NON-CROSS	233-236	305-307	1636	angiotensin converting enzyme	GeneOrGeneProduct	233	236	6	4524	methylenetetrahydrofolate reductase	GeneOrGeneProduct	305	307	6	1:NR:2	L2R	NON-CROSS	251-252	256-260	3026	factor VII - activating protease|FSAP	GeneOrGeneProduct	242:251	247:252	6:6	5054	plasminogen activator inhibitor 1	GeneOrGeneProduct	256	260	6	1:NR:2	L2R	NON-CROSS	251-252	271-274	3026	factor VII - activating protease|FSAP	GeneOrGeneProduct	242:251	247:252	6:6	5327	tissue plasminogen activator	GeneOrGeneProduct	271	274	6	1:NR:2	L2R	NON-CROSS	251-252	289-291	3026	factor VII - activating protease|FSAP	GeneOrGeneProduct	242:251	247:252	6:6	D013923	thromboembolic diseases	DiseaseOrPhenotypicFeature	289	291	6	1:NR:2	L2R	NON-CROSS	251-252	292-301	3026	factor VII - activating protease|FSAP	GeneOrGeneProduct	242:251	247:252	6:6	22915	apolipoprotein E2 / E3 / E4 , glycoprotein Ia|glycoprotein Ia	GeneOrGeneProduct	292:317	301:319	6:7	1:NR:2	L2R	NON-CROSS	251-252	305-307	3026	factor VII - activating protease|FSAP	GeneOrGeneProduct	242:251	247:252	6:6	4524	methylenetetrahydrofolate reductase	GeneOrGeneProduct	305	307	6	1:NR:2	L2R	NON-CROSS	247-250	289-291	c|SUB|G|1601|A	1601G > A	SequenceVariant	247	250	6	D013923	thromboembolic diseases	DiseaseOrPhenotypicFeature	289	291	6	1:NR:2	L2R	NON-CROSS	256-260	271-274	5054	plasminogen activator inhibitor 1	GeneOrGeneProduct	256	260	6	5327	tissue plasminogen activator	GeneOrGeneProduct	271	274	6	1:NR:2	L2R	NON-CROSS	256-260	289-291	5054	plasminogen activator inhibitor 1	GeneOrGeneProduct	256	260	6	D013923	thromboembolic diseases	DiseaseOrPhenotypicFeature	289	291	6	1:NR:2	L2R	NON-CROSS	256-260	292-301	5054	plasminogen activator inhibitor 1	GeneOrGeneProduct	256	260	6	22915	apolipoprotein E2 / E3 / E4 , glycoprotein Ia|glycoprotein Ia	GeneOrGeneProduct	292:317	301:319	6:7	1:NR:2	L2R	NON-CROSS	256-260	305-307	5054	plasminogen activator inhibitor 1	GeneOrGeneProduct	256	260	6	4524	methylenetetrahydrofolate reductase	GeneOrGeneProduct	305	307	6	1:NR:2	L2R	NON-CROSS	261-265	289-291	c|INDEL|675|	675 insertion / deletion	SequenceVariant	261	265	6	D013923	thromboembolic diseases	DiseaseOrPhenotypicFeature	289	291	6	1:NR:2	L2R	NON-CROSS	271-274	289-291	5327	tissue plasminogen activator	GeneOrGeneProduct	271	274	6	D013923	thromboembolic diseases	DiseaseOrPhenotypicFeature	289	291	6	1:NR:2	L2R	NON-CROSS	271-274	292-301	5327	tissue plasminogen activator	GeneOrGeneProduct	271	274	6	22915	apolipoprotein E2 / E3 / E4 , glycoprotein Ia|glycoprotein Ia	GeneOrGeneProduct	292:317	301:319	6:7	1:NR:2	L2R	NON-CROSS	271-274	305-307	5327	tissue plasminogen activator	GeneOrGeneProduct	271	274	6	4524	methylenetetrahydrofolate reductase	GeneOrGeneProduct	305	307	6	1:Association:2	R2L	NON-CROSS	292-301	289-291	22915	apolipoprotein E2 / E3 / E4 , glycoprotein Ia|glycoprotein Ia	GeneOrGeneProduct	292:317	301:319	6:7	D013923	thromboembolic diseases	DiseaseOrPhenotypicFeature	289	291	6	1:Association:2	R2L	NON-CROSS	301-304	289-291	c|SUB|C|807|T	807C > T|807C > T	SequenceVariant	301:319	304:322	6:7	D013923	thromboembolic diseases	DiseaseOrPhenotypicFeature	289	291	6	1:Association:2	R2L	NON-CROSS	305-307	289-291	4524	methylenetetrahydrofolate reductase	GeneOrGeneProduct	305	307	6	D013923	thromboembolic diseases	DiseaseOrPhenotypicFeature	289	291	6	1:Association:2	R2L	NON-CROSS	307-310	289-291	c|SUB|C|677|T	677C > T	SequenceVariant	307	310	6	D013923	thromboembolic diseases	DiseaseOrPhenotypicFeature	289	291	6	1:NR:2	L2R	NON-CROSS	292-301	305-307	22915	apolipoprotein E2 / E3 / E4 , glycoprotein Ia|glycoprotein Ia	GeneOrGeneProduct	292:317	301:319	6:7	4524	methylenetetrahydrofolate reductase	GeneOrGeneProduct	305	307	6
24671324	Necrotising fasciitis after bortezomib and dexamethasone - containing regimen in an elderly patient of Waldenstrom macroglobulinaemia .|Bortezomib and high - dose dexamethasone - containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B - cell malignancies .|However , information is limited concerning the safety of the regimen in elderly patients .|We report a case of a 76 - year - old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib , high - dose dexamethasone and rituximab .|Despite immediate intravenous antimicrobial therapy , he succumbed 23 h after the onset .|Physicians should recognise the possibility of fatal bacterial infections related to bortezomib plus high - dose dexamethasone in elderly patients , and we believe this case warrants further investigation .	1:Positive_Correlation:2	L2R	NON-CROSS	0-2	3-4	D019115	Necrotising fasciitis|necrotising fasciitis	DiseaseOrPhenotypicFeature	0:77	2:79	0:3	D000069286	bortezomib|Bortezomib|bortezomib|bortezomib	ChemicalEntity	3:17:86:120	4:18:87:121	0:1:3:5	1:Positive_Correlation:2	L2R	NON-CROSS	0-2	5-6	D019115	Necrotising fasciitis|necrotising fasciitis	DiseaseOrPhenotypicFeature	0:77	2:79	0:3	D003907	dexamethasone|dexamethasone|dexamethasone|dexamethasone	ChemicalEntity	5:22:91:125	6:23:92:126	0:1:3:5	1:NR:2	L2R	NON-CROSS	77-79	93-94	D019115	Necrotising fasciitis|necrotising fasciitis	DiseaseOrPhenotypicFeature	0:77	2:79	0:3	D000069283	rituximab	ChemicalEntity	93	94	3	1:Cotreatment:2	L2R	NON-CROSS	3-4	5-6	D000069286	bortezomib|Bortezomib|bortezomib|bortezomib	ChemicalEntity	3:17:86:120	4:18:87:121	0:1:3:5	D003907	dexamethasone|dexamethasone|dexamethasone|dexamethasone	ChemicalEntity	5:22:91:125	6:23:92:126	0:1:3:5	1:Negative_Correlation:2	L2R	NON-CROSS	14-16	17-18	D000069286	bortezomib|Bortezomib|bortezomib|bortezomib	ChemicalEntity	3:17:86:120	4:18:87:121	0:1:3:5	D008258	Waldenstrom macroglobulinaemia|Waldenstrom macroglobulinaemia	DiseaseOrPhenotypicFeature	14:73	16:75	0:3	1:Positive_Correlation:2	R2L	NON-CROSS	120-121	116-118	D001424	bacterial infections|bacterial infections	DiseaseOrPhenotypicFeature	35:116	37:118	1:5	D000069286	bortezomib|Bortezomib|bortezomib|bortezomib	ChemicalEntity	3:17:86:120	4:18:87:121	0:1:3:5	1:Negative_Correlation:2	L2R	NON-CROSS	17-18	43-44	D000069286	bortezomib|Bortezomib|bortezomib|bortezomib	ChemicalEntity	3:17:86:120	4:18:87:121	0:1:3:5	D009369	malignancies	DiseaseOrPhenotypicFeature	43	44	1	1:NR:2	L2R	NON-CROSS	80-81	86-87	D000069286	bortezomib|Bortezomib|bortezomib|bortezomib	ChemicalEntity	3:17:86:120	4:18:87:121	0:1:3:5	D009503	neutropenia	DiseaseOrPhenotypicFeature	80	81	3	1:Cotreatment:2	L2R	NON-CROSS	86-87	93-94	D000069286	bortezomib|Bortezomib|bortezomib|bortezomib	ChemicalEntity	3:17:86:120	4:18:87:121	0:1:3:5	D000069283	rituximab	ChemicalEntity	93	94	3	1:Negative_Correlation:2	L2R	NON-CROSS	14-16	22-23	D003907	dexamethasone|dexamethasone|dexamethasone|dexamethasone	ChemicalEntity	5:22:91:125	6:23:92:126	0:1:3:5	D008258	Waldenstrom macroglobulinaemia|Waldenstrom macroglobulinaemia	DiseaseOrPhenotypicFeature	14:73	16:75	0:3	1:Positive_Correlation:2	R2L	NON-CROSS	125-126	116-118	D001424	bacterial infections|bacterial infections	DiseaseOrPhenotypicFeature	35:116	37:118	1:5	D003907	dexamethasone|dexamethasone|dexamethasone|dexamethasone	ChemicalEntity	5:22:91:125	6:23:92:126	0:1:3:5	1:Negative_Correlation:2	L2R	NON-CROSS	22-23	43-44	D003907	dexamethasone|dexamethasone|dexamethasone|dexamethasone	ChemicalEntity	5:22:91:125	6:23:92:126	0:1:3:5	D009369	malignancies	DiseaseOrPhenotypicFeature	43	44	1	1:NR:2	L2R	NON-CROSS	80-81	91-92	D003907	dexamethasone|dexamethasone|dexamethasone|dexamethasone	ChemicalEntity	5:22:91:125	6:23:92:126	0:1:3:5	D009503	neutropenia	DiseaseOrPhenotypicFeature	80	81	3	1:Cotreatment:2	L2R	NON-CROSS	91-92	93-94	D003907	dexamethasone|dexamethasone|dexamethasone|dexamethasone	ChemicalEntity	5:22:91:125	6:23:92:126	0:1:3:5	D000069283	rituximab	ChemicalEntity	93	94	3	1:Negative_Correlation:2	R2L	NON-CROSS	93-94	73-75	D000069283	rituximab	ChemicalEntity	93	94	3	D008258	Waldenstrom macroglobulinaemia|Waldenstrom macroglobulinaemia	DiseaseOrPhenotypicFeature	14:73	16:75	0:3	1:NR:2	L2R	CROSS	93-94	116-118	D001424	bacterial infections|bacterial infections	DiseaseOrPhenotypicFeature	35:116	37:118	1:5	D000069283	rituximab	ChemicalEntity	93	94	3	1:NR:2	L2R	CROSS	43-44	93-94	D009369	malignancies	DiseaseOrPhenotypicFeature	43	44	1	D000069283	rituximab	ChemicalEntity	93	94	3	1:NR:2	L2R	NON-CROSS	80-81	93-94	D009503	neutropenia	DiseaseOrPhenotypicFeature	80	81	3	D000069283	rituximab	ChemicalEntity	93	94	3
16116131	rTMS of supplementary motor area modulates therapy - induced dyskinesias in Parkinson disease .|The neural mechanisms and circuitry involved in levodopa - induced dyskinesia are unclear .|Using repetitive transcranial magnetic stimulation ( rTMS ) over the supplementary motor area ( SMA ) in a group of patients with advanced Parkinson disease , the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion .|rTMS at 1 Hz was observed to markedly reduce drug - induced dyskinesias , whereas 5 - Hz rTMS induced a slight but not significant increase .	1:Positive_Correlation:2	R2L	NON-CROSS	24-25	21-22	D007980	levodopa	ChemicalEntity	21	22	1	D004409	dyskinesias|dyskinesia|dyskinetic|drug - induced dyskinesias	DiseaseOrPhenotypicFeature	9:24:69:86	10:25:70:90	0:1:2:3	1:Positive_Correlation:2	R2L	NON-CROSS	74-75	69-70	D001058	apomorphine	ChemicalEntity	74	75	2	D004409	dyskinesias|dyskinesia|dyskinetic|drug - induced dyskinesias	DiseaseOrPhenotypicFeature	9:24:69:86	10:25:70:90	0:1:2:3	1:NR:2	L2R	CROSS	11-13	21-22	D010300	Parkinson disease|Parkinson disease	DiseaseOrPhenotypicFeature	11:51	13:53	0:2	D007980	levodopa	ChemicalEntity	21	22	1	1:NR:2	L2R	NON-CROSS	51-53	74-75	D010300	Parkinson disease|Parkinson disease	DiseaseOrPhenotypicFeature	11:51	13:53	0:2	D001058	apomorphine	ChemicalEntity	74	75	2	1:NR:2	L2R	CROSS	21-22	74-75	D007980	levodopa	ChemicalEntity	21	22	1	D001058	apomorphine	ChemicalEntity	74	75	2
19484664	Angiotensin converting enzyme gene polymorphism in Turkish asthmatic patients .|Asthma is a chronic inflammatory disease of the airways .|Several candidate genes have been identified with a potential role in the pathogenesis of asthma , including the angiotensin converting enzyme ( ACE ) gene .|We aimed to investigate the frequency of an ACE gene polymorphism in Turkish asthmatic patients and to determine its impact on clinical parameters and disease severity .|Ninety - seven asthmatic patients ( M / F 25 / 72 , mean age 39 + / - 13 years ) and 96 healthy subjects ( M / F 26 / 70 , mean age 38 + / - 12 years ) were included .|At baseline , all participants completed a questionnaire on demographics , symptoms , triggering factors , severity of asthma , and the presence of atopism .|Blood samples were obtained from all patients and genomic DNA was isolated .|The frequency of the ACE genotypes ( I = insertion and D = deletion ) among asthmatics and controls were compared : asthmatics showed a 40 . 2 % prevalence of the DD genotype ( n = 39 ) , ID was 45 . 4 % ( n = 44 ) , and II was 14 . 4 % ( n = 14 . 4 ) .|In the control subjects , the frequency of DD was 18 . 8 % ( n = 18 ) , ID was 50 % ( n = 48 ) and II was 31 . 3 % ( n = 30 ) .|The DD ACE genotype was significantly more frequent in asthmatics compared with controls ( p < 0 . 001 ) .|Asthmatics with the ID ACE genotype showed a higher frequency of drug allergies , although this was not statistically significant ( p = 0 . 08 ) .|Asthmatics with the DD genotype appeared to have a higher incidence of asthmatic episode exacerbations due to viral infections , but again this was not statistically significant ( p = 0 . 08 ) .|Patients with mild or moderate - severe asthma had similar frequencies of these mutations .|We found a higher frequency of the ACE DD gene mutation in Turkish asthmatic patients compared with non - asthmatics , suggesting that this ACE gene polymorphism may be a risk factor for asthma but does not increase the severity of the disease .	1:Association:2	R2L	NON-CROSS	292-293	288-289	D001249	asthmatic|Asthma|asthma|asthmatic|asthmatic|asthma|asthmatics|asthmatics|asthmatics|Asthmatics|Asthmatics|asthmatic|asthma|asthmatic|asthmatics|asthma	DiseaseOrPhenotypicFeature	7:10:34:59:76:137:174:180:276:288:316:328:358:379:385:399	8:11:35:60:77:138:175:181:277:289:317:329:359:380:386:400	0:1:2:3:4:5:7:7:9:10:11:11:12:13:13:13	1636	Angiotensin converting enzyme|angiotensin converting enzyme|ACE|ACE|ACE|ACE|ACE|ACE|ACE	GeneOrGeneProduct	0:38:42:54:162:269:292:373:390	3:41:43:55:163:270:293:374:391	0:2:2:3:7:9:10:13:13	1:NR:2	L2R	CROSS	0-3	14-16	1636	Angiotensin converting enzyme|angiotensin converting enzyme|ACE|ACE|ACE|ACE|ACE|ACE|ACE	GeneOrGeneProduct	0:38:42:54:162:269:292:373:390	3:41:43:55:163:270:293:374:391	0:2:2:3:7:9:10:13:13	D007249	inflammatory disease	DiseaseOrPhenotypicFeature	14	16	1	1:NR:2	L2R	CROSS	143-144	162-163	1636	Angiotensin converting enzyme|angiotensin converting enzyme|ACE|ACE|ACE|ACE|ACE|ACE|ACE	GeneOrGeneProduct	0:38:42:54:162:269:292:373:390	3:41:43:55:163:270:293:374:391	0:2:2:3:7:9:10:13:13	C566404	atopism	DiseaseOrPhenotypicFeature	143	144	5	1:NR:2	L2R	NON-CROSS	292-293	299-301	1636	Angiotensin converting enzyme|angiotensin converting enzyme|ACE|ACE|ACE|ACE|ACE|ACE|ACE	GeneOrGeneProduct	0:38:42:54:162:269:292:373:390	3:41:43:55:163:270:293:374:391	0:2:2:3:7:9:10:13:13	D004342	drug allergies	DiseaseOrPhenotypicFeature	299	301	10	1:NR:2	L2R	CROSS	333-335	373-374	1636	Angiotensin converting enzyme|angiotensin converting enzyme|ACE|ACE|ACE|ACE|ACE|ACE|ACE	GeneOrGeneProduct	0:38:42:54:162:269:292:373:390	3:41:43:55:163:270:293:374:391	0:2:2:3:7:9:10:13:13	D001102	viral infections	DiseaseOrPhenotypicFeature	333	335	11
26449539	The impact of PPARa activation on whole genome gene expression in human precision cut liver slices .|BACKGROUND : Studies in mice have shown that PPARa is an important regulator of lipid metabolism in liver and key transcription factor involved in the adaptive response to fasting .|However , much less is known about the role of PPARa in human liver .|METHODS : Here we set out to study the function of PPARa in human liver via analysis of whole genome gene regulation in human liver slices treated with the PPARa agonist Wy14643 .|RESULTS : Quantitative PCR indicated that PPARa is well expressed in human liver and human liver slices and that the classical PPARa targets PLIN2 , VLDLR , ANGPTL4 , CPT1A and PDK4 are robustly induced by PPARa activation .|Transcriptomics analysis indicated that 617 genes were upregulated and 665 genes were downregulated by PPARa activation ( q value < 0 . 05 ) .|Many genes induced by PPARa activation were involved in lipid metabolism ( ACSL5 , AGPAT9 , FADS1 , SLC27A4 ) , xenobiotic metabolism ( POR , ABCC2 , CYP3A5 ) or the unfolded protein response , whereas most of the downregulated genes were involved in immune - related pathways .|Among the most highly repressed genes upon PPARa activation were several chemokines ( e . g . CXCL9 - 11 , CCL8 , CX3CL1 , CXCL6 ) , interferon g - induced genes ( e . g . IFITM1 , IFIT1 , IFIT2 , IFIT3 ) and numerous other immune - related genes ( e . g . TLR3 , NOS2 , and LCN2 ) .|Comparative analysis of gene regulation by Wy14643 between human liver slices and primary human hepatocytes showed that down - regulation of gene expression by PPARa is much better captured by liver slices as compared to primary hepatocytes .|In particular , PPARa activation markedly suppressed immunity / inflammation - related genes in human liver slices but not in primary hepatocytes .|Finally , several putative new target genes of PPARa were identified that were commonly induced by PPARa activation in the two human liver model systems , including TSKU , RHOF , CA12 and VSIG10L .|CONCLUSION : Our paper demonstrates the suitability and superiority of human liver slices over primary hepatocytes for studying the functional role of PPARa in human liver .|Our data underscore the major role of PPARa in regulation of hepatic lipid and xenobiotic metabolism in human liver and reveal a marked immuno - suppressive / anti - inflammatory effect of PPARa in human liver slices that may be therapeutically relevant for non - alcoholic fatty liver disease .	1:NR:2	L2R	CROSS	3-4	25-26	5465	PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	3:57:73:91:101:116:131:148:163:216:299:316:344:352:393:405:430	4:58:74:92:102:117:132:149:164:217:300:317:345:353:394:406:431	0:2:3:3:4:4:4:5:6:7:8:9:10:10:11:12:12	19013	PPARa	GeneOrGeneProduct	25	26	1	1:Association:2	L2R	NON-CROSS	163-164	168-169	5465	PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	3:57:73:91:101:116:131:148:163:216:299:316:344:352:393:405:430	4:58:74:92:102:117:132:149:164:217:300:317:345:353:394:406:431	0:2:3:3:4:4:4:5:6:7:8:9:10:10:11:12:12	D008055	lipid|lipid|lipid	ChemicalEntity	31:168:410	32:169:411	1:6:12	1:Positive_Correlation:2	L2R	NON-CROSS	91-92	93-94	5465	PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	3:57:73:91:101:116:131:148:163:216:299:316:344:352:393:405:430	4:58:74:92:102:117:132:149:164:217:300:317:345:353:394:406:431	0:2:3:3:4:4:4:5:6:7:8:9:10:10:11:12:12	C006253	Wy14643|Wy14643	ChemicalEntity	93:281	94:282	3:8	1:Positive_Correlation:2	L2R	NON-CROSS	116-117	118-119	5465	PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	3:57:73:91:101:116:131:148:163:216:299:316:344:352:393:405:430	4:58:74:92:102:117:132:149:164:217:300:317:345:353:394:406:431	0:2:3:3:4:4:4:5:6:7:8:9:10:10:11:12:12	123	PLIN2	GeneOrGeneProduct	118	119	4	1:Positive_Correlation:2	R2L	NON-CROSS	120-121	116-117	7436	VLDLR	GeneOrGeneProduct	120	121	4	5465	PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	3:57:73:91:101:116:131:148:163:216:299:316:344:352:393:405:430	4:58:74:92:102:117:132:149:164:217:300:317:345:353:394:406:431	0:2:3:3:4:4:4:5:6:7:8:9:10:10:11:12:12	1:Positive_Correlation:2	R2L	NON-CROSS	122-123	116-117	51129	ANGPTL4	GeneOrGeneProduct	122	123	4	5465	PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	3:57:73:91:101:116:131:148:163:216:299:316:344:352:393:405:430	4:58:74:92:102:117:132:149:164:217:300:317:345:353:394:406:431	0:2:3:3:4:4:4:5:6:7:8:9:10:10:11:12:12	1:Positive_Correlation:2	R2L	NON-CROSS	131-132	124-125	1374	CPT1A	GeneOrGeneProduct	124	125	4	5465	PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	3:57:73:91:101:116:131:148:163:216:299:316:344:352:393:405:430	4:58:74:92:102:117:132:149:164:217:300:317:345:353:394:406:431	0:2:3:3:4:4:4:5:6:7:8:9:10:10:11:12:12	1:Positive_Correlation:2	R2L	NON-CROSS	131-132	126-127	5166	PDK4	GeneOrGeneProduct	126	127	4	5465	PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	3:57:73:91:101:116:131:148:163:216:299:316:344:352:393:405:430	4:58:74:92:102:117:132:149:164:217:300:317:345:353:394:406:431	0:2:3:3:4:4:4:5:6:7:8:9:10:10:11:12:12	1:Positive_Correlation:2	L2R	NON-CROSS	163-164	171-172	5465	PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	3:57:73:91:101:116:131:148:163:216:299:316:344:352:393:405:430	4:58:74:92:102:117:132:149:164:217:300:317:345:353:394:406:431	0:2:3:3:4:4:4:5:6:7:8:9:10:10:11:12:12	51703	ACSL5	GeneOrGeneProduct	171	172	6	1:Positive_Correlation:2	L2R	NON-CROSS	163-164	173-174	5465	PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	3:57:73:91:101:116:131:148:163:216:299:316:344:352:393:405:430	4:58:74:92:102:117:132:149:164:217:300:317:345:353:394:406:431	0:2:3:3:4:4:4:5:6:7:8:9:10:10:11:12:12	84803	AGPAT9	GeneOrGeneProduct	173	174	6	1:Positive_Correlation:2	L2R	NON-CROSS	163-164	175-176	5465	PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	3:57:73:91:101:116:131:148:163:216:299:316:344:352:393:405:430	4:58:74:92:102:117:132:149:164:217:300:317:345:353:394:406:431	0:2:3:3:4:4:4:5:6:7:8:9:10:10:11:12:12	3992	FADS1	GeneOrGeneProduct	175	176	6	1:Positive_Correlation:2	L2R	NON-CROSS	163-164	177-178	5465	PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	3:57:73:91:101:116:131:148:163:216:299:316:344:352:393:405:430	4:58:74:92:102:117:132:149:164:217:300:317:345:353:394:406:431	0:2:3:3:4:4:4:5:6:7:8:9:10:10:11:12:12	10999	SLC27A4	GeneOrGeneProduct	177	178	6	1:Positive_Correlation:2	L2R	NON-CROSS	163-164	183-184	5465	PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	3:57:73:91:101:116:131:148:163:216:299:316:344:352:393:405:430	4:58:74:92:102:117:132:149:164:217:300:317:345:353:394:406:431	0:2:3:3:4:4:4:5:6:7:8:9:10:10:11:12:12	5447	POR	GeneOrGeneProduct	183	184	6	1:Positive_Correlation:2	L2R	NON-CROSS	163-164	185-186	5465	PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	3:57:73:91:101:116:131:148:163:216:299:316:344:352:393:405:430	4:58:74:92:102:117:132:149:164:217:300:317:345:353:394:406:431	0:2:3:3:4:4:4:5:6:7:8:9:10:10:11:12:12	1244	ABCC2	GeneOrGeneProduct	185	186	6	1:Positive_Correlation:2	L2R	NON-CROSS	163-164	187-188	5465	PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	3:57:73:91:101:116:131:148:163:216:299:316:344:352:393:405:430	4:58:74:92:102:117:132:149:164:217:300:317:345:353:394:406:431	0:2:3:3:4:4:4:5:6:7:8:9:10:10:11:12:12	1577	CYP3A5	GeneOrGeneProduct	187	188	6	1:NR:2	L2R	NON-CROSS	216-217	220-221	5465	PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	3:57:73:91:101:116:131:148:163:216:299:316:344:352:393:405:430	4:58:74:92:102:117:132:149:164:217:300:317:345:353:394:406:431	0:2:3:3:4:4:4:5:6:7:8:9:10:10:11:12:12	4283,6355,6372,6376	chemokines	GeneOrGeneProduct	220	221	7	1:Negative_Correlation:2	L2R	NON-CROSS	216-217	226-229	5465	PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	3:57:73:91:101:116:131:148:163:216:299:316:344:352:393:405:430	4:58:74:92:102:117:132:149:164:217:300:317:345:353:394:406:431	0:2:3:3:4:4:4:5:6:7:8:9:10:10:11:12:12	4283	CXCL9 - 11	GeneOrGeneProduct	226	229	7	1:Negative_Correlation:2	L2R	NON-CROSS	216-217	230-231	5465	PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	3:57:73:91:101:116:131:148:163:216:299:316:344:352:393:405:430	4:58:74:92:102:117:132:149:164:217:300:317:345:353:394:406:431	0:2:3:3:4:4:4:5:6:7:8:9:10:10:11:12:12	6355	CCL8	GeneOrGeneProduct	230	231	7	1:Negative_Correlation:2	L2R	NON-CROSS	216-217	232-233	5465	PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	3:57:73:91:101:116:131:148:163:216:299:316:344:352:393:405:430	4:58:74:92:102:117:132:149:164:217:300:317:345:353:394:406:431	0:2:3:3:4:4:4:5:6:7:8:9:10:10:11:12:12	6376	CX3CL1	GeneOrGeneProduct	232	233	7	1:Negative_Correlation:2	L2R	NON-CROSS	216-217	234-235	5465	PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	3:57:73:91:101:116:131:148:163:216:299:316:344:352:393:405:430	4:58:74:92:102:117:132:149:164:217:300:317:345:353:394:406:431	0:2:3:3:4:4:4:5:6:7:8:9:10:10:11:12:12	6372	CXCL6	GeneOrGeneProduct	234	235	7	1:Association:2	L2R	NON-CROSS	216-217	237-239	5465	PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	3:57:73:91:101:116:131:148:163:216:299:316:344:352:393:405:430	4:58:74:92:102:117:132:149:164:217:300:317:345:353:394:406:431	0:2:3:3:4:4:4:5:6:7:8:9:10:10:11:12:12	3458	interferon g	GeneOrGeneProduct	237	239	7	1:Negative_Correlation:2	L2R	NON-CROSS	216-217	247-248	5465	PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	3:57:73:91:101:116:131:148:163:216:299:316:344:352:393:405:430	4:58:74:92:102:117:132:149:164:217:300:317:345:353:394:406:431	0:2:3:3:4:4:4:5:6:7:8:9:10:10:11:12:12	8519	IFITM1	GeneOrGeneProduct	247	248	7	1:Negative_Correlation:2	L2R	NON-CROSS	216-217	249-250	5465	PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	3:57:73:91:101:116:131:148:163:216:299:316:344:352:393:405:430	4:58:74:92:102:117:132:149:164:217:300:317:345:353:394:406:431	0:2:3:3:4:4:4:5:6:7:8:9:10:10:11:12:12	3434	IFIT1	GeneOrGeneProduct	249	250	7	1:Negative_Correlation:2	L2R	NON-CROSS	216-217	251-252	5465	PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	3:57:73:91:101:116:131:148:163:216:299:316:344:352:393:405:430	4:58:74:92:102:117:132:149:164:217:300:317:345:353:394:406:431	0:2:3:3:4:4:4:5:6:7:8:9:10:10:11:12:12	3433	IFIT2	GeneOrGeneProduct	251	252	7	1:Negative_Correlation:2	L2R	NON-CROSS	216-217	253-254	5465	PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	3:57:73:91:101:116:131:148:163:216:299:316:344:352:393:405:430	4:58:74:92:102:117:132:149:164:217:300:317:345:353:394:406:431	0:2:3:3:4:4:4:5:6:7:8:9:10:10:11:12:12	3437	IFIT3	GeneOrGeneProduct	253	254	7	1:Negative_Correlation:2	L2R	NON-CROSS	267-268	299-300	5465	PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	3:57:73:91:101:116:131:148:163:216:299:316:344:352:393:405:430	4:58:74:92:102:117:132:149:164:217:300:317:345:353:394:406:431	0:2:3:3:4:4:4:5:6:7:8:9:10:10:11:12:12	7098	TLR3	GeneOrGeneProduct	267	268	7	1:Negative_Correlation:2	L2R	NON-CROSS	269-270	299-300	5465	PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	3:57:73:91:101:116:131:148:163:216:299:316:344:352:393:405:430	4:58:74:92:102:117:132:149:164:217:300:317:345:353:394:406:431	0:2:3:3:4:4:4:5:6:7:8:9:10:10:11:12:12	4843	NOS2	GeneOrGeneProduct	269	270	7	1:Negative_Correlation:2	L2R	NON-CROSS	272-273	299-300	5465	PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	3:57:73:91:101:116:131:148:163:216:299:316:344:352:393:405:430	4:58:74:92:102:117:132:149:164:217:300:317:345:353:394:406:431	0:2:3:3:4:4:4:5:6:7:8:9:10:10:11:12:12	3934	LCN2	GeneOrGeneProduct	272	273	7	1:Association:2	L2R	NON-CROSS	427-428	430-431	5465	PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	3:57:73:91:101:116:131:148:163:216:299:316:344:352:393:405:430	4:58:74:92:102:117:132:149:164:217:300:317:345:353:394:406:431	0:2:3:3:4:4:4:5:6:7:8:9:10:10:11:12:12	D007249	inflammation|inflammatory	DiseaseOrPhenotypicFeature	322:427	323:428	9:12	1:Positive_Correlation:2	L2R	NON-CROSS	352-353	363-364	5465	PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	3:57:73:91:101:116:131:148:163:216:299:316:344:352:393:405:430	4:58:74:92:102:117:132:149:164:217:300:317:345:353:394:406:431	0:2:3:3:4:4:4:5:6:7:8:9:10:10:11:12:12	25987	TSKU	GeneOrGeneProduct	363	364	10	1:Positive_Correlation:2	L2R	NON-CROSS	352-353	365-366	5465	PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	3:57:73:91:101:116:131:148:163:216:299:316:344:352:393:405:430	4:58:74:92:102:117:132:149:164:217:300:317:345:353:394:406:431	0:2:3:3:4:4:4:5:6:7:8:9:10:10:11:12:12	54509	RHOF	GeneOrGeneProduct	365	366	10	1:Positive_Correlation:2	L2R	NON-CROSS	352-353	367-368	5465	PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	3:57:73:91:101:116:131:148:163:216:299:316:344:352:393:405:430	4:58:74:92:102:117:132:149:164:217:300:317:345:353:394:406:431	0:2:3:3:4:4:4:5:6:7:8:9:10:10:11:12:12	771	CA12	GeneOrGeneProduct	367	368	10	1:Positive_Correlation:2	L2R	NON-CROSS	352-353	369-370	5465	PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	3:57:73:91:101:116:131:148:163:216:299:316:344:352:393:405:430	4:58:74:92:102:117:132:149:164:217:300:317:345:353:394:406:431	0:2:3:3:4:4:4:5:6:7:8:9:10:10:11:12:12	147645	VSIG10L	GeneOrGeneProduct	369	370	10	1:Association:2	R2L	NON-CROSS	441-447	430-431	D065626	non - alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	441	447	12	5465	PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa|PPARa	GeneOrGeneProduct	3:57:73:91:101:116:131:148:163:216:299:316:344:352:393:405:430	4:58:74:92:102:117:132:149:164:217:300:317:345:353:394:406:431	0:2:3:3:4:4:4:5:6:7:8:9:10:10:11:12:12	1:Association:2	L2R	NON-CROSS	25-26	31-32	19013	PPARa	GeneOrGeneProduct	25	26	1	D008055	lipid|lipid|lipid	ChemicalEntity	31:168:410	32:169:411	1:6:12	1:NR:2	L2R	CROSS	25-26	93-94	19013	PPARa	GeneOrGeneProduct	25	26	1	C006253	Wy14643|Wy14643	ChemicalEntity	93:281	94:282	3:8	1:NR:2	L2R	CROSS	25-26	118-119	19013	PPARa	GeneOrGeneProduct	25	26	1	123	PLIN2	GeneOrGeneProduct	118	119	4	1:NR:2	L2R	CROSS	25-26	120-121	19013	PPARa	GeneOrGeneProduct	25	26	1	7436	VLDLR	GeneOrGeneProduct	120	121	4	1:NR:2	L2R	CROSS	25-26	122-123	19013	PPARa	GeneOrGeneProduct	25	26	1	51129	ANGPTL4	GeneOrGeneProduct	122	123	4	1:NR:2	L2R	CROSS	25-26	124-125	19013	PPARa	GeneOrGeneProduct	25	26	1	1374	CPT1A	GeneOrGeneProduct	124	125	4	1:NR:2	L2R	CROSS	25-26	126-127	19013	PPARa	GeneOrGeneProduct	25	26	1	5166	PDK4	GeneOrGeneProduct	126	127	4	1:NR:2	L2R	CROSS	25-26	171-172	19013	PPARa	GeneOrGeneProduct	25	26	1	51703	ACSL5	GeneOrGeneProduct	171	172	6	1:NR:2	L2R	CROSS	25-26	173-174	19013	PPARa	GeneOrGeneProduct	25	26	1	84803	AGPAT9	GeneOrGeneProduct	173	174	6	1:NR:2	L2R	CROSS	25-26	175-176	19013	PPARa	GeneOrGeneProduct	25	26	1	3992	FADS1	GeneOrGeneProduct	175	176	6	1:NR:2	L2R	CROSS	25-26	177-178	19013	PPARa	GeneOrGeneProduct	25	26	1	10999	SLC27A4	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	CROSS	25-26	183-184	19013	PPARa	GeneOrGeneProduct	25	26	1	5447	POR	GeneOrGeneProduct	183	184	6	1:NR:2	L2R	CROSS	25-26	185-186	19013	PPARa	GeneOrGeneProduct	25	26	1	1244	ABCC2	GeneOrGeneProduct	185	186	6	1:NR:2	L2R	CROSS	25-26	187-188	19013	PPARa	GeneOrGeneProduct	25	26	1	1577	CYP3A5	GeneOrGeneProduct	187	188	6	1:NR:2	L2R	CROSS	25-26	220-221	19013	PPARa	GeneOrGeneProduct	25	26	1	4283,6355,6372,6376	chemokines	GeneOrGeneProduct	220	221	7	1:NR:2	L2R	CROSS	25-26	226-229	19013	PPARa	GeneOrGeneProduct	25	26	1	4283	CXCL9 - 11	GeneOrGeneProduct	226	229	7	1:NR:2	L2R	CROSS	25-26	230-231	19013	PPARa	GeneOrGeneProduct	25	26	1	6355	CCL8	GeneOrGeneProduct	230	231	7	1:NR:2	L2R	CROSS	25-26	232-233	19013	PPARa	GeneOrGeneProduct	25	26	1	6376	CX3CL1	GeneOrGeneProduct	232	233	7	1:NR:2	L2R	CROSS	25-26	234-235	19013	PPARa	GeneOrGeneProduct	25	26	1	6372	CXCL6	GeneOrGeneProduct	234	235	7	1:NR:2	L2R	CROSS	25-26	237-239	19013	PPARa	GeneOrGeneProduct	25	26	1	3458	interferon g	GeneOrGeneProduct	237	239	7	1:NR:2	L2R	CROSS	25-26	247-248	19013	PPARa	GeneOrGeneProduct	25	26	1	8519	IFITM1	GeneOrGeneProduct	247	248	7	1:NR:2	L2R	CROSS	25-26	249-250	19013	PPARa	GeneOrGeneProduct	25	26	1	3434	IFIT1	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	CROSS	25-26	251-252	19013	PPARa	GeneOrGeneProduct	25	26	1	3433	IFIT2	GeneOrGeneProduct	251	252	7	1:NR:2	L2R	CROSS	25-26	253-254	19013	PPARa	GeneOrGeneProduct	25	26	1	3437	IFIT3	GeneOrGeneProduct	253	254	7	1:NR:2	L2R	CROSS	25-26	267-268	19013	PPARa	GeneOrGeneProduct	25	26	1	7098	TLR3	GeneOrGeneProduct	267	268	7	1:NR:2	L2R	CROSS	25-26	269-270	19013	PPARa	GeneOrGeneProduct	25	26	1	4843	NOS2	GeneOrGeneProduct	269	270	7	1:NR:2	L2R	CROSS	25-26	272-273	19013	PPARa	GeneOrGeneProduct	25	26	1	3934	LCN2	GeneOrGeneProduct	272	273	7	1:NR:2	L2R	CROSS	25-26	322-323	19013	PPARa	GeneOrGeneProduct	25	26	1	D007249	inflammation|inflammatory	DiseaseOrPhenotypicFeature	322:427	323:428	9:12	1:NR:2	L2R	CROSS	25-26	363-364	19013	PPARa	GeneOrGeneProduct	25	26	1	25987	TSKU	GeneOrGeneProduct	363	364	10	1:NR:2	L2R	CROSS	25-26	365-366	19013	PPARa	GeneOrGeneProduct	25	26	1	54509	RHOF	GeneOrGeneProduct	365	366	10	1:NR:2	L2R	CROSS	25-26	367-368	19013	PPARa	GeneOrGeneProduct	25	26	1	771	CA12	GeneOrGeneProduct	367	368	10	1:NR:2	L2R	CROSS	25-26	369-370	19013	PPARa	GeneOrGeneProduct	25	26	1	147645	VSIG10L	GeneOrGeneProduct	369	370	10	1:NR:2	L2R	CROSS	25-26	441-447	19013	PPARa	GeneOrGeneProduct	25	26	1	D065626	non - alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	441	447	12	1:NR:2	L2R	CROSS	31-32	93-94	D008055	lipid|lipid|lipid	ChemicalEntity	31:168:410	32:169:411	1:6:12	C006253	Wy14643|Wy14643	ChemicalEntity	93:281	94:282	3:8	1:NR:2	L2R	CROSS	118-119	168-169	D008055	lipid|lipid|lipid	ChemicalEntity	31:168:410	32:169:411	1:6:12	123	PLIN2	GeneOrGeneProduct	118	119	4	1:NR:2	L2R	CROSS	120-121	168-169	D008055	lipid|lipid|lipid	ChemicalEntity	31:168:410	32:169:411	1:6:12	7436	VLDLR	GeneOrGeneProduct	120	121	4	1:NR:2	L2R	CROSS	122-123	168-169	D008055	lipid|lipid|lipid	ChemicalEntity	31:168:410	32:169:411	1:6:12	51129	ANGPTL4	GeneOrGeneProduct	122	123	4	1:NR:2	L2R	CROSS	124-125	168-169	D008055	lipid|lipid|lipid	ChemicalEntity	31:168:410	32:169:411	1:6:12	1374	CPT1A	GeneOrGeneProduct	124	125	4	1:NR:2	L2R	CROSS	126-127	168-169	D008055	lipid|lipid|lipid	ChemicalEntity	31:168:410	32:169:411	1:6:12	5166	PDK4	GeneOrGeneProduct	126	127	4	1:Association:2	L2R	NON-CROSS	168-169	171-172	D008055	lipid|lipid|lipid	ChemicalEntity	31:168:410	32:169:411	1:6:12	51703	ACSL5	GeneOrGeneProduct	171	172	6	1:Association:2	L2R	NON-CROSS	168-169	173-174	D008055	lipid|lipid|lipid	ChemicalEntity	31:168:410	32:169:411	1:6:12	84803	AGPAT9	GeneOrGeneProduct	173	174	6	1:Association:2	L2R	NON-CROSS	168-169	175-176	D008055	lipid|lipid|lipid	ChemicalEntity	31:168:410	32:169:411	1:6:12	3992	FADS1	GeneOrGeneProduct	175	176	6	1:Association:2	L2R	NON-CROSS	168-169	177-178	D008055	lipid|lipid|lipid	ChemicalEntity	31:168:410	32:169:411	1:6:12	10999	SLC27A4	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	NON-CROSS	168-169	183-184	D008055	lipid|lipid|lipid	ChemicalEntity	31:168:410	32:169:411	1:6:12	5447	POR	GeneOrGeneProduct	183	184	6	1:NR:2	L2R	NON-CROSS	168-169	185-186	D008055	lipid|lipid|lipid	ChemicalEntity	31:168:410	32:169:411	1:6:12	1244	ABCC2	GeneOrGeneProduct	185	186	6	1:NR:2	L2R	NON-CROSS	168-169	187-188	D008055	lipid|lipid|lipid	ChemicalEntity	31:168:410	32:169:411	1:6:12	1577	CYP3A5	GeneOrGeneProduct	187	188	6	1:NR:2	L2R	CROSS	168-169	220-221	D008055	lipid|lipid|lipid	ChemicalEntity	31:168:410	32:169:411	1:6:12	4283,6355,6372,6376	chemokines	GeneOrGeneProduct	220	221	7	1:NR:2	L2R	CROSS	168-169	226-229	D008055	lipid|lipid|lipid	ChemicalEntity	31:168:410	32:169:411	1:6:12	4283	CXCL9 - 11	GeneOrGeneProduct	226	229	7	1:NR:2	L2R	CROSS	168-169	230-231	D008055	lipid|lipid|lipid	ChemicalEntity	31:168:410	32:169:411	1:6:12	6355	CCL8	GeneOrGeneProduct	230	231	7	1:NR:2	L2R	CROSS	168-169	232-233	D008055	lipid|lipid|lipid	ChemicalEntity	31:168:410	32:169:411	1:6:12	6376	CX3CL1	GeneOrGeneProduct	232	233	7	1:NR:2	L2R	CROSS	168-169	234-235	D008055	lipid|lipid|lipid	ChemicalEntity	31:168:410	32:169:411	1:6:12	6372	CXCL6	GeneOrGeneProduct	234	235	7	1:NR:2	L2R	CROSS	168-169	237-239	D008055	lipid|lipid|lipid	ChemicalEntity	31:168:410	32:169:411	1:6:12	3458	interferon g	GeneOrGeneProduct	237	239	7	1:NR:2	L2R	CROSS	168-169	247-248	D008055	lipid|lipid|lipid	ChemicalEntity	31:168:410	32:169:411	1:6:12	8519	IFITM1	GeneOrGeneProduct	247	248	7	1:NR:2	L2R	CROSS	168-169	249-250	D008055	lipid|lipid|lipid	ChemicalEntity	31:168:410	32:169:411	1:6:12	3434	IFIT1	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	CROSS	168-169	251-252	D008055	lipid|lipid|lipid	ChemicalEntity	31:168:410	32:169:411	1:6:12	3433	IFIT2	GeneOrGeneProduct	251	252	7	1:NR:2	L2R	CROSS	168-169	253-254	D008055	lipid|lipid|lipid	ChemicalEntity	31:168:410	32:169:411	1:6:12	3437	IFIT3	GeneOrGeneProduct	253	254	7	1:NR:2	L2R	CROSS	168-169	267-268	D008055	lipid|lipid|lipid	ChemicalEntity	31:168:410	32:169:411	1:6:12	7098	TLR3	GeneOrGeneProduct	267	268	7	1:NR:2	L2R	CROSS	168-169	269-270	D008055	lipid|lipid|lipid	ChemicalEntity	31:168:410	32:169:411	1:6:12	4843	NOS2	GeneOrGeneProduct	269	270	7	1:NR:2	L2R	CROSS	168-169	272-273	D008055	lipid|lipid|lipid	ChemicalEntity	31:168:410	32:169:411	1:6:12	3934	LCN2	GeneOrGeneProduct	272	273	7	1:NR:2	L2R	NON-CROSS	410-411	427-428	D008055	lipid|lipid|lipid	ChemicalEntity	31:168:410	32:169:411	1:6:12	D007249	inflammation|inflammatory	DiseaseOrPhenotypicFeature	322:427	323:428	9:12	1:NR:2	L2R	CROSS	363-364	410-411	D008055	lipid|lipid|lipid	ChemicalEntity	31:168:410	32:169:411	1:6:12	25987	TSKU	GeneOrGeneProduct	363	364	10	1:NR:2	L2R	CROSS	365-366	410-411	D008055	lipid|lipid|lipid	ChemicalEntity	31:168:410	32:169:411	1:6:12	54509	RHOF	GeneOrGeneProduct	365	366	10	1:NR:2	L2R	CROSS	367-368	410-411	D008055	lipid|lipid|lipid	ChemicalEntity	31:168:410	32:169:411	1:6:12	771	CA12	GeneOrGeneProduct	367	368	10	1:NR:2	L2R	CROSS	369-370	410-411	D008055	lipid|lipid|lipid	ChemicalEntity	31:168:410	32:169:411	1:6:12	147645	VSIG10L	GeneOrGeneProduct	369	370	10	1:NR:2	L2R	NON-CROSS	410-411	441-447	D008055	lipid|lipid|lipid	ChemicalEntity	31:168:410	32:169:411	1:6:12	D065626	non - alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	441	447	12	1:NR:2	L2R	CROSS	93-94	118-119	C006253	Wy14643|Wy14643	ChemicalEntity	93:281	94:282	3:8	123	PLIN2	GeneOrGeneProduct	118	119	4	1:NR:2	L2R	CROSS	93-94	120-121	C006253	Wy14643|Wy14643	ChemicalEntity	93:281	94:282	3:8	7436	VLDLR	GeneOrGeneProduct	120	121	4	1:NR:2	L2R	CROSS	93-94	122-123	C006253	Wy14643|Wy14643	ChemicalEntity	93:281	94:282	3:8	51129	ANGPTL4	GeneOrGeneProduct	122	123	4	1:NR:2	L2R	CROSS	93-94	124-125	C006253	Wy14643|Wy14643	ChemicalEntity	93:281	94:282	3:8	1374	CPT1A	GeneOrGeneProduct	124	125	4	1:NR:2	L2R	CROSS	93-94	126-127	C006253	Wy14643|Wy14643	ChemicalEntity	93:281	94:282	3:8	5166	PDK4	GeneOrGeneProduct	126	127	4	1:NR:2	L2R	CROSS	93-94	171-172	C006253	Wy14643|Wy14643	ChemicalEntity	93:281	94:282	3:8	51703	ACSL5	GeneOrGeneProduct	171	172	6	1:NR:2	L2R	CROSS	93-94	173-174	C006253	Wy14643|Wy14643	ChemicalEntity	93:281	94:282	3:8	84803	AGPAT9	GeneOrGeneProduct	173	174	6	1:NR:2	L2R	CROSS	93-94	175-176	C006253	Wy14643|Wy14643	ChemicalEntity	93:281	94:282	3:8	3992	FADS1	GeneOrGeneProduct	175	176	6	1:NR:2	L2R	CROSS	93-94	177-178	C006253	Wy14643|Wy14643	ChemicalEntity	93:281	94:282	3:8	10999	SLC27A4	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	CROSS	93-94	183-184	C006253	Wy14643|Wy14643	ChemicalEntity	93:281	94:282	3:8	5447	POR	GeneOrGeneProduct	183	184	6	1:NR:2	L2R	CROSS	93-94	185-186	C006253	Wy14643|Wy14643	ChemicalEntity	93:281	94:282	3:8	1244	ABCC2	GeneOrGeneProduct	185	186	6	1:NR:2	L2R	CROSS	93-94	187-188	C006253	Wy14643|Wy14643	ChemicalEntity	93:281	94:282	3:8	1577	CYP3A5	GeneOrGeneProduct	187	188	6	1:NR:2	L2R	CROSS	220-221	281-282	C006253	Wy14643|Wy14643	ChemicalEntity	93:281	94:282	3:8	4283,6355,6372,6376	chemokines	GeneOrGeneProduct	220	221	7	1:NR:2	L2R	CROSS	226-229	281-282	C006253	Wy14643|Wy14643	ChemicalEntity	93:281	94:282	3:8	4283	CXCL9 - 11	GeneOrGeneProduct	226	229	7	1:NR:2	L2R	CROSS	230-231	281-282	C006253	Wy14643|Wy14643	ChemicalEntity	93:281	94:282	3:8	6355	CCL8	GeneOrGeneProduct	230	231	7	1:NR:2	L2R	CROSS	232-233	281-282	C006253	Wy14643|Wy14643	ChemicalEntity	93:281	94:282	3:8	6376	CX3CL1	GeneOrGeneProduct	232	233	7	1:NR:2	L2R	CROSS	234-235	281-282	C006253	Wy14643|Wy14643	ChemicalEntity	93:281	94:282	3:8	6372	CXCL6	GeneOrGeneProduct	234	235	7	1:NR:2	L2R	CROSS	237-239	281-282	C006253	Wy14643|Wy14643	ChemicalEntity	93:281	94:282	3:8	3458	interferon g	GeneOrGeneProduct	237	239	7	1:NR:2	L2R	CROSS	247-248	281-282	C006253	Wy14643|Wy14643	ChemicalEntity	93:281	94:282	3:8	8519	IFITM1	GeneOrGeneProduct	247	248	7	1:NR:2	L2R	CROSS	249-250	281-282	C006253	Wy14643|Wy14643	ChemicalEntity	93:281	94:282	3:8	3434	IFIT1	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	CROSS	251-252	281-282	C006253	Wy14643|Wy14643	ChemicalEntity	93:281	94:282	3:8	3433	IFIT2	GeneOrGeneProduct	251	252	7	1:NR:2	L2R	CROSS	253-254	281-282	C006253	Wy14643|Wy14643	ChemicalEntity	93:281	94:282	3:8	3437	IFIT3	GeneOrGeneProduct	253	254	7	1:NR:2	L2R	CROSS	267-268	281-282	C006253	Wy14643|Wy14643	ChemicalEntity	93:281	94:282	3:8	7098	TLR3	GeneOrGeneProduct	267	268	7	1:NR:2	L2R	CROSS	269-270	281-282	C006253	Wy14643|Wy14643	ChemicalEntity	93:281	94:282	3:8	4843	NOS2	GeneOrGeneProduct	269	270	7	1:NR:2	L2R	CROSS	272-273	281-282	C006253	Wy14643|Wy14643	ChemicalEntity	93:281	94:282	3:8	3934	LCN2	GeneOrGeneProduct	272	273	7	1:NR:2	L2R	CROSS	281-282	322-323	C006253	Wy14643|Wy14643	ChemicalEntity	93:281	94:282	3:8	D007249	inflammation|inflammatory	DiseaseOrPhenotypicFeature	322:427	323:428	9:12	1:NR:2	L2R	CROSS	281-282	363-364	C006253	Wy14643|Wy14643	ChemicalEntity	93:281	94:282	3:8	25987	TSKU	GeneOrGeneProduct	363	364	10	1:NR:2	L2R	CROSS	281-282	365-366	C006253	Wy14643|Wy14643	ChemicalEntity	93:281	94:282	3:8	54509	RHOF	GeneOrGeneProduct	365	366	10	1:NR:2	L2R	CROSS	281-282	367-368	C006253	Wy14643|Wy14643	ChemicalEntity	93:281	94:282	3:8	771	CA12	GeneOrGeneProduct	367	368	10	1:NR:2	L2R	CROSS	281-282	369-370	C006253	Wy14643|Wy14643	ChemicalEntity	93:281	94:282	3:8	147645	VSIG10L	GeneOrGeneProduct	369	370	10	1:NR:2	L2R	CROSS	281-282	441-447	C006253	Wy14643|Wy14643	ChemicalEntity	93:281	94:282	3:8	D065626	non - alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	441	447	12	1:NR:2	L2R	NON-CROSS	118-119	120-121	123	PLIN2	GeneOrGeneProduct	118	119	4	7436	VLDLR	GeneOrGeneProduct	120	121	4	1:NR:2	L2R	NON-CROSS	118-119	122-123	123	PLIN2	GeneOrGeneProduct	118	119	4	51129	ANGPTL4	GeneOrGeneProduct	122	123	4	1:NR:2	L2R	NON-CROSS	118-119	124-125	123	PLIN2	GeneOrGeneProduct	118	119	4	1374	CPT1A	GeneOrGeneProduct	124	125	4	1:NR:2	L2R	NON-CROSS	118-119	126-127	123	PLIN2	GeneOrGeneProduct	118	119	4	5166	PDK4	GeneOrGeneProduct	126	127	4	1:NR:2	L2R	CROSS	118-119	171-172	123	PLIN2	GeneOrGeneProduct	118	119	4	51703	ACSL5	GeneOrGeneProduct	171	172	6	1:NR:2	L2R	CROSS	118-119	173-174	123	PLIN2	GeneOrGeneProduct	118	119	4	84803	AGPAT9	GeneOrGeneProduct	173	174	6	1:NR:2	L2R	CROSS	118-119	175-176	123	PLIN2	GeneOrGeneProduct	118	119	4	3992	FADS1	GeneOrGeneProduct	175	176	6	1:NR:2	L2R	CROSS	118-119	177-178	123	PLIN2	GeneOrGeneProduct	118	119	4	10999	SLC27A4	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	CROSS	118-119	183-184	123	PLIN2	GeneOrGeneProduct	118	119	4	5447	POR	GeneOrGeneProduct	183	184	6	1:NR:2	L2R	CROSS	118-119	185-186	123	PLIN2	GeneOrGeneProduct	118	119	4	1244	ABCC2	GeneOrGeneProduct	185	186	6	1:NR:2	L2R	CROSS	118-119	187-188	123	PLIN2	GeneOrGeneProduct	118	119	4	1577	CYP3A5	GeneOrGeneProduct	187	188	6	1:NR:2	L2R	CROSS	118-119	220-221	123	PLIN2	GeneOrGeneProduct	118	119	4	4283,6355,6372,6376	chemokines	GeneOrGeneProduct	220	221	7	1:NR:2	L2R	CROSS	118-119	226-229	123	PLIN2	GeneOrGeneProduct	118	119	4	4283	CXCL9 - 11	GeneOrGeneProduct	226	229	7	1:NR:2	L2R	CROSS	118-119	230-231	123	PLIN2	GeneOrGeneProduct	118	119	4	6355	CCL8	GeneOrGeneProduct	230	231	7	1:NR:2	L2R	CROSS	118-119	232-233	123	PLIN2	GeneOrGeneProduct	118	119	4	6376	CX3CL1	GeneOrGeneProduct	232	233	7	1:NR:2	L2R	CROSS	118-119	234-235	123	PLIN2	GeneOrGeneProduct	118	119	4	6372	CXCL6	GeneOrGeneProduct	234	235	7	1:NR:2	L2R	CROSS	118-119	237-239	123	PLIN2	GeneOrGeneProduct	118	119	4	3458	interferon g	GeneOrGeneProduct	237	239	7	1:NR:2	L2R	CROSS	118-119	247-248	123	PLIN2	GeneOrGeneProduct	118	119	4	8519	IFITM1	GeneOrGeneProduct	247	248	7	1:NR:2	L2R	CROSS	118-119	249-250	123	PLIN2	GeneOrGeneProduct	118	119	4	3434	IFIT1	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	CROSS	118-119	251-252	123	PLIN2	GeneOrGeneProduct	118	119	4	3433	IFIT2	GeneOrGeneProduct	251	252	7	1:NR:2	L2R	CROSS	118-119	253-254	123	PLIN2	GeneOrGeneProduct	118	119	4	3437	IFIT3	GeneOrGeneProduct	253	254	7	1:NR:2	L2R	CROSS	118-119	267-268	123	PLIN2	GeneOrGeneProduct	118	119	4	7098	TLR3	GeneOrGeneProduct	267	268	7	1:NR:2	L2R	CROSS	118-119	269-270	123	PLIN2	GeneOrGeneProduct	118	119	4	4843	NOS2	GeneOrGeneProduct	269	270	7	1:NR:2	L2R	CROSS	118-119	272-273	123	PLIN2	GeneOrGeneProduct	118	119	4	3934	LCN2	GeneOrGeneProduct	272	273	7	1:NR:2	L2R	CROSS	118-119	322-323	123	PLIN2	GeneOrGeneProduct	118	119	4	D007249	inflammation|inflammatory	DiseaseOrPhenotypicFeature	322:427	323:428	9:12	1:NR:2	L2R	CROSS	118-119	363-364	123	PLIN2	GeneOrGeneProduct	118	119	4	25987	TSKU	GeneOrGeneProduct	363	364	10	1:NR:2	L2R	CROSS	118-119	365-366	123	PLIN2	GeneOrGeneProduct	118	119	4	54509	RHOF	GeneOrGeneProduct	365	366	10	1:NR:2	L2R	CROSS	118-119	367-368	123	PLIN2	GeneOrGeneProduct	118	119	4	771	CA12	GeneOrGeneProduct	367	368	10	1:NR:2	L2R	CROSS	118-119	369-370	123	PLIN2	GeneOrGeneProduct	118	119	4	147645	VSIG10L	GeneOrGeneProduct	369	370	10	1:NR:2	L2R	CROSS	118-119	441-447	123	PLIN2	GeneOrGeneProduct	118	119	4	D065626	non - alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	441	447	12	1:NR:2	L2R	NON-CROSS	120-121	122-123	7436	VLDLR	GeneOrGeneProduct	120	121	4	51129	ANGPTL4	GeneOrGeneProduct	122	123	4	1:NR:2	L2R	NON-CROSS	120-121	124-125	7436	VLDLR	GeneOrGeneProduct	120	121	4	1374	CPT1A	GeneOrGeneProduct	124	125	4	1:NR:2	L2R	NON-CROSS	120-121	126-127	7436	VLDLR	GeneOrGeneProduct	120	121	4	5166	PDK4	GeneOrGeneProduct	126	127	4	1:NR:2	L2R	CROSS	120-121	171-172	7436	VLDLR	GeneOrGeneProduct	120	121	4	51703	ACSL5	GeneOrGeneProduct	171	172	6	1:NR:2	L2R	CROSS	120-121	173-174	7436	VLDLR	GeneOrGeneProduct	120	121	4	84803	AGPAT9	GeneOrGeneProduct	173	174	6	1:NR:2	L2R	CROSS	120-121	175-176	7436	VLDLR	GeneOrGeneProduct	120	121	4	3992	FADS1	GeneOrGeneProduct	175	176	6	1:NR:2	L2R	CROSS	120-121	177-178	7436	VLDLR	GeneOrGeneProduct	120	121	4	10999	SLC27A4	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	CROSS	120-121	183-184	7436	VLDLR	GeneOrGeneProduct	120	121	4	5447	POR	GeneOrGeneProduct	183	184	6	1:NR:2	L2R	CROSS	120-121	185-186	7436	VLDLR	GeneOrGeneProduct	120	121	4	1244	ABCC2	GeneOrGeneProduct	185	186	6	1:NR:2	L2R	CROSS	120-121	187-188	7436	VLDLR	GeneOrGeneProduct	120	121	4	1577	CYP3A5	GeneOrGeneProduct	187	188	6	1:NR:2	L2R	CROSS	120-121	220-221	7436	VLDLR	GeneOrGeneProduct	120	121	4	4283,6355,6372,6376	chemokines	GeneOrGeneProduct	220	221	7	1:NR:2	L2R	CROSS	120-121	226-229	7436	VLDLR	GeneOrGeneProduct	120	121	4	4283	CXCL9 - 11	GeneOrGeneProduct	226	229	7	1:NR:2	L2R	CROSS	120-121	230-231	7436	VLDLR	GeneOrGeneProduct	120	121	4	6355	CCL8	GeneOrGeneProduct	230	231	7	1:NR:2	L2R	CROSS	120-121	232-233	7436	VLDLR	GeneOrGeneProduct	120	121	4	6376	CX3CL1	GeneOrGeneProduct	232	233	7	1:NR:2	L2R	CROSS	120-121	234-235	7436	VLDLR	GeneOrGeneProduct	120	121	4	6372	CXCL6	GeneOrGeneProduct	234	235	7	1:NR:2	L2R	CROSS	120-121	237-239	7436	VLDLR	GeneOrGeneProduct	120	121	4	3458	interferon g	GeneOrGeneProduct	237	239	7	1:NR:2	L2R	CROSS	120-121	247-248	7436	VLDLR	GeneOrGeneProduct	120	121	4	8519	IFITM1	GeneOrGeneProduct	247	248	7	1:NR:2	L2R	CROSS	120-121	249-250	7436	VLDLR	GeneOrGeneProduct	120	121	4	3434	IFIT1	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	CROSS	120-121	251-252	7436	VLDLR	GeneOrGeneProduct	120	121	4	3433	IFIT2	GeneOrGeneProduct	251	252	7	1:NR:2	L2R	CROSS	120-121	253-254	7436	VLDLR	GeneOrGeneProduct	120	121	4	3437	IFIT3	GeneOrGeneProduct	253	254	7	1:NR:2	L2R	CROSS	120-121	267-268	7436	VLDLR	GeneOrGeneProduct	120	121	4	7098	TLR3	GeneOrGeneProduct	267	268	7	1:NR:2	L2R	CROSS	120-121	269-270	7436	VLDLR	GeneOrGeneProduct	120	121	4	4843	NOS2	GeneOrGeneProduct	269	270	7	1:NR:2	L2R	CROSS	120-121	272-273	7436	VLDLR	GeneOrGeneProduct	120	121	4	3934	LCN2	GeneOrGeneProduct	272	273	7	1:NR:2	L2R	CROSS	120-121	322-323	7436	VLDLR	GeneOrGeneProduct	120	121	4	D007249	inflammation|inflammatory	DiseaseOrPhenotypicFeature	322:427	323:428	9:12	1:NR:2	L2R	CROSS	120-121	363-364	7436	VLDLR	GeneOrGeneProduct	120	121	4	25987	TSKU	GeneOrGeneProduct	363	364	10	1:NR:2	L2R	CROSS	120-121	365-366	7436	VLDLR	GeneOrGeneProduct	120	121	4	54509	RHOF	GeneOrGeneProduct	365	366	10	1:NR:2	L2R	CROSS	120-121	367-368	7436	VLDLR	GeneOrGeneProduct	120	121	4	771	CA12	GeneOrGeneProduct	367	368	10	1:NR:2	L2R	CROSS	120-121	369-370	7436	VLDLR	GeneOrGeneProduct	120	121	4	147645	VSIG10L	GeneOrGeneProduct	369	370	10	1:NR:2	L2R	CROSS	120-121	441-447	7436	VLDLR	GeneOrGeneProduct	120	121	4	D065626	non - alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	441	447	12	1:NR:2	L2R	NON-CROSS	122-123	124-125	51129	ANGPTL4	GeneOrGeneProduct	122	123	4	1374	CPT1A	GeneOrGeneProduct	124	125	4	1:NR:2	L2R	NON-CROSS	122-123	126-127	51129	ANGPTL4	GeneOrGeneProduct	122	123	4	5166	PDK4	GeneOrGeneProduct	126	127	4	1:NR:2	L2R	CROSS	122-123	171-172	51129	ANGPTL4	GeneOrGeneProduct	122	123	4	51703	ACSL5	GeneOrGeneProduct	171	172	6	1:NR:2	L2R	CROSS	122-123	173-174	51129	ANGPTL4	GeneOrGeneProduct	122	123	4	84803	AGPAT9	GeneOrGeneProduct	173	174	6	1:NR:2	L2R	CROSS	122-123	175-176	51129	ANGPTL4	GeneOrGeneProduct	122	123	4	3992	FADS1	GeneOrGeneProduct	175	176	6	1:NR:2	L2R	CROSS	122-123	177-178	51129	ANGPTL4	GeneOrGeneProduct	122	123	4	10999	SLC27A4	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	CROSS	122-123	183-184	51129	ANGPTL4	GeneOrGeneProduct	122	123	4	5447	POR	GeneOrGeneProduct	183	184	6	1:NR:2	L2R	CROSS	122-123	185-186	51129	ANGPTL4	GeneOrGeneProduct	122	123	4	1244	ABCC2	GeneOrGeneProduct	185	186	6	1:NR:2	L2R	CROSS	122-123	187-188	51129	ANGPTL4	GeneOrGeneProduct	122	123	4	1577	CYP3A5	GeneOrGeneProduct	187	188	6	1:NR:2	L2R	CROSS	122-123	220-221	51129	ANGPTL4	GeneOrGeneProduct	122	123	4	4283,6355,6372,6376	chemokines	GeneOrGeneProduct	220	221	7	1:NR:2	L2R	CROSS	122-123	226-229	51129	ANGPTL4	GeneOrGeneProduct	122	123	4	4283	CXCL9 - 11	GeneOrGeneProduct	226	229	7	1:NR:2	L2R	CROSS	122-123	230-231	51129	ANGPTL4	GeneOrGeneProduct	122	123	4	6355	CCL8	GeneOrGeneProduct	230	231	7	1:NR:2	L2R	CROSS	122-123	232-233	51129	ANGPTL4	GeneOrGeneProduct	122	123	4	6376	CX3CL1	GeneOrGeneProduct	232	233	7	1:NR:2	L2R	CROSS	122-123	234-235	51129	ANGPTL4	GeneOrGeneProduct	122	123	4	6372	CXCL6	GeneOrGeneProduct	234	235	7	1:NR:2	L2R	CROSS	122-123	237-239	51129	ANGPTL4	GeneOrGeneProduct	122	123	4	3458	interferon g	GeneOrGeneProduct	237	239	7	1:NR:2	L2R	CROSS	122-123	247-248	51129	ANGPTL4	GeneOrGeneProduct	122	123	4	8519	IFITM1	GeneOrGeneProduct	247	248	7	1:NR:2	L2R	CROSS	122-123	249-250	51129	ANGPTL4	GeneOrGeneProduct	122	123	4	3434	IFIT1	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	CROSS	122-123	251-252	51129	ANGPTL4	GeneOrGeneProduct	122	123	4	3433	IFIT2	GeneOrGeneProduct	251	252	7	1:NR:2	L2R	CROSS	122-123	253-254	51129	ANGPTL4	GeneOrGeneProduct	122	123	4	3437	IFIT3	GeneOrGeneProduct	253	254	7	1:NR:2	L2R	CROSS	122-123	267-268	51129	ANGPTL4	GeneOrGeneProduct	122	123	4	7098	TLR3	GeneOrGeneProduct	267	268	7	1:NR:2	L2R	CROSS	122-123	269-270	51129	ANGPTL4	GeneOrGeneProduct	122	123	4	4843	NOS2	GeneOrGeneProduct	269	270	7	1:NR:2	L2R	CROSS	122-123	272-273	51129	ANGPTL4	GeneOrGeneProduct	122	123	4	3934	LCN2	GeneOrGeneProduct	272	273	7	1:NR:2	L2R	CROSS	122-123	322-323	51129	ANGPTL4	GeneOrGeneProduct	122	123	4	D007249	inflammation|inflammatory	DiseaseOrPhenotypicFeature	322:427	323:428	9:12	1:NR:2	L2R	CROSS	122-123	363-364	51129	ANGPTL4	GeneOrGeneProduct	122	123	4	25987	TSKU	GeneOrGeneProduct	363	364	10	1:NR:2	L2R	CROSS	122-123	365-366	51129	ANGPTL4	GeneOrGeneProduct	122	123	4	54509	RHOF	GeneOrGeneProduct	365	366	10	1:NR:2	L2R	CROSS	122-123	367-368	51129	ANGPTL4	GeneOrGeneProduct	122	123	4	771	CA12	GeneOrGeneProduct	367	368	10	1:NR:2	L2R	CROSS	122-123	369-370	51129	ANGPTL4	GeneOrGeneProduct	122	123	4	147645	VSIG10L	GeneOrGeneProduct	369	370	10	1:NR:2	L2R	CROSS	122-123	441-447	51129	ANGPTL4	GeneOrGeneProduct	122	123	4	D065626	non - alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	441	447	12	1:NR:2	L2R	NON-CROSS	124-125	126-127	1374	CPT1A	GeneOrGeneProduct	124	125	4	5166	PDK4	GeneOrGeneProduct	126	127	4	1:NR:2	L2R	CROSS	124-125	171-172	1374	CPT1A	GeneOrGeneProduct	124	125	4	51703	ACSL5	GeneOrGeneProduct	171	172	6	1:NR:2	L2R	CROSS	124-125	173-174	1374	CPT1A	GeneOrGeneProduct	124	125	4	84803	AGPAT9	GeneOrGeneProduct	173	174	6	1:NR:2	L2R	CROSS	124-125	175-176	1374	CPT1A	GeneOrGeneProduct	124	125	4	3992	FADS1	GeneOrGeneProduct	175	176	6	1:NR:2	L2R	CROSS	124-125	177-178	1374	CPT1A	GeneOrGeneProduct	124	125	4	10999	SLC27A4	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	CROSS	124-125	183-184	1374	CPT1A	GeneOrGeneProduct	124	125	4	5447	POR	GeneOrGeneProduct	183	184	6	1:NR:2	L2R	CROSS	124-125	185-186	1374	CPT1A	GeneOrGeneProduct	124	125	4	1244	ABCC2	GeneOrGeneProduct	185	186	6	1:NR:2	L2R	CROSS	124-125	187-188	1374	CPT1A	GeneOrGeneProduct	124	125	4	1577	CYP3A5	GeneOrGeneProduct	187	188	6	1:NR:2	L2R	CROSS	124-125	220-221	1374	CPT1A	GeneOrGeneProduct	124	125	4	4283,6355,6372,6376	chemokines	GeneOrGeneProduct	220	221	7	1:NR:2	L2R	CROSS	124-125	226-229	1374	CPT1A	GeneOrGeneProduct	124	125	4	4283	CXCL9 - 11	GeneOrGeneProduct	226	229	7	1:NR:2	L2R	CROSS	124-125	230-231	1374	CPT1A	GeneOrGeneProduct	124	125	4	6355	CCL8	GeneOrGeneProduct	230	231	7	1:NR:2	L2R	CROSS	124-125	232-233	1374	CPT1A	GeneOrGeneProduct	124	125	4	6376	CX3CL1	GeneOrGeneProduct	232	233	7	1:NR:2	L2R	CROSS	124-125	234-235	1374	CPT1A	GeneOrGeneProduct	124	125	4	6372	CXCL6	GeneOrGeneProduct	234	235	7	1:NR:2	L2R	CROSS	124-125	237-239	1374	CPT1A	GeneOrGeneProduct	124	125	4	3458	interferon g	GeneOrGeneProduct	237	239	7	1:NR:2	L2R	CROSS	124-125	247-248	1374	CPT1A	GeneOrGeneProduct	124	125	4	8519	IFITM1	GeneOrGeneProduct	247	248	7	1:NR:2	L2R	CROSS	124-125	249-250	1374	CPT1A	GeneOrGeneProduct	124	125	4	3434	IFIT1	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	CROSS	124-125	251-252	1374	CPT1A	GeneOrGeneProduct	124	125	4	3433	IFIT2	GeneOrGeneProduct	251	252	7	1:NR:2	L2R	CROSS	124-125	253-254	1374	CPT1A	GeneOrGeneProduct	124	125	4	3437	IFIT3	GeneOrGeneProduct	253	254	7	1:NR:2	L2R	CROSS	124-125	267-268	1374	CPT1A	GeneOrGeneProduct	124	125	4	7098	TLR3	GeneOrGeneProduct	267	268	7	1:NR:2	L2R	CROSS	124-125	269-270	1374	CPT1A	GeneOrGeneProduct	124	125	4	4843	NOS2	GeneOrGeneProduct	269	270	7	1:NR:2	L2R	CROSS	124-125	272-273	1374	CPT1A	GeneOrGeneProduct	124	125	4	3934	LCN2	GeneOrGeneProduct	272	273	7	1:NR:2	L2R	CROSS	124-125	322-323	1374	CPT1A	GeneOrGeneProduct	124	125	4	D007249	inflammation|inflammatory	DiseaseOrPhenotypicFeature	322:427	323:428	9:12	1:NR:2	L2R	CROSS	124-125	363-364	1374	CPT1A	GeneOrGeneProduct	124	125	4	25987	TSKU	GeneOrGeneProduct	363	364	10	1:NR:2	L2R	CROSS	124-125	365-366	1374	CPT1A	GeneOrGeneProduct	124	125	4	54509	RHOF	GeneOrGeneProduct	365	366	10	1:NR:2	L2R	CROSS	124-125	367-368	1374	CPT1A	GeneOrGeneProduct	124	125	4	771	CA12	GeneOrGeneProduct	367	368	10	1:NR:2	L2R	CROSS	124-125	369-370	1374	CPT1A	GeneOrGeneProduct	124	125	4	147645	VSIG10L	GeneOrGeneProduct	369	370	10	1:NR:2	L2R	CROSS	124-125	441-447	1374	CPT1A	GeneOrGeneProduct	124	125	4	D065626	non - alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	441	447	12	1:NR:2	L2R	CROSS	126-127	171-172	5166	PDK4	GeneOrGeneProduct	126	127	4	51703	ACSL5	GeneOrGeneProduct	171	172	6	1:NR:2	L2R	CROSS	126-127	173-174	5166	PDK4	GeneOrGeneProduct	126	127	4	84803	AGPAT9	GeneOrGeneProduct	173	174	6	1:NR:2	L2R	CROSS	126-127	175-176	5166	PDK4	GeneOrGeneProduct	126	127	4	3992	FADS1	GeneOrGeneProduct	175	176	6	1:NR:2	L2R	CROSS	126-127	177-178	5166	PDK4	GeneOrGeneProduct	126	127	4	10999	SLC27A4	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	CROSS	126-127	183-184	5166	PDK4	GeneOrGeneProduct	126	127	4	5447	POR	GeneOrGeneProduct	183	184	6	1:NR:2	L2R	CROSS	126-127	185-186	5166	PDK4	GeneOrGeneProduct	126	127	4	1244	ABCC2	GeneOrGeneProduct	185	186	6	1:NR:2	L2R	CROSS	126-127	187-188	5166	PDK4	GeneOrGeneProduct	126	127	4	1577	CYP3A5	GeneOrGeneProduct	187	188	6	1:NR:2	L2R	CROSS	126-127	220-221	5166	PDK4	GeneOrGeneProduct	126	127	4	4283,6355,6372,6376	chemokines	GeneOrGeneProduct	220	221	7	1:NR:2	L2R	CROSS	126-127	226-229	5166	PDK4	GeneOrGeneProduct	126	127	4	4283	CXCL9 - 11	GeneOrGeneProduct	226	229	7	1:NR:2	L2R	CROSS	126-127	230-231	5166	PDK4	GeneOrGeneProduct	126	127	4	6355	CCL8	GeneOrGeneProduct	230	231	7	1:NR:2	L2R	CROSS	126-127	232-233	5166	PDK4	GeneOrGeneProduct	126	127	4	6376	CX3CL1	GeneOrGeneProduct	232	233	7	1:NR:2	L2R	CROSS	126-127	234-235	5166	PDK4	GeneOrGeneProduct	126	127	4	6372	CXCL6	GeneOrGeneProduct	234	235	7	1:NR:2	L2R	CROSS	126-127	237-239	5166	PDK4	GeneOrGeneProduct	126	127	4	3458	interferon g	GeneOrGeneProduct	237	239	7	1:NR:2	L2R	CROSS	126-127	247-248	5166	PDK4	GeneOrGeneProduct	126	127	4	8519	IFITM1	GeneOrGeneProduct	247	248	7	1:NR:2	L2R	CROSS	126-127	249-250	5166	PDK4	GeneOrGeneProduct	126	127	4	3434	IFIT1	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	CROSS	126-127	251-252	5166	PDK4	GeneOrGeneProduct	126	127	4	3433	IFIT2	GeneOrGeneProduct	251	252	7	1:NR:2	L2R	CROSS	126-127	253-254	5166	PDK4	GeneOrGeneProduct	126	127	4	3437	IFIT3	GeneOrGeneProduct	253	254	7	1:NR:2	L2R	CROSS	126-127	267-268	5166	PDK4	GeneOrGeneProduct	126	127	4	7098	TLR3	GeneOrGeneProduct	267	268	7	1:NR:2	L2R	CROSS	126-127	269-270	5166	PDK4	GeneOrGeneProduct	126	127	4	4843	NOS2	GeneOrGeneProduct	269	270	7	1:NR:2	L2R	CROSS	126-127	272-273	5166	PDK4	GeneOrGeneProduct	126	127	4	3934	LCN2	GeneOrGeneProduct	272	273	7	1:NR:2	L2R	CROSS	126-127	322-323	5166	PDK4	GeneOrGeneProduct	126	127	4	D007249	inflammation|inflammatory	DiseaseOrPhenotypicFeature	322:427	323:428	9:12	1:NR:2	L2R	CROSS	126-127	363-364	5166	PDK4	GeneOrGeneProduct	126	127	4	25987	TSKU	GeneOrGeneProduct	363	364	10	1:NR:2	L2R	CROSS	126-127	365-366	5166	PDK4	GeneOrGeneProduct	126	127	4	54509	RHOF	GeneOrGeneProduct	365	366	10	1:NR:2	L2R	CROSS	126-127	367-368	5166	PDK4	GeneOrGeneProduct	126	127	4	771	CA12	GeneOrGeneProduct	367	368	10	1:NR:2	L2R	CROSS	126-127	369-370	5166	PDK4	GeneOrGeneProduct	126	127	4	147645	VSIG10L	GeneOrGeneProduct	369	370	10	1:NR:2	L2R	CROSS	126-127	441-447	5166	PDK4	GeneOrGeneProduct	126	127	4	D065626	non - alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	441	447	12	1:NR:2	L2R	NON-CROSS	171-172	173-174	51703	ACSL5	GeneOrGeneProduct	171	172	6	84803	AGPAT9	GeneOrGeneProduct	173	174	6	1:NR:2	L2R	NON-CROSS	171-172	175-176	51703	ACSL5	GeneOrGeneProduct	171	172	6	3992	FADS1	GeneOrGeneProduct	175	176	6	1:NR:2	L2R	NON-CROSS	171-172	177-178	51703	ACSL5	GeneOrGeneProduct	171	172	6	10999	SLC27A4	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	NON-CROSS	171-172	183-184	51703	ACSL5	GeneOrGeneProduct	171	172	6	5447	POR	GeneOrGeneProduct	183	184	6	1:NR:2	L2R	NON-CROSS	171-172	185-186	51703	ACSL5	GeneOrGeneProduct	171	172	6	1244	ABCC2	GeneOrGeneProduct	185	186	6	1:NR:2	L2R	NON-CROSS	171-172	187-188	51703	ACSL5	GeneOrGeneProduct	171	172	6	1577	CYP3A5	GeneOrGeneProduct	187	188	6	1:NR:2	L2R	CROSS	171-172	220-221	51703	ACSL5	GeneOrGeneProduct	171	172	6	4283,6355,6372,6376	chemokines	GeneOrGeneProduct	220	221	7	1:NR:2	L2R	CROSS	171-172	226-229	51703	ACSL5	GeneOrGeneProduct	171	172	6	4283	CXCL9 - 11	GeneOrGeneProduct	226	229	7	1:NR:2	L2R	CROSS	171-172	230-231	51703	ACSL5	GeneOrGeneProduct	171	172	6	6355	CCL8	GeneOrGeneProduct	230	231	7	1:NR:2	L2R	CROSS	171-172	232-233	51703	ACSL5	GeneOrGeneProduct	171	172	6	6376	CX3CL1	GeneOrGeneProduct	232	233	7	1:NR:2	L2R	CROSS	171-172	234-235	51703	ACSL5	GeneOrGeneProduct	171	172	6	6372	CXCL6	GeneOrGeneProduct	234	235	7	1:NR:2	L2R	CROSS	171-172	237-239	51703	ACSL5	GeneOrGeneProduct	171	172	6	3458	interferon g	GeneOrGeneProduct	237	239	7	1:NR:2	L2R	CROSS	171-172	247-248	51703	ACSL5	GeneOrGeneProduct	171	172	6	8519	IFITM1	GeneOrGeneProduct	247	248	7	1:NR:2	L2R	CROSS	171-172	249-250	51703	ACSL5	GeneOrGeneProduct	171	172	6	3434	IFIT1	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	CROSS	171-172	251-252	51703	ACSL5	GeneOrGeneProduct	171	172	6	3433	IFIT2	GeneOrGeneProduct	251	252	7	1:NR:2	L2R	CROSS	171-172	253-254	51703	ACSL5	GeneOrGeneProduct	171	172	6	3437	IFIT3	GeneOrGeneProduct	253	254	7	1:NR:2	L2R	CROSS	171-172	267-268	51703	ACSL5	GeneOrGeneProduct	171	172	6	7098	TLR3	GeneOrGeneProduct	267	268	7	1:NR:2	L2R	CROSS	171-172	269-270	51703	ACSL5	GeneOrGeneProduct	171	172	6	4843	NOS2	GeneOrGeneProduct	269	270	7	1:NR:2	L2R	CROSS	171-172	272-273	51703	ACSL5	GeneOrGeneProduct	171	172	6	3934	LCN2	GeneOrGeneProduct	272	273	7	1:NR:2	L2R	CROSS	171-172	322-323	51703	ACSL5	GeneOrGeneProduct	171	172	6	D007249	inflammation|inflammatory	DiseaseOrPhenotypicFeature	322:427	323:428	9:12	1:NR:2	L2R	CROSS	171-172	363-364	51703	ACSL5	GeneOrGeneProduct	171	172	6	25987	TSKU	GeneOrGeneProduct	363	364	10	1:NR:2	L2R	CROSS	171-172	365-366	51703	ACSL5	GeneOrGeneProduct	171	172	6	54509	RHOF	GeneOrGeneProduct	365	366	10	1:NR:2	L2R	CROSS	171-172	367-368	51703	ACSL5	GeneOrGeneProduct	171	172	6	771	CA12	GeneOrGeneProduct	367	368	10	1:NR:2	L2R	CROSS	171-172	369-370	51703	ACSL5	GeneOrGeneProduct	171	172	6	147645	VSIG10L	GeneOrGeneProduct	369	370	10	1:NR:2	L2R	CROSS	171-172	441-447	51703	ACSL5	GeneOrGeneProduct	171	172	6	D065626	non - alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	441	447	12	1:NR:2	L2R	NON-CROSS	173-174	175-176	84803	AGPAT9	GeneOrGeneProduct	173	174	6	3992	FADS1	GeneOrGeneProduct	175	176	6	1:NR:2	L2R	NON-CROSS	173-174	177-178	84803	AGPAT9	GeneOrGeneProduct	173	174	6	10999	SLC27A4	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	NON-CROSS	173-174	183-184	84803	AGPAT9	GeneOrGeneProduct	173	174	6	5447	POR	GeneOrGeneProduct	183	184	6	1:NR:2	L2R	NON-CROSS	173-174	185-186	84803	AGPAT9	GeneOrGeneProduct	173	174	6	1244	ABCC2	GeneOrGeneProduct	185	186	6	1:NR:2	L2R	NON-CROSS	173-174	187-188	84803	AGPAT9	GeneOrGeneProduct	173	174	6	1577	CYP3A5	GeneOrGeneProduct	187	188	6	1:NR:2	L2R	CROSS	173-174	220-221	84803	AGPAT9	GeneOrGeneProduct	173	174	6	4283,6355,6372,6376	chemokines	GeneOrGeneProduct	220	221	7	1:NR:2	L2R	CROSS	173-174	226-229	84803	AGPAT9	GeneOrGeneProduct	173	174	6	4283	CXCL9 - 11	GeneOrGeneProduct	226	229	7	1:NR:2	L2R	CROSS	173-174	230-231	84803	AGPAT9	GeneOrGeneProduct	173	174	6	6355	CCL8	GeneOrGeneProduct	230	231	7	1:NR:2	L2R	CROSS	173-174	232-233	84803	AGPAT9	GeneOrGeneProduct	173	174	6	6376	CX3CL1	GeneOrGeneProduct	232	233	7	1:NR:2	L2R	CROSS	173-174	234-235	84803	AGPAT9	GeneOrGeneProduct	173	174	6	6372	CXCL6	GeneOrGeneProduct	234	235	7	1:NR:2	L2R	CROSS	173-174	237-239	84803	AGPAT9	GeneOrGeneProduct	173	174	6	3458	interferon g	GeneOrGeneProduct	237	239	7	1:NR:2	L2R	CROSS	173-174	247-248	84803	AGPAT9	GeneOrGeneProduct	173	174	6	8519	IFITM1	GeneOrGeneProduct	247	248	7	1:NR:2	L2R	CROSS	173-174	249-250	84803	AGPAT9	GeneOrGeneProduct	173	174	6	3434	IFIT1	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	CROSS	173-174	251-252	84803	AGPAT9	GeneOrGeneProduct	173	174	6	3433	IFIT2	GeneOrGeneProduct	251	252	7	1:NR:2	L2R	CROSS	173-174	253-254	84803	AGPAT9	GeneOrGeneProduct	173	174	6	3437	IFIT3	GeneOrGeneProduct	253	254	7	1:NR:2	L2R	CROSS	173-174	267-268	84803	AGPAT9	GeneOrGeneProduct	173	174	6	7098	TLR3	GeneOrGeneProduct	267	268	7	1:NR:2	L2R	CROSS	173-174	269-270	84803	AGPAT9	GeneOrGeneProduct	173	174	6	4843	NOS2	GeneOrGeneProduct	269	270	7	1:NR:2	L2R	CROSS	173-174	272-273	84803	AGPAT9	GeneOrGeneProduct	173	174	6	3934	LCN2	GeneOrGeneProduct	272	273	7	1:NR:2	L2R	CROSS	173-174	322-323	84803	AGPAT9	GeneOrGeneProduct	173	174	6	D007249	inflammation|inflammatory	DiseaseOrPhenotypicFeature	322:427	323:428	9:12	1:NR:2	L2R	CROSS	173-174	363-364	84803	AGPAT9	GeneOrGeneProduct	173	174	6	25987	TSKU	GeneOrGeneProduct	363	364	10	1:NR:2	L2R	CROSS	173-174	365-366	84803	AGPAT9	GeneOrGeneProduct	173	174	6	54509	RHOF	GeneOrGeneProduct	365	366	10	1:NR:2	L2R	CROSS	173-174	367-368	84803	AGPAT9	GeneOrGeneProduct	173	174	6	771	CA12	GeneOrGeneProduct	367	368	10	1:NR:2	L2R	CROSS	173-174	369-370	84803	AGPAT9	GeneOrGeneProduct	173	174	6	147645	VSIG10L	GeneOrGeneProduct	369	370	10	1:NR:2	L2R	CROSS	173-174	441-447	84803	AGPAT9	GeneOrGeneProduct	173	174	6	D065626	non - alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	441	447	12	1:NR:2	L2R	NON-CROSS	175-176	177-178	3992	FADS1	GeneOrGeneProduct	175	176	6	10999	SLC27A4	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	NON-CROSS	175-176	183-184	3992	FADS1	GeneOrGeneProduct	175	176	6	5447	POR	GeneOrGeneProduct	183	184	6	1:NR:2	L2R	NON-CROSS	175-176	185-186	3992	FADS1	GeneOrGeneProduct	175	176	6	1244	ABCC2	GeneOrGeneProduct	185	186	6	1:NR:2	L2R	NON-CROSS	175-176	187-188	3992	FADS1	GeneOrGeneProduct	175	176	6	1577	CYP3A5	GeneOrGeneProduct	187	188	6	1:NR:2	L2R	CROSS	175-176	220-221	3992	FADS1	GeneOrGeneProduct	175	176	6	4283,6355,6372,6376	chemokines	GeneOrGeneProduct	220	221	7	1:NR:2	L2R	CROSS	175-176	226-229	3992	FADS1	GeneOrGeneProduct	175	176	6	4283	CXCL9 - 11	GeneOrGeneProduct	226	229	7	1:NR:2	L2R	CROSS	175-176	230-231	3992	FADS1	GeneOrGeneProduct	175	176	6	6355	CCL8	GeneOrGeneProduct	230	231	7	1:NR:2	L2R	CROSS	175-176	232-233	3992	FADS1	GeneOrGeneProduct	175	176	6	6376	CX3CL1	GeneOrGeneProduct	232	233	7	1:NR:2	L2R	CROSS	175-176	234-235	3992	FADS1	GeneOrGeneProduct	175	176	6	6372	CXCL6	GeneOrGeneProduct	234	235	7	1:NR:2	L2R	CROSS	175-176	237-239	3992	FADS1	GeneOrGeneProduct	175	176	6	3458	interferon g	GeneOrGeneProduct	237	239	7	1:NR:2	L2R	CROSS	175-176	247-248	3992	FADS1	GeneOrGeneProduct	175	176	6	8519	IFITM1	GeneOrGeneProduct	247	248	7	1:NR:2	L2R	CROSS	175-176	249-250	3992	FADS1	GeneOrGeneProduct	175	176	6	3434	IFIT1	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	CROSS	175-176	251-252	3992	FADS1	GeneOrGeneProduct	175	176	6	3433	IFIT2	GeneOrGeneProduct	251	252	7	1:NR:2	L2R	CROSS	175-176	253-254	3992	FADS1	GeneOrGeneProduct	175	176	6	3437	IFIT3	GeneOrGeneProduct	253	254	7	1:NR:2	L2R	CROSS	175-176	267-268	3992	FADS1	GeneOrGeneProduct	175	176	6	7098	TLR3	GeneOrGeneProduct	267	268	7	1:NR:2	L2R	CROSS	175-176	269-270	3992	FADS1	GeneOrGeneProduct	175	176	6	4843	NOS2	GeneOrGeneProduct	269	270	7	1:NR:2	L2R	CROSS	175-176	272-273	3992	FADS1	GeneOrGeneProduct	175	176	6	3934	LCN2	GeneOrGeneProduct	272	273	7	1:NR:2	L2R	CROSS	175-176	322-323	3992	FADS1	GeneOrGeneProduct	175	176	6	D007249	inflammation|inflammatory	DiseaseOrPhenotypicFeature	322:427	323:428	9:12	1:NR:2	L2R	CROSS	175-176	363-364	3992	FADS1	GeneOrGeneProduct	175	176	6	25987	TSKU	GeneOrGeneProduct	363	364	10	1:NR:2	L2R	CROSS	175-176	365-366	3992	FADS1	GeneOrGeneProduct	175	176	6	54509	RHOF	GeneOrGeneProduct	365	366	10	1:NR:2	L2R	CROSS	175-176	367-368	3992	FADS1	GeneOrGeneProduct	175	176	6	771	CA12	GeneOrGeneProduct	367	368	10	1:NR:2	L2R	CROSS	175-176	369-370	3992	FADS1	GeneOrGeneProduct	175	176	6	147645	VSIG10L	GeneOrGeneProduct	369	370	10	1:NR:2	L2R	CROSS	175-176	441-447	3992	FADS1	GeneOrGeneProduct	175	176	6	D065626	non - alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	441	447	12	1:NR:2	L2R	NON-CROSS	177-178	183-184	10999	SLC27A4	GeneOrGeneProduct	177	178	6	5447	POR	GeneOrGeneProduct	183	184	6	1:NR:2	L2R	NON-CROSS	177-178	185-186	10999	SLC27A4	GeneOrGeneProduct	177	178	6	1244	ABCC2	GeneOrGeneProduct	185	186	6	1:NR:2	L2R	NON-CROSS	177-178	187-188	10999	SLC27A4	GeneOrGeneProduct	177	178	6	1577	CYP3A5	GeneOrGeneProduct	187	188	6	1:NR:2	L2R	CROSS	177-178	220-221	10999	SLC27A4	GeneOrGeneProduct	177	178	6	4283,6355,6372,6376	chemokines	GeneOrGeneProduct	220	221	7	1:NR:2	L2R	CROSS	177-178	226-229	10999	SLC27A4	GeneOrGeneProduct	177	178	6	4283	CXCL9 - 11	GeneOrGeneProduct	226	229	7	1:NR:2	L2R	CROSS	177-178	230-231	10999	SLC27A4	GeneOrGeneProduct	177	178	6	6355	CCL8	GeneOrGeneProduct	230	231	7	1:NR:2	L2R	CROSS	177-178	232-233	10999	SLC27A4	GeneOrGeneProduct	177	178	6	6376	CX3CL1	GeneOrGeneProduct	232	233	7	1:NR:2	L2R	CROSS	177-178	234-235	10999	SLC27A4	GeneOrGeneProduct	177	178	6	6372	CXCL6	GeneOrGeneProduct	234	235	7	1:NR:2	L2R	CROSS	177-178	237-239	10999	SLC27A4	GeneOrGeneProduct	177	178	6	3458	interferon g	GeneOrGeneProduct	237	239	7	1:NR:2	L2R	CROSS	177-178	247-248	10999	SLC27A4	GeneOrGeneProduct	177	178	6	8519	IFITM1	GeneOrGeneProduct	247	248	7	1:NR:2	L2R	CROSS	177-178	249-250	10999	SLC27A4	GeneOrGeneProduct	177	178	6	3434	IFIT1	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	CROSS	177-178	251-252	10999	SLC27A4	GeneOrGeneProduct	177	178	6	3433	IFIT2	GeneOrGeneProduct	251	252	7	1:NR:2	L2R	CROSS	177-178	253-254	10999	SLC27A4	GeneOrGeneProduct	177	178	6	3437	IFIT3	GeneOrGeneProduct	253	254	7	1:NR:2	L2R	CROSS	177-178	267-268	10999	SLC27A4	GeneOrGeneProduct	177	178	6	7098	TLR3	GeneOrGeneProduct	267	268	7	1:NR:2	L2R	CROSS	177-178	269-270	10999	SLC27A4	GeneOrGeneProduct	177	178	6	4843	NOS2	GeneOrGeneProduct	269	270	7	1:NR:2	L2R	CROSS	177-178	272-273	10999	SLC27A4	GeneOrGeneProduct	177	178	6	3934	LCN2	GeneOrGeneProduct	272	273	7	1:NR:2	L2R	CROSS	177-178	322-323	10999	SLC27A4	GeneOrGeneProduct	177	178	6	D007249	inflammation|inflammatory	DiseaseOrPhenotypicFeature	322:427	323:428	9:12	1:NR:2	L2R	CROSS	177-178	363-364	10999	SLC27A4	GeneOrGeneProduct	177	178	6	25987	TSKU	GeneOrGeneProduct	363	364	10	1:NR:2	L2R	CROSS	177-178	365-366	10999	SLC27A4	GeneOrGeneProduct	177	178	6	54509	RHOF	GeneOrGeneProduct	365	366	10	1:NR:2	L2R	CROSS	177-178	367-368	10999	SLC27A4	GeneOrGeneProduct	177	178	6	771	CA12	GeneOrGeneProduct	367	368	10	1:NR:2	L2R	CROSS	177-178	369-370	10999	SLC27A4	GeneOrGeneProduct	177	178	6	147645	VSIG10L	GeneOrGeneProduct	369	370	10	1:NR:2	L2R	CROSS	177-178	441-447	10999	SLC27A4	GeneOrGeneProduct	177	178	6	D065626	non - alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	441	447	12	1:NR:2	L2R	NON-CROSS	183-184	185-186	5447	POR	GeneOrGeneProduct	183	184	6	1244	ABCC2	GeneOrGeneProduct	185	186	6	1:NR:2	L2R	NON-CROSS	183-184	187-188	5447	POR	GeneOrGeneProduct	183	184	6	1577	CYP3A5	GeneOrGeneProduct	187	188	6	1:NR:2	L2R	CROSS	183-184	220-221	5447	POR	GeneOrGeneProduct	183	184	6	4283,6355,6372,6376	chemokines	GeneOrGeneProduct	220	221	7	1:NR:2	L2R	CROSS	183-184	226-229	5447	POR	GeneOrGeneProduct	183	184	6	4283	CXCL9 - 11	GeneOrGeneProduct	226	229	7	1:NR:2	L2R	CROSS	183-184	230-231	5447	POR	GeneOrGeneProduct	183	184	6	6355	CCL8	GeneOrGeneProduct	230	231	7	1:NR:2	L2R	CROSS	183-184	232-233	5447	POR	GeneOrGeneProduct	183	184	6	6376	CX3CL1	GeneOrGeneProduct	232	233	7	1:NR:2	L2R	CROSS	183-184	234-235	5447	POR	GeneOrGeneProduct	183	184	6	6372	CXCL6	GeneOrGeneProduct	234	235	7	1:NR:2	L2R	CROSS	183-184	237-239	5447	POR	GeneOrGeneProduct	183	184	6	3458	interferon g	GeneOrGeneProduct	237	239	7	1:NR:2	L2R	CROSS	183-184	247-248	5447	POR	GeneOrGeneProduct	183	184	6	8519	IFITM1	GeneOrGeneProduct	247	248	7	1:NR:2	L2R	CROSS	183-184	249-250	5447	POR	GeneOrGeneProduct	183	184	6	3434	IFIT1	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	CROSS	183-184	251-252	5447	POR	GeneOrGeneProduct	183	184	6	3433	IFIT2	GeneOrGeneProduct	251	252	7	1:NR:2	L2R	CROSS	183-184	253-254	5447	POR	GeneOrGeneProduct	183	184	6	3437	IFIT3	GeneOrGeneProduct	253	254	7	1:NR:2	L2R	CROSS	183-184	267-268	5447	POR	GeneOrGeneProduct	183	184	6	7098	TLR3	GeneOrGeneProduct	267	268	7	1:NR:2	L2R	CROSS	183-184	269-270	5447	POR	GeneOrGeneProduct	183	184	6	4843	NOS2	GeneOrGeneProduct	269	270	7	1:NR:2	L2R	CROSS	183-184	272-273	5447	POR	GeneOrGeneProduct	183	184	6	3934	LCN2	GeneOrGeneProduct	272	273	7	1:NR:2	L2R	CROSS	183-184	322-323	5447	POR	GeneOrGeneProduct	183	184	6	D007249	inflammation|inflammatory	DiseaseOrPhenotypicFeature	322:427	323:428	9:12	1:NR:2	L2R	CROSS	183-184	363-364	5447	POR	GeneOrGeneProduct	183	184	6	25987	TSKU	GeneOrGeneProduct	363	364	10	1:NR:2	L2R	CROSS	183-184	365-366	5447	POR	GeneOrGeneProduct	183	184	6	54509	RHOF	GeneOrGeneProduct	365	366	10	1:NR:2	L2R	CROSS	183-184	367-368	5447	POR	GeneOrGeneProduct	183	184	6	771	CA12	GeneOrGeneProduct	367	368	10	1:NR:2	L2R	CROSS	183-184	369-370	5447	POR	GeneOrGeneProduct	183	184	6	147645	VSIG10L	GeneOrGeneProduct	369	370	10	1:NR:2	L2R	CROSS	183-184	441-447	5447	POR	GeneOrGeneProduct	183	184	6	D065626	non - alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	441	447	12	1:NR:2	L2R	NON-CROSS	185-186	187-188	1244	ABCC2	GeneOrGeneProduct	185	186	6	1577	CYP3A5	GeneOrGeneProduct	187	188	6	1:NR:2	L2R	CROSS	185-186	220-221	1244	ABCC2	GeneOrGeneProduct	185	186	6	4283,6355,6372,6376	chemokines	GeneOrGeneProduct	220	221	7	1:NR:2	L2R	CROSS	185-186	226-229	1244	ABCC2	GeneOrGeneProduct	185	186	6	4283	CXCL9 - 11	GeneOrGeneProduct	226	229	7	1:NR:2	L2R	CROSS	185-186	230-231	1244	ABCC2	GeneOrGeneProduct	185	186	6	6355	CCL8	GeneOrGeneProduct	230	231	7	1:NR:2	L2R	CROSS	185-186	232-233	1244	ABCC2	GeneOrGeneProduct	185	186	6	6376	CX3CL1	GeneOrGeneProduct	232	233	7	1:NR:2	L2R	CROSS	185-186	234-235	1244	ABCC2	GeneOrGeneProduct	185	186	6	6372	CXCL6	GeneOrGeneProduct	234	235	7	1:NR:2	L2R	CROSS	185-186	237-239	1244	ABCC2	GeneOrGeneProduct	185	186	6	3458	interferon g	GeneOrGeneProduct	237	239	7	1:NR:2	L2R	CROSS	185-186	247-248	1244	ABCC2	GeneOrGeneProduct	185	186	6	8519	IFITM1	GeneOrGeneProduct	247	248	7	1:NR:2	L2R	CROSS	185-186	249-250	1244	ABCC2	GeneOrGeneProduct	185	186	6	3434	IFIT1	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	CROSS	185-186	251-252	1244	ABCC2	GeneOrGeneProduct	185	186	6	3433	IFIT2	GeneOrGeneProduct	251	252	7	1:NR:2	L2R	CROSS	185-186	253-254	1244	ABCC2	GeneOrGeneProduct	185	186	6	3437	IFIT3	GeneOrGeneProduct	253	254	7	1:NR:2	L2R	CROSS	185-186	267-268	1244	ABCC2	GeneOrGeneProduct	185	186	6	7098	TLR3	GeneOrGeneProduct	267	268	7	1:NR:2	L2R	CROSS	185-186	269-270	1244	ABCC2	GeneOrGeneProduct	185	186	6	4843	NOS2	GeneOrGeneProduct	269	270	7	1:NR:2	L2R	CROSS	185-186	272-273	1244	ABCC2	GeneOrGeneProduct	185	186	6	3934	LCN2	GeneOrGeneProduct	272	273	7	1:NR:2	L2R	CROSS	185-186	322-323	1244	ABCC2	GeneOrGeneProduct	185	186	6	D007249	inflammation|inflammatory	DiseaseOrPhenotypicFeature	322:427	323:428	9:12	1:NR:2	L2R	CROSS	185-186	363-364	1244	ABCC2	GeneOrGeneProduct	185	186	6	25987	TSKU	GeneOrGeneProduct	363	364	10	1:NR:2	L2R	CROSS	185-186	365-366	1244	ABCC2	GeneOrGeneProduct	185	186	6	54509	RHOF	GeneOrGeneProduct	365	366	10	1:NR:2	L2R	CROSS	185-186	367-368	1244	ABCC2	GeneOrGeneProduct	185	186	6	771	CA12	GeneOrGeneProduct	367	368	10	1:NR:2	L2R	CROSS	185-186	369-370	1244	ABCC2	GeneOrGeneProduct	185	186	6	147645	VSIG10L	GeneOrGeneProduct	369	370	10	1:NR:2	L2R	CROSS	185-186	441-447	1244	ABCC2	GeneOrGeneProduct	185	186	6	D065626	non - alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	441	447	12	1:NR:2	L2R	CROSS	187-188	220-221	1577	CYP3A5	GeneOrGeneProduct	187	188	6	4283,6355,6372,6376	chemokines	GeneOrGeneProduct	220	221	7	1:NR:2	L2R	CROSS	187-188	226-229	1577	CYP3A5	GeneOrGeneProduct	187	188	6	4283	CXCL9 - 11	GeneOrGeneProduct	226	229	7	1:NR:2	L2R	CROSS	187-188	230-231	1577	CYP3A5	GeneOrGeneProduct	187	188	6	6355	CCL8	GeneOrGeneProduct	230	231	7	1:NR:2	L2R	CROSS	187-188	232-233	1577	CYP3A5	GeneOrGeneProduct	187	188	6	6376	CX3CL1	GeneOrGeneProduct	232	233	7	1:NR:2	L2R	CROSS	187-188	234-235	1577	CYP3A5	GeneOrGeneProduct	187	188	6	6372	CXCL6	GeneOrGeneProduct	234	235	7	1:NR:2	L2R	CROSS	187-188	237-239	1577	CYP3A5	GeneOrGeneProduct	187	188	6	3458	interferon g	GeneOrGeneProduct	237	239	7	1:NR:2	L2R	CROSS	187-188	247-248	1577	CYP3A5	GeneOrGeneProduct	187	188	6	8519	IFITM1	GeneOrGeneProduct	247	248	7	1:NR:2	L2R	CROSS	187-188	249-250	1577	CYP3A5	GeneOrGeneProduct	187	188	6	3434	IFIT1	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	CROSS	187-188	251-252	1577	CYP3A5	GeneOrGeneProduct	187	188	6	3433	IFIT2	GeneOrGeneProduct	251	252	7	1:NR:2	L2R	CROSS	187-188	253-254	1577	CYP3A5	GeneOrGeneProduct	187	188	6	3437	IFIT3	GeneOrGeneProduct	253	254	7	1:NR:2	L2R	CROSS	187-188	267-268	1577	CYP3A5	GeneOrGeneProduct	187	188	6	7098	TLR3	GeneOrGeneProduct	267	268	7	1:NR:2	L2R	CROSS	187-188	269-270	1577	CYP3A5	GeneOrGeneProduct	187	188	6	4843	NOS2	GeneOrGeneProduct	269	270	7	1:NR:2	L2R	CROSS	187-188	272-273	1577	CYP3A5	GeneOrGeneProduct	187	188	6	3934	LCN2	GeneOrGeneProduct	272	273	7	1:NR:2	L2R	CROSS	187-188	322-323	1577	CYP3A5	GeneOrGeneProduct	187	188	6	D007249	inflammation|inflammatory	DiseaseOrPhenotypicFeature	322:427	323:428	9:12	1:NR:2	L2R	CROSS	187-188	363-364	1577	CYP3A5	GeneOrGeneProduct	187	188	6	25987	TSKU	GeneOrGeneProduct	363	364	10	1:NR:2	L2R	CROSS	187-188	365-366	1577	CYP3A5	GeneOrGeneProduct	187	188	6	54509	RHOF	GeneOrGeneProduct	365	366	10	1:NR:2	L2R	CROSS	187-188	367-368	1577	CYP3A5	GeneOrGeneProduct	187	188	6	771	CA12	GeneOrGeneProduct	367	368	10	1:NR:2	L2R	CROSS	187-188	369-370	1577	CYP3A5	GeneOrGeneProduct	187	188	6	147645	VSIG10L	GeneOrGeneProduct	369	370	10	1:NR:2	L2R	CROSS	187-188	441-447	1577	CYP3A5	GeneOrGeneProduct	187	188	6	D065626	non - alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	441	447	12	1:NR:2	L2R	NON-CROSS	220-221	226-229	4283,6355,6372,6376	chemokines	GeneOrGeneProduct	220	221	7	4283	CXCL9 - 11	GeneOrGeneProduct	226	229	7	1:NR:2	L2R	NON-CROSS	220-221	230-231	4283,6355,6372,6376	chemokines	GeneOrGeneProduct	220	221	7	6355	CCL8	GeneOrGeneProduct	230	231	7	1:NR:2	L2R	NON-CROSS	220-221	232-233	4283,6355,6372,6376	chemokines	GeneOrGeneProduct	220	221	7	6376	CX3CL1	GeneOrGeneProduct	232	233	7	1:NR:2	L2R	NON-CROSS	220-221	234-235	4283,6355,6372,6376	chemokines	GeneOrGeneProduct	220	221	7	6372	CXCL6	GeneOrGeneProduct	234	235	7	1:NR:2	L2R	NON-CROSS	220-221	237-239	4283,6355,6372,6376	chemokines	GeneOrGeneProduct	220	221	7	3458	interferon g	GeneOrGeneProduct	237	239	7	1:NR:2	L2R	NON-CROSS	220-221	247-248	4283,6355,6372,6376	chemokines	GeneOrGeneProduct	220	221	7	8519	IFITM1	GeneOrGeneProduct	247	248	7	1:NR:2	L2R	NON-CROSS	220-221	249-250	4283,6355,6372,6376	chemokines	GeneOrGeneProduct	220	221	7	3434	IFIT1	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	NON-CROSS	220-221	251-252	4283,6355,6372,6376	chemokines	GeneOrGeneProduct	220	221	7	3433	IFIT2	GeneOrGeneProduct	251	252	7	1:NR:2	L2R	NON-CROSS	220-221	253-254	4283,6355,6372,6376	chemokines	GeneOrGeneProduct	220	221	7	3437	IFIT3	GeneOrGeneProduct	253	254	7	1:NR:2	L2R	NON-CROSS	220-221	267-268	4283,6355,6372,6376	chemokines	GeneOrGeneProduct	220	221	7	7098	TLR3	GeneOrGeneProduct	267	268	7	1:NR:2	L2R	NON-CROSS	220-221	269-270	4283,6355,6372,6376	chemokines	GeneOrGeneProduct	220	221	7	4843	NOS2	GeneOrGeneProduct	269	270	7	1:NR:2	L2R	NON-CROSS	220-221	272-273	4283,6355,6372,6376	chemokines	GeneOrGeneProduct	220	221	7	3934	LCN2	GeneOrGeneProduct	272	273	7	1:NR:2	L2R	CROSS	220-221	322-323	4283,6355,6372,6376	chemokines	GeneOrGeneProduct	220	221	7	D007249	inflammation|inflammatory	DiseaseOrPhenotypicFeature	322:427	323:428	9:12	1:NR:2	L2R	CROSS	220-221	363-364	4283,6355,6372,6376	chemokines	GeneOrGeneProduct	220	221	7	25987	TSKU	GeneOrGeneProduct	363	364	10	1:NR:2	L2R	CROSS	220-221	365-366	4283,6355,6372,6376	chemokines	GeneOrGeneProduct	220	221	7	54509	RHOF	GeneOrGeneProduct	365	366	10	1:NR:2	L2R	CROSS	220-221	367-368	4283,6355,6372,6376	chemokines	GeneOrGeneProduct	220	221	7	771	CA12	GeneOrGeneProduct	367	368	10	1:NR:2	L2R	CROSS	220-221	369-370	4283,6355,6372,6376	chemokines	GeneOrGeneProduct	220	221	7	147645	VSIG10L	GeneOrGeneProduct	369	370	10	1:NR:2	L2R	CROSS	220-221	441-447	4283,6355,6372,6376	chemokines	GeneOrGeneProduct	220	221	7	D065626	non - alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	441	447	12	1:NR:2	L2R	NON-CROSS	226-229	230-231	4283	CXCL9 - 11	GeneOrGeneProduct	226	229	7	6355	CCL8	GeneOrGeneProduct	230	231	7	1:NR:2	L2R	NON-CROSS	226-229	232-233	4283	CXCL9 - 11	GeneOrGeneProduct	226	229	7	6376	CX3CL1	GeneOrGeneProduct	232	233	7	1:NR:2	L2R	NON-CROSS	226-229	234-235	4283	CXCL9 - 11	GeneOrGeneProduct	226	229	7	6372	CXCL6	GeneOrGeneProduct	234	235	7	1:NR:2	L2R	NON-CROSS	226-229	237-239	4283	CXCL9 - 11	GeneOrGeneProduct	226	229	7	3458	interferon g	GeneOrGeneProduct	237	239	7	1:NR:2	L2R	NON-CROSS	226-229	247-248	4283	CXCL9 - 11	GeneOrGeneProduct	226	229	7	8519	IFITM1	GeneOrGeneProduct	247	248	7	1:NR:2	L2R	NON-CROSS	226-229	249-250	4283	CXCL9 - 11	GeneOrGeneProduct	226	229	7	3434	IFIT1	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	NON-CROSS	226-229	251-252	4283	CXCL9 - 11	GeneOrGeneProduct	226	229	7	3433	IFIT2	GeneOrGeneProduct	251	252	7	1:NR:2	L2R	NON-CROSS	226-229	253-254	4283	CXCL9 - 11	GeneOrGeneProduct	226	229	7	3437	IFIT3	GeneOrGeneProduct	253	254	7	1:NR:2	L2R	NON-CROSS	226-229	267-268	4283	CXCL9 - 11	GeneOrGeneProduct	226	229	7	7098	TLR3	GeneOrGeneProduct	267	268	7	1:NR:2	L2R	NON-CROSS	226-229	269-270	4283	CXCL9 - 11	GeneOrGeneProduct	226	229	7	4843	NOS2	GeneOrGeneProduct	269	270	7	1:NR:2	L2R	NON-CROSS	226-229	272-273	4283	CXCL9 - 11	GeneOrGeneProduct	226	229	7	3934	LCN2	GeneOrGeneProduct	272	273	7	1:NR:2	L2R	CROSS	226-229	322-323	4283	CXCL9 - 11	GeneOrGeneProduct	226	229	7	D007249	inflammation|inflammatory	DiseaseOrPhenotypicFeature	322:427	323:428	9:12	1:NR:2	L2R	CROSS	226-229	363-364	4283	CXCL9 - 11	GeneOrGeneProduct	226	229	7	25987	TSKU	GeneOrGeneProduct	363	364	10	1:NR:2	L2R	CROSS	226-229	365-366	4283	CXCL9 - 11	GeneOrGeneProduct	226	229	7	54509	RHOF	GeneOrGeneProduct	365	366	10	1:NR:2	L2R	CROSS	226-229	367-368	4283	CXCL9 - 11	GeneOrGeneProduct	226	229	7	771	CA12	GeneOrGeneProduct	367	368	10	1:NR:2	L2R	CROSS	226-229	369-370	4283	CXCL9 - 11	GeneOrGeneProduct	226	229	7	147645	VSIG10L	GeneOrGeneProduct	369	370	10	1:NR:2	L2R	CROSS	226-229	441-447	4283	CXCL9 - 11	GeneOrGeneProduct	226	229	7	D065626	non - alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	441	447	12	1:NR:2	L2R	NON-CROSS	230-231	232-233	6355	CCL8	GeneOrGeneProduct	230	231	7	6376	CX3CL1	GeneOrGeneProduct	232	233	7	1:NR:2	L2R	NON-CROSS	230-231	234-235	6355	CCL8	GeneOrGeneProduct	230	231	7	6372	CXCL6	GeneOrGeneProduct	234	235	7	1:NR:2	L2R	NON-CROSS	230-231	237-239	6355	CCL8	GeneOrGeneProduct	230	231	7	3458	interferon g	GeneOrGeneProduct	237	239	7	1:NR:2	L2R	NON-CROSS	230-231	247-248	6355	CCL8	GeneOrGeneProduct	230	231	7	8519	IFITM1	GeneOrGeneProduct	247	248	7	1:NR:2	L2R	NON-CROSS	230-231	249-250	6355	CCL8	GeneOrGeneProduct	230	231	7	3434	IFIT1	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	NON-CROSS	230-231	251-252	6355	CCL8	GeneOrGeneProduct	230	231	7	3433	IFIT2	GeneOrGeneProduct	251	252	7	1:NR:2	L2R	NON-CROSS	230-231	253-254	6355	CCL8	GeneOrGeneProduct	230	231	7	3437	IFIT3	GeneOrGeneProduct	253	254	7	1:NR:2	L2R	NON-CROSS	230-231	267-268	6355	CCL8	GeneOrGeneProduct	230	231	7	7098	TLR3	GeneOrGeneProduct	267	268	7	1:NR:2	L2R	NON-CROSS	230-231	269-270	6355	CCL8	GeneOrGeneProduct	230	231	7	4843	NOS2	GeneOrGeneProduct	269	270	7	1:NR:2	L2R	NON-CROSS	230-231	272-273	6355	CCL8	GeneOrGeneProduct	230	231	7	3934	LCN2	GeneOrGeneProduct	272	273	7	1:NR:2	L2R	CROSS	230-231	322-323	6355	CCL8	GeneOrGeneProduct	230	231	7	D007249	inflammation|inflammatory	DiseaseOrPhenotypicFeature	322:427	323:428	9:12	1:NR:2	L2R	CROSS	230-231	363-364	6355	CCL8	GeneOrGeneProduct	230	231	7	25987	TSKU	GeneOrGeneProduct	363	364	10	1:NR:2	L2R	CROSS	230-231	365-366	6355	CCL8	GeneOrGeneProduct	230	231	7	54509	RHOF	GeneOrGeneProduct	365	366	10	1:NR:2	L2R	CROSS	230-231	367-368	6355	CCL8	GeneOrGeneProduct	230	231	7	771	CA12	GeneOrGeneProduct	367	368	10	1:NR:2	L2R	CROSS	230-231	369-370	6355	CCL8	GeneOrGeneProduct	230	231	7	147645	VSIG10L	GeneOrGeneProduct	369	370	10	1:NR:2	L2R	CROSS	230-231	441-447	6355	CCL8	GeneOrGeneProduct	230	231	7	D065626	non - alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	441	447	12	1:NR:2	L2R	NON-CROSS	232-233	234-235	6376	CX3CL1	GeneOrGeneProduct	232	233	7	6372	CXCL6	GeneOrGeneProduct	234	235	7	1:NR:2	L2R	NON-CROSS	232-233	237-239	6376	CX3CL1	GeneOrGeneProduct	232	233	7	3458	interferon g	GeneOrGeneProduct	237	239	7	1:NR:2	L2R	NON-CROSS	232-233	247-248	6376	CX3CL1	GeneOrGeneProduct	232	233	7	8519	IFITM1	GeneOrGeneProduct	247	248	7	1:NR:2	L2R	NON-CROSS	232-233	249-250	6376	CX3CL1	GeneOrGeneProduct	232	233	7	3434	IFIT1	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	NON-CROSS	232-233	251-252	6376	CX3CL1	GeneOrGeneProduct	232	233	7	3433	IFIT2	GeneOrGeneProduct	251	252	7	1:NR:2	L2R	NON-CROSS	232-233	253-254	6376	CX3CL1	GeneOrGeneProduct	232	233	7	3437	IFIT3	GeneOrGeneProduct	253	254	7	1:NR:2	L2R	NON-CROSS	232-233	267-268	6376	CX3CL1	GeneOrGeneProduct	232	233	7	7098	TLR3	GeneOrGeneProduct	267	268	7	1:NR:2	L2R	NON-CROSS	232-233	269-270	6376	CX3CL1	GeneOrGeneProduct	232	233	7	4843	NOS2	GeneOrGeneProduct	269	270	7	1:NR:2	L2R	NON-CROSS	232-233	272-273	6376	CX3CL1	GeneOrGeneProduct	232	233	7	3934	LCN2	GeneOrGeneProduct	272	273	7	1:NR:2	L2R	CROSS	232-233	322-323	6376	CX3CL1	GeneOrGeneProduct	232	233	7	D007249	inflammation|inflammatory	DiseaseOrPhenotypicFeature	322:427	323:428	9:12	1:NR:2	L2R	CROSS	232-233	363-364	6376	CX3CL1	GeneOrGeneProduct	232	233	7	25987	TSKU	GeneOrGeneProduct	363	364	10	1:NR:2	L2R	CROSS	232-233	365-366	6376	CX3CL1	GeneOrGeneProduct	232	233	7	54509	RHOF	GeneOrGeneProduct	365	366	10	1:NR:2	L2R	CROSS	232-233	367-368	6376	CX3CL1	GeneOrGeneProduct	232	233	7	771	CA12	GeneOrGeneProduct	367	368	10	1:NR:2	L2R	CROSS	232-233	369-370	6376	CX3CL1	GeneOrGeneProduct	232	233	7	147645	VSIG10L	GeneOrGeneProduct	369	370	10	1:NR:2	L2R	CROSS	232-233	441-447	6376	CX3CL1	GeneOrGeneProduct	232	233	7	D065626	non - alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	441	447	12	1:NR:2	L2R	NON-CROSS	234-235	237-239	6372	CXCL6	GeneOrGeneProduct	234	235	7	3458	interferon g	GeneOrGeneProduct	237	239	7	1:NR:2	L2R	NON-CROSS	234-235	247-248	6372	CXCL6	GeneOrGeneProduct	234	235	7	8519	IFITM1	GeneOrGeneProduct	247	248	7	1:NR:2	L2R	NON-CROSS	234-235	249-250	6372	CXCL6	GeneOrGeneProduct	234	235	7	3434	IFIT1	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	NON-CROSS	234-235	251-252	6372	CXCL6	GeneOrGeneProduct	234	235	7	3433	IFIT2	GeneOrGeneProduct	251	252	7	1:NR:2	L2R	NON-CROSS	234-235	253-254	6372	CXCL6	GeneOrGeneProduct	234	235	7	3437	IFIT3	GeneOrGeneProduct	253	254	7	1:NR:2	L2R	NON-CROSS	234-235	267-268	6372	CXCL6	GeneOrGeneProduct	234	235	7	7098	TLR3	GeneOrGeneProduct	267	268	7	1:NR:2	L2R	NON-CROSS	234-235	269-270	6372	CXCL6	GeneOrGeneProduct	234	235	7	4843	NOS2	GeneOrGeneProduct	269	270	7	1:NR:2	L2R	NON-CROSS	234-235	272-273	6372	CXCL6	GeneOrGeneProduct	234	235	7	3934	LCN2	GeneOrGeneProduct	272	273	7	1:NR:2	L2R	CROSS	234-235	322-323	6372	CXCL6	GeneOrGeneProduct	234	235	7	D007249	inflammation|inflammatory	DiseaseOrPhenotypicFeature	322:427	323:428	9:12	1:NR:2	L2R	CROSS	234-235	363-364	6372	CXCL6	GeneOrGeneProduct	234	235	7	25987	TSKU	GeneOrGeneProduct	363	364	10	1:NR:2	L2R	CROSS	234-235	365-366	6372	CXCL6	GeneOrGeneProduct	234	235	7	54509	RHOF	GeneOrGeneProduct	365	366	10	1:NR:2	L2R	CROSS	234-235	367-368	6372	CXCL6	GeneOrGeneProduct	234	235	7	771	CA12	GeneOrGeneProduct	367	368	10	1:NR:2	L2R	CROSS	234-235	369-370	6372	CXCL6	GeneOrGeneProduct	234	235	7	147645	VSIG10L	GeneOrGeneProduct	369	370	10	1:NR:2	L2R	CROSS	234-235	441-447	6372	CXCL6	GeneOrGeneProduct	234	235	7	D065626	non - alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	441	447	12	1:Positive_Correlation:2	L2R	NON-CROSS	237-239	247-248	3458	interferon g	GeneOrGeneProduct	237	239	7	8519	IFITM1	GeneOrGeneProduct	247	248	7	1:Positive_Correlation:2	L2R	NON-CROSS	237-239	249-250	3458	interferon g	GeneOrGeneProduct	237	239	7	3434	IFIT1	GeneOrGeneProduct	249	250	7	1:Positive_Correlation:2	L2R	NON-CROSS	237-239	251-252	3458	interferon g	GeneOrGeneProduct	237	239	7	3433	IFIT2	GeneOrGeneProduct	251	252	7	1:Positive_Correlation:2	L2R	NON-CROSS	237-239	253-254	3458	interferon g	GeneOrGeneProduct	237	239	7	3437	IFIT3	GeneOrGeneProduct	253	254	7	1:NR:2	L2R	NON-CROSS	237-239	267-268	3458	interferon g	GeneOrGeneProduct	237	239	7	7098	TLR3	GeneOrGeneProduct	267	268	7	1:NR:2	L2R	NON-CROSS	237-239	269-270	3458	interferon g	GeneOrGeneProduct	237	239	7	4843	NOS2	GeneOrGeneProduct	269	270	7	1:NR:2	L2R	NON-CROSS	237-239	272-273	3458	interferon g	GeneOrGeneProduct	237	239	7	3934	LCN2	GeneOrGeneProduct	272	273	7	1:NR:2	L2R	CROSS	237-239	322-323	3458	interferon g	GeneOrGeneProduct	237	239	7	D007249	inflammation|inflammatory	DiseaseOrPhenotypicFeature	322:427	323:428	9:12	1:NR:2	L2R	CROSS	237-239	363-364	3458	interferon g	GeneOrGeneProduct	237	239	7	25987	TSKU	GeneOrGeneProduct	363	364	10	1:NR:2	L2R	CROSS	237-239	365-366	3458	interferon g	GeneOrGeneProduct	237	239	7	54509	RHOF	GeneOrGeneProduct	365	366	10	1:NR:2	L2R	CROSS	237-239	367-368	3458	interferon g	GeneOrGeneProduct	237	239	7	771	CA12	GeneOrGeneProduct	367	368	10	1:NR:2	L2R	CROSS	237-239	369-370	3458	interferon g	GeneOrGeneProduct	237	239	7	147645	VSIG10L	GeneOrGeneProduct	369	370	10	1:NR:2	L2R	CROSS	237-239	441-447	3458	interferon g	GeneOrGeneProduct	237	239	7	D065626	non - alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	441	447	12	1:NR:2	L2R	NON-CROSS	247-248	249-250	8519	IFITM1	GeneOrGeneProduct	247	248	7	3434	IFIT1	GeneOrGeneProduct	249	250	7	1:NR:2	L2R	NON-CROSS	247-248	251-252	8519	IFITM1	GeneOrGeneProduct	247	248	7	3433	IFIT2	GeneOrGeneProduct	251	252	7	1:NR:2	L2R	NON-CROSS	247-248	253-254	8519	IFITM1	GeneOrGeneProduct	247	248	7	3437	IFIT3	GeneOrGeneProduct	253	254	7	1:NR:2	L2R	NON-CROSS	247-248	267-268	8519	IFITM1	GeneOrGeneProduct	247	248	7	7098	TLR3	GeneOrGeneProduct	267	268	7	1:NR:2	L2R	NON-CROSS	247-248	269-270	8519	IFITM1	GeneOrGeneProduct	247	248	7	4843	NOS2	GeneOrGeneProduct	269	270	7	1:NR:2	L2R	NON-CROSS	247-248	272-273	8519	IFITM1	GeneOrGeneProduct	247	248	7	3934	LCN2	GeneOrGeneProduct	272	273	7	1:NR:2	L2R	CROSS	247-248	322-323	8519	IFITM1	GeneOrGeneProduct	247	248	7	D007249	inflammation|inflammatory	DiseaseOrPhenotypicFeature	322:427	323:428	9:12	1:NR:2	L2R	CROSS	247-248	363-364	8519	IFITM1	GeneOrGeneProduct	247	248	7	25987	TSKU	GeneOrGeneProduct	363	364	10	1:NR:2	L2R	CROSS	247-248	365-366	8519	IFITM1	GeneOrGeneProduct	247	248	7	54509	RHOF	GeneOrGeneProduct	365	366	10	1:NR:2	L2R	CROSS	247-248	367-368	8519	IFITM1	GeneOrGeneProduct	247	248	7	771	CA12	GeneOrGeneProduct	367	368	10	1:NR:2	L2R	CROSS	247-248	369-370	8519	IFITM1	GeneOrGeneProduct	247	248	7	147645	VSIG10L	GeneOrGeneProduct	369	370	10	1:NR:2	L2R	CROSS	247-248	441-447	8519	IFITM1	GeneOrGeneProduct	247	248	7	D065626	non - alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	441	447	12	1:NR:2	L2R	NON-CROSS	249-250	251-252	3434	IFIT1	GeneOrGeneProduct	249	250	7	3433	IFIT2	GeneOrGeneProduct	251	252	7	1:NR:2	L2R	NON-CROSS	249-250	253-254	3434	IFIT1	GeneOrGeneProduct	249	250	7	3437	IFIT3	GeneOrGeneProduct	253	254	7	1:NR:2	L2R	NON-CROSS	249-250	267-268	3434	IFIT1	GeneOrGeneProduct	249	250	7	7098	TLR3	GeneOrGeneProduct	267	268	7	1:NR:2	L2R	NON-CROSS	249-250	269-270	3434	IFIT1	GeneOrGeneProduct	249	250	7	4843	NOS2	GeneOrGeneProduct	269	270	7	1:NR:2	L2R	NON-CROSS	249-250	272-273	3434	IFIT1	GeneOrGeneProduct	249	250	7	3934	LCN2	GeneOrGeneProduct	272	273	7	1:NR:2	L2R	CROSS	249-250	322-323	3434	IFIT1	GeneOrGeneProduct	249	250	7	D007249	inflammation|inflammatory	DiseaseOrPhenotypicFeature	322:427	323:428	9:12	1:NR:2	L2R	CROSS	249-250	363-364	3434	IFIT1	GeneOrGeneProduct	249	250	7	25987	TSKU	GeneOrGeneProduct	363	364	10	1:NR:2	L2R	CROSS	249-250	365-366	3434	IFIT1	GeneOrGeneProduct	249	250	7	54509	RHOF	GeneOrGeneProduct	365	366	10	1:NR:2	L2R	CROSS	249-250	367-368	3434	IFIT1	GeneOrGeneProduct	249	250	7	771	CA12	GeneOrGeneProduct	367	368	10	1:NR:2	L2R	CROSS	249-250	369-370	3434	IFIT1	GeneOrGeneProduct	249	250	7	147645	VSIG10L	GeneOrGeneProduct	369	370	10	1:NR:2	L2R	CROSS	249-250	441-447	3434	IFIT1	GeneOrGeneProduct	249	250	7	D065626	non - alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	441	447	12	1:NR:2	L2R	NON-CROSS	251-252	253-254	3433	IFIT2	GeneOrGeneProduct	251	252	7	3437	IFIT3	GeneOrGeneProduct	253	254	7	1:NR:2	L2R	NON-CROSS	251-252	267-268	3433	IFIT2	GeneOrGeneProduct	251	252	7	7098	TLR3	GeneOrGeneProduct	267	268	7	1:NR:2	L2R	NON-CROSS	251-252	269-270	3433	IFIT2	GeneOrGeneProduct	251	252	7	4843	NOS2	GeneOrGeneProduct	269	270	7	1:NR:2	L2R	NON-CROSS	251-252	272-273	3433	IFIT2	GeneOrGeneProduct	251	252	7	3934	LCN2	GeneOrGeneProduct	272	273	7	1:NR:2	L2R	CROSS	251-252	322-323	3433	IFIT2	GeneOrGeneProduct	251	252	7	D007249	inflammation|inflammatory	DiseaseOrPhenotypicFeature	322:427	323:428	9:12	1:NR:2	L2R	CROSS	251-252	363-364	3433	IFIT2	GeneOrGeneProduct	251	252	7	25987	TSKU	GeneOrGeneProduct	363	364	10	1:NR:2	L2R	CROSS	251-252	365-366	3433	IFIT2	GeneOrGeneProduct	251	252	7	54509	RHOF	GeneOrGeneProduct	365	366	10	1:NR:2	L2R	CROSS	251-252	367-368	3433	IFIT2	GeneOrGeneProduct	251	252	7	771	CA12	GeneOrGeneProduct	367	368	10	1:NR:2	L2R	CROSS	251-252	369-370	3433	IFIT2	GeneOrGeneProduct	251	252	7	147645	VSIG10L	GeneOrGeneProduct	369	370	10	1:NR:2	L2R	CROSS	251-252	441-447	3433	IFIT2	GeneOrGeneProduct	251	252	7	D065626	non - alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	441	447	12	1:NR:2	L2R	NON-CROSS	253-254	267-268	3437	IFIT3	GeneOrGeneProduct	253	254	7	7098	TLR3	GeneOrGeneProduct	267	268	7	1:NR:2	L2R	NON-CROSS	253-254	269-270	3437	IFIT3	GeneOrGeneProduct	253	254	7	4843	NOS2	GeneOrGeneProduct	269	270	7	1:NR:2	L2R	NON-CROSS	253-254	272-273	3437	IFIT3	GeneOrGeneProduct	253	254	7	3934	LCN2	GeneOrGeneProduct	272	273	7	1:NR:2	L2R	CROSS	253-254	322-323	3437	IFIT3	GeneOrGeneProduct	253	254	7	D007249	inflammation|inflammatory	DiseaseOrPhenotypicFeature	322:427	323:428	9:12	1:NR:2	L2R	CROSS	253-254	363-364	3437	IFIT3	GeneOrGeneProduct	253	254	7	25987	TSKU	GeneOrGeneProduct	363	364	10	1:NR:2	L2R	CROSS	253-254	365-366	3437	IFIT3	GeneOrGeneProduct	253	254	7	54509	RHOF	GeneOrGeneProduct	365	366	10	1:NR:2	L2R	CROSS	253-254	367-368	3437	IFIT3	GeneOrGeneProduct	253	254	7	771	CA12	GeneOrGeneProduct	367	368	10	1:NR:2	L2R	CROSS	253-254	369-370	3437	IFIT3	GeneOrGeneProduct	253	254	7	147645	VSIG10L	GeneOrGeneProduct	369	370	10	1:NR:2	L2R	CROSS	253-254	441-447	3437	IFIT3	GeneOrGeneProduct	253	254	7	D065626	non - alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	441	447	12	1:NR:2	L2R	NON-CROSS	267-268	269-270	7098	TLR3	GeneOrGeneProduct	267	268	7	4843	NOS2	GeneOrGeneProduct	269	270	7	1:NR:2	L2R	NON-CROSS	267-268	272-273	7098	TLR3	GeneOrGeneProduct	267	268	7	3934	LCN2	GeneOrGeneProduct	272	273	7	1:NR:2	L2R	CROSS	267-268	322-323	7098	TLR3	GeneOrGeneProduct	267	268	7	D007249	inflammation|inflammatory	DiseaseOrPhenotypicFeature	322:427	323:428	9:12	1:NR:2	L2R	CROSS	267-268	363-364	7098	TLR3	GeneOrGeneProduct	267	268	7	25987	TSKU	GeneOrGeneProduct	363	364	10	1:NR:2	L2R	CROSS	267-268	365-366	7098	TLR3	GeneOrGeneProduct	267	268	7	54509	RHOF	GeneOrGeneProduct	365	366	10	1:NR:2	L2R	CROSS	267-268	367-368	7098	TLR3	GeneOrGeneProduct	267	268	7	771	CA12	GeneOrGeneProduct	367	368	10	1:NR:2	L2R	CROSS	267-268	369-370	7098	TLR3	GeneOrGeneProduct	267	268	7	147645	VSIG10L	GeneOrGeneProduct	369	370	10	1:NR:2	L2R	CROSS	267-268	441-447	7098	TLR3	GeneOrGeneProduct	267	268	7	D065626	non - alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	441	447	12	1:NR:2	L2R	NON-CROSS	269-270	272-273	4843	NOS2	GeneOrGeneProduct	269	270	7	3934	LCN2	GeneOrGeneProduct	272	273	7	1:NR:2	L2R	CROSS	269-270	322-323	4843	NOS2	GeneOrGeneProduct	269	270	7	D007249	inflammation|inflammatory	DiseaseOrPhenotypicFeature	322:427	323:428	9:12	1:NR:2	L2R	CROSS	269-270	363-364	4843	NOS2	GeneOrGeneProduct	269	270	7	25987	TSKU	GeneOrGeneProduct	363	364	10	1:NR:2	L2R	CROSS	269-270	365-366	4843	NOS2	GeneOrGeneProduct	269	270	7	54509	RHOF	GeneOrGeneProduct	365	366	10	1:NR:2	L2R	CROSS	269-270	367-368	4843	NOS2	GeneOrGeneProduct	269	270	7	771	CA12	GeneOrGeneProduct	367	368	10	1:NR:2	L2R	CROSS	269-270	369-370	4843	NOS2	GeneOrGeneProduct	269	270	7	147645	VSIG10L	GeneOrGeneProduct	369	370	10	1:NR:2	L2R	CROSS	269-270	441-447	4843	NOS2	GeneOrGeneProduct	269	270	7	D065626	non - alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	441	447	12	1:NR:2	L2R	CROSS	272-273	322-323	3934	LCN2	GeneOrGeneProduct	272	273	7	D007249	inflammation|inflammatory	DiseaseOrPhenotypicFeature	322:427	323:428	9:12	1:NR:2	L2R	CROSS	272-273	363-364	3934	LCN2	GeneOrGeneProduct	272	273	7	25987	TSKU	GeneOrGeneProduct	363	364	10	1:NR:2	L2R	CROSS	272-273	365-366	3934	LCN2	GeneOrGeneProduct	272	273	7	54509	RHOF	GeneOrGeneProduct	365	366	10	1:NR:2	L2R	CROSS	272-273	367-368	3934	LCN2	GeneOrGeneProduct	272	273	7	771	CA12	GeneOrGeneProduct	367	368	10	1:NR:2	L2R	CROSS	272-273	369-370	3934	LCN2	GeneOrGeneProduct	272	273	7	147645	VSIG10L	GeneOrGeneProduct	369	370	10	1:NR:2	L2R	CROSS	272-273	441-447	3934	LCN2	GeneOrGeneProduct	272	273	7	D065626	non - alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	441	447	12	1:NR:2	L2R	CROSS	322-323	363-364	D007249	inflammation|inflammatory	DiseaseOrPhenotypicFeature	322:427	323:428	9:12	25987	TSKU	GeneOrGeneProduct	363	364	10	1:NR:2	L2R	CROSS	322-323	365-366	D007249	inflammation|inflammatory	DiseaseOrPhenotypicFeature	322:427	323:428	9:12	54509	RHOF	GeneOrGeneProduct	365	366	10	1:NR:2	L2R	CROSS	322-323	367-368	D007249	inflammation|inflammatory	DiseaseOrPhenotypicFeature	322:427	323:428	9:12	771	CA12	GeneOrGeneProduct	367	368	10	1:NR:2	L2R	CROSS	322-323	369-370	D007249	inflammation|inflammatory	DiseaseOrPhenotypicFeature	322:427	323:428	9:12	147645	VSIG10L	GeneOrGeneProduct	369	370	10	1:NR:2	L2R	NON-CROSS	363-364	365-366	25987	TSKU	GeneOrGeneProduct	363	364	10	54509	RHOF	GeneOrGeneProduct	365	366	10	1:NR:2	L2R	NON-CROSS	363-364	367-368	25987	TSKU	GeneOrGeneProduct	363	364	10	771	CA12	GeneOrGeneProduct	367	368	10	1:NR:2	L2R	NON-CROSS	363-364	369-370	25987	TSKU	GeneOrGeneProduct	363	364	10	147645	VSIG10L	GeneOrGeneProduct	369	370	10	1:NR:2	L2R	CROSS	363-364	441-447	25987	TSKU	GeneOrGeneProduct	363	364	10	D065626	non - alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	441	447	12	1:NR:2	L2R	NON-CROSS	365-366	367-368	54509	RHOF	GeneOrGeneProduct	365	366	10	771	CA12	GeneOrGeneProduct	367	368	10	1:NR:2	L2R	NON-CROSS	365-366	369-370	54509	RHOF	GeneOrGeneProduct	365	366	10	147645	VSIG10L	GeneOrGeneProduct	369	370	10	1:NR:2	L2R	CROSS	365-366	441-447	54509	RHOF	GeneOrGeneProduct	365	366	10	D065626	non - alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	441	447	12	1:NR:2	L2R	NON-CROSS	367-368	369-370	771	CA12	GeneOrGeneProduct	367	368	10	147645	VSIG10L	GeneOrGeneProduct	369	370	10	1:NR:2	L2R	CROSS	367-368	441-447	771	CA12	GeneOrGeneProduct	367	368	10	D065626	non - alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	441	447	12	1:NR:2	L2R	CROSS	369-370	441-447	147645	VSIG10L	GeneOrGeneProduct	369	370	10	D065626	non - alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	441	447	12
28481876	Oncogenic activity of amplified miniature chromosome maintenance 8 in human malignancies .|Miniature chromosome maintenance ( MCM ) proteins play critical roles in DNA replication licensing , initiation and elongation .|MCM8 , one of the MCM proteins playing a critical role in DNA repairing and recombination , was found to have overexpression and increased DNA copy number in a variety of human malignancies .|The gain of MCM8 is associated with aggressive clinical features of several human cancers .|Increased expression of MCM8 in prostate cancer is associated with cancer recurrence .|Forced expression of MCM8 in RWPE1 cells , the immortalized but non - transformed prostate epithelial cell line , exhibited fast cell growth and transformation , while knock down of MCM8 in PC3 , DU145 and LNCaP cells induced cell growth arrest , and decreased tumour volumes and mortality of severe combined immunodeficiency mice xenografted with PC3 and DU145 cells .|MCM8 bound cyclin D1 and activated Rb protein phosphorylation by cyclin - dependent kinase 4 in vitro and in vivo .|The cyclin D1 / MCM8 interaction is required for Rb phosphorylation and S - phase entry in cancer cells .|As a result , our study showed that copy number increase and overexpression of MCM8 may play critical roles in human cancer development .	1:Association:2	L2R	NON-CROSS	10-11	12-15	84515	miniature chromosome maintenance 8|Miniature chromosome maintenance|MCM|MCM8|MCM|MCM8|MCM8|MCM8|MCM8|MCM8|MCM8|MCM8	GeneOrGeneProduct	4:12:16:31:36:68:83:96:123:154:179:209	8:15:17:32:37:69:84:97:124:155:180:210	0:1:1:2:2:3:4:5:5:6:7:8	D009369	malignancies|malignancies|cancers|cancer|tumour|cancer|cancer	DiseaseOrPhenotypicFeature	10:63:78:90:138:192:216	11:64:79:91:139:193:217	0:2:3:4:5:7:8	1:Association:2	L2R	NON-CROSS	83-84	85-87	84515	miniature chromosome maintenance 8|Miniature chromosome maintenance|MCM|MCM8|MCM|MCM8|MCM8|MCM8|MCM8|MCM8|MCM8|MCM8	GeneOrGeneProduct	4:12:16:31:36:68:83:96:123:154:179:209	8:15:17:32:37:69:84:97:124:155:180:210	0:1:1:2:2:3:4:5:5:6:7:8	D011471	prostate cancer	DiseaseOrPhenotypicFeature	85	87	4	1:Association:2	L2R	NON-CROSS	145-146	154-155	84515	miniature chromosome maintenance 8|Miniature chromosome maintenance|MCM|MCM8|MCM|MCM8|MCM8|MCM8|MCM8|MCM8|MCM8|MCM8	GeneOrGeneProduct	4:12:16:31:36:68:83:96:123:154:179:209	8:15:17:32:37:69:84:97:124:155:180:210	0:1:1:2:2:3:4:5:5:6:7:8	D007153	immunodeficiency	DiseaseOrPhenotypicFeature	145	146	5	1:Bind:2	L2R	NON-CROSS	154-155	156-158	84515	miniature chromosome maintenance 8|Miniature chromosome maintenance|MCM|MCM8|MCM|MCM8|MCM8|MCM8|MCM8|MCM8|MCM8|MCM8	GeneOrGeneProduct	4:12:16:31:36:68:83:96:123:154:179:209	8:15:17:32:37:69:84:97:124:155:180:210	0:1:1:2:2:3:4:5:5:6:7:8	595	cyclin D1|cyclin D1	GeneOrGeneProduct	156:176	158:178	6:7	1:Association:2	L2R	NON-CROSS	179-180	184-185	84515	miniature chromosome maintenance 8|Miniature chromosome maintenance|MCM|MCM8|MCM|MCM8|MCM8|MCM8|MCM8|MCM8|MCM8|MCM8	GeneOrGeneProduct	4:12:16:31:36:68:83:96:123:154:179:209	8:15:17:32:37:69:84:97:124:155:180:210	0:1:1:2:2:3:4:5:5:6:7:8	5925	Rb|Rb	GeneOrGeneProduct	160:184	161:185	6:7	1:Association:2	L2R	NON-CROSS	154-155	164-169	84515	miniature chromosome maintenance 8|Miniature chromosome maintenance|MCM|MCM8|MCM|MCM8|MCM8|MCM8|MCM8|MCM8|MCM8|MCM8	GeneOrGeneProduct	4:12:16:31:36:68:83:96:123:154:179:209	8:15:17:32:37:69:84:97:124:155:180:210	0:1:1:2:2:3:4:5:5:6:7:8	1019	cyclin - dependent kinase 4	GeneOrGeneProduct	164	169	6	1:NR:2	L2R	NON-CROSS	176-178	192-193	D009369	malignancies|malignancies|cancers|cancer|tumour|cancer|cancer	DiseaseOrPhenotypicFeature	10:63:78:90:138:192:216	11:64:79:91:139:193:217	0:2:3:4:5:7:8	595	cyclin D1|cyclin D1	GeneOrGeneProduct	156:176	158:178	6:7	1:NR:2	L2R	NON-CROSS	184-185	192-193	D009369	malignancies|malignancies|cancers|cancer|tumour|cancer|cancer	DiseaseOrPhenotypicFeature	10:63:78:90:138:192:216	11:64:79:91:139:193:217	0:2:3:4:5:7:8	5925	Rb|Rb	GeneOrGeneProduct	160:184	161:185	6:7	1:NR:2	L2R	CROSS	164-169	192-193	D009369	malignancies|malignancies|cancers|cancer|tumour|cancer|cancer	DiseaseOrPhenotypicFeature	10:63:78:90:138:192:216	11:64:79:91:139:193:217	0:2:3:4:5:7:8	1019	cyclin - dependent kinase 4	GeneOrGeneProduct	164	169	6	1:NR:2	L2R	CROSS	85-87	156-158	D011471	prostate cancer	DiseaseOrPhenotypicFeature	85	87	4	595	cyclin D1|cyclin D1	GeneOrGeneProduct	156:176	158:178	6:7	1:NR:2	L2R	CROSS	85-87	160-161	D011471	prostate cancer	DiseaseOrPhenotypicFeature	85	87	4	5925	Rb|Rb	GeneOrGeneProduct	160:184	161:185	6:7	1:NR:2	L2R	CROSS	85-87	164-169	D011471	prostate cancer	DiseaseOrPhenotypicFeature	85	87	4	1019	cyclin - dependent kinase 4	GeneOrGeneProduct	164	169	6	1:NR:2	L2R	CROSS	145-146	156-158	D007153	immunodeficiency	DiseaseOrPhenotypicFeature	145	146	5	595	cyclin D1|cyclin D1	GeneOrGeneProduct	156:176	158:178	6:7	1:NR:2	L2R	CROSS	145-146	160-161	D007153	immunodeficiency	DiseaseOrPhenotypicFeature	145	146	5	5925	Rb|Rb	GeneOrGeneProduct	160:184	161:185	6:7	1:NR:2	L2R	CROSS	145-146	164-169	D007153	immunodeficiency	DiseaseOrPhenotypicFeature	145	146	5	1019	cyclin - dependent kinase 4	GeneOrGeneProduct	164	169	6	1:Association:2	L2R	NON-CROSS	156-158	160-161	595	cyclin D1|cyclin D1	GeneOrGeneProduct	156:176	158:178	6:7	5925	Rb|Rb	GeneOrGeneProduct	160:184	161:185	6:7	1:NR:2	L2R	NON-CROSS	156-158	164-169	595	cyclin D1|cyclin D1	GeneOrGeneProduct	156:176	158:178	6:7	1019	cyclin - dependent kinase 4	GeneOrGeneProduct	164	169	6	1:Association:2	L2R	NON-CROSS	160-161	164-169	5925	Rb|Rb	GeneOrGeneProduct	160:184	161:185	6:7	1019	cyclin - dependent kinase 4	GeneOrGeneProduct	164	169	6
16731636	Enhanced isoproterenol - induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen .|We have previously shown that a permanent deficiency in the brain renin - angiotensin system ( RAS ) may increase the sensitivity of the baroreflex control of heart rate .|In this study we aimed at studying the involvement of the brain RAS in the cardiac reactivity to the beta - adrenoceptor ( beta - AR ) agonist isoproterenol ( Iso ) .|Transgenic rats with low brain angiotensinogen ( TGR ) were used .|In isolated hearts , Iso induced a significantly greater increase in left ventricular ( LV ) pressure and maximal contraction ( + dP / dt ( max ) ) in the TGR than in the Sprague - Dawley ( SD ) rats .|LV hypertrophy induced by Iso treatment was significantly higher in TGR than in SD rats ( in g LV wt / 100 g body wt , 0 . 28 + / - 0 . 004 vs . 0 . 24 + / - 0 . 004 , respectively ) .|The greater LV hypertrophy in TGR rats was associated with more pronounced downregulation of beta - AR and upregulation of LV beta - AR kinase - 1 mRNA levels compared with those in SD rats .|The decrease in the heart rate ( HR ) induced by the beta - AR antagonist metoprolol in conscious rats was significantly attenuated in TGR compared with SD rats ( - 9 . 9 + / - 1 . 7 % vs . - 18 . 1 + / - 1 . 5 % ) , whereas the effect of parasympathetic blockade by atropine on HR was similar in both strains .|These results indicate that TGR are more sensitive to beta - AR agonist - induced cardiac inotropic response and hypertrophy , possibly due to chronically low sympathetic outflow directed to the heart .	1:Positive_Correlation:2	L2R	NON-CROSS	1-2	4-6	D007545	isoproterenol|isoproterenol|Iso|Iso|Iso	ChemicalEntity	1:72:74:93:136	2:73:75:94:137	0:2:2:4:5	D006332	cardiac hypertrophy|LV hypertrophy|LV hypertrophy	DiseaseOrPhenotypicFeature	4:132:184	6:134:186	0:5:6	1:Association:2	R2L	NON-CROSS	82-83	74-75	24179	angiotensinogen|angiotensin|angiotensinogen	GeneOrGeneProduct	12:27:82	13:28:83	0:1:3	D007545	isoproterenol|isoproterenol|Iso|Iso|Iso	ChemicalEntity	1:72:74:93:136	2:73:75:94:137	0:2:2:4:5	1:NR:2	L2R	CROSS	1-2	25-26	D007545	isoproterenol|isoproterenol|Iso|Iso|Iso	ChemicalEntity	1:72:74:93:136	2:73:75:94:137	0:2:2:4:5	24715	renin	GeneOrGeneProduct	25	26	1	1:Positive_Correlation:2	R2L	NON-CROSS	72-73	67-70	24925	beta - adrenoceptor|beta - AR|beta - AR|beta - AR|beta - AR	GeneOrGeneProduct	63:67:196:230:299	66:70:199:233:302	2:2:6:7:8	D007545	isoproterenol|isoproterenol|Iso|Iso|Iso	ChemicalEntity	1:72:74:93:136	2:73:75:94:137	0:2:2:4:5	1:NR:2	L2R	CROSS	136-137	203-209	D007545	isoproterenol|isoproterenol|Iso|Iso|Iso	ChemicalEntity	1:72:74:93:136	2:73:75:94:137	0:2:2:4:5	25238	beta - AR kinase - 1	GeneOrGeneProduct	203	209	6	1:NR:2	L2R	CROSS	136-137	234-235	D007545	isoproterenol|isoproterenol|Iso|Iso|Iso	ChemicalEntity	1:72:74:93:136	2:73:75:94:137	0:2:2:4:5	D008790	metoprolol	ChemicalEntity	234	235	7	1:NR:2	L2R	CROSS	136-137	281-282	D007545	isoproterenol|isoproterenol|Iso|Iso|Iso	ChemicalEntity	1:72:74:93:136	2:73:75:94:137	0:2:2:4:5	D001285	atropine	ChemicalEntity	281	282	7	1:NR:2	L2R	CROSS	136-137	309-310	D007545	isoproterenol|isoproterenol|Iso|Iso|Iso	ChemicalEntity	1:72:74:93:136	2:73:75:94:137	0:2:2:4:5	D006984	hypertrophy	DiseaseOrPhenotypicFeature	309	310	8	1:Association:2	R2L	NON-CROSS	12-13	4-6	24179	angiotensinogen|angiotensin|angiotensinogen	GeneOrGeneProduct	12:27:82	13:28:83	0:1:3	D006332	cardiac hypertrophy|LV hypertrophy|LV hypertrophy	DiseaseOrPhenotypicFeature	4:132:184	6:134:186	0:5:6	1:NR:2	L2R	CROSS	4-6	25-26	D006332	cardiac hypertrophy|LV hypertrophy|LV hypertrophy	DiseaseOrPhenotypicFeature	4:132:184	6:134:186	0:5:6	24715	renin	GeneOrGeneProduct	25	26	1	1:Association:2	L2R	NON-CROSS	184-186	196-199	D006332	cardiac hypertrophy|LV hypertrophy|LV hypertrophy	DiseaseOrPhenotypicFeature	4:132:184	6:134:186	0:5:6	24925	beta - adrenoceptor|beta - AR|beta - AR|beta - AR|beta - AR	GeneOrGeneProduct	63:67:196:230:299	66:70:199:233:302	2:2:6:7:8	1:Association:2	L2R	NON-CROSS	184-186	203-209	D006332	cardiac hypertrophy|LV hypertrophy|LV hypertrophy	DiseaseOrPhenotypicFeature	4:132:184	6:134:186	0:5:6	25238	beta - AR kinase - 1	GeneOrGeneProduct	203	209	6	1:NR:2	L2R	CROSS	184-186	234-235	D006332	cardiac hypertrophy|LV hypertrophy|LV hypertrophy	DiseaseOrPhenotypicFeature	4:132:184	6:134:186	0:5:6	D008790	metoprolol	ChemicalEntity	234	235	7	1:NR:2	L2R	CROSS	184-186	281-282	D006332	cardiac hypertrophy|LV hypertrophy|LV hypertrophy	DiseaseOrPhenotypicFeature	4:132:184	6:134:186	0:5:6	D001285	atropine	ChemicalEntity	281	282	7	1:Association:2	R2L	NON-CROSS	27-28	25-26	24715	renin	GeneOrGeneProduct	25	26	1	24179	angiotensinogen|angiotensin|angiotensinogen	GeneOrGeneProduct	12:27:82	13:28:83	0:1:3	1:Association:2	R2L	CROSS	82-83	67-70	24925	beta - adrenoceptor|beta - AR|beta - AR|beta - AR|beta - AR	GeneOrGeneProduct	63:67:196:230:299	66:70:199:233:302	2:2:6:7:8	24179	angiotensinogen|angiotensin|angiotensinogen	GeneOrGeneProduct	12:27:82	13:28:83	0:1:3	1:NR:2	L2R	CROSS	82-83	203-209	24179	angiotensinogen|angiotensin|angiotensinogen	GeneOrGeneProduct	12:27:82	13:28:83	0:1:3	25238	beta - AR kinase - 1	GeneOrGeneProduct	203	209	6	1:NR:2	L2R	CROSS	82-83	234-235	24179	angiotensinogen|angiotensin|angiotensinogen	GeneOrGeneProduct	12:27:82	13:28:83	0:1:3	D008790	metoprolol	ChemicalEntity	234	235	7	1:NR:2	L2R	CROSS	82-83	281-282	24179	angiotensinogen|angiotensin|angiotensinogen	GeneOrGeneProduct	12:27:82	13:28:83	0:1:3	D001285	atropine	ChemicalEntity	281	282	7	1:Association:2	L2R	CROSS	82-83	309-310	24179	angiotensinogen|angiotensin|angiotensinogen	GeneOrGeneProduct	12:27:82	13:28:83	0:1:3	D006984	hypertrophy	DiseaseOrPhenotypicFeature	309	310	8	1:NR:2	L2R	CROSS	25-26	63-66	24715	renin	GeneOrGeneProduct	25	26	1	24925	beta - adrenoceptor|beta - AR|beta - AR|beta - AR|beta - AR	GeneOrGeneProduct	63:67:196:230:299	66:70:199:233:302	2:2:6:7:8	1:NR:2	L2R	CROSS	25-26	203-209	24715	renin	GeneOrGeneProduct	25	26	1	25238	beta - AR kinase - 1	GeneOrGeneProduct	203	209	6	1:NR:2	L2R	CROSS	25-26	234-235	24715	renin	GeneOrGeneProduct	25	26	1	D008790	metoprolol	ChemicalEntity	234	235	7	1:NR:2	L2R	CROSS	25-26	281-282	24715	renin	GeneOrGeneProduct	25	26	1	D001285	atropine	ChemicalEntity	281	282	7	1:NR:2	L2R	CROSS	25-26	309-310	24715	renin	GeneOrGeneProduct	25	26	1	D006984	hypertrophy	DiseaseOrPhenotypicFeature	309	310	8	1:NR:2	L2R	NON-CROSS	196-199	203-209	24925	beta - adrenoceptor|beta - AR|beta - AR|beta - AR|beta - AR	GeneOrGeneProduct	63:67:196:230:299	66:70:199:233:302	2:2:6:7:8	25238	beta - AR kinase - 1	GeneOrGeneProduct	203	209	6	1:Negative_Correlation:2	L2R	NON-CROSS	230-233	234-235	24925	beta - adrenoceptor|beta - AR|beta - AR|beta - AR|beta - AR	GeneOrGeneProduct	63:67:196:230:299	66:70:199:233:302	2:2:6:7:8	D008790	metoprolol	ChemicalEntity	234	235	7	1:NR:2	L2R	NON-CROSS	281-282	299-302	24925	beta - adrenoceptor|beta - AR|beta - AR|beta - AR|beta - AR	GeneOrGeneProduct	63:67:196:230:299	66:70:199:233:302	2:2:6:7:8	D001285	atropine	ChemicalEntity	281	282	7	1:Association:2	L2R	NON-CROSS	299-302	309-310	24925	beta - adrenoceptor|beta - AR|beta - AR|beta - AR|beta - AR	GeneOrGeneProduct	63:67:196:230:299	66:70:199:233:302	2:2:6:7:8	D006984	hypertrophy	DiseaseOrPhenotypicFeature	309	310	8	1:NR:2	L2R	CROSS	203-209	234-235	25238	beta - AR kinase - 1	GeneOrGeneProduct	203	209	6	D008790	metoprolol	ChemicalEntity	234	235	7	1:NR:2	L2R	CROSS	203-209	281-282	25238	beta - AR kinase - 1	GeneOrGeneProduct	203	209	6	D001285	atropine	ChemicalEntity	281	282	7	1:NR:2	L2R	CROSS	203-209	309-310	25238	beta - AR kinase - 1	GeneOrGeneProduct	203	209	6	D006984	hypertrophy	DiseaseOrPhenotypicFeature	309	310	8	1:NR:2	L2R	NON-CROSS	234-235	281-282	D008790	metoprolol	ChemicalEntity	234	235	7	D001285	atropine	ChemicalEntity	281	282	7	1:NR:2	L2R	CROSS	234-235	309-310	D008790	metoprolol	ChemicalEntity	234	235	7	D006984	hypertrophy	DiseaseOrPhenotypicFeature	309	310	8	1:NR:2	L2R	CROSS	281-282	309-310	D001285	atropine	ChemicalEntity	281	282	7	D006984	hypertrophy	DiseaseOrPhenotypicFeature	309	310	8
16849419	Intronic deletions in the SLC34A3 gene cause hereditary hypophosphatemic rickets with hypercalciuria .|CONTEXT : Hereditary hypophosphatemic rickets with hypercalciuria ( HHRH ) is a rare metabolic disorder , characterized by hypophosphatemia and rickets / osteomalacia with increased serum 1 , 25 - dihydroxyvitamin D [ 1 , 25 - ( OH ) ( 2 ) D ] resulting in hypercalciuria .|OBJECTIVE : Our objective was to determine whether mutations in the SLC34A3 gene , which encodes sodium - phosphate cotransporter type IIc , are responsible for the occurrence of HHRH .|DESIGN AND SETTING : Mutation analysis of exons and adjacent introns in the SLC34A3 gene was conducted at an academic research laboratory and medical center .|PATIENTS OR OTHER PARTICIPANTS : Members of two unrelated families with HHRH participated in the study .|RESULTS : Two affected siblings in one family were homozygous for a 101 - bp deletion in intron 9 .|Haplotype analysis of the SLC34A3 locus in the family showed that the two deletions are on different haplotypes .|An unrelated individual with HHRH was a compound heterozygote for an 85 - bp deletion in intron 10 and a G - to - A substitution at the last nucleotide in exon 7 .|The intron 9 deletion ( and likely the other two mutations ) identified in this study causes aberrant RNA splicing .|Sequence analysis of the deleted regions revealed the presence of direct repeats of homologous sequences .|CONCLUSION : HHRH is caused by biallelic mutations in the SLC34A3 gene .|Haplotype analysis suggests that the two intron 9 deletions arose independently .|The identification of three independent deletions in introns 9 and 10 suggests that the SLC34A3 gene may be susceptible to unequal crossing over because of sequence misalignment during meiosis .	1:Association:2	L2R	NON-CROSS	4-5	7-12	142680	SLC34A3|SLC34A3|sodium - phosphate cotransporter type IIc|SLC34A3|SLC34A3|SLC34A3|SLC34A3	GeneOrGeneProduct	4:73:78:106:160:256:285	5:74:84:107:161:257:286	0:2:2:3:6:10:12	C562793	hereditary hypophosphatemic rickets with hypercalciuria|Hereditary hypophosphatemic rickets with hypercalciuria|HHRH|HHRH|HHRH|HHRH|HHRH	DiseaseOrPhenotypicFeature	7:15:21:91:130:179:248	12:20:22:92:131:180:249	0:1:1:2:4:7:10	1:NR:2	L2R	CROSS	4-5	26-28	142680	SLC34A3|SLC34A3|sodium - phosphate cotransporter type IIc|SLC34A3|SLC34A3|SLC34A3|SLC34A3	GeneOrGeneProduct	4:73:78:106:160:256:285	5:74:84:107:161:257:286	0:2:2:3:6:10:12	D008659	metabolic disorder	DiseaseOrPhenotypicFeature	26	28	1	1:NR:2	L2R	CROSS	4-5	31-32	142680	SLC34A3|SLC34A3|sodium - phosphate cotransporter type IIc|SLC34A3|SLC34A3|SLC34A3|SLC34A3	GeneOrGeneProduct	4:73:78:106:160:256:285	5:74:84:107:161:257:286	0:2:2:3:6:10:12	D017674	hypophosphatemia	DiseaseOrPhenotypicFeature	31	32	1	1:NR:2	L2R	CROSS	4-5	33-34	142680	SLC34A3|SLC34A3|sodium - phosphate cotransporter type IIc|SLC34A3|SLC34A3|SLC34A3|SLC34A3	GeneOrGeneProduct	4:73:78:106:160:256:285	5:74:84:107:161:257:286	0:2:2:3:6:10:12	D012279	rickets	DiseaseOrPhenotypicFeature	33	34	1	1:NR:2	L2R	CROSS	4-5	35-36	142680	SLC34A3|SLC34A3|sodium - phosphate cotransporter type IIc|SLC34A3|SLC34A3|SLC34A3|SLC34A3	GeneOrGeneProduct	4:73:78:106:160:256:285	5:74:84:107:161:257:286	0:2:2:3:6:10:12	D010018	osteomalacia	DiseaseOrPhenotypicFeature	35	36	1	1:NR:2	L2R	CROSS	46-57	78-84	142680	SLC34A3|SLC34A3|sodium - phosphate cotransporter type IIc|SLC34A3|SLC34A3|SLC34A3|SLC34A3	GeneOrGeneProduct	4:73:78:106:160:256:285	5:74:84:107:161:257:286	0:2:2:3:6:10:12	C097949	1 , 25 - dihydroxyvitamin D|1 , 25 - ( OH ) ( 2 ) D	ChemicalEntity	39:46	45:57	1:1	1:NR:2	L2R	CROSS	60-61	73-74	142680	SLC34A3|SLC34A3|sodium - phosphate cotransporter type IIc|SLC34A3|SLC34A3|SLC34A3|SLC34A3	GeneOrGeneProduct	4:73:78:106:160:256:285	5:74:84:107:161:257:286	0:2:2:3:6:10:12	D053565	hypercalciuria	DiseaseOrPhenotypicFeature	60	61	1	1:Positive_Correlation:2	L2R	NON-CROSS	21-22	39-45	C562793	hereditary hypophosphatemic rickets with hypercalciuria|Hereditary hypophosphatemic rickets with hypercalciuria|HHRH|HHRH|HHRH|HHRH|HHRH	DiseaseOrPhenotypicFeature	7:15:21:91:130:179:248	12:20:22:92:131:180:249	0:1:1:2:4:7:10	C097949	1 , 25 - dihydroxyvitamin D|1 , 25 - ( OH ) ( 2 ) D	ChemicalEntity	39:46	45:57	1:1	1:Positive_Correlation:2	L2R	CROSS	130-131	148-152	C562793	hereditary hypophosphatemic rickets with hypercalciuria|Hereditary hypophosphatemic rickets with hypercalciuria|HHRH|HHRH|HHRH|HHRH|HHRH	DiseaseOrPhenotypicFeature	7:15:21:91:130:179:248	12:20:22:92:131:180:249	0:1:1:2:4:7:10	c|DEL||101	101 - bp deletion	SequenceVariant	148	152	5	1:Positive_Correlation:2	L2R	NON-CROSS	179-180	186-190	C562793	hereditary hypophosphatemic rickets with hypercalciuria|Hereditary hypophosphatemic rickets with hypercalciuria|HHRH|HHRH|HHRH|HHRH|HHRH	DiseaseOrPhenotypicFeature	7:15:21:91:130:179:248	12:20:22:92:131:180:249	0:1:1:2:4:7:10	c|DEL||85	85 - bp deletion	SequenceVariant	186	190	7	1:Association:2	L2R	NON-CROSS	179-180	195-200	C562793	hereditary hypophosphatemic rickets with hypercalciuria|Hereditary hypophosphatemic rickets with hypercalciuria|HHRH|HHRH|HHRH|HHRH|HHRH	DiseaseOrPhenotypicFeature	7:15:21:91:130:179:248	12:20:22:92:131:180:249	0:1:1:2:4:7:10	c|SUB|G||A	G - to - A	SequenceVariant	195	200	7	1:NR:2	L2R	NON-CROSS	26-28	39-45	D008659	metabolic disorder	DiseaseOrPhenotypicFeature	26	28	1	C097949	1 , 25 - dihydroxyvitamin D|1 , 25 - ( OH ) ( 2 ) D	ChemicalEntity	39:46	45:57	1:1	1:NR:2	L2R	CROSS	26-28	148-152	D008659	metabolic disorder	DiseaseOrPhenotypicFeature	26	28	1	c|DEL||101	101 - bp deletion	SequenceVariant	148	152	5	1:NR:2	L2R	CROSS	26-28	186-190	D008659	metabolic disorder	DiseaseOrPhenotypicFeature	26	28	1	c|DEL||85	85 - bp deletion	SequenceVariant	186	190	7	1:NR:2	L2R	CROSS	26-28	195-200	D008659	metabolic disorder	DiseaseOrPhenotypicFeature	26	28	1	c|SUB|G||A	G - to - A	SequenceVariant	195	200	7	1:NR:2	L2R	NON-CROSS	31-32	39-45	D017674	hypophosphatemia	DiseaseOrPhenotypicFeature	31	32	1	C097949	1 , 25 - dihydroxyvitamin D|1 , 25 - ( OH ) ( 2 ) D	ChemicalEntity	39:46	45:57	1:1	1:NR:2	L2R	CROSS	31-32	148-152	D017674	hypophosphatemia	DiseaseOrPhenotypicFeature	31	32	1	c|DEL||101	101 - bp deletion	SequenceVariant	148	152	5	1:NR:2	L2R	CROSS	31-32	186-190	D017674	hypophosphatemia	DiseaseOrPhenotypicFeature	31	32	1	c|DEL||85	85 - bp deletion	SequenceVariant	186	190	7	1:NR:2	L2R	CROSS	31-32	195-200	D017674	hypophosphatemia	DiseaseOrPhenotypicFeature	31	32	1	c|SUB|G||A	G - to - A	SequenceVariant	195	200	7	1:NR:2	L2R	NON-CROSS	33-34	39-45	D012279	rickets	DiseaseOrPhenotypicFeature	33	34	1	C097949	1 , 25 - dihydroxyvitamin D|1 , 25 - ( OH ) ( 2 ) D	ChemicalEntity	39:46	45:57	1:1	1:NR:2	L2R	CROSS	33-34	148-152	D012279	rickets	DiseaseOrPhenotypicFeature	33	34	1	c|DEL||101	101 - bp deletion	SequenceVariant	148	152	5	1:NR:2	L2R	CROSS	33-34	186-190	D012279	rickets	DiseaseOrPhenotypicFeature	33	34	1	c|DEL||85	85 - bp deletion	SequenceVariant	186	190	7	1:NR:2	L2R	CROSS	33-34	195-200	D012279	rickets	DiseaseOrPhenotypicFeature	33	34	1	c|SUB|G||A	G - to - A	SequenceVariant	195	200	7	1:NR:2	L2R	NON-CROSS	35-36	39-45	D010018	osteomalacia	DiseaseOrPhenotypicFeature	35	36	1	C097949	1 , 25 - dihydroxyvitamin D|1 , 25 - ( OH ) ( 2 ) D	ChemicalEntity	39:46	45:57	1:1	1:NR:2	L2R	CROSS	35-36	148-152	D010018	osteomalacia	DiseaseOrPhenotypicFeature	35	36	1	c|DEL||101	101 - bp deletion	SequenceVariant	148	152	5	1:NR:2	L2R	CROSS	35-36	186-190	D010018	osteomalacia	DiseaseOrPhenotypicFeature	35	36	1	c|DEL||85	85 - bp deletion	SequenceVariant	186	190	7	1:NR:2	L2R	CROSS	35-36	195-200	D010018	osteomalacia	DiseaseOrPhenotypicFeature	35	36	1	c|SUB|G||A	G - to - A	SequenceVariant	195	200	7	1:Positive_Correlation:2	L2R	NON-CROSS	46-57	60-61	C097949	1 , 25 - dihydroxyvitamin D|1 , 25 - ( OH ) ( 2 ) D	ChemicalEntity	39:46	45:57	1:1	D053565	hypercalciuria	DiseaseOrPhenotypicFeature	60	61	1	1:NR:2	L2R	CROSS	46-57	148-152	C097949	1 , 25 - dihydroxyvitamin D|1 , 25 - ( OH ) ( 2 ) D	ChemicalEntity	39:46	45:57	1:1	c|DEL||101	101 - bp deletion	SequenceVariant	148	152	5	1:NR:2	L2R	CROSS	46-57	186-190	C097949	1 , 25 - dihydroxyvitamin D|1 , 25 - ( OH ) ( 2 ) D	ChemicalEntity	39:46	45:57	1:1	c|DEL||85	85 - bp deletion	SequenceVariant	186	190	7	1:NR:2	L2R	CROSS	46-57	195-200	C097949	1 , 25 - dihydroxyvitamin D|1 , 25 - ( OH ) ( 2 ) D	ChemicalEntity	39:46	45:57	1:1	c|SUB|G||A	G - to - A	SequenceVariant	195	200	7	1:NR:2	L2R	CROSS	60-61	148-152	D053565	hypercalciuria	DiseaseOrPhenotypicFeature	60	61	1	c|DEL||101	101 - bp deletion	SequenceVariant	148	152	5	1:NR:2	L2R	CROSS	60-61	186-190	D053565	hypercalciuria	DiseaseOrPhenotypicFeature	60	61	1	c|DEL||85	85 - bp deletion	SequenceVariant	186	190	7	1:NR:2	L2R	CROSS	60-61	195-200	D053565	hypercalciuria	DiseaseOrPhenotypicFeature	60	61	1	c|SUB|G||A	G - to - A	SequenceVariant	195	200	7
19789368	Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer .|Vitamin D is associated with decreased risks of various cancers , including colon cancer .|The vitamin D receptor ( VDR ) is a transcription factor , which plays an important role in cellular differentiation and inhibition of proliferation .|A link between VDR and the RAS - mitogen - activated protein kinase ( MAPK ) or phosphatidylinositol 3 - kinase ( PI3K ) - AKT pathway has been suggested .|However , the prognostic role of VDR expression or its relationship with PIK3CA or KRAS mutation remains uncertain .|Among 619 colorectal cancers in two prospective cohort studies , 233 ( 38 % ) tumors showed VDR overexpression by immunohistochemistry .|We analyzed for PIK3CA and KRAS mutations and LINE - 1 methylation by Pyrosequencing , microsatellite instability ( MSI ) , and DNA methylation ( epigenetic changes ) in eight CpG island methylator phenotype ( CIMP ) - specific promoters [ CACNA1G , CDKN2A ( p16 ) , CRABP1 , IGF2 , MLH1 , NEUROG1 , RUNX3 , and SOCS1 ] by MethyLight ( real - time PCR ) .|VDR overexpression was significantly associated with KRAS mutation ( odds ratio , 1 . 55 ; 95 % confidence interval , 1 . 11 - 2 . 16 ) and PIK3CA mutation ( odds ratio , 2 . 17 ; 95 % confidence interval , 1 . 36 - 3 . 47 ) , both of which persisted in multivariate logistic regression analysis .|VDR was not independently associated with body mass index , family history of colorectal cancer , tumor location ( colon versus rectum ) , stage , tumor grade , signet ring cells , CIMP , MSI , LINE - 1 hypomethylation , BRAF , p53 , p21 , beta - catenin , or cyclooxygenase - 2 .|VDR expression was not significantly related with patient survival , prognosis , or clinical outcome .|In conclusion , VDR overexpression in colorectal cancer is independently associated with PIK3CA and KRAS mutations .|Our data support potential interactions between the VDR , RAS - MAPK and PI3K - AKT pathways , and possible influence by KRAS or PIK3CA mutation on therapy or chemoprevention targeting VDR .	1:Association:2	L2R	NON-CROSS	0-3	7-8	7421	Vitamin D receptor|vitamin D receptor|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR	GeneOrGeneProduct	0:31:35:58:92:122:197:261:318:337:358:382	3:34:36:59:93:123:198:262:319:338:359:383	0:2:2:3:4:5:7:8:9:10:11:11	5290	PIK3CA|phosphatidylinositol 3 - kinase|PI3K|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PI3K|PIK3CA	GeneOrGeneProduct	7:72:77:98:130:227:346:364:375	8:76:78:99:131:228:347:365:376	0:3:3:4:6:7:10:11:11	1:Association:2	L2R	NON-CROSS	358-359	360-361	7421	Vitamin D receptor|vitamin D receptor|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR	GeneOrGeneProduct	0:31:35:58:92:122:197:261:318:337:358:382	3:34:36:59:93:123:198:262:319:338:359:383	0:2:2:3:4:5:7:8:9:10:11:11	3845	KRAS|RAS|KRAS|KRAS|KRAS|KRAS|RAS|KRAS	GeneOrGeneProduct	9:61:100:132:203:348:360:373	10:62:101:133:204:349:361:374	0:3:4:6:7:10:11:11	1:Positive_Correlation:2	L2R	NON-CROSS	337-338	340-342	7421	Vitamin D receptor|vitamin D receptor|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR	GeneOrGeneProduct	0:31:35:58:92:122:197:261:318:337:358:382	3:34:36:59:93:123:198:262:319:338:359:383	0:2:2:3:4:5:7:8:9:10:11:11	D015179	colorectal cancer|colon cancer|colorectal cancers|colorectal cancer|colorectal cancer	DiseaseOrPhenotypicFeature	12:27:107:274:340	14:29:109:276:342	0:1:5:8:10	1:Bind:2	L2R	CROSS	0-3	15-17	7421	Vitamin D receptor|vitamin D receptor|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR	GeneOrGeneProduct	0:31:35:58:92:122:197:261:318:337:358:382	3:34:36:59:93:123:198:262:319:338:359:383	0:2:2:3:4:5:7:8:9:10:11:11	D014807	Vitamin D	ChemicalEntity	15	17	1	1:Positive_Correlation:2	R2L	NON-CROSS	122-123	120-121	D009369	cancers|tumors|tumor|tumor	DiseaseOrPhenotypicFeature	24:120:277:287	25:121:278:288	1:5:8:8	7421	Vitamin D receptor|vitamin D receptor|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR	GeneOrGeneProduct	0:31:35:58:92:122:197:261:318:337:358:382	3:34:36:59:93:123:198:262:319:338:359:383	0:2:2:3:4:5:7:8:9:10:11:11	1:NR:2	L2R	NON-CROSS	358-359	362-363	7421	Vitamin D receptor|vitamin D receptor|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR	GeneOrGeneProduct	0:31:35:58:92:122:197:261:318:337:358:382	3:34:36:59:93:123:198:262:319:338:359:383	0:2:2:3:4:5:7:8:9:10:11:11	1432	mitogen - activated protein kinase|MAPK|MAPK	GeneOrGeneProduct	63:69:362	68:70:363	3:3:11	1:NR:2	L2R	NON-CROSS	358-359	366-367	7421	Vitamin D receptor|vitamin D receptor|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR	GeneOrGeneProduct	0:31:35:58:92:122:197:261:318:337:358:382	3:34:36:59:93:123:198:262:319:338:359:383	0:2:2:3:4:5:7:8:9:10:11:11	207	AKT|AKT	GeneOrGeneProduct	80:366	81:367	3:11	1:NR:2	L2R	CROSS	168-169	197-198	7421	Vitamin D receptor|vitamin D receptor|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR	GeneOrGeneProduct	0:31:35:58:92:122:197:261:318:337:358:382	3:34:36:59:93:123:198:262:319:338:359:383	0:2:2:3:4:5:7:8:9:10:11:11	8913	CACNA1G	GeneOrGeneProduct	168	169	6	1:NR:2	L2R	CROSS	172-173	197-198	7421	Vitamin D receptor|vitamin D receptor|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR	GeneOrGeneProduct	0:31:35:58:92:122:197:261:318:337:358:382	3:34:36:59:93:123:198:262:319:338:359:383	0:2:2:3:4:5:7:8:9:10:11:11	1029	CDKN2A|p16	GeneOrGeneProduct	170:172	171:173	6:6	1:NR:2	L2R	CROSS	175-176	197-198	7421	Vitamin D receptor|vitamin D receptor|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR	GeneOrGeneProduct	0:31:35:58:92:122:197:261:318:337:358:382	3:34:36:59:93:123:198:262:319:338:359:383	0:2:2:3:4:5:7:8:9:10:11:11	1381	CRABP1	GeneOrGeneProduct	175	176	6	1:NR:2	L2R	CROSS	177-178	197-198	7421	Vitamin D receptor|vitamin D receptor|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR	GeneOrGeneProduct	0:31:35:58:92:122:197:261:318:337:358:382	3:34:36:59:93:123:198:262:319:338:359:383	0:2:2:3:4:5:7:8:9:10:11:11	3481	IGF2	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	CROSS	179-180	197-198	7421	Vitamin D receptor|vitamin D receptor|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR	GeneOrGeneProduct	0:31:35:58:92:122:197:261:318:337:358:382	3:34:36:59:93:123:198:262:319:338:359:383	0:2:2:3:4:5:7:8:9:10:11:11	4292	MLH1	GeneOrGeneProduct	179	180	6	1:NR:2	L2R	CROSS	181-182	197-198	7421	Vitamin D receptor|vitamin D receptor|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR	GeneOrGeneProduct	0:31:35:58:92:122:197:261:318:337:358:382	3:34:36:59:93:123:198:262:319:338:359:383	0:2:2:3:4:5:7:8:9:10:11:11	4762	NEUROG1	GeneOrGeneProduct	181	182	6	1:NR:2	L2R	CROSS	183-184	197-198	7421	Vitamin D receptor|vitamin D receptor|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR	GeneOrGeneProduct	0:31:35:58:92:122:197:261:318:337:358:382	3:34:36:59:93:123:198:262:319:338:359:383	0:2:2:3:4:5:7:8:9:10:11:11	864	RUNX3	GeneOrGeneProduct	183	184	6	1:NR:2	L2R	CROSS	186-187	197-198	7421	Vitamin D receptor|vitamin D receptor|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR	GeneOrGeneProduct	0:31:35:58:92:122:197:261:318:337:358:382	3:34:36:59:93:123:198:262:319:338:359:383	0:2:2:3:4:5:7:8:9:10:11:11	8651	SOCS1	GeneOrGeneProduct	186	187	6	1:NR:2	L2R	NON-CROSS	303-304	318-319	7421	Vitamin D receptor|vitamin D receptor|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR	GeneOrGeneProduct	0:31:35:58:92:122:197:261:318:337:358:382	3:34:36:59:93:123:198:262:319:338:359:383	0:2:2:3:4:5:7:8:9:10:11:11	673	BRAF	GeneOrGeneProduct	303	304	8	1:NR:2	L2R	NON-CROSS	305-306	318-319	7421	Vitamin D receptor|vitamin D receptor|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR	GeneOrGeneProduct	0:31:35:58:92:122:197:261:318:337:358:382	3:34:36:59:93:123:198:262:319:338:359:383	0:2:2:3:4:5:7:8:9:10:11:11	7157	p53	GeneOrGeneProduct	305	306	8	1:NR:2	L2R	NON-CROSS	307-308	318-319	7421	Vitamin D receptor|vitamin D receptor|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR	GeneOrGeneProduct	0:31:35:58:92:122:197:261:318:337:358:382	3:34:36:59:93:123:198:262:319:338:359:383	0:2:2:3:4:5:7:8:9:10:11:11	1026	p21	GeneOrGeneProduct	307	308	8	1:NR:2	L2R	NON-CROSS	309-312	318-319	7421	Vitamin D receptor|vitamin D receptor|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR	GeneOrGeneProduct	0:31:35:58:92:122:197:261:318:337:358:382	3:34:36:59:93:123:198:262:319:338:359:383	0:2:2:3:4:5:7:8:9:10:11:11	1499	beta - catenin	GeneOrGeneProduct	309	312	8	1:NR:2	L2R	NON-CROSS	314-317	318-319	7421	Vitamin D receptor|vitamin D receptor|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR|VDR	GeneOrGeneProduct	0:31:35:58:92:122:197:261:318:337:358:382	3:34:36:59:93:123:198:262:319:338:359:383	0:2:2:3:4:5:7:8:9:10:11:11	5743	cyclooxygenase - 2	GeneOrGeneProduct	314	317	8	1:NR:2	L2R	NON-CROSS	7-8	9-10	5290	PIK3CA|phosphatidylinositol 3 - kinase|PI3K|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PI3K|PIK3CA	GeneOrGeneProduct	7:72:77:98:130:227:346:364:375	8:76:78:99:131:228:347:365:376	0:3:3:4:6:7:10:11:11	3845	KRAS|RAS|KRAS|KRAS|KRAS|KRAS|RAS|KRAS	GeneOrGeneProduct	9:61:100:132:203:348:360:373	10:62:101:133:204:349:361:374	0:3:4:6:7:10:11:11	1:Association:2	L2R	NON-CROSS	7-8	12-14	5290	PIK3CA|phosphatidylinositol 3 - kinase|PI3K|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PI3K|PIK3CA	GeneOrGeneProduct	7:72:77:98:130:227:346:364:375	8:76:78:99:131:228:347:365:376	0:3:3:4:6:7:10:11:11	D015179	colorectal cancer|colon cancer|colorectal cancers|colorectal cancer|colorectal cancer	DiseaseOrPhenotypicFeature	12:27:107:274:340	14:29:109:276:342	0:1:5:8:10	1:NR:2	L2R	CROSS	7-8	15-17	5290	PIK3CA|phosphatidylinositol 3 - kinase|PI3K|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PI3K|PIK3CA	GeneOrGeneProduct	7:72:77:98:130:227:346:364:375	8:76:78:99:131:228:347:365:376	0:3:3:4:6:7:10:11:11	D014807	Vitamin D	ChemicalEntity	15	17	1	1:NR:2	L2R	CROSS	120-121	130-131	5290	PIK3CA|phosphatidylinositol 3 - kinase|PI3K|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PI3K|PIK3CA	GeneOrGeneProduct	7:72:77:98:130:227:346:364:375	8:76:78:99:131:228:347:365:376	0:3:3:4:6:7:10:11:11	D009369	cancers|tumors|tumor|tumor	DiseaseOrPhenotypicFeature	24:120:277:287	25:121:278:288	1:5:8:8	1:NR:2	L2R	NON-CROSS	362-363	364-365	5290	PIK3CA|phosphatidylinositol 3 - kinase|PI3K|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PI3K|PIK3CA	GeneOrGeneProduct	7:72:77:98:130:227:346:364:375	8:76:78:99:131:228:347:365:376	0:3:3:4:6:7:10:11:11	1432	mitogen - activated protein kinase|MAPK|MAPK	GeneOrGeneProduct	63:69:362	68:70:363	3:3:11	1:Association:2	L2R	NON-CROSS	364-365	366-367	5290	PIK3CA|phosphatidylinositol 3 - kinase|PI3K|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PI3K|PIK3CA	GeneOrGeneProduct	7:72:77:98:130:227:346:364:375	8:76:78:99:131:228:347:365:376	0:3:3:4:6:7:10:11:11	207	AKT|AKT	GeneOrGeneProduct	80:366	81:367	3:11	1:NR:2	L2R	NON-CROSS	130-131	168-169	5290	PIK3CA|phosphatidylinositol 3 - kinase|PI3K|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PI3K|PIK3CA	GeneOrGeneProduct	7:72:77:98:130:227:346:364:375	8:76:78:99:131:228:347:365:376	0:3:3:4:6:7:10:11:11	8913	CACNA1G	GeneOrGeneProduct	168	169	6	1:NR:2	L2R	NON-CROSS	130-131	170-171	5290	PIK3CA|phosphatidylinositol 3 - kinase|PI3K|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PI3K|PIK3CA	GeneOrGeneProduct	7:72:77:98:130:227:346:364:375	8:76:78:99:131:228:347:365:376	0:3:3:4:6:7:10:11:11	1029	CDKN2A|p16	GeneOrGeneProduct	170:172	171:173	6:6	1:NR:2	L2R	NON-CROSS	130-131	175-176	5290	PIK3CA|phosphatidylinositol 3 - kinase|PI3K|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PI3K|PIK3CA	GeneOrGeneProduct	7:72:77:98:130:227:346:364:375	8:76:78:99:131:228:347:365:376	0:3:3:4:6:7:10:11:11	1381	CRABP1	GeneOrGeneProduct	175	176	6	1:NR:2	L2R	NON-CROSS	130-131	177-178	5290	PIK3CA|phosphatidylinositol 3 - kinase|PI3K|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PI3K|PIK3CA	GeneOrGeneProduct	7:72:77:98:130:227:346:364:375	8:76:78:99:131:228:347:365:376	0:3:3:4:6:7:10:11:11	3481	IGF2	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	NON-CROSS	179-180	227-228	5290	PIK3CA|phosphatidylinositol 3 - kinase|PI3K|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PI3K|PIK3CA	GeneOrGeneProduct	7:72:77:98:130:227:346:364:375	8:76:78:99:131:228:347:365:376	0:3:3:4:6:7:10:11:11	4292	MLH1	GeneOrGeneProduct	179	180	6	1:NR:2	L2R	NON-CROSS	181-182	227-228	5290	PIK3CA|phosphatidylinositol 3 - kinase|PI3K|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PI3K|PIK3CA	GeneOrGeneProduct	7:72:77:98:130:227:346:364:375	8:76:78:99:131:228:347:365:376	0:3:3:4:6:7:10:11:11	4762	NEUROG1	GeneOrGeneProduct	181	182	6	1:NR:2	L2R	NON-CROSS	183-184	227-228	5290	PIK3CA|phosphatidylinositol 3 - kinase|PI3K|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PI3K|PIK3CA	GeneOrGeneProduct	7:72:77:98:130:227:346:364:375	8:76:78:99:131:228:347:365:376	0:3:3:4:6:7:10:11:11	864	RUNX3	GeneOrGeneProduct	183	184	6	1:NR:2	L2R	NON-CROSS	186-187	227-228	5290	PIK3CA|phosphatidylinositol 3 - kinase|PI3K|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PI3K|PIK3CA	GeneOrGeneProduct	7:72:77:98:130:227:346:364:375	8:76:78:99:131:228:347:365:376	0:3:3:4:6:7:10:11:11	8651	SOCS1	GeneOrGeneProduct	186	187	6	1:NR:2	L2R	CROSS	303-304	346-347	5290	PIK3CA|phosphatidylinositol 3 - kinase|PI3K|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PI3K|PIK3CA	GeneOrGeneProduct	7:72:77:98:130:227:346:364:375	8:76:78:99:131:228:347:365:376	0:3:3:4:6:7:10:11:11	673	BRAF	GeneOrGeneProduct	303	304	8	1:NR:2	L2R	CROSS	305-306	346-347	5290	PIK3CA|phosphatidylinositol 3 - kinase|PI3K|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PI3K|PIK3CA	GeneOrGeneProduct	7:72:77:98:130:227:346:364:375	8:76:78:99:131:228:347:365:376	0:3:3:4:6:7:10:11:11	7157	p53	GeneOrGeneProduct	305	306	8	1:NR:2	L2R	CROSS	307-308	346-347	5290	PIK3CA|phosphatidylinositol 3 - kinase|PI3K|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PI3K|PIK3CA	GeneOrGeneProduct	7:72:77:98:130:227:346:364:375	8:76:78:99:131:228:347:365:376	0:3:3:4:6:7:10:11:11	1026	p21	GeneOrGeneProduct	307	308	8	1:NR:2	L2R	CROSS	309-312	346-347	5290	PIK3CA|phosphatidylinositol 3 - kinase|PI3K|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PI3K|PIK3CA	GeneOrGeneProduct	7:72:77:98:130:227:346:364:375	8:76:78:99:131:228:347:365:376	0:3:3:4:6:7:10:11:11	1499	beta - catenin	GeneOrGeneProduct	309	312	8	1:NR:2	L2R	CROSS	314-317	346-347	5290	PIK3CA|phosphatidylinositol 3 - kinase|PI3K|PIK3CA|PIK3CA|PIK3CA|PIK3CA|PI3K|PIK3CA	GeneOrGeneProduct	7:72:77:98:130:227:346:364:375	8:76:78:99:131:228:347:365:376	0:3:3:4:6:7:10:11:11	5743	cyclooxygenase - 2	GeneOrGeneProduct	314	317	8	1:Association:2	L2R	NON-CROSS	9-10	12-14	3845	KRAS|RAS|KRAS|KRAS|KRAS|KRAS|RAS|KRAS	GeneOrGeneProduct	9:61:100:132:203:348:360:373	10:62:101:133:204:349:361:374	0:3:4:6:7:10:11:11	D015179	colorectal cancer|colon cancer|colorectal cancers|colorectal cancer|colorectal cancer	DiseaseOrPhenotypicFeature	12:27:107:274:340	14:29:109:276:342	0:1:5:8:10	1:NR:2	L2R	CROSS	9-10	15-17	3845	KRAS|RAS|KRAS|KRAS|KRAS|KRAS|RAS|KRAS	GeneOrGeneProduct	9:61:100:132:203:348:360:373	10:62:101:133:204:349:361:374	0:3:4:6:7:10:11:11	D014807	Vitamin D	ChemicalEntity	15	17	1	1:NR:2	L2R	CROSS	120-121	132-133	3845	KRAS|RAS|KRAS|KRAS|KRAS|KRAS|RAS|KRAS	GeneOrGeneProduct	9:61:100:132:203:348:360:373	10:62:101:133:204:349:361:374	0:3:4:6:7:10:11:11	D009369	cancers|tumors|tumor|tumor	DiseaseOrPhenotypicFeature	24:120:277:287	25:121:278:288	1:5:8:8	1:Association:2	L2R	NON-CROSS	61-62	63-68	3845	KRAS|RAS|KRAS|KRAS|KRAS|KRAS|RAS|KRAS	GeneOrGeneProduct	9:61:100:132:203:348:360:373	10:62:101:133:204:349:361:374	0:3:4:6:7:10:11:11	1432	mitogen - activated protein kinase|MAPK|MAPK	GeneOrGeneProduct	63:69:362	68:70:363	3:3:11	1:NR:2	L2R	NON-CROSS	360-361	366-367	3845	KRAS|RAS|KRAS|KRAS|KRAS|KRAS|RAS|KRAS	GeneOrGeneProduct	9:61:100:132:203:348:360:373	10:62:101:133:204:349:361:374	0:3:4:6:7:10:11:11	207	AKT|AKT	GeneOrGeneProduct	80:366	81:367	3:11	1:NR:2	L2R	NON-CROSS	168-169	203-204	3845	KRAS|RAS|KRAS|KRAS|KRAS|KRAS|RAS|KRAS	GeneOrGeneProduct	9:61:100:132:203:348:360:373	10:62:101:133:204:349:361:374	0:3:4:6:7:10:11:11	8913	CACNA1G	GeneOrGeneProduct	168	169	6	1:NR:2	L2R	NON-CROSS	172-173	203-204	3845	KRAS|RAS|KRAS|KRAS|KRAS|KRAS|RAS|KRAS	GeneOrGeneProduct	9:61:100:132:203:348:360:373	10:62:101:133:204:349:361:374	0:3:4:6:7:10:11:11	1029	CDKN2A|p16	GeneOrGeneProduct	170:172	171:173	6:6	1:NR:2	L2R	NON-CROSS	175-176	203-204	3845	KRAS|RAS|KRAS|KRAS|KRAS|KRAS|RAS|KRAS	GeneOrGeneProduct	9:61:100:132:203:348:360:373	10:62:101:133:204:349:361:374	0:3:4:6:7:10:11:11	1381	CRABP1	GeneOrGeneProduct	175	176	6	1:NR:2	L2R	NON-CROSS	177-178	203-204	3845	KRAS|RAS|KRAS|KRAS|KRAS|KRAS|RAS|KRAS	GeneOrGeneProduct	9:61:100:132:203:348:360:373	10:62:101:133:204:349:361:374	0:3:4:6:7:10:11:11	3481	IGF2	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	NON-CROSS	179-180	203-204	3845	KRAS|RAS|KRAS|KRAS|KRAS|KRAS|RAS|KRAS	GeneOrGeneProduct	9:61:100:132:203:348:360:373	10:62:101:133:204:349:361:374	0:3:4:6:7:10:11:11	4292	MLH1	GeneOrGeneProduct	179	180	6	1:NR:2	L2R	NON-CROSS	181-182	203-204	3845	KRAS|RAS|KRAS|KRAS|KRAS|KRAS|RAS|KRAS	GeneOrGeneProduct	9:61:100:132:203:348:360:373	10:62:101:133:204:349:361:374	0:3:4:6:7:10:11:11	4762	NEUROG1	GeneOrGeneProduct	181	182	6	1:NR:2	L2R	NON-CROSS	183-184	203-204	3845	KRAS|RAS|KRAS|KRAS|KRAS|KRAS|RAS|KRAS	GeneOrGeneProduct	9:61:100:132:203:348:360:373	10:62:101:133:204:349:361:374	0:3:4:6:7:10:11:11	864	RUNX3	GeneOrGeneProduct	183	184	6	1:NR:2	L2R	NON-CROSS	186-187	203-204	3845	KRAS|RAS|KRAS|KRAS|KRAS|KRAS|RAS|KRAS	GeneOrGeneProduct	9:61:100:132:203:348:360:373	10:62:101:133:204:349:361:374	0:3:4:6:7:10:11:11	8651	SOCS1	GeneOrGeneProduct	186	187	6	1:NR:2	L2R	CROSS	303-304	348-349	3845	KRAS|RAS|KRAS|KRAS|KRAS|KRAS|RAS|KRAS	GeneOrGeneProduct	9:61:100:132:203:348:360:373	10:62:101:133:204:349:361:374	0:3:4:6:7:10:11:11	673	BRAF	GeneOrGeneProduct	303	304	8	1:NR:2	L2R	CROSS	305-306	348-349	3845	KRAS|RAS|KRAS|KRAS|KRAS|KRAS|RAS|KRAS	GeneOrGeneProduct	9:61:100:132:203:348:360:373	10:62:101:133:204:349:361:374	0:3:4:6:7:10:11:11	7157	p53	GeneOrGeneProduct	305	306	8	1:NR:2	L2R	CROSS	307-308	348-349	3845	KRAS|RAS|KRAS|KRAS|KRAS|KRAS|RAS|KRAS	GeneOrGeneProduct	9:61:100:132:203:348:360:373	10:62:101:133:204:349:361:374	0:3:4:6:7:10:11:11	1026	p21	GeneOrGeneProduct	307	308	8	1:NR:2	L2R	CROSS	309-312	348-349	3845	KRAS|RAS|KRAS|KRAS|KRAS|KRAS|RAS|KRAS	GeneOrGeneProduct	9:61:100:132:203:348:360:373	10:62:101:133:204:349:361:374	0:3:4:6:7:10:11:11	1499	beta - catenin	GeneOrGeneProduct	309	312	8	1:NR:2	L2R	CROSS	314-317	348-349	3845	KRAS|RAS|KRAS|KRAS|KRAS|KRAS|RAS|KRAS	GeneOrGeneProduct	9:61:100:132:203:348:360:373	10:62:101:133:204:349:361:374	0:3:4:6:7:10:11:11	5743	cyclooxygenase - 2	GeneOrGeneProduct	314	317	8	1:Negative_Correlation:2	R2L	NON-CROSS	15-17	12-14	D014807	Vitamin D	ChemicalEntity	15	17	1	D015179	colorectal cancer|colon cancer|colorectal cancers|colorectal cancer|colorectal cancer	DiseaseOrPhenotypicFeature	12:27:107:274:340	14:29:109:276:342	0:1:5:8:10	1:NR:2	L2R	CROSS	340-342	362-363	D015179	colorectal cancer|colon cancer|colorectal cancers|colorectal cancer|colorectal cancer	DiseaseOrPhenotypicFeature	12:27:107:274:340	14:29:109:276:342	0:1:5:8:10	1432	mitogen - activated protein kinase|MAPK|MAPK	GeneOrGeneProduct	63:69:362	68:70:363	3:3:11	1:NR:2	L2R	CROSS	340-342	366-367	D015179	colorectal cancer|colon cancer|colorectal cancers|colorectal cancer|colorectal cancer	DiseaseOrPhenotypicFeature	12:27:107:274:340	14:29:109:276:342	0:1:5:8:10	207	AKT|AKT	GeneOrGeneProduct	80:366	81:367	3:11	1:NR:2	L2R	CROSS	107-109	168-169	D015179	colorectal cancer|colon cancer|colorectal cancers|colorectal cancer|colorectal cancer	DiseaseOrPhenotypicFeature	12:27:107:274:340	14:29:109:276:342	0:1:5:8:10	8913	CACNA1G	GeneOrGeneProduct	168	169	6	1:NR:2	L2R	CROSS	107-109	170-171	D015179	colorectal cancer|colon cancer|colorectal cancers|colorectal cancer|colorectal cancer	DiseaseOrPhenotypicFeature	12:27:107:274:340	14:29:109:276:342	0:1:5:8:10	1029	CDKN2A|p16	GeneOrGeneProduct	170:172	171:173	6:6	1:NR:2	L2R	CROSS	107-109	175-176	D015179	colorectal cancer|colon cancer|colorectal cancers|colorectal cancer|colorectal cancer	DiseaseOrPhenotypicFeature	12:27:107:274:340	14:29:109:276:342	0:1:5:8:10	1381	CRABP1	GeneOrGeneProduct	175	176	6	1:NR:2	L2R	CROSS	107-109	177-178	D015179	colorectal cancer|colon cancer|colorectal cancers|colorectal cancer|colorectal cancer	DiseaseOrPhenotypicFeature	12:27:107:274:340	14:29:109:276:342	0:1:5:8:10	3481	IGF2	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	CROSS	107-109	179-180	D015179	colorectal cancer|colon cancer|colorectal cancers|colorectal cancer|colorectal cancer	DiseaseOrPhenotypicFeature	12:27:107:274:340	14:29:109:276:342	0:1:5:8:10	4292	MLH1	GeneOrGeneProduct	179	180	6	1:NR:2	L2R	CROSS	107-109	181-182	D015179	colorectal cancer|colon cancer|colorectal cancers|colorectal cancer|colorectal cancer	DiseaseOrPhenotypicFeature	12:27:107:274:340	14:29:109:276:342	0:1:5:8:10	4762	NEUROG1	GeneOrGeneProduct	181	182	6	1:NR:2	L2R	CROSS	107-109	183-184	D015179	colorectal cancer|colon cancer|colorectal cancers|colorectal cancer|colorectal cancer	DiseaseOrPhenotypicFeature	12:27:107:274:340	14:29:109:276:342	0:1:5:8:10	864	RUNX3	GeneOrGeneProduct	183	184	6	1:NR:2	L2R	CROSS	107-109	186-187	D015179	colorectal cancer|colon cancer|colorectal cancers|colorectal cancer|colorectal cancer	DiseaseOrPhenotypicFeature	12:27:107:274:340	14:29:109:276:342	0:1:5:8:10	8651	SOCS1	GeneOrGeneProduct	186	187	6	1:NR:2	L2R	NON-CROSS	274-276	303-304	D015179	colorectal cancer|colon cancer|colorectal cancers|colorectal cancer|colorectal cancer	DiseaseOrPhenotypicFeature	12:27:107:274:340	14:29:109:276:342	0:1:5:8:10	673	BRAF	GeneOrGeneProduct	303	304	8	1:NR:2	L2R	NON-CROSS	274-276	305-306	D015179	colorectal cancer|colon cancer|colorectal cancers|colorectal cancer|colorectal cancer	DiseaseOrPhenotypicFeature	12:27:107:274:340	14:29:109:276:342	0:1:5:8:10	7157	p53	GeneOrGeneProduct	305	306	8	1:NR:2	L2R	NON-CROSS	274-276	307-308	D015179	colorectal cancer|colon cancer|colorectal cancers|colorectal cancer|colorectal cancer	DiseaseOrPhenotypicFeature	12:27:107:274:340	14:29:109:276:342	0:1:5:8:10	1026	p21	GeneOrGeneProduct	307	308	8	1:NR:2	L2R	NON-CROSS	309-312	340-342	D015179	colorectal cancer|colon cancer|colorectal cancers|colorectal cancer|colorectal cancer	DiseaseOrPhenotypicFeature	12:27:107:274:340	14:29:109:276:342	0:1:5:8:10	1499	beta - catenin	GeneOrGeneProduct	309	312	8	1:NR:2	L2R	NON-CROSS	314-317	340-342	D015179	colorectal cancer|colon cancer|colorectal cancers|colorectal cancer|colorectal cancer	DiseaseOrPhenotypicFeature	12:27:107:274:340	14:29:109:276:342	0:1:5:8:10	5743	cyclooxygenase - 2	GeneOrGeneProduct	314	317	8	1:Negative_Correlation:2	L2R	NON-CROSS	15-17	24-25	D014807	Vitamin D	ChemicalEntity	15	17	1	D009369	cancers|tumors|tumor|tumor	DiseaseOrPhenotypicFeature	24:120:277:287	25:121:278:288	1:5:8:8	1:NR:2	L2R	CROSS	15-17	63-68	D014807	Vitamin D	ChemicalEntity	15	17	1	1432	mitogen - activated protein kinase|MAPK|MAPK	GeneOrGeneProduct	63:69:362	68:70:363	3:3:11	1:NR:2	L2R	CROSS	15-17	80-81	D014807	Vitamin D	ChemicalEntity	15	17	1	207	AKT|AKT	GeneOrGeneProduct	80:366	81:367	3:11	1:NR:2	L2R	CROSS	15-17	168-169	D014807	Vitamin D	ChemicalEntity	15	17	1	8913	CACNA1G	GeneOrGeneProduct	168	169	6	1:NR:2	L2R	CROSS	15-17	170-171	D014807	Vitamin D	ChemicalEntity	15	17	1	1029	CDKN2A|p16	GeneOrGeneProduct	170:172	171:173	6:6	1:NR:2	L2R	CROSS	15-17	175-176	D014807	Vitamin D	ChemicalEntity	15	17	1	1381	CRABP1	GeneOrGeneProduct	175	176	6	1:NR:2	L2R	CROSS	15-17	177-178	D014807	Vitamin D	ChemicalEntity	15	17	1	3481	IGF2	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	CROSS	15-17	179-180	D014807	Vitamin D	ChemicalEntity	15	17	1	4292	MLH1	GeneOrGeneProduct	179	180	6	1:NR:2	L2R	CROSS	15-17	181-182	D014807	Vitamin D	ChemicalEntity	15	17	1	4762	NEUROG1	GeneOrGeneProduct	181	182	6	1:NR:2	L2R	CROSS	15-17	183-184	D014807	Vitamin D	ChemicalEntity	15	17	1	864	RUNX3	GeneOrGeneProduct	183	184	6	1:NR:2	L2R	CROSS	15-17	186-187	D014807	Vitamin D	ChemicalEntity	15	17	1	8651	SOCS1	GeneOrGeneProduct	186	187	6	1:NR:2	L2R	CROSS	15-17	303-304	D014807	Vitamin D	ChemicalEntity	15	17	1	673	BRAF	GeneOrGeneProduct	303	304	8	1:NR:2	L2R	CROSS	15-17	305-306	D014807	Vitamin D	ChemicalEntity	15	17	1	7157	p53	GeneOrGeneProduct	305	306	8	1:NR:2	L2R	CROSS	15-17	307-308	D014807	Vitamin D	ChemicalEntity	15	17	1	1026	p21	GeneOrGeneProduct	307	308	8	1:NR:2	L2R	CROSS	15-17	309-312	D014807	Vitamin D	ChemicalEntity	15	17	1	1499	beta - catenin	GeneOrGeneProduct	309	312	8	1:NR:2	L2R	CROSS	15-17	314-317	D014807	Vitamin D	ChemicalEntity	15	17	1	5743	cyclooxygenase - 2	GeneOrGeneProduct	314	317	8	1:NR:2	L2R	CROSS	24-25	63-68	D009369	cancers|tumors|tumor|tumor	DiseaseOrPhenotypicFeature	24:120:277:287	25:121:278:288	1:5:8:8	1432	mitogen - activated protein kinase|MAPK|MAPK	GeneOrGeneProduct	63:69:362	68:70:363	3:3:11	1:NR:2	L2R	CROSS	80-81	120-121	D009369	cancers|tumors|tumor|tumor	DiseaseOrPhenotypicFeature	24:120:277:287	25:121:278:288	1:5:8:8	207	AKT|AKT	GeneOrGeneProduct	80:366	81:367	3:11	1:NR:2	L2R	CROSS	120-121	168-169	D009369	cancers|tumors|tumor|tumor	DiseaseOrPhenotypicFeature	24:120:277:287	25:121:278:288	1:5:8:8	8913	CACNA1G	GeneOrGeneProduct	168	169	6	1:NR:2	L2R	CROSS	120-121	170-171	D009369	cancers|tumors|tumor|tumor	DiseaseOrPhenotypicFeature	24:120:277:287	25:121:278:288	1:5:8:8	1029	CDKN2A|p16	GeneOrGeneProduct	170:172	171:173	6:6	1:NR:2	L2R	CROSS	120-121	175-176	D009369	cancers|tumors|tumor|tumor	DiseaseOrPhenotypicFeature	24:120:277:287	25:121:278:288	1:5:8:8	1381	CRABP1	GeneOrGeneProduct	175	176	6	1:NR:2	L2R	CROSS	120-121	177-178	D009369	cancers|tumors|tumor|tumor	DiseaseOrPhenotypicFeature	24:120:277:287	25:121:278:288	1:5:8:8	3481	IGF2	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	CROSS	120-121	179-180	D009369	cancers|tumors|tumor|tumor	DiseaseOrPhenotypicFeature	24:120:277:287	25:121:278:288	1:5:8:8	4292	MLH1	GeneOrGeneProduct	179	180	6	1:NR:2	L2R	CROSS	120-121	181-182	D009369	cancers|tumors|tumor|tumor	DiseaseOrPhenotypicFeature	24:120:277:287	25:121:278:288	1:5:8:8	4762	NEUROG1	GeneOrGeneProduct	181	182	6	1:NR:2	L2R	CROSS	120-121	183-184	D009369	cancers|tumors|tumor|tumor	DiseaseOrPhenotypicFeature	24:120:277:287	25:121:278:288	1:5:8:8	864	RUNX3	GeneOrGeneProduct	183	184	6	1:NR:2	L2R	CROSS	120-121	186-187	D009369	cancers|tumors|tumor|tumor	DiseaseOrPhenotypicFeature	24:120:277:287	25:121:278:288	1:5:8:8	8651	SOCS1	GeneOrGeneProduct	186	187	6	1:NR:2	L2R	NON-CROSS	287-288	303-304	D009369	cancers|tumors|tumor|tumor	DiseaseOrPhenotypicFeature	24:120:277:287	25:121:278:288	1:5:8:8	673	BRAF	GeneOrGeneProduct	303	304	8	1:NR:2	L2R	NON-CROSS	287-288	305-306	D009369	cancers|tumors|tumor|tumor	DiseaseOrPhenotypicFeature	24:120:277:287	25:121:278:288	1:5:8:8	7157	p53	GeneOrGeneProduct	305	306	8	1:NR:2	L2R	NON-CROSS	287-288	307-308	D009369	cancers|tumors|tumor|tumor	DiseaseOrPhenotypicFeature	24:120:277:287	25:121:278:288	1:5:8:8	1026	p21	GeneOrGeneProduct	307	308	8	1:NR:2	L2R	NON-CROSS	287-288	309-312	D009369	cancers|tumors|tumor|tumor	DiseaseOrPhenotypicFeature	24:120:277:287	25:121:278:288	1:5:8:8	1499	beta - catenin	GeneOrGeneProduct	309	312	8	1:NR:2	L2R	NON-CROSS	287-288	314-317	D009369	cancers|tumors|tumor|tumor	DiseaseOrPhenotypicFeature	24:120:277:287	25:121:278:288	1:5:8:8	5743	cyclooxygenase - 2	GeneOrGeneProduct	314	317	8	1:NR:2	L2R	NON-CROSS	362-363	366-367	1432	mitogen - activated protein kinase|MAPK|MAPK	GeneOrGeneProduct	63:69:362	68:70:363	3:3:11	207	AKT|AKT	GeneOrGeneProduct	80:366	81:367	3:11	1:NR:2	L2R	CROSS	69-70	168-169	1432	mitogen - activated protein kinase|MAPK|MAPK	GeneOrGeneProduct	63:69:362	68:70:363	3:3:11	8913	CACNA1G	GeneOrGeneProduct	168	169	6	1:NR:2	L2R	CROSS	69-70	170-171	1432	mitogen - activated protein kinase|MAPK|MAPK	GeneOrGeneProduct	63:69:362	68:70:363	3:3:11	1029	CDKN2A|p16	GeneOrGeneProduct	170:172	171:173	6:6	1:NR:2	L2R	CROSS	69-70	175-176	1432	mitogen - activated protein kinase|MAPK|MAPK	GeneOrGeneProduct	63:69:362	68:70:363	3:3:11	1381	CRABP1	GeneOrGeneProduct	175	176	6	1:NR:2	L2R	CROSS	69-70	177-178	1432	mitogen - activated protein kinase|MAPK|MAPK	GeneOrGeneProduct	63:69:362	68:70:363	3:3:11	3481	IGF2	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	CROSS	69-70	179-180	1432	mitogen - activated protein kinase|MAPK|MAPK	GeneOrGeneProduct	63:69:362	68:70:363	3:3:11	4292	MLH1	GeneOrGeneProduct	179	180	6	1:NR:2	L2R	CROSS	69-70	181-182	1432	mitogen - activated protein kinase|MAPK|MAPK	GeneOrGeneProduct	63:69:362	68:70:363	3:3:11	4762	NEUROG1	GeneOrGeneProduct	181	182	6	1:NR:2	L2R	CROSS	69-70	183-184	1432	mitogen - activated protein kinase|MAPK|MAPK	GeneOrGeneProduct	63:69:362	68:70:363	3:3:11	864	RUNX3	GeneOrGeneProduct	183	184	6	1:NR:2	L2R	CROSS	69-70	186-187	1432	mitogen - activated protein kinase|MAPK|MAPK	GeneOrGeneProduct	63:69:362	68:70:363	3:3:11	8651	SOCS1	GeneOrGeneProduct	186	187	6	1:NR:2	L2R	CROSS	303-304	362-363	1432	mitogen - activated protein kinase|MAPK|MAPK	GeneOrGeneProduct	63:69:362	68:70:363	3:3:11	673	BRAF	GeneOrGeneProduct	303	304	8	1:NR:2	L2R	CROSS	305-306	362-363	1432	mitogen - activated protein kinase|MAPK|MAPK	GeneOrGeneProduct	63:69:362	68:70:363	3:3:11	7157	p53	GeneOrGeneProduct	305	306	8	1:NR:2	L2R	CROSS	307-308	362-363	1432	mitogen - activated protein kinase|MAPK|MAPK	GeneOrGeneProduct	63:69:362	68:70:363	3:3:11	1026	p21	GeneOrGeneProduct	307	308	8	1:NR:2	L2R	CROSS	309-312	362-363	1432	mitogen - activated protein kinase|MAPK|MAPK	GeneOrGeneProduct	63:69:362	68:70:363	3:3:11	1499	beta - catenin	GeneOrGeneProduct	309	312	8	1:NR:2	L2R	CROSS	314-317	362-363	1432	mitogen - activated protein kinase|MAPK|MAPK	GeneOrGeneProduct	63:69:362	68:70:363	3:3:11	5743	cyclooxygenase - 2	GeneOrGeneProduct	314	317	8	1:NR:2	L2R	CROSS	80-81	168-169	207	AKT|AKT	GeneOrGeneProduct	80:366	81:367	3:11	8913	CACNA1G	GeneOrGeneProduct	168	169	6	1:NR:2	L2R	CROSS	80-81	170-171	207	AKT|AKT	GeneOrGeneProduct	80:366	81:367	3:11	1029	CDKN2A|p16	GeneOrGeneProduct	170:172	171:173	6:6	1:NR:2	L2R	CROSS	80-81	175-176	207	AKT|AKT	GeneOrGeneProduct	80:366	81:367	3:11	1381	CRABP1	GeneOrGeneProduct	175	176	6	1:NR:2	L2R	CROSS	80-81	177-178	207	AKT|AKT	GeneOrGeneProduct	80:366	81:367	3:11	3481	IGF2	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	CROSS	80-81	179-180	207	AKT|AKT	GeneOrGeneProduct	80:366	81:367	3:11	4292	MLH1	GeneOrGeneProduct	179	180	6	1:NR:2	L2R	CROSS	80-81	181-182	207	AKT|AKT	GeneOrGeneProduct	80:366	81:367	3:11	4762	NEUROG1	GeneOrGeneProduct	181	182	6	1:NR:2	L2R	CROSS	80-81	183-184	207	AKT|AKT	GeneOrGeneProduct	80:366	81:367	3:11	864	RUNX3	GeneOrGeneProduct	183	184	6	1:NR:2	L2R	CROSS	80-81	186-187	207	AKT|AKT	GeneOrGeneProduct	80:366	81:367	3:11	8651	SOCS1	GeneOrGeneProduct	186	187	6	1:NR:2	L2R	CROSS	303-304	366-367	207	AKT|AKT	GeneOrGeneProduct	80:366	81:367	3:11	673	BRAF	GeneOrGeneProduct	303	304	8	1:NR:2	L2R	CROSS	305-306	366-367	207	AKT|AKT	GeneOrGeneProduct	80:366	81:367	3:11	7157	p53	GeneOrGeneProduct	305	306	8	1:NR:2	L2R	CROSS	307-308	366-367	207	AKT|AKT	GeneOrGeneProduct	80:366	81:367	3:11	1026	p21	GeneOrGeneProduct	307	308	8	1:NR:2	L2R	CROSS	309-312	366-367	207	AKT|AKT	GeneOrGeneProduct	80:366	81:367	3:11	1499	beta - catenin	GeneOrGeneProduct	309	312	8	1:NR:2	L2R	CROSS	314-317	366-367	207	AKT|AKT	GeneOrGeneProduct	80:366	81:367	3:11	5743	cyclooxygenase - 2	GeneOrGeneProduct	314	317	8	1:NR:2	L2R	NON-CROSS	168-169	170-171	8913	CACNA1G	GeneOrGeneProduct	168	169	6	1029	CDKN2A|p16	GeneOrGeneProduct	170:172	171:173	6:6	1:NR:2	L2R	NON-CROSS	168-169	175-176	8913	CACNA1G	GeneOrGeneProduct	168	169	6	1381	CRABP1	GeneOrGeneProduct	175	176	6	1:NR:2	L2R	NON-CROSS	168-169	177-178	8913	CACNA1G	GeneOrGeneProduct	168	169	6	3481	IGF2	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	NON-CROSS	168-169	179-180	8913	CACNA1G	GeneOrGeneProduct	168	169	6	4292	MLH1	GeneOrGeneProduct	179	180	6	1:NR:2	L2R	NON-CROSS	168-169	181-182	8913	CACNA1G	GeneOrGeneProduct	168	169	6	4762	NEUROG1	GeneOrGeneProduct	181	182	6	1:NR:2	L2R	NON-CROSS	168-169	183-184	8913	CACNA1G	GeneOrGeneProduct	168	169	6	864	RUNX3	GeneOrGeneProduct	183	184	6	1:NR:2	L2R	NON-CROSS	168-169	186-187	8913	CACNA1G	GeneOrGeneProduct	168	169	6	8651	SOCS1	GeneOrGeneProduct	186	187	6	1:NR:2	L2R	CROSS	168-169	303-304	8913	CACNA1G	GeneOrGeneProduct	168	169	6	673	BRAF	GeneOrGeneProduct	303	304	8	1:NR:2	L2R	CROSS	168-169	305-306	8913	CACNA1G	GeneOrGeneProduct	168	169	6	7157	p53	GeneOrGeneProduct	305	306	8	1:NR:2	L2R	CROSS	168-169	307-308	8913	CACNA1G	GeneOrGeneProduct	168	169	6	1026	p21	GeneOrGeneProduct	307	308	8	1:NR:2	L2R	CROSS	168-169	309-312	8913	CACNA1G	GeneOrGeneProduct	168	169	6	1499	beta - catenin	GeneOrGeneProduct	309	312	8	1:NR:2	L2R	CROSS	168-169	314-317	8913	CACNA1G	GeneOrGeneProduct	168	169	6	5743	cyclooxygenase - 2	GeneOrGeneProduct	314	317	8	1:NR:2	L2R	NON-CROSS	172-173	175-176	1029	CDKN2A|p16	GeneOrGeneProduct	170:172	171:173	6:6	1381	CRABP1	GeneOrGeneProduct	175	176	6	1:NR:2	L2R	NON-CROSS	172-173	177-178	1029	CDKN2A|p16	GeneOrGeneProduct	170:172	171:173	6:6	3481	IGF2	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	NON-CROSS	172-173	179-180	1029	CDKN2A|p16	GeneOrGeneProduct	170:172	171:173	6:6	4292	MLH1	GeneOrGeneProduct	179	180	6	1:NR:2	L2R	NON-CROSS	172-173	181-182	1029	CDKN2A|p16	GeneOrGeneProduct	170:172	171:173	6:6	4762	NEUROG1	GeneOrGeneProduct	181	182	6	1:NR:2	L2R	NON-CROSS	172-173	183-184	1029	CDKN2A|p16	GeneOrGeneProduct	170:172	171:173	6:6	864	RUNX3	GeneOrGeneProduct	183	184	6	1:NR:2	L2R	NON-CROSS	172-173	186-187	1029	CDKN2A|p16	GeneOrGeneProduct	170:172	171:173	6:6	8651	SOCS1	GeneOrGeneProduct	186	187	6	1:NR:2	L2R	CROSS	172-173	303-304	1029	CDKN2A|p16	GeneOrGeneProduct	170:172	171:173	6:6	673	BRAF	GeneOrGeneProduct	303	304	8	1:NR:2	L2R	CROSS	172-173	305-306	1029	CDKN2A|p16	GeneOrGeneProduct	170:172	171:173	6:6	7157	p53	GeneOrGeneProduct	305	306	8	1:NR:2	L2R	CROSS	172-173	307-308	1029	CDKN2A|p16	GeneOrGeneProduct	170:172	171:173	6:6	1026	p21	GeneOrGeneProduct	307	308	8	1:NR:2	L2R	CROSS	172-173	309-312	1029	CDKN2A|p16	GeneOrGeneProduct	170:172	171:173	6:6	1499	beta - catenin	GeneOrGeneProduct	309	312	8	1:NR:2	L2R	CROSS	172-173	314-317	1029	CDKN2A|p16	GeneOrGeneProduct	170:172	171:173	6:6	5743	cyclooxygenase - 2	GeneOrGeneProduct	314	317	8	1:NR:2	L2R	NON-CROSS	175-176	177-178	1381	CRABP1	GeneOrGeneProduct	175	176	6	3481	IGF2	GeneOrGeneProduct	177	178	6	1:NR:2	L2R	NON-CROSS	175-176	179-180	1381	CRABP1	GeneOrGeneProduct	175	176	6	4292	MLH1	GeneOrGeneProduct	179	180	6	1:NR:2	L2R	NON-CROSS	175-176	181-182	1381	CRABP1	GeneOrGeneProduct	175	176	6	4762	NEUROG1	GeneOrGeneProduct	181	182	6	1:NR:2	L2R	NON-CROSS	175-176	183-184	1381	CRABP1	GeneOrGeneProduct	175	176	6	864	RUNX3	GeneOrGeneProduct	183	184	6	1:NR:2	L2R	NON-CROSS	175-176	186-187	1381	CRABP1	GeneOrGeneProduct	175	176	6	8651	SOCS1	GeneOrGeneProduct	186	187	6	1:NR:2	L2R	CROSS	175-176	303-304	1381	CRABP1	GeneOrGeneProduct	175	176	6	673	BRAF	GeneOrGeneProduct	303	304	8	1:NR:2	L2R	CROSS	175-176	305-306	1381	CRABP1	GeneOrGeneProduct	175	176	6	7157	p53	GeneOrGeneProduct	305	306	8	1:NR:2	L2R	CROSS	175-176	307-308	1381	CRABP1	GeneOrGeneProduct	175	176	6	1026	p21	GeneOrGeneProduct	307	308	8	1:NR:2	L2R	CROSS	175-176	309-312	1381	CRABP1	GeneOrGeneProduct	175	176	6	1499	beta - catenin	GeneOrGeneProduct	309	312	8	1:NR:2	L2R	CROSS	175-176	314-317	1381	CRABP1	GeneOrGeneProduct	175	176	6	5743	cyclooxygenase - 2	GeneOrGeneProduct	314	317	8	1:NR:2	L2R	NON-CROSS	177-178	179-180	3481	IGF2	GeneOrGeneProduct	177	178	6	4292	MLH1	GeneOrGeneProduct	179	180	6	1:NR:2	L2R	NON-CROSS	177-178	181-182	3481	IGF2	GeneOrGeneProduct	177	178	6	4762	NEUROG1	GeneOrGeneProduct	181	182	6	1:NR:2	L2R	NON-CROSS	177-178	183-184	3481	IGF2	GeneOrGeneProduct	177	178	6	864	RUNX3	GeneOrGeneProduct	183	184	6	1:NR:2	L2R	NON-CROSS	177-178	186-187	3481	IGF2	GeneOrGeneProduct	177	178	6	8651	SOCS1	GeneOrGeneProduct	186	187	6	1:NR:2	L2R	CROSS	177-178	303-304	3481	IGF2	GeneOrGeneProduct	177	178	6	673	BRAF	GeneOrGeneProduct	303	304	8	1:NR:2	L2R	CROSS	177-178	305-306	3481	IGF2	GeneOrGeneProduct	177	178	6	7157	p53	GeneOrGeneProduct	305	306	8	1:NR:2	L2R	CROSS	177-178	307-308	3481	IGF2	GeneOrGeneProduct	177	178	6	1026	p21	GeneOrGeneProduct	307	308	8	1:NR:2	L2R	CROSS	177-178	309-312	3481	IGF2	GeneOrGeneProduct	177	178	6	1499	beta - catenin	GeneOrGeneProduct	309	312	8	1:NR:2	L2R	CROSS	177-178	314-317	3481	IGF2	GeneOrGeneProduct	177	178	6	5743	cyclooxygenase - 2	GeneOrGeneProduct	314	317	8	1:NR:2	L2R	NON-CROSS	179-180	181-182	4292	MLH1	GeneOrGeneProduct	179	180	6	4762	NEUROG1	GeneOrGeneProduct	181	182	6	1:NR:2	L2R	NON-CROSS	179-180	183-184	4292	MLH1	GeneOrGeneProduct	179	180	6	864	RUNX3	GeneOrGeneProduct	183	184	6	1:NR:2	L2R	NON-CROSS	179-180	186-187	4292	MLH1	GeneOrGeneProduct	179	180	6	8651	SOCS1	GeneOrGeneProduct	186	187	6	1:NR:2	L2R	CROSS	179-180	303-304	4292	MLH1	GeneOrGeneProduct	179	180	6	673	BRAF	GeneOrGeneProduct	303	304	8	1:NR:2	L2R	CROSS	179-180	305-306	4292	MLH1	GeneOrGeneProduct	179	180	6	7157	p53	GeneOrGeneProduct	305	306	8	1:NR:2	L2R	CROSS	179-180	307-308	4292	MLH1	GeneOrGeneProduct	179	180	6	1026	p21	GeneOrGeneProduct	307	308	8	1:NR:2	L2R	CROSS	179-180	309-312	4292	MLH1	GeneOrGeneProduct	179	180	6	1499	beta - catenin	GeneOrGeneProduct	309	312	8	1:NR:2	L2R	CROSS	179-180	314-317	4292	MLH1	GeneOrGeneProduct	179	180	6	5743	cyclooxygenase - 2	GeneOrGeneProduct	314	317	8	1:NR:2	L2R	NON-CROSS	181-182	183-184	4762	NEUROG1	GeneOrGeneProduct	181	182	6	864	RUNX3	GeneOrGeneProduct	183	184	6	1:NR:2	L2R	NON-CROSS	181-182	186-187	4762	NEUROG1	GeneOrGeneProduct	181	182	6	8651	SOCS1	GeneOrGeneProduct	186	187	6	1:NR:2	L2R	CROSS	181-182	303-304	4762	NEUROG1	GeneOrGeneProduct	181	182	6	673	BRAF	GeneOrGeneProduct	303	304	8	1:NR:2	L2R	CROSS	181-182	305-306	4762	NEUROG1	GeneOrGeneProduct	181	182	6	7157	p53	GeneOrGeneProduct	305	306	8	1:NR:2	L2R	CROSS	181-182	307-308	4762	NEUROG1	GeneOrGeneProduct	181	182	6	1026	p21	GeneOrGeneProduct	307	308	8	1:NR:2	L2R	CROSS	181-182	309-312	4762	NEUROG1	GeneOrGeneProduct	181	182	6	1499	beta - catenin	GeneOrGeneProduct	309	312	8	1:NR:2	L2R	CROSS	181-182	314-317	4762	NEUROG1	GeneOrGeneProduct	181	182	6	5743	cyclooxygenase - 2	GeneOrGeneProduct	314	317	8	1:NR:2	L2R	NON-CROSS	183-184	186-187	864	RUNX3	GeneOrGeneProduct	183	184	6	8651	SOCS1	GeneOrGeneProduct	186	187	6	1:NR:2	L2R	CROSS	183-184	303-304	864	RUNX3	GeneOrGeneProduct	183	184	6	673	BRAF	GeneOrGeneProduct	303	304	8	1:NR:2	L2R	CROSS	183-184	305-306	864	RUNX3	GeneOrGeneProduct	183	184	6	7157	p53	GeneOrGeneProduct	305	306	8	1:NR:2	L2R	CROSS	183-184	307-308	864	RUNX3	GeneOrGeneProduct	183	184	6	1026	p21	GeneOrGeneProduct	307	308	8	1:NR:2	L2R	CROSS	183-184	309-312	864	RUNX3	GeneOrGeneProduct	183	184	6	1499	beta - catenin	GeneOrGeneProduct	309	312	8	1:NR:2	L2R	CROSS	183-184	314-317	864	RUNX3	GeneOrGeneProduct	183	184	6	5743	cyclooxygenase - 2	GeneOrGeneProduct	314	317	8	1:NR:2	L2R	CROSS	186-187	303-304	8651	SOCS1	GeneOrGeneProduct	186	187	6	673	BRAF	GeneOrGeneProduct	303	304	8	1:NR:2	L2R	CROSS	186-187	305-306	8651	SOCS1	GeneOrGeneProduct	186	187	6	7157	p53	GeneOrGeneProduct	305	306	8	1:NR:2	L2R	CROSS	186-187	307-308	8651	SOCS1	GeneOrGeneProduct	186	187	6	1026	p21	GeneOrGeneProduct	307	308	8	1:NR:2	L2R	CROSS	186-187	309-312	8651	SOCS1	GeneOrGeneProduct	186	187	6	1499	beta - catenin	GeneOrGeneProduct	309	312	8	1:NR:2	L2R	CROSS	186-187	314-317	8651	SOCS1	GeneOrGeneProduct	186	187	6	5743	cyclooxygenase - 2	GeneOrGeneProduct	314	317	8	1:NR:2	L2R	NON-CROSS	303-304	305-306	673	BRAF	GeneOrGeneProduct	303	304	8	7157	p53	GeneOrGeneProduct	305	306	8	1:NR:2	L2R	NON-CROSS	303-304	307-308	673	BRAF	GeneOrGeneProduct	303	304	8	1026	p21	GeneOrGeneProduct	307	308	8	1:NR:2	L2R	NON-CROSS	303-304	309-312	673	BRAF	GeneOrGeneProduct	303	304	8	1499	beta - catenin	GeneOrGeneProduct	309	312	8	1:NR:2	L2R	NON-CROSS	303-304	314-317	673	BRAF	GeneOrGeneProduct	303	304	8	5743	cyclooxygenase - 2	GeneOrGeneProduct	314	317	8	1:NR:2	L2R	NON-CROSS	305-306	307-308	7157	p53	GeneOrGeneProduct	305	306	8	1026	p21	GeneOrGeneProduct	307	308	8	1:NR:2	L2R	NON-CROSS	305-306	309-312	7157	p53	GeneOrGeneProduct	305	306	8	1499	beta - catenin	GeneOrGeneProduct	309	312	8	1:NR:2	L2R	NON-CROSS	305-306	314-317	7157	p53	GeneOrGeneProduct	305	306	8	5743	cyclooxygenase - 2	GeneOrGeneProduct	314	317	8	1:NR:2	L2R	NON-CROSS	307-308	309-312	1026	p21	GeneOrGeneProduct	307	308	8	1499	beta - catenin	GeneOrGeneProduct	309	312	8	1:NR:2	L2R	NON-CROSS	307-308	314-317	1026	p21	GeneOrGeneProduct	307	308	8	5743	cyclooxygenase - 2	GeneOrGeneProduct	314	317	8	1:NR:2	L2R	NON-CROSS	309-312	314-317	1499	beta - catenin	GeneOrGeneProduct	309	312	8	5743	cyclooxygenase - 2	GeneOrGeneProduct	314	317	8
24442316	Cultured mycelium Cordyceps sinensis protects liver sinusoidal endothelial cells in acute liver injured mice .|Cultured mycelium Cordyceps sinensis ( CMCS ) was widely used for a variety of diseases including liver injury , the current study aims to investigate the protective effects of CMCS on liver sinusoidal endothelial cells ( LSECs ) in acute injury liver and related action mechanisms .|The mice were injected intraperitoneally with lipopolysaccharide ( LPS ) and D - galactosamine ( D - GalN ) .|39 male BABL / c mice were randomly divided into four groups : normal control , model control , CMCS treatment and 1 , 10 - phenanthroline treatment groups .|The Serum liver function parameters including alanine aminotransferase ( ALT ) and aspartate aminotransferase ( AST ) levels were assayed with the commercial kit .|The inflammation and scaffold structure in liver were stained with hematoxylin and eosin and silver staining respectively .|The LSECs and sub - endothelial basement membrane were observed with the scanning and transmission electronic microscope .|The protein expressions of intercellular adhesion molecule - 1 ( ICAM - 1 ) and vascular cell adhesion molecule - 1 ( VCAM - 1 ) in liver were analyzed with Western blotting .|Expression of von Willebrand factor ( vWF ) was investigated with immunofluorescence staining .|The lipid peroxidation indicators including antisuperoxideanion ( ASAFR ) , hydroxyl free radical ( . OH ) , superoxide dismutase ( SOD ) , malondialdehyde and glutathione S - transferase ( GST ) were determined with kits , and matrix metalloproteinase - 2 and 9 ( MMP - 2 / 9 ) activities in liver were analyzed with gelatin zymography and in situ fluorescent zymography respectively .|The model mice had much higher serum levels of ALT and AST than the normal mice .|Compared to that in the normal control , more severe liver inflammation and hepatocyte apoptosis , worse hepatic lipid peroxidation demonstrated by the increased ASAFR , . OH and MDA , but decreased SOD and GST , increased MMP - 2 / 9 activities and VCAM - 1 , ICAM - 1 and vWF expressions , which revealed obvious LSEC injury and scaffold structure broken , were shown in the model control .|Compared with the model group , CMCS and 1 , 10 - phenanthroline significantly improved serum ALT / AST , attenuated hepatic inflammation and improved peroxidative injury in liver , decreased MMP - 2 / 9 activities in liver tissue , improved integration of scaffold structure , and decreased protein expression of VCAM - 1 and ICAM - 1 .|CMCS could protect LSECs from injury and maintain the microvasculature integration in acute injured liver of mice induced by LPS / D - GalN .|Its action mechanism was associated with the down - regulation of MMP - 2 / 9 activities and inhibition of peroxidation in injured liver .	1:NR:2	L2R	NON-CROSS	438-439	441-444	-	Cultured mycelium Cordyceps sinensis|Cultured mycelium Cordyceps sinensis|CMCS|CMCS|CMCS|CMCS|CMCS	ChemicalEntity	0:15:20:44:101:384:438	4:19:21:45:102:385:439	0:1:1:1:3:12:13	D008107	liver injured|liver injury|injury liver|liver inflammation|LSEC injury|hepatic inflammation|injury in liver|LSECs from injury|injured liver|injured liver	DiseaseOrPhenotypicFeature	11:31:55:315:364:399:404:441:451:485	13:33:57:317:366:401:407:444:453:487	0:1:1:11:11:12:12:13:13:14	1:NR:2	L2R	NON-CROSS	438-439	457-458	-	Cultured mycelium Cordyceps sinensis|Cultured mycelium Cordyceps sinensis|CMCS|CMCS|CMCS|CMCS|CMCS	ChemicalEntity	0:15:20:44:101:384:438	4:19:21:45:102:385:439	0:1:1:1:3:12:13	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	68:70:457	69:71:458	2:2:13	1:NR:2	L2R	NON-CROSS	438-439	459-462	-	Cultured mycelium Cordyceps sinensis|Cultured mycelium Cordyceps sinensis|CMCS|CMCS|CMCS|CMCS|CMCS	ChemicalEntity	0:15:20:44:101:384:438	4:19:21:45:102:385:439	0:1:1:1:3:12:13	D005688	D - galactosamine|D - GalN|D - GalN	ChemicalEntity	73:77:459	76:80:462	2:2:13	1:NR:2	L2R	NON-CROSS	384-385	386-391	-	Cultured mycelium Cordyceps sinensis|Cultured mycelium Cordyceps sinensis|CMCS|CMCS|CMCS|CMCS|CMCS	ChemicalEntity	0:15:20:44:101:384:438	4:19:21:45:102:385:439	0:1:1:1:3:12:13	C025205	1 , 10 - phenanthroline|1 , 10 - phenanthroline	ChemicalEntity	104:386	109:391	3:12	1:NR:2	L2R	NON-CROSS	384-385	394-395	-	Cultured mycelium Cordyceps sinensis|Cultured mycelium Cordyceps sinensis|CMCS|CMCS|CMCS|CMCS|CMCS	ChemicalEntity	0:15:20:44:101:384:438	4:19:21:45:102:385:439	0:1:1:1:3:12:13	76282	alanine aminotransferase|ALT|ALT|ALT	GeneOrGeneProduct	118:121:297:394	120:122:298:395	4:4:10:12	1:NR:2	L2R	NON-CROSS	384-385	396-397	-	Cultured mycelium Cordyceps sinensis|Cultured mycelium Cordyceps sinensis|CMCS|CMCS|CMCS|CMCS|CMCS	ChemicalEntity	0:15:20:44:101:384:438	4:19:21:45:102:385:439	0:1:1:1:3:12:13	14718	aspartate aminotransferase|AST|AST|AST	GeneOrGeneProduct	124:127:299:396	126:128:300:397	4:4:10:12	1:NR:2	L2R	CROSS	101-102	138-139	-	Cultured mycelium Cordyceps sinensis|Cultured mycelium Cordyceps sinensis|CMCS|CMCS|CMCS|CMCS|CMCS	ChemicalEntity	0:15:20:44:101:384:438	4:19:21:45:102:385:439	0:1:1:1:3:12:13	D007249	inflammation	DiseaseOrPhenotypicFeature	138	139	5	1:NR:2	L2R	NON-CROSS	434-437	438-439	-	Cultured mycelium Cordyceps sinensis|Cultured mycelium Cordyceps sinensis|CMCS|CMCS|CMCS|CMCS|CMCS	ChemicalEntity	0:15:20:44:101:384:438	4:19:21:45:102:385:439	0:1:1:1:3:12:13	15894	intercellular adhesion molecule - 1|ICAM - 1|ICAM - 1|ICAM - 1	GeneOrGeneProduct	177:183:354:434	182:186:357:437	7:7:11:12	1:NR:2	L2R	NON-CROSS	430-433	438-439	-	Cultured mycelium Cordyceps sinensis|Cultured mycelium Cordyceps sinensis|CMCS|CMCS|CMCS|CMCS|CMCS	ChemicalEntity	0:15:20:44:101:384:438	4:19:21:45:102:385:439	0:1:1:1:3:12:13	22329	vascular cell adhesion molecule - 1|VCAM - 1|VCAM - 1|VCAM - 1	GeneOrGeneProduct	188:195:350:430	194:198:353:433	7:7:11:12	1:NR:2	L2R	CROSS	358-359	384-385	-	Cultured mycelium Cordyceps sinensis|Cultured mycelium Cordyceps sinensis|CMCS|CMCS|CMCS|CMCS|CMCS	ChemicalEntity	0:15:20:44:101:384:438	4:19:21:45:102:385:439	0:1:1:1:3:12:13	22371	von Willebrand factor|vWF|vWF	GeneOrGeneProduct	209:213:358	212:214:359	8:8:11	1:NR:2	L2R	CROSS	323-324	384-385	-	Cultured mycelium Cordyceps sinensis|Cultured mycelium Cordyceps sinensis|CMCS|CMCS|CMCS|CMCS|CMCS	ChemicalEntity	0:15:20:44:101:384:438	4:19:21:45:102:385:439	0:1:1:1:3:12:13	D008055	lipid|lipid	ChemicalEntity	222:323	223:324	9:11	1:NR:2	L2R	CROSS	331-333	384-385	-	Cultured mycelium Cordyceps sinensis|Cultured mycelium Cordyceps sinensis|CMCS|CMCS|CMCS|CMCS|CMCS	ChemicalEntity	0:15:20:44:101:384:438	4:19:21:45:102:385:439	0:1:1:1:3:12:13	D017665	hydroxyl free radical|. OH|. OH	ChemicalEntity	231:235:331	234:237:333	9:9:11	1:NR:2	L2R	CROSS	338-339	384-385	-	Cultured mycelium Cordyceps sinensis|Cultured mycelium Cordyceps sinensis|CMCS|CMCS|CMCS|CMCS|CMCS	ChemicalEntity	0:15:20:44:101:384:438	4:19:21:45:102:385:439	0:1:1:1:3:12:13	20655	superoxide dismutase|SOD|SOD	GeneOrGeneProduct	239:242:338	241:243:339	9:9:11	1:NR:2	L2R	CROSS	334-335	384-385	-	Cultured mycelium Cordyceps sinensis|Cultured mycelium Cordyceps sinensis|CMCS|CMCS|CMCS|CMCS|CMCS	ChemicalEntity	0:15:20:44:101:384:438	4:19:21:45:102:385:439	0:1:1:1:3:12:13	D008315	malondialdehyde|MDA	ChemicalEntity	245:334	246:335	9:11	1:NR:2	L2R	CROSS	340-341	384-385	-	Cultured mycelium Cordyceps sinensis|Cultured mycelium Cordyceps sinensis|CMCS|CMCS|CMCS|CMCS|CMCS	ChemicalEntity	0:15:20:44:101:384:438	4:19:21:45:102:385:439	0:1:1:1:3:12:13	54486	glutathione S - transferase|GST	GeneOrGeneProduct	247:340	251:341	9:11	1:NR:2	L2R	CROSS	252-253	384-385	-	Cultured mycelium Cordyceps sinensis|Cultured mycelium Cordyceps sinensis|CMCS|CMCS|CMCS|CMCS|CMCS	ChemicalEntity	0:15:20:44:101:384:438	4:19:21:45:102:385:439	0:1:1:1:3:12:13	14870	GST	GeneOrGeneProduct	252	253	9	1:NR:2	L2R	NON-CROSS	384-385	409-414	-	Cultured mycelium Cordyceps sinensis|Cultured mycelium Cordyceps sinensis|CMCS|CMCS|CMCS|CMCS|CMCS	ChemicalEntity	0:15:20:44:101:384:438	4:19:21:45:102:385:439	0:1:1:1:3:12:13	17390,17395	matrix metalloproteinase - 2 and 9|MMP - 2 / 9|MMP - 2 / 9|MMP - 2 / 9|MMP - 2 / 9	GeneOrGeneProduct	260:267:343:409:474	266:272:348:414:479	9:9:11:12:14	1:Positive_Correlation:2	L2R	NON-CROSS	451-453	457-458	D008107	liver injured|liver injury|injury liver|liver inflammation|LSEC injury|hepatic inflammation|injury in liver|LSECs from injury|injured liver|injured liver	DiseaseOrPhenotypicFeature	11:31:55:315:364:399:404:441:451:485	13:33:57:317:366:401:407:444:453:487	0:1:1:11:11:12:12:13:13:14	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	68:70:457	69:71:458	2:2:13	1:Positive_Correlation:2	R2L	NON-CROSS	459-462	451-453	D005688	D - galactosamine|D - GalN|D - GalN	ChemicalEntity	73:77:459	76:80:462	2:2:13	D008107	liver injured|liver injury|injury liver|liver inflammation|LSEC injury|hepatic inflammation|injury in liver|LSECs from injury|injured liver|injured liver	DiseaseOrPhenotypicFeature	11:31:55:315:364:399:404:441:451:485	13:33:57:317:366:401:407:444:453:487	0:1:1:11:11:12:12:13:13:14	1:Negative_Correlation:2	R2L	NON-CROSS	399-401	386-391	C025205	1 , 10 - phenanthroline|1 , 10 - phenanthroline	ChemicalEntity	104:386	109:391	3:12	D008107	liver injured|liver injury|injury liver|liver inflammation|LSEC injury|hepatic inflammation|injury in liver|LSECs from injury|injured liver|injured liver	DiseaseOrPhenotypicFeature	11:31:55:315:364:399:404:441:451:485	13:33:57:317:366:401:407:444:453:487	0:1:1:11:11:12:12:13:13:14	1:Association:2	R2L	NON-CROSS	399-401	394-395	76282	alanine aminotransferase|ALT|ALT|ALT	GeneOrGeneProduct	118:121:297:394	120:122:298:395	4:4:10:12	D008107	liver injured|liver injury|injury liver|liver inflammation|LSEC injury|hepatic inflammation|injury in liver|LSECs from injury|injured liver|injured liver	DiseaseOrPhenotypicFeature	11:31:55:315:364:399:404:441:451:485	13:33:57:317:366:401:407:444:453:487	0:1:1:11:11:12:12:13:13:14	1:Association:2	R2L	NON-CROSS	399-401	396-397	14718	aspartate aminotransferase|AST|AST|AST	GeneOrGeneProduct	124:127:299:396	126:128:300:397	4:4:10:12	D008107	liver injured|liver injury|injury liver|liver inflammation|LSEC injury|hepatic inflammation|injury in liver|LSECs from injury|injured liver|injured liver	DiseaseOrPhenotypicFeature	11:31:55:315:364:399:404:441:451:485	13:33:57:317:366:401:407:444:453:487	0:1:1:11:11:12:12:13:13:14	1:Association:2	L2R	NON-CROSS	434-437	441-444	D008107	liver injured|liver injury|injury liver|liver inflammation|LSEC injury|hepatic inflammation|injury in liver|LSECs from injury|injured liver|injured liver	DiseaseOrPhenotypicFeature	11:31:55:315:364:399:404:441:451:485	13:33:57:317:366:401:407:444:453:487	0:1:1:11:11:12:12:13:13:14	15894	intercellular adhesion molecule - 1|ICAM - 1|ICAM - 1|ICAM - 1	GeneOrGeneProduct	177:183:354:434	182:186:357:437	7:7:11:12	1:Association:2	L2R	NON-CROSS	430-433	441-444	D008107	liver injured|liver injury|injury liver|liver inflammation|LSEC injury|hepatic inflammation|injury in liver|LSECs from injury|injured liver|injured liver	DiseaseOrPhenotypicFeature	11:31:55:315:364:399:404:441:451:485	13:33:57:317:366:401:407:444:453:487	0:1:1:11:11:12:12:13:13:14	22329	vascular cell adhesion molecule - 1|VCAM - 1|VCAM - 1|VCAM - 1	GeneOrGeneProduct	188:195:350:430	194:198:353:433	7:7:11:12	1:Association:2	L2R	NON-CROSS	358-359	364-366	D008107	liver injured|liver injury|injury liver|liver inflammation|LSEC injury|hepatic inflammation|injury in liver|LSECs from injury|injured liver|injured liver	DiseaseOrPhenotypicFeature	11:31:55:315:364:399:404:441:451:485	13:33:57:317:366:401:407:444:453:487	0:1:1:11:11:12:12:13:13:14	22371	von Willebrand factor|vWF|vWF	GeneOrGeneProduct	209:213:358	212:214:359	8:8:11	1:Association:2	L2R	NON-CROSS	315-317	323-324	D008107	liver injured|liver injury|injury liver|liver inflammation|LSEC injury|hepatic inflammation|injury in liver|LSECs from injury|injured liver|injured liver	DiseaseOrPhenotypicFeature	11:31:55:315:364:399:404:441:451:485	13:33:57:317:366:401:407:444:453:487	0:1:1:11:11:12:12:13:13:14	D008055	lipid|lipid	ChemicalEntity	222:323	223:324	9:11	1:Positive_Correlation:2	L2R	NON-CROSS	315-317	331-333	D008107	liver injured|liver injury|injury liver|liver inflammation|LSEC injury|hepatic inflammation|injury in liver|LSECs from injury|injured liver|injured liver	DiseaseOrPhenotypicFeature	11:31:55:315:364:399:404:441:451:485	13:33:57:317:366:401:407:444:453:487	0:1:1:11:11:12:12:13:13:14	D017665	hydroxyl free radical|. OH|. OH	ChemicalEntity	231:235:331	234:237:333	9:9:11	1:Association:2	L2R	NON-CROSS	315-317	338-339	D008107	liver injured|liver injury|injury liver|liver inflammation|LSEC injury|hepatic inflammation|injury in liver|LSECs from injury|injured liver|injured liver	DiseaseOrPhenotypicFeature	11:31:55:315:364:399:404:441:451:485	13:33:57:317:366:401:407:444:453:487	0:1:1:11:11:12:12:13:13:14	20655	superoxide dismutase|SOD|SOD	GeneOrGeneProduct	239:242:338	241:243:339	9:9:11	1:Positive_Correlation:2	L2R	NON-CROSS	315-317	334-335	D008107	liver injured|liver injury|injury liver|liver inflammation|LSEC injury|hepatic inflammation|injury in liver|LSECs from injury|injured liver|injured liver	DiseaseOrPhenotypicFeature	11:31:55:315:364:399:404:441:451:485	13:33:57:317:366:401:407:444:453:487	0:1:1:11:11:12:12:13:13:14	D008315	malondialdehyde|MDA	ChemicalEntity	245:334	246:335	9:11	1:Association:2	L2R	NON-CROSS	315-317	340-341	D008107	liver injured|liver injury|injury liver|liver inflammation|LSEC injury|hepatic inflammation|injury in liver|LSECs from injury|injured liver|injured liver	DiseaseOrPhenotypicFeature	11:31:55:315:364:399:404:441:451:485	13:33:57:317:366:401:407:444:453:487	0:1:1:11:11:12:12:13:13:14	54486	glutathione S - transferase|GST	GeneOrGeneProduct	247:340	251:341	9:11	1:NR:2	L2R	CROSS	252-253	315-317	D008107	liver injured|liver injury|injury liver|liver inflammation|LSEC injury|hepatic inflammation|injury in liver|LSECs from injury|injured liver|injured liver	DiseaseOrPhenotypicFeature	11:31:55:315:364:399:404:441:451:485	13:33:57:317:366:401:407:444:453:487	0:1:1:11:11:12:12:13:13:14	14870	GST	GeneOrGeneProduct	252	253	9	1:NR:2	L2R	NON-CROSS	404-407	409-414	D008107	liver injured|liver injury|injury liver|liver inflammation|LSEC injury|hepatic inflammation|injury in liver|LSECs from injury|injured liver|injured liver	DiseaseOrPhenotypicFeature	11:31:55:315:364:399:404:441:451:485	13:33:57:317:366:401:407:444:453:487	0:1:1:11:11:12:12:13:13:14	17390,17395	matrix metalloproteinase - 2 and 9|MMP - 2 / 9|MMP - 2 / 9|MMP - 2 / 9|MMP - 2 / 9	GeneOrGeneProduct	260:267:343:409:474	266:272:348:414:479	9:9:11:12:14	1:NR:2	L2R	NON-CROSS	457-458	459-462	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	68:70:457	69:71:458	2:2:13	D005688	D - galactosamine|D - GalN|D - GalN	ChemicalEntity	73:77:459	76:80:462	2:2:13	1:NR:2	L2R	CROSS	70-71	104-109	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	68:70:457	69:71:458	2:2:13	C025205	1 , 10 - phenanthroline|1 , 10 - phenanthroline	ChemicalEntity	104:386	109:391	3:12	1:NR:2	L2R	CROSS	70-71	118-120	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	68:70:457	69:71:458	2:2:13	76282	alanine aminotransferase|ALT|ALT|ALT	GeneOrGeneProduct	118:121:297:394	120:122:298:395	4:4:10:12	1:NR:2	L2R	CROSS	70-71	124-126	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	68:70:457	69:71:458	2:2:13	14718	aspartate aminotransferase|AST|AST|AST	GeneOrGeneProduct	124:127:299:396	126:128:300:397	4:4:10:12	1:NR:2	L2R	CROSS	70-71	138-139	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	68:70:457	69:71:458	2:2:13	D007249	inflammation	DiseaseOrPhenotypicFeature	138	139	5	1:NR:2	L2R	CROSS	434-437	457-458	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	68:70:457	69:71:458	2:2:13	15894	intercellular adhesion molecule - 1|ICAM - 1|ICAM - 1|ICAM - 1	GeneOrGeneProduct	177:183:354:434	182:186:357:437	7:7:11:12	1:NR:2	L2R	CROSS	430-433	457-458	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	68:70:457	69:71:458	2:2:13	22329	vascular cell adhesion molecule - 1|VCAM - 1|VCAM - 1|VCAM - 1	GeneOrGeneProduct	188:195:350:430	194:198:353:433	7:7:11:12	1:NR:2	L2R	CROSS	358-359	457-458	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	68:70:457	69:71:458	2:2:13	22371	von Willebrand factor|vWF|vWF	GeneOrGeneProduct	209:213:358	212:214:359	8:8:11	1:NR:2	L2R	CROSS	323-324	457-458	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	68:70:457	69:71:458	2:2:13	D008055	lipid|lipid	ChemicalEntity	222:323	223:324	9:11	1:NR:2	L2R	CROSS	331-333	457-458	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	68:70:457	69:71:458	2:2:13	D017665	hydroxyl free radical|. OH|. OH	ChemicalEntity	231:235:331	234:237:333	9:9:11	1:NR:2	L2R	CROSS	338-339	457-458	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	68:70:457	69:71:458	2:2:13	20655	superoxide dismutase|SOD|SOD	GeneOrGeneProduct	239:242:338	241:243:339	9:9:11	1:NR:2	L2R	CROSS	334-335	457-458	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	68:70:457	69:71:458	2:2:13	D008315	malondialdehyde|MDA	ChemicalEntity	245:334	246:335	9:11	1:NR:2	L2R	CROSS	340-341	457-458	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	68:70:457	69:71:458	2:2:13	54486	glutathione S - transferase|GST	GeneOrGeneProduct	247:340	251:341	9:11	1:NR:2	L2R	CROSS	70-71	252-253	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	68:70:457	69:71:458	2:2:13	14870	GST	GeneOrGeneProduct	252	253	9	1:NR:2	L2R	CROSS	457-458	474-479	D008070	lipopolysaccharide|LPS|LPS	ChemicalEntity	68:70:457	69:71:458	2:2:13	17390,17395	matrix metalloproteinase - 2 and 9|MMP - 2 / 9|MMP - 2 / 9|MMP - 2 / 9|MMP - 2 / 9	GeneOrGeneProduct	260:267:343:409:474	266:272:348:414:479	9:9:11:12:14	1:NR:2	L2R	CROSS	77-80	104-109	D005688	D - galactosamine|D - GalN|D - GalN	ChemicalEntity	73:77:459	76:80:462	2:2:13	C025205	1 , 10 - phenanthroline|1 , 10 - phenanthroline	ChemicalEntity	104:386	109:391	3:12	1:NR:2	L2R	CROSS	77-80	118-120	D005688	D - galactosamine|D - GalN|D - GalN	ChemicalEntity	73:77:459	76:80:462	2:2:13	76282	alanine aminotransferase|ALT|ALT|ALT	GeneOrGeneProduct	118:121:297:394	120:122:298:395	4:4:10:12	1:NR:2	L2R	CROSS	77-80	124-126	D005688	D - galactosamine|D - GalN|D - GalN	ChemicalEntity	73:77:459	76:80:462	2:2:13	14718	aspartate aminotransferase|AST|AST|AST	GeneOrGeneProduct	124:127:299:396	126:128:300:397	4:4:10:12	1:NR:2	L2R	CROSS	77-80	138-139	D005688	D - galactosamine|D - GalN|D - GalN	ChemicalEntity	73:77:459	76:80:462	2:2:13	D007249	inflammation	DiseaseOrPhenotypicFeature	138	139	5	1:NR:2	L2R	CROSS	434-437	459-462	D005688	D - galactosamine|D - GalN|D - GalN	ChemicalEntity	73:77:459	76:80:462	2:2:13	15894	intercellular adhesion molecule - 1|ICAM - 1|ICAM - 1|ICAM - 1	GeneOrGeneProduct	177:183:354:434	182:186:357:437	7:7:11:12	1:NR:2	L2R	CROSS	430-433	459-462	D005688	D - galactosamine|D - GalN|D - GalN	ChemicalEntity	73:77:459	76:80:462	2:2:13	22329	vascular cell adhesion molecule - 1|VCAM - 1|VCAM - 1|VCAM - 1	GeneOrGeneProduct	188:195:350:430	194:198:353:433	7:7:11:12	1:NR:2	L2R	CROSS	358-359	459-462	D005688	D - galactosamine|D - GalN|D - GalN	ChemicalEntity	73:77:459	76:80:462	2:2:13	22371	von Willebrand factor|vWF|vWF	GeneOrGeneProduct	209:213:358	212:214:359	8:8:11	1:NR:2	L2R	CROSS	323-324	459-462	D005688	D - galactosamine|D - GalN|D - GalN	ChemicalEntity	73:77:459	76:80:462	2:2:13	D008055	lipid|lipid	ChemicalEntity	222:323	223:324	9:11	1:NR:2	L2R	CROSS	331-333	459-462	D005688	D - galactosamine|D - GalN|D - GalN	ChemicalEntity	73:77:459	76:80:462	2:2:13	D017665	hydroxyl free radical|. OH|. OH	ChemicalEntity	231:235:331	234:237:333	9:9:11	1:NR:2	L2R	CROSS	338-339	459-462	D005688	D - galactosamine|D - GalN|D - GalN	ChemicalEntity	73:77:459	76:80:462	2:2:13	20655	superoxide dismutase|SOD|SOD	GeneOrGeneProduct	239:242:338	241:243:339	9:9:11	1:NR:2	L2R	CROSS	334-335	459-462	D005688	D - galactosamine|D - GalN|D - GalN	ChemicalEntity	73:77:459	76:80:462	2:2:13	D008315	malondialdehyde|MDA	ChemicalEntity	245:334	246:335	9:11	1:NR:2	L2R	CROSS	340-341	459-462	D005688	D - galactosamine|D - GalN|D - GalN	ChemicalEntity	73:77:459	76:80:462	2:2:13	54486	glutathione S - transferase|GST	GeneOrGeneProduct	247:340	251:341	9:11	1:NR:2	L2R	CROSS	77-80	252-253	D005688	D - galactosamine|D - GalN|D - GalN	ChemicalEntity	73:77:459	76:80:462	2:2:13	14870	GST	GeneOrGeneProduct	252	253	9	1:NR:2	L2R	CROSS	459-462	474-479	D005688	D - galactosamine|D - GalN|D - GalN	ChemicalEntity	73:77:459	76:80:462	2:2:13	17390,17395	matrix metalloproteinase - 2 and 9|MMP - 2 / 9|MMP - 2 / 9|MMP - 2 / 9|MMP - 2 / 9	GeneOrGeneProduct	260:267:343:409:474	266:272:348:414:479	9:9:11:12:14	1:Positive_Correlation:2	L2R	NON-CROSS	386-391	394-395	C025205	1 , 10 - phenanthroline|1 , 10 - phenanthroline	ChemicalEntity	104:386	109:391	3:12	76282	alanine aminotransferase|ALT|ALT|ALT	GeneOrGeneProduct	118:121:297:394	120:122:298:395	4:4:10:12	1:Positive_Correlation:2	L2R	NON-CROSS	386-391	396-397	C025205	1 , 10 - phenanthroline|1 , 10 - phenanthroline	ChemicalEntity	104:386	109:391	3:12	14718	aspartate aminotransferase|AST|AST|AST	GeneOrGeneProduct	124:127:299:396	126:128:300:397	4:4:10:12	1:NR:2	L2R	CROSS	104-109	138-139	C025205	1 , 10 - phenanthroline|1 , 10 - phenanthroline	ChemicalEntity	104:386	109:391	3:12	D007249	inflammation	DiseaseOrPhenotypicFeature	138	139	5	1:Negative_Correlation:2	L2R	NON-CROSS	354-357	386-391	C025205	1 , 10 - phenanthroline|1 , 10 - phenanthroline	ChemicalEntity	104:386	109:391	3:12	15894	intercellular adhesion molecule - 1|ICAM - 1|ICAM - 1|ICAM - 1	GeneOrGeneProduct	177:183:354:434	182:186:357:437	7:7:11:12	1:Negative_Correlation:2	L2R	NON-CROSS	350-353	386-391	C025205	1 , 10 - phenanthroline|1 , 10 - phenanthroline	ChemicalEntity	104:386	109:391	3:12	22329	vascular cell adhesion molecule - 1|VCAM - 1|VCAM - 1|VCAM - 1	GeneOrGeneProduct	188:195:350:430	194:198:353:433	7:7:11:12	1:NR:2	L2R	CROSS	358-359	386-391	C025205	1 , 10 - phenanthroline|1 , 10 - phenanthroline	ChemicalEntity	104:386	109:391	3:12	22371	von Willebrand factor|vWF|vWF	GeneOrGeneProduct	209:213:358	212:214:359	8:8:11	1:NR:2	L2R	CROSS	323-324	386-391	C025205	1 , 10 - phenanthroline|1 , 10 - phenanthroline	ChemicalEntity	104:386	109:391	3:12	D008055	lipid|lipid	ChemicalEntity	222:323	223:324	9:11	1:NR:2	L2R	CROSS	331-333	386-391	C025205	1 , 10 - phenanthroline|1 , 10 - phenanthroline	ChemicalEntity	104:386	109:391	3:12	D017665	hydroxyl free radical|. OH|. OH	ChemicalEntity	231:235:331	234:237:333	9:9:11	1:NR:2	L2R	CROSS	338-339	386-391	C025205	1 , 10 - phenanthroline|1 , 10 - phenanthroline	ChemicalEntity	104:386	109:391	3:12	20655	superoxide dismutase|SOD|SOD	GeneOrGeneProduct	239:242:338	241:243:339	9:9:11	1:NR:2	L2R	CROSS	334-335	386-391	C025205	1 , 10 - phenanthroline|1 , 10 - phenanthroline	ChemicalEntity	104:386	109:391	3:12	D008315	malondialdehyde|MDA	ChemicalEntity	245:334	246:335	9:11	1:NR:2	L2R	CROSS	340-341	386-391	C025205	1 , 10 - phenanthroline|1 , 10 - phenanthroline	ChemicalEntity	104:386	109:391	3:12	54486	glutathione S - transferase|GST	GeneOrGeneProduct	247:340	251:341	9:11	1:NR:2	L2R	CROSS	252-253	386-391	C025205	1 , 10 - phenanthroline|1 , 10 - phenanthroline	ChemicalEntity	104:386	109:391	3:12	14870	GST	GeneOrGeneProduct	252	253	9	1:NR:2	L2R	NON-CROSS	386-391	409-414	C025205	1 , 10 - phenanthroline|1 , 10 - phenanthroline	ChemicalEntity	104:386	109:391	3:12	17390,17395	matrix metalloproteinase - 2 and 9|MMP - 2 / 9|MMP - 2 / 9|MMP - 2 / 9|MMP - 2 / 9	GeneOrGeneProduct	260:267:343:409:474	266:272:348:414:479	9:9:11:12:14	1:NR:2	L2R	NON-CROSS	297-298	299-300	76282	alanine aminotransferase|ALT|ALT|ALT	GeneOrGeneProduct	118:121:297:394	120:122:298:395	4:4:10:12	14718	aspartate aminotransferase|AST|AST|AST	GeneOrGeneProduct	124:127:299:396	126:128:300:397	4:4:10:12	1:NR:2	L2R	CROSS	121-122	138-139	76282	alanine aminotransferase|ALT|ALT|ALT	GeneOrGeneProduct	118:121:297:394	120:122:298:395	4:4:10:12	D007249	inflammation	DiseaseOrPhenotypicFeature	138	139	5	1:NR:2	L2R	NON-CROSS	354-357	394-395	76282	alanine aminotransferase|ALT|ALT|ALT	GeneOrGeneProduct	118:121:297:394	120:122:298:395	4:4:10:12	15894	intercellular adhesion molecule - 1|ICAM - 1|ICAM - 1|ICAM - 1	GeneOrGeneProduct	177:183:354:434	182:186:357:437	7:7:11:12	1:NR:2	L2R	NON-CROSS	394-395	430-433	76282	alanine aminotransferase|ALT|ALT|ALT	GeneOrGeneProduct	118:121:297:394	120:122:298:395	4:4:10:12	22329	vascular cell adhesion molecule - 1|VCAM - 1|VCAM - 1|VCAM - 1	GeneOrGeneProduct	188:195:350:430	194:198:353:433	7:7:11:12	1:NR:2	L2R	CROSS	358-359	394-395	76282	alanine aminotransferase|ALT|ALT|ALT	GeneOrGeneProduct	118:121:297:394	120:122:298:395	4:4:10:12	22371	von Willebrand factor|vWF|vWF	GeneOrGeneProduct	209:213:358	212:214:359	8:8:11	1:NR:2	L2R	CROSS	297-298	323-324	76282	alanine aminotransferase|ALT|ALT|ALT	GeneOrGeneProduct	118:121:297:394	120:122:298:395	4:4:10:12	D008055	lipid|lipid	ChemicalEntity	222:323	223:324	9:11	1:NR:2	L2R	CROSS	297-298	331-333	76282	alanine aminotransferase|ALT|ALT|ALT	GeneOrGeneProduct	118:121:297:394	120:122:298:395	4:4:10:12	D017665	hydroxyl free radical|. OH|. OH	ChemicalEntity	231:235:331	234:237:333	9:9:11	1:NR:2	L2R	CROSS	297-298	338-339	76282	alanine aminotransferase|ALT|ALT|ALT	GeneOrGeneProduct	118:121:297:394	120:122:298:395	4:4:10:12	20655	superoxide dismutase|SOD|SOD	GeneOrGeneProduct	239:242:338	241:243:339	9:9:11	1:NR:2	L2R	CROSS	297-298	334-335	76282	alanine aminotransferase|ALT|ALT|ALT	GeneOrGeneProduct	118:121:297:394	120:122:298:395	4:4:10:12	D008315	malondialdehyde|MDA	ChemicalEntity	245:334	246:335	9:11	1:NR:2	L2R	CROSS	297-298	340-341	76282	alanine aminotransferase|ALT|ALT|ALT	GeneOrGeneProduct	118:121:297:394	120:122:298:395	4:4:10:12	54486	glutathione S - transferase|GST	GeneOrGeneProduct	247:340	251:341	9:11	1:NR:2	L2R	CROSS	252-253	297-298	76282	alanine aminotransferase|ALT|ALT|ALT	GeneOrGeneProduct	118:121:297:394	120:122:298:395	4:4:10:12	14870	GST	GeneOrGeneProduct	252	253	9	1:NR:2	L2R	NON-CROSS	394-395	409-414	76282	alanine aminotransferase|ALT|ALT|ALT	GeneOrGeneProduct	118:121:297:394	120:122:298:395	4:4:10:12	17390,17395	matrix metalloproteinase - 2 and 9|MMP - 2 / 9|MMP - 2 / 9|MMP - 2 / 9|MMP - 2 / 9	GeneOrGeneProduct	260:267:343:409:474	266:272:348:414:479	9:9:11:12:14	1:NR:2	L2R	CROSS	127-128	138-139	14718	aspartate aminotransferase|AST|AST|AST	GeneOrGeneProduct	124:127:299:396	126:128:300:397	4:4:10:12	D007249	inflammation	DiseaseOrPhenotypicFeature	138	139	5	1:NR:2	L2R	NON-CROSS	396-397	434-437	14718	aspartate aminotransferase|AST|AST|AST	GeneOrGeneProduct	124:127:299:396	126:128:300:397	4:4:10:12	15894	intercellular adhesion molecule - 1|ICAM - 1|ICAM - 1|ICAM - 1	GeneOrGeneProduct	177:183:354:434	182:186:357:437	7:7:11:12	1:NR:2	L2R	NON-CROSS	396-397	430-433	14718	aspartate aminotransferase|AST|AST|AST	GeneOrGeneProduct	124:127:299:396	126:128:300:397	4:4:10:12	22329	vascular cell adhesion molecule - 1|VCAM - 1|VCAM - 1|VCAM - 1	GeneOrGeneProduct	188:195:350:430	194:198:353:433	7:7:11:12	1:NR:2	L2R	CROSS	358-359	396-397	14718	aspartate aminotransferase|AST|AST|AST	GeneOrGeneProduct	124:127:299:396	126:128:300:397	4:4:10:12	22371	von Willebrand factor|vWF|vWF	GeneOrGeneProduct	209:213:358	212:214:359	8:8:11	1:NR:2	L2R	CROSS	299-300	323-324	14718	aspartate aminotransferase|AST|AST|AST	GeneOrGeneProduct	124:127:299:396	126:128:300:397	4:4:10:12	D008055	lipid|lipid	ChemicalEntity	222:323	223:324	9:11	1:NR:2	L2R	CROSS	299-300	331-333	14718	aspartate aminotransferase|AST|AST|AST	GeneOrGeneProduct	124:127:299:396	126:128:300:397	4:4:10:12	D017665	hydroxyl free radical|. OH|. OH	ChemicalEntity	231:235:331	234:237:333	9:9:11	1:NR:2	L2R	CROSS	299-300	338-339	14718	aspartate aminotransferase|AST|AST|AST	GeneOrGeneProduct	124:127:299:396	126:128:300:397	4:4:10:12	20655	superoxide dismutase|SOD|SOD	GeneOrGeneProduct	239:242:338	241:243:339	9:9:11	1:NR:2	L2R	CROSS	299-300	334-335	14718	aspartate aminotransferase|AST|AST|AST	GeneOrGeneProduct	124:127:299:396	126:128:300:397	4:4:10:12	D008315	malondialdehyde|MDA	ChemicalEntity	245:334	246:335	9:11	1:NR:2	L2R	CROSS	299-300	340-341	14718	aspartate aminotransferase|AST|AST|AST	GeneOrGeneProduct	124:127:299:396	126:128:300:397	4:4:10:12	54486	glutathione S - transferase|GST	GeneOrGeneProduct	247:340	251:341	9:11	1:NR:2	L2R	CROSS	252-253	299-300	14718	aspartate aminotransferase|AST|AST|AST	GeneOrGeneProduct	124:127:299:396	126:128:300:397	4:4:10:12	14870	GST	GeneOrGeneProduct	252	253	9	1:NR:2	L2R	NON-CROSS	396-397	409-414	14718	aspartate aminotransferase|AST|AST|AST	GeneOrGeneProduct	124:127:299:396	126:128:300:397	4:4:10:12	17390,17395	matrix metalloproteinase - 2 and 9|MMP - 2 / 9|MMP - 2 / 9|MMP - 2 / 9|MMP - 2 / 9	GeneOrGeneProduct	260:267:343:409:474	266:272:348:414:479	9:9:11:12:14	1:NR:2	L2R	CROSS	138-139	177-182	D007249	inflammation	DiseaseOrPhenotypicFeature	138	139	5	15894	intercellular adhesion molecule - 1|ICAM - 1|ICAM - 1|ICAM - 1	GeneOrGeneProduct	177:183:354:434	182:186:357:437	7:7:11:12	1:NR:2	L2R	CROSS	138-139	188-194	D007249	inflammation	DiseaseOrPhenotypicFeature	138	139	5	22329	vascular cell adhesion molecule - 1|VCAM - 1|VCAM - 1|VCAM - 1	GeneOrGeneProduct	188:195:350:430	194:198:353:433	7:7:11:12	1:NR:2	L2R	CROSS	138-139	209-212	D007249	inflammation	DiseaseOrPhenotypicFeature	138	139	5	22371	von Willebrand factor|vWF|vWF	GeneOrGeneProduct	209:213:358	212:214:359	8:8:11	1:NR:2	L2R	CROSS	138-139	222-223	D007249	inflammation	DiseaseOrPhenotypicFeature	138	139	5	D008055	lipid|lipid	ChemicalEntity	222:323	223:324	9:11	1:NR:2	L2R	CROSS	138-139	231-234	D007249	inflammation	DiseaseOrPhenotypicFeature	138	139	5	D017665	hydroxyl free radical|. OH|. OH	ChemicalEntity	231:235:331	234:237:333	9:9:11	1:NR:2	L2R	CROSS	138-139	239-241	D007249	inflammation	DiseaseOrPhenotypicFeature	138	139	5	20655	superoxide dismutase|SOD|SOD	GeneOrGeneProduct	239:242:338	241:243:339	9:9:11	1:NR:2	L2R	CROSS	138-139	245-246	D007249	inflammation	DiseaseOrPhenotypicFeature	138	139	5	D008315	malondialdehyde|MDA	ChemicalEntity	245:334	246:335	9:11	1:NR:2	L2R	CROSS	138-139	247-251	D007249	inflammation	DiseaseOrPhenotypicFeature	138	139	5	54486	glutathione S - transferase|GST	GeneOrGeneProduct	247:340	251:341	9:11	1:NR:2	L2R	CROSS	138-139	252-253	D007249	inflammation	DiseaseOrPhenotypicFeature	138	139	5	14870	GST	GeneOrGeneProduct	252	253	9	1:NR:2	L2R	CROSS	138-139	260-266	D007249	inflammation	DiseaseOrPhenotypicFeature	138	139	5	17390,17395	matrix metalloproteinase - 2 and 9|MMP - 2 / 9|MMP - 2 / 9|MMP - 2 / 9|MMP - 2 / 9	GeneOrGeneProduct	260:267:343:409:474	266:272:348:414:479	9:9:11:12:14	1:NR:2	L2R	NON-CROSS	430-433	434-437	15894	intercellular adhesion molecule - 1|ICAM - 1|ICAM - 1|ICAM - 1	GeneOrGeneProduct	177:183:354:434	182:186:357:437	7:7:11:12	22329	vascular cell adhesion molecule - 1|VCAM - 1|VCAM - 1|VCAM - 1	GeneOrGeneProduct	188:195:350:430	194:198:353:433	7:7:11:12	1:NR:2	L2R	NON-CROSS	354-357	358-359	15894	intercellular adhesion molecule - 1|ICAM - 1|ICAM - 1|ICAM - 1	GeneOrGeneProduct	177:183:354:434	182:186:357:437	7:7:11:12	22371	von Willebrand factor|vWF|vWF	GeneOrGeneProduct	209:213:358	212:214:359	8:8:11	1:NR:2	L2R	NON-CROSS	323-324	354-357	15894	intercellular adhesion molecule - 1|ICAM - 1|ICAM - 1|ICAM - 1	GeneOrGeneProduct	177:183:354:434	182:186:357:437	7:7:11:12	D008055	lipid|lipid	ChemicalEntity	222:323	223:324	9:11	1:NR:2	L2R	NON-CROSS	331-333	354-357	15894	intercellular adhesion molecule - 1|ICAM - 1|ICAM - 1|ICAM - 1	GeneOrGeneProduct	177:183:354:434	182:186:357:437	7:7:11:12	D017665	hydroxyl free radical|. OH|. OH	ChemicalEntity	231:235:331	234:237:333	9:9:11	1:NR:2	L2R	NON-CROSS	338-339	354-357	15894	intercellular adhesion molecule - 1|ICAM - 1|ICAM - 1|ICAM - 1	GeneOrGeneProduct	177:183:354:434	182:186:357:437	7:7:11:12	20655	superoxide dismutase|SOD|SOD	GeneOrGeneProduct	239:242:338	241:243:339	9:9:11	1:NR:2	L2R	NON-CROSS	334-335	354-357	15894	intercellular adhesion molecule - 1|ICAM - 1|ICAM - 1|ICAM - 1	GeneOrGeneProduct	177:183:354:434	182:186:357:437	7:7:11:12	D008315	malondialdehyde|MDA	ChemicalEntity	245:334	246:335	9:11	1:NR:2	L2R	NON-CROSS	340-341	354-357	15894	intercellular adhesion molecule - 1|ICAM - 1|ICAM - 1|ICAM - 1	GeneOrGeneProduct	177:183:354:434	182:186:357:437	7:7:11:12	54486	glutathione S - transferase|GST	GeneOrGeneProduct	247:340	251:341	9:11	1:NR:2	L2R	CROSS	183-186	252-253	15894	intercellular adhesion molecule - 1|ICAM - 1|ICAM - 1|ICAM - 1	GeneOrGeneProduct	177:183:354:434	182:186:357:437	7:7:11:12	14870	GST	GeneOrGeneProduct	252	253	9	1:NR:2	L2R	NON-CROSS	343-348	354-357	15894	intercellular adhesion molecule - 1|ICAM - 1|ICAM - 1|ICAM - 1	GeneOrGeneProduct	177:183:354:434	182:186:357:437	7:7:11:12	17390,17395	matrix metalloproteinase - 2 and 9|MMP - 2 / 9|MMP - 2 / 9|MMP - 2 / 9|MMP - 2 / 9	GeneOrGeneProduct	260:267:343:409:474	266:272:348:414:479	9:9:11:12:14	1:NR:2	L2R	NON-CROSS	350-353	358-359	22329	vascular cell adhesion molecule - 1|VCAM - 1|VCAM - 1|VCAM - 1	GeneOrGeneProduct	188:195:350:430	194:198:353:433	7:7:11:12	22371	von Willebrand factor|vWF|vWF	GeneOrGeneProduct	209:213:358	212:214:359	8:8:11	1:NR:2	L2R	NON-CROSS	195-198	222-223	22329	vascular cell adhesion molecule - 1|VCAM - 1|VCAM - 1|VCAM - 1	GeneOrGeneProduct	188:195:350:430	194:198:353:433	7:7:11:12	D008055	lipid|lipid	ChemicalEntity	222:323	223:324	9:11	1:NR:2	L2R	NON-CROSS	331-333	350-353	22329	vascular cell adhesion molecule - 1|VCAM - 1|VCAM - 1|VCAM - 1	GeneOrGeneProduct	188:195:350:430	194:198:353:433	7:7:11:12	D017665	hydroxyl free radical|. OH|. OH	ChemicalEntity	231:235:331	234:237:333	9:9:11	1:NR:2	L2R	NON-CROSS	338-339	350-353	22329	vascular cell adhesion molecule - 1|VCAM - 1|VCAM - 1|VCAM - 1	GeneOrGeneProduct	188:195:350:430	194:198:353:433	7:7:11:12	20655	superoxide dismutase|SOD|SOD	GeneOrGeneProduct	239:242:338	241:243:339	9:9:11	1:NR:2	L2R	NON-CROSS	334-335	350-353	22329	vascular cell adhesion molecule - 1|VCAM - 1|VCAM - 1|VCAM - 1	GeneOrGeneProduct	188:195:350:430	194:198:353:433	7:7:11:12	D008315	malondialdehyde|MDA	ChemicalEntity	245:334	246:335	9:11	1:NR:2	L2R	NON-CROSS	340-341	350-353	22329	vascular cell adhesion molecule - 1|VCAM - 1|VCAM - 1|VCAM - 1	GeneOrGeneProduct	188:195:350:430	194:198:353:433	7:7:11:12	54486	glutathione S - transferase|GST	GeneOrGeneProduct	247:340	251:341	9:11	1:NR:2	L2R	CROSS	195-198	252-253	22329	vascular cell adhesion molecule - 1|VCAM - 1|VCAM - 1|VCAM - 1	GeneOrGeneProduct	188:195:350:430	194:198:353:433	7:7:11:12	14870	GST	GeneOrGeneProduct	252	253	9	1:NR:2	L2R	NON-CROSS	343-348	350-353	22329	vascular cell adhesion molecule - 1|VCAM - 1|VCAM - 1|VCAM - 1	GeneOrGeneProduct	188:195:350:430	194:198:353:433	7:7:11:12	17390,17395	matrix metalloproteinase - 2 and 9|MMP - 2 / 9|MMP - 2 / 9|MMP - 2 / 9|MMP - 2 / 9	GeneOrGeneProduct	260:267:343:409:474	266:272:348:414:479	9:9:11:12:14	1:NR:2	L2R	NON-CROSS	213-214	222-223	22371	von Willebrand factor|vWF|vWF	GeneOrGeneProduct	209:213:358	212:214:359	8:8:11	D008055	lipid|lipid	ChemicalEntity	222:323	223:324	9:11	1:NR:2	L2R	NON-CROSS	213-214	231-234	22371	von Willebrand factor|vWF|vWF	GeneOrGeneProduct	209:213:358	212:214:359	8:8:11	D017665	hydroxyl free radical|. OH|. OH	ChemicalEntity	231:235:331	234:237:333	9:9:11	1:NR:2	L2R	NON-CROSS	338-339	358-359	22371	von Willebrand factor|vWF|vWF	GeneOrGeneProduct	209:213:358	212:214:359	8:8:11	20655	superoxide dismutase|SOD|SOD	GeneOrGeneProduct	239:242:338	241:243:339	9:9:11	1:NR:2	L2R	NON-CROSS	334-335	358-359	22371	von Willebrand factor|vWF|vWF	GeneOrGeneProduct	209:213:358	212:214:359	8:8:11	D008315	malondialdehyde|MDA	ChemicalEntity	245:334	246:335	9:11	1:NR:2	L2R	NON-CROSS	340-341	358-359	22371	von Willebrand factor|vWF|vWF	GeneOrGeneProduct	209:213:358	212:214:359	8:8:11	54486	glutathione S - transferase|GST	GeneOrGeneProduct	247:340	251:341	9:11	1:NR:2	L2R	CROSS	213-214	252-253	22371	von Willebrand factor|vWF|vWF	GeneOrGeneProduct	209:213:358	212:214:359	8:8:11	14870	GST	GeneOrGeneProduct	252	253	9	1:NR:2	L2R	NON-CROSS	343-348	358-359	22371	von Willebrand factor|vWF|vWF	GeneOrGeneProduct	209:213:358	212:214:359	8:8:11	17390,17395	matrix metalloproteinase - 2 and 9|MMP - 2 / 9|MMP - 2 / 9|MMP - 2 / 9|MMP - 2 / 9	GeneOrGeneProduct	260:267:343:409:474	266:272:348:414:479	9:9:11:12:14	1:NR:2	L2R	NON-CROSS	323-324	331-333	D008055	lipid|lipid	ChemicalEntity	222:323	223:324	9:11	D017665	hydroxyl free radical|. OH|. OH	ChemicalEntity	231:235:331	234:237:333	9:9:11	1:NR:2	L2R	NON-CROSS	323-324	338-339	D008055	lipid|lipid	ChemicalEntity	222:323	223:324	9:11	20655	superoxide dismutase|SOD|SOD	GeneOrGeneProduct	239:242:338	241:243:339	9:9:11	1:NR:2	L2R	NON-CROSS	323-324	334-335	D008055	lipid|lipid	ChemicalEntity	222:323	223:324	9:11	D008315	malondialdehyde|MDA	ChemicalEntity	245:334	246:335	9:11	1:NR:2	L2R	NON-CROSS	323-324	340-341	D008055	lipid|lipid	ChemicalEntity	222:323	223:324	9:11	54486	glutathione S - transferase|GST	GeneOrGeneProduct	247:340	251:341	9:11	1:NR:2	L2R	NON-CROSS	222-223	252-253	D008055	lipid|lipid	ChemicalEntity	222:323	223:324	9:11	14870	GST	GeneOrGeneProduct	252	253	9	1:NR:2	L2R	NON-CROSS	323-324	343-348	D008055	lipid|lipid	ChemicalEntity	222:323	223:324	9:11	17390,17395	matrix metalloproteinase - 2 and 9|MMP - 2 / 9|MMP - 2 / 9|MMP - 2 / 9|MMP - 2 / 9	GeneOrGeneProduct	260:267:343:409:474	266:272:348:414:479	9:9:11:12:14	1:NR:2	L2R	NON-CROSS	235-237	239-241	D017665	hydroxyl free radical|. OH|. OH	ChemicalEntity	231:235:331	234:237:333	9:9:11	20655	superoxide dismutase|SOD|SOD	GeneOrGeneProduct	239:242:338	241:243:339	9:9:11	1:NR:2	L2R	NON-CROSS	331-333	334-335	D017665	hydroxyl free radical|. OH|. OH	ChemicalEntity	231:235:331	234:237:333	9:9:11	D008315	malondialdehyde|MDA	ChemicalEntity	245:334	246:335	9:11	1:NR:2	L2R	NON-CROSS	331-333	340-341	D017665	hydroxyl free radical|. OH|. OH	ChemicalEntity	231:235:331	234:237:333	9:9:11	54486	glutathione S - transferase|GST	GeneOrGeneProduct	247:340	251:341	9:11	1:NR:2	L2R	NON-CROSS	235-237	252-253	D017665	hydroxyl free radical|. OH|. OH	ChemicalEntity	231:235:331	234:237:333	9:9:11	14870	GST	GeneOrGeneProduct	252	253	9	1:NR:2	L2R	NON-CROSS	331-333	343-348	D017665	hydroxyl free radical|. OH|. OH	ChemicalEntity	231:235:331	234:237:333	9:9:11	17390,17395	matrix metalloproteinase - 2 and 9|MMP - 2 / 9|MMP - 2 / 9|MMP - 2 / 9|MMP - 2 / 9	GeneOrGeneProduct	260:267:343:409:474	266:272:348:414:479	9:9:11:12:14	1:NR:2	L2R	NON-CROSS	242-243	245-246	20655	superoxide dismutase|SOD|SOD	GeneOrGeneProduct	239:242:338	241:243:339	9:9:11	D008315	malondialdehyde|MDA	ChemicalEntity	245:334	246:335	9:11	1:NR:2	L2R	NON-CROSS	338-339	340-341	20655	superoxide dismutase|SOD|SOD	GeneOrGeneProduct	239:242:338	241:243:339	9:9:11	54486	glutathione S - transferase|GST	GeneOrGeneProduct	247:340	251:341	9:11	1:NR:2	L2R	NON-CROSS	242-243	252-253	20655	superoxide dismutase|SOD|SOD	GeneOrGeneProduct	239:242:338	241:243:339	9:9:11	14870	GST	GeneOrGeneProduct	252	253	9	1:NR:2	L2R	NON-CROSS	338-339	343-348	20655	superoxide dismutase|SOD|SOD	GeneOrGeneProduct	239:242:338	241:243:339	9:9:11	17390,17395	matrix metalloproteinase - 2 and 9|MMP - 2 / 9|MMP - 2 / 9|MMP - 2 / 9|MMP - 2 / 9	GeneOrGeneProduct	260:267:343:409:474	266:272:348:414:479	9:9:11:12:14	1:NR:2	L2R	NON-CROSS	245-246	247-251	D008315	malondialdehyde|MDA	ChemicalEntity	245:334	246:335	9:11	54486	glutathione S - transferase|GST	GeneOrGeneProduct	247:340	251:341	9:11	1:NR:2	L2R	NON-CROSS	245-246	252-253	D008315	malondialdehyde|MDA	ChemicalEntity	245:334	246:335	9:11	14870	GST	GeneOrGeneProduct	252	253	9	1:NR:2	L2R	NON-CROSS	334-335	343-348	D008315	malondialdehyde|MDA	ChemicalEntity	245:334	246:335	9:11	17390,17395	matrix metalloproteinase - 2 and 9|MMP - 2 / 9|MMP - 2 / 9|MMP - 2 / 9|MMP - 2 / 9	GeneOrGeneProduct	260:267:343:409:474	266:272:348:414:479	9:9:11:12:14	1:NR:2	L2R	NON-CROSS	247-251	252-253	54486	glutathione S - transferase|GST	GeneOrGeneProduct	247:340	251:341	9:11	14870	GST	GeneOrGeneProduct	252	253	9	1:NR:2	L2R	NON-CROSS	340-341	343-348	54486	glutathione S - transferase|GST	GeneOrGeneProduct	247:340	251:341	9:11	17390,17395	matrix metalloproteinase - 2 and 9|MMP - 2 / 9|MMP - 2 / 9|MMP - 2 / 9|MMP - 2 / 9	GeneOrGeneProduct	260:267:343:409:474	266:272:348:414:479	9:9:11:12:14	1:NR:2	L2R	NON-CROSS	252-253	260-266	14870	GST	GeneOrGeneProduct	252	253	9	17390,17395	matrix metalloproteinase - 2 and 9|MMP - 2 / 9|MMP - 2 / 9|MMP - 2 / 9|MMP - 2 / 9	GeneOrGeneProduct	260:267:343:409:474	266:272:348:414:479	9:9:11:12:14
28684635	A Type 2 Diabetes - Associated Functional Regulatory Variant in a Pancreatic Islet Enhancer at the ADCY5 Locus .|Molecular mechanisms remain unknown for most type 2 diabetes genome - wide association study identified loci .|Variants associated with type 2 diabetes and fasting glucose levels reside in introns of ADCY5 , a gene that encodes adenylate cyclase 5 .|Adenylate cyclase 5 catalyzes the production of cyclic AMP , which is a second messenger molecule involved in cell signaling and pancreatic b - cell insulin secretion .|We demonstrated that type 2 diabetes risk alleles are associated with decreased ADCY5 expression in human islets and examined candidate variants for regulatory function .|rs11708067 overlaps a predicted enhancer region in pancreatic islets .|The type 2 diabetes risk rs11708067 - A allele showed fewer H3K27ac ChIP - seq reads in human islets , lower transcriptional activity in reporter assays in rodent b - cells ( rat 832 / 13 and mouse MIN6 ) , and increased nuclear protein binding compared with the rs11708067 - G allele .|Homozygous deletion of the orthologous enhancer region in 832 / 13 cells resulted in a 64 % reduction in expression level of Adcy5 , but not adjacent gene Sec22a , and a 39 % reduction in insulin secretion .|Together , these data suggest that rs11708067 - A risk allele contributes to type 2 diabetes by disrupting an islet enhancer , which results in reduced ADCY5 expression and impaired insulin secretion .	1:Negative_Correlation:2	L2R	NON-CROSS	91-94	100-101	D003924	Type 2 Diabetes|type 2 diabetes|type 2 diabetes|type 2 diabetes|type 2 diabetes|type 2 diabetes	DiseaseOrPhenotypicFeature	1:25:39:91:124:229	4:28:42:94:127:232	0:1:2:4:6:8	111	ADCY5|ADCY5|adenylate cyclase 5|Adenylate cyclase 5|ADCY5|ADCY5	GeneOrGeneProduct	16:50:56:60:100:242	17:51:59:63:101:243	0:2:2:3:4:8	1:Association:2	L2R	NON-CROSS	39-42	44-45	D003924	Type 2 Diabetes|type 2 diabetes|type 2 diabetes|type 2 diabetes|type 2 diabetes|type 2 diabetes	DiseaseOrPhenotypicFeature	1:25:39:91:124:229	4:28:42:94:127:232	0:1:2:4:6:8	D005947	glucose	ChemicalEntity	44	45	2	1:NR:2	L2R	CROSS	67-69	91-94	D003924	Type 2 Diabetes|type 2 diabetes|type 2 diabetes|type 2 diabetes|type 2 diabetes|type 2 diabetes	DiseaseOrPhenotypicFeature	1:25:39:91:124:229	4:28:42:94:127:232	0:1:2:4:6:8	D000242	cyclic AMP	ChemicalEntity	67	69	3	1:NR:2	L2R	CROSS	85-86	91-94	D003924	Type 2 Diabetes|type 2 diabetes|type 2 diabetes|type 2 diabetes|type 2 diabetes|type 2 diabetes	DiseaseOrPhenotypicFeature	1:25:39:91:124:229	4:28:42:94:127:232	0:1:2:4:6:8	3630	insulin	GeneOrGeneProduct	85	86	3	1:Positive_Correlation:2	L2R	NON-CROSS	124-127	128-129	D003924	Type 2 Diabetes|type 2 diabetes|type 2 diabetes|type 2 diabetes|type 2 diabetes|type 2 diabetes	DiseaseOrPhenotypicFeature	1:25:39:91:124:229	4:28:42:94:127:232	0:1:2:4:6:8	rs11708067	rs11708067|rs11708067|rs11708067|rs11708067	SequenceVariant	113:128:172:222	114:129:173:223	5:6:6:8	1:NR:2	L2R	CROSS	199-200	229-232	D003924	Type 2 Diabetes|type 2 diabetes|type 2 diabetes|type 2 diabetes|type 2 diabetes|type 2 diabetes	DiseaseOrPhenotypicFeature	1:25:39:91:124:229	4:28:42:94:127:232	0:1:2:4:6:8	64532	Adcy5	GeneOrGeneProduct	199	200	7	1:NR:2	L2R	CROSS	205-206	229-232	D003924	Type 2 Diabetes|type 2 diabetes|type 2 diabetes|type 2 diabetes|type 2 diabetes|type 2 diabetes	DiseaseOrPhenotypicFeature	1:25:39:91:124:229	4:28:42:94:127:232	0:1:2:4:6:8	117513	Sec22a	GeneOrGeneProduct	205	206	7	1:NR:2	L2R	CROSS	213-214	229-232	D003924	Type 2 Diabetes|type 2 diabetes|type 2 diabetes|type 2 diabetes|type 2 diabetes|type 2 diabetes	DiseaseOrPhenotypicFeature	1:25:39:91:124:229	4:28:42:94:127:232	0:1:2:4:6:8	24506	insulin	GeneOrGeneProduct	213	214	7	1:Association:2	R2L	NON-CROSS	50-51	44-45	D005947	glucose	ChemicalEntity	44	45	2	111	ADCY5|ADCY5|adenylate cyclase 5|Adenylate cyclase 5|ADCY5|ADCY5	GeneOrGeneProduct	16:50:56:60:100:242	17:51:59:63:101:243	0:2:2:3:4:8	1:Positive_Correlation:2	L2R	NON-CROSS	60-63	67-69	111	ADCY5|ADCY5|adenylate cyclase 5|Adenylate cyclase 5|ADCY5|ADCY5	GeneOrGeneProduct	16:50:56:60:100:242	17:51:59:63:101:243	0:2:2:3:4:8	D000242	cyclic AMP	ChemicalEntity	67	69	3	1:NR:2	L2R	NON-CROSS	85-86	100-101	111	ADCY5|ADCY5|adenylate cyclase 5|Adenylate cyclase 5|ADCY5|ADCY5	GeneOrGeneProduct	16:50:56:60:100:242	17:51:59:63:101:243	0:2:2:3:4:8	3630	insulin	GeneOrGeneProduct	85	86	3	1:NR:2	L2R	CROSS	199-200	242-243	111	ADCY5|ADCY5|adenylate cyclase 5|Adenylate cyclase 5|ADCY5|ADCY5	GeneOrGeneProduct	16:50:56:60:100:242	17:51:59:63:101:243	0:2:2:3:4:8	64532	Adcy5	GeneOrGeneProduct	199	200	7	1:NR:2	L2R	CROSS	205-206	242-243	111	ADCY5|ADCY5|adenylate cyclase 5|Adenylate cyclase 5|ADCY5|ADCY5	GeneOrGeneProduct	16:50:56:60:100:242	17:51:59:63:101:243	0:2:2:3:4:8	117513	Sec22a	GeneOrGeneProduct	205	206	7	1:NR:2	L2R	CROSS	213-214	242-243	111	ADCY5|ADCY5|adenylate cyclase 5|Adenylate cyclase 5|ADCY5|ADCY5	GeneOrGeneProduct	16:50:56:60:100:242	17:51:59:63:101:243	0:2:2:3:4:8	24506	insulin	GeneOrGeneProduct	213	214	7	1:Association:2	L2R	NON-CROSS	242-243	245-248	111	ADCY5|ADCY5|adenylate cyclase 5|Adenylate cyclase 5|ADCY5|ADCY5	GeneOrGeneProduct	16:50:56:60:100:242	17:51:59:63:101:243	0:2:2:3:4:8	D003920	impaired insulin secretion	DiseaseOrPhenotypicFeature	245	248	8	1:NR:2	L2R	CROSS	44-45	67-69	D005947	glucose	ChemicalEntity	44	45	2	D000242	cyclic AMP	ChemicalEntity	67	69	3	1:NR:2	L2R	CROSS	44-45	85-86	D005947	glucose	ChemicalEntity	44	45	2	3630	insulin	GeneOrGeneProduct	85	86	3	1:NR:2	L2R	CROSS	44-45	113-114	D005947	glucose	ChemicalEntity	44	45	2	rs11708067	rs11708067|rs11708067|rs11708067|rs11708067	SequenceVariant	113:128:172:222	114:129:173:223	5:6:6:8	1:NR:2	L2R	CROSS	44-45	199-200	D005947	glucose	ChemicalEntity	44	45	2	64532	Adcy5	GeneOrGeneProduct	199	200	7	1:NR:2	L2R	CROSS	44-45	205-206	D005947	glucose	ChemicalEntity	44	45	2	117513	Sec22a	GeneOrGeneProduct	205	206	7	1:NR:2	L2R	CROSS	44-45	213-214	D005947	glucose	ChemicalEntity	44	45	2	24506	insulin	GeneOrGeneProduct	213	214	7	1:NR:2	L2R	CROSS	44-45	245-248	D005947	glucose	ChemicalEntity	44	45	2	D003920	impaired insulin secretion	DiseaseOrPhenotypicFeature	245	248	8	1:Association:2	L2R	NON-CROSS	67-69	85-86	D000242	cyclic AMP	ChemicalEntity	67	69	3	3630	insulin	GeneOrGeneProduct	85	86	3	1:NR:2	L2R	CROSS	67-69	113-114	D000242	cyclic AMP	ChemicalEntity	67	69	3	rs11708067	rs11708067|rs11708067|rs11708067|rs11708067	SequenceVariant	113:128:172:222	114:129:173:223	5:6:6:8	1:NR:2	L2R	CROSS	67-69	199-200	D000242	cyclic AMP	ChemicalEntity	67	69	3	64532	Adcy5	GeneOrGeneProduct	199	200	7	1:NR:2	L2R	CROSS	67-69	205-206	D000242	cyclic AMP	ChemicalEntity	67	69	3	117513	Sec22a	GeneOrGeneProduct	205	206	7	1:NR:2	L2R	CROSS	67-69	213-214	D000242	cyclic AMP	ChemicalEntity	67	69	3	24506	insulin	GeneOrGeneProduct	213	214	7	1:NR:2	L2R	CROSS	67-69	245-248	D000242	cyclic AMP	ChemicalEntity	67	69	3	D003920	impaired insulin secretion	DiseaseOrPhenotypicFeature	245	248	8	1:NR:2	L2R	CROSS	85-86	199-200	3630	insulin	GeneOrGeneProduct	85	86	3	64532	Adcy5	GeneOrGeneProduct	199	200	7	1:NR:2	L2R	CROSS	85-86	205-206	3630	insulin	GeneOrGeneProduct	85	86	3	117513	Sec22a	GeneOrGeneProduct	205	206	7	1:NR:2	L2R	CROSS	85-86	213-214	3630	insulin	GeneOrGeneProduct	85	86	3	24506	insulin	GeneOrGeneProduct	213	214	7	1:NR:2	L2R	CROSS	85-86	245-248	3630	insulin	GeneOrGeneProduct	85	86	3	D003920	impaired insulin secretion	DiseaseOrPhenotypicFeature	245	248	8	1:Positive_Correlation:2	L2R	NON-CROSS	222-223	245-248	rs11708067	rs11708067|rs11708067|rs11708067|rs11708067	SequenceVariant	113:128:172:222	114:129:173:223	5:6:6:8	D003920	impaired insulin secretion	DiseaseOrPhenotypicFeature	245	248	8	1:NR:2	L2R	NON-CROSS	199-200	205-206	64532	Adcy5	GeneOrGeneProduct	199	200	7	117513	Sec22a	GeneOrGeneProduct	205	206	7	1:NR:2	L2R	NON-CROSS	199-200	213-214	64532	Adcy5	GeneOrGeneProduct	199	200	7	24506	insulin	GeneOrGeneProduct	213	214	7	1:NR:2	L2R	CROSS	199-200	245-248	64532	Adcy5	GeneOrGeneProduct	199	200	7	D003920	impaired insulin secretion	DiseaseOrPhenotypicFeature	245	248	8	1:NR:2	L2R	NON-CROSS	205-206	213-214	117513	Sec22a	GeneOrGeneProduct	205	206	7	24506	insulin	GeneOrGeneProduct	213	214	7	1:NR:2	L2R	CROSS	205-206	245-248	117513	Sec22a	GeneOrGeneProduct	205	206	7	D003920	impaired insulin secretion	DiseaseOrPhenotypicFeature	245	248	8	1:NR:2	L2R	CROSS	213-214	245-248	24506	insulin	GeneOrGeneProduct	213	214	7	D003920	impaired insulin secretion	DiseaseOrPhenotypicFeature	245	248	8
21750150	Homozygously deleted gene DACH1 regulates tumor - initiating activity of glioma cells .|Loss or reduction in function of tumor suppressor genes contributes to tumorigenesis .|Here , by allelic DNA copy number analysis using single - nucleotide polymorphism genotyping array and mass spectrometry , we report homozygous deletion in glioblastoma multiformes at chromosome 13q21 , where DACH1 gene is located .|We found decreased cell proliferation of a series of glioma cell lines by forced expression of DACH1 .|We then generated U87TR - Da glioma cells , where DACH1 expression could be activated by exposure of the cells to doxycycline .|Both ex vivo cellular proliferation and in vivo growth of s . c .|transplanted tumors in mice are reduced in U87TR - Da cells with DACH1 expression ( U87 - DACH1 - high ) , compared with DACH1 - nonexpressing U87TR - Da cells ( U87 - DACH1 - low ) .|U87 - DACH1 - low cells form spheroids with CD133 and Nestin expression in serum - free medium but U87 - DACH1 - high cells do not .|Compared with spheroid - forming U87 - DACH1 - low cells , adherent U87 - DACH1 - high cells display lower tumorigenicity , indicating DACH1 decreases the number of tumor - initiating cells .|Gene expression analysis and chromatin immunoprecipitation assay reveal that fibroblast growth factor 2 ( FGF2 / bFGF ) is transcriptionally repressed by DACH1 , especially in cells cultured in serum - free medium .|Exogenous bFGF rescues spheroid - forming activity and tumorigenicity of the U87 - DACH1 - high cells , suggesting that loss of DACH1 increases the number of tumor - initiating cells through transcriptional activation of bFGF .|These results illustrate that DACH1 is a distinctive tumor suppressor , which does not only suppress growth of tumor cells but also regulates bFGF - mediated tumor - initiating activity of glioma cells .	1:Association:2	L2R	NON-CROSS	3-4	5-6	1602	DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1	GeneOrGeneProduct	3:57:78:90:129:134:141:151:158:177:191:199:208:240:265:274:293	4:58:79:91:130:135:142:152:159:178:192:200:209:241:266:275:294	0:2:3:4:6:6:6:6:7:7:8:8:8:9:10:10:11	D009369	tumor|tumor|tumorigenesis|tumors|tumor|tumor|tumor|tumor|tumor	DiseaseOrPhenotypicFeature	5:19:24:118:213:279:297:307:315	6:20:25:119:214:280:298:308:316	0:1:1:6:8:10:11:11:11	1:Association:2	L2R	NON-CROSS	86-87	90-91	1602	DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1	GeneOrGeneProduct	3:57:78:90:129:134:141:151:158:177:191:199:208:240:265:274:293	4:58:79:91:130:135:142:152:159:178:192:200:209:241:266:275:294	0:2:3:4:6:6:6:6:7:7:8:8:8:9:10:10:11	D005910	glioma|glioma|glioma|glioma	DiseaseOrPhenotypicFeature	10:71:86:320	11:72:87:321	0:3:4:11	1:NR:2	L2R	NON-CROSS	50-51	57-58	1602	DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1	GeneOrGeneProduct	3:57:78:90:129:134:141:151:158:177:191:199:208:240:265:274:293	4:58:79:91:130:135:142:152:159:178:192:200:209:241:266:275:294	0:2:3:4:6:6:6:6:7:7:8:8:8:9:10:10:11	D005909	glioblastoma	DiseaseOrPhenotypicFeature	50	51	2	1:Positive_Correlation:2	R2L	NON-CROSS	101-102	90-91	D004318	doxycycline	ChemicalEntity	101	102	4	1602	DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1	GeneOrGeneProduct	3:57:78:90:129:134:141:151:158:177:191:199:208:240:265:274:293	4:58:79:91:130:135:142:152:159:178:192:200:209:241:266:275:294	0:2:3:4:6:6:6:6:7:7:8:8:8:9:10:10:11	1:Association:2	L2R	NON-CROSS	158-159	165-166	1602	DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1	GeneOrGeneProduct	3:57:78:90:129:134:141:151:158:177:191:199:208:240:265:274:293	4:58:79:91:130:135:142:152:159:178:192:200:209:241:266:275:294	0:2:3:4:6:6:6:6:7:7:8:8:8:9:10:10:11	8842	CD133	GeneOrGeneProduct	165	166	7	1:Association:2	L2R	NON-CROSS	158-159	167-168	1602	DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1	GeneOrGeneProduct	3:57:78:90:129:134:141:151:158:177:191:199:208:240:265:274:293	4:58:79:91:130:135:142:152:159:178:192:200:209:241:266:275:294	0:2:3:4:6:6:6:6:7:7:8:8:8:9:10:10:11	10763	Nestin	GeneOrGeneProduct	167	168	7	1:Negative_Correlation:2	R2L	NON-CROSS	240-241	234-235	2247	fibroblast growth factor 2|FGF2|bFGF|bFGF|bFGF|bFGF	GeneOrGeneProduct	227:232:234:253:287:312	231:233:235:254:288:313	9:9:9:10:10:11	1602	DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1|DACH1	GeneOrGeneProduct	3:57:78:90:129:134:141:151:158:177:191:199:208:240:265:274:293	4:58:79:91:130:135:142:152:159:178:192:200:209:241:266:275:294	0:2:3:4:6:6:6:6:7:7:8:8:8:9:10:10:11	1:NR:2	L2R	CROSS	101-102	118-119	D009369	tumor|tumor|tumorigenesis|tumors|tumor|tumor|tumor|tumor|tumor	DiseaseOrPhenotypicFeature	5:19:24:118:213:279:297:307:315	6:20:25:119:214:280:298:308:316	0:1:1:6:8:10:11:11:11	D004318	doxycycline	ChemicalEntity	101	102	4	1:NR:2	L2R	CROSS	118-119	165-166	D009369	tumor|tumor|tumorigenesis|tumors|tumor|tumor|tumor|tumor|tumor	DiseaseOrPhenotypicFeature	5:19:24:118:213:279:297:307:315	6:20:25:119:214:280:298:308:316	0:1:1:6:8:10:11:11:11	8842	CD133	GeneOrGeneProduct	165	166	7	1:NR:2	L2R	CROSS	167-168	213-214	D009369	tumor|tumor|tumorigenesis|tumors|tumor|tumor|tumor|tumor|tumor	DiseaseOrPhenotypicFeature	5:19:24:118:213:279:297:307:315	6:20:25:119:214:280:298:308:316	0:1:1:6:8:10:11:11:11	10763	Nestin	GeneOrGeneProduct	167	168	7	1:Association:2	R2L	NON-CROSS	315-316	312-313	2247	fibroblast growth factor 2|FGF2|bFGF|bFGF|bFGF|bFGF	GeneOrGeneProduct	227:232:234:253:287:312	231:233:235:254:288:313	9:9:9:10:10:11	D009369	tumor|tumor|tumorigenesis|tumors|tumor|tumor|tumor|tumor|tumor	DiseaseOrPhenotypicFeature	5:19:24:118:213:279:297:307:315	6:20:25:119:214:280:298:308:316	0:1:1:6:8:10:11:11:11	1:NR:2	L2R	NON-CROSS	86-87	101-102	D005910	glioma|glioma|glioma|glioma	DiseaseOrPhenotypicFeature	10:71:86:320	11:72:87:321	0:3:4:11	D004318	doxycycline	ChemicalEntity	101	102	4	1:NR:2	L2R	CROSS	86-87	165-166	D005910	glioma|glioma|glioma|glioma	DiseaseOrPhenotypicFeature	10:71:86:320	11:72:87:321	0:3:4:11	8842	CD133	GeneOrGeneProduct	165	166	7	1:NR:2	L2R	CROSS	86-87	167-168	D005910	glioma|glioma|glioma|glioma	DiseaseOrPhenotypicFeature	10:71:86:320	11:72:87:321	0:3:4:11	10763	Nestin	GeneOrGeneProduct	167	168	7	1:Association:2	R2L	NON-CROSS	320-321	312-313	2247	fibroblast growth factor 2|FGF2|bFGF|bFGF|bFGF|bFGF	GeneOrGeneProduct	227:232:234:253:287:312	231:233:235:254:288:313	9:9:9:10:10:11	D005910	glioma|glioma|glioma|glioma	DiseaseOrPhenotypicFeature	10:71:86:320	11:72:87:321	0:3:4:11	1:NR:2	L2R	CROSS	50-51	101-102	D005909	glioblastoma	DiseaseOrPhenotypicFeature	50	51	2	D004318	doxycycline	ChemicalEntity	101	102	4	1:NR:2	L2R	CROSS	50-51	165-166	D005909	glioblastoma	DiseaseOrPhenotypicFeature	50	51	2	8842	CD133	GeneOrGeneProduct	165	166	7	1:NR:2	L2R	CROSS	50-51	167-168	D005909	glioblastoma	DiseaseOrPhenotypicFeature	50	51	2	10763	Nestin	GeneOrGeneProduct	167	168	7	1:NR:2	L2R	CROSS	50-51	227-231	D005909	glioblastoma	DiseaseOrPhenotypicFeature	50	51	2	2247	fibroblast growth factor 2|FGF2|bFGF|bFGF|bFGF|bFGF	GeneOrGeneProduct	227:232:234:253:287:312	231:233:235:254:288:313	9:9:9:10:10:11	1:NR:2	L2R	CROSS	101-102	165-166	D004318	doxycycline	ChemicalEntity	101	102	4	8842	CD133	GeneOrGeneProduct	165	166	7	1:NR:2	L2R	CROSS	101-102	167-168	D004318	doxycycline	ChemicalEntity	101	102	4	10763	Nestin	GeneOrGeneProduct	167	168	7	1:NR:2	L2R	CROSS	101-102	227-231	D004318	doxycycline	ChemicalEntity	101	102	4	2247	fibroblast growth factor 2|FGF2|bFGF|bFGF|bFGF|bFGF	GeneOrGeneProduct	227:232:234:253:287:312	231:233:235:254:288:313	9:9:9:10:10:11	1:NR:2	L2R	NON-CROSS	165-166	167-168	8842	CD133	GeneOrGeneProduct	165	166	7	10763	Nestin	GeneOrGeneProduct	167	168	7	1:NR:2	L2R	CROSS	165-166	227-231	8842	CD133	GeneOrGeneProduct	165	166	7	2247	fibroblast growth factor 2|FGF2|bFGF|bFGF|bFGF|bFGF	GeneOrGeneProduct	227:232:234:253:287:312	231:233:235:254:288:313	9:9:9:10:10:11	1:NR:2	L2R	CROSS	167-168	227-231	10763	Nestin	GeneOrGeneProduct	167	168	7	2247	fibroblast growth factor 2|FGF2|bFGF|bFGF|bFGF|bFGF	GeneOrGeneProduct	227:232:234:253:287:312	231:233:235:254:288:313	9:9:9:10:10:11
16629641	Definition and management of anemia in patients infected with hepatitis C virus .|Chronic infection with hepatitis C virus ( HCV ) can progress to cirrhosis , hepatocellular carcinoma , and end - stage liver disease .|The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin .|Although this regimen produces sustained virologic responses ( SVRs ) in approximately 50 % of patients , it can be associated with a potentially dose - limiting hemolytic anemia .|Hemoglobin concentrations decrease mainly as a result of ribavirin - induced hemolysis , and this anemia can be problematic in patients with HCV infection , especially those who have comorbid renal or cardiovascular disorders .|In general , anemia can increase the risk of morbidity and mortality , and may have negative effects on cerebral function and quality of life .|Although ribavirin - associated anemia can be reversed by dose reduction or discontinuation , this approach compromises outcomes by significantly decreasing SVR rates .|Recombinant human erythropoietin has been used to manage ribavirin - associated anemia but has other potential disadvantages .|Viramidine , a liver - targeting prodrug of ribavirin , has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C .	1:NR:2	L2R	CROSS	4-5	48-50	D000740	anemia|anemia|anemia|anemia|anemia	DiseaseOrPhenotypicFeature	4:98:121:148:179	5:99:122:149:180	0:4:5:6:7	3439	pegylated interferon	GeneOrGeneProduct	48	50	2	1:Positive_Correlation:2	R2L	NON-CROSS	148-149	145-146	D012254	ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	ChemicalEntity	51:91:145:176:194:205	52:92:146:177:195:206	2:4:6:7:8:8	D000740	anemia|anemia|anemia|anemia|anemia	DiseaseOrPhenotypicFeature	4:98:121:148:179	5:99:122:149:180	0:4:5:6:7	1:NR:2	L2R	NON-CROSS	83-84	98-99	D000740	anemia|anemia|anemia|anemia|anemia	DiseaseOrPhenotypicFeature	4:98:121:148:179	5:99:122:149:180	0:4:5:6:7	3039	Hemoglobin	GeneOrGeneProduct	83	84	4	1:Association:2	R2L	NON-CROSS	179-180	170-171	2056	erythropoietin	GeneOrGeneProduct	170	171	7	D000740	anemia|anemia|anemia|anemia|anemia	DiseaseOrPhenotypicFeature	4:98:121:148:179	5:99:122:149:180	0:4:5:6:7	1:NR:2	L2R	CROSS	179-180	186-187	D000740	anemia|anemia|anemia|anemia|anemia	DiseaseOrPhenotypicFeature	4:98:121:148:179	5:99:122:149:180	0:4:5:6:7	C026956	Viramidine	ChemicalEntity	186	187	8	1:Negative_Correlation:2	L2R	NON-CROSS	42-44	48-50	D006526	infected with hepatitis C virus|HCV infection|HCV infection	DiseaseOrPhenotypicFeature	7:42:105	12:44:107	0:2:4	3439	pegylated interferon	GeneOrGeneProduct	48	50	2	1:Negative_Correlation:2	L2R	NON-CROSS	42-44	51-52	D006526	infected with hepatitis C virus|HCV infection|HCV infection	DiseaseOrPhenotypicFeature	7:42:105	12:44:107	0:2:4	D012254	ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	ChemicalEntity	51:91:145:176:194:205	52:92:146:177:195:206	2:4:6:7:8:8	1:NR:2	L2R	NON-CROSS	83-84	105-107	D006526	infected with hepatitis C virus|HCV infection|HCV infection	DiseaseOrPhenotypicFeature	7:42:105	12:44:107	0:2:4	3039	Hemoglobin	GeneOrGeneProduct	83	84	4	1:NR:2	L2R	CROSS	105-107	170-171	D006526	infected with hepatitis C virus|HCV infection|HCV infection	DiseaseOrPhenotypicFeature	7:42:105	12:44:107	0:2:4	2056	erythropoietin	GeneOrGeneProduct	170	171	7	1:NR:2	L2R	CROSS	105-107	186-187	D006526	infected with hepatitis C virus|HCV infection|HCV infection	DiseaseOrPhenotypicFeature	7:42:105	12:44:107	0:2:4	C026956	Viramidine	ChemicalEntity	186	187	8	1:NR:2	L2R	CROSS	13-19	48-50	D019698	Chronic infection with hepatitis C virus|chronic hepatitis C	DiseaseOrPhenotypicFeature	13:216	19:219	1:8	3439	pegylated interferon	GeneOrGeneProduct	48	50	2	1:Association:2	R2L	NON-CROSS	216-219	205-206	D012254	ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	ChemicalEntity	51:91:145:176:194:205	52:92:146:177:195:206	2:4:6:7:8:8	D019698	Chronic infection with hepatitis C virus|chronic hepatitis C	DiseaseOrPhenotypicFeature	13:216	19:219	1:8	1:NR:2	L2R	CROSS	13-19	83-84	D019698	Chronic infection with hepatitis C virus|chronic hepatitis C	DiseaseOrPhenotypicFeature	13:216	19:219	1:8	3039	Hemoglobin	GeneOrGeneProduct	83	84	4	1:NR:2	L2R	CROSS	170-171	216-219	D019698	Chronic infection with hepatitis C virus|chronic hepatitis C	DiseaseOrPhenotypicFeature	13:216	19:219	1:8	2056	erythropoietin	GeneOrGeneProduct	170	171	7	1:Association:2	R2L	NON-CROSS	216-219	186-187	C026956	Viramidine	ChemicalEntity	186	187	8	D019698	Chronic infection with hepatitis C virus|chronic hepatitis C	DiseaseOrPhenotypicFeature	13:216	19:219	1:8	1:NR:2	L2R	CROSS	25-26	48-50	D005355	cirrhosis	DiseaseOrPhenotypicFeature	25	26	1	3439	pegylated interferon	GeneOrGeneProduct	48	50	2	1:NR:2	L2R	CROSS	25-26	51-52	D005355	cirrhosis	DiseaseOrPhenotypicFeature	25	26	1	D012254	ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	ChemicalEntity	51:91:145:176:194:205	52:92:146:177:195:206	2:4:6:7:8:8	1:NR:2	L2R	CROSS	25-26	83-84	D005355	cirrhosis	DiseaseOrPhenotypicFeature	25	26	1	3039	Hemoglobin	GeneOrGeneProduct	83	84	4	1:NR:2	L2R	CROSS	25-26	170-171	D005355	cirrhosis	DiseaseOrPhenotypicFeature	25	26	1	2056	erythropoietin	GeneOrGeneProduct	170	171	7	1:NR:2	L2R	CROSS	25-26	186-187	D005355	cirrhosis	DiseaseOrPhenotypicFeature	25	26	1	C026956	Viramidine	ChemicalEntity	186	187	8	1:NR:2	L2R	CROSS	27-29	48-50	D006528	hepatocellular carcinoma	DiseaseOrPhenotypicFeature	27	29	1	3439	pegylated interferon	GeneOrGeneProduct	48	50	2	1:NR:2	L2R	CROSS	27-29	51-52	D006528	hepatocellular carcinoma	DiseaseOrPhenotypicFeature	27	29	1	D012254	ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	ChemicalEntity	51:91:145:176:194:205	52:92:146:177:195:206	2:4:6:7:8:8	1:NR:2	L2R	CROSS	27-29	83-84	D006528	hepatocellular carcinoma	DiseaseOrPhenotypicFeature	27	29	1	3039	Hemoglobin	GeneOrGeneProduct	83	84	4	1:NR:2	L2R	CROSS	27-29	170-171	D006528	hepatocellular carcinoma	DiseaseOrPhenotypicFeature	27	29	1	2056	erythropoietin	GeneOrGeneProduct	170	171	7	1:NR:2	L2R	CROSS	27-29	186-187	D006528	hepatocellular carcinoma	DiseaseOrPhenotypicFeature	27	29	1	C026956	Viramidine	ChemicalEntity	186	187	8	1:NR:2	L2R	CROSS	31-36	48-50	D058625	end - stage liver disease	DiseaseOrPhenotypicFeature	31	36	1	3439	pegylated interferon	GeneOrGeneProduct	48	50	2	1:NR:2	L2R	CROSS	31-36	51-52	D058625	end - stage liver disease	DiseaseOrPhenotypicFeature	31	36	1	D012254	ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	ChemicalEntity	51:91:145:176:194:205	52:92:146:177:195:206	2:4:6:7:8:8	1:NR:2	L2R	CROSS	31-36	83-84	D058625	end - stage liver disease	DiseaseOrPhenotypicFeature	31	36	1	3039	Hemoglobin	GeneOrGeneProduct	83	84	4	1:NR:2	L2R	CROSS	31-36	170-171	D058625	end - stage liver disease	DiseaseOrPhenotypicFeature	31	36	1	2056	erythropoietin	GeneOrGeneProduct	170	171	7	1:NR:2	L2R	CROSS	31-36	186-187	D058625	end - stage liver disease	DiseaseOrPhenotypicFeature	31	36	1	C026956	Viramidine	ChemicalEntity	186	187	8	1:Cotreatment:2	L2R	NON-CROSS	48-50	51-52	3439	pegylated interferon	GeneOrGeneProduct	48	50	2	D012254	ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	ChemicalEntity	51:91:145:176:194:205	52:92:146:177:195:206	2:4:6:7:8:8	1:NR:2	L2R	CROSS	48-50	80-82	3439	pegylated interferon	GeneOrGeneProduct	48	50	2	D000743	hemolytic anemia|hemolytic anemia	DiseaseOrPhenotypicFeature	80:211	82:213	3:8	1:NR:2	L2R	CROSS	48-50	83-84	3439	pegylated interferon	GeneOrGeneProduct	48	50	2	3039	Hemoglobin	GeneOrGeneProduct	83	84	4	1:NR:2	L2R	CROSS	48-50	94-95	3439	pegylated interferon	GeneOrGeneProduct	48	50	2	D006461	hemolysis	DiseaseOrPhenotypicFeature	94	95	4	1:NR:2	L2R	CROSS	48-50	113-117	3439	pegylated interferon	GeneOrGeneProduct	48	50	2	D002318,D007674	renal or cardiovascular disorders	DiseaseOrPhenotypicFeature	113	117	4	1:NR:2	L2R	CROSS	48-50	170-171	3439	pegylated interferon	GeneOrGeneProduct	48	50	2	2056	erythropoietin	GeneOrGeneProduct	170	171	7	1:NR:2	L2R	CROSS	48-50	186-187	3439	pegylated interferon	GeneOrGeneProduct	48	50	2	C026956	Viramidine	ChemicalEntity	186	187	8	1:Positive_Correlation:2	L2R	NON-CROSS	205-206	211-213	D012254	ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	ChemicalEntity	51:91:145:176:194:205	52:92:146:177:195:206	2:4:6:7:8:8	D000743	hemolytic anemia|hemolytic anemia	DiseaseOrPhenotypicFeature	80:211	82:213	3:8	1:Negative_Correlation:2	R2L	NON-CROSS	91-92	83-84	3039	Hemoglobin	GeneOrGeneProduct	83	84	4	D012254	ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	ChemicalEntity	51:91:145:176:194:205	52:92:146:177:195:206	2:4:6:7:8:8	1:Positive_Correlation:2	L2R	NON-CROSS	91-92	94-95	D012254	ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	ChemicalEntity	51:91:145:176:194:205	52:92:146:177:195:206	2:4:6:7:8:8	D006461	hemolysis	DiseaseOrPhenotypicFeature	94	95	4	1:NR:2	L2R	NON-CROSS	91-92	113-117	D012254	ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	ChemicalEntity	51:91:145:176:194:205	52:92:146:177:195:206	2:4:6:7:8:8	D002318,D007674	renal or cardiovascular disorders	DiseaseOrPhenotypicFeature	113	117	4	1:Association:2	R2L	NON-CROSS	176-177	170-171	2056	erythropoietin	GeneOrGeneProduct	170	171	7	D012254	ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	ChemicalEntity	51:91:145:176:194:205	52:92:146:177:195:206	2:4:6:7:8:8	1:Association:2	R2L	NON-CROSS	194-195	186-187	C026956	Viramidine	ChemicalEntity	186	187	8	D012254	ribavirin|ribavirin|ribavirin|ribavirin|ribavirin|ribavirin	ChemicalEntity	51:91:145:176:194:205	52:92:146:177:195:206	2:4:6:7:8:8	1:NR:2	L2R	CROSS	80-82	83-84	D000743	hemolytic anemia|hemolytic anemia	DiseaseOrPhenotypicFeature	80:211	82:213	3:8	3039	Hemoglobin	GeneOrGeneProduct	83	84	4	1:NR:2	L2R	CROSS	170-171	211-213	D000743	hemolytic anemia|hemolytic anemia	DiseaseOrPhenotypicFeature	80:211	82:213	3:8	2056	erythropoietin	GeneOrGeneProduct	170	171	7	1:Negative_Correlation:2	R2L	NON-CROSS	211-213	186-187	C026956	Viramidine	ChemicalEntity	186	187	8	D000743	hemolytic anemia|hemolytic anemia	DiseaseOrPhenotypicFeature	80:211	82:213	3:8	1:Negative_Correlation:2	L2R	NON-CROSS	83-84	94-95	3039	Hemoglobin	GeneOrGeneProduct	83	84	4	D006461	hemolysis	DiseaseOrPhenotypicFeature	94	95	4	1:NR:2	L2R	NON-CROSS	83-84	113-117	3039	Hemoglobin	GeneOrGeneProduct	83	84	4	D002318,D007674	renal or cardiovascular disorders	DiseaseOrPhenotypicFeature	113	117	4	1:NR:2	L2R	CROSS	83-84	170-171	3039	Hemoglobin	GeneOrGeneProduct	83	84	4	2056	erythropoietin	GeneOrGeneProduct	170	171	7	1:NR:2	L2R	CROSS	83-84	186-187	3039	Hemoglobin	GeneOrGeneProduct	83	84	4	C026956	Viramidine	ChemicalEntity	186	187	8	1:NR:2	L2R	CROSS	94-95	170-171	D006461	hemolysis	DiseaseOrPhenotypicFeature	94	95	4	2056	erythropoietin	GeneOrGeneProduct	170	171	7	1:NR:2	L2R	CROSS	94-95	186-187	D006461	hemolysis	DiseaseOrPhenotypicFeature	94	95	4	C026956	Viramidine	ChemicalEntity	186	187	8	1:NR:2	L2R	CROSS	113-117	170-171	D002318,D007674	renal or cardiovascular disorders	DiseaseOrPhenotypicFeature	113	117	4	2056	erythropoietin	GeneOrGeneProduct	170	171	7	1:NR:2	L2R	CROSS	113-117	186-187	D002318,D007674	renal or cardiovascular disorders	DiseaseOrPhenotypicFeature	113	117	4	C026956	Viramidine	ChemicalEntity	186	187	8	1:NR:2	L2R	CROSS	170-171	186-187	2056	erythropoietin	GeneOrGeneProduct	170	171	7	C026956	Viramidine	ChemicalEntity	186	187	8
17166870	Association between an endoglin gene polymorphism and systemic sclerosis - related pulmonary arterial hypertension .|Systemic sclerosis ( SSc ) is a connective tissue disorder characterized by early generalized microangiopathy with disturbed angiogenesis .|Endoglin gene ( ENG ) encodes a transmembrane glycoprotein which acts as an accessory receptor for the transforming growth factor - beta ( TGF - beta ) superfamily , and is crucial for maintaining vascular integrity .|A 6 - base insertion in intron 7 ( 6bINS ) of ENG has been reported to be associated with microvascular disturbance .|OBJECTIVES : Our objective was to investigate the relationship between 6bINS and the vascular complication pulmonary arterial hypertension ( PAH ) in SSc in a French Caucasian population .|METHODS : Two hundred eighty SSc cases containing 29 / 280 having PAH diagnosed by catheterism were compared with 140 patients with osteoarthritis .|Genotyping was performed by polymerase - chain - reaction - based fluorescence and direct sequencing of genomic DNA .|RESULTS : The polymorphism was in Hardy - Weinberg equilibrium .|We observed a significant lower frequency of 6bINS allele in SSc patients with associated PAH compared with controls [ 10 . 3 vs 23 . 9 % , P = 0 . 01 ; odds ratio ( OR ) 0 . 37 , 95 % confidence interval ( CI ) 0 . 15 - 0 . 89 ] , and a trend in comparison with SSc patients without PAH ( 10 . 3 vs 20 . 3 % , P = 0 . 05 ; OR : 0 . 45 , 95 % CI : 0 . 19 - 1 . 08 ) .|Genotypes carrying allele 6bINS were also less frequent in SSc patients with PAH than in controls ( 20 . 7 vs 42 . 9 % , P = 0 . 02 ) .|CONCLUSIONS : Thus the frequency of 6bINS differs between SSc patients with or without PAH , suggesting the implication of ENG in this devastating vascular complication of SSc .	1:Association:2	L2R	NON-CROSS	3-4	7-9	2022	endoglin|Endoglin|ENG|ENG|ENG	GeneOrGeneProduct	3:34:37:83:334	4:35:38:84:335	0:2:2:3:10	D012595	systemic sclerosis|Systemic sclerosis|SSc|SSc|SSc|SSc|SSc|SSc|SSc|SSc	DiseaseOrPhenotypicFeature	7:15:18:116:128:187:242:290:323:341	9:17:19:117:129:188:243:291:324:342	0:1:1:4:5:8:8:9:10:10	1:Association:2	R2L	NON-CROSS	334-335	328-329	D000081029	pulmonary arterial hypertension|pulmonary arterial hypertension|PAH|PAH|PAH|PAH|PAH|PAH	DiseaseOrPhenotypicFeature	11:109:113:135:191:245:293:328	14:112:114:136:192:246:294:329	0:4:4:5:8:8:9:10	2022	endoglin|Endoglin|ENG|ENG|ENG	GeneOrGeneProduct	3:34:37:83:334	4:35:38:84:335	0:2:2:3:10	1:NR:2	L2R	CROSS	29-30	34-35	2022	endoglin|Endoglin|ENG|ENG|ENG	GeneOrGeneProduct	3:34:37:83:334	4:35:38:84:335	0:2:2:3:10	D057049	microangiopathy	DiseaseOrPhenotypicFeature	29	30	1	1:NR:2	L2R	NON-CROSS	37-38	42-43	2022	endoglin|Endoglin|ENG|ENG|ENG	GeneOrGeneProduct	3:34:37:83:334	4:35:38:84:335	0:2:2:3:10	351	glycoprotein	GeneOrGeneProduct	42	43	2	1:Bind:2	L2R	NON-CROSS	37-38	51-56	2022	endoglin|Endoglin|ENG|ENG|ENG	GeneOrGeneProduct	3:34:37:83:334	4:35:38:84:335	0:2:2:3:10	7040	transforming growth factor - beta|TGF - beta	GeneOrGeneProduct	51:57	56:60	2:2	1:Association:2	L2R	NON-CROSS	334-335	338-340	2022	endoglin|Endoglin|ENG|ENG|ENG	GeneOrGeneProduct	3:34:37:83:334	4:35:38:84:335	0:2:2:3:10	D014652	vascular complication|vascular complication	DiseaseOrPhenotypicFeature	107:338	109:340	4:10	1:NR:2	L2R	CROSS	83-84	145-146	2022	endoglin|Endoglin|ENG|ENG|ENG	GeneOrGeneProduct	3:34:37:83:334	4:35:38:84:335	0:2:2:3:10	D010003	osteoarthritis	DiseaseOrPhenotypicFeature	145	146	5	1:NR:2	L2R	CROSS	18-19	42-43	D012595	systemic sclerosis|Systemic sclerosis|SSc|SSc|SSc|SSc|SSc|SSc|SSc|SSc	DiseaseOrPhenotypicFeature	7:15:18:116:128:187:242:290:323:341	9:17:19:117:129:188:243:291:324:342	0:1:1:4:5:8:8:9:10:10	351	glycoprotein	GeneOrGeneProduct	42	43	2	1:NR:2	L2R	CROSS	18-19	51-56	D012595	systemic sclerosis|Systemic sclerosis|SSc|SSc|SSc|SSc|SSc|SSc|SSc|SSc	DiseaseOrPhenotypicFeature	7:15:18:116:128:187:242:290:323:341	9:17:19:117:129:188:243:291:324:342	0:1:1:4:5:8:8:9:10:10	7040	transforming growth factor - beta|TGF - beta	GeneOrGeneProduct	51:57	56:60	2:2	1:Association:2	R2L	NON-CROSS	187-188	184-185	c|INS||6	6 - base insertion|6bINS|6bINS|6bINS|6bINS|6bINS	SequenceVariant	72:80:104:184:284:320	76:81:105:185:285:321	3:3:4:8:9:10	D012595	systemic sclerosis|Systemic sclerosis|SSc|SSc|SSc|SSc|SSc|SSc|SSc|SSc	DiseaseOrPhenotypicFeature	7:15:18:116:128:187:242:290:323:341	9:17:19:117:129:188:243:291:324:342	0:1:1:4:5:8:8:9:10:10	1:NR:2	L2R	CROSS	11-14	42-43	D000081029	pulmonary arterial hypertension|pulmonary arterial hypertension|PAH|PAH|PAH|PAH|PAH|PAH	DiseaseOrPhenotypicFeature	11:109:113:135:191:245:293:328	14:112:114:136:192:246:294:329	0:4:4:5:8:8:9:10	351	glycoprotein	GeneOrGeneProduct	42	43	2	1:NR:2	L2R	CROSS	11-14	51-56	D000081029	pulmonary arterial hypertension|pulmonary arterial hypertension|PAH|PAH|PAH|PAH|PAH|PAH	DiseaseOrPhenotypicFeature	11:109:113:135:191:245:293:328	14:112:114:136:192:246:294:329	0:4:4:5:8:8:9:10	7040	transforming growth factor - beta|TGF - beta	GeneOrGeneProduct	51:57	56:60	2:2	1:Negative_Correlation:2	R2L	NON-CROSS	109-112	104-105	c|INS||6	6 - base insertion|6bINS|6bINS|6bINS|6bINS|6bINS	SequenceVariant	72:80:104:184:284:320	76:81:105:185:285:321	3:3:4:8:9:10	D000081029	pulmonary arterial hypertension|pulmonary arterial hypertension|PAH|PAH|PAH|PAH|PAH|PAH	DiseaseOrPhenotypicFeature	11:109:113:135:191:245:293:328	14:112:114:136:192:246:294:329	0:4:4:5:8:8:9:10	1:NR:2	L2R	CROSS	29-30	42-43	D057049	microangiopathy	DiseaseOrPhenotypicFeature	29	30	1	351	glycoprotein	GeneOrGeneProduct	42	43	2	1:NR:2	L2R	CROSS	29-30	51-56	D057049	microangiopathy	DiseaseOrPhenotypicFeature	29	30	1	7040	transforming growth factor - beta|TGF - beta	GeneOrGeneProduct	51:57	56:60	2:2	1:NR:2	L2R	CROSS	29-30	72-76	D057049	microangiopathy	DiseaseOrPhenotypicFeature	29	30	1	c|INS||6	6 - base insertion|6bINS|6bINS|6bINS|6bINS|6bINS	SequenceVariant	72:80:104:184:284:320	76:81:105:185:285:321	3:3:4:8:9:10	1:NR:2	L2R	NON-CROSS	42-43	51-56	351	glycoprotein	GeneOrGeneProduct	42	43	2	7040	transforming growth factor - beta|TGF - beta	GeneOrGeneProduct	51:57	56:60	2:2	1:NR:2	L2R	CROSS	42-43	107-109	351	glycoprotein	GeneOrGeneProduct	42	43	2	D014652	vascular complication|vascular complication	DiseaseOrPhenotypicFeature	107:338	109:340	4:10	1:NR:2	L2R	CROSS	42-43	145-146	351	glycoprotein	GeneOrGeneProduct	42	43	2	D010003	osteoarthritis	DiseaseOrPhenotypicFeature	145	146	5	1:NR:2	L2R	CROSS	57-60	107-109	7040	transforming growth factor - beta|TGF - beta	GeneOrGeneProduct	51:57	56:60	2:2	D014652	vascular complication|vascular complication	DiseaseOrPhenotypicFeature	107:338	109:340	4:10	1:NR:2	L2R	CROSS	57-60	145-146	7040	transforming growth factor - beta|TGF - beta	GeneOrGeneProduct	51:57	56:60	2:2	D010003	osteoarthritis	DiseaseOrPhenotypicFeature	145	146	5	1:Association:2	L2R	NON-CROSS	104-105	107-109	c|INS||6	6 - base insertion|6bINS|6bINS|6bINS|6bINS|6bINS	SequenceVariant	72:80:104:184:284:320	76:81:105:185:285:321	3:3:4:8:9:10	D014652	vascular complication|vascular complication	DiseaseOrPhenotypicFeature	107:338	109:340	4:10	1:NR:2	L2R	CROSS	145-146	184-185	c|INS||6	6 - base insertion|6bINS|6bINS|6bINS|6bINS|6bINS	SequenceVariant	72:80:104:184:284:320	76:81:105:185:285:321	3:3:4:8:9:10	D010003	osteoarthritis	DiseaseOrPhenotypicFeature	145	146	5
17491223	Assessment of a new non - invasive index of cardiac performance for detection of dobutamine - induced myocardial ischemia .|BACKGROUND : Electrocardiography has a very low sensitivity in detecting dobutamine - induced myocardial ischemia .|OBJECTIVES : To assess the added diagnostic value of a new cardiac performance index ( dP / dtejc ) measurement , based on brachial artery flow changes , as compared to standard 12 - lead ECG , for detecting dobutamine - induced myocardial ischemia , using Tc99m - Sestamibi single - photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia .|METHODS : The study group comprised 40 patients undergoing Sestamibi - SPECT / dobutamine stress test .|Simultaneous measurements of ECG and brachial artery dP / dtejc were performed at each dobutamine level .|In 19 of the 40 patients perfusion defects compatible with ischemia were detected on SPECT .|The increase in dP / dtejc during infusion of dobutamine in this group was severely impaired as compared to the non - ischemic group .|dP / dtejc outcome was combined with the ECG results , giving an ECG - enhanced value , and compared to ECG alone .|RESULTS : The sensitivity improved dramatically from 16 % to 79 % , positive predictive value increased from 60 % to 68 % and negative predictive value from 54 % to 78 % , and specificity decreased from 90 % to 67 % .|CONCLUSIONS : If ECG alone is used for specificity , the combination with dP / dtejc improved the sensitivity of the test and could be a cost - savings alternative to cardiac imaging or perfusion studies to detect myocardial ischemia , especially in patients unable to exercise .	1:Positive_Correlation:2	L2R	NON-CROSS	14-15	17-19	D004280	dobutamine|dobutamine|dobutamine|dobutamine|dobutamine|dobutamine	ChemicalEntity	14:30:75:119:137:165	15:31:76:120:138:166	0:1:2:3:4:6	D017202	myocardial ischemia|myocardial ischemia|myocardial ischemia|myocardial ischemia	DiseaseOrPhenotypicFeature	17:33:78:287	19:35:80:289	0:1:2:9	1:Association:2	L2R	NON-CROSS	137-138	150-151	D004280	dobutamine|dobutamine|dobutamine|dobutamine|dobutamine|dobutamine	ChemicalEntity	14:30:75:119:137:165	15:31:76:120:138:166	0:1:2:3:4:6	D007511	ischemia|ischemia	DiseaseOrPhenotypicFeature	104:150	105:151	2:5
18507837	Effects of common germline genetic variation in cell cycle control genes on breast cancer survival : results from a population - based cohort .|INTRODUCTION : Somatic alterations have been shown to correlate with breast cancer prognosis and survival , but less is known about the effects of common inherited genetic variation .|Of particular interest are genes involved in cell cycle pathways , which regulate cell division .|METHODS : We examined associations between common germline genetic variation in 13 genes involved in cell cycle control ( CCND1 , CCND2 , CCND3 , CCNE1 , CDK2 [ p33 ] , CDK4 , CDK6 , CDKN1A [ p21 , Cip1 ] , CDKN1B [ p27 , Kip1 ] , CDKN2A [ p16 ] , CDKN2B [ p15 ] , CDKN2C [ p18 ] , and CDKN2D [ p19 ] ) and survival among women diagnosed with invasive breast cancer participating in the SEARCH ( Studies of Epidemiology and Risk factors in Cancer Heredity ) breast cancer study .|DNA from up to 4 , 470 women was genotyped for 85 polymorphisms that tag the known common polymorphisms ( minor allele frequency > 0 . 05 ) in the genes .|The genotypes of each polymorphism were tested for association with survival using Cox regression analysis .|RESULTS : The rare allele of the tagging single nucleotide polymorphism ( SNP ) rs2479717 is associated with an increased risk of death ( hazard ratio = 1 . 26 per rare allele carried , 95 % confidence interval : 1 . 12 to 1 . 42 ; P = 0 . 0001 ) , which was not attenuated after adjusting for tumour stage , grade , and treatment .|This SNP is part of a large linkage disequilibrium block , which contains CCND3 , BYSL , TRFP , USP49 , C6ofr49 , FRS3 , and PGC .|We evaluated the association of survival and somatic expression of these genes in breast tumours using expression microarray data from seven published datasets .|Elevated expression of the C6orf49 transcript was associated with breast cancer survival , adding biological interest to the finding .|CONCLUSION : It is possible that CCND3 rs2479717 , or another variant it tags , is associated with prognosis after a diagnosis of breast cancer .|Further study is required to validate this finding .	1:NR:2	L2R	NON-CROSS	34-36	88-89	D001943	breast cancer|breast cancer|invasive breast cancer|breast cancer|breast tumours|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	12:34:146:164:327:347:381	14:36:149:166:329:349:383	0:1:3:3:8:9:10	595	CCND1	GeneOrGeneProduct	88	89	3	1:NR:2	L2R	NON-CROSS	34-36	90-91	D001943	breast cancer|breast cancer|invasive breast cancer|breast cancer|breast tumours|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	12:34:146:164:327:347:381	14:36:149:166:329:349:383	0:1:3:3:8:9:10	894	CCND2	GeneOrGeneProduct	90	91	3	1:Association:2	R2L	NON-CROSS	364-365	347-349	896	CCND3|CCND3|CCND3	GeneOrGeneProduct	92:299:364	93:300:365	3:7:10	D001943	breast cancer|breast cancer|invasive breast cancer|breast cancer|breast tumours|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	12:34:146:164:327:347:381	14:36:149:166:329:349:383	0:1:3:3:8:9:10	1:NR:2	L2R	NON-CROSS	94-95	146-149	D001943	breast cancer|breast cancer|invasive breast cancer|breast cancer|breast tumours|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	12:34:146:164:327:347:381	14:36:149:166:329:349:383	0:1:3:3:8:9:10	898	CCNE1	GeneOrGeneProduct	94	95	3	1:NR:2	L2R	NON-CROSS	96-100	146-149	D001943	breast cancer|breast cancer|invasive breast cancer|breast cancer|breast tumours|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	12:34:146:164:327:347:381	14:36:149:166:329:349:383	0:1:3:3:8:9:10	1017	CDK2 [ p33 ]	GeneOrGeneProduct	96	100	3	1:NR:2	L2R	NON-CROSS	101-102	146-149	D001943	breast cancer|breast cancer|invasive breast cancer|breast cancer|breast tumours|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	12:34:146:164:327:347:381	14:36:149:166:329:349:383	0:1:3:3:8:9:10	1019	CDK4	GeneOrGeneProduct	101	102	3	1:NR:2	L2R	NON-CROSS	103-104	146-149	D001943	breast cancer|breast cancer|invasive breast cancer|breast cancer|breast tumours|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	12:34:146:164:327:347:381	14:36:149:166:329:349:383	0:1:3:3:8:9:10	1021	CDK6	GeneOrGeneProduct	103	104	3	1:NR:2	L2R	NON-CROSS	109-110	146-149	D001943	breast cancer|breast cancer|invasive breast cancer|breast cancer|breast tumours|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	12:34:146:164:327:347:381	14:36:149:166:329:349:383	0:1:3:3:8:9:10	1026	CDKN1A|p21|Cip1	GeneOrGeneProduct	105:107:109	106:108:110	3:3:3	1:NR:2	L2R	NON-CROSS	114-117	146-149	D001943	breast cancer|breast cancer|invasive breast cancer|breast cancer|breast tumours|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	12:34:146:164:327:347:381	14:36:149:166:329:349:383	0:1:3:3:8:9:10	1027	CDKN1B|p27 , Kip1	GeneOrGeneProduct	112:114	113:117	3:3	1:NR:2	L2R	NON-CROSS	137-138	146-149	D001943	breast cancer|breast cancer|invasive breast cancer|breast cancer|breast tumours|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	12:34:146:164:327:347:381	14:36:149:166:329:349:383	0:1:3:3:8:9:10	1029	CDKN2A|p16|p19	GeneOrGeneProduct	119:121:137	120:122:138	3:3:3	1:NR:2	L2R	NON-CROSS	126-127	146-149	D001943	breast cancer|breast cancer|invasive breast cancer|breast cancer|breast tumours|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	12:34:146:164:327:347:381	14:36:149:166:329:349:383	0:1:3:3:8:9:10	1030	CDKN2B|p15	GeneOrGeneProduct	124:126	125:127	3:3	1:NR:2	L2R	NON-CROSS	131-132	146-149	D001943	breast cancer|breast cancer|invasive breast cancer|breast cancer|breast tumours|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	12:34:146:164:327:347:381	14:36:149:166:329:349:383	0:1:3:3:8:9:10	1031	CDKN2C|p18	GeneOrGeneProduct	129:131	130:132	3:3	1:NR:2	L2R	NON-CROSS	135-136	146-149	D001943	breast cancer|breast cancer|invasive breast cancer|breast cancer|breast tumours|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	12:34:146:164:327:347:381	14:36:149:166:329:349:383	0:1:3:3:8:9:10	1032	CDKN2D	GeneOrGeneProduct	135	136	3	1:Association:2	R2L	NON-CROSS	381-383	365-366	rs2479717	rs2479717|rs2479717	SequenceVariant	230:365	231:366	6:10	D001943	breast cancer|breast cancer|invasive breast cancer|breast cancer|breast tumours|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	12:34:146:164:327:347:381	14:36:149:166:329:349:383	0:1:3:3:8:9:10	1:NR:2	L2R	CROSS	301-302	327-329	D001943	breast cancer|breast cancer|invasive breast cancer|breast cancer|breast tumours|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	12:34:146:164:327:347:381	14:36:149:166:329:349:383	0:1:3:3:8:9:10	705	BYSL	GeneOrGeneProduct	301	302	7	1:NR:2	L2R	CROSS	303-304	327-329	D001943	breast cancer|breast cancer|invasive breast cancer|breast cancer|breast tumours|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	12:34:146:164:327:347:381	14:36:149:166:329:349:383	0:1:3:3:8:9:10	55031	TRFP	GeneOrGeneProduct	303	304	7	1:NR:2	L2R	CROSS	305-306	327-329	D001943	breast cancer|breast cancer|invasive breast cancer|breast cancer|breast tumours|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	12:34:146:164:327:347:381	14:36:149:166:329:349:383	0:1:3:3:8:9:10	25862	USP49	GeneOrGeneProduct	305	306	7	1:Association:2	R2L	NON-CROSS	347-349	342-343	29964	C6ofr49|C6orf49	GeneOrGeneProduct	307:342	308:343	7:9	D001943	breast cancer|breast cancer|invasive breast cancer|breast cancer|breast tumours|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	12:34:146:164:327:347:381	14:36:149:166:329:349:383	0:1:3:3:8:9:10	1:NR:2	L2R	CROSS	309-310	327-329	D001943	breast cancer|breast cancer|invasive breast cancer|breast cancer|breast tumours|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	12:34:146:164:327:347:381	14:36:149:166:329:349:383	0:1:3:3:8:9:10	10817	FRS3	GeneOrGeneProduct	309	310	7	1:NR:2	L2R	CROSS	312-313	327-329	D001943	breast cancer|breast cancer|invasive breast cancer|breast cancer|breast tumours|breast cancer|breast cancer	DiseaseOrPhenotypicFeature	12:34:146:164:327:347:381	14:36:149:166:329:349:383	0:1:3:3:8:9:10	5225	PGC	GeneOrGeneProduct	312	313	7	1:NR:2	L2R	NON-CROSS	88-89	90-91	595	CCND1	GeneOrGeneProduct	88	89	3	894	CCND2	GeneOrGeneProduct	90	91	3	1:NR:2	L2R	NON-CROSS	88-89	92-93	595	CCND1	GeneOrGeneProduct	88	89	3	896	CCND3|CCND3|CCND3	GeneOrGeneProduct	92:299:364	93:300:365	3:7:10	1:NR:2	L2R	NON-CROSS	88-89	94-95	595	CCND1	GeneOrGeneProduct	88	89	3	898	CCNE1	GeneOrGeneProduct	94	95	3	1:NR:2	L2R	NON-CROSS	88-89	96-100	595	CCND1	GeneOrGeneProduct	88	89	3	1017	CDK2 [ p33 ]	GeneOrGeneProduct	96	100	3	1:NR:2	L2R	NON-CROSS	88-89	101-102	595	CCND1	GeneOrGeneProduct	88	89	3	1019	CDK4	GeneOrGeneProduct	101	102	3	1:NR:2	L2R	NON-CROSS	88-89	103-104	595	CCND1	GeneOrGeneProduct	88	89	3	1021	CDK6	GeneOrGeneProduct	103	104	3	1:NR:2	L2R	NON-CROSS	88-89	105-106	595	CCND1	GeneOrGeneProduct	88	89	3	1026	CDKN1A|p21|Cip1	GeneOrGeneProduct	105:107:109	106:108:110	3:3:3	1:NR:2	L2R	NON-CROSS	88-89	112-113	595	CCND1	GeneOrGeneProduct	88	89	3	1027	CDKN1B|p27 , Kip1	GeneOrGeneProduct	112:114	113:117	3:3	1:NR:2	L2R	NON-CROSS	88-89	119-120	595	CCND1	GeneOrGeneProduct	88	89	3	1029	CDKN2A|p16|p19	GeneOrGeneProduct	119:121:137	120:122:138	3:3:3	1:NR:2	L2R	NON-CROSS	88-89	124-125	595	CCND1	GeneOrGeneProduct	88	89	3	1030	CDKN2B|p15	GeneOrGeneProduct	124:126	125:127	3:3	1:NR:2	L2R	NON-CROSS	88-89	129-130	595	CCND1	GeneOrGeneProduct	88	89	3	1031	CDKN2C|p18	GeneOrGeneProduct	129:131	130:132	3:3	1:NR:2	L2R	NON-CROSS	88-89	135-136	595	CCND1	GeneOrGeneProduct	88	89	3	1032	CDKN2D	GeneOrGeneProduct	135	136	3	1:NR:2	L2R	CROSS	88-89	238-239	595	CCND1	GeneOrGeneProduct	88	89	3	D003643	death	DiseaseOrPhenotypicFeature	238	239	6	1:NR:2	L2R	CROSS	88-89	278-279	595	CCND1	GeneOrGeneProduct	88	89	3	D009369	tumour	DiseaseOrPhenotypicFeature	278	279	6	1:NR:2	L2R	CROSS	88-89	301-302	595	CCND1	GeneOrGeneProduct	88	89	3	705	BYSL	GeneOrGeneProduct	301	302	7	1:NR:2	L2R	CROSS	88-89	303-304	595	CCND1	GeneOrGeneProduct	88	89	3	55031	TRFP	GeneOrGeneProduct	303	304	7	1:NR:2	L2R	CROSS	88-89	305-306	595	CCND1	GeneOrGeneProduct	88	89	3	25862	USP49	GeneOrGeneProduct	305	306	7	1:NR:2	L2R	CROSS	88-89	307-308	595	CCND1	GeneOrGeneProduct	88	89	3	29964	C6ofr49|C6orf49	GeneOrGeneProduct	307:342	308:343	7:9	1:NR:2	L2R	CROSS	88-89	309-310	595	CCND1	GeneOrGeneProduct	88	89	3	10817	FRS3	GeneOrGeneProduct	309	310	7	1:NR:2	L2R	CROSS	88-89	312-313	595	CCND1	GeneOrGeneProduct	88	89	3	5225	PGC	GeneOrGeneProduct	312	313	7	1:NR:2	L2R	NON-CROSS	90-91	92-93	894	CCND2	GeneOrGeneProduct	90	91	3	896	CCND3|CCND3|CCND3	GeneOrGeneProduct	92:299:364	93:300:365	3:7:10	1:NR:2	L2R	NON-CROSS	90-91	94-95	894	CCND2	GeneOrGeneProduct	90	91	3	898	CCNE1	GeneOrGeneProduct	94	95	3	1:NR:2	L2R	NON-CROSS	90-91	96-100	894	CCND2	GeneOrGeneProduct	90	91	3	1017	CDK2 [ p33 ]	GeneOrGeneProduct	96	100	3	1:NR:2	L2R	NON-CROSS	90-91	101-102	894	CCND2	GeneOrGeneProduct	90	91	3	1019	CDK4	GeneOrGeneProduct	101	102	3	1:NR:2	L2R	NON-CROSS	90-91	103-104	894	CCND2	GeneOrGeneProduct	90	91	3	1021	CDK6	GeneOrGeneProduct	103	104	3	1:NR:2	L2R	NON-CROSS	90-91	105-106	894	CCND2	GeneOrGeneProduct	90	91	3	1026	CDKN1A|p21|Cip1	GeneOrGeneProduct	105:107:109	106:108:110	3:3:3	1:NR:2	L2R	NON-CROSS	90-91	112-113	894	CCND2	GeneOrGeneProduct	90	91	3	1027	CDKN1B|p27 , Kip1	GeneOrGeneProduct	112:114	113:117	3:3	1:NR:2	L2R	NON-CROSS	90-91	119-120	894	CCND2	GeneOrGeneProduct	90	91	3	1029	CDKN2A|p16|p19	GeneOrGeneProduct	119:121:137	120:122:138	3:3:3	1:NR:2	L2R	NON-CROSS	90-91	124-125	894	CCND2	GeneOrGeneProduct	90	91	3	1030	CDKN2B|p15	GeneOrGeneProduct	124:126	125:127	3:3	1:NR:2	L2R	NON-CROSS	90-91	129-130	894	CCND2	GeneOrGeneProduct	90	91	3	1031	CDKN2C|p18	GeneOrGeneProduct	129:131	130:132	3:3	1:NR:2	L2R	NON-CROSS	90-91	135-136	894	CCND2	GeneOrGeneProduct	90	91	3	1032	CDKN2D	GeneOrGeneProduct	135	136	3	1:NR:2	L2R	CROSS	90-91	238-239	894	CCND2	GeneOrGeneProduct	90	91	3	D003643	death	DiseaseOrPhenotypicFeature	238	239	6	1:NR:2	L2R	CROSS	90-91	278-279	894	CCND2	GeneOrGeneProduct	90	91	3	D009369	tumour	DiseaseOrPhenotypicFeature	278	279	6	1:NR:2	L2R	CROSS	90-91	301-302	894	CCND2	GeneOrGeneProduct	90	91	3	705	BYSL	GeneOrGeneProduct	301	302	7	1:NR:2	L2R	CROSS	90-91	303-304	894	CCND2	GeneOrGeneProduct	90	91	3	55031	TRFP	GeneOrGeneProduct	303	304	7	1:NR:2	L2R	CROSS	90-91	305-306	894	CCND2	GeneOrGeneProduct	90	91	3	25862	USP49	GeneOrGeneProduct	305	306	7	1:NR:2	L2R	CROSS	90-91	307-308	894	CCND2	GeneOrGeneProduct	90	91	3	29964	C6ofr49|C6orf49	GeneOrGeneProduct	307:342	308:343	7:9	1:NR:2	L2R	CROSS	90-91	309-310	894	CCND2	GeneOrGeneProduct	90	91	3	10817	FRS3	GeneOrGeneProduct	309	310	7	1:NR:2	L2R	CROSS	90-91	312-313	894	CCND2	GeneOrGeneProduct	90	91	3	5225	PGC	GeneOrGeneProduct	312	313	7	1:NR:2	L2R	NON-CROSS	92-93	94-95	896	CCND3|CCND3|CCND3	GeneOrGeneProduct	92:299:364	93:300:365	3:7:10	898	CCNE1	GeneOrGeneProduct	94	95	3	1:NR:2	L2R	NON-CROSS	92-93	96-100	896	CCND3|CCND3|CCND3	GeneOrGeneProduct	92:299:364	93:300:365	3:7:10	1017	CDK2 [ p33 ]	GeneOrGeneProduct	96	100	3	1:NR:2	L2R	NON-CROSS	92-93	101-102	896	CCND3|CCND3|CCND3	GeneOrGeneProduct	92:299:364	93:300:365	3:7:10	1019	CDK4	GeneOrGeneProduct	101	102	3	1:NR:2	L2R	NON-CROSS	92-93	103-104	896	CCND3|CCND3|CCND3	GeneOrGeneProduct	92:299:364	93:300:365	3:7:10	1021	CDK6	GeneOrGeneProduct	103	104	3	1:NR:2	L2R	NON-CROSS	92-93	105-106	896	CCND3|CCND3|CCND3	GeneOrGeneProduct	92:299:364	93:300:365	3:7:10	1026	CDKN1A|p21|Cip1	GeneOrGeneProduct	105:107:109	106:108:110	3:3:3	1:NR:2	L2R	NON-CROSS	92-93	112-113	896	CCND3|CCND3|CCND3	GeneOrGeneProduct	92:299:364	93:300:365	3:7:10	1027	CDKN1B|p27 , Kip1	GeneOrGeneProduct	112:114	113:117	3:3	1:NR:2	L2R	NON-CROSS	92-93	119-120	896	CCND3|CCND3|CCND3	GeneOrGeneProduct	92:299:364	93:300:365	3:7:10	1029	CDKN2A|p16|p19	GeneOrGeneProduct	119:121:137	120:122:138	3:3:3	1:NR:2	L2R	NON-CROSS	92-93	124-125	896	CCND3|CCND3|CCND3	GeneOrGeneProduct	92:299:364	93:300:365	3:7:10	1030	CDKN2B|p15	GeneOrGeneProduct	124:126	125:127	3:3	1:NR:2	L2R	NON-CROSS	92-93	129-130	896	CCND3|CCND3|CCND3	GeneOrGeneProduct	92:299:364	93:300:365	3:7:10	1031	CDKN2C|p18	GeneOrGeneProduct	129:131	130:132	3:3	1:NR:2	L2R	NON-CROSS	92-93	135-136	896	CCND3|CCND3|CCND3	GeneOrGeneProduct	92:299:364	93:300:365	3:7:10	1032	CDKN2D	GeneOrGeneProduct	135	136	3	1:Association:2	L2R	CROSS	238-239	299-300	896	CCND3|CCND3|CCND3	GeneOrGeneProduct	92:299:364	93:300:365	3:7:10	D003643	death	DiseaseOrPhenotypicFeature	238	239	6	1:NR:2	L2R	CROSS	278-279	299-300	896	CCND3|CCND3|CCND3	GeneOrGeneProduct	92:299:364	93:300:365	3:7:10	D009369	tumour	DiseaseOrPhenotypicFeature	278	279	6	1:Association:2	L2R	NON-CROSS	299-300	301-302	896	CCND3|CCND3|CCND3	GeneOrGeneProduct	92:299:364	93:300:365	3:7:10	705	BYSL	GeneOrGeneProduct	301	302	7	1:Association:2	L2R	NON-CROSS	299-300	303-304	896	CCND3|CCND3|CCND3	GeneOrGeneProduct	92:299:364	93:300:365	3:7:10	55031	TRFP	GeneOrGeneProduct	303	304	7	1:Association:2	L2R	NON-CROSS	299-300	305-306	896	CCND3|CCND3|CCND3	GeneOrGeneProduct	92:299:364	93:300:365	3:7:10	25862	USP49	GeneOrGeneProduct	305	306	7	1:Association:2	L2R	NON-CROSS	299-300	307-308	896	CCND3|CCND3|CCND3	GeneOrGeneProduct	92:299:364	93:300:365	3:7:10	29964	C6ofr49|C6orf49	GeneOrGeneProduct	307:342	308:343	7:9	1:Association:2	L2R	NON-CROSS	299-300	309-310	896	CCND3|CCND3|CCND3	GeneOrGeneProduct	92:299:364	93:300:365	3:7:10	10817	FRS3	GeneOrGeneProduct	309	310	7	1:Association:2	L2R	NON-CROSS	299-300	312-313	896	CCND3|CCND3|CCND3	GeneOrGeneProduct	92:299:364	93:300:365	3:7:10	5225	PGC	GeneOrGeneProduct	312	313	7	1:NR:2	L2R	NON-CROSS	94-95	96-100	898	CCNE1	GeneOrGeneProduct	94	95	3	1017	CDK2 [ p33 ]	GeneOrGeneProduct	96	100	3	1:NR:2	L2R	NON-CROSS	94-95	101-102	898	CCNE1	GeneOrGeneProduct	94	95	3	1019	CDK4	GeneOrGeneProduct	101	102	3	1:NR:2	L2R	NON-CROSS	94-95	103-104	898	CCNE1	GeneOrGeneProduct	94	95	3	1021	CDK6	GeneOrGeneProduct	103	104	3	1:NR:2	L2R	NON-CROSS	94-95	105-106	898	CCNE1	GeneOrGeneProduct	94	95	3	1026	CDKN1A|p21|Cip1	GeneOrGeneProduct	105:107:109	106:108:110	3:3:3	1:NR:2	L2R	NON-CROSS	94-95	112-113	898	CCNE1	GeneOrGeneProduct	94	95	3	1027	CDKN1B|p27 , Kip1	GeneOrGeneProduct	112:114	113:117	3:3	1:NR:2	L2R	NON-CROSS	94-95	119-120	898	CCNE1	GeneOrGeneProduct	94	95	3	1029	CDKN2A|p16|p19	GeneOrGeneProduct	119:121:137	120:122:138	3:3:3	1:NR:2	L2R	NON-CROSS	94-95	124-125	898	CCNE1	GeneOrGeneProduct	94	95	3	1030	CDKN2B|p15	GeneOrGeneProduct	124:126	125:127	3:3	1:NR:2	L2R	NON-CROSS	94-95	129-130	898	CCNE1	GeneOrGeneProduct	94	95	3	1031	CDKN2C|p18	GeneOrGeneProduct	129:131	130:132	3:3	1:NR:2	L2R	NON-CROSS	94-95	135-136	898	CCNE1	GeneOrGeneProduct	94	95	3	1032	CDKN2D	GeneOrGeneProduct	135	136	3	1:NR:2	L2R	CROSS	94-95	238-239	898	CCNE1	GeneOrGeneProduct	94	95	3	D003643	death	DiseaseOrPhenotypicFeature	238	239	6	1:NR:2	L2R	CROSS	94-95	278-279	898	CCNE1	GeneOrGeneProduct	94	95	3	D009369	tumour	DiseaseOrPhenotypicFeature	278	279	6	1:NR:2	L2R	CROSS	94-95	301-302	898	CCNE1	GeneOrGeneProduct	94	95	3	705	BYSL	GeneOrGeneProduct	301	302	7	1:NR:2	L2R	CROSS	94-95	303-304	898	CCNE1	GeneOrGeneProduct	94	95	3	55031	TRFP	GeneOrGeneProduct	303	304	7	1:NR:2	L2R	CROSS	94-95	305-306	898	CCNE1	GeneOrGeneProduct	94	95	3	25862	USP49	GeneOrGeneProduct	305	306	7	1:NR:2	L2R	CROSS	94-95	307-308	898	CCNE1	GeneOrGeneProduct	94	95	3	29964	C6ofr49|C6orf49	GeneOrGeneProduct	307:342	308:343	7:9	1:NR:2	L2R	CROSS	94-95	309-310	898	CCNE1	GeneOrGeneProduct	94	95	3	10817	FRS3	GeneOrGeneProduct	309	310	7	1:NR:2	L2R	CROSS	94-95	312-313	898	CCNE1	GeneOrGeneProduct	94	95	3	5225	PGC	GeneOrGeneProduct	312	313	7	1:NR:2	L2R	NON-CROSS	96-100	101-102	1017	CDK2 [ p33 ]	GeneOrGeneProduct	96	100	3	1019	CDK4	GeneOrGeneProduct	101	102	3	1:NR:2	L2R	NON-CROSS	96-100	103-104	1017	CDK2 [ p33 ]	GeneOrGeneProduct	96	100	3	1021	CDK6	GeneOrGeneProduct	103	104	3	1:NR:2	L2R	NON-CROSS	96-100	105-106	1017	CDK2 [ p33 ]	GeneOrGeneProduct	96	100	3	1026	CDKN1A|p21|Cip1	GeneOrGeneProduct	105:107:109	106:108:110	3:3:3	1:NR:2	L2R	NON-CROSS	96-100	112-113	1017	CDK2 [ p33 ]	GeneOrGeneProduct	96	100	3	1027	CDKN1B|p27 , Kip1	GeneOrGeneProduct	112:114	113:117	3:3	1:NR:2	L2R	NON-CROSS	96-100	119-120	1017	CDK2 [ p33 ]	GeneOrGeneProduct	96	100	3	1029	CDKN2A|p16|p19	GeneOrGeneProduct	119:121:137	120:122:138	3:3:3	1:NR:2	L2R	NON-CROSS	96-100	124-125	1017	CDK2 [ p33 ]	GeneOrGeneProduct	96	100	3	1030	CDKN2B|p15	GeneOrGeneProduct	124:126	125:127	3:3	1:NR:2	L2R	NON-CROSS	96-100	129-130	1017	CDK2 [ p33 ]	GeneOrGeneProduct	96	100	3	1031	CDKN2C|p18	GeneOrGeneProduct	129:131	130:132	3:3	1:NR:2	L2R	NON-CROSS	96-100	135-136	1017	CDK2 [ p33 ]	GeneOrGeneProduct	96	100	3	1032	CDKN2D	GeneOrGeneProduct	135	136	3	1:NR:2	L2R	CROSS	96-100	238-239	1017	CDK2 [ p33 ]	GeneOrGeneProduct	96	100	3	D003643	death	DiseaseOrPhenotypicFeature	238	239	6	1:NR:2	L2R	CROSS	96-100	278-279	1017	CDK2 [ p33 ]	GeneOrGeneProduct	96	100	3	D009369	tumour	DiseaseOrPhenotypicFeature	278	279	6	1:NR:2	L2R	CROSS	96-100	301-302	1017	CDK2 [ p33 ]	GeneOrGeneProduct	96	100	3	705	BYSL	GeneOrGeneProduct	301	302	7	1:NR:2	L2R	CROSS	96-100	303-304	1017	CDK2 [ p33 ]	GeneOrGeneProduct	96	100	3	55031	TRFP	GeneOrGeneProduct	303	304	7	1:NR:2	L2R	CROSS	96-100	305-306	1017	CDK2 [ p33 ]	GeneOrGeneProduct	96	100	3	25862	USP49	GeneOrGeneProduct	305	306	7	1:NR:2	L2R	CROSS	96-100	307-308	1017	CDK2 [ p33 ]	GeneOrGeneProduct	96	100	3	29964	C6ofr49|C6orf49	GeneOrGeneProduct	307:342	308:343	7:9	1:NR:2	L2R	CROSS	96-100	309-310	1017	CDK2 [ p33 ]	GeneOrGeneProduct	96	100	3	10817	FRS3	GeneOrGeneProduct	309	310	7	1:NR:2	L2R	CROSS	96-100	312-313	1017	CDK2 [ p33 ]	GeneOrGeneProduct	96	100	3	5225	PGC	GeneOrGeneProduct	312	313	7	1:NR:2	L2R	NON-CROSS	101-102	103-104	1019	CDK4	GeneOrGeneProduct	101	102	3	1021	CDK6	GeneOrGeneProduct	103	104	3	1:NR:2	L2R	NON-CROSS	101-102	105-106	1019	CDK4	GeneOrGeneProduct	101	102	3	1026	CDKN1A|p21|Cip1	GeneOrGeneProduct	105:107:109	106:108:110	3:3:3	1:NR:2	L2R	NON-CROSS	101-102	112-113	1019	CDK4	GeneOrGeneProduct	101	102	3	1027	CDKN1B|p27 , Kip1	GeneOrGeneProduct	112:114	113:117	3:3	1:NR:2	L2R	NON-CROSS	101-102	119-120	1019	CDK4	GeneOrGeneProduct	101	102	3	1029	CDKN2A|p16|p19	GeneOrGeneProduct	119:121:137	120:122:138	3:3:3	1:NR:2	L2R	NON-CROSS	101-102	124-125	1019	CDK4	GeneOrGeneProduct	101	102	3	1030	CDKN2B|p15	GeneOrGeneProduct	124:126	125:127	3:3	1:NR:2	L2R	NON-CROSS	101-102	129-130	1019	CDK4	GeneOrGeneProduct	101	102	3	1031	CDKN2C|p18	GeneOrGeneProduct	129:131	130:132	3:3	1:NR:2	L2R	NON-CROSS	101-102	135-136	1019	CDK4	GeneOrGeneProduct	101	102	3	1032	CDKN2D	GeneOrGeneProduct	135	136	3	1:NR:2	L2R	CROSS	101-102	238-239	1019	CDK4	GeneOrGeneProduct	101	102	3	D003643	death	DiseaseOrPhenotypicFeature	238	239	6	1:NR:2	L2R	CROSS	101-102	278-279	1019	CDK4	GeneOrGeneProduct	101	102	3	D009369	tumour	DiseaseOrPhenotypicFeature	278	279	6	1:NR:2	L2R	CROSS	101-102	301-302	1019	CDK4	GeneOrGeneProduct	101	102	3	705	BYSL	GeneOrGeneProduct	301	302	7	1:NR:2	L2R	CROSS	101-102	303-304	1019	CDK4	GeneOrGeneProduct	101	102	3	55031	TRFP	GeneOrGeneProduct	303	304	7	1:NR:2	L2R	CROSS	101-102	305-306	1019	CDK4	GeneOrGeneProduct	101	102	3	25862	USP49	GeneOrGeneProduct	305	306	7	1:NR:2	L2R	CROSS	101-102	307-308	1019	CDK4	GeneOrGeneProduct	101	102	3	29964	C6ofr49|C6orf49	GeneOrGeneProduct	307:342	308:343	7:9	1:NR:2	L2R	CROSS	101-102	309-310	1019	CDK4	GeneOrGeneProduct	101	102	3	10817	FRS3	GeneOrGeneProduct	309	310	7	1:NR:2	L2R	CROSS	101-102	312-313	1019	CDK4	GeneOrGeneProduct	101	102	3	5225	PGC	GeneOrGeneProduct	312	313	7	1:NR:2	L2R	NON-CROSS	103-104	105-106	1021	CDK6	GeneOrGeneProduct	103	104	3	1026	CDKN1A|p21|Cip1	GeneOrGeneProduct	105:107:109	106:108:110	3:3:3	1:NR:2	L2R	NON-CROSS	103-104	112-113	1021	CDK6	GeneOrGeneProduct	103	104	3	1027	CDKN1B|p27 , Kip1	GeneOrGeneProduct	112:114	113:117	3:3	1:NR:2	L2R	NON-CROSS	103-104	119-120	1021	CDK6	GeneOrGeneProduct	103	104	3	1029	CDKN2A|p16|p19	GeneOrGeneProduct	119:121:137	120:122:138	3:3:3	1:NR:2	L2R	NON-CROSS	103-104	124-125	1021	CDK6	GeneOrGeneProduct	103	104	3	1030	CDKN2B|p15	GeneOrGeneProduct	124:126	125:127	3:3	1:NR:2	L2R	NON-CROSS	103-104	129-130	1021	CDK6	GeneOrGeneProduct	103	104	3	1031	CDKN2C|p18	GeneOrGeneProduct	129:131	130:132	3:3	1:NR:2	L2R	NON-CROSS	103-104	135-136	1021	CDK6	GeneOrGeneProduct	103	104	3	1032	CDKN2D	GeneOrGeneProduct	135	136	3	1:NR:2	L2R	CROSS	103-104	238-239	1021	CDK6	GeneOrGeneProduct	103	104	3	D003643	death	DiseaseOrPhenotypicFeature	238	239	6	1:NR:2	L2R	CROSS	103-104	278-279	1021	CDK6	GeneOrGeneProduct	103	104	3	D009369	tumour	DiseaseOrPhenotypicFeature	278	279	6	1:NR:2	L2R	CROSS	103-104	301-302	1021	CDK6	GeneOrGeneProduct	103	104	3	705	BYSL	GeneOrGeneProduct	301	302	7	1:NR:2	L2R	CROSS	103-104	303-304	1021	CDK6	GeneOrGeneProduct	103	104	3	55031	TRFP	GeneOrGeneProduct	303	304	7	1:NR:2	L2R	CROSS	103-104	305-306	1021	CDK6	GeneOrGeneProduct	103	104	3	25862	USP49	GeneOrGeneProduct	305	306	7	1:NR:2	L2R	CROSS	103-104	307-308	1021	CDK6	GeneOrGeneProduct	103	104	3	29964	C6ofr49|C6orf49	GeneOrGeneProduct	307:342	308:343	7:9	1:NR:2	L2R	CROSS	103-104	309-310	1021	CDK6	GeneOrGeneProduct	103	104	3	10817	FRS3	GeneOrGeneProduct	309	310	7	1:NR:2	L2R	CROSS	103-104	312-313	1021	CDK6	GeneOrGeneProduct	103	104	3	5225	PGC	GeneOrGeneProduct	312	313	7	1:NR:2	L2R	NON-CROSS	109-110	112-113	1026	CDKN1A|p21|Cip1	GeneOrGeneProduct	105:107:109	106:108:110	3:3:3	1027	CDKN1B|p27 , Kip1	GeneOrGeneProduct	112:114	113:117	3:3	1:NR:2	L2R	NON-CROSS	109-110	119-120	1026	CDKN1A|p21|Cip1	GeneOrGeneProduct	105:107:109	106:108:110	3:3:3	1029	CDKN2A|p16|p19	GeneOrGeneProduct	119:121:137	120:122:138	3:3:3	1:NR:2	L2R	NON-CROSS	109-110	124-125	1026	CDKN1A|p21|Cip1	GeneOrGeneProduct	105:107:109	106:108:110	3:3:3	1030	CDKN2B|p15	GeneOrGeneProduct	124:126	125:127	3:3	1:NR:2	L2R	NON-CROSS	109-110	129-130	1026	CDKN1A|p21|Cip1	GeneOrGeneProduct	105:107:109	106:108:110	3:3:3	1031	CDKN2C|p18	GeneOrGeneProduct	129:131	130:132	3:3	1:NR:2	L2R	NON-CROSS	109-110	135-136	1026	CDKN1A|p21|Cip1	GeneOrGeneProduct	105:107:109	106:108:110	3:3:3	1032	CDKN2D	GeneOrGeneProduct	135	136	3	1:NR:2	L2R	CROSS	109-110	238-239	1026	CDKN1A|p21|Cip1	GeneOrGeneProduct	105:107:109	106:108:110	3:3:3	D003643	death	DiseaseOrPhenotypicFeature	238	239	6	1:NR:2	L2R	CROSS	109-110	278-279	1026	CDKN1A|p21|Cip1	GeneOrGeneProduct	105:107:109	106:108:110	3:3:3	D009369	tumour	DiseaseOrPhenotypicFeature	278	279	6	1:NR:2	L2R	CROSS	109-110	301-302	1026	CDKN1A|p21|Cip1	GeneOrGeneProduct	105:107:109	106:108:110	3:3:3	705	BYSL	GeneOrGeneProduct	301	302	7	1:NR:2	L2R	CROSS	109-110	303-304	1026	CDKN1A|p21|Cip1	GeneOrGeneProduct	105:107:109	106:108:110	3:3:3	55031	TRFP	GeneOrGeneProduct	303	304	7	1:NR:2	L2R	CROSS	109-110	305-306	1026	CDKN1A|p21|Cip1	GeneOrGeneProduct	105:107:109	106:108:110	3:3:3	25862	USP49	GeneOrGeneProduct	305	306	7	1:NR:2	L2R	CROSS	109-110	307-308	1026	CDKN1A|p21|Cip1	GeneOrGeneProduct	105:107:109	106:108:110	3:3:3	29964	C6ofr49|C6orf49	GeneOrGeneProduct	307:342	308:343	7:9	1:NR:2	L2R	CROSS	109-110	309-310	1026	CDKN1A|p21|Cip1	GeneOrGeneProduct	105:107:109	106:108:110	3:3:3	10817	FRS3	GeneOrGeneProduct	309	310	7	1:NR:2	L2R	CROSS	109-110	312-313	1026	CDKN1A|p21|Cip1	GeneOrGeneProduct	105:107:109	106:108:110	3:3:3	5225	PGC	GeneOrGeneProduct	312	313	7	1:NR:2	L2R	NON-CROSS	114-117	119-120	1027	CDKN1B|p27 , Kip1	GeneOrGeneProduct	112:114	113:117	3:3	1029	CDKN2A|p16|p19	GeneOrGeneProduct	119:121:137	120:122:138	3:3:3	1:NR:2	L2R	NON-CROSS	114-117	124-125	1027	CDKN1B|p27 , Kip1	GeneOrGeneProduct	112:114	113:117	3:3	1030	CDKN2B|p15	GeneOrGeneProduct	124:126	125:127	3:3	1:NR:2	L2R	NON-CROSS	114-117	129-130	1027	CDKN1B|p27 , Kip1	GeneOrGeneProduct	112:114	113:117	3:3	1031	CDKN2C|p18	GeneOrGeneProduct	129:131	130:132	3:3	1:NR:2	L2R	NON-CROSS	114-117	135-136	1027	CDKN1B|p27 , Kip1	GeneOrGeneProduct	112:114	113:117	3:3	1032	CDKN2D	GeneOrGeneProduct	135	136	3	1:NR:2	L2R	CROSS	114-117	238-239	1027	CDKN1B|p27 , Kip1	GeneOrGeneProduct	112:114	113:117	3:3	D003643	death	DiseaseOrPhenotypicFeature	238	239	6	1:NR:2	L2R	CROSS	114-117	278-279	1027	CDKN1B|p27 , Kip1	GeneOrGeneProduct	112:114	113:117	3:3	D009369	tumour	DiseaseOrPhenotypicFeature	278	279	6	1:NR:2	L2R	CROSS	114-117	301-302	1027	CDKN1B|p27 , Kip1	GeneOrGeneProduct	112:114	113:117	3:3	705	BYSL	GeneOrGeneProduct	301	302	7	1:NR:2	L2R	CROSS	114-117	303-304	1027	CDKN1B|p27 , Kip1	GeneOrGeneProduct	112:114	113:117	3:3	55031	TRFP	GeneOrGeneProduct	303	304	7	1:NR:2	L2R	CROSS	114-117	305-306	1027	CDKN1B|p27 , Kip1	GeneOrGeneProduct	112:114	113:117	3:3	25862	USP49	GeneOrGeneProduct	305	306	7	1:NR:2	L2R	CROSS	114-117	307-308	1027	CDKN1B|p27 , Kip1	GeneOrGeneProduct	112:114	113:117	3:3	29964	C6ofr49|C6orf49	GeneOrGeneProduct	307:342	308:343	7:9	1:NR:2	L2R	CROSS	114-117	309-310	1027	CDKN1B|p27 , Kip1	GeneOrGeneProduct	112:114	113:117	3:3	10817	FRS3	GeneOrGeneProduct	309	310	7	1:NR:2	L2R	CROSS	114-117	312-313	1027	CDKN1B|p27 , Kip1	GeneOrGeneProduct	112:114	113:117	3:3	5225	PGC	GeneOrGeneProduct	312	313	7	1:NR:2	L2R	NON-CROSS	121-122	124-125	1029	CDKN2A|p16|p19	GeneOrGeneProduct	119:121:137	120:122:138	3:3:3	1030	CDKN2B|p15	GeneOrGeneProduct	124:126	125:127	3:3	1:NR:2	L2R	NON-CROSS	131-132	137-138	1029	CDKN2A|p16|p19	GeneOrGeneProduct	119:121:137	120:122:138	3:3:3	1031	CDKN2C|p18	GeneOrGeneProduct	129:131	130:132	3:3	1:NR:2	L2R	NON-CROSS	135-136	137-138	1029	CDKN2A|p16|p19	GeneOrGeneProduct	119:121:137	120:122:138	3:3:3	1032	CDKN2D	GeneOrGeneProduct	135	136	3	1:NR:2	L2R	CROSS	137-138	238-239	1029	CDKN2A|p16|p19	GeneOrGeneProduct	119:121:137	120:122:138	3:3:3	D003643	death	DiseaseOrPhenotypicFeature	238	239	6	1:NR:2	L2R	CROSS	137-138	278-279	1029	CDKN2A|p16|p19	GeneOrGeneProduct	119:121:137	120:122:138	3:3:3	D009369	tumour	DiseaseOrPhenotypicFeature	278	279	6	1:NR:2	L2R	CROSS	137-138	301-302	1029	CDKN2A|p16|p19	GeneOrGeneProduct	119:121:137	120:122:138	3:3:3	705	BYSL	GeneOrGeneProduct	301	302	7	1:NR:2	L2R	CROSS	137-138	303-304	1029	CDKN2A|p16|p19	GeneOrGeneProduct	119:121:137	120:122:138	3:3:3	55031	TRFP	GeneOrGeneProduct	303	304	7	1:NR:2	L2R	CROSS	137-138	305-306	1029	CDKN2A|p16|p19	GeneOrGeneProduct	119:121:137	120:122:138	3:3:3	25862	USP49	GeneOrGeneProduct	305	306	7	1:NR:2	L2R	CROSS	137-138	307-308	1029	CDKN2A|p16|p19	GeneOrGeneProduct	119:121:137	120:122:138	3:3:3	29964	C6ofr49|C6orf49	GeneOrGeneProduct	307:342	308:343	7:9	1:NR:2	L2R	CROSS	137-138	309-310	1029	CDKN2A|p16|p19	GeneOrGeneProduct	119:121:137	120:122:138	3:3:3	10817	FRS3	GeneOrGeneProduct	309	310	7	1:NR:2	L2R	CROSS	137-138	312-313	1029	CDKN2A|p16|p19	GeneOrGeneProduct	119:121:137	120:122:138	3:3:3	5225	PGC	GeneOrGeneProduct	312	313	7	1:NR:2	L2R	NON-CROSS	126-127	129-130	1030	CDKN2B|p15	GeneOrGeneProduct	124:126	125:127	3:3	1031	CDKN2C|p18	GeneOrGeneProduct	129:131	130:132	3:3	1:NR:2	L2R	NON-CROSS	126-127	135-136	1030	CDKN2B|p15	GeneOrGeneProduct	124:126	125:127	3:3	1032	CDKN2D	GeneOrGeneProduct	135	136	3	1:NR:2	L2R	CROSS	126-127	238-239	1030	CDKN2B|p15	GeneOrGeneProduct	124:126	125:127	3:3	D003643	death	DiseaseOrPhenotypicFeature	238	239	6	1:NR:2	L2R	CROSS	126-127	278-279	1030	CDKN2B|p15	GeneOrGeneProduct	124:126	125:127	3:3	D009369	tumour	DiseaseOrPhenotypicFeature	278	279	6	1:NR:2	L2R	CROSS	126-127	301-302	1030	CDKN2B|p15	GeneOrGeneProduct	124:126	125:127	3:3	705	BYSL	GeneOrGeneProduct	301	302	7	1:NR:2	L2R	CROSS	126-127	303-304	1030	CDKN2B|p15	GeneOrGeneProduct	124:126	125:127	3:3	55031	TRFP	GeneOrGeneProduct	303	304	7	1:NR:2	L2R	CROSS	126-127	305-306	1030	CDKN2B|p15	GeneOrGeneProduct	124:126	125:127	3:3	25862	USP49	GeneOrGeneProduct	305	306	7	1:NR:2	L2R	CROSS	126-127	307-308	1030	CDKN2B|p15	GeneOrGeneProduct	124:126	125:127	3:3	29964	C6ofr49|C6orf49	GeneOrGeneProduct	307:342	308:343	7:9	1:NR:2	L2R	CROSS	126-127	309-310	1030	CDKN2B|p15	GeneOrGeneProduct	124:126	125:127	3:3	10817	FRS3	GeneOrGeneProduct	309	310	7	1:NR:2	L2R	CROSS	126-127	312-313	1030	CDKN2B|p15	GeneOrGeneProduct	124:126	125:127	3:3	5225	PGC	GeneOrGeneProduct	312	313	7	1:NR:2	L2R	NON-CROSS	131-132	135-136	1031	CDKN2C|p18	GeneOrGeneProduct	129:131	130:132	3:3	1032	CDKN2D	GeneOrGeneProduct	135	136	3	1:NR:2	L2R	CROSS	131-132	238-239	1031	CDKN2C|p18	GeneOrGeneProduct	129:131	130:132	3:3	D003643	death	DiseaseOrPhenotypicFeature	238	239	6	1:NR:2	L2R	CROSS	131-132	278-279	1031	CDKN2C|p18	GeneOrGeneProduct	129:131	130:132	3:3	D009369	tumour	DiseaseOrPhenotypicFeature	278	279	6	1:NR:2	L2R	CROSS	131-132	301-302	1031	CDKN2C|p18	GeneOrGeneProduct	129:131	130:132	3:3	705	BYSL	GeneOrGeneProduct	301	302	7	1:NR:2	L2R	CROSS	131-132	303-304	1031	CDKN2C|p18	GeneOrGeneProduct	129:131	130:132	3:3	55031	TRFP	GeneOrGeneProduct	303	304	7	1:NR:2	L2R	CROSS	131-132	305-306	1031	CDKN2C|p18	GeneOrGeneProduct	129:131	130:132	3:3	25862	USP49	GeneOrGeneProduct	305	306	7	1:NR:2	L2R	CROSS	131-132	307-308	1031	CDKN2C|p18	GeneOrGeneProduct	129:131	130:132	3:3	29964	C6ofr49|C6orf49	GeneOrGeneProduct	307:342	308:343	7:9	1:NR:2	L2R	CROSS	131-132	309-310	1031	CDKN2C|p18	GeneOrGeneProduct	129:131	130:132	3:3	10817	FRS3	GeneOrGeneProduct	309	310	7	1:NR:2	L2R	CROSS	131-132	312-313	1031	CDKN2C|p18	GeneOrGeneProduct	129:131	130:132	3:3	5225	PGC	GeneOrGeneProduct	312	313	7	1:NR:2	L2R	CROSS	135-136	238-239	1032	CDKN2D	GeneOrGeneProduct	135	136	3	D003643	death	DiseaseOrPhenotypicFeature	238	239	6	1:NR:2	L2R	CROSS	135-136	278-279	1032	CDKN2D	GeneOrGeneProduct	135	136	3	D009369	tumour	DiseaseOrPhenotypicFeature	278	279	6	1:NR:2	L2R	CROSS	135-136	301-302	1032	CDKN2D	GeneOrGeneProduct	135	136	3	705	BYSL	GeneOrGeneProduct	301	302	7	1:NR:2	L2R	CROSS	135-136	303-304	1032	CDKN2D	GeneOrGeneProduct	135	136	3	55031	TRFP	GeneOrGeneProduct	303	304	7	1:NR:2	L2R	CROSS	135-136	305-306	1032	CDKN2D	GeneOrGeneProduct	135	136	3	25862	USP49	GeneOrGeneProduct	305	306	7	1:NR:2	L2R	CROSS	135-136	307-308	1032	CDKN2D	GeneOrGeneProduct	135	136	3	29964	C6ofr49|C6orf49	GeneOrGeneProduct	307:342	308:343	7:9	1:NR:2	L2R	CROSS	135-136	309-310	1032	CDKN2D	GeneOrGeneProduct	135	136	3	10817	FRS3	GeneOrGeneProduct	309	310	7	1:NR:2	L2R	CROSS	135-136	312-313	1032	CDKN2D	GeneOrGeneProduct	135	136	3	5225	PGC	GeneOrGeneProduct	312	313	7	1:Positive_Correlation:2	L2R	NON-CROSS	230-231	238-239	rs2479717	rs2479717|rs2479717	SequenceVariant	230:365	231:366	6:10	D003643	death	DiseaseOrPhenotypicFeature	238	239	6	1:NR:2	L2R	NON-CROSS	230-231	278-279	rs2479717	rs2479717|rs2479717	SequenceVariant	230:365	231:366	6:10	D009369	tumour	DiseaseOrPhenotypicFeature	278	279	6	1:NR:2	L2R	CROSS	238-239	301-302	D003643	death	DiseaseOrPhenotypicFeature	238	239	6	705	BYSL	GeneOrGeneProduct	301	302	7	1:NR:2	L2R	CROSS	238-239	303-304	D003643	death	DiseaseOrPhenotypicFeature	238	239	6	55031	TRFP	GeneOrGeneProduct	303	304	7	1:NR:2	L2R	CROSS	238-239	305-306	D003643	death	DiseaseOrPhenotypicFeature	238	239	6	25862	USP49	GeneOrGeneProduct	305	306	7	1:NR:2	L2R	CROSS	238-239	307-308	D003643	death	DiseaseOrPhenotypicFeature	238	239	6	29964	C6ofr49|C6orf49	GeneOrGeneProduct	307:342	308:343	7:9	1:NR:2	L2R	CROSS	238-239	309-310	D003643	death	DiseaseOrPhenotypicFeature	238	239	6	10817	FRS3	GeneOrGeneProduct	309	310	7	1:NR:2	L2R	CROSS	238-239	312-313	D003643	death	DiseaseOrPhenotypicFeature	238	239	6	5225	PGC	GeneOrGeneProduct	312	313	7	1:NR:2	L2R	CROSS	278-279	301-302	D009369	tumour	DiseaseOrPhenotypicFeature	278	279	6	705	BYSL	GeneOrGeneProduct	301	302	7	1:NR:2	L2R	CROSS	278-279	303-304	D009369	tumour	DiseaseOrPhenotypicFeature	278	279	6	55031	TRFP	GeneOrGeneProduct	303	304	7	1:NR:2	L2R	CROSS	278-279	305-306	D009369	tumour	DiseaseOrPhenotypicFeature	278	279	6	25862	USP49	GeneOrGeneProduct	305	306	7	1:NR:2	L2R	CROSS	278-279	307-308	D009369	tumour	DiseaseOrPhenotypicFeature	278	279	6	29964	C6ofr49|C6orf49	GeneOrGeneProduct	307:342	308:343	7:9	1:NR:2	L2R	CROSS	278-279	309-310	D009369	tumour	DiseaseOrPhenotypicFeature	278	279	6	10817	FRS3	GeneOrGeneProduct	309	310	7	1:NR:2	L2R	CROSS	278-279	312-313	D009369	tumour	DiseaseOrPhenotypicFeature	278	279	6	5225	PGC	GeneOrGeneProduct	312	313	7	1:NR:2	L2R	NON-CROSS	301-302	303-304	705	BYSL	GeneOrGeneProduct	301	302	7	55031	TRFP	GeneOrGeneProduct	303	304	7	1:NR:2	L2R	NON-CROSS	301-302	305-306	705	BYSL	GeneOrGeneProduct	301	302	7	25862	USP49	GeneOrGeneProduct	305	306	7	1:NR:2	L2R	NON-CROSS	301-302	307-308	705	BYSL	GeneOrGeneProduct	301	302	7	29964	C6ofr49|C6orf49	GeneOrGeneProduct	307:342	308:343	7:9	1:NR:2	L2R	NON-CROSS	301-302	309-310	705	BYSL	GeneOrGeneProduct	301	302	7	10817	FRS3	GeneOrGeneProduct	309	310	7	1:NR:2	L2R	NON-CROSS	301-302	312-313	705	BYSL	GeneOrGeneProduct	301	302	7	5225	PGC	GeneOrGeneProduct	312	313	7	1:NR:2	L2R	NON-CROSS	303-304	305-306	55031	TRFP	GeneOrGeneProduct	303	304	7	25862	USP49	GeneOrGeneProduct	305	306	7	1:NR:2	L2R	NON-CROSS	303-304	307-308	55031	TRFP	GeneOrGeneProduct	303	304	7	29964	C6ofr49|C6orf49	GeneOrGeneProduct	307:342	308:343	7:9	1:NR:2	L2R	NON-CROSS	303-304	309-310	55031	TRFP	GeneOrGeneProduct	303	304	7	10817	FRS3	GeneOrGeneProduct	309	310	7	1:NR:2	L2R	NON-CROSS	303-304	312-313	55031	TRFP	GeneOrGeneProduct	303	304	7	5225	PGC	GeneOrGeneProduct	312	313	7	1:NR:2	L2R	NON-CROSS	305-306	307-308	25862	USP49	GeneOrGeneProduct	305	306	7	29964	C6ofr49|C6orf49	GeneOrGeneProduct	307:342	308:343	7:9	1:NR:2	L2R	NON-CROSS	305-306	309-310	25862	USP49	GeneOrGeneProduct	305	306	7	10817	FRS3	GeneOrGeneProduct	309	310	7	1:NR:2	L2R	NON-CROSS	305-306	312-313	25862	USP49	GeneOrGeneProduct	305	306	7	5225	PGC	GeneOrGeneProduct	312	313	7	1:NR:2	L2R	NON-CROSS	307-308	309-310	29964	C6ofr49|C6orf49	GeneOrGeneProduct	307:342	308:343	7:9	10817	FRS3	GeneOrGeneProduct	309	310	7	1:NR:2	L2R	NON-CROSS	307-308	312-313	29964	C6ofr49|C6orf49	GeneOrGeneProduct	307:342	308:343	7:9	5225	PGC	GeneOrGeneProduct	312	313	7	1:NR:2	L2R	NON-CROSS	309-310	312-313	10817	FRS3	GeneOrGeneProduct	309	310	7	5225	PGC	GeneOrGeneProduct	312	313	7
26615423	Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma .|Centrosomal protein 55 ( CEP55 ) is a cell cycle regulator implicated in development of certain cancers .|However , characteristics of CEP55 expression and its clinical / prognostic significance are unclear in human epithelial ovarian carcinoma ( EOC ) .|Therefore , we investigated the expression and clinicopathological significance of CEP55 in patients with EOC and its role in regulating invasion and metastasis of ovarian cell lines .|CEP55 mRNA and protein expression levels were detected by quantitative real - time PCR ( qRT - PCR ) , Western blotting , and immunohistochemistry ( IHC ) .|Potential associations of CEP55 expression scores with clinical parameters and patient survival were evaluated .|CEP55 function was investigated further using RNA interference , wound healing assay , transwell assay , immunofluorescence analysis , qRT - PCR , and Western blotting .|CEP55 was significantly upregulated in ovarian cancer cell lines and lesions compared with normal cells and adjacent noncancerous ovarian tissues .|In the 213 EOC samples , CEP55 protein levels were positively correlated with clinical stage ( P < 0 . 001 ) , lymph node metastasis ( P < 0 . 001 ) , intraperitoneal metastasis ( P < 0 . 001 ) , tumor recurrence ( P < 0 . 001 ) , differentiation grade ( P < 0 . 001 ) , residual tumor size ( P < 0 . 001 ) , ascites see tumor cells ( P = 0 . 020 ) , and serum CA153 level ( P < 0 . 001 ) .|Moreover , patients with aberrant CEP55 protein expression showed tendencies to receive neoadjuvant chemotherapy ( P < 0 . 001 ) and cytoreductive surgery ( P = 0 . 020 ) .|By contrast , no significant correlation was detected between the protein levels and patient age , histological type , or serum CA125 , CA199 , CA724 , NSE , CEA , and b - HCG levels .|Patients with high CEP55 protein expression had shorter overall survival and disease - free survival compared with those with low CEP55 expression .|Multivariate analysis implicated CEP55 as an independent prognostic indicator for EOC patients .|Additionally , downregulation of CEP55 in ovarian cancer cells remarkably inhibited cellular motility and invasion .|Aberrant CEP55 expression may predict unfavorable clinical outcomes in EOC patients and play an important role in regulating invasion in ovarian cancer cells .|Thus , CEP55 may serve as a prognostic marker and therapeutic target for EOC .	1:Positive_Correlation:2	L2R	NON-CROSS	34-35	40-41	55165	centrosomal protein 55|Centrosomal protein 55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55	GeneOrGeneProduct	2:18:22:40:69:87:119:131:158:185:283:350:367:373:387:400:425	5:21:23:41:70:88:120:132:159:186:284:351:368:374:388:401:426	0:1:1:2:3:4:5:6:7:8:9:11:11:12:13:14:15	D009369	tumor|cancers|tumor|tumor|tumor	DiseaseOrPhenotypicFeature	11:34:223:244:256	12:35:224:245:257	0:1:8:8:8	1:Association:2	L2R	NON-CROSS	182-183	185-186	55165	centrosomal protein 55|Centrosomal protein 55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55	GeneOrGeneProduct	2:18:22:40:69:87:119:131:158:185:283:350:367:373:387:400:425	5:21:23:41:70:88:120:132:159:186:284:351:368:374:388:401:426	0:1:1:2:3:4:5:6:7:8:9:11:11:12:13:14:15	D000077216	epithelial ovarian carcinoma|epithelial ovarian carcinoma|EOC|EOC|EOC|EOC|EOC|EOC	DiseaseOrPhenotypicFeature	14:52:56:73:182:380:408:436	17:55:57:74:183:381:409:437	0:2:2:3:8:12:14:15	1:Positive_Correlation:2	L2R	NON-CROSS	387-388	389-391	55165	centrosomal protein 55|Centrosomal protein 55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55	GeneOrGeneProduct	2:18:22:40:69:87:119:131:158:185:283:350:367:373:387:400:425	5:21:23:41:70:88:120:132:159:186:284:351:368:374:388:401:426	0:1:1:2:3:4:5:6:7:8:9:11:11:12:13:14:15	D010051	metastasis of ovarian|ovarian cancer|ovarian cancer|ovarian cancer	DiseaseOrPhenotypicFeature	81:163:389:419	84:165:391:421	3:7:13:14	1:Positive_Correlation:2	L2R	NON-CROSS	185-186	202-205	55165	centrosomal protein 55|Centrosomal protein 55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55	GeneOrGeneProduct	2:18:22:40:69:87:119:131:158:185:283:350:367:373:387:400:425	5:21:23:41:70:88:120:132:159:186:284:351:368:374:388:401:426	0:1:1:2:3:4:5:6:7:8:9:11:11:12:13:14:15	D008207	lymph node metastasis	DiseaseOrPhenotypicFeature	202	205	8	1:Positive_Correlation:2	L2R	NON-CROSS	185-186	213-215	55165	centrosomal protein 55|Centrosomal protein 55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55	GeneOrGeneProduct	2:18:22:40:69:87:119:131:158:185:283:350:367:373:387:400:425	5:21:23:41:70:88:120:132:159:186:284:351:368:374:388:401:426	0:1:1:2:3:4:5:6:7:8:9:11:11:12:13:14:15	D009362	intraperitoneal metastasis	DiseaseOrPhenotypicFeature	213	215	8	1:NR:2	L2R	NON-CROSS	254-255	283-284	55165	centrosomal protein 55|Centrosomal protein 55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55	GeneOrGeneProduct	2:18:22:40:69:87:119:131:158:185:283:350:367:373:387:400:425	5:21:23:41:70:88:120:132:159:186:284:351:368:374:388:401:426	0:1:1:2:3:4:5:6:7:8:9:11:11:12:13:14:15	D001201	ascites	DiseaseOrPhenotypicFeature	254	255	8	1:Positive_Correlation:2	L2R	NON-CROSS	268-269	283-284	55165	centrosomal protein 55|Centrosomal protein 55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55	GeneOrGeneProduct	2:18:22:40:69:87:119:131:158:185:283:350:367:373:387:400:425	5:21:23:41:70:88:120:132:159:186:284:351:368:374:388:401:426	0:1:1:2:3:4:5:6:7:8:9:11:11:12:13:14:15	4582	CA153	GeneOrGeneProduct	268	269	8	1:NR:2	L2R	CROSS	335-336	350-351	55165	centrosomal protein 55|Centrosomal protein 55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55	GeneOrGeneProduct	2:18:22:40:69:87:119:131:158:185:283:350:367:373:387:400:425	5:21:23:41:70:88:120:132:159:186:284:351:368:374:388:401:426	0:1:1:2:3:4:5:6:7:8:9:11:11:12:13:14:15	94025	CA125|CA199|CA724	GeneOrGeneProduct	331:333:335	332:334:336	10:10:10	1:NR:2	L2R	CROSS	337-338	350-351	55165	centrosomal protein 55|Centrosomal protein 55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55	GeneOrGeneProduct	2:18:22:40:69:87:119:131:158:185:283:350:367:373:387:400:425	5:21:23:41:70:88:120:132:159:186:284:351:368:374:388:401:426	0:1:1:2:3:4:5:6:7:8:9:11:11:12:13:14:15	2026	NSE	GeneOrGeneProduct	337	338	10	1:NR:2	L2R	CROSS	339-340	350-351	55165	centrosomal protein 55|Centrosomal protein 55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55	GeneOrGeneProduct	2:18:22:40:69:87:119:131:158:185:283:350:367:373:387:400:425	5:21:23:41:70:88:120:132:159:186:284:351:368:374:388:401:426	0:1:1:2:3:4:5:6:7:8:9:11:11:12:13:14:15	1084	CEA	GeneOrGeneProduct	339	340	10	1:NR:2	L2R	CROSS	342-345	350-351	55165	centrosomal protein 55|Centrosomal protein 55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55|CEP55	GeneOrGeneProduct	2:18:22:40:69:87:119:131:158:185:283:350:367:373:387:400:425	5:21:23:41:70:88:120:132:159:186:284:351:368:374:388:401:426	0:1:1:2:3:4:5:6:7:8:9:11:11:12:13:14:15	93659	b - HCG	GeneOrGeneProduct	342	345	10	1:NR:2	L2R	NON-CROSS	256-257	268-269	D009369	tumor|cancers|tumor|tumor|tumor	DiseaseOrPhenotypicFeature	11:34:223:244:256	12:35:224:245:257	0:1:8:8:8	4582	CA153	GeneOrGeneProduct	268	269	8	1:NR:2	L2R	CROSS	256-257	331-332	D009369	tumor|cancers|tumor|tumor|tumor	DiseaseOrPhenotypicFeature	11:34:223:244:256	12:35:224:245:257	0:1:8:8:8	94025	CA125|CA199|CA724	GeneOrGeneProduct	331:333:335	332:334:336	10:10:10	1:NR:2	L2R	CROSS	256-257	337-338	D009369	tumor|cancers|tumor|tumor|tumor	DiseaseOrPhenotypicFeature	11:34:223:244:256	12:35:224:245:257	0:1:8:8:8	2026	NSE	GeneOrGeneProduct	337	338	10	1:NR:2	L2R	CROSS	256-257	339-340	D009369	tumor|cancers|tumor|tumor|tumor	DiseaseOrPhenotypicFeature	11:34:223:244:256	12:35:224:245:257	0:1:8:8:8	1084	CEA	GeneOrGeneProduct	339	340	10	1:NR:2	L2R	CROSS	256-257	342-345	D009369	tumor|cancers|tumor|tumor|tumor	DiseaseOrPhenotypicFeature	11:34:223:244:256	12:35:224:245:257	0:1:8:8:8	93659	b - HCG	GeneOrGeneProduct	342	345	10	1:NR:2	L2R	NON-CROSS	182-183	268-269	D000077216	epithelial ovarian carcinoma|epithelial ovarian carcinoma|EOC|EOC|EOC|EOC|EOC|EOC	DiseaseOrPhenotypicFeature	14:52:56:73:182:380:408:436	17:55:57:74:183:381:409:437	0:2:2:3:8:12:14:15	4582	CA153	GeneOrGeneProduct	268	269	8	1:NR:2	L2R	CROSS	335-336	380-381	D000077216	epithelial ovarian carcinoma|epithelial ovarian carcinoma|EOC|EOC|EOC|EOC|EOC|EOC	DiseaseOrPhenotypicFeature	14:52:56:73:182:380:408:436	17:55:57:74:183:381:409:437	0:2:2:3:8:12:14:15	94025	CA125|CA199|CA724	GeneOrGeneProduct	331:333:335	332:334:336	10:10:10	1:NR:2	L2R	CROSS	337-338	380-381	D000077216	epithelial ovarian carcinoma|epithelial ovarian carcinoma|EOC|EOC|EOC|EOC|EOC|EOC	DiseaseOrPhenotypicFeature	14:52:56:73:182:380:408:436	17:55:57:74:183:381:409:437	0:2:2:3:8:12:14:15	2026	NSE	GeneOrGeneProduct	337	338	10	1:NR:2	L2R	CROSS	339-340	380-381	D000077216	epithelial ovarian carcinoma|epithelial ovarian carcinoma|EOC|EOC|EOC|EOC|EOC|EOC	DiseaseOrPhenotypicFeature	14:52:56:73:182:380:408:436	17:55:57:74:183:381:409:437	0:2:2:3:8:12:14:15	1084	CEA	GeneOrGeneProduct	339	340	10	1:NR:2	L2R	CROSS	342-345	380-381	D000077216	epithelial ovarian carcinoma|epithelial ovarian carcinoma|EOC|EOC|EOC|EOC|EOC|EOC	DiseaseOrPhenotypicFeature	14:52:56:73:182:380:408:436	17:55:57:74:183:381:409:437	0:2:2:3:8:12:14:15	93659	b - HCG	GeneOrGeneProduct	342	345	10	1:NR:2	L2R	CROSS	163-165	268-269	D010051	metastasis of ovarian|ovarian cancer|ovarian cancer|ovarian cancer	DiseaseOrPhenotypicFeature	81:163:389:419	84:165:391:421	3:7:13:14	4582	CA153	GeneOrGeneProduct	268	269	8	1:NR:2	L2R	CROSS	335-336	389-391	D010051	metastasis of ovarian|ovarian cancer|ovarian cancer|ovarian cancer	DiseaseOrPhenotypicFeature	81:163:389:419	84:165:391:421	3:7:13:14	94025	CA125|CA199|CA724	GeneOrGeneProduct	331:333:335	332:334:336	10:10:10	1:NR:2	L2R	CROSS	337-338	389-391	D010051	metastasis of ovarian|ovarian cancer|ovarian cancer|ovarian cancer	DiseaseOrPhenotypicFeature	81:163:389:419	84:165:391:421	3:7:13:14	2026	NSE	GeneOrGeneProduct	337	338	10	1:NR:2	L2R	CROSS	339-340	389-391	D010051	metastasis of ovarian|ovarian cancer|ovarian cancer|ovarian cancer	DiseaseOrPhenotypicFeature	81:163:389:419	84:165:391:421	3:7:13:14	1084	CEA	GeneOrGeneProduct	339	340	10	1:NR:2	L2R	CROSS	342-345	389-391	D010051	metastasis of ovarian|ovarian cancer|ovarian cancer|ovarian cancer	DiseaseOrPhenotypicFeature	81:163:389:419	84:165:391:421	3:7:13:14	93659	b - HCG	GeneOrGeneProduct	342	345	10	1:NR:2	L2R	NON-CROSS	202-205	268-269	D008207	lymph node metastasis	DiseaseOrPhenotypicFeature	202	205	8	4582	CA153	GeneOrGeneProduct	268	269	8	1:NR:2	L2R	CROSS	202-205	331-332	D008207	lymph node metastasis	DiseaseOrPhenotypicFeature	202	205	8	94025	CA125|CA199|CA724	GeneOrGeneProduct	331:333:335	332:334:336	10:10:10	1:NR:2	L2R	CROSS	202-205	337-338	D008207	lymph node metastasis	DiseaseOrPhenotypicFeature	202	205	8	2026	NSE	GeneOrGeneProduct	337	338	10	1:NR:2	L2R	CROSS	202-205	339-340	D008207	lymph node metastasis	DiseaseOrPhenotypicFeature	202	205	8	1084	CEA	GeneOrGeneProduct	339	340	10	1:NR:2	L2R	CROSS	202-205	342-345	D008207	lymph node metastasis	DiseaseOrPhenotypicFeature	202	205	8	93659	b - HCG	GeneOrGeneProduct	342	345	10	1:NR:2	L2R	NON-CROSS	213-215	268-269	D009362	intraperitoneal metastasis	DiseaseOrPhenotypicFeature	213	215	8	4582	CA153	GeneOrGeneProduct	268	269	8	1:NR:2	L2R	CROSS	213-215	331-332	D009362	intraperitoneal metastasis	DiseaseOrPhenotypicFeature	213	215	8	94025	CA125|CA199|CA724	GeneOrGeneProduct	331:333:335	332:334:336	10:10:10	1:NR:2	L2R	CROSS	213-215	337-338	D009362	intraperitoneal metastasis	DiseaseOrPhenotypicFeature	213	215	8	2026	NSE	GeneOrGeneProduct	337	338	10	1:NR:2	L2R	CROSS	213-215	339-340	D009362	intraperitoneal metastasis	DiseaseOrPhenotypicFeature	213	215	8	1084	CEA	GeneOrGeneProduct	339	340	10	1:NR:2	L2R	CROSS	213-215	342-345	D009362	intraperitoneal metastasis	DiseaseOrPhenotypicFeature	213	215	8	93659	b - HCG	GeneOrGeneProduct	342	345	10	1:NR:2	L2R	NON-CROSS	254-255	268-269	D001201	ascites	DiseaseOrPhenotypicFeature	254	255	8	4582	CA153	GeneOrGeneProduct	268	269	8	1:NR:2	L2R	CROSS	254-255	331-332	D001201	ascites	DiseaseOrPhenotypicFeature	254	255	8	94025	CA125|CA199|CA724	GeneOrGeneProduct	331:333:335	332:334:336	10:10:10	1:NR:2	L2R	CROSS	254-255	337-338	D001201	ascites	DiseaseOrPhenotypicFeature	254	255	8	2026	NSE	GeneOrGeneProduct	337	338	10	1:NR:2	L2R	CROSS	254-255	339-340	D001201	ascites	DiseaseOrPhenotypicFeature	254	255	8	1084	CEA	GeneOrGeneProduct	339	340	10	1:NR:2	L2R	CROSS	254-255	342-345	D001201	ascites	DiseaseOrPhenotypicFeature	254	255	8	93659	b - HCG	GeneOrGeneProduct	342	345	10	1:NR:2	L2R	CROSS	268-269	331-332	4582	CA153	GeneOrGeneProduct	268	269	8	94025	CA125|CA199|CA724	GeneOrGeneProduct	331:333:335	332:334:336	10:10:10	1:NR:2	L2R	CROSS	268-269	337-338	4582	CA153	GeneOrGeneProduct	268	269	8	2026	NSE	GeneOrGeneProduct	337	338	10	1:NR:2	L2R	CROSS	268-269	339-340	4582	CA153	GeneOrGeneProduct	268	269	8	1084	CEA	GeneOrGeneProduct	339	340	10	1:NR:2	L2R	CROSS	268-269	342-345	4582	CA153	GeneOrGeneProduct	268	269	8	93659	b - HCG	GeneOrGeneProduct	342	345	10	1:NR:2	L2R	NON-CROSS	335-336	337-338	94025	CA125|CA199|CA724	GeneOrGeneProduct	331:333:335	332:334:336	10:10:10	2026	NSE	GeneOrGeneProduct	337	338	10	1:NR:2	L2R	NON-CROSS	335-336	339-340	94025	CA125|CA199|CA724	GeneOrGeneProduct	331:333:335	332:334:336	10:10:10	1084	CEA	GeneOrGeneProduct	339	340	10	1:NR:2	L2R	NON-CROSS	335-336	342-345	94025	CA125|CA199|CA724	GeneOrGeneProduct	331:333:335	332:334:336	10:10:10	93659	b - HCG	GeneOrGeneProduct	342	345	10	1:NR:2	L2R	NON-CROSS	337-338	339-340	2026	NSE	GeneOrGeneProduct	337	338	10	1084	CEA	GeneOrGeneProduct	339	340	10	1:NR:2	L2R	NON-CROSS	337-338	342-345	2026	NSE	GeneOrGeneProduct	337	338	10	93659	b - HCG	GeneOrGeneProduct	342	345	10	1:NR:2	L2R	NON-CROSS	339-340	342-345	1084	CEA	GeneOrGeneProduct	339	340	10	93659	b - HCG	GeneOrGeneProduct	342	345	10
27384305	Male 11b - HSD1 Knockout Mice Fed Trans - Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease .|Nonalcoholic fatty liver disease ( NAFLD ) defines a spectrum of conditions from simple steatosis to nonalcoholic steatohepatitis ( NASH ) and cirrhosis and is regarded as the hepatic manifestation of the metabolic syndrome .|Glucocorticoids can promote steatosis by stimulating lipolysis within adipose tissue , free fatty acid delivery to liver and hepatic de novo lipogenesis .|Glucocorticoids can be reactivated in liver through 11b - hydroxysteroid dehydrogenase type 1 ( 11b - HSD1 ) enzyme activity .|Inhibition of 11b - HSD1 has been suggested as a potential treatment for NAFLD .|To test this , male mice with global ( 11b - HSD1 knockout [ KO ] ) and liver - specific ( LKO ) 11b - HSD1 loss of function were fed the American Lifestyle Induced Obesity Syndrome ( ALIOS ) diet , known to recapitulate the spectrum of NAFLD , and metabolic and liver phenotypes assessed .|Body weight , muscle and adipose tissue masses , and parameters of glucose homeostasis showed that 11b - HSD1KO and LKO mice were not protected from systemic metabolic disease .|Evaluation of hepatic histology , triglyceride content , and blinded NAFLD activity score assessment indicated that levels of steatosis were similar between 11b - HSD1KO , LKO , and control mice .|Unexpectedly , histological analysis revealed significantly increased levels of immune foci present in livers of 11b - HSD1KO but not LKO or control mice , suggestive of a transition to NASH .|This was endorsed by elevated hepatic expression of key immune cell and inflammatory markers .|These data indicate that 11b - HSD1 - deficient mice are not protected from metabolic disease or hepatosteatosis in the face of a NAFLD - inducing diet .|However , global deficiency of 11b - HSD1 did increase markers of hepatic inflammation and suggests a critical role for 11b - HSD1 in restraining the transition to NASH .	1:NR:2	L2R	NON-CROSS	1-4	7-10	15483	11b - HSD1|11b - hydroxysteroid dehydrogenase type 1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1	GeneOrGeneProduct	1:89:96:105:127:142:192:228:253:289:318:333	4:95:99:108:130:145:195:231:256:292:321:336	0:3:3:4:5:5:6:7:8:10:11:11	D044242	Trans - Fats	ChemicalEntity	7	10	0	1:NR:2	L2R	NON-CROSS	1-4	11-12	15483	11b - HSD1|11b - hydroxysteroid dehydrogenase type 1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1	GeneOrGeneProduct	1:89:96:105:127:142:192:228:253:289:318:333	4:95:99:108:130:145:195:231:256:292:321:336	0:3:3:4:5:5:6:7:8:10:11:11	D005632	Fructose	ChemicalEntity	11	12	0	1:NR:2	L2R	NON-CROSS	289-292	299-301	15483	11b - HSD1|11b - hydroxysteroid dehydrogenase type 1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1	GeneOrGeneProduct	1:89:96:105:127:142:192:228:253:289:318:333	4:95:99:108:130:145:195:231:256:292:321:336	0:3:3:4:5:5:6:7:8:10:11:11	D008659	Metabolic Syndrome|metabolic syndrome|metabolic disease|metabolic disease	DiseaseOrPhenotypicFeature	16:56:203:299	18:58:205:301	0:1:6:10	1:Positive_Correlation:2	L2R	NON-CROSS	333-336	341-342	15483	11b - HSD1|11b - hydroxysteroid dehydrogenase type 1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1	GeneOrGeneProduct	1:89:96:105:127:142:192:228:253:289:318:333	4:95:99:108:130:145:195:231:256:292:321:336	0:3:3:4:5:5:6:7:8:10:11:11	D065626	Nonalcoholic Fatty Liver Disease|Nonalcoholic fatty liver disease|NAFLD|nonalcoholic steatohepatitis|NASH|NAFLD|NAFLD|NAFLD|NASH|NAFLD|NASH	DiseaseOrPhenotypicFeature	19:24:29:40:43:116:167:216:268:308:341	23:28:30:42:44:117:168:217:269:309:342	0:1:1:1:1:4:5:7:8:10:11	1:NR:2	L2R	NON-CROSS	224-225	228-231	15483	11b - HSD1|11b - hydroxysteroid dehydrogenase type 1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1	GeneOrGeneProduct	1:89:96:105:127:142:192:228:253:289:318:333	4:95:99:108:130:145:195:231:256:292:321:336	0:3:3:4:5:5:6:7:8:10:11:11	D005234	steatosis|steatosis|steatosis|hepatosteatosis	DiseaseOrPhenotypicFeature	38:62:224:302	39:63:225:303	1:2:7:10	1:NR:2	L2R	CROSS	1-4	46-47	15483	11b - HSD1|11b - hydroxysteroid dehydrogenase type 1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1	GeneOrGeneProduct	1:89:96:105:127:142:192:228:253:289:318:333	4:95:99:108:130:145:195:231:256:292:321:336	0:3:3:4:5:5:6:7:8:10:11:11	D005355	cirrhosis	DiseaseOrPhenotypicFeature	46	47	1	1:Positive_Correlation:2	R2L	NON-CROSS	89-95	82-83	D005938	Glucocorticoids|Glucocorticoids	ChemicalEntity	59:82	60:83	2:3	15483	11b - HSD1|11b - hydroxysteroid dehydrogenase type 1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1	GeneOrGeneProduct	1:89:96:105:127:142:192:228:253:289:318:333	4:95:99:108:130:145:195:231:256:292:321:336	0:3:3:4:5:5:6:7:8:10:11:11	1:NR:2	L2R	CROSS	70-73	89-95	15483	11b - HSD1|11b - hydroxysteroid dehydrogenase type 1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1	GeneOrGeneProduct	1:89:96:105:127:142:192:228:253:289:318:333	4:95:99:108:130:145:195:231:256:292:321:336	0:3:3:4:5:5:6:7:8:10:11:11	D005230	free fatty acid	ChemicalEntity	70	73	2	1:Association:2	R2L	NON-CROSS	192-195	188-189	D005947	glucose	ChemicalEntity	188	189	6	15483	11b - HSD1|11b - hydroxysteroid dehydrogenase type 1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1	GeneOrGeneProduct	1:89:96:105:127:142:192:228:253:289:318:333	4:95:99:108:130:145:195:231:256:292:321:336	0:3:3:4:5:5:6:7:8:10:11:11	1:NR:2	L2R	NON-CROSS	192-195	211-212	15483	11b - HSD1|11b - hydroxysteroid dehydrogenase type 1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1	GeneOrGeneProduct	1:89:96:105:127:142:192:228:253:289:318:333	4:95:99:108:130:145:195:231:256:292:321:336	0:3:3:4:5:5:6:7:8:10:11:11	D014280	triglyceride	ChemicalEntity	211	212	7	1:NR:2	L2R	CROSS	282-283	289-292	15483	11b - HSD1|11b - hydroxysteroid dehydrogenase type 1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1	GeneOrGeneProduct	1:89:96:105:127:142:192:228:253:289:318:333	4:95:99:108:130:145:195:231:256:292:321:336	0:3:3:4:5:5:6:7:8:10:11:11	D007249	inflammatory	DiseaseOrPhenotypicFeature	282	283	9	1:Association:2	L2R	NON-CROSS	318-321	325-327	15483	11b - HSD1|11b - hydroxysteroid dehydrogenase type 1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1|11b - HSD1	GeneOrGeneProduct	1:89:96:105:127:142:192:228:253:289:318:333	4:95:99:108:130:145:195:231:256:292:321:336	0:3:3:4:5:5:6:7:8:10:11:11	D008107	hepatic inflammation	DiseaseOrPhenotypicFeature	325	327	11	1:NR:2	L2R	NON-CROSS	7-10	11-12	D044242	Trans - Fats	ChemicalEntity	7	10	0	D005632	Fructose	ChemicalEntity	11	12	0	1:Positive_Correlation:2	L2R	NON-CROSS	7-10	16-18	D044242	Trans - Fats	ChemicalEntity	7	10	0	D008659	Metabolic Syndrome|metabolic syndrome|metabolic disease|metabolic disease	DiseaseOrPhenotypicFeature	16:56:203:299	18:58:205:301	0:1:6:10	1:Positive_Correlation:2	L2R	NON-CROSS	7-10	19-23	D044242	Trans - Fats	ChemicalEntity	7	10	0	D065626	Nonalcoholic Fatty Liver Disease|Nonalcoholic fatty liver disease|NAFLD|nonalcoholic steatohepatitis|NASH|NAFLD|NAFLD|NAFLD|NASH|NAFLD|NASH	DiseaseOrPhenotypicFeature	19:24:29:40:43:116:167:216:268:308:341	23:28:30:42:44:117:168:217:269:309:342	0:1:1:1:1:4:5:7:8:10:11	1:NR:2	L2R	CROSS	7-10	38-39	D044242	Trans - Fats	ChemicalEntity	7	10	0	D005234	steatosis|steatosis|steatosis|hepatosteatosis	DiseaseOrPhenotypicFeature	38:62:224:302	39:63:225:303	1:2:7:10	1:NR:2	L2R	CROSS	7-10	46-47	D044242	Trans - Fats	ChemicalEntity	7	10	0	D005355	cirrhosis	DiseaseOrPhenotypicFeature	46	47	1	1:NR:2	L2R	CROSS	7-10	59-60	D044242	Trans - Fats	ChemicalEntity	7	10	0	D005938	Glucocorticoids|Glucocorticoids	ChemicalEntity	59:82	60:83	2:3	1:NR:2	L2R	CROSS	7-10	70-73	D044242	Trans - Fats	ChemicalEntity	7	10	0	D005230	free fatty acid	ChemicalEntity	70	73	2	1:NR:2	L2R	CROSS	7-10	188-189	D044242	Trans - Fats	ChemicalEntity	7	10	0	D005947	glucose	ChemicalEntity	188	189	6	1:NR:2	L2R	CROSS	7-10	211-212	D044242	Trans - Fats	ChemicalEntity	7	10	0	D014280	triglyceride	ChemicalEntity	211	212	7	1:NR:2	L2R	CROSS	7-10	282-283	D044242	Trans - Fats	ChemicalEntity	7	10	0	D007249	inflammatory	DiseaseOrPhenotypicFeature	282	283	9	1:NR:2	L2R	CROSS	7-10	325-327	D044242	Trans - Fats	ChemicalEntity	7	10	0	D008107	hepatic inflammation	DiseaseOrPhenotypicFeature	325	327	11	1:Positive_Correlation:2	L2R	NON-CROSS	11-12	16-18	D005632	Fructose	ChemicalEntity	11	12	0	D008659	Metabolic Syndrome|metabolic syndrome|metabolic disease|metabolic disease	DiseaseOrPhenotypicFeature	16:56:203:299	18:58:205:301	0:1:6:10	1:Positive_Correlation:2	L2R	NON-CROSS	11-12	19-23	D005632	Fructose	ChemicalEntity	11	12	0	D065626	Nonalcoholic Fatty Liver Disease|Nonalcoholic fatty liver disease|NAFLD|nonalcoholic steatohepatitis|NASH|NAFLD|NAFLD|NAFLD|NASH|NAFLD|NASH	DiseaseOrPhenotypicFeature	19:24:29:40:43:116:167:216:268:308:341	23:28:30:42:44:117:168:217:269:309:342	0:1:1:1:1:4:5:7:8:10:11	1:NR:2	L2R	CROSS	11-12	38-39	D005632	Fructose	ChemicalEntity	11	12	0	D005234	steatosis|steatosis|steatosis|hepatosteatosis	DiseaseOrPhenotypicFeature	38:62:224:302	39:63:225:303	1:2:7:10	1:NR:2	L2R	CROSS	11-12	46-47	D005632	Fructose	ChemicalEntity	11	12	0	D005355	cirrhosis	DiseaseOrPhenotypicFeature	46	47	1	1:NR:2	L2R	CROSS	11-12	59-60	D005632	Fructose	ChemicalEntity	11	12	0	D005938	Glucocorticoids|Glucocorticoids	ChemicalEntity	59:82	60:83	2:3	1:NR:2	L2R	CROSS	11-12	70-73	D005632	Fructose	ChemicalEntity	11	12	0	D005230	free fatty acid	ChemicalEntity	70	73	2	1:NR:2	L2R	CROSS	11-12	188-189	D005632	Fructose	ChemicalEntity	11	12	0	D005947	glucose	ChemicalEntity	188	189	6	1:NR:2	L2R	CROSS	11-12	211-212	D005632	Fructose	ChemicalEntity	11	12	0	D014280	triglyceride	ChemicalEntity	211	212	7	1:NR:2	L2R	CROSS	11-12	282-283	D005632	Fructose	ChemicalEntity	11	12	0	D007249	inflammatory	DiseaseOrPhenotypicFeature	282	283	9	1:NR:2	L2R	CROSS	11-12	325-327	D005632	Fructose	ChemicalEntity	11	12	0	D008107	hepatic inflammation	DiseaseOrPhenotypicFeature	325	327	11	1:NR:2	L2R	CROSS	56-58	59-60	D008659	Metabolic Syndrome|metabolic syndrome|metabolic disease|metabolic disease	DiseaseOrPhenotypicFeature	16:56:203:299	18:58:205:301	0:1:6:10	D005938	Glucocorticoids|Glucocorticoids	ChemicalEntity	59:82	60:83	2:3	1:NR:2	L2R	CROSS	56-58	70-73	D008659	Metabolic Syndrome|metabolic syndrome|metabolic disease|metabolic disease	DiseaseOrPhenotypicFeature	16:56:203:299	18:58:205:301	0:1:6:10	D005230	free fatty acid	ChemicalEntity	70	73	2	1:Association:2	R2L	NON-CROSS	203-205	188-189	D005947	glucose	ChemicalEntity	188	189	6	D008659	Metabolic Syndrome|metabolic syndrome|metabolic disease|metabolic disease	DiseaseOrPhenotypicFeature	16:56:203:299	18:58:205:301	0:1:6:10	1:NR:2	L2R	CROSS	203-205	211-212	D008659	Metabolic Syndrome|metabolic syndrome|metabolic disease|metabolic disease	DiseaseOrPhenotypicFeature	16:56:203:299	18:58:205:301	0:1:6:10	D014280	triglyceride	ChemicalEntity	211	212	7	1:NR:2	L2R	CROSS	43-44	59-60	D065626	Nonalcoholic Fatty Liver Disease|Nonalcoholic fatty liver disease|NAFLD|nonalcoholic steatohepatitis|NASH|NAFLD|NAFLD|NAFLD|NASH|NAFLD|NASH	DiseaseOrPhenotypicFeature	19:24:29:40:43:116:167:216:268:308:341	23:28:30:42:44:117:168:217:269:309:342	0:1:1:1:1:4:5:7:8:10:11	D005938	Glucocorticoids|Glucocorticoids	ChemicalEntity	59:82	60:83	2:3	1:NR:2	L2R	CROSS	43-44	70-73	D065626	Nonalcoholic Fatty Liver Disease|Nonalcoholic fatty liver disease|NAFLD|nonalcoholic steatohepatitis|NASH|NAFLD|NAFLD|NAFLD|NASH|NAFLD|NASH	DiseaseOrPhenotypicFeature	19:24:29:40:43:116:167:216:268:308:341	23:28:30:42:44:117:168:217:269:309:342	0:1:1:1:1:4:5:7:8:10:11	D005230	free fatty acid	ChemicalEntity	70	73	2	1:NR:2	L2R	CROSS	167-168	188-189	D065626	Nonalcoholic Fatty Liver Disease|Nonalcoholic fatty liver disease|NAFLD|nonalcoholic steatohepatitis|NASH|NAFLD|NAFLD|NAFLD|NASH|NAFLD|NASH	DiseaseOrPhenotypicFeature	19:24:29:40:43:116:167:216:268:308:341	23:28:30:42:44:117:168:217:269:309:342	0:1:1:1:1:4:5:7:8:10:11	D005947	glucose	ChemicalEntity	188	189	6	1:NR:2	L2R	NON-CROSS	211-212	216-217	D065626	Nonalcoholic Fatty Liver Disease|Nonalcoholic fatty liver disease|NAFLD|nonalcoholic steatohepatitis|NASH|NAFLD|NAFLD|NAFLD|NASH|NAFLD|NASH	DiseaseOrPhenotypicFeature	19:24:29:40:43:116:167:216:268:308:341	23:28:30:42:44:117:168:217:269:309:342	0:1:1:1:1:4:5:7:8:10:11	D014280	triglyceride	ChemicalEntity	211	212	7	1:NR:2	L2R	NON-CROSS	59-60	62-63	D005234	steatosis|steatosis|steatosis|hepatosteatosis	DiseaseOrPhenotypicFeature	38:62:224:302	39:63:225:303	1:2:7:10	D005938	Glucocorticoids|Glucocorticoids	ChemicalEntity	59:82	60:83	2:3	1:Association:2	L2R	NON-CROSS	62-63	70-73	D005234	steatosis|steatosis|steatosis|hepatosteatosis	DiseaseOrPhenotypicFeature	38:62:224:302	39:63:225:303	1:2:7:10	D005230	free fatty acid	ChemicalEntity	70	73	2	1:NR:2	L2R	CROSS	188-189	224-225	D005234	steatosis|steatosis|steatosis|hepatosteatosis	DiseaseOrPhenotypicFeature	38:62:224:302	39:63:225:303	1:2:7:10	D005947	glucose	ChemicalEntity	188	189	6	1:NR:2	L2R	NON-CROSS	211-212	224-225	D005234	steatosis|steatosis|steatosis|hepatosteatosis	DiseaseOrPhenotypicFeature	38:62:224:302	39:63:225:303	1:2:7:10	D014280	triglyceride	ChemicalEntity	211	212	7	1:NR:2	L2R	CROSS	46-47	59-60	D005355	cirrhosis	DiseaseOrPhenotypicFeature	46	47	1	D005938	Glucocorticoids|Glucocorticoids	ChemicalEntity	59:82	60:83	2:3	1:NR:2	L2R	CROSS	46-47	70-73	D005355	cirrhosis	DiseaseOrPhenotypicFeature	46	47	1	D005230	free fatty acid	ChemicalEntity	70	73	2	1:NR:2	L2R	CROSS	46-47	188-189	D005355	cirrhosis	DiseaseOrPhenotypicFeature	46	47	1	D005947	glucose	ChemicalEntity	188	189	6	1:NR:2	L2R	CROSS	46-47	211-212	D005355	cirrhosis	DiseaseOrPhenotypicFeature	46	47	1	D014280	triglyceride	ChemicalEntity	211	212	7	1:Association:2	L2R	NON-CROSS	70-73	82-83	D005938	Glucocorticoids|Glucocorticoids	ChemicalEntity	59:82	60:83	2:3	D005230	free fatty acid	ChemicalEntity	70	73	2	1:NR:2	L2R	CROSS	82-83	188-189	D005938	Glucocorticoids|Glucocorticoids	ChemicalEntity	59:82	60:83	2:3	D005947	glucose	ChemicalEntity	188	189	6	1:NR:2	L2R	CROSS	82-83	211-212	D005938	Glucocorticoids|Glucocorticoids	ChemicalEntity	59:82	60:83	2:3	D014280	triglyceride	ChemicalEntity	211	212	7	1:NR:2	L2R	CROSS	82-83	282-283	D005938	Glucocorticoids|Glucocorticoids	ChemicalEntity	59:82	60:83	2:3	D007249	inflammatory	DiseaseOrPhenotypicFeature	282	283	9	1:NR:2	L2R	CROSS	82-83	325-327	D005938	Glucocorticoids|Glucocorticoids	ChemicalEntity	59:82	60:83	2:3	D008107	hepatic inflammation	DiseaseOrPhenotypicFeature	325	327	11	1:NR:2	L2R	CROSS	70-73	188-189	D005230	free fatty acid	ChemicalEntity	70	73	2	D005947	glucose	ChemicalEntity	188	189	6	1:NR:2	L2R	CROSS	70-73	211-212	D005230	free fatty acid	ChemicalEntity	70	73	2	D014280	triglyceride	ChemicalEntity	211	212	7	1:NR:2	L2R	CROSS	70-73	282-283	D005230	free fatty acid	ChemicalEntity	70	73	2	D007249	inflammatory	DiseaseOrPhenotypicFeature	282	283	9	1:NR:2	L2R	CROSS	70-73	325-327	D005230	free fatty acid	ChemicalEntity	70	73	2	D008107	hepatic inflammation	DiseaseOrPhenotypicFeature	325	327	11	1:NR:2	L2R	CROSS	188-189	211-212	D005947	glucose	ChemicalEntity	188	189	6	D014280	triglyceride	ChemicalEntity	211	212	7	1:NR:2	L2R	CROSS	188-189	282-283	D005947	glucose	ChemicalEntity	188	189	6	D007249	inflammatory	DiseaseOrPhenotypicFeature	282	283	9	1:NR:2	L2R	CROSS	188-189	325-327	D005947	glucose	ChemicalEntity	188	189	6	D008107	hepatic inflammation	DiseaseOrPhenotypicFeature	325	327	11	1:NR:2	L2R	CROSS	211-212	282-283	D014280	triglyceride	ChemicalEntity	211	212	7	D007249	inflammatory	DiseaseOrPhenotypicFeature	282	283	9	1:NR:2	L2R	CROSS	211-212	325-327	D014280	triglyceride	ChemicalEntity	211	212	7	D008107	hepatic inflammation	DiseaseOrPhenotypicFeature	325	327	11
15000256	Single - strand conformation polymorphism analysis of the FMR1 gene in autistic and mentally retarded children in Japan .|Fragile X syndrome is one of the most common causes of mental retardation in males , and patients with fragile X syndrome occasionally develop autism .|It is usually caused by an expansion of the trinucleotide repeat in the 5 ' - untranslated region of the FMR1 gene , but in a small number of patients deletions and point mutations have been identified .|We screened all 17 exons of the FMR1 gene for mutations in 90 autistic or mentally retarded children using polymerase chain reaction ( PCR ) - single strand conformation polymorphism ( SSCP ) analysis .|No mutations were found in 76 male patients .|However , one female patient was heterozygous for a normal allele and a mutant allele with an A to C substitution at nucleotide 879 in exon 9 .|This mutation was not found in 50 controls .|Reverse transcription - PCR revealed that a large proportion of the mutant transcripts were spliced aberrantly , causing premature termination of the protein synthesis .|Although uncommon , point mutations in the FMR1 gene may be a cause of autism and mental retardation in Japanese patients .	1:Association:2	L2R	NON-CROSS	8-9	11-12	2332	FMR1|FMR1|FMR1|FMR1	GeneOrGeneProduct	8:65:90:196	9:66:91:197	0:2:3:8	D001321	autistic|autism|autistic|autism	DiseaseOrPhenotypicFeature	11:43:96:203	12:44:97:204	0:1:3:8	1:Association:2	L2R	NON-CROSS	8-9	13-15	2332	FMR1|FMR1|FMR1|FMR1	GeneOrGeneProduct	8:65:90:196	9:66:91:197	0:2:3:8	D008607	mentally retarded|mental retardation|mentally retarded|mental retardation	DiseaseOrPhenotypicFeature	13:30:98:205	15:32:100:207	0:1:3:8	1:Association:2	L2R	CROSS	8-9	19-22	2332	FMR1|FMR1|FMR1|FMR1	GeneOrGeneProduct	8:65:90:196	9:66:91:197	0:2:3:8	D005600	Fragile X syndrome|fragile X syndrome	DiseaseOrPhenotypicFeature	19:38	22:41	1:1	1:Positive_Correlation:2	R2L	CROSS	144-151	96-97	rs782013865	A to C substitution at nucleotide 879	SequenceVariant	144	151	5	D001321	autistic|autism|autistic|autism	DiseaseOrPhenotypicFeature	11:43:96:203	12:44:97:204	0:1:3:8	1:Positive_Correlation:2	R2L	CROSS	144-151	98-100	rs782013865	A to C substitution at nucleotide 879	SequenceVariant	144	151	5	D008607	mentally retarded|mental retardation|mentally retarded|mental retardation	DiseaseOrPhenotypicFeature	13:30:98:205	15:32:100:207	0:1:3:8	1:Association:2	R2L	CROSS	144-151	38-41	rs782013865	A to C substitution at nucleotide 879	SequenceVariant	144	151	5	D005600	Fragile X syndrome|fragile X syndrome	DiseaseOrPhenotypicFeature	19:38	22:41	1:1
15811908	Pheochromocytoma unmasked by amisulpride and tiapride .|OBJECTIVE : To describe the unmasking of pheochromocytoma in a patient treated with amisulpride and tiapride .|CASE SUMMARY : A 42 - year - old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg .|Both drugs were immediately discontinued , and the patient recovered after subsequent nicardipine and verapamil treatment .|Abdominal ultrasound showed an adrenal mass , and postoperative histologic examination confirmed the diagnosis of pheochromocytoma .|DISCUSSION : Drug - induced symptoms of pheochromocytoma are often associated with the use of substituted benzamide drugs , but the underlying mechanism is unknown .|In our case , use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy .|CONCLUSIONS : As of March 24 , 2005 , this is the first reported case of amisulpride - and tiapride - induced hypertensive crisis in a patient with pheochromocytoma .|Physicians and other healthcare professionals should be aware of this potential adverse effect of tiapride and amisulpride .	1:Association:2	L2R	NON-CROSS	0-1	3-4	D010673	Pheochromocytoma|pheochromocytoma|pheochromocytoma|pheochromocytoma|pheochromocytoma	DiseaseOrPhenotypicFeature	0:14:90:99:170	1:15:91:100:171	0:1:4:5:7	D000077582	amisulpride|amisulpride|amisulpride|amisulpride|amisulpride|amisulpride	ChemicalEntity	3:20:50:137:158:188	4:21:51:138:159:189	0:1:2:6:7:8	1:Association:2	L2R	NON-CROSS	0-1	5-6	D010673	Pheochromocytoma|pheochromocytoma|pheochromocytoma|pheochromocytoma|pheochromocytoma	DiseaseOrPhenotypicFeature	0:14:90:99:170	1:15:91:100:171	0:1:4:5:7	D063325	tiapride|tiapride|tiapride|tiapride|tiapride|tiapride	ChemicalEntity	5:22:54:139:161:186	6:23:55:140:162:187	0:1:2:6:7:8	1:NR:2	L2R	CROSS	70-71	90-91	D010673	Pheochromocytoma|pheochromocytoma|pheochromocytoma|pheochromocytoma|pheochromocytoma	DiseaseOrPhenotypicFeature	0:14:90:99:170	1:15:91:100:171	0:1:4:5:7	D009529	nicardipine	ChemicalEntity	70	71	3	1:NR:2	L2R	CROSS	72-73	90-91	D010673	Pheochromocytoma|pheochromocytoma|pheochromocytoma|pheochromocytoma|pheochromocytoma	DiseaseOrPhenotypicFeature	0:14:90:99:170	1:15:91:100:171	0:1:4:5:7	D014700	verapamil	ChemicalEntity	72	73	3	1:Association:2	R2L	NON-CROSS	108-110	99-100	D001549	benzamide drugs	ChemicalEntity	108	110	5	D010673	Pheochromocytoma|pheochromocytoma|pheochromocytoma|pheochromocytoma|pheochromocytoma	DiseaseOrPhenotypicFeature	0:14:90:99:170	1:15:91:100:171	0:1:4:5:7	1:Drug_Interaction:2	L2R	NON-CROSS	3-4	5-6	D000077582	amisulpride|amisulpride|amisulpride|amisulpride|amisulpride|amisulpride	ChemicalEntity	3:20:50:137:158:188	4:21:51:138:159:189	0:1:2:6:7:8	D063325	tiapride|tiapride|tiapride|tiapride|tiapride|tiapride	ChemicalEntity	5:22:54:139:161:186	6:23:55:140:162:187	0:1:2:6:7:8	1:Positive_Correlation:2	R2L	NON-CROSS	137-138	134-135	D006973	hypertension|hypertensive|hypertensive	DiseaseOrPhenotypicFeature	37:134:164	38:135:165	2:6:7	D000077582	amisulpride|amisulpride|amisulpride|amisulpride|amisulpride|amisulpride	ChemicalEntity	3:20:50:137:158:188	4:21:51:138:159:189	0:1:2:6:7:8	1:Positive_Correlation:2	R2L	NON-CROSS	50-51	40-41	D006261	headache	DiseaseOrPhenotypicFeature	40	41	2	D000077582	amisulpride|amisulpride|amisulpride|amisulpride|amisulpride|amisulpride	ChemicalEntity	3:20:50:137:158:188	4:21:51:138:159:189	0:1:2:6:7:8	1:Positive_Correlation:2	R2L	NON-CROSS	50-51	42-43	D014839	vomiting	DiseaseOrPhenotypicFeature	42	43	2	D000077582	amisulpride|amisulpride|amisulpride|amisulpride|amisulpride|amisulpride	ChemicalEntity	3:20:50:137:158:188	4:21:51:138:159:189	0:1:2:6:7:8	1:NR:2	L2R	CROSS	50-51	70-71	D000077582	amisulpride|amisulpride|amisulpride|amisulpride|amisulpride|amisulpride	ChemicalEntity	3:20:50:137:158:188	4:21:51:138:159:189	0:1:2:6:7:8	D009529	nicardipine	ChemicalEntity	70	71	3	1:NR:2	L2R	CROSS	50-51	72-73	D000077582	amisulpride|amisulpride|amisulpride|amisulpride|amisulpride|amisulpride	ChemicalEntity	3:20:50:137:158:188	4:21:51:138:159:189	0:1:2:6:7:8	D014700	verapamil	ChemicalEntity	72	73	3	1:NR:2	L2R	CROSS	108-110	137-138	D000077582	amisulpride|amisulpride|amisulpride|amisulpride|amisulpride|amisulpride	ChemicalEntity	3:20:50:137:158:188	4:21:51:138:159:189	0:1:2:6:7:8	D001549	benzamide drugs	ChemicalEntity	108	110	5	1:Positive_Correlation:2	R2L	NON-CROSS	164-165	161-162	D006973	hypertension|hypertensive|hypertensive	DiseaseOrPhenotypicFeature	37:134:164	38:135:165	2:6:7	D063325	tiapride|tiapride|tiapride|tiapride|tiapride|tiapride	ChemicalEntity	5:22:54:139:161:186	6:23:55:140:162:187	0:1:2:6:7:8	1:Positive_Correlation:2	R2L	NON-CROSS	54-55	40-41	D006261	headache	DiseaseOrPhenotypicFeature	40	41	2	D063325	tiapride|tiapride|tiapride|tiapride|tiapride|tiapride	ChemicalEntity	5:22:54:139:161:186	6:23:55:140:162:187	0:1:2:6:7:8	1:Positive_Correlation:2	R2L	NON-CROSS	54-55	42-43	D014839	vomiting	DiseaseOrPhenotypicFeature	42	43	2	D063325	tiapride|tiapride|tiapride|tiapride|tiapride|tiapride	ChemicalEntity	5:22:54:139:161:186	6:23:55:140:162:187	0:1:2:6:7:8	1:NR:2	L2R	CROSS	54-55	70-71	D063325	tiapride|tiapride|tiapride|tiapride|tiapride|tiapride	ChemicalEntity	5:22:54:139:161:186	6:23:55:140:162:187	0:1:2:6:7:8	D009529	nicardipine	ChemicalEntity	70	71	3	1:NR:2	L2R	CROSS	54-55	72-73	D063325	tiapride|tiapride|tiapride|tiapride|tiapride|tiapride	ChemicalEntity	5:22:54:139:161:186	6:23:55:140:162:187	0:1:2:6:7:8	D014700	verapamil	ChemicalEntity	72	73	3	1:NR:2	L2R	CROSS	108-110	139-140	D063325	tiapride|tiapride|tiapride|tiapride|tiapride|tiapride	ChemicalEntity	5:22:54:139:161:186	6:23:55:140:162:187	0:1:2:6:7:8	D001549	benzamide drugs	ChemicalEntity	108	110	5	1:Negative_Correlation:2	R2L	CROSS	70-71	37-38	D009529	nicardipine	ChemicalEntity	70	71	3	D006973	hypertension|hypertensive|hypertensive	DiseaseOrPhenotypicFeature	37:134:164	38:135:165	2:6:7	1:Negative_Correlation:2	R2L	CROSS	72-73	37-38	D014700	verapamil	ChemicalEntity	72	73	3	D006973	hypertension|hypertensive|hypertensive	DiseaseOrPhenotypicFeature	37:134:164	38:135:165	2:6:7	1:NR:2	L2R	CROSS	108-110	134-135	D006973	hypertension|hypertensive|hypertensive	DiseaseOrPhenotypicFeature	37:134:164	38:135:165	2:6:7	D001549	benzamide drugs	ChemicalEntity	108	110	5	1:Negative_Correlation:2	R2L	CROSS	70-71	40-41	D009529	nicardipine	ChemicalEntity	70	71	3	D006261	headache	DiseaseOrPhenotypicFeature	40	41	2	1:Negative_Correlation:2	R2L	CROSS	72-73	40-41	D014700	verapamil	ChemicalEntity	72	73	3	D006261	headache	DiseaseOrPhenotypicFeature	40	41	2	1:NR:2	L2R	CROSS	40-41	108-110	D006261	headache	DiseaseOrPhenotypicFeature	40	41	2	D001549	benzamide drugs	ChemicalEntity	108	110	5	1:Negative_Correlation:2	R2L	CROSS	70-71	42-43	D009529	nicardipine	ChemicalEntity	70	71	3	D014839	vomiting	DiseaseOrPhenotypicFeature	42	43	2	1:Negative_Correlation:2	R2L	CROSS	72-73	42-43	D014700	verapamil	ChemicalEntity	72	73	3	D014839	vomiting	DiseaseOrPhenotypicFeature	42	43	2	1:NR:2	L2R	CROSS	42-43	108-110	D014839	vomiting	DiseaseOrPhenotypicFeature	42	43	2	D001549	benzamide drugs	ChemicalEntity	108	110	5	1:Cotreatment:2	L2R	NON-CROSS	70-71	72-73	D009529	nicardipine	ChemicalEntity	70	71	3	D014700	verapamil	ChemicalEntity	72	73	3	1:NR:2	L2R	CROSS	70-71	108-110	D009529	nicardipine	ChemicalEntity	70	71	3	D001549	benzamide drugs	ChemicalEntity	108	110	5	1:NR:2	L2R	CROSS	72-73	108-110	D014700	verapamil	ChemicalEntity	72	73	3	D001549	benzamide drugs	ChemicalEntity	108	110	5
19957053	Phenylephrine but not ephedrine reduces frontal lobe oxygenation following anesthesia - induced hypotension .|BACKGROUND : Vasopressor agents are used to correct anesthesia - induced hypotension .|We describe the effect of phenylephrine and ephedrine on frontal lobe oxygenation ( S ( c ) O ( 2 ) ) following anesthesia - induced hypotension .|METHODS : Following induction of anesthesia by fentanyl ( 0 . 15 mg kg ( - 1 ) ) and propofol ( 2 . 0 mg kg ( - 1 ) ) , 13 patients received phenylephrine ( 0 . 1 mg iv ) and 12 patients received ephedrine ( 10 mg iv ) to restore mean arterial pressure ( MAP ) .|Heart rate ( HR ) , MAP , stroke volume ( SV ) , cardiac output ( CO ) , and frontal lobe oxygenation ( S ( c ) O ( 2 ) ) were registered .|RESULTS : Induction of anesthesia was followed by a decrease in MAP , HR , SV , and CO concomitant with an elevation in S ( c ) O ( 2 ) .|After administration of phenylephrine , MAP increased ( 51 + / - 12 to 81 + / - 13 mmHg ; P < 0 . 001 ; mean + / - SD ) .|However , a 14 % ( from 70 + / - 8 % to 60 + / - 7 % ) reduction in S ( c ) O ( 2 ) ( P < 0 . 05 ) followed with no change in CO ( 3 . 7 + / - 1 . 1 to 3 . 4 + / - 0 . 9 l min ( - 1 ) ) .|The administration of ephedrine led to a similar increase in MAP ( 53 + / - 9 to 79 + / - 8 mmHg ; P < 0 . 001 ) , restored CO ( 3 . 2 + / - 1 . 2 to 5 . 0 + / - 1 . 3 l min ( - 1 ) ) , and preserved S ( c ) O ( 2 ) .|CONCLUSIONS : The utilization of phenylephrine to correct hypotension induced by anesthesia has a negative impact on S ( c ) O ( 2 ) while ephedrine maintains frontal lobe oxygenation potentially related to an increase in CO .	1:Comparison:2	L2R	NON-CROSS	32-33	34-35	D010656	Phenylephrine|phenylephrine|phenylephrine|phenylephrine|phenylephrine	ChemicalEntity	0:32:91:191:372	1:33:92:192:373	0:2:3:6:9	D004809	ephedrine|ephedrine|ephedrine|ephedrine|ephedrine	ChemicalEntity	3:34:103:297:393	4:35:104:298:394	0:2:3:8:9	1:Negative_Correlation:2	L2R	NON-CROSS	372-373	375-376	D010656	Phenylephrine|phenylephrine|phenylephrine|phenylephrine|phenylephrine	ChemicalEntity	0:32:91:191:372	1:33:92:192:373	0:2:3:6:9	D007022	hypotension|hypotension|hypotension|hypotension	DiseaseOrPhenotypicFeature	12:25:53:375	13:26:54:376	0:1:2:9	1:NR:2	L2R	NON-CROSS	62-63	91-92	D010656	Phenylephrine|phenylephrine|phenylephrine|phenylephrine|phenylephrine	ChemicalEntity	0:32:91:191:372	1:33:92:192:373	0:2:3:6:9	D005283	fentanyl	ChemicalEntity	62	63	3	1:NR:2	L2R	NON-CROSS	75-76	91-92	D010656	Phenylephrine|phenylephrine|phenylephrine|phenylephrine|phenylephrine	ChemicalEntity	0:32:91:191:372	1:33:92:192:373	0:2:3:6:9	D015742	propofol	ChemicalEntity	75	76	3	1:NR:2	L2R	CROSS	91-92	126-127	D010656	Phenylephrine|phenylephrine|phenylephrine|phenylephrine|phenylephrine	ChemicalEntity	0:32:91:191:372	1:33:92:192:373	0:2:3:6:9	D020521	stroke	DiseaseOrPhenotypicFeature	126	127	4	1:Negative_Correlation:2	L2R	NON-CROSS	3-4	12-13	D004809	ephedrine|ephedrine|ephedrine|ephedrine|ephedrine	ChemicalEntity	3:34:103:297:393	4:35:104:298:394	0:2:3:8:9	D007022	hypotension|hypotension|hypotension|hypotension	DiseaseOrPhenotypicFeature	12:25:53:375	13:26:54:376	0:1:2:9	1:NR:2	L2R	NON-CROSS	34-35	62-63	D004809	ephedrine|ephedrine|ephedrine|ephedrine|ephedrine	ChemicalEntity	3:34:103:297:393	4:35:104:298:394	0:2:3:8:9	D005283	fentanyl	ChemicalEntity	62	63	3	1:NR:2	L2R	NON-CROSS	75-76	103-104	D004809	ephedrine|ephedrine|ephedrine|ephedrine|ephedrine	ChemicalEntity	3:34:103:297:393	4:35:104:298:394	0:2:3:8:9	D015742	propofol	ChemicalEntity	75	76	3	1:NR:2	L2R	CROSS	103-104	126-127	D004809	ephedrine|ephedrine|ephedrine|ephedrine|ephedrine	ChemicalEntity	3:34:103:297:393	4:35:104:298:394	0:2:3:8:9	D020521	stroke	DiseaseOrPhenotypicFeature	126	127	4	1:Positive_Correlation:2	L2R	CROSS	53-54	62-63	D007022	hypotension|hypotension|hypotension|hypotension	DiseaseOrPhenotypicFeature	12:25:53:375	13:26:54:376	0:1:2:9	D005283	fentanyl	ChemicalEntity	62	63	3	1:Positive_Correlation:2	L2R	CROSS	53-54	75-76	D007022	hypotension|hypotension|hypotension|hypotension	DiseaseOrPhenotypicFeature	12:25:53:375	13:26:54:376	0:1:2:9	D015742	propofol	ChemicalEntity	75	76	3	1:NR:2	L2R	NON-CROSS	62-63	75-76	D005283	fentanyl	ChemicalEntity	62	63	3	D015742	propofol	ChemicalEntity	75	76	3	1:NR:2	L2R	CROSS	62-63	126-127	D005283	fentanyl	ChemicalEntity	62	63	3	D020521	stroke	DiseaseOrPhenotypicFeature	126	127	4	1:NR:2	L2R	CROSS	75-76	126-127	D015742	propofol	ChemicalEntity	75	76	3	D020521	stroke	DiseaseOrPhenotypicFeature	126	127	4
17935240	Somatic and gonadal mosaicism in X - linked retinitis pigmentosa .|The g . ORF15 + 652 - 653delAG mutation in the RPGR gene is the most frequent mutation in X - linked retinitis pigmentosa ( XLRP ) .|The objective of this study was to investigate the possibility of mosaicism in an XLRP family .|Eight subjects in the RP family were recruited .|Blood samples were collected for DNA extraction .|Haplotype analysis and mutational screening on the RPGR gene were performed .|Additionally , samples of hair follicles and buccal cells from the mother of the proband were acquired for DNA extraction and molecular analysis .|Phenotype was characterized with routine ophthalmic examination , Goldmann perimetry , electroretinography , and color fundus photography .|A g . ORF15 + 652 - 653delAG mutation was identified in second - and third - generation patients / carriers .|A first - generation female , who was considered to be an obligate carrier , demonstrated a normal phenotype as well as a normal genotype in lymphocytic DNA , indicating the gonadal mosaicism ; however , a heterozygous AG - deletion at nucleotide 652 and 653 was identified in the genomic DNA of hair follicles , hair shaft , and buccal cells , indicating that the mutation is somatic .|In conclusion , we reported on a family in which an asymptomatic woman with somatic - gonadal mosaicism for a RPGR gene mutation transmitted the mutation to an asymptomatic daughter and to a son with XLRP .|Gonadal mosaicism may be responsible for a proportion of multiplex or simplex RP families , in which more than 50 % of all cases of RP are found .|( c ) 2007 Wiley - Liss , Inc .	1:Positive_Correlation:2	R2L	NON-CROSS	12-19	5-10	g|DEL|ORF15+652_653|AG	g . ORF15 + 652 - 653delAG|g . ORF15 + 652 - 653delAG	SequenceVariant	12:128	19:135	1:8	D012174	X - linked retinitis pigmentosa|X - linked retinitis pigmentosa|XLRP|XLRP|RP|XLRP|RP|RP	DiseaseOrPhenotypicFeature	5:30:36:53:60:254:268:281	10:35:37:54:61:255:269:282	0:1:1:2:3:10:11:11	1:Association:2	R2L	NON-CROSS	30-35	22-23	6103	RPGR|RPGR|RPGR	GeneOrGeneProduct	22:80:239	23:81:240	1:5:10	D012174	X - linked retinitis pigmentosa|X - linked retinitis pigmentosa|XLRP|XLRP|RP|XLRP|RP|RP	DiseaseOrPhenotypicFeature	5:30:36:53:60:254:268:281	10:35:37:54:61:255:269:282	0:1:1:2:3:10:11:11	1:Association:2	R2L	CROSS	254-255	187-195	g|DEL|652_653|AG	AG - deletion at nucleotide 652 and 653	SequenceVariant	187	195	9	D012174	X - linked retinitis pigmentosa|X - linked retinitis pigmentosa|XLRP|XLRP|RP|XLRP|RP|RP	DiseaseOrPhenotypicFeature	5:30:36:53:60:254:268:281	10:35:37:54:61:255:269:282	0:1:1:2:3:10:11:11
18441470	Complete atrioventricular block secondary to lithium therapy .|Sinus node dysfunction has been reported most frequently among the adverse cardiovascular effects of lithium .|In the present case , complete atrioventricular ( AV ) block with syncopal attacks developed secondary to lithium therapy , necessitating permanent pacemaker implantation .|Serum lithium levels remained under or within the therapeutic range during the syncopal attacks .|Lithium should be used with extreme caution , especially in patients with mild disturbance of AV conduction .	1:Positive_Correlation:2	L2R	NON-CROSS	0-3	5-6	D054537	Complete atrioventricular block|complete atrioventricular ( AV ) block	DiseaseOrPhenotypicFeature	0:29	3:35	0:2	D008094	lithium|lithium|lithium|lithium|Lithium	ChemicalEntity	5:22:41:50:64	6:23:42:51:65	0:1:2:3:4	1:Positive_Correlation:2	L2R	NON-CROSS	5-6	8-11	D008094	lithium|lithium|lithium|lithium|Lithium	ChemicalEntity	5:22:41:50:64	6:23:42:51:65	0:1:2:3:4	D012804	Sinus node dysfunction	DiseaseOrPhenotypicFeature	8	11	1	1:Positive_Correlation:2	L2R	NON-CROSS	18-21	22-23	D008094	lithium|lithium|lithium|lithium|Lithium	ChemicalEntity	5:22:41:50:64	6:23:42:51:65	0:1:2:3:4	D018376	adverse cardiovascular effects	DiseaseOrPhenotypicFeature	18	21	1	1:Positive_Correlation:2	R2L	NON-CROSS	64-65	61-63	D013575	syncopal attacks|syncopal attacks	DiseaseOrPhenotypicFeature	36:61	38:63	2:3	D008094	lithium|lithium|lithium|lithium|Lithium	ChemicalEntity	5:22:41:50:64	6:23:42:51:65	0:1:2:3:4
15036754	Organophosphate - induced convulsions and prevention of neuropathological damages .|Such organophosphorus ( OP ) compounds as diisopropylfluorophosphate ( DFP ) , sarin and soman are potent inhibitors of acetylcholinesterases ( AChEs ) and butyrylcholinesterases ( BChEs ) .|The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system ( CNS ) , which elevates acetylcholine ( ACh ) levels .|The protective action of subcutaneously ( SC ) administered antidotes or their combinations in DFP ( 2 . 0 mg / kg BW ) intoxication was studied in 9 - 10 - weeks - old Han - Wistar male rats .|The rats received AChE reactivator pralidoxime - 2 - chloride ( 2PAM ) ( 30 . 0 mg / kg BW ) , anticonvulsant diazepam ( 2 . 0 mg / kg BW ) , A ( 1 ) - adenosine receptor agonist N ( 6 ) - cyclopentyl adenosine ( CPA ) ( 2 . 0 mg / kg BW ) , NMDA - receptor antagonist dizocilpine maleate ( + - MK801 hydrogen maleate ) ( 2 . 0 mg / kg BW ) or their combinations with cholinolytic drug atropine sulfate ( 50 . 0 mg / kg BW ) immediately or 30 min after the single SC injection of DFP .|The control rats received atropine sulfate , but also saline and olive oil instead of other antidotes and DFP , respectively .|All rats were terminated either 24 h or 3 weeks after the DFP injection .|The rats treated with DFP - atropine showed severe typical OP - induced toxicity signs .|When CPA , diazepam or 2PAM was given immediately after DFP - atropine , these treatments prevented , delayed or shortened the occurrence of serious signs of poisoning .|Atropine - MK801 did not offer any additional protection against DFP toxicity .|In conclusion , CPA , diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat .	1:Positive_Correlation:2	L2R	NON-CROSS	0-1	3-4	D010755	Organophosphate|organophosphorus|OP|OPs|OP	ChemicalEntity	0:11:13:43:272	1:12:14:44:273	0:1:1:2:7	D012640	convulsions	DiseaseOrPhenotypicFeature	3	4	0	1:Association:2	L2R	NON-CROSS	7-9	11-12	D010755	Organophosphate|organophosphorus|OP|OPs|OP	ChemicalEntity	0:11:13:43:272	1:12:14:44:273	0:1:1:2:7	D004194	neuropathological damages	DiseaseOrPhenotypicFeature	7	9	0	1:NR:2	L2R	NON-CROSS	13-14	17-18	D010755	Organophosphate|organophosphorus|OP|OPs|OP	ChemicalEntity	0:11:13:43:272	1:12:14:44:273	0:1:1:2:7	D007531	diisopropylfluorophosphate|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP	ChemicalEntity	17:19:84:223:243:259:266:288:317:346	18:20:85:224:244:260:267:289:318:347	1:1:3:4:5:6:7:8:9:10	1:NR:2	L2R	NON-CROSS	13-14	22-23	D010755	Organophosphate|organophosphorus|OP|OPs|OP	ChemicalEntity	0:11:13:43:272	1:12:14:44:273	0:1:1:2:7	D012524	sarin	ChemicalEntity	22	23	1	1:NR:2	L2R	NON-CROSS	13-14	24-25	D010755	Organophosphate|organophosphorus|OP|OPs|OP	ChemicalEntity	0:11:13:43:272	1:12:14:44:273	0:1:1:2:7	D012999	soman	ChemicalEntity	24	25	1	1:Negative_Correlation:2	L2R	NON-CROSS	43-44	52-53	D010755	Organophosphate|organophosphorus|OP|OPs|OP	ChemicalEntity	0:11:13:43:272	1:12:14:44:273	0:1:1:2:7	83817	acetylcholinesterases|AChEs|AChEs|AChE	GeneOrGeneProduct	29:31:52:114	30:32:53:115	1:1:2:4	1:Negative_Correlation:2	L2R	NON-CROSS	36-37	43-44	D010755	Organophosphate|organophosphorus|OP|OPs|OP	ChemicalEntity	0:11:13:43:272	1:12:14:44:273	0:1:1:2:7	65036	butyrylcholinesterases|BChEs	GeneOrGeneProduct	34:36	35:37	1:1	1:NR:2	L2R	NON-CROSS	41-42	43-44	D010755	Organophosphate|organophosphorus|OP|OPs|OP	ChemicalEntity	0:11:13:43:272	1:12:14:44:273	0:1:1:2:7	D064420	toxicity|toxicity|toxicity|toxicity	DiseaseOrPhenotypicFeature	41:275:318:344	42:276:319:345	2:7:9:10	1:Association:2	L2R	NON-CROSS	43-44	64-65	D010755	Organophosphate|organophosphorus|OP|OPs|OP	ChemicalEntity	0:11:13:43:272	1:12:14:44:273	0:1:1:2:7	D000109	acetylcholine|ACh	ChemicalEntity	64:66	65:67	2:2	1:NR:2	L2R	CROSS	272-273	283-284	D010755	Organophosphate|organophosphorus|OP|OPs|OP	ChemicalEntity	0:11:13:43:272	1:12:14:44:273	0:1:1:2:7	D011220	pralidoxime - 2 - chloride|2PAM|2PAM|2PAM	ChemicalEntity	116:122:283:327	121:123:284:328	4:4:8:10	1:NR:2	L2R	CROSS	272-273	281-282	D010755	Organophosphate|organophosphorus|OP|OPs|OP	ChemicalEntity	0:11:13:43:272	1:12:14:44:273	0:1:1:2:7	D003975	diazepam|diazepam|diazepam	ChemicalEntity	135:281:325	136:282:326	4:8:10	1:NR:2	L2R	CROSS	43-44	146-153	D010755	Organophosphate|organophosphorus|OP|OPs|OP	ChemicalEntity	0:11:13:43:272	1:12:14:44:273	0:1:1:2:7	29290	A ( 1 ) - adenosine receptor	GeneOrGeneProduct	146	153	4	1:NR:2	L2R	CROSS	272-273	279-280	D010755	Organophosphate|organophosphorus|OP|OPs|OP	ChemicalEntity	0:11:13:43:272	1:12:14:44:273	0:1:1:2:7	C048599	N ( 6 ) - cyclopentyl adenosine|CPA|CPA|CPA	ChemicalEntity	154:162:279:323	161:163:280:324	4:4:8:10	1:NR:2	L2R	CROSS	174-177	272-273	D010755	Organophosphate|organophosphorus|OP|OPs|OP	ChemicalEntity	0:11:13:43:272	1:12:14:44:273	0:1:1:2:7	24408	NMDA - receptor	GeneOrGeneProduct	174	177	4	1:NR:2	L2R	CROSS	272-273	309-310	D010755	Organophosphate|organophosphorus|OP|OPs|OP	ChemicalEntity	0:11:13:43:272	1:12:14:44:273	0:1:1:2:7	D016291	dizocilpine maleate|MK801 hydrogen maleate|MK801	ChemicalEntity	178:183:309	180:186:310	4:4:9	1:NR:2	L2R	NON-CROSS	268-269	272-273	D010755	Organophosphate|organophosphorus|OP|OPs|OP	ChemicalEntity	0:11:13:43:272	1:12:14:44:273	0:1:1:2:7	D001285	atropine sulfate|atropine sulfate|atropine|atropine|Atropine|atropine	ChemicalEntity	202:229:268:290:307:331	204:231:269:291:308:332	4:5:7:8:9:10	1:NR:2	L2R	CROSS	236-238	272-273	D010755	Organophosphate|organophosphorus|OP|OPs|OP	ChemicalEntity	0:11:13:43:272	1:12:14:44:273	0:1:1:2:7	D000069463	olive oil	ChemicalEntity	236	238	5	1:NR:2	L2R	CROSS	272-273	305-306	D010755	Organophosphate|organophosphorus|OP|OPs|OP	ChemicalEntity	0:11:13:43:272	1:12:14:44:273	0:1:1:2:7	D011041	poisoning|poisoning	DiseaseOrPhenotypicFeature	305:339	306:340	8:10	1:NR:2	L2R	CROSS	3-4	17-18	D012640	convulsions	DiseaseOrPhenotypicFeature	3	4	0	D007531	diisopropylfluorophosphate|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP	ChemicalEntity	17:19:84:223:243:259:266:288:317:346	18:20:85:224:244:260:267:289:318:347	1:1:3:4:5:6:7:8:9:10	1:NR:2	L2R	CROSS	3-4	22-23	D012640	convulsions	DiseaseOrPhenotypicFeature	3	4	0	D012524	sarin	ChemicalEntity	22	23	1	1:NR:2	L2R	CROSS	3-4	24-25	D012640	convulsions	DiseaseOrPhenotypicFeature	3	4	0	D012999	soman	ChemicalEntity	24	25	1	1:NR:2	L2R	CROSS	3-4	29-30	D012640	convulsions	DiseaseOrPhenotypicFeature	3	4	0	83817	acetylcholinesterases|AChEs|AChEs|AChE	GeneOrGeneProduct	29:31:52:114	30:32:53:115	1:1:2:4	1:NR:2	L2R	CROSS	3-4	34-35	D012640	convulsions	DiseaseOrPhenotypicFeature	3	4	0	65036	butyrylcholinesterases|BChEs	GeneOrGeneProduct	34:36	35:37	1:1	1:NR:2	L2R	CROSS	3-4	64-65	D012640	convulsions	DiseaseOrPhenotypicFeature	3	4	0	D000109	acetylcholine|ACh	ChemicalEntity	64:66	65:67	2:2	1:NR:2	L2R	CROSS	3-4	116-121	D012640	convulsions	DiseaseOrPhenotypicFeature	3	4	0	D011220	pralidoxime - 2 - chloride|2PAM|2PAM|2PAM	ChemicalEntity	116:122:283:327	121:123:284:328	4:4:8:10	1:NR:2	L2R	CROSS	3-4	135-136	D012640	convulsions	DiseaseOrPhenotypicFeature	3	4	0	D003975	diazepam|diazepam|diazepam	ChemicalEntity	135:281:325	136:282:326	4:8:10	1:NR:2	L2R	CROSS	3-4	146-153	D012640	convulsions	DiseaseOrPhenotypicFeature	3	4	0	29290	A ( 1 ) - adenosine receptor	GeneOrGeneProduct	146	153	4	1:NR:2	L2R	CROSS	3-4	154-161	D012640	convulsions	DiseaseOrPhenotypicFeature	3	4	0	C048599	N ( 6 ) - cyclopentyl adenosine|CPA|CPA|CPA	ChemicalEntity	154:162:279:323	161:163:280:324	4:4:8:10	1:NR:2	L2R	CROSS	3-4	174-177	D012640	convulsions	DiseaseOrPhenotypicFeature	3	4	0	24408	NMDA - receptor	GeneOrGeneProduct	174	177	4	1:NR:2	L2R	CROSS	3-4	178-180	D012640	convulsions	DiseaseOrPhenotypicFeature	3	4	0	D016291	dizocilpine maleate|MK801 hydrogen maleate|MK801	ChemicalEntity	178:183:309	180:186:310	4:4:9	1:NR:2	L2R	CROSS	3-4	202-204	D012640	convulsions	DiseaseOrPhenotypicFeature	3	4	0	D001285	atropine sulfate|atropine sulfate|atropine|atropine|Atropine|atropine	ChemicalEntity	202:229:268:290:307:331	204:231:269:291:308:332	4:5:7:8:9:10	1:NR:2	L2R	CROSS	3-4	236-238	D012640	convulsions	DiseaseOrPhenotypicFeature	3	4	0	D000069463	olive oil	ChemicalEntity	236	238	5	1:NR:2	L2R	CROSS	7-9	17-18	D004194	neuropathological damages	DiseaseOrPhenotypicFeature	7	9	0	D007531	diisopropylfluorophosphate|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP	ChemicalEntity	17:19:84:223:243:259:266:288:317:346	18:20:85:224:244:260:267:289:318:347	1:1:3:4:5:6:7:8:9:10	1:NR:2	L2R	CROSS	7-9	22-23	D004194	neuropathological damages	DiseaseOrPhenotypicFeature	7	9	0	D012524	sarin	ChemicalEntity	22	23	1	1:NR:2	L2R	CROSS	7-9	24-25	D004194	neuropathological damages	DiseaseOrPhenotypicFeature	7	9	0	D012999	soman	ChemicalEntity	24	25	1	1:NR:2	L2R	CROSS	7-9	29-30	D004194	neuropathological damages	DiseaseOrPhenotypicFeature	7	9	0	83817	acetylcholinesterases|AChEs|AChEs|AChE	GeneOrGeneProduct	29:31:52:114	30:32:53:115	1:1:2:4	1:NR:2	L2R	CROSS	7-9	34-35	D004194	neuropathological damages	DiseaseOrPhenotypicFeature	7	9	0	65036	butyrylcholinesterases|BChEs	GeneOrGeneProduct	34:36	35:37	1:1	1:NR:2	L2R	CROSS	7-9	64-65	D004194	neuropathological damages	DiseaseOrPhenotypicFeature	7	9	0	D000109	acetylcholine|ACh	ChemicalEntity	64:66	65:67	2:2	1:NR:2	L2R	CROSS	7-9	116-121	D004194	neuropathological damages	DiseaseOrPhenotypicFeature	7	9	0	D011220	pralidoxime - 2 - chloride|2PAM|2PAM|2PAM	ChemicalEntity	116:122:283:327	121:123:284:328	4:4:8:10	1:NR:2	L2R	CROSS	7-9	135-136	D004194	neuropathological damages	DiseaseOrPhenotypicFeature	7	9	0	D003975	diazepam|diazepam|diazepam	ChemicalEntity	135:281:325	136:282:326	4:8:10	1:NR:2	L2R	CROSS	7-9	146-153	D004194	neuropathological damages	DiseaseOrPhenotypicFeature	7	9	0	29290	A ( 1 ) - adenosine receptor	GeneOrGeneProduct	146	153	4	1:NR:2	L2R	CROSS	7-9	154-161	D004194	neuropathological damages	DiseaseOrPhenotypicFeature	7	9	0	C048599	N ( 6 ) - cyclopentyl adenosine|CPA|CPA|CPA	ChemicalEntity	154:162:279:323	161:163:280:324	4:4:8:10	1:NR:2	L2R	CROSS	7-9	174-177	D004194	neuropathological damages	DiseaseOrPhenotypicFeature	7	9	0	24408	NMDA - receptor	GeneOrGeneProduct	174	177	4	1:NR:2	L2R	CROSS	7-9	178-180	D004194	neuropathological damages	DiseaseOrPhenotypicFeature	7	9	0	D016291	dizocilpine maleate|MK801 hydrogen maleate|MK801	ChemicalEntity	178:183:309	180:186:310	4:4:9	1:NR:2	L2R	CROSS	7-9	202-204	D004194	neuropathological damages	DiseaseOrPhenotypicFeature	7	9	0	D001285	atropine sulfate|atropine sulfate|atropine|atropine|Atropine|atropine	ChemicalEntity	202:229:268:290:307:331	204:231:269:291:308:332	4:5:7:8:9:10	1:NR:2	L2R	CROSS	7-9	236-238	D004194	neuropathological damages	DiseaseOrPhenotypicFeature	7	9	0	D000069463	olive oil	ChemicalEntity	236	238	5	1:NR:2	L2R	NON-CROSS	19-20	22-23	D007531	diisopropylfluorophosphate|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP	ChemicalEntity	17:19:84:223:243:259:266:288:317:346	18:20:85:224:244:260:267:289:318:347	1:1:3:4:5:6:7:8:9:10	D012524	sarin	ChemicalEntity	22	23	1	1:NR:2	L2R	NON-CROSS	19-20	24-25	D007531	diisopropylfluorophosphate|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP	ChemicalEntity	17:19:84:223:243:259:266:288:317:346	18:20:85:224:244:260:267:289:318:347	1:1:3:4:5:6:7:8:9:10	D012999	soman	ChemicalEntity	24	25	1	1:Negative_Correlation:2	L2R	NON-CROSS	19-20	29-30	D007531	diisopropylfluorophosphate|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP	ChemicalEntity	17:19:84:223:243:259:266:288:317:346	18:20:85:224:244:260:267:289:318:347	1:1:3:4:5:6:7:8:9:10	83817	acetylcholinesterases|AChEs|AChEs|AChE	GeneOrGeneProduct	29:31:52:114	30:32:53:115	1:1:2:4	1:Negative_Correlation:2	L2R	NON-CROSS	19-20	34-35	D007531	diisopropylfluorophosphate|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP	ChemicalEntity	17:19:84:223:243:259:266:288:317:346	18:20:85:224:244:260:267:289:318:347	1:1:3:4:5:6:7:8:9:10	65036	butyrylcholinesterases|BChEs	GeneOrGeneProduct	34:36	35:37	1:1	1:NR:2	L2R	NON-CROSS	317-318	318-319	D007531	diisopropylfluorophosphate|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP	ChemicalEntity	17:19:84:223:243:259:266:288:317:346	18:20:85:224:244:260:267:289:318:347	1:1:3:4:5:6:7:8:9:10	D064420	toxicity|toxicity|toxicity|toxicity	DiseaseOrPhenotypicFeature	41:275:318:344	42:276:319:345	2:7:9:10	1:NR:2	L2R	CROSS	66-67	84-85	D007531	diisopropylfluorophosphate|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP	ChemicalEntity	17:19:84:223:243:259:266:288:317:346	18:20:85:224:244:260:267:289:318:347	1:1:3:4:5:6:7:8:9:10	D000109	acetylcholine|ACh	ChemicalEntity	64:66	65:67	2:2	1:Negative_Correlation:2	R2L	NON-CROSS	288-289	283-284	D011220	pralidoxime - 2 - chloride|2PAM|2PAM|2PAM	ChemicalEntity	116:122:283:327	121:123:284:328	4:4:8:10	D007531	diisopropylfluorophosphate|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP	ChemicalEntity	17:19:84:223:243:259:266:288:317:346	18:20:85:224:244:260:267:289:318:347	1:1:3:4:5:6:7:8:9:10	1:Negative_Correlation:2	R2L	NON-CROSS	288-289	281-282	D003975	diazepam|diazepam|diazepam	ChemicalEntity	135:281:325	136:282:326	4:8:10	D007531	diisopropylfluorophosphate|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP	ChemicalEntity	17:19:84:223:243:259:266:288:317:346	18:20:85:224:244:260:267:289:318:347	1:1:3:4:5:6:7:8:9:10	1:NR:2	L2R	NON-CROSS	84-85	146-153	D007531	diisopropylfluorophosphate|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP	ChemicalEntity	17:19:84:223:243:259:266:288:317:346	18:20:85:224:244:260:267:289:318:347	1:1:3:4:5:6:7:8:9:10	29290	A ( 1 ) - adenosine receptor	GeneOrGeneProduct	146	153	4	1:Negative_Correlation:2	R2L	NON-CROSS	323-324	317-318	C048599	N ( 6 ) - cyclopentyl adenosine|CPA|CPA|CPA	ChemicalEntity	154:162:279:323	161:163:280:324	4:4:8:10	D007531	diisopropylfluorophosphate|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP	ChemicalEntity	17:19:84:223:243:259:266:288:317:346	18:20:85:224:244:260:267:289:318:347	1:1:3:4:5:6:7:8:9:10	1:NR:2	L2R	NON-CROSS	174-177	223-224	D007531	diisopropylfluorophosphate|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP	ChemicalEntity	17:19:84:223:243:259:266:288:317:346	18:20:85:224:244:260:267:289:318:347	1:1:3:4:5:6:7:8:9:10	24408	NMDA - receptor	GeneOrGeneProduct	174	177	4	1:NR:2	L2R	NON-CROSS	309-310	317-318	D007531	diisopropylfluorophosphate|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP	ChemicalEntity	17:19:84:223:243:259:266:288:317:346	18:20:85:224:244:260:267:289:318:347	1:1:3:4:5:6:7:8:9:10	D016291	dizocilpine maleate|MK801 hydrogen maleate|MK801	ChemicalEntity	178:183:309	180:186:310	4:4:9	1:Negative_Correlation:2	R2L	NON-CROSS	268-269	266-267	D001285	atropine sulfate|atropine sulfate|atropine|atropine|Atropine|atropine	ChemicalEntity	202:229:268:290:307:331	204:231:269:291:308:332	4:5:7:8:9:10	D007531	diisopropylfluorophosphate|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP	ChemicalEntity	17:19:84:223:243:259:266:288:317:346	18:20:85:224:244:260:267:289:318:347	1:1:3:4:5:6:7:8:9:10	1:NR:2	L2R	NON-CROSS	236-238	243-244	D007531	diisopropylfluorophosphate|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP	ChemicalEntity	17:19:84:223:243:259:266:288:317:346	18:20:85:224:244:260:267:289:318:347	1:1:3:4:5:6:7:8:9:10	D000069463	olive oil	ChemicalEntity	236	238	5	1:NR:2	L2R	NON-CROSS	339-340	346-347	D007531	diisopropylfluorophosphate|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP|DFP	ChemicalEntity	17:19:84:223:243:259:266:288:317:346	18:20:85:224:244:260:267:289:318:347	1:1:3:4:5:6:7:8:9:10	D011041	poisoning|poisoning	DiseaseOrPhenotypicFeature	305:339	306:340	8:10	1:NR:2	L2R	NON-CROSS	22-23	24-25	D012524	sarin	ChemicalEntity	22	23	1	D012999	soman	ChemicalEntity	24	25	1	1:Negative_Correlation:2	L2R	NON-CROSS	22-23	29-30	D012524	sarin	ChemicalEntity	22	23	1	83817	acetylcholinesterases|AChEs|AChEs|AChE	GeneOrGeneProduct	29:31:52:114	30:32:53:115	1:1:2:4	1:Negative_Correlation:2	L2R	NON-CROSS	22-23	34-35	D012524	sarin	ChemicalEntity	22	23	1	65036	butyrylcholinesterases|BChEs	GeneOrGeneProduct	34:36	35:37	1:1	1:NR:2	L2R	CROSS	22-23	41-42	D012524	sarin	ChemicalEntity	22	23	1	D064420	toxicity|toxicity|toxicity|toxicity	DiseaseOrPhenotypicFeature	41:275:318:344	42:276:319:345	2:7:9:10	1:NR:2	L2R	CROSS	22-23	64-65	D012524	sarin	ChemicalEntity	22	23	1	D000109	acetylcholine|ACh	ChemicalEntity	64:66	65:67	2:2	1:NR:2	L2R	CROSS	22-23	116-121	D012524	sarin	ChemicalEntity	22	23	1	D011220	pralidoxime - 2 - chloride|2PAM|2PAM|2PAM	ChemicalEntity	116:122:283:327	121:123:284:328	4:4:8:10	1:NR:2	L2R	CROSS	22-23	135-136	D012524	sarin	ChemicalEntity	22	23	1	D003975	diazepam|diazepam|diazepam	ChemicalEntity	135:281:325	136:282:326	4:8:10	1:NR:2	L2R	CROSS	22-23	146-153	D012524	sarin	ChemicalEntity	22	23	1	29290	A ( 1 ) - adenosine receptor	GeneOrGeneProduct	146	153	4	1:NR:2	L2R	CROSS	22-23	154-161	D012524	sarin	ChemicalEntity	22	23	1	C048599	N ( 6 ) - cyclopentyl adenosine|CPA|CPA|CPA	ChemicalEntity	154:162:279:323	161:163:280:324	4:4:8:10	1:NR:2	L2R	CROSS	22-23	174-177	D012524	sarin	ChemicalEntity	22	23	1	24408	NMDA - receptor	GeneOrGeneProduct	174	177	4	1:NR:2	L2R	CROSS	22-23	178-180	D012524	sarin	ChemicalEntity	22	23	1	D016291	dizocilpine maleate|MK801 hydrogen maleate|MK801	ChemicalEntity	178:183:309	180:186:310	4:4:9	1:NR:2	L2R	CROSS	22-23	202-204	D012524	sarin	ChemicalEntity	22	23	1	D001285	atropine sulfate|atropine sulfate|atropine|atropine|Atropine|atropine	ChemicalEntity	202:229:268:290:307:331	204:231:269:291:308:332	4:5:7:8:9:10	1:NR:2	L2R	CROSS	22-23	236-238	D012524	sarin	ChemicalEntity	22	23	1	D000069463	olive oil	ChemicalEntity	236	238	5	1:NR:2	L2R	CROSS	22-23	305-306	D012524	sarin	ChemicalEntity	22	23	1	D011041	poisoning|poisoning	DiseaseOrPhenotypicFeature	305:339	306:340	8:10	1:Negative_Correlation:2	L2R	NON-CROSS	24-25	29-30	D012999	soman	ChemicalEntity	24	25	1	83817	acetylcholinesterases|AChEs|AChEs|AChE	GeneOrGeneProduct	29:31:52:114	30:32:53:115	1:1:2:4	1:Negative_Correlation:2	L2R	NON-CROSS	24-25	34-35	D012999	soman	ChemicalEntity	24	25	1	65036	butyrylcholinesterases|BChEs	GeneOrGeneProduct	34:36	35:37	1:1	1:NR:2	L2R	CROSS	24-25	41-42	D012999	soman	ChemicalEntity	24	25	1	D064420	toxicity|toxicity|toxicity|toxicity	DiseaseOrPhenotypicFeature	41:275:318:344	42:276:319:345	2:7:9:10	1:NR:2	L2R	CROSS	24-25	64-65	D012999	soman	ChemicalEntity	24	25	1	D000109	acetylcholine|ACh	ChemicalEntity	64:66	65:67	2:2	1:NR:2	L2R	CROSS	24-25	116-121	D012999	soman	ChemicalEntity	24	25	1	D011220	pralidoxime - 2 - chloride|2PAM|2PAM|2PAM	ChemicalEntity	116:122:283:327	121:123:284:328	4:4:8:10	1:NR:2	L2R	CROSS	24-25	135-136	D012999	soman	ChemicalEntity	24	25	1	D003975	diazepam|diazepam|diazepam	ChemicalEntity	135:281:325	136:282:326	4:8:10	1:NR:2	L2R	CROSS	24-25	146-153	D012999	soman	ChemicalEntity	24	25	1	29290	A ( 1 ) - adenosine receptor	GeneOrGeneProduct	146	153	4	1:NR:2	L2R	CROSS	24-25	154-161	D012999	soman	ChemicalEntity	24	25	1	C048599	N ( 6 ) - cyclopentyl adenosine|CPA|CPA|CPA	ChemicalEntity	154:162:279:323	161:163:280:324	4:4:8:10	1:NR:2	L2R	CROSS	24-25	174-177	D012999	soman	ChemicalEntity	24	25	1	24408	NMDA - receptor	GeneOrGeneProduct	174	177	4	1:NR:2	L2R	CROSS	24-25	178-180	D012999	soman	ChemicalEntity	24	25	1	D016291	dizocilpine maleate|MK801 hydrogen maleate|MK801	ChemicalEntity	178:183:309	180:186:310	4:4:9	1:NR:2	L2R	CROSS	24-25	202-204	D012999	soman	ChemicalEntity	24	25	1	D001285	atropine sulfate|atropine sulfate|atropine|atropine|Atropine|atropine	ChemicalEntity	202:229:268:290:307:331	204:231:269:291:308:332	4:5:7:8:9:10	1:NR:2	L2R	CROSS	24-25	236-238	D012999	soman	ChemicalEntity	24	25	1	D000069463	olive oil	ChemicalEntity	236	238	5	1:NR:2	L2R	CROSS	24-25	305-306	D012999	soman	ChemicalEntity	24	25	1	D011041	poisoning|poisoning	DiseaseOrPhenotypicFeature	305:339	306:340	8:10	1:NR:2	L2R	NON-CROSS	31-32	34-35	83817	acetylcholinesterases|AChEs|AChEs|AChE	GeneOrGeneProduct	29:31:52:114	30:32:53:115	1:1:2:4	65036	butyrylcholinesterases|BChEs	GeneOrGeneProduct	34:36	35:37	1:1	1:NR:2	L2R	NON-CROSS	31-32	41-42	83817	acetylcholinesterases|AChEs|AChEs|AChE	GeneOrGeneProduct	29:31:52:114	30:32:53:115	1:1:2:4	D064420	toxicity|toxicity|toxicity|toxicity	DiseaseOrPhenotypicFeature	41:275:318:344	42:276:319:345	2:7:9:10	1:Association:2	L2R	NON-CROSS	52-53	64-65	83817	acetylcholinesterases|AChEs|AChEs|AChE	GeneOrGeneProduct	29:31:52:114	30:32:53:115	1:1:2:4	D000109	acetylcholine|ACh	ChemicalEntity	64:66	65:67	2:2	1:Positive_Correlation:2	L2R	NON-CROSS	114-115	116-121	83817	acetylcholinesterases|AChEs|AChEs|AChE	GeneOrGeneProduct	29:31:52:114	30:32:53:115	1:1:2:4	D011220	pralidoxime - 2 - chloride|2PAM|2PAM|2PAM	ChemicalEntity	116:122:283:327	121:123:284:328	4:4:8:10	1:NR:2	L2R	NON-CROSS	114-115	135-136	83817	acetylcholinesterases|AChEs|AChEs|AChE	GeneOrGeneProduct	29:31:52:114	30:32:53:115	1:1:2:4	D003975	diazepam|diazepam|diazepam	ChemicalEntity	135:281:325	136:282:326	4:8:10	1:NR:2	L2R	NON-CROSS	114-115	146-153	83817	acetylcholinesterases|AChEs|AChEs|AChE	GeneOrGeneProduct	29:31:52:114	30:32:53:115	1:1:2:4	29290	A ( 1 ) - adenosine receptor	GeneOrGeneProduct	146	153	4	1:NR:2	L2R	NON-CROSS	114-115	154-161	83817	acetylcholinesterases|AChEs|AChEs|AChE	GeneOrGeneProduct	29:31:52:114	30:32:53:115	1:1:2:4	C048599	N ( 6 ) - cyclopentyl adenosine|CPA|CPA|CPA	ChemicalEntity	154:162:279:323	161:163:280:324	4:4:8:10	1:NR:2	L2R	NON-CROSS	114-115	174-177	83817	acetylcholinesterases|AChEs|AChEs|AChE	GeneOrGeneProduct	29:31:52:114	30:32:53:115	1:1:2:4	24408	NMDA - receptor	GeneOrGeneProduct	174	177	4	1:NR:2	L2R	NON-CROSS	114-115	178-180	83817	acetylcholinesterases|AChEs|AChEs|AChE	GeneOrGeneProduct	29:31:52:114	30:32:53:115	1:1:2:4	D016291	dizocilpine maleate|MK801 hydrogen maleate|MK801	ChemicalEntity	178:183:309	180:186:310	4:4:9	1:NR:2	L2R	NON-CROSS	114-115	202-204	83817	acetylcholinesterases|AChEs|AChEs|AChE	GeneOrGeneProduct	29:31:52:114	30:32:53:115	1:1:2:4	D001285	atropine sulfate|atropine sulfate|atropine|atropine|Atropine|atropine	ChemicalEntity	202:229:268:290:307:331	204:231:269:291:308:332	4:5:7:8:9:10	1:NR:2	L2R	CROSS	114-115	236-238	83817	acetylcholinesterases|AChEs|AChEs|AChE	GeneOrGeneProduct	29:31:52:114	30:32:53:115	1:1:2:4	D000069463	olive oil	ChemicalEntity	236	238	5	1:NR:2	L2R	CROSS	114-115	305-306	83817	acetylcholinesterases|AChEs|AChEs|AChE	GeneOrGeneProduct	29:31:52:114	30:32:53:115	1:1:2:4	D011041	poisoning|poisoning	DiseaseOrPhenotypicFeature	305:339	306:340	8:10	1:NR:2	L2R	CROSS	36-37	41-42	65036	butyrylcholinesterases|BChEs	GeneOrGeneProduct	34:36	35:37	1:1	D064420	toxicity|toxicity|toxicity|toxicity	DiseaseOrPhenotypicFeature	41:275:318:344	42:276:319:345	2:7:9:10	1:NR:2	L2R	CROSS	36-37	64-65	65036	butyrylcholinesterases|BChEs	GeneOrGeneProduct	34:36	35:37	1:1	D000109	acetylcholine|ACh	ChemicalEntity	64:66	65:67	2:2	1:NR:2	L2R	CROSS	36-37	116-121	65036	butyrylcholinesterases|BChEs	GeneOrGeneProduct	34:36	35:37	1:1	D011220	pralidoxime - 2 - chloride|2PAM|2PAM|2PAM	ChemicalEntity	116:122:283:327	121:123:284:328	4:4:8:10	1:NR:2	L2R	CROSS	36-37	135-136	65036	butyrylcholinesterases|BChEs	GeneOrGeneProduct	34:36	35:37	1:1	D003975	diazepam|diazepam|diazepam	ChemicalEntity	135:281:325	136:282:326	4:8:10	1:NR:2	L2R	CROSS	36-37	146-153	65036	butyrylcholinesterases|BChEs	GeneOrGeneProduct	34:36	35:37	1:1	29290	A ( 1 ) - adenosine receptor	GeneOrGeneProduct	146	153	4	1:NR:2	L2R	CROSS	36-37	154-161	65036	butyrylcholinesterases|BChEs	GeneOrGeneProduct	34:36	35:37	1:1	C048599	N ( 6 ) - cyclopentyl adenosine|CPA|CPA|CPA	ChemicalEntity	154:162:279:323	161:163:280:324	4:4:8:10	1:NR:2	L2R	CROSS	36-37	174-177	65036	butyrylcholinesterases|BChEs	GeneOrGeneProduct	34:36	35:37	1:1	24408	NMDA - receptor	GeneOrGeneProduct	174	177	4	1:NR:2	L2R	CROSS	36-37	178-180	65036	butyrylcholinesterases|BChEs	GeneOrGeneProduct	34:36	35:37	1:1	D016291	dizocilpine maleate|MK801 hydrogen maleate|MK801	ChemicalEntity	178:183:309	180:186:310	4:4:9	1:NR:2	L2R	CROSS	36-37	202-204	65036	butyrylcholinesterases|BChEs	GeneOrGeneProduct	34:36	35:37	1:1	D001285	atropine sulfate|atropine sulfate|atropine|atropine|Atropine|atropine	ChemicalEntity	202:229:268:290:307:331	204:231:269:291:308:332	4:5:7:8:9:10	1:NR:2	L2R	CROSS	36-37	236-238	65036	butyrylcholinesterases|BChEs	GeneOrGeneProduct	34:36	35:37	1:1	D000069463	olive oil	ChemicalEntity	236	238	5	1:NR:2	L2R	CROSS	36-37	305-306	65036	butyrylcholinesterases|BChEs	GeneOrGeneProduct	34:36	35:37	1:1	D011041	poisoning|poisoning	DiseaseOrPhenotypicFeature	305:339	306:340	8:10	1:NR:2	L2R	NON-CROSS	41-42	64-65	D064420	toxicity|toxicity|toxicity|toxicity	DiseaseOrPhenotypicFeature	41:275:318:344	42:276:319:345	2:7:9:10	D000109	acetylcholine|ACh	ChemicalEntity	64:66	65:67	2:2	1:NR:2	L2R	NON-CROSS	275-276	283-284	D064420	toxicity|toxicity|toxicity|toxicity	DiseaseOrPhenotypicFeature	41:275:318:344	42:276:319:345	2:7:9:10	D011220	pralidoxime - 2 - chloride|2PAM|2PAM|2PAM	ChemicalEntity	116:122:283:327	121:123:284:328	4:4:8:10	1:NR:2	L2R	NON-CROSS	275-276	281-282	D064420	toxicity|toxicity|toxicity|toxicity	DiseaseOrPhenotypicFeature	41:275:318:344	42:276:319:345	2:7:9:10	D003975	diazepam|diazepam|diazepam	ChemicalEntity	135:281:325	136:282:326	4:8:10	1:NR:2	L2R	CROSS	41-42	146-153	D064420	toxicity|toxicity|toxicity|toxicity	DiseaseOrPhenotypicFeature	41:275:318:344	42:276:319:345	2:7:9:10	29290	A ( 1 ) - adenosine receptor	GeneOrGeneProduct	146	153	4	1:NR:2	L2R	NON-CROSS	275-276	279-280	D064420	toxicity|toxicity|toxicity|toxicity	DiseaseOrPhenotypicFeature	41:275:318:344	42:276:319:345	2:7:9:10	C048599	N ( 6 ) - cyclopentyl adenosine|CPA|CPA|CPA	ChemicalEntity	154:162:279:323	161:163:280:324	4:4:8:10	1:NR:2	L2R	CROSS	174-177	275-276	D064420	toxicity|toxicity|toxicity|toxicity	DiseaseOrPhenotypicFeature	41:275:318:344	42:276:319:345	2:7:9:10	24408	NMDA - receptor	GeneOrGeneProduct	174	177	4	1:NR:2	L2R	NON-CROSS	309-310	318-319	D064420	toxicity|toxicity|toxicity|toxicity	DiseaseOrPhenotypicFeature	41:275:318:344	42:276:319:345	2:7:9:10	D016291	dizocilpine maleate|MK801 hydrogen maleate|MK801	ChemicalEntity	178:183:309	180:186:310	4:4:9	1:NR:2	L2R	NON-CROSS	268-269	275-276	D064420	toxicity|toxicity|toxicity|toxicity	DiseaseOrPhenotypicFeature	41:275:318:344	42:276:319:345	2:7:9:10	D001285	atropine sulfate|atropine sulfate|atropine|atropine|Atropine|atropine	ChemicalEntity	202:229:268:290:307:331	204:231:269:291:308:332	4:5:7:8:9:10	1:NR:2	L2R	CROSS	236-238	275-276	D064420	toxicity|toxicity|toxicity|toxicity	DiseaseOrPhenotypicFeature	41:275:318:344	42:276:319:345	2:7:9:10	D000069463	olive oil	ChemicalEntity	236	238	5	1:NR:2	L2R	CROSS	66-67	116-121	D000109	acetylcholine|ACh	ChemicalEntity	64:66	65:67	2:2	D011220	pralidoxime - 2 - chloride|2PAM|2PAM|2PAM	ChemicalEntity	116:122:283:327	121:123:284:328	4:4:8:10	1:NR:2	L2R	CROSS	66-67	135-136	D000109	acetylcholine|ACh	ChemicalEntity	64:66	65:67	2:2	D003975	diazepam|diazepam|diazepam	ChemicalEntity	135:281:325	136:282:326	4:8:10	1:NR:2	L2R	CROSS	66-67	146-153	D000109	acetylcholine|ACh	ChemicalEntity	64:66	65:67	2:2	29290	A ( 1 ) - adenosine receptor	GeneOrGeneProduct	146	153	4	1:NR:2	L2R	CROSS	66-67	154-161	D000109	acetylcholine|ACh	ChemicalEntity	64:66	65:67	2:2	C048599	N ( 6 ) - cyclopentyl adenosine|CPA|CPA|CPA	ChemicalEntity	154:162:279:323	161:163:280:324	4:4:8:10	1:NR:2	L2R	CROSS	66-67	174-177	D000109	acetylcholine|ACh	ChemicalEntity	64:66	65:67	2:2	24408	NMDA - receptor	GeneOrGeneProduct	174	177	4	1:NR:2	L2R	CROSS	66-67	178-180	D000109	acetylcholine|ACh	ChemicalEntity	64:66	65:67	2:2	D016291	dizocilpine maleate|MK801 hydrogen maleate|MK801	ChemicalEntity	178:183:309	180:186:310	4:4:9	1:NR:2	L2R	CROSS	66-67	202-204	D000109	acetylcholine|ACh	ChemicalEntity	64:66	65:67	2:2	D001285	atropine sulfate|atropine sulfate|atropine|atropine|Atropine|atropine	ChemicalEntity	202:229:268:290:307:331	204:231:269:291:308:332	4:5:7:8:9:10	1:NR:2	L2R	CROSS	66-67	236-238	D000109	acetylcholine|ACh	ChemicalEntity	64:66	65:67	2:2	D000069463	olive oil	ChemicalEntity	236	238	5	1:NR:2	L2R	CROSS	66-67	305-306	D000109	acetylcholine|ACh	ChemicalEntity	64:66	65:67	2:2	D011041	poisoning|poisoning	DiseaseOrPhenotypicFeature	305:339	306:340	8:10	1:Cotreatment:2	L2R	NON-CROSS	281-282	283-284	D011220	pralidoxime - 2 - chloride|2PAM|2PAM|2PAM	ChemicalEntity	116:122:283:327	121:123:284:328	4:4:8:10	D003975	diazepam|diazepam|diazepam	ChemicalEntity	135:281:325	136:282:326	4:8:10	1:NR:2	L2R	NON-CROSS	122-123	146-153	D011220	pralidoxime - 2 - chloride|2PAM|2PAM|2PAM	ChemicalEntity	116:122:283:327	121:123:284:328	4:4:8:10	29290	A ( 1 ) - adenosine receptor	GeneOrGeneProduct	146	153	4	1:Cotreatment:2	L2R	NON-CROSS	279-280	283-284	D011220	pralidoxime - 2 - chloride|2PAM|2PAM|2PAM	ChemicalEntity	116:122:283:327	121:123:284:328	4:4:8:10	C048599	N ( 6 ) - cyclopentyl adenosine|CPA|CPA|CPA	ChemicalEntity	154:162:279:323	161:163:280:324	4:4:8:10	1:NR:2	L2R	NON-CROSS	122-123	174-177	D011220	pralidoxime - 2 - chloride|2PAM|2PAM|2PAM	ChemicalEntity	116:122:283:327	121:123:284:328	4:4:8:10	24408	NMDA - receptor	GeneOrGeneProduct	174	177	4	1:NR:2	L2R	NON-CROSS	309-310	327-328	D011220	pralidoxime - 2 - chloride|2PAM|2PAM|2PAM	ChemicalEntity	116:122:283:327	121:123:284:328	4:4:8:10	D016291	dizocilpine maleate|MK801 hydrogen maleate|MK801	ChemicalEntity	178:183:309	180:186:310	4:4:9	1:Cotreatment:2	L2R	NON-CROSS	327-328	331-332	D011220	pralidoxime - 2 - chloride|2PAM|2PAM|2PAM	ChemicalEntity	116:122:283:327	121:123:284:328	4:4:8:10	D001285	atropine sulfate|atropine sulfate|atropine|atropine|Atropine|atropine	ChemicalEntity	202:229:268:290:307:331	204:231:269:291:308:332	4:5:7:8:9:10	1:NR:2	L2R	CROSS	236-238	283-284	D011220	pralidoxime - 2 - chloride|2PAM|2PAM|2PAM	ChemicalEntity	116:122:283:327	121:123:284:328	4:4:8:10	D000069463	olive oil	ChemicalEntity	236	238	5	1:NR:2	L2R	NON-CROSS	327-328	339-340	D011220	pralidoxime - 2 - chloride|2PAM|2PAM|2PAM	ChemicalEntity	116:122:283:327	121:123:284:328	4:4:8:10	D011041	poisoning|poisoning	DiseaseOrPhenotypicFeature	305:339	306:340	8:10	1:NR:2	L2R	NON-CROSS	135-136	146-153	D003975	diazepam|diazepam|diazepam	ChemicalEntity	135:281:325	136:282:326	4:8:10	29290	A ( 1 ) - adenosine receptor	GeneOrGeneProduct	146	153	4	1:Cotreatment:2	R2L	NON-CROSS	281-282	279-280	C048599	N ( 6 ) - cyclopentyl adenosine|CPA|CPA|CPA	ChemicalEntity	154:162:279:323	161:163:280:324	4:4:8:10	D003975	diazepam|diazepam|diazepam	ChemicalEntity	135:281:325	136:282:326	4:8:10	1:NR:2	L2R	NON-CROSS	135-136	174-177	D003975	diazepam|diazepam|diazepam	ChemicalEntity	135:281:325	136:282:326	4:8:10	24408	NMDA - receptor	GeneOrGeneProduct	174	177	4	1:NR:2	L2R	NON-CROSS	309-310	325-326	D003975	diazepam|diazepam|diazepam	ChemicalEntity	135:281:325	136:282:326	4:8:10	D016291	dizocilpine maleate|MK801 hydrogen maleate|MK801	ChemicalEntity	178:183:309	180:186:310	4:4:9	1:Cotreatment:2	L2R	NON-CROSS	325-326	331-332	D003975	diazepam|diazepam|diazepam	ChemicalEntity	135:281:325	136:282:326	4:8:10	D001285	atropine sulfate|atropine sulfate|atropine|atropine|Atropine|atropine	ChemicalEntity	202:229:268:290:307:331	204:231:269:291:308:332	4:5:7:8:9:10	1:NR:2	L2R	CROSS	236-238	281-282	D003975	diazepam|diazepam|diazepam	ChemicalEntity	135:281:325	136:282:326	4:8:10	D000069463	olive oil	ChemicalEntity	236	238	5	1:NR:2	L2R	NON-CROSS	325-326	339-340	D003975	diazepam|diazepam|diazepam	ChemicalEntity	135:281:325	136:282:326	4:8:10	D011041	poisoning|poisoning	DiseaseOrPhenotypicFeature	305:339	306:340	8:10	1:Positive_Correlation:2	L2R	NON-CROSS	146-153	154-161	29290	A ( 1 ) - adenosine receptor	GeneOrGeneProduct	146	153	4	C048599	N ( 6 ) - cyclopentyl adenosine|CPA|CPA|CPA	ChemicalEntity	154:162:279:323	161:163:280:324	4:4:8:10	1:NR:2	L2R	NON-CROSS	146-153	174-177	29290	A ( 1 ) - adenosine receptor	GeneOrGeneProduct	146	153	4	24408	NMDA - receptor	GeneOrGeneProduct	174	177	4	1:NR:2	L2R	NON-CROSS	146-153	178-180	29290	A ( 1 ) - adenosine receptor	GeneOrGeneProduct	146	153	4	D016291	dizocilpine maleate|MK801 hydrogen maleate|MK801	ChemicalEntity	178:183:309	180:186:310	4:4:9	1:NR:2	L2R	NON-CROSS	146-153	202-204	29290	A ( 1 ) - adenosine receptor	GeneOrGeneProduct	146	153	4	D001285	atropine sulfate|atropine sulfate|atropine|atropine|Atropine|atropine	ChemicalEntity	202:229:268:290:307:331	204:231:269:291:308:332	4:5:7:8:9:10	1:NR:2	L2R	CROSS	146-153	236-238	29290	A ( 1 ) - adenosine receptor	GeneOrGeneProduct	146	153	4	D000069463	olive oil	ChemicalEntity	236	238	5	1:NR:2	L2R	CROSS	146-153	305-306	29290	A ( 1 ) - adenosine receptor	GeneOrGeneProduct	146	153	4	D011041	poisoning|poisoning	DiseaseOrPhenotypicFeature	305:339	306:340	8:10	1:NR:2	L2R	NON-CROSS	162-163	174-177	C048599	N ( 6 ) - cyclopentyl adenosine|CPA|CPA|CPA	ChemicalEntity	154:162:279:323	161:163:280:324	4:4:8:10	24408	NMDA - receptor	GeneOrGeneProduct	174	177	4	1:NR:2	L2R	NON-CROSS	309-310	323-324	C048599	N ( 6 ) - cyclopentyl adenosine|CPA|CPA|CPA	ChemicalEntity	154:162:279:323	161:163:280:324	4:4:8:10	D016291	dizocilpine maleate|MK801 hydrogen maleate|MK801	ChemicalEntity	178:183:309	180:186:310	4:4:9	1:Cotreatment:2	L2R	NON-CROSS	323-324	331-332	C048599	N ( 6 ) - cyclopentyl adenosine|CPA|CPA|CPA	ChemicalEntity	154:162:279:323	161:163:280:324	4:4:8:10	D001285	atropine sulfate|atropine sulfate|atropine|atropine|Atropine|atropine	ChemicalEntity	202:229:268:290:307:331	204:231:269:291:308:332	4:5:7:8:9:10	1:NR:2	L2R	CROSS	236-238	279-280	C048599	N ( 6 ) - cyclopentyl adenosine|CPA|CPA|CPA	ChemicalEntity	154:162:279:323	161:163:280:324	4:4:8:10	D000069463	olive oil	ChemicalEntity	236	238	5	1:NR:2	L2R	NON-CROSS	323-324	339-340	C048599	N ( 6 ) - cyclopentyl adenosine|CPA|CPA|CPA	ChemicalEntity	154:162:279:323	161:163:280:324	4:4:8:10	D011041	poisoning|poisoning	DiseaseOrPhenotypicFeature	305:339	306:340	8:10	1:Negative_Correlation:2	L2R	NON-CROSS	174-177	178-180	24408	NMDA - receptor	GeneOrGeneProduct	174	177	4	D016291	dizocilpine maleate|MK801 hydrogen maleate|MK801	ChemicalEntity	178:183:309	180:186:310	4:4:9	1:NR:2	L2R	NON-CROSS	174-177	202-204	24408	NMDA - receptor	GeneOrGeneProduct	174	177	4	D001285	atropine sulfate|atropine sulfate|atropine|atropine|Atropine|atropine	ChemicalEntity	202:229:268:290:307:331	204:231:269:291:308:332	4:5:7:8:9:10	1:NR:2	L2R	CROSS	174-177	236-238	24408	NMDA - receptor	GeneOrGeneProduct	174	177	4	D000069463	olive oil	ChemicalEntity	236	238	5	1:NR:2	L2R	CROSS	174-177	305-306	24408	NMDA - receptor	GeneOrGeneProduct	174	177	4	D011041	poisoning|poisoning	DiseaseOrPhenotypicFeature	305:339	306:340	8:10	1:NR:2	L2R	NON-CROSS	307-308	309-310	D016291	dizocilpine maleate|MK801 hydrogen maleate|MK801	ChemicalEntity	178:183:309	180:186:310	4:4:9	D001285	atropine sulfate|atropine sulfate|atropine|atropine|Atropine|atropine	ChemicalEntity	202:229:268:290:307:331	204:231:269:291:308:332	4:5:7:8:9:10	1:NR:2	L2R	CROSS	183-186	236-238	D016291	dizocilpine maleate|MK801 hydrogen maleate|MK801	ChemicalEntity	178:183:309	180:186:310	4:4:9	D000069463	olive oil	ChemicalEntity	236	238	5	1:NR:2	L2R	CROSS	305-306	309-310	D016291	dizocilpine maleate|MK801 hydrogen maleate|MK801	ChemicalEntity	178:183:309	180:186:310	4:4:9	D011041	poisoning|poisoning	DiseaseOrPhenotypicFeature	305:339	306:340	8:10	1:NR:2	L2R	NON-CROSS	229-231	236-238	D001285	atropine sulfate|atropine sulfate|atropine|atropine|Atropine|atropine	ChemicalEntity	202:229:268:290:307:331	204:231:269:291:308:332	4:5:7:8:9:10	D000069463	olive oil	ChemicalEntity	236	238	5	1:NR:2	L2R	NON-CROSS	305-306	307-308	D001285	atropine sulfate|atropine sulfate|atropine|atropine|Atropine|atropine	ChemicalEntity	202:229:268:290:307:331	204:231:269:291:308:332	4:5:7:8:9:10	D011041	poisoning|poisoning	DiseaseOrPhenotypicFeature	305:339	306:340	8:10	1:NR:2	L2R	CROSS	236-238	305-306	D000069463	olive oil	ChemicalEntity	236	238	5	D011041	poisoning|poisoning	DiseaseOrPhenotypicFeature	305:339	306:340	8:10
15673851	The activation of spinal N - methyl - D - aspartate receptors may contribute to degeneration of spinal motor neurons induced by neuraxial morphine after a noninjurious interval of spinal cord ischemia .|We investigated the relationship between the degeneration of spinal motor neurons and activation of N - methyl - d - aspartate ( NMDA ) receptors after neuraxial morphine following a noninjurious interval of aortic occlusion in rats .|Spinal cord ischemia was induced by aortic occlusion for 6 min with a balloon catheter .|In a microdialysis study , 10 muL of saline ( group C ; n = 8 ) or 30 mug of morphine ( group M ; n = 8 ) was injected intrathecally ( IT ) 0 . 5 h after reflow , and 30 mug of morphine ( group SM ; n = 8 ) or 10 muL of saline ( group SC ; n = 8 ) was injected IT 0 . 5 h after sham operation .|Microdialysis samples were collected preischemia , before IT injection , and at 2 , 4 , 8 , 24 , and 48 h of reperfusion ( after IT injection ) .|Second , we investigated the effect of IT MK - 801 ( 30 mug ) on the histopathologic changes in the spinal cord after morphine - induced spastic paraparesis .|After IT morphine , the cerebrospinal fluid ( CSF ) glutamate concentration was increased in group M relative to both baseline and group C ( P < 0 . 05 ) .|This increase persisted for 8 hrs .|IT MK - 801 significantly reduced the number of dark - stained alpha - motoneurons after morphine - induced spastic paraparesis compared with the saline group .|These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate , which is involved in NMDA receptor activation .|We suggest that opioids may be neurotoxic in the setting of spinal cord ischemia via NMDA receptor activation .	1:Association:2	R2L	NON-CROSS	60-61	47-58	D009020	morphine|morphine|morphine|morphine|morphine|morphine|morphine|morphine	ChemicalEntity	23:60:108:134:222:230:283:299	24:61:109:135:223:231:284:300	0:1:3:3:5:6:8:9	24408	N - methyl - D - aspartate receptors|N - methyl - d - aspartate ( NMDA ) receptors|NMDA receptor|NMDA receptor	GeneOrGeneProduct	4:47:315:334	12:58:317:336	0:1:9:10	1:Association:2	R2L	NON-CROSS	334-336	330-333	D020760	spinal cord ischemia|Spinal cord ischemia|spinal cord ischemia	DiseaseOrPhenotypicFeature	29:71:330	32:74:333	0:2:10	24408	N - methyl - D - aspartate receptors|N - methyl - d - aspartate ( NMDA ) receptors|NMDA receptor|NMDA receptor	GeneOrGeneProduct	4:47:315:334	12:58:317:336	0:1:9:10	1:NR:2	L2R	NON-CROSS	47-58	66-68	24408	N - methyl - D - aspartate receptors|N - methyl - d - aspartate ( NMDA ) receptors|NMDA receptor|NMDA receptor	GeneOrGeneProduct	4:47:315:334	12:58:317:336	0:1:9:10	D001157	aortic occlusion|aortic occlusion	DiseaseOrPhenotypicFeature	66:77	68:79	1:2	1:NR:2	L2R	CROSS	268-271	315-317	24408	N - methyl - D - aspartate receptors|N - methyl - d - aspartate ( NMDA ) receptors|NMDA receptor|NMDA receptor	GeneOrGeneProduct	4:47:315:334	12:58:317:336	0:1:9:10	D016291	MK - 801|MK - 801	ChemicalEntity	206:268	209:271	5:8	1:Association:2	R2L	NON-CROSS	315-317	301-303	D020336	spastic paraparesis|spastic paraparesis|spastic paraparesis	DiseaseOrPhenotypicFeature	225:286:301	227:288:303	5:8:9	24408	N - methyl - D - aspartate receptors|N - methyl - d - aspartate ( NMDA ) receptors|NMDA receptor|NMDA receptor	GeneOrGeneProduct	4:47:315:334	12:58:317:336	0:1:9:10	1:Association:2	R2L	NON-CROSS	315-317	309-310	D018698	glutamate|glutamate	ChemicalEntity	238:309	239:310	6:9	24408	N - methyl - D - aspartate receptors|N - methyl - d - aspartate ( NMDA ) receptors|NMDA receptor|NMDA receptor	GeneOrGeneProduct	4:47:315:334	12:58:317:336	0:1:9:10	1:Association:2	R2L	NON-CROSS	322-323	315-317	D000701	opioids	ChemicalEntity	322	323	10	24408	N - methyl - D - aspartate receptors|N - methyl - d - aspartate ( NMDA ) receptors|NMDA receptor|NMDA receptor	GeneOrGeneProduct	4:47:315:334	12:58:317:336	0:1:9:10	1:Association:2	R2L	NON-CROSS	325-326	315-317	D020258	neurotoxic	DiseaseOrPhenotypicFeature	325	326	10	24408	N - methyl - D - aspartate receptors|N - methyl - d - aspartate ( NMDA ) receptors|NMDA receptor|NMDA receptor	GeneOrGeneProduct	4:47:315:334	12:58:317:336	0:1:9:10	1:NR:2	L2R	NON-CROSS	23-24	29-32	D009020	morphine|morphine|morphine|morphine|morphine|morphine|morphine|morphine	ChemicalEntity	23:60:108:134:222:230:283:299	24:61:109:135:223:231:284:300	0:1:3:3:5:6:8:9	D020760	spinal cord ischemia|Spinal cord ischemia|spinal cord ischemia	DiseaseOrPhenotypicFeature	29:71:330	32:74:333	0:2:10	1:NR:2	L2R	NON-CROSS	60-61	66-68	D009020	morphine|morphine|morphine|morphine|morphine|morphine|morphine|morphine	ChemicalEntity	23:60:108:134:222:230:283:299	24:61:109:135:223:231:284:300	0:1:3:3:5:6:8:9	D001157	aortic occlusion|aortic occlusion	DiseaseOrPhenotypicFeature	66:77	68:79	1:2	1:Association:2	R2L	NON-CROSS	283-284	268-271	D016291	MK - 801|MK - 801	ChemicalEntity	206:268	209:271	5:8	D009020	morphine|morphine|morphine|morphine|morphine|morphine|morphine|morphine	ChemicalEntity	23:60:108:134:222:230:283:299	24:61:109:135:223:231:284:300	0:1:3:3:5:6:8:9	1:Positive_Correlation:2	L2R	NON-CROSS	299-300	301-303	D009020	morphine|morphine|morphine|morphine|morphine|morphine|morphine|morphine	ChemicalEntity	23:60:108:134:222:230:283:299	24:61:109:135:223:231:284:300	0:1:3:3:5:6:8:9	D020336	spastic paraparesis|spastic paraparesis|spastic paraparesis	DiseaseOrPhenotypicFeature	225:286:301	227:288:303	5:8:9	1:Positive_Correlation:2	L2R	NON-CROSS	230-231	238-239	D009020	morphine|morphine|morphine|morphine|morphine|morphine|morphine|morphine	ChemicalEntity	23:60:108:134:222:230:283:299	24:61:109:135:223:231:284:300	0:1:3:3:5:6:8:9	D018698	glutamate|glutamate	ChemicalEntity	238:309	239:310	6:9	1:NR:2	L2R	CROSS	299-300	322-323	D009020	morphine|morphine|morphine|morphine|morphine|morphine|morphine|morphine	ChemicalEntity	23:60:108:134:222:230:283:299	24:61:109:135:223:231:284:300	0:1:3:3:5:6:8:9	D000701	opioids	ChemicalEntity	322	323	10	1:NR:2	L2R	CROSS	299-300	325-326	D009020	morphine|morphine|morphine|morphine|morphine|morphine|morphine|morphine	ChemicalEntity	23:60:108:134:222:230:283:299	24:61:109:135:223:231:284:300	0:1:3:3:5:6:8:9	D020258	neurotoxic	DiseaseOrPhenotypicFeature	325	326	10	1:NR:2	L2R	CROSS	268-271	330-333	D020760	spinal cord ischemia|Spinal cord ischemia|spinal cord ischemia	DiseaseOrPhenotypicFeature	29:71:330	32:74:333	0:2:10	D016291	MK - 801|MK - 801	ChemicalEntity	206:268	209:271	5:8	1:NR:2	L2R	CROSS	309-310	330-333	D020760	spinal cord ischemia|Spinal cord ischemia|spinal cord ischemia	DiseaseOrPhenotypicFeature	29:71:330	32:74:333	0:2:10	D018698	glutamate|glutamate	ChemicalEntity	238:309	239:310	6:9	1:Association:2	R2L	NON-CROSS	330-333	322-323	D000701	opioids	ChemicalEntity	322	323	10	D020760	spinal cord ischemia|Spinal cord ischemia|spinal cord ischemia	DiseaseOrPhenotypicFeature	29:71:330	32:74:333	0:2:10	1:NR:2	L2R	CROSS	77-79	206-209	D001157	aortic occlusion|aortic occlusion	DiseaseOrPhenotypicFeature	66:77	68:79	1:2	D016291	MK - 801|MK - 801	ChemicalEntity	206:268	209:271	5:8	1:NR:2	L2R	CROSS	77-79	238-239	D001157	aortic occlusion|aortic occlusion	DiseaseOrPhenotypicFeature	66:77	68:79	1:2	D018698	glutamate|glutamate	ChemicalEntity	238:309	239:310	6:9	1:NR:2	L2R	CROSS	77-79	322-323	D001157	aortic occlusion|aortic occlusion	DiseaseOrPhenotypicFeature	66:77	68:79	1:2	D000701	opioids	ChemicalEntity	322	323	10	1:Association:2	L2R	NON-CROSS	268-271	286-288	D016291	MK - 801|MK - 801	ChemicalEntity	206:268	209:271	5:8	D020336	spastic paraparesis|spastic paraparesis|spastic paraparesis	DiseaseOrPhenotypicFeature	225:286:301	227:288:303	5:8:9	1:NR:2	L2R	CROSS	206-209	238-239	D016291	MK - 801|MK - 801	ChemicalEntity	206:268	209:271	5:8	D018698	glutamate|glutamate	ChemicalEntity	238:309	239:310	6:9	1:NR:2	L2R	CROSS	268-271	322-323	D016291	MK - 801|MK - 801	ChemicalEntity	206:268	209:271	5:8	D000701	opioids	ChemicalEntity	322	323	10	1:NR:2	L2R	CROSS	268-271	325-326	D016291	MK - 801|MK - 801	ChemicalEntity	206:268	209:271	5:8	D020258	neurotoxic	DiseaseOrPhenotypicFeature	325	326	10	1:NR:2	L2R	NON-CROSS	301-303	309-310	D020336	spastic paraparesis|spastic paraparesis|spastic paraparesis	DiseaseOrPhenotypicFeature	225:286:301	227:288:303	5:8:9	D018698	glutamate|glutamate	ChemicalEntity	238:309	239:310	6:9	1:NR:2	L2R	CROSS	301-303	322-323	D020336	spastic paraparesis|spastic paraparesis|spastic paraparesis	DiseaseOrPhenotypicFeature	225:286:301	227:288:303	5:8:9	D000701	opioids	ChemicalEntity	322	323	10	1:NR:2	L2R	CROSS	309-310	322-323	D018698	glutamate|glutamate	ChemicalEntity	238:309	239:310	6:9	D000701	opioids	ChemicalEntity	322	323	10	1:NR:2	L2R	CROSS	309-310	325-326	D018698	glutamate|glutamate	ChemicalEntity	238:309	239:310	6:9	D020258	neurotoxic	DiseaseOrPhenotypicFeature	325	326	10	1:Positive_Correlation:2	L2R	NON-CROSS	322-323	325-326	D000701	opioids	ChemicalEntity	322	323	10	D020258	neurotoxic	DiseaseOrPhenotypicFeature	325	326	10
15987266	Growth - associated protein 43 expression in hippocampal molecular layer of chronic epileptic rats treated with cycloheximide .|PURPOSE : GAP43 has been thought to be linked with mossy fiber sprouting ( MFS ) in various experimental models of epilepsy .|To investigate how GAP43 expression ( GAP43 - ir ) correlates with MFS , we assessed the intensity ( densitometry ) and extension ( width ) of GAP43 - ir in the inner molecular layer of the dentate gyrus ( IML ) of rats subject to status epilepticus induced by pilocarpine ( Pilo ) , previously injected or not with cycloheximide ( CHX ) , which has been shown to inhibit MFS .|METHODS : CHX was injected before the Pilo injection in adult Wistar rats .|The Pilo group was injected with the same drugs , except for CHX .|Animals were killed between 30 and 60 days later , and brain sections were processed for GAP43 immunohistochemistry .|RESULTS : Densitometry showed no significant difference regarding GAP43 - ir in the IML between Pilo , CHX + Pilo , and control groups .|However , the results of the width of the GAP43 - ir band in the IML showed that CHX + Pilo and control animals had a significantly larger band ( p = 0 . 03 ) as compared with that in the Pilo group .|CONCLUSIONS : Our current finding that animals in the CHX + Pilo group have a GAP43 - ir band in the IML , similar to that of controls , reinforces prior data on the blockade of MFS in these animals .|The change in GAP43 - ir present in Pilo - treated animals was a thinning of the band to a very narrow layer just above the granule cell layer that is likely to be associated with the loss of hilar cell projections that express GAP - 43 .	1:Association:2	L2R	NON-CROSS	39-40	44-45	29423	Growth - associated protein 43|GAP43|GAP43|GAP43|GAP43|GAP43|GAP43|GAP43|GAP43|GAP43|GAP - 43	GeneOrGeneProduct	0:20:44:47:68:158:169:195:246:275:316	5:21:45:48:69:159:170:196:247:276:319	0:1:2:2:2:5:6:7:8:9:9	D004827	epileptic|epilepsy	DiseaseOrPhenotypicFeature	12:39	13:40	0:1	1:Association:2	R2L	NON-CROSS	20-21	16-17	D003513	cycloheximide|cycloheximide|CHX|CHX|CHX|CHX|CHX|CHX	ChemicalEntity	16:101:103:116:140:178:204:240	17:102:104:117:141:179:205:241	0:2:2:3:4:6:7:8	29423	Growth - associated protein 43|GAP43|GAP43|GAP43|GAP43|GAP43|GAP43|GAP43|GAP43|GAP43|GAP - 43	GeneOrGeneProduct	0:20:44:47:68:158:169:195:246:275:316	5:21:45:48:69:159:170:196:247:276:319	0:1:2:2:2:5:6:7:8:9:9	1:NR:2	L2R	NON-CROSS	68-69	87-89	29423	Growth - associated protein 43|GAP43|GAP43|GAP43|GAP43|GAP43|GAP43|GAP43|GAP43|GAP43|GAP - 43	GeneOrGeneProduct	0:20:44:47:68:158:169:195:246:275:316	5:21:45:48:69:159:170:196:247:276:319	0:1:2:2:2:5:6:7:8:9:9	D013226	status epilepticus	DiseaseOrPhenotypicFeature	87	89	2	1:Association:2	R2L	NON-CROSS	246-247	242-243	D010862	pilocarpine|Pilo|Pilo|Pilo|Pilo|Pilo|Pilo|Pilo|Pilo|Pilo	ChemicalEntity	91:93:121:129:176:180:206:228:242:280	92:94:122:130:177:181:207:229:243:281	2:2:3:4:6:6:7:7:8:9	29423	Growth - associated protein 43|GAP43|GAP43|GAP43|GAP43|GAP43|GAP43|GAP43|GAP43|GAP43|GAP - 43	GeneOrGeneProduct	0:20:44:47:68:158:169:195:246:275:316	5:21:45:48:69:159:170:196:247:276:319	0:1:2:2:2:5:6:7:8:9:9	1:Negative_Correlation:2	L2R	NON-CROSS	12-13	16-17	D004827	epileptic|epilepsy	DiseaseOrPhenotypicFeature	12:39	13:40	0:1	D003513	cycloheximide|cycloheximide|CHX|CHX|CHX|CHX|CHX|CHX	ChemicalEntity	16:101:103:116:140:178:204:240	17:102:104:117:141:179:205:241	0:2:2:3:4:6:7:8	1:NR:2	L2R	CROSS	39-40	91-92	D004827	epileptic|epilepsy	DiseaseOrPhenotypicFeature	12:39	13:40	0:1	D010862	pilocarpine|Pilo|Pilo|Pilo|Pilo|Pilo|Pilo|Pilo|Pilo|Pilo	ChemicalEntity	91:93:121:129:176:180:206:228:242:280	92:94:122:130:177:181:207:229:243:281	2:2:3:4:6:6:7:7:8:9	1:NR:2	L2R	NON-CROSS	87-89	101-102	D003513	cycloheximide|cycloheximide|CHX|CHX|CHX|CHX|CHX|CHX	ChemicalEntity	16:101:103:116:140:178:204:240	17:102:104:117:141:179:205:241	0:2:2:3:4:6:7:8	D013226	status epilepticus	DiseaseOrPhenotypicFeature	87	89	2	1:NR:2	L2R	NON-CROSS	176-177	178-179	D003513	cycloheximide|cycloheximide|CHX|CHX|CHX|CHX|CHX|CHX	ChemicalEntity	16:101:103:116:140:178:204:240	17:102:104:117:141:179:205:241	0:2:2:3:4:6:7:8	D010862	pilocarpine|Pilo|Pilo|Pilo|Pilo|Pilo|Pilo|Pilo|Pilo|Pilo	ChemicalEntity	91:93:121:129:176:180:206:228:242:280	92:94:122:130:177:181:207:229:243:281	2:2:3:4:6:6:7:7:8:9	1:Positive_Correlation:2	L2R	NON-CROSS	87-89	91-92	D013226	status epilepticus	DiseaseOrPhenotypicFeature	87	89	2	D010862	pilocarpine|Pilo|Pilo|Pilo|Pilo|Pilo|Pilo|Pilo|Pilo|Pilo	ChemicalEntity	91:93:121:129:176:180:206:228:242:280	92:94:122:130:177:181:207:229:243:281	2:2:3:4:6:6:7:7:8:9
16428827	Daidzein activates choline acetyltransferase from MC - IXC cells and improves drug - induced amnesia .|The choline acetyltransferase ( ChAT ) activator , which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine ( ACh ) , is an important factor in the treatment of Alzheimer 's disease ( AD ) .|Methanolic extracts from Pueraria thunbergiana exhibited an activation effect ( 46 % ) on ChAT in vitro .|Via the sequential isolation of Pueraria thunbergiana , the active component was ultimately identified as daidzein ( 4 ' , 7 - dihydroxy - isoflavone ) .|In order to investigate the effects of daidzein from Pueraria thunbergiana on scopolamine - induced impairments of learning and memory , we conducted a series of in vivo tests .|Administration of daidzein ( 4 . 5 mg / kg body weight ) to mice was shown significantly to reverse scopolamine - induced amnesia , according to the results of a Y - maze test .|Injections of scopolamine into mice resulted in impaired performance on Y - maze tests ( a 37 % decreases in alternation behavior ) .|By way of contrast , mice treated with daidzein prior to the scopolamine injections were noticeably protected from this performance impairment ( an approximately 12 % - 21 % decrease in alternation behavior ) .|These results indicate that daidzein might play a role in acetylcholine biosynthesis as a ChAT activator , and that it also ameliorates scopolamine - induced amnesia .	1:Positive_Correlation:2	L2R	NON-CROSS	0-1	2-4	C004742	Daidzein|daidzein|4 ' , 7 - dihydroxy - isoflavone|daidzein|daidzein|daidzein|daidzein	ChemicalEntity	0:89:91:108:133:199:230	1:90:99:109:134:200:231	0:3:3:4:5:7:8	1103	choline acetyltransferase|choline acetyltransferase|ChAT|ChAT	GeneOrGeneProduct	2:17:20:70	4:19:21:71	0:1:1:2	1:Negative_Correlation:2	L2R	NON-CROSS	0-1	14-15	C004742	Daidzein|daidzein|4 ' , 7 - dihydroxy - isoflavone|daidzein|daidzein|daidzein|daidzein	ChemicalEntity	0:89:91:108:133:199:230	1:90:99:109:134:200:231	0:3:3:4:5:7:8	D000647	amnesia|amnesia|amnesia	DiseaseOrPhenotypicFeature	14:154:251	15:155:252	0:5:8	1:Association:2	L2R	NON-CROSS	230-231	236-237	C004742	Daidzein|daidzein|4 ' , 7 - dihydroxy - isoflavone|daidzein|daidzein|daidzein|daidzein	ChemicalEntity	0:89:91:108:133:199:230	1:90:99:109:134:200:231	0:3:3:4:5:7:8	D000109	acetylcholine|ACh|acetylcholine	ChemicalEntity	36:38:236	37:39:237	1:1:8	1:NR:2	L2R	CROSS	53-54	89-90	C004742	Daidzein|daidzein|4 ' , 7 - dihydroxy - isoflavone|daidzein|daidzein|daidzein|daidzein	ChemicalEntity	0:89:91:108:133:199:230	1:90:99:109:134:200:231	0:3:3:4:5:7:8	D000544	Alzheimer 's disease|AD	DiseaseOrPhenotypicFeature	49:53	52:54	1:1	1:NR:2	L2R	CROSS	56-57	89-90	C004742	Daidzein|daidzein|4 ' , 7 - dihydroxy - isoflavone|daidzein|daidzein|daidzein|daidzein	ChemicalEntity	0:89:91:108:133:199:230	1:90:99:109:134:200:231	0:3:3:4:5:7:8	D000432	Methanolic	ChemicalEntity	56	57	2	1:Negative_Correlation:2	L2R	NON-CROSS	199-200	203-204	C004742	Daidzein|daidzein|4 ' , 7 - dihydroxy - isoflavone|daidzein|daidzein|daidzein|daidzein	ChemicalEntity	0:89:91:108:133:199:230	1:90:99:109:134:200:231	0:3:3:4:5:7:8	D012601	scopolamine|scopolamine|scopolamine|scopolamine|scopolamine	ChemicalEntity	113:151:169:203:248	114:152:170:204:249	4:5:6:7:8	1:NR:2	L2R	NON-CROSS	108-109	116-121	C004742	Daidzein|daidzein|4 ' , 7 - dihydroxy - isoflavone|daidzein|daidzein|daidzein|daidzein	ChemicalEntity	0:89:91:108:133:199:230	1:90:99:109:134:200:231	0:3:3:4:5:7:8	D007859|D008569	impairments of learning and memory	DiseaseOrPhenotypicFeature	116	121	4	1:NR:2	L2R	NON-CROSS	230-231	240-241	C004742	Daidzein|daidzein|4 ' , 7 - dihydroxy - isoflavone|daidzein|daidzein|daidzein|daidzein	ChemicalEntity	0:89:91:108:133:199:230	1:90:99:109:134:200:231	0:3:3:4:5:7:8	12647	ChAT	GeneOrGeneProduct	240	241	8	1:NR:2	L2R	NON-CROSS	14-15	17-19	1103	choline acetyltransferase|choline acetyltransferase|ChAT|ChAT	GeneOrGeneProduct	2:17:20:70	4:19:21:71	0:1:1:2	D000647	amnesia|amnesia|amnesia	DiseaseOrPhenotypicFeature	14:154:251	15:155:252	0:5:8	1:Association:2	L2R	NON-CROSS	20-21	36-37	1103	choline acetyltransferase|choline acetyltransferase|ChAT|ChAT	GeneOrGeneProduct	2:17:20:70	4:19:21:71	0:1:1:2	D000109	acetylcholine|ACh|acetylcholine	ChemicalEntity	36:38:236	37:39:237	1:1:8	1:Association:2	L2R	NON-CROSS	53-54	70-71	1103	choline acetyltransferase|choline acetyltransferase|ChAT|ChAT	GeneOrGeneProduct	2:17:20:70	4:19:21:71	0:1:1:2	D000544	Alzheimer 's disease|AD	DiseaseOrPhenotypicFeature	49:53	52:54	1:1	1:Positive_Correlation:2	R2L	NON-CROSS	70-71	56-57	D000432	Methanolic	ChemicalEntity	56	57	2	1103	choline acetyltransferase|choline acetyltransferase|ChAT|ChAT	GeneOrGeneProduct	2:17:20:70	4:19:21:71	0:1:1:2	1:NR:2	L2R	CROSS	70-71	113-114	1103	choline acetyltransferase|choline acetyltransferase|ChAT|ChAT	GeneOrGeneProduct	2:17:20:70	4:19:21:71	0:1:1:2	D012601	scopolamine|scopolamine|scopolamine|scopolamine|scopolamine	ChemicalEntity	113:151:169:203:248	114:152:170:204:249	4:5:6:7:8	1:NR:2	L2R	CROSS	70-71	116-121	1103	choline acetyltransferase|choline acetyltransferase|ChAT|ChAT	GeneOrGeneProduct	2:17:20:70	4:19:21:71	0:1:1:2	D007859|D008569	impairments of learning and memory	DiseaseOrPhenotypicFeature	116	121	4	1:NR:2	L2R	CROSS	70-71	240-241	1103	choline acetyltransferase|choline acetyltransferase|ChAT|ChAT	GeneOrGeneProduct	2:17:20:70	4:19:21:71	0:1:1:2	12647	ChAT	GeneOrGeneProduct	240	241	8	1:NR:2	L2R	NON-CROSS	236-237	251-252	D000647	amnesia|amnesia|amnesia	DiseaseOrPhenotypicFeature	14:154:251	15:155:252	0:5:8	D000109	acetylcholine|ACh|acetylcholine	ChemicalEntity	36:38:236	37:39:237	1:1:8	1:NR:2	L2R	CROSS	14-15	56-57	D000647	amnesia|amnesia|amnesia	DiseaseOrPhenotypicFeature	14:154:251	15:155:252	0:5:8	D000432	Methanolic	ChemicalEntity	56	57	2	1:Positive_Correlation:2	R2L	NON-CROSS	154-155	151-152	D012601	scopolamine|scopolamine|scopolamine|scopolamine|scopolamine	ChemicalEntity	113:151:169:203:248	114:152:170:204:249	4:5:6:7:8	D000647	amnesia|amnesia|amnesia	DiseaseOrPhenotypicFeature	14:154:251	15:155:252	0:5:8	1:NR:2	L2R	NON-CROSS	240-241	251-252	D000647	amnesia|amnesia|amnesia	DiseaseOrPhenotypicFeature	14:154:251	15:155:252	0:5:8	12647	ChAT	GeneOrGeneProduct	240	241	8	1:Association:2	L2R	NON-CROSS	38-39	49-52	D000109	acetylcholine|ACh|acetylcholine	ChemicalEntity	36:38:236	37:39:237	1:1:8	D000544	Alzheimer 's disease|AD	DiseaseOrPhenotypicFeature	49:53	52:54	1:1	1:NR:2	L2R	CROSS	38-39	56-57	D000109	acetylcholine|ACh|acetylcholine	ChemicalEntity	36:38:236	37:39:237	1:1:8	D000432	Methanolic	ChemicalEntity	56	57	2	1:NR:2	L2R	NON-CROSS	236-237	248-249	D000109	acetylcholine|ACh|acetylcholine	ChemicalEntity	36:38:236	37:39:237	1:1:8	D012601	scopolamine|scopolamine|scopolamine|scopolamine|scopolamine	ChemicalEntity	113:151:169:203:248	114:152:170:204:249	4:5:6:7:8	1:NR:2	L2R	CROSS	38-39	116-121	D000109	acetylcholine|ACh|acetylcholine	ChemicalEntity	36:38:236	37:39:237	1:1:8	D007859|D008569	impairments of learning and memory	DiseaseOrPhenotypicFeature	116	121	4	1:NR:2	L2R	NON-CROSS	236-237	240-241	D000109	acetylcholine|ACh|acetylcholine	ChemicalEntity	36:38:236	37:39:237	1:1:8	12647	ChAT	GeneOrGeneProduct	240	241	8	1:NR:2	L2R	CROSS	53-54	56-57	D000544	Alzheimer 's disease|AD	DiseaseOrPhenotypicFeature	49:53	52:54	1:1	D000432	Methanolic	ChemicalEntity	56	57	2	1:NR:2	L2R	CROSS	53-54	113-114	D000544	Alzheimer 's disease|AD	DiseaseOrPhenotypicFeature	49:53	52:54	1:1	D012601	scopolamine|scopolamine|scopolamine|scopolamine|scopolamine	ChemicalEntity	113:151:169:203:248	114:152:170:204:249	4:5:6:7:8	1:NR:2	L2R	CROSS	53-54	240-241	D000544	Alzheimer 's disease|AD	DiseaseOrPhenotypicFeature	49:53	52:54	1:1	12647	ChAT	GeneOrGeneProduct	240	241	8	1:NR:2	L2R	CROSS	56-57	113-114	D000432	Methanolic	ChemicalEntity	56	57	2	D012601	scopolamine|scopolamine|scopolamine|scopolamine|scopolamine	ChemicalEntity	113:151:169:203:248	114:152:170:204:249	4:5:6:7:8	1:NR:2	L2R	CROSS	56-57	116-121	D000432	Methanolic	ChemicalEntity	56	57	2	D007859|D008569	impairments of learning and memory	DiseaseOrPhenotypicFeature	116	121	4	1:NR:2	L2R	CROSS	56-57	240-241	D000432	Methanolic	ChemicalEntity	56	57	2	12647	ChAT	GeneOrGeneProduct	240	241	8	1:Positive_Correlation:2	L2R	NON-CROSS	113-114	116-121	D012601	scopolamine|scopolamine|scopolamine|scopolamine|scopolamine	ChemicalEntity	113:151:169:203:248	114:152:170:204:249	4:5:6:7:8	D007859|D008569	impairments of learning and memory	DiseaseOrPhenotypicFeature	116	121	4	1:NR:2	L2R	NON-CROSS	240-241	248-249	D012601	scopolamine|scopolamine|scopolamine|scopolamine|scopolamine	ChemicalEntity	113:151:169:203:248	114:152:170:204:249	4:5:6:7:8	12647	ChAT	GeneOrGeneProduct	240	241	8	1:NR:2	L2R	CROSS	116-121	240-241	D007859|D008569	impairments of learning and memory	DiseaseOrPhenotypicFeature	116	121	4	12647	ChAT	GeneOrGeneProduct	240	241	8
16844102	Effect of alpha - tocopherol and deferoxamine on methamphetamine - induced neurotoxicity .|Methamphetamine ( MA ) - induced dopaminergic neurotoxicity is believed to be associated with the increased formation of free radicals .|This study examined the effect of alpha - tocopherol ( alpha - TC ) , a scavenger of reactive oxygen species , and deferoxamine ( DFO ) , an iron chelator , on the MA - induced neurotoxicity .|Male rats were treated with MA ( 10 mg / kg , every 2 h for four injections ) .|The rat received either alpha - TC ( 20 mg / kg ) intraperitoneally for 3 days and 30 min prior to MA administration or DFO ( 50 mg / kg ) subcutaneously 30 min before MA administration .|The concentrations of dopamine ( DA ) , serotonin and their metabolites decreased significantly after MA administration , which was inhibited by the alpha - TC and DFO pretreatment .|alpha - TC and DFO attenuated the MA - induced hyperthermia as well as the alterations in the locomotor activity .|The level of lipid peroxidation was higher and the reduced glutathione concentration was lower in the MA - treated rats .|These changes were significantly attenuated by alpha - TC and DFO .|This suggests that alpha - TC and DFO ameliorate the MA - induced neuronal damage by decreasing the level of oxidative stress .	1:NR:2	L2R	NON-CROSS	2-5	6-7	D024502	alpha - tocopherol|alpha - tocopherol|alpha - TC|alpha - TC|alpha - TC|alpha - TC|alpha - TC|alpha - TC	ChemicalEntity	2:40:44:97:155:162:210:219	5:43:47:100:158:165:213:222	0:2:2:4:5:6:8:9	D003676	deferoxamine|deferoxamine|DFO|DFO|DFO|DFO|DFO|DFO	ChemicalEntity	6:57:59:118:159:166:214:223	7:58:60:119:160:167:215:224	0:2:2:4:5:6:8:9	1:Negative_Correlation:2	L2R	NON-CROSS	2-5	8-9	D024502	alpha - tocopherol|alpha - tocopherol|alpha - TC|alpha - TC|alpha - TC|alpha - TC|alpha - TC|alpha - TC	ChemicalEntity	2:40:44:97:155:162:210:219	5:43:47:100:158:165:213:222	0:2:2:4:5:6:8:9	D008694	methamphetamine|Methamphetamine|MA|MA|MA|MA|MA|MA|MA|MA|MA	ChemicalEntity	8:13:15:68:78:115:129:147:169:199:226	9:14:16:69:79:116:130:148:170:200:227	0:1:1:2:3:4:4:5:6:7:9	1:NR:2	L2R	NON-CROSS	2-5	11-12	D024502	alpha - tocopherol|alpha - tocopherol|alpha - TC|alpha - TC|alpha - TC|alpha - TC|alpha - TC|alpha - TC	ChemicalEntity	2:40:44:97:155:162:210:219	5:43:47:100:158:165:213:222	0:2:2:4:5:6:8:9	D020258	neurotoxicity|neurotoxicity|neurotoxicity	DiseaseOrPhenotypicFeature	11:20:71	12:21:72	0:1:2	1:Positive_Correlation:2	L2R	NON-CROSS	2-5	19-20	D024502	alpha - tocopherol|alpha - tocopherol|alpha - TC|alpha - TC|alpha - TC|alpha - TC|alpha - TC|alpha - TC	ChemicalEntity	2:40:44:97:155:162:210:219	5:43:47:100:158:165:213:222	0:2:2:4:5:6:8:9	D004298	dopaminergic|dopamine|DA	ChemicalEntity	19:135:137	20:136:138	1:5:5	1:Association:2	L2R	NON-CROSS	44-47	52-55	D024502	alpha - tocopherol|alpha - tocopherol|alpha - TC|alpha - TC|alpha - TC|alpha - TC|alpha - TC|alpha - TC	ChemicalEntity	2:40:44:97:155:162:210:219	5:43:47:100:158:165:213:222	0:2:2:4:5:6:8:9	D017382	reactive oxygen species	ChemicalEntity	52	55	2	1:NR:2	L2R	NON-CROSS	44-47	63-64	D024502	alpha - tocopherol|alpha - tocopherol|alpha - TC|alpha - TC|alpha - TC|alpha - TC|alpha - TC|alpha - TC	ChemicalEntity	2:40:44:97:155:162:210:219	5:43:47:100:158:165:213:222	0:2:2:4:5:6:8:9	D007501	iron	ChemicalEntity	63	64	2	1:Positive_Correlation:2	L2R	NON-CROSS	140-141	155-158	D024502	alpha - tocopherol|alpha - tocopherol|alpha - TC|alpha - TC|alpha - TC|alpha - TC|alpha - TC|alpha - TC	ChemicalEntity	2:40:44:97:155:162:210:219	5:43:47:100:158:165:213:222	0:2:2:4:5:6:8:9	D012701	serotonin	ChemicalEntity	140	141	5	1:Negative_Correlation:2	L2R	NON-CROSS	162-165	172-173	D024502	alpha - tocopherol|alpha - tocopherol|alpha - TC|alpha - TC|alpha - TC|alpha - TC|alpha - TC|alpha - TC	ChemicalEntity	2:40:44:97:155:162:210:219	5:43:47:100:158:165:213:222	0:2:2:4:5:6:8:9	D005334	hyperthermia	DiseaseOrPhenotypicFeature	172	173	6	1:Association:2	L2R	CROSS	162-165	186-187	D024502	alpha - tocopherol|alpha - tocopherol|alpha - TC|alpha - TC|alpha - TC|alpha - TC|alpha - TC|alpha - TC	ChemicalEntity	2:40:44:97:155:162:210:219	5:43:47:100:158:165:213:222	0:2:2:4:5:6:8:9	D008055	lipid	ChemicalEntity	186	187	7	1:Association:2	L2R	CROSS	193-194	210-213	D024502	alpha - tocopherol|alpha - tocopherol|alpha - TC|alpha - TC|alpha - TC|alpha - TC|alpha - TC|alpha - TC	ChemicalEntity	2:40:44:97:155:162:210:219	5:43:47:100:158:165:213:222	0:2:2:4:5:6:8:9	D005978	glutathione	ChemicalEntity	193	194	7	1:Negative_Correlation:2	L2R	NON-CROSS	219-222	229-231	D024502	alpha - tocopherol|alpha - tocopherol|alpha - TC|alpha - TC|alpha - TC|alpha - TC|alpha - TC|alpha - TC	ChemicalEntity	2:40:44:97:155:162:210:219	5:43:47:100:158:165:213:222	0:2:2:4:5:6:8:9	D009422	neuronal damage	DiseaseOrPhenotypicFeature	229	231	9	1:Negative_Correlation:2	L2R	NON-CROSS	6-7	8-9	D003676	deferoxamine|deferoxamine|DFO|DFO|DFO|DFO|DFO|DFO	ChemicalEntity	6:57:59:118:159:166:214:223	7:58:60:119:160:167:215:224	0:2:2:4:5:6:8:9	D008694	methamphetamine|Methamphetamine|MA|MA|MA|MA|MA|MA|MA|MA|MA	ChemicalEntity	8:13:15:68:78:115:129:147:169:199:226	9:14:16:69:79:116:130:148:170:200:227	0:1:1:2:3:4:4:5:6:7:9	1:NR:2	L2R	NON-CROSS	6-7	11-12	D003676	deferoxamine|deferoxamine|DFO|DFO|DFO|DFO|DFO|DFO	ChemicalEntity	6:57:59:118:159:166:214:223	7:58:60:119:160:167:215:224	0:2:2:4:5:6:8:9	D020258	neurotoxicity|neurotoxicity|neurotoxicity	DiseaseOrPhenotypicFeature	11:20:71	12:21:72	0:1:2	1:Positive_Correlation:2	L2R	NON-CROSS	6-7	19-20	D003676	deferoxamine|deferoxamine|DFO|DFO|DFO|DFO|DFO|DFO	ChemicalEntity	6:57:59:118:159:166:214:223	7:58:60:119:160:167:215:224	0:2:2:4:5:6:8:9	D004298	dopaminergic|dopamine|DA	ChemicalEntity	19:135:137	20:136:138	1:5:5	1:NR:2	L2R	NON-CROSS	52-55	57-58	D003676	deferoxamine|deferoxamine|DFO|DFO|DFO|DFO|DFO|DFO	ChemicalEntity	6:57:59:118:159:166:214:223	7:58:60:119:160:167:215:224	0:2:2:4:5:6:8:9	D017382	reactive oxygen species	ChemicalEntity	52	55	2	1:Association:2	L2R	NON-CROSS	59-60	63-64	D003676	deferoxamine|deferoxamine|DFO|DFO|DFO|DFO|DFO|DFO	ChemicalEntity	6:57:59:118:159:166:214:223	7:58:60:119:160:167:215:224	0:2:2:4:5:6:8:9	D007501	iron	ChemicalEntity	63	64	2	1:Positive_Correlation:2	L2R	NON-CROSS	140-141	159-160	D003676	deferoxamine|deferoxamine|DFO|DFO|DFO|DFO|DFO|DFO	ChemicalEntity	6:57:59:118:159:166:214:223	7:58:60:119:160:167:215:224	0:2:2:4:5:6:8:9	D012701	serotonin	ChemicalEntity	140	141	5	1:Negative_Correlation:2	L2R	NON-CROSS	166-167	172-173	D003676	deferoxamine|deferoxamine|DFO|DFO|DFO|DFO|DFO|DFO	ChemicalEntity	6:57:59:118:159:166:214:223	7:58:60:119:160:167:215:224	0:2:2:4:5:6:8:9	D005334	hyperthermia	DiseaseOrPhenotypicFeature	172	173	6	1:Association:2	L2R	CROSS	166-167	186-187	D003676	deferoxamine|deferoxamine|DFO|DFO|DFO|DFO|DFO|DFO	ChemicalEntity	6:57:59:118:159:166:214:223	7:58:60:119:160:167:215:224	0:2:2:4:5:6:8:9	D008055	lipid	ChemicalEntity	186	187	7	1:Association:2	L2R	CROSS	193-194	214-215	D003676	deferoxamine|deferoxamine|DFO|DFO|DFO|DFO|DFO|DFO	ChemicalEntity	6:57:59:118:159:166:214:223	7:58:60:119:160:167:215:224	0:2:2:4:5:6:8:9	D005978	glutathione	ChemicalEntity	193	194	7	1:Negative_Correlation:2	L2R	NON-CROSS	223-224	229-231	D003676	deferoxamine|deferoxamine|DFO|DFO|DFO|DFO|DFO|DFO	ChemicalEntity	6:57:59:118:159:166:214:223	7:58:60:119:160:167:215:224	0:2:2:4:5:6:8:9	D009422	neuronal damage	DiseaseOrPhenotypicFeature	229	231	9	1:Positive_Correlation:2	L2R	NON-CROSS	11-12	13-14	D008694	methamphetamine|Methamphetamine|MA|MA|MA|MA|MA|MA|MA|MA|MA	ChemicalEntity	8:13:15:68:78:115:129:147:169:199:226	9:14:16:69:79:116:130:148:170:200:227	0:1:1:2:3:4:4:5:6:7:9	D020258	neurotoxicity|neurotoxicity|neurotoxicity	DiseaseOrPhenotypicFeature	11:20:71	12:21:72	0:1:2	1:Negative_Correlation:2	R2L	NON-CROSS	19-20	15-16	D004298	dopaminergic|dopamine|DA	ChemicalEntity	19:135:137	20:136:138	1:5:5	D008694	methamphetamine|Methamphetamine|MA|MA|MA|MA|MA|MA|MA|MA|MA	ChemicalEntity	8:13:15:68:78:115:129:147:169:199:226	9:14:16:69:79:116:130:148:170:200:227	0:1:1:2:3:4:4:5:6:7:9	1:NR:2	L2R	NON-CROSS	52-55	68-69	D008694	methamphetamine|Methamphetamine|MA|MA|MA|MA|MA|MA|MA|MA|MA	ChemicalEntity	8:13:15:68:78:115:129:147:169:199:226	9:14:16:69:79:116:130:148:170:200:227	0:1:1:2:3:4:4:5:6:7:9	D017382	reactive oxygen species	ChemicalEntity	52	55	2	1:NR:2	L2R	NON-CROSS	63-64	68-69	D008694	methamphetamine|Methamphetamine|MA|MA|MA|MA|MA|MA|MA|MA|MA	ChemicalEntity	8:13:15:68:78:115:129:147:169:199:226	9:14:16:69:79:116:130:148:170:200:227	0:1:1:2:3:4:4:5:6:7:9	D007501	iron	ChemicalEntity	63	64	2	1:Negative_Correlation:2	R2L	NON-CROSS	147-148	140-141	D012701	serotonin	ChemicalEntity	140	141	5	D008694	methamphetamine|Methamphetamine|MA|MA|MA|MA|MA|MA|MA|MA|MA	ChemicalEntity	8:13:15:68:78:115:129:147:169:199:226	9:14:16:69:79:116:130:148:170:200:227	0:1:1:2:3:4:4:5:6:7:9	1:Positive_Correlation:2	L2R	NON-CROSS	169-170	172-173	D008694	methamphetamine|Methamphetamine|MA|MA|MA|MA|MA|MA|MA|MA|MA	ChemicalEntity	8:13:15:68:78:115:129:147:169:199:226	9:14:16:69:79:116:130:148:170:200:227	0:1:1:2:3:4:4:5:6:7:9	D005334	hyperthermia	DiseaseOrPhenotypicFeature	172	173	6	1:Positive_Correlation:2	R2L	NON-CROSS	199-200	186-187	D008055	lipid	ChemicalEntity	186	187	7	D008694	methamphetamine|Methamphetamine|MA|MA|MA|MA|MA|MA|MA|MA|MA	ChemicalEntity	8:13:15:68:78:115:129:147:169:199:226	9:14:16:69:79:116:130:148:170:200:227	0:1:1:2:3:4:4:5:6:7:9	1:Negative_Correlation:2	R2L	NON-CROSS	199-200	193-194	D005978	glutathione	ChemicalEntity	193	194	7	D008694	methamphetamine|Methamphetamine|MA|MA|MA|MA|MA|MA|MA|MA|MA	ChemicalEntity	8:13:15:68:78:115:129:147:169:199:226	9:14:16:69:79:116:130:148:170:200:227	0:1:1:2:3:4:4:5:6:7:9	1:Positive_Correlation:2	L2R	NON-CROSS	226-227	229-231	D008694	methamphetamine|Methamphetamine|MA|MA|MA|MA|MA|MA|MA|MA|MA	ChemicalEntity	8:13:15:68:78:115:129:147:169:199:226	9:14:16:69:79:116:130:148:170:200:227	0:1:1:2:3:4:4:5:6:7:9	D009422	neuronal damage	DiseaseOrPhenotypicFeature	229	231	9	1:Positive_Correlation:2	R2L	NON-CROSS	20-21	19-20	D004298	dopaminergic|dopamine|DA	ChemicalEntity	19:135:137	20:136:138	1:5:5	D020258	neurotoxicity|neurotoxicity|neurotoxicity	DiseaseOrPhenotypicFeature	11:20:71	12:21:72	0:1:2	1:NR:2	L2R	NON-CROSS	52-55	71-72	D020258	neurotoxicity|neurotoxicity|neurotoxicity	DiseaseOrPhenotypicFeature	11:20:71	12:21:72	0:1:2	D017382	reactive oxygen species	ChemicalEntity	52	55	2	1:NR:2	L2R	NON-CROSS	63-64	71-72	D020258	neurotoxicity|neurotoxicity|neurotoxicity	DiseaseOrPhenotypicFeature	11:20:71	12:21:72	0:1:2	D007501	iron	ChemicalEntity	63	64	2	1:NR:2	L2R	CROSS	71-72	140-141	D020258	neurotoxicity|neurotoxicity|neurotoxicity	DiseaseOrPhenotypicFeature	11:20:71	12:21:72	0:1:2	D012701	serotonin	ChemicalEntity	140	141	5	1:NR:2	L2R	CROSS	71-72	186-187	D020258	neurotoxicity|neurotoxicity|neurotoxicity	DiseaseOrPhenotypicFeature	11:20:71	12:21:72	0:1:2	D008055	lipid	ChemicalEntity	186	187	7	1:NR:2	L2R	CROSS	71-72	193-194	D020258	neurotoxicity|neurotoxicity|neurotoxicity	DiseaseOrPhenotypicFeature	11:20:71	12:21:72	0:1:2	D005978	glutathione	ChemicalEntity	193	194	7	1:NR:2	L2R	CROSS	19-20	52-55	D004298	dopaminergic|dopamine|DA	ChemicalEntity	19:135:137	20:136:138	1:5:5	D017382	reactive oxygen species	ChemicalEntity	52	55	2	1:NR:2	L2R	CROSS	19-20	63-64	D004298	dopaminergic|dopamine|DA	ChemicalEntity	19:135:137	20:136:138	1:5:5	D007501	iron	ChemicalEntity	63	64	2	1:NR:2	L2R	NON-CROSS	137-138	140-141	D004298	dopaminergic|dopamine|DA	ChemicalEntity	19:135:137	20:136:138	1:5:5	D012701	serotonin	ChemicalEntity	140	141	5	1:NR:2	L2R	CROSS	137-138	172-173	D004298	dopaminergic|dopamine|DA	ChemicalEntity	19:135:137	20:136:138	1:5:5	D005334	hyperthermia	DiseaseOrPhenotypicFeature	172	173	6	1:NR:2	L2R	CROSS	137-138	186-187	D004298	dopaminergic|dopamine|DA	ChemicalEntity	19:135:137	20:136:138	1:5:5	D008055	lipid	ChemicalEntity	186	187	7	1:NR:2	L2R	CROSS	137-138	193-194	D004298	dopaminergic|dopamine|DA	ChemicalEntity	19:135:137	20:136:138	1:5:5	D005978	glutathione	ChemicalEntity	193	194	7	1:NR:2	L2R	CROSS	137-138	229-231	D004298	dopaminergic|dopamine|DA	ChemicalEntity	19:135:137	20:136:138	1:5:5	D009422	neuronal damage	DiseaseOrPhenotypicFeature	229	231	9	1:NR:2	L2R	NON-CROSS	52-55	63-64	D017382	reactive oxygen species	ChemicalEntity	52	55	2	D007501	iron	ChemicalEntity	63	64	2	1:NR:2	L2R	CROSS	52-55	140-141	D017382	reactive oxygen species	ChemicalEntity	52	55	2	D012701	serotonin	ChemicalEntity	140	141	5	1:NR:2	L2R	CROSS	52-55	172-173	D017382	reactive oxygen species	ChemicalEntity	52	55	2	D005334	hyperthermia	DiseaseOrPhenotypicFeature	172	173	6	1:NR:2	L2R	CROSS	52-55	186-187	D017382	reactive oxygen species	ChemicalEntity	52	55	2	D008055	lipid	ChemicalEntity	186	187	7	1:NR:2	L2R	CROSS	52-55	193-194	D017382	reactive oxygen species	ChemicalEntity	52	55	2	D005978	glutathione	ChemicalEntity	193	194	7	1:NR:2	L2R	CROSS	52-55	229-231	D017382	reactive oxygen species	ChemicalEntity	52	55	2	D009422	neuronal damage	DiseaseOrPhenotypicFeature	229	231	9	1:NR:2	L2R	CROSS	63-64	140-141	D007501	iron	ChemicalEntity	63	64	2	D012701	serotonin	ChemicalEntity	140	141	5	1:NR:2	L2R	CROSS	63-64	172-173	D007501	iron	ChemicalEntity	63	64	2	D005334	hyperthermia	DiseaseOrPhenotypicFeature	172	173	6	1:NR:2	L2R	CROSS	63-64	186-187	D007501	iron	ChemicalEntity	63	64	2	D008055	lipid	ChemicalEntity	186	187	7	1:NR:2	L2R	CROSS	63-64	193-194	D007501	iron	ChemicalEntity	63	64	2	D005978	glutathione	ChemicalEntity	193	194	7	1:NR:2	L2R	CROSS	63-64	229-231	D007501	iron	ChemicalEntity	63	64	2	D009422	neuronal damage	DiseaseOrPhenotypicFeature	229	231	9	1:NR:2	L2R	CROSS	140-141	172-173	D012701	serotonin	ChemicalEntity	140	141	5	D005334	hyperthermia	DiseaseOrPhenotypicFeature	172	173	6	1:NR:2	L2R	CROSS	140-141	186-187	D012701	serotonin	ChemicalEntity	140	141	5	D008055	lipid	ChemicalEntity	186	187	7	1:NR:2	L2R	CROSS	140-141	193-194	D012701	serotonin	ChemicalEntity	140	141	5	D005978	glutathione	ChemicalEntity	193	194	7	1:NR:2	L2R	CROSS	140-141	229-231	D012701	serotonin	ChemicalEntity	140	141	5	D009422	neuronal damage	DiseaseOrPhenotypicFeature	229	231	9	1:NR:2	L2R	CROSS	172-173	186-187	D005334	hyperthermia	DiseaseOrPhenotypicFeature	172	173	6	D008055	lipid	ChemicalEntity	186	187	7	1:NR:2	L2R	CROSS	172-173	193-194	D005334	hyperthermia	DiseaseOrPhenotypicFeature	172	173	6	D005978	glutathione	ChemicalEntity	193	194	7	1:NR:2	L2R	NON-CROSS	186-187	193-194	D008055	lipid	ChemicalEntity	186	187	7	D005978	glutathione	ChemicalEntity	193	194	7	1:NR:2	L2R	CROSS	186-187	229-231	D008055	lipid	ChemicalEntity	186	187	7	D009422	neuronal damage	DiseaseOrPhenotypicFeature	229	231	9	1:NR:2	L2R	CROSS	193-194	229-231	D005978	glutathione	ChemicalEntity	193	194	7	D009422	neuronal damage	DiseaseOrPhenotypicFeature	229	231	9
17562951	Cardiac Angiography in Renally Impaired Patients ( CARE ) study : a randomized double - blind trial of contrast - induced nephropathy in patients with chronic kidney disease .|BACKGROUND : No direct comparisons exist of the renal tolerability of the low - osmolality contrast medium iopamidol with that of the iso - osmolality contrast medium iodixanol in high - risk patients .|METHODS AND RESULTS : The present study is a multicenter , randomized , double - blind comparison of iopamidol and iodixanol in patients with chronic kidney disease ( estimated glomerular filtration rate , 20 to 59 mL / min ) who underwent cardiac angiography or percutaneous coronary interventions .|Serum creatinine ( SCr ) levels and estimated glomerular filtration rate were assessed at baseline and 2 to 5 days after receiving medications .|The primary outcome was a postdose SCr increase > or = 0 . 5 mg / dL ( 44 . 2 micromol / L ) over baseline .|Secondary outcomes were a postdose SCr increase > or = 25 % , a postdose estimated glomerular filtration rate decrease of > or = 25 % , and the mean peak change in SCr .|In 414 patients , contrast volume , presence of diabetes mellitus , use of N - acetylcysteine , mean baseline SCr , and estimated glomerular filtration rate were comparable in the 2 groups .|SCr increases > or = 0 . 5 mg / dL occurred in 4 . 4 % ( 9 of 204 patients ) after iopamidol and 6 . 7 % ( 14 of 210 patients ) after iodixanol ( P = 0 . 39 ) , whereas rates of SCr increases > or = 25 % were 9 . 8 % and 12 . 4 % , respectively ( P = 0 . 44 ) .|In patients with diabetes , SCr increases > or = 0 . 5 mg / dL were 5 . 1 % ( 4 of 78 patients ) with iopamidol and 13 . 0 % ( 12 of 92 patients ) with iodixanol ( P = 0 . 11 ) , whereas SCr increases > or = 25 % were 10 . 3 % and 15 . 2 % , respectively ( P = 0 . 37 ) .|Mean post - SCr increases were significantly less with iopamidol ( all patients : 0 . 07 versus 0 . 12 mg / dL , 6 . 2 versus 10 . 6 micromol / L , P = 0 . 03 ; patients with diabetes : 0 . 07 versus 0 . 16 mg / dL , 6 . 2 versus 14 . 1 micromol / L , P = 0 . 01 ) .|CONCLUSIONS : The rate of contrast - induced nephropathy , defined by multiple end points , is not statistically different after the intraarterial administration of iopamidol or iodixanol to high - risk patients , with or without diabetes mellitus .|Any true difference between the agents is small and not likely to be clinically significant .	1:Positive_Correlation:2	L2R	NON-CROSS	18-19	21-22	D003287	contrast|contrast medium|contrast medium|contrast|contrast	ChemicalEntity	18:44:54:203:467	19:46:56:204:468	0:1:1:6:10	D007674	nephropathy|nephropathy	DiseaseOrPhenotypicFeature	21:470	22:471	0:10	1:NR:2	L2R	NON-CROSS	18-19	25-28	D003287	contrast|contrast medium|contrast medium|contrast|contrast	ChemicalEntity	18:44:54:203:467	19:46:56:204:468	0:1:1:6:10	D051436	chronic kidney disease|chronic kidney disease	DiseaseOrPhenotypicFeature	25:87	28:90	0:2	1:NR:2	L2R	NON-CROSS	44-46	46-47	D003287	contrast|contrast medium|contrast medium|contrast|contrast	ChemicalEntity	18:44:54:203:467	19:46:56:204:468	0:1:1:6:10	D007479	iopamidol|iopamidol|iopamidol|iopamidol|iopamidol|iopamidol	ChemicalEntity	46:81:257:337:396:487	47:82:258:338:397:488	1:2:7:8:9:10	1:NR:2	L2R	NON-CROSS	54-56	56-57	D003287	contrast|contrast medium|contrast medium|contrast|contrast	ChemicalEntity	18:44:54:203:467	19:46:56:204:468	0:1:1:6:10	C044834	iodixanol|iodixanol|iodixanol|iodixanol|iodixanol	ChemicalEntity	56:83:270:350:489	57:84:271:351:490	1:2:7:8:10	1:NR:2	L2R	NON-CROSS	197-198	203-204	D003287	contrast|contrast medium|contrast medium|contrast|contrast	ChemicalEntity	18:44:54:203:467	19:46:56:204:468	0:1:1:6:10	D003404	creatinine|SCr|SCr|SCr|SCr|SCr|SCr|SCr|SCr|SCr|SCr	ChemicalEntity	113:115:142:169:197:219:233:282:314:360:390	114:116:143:170:198:220:234:283:315:361:391	3:3:4:5:5:6:7:7:8:8:9	1:NR:2	L2R	NON-CROSS	203-204	208-210	D003287	contrast|contrast medium|contrast medium|contrast|contrast	ChemicalEntity	18:44:54:203:467	19:46:56:204:468	0:1:1:6:10	D003920	diabetes mellitus|diabetes|diabetes|diabetes mellitus	DiseaseOrPhenotypicFeature	208:312:431:499	210:313:432:501	6:8:9:10	1:NR:2	L2R	NON-CROSS	203-204	213-216	D003287	contrast|contrast medium|contrast medium|contrast|contrast	ChemicalEntity	18:44:54:203:467	19:46:56:204:468	0:1:1:6:10	D000111	N - acetylcysteine	ChemicalEntity	213	216	6	1:Positive_Correlation:2	R2L	NON-CROSS	487-488	470-471	D007479	iopamidol|iopamidol|iopamidol|iopamidol|iopamidol|iopamidol	ChemicalEntity	46:81:257:337:396:487	47:82:258:338:397:488	1:2:7:8:9:10	D007674	nephropathy|nephropathy	DiseaseOrPhenotypicFeature	21:470	22:471	0:10	1:Positive_Correlation:2	R2L	NON-CROSS	489-490	470-471	C044834	iodixanol|iodixanol|iodixanol|iodixanol|iodixanol	ChemicalEntity	56:83:270:350:489	57:84:271:351:490	1:2:7:8:10	D007674	nephropathy|nephropathy	DiseaseOrPhenotypicFeature	21:470	22:471	0:10	1:NR:2	L2R	CROSS	390-391	470-471	D007674	nephropathy|nephropathy	DiseaseOrPhenotypicFeature	21:470	22:471	0:10	D003404	creatinine|SCr|SCr|SCr|SCr|SCr|SCr|SCr|SCr|SCr|SCr	ChemicalEntity	113:115:142:169:197:219:233:282:314:360:390	114:116:143:170:198:220:234:283:315:361:391	3:3:4:5:5:6:7:7:8:8:9	1:NR:2	L2R	CROSS	21-22	213-216	D007674	nephropathy|nephropathy	DiseaseOrPhenotypicFeature	21:470	22:471	0:10	D000111	N - acetylcysteine	ChemicalEntity	213	216	6	1:NR:2	L2R	NON-CROSS	81-82	87-90	D051436	chronic kidney disease|chronic kidney disease	DiseaseOrPhenotypicFeature	25:87	28:90	0:2	D007479	iopamidol|iopamidol|iopamidol|iopamidol|iopamidol|iopamidol	ChemicalEntity	46:81:257:337:396:487	47:82:258:338:397:488	1:2:7:8:9:10	1:NR:2	L2R	NON-CROSS	83-84	87-90	D051436	chronic kidney disease|chronic kidney disease	DiseaseOrPhenotypicFeature	25:87	28:90	0:2	C044834	iodixanol|iodixanol|iodixanol|iodixanol|iodixanol	ChemicalEntity	56:83:270:350:489	57:84:271:351:490	1:2:7:8:10	1:NR:2	L2R	CROSS	87-90	113-114	D051436	chronic kidney disease|chronic kidney disease	DiseaseOrPhenotypicFeature	25:87	28:90	0:2	D003404	creatinine|SCr|SCr|SCr|SCr|SCr|SCr|SCr|SCr|SCr|SCr	ChemicalEntity	113:115:142:169:197:219:233:282:314:360:390	114:116:143:170:198:220:234:283:315:361:391	3:3:4:5:5:6:7:7:8:8:9	1:NR:2	L2R	CROSS	87-90	213-216	D051436	chronic kidney disease|chronic kidney disease	DiseaseOrPhenotypicFeature	25:87	28:90	0:2	D000111	N - acetylcysteine	ChemicalEntity	213	216	6	1:Comparison:2	L2R	NON-CROSS	81-82	83-84	D007479	iopamidol|iopamidol|iopamidol|iopamidol|iopamidol|iopamidol	ChemicalEntity	46:81:257:337:396:487	47:82:258:338:397:488	1:2:7:8:9:10	C044834	iodixanol|iodixanol|iodixanol|iodixanol|iodixanol	ChemicalEntity	56:83:270:350:489	57:84:271:351:490	1:2:7:8:10	1:Positive_Correlation:2	R2L	NON-CROSS	396-397	390-391	D003404	creatinine|SCr|SCr|SCr|SCr|SCr|SCr|SCr|SCr|SCr|SCr	ChemicalEntity	113:115:142:169:197:219:233:282:314:360:390	114:116:143:170:198:220:234:283:315:361:391	3:3:4:5:5:6:7:7:8:8:9	D007479	iopamidol|iopamidol|iopamidol|iopamidol|iopamidol|iopamidol	ChemicalEntity	46:81:257:337:396:487	47:82:258:338:397:488	1:2:7:8:9:10	1:NR:2	L2R	NON-CROSS	487-488	499-501	D007479	iopamidol|iopamidol|iopamidol|iopamidol|iopamidol|iopamidol	ChemicalEntity	46:81:257:337:396:487	47:82:258:338:397:488	1:2:7:8:9:10	D003920	diabetes mellitus|diabetes|diabetes|diabetes mellitus	DiseaseOrPhenotypicFeature	208:312:431:499	210:313:432:501	6:8:9:10	1:NR:2	L2R	CROSS	213-216	257-258	D007479	iopamidol|iopamidol|iopamidol|iopamidol|iopamidol|iopamidol	ChemicalEntity	46:81:257:337:396:487	47:82:258:338:397:488	1:2:7:8:9:10	D000111	N - acetylcysteine	ChemicalEntity	213	216	6	1:Positive_Correlation:2	R2L	NON-CROSS	360-361	350-351	D003404	creatinine|SCr|SCr|SCr|SCr|SCr|SCr|SCr|SCr|SCr|SCr	ChemicalEntity	113:115:142:169:197:219:233:282:314:360:390	114:116:143:170:198:220:234:283:315:361:391	3:3:4:5:5:6:7:7:8:8:9	C044834	iodixanol|iodixanol|iodixanol|iodixanol|iodixanol	ChemicalEntity	56:83:270:350:489	57:84:271:351:490	1:2:7:8:10	1:NR:2	L2R	NON-CROSS	489-490	499-501	C044834	iodixanol|iodixanol|iodixanol|iodixanol|iodixanol	ChemicalEntity	56:83:270:350:489	57:84:271:351:490	1:2:7:8:10	D003920	diabetes mellitus|diabetes|diabetes|diabetes mellitus	DiseaseOrPhenotypicFeature	208:312:431:499	210:313:432:501	6:8:9:10	1:NR:2	L2R	CROSS	213-216	270-271	C044834	iodixanol|iodixanol|iodixanol|iodixanol|iodixanol	ChemicalEntity	56:83:270:350:489	57:84:271:351:490	1:2:7:8:10	D000111	N - acetylcysteine	ChemicalEntity	213	216	6	1:NR:2	L2R	NON-CROSS	312-313	314-315	D003404	creatinine|SCr|SCr|SCr|SCr|SCr|SCr|SCr|SCr|SCr|SCr	ChemicalEntity	113:115:142:169:197:219:233:282:314:360:390	114:116:143:170:198:220:234:283:315:361:391	3:3:4:5:5:6:7:7:8:8:9	D003920	diabetes mellitus|diabetes|diabetes|diabetes mellitus	DiseaseOrPhenotypicFeature	208:312:431:499	210:313:432:501	6:8:9:10	1:NR:2	L2R	NON-CROSS	213-216	219-220	D003404	creatinine|SCr|SCr|SCr|SCr|SCr|SCr|SCr|SCr|SCr|SCr	ChemicalEntity	113:115:142:169:197:219:233:282:314:360:390	114:116:143:170:198:220:234:283:315:361:391	3:3:4:5:5:6:7:7:8:8:9	D000111	N - acetylcysteine	ChemicalEntity	213	216	6	1:NR:2	L2R	NON-CROSS	208-210	213-216	D003920	diabetes mellitus|diabetes|diabetes|diabetes mellitus	DiseaseOrPhenotypicFeature	208:312:431:499	210:313:432:501	6:8:9:10	D000111	N - acetylcysteine	ChemicalEntity	213	216	6
17879945	Estrogen prevents cholesteryl ester accumulation in macrophages induced by the HIV protease inhibitor ritonavir .|Individuals with HIV can now live long lives with drug therapy that often includes protease inhibitors such as ritonavir .|Many patients , however , develop negative long - term side effects such as premature atherosclerosis .|We have previously demonstrated that ritonavir treatment increases atherosclerotic lesion formation in male mice to a greater extent than in female mice .|Furthermore , peripheral blood monocytes isolated from ritonavir - treated females had less cholesteryl ester accumulation .|In the present study , we have investigated the molecular mechanisms by which female hormones influence cholesterol metabolism in macrophages in response to the HIV protease inhibitor ritonavir .|We have utilized the human monocyte cell line , THP - 1 as a model to address this question .|Briefly , cells were differentiated for 72 h with 100 nM PMA to obtain a macrophage - like phenotype in the presence or absence of 1 nM 17beta - estradiol ( E2 ) , 100 nM progesterone or vehicle ( 0 . 01 % ethanol ) .|Cells were then treated with 30 ng / ml ritonavir or vehicle in the presence of aggregated LDL for 24 h .|Cell extracts were harvested , and lipid or total RNA was isolated .|E2 decreased the accumulation of cholesteryl esters in macrophages following ritonavir treatment .|Ritonavir increased the expression of the scavenger receptor , CD36 mRNA , responsible for the uptake of LDL .|Additionally , ritonavir treatment selectively increased the relative levels of PPARgamma mRNA , a transcription factor responsible for the regulation of CD36 mRNA expression .|Treatment with E2 , however , failed to prevent these increases at the mRNA level .|E2 did , however , significantly suppress CD36 protein levels as measured by fluorescent immunocytochemistry .|This data suggests that E2 modifies the expression of CD36 at the level of protein expression in monocyte - derived macrophages resulting in reduced cholesteryl ester accumulation following ritonavir treatment .	1:Negative_Correlation:2	L2R	NON-CROSS	0-1	2-4	D004967	Estrogen	ChemicalEntity	0	1	0	D002788	cholesteryl ester|cholesteryl ester|cholesteryl esters|cholesteryl ester	ChemicalEntity	2:88:228:336	4:90:230:338	0:4:10:15	1:NR:2	L2R	NON-CROSS	0-1	10-12	D004967	Estrogen	ChemicalEntity	0	1	0	-	HIV protease|HIV protease	GeneOrGeneProduct	10:116	12:118	0:5	1:NR:2	L2R	NON-CROSS	0-1	13-14	D004967	Estrogen	ChemicalEntity	0	1	0	D019438	ritonavir|ritonavir|ritonavir|ritonavir|ritonavir|ritonavir|ritonavir|Ritonavir|ritonavir|ritonavir	ChemicalEntity	13:33:57:82:119:197:233:236:257:340	14:34:58:83:120:198:234:237:258:341	0:1:3:4:5:8:10:11:12:15	1:NR:2	L2R	CROSS	0-1	49-51	D004967	Estrogen	ChemicalEntity	0	1	0	D050197	premature atherosclerosis|atherosclerotic lesion	DiseaseOrPhenotypicFeature	49:60	51:62	2:3	1:NR:2	L2R	CROSS	0-1	108-109	D004967	Estrogen	ChemicalEntity	0	1	0	D002784	cholesterol	ChemicalEntity	108	109	5	1:NR:2	L2R	CROSS	0-1	168-171	D004967	Estrogen	ChemicalEntity	0	1	0	D004958	17beta - estradiol|E2|E2|E2|E2|E2	ChemicalEntity	168:172:223:282:296:316	171:173:224:283:297:317	7:7:10:13:14:15	1:NR:2	L2R	CROSS	0-1	177-178	D004967	Estrogen	ChemicalEntity	0	1	0	D011374	progesterone	ChemicalEntity	177	178	7	1:NR:2	L2R	CROSS	0-1	185-186	D004967	Estrogen	ChemicalEntity	0	1	0	D000431	ethanol	ChemicalEntity	185	186	7	1:NR:2	L2R	CROSS	0-1	216-217	D004967	Estrogen	ChemicalEntity	0	1	0	D008055	lipid	ChemicalEntity	216	217	9	1:NR:2	L2R	CROSS	0-1	245-246	D004967	Estrogen	ChemicalEntity	0	1	0	948	CD36|CD36|CD36|CD36	GeneOrGeneProduct	245:276:303:321	246:277:304:322	11:12:14:15	1:NR:2	L2R	CROSS	0-1	265-266	D004967	Estrogen	ChemicalEntity	0	1	0	5468	PPARgamma	GeneOrGeneProduct	265	266	12	1:NR:2	L2R	NON-CROSS	2-4	10-12	D002788	cholesteryl ester|cholesteryl ester|cholesteryl esters|cholesteryl ester	ChemicalEntity	2:88:228:336	4:90:230:338	0:4:10:15	-	HIV protease|HIV protease	GeneOrGeneProduct	10:116	12:118	0:5	1:Negative_Correlation:2	R2L	NON-CROSS	340-341	336-338	D019438	ritonavir|ritonavir|ritonavir|ritonavir|ritonavir|ritonavir|ritonavir|Ritonavir|ritonavir|ritonavir	ChemicalEntity	13:33:57:82:119:197:233:236:257:340	14:34:58:83:120:198:234:237:258:341	0:1:3:4:5:8:10:11:12:15	D002788	cholesteryl ester|cholesteryl ester|cholesteryl esters|cholesteryl ester	ChemicalEntity	2:88:228:336	4:90:230:338	0:4:10:15	1:NR:2	L2R	CROSS	60-62	88-90	D002788	cholesteryl ester|cholesteryl ester|cholesteryl esters|cholesteryl ester	ChemicalEntity	2:88:228:336	4:90:230:338	0:4:10:15	D050197	premature atherosclerosis|atherosclerotic lesion	DiseaseOrPhenotypicFeature	49:60	51:62	2:3	1:NR:2	L2R	CROSS	88-90	108-109	D002788	cholesteryl ester|cholesteryl ester|cholesteryl esters|cholesteryl ester	ChemicalEntity	2:88:228:336	4:90:230:338	0:4:10:15	D002784	cholesterol	ChemicalEntity	108	109	5	1:Negative_Correlation:2	R2L	NON-CROSS	228-230	223-224	D004958	17beta - estradiol|E2|E2|E2|E2|E2	ChemicalEntity	168:172:223:282:296:316	171:173:224:283:297:317	7:7:10:13:14:15	D002788	cholesteryl ester|cholesteryl ester|cholesteryl esters|cholesteryl ester	ChemicalEntity	2:88:228:336	4:90:230:338	0:4:10:15	1:NR:2	L2R	CROSS	177-178	228-230	D002788	cholesteryl ester|cholesteryl ester|cholesteryl esters|cholesteryl ester	ChemicalEntity	2:88:228:336	4:90:230:338	0:4:10:15	D011374	progesterone	ChemicalEntity	177	178	7	1:NR:2	L2R	CROSS	185-186	228-230	D002788	cholesteryl ester|cholesteryl ester|cholesteryl esters|cholesteryl ester	ChemicalEntity	2:88:228:336	4:90:230:338	0:4:10:15	D000431	ethanol	ChemicalEntity	185	186	7	1:NR:2	L2R	CROSS	216-217	228-230	D002788	cholesteryl ester|cholesteryl ester|cholesteryl esters|cholesteryl ester	ChemicalEntity	2:88:228:336	4:90:230:338	0:4:10:15	D008055	lipid	ChemicalEntity	216	217	9	1:Association:2	R2L	NON-CROSS	336-338	321-322	948	CD36|CD36|CD36|CD36	GeneOrGeneProduct	245:276:303:321	246:277:304:322	11:12:14:15	D002788	cholesteryl ester|cholesteryl ester|cholesteryl esters|cholesteryl ester	ChemicalEntity	2:88:228:336	4:90:230:338	0:4:10:15	1:NR:2	L2R	CROSS	228-230	265-266	D002788	cholesteryl ester|cholesteryl ester|cholesteryl esters|cholesteryl ester	ChemicalEntity	2:88:228:336	4:90:230:338	0:4:10:15	5468	PPARgamma	GeneOrGeneProduct	265	266	12	1:NR:2	L2R	NON-CROSS	10-12	13-14	-	HIV protease|HIV protease	GeneOrGeneProduct	10:116	12:118	0:5	D019438	ritonavir|ritonavir|ritonavir|ritonavir|ritonavir|ritonavir|ritonavir|Ritonavir|ritonavir|ritonavir	ChemicalEntity	13:33:57:82:119:197:233:236:257:340	14:34:58:83:120:198:234:237:258:341	0:1:3:4:5:8:10:11:12:15	1:NR:2	L2R	CROSS	10-12	49-51	-	HIV protease|HIV protease	GeneOrGeneProduct	10:116	12:118	0:5	D050197	premature atherosclerosis|atherosclerotic lesion	DiseaseOrPhenotypicFeature	49:60	51:62	2:3	1:NR:2	L2R	NON-CROSS	108-109	116-118	-	HIV protease|HIV protease	GeneOrGeneProduct	10:116	12:118	0:5	D002784	cholesterol	ChemicalEntity	108	109	5	1:NR:2	L2R	CROSS	116-118	168-171	-	HIV protease|HIV protease	GeneOrGeneProduct	10:116	12:118	0:5	D004958	17beta - estradiol|E2|E2|E2|E2|E2	ChemicalEntity	168:172:223:282:296:316	171:173:224:283:297:317	7:7:10:13:14:15	1:NR:2	L2R	CROSS	116-118	177-178	-	HIV protease|HIV protease	GeneOrGeneProduct	10:116	12:118	0:5	D011374	progesterone	ChemicalEntity	177	178	7	1:NR:2	L2R	CROSS	116-118	185-186	-	HIV protease|HIV protease	GeneOrGeneProduct	10:116	12:118	0:5	D000431	ethanol	ChemicalEntity	185	186	7	1:NR:2	L2R	CROSS	116-118	216-217	-	HIV protease|HIV protease	GeneOrGeneProduct	10:116	12:118	0:5	D008055	lipid	ChemicalEntity	216	217	9	1:NR:2	L2R	CROSS	116-118	245-246	-	HIV protease|HIV protease	GeneOrGeneProduct	10:116	12:118	0:5	948	CD36|CD36|CD36|CD36	GeneOrGeneProduct	245:276:303:321	246:277:304:322	11:12:14:15	1:NR:2	L2R	CROSS	116-118	265-266	-	HIV protease|HIV protease	GeneOrGeneProduct	10:116	12:118	0:5	5468	PPARgamma	GeneOrGeneProduct	265	266	12	1:Positive_Correlation:2	L2R	NON-CROSS	57-58	60-62	D019438	ritonavir|ritonavir|ritonavir|ritonavir|ritonavir|ritonavir|ritonavir|Ritonavir|ritonavir|ritonavir	ChemicalEntity	13:33:57:82:119:197:233:236:257:340	14:34:58:83:120:198:234:237:258:341	0:1:3:4:5:8:10:11:12:15	D050197	premature atherosclerosis|atherosclerotic lesion	DiseaseOrPhenotypicFeature	49:60	51:62	2:3	1:NR:2	L2R	NON-CROSS	108-109	119-120	D019438	ritonavir|ritonavir|ritonavir|ritonavir|ritonavir|ritonavir|ritonavir|Ritonavir|ritonavir|ritonavir	ChemicalEntity	13:33:57:82:119:197:233:236:257:340	14:34:58:83:120:198:234:237:258:341	0:1:3:4:5:8:10:11:12:15	D002784	cholesterol	ChemicalEntity	108	109	5	1:Association:2	L2R	NON-CROSS	223-224	233-234	D019438	ritonavir|ritonavir|ritonavir|ritonavir|ritonavir|ritonavir|ritonavir|Ritonavir|ritonavir|ritonavir	ChemicalEntity	13:33:57:82:119:197:233:236:257:340	14:34:58:83:120:198:234:237:258:341	0:1:3:4:5:8:10:11:12:15	D004958	17beta - estradiol|E2|E2|E2|E2|E2	ChemicalEntity	168:172:223:282:296:316	171:173:224:283:297:317	7:7:10:13:14:15	1:NR:2	L2R	CROSS	177-178	197-198	D019438	ritonavir|ritonavir|ritonavir|ritonavir|ritonavir|ritonavir|ritonavir|Ritonavir|ritonavir|ritonavir	ChemicalEntity	13:33:57:82:119:197:233:236:257:340	14:34:58:83:120:198:234:237:258:341	0:1:3:4:5:8:10:11:12:15	D011374	progesterone	ChemicalEntity	177	178	7	1:NR:2	L2R	CROSS	185-186	197-198	D019438	ritonavir|ritonavir|ritonavir|ritonavir|ritonavir|ritonavir|ritonavir|Ritonavir|ritonavir|ritonavir	ChemicalEntity	13:33:57:82:119:197:233:236:257:340	14:34:58:83:120:198:234:237:258:341	0:1:3:4:5:8:10:11:12:15	D000431	ethanol	ChemicalEntity	185	186	7	1:NR:2	L2R	CROSS	216-217	233-234	D019438	ritonavir|ritonavir|ritonavir|ritonavir|ritonavir|ritonavir|ritonavir|Ritonavir|ritonavir|ritonavir	ChemicalEntity	13:33:57:82:119:197:233:236:257:340	14:34:58:83:120:198:234:237:258:341	0:1:3:4:5:8:10:11:12:15	D008055	lipid	ChemicalEntity	216	217	9	1:Positive_Correlation:2	L2R	NON-CROSS	236-237	245-246	D019438	ritonavir|ritonavir|ritonavir|ritonavir|ritonavir|ritonavir|ritonavir|Ritonavir|ritonavir|ritonavir	ChemicalEntity	13:33:57:82:119:197:233:236:257:340	14:34:58:83:120:198:234:237:258:341	0:1:3:4:5:8:10:11:12:15	948	CD36|CD36|CD36|CD36	GeneOrGeneProduct	245:276:303:321	246:277:304:322	11:12:14:15	1:Positive_Correlation:2	L2R	NON-CROSS	257-258	265-266	D019438	ritonavir|ritonavir|ritonavir|ritonavir|ritonavir|ritonavir|ritonavir|Ritonavir|ritonavir|ritonavir	ChemicalEntity	13:33:57:82:119:197:233:236:257:340	14:34:58:83:120:198:234:237:258:341	0:1:3:4:5:8:10:11:12:15	5468	PPARgamma	GeneOrGeneProduct	265	266	12	1:NR:2	L2R	CROSS	60-62	108-109	D050197	premature atherosclerosis|atherosclerotic lesion	DiseaseOrPhenotypicFeature	49:60	51:62	2:3	D002784	cholesterol	ChemicalEntity	108	109	5	1:NR:2	L2R	CROSS	60-62	168-171	D050197	premature atherosclerosis|atherosclerotic lesion	DiseaseOrPhenotypicFeature	49:60	51:62	2:3	D004958	17beta - estradiol|E2|E2|E2|E2|E2	ChemicalEntity	168:172:223:282:296:316	171:173:224:283:297:317	7:7:10:13:14:15	1:NR:2	L2R	CROSS	60-62	177-178	D050197	premature atherosclerosis|atherosclerotic lesion	DiseaseOrPhenotypicFeature	49:60	51:62	2:3	D011374	progesterone	ChemicalEntity	177	178	7	1:NR:2	L2R	CROSS	60-62	185-186	D050197	premature atherosclerosis|atherosclerotic lesion	DiseaseOrPhenotypicFeature	49:60	51:62	2:3	D000431	ethanol	ChemicalEntity	185	186	7	1:NR:2	L2R	CROSS	60-62	216-217	D050197	premature atherosclerosis|atherosclerotic lesion	DiseaseOrPhenotypicFeature	49:60	51:62	2:3	D008055	lipid	ChemicalEntity	216	217	9	1:NR:2	L2R	CROSS	60-62	245-246	D050197	premature atherosclerosis|atherosclerotic lesion	DiseaseOrPhenotypicFeature	49:60	51:62	2:3	948	CD36|CD36|CD36|CD36	GeneOrGeneProduct	245:276:303:321	246:277:304:322	11:12:14:15	1:NR:2	L2R	CROSS	60-62	265-266	D050197	premature atherosclerosis|atherosclerotic lesion	DiseaseOrPhenotypicFeature	49:60	51:62	2:3	5468	PPARgamma	GeneOrGeneProduct	265	266	12	1:NR:2	L2R	CROSS	108-109	168-171	D002784	cholesterol	ChemicalEntity	108	109	5	D004958	17beta - estradiol|E2|E2|E2|E2|E2	ChemicalEntity	168:172:223:282:296:316	171:173:224:283:297:317	7:7:10:13:14:15	1:NR:2	L2R	CROSS	108-109	177-178	D002784	cholesterol	ChemicalEntity	108	109	5	D011374	progesterone	ChemicalEntity	177	178	7	1:NR:2	L2R	CROSS	108-109	185-186	D002784	cholesterol	ChemicalEntity	108	109	5	D000431	ethanol	ChemicalEntity	185	186	7	1:NR:2	L2R	CROSS	108-109	216-217	D002784	cholesterol	ChemicalEntity	108	109	5	D008055	lipid	ChemicalEntity	216	217	9	1:NR:2	L2R	CROSS	108-109	245-246	D002784	cholesterol	ChemicalEntity	108	109	5	948	CD36|CD36|CD36|CD36	GeneOrGeneProduct	245:276:303:321	246:277:304:322	11:12:14:15	1:NR:2	L2R	CROSS	108-109	265-266	D002784	cholesterol	ChemicalEntity	108	109	5	5468	PPARgamma	GeneOrGeneProduct	265	266	12	1:NR:2	L2R	NON-CROSS	172-173	177-178	D004958	17beta - estradiol|E2|E2|E2|E2|E2	ChemicalEntity	168:172:223:282:296:316	171:173:224:283:297:317	7:7:10:13:14:15	D011374	progesterone	ChemicalEntity	177	178	7	1:NR:2	L2R	NON-CROSS	172-173	185-186	D004958	17beta - estradiol|E2|E2|E2|E2|E2	ChemicalEntity	168:172:223:282:296:316	171:173:224:283:297:317	7:7:10:13:14:15	D000431	ethanol	ChemicalEntity	185	186	7	1:NR:2	L2R	CROSS	216-217	223-224	D004958	17beta - estradiol|E2|E2|E2|E2|E2	ChemicalEntity	168:172:223:282:296:316	171:173:224:283:297:317	7:7:10:13:14:15	D008055	lipid	ChemicalEntity	216	217	9	1:Negative_Correlation:2	L2R	NON-CROSS	316-317	321-322	D004958	17beta - estradiol|E2|E2|E2|E2|E2	ChemicalEntity	168:172:223:282:296:316	171:173:224:283:297:317	7:7:10:13:14:15	948	CD36|CD36|CD36|CD36	GeneOrGeneProduct	245:276:303:321	246:277:304:322	11:12:14:15	1:NR:2	L2R	CROSS	265-266	282-283	D004958	17beta - estradiol|E2|E2|E2|E2|E2	ChemicalEntity	168:172:223:282:296:316	171:173:224:283:297:317	7:7:10:13:14:15	5468	PPARgamma	GeneOrGeneProduct	265	266	12	1:NR:2	L2R	NON-CROSS	177-178	185-186	D011374	progesterone	ChemicalEntity	177	178	7	D000431	ethanol	ChemicalEntity	185	186	7	1:NR:2	L2R	CROSS	177-178	216-217	D011374	progesterone	ChemicalEntity	177	178	7	D008055	lipid	ChemicalEntity	216	217	9	1:NR:2	L2R	CROSS	177-178	245-246	D011374	progesterone	ChemicalEntity	177	178	7	948	CD36|CD36|CD36|CD36	GeneOrGeneProduct	245:276:303:321	246:277:304:322	11:12:14:15	1:NR:2	L2R	CROSS	177-178	265-266	D011374	progesterone	ChemicalEntity	177	178	7	5468	PPARgamma	GeneOrGeneProduct	265	266	12	1:NR:2	L2R	CROSS	185-186	216-217	D000431	ethanol	ChemicalEntity	185	186	7	D008055	lipid	ChemicalEntity	216	217	9	1:NR:2	L2R	CROSS	185-186	245-246	D000431	ethanol	ChemicalEntity	185	186	7	948	CD36|CD36|CD36|CD36	GeneOrGeneProduct	245:276:303:321	246:277:304:322	11:12:14:15	1:NR:2	L2R	CROSS	185-186	265-266	D000431	ethanol	ChemicalEntity	185	186	7	5468	PPARgamma	GeneOrGeneProduct	265	266	12	1:NR:2	L2R	CROSS	216-217	245-246	D008055	lipid	ChemicalEntity	216	217	9	948	CD36|CD36|CD36|CD36	GeneOrGeneProduct	245:276:303:321	246:277:304:322	11:12:14:15	1:NR:2	L2R	CROSS	216-217	265-266	D008055	lipid	ChemicalEntity	216	217	9	5468	PPARgamma	GeneOrGeneProduct	265	266	12	1:Association:2	R2L	NON-CROSS	276-277	265-266	5468	PPARgamma	GeneOrGeneProduct	265	266	12	948	CD36|CD36|CD36|CD36	GeneOrGeneProduct	245:276:303:321	246:277:304:322	11:12:14:15
18399341	Clinical comparison of cardiorespiratory effects during unilateral and conventional spinal anaesthesia .|BACKGROUND : Spinal anaesthesia is widely employed in clinical practice but has the main drawback of post - spinal block hypotension .|Efforts must therefore continue to be made to obviate this setback OBJECTIVE : To evaluate the cardiovascular and respiratory changes during unilateral and conventional spinal anaesthesia .|METHODS : With ethical approval , we studied 74 American Society of Anesthesiologists ( ASA ) , physical status class 1 and 2 patients scheduled for elective unilateral lower limb surgery .|Patients were randomly allocated into one of two groups : lateral and conventional spinal anaesthesia groups .|In the lateral position with operative side down , patients recived 10 mg ( 2mls ) of 0 . 5 % hyperbaric bupivacaine through a 25 - gauge spinal needle .|Patients in the unilateral group were maintained in the lateral position for 15 minutes following spinal injection while those in the conventional group were turned supine immediately after injection .|Blood pressure , heart rate , respiratory rate and oxygen saturation were monitored over 1 hour .|RESULTS : Three patients ( 8 . 1 % ) in the unilateral group and 5 ( 13 . 5 % ) in the conventional group developed hypotension , P = 0 . 71 .|Four ( 10 . 8 % ) patients in the conventional group and 1 ( 2 . 7 % ) in the unilateral group , P = 0 . 17 required epinephrine infusion to treat hypotension .|Patients in the conventional group had statistically significant greater fall in the systolic blood pressures at 15 , 30 and 45 minutes when compared to the baseline ( P = 0 . 003 , 0 . 001 and 0 . 004 ) .|The mean respiratory rate and oxygen saturations in the two groups were similar .|CONCLUSION : Compared to conventional spinal anaesthesia , unilateral spinal anaesthesia was associated with fewer cardiovascular perturbations .|Also , the type of spinal block instituted affected neither the respiratory rate nor the arterial oxygen saturation .	1:NR:2	L2R	CROSS	132-133	215-216	D007022	hypotension|hypotension|hypotension	DiseaseOrPhenotypicFeature	32:215:258	33:216:259	1:8:9	D002045	bupivacaine	ChemicalEntity	132	133	5	1:NR:2	L2R	CROSS	180-181	215-216	D007022	hypotension|hypotension|hypotension	DiseaseOrPhenotypicFeature	32:215:258	33:216:259	1:8:9	D010100	oxygen|oxygen|oxygen	ChemicalEntity	180:308:351	181:309:352	7:11:13	1:Negative_Correlation:2	R2L	NON-CROSS	258-259	254-255	D004837	epinephrine	ChemicalEntity	254	255	9	D007022	hypotension|hypotension|hypotension	DiseaseOrPhenotypicFeature	32:215:258	33:216:259	1:8:9	1:NR:2	L2R	CROSS	132-133	180-181	D002045	bupivacaine	ChemicalEntity	132	133	5	D010100	oxygen|oxygen|oxygen	ChemicalEntity	180:308:351	181:309:352	7:11:13	1:NR:2	L2R	CROSS	132-133	254-255	D002045	bupivacaine	ChemicalEntity	132	133	5	D004837	epinephrine	ChemicalEntity	254	255	9	1:NR:2	L2R	CROSS	254-255	308-309	D010100	oxygen|oxygen|oxygen	ChemicalEntity	180:308:351	181:309:352	7:11:13	D004837	epinephrine	ChemicalEntity	254	255	9
18439803	Acute effects of N - ( 2 - propylpentanoyl ) urea on hippocampal amino acid neurotransmitters in pilocarpine - induced seizure in rats .|The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters ( glutamate , aspartate , glycine and GABA ) of N - ( 2 - propylpentanoyl ) urea ( VPU ) in comparison to its parent compound , valproic acid ( VPA ) .|VPU was more potent than VPA , exhibiting the median effective dose ( ED ( 50 ) ) of 49 mg / kg in protecting rats against pilocarpine - induced seizure whereas the corresponding value for VPA was 322 mg / kg .|In vivo microdialysis demonstrated that an intraperitoneal administration of pilocarpine induced a pronounced increment of hippocampal glutamate and aspartate whereas no significant change was observed on the level of glycine and GABA .|Pretreatment with either VPU ( 50 and 100 mg / kg ) or VPA ( 300 and 600 mg / kg ) completely abolished pilocarpine - evoked increases in extracellular glutamate and aspartate .|In addition , a statistically significant reduction was also observed on the level of GABA and glycine but less than a drastic reduction of glutamate and aspartate level .|Based on the finding that VPU and VPA could protect the animals against pilocarpine - induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate .|Therefore , like VPA , the finding that VPU could drastically reduce pilocarpine - induced increases in glutamate and aspartate should account , at least partly , for its anticonvulsant activity observed in pilocarpine - induced seizure in experimental animals .|Some other mechanism than those being reported herein should be further investigated .	1:Negative_Correlation:2	L2R	NON-CROSS	269-270	273-274	C108761	N - ( 2 - propylpentanoyl ) urea|N - ( 2 - propylpentanoyl ) urea|VPU|VPU|VPU|VPU|VPU	ChemicalEntity	3:56:65:80:159:224:269	11:64:66:81:160:225:270	0:1:1:2:4:6:7	D010862	pilocarpine|pilocarpine|pilocarpine|pilocarpine|pilocarpine|pilocarpine|pilocarpine	ChemicalEntity	17:107:132:180:232:273:294	18:108:133:181:233:274:295	0:2:3:4:6:7:7	1:Negative_Correlation:2	L2R	NON-CROSS	3-11	20-21	C108761	N - ( 2 - propylpentanoyl ) urea|N - ( 2 - propylpentanoyl ) urea|VPU|VPU|VPU|VPU|VPU	ChemicalEntity	3:56:65:80:159:224:269	11:64:66:81:160:225:270	0:1:1:2:4:6:7	D012640	seizure|seizure|seizure|seizure	DiseaseOrPhenotypicFeature	20:110:235:297	21:111:236:298	0:2:6:7	1:Negative_Correlation:2	L2R	NON-CROSS	269-270	278-279	C108761	N - ( 2 - propylpentanoyl ) urea|N - ( 2 - propylpentanoyl ) urea|VPU|VPU|VPU|VPU|VPU	ChemicalEntity	3:56:65:80:159:224:269	11:64:66:81:160:225:270	0:1:1:2:4:6:7	D018698	glutamate|glutamate|glutamate|glutamate|glutamate|glutamate	ChemicalEntity	47:139:186:214:257:278	48:140:187:215:258:279	1:3:4:5:6:7	1:Negative_Correlation:2	L2R	NON-CROSS	216-217	224-225	C108761	N - ( 2 - propylpentanoyl ) urea|N - ( 2 - propylpentanoyl ) urea|VPU|VPU|VPU|VPU|VPU	ChemicalEntity	3:56:65:80:159:224:269	11:64:66:81:160:225:270	0:1:1:2:4:6:7	D001224	aspartate|aspartate|aspartate|aspartate|aspartate|aspartate	ChemicalEntity	49:141:188:216:259:280	50:142:189:217:260:281	1:3:4:5:6:7	1:Association:2	L2R	NON-CROSS	152-153	159-160	C108761	N - ( 2 - propylpentanoyl ) urea|N - ( 2 - propylpentanoyl ) urea|VPU|VPU|VPU|VPU|VPU	ChemicalEntity	3:56:65:80:159:224:269	11:64:66:81:160:225:270	0:1:1:2:4:6:7	D005998	glycine|glycine|glycine	ChemicalEntity	51:152:206	52:153:207	1:3:5	1:Association:2	L2R	NON-CROSS	154-155	159-160	C108761	N - ( 2 - propylpentanoyl ) urea|N - ( 2 - propylpentanoyl ) urea|VPU|VPU|VPU|VPU|VPU	ChemicalEntity	3:56:65:80:159:224:269	11:64:66:81:160:225:270	0:1:1:2:4:6:7	D005680	GABA|GABA|GABA	ChemicalEntity	53:154:204	54:155:205	1:3:5	1:Comparison:2	L2R	NON-CROSS	224-225	226-227	C108761	N - ( 2 - propylpentanoyl ) urea|N - ( 2 - propylpentanoyl ) urea|VPU|VPU|VPU|VPU|VPU	ChemicalEntity	3:56:65:80:159:224:269	11:64:66:81:160:225:270	0:1:1:2:4:6:7	D014635	valproic acid|VPA|VPA|VPA|VPA|VPA|VPA	ChemicalEntity	74:77:85:116:169:226:264	76:78:86:117:170:227:265	1:1:2:2:4:6:7	1:Positive_Correlation:2	L2R	NON-CROSS	17-18	20-21	D010862	pilocarpine|pilocarpine|pilocarpine|pilocarpine|pilocarpine|pilocarpine|pilocarpine	ChemicalEntity	17:107:132:180:232:273:294	18:108:133:181:233:274:295	0:2:3:4:6:7:7	D012640	seizure|seizure|seizure|seizure	DiseaseOrPhenotypicFeature	20:110:235:297	21:111:236:298	0:2:6:7	1:Positive_Correlation:2	L2R	NON-CROSS	273-274	278-279	D010862	pilocarpine|pilocarpine|pilocarpine|pilocarpine|pilocarpine|pilocarpine|pilocarpine	ChemicalEntity	17:107:132:180:232:273:294	18:108:133:181:233:274:295	0:2:3:4:6:7:7	D018698	glutamate|glutamate|glutamate|glutamate|glutamate|glutamate	ChemicalEntity	47:139:186:214:257:278	48:140:187:215:258:279	1:3:4:5:6:7	1:Positive_Correlation:2	L2R	NON-CROSS	273-274	280-281	D010862	pilocarpine|pilocarpine|pilocarpine|pilocarpine|pilocarpine|pilocarpine|pilocarpine	ChemicalEntity	17:107:132:180:232:273:294	18:108:133:181:233:274:295	0:2:3:4:6:7:7	D001224	aspartate|aspartate|aspartate|aspartate|aspartate|aspartate	ChemicalEntity	49:141:188:216:259:280	50:142:189:217:260:281	1:3:4:5:6:7	1:NR:2	L2R	NON-CROSS	132-133	152-153	D010862	pilocarpine|pilocarpine|pilocarpine|pilocarpine|pilocarpine|pilocarpine|pilocarpine	ChemicalEntity	17:107:132:180:232:273:294	18:108:133:181:233:274:295	0:2:3:4:6:7:7	D005998	glycine|glycine|glycine	ChemicalEntity	51:152:206	52:153:207	1:3:5	1:NR:2	L2R	NON-CROSS	132-133	154-155	D010862	pilocarpine|pilocarpine|pilocarpine|pilocarpine|pilocarpine|pilocarpine|pilocarpine	ChemicalEntity	17:107:132:180:232:273:294	18:108:133:181:233:274:295	0:2:3:4:6:7:7	D005680	GABA|GABA|GABA	ChemicalEntity	53:154:204	54:155:205	1:3:5	1:Negative_Correlation:2	R2L	NON-CROSS	232-233	226-227	D014635	valproic acid|VPA|VPA|VPA|VPA|VPA|VPA	ChemicalEntity	74:77:85:116:169:226:264	76:78:86:117:170:227:265	1:1:2:2:4:6:7	D010862	pilocarpine|pilocarpine|pilocarpine|pilocarpine|pilocarpine|pilocarpine|pilocarpine	ChemicalEntity	17:107:132:180:232:273:294	18:108:133:181:233:274:295	0:2:3:4:6:7:7	1:NR:2	L2R	NON-CROSS	278-279	297-298	D012640	seizure|seizure|seizure|seizure	DiseaseOrPhenotypicFeature	20:110:235:297	21:111:236:298	0:2:6:7	D018698	glutamate|glutamate|glutamate|glutamate|glutamate|glutamate	ChemicalEntity	47:139:186:214:257:278	48:140:187:215:258:279	1:3:4:5:6:7	1:NR:2	L2R	NON-CROSS	280-281	297-298	D012640	seizure|seizure|seizure|seizure	DiseaseOrPhenotypicFeature	20:110:235:297	21:111:236:298	0:2:6:7	D001224	aspartate|aspartate|aspartate|aspartate|aspartate|aspartate	ChemicalEntity	49:141:188:216:259:280	50:142:189:217:260:281	1:3:4:5:6:7	1:NR:2	L2R	CROSS	206-207	235-236	D012640	seizure|seizure|seizure|seizure	DiseaseOrPhenotypicFeature	20:110:235:297	21:111:236:298	0:2:6:7	D005998	glycine|glycine|glycine	ChemicalEntity	51:152:206	52:153:207	1:3:5	1:NR:2	L2R	CROSS	204-205	235-236	D012640	seizure|seizure|seizure|seizure	DiseaseOrPhenotypicFeature	20:110:235:297	21:111:236:298	0:2:6:7	D005680	GABA|GABA|GABA	ChemicalEntity	53:154:204	54:155:205	1:3:5	1:Negative_Correlation:2	L2R	NON-CROSS	110-111	116-117	D012640	seizure|seizure|seizure|seizure	DiseaseOrPhenotypicFeature	20:110:235:297	21:111:236:298	0:2:6:7	D014635	valproic acid|VPA|VPA|VPA|VPA|VPA|VPA	ChemicalEntity	74:77:85:116:169:226:264	76:78:86:117:170:227:265	1:1:2:2:4:6:7	1:NR:2	L2R	NON-CROSS	47-48	49-50	D018698	glutamate|glutamate|glutamate|glutamate|glutamate|glutamate	ChemicalEntity	47:139:186:214:257:278	48:140:187:215:258:279	1:3:4:5:6:7	D001224	aspartate|aspartate|aspartate|aspartate|aspartate|aspartate	ChemicalEntity	49:141:188:216:259:280	50:142:189:217:260:281	1:3:4:5:6:7	1:NR:2	L2R	NON-CROSS	47-48	51-52	D018698	glutamate|glutamate|glutamate|glutamate|glutamate|glutamate	ChemicalEntity	47:139:186:214:257:278	48:140:187:215:258:279	1:3:4:5:6:7	D005998	glycine|glycine|glycine	ChemicalEntity	51:152:206	52:153:207	1:3:5	1:NR:2	L2R	NON-CROSS	47-48	53-54	D018698	glutamate|glutamate|glutamate|glutamate|glutamate|glutamate	ChemicalEntity	47:139:186:214:257:278	48:140:187:215:258:279	1:3:4:5:6:7	D005680	GABA|GABA|GABA	ChemicalEntity	53:154:204	54:155:205	1:3:5	1:Negative_Correlation:2	R2L	NON-CROSS	264-265	257-258	D014635	valproic acid|VPA|VPA|VPA|VPA|VPA|VPA	ChemicalEntity	74:77:85:116:169:226:264	76:78:86:117:170:227:265	1:1:2:2:4:6:7	D018698	glutamate|glutamate|glutamate|glutamate|glutamate|glutamate	ChemicalEntity	47:139:186:214:257:278	48:140:187:215:258:279	1:3:4:5:6:7	1:NR:2	L2R	NON-CROSS	49-50	51-52	D001224	aspartate|aspartate|aspartate|aspartate|aspartate|aspartate	ChemicalEntity	49:141:188:216:259:280	50:142:189:217:260:281	1:3:4:5:6:7	D005998	glycine|glycine|glycine	ChemicalEntity	51:152:206	52:153:207	1:3:5	1:NR:2	L2R	NON-CROSS	49-50	53-54	D001224	aspartate|aspartate|aspartate|aspartate|aspartate|aspartate	ChemicalEntity	49:141:188:216:259:280	50:142:189:217:260:281	1:3:4:5:6:7	D005680	GABA|GABA|GABA	ChemicalEntity	53:154:204	54:155:205	1:3:5	1:Negative_Correlation:2	R2L	NON-CROSS	264-265	259-260	D014635	valproic acid|VPA|VPA|VPA|VPA|VPA|VPA	ChemicalEntity	74:77:85:116:169:226:264	76:78:86:117:170:227:265	1:1:2:2:4:6:7	D001224	aspartate|aspartate|aspartate|aspartate|aspartate|aspartate	ChemicalEntity	49:141:188:216:259:280	50:142:189:217:260:281	1:3:4:5:6:7	1:NR:2	L2R	NON-CROSS	51-52	53-54	D005998	glycine|glycine|glycine	ChemicalEntity	51:152:206	52:153:207	1:3:5	D005680	GABA|GABA|GABA	ChemicalEntity	53:154:204	54:155:205	1:3:5	1:NR:2	L2R	NON-CROSS	152-153	169-170	D005998	glycine|glycine|glycine	ChemicalEntity	51:152:206	52:153:207	1:3:5	D014635	valproic acid|VPA|VPA|VPA|VPA|VPA|VPA	ChemicalEntity	74:77:85:116:169:226:264	76:78:86:117:170:227:265	1:1:2:2:4:6:7	1:NR:2	L2R	NON-CROSS	154-155	169-170	D005680	GABA|GABA|GABA	ChemicalEntity	53:154:204	54:155:205	1:3:5	D014635	valproic acid|VPA|VPA|VPA|VPA|VPA|VPA	ChemicalEntity	74:77:85:116:169:226:264	76:78:86:117:170:227:265	1:1:2:2:4:6:7
19531695	Delirium in a patient with toxic flecainide plasma concentrations : the role of a pharmacokinetic drug interaction with paroxetine .|OBJECTIVE : To describe a case of flecainide - induced delirium associated with a pharmacokinetic drug interaction with paroxetine .|CASE SUMMARY : A 69 - year - old white female presented to the emergency department with a history of confusion and paranoia over the past several days .|On admission the patient was taking carvedilol 12 mg twice daily , warfarin 2 mg / day , folic acid 1 mg / day , levothyroxine 100 microg / day , pantoprazole 40 mg / day , paroxetine 40 mg / day , and flecainide 100 mg twice daily .|Flecainide had been started 2 weeks prior for atrial fibrillation .|Laboratory test findings on admission were notable only for a flecainide plasma concentration of 1360 microg / L ( reference range 200 - 1000 ) .|A metabolic drug interaction between flecainide and paroxetine , which the patient had been taking for more than 5 years , was considered .|Paroxetine was discontinued and the dose of flecainide was reduced to 50 mg twice daily .|Her delirium resolved 3 days later .|DISCUSSION : Flecainide and pharmacologically similar agents that interact with sodium channels may cause delirium in susceptible patients .|A MEDLINE search ( 1966 - January 2009 ) revealed one in vivo pharmacokinetic study on the interaction between flecainide , a CYP2D6 substrate , and paroxetine , a CYP2D6 inhibitor , as well as 3 case reports of flecainide - induced delirium .|According to the Naranjo probability scale , flecainide was the probable cause of the patient 's delirium ; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine .|CONCLUSIONS : Supratherapeutic flecainide plasma concentrations may cause delirium .|Because toxicity may occur when flecainide is prescribed with paroxetine and other potent CYP2D6 inhibitors , flecainide plasma concentrations should be monitored closely with commencement of CYP2D6 inhibitors .	1:Positive_Correlation:2	R2L	NON-CROSS	30-31	27-28	D005424	flecainide|flecainide|flecainide|Flecainide|flecainide|flecainide|flecainide|Flecainide|flecainide|flecainide|flecainide|flecainide|flecainide|flecainide|flecainide	ChemicalEntity	6:27:113:119:140:161:187:205:241:261:273:297:304:316:327	7:28:114:120:141:162:188:206:242:262:274:298:305:317:328	0:1:3:4:5:6:7:9:10:10:11:11:12:13:13	D003693	Delirium|delirium|delirium|delirium|delirium|delirium|delirium	DiseaseOrPhenotypicFeature	0:30:197:217:264:282:309	1:31:198:218:265:283:310	0:1:8:9:10:11:12	1:Positive_Correlation:2	R2L	NON-CROSS	38-39	30-31	D017374	paroxetine|paroxetine|paroxetine|paroxetine|Paroxetine|paroxetine|paroxetine|paroxetine	ChemicalEntity	18:38:106:163:180:248:299:320	19:39:107:164:181:249:300:321	0:1:3:6:7:10:11:13	D003693	Delirium|delirium|delirium|delirium|delirium|delirium|delirium	DiseaseOrPhenotypicFeature	0:30:197:217:264:282:309	1:31:198:218:265:283:310	0:1:8:9:10:11:12	1:NR:2	L2R	CROSS	30-31	75-76	D003693	Delirium|delirium|delirium|delirium|delirium|delirium|delirium	DiseaseOrPhenotypicFeature	0:30:197:217:264:282:309	1:31:198:218:265:283:310	0:1:8:9:10:11:12	C043211	carvedilol	ChemicalEntity	75	76	3	1:NR:2	L2R	CROSS	30-31	81-82	D003693	Delirium|delirium|delirium|delirium|delirium|delirium|delirium	DiseaseOrPhenotypicFeature	0:30:197:217:264:282:309	1:31:198:218:265:283:310	0:1:8:9:10:11:12	D014859	warfarin	ChemicalEntity	81	82	3	1:NR:2	L2R	CROSS	30-31	87-89	D003693	Delirium|delirium|delirium|delirium|delirium|delirium|delirium	DiseaseOrPhenotypicFeature	0:30:197:217:264:282:309	1:31:198:218:265:283:310	0:1:8:9:10:11:12	D005492	folic acid	ChemicalEntity	87	89	3	1:NR:2	L2R	CROSS	30-31	94-95	D003693	Delirium|delirium|delirium|delirium|delirium|delirium|delirium	DiseaseOrPhenotypicFeature	0:30:197:217:264:282:309	1:31:198:218:265:283:310	0:1:8:9:10:11:12	D013974	levothyroxine	ChemicalEntity	94	95	3	1:NR:2	L2R	CROSS	30-31	100-101	D003693	Delirium|delirium|delirium|delirium|delirium|delirium|delirium	DiseaseOrPhenotypicFeature	0:30:197:217:264:282:309	1:31:198:218:265:283:310	0:1:8:9:10:11:12	C064276	pantoprazole	ChemicalEntity	100	101	3	1:Association:2	R2L	NON-CROSS	217-218	213-214	D012964	sodium	ChemicalEntity	213	214	9	D003693	Delirium|delirium|delirium|delirium|delirium|delirium|delirium	DiseaseOrPhenotypicFeature	0:30:197:217:264:282:309	1:31:198:218:265:283:310	0:1:8:9:10:11:12	1:NR:2	L2R	NON-CROSS	251-252	264-265	D003693	Delirium|delirium|delirium|delirium|delirium|delirium|delirium	DiseaseOrPhenotypicFeature	0:30:197:217:264:282:309	1:31:198:218:265:283:310	0:1:8:9:10:11:12	1565	CYP2D6|CYP2D6|CYP2D6|CYP2D6	GeneOrGeneProduct	244:251:324:337	245:252:325:338	10:10:13:13	1:Drug_Interaction:2	L2R	NON-CROSS	161-162	163-164	D005424	flecainide|flecainide|flecainide|Flecainide|flecainide|flecainide|flecainide|Flecainide|flecainide|flecainide|flecainide|flecainide|flecainide|flecainide|flecainide	ChemicalEntity	6:27:113:119:140:161:187:205:241:261:273:297:304:316:327	7:28:114:120:141:162:188:206:242:262:274:298:305:317:328	0:1:3:4:5:6:7:9:10:10:11:11:12:13:13	D017374	paroxetine|paroxetine|paroxetine|paroxetine|Paroxetine|paroxetine|paroxetine|paroxetine	ChemicalEntity	18:38:106:163:180:248:299:320	19:39:107:164:181:249:300:321	0:1:3:6:7:10:11:13	1:NR:2	L2R	CROSS	27-28	60-61	D005424	flecainide|flecainide|flecainide|Flecainide|flecainide|flecainide|flecainide|Flecainide|flecainide|flecainide|flecainide|flecainide|flecainide|flecainide|flecainide	ChemicalEntity	6:27:113:119:140:161:187:205:241:261:273:297:304:316:327	7:28:114:120:141:162:188:206:242:262:274:298:305:317:328	0:1:3:4:5:6:7:9:10:10:11:11:12:13:13	D003221	confusion	DiseaseOrPhenotypicFeature	60	61	2	1:NR:2	L2R	CROSS	27-28	62-63	D005424	flecainide|flecainide|flecainide|Flecainide|flecainide|flecainide|flecainide|Flecainide|flecainide|flecainide|flecainide|flecainide|flecainide|flecainide|flecainide	ChemicalEntity	6:27:113:119:140:161:187:205:241:261:273:297:304:316:327	7:28:114:120:141:162:188:206:242:262:274:298:305:317:328	0:1:3:4:5:6:7:9:10:10:11:11:12:13:13	D010259	paranoia	DiseaseOrPhenotypicFeature	62	63	2	1:NR:2	L2R	NON-CROSS	75-76	113-114	D005424	flecainide|flecainide|flecainide|Flecainide|flecainide|flecainide|flecainide|Flecainide|flecainide|flecainide|flecainide|flecainide|flecainide|flecainide|flecainide	ChemicalEntity	6:27:113:119:140:161:187:205:241:261:273:297:304:316:327	7:28:114:120:141:162:188:206:242:262:274:298:305:317:328	0:1:3:4:5:6:7:9:10:10:11:11:12:13:13	C043211	carvedilol	ChemicalEntity	75	76	3	1:NR:2	L2R	NON-CROSS	81-82	113-114	D005424	flecainide|flecainide|flecainide|Flecainide|flecainide|flecainide|flecainide|Flecainide|flecainide|flecainide|flecainide|flecainide|flecainide|flecainide|flecainide	ChemicalEntity	6:27:113:119:140:161:187:205:241:261:273:297:304:316:327	7:28:114:120:141:162:188:206:242:262:274:298:305:317:328	0:1:3:4:5:6:7:9:10:10:11:11:12:13:13	D014859	warfarin	ChemicalEntity	81	82	3	1:NR:2	L2R	NON-CROSS	87-89	113-114	D005424	flecainide|flecainide|flecainide|Flecainide|flecainide|flecainide|flecainide|Flecainide|flecainide|flecainide|flecainide|flecainide|flecainide|flecainide|flecainide	ChemicalEntity	6:27:113:119:140:161:187:205:241:261:273:297:304:316:327	7:28:114:120:141:162:188:206:242:262:274:298:305:317:328	0:1:3:4:5:6:7:9:10:10:11:11:12:13:13	D005492	folic acid	ChemicalEntity	87	89	3	1:NR:2	L2R	NON-CROSS	94-95	113-114	D005424	flecainide|flecainide|flecainide|Flecainide|flecainide|flecainide|flecainide|Flecainide|flecainide|flecainide|flecainide|flecainide|flecainide|flecainide|flecainide	ChemicalEntity	6:27:113:119:140:161:187:205:241:261:273:297:304:316:327	7:28:114:120:141:162:188:206:242:262:274:298:305:317:328	0:1:3:4:5:6:7:9:10:10:11:11:12:13:13	D013974	levothyroxine	ChemicalEntity	94	95	3	1:NR:2	L2R	NON-CROSS	100-101	113-114	D005424	flecainide|flecainide|flecainide|Flecainide|flecainide|flecainide|flecainide|Flecainide|flecainide|flecainide|flecainide|flecainide|flecainide|flecainide|flecainide	ChemicalEntity	6:27:113:119:140:161:187:205:241:261:273:297:304:316:327	7:28:114:120:141:162:188:206:242:262:274:298:305:317:328	0:1:3:4:5:6:7:9:10:10:11:11:12:13:13	C064276	pantoprazole	ChemicalEntity	100	101	3	1:Negative_Correlation:2	L2R	NON-CROSS	119-120	127-129	D005424	flecainide|flecainide|flecainide|Flecainide|flecainide|flecainide|flecainide|Flecainide|flecainide|flecainide|flecainide|flecainide|flecainide|flecainide|flecainide	ChemicalEntity	6:27:113:119:140:161:187:205:241:261:273:297:304:316:327	7:28:114:120:141:162:188:206:242:262:274:298:305:317:328	0:1:3:4:5:6:7:9:10:10:11:11:12:13:13	D001281	atrial fibrillation	DiseaseOrPhenotypicFeature	127	129	4	1:Association:2	L2R	NON-CROSS	205-206	213-214	D005424	flecainide|flecainide|flecainide|Flecainide|flecainide|flecainide|flecainide|Flecainide|flecainide|flecainide|flecainide|flecainide|flecainide|flecainide|flecainide	ChemicalEntity	6:27:113:119:140:161:187:205:241:261:273:297:304:316:327	7:28:114:120:141:162:188:206:242:262:274:298:305:317:328	0:1:3:4:5:6:7:9:10:10:11:11:12:13:13	D012964	sodium	ChemicalEntity	213	214	9	1:Association:2	L2R	NON-CROSS	241-242	244-245	D005424	flecainide|flecainide|flecainide|Flecainide|flecainide|flecainide|flecainide|Flecainide|flecainide|flecainide|flecainide|flecainide|flecainide|flecainide|flecainide	ChemicalEntity	6:27:113:119:140:161:187:205:241:261:273:297:304:316:327	7:28:114:120:141:162:188:206:242:262:274:298:305:317:328	0:1:3:4:5:6:7:9:10:10:11:11:12:13:13	1565	CYP2D6|CYP2D6|CYP2D6|CYP2D6	GeneOrGeneProduct	244:251:324:337	245:252:325:338	10:10:13:13	1:NR:2	L2R	NON-CROSS	312-313	316-317	D005424	flecainide|flecainide|flecainide|Flecainide|flecainide|flecainide|flecainide|Flecainide|flecainide|flecainide|flecainide|flecainide|flecainide|flecainide|flecainide	ChemicalEntity	6:27:113:119:140:161:187:205:241:261:273:297:304:316:327	7:28:114:120:141:162:188:206:242:262:274:298:305:317:328	0:1:3:4:5:6:7:9:10:10:11:11:12:13:13	D064420	toxicity	DiseaseOrPhenotypicFeature	312	313	13	1:NR:2	L2R	CROSS	38-39	60-61	D017374	paroxetine|paroxetine|paroxetine|paroxetine|Paroxetine|paroxetine|paroxetine|paroxetine	ChemicalEntity	18:38:106:163:180:248:299:320	19:39:107:164:181:249:300:321	0:1:3:6:7:10:11:13	D003221	confusion	DiseaseOrPhenotypicFeature	60	61	2	1:NR:2	L2R	CROSS	38-39	62-63	D017374	paroxetine|paroxetine|paroxetine|paroxetine|Paroxetine|paroxetine|paroxetine|paroxetine	ChemicalEntity	18:38:106:163:180:248:299:320	19:39:107:164:181:249:300:321	0:1:3:6:7:10:11:13	D010259	paranoia	DiseaseOrPhenotypicFeature	62	63	2	1:NR:2	L2R	NON-CROSS	75-76	106-107	D017374	paroxetine|paroxetine|paroxetine|paroxetine|Paroxetine|paroxetine|paroxetine|paroxetine	ChemicalEntity	18:38:106:163:180:248:299:320	19:39:107:164:181:249:300:321	0:1:3:6:7:10:11:13	C043211	carvedilol	ChemicalEntity	75	76	3	1:NR:2	L2R	NON-CROSS	81-82	106-107	D017374	paroxetine|paroxetine|paroxetine|paroxetine|Paroxetine|paroxetine|paroxetine|paroxetine	ChemicalEntity	18:38:106:163:180:248:299:320	19:39:107:164:181:249:300:321	0:1:3:6:7:10:11:13	D014859	warfarin	ChemicalEntity	81	82	3	1:NR:2	L2R	NON-CROSS	87-89	106-107	D017374	paroxetine|paroxetine|paroxetine|paroxetine|Paroxetine|paroxetine|paroxetine|paroxetine	ChemicalEntity	18:38:106:163:180:248:299:320	19:39:107:164:181:249:300:321	0:1:3:6:7:10:11:13	D005492	folic acid	ChemicalEntity	87	89	3	1:NR:2	L2R	NON-CROSS	94-95	106-107	D017374	paroxetine|paroxetine|paroxetine|paroxetine|Paroxetine|paroxetine|paroxetine|paroxetine	ChemicalEntity	18:38:106:163:180:248:299:320	19:39:107:164:181:249:300:321	0:1:3:6:7:10:11:13	D013974	levothyroxine	ChemicalEntity	94	95	3	1:NR:2	L2R	NON-CROSS	100-101	106-107	D017374	paroxetine|paroxetine|paroxetine|paroxetine|Paroxetine|paroxetine|paroxetine|paroxetine	ChemicalEntity	18:38:106:163:180:248:299:320	19:39:107:164:181:249:300:321	0:1:3:6:7:10:11:13	C064276	pantoprazole	ChemicalEntity	100	101	3	1:NR:2	L2R	CROSS	106-107	127-129	D017374	paroxetine|paroxetine|paroxetine|paroxetine|Paroxetine|paroxetine|paroxetine|paroxetine	ChemicalEntity	18:38:106:163:180:248:299:320	19:39:107:164:181:249:300:321	0:1:3:6:7:10:11:13	D001281	atrial fibrillation	DiseaseOrPhenotypicFeature	127	129	4	1:NR:2	L2R	CROSS	180-181	213-214	D017374	paroxetine|paroxetine|paroxetine|paroxetine|Paroxetine|paroxetine|paroxetine|paroxetine	ChemicalEntity	18:38:106:163:180:248:299:320	19:39:107:164:181:249:300:321	0:1:3:6:7:10:11:13	D012964	sodium	ChemicalEntity	213	214	9	1:Negative_Correlation:2	L2R	NON-CROSS	248-249	251-252	D017374	paroxetine|paroxetine|paroxetine|paroxetine|Paroxetine|paroxetine|paroxetine|paroxetine	ChemicalEntity	18:38:106:163:180:248:299:320	19:39:107:164:181:249:300:321	0:1:3:6:7:10:11:13	1565	CYP2D6|CYP2D6|CYP2D6|CYP2D6	GeneOrGeneProduct	244:251:324:337	245:252:325:338	10:10:13:13	1:NR:2	L2R	NON-CROSS	312-313	320-321	D017374	paroxetine|paroxetine|paroxetine|paroxetine|Paroxetine|paroxetine|paroxetine|paroxetine	ChemicalEntity	18:38:106:163:180:248:299:320	19:39:107:164:181:249:300:321	0:1:3:6:7:10:11:13	D064420	toxicity	DiseaseOrPhenotypicFeature	312	313	13	1:NR:2	L2R	CROSS	60-61	75-76	D003221	confusion	DiseaseOrPhenotypicFeature	60	61	2	C043211	carvedilol	ChemicalEntity	75	76	3	1:NR:2	L2R	CROSS	60-61	81-82	D003221	confusion	DiseaseOrPhenotypicFeature	60	61	2	D014859	warfarin	ChemicalEntity	81	82	3	1:NR:2	L2R	CROSS	60-61	87-89	D003221	confusion	DiseaseOrPhenotypicFeature	60	61	2	D005492	folic acid	ChemicalEntity	87	89	3	1:NR:2	L2R	CROSS	60-61	94-95	D003221	confusion	DiseaseOrPhenotypicFeature	60	61	2	D013974	levothyroxine	ChemicalEntity	94	95	3	1:NR:2	L2R	CROSS	60-61	100-101	D003221	confusion	DiseaseOrPhenotypicFeature	60	61	2	C064276	pantoprazole	ChemicalEntity	100	101	3	1:NR:2	L2R	CROSS	60-61	213-214	D003221	confusion	DiseaseOrPhenotypicFeature	60	61	2	D012964	sodium	ChemicalEntity	213	214	9	1:NR:2	L2R	CROSS	60-61	244-245	D003221	confusion	DiseaseOrPhenotypicFeature	60	61	2	1565	CYP2D6|CYP2D6|CYP2D6|CYP2D6	GeneOrGeneProduct	244:251:324:337	245:252:325:338	10:10:13:13	1:NR:2	L2R	CROSS	62-63	75-76	D010259	paranoia	DiseaseOrPhenotypicFeature	62	63	2	C043211	carvedilol	ChemicalEntity	75	76	3	1:NR:2	L2R	CROSS	62-63	81-82	D010259	paranoia	DiseaseOrPhenotypicFeature	62	63	2	D014859	warfarin	ChemicalEntity	81	82	3	1:NR:2	L2R	CROSS	62-63	87-89	D010259	paranoia	DiseaseOrPhenotypicFeature	62	63	2	D005492	folic acid	ChemicalEntity	87	89	3	1:NR:2	L2R	CROSS	62-63	94-95	D010259	paranoia	DiseaseOrPhenotypicFeature	62	63	2	D013974	levothyroxine	ChemicalEntity	94	95	3	1:NR:2	L2R	CROSS	62-63	100-101	D010259	paranoia	DiseaseOrPhenotypicFeature	62	63	2	C064276	pantoprazole	ChemicalEntity	100	101	3	1:NR:2	L2R	CROSS	62-63	213-214	D010259	paranoia	DiseaseOrPhenotypicFeature	62	63	2	D012964	sodium	ChemicalEntity	213	214	9	1:NR:2	L2R	CROSS	62-63	244-245	D010259	paranoia	DiseaseOrPhenotypicFeature	62	63	2	1565	CYP2D6|CYP2D6|CYP2D6|CYP2D6	GeneOrGeneProduct	244:251:324:337	245:252:325:338	10:10:13:13	1:NR:2	L2R	NON-CROSS	75-76	81-82	C043211	carvedilol	ChemicalEntity	75	76	3	D014859	warfarin	ChemicalEntity	81	82	3	1:NR:2	L2R	NON-CROSS	75-76	87-89	C043211	carvedilol	ChemicalEntity	75	76	3	D005492	folic acid	ChemicalEntity	87	89	3	1:NR:2	L2R	NON-CROSS	75-76	94-95	C043211	carvedilol	ChemicalEntity	75	76	3	D013974	levothyroxine	ChemicalEntity	94	95	3	1:NR:2	L2R	NON-CROSS	75-76	100-101	C043211	carvedilol	ChemicalEntity	75	76	3	C064276	pantoprazole	ChemicalEntity	100	101	3	1:NR:2	L2R	CROSS	75-76	127-129	C043211	carvedilol	ChemicalEntity	75	76	3	D001281	atrial fibrillation	DiseaseOrPhenotypicFeature	127	129	4	1:NR:2	L2R	CROSS	75-76	213-214	C043211	carvedilol	ChemicalEntity	75	76	3	D012964	sodium	ChemicalEntity	213	214	9	1:NR:2	L2R	CROSS	75-76	244-245	C043211	carvedilol	ChemicalEntity	75	76	3	1565	CYP2D6|CYP2D6|CYP2D6|CYP2D6	GeneOrGeneProduct	244:251:324:337	245:252:325:338	10:10:13:13	1:NR:2	L2R	CROSS	75-76	312-313	C043211	carvedilol	ChemicalEntity	75	76	3	D064420	toxicity	DiseaseOrPhenotypicFeature	312	313	13	1:NR:2	L2R	NON-CROSS	81-82	87-89	D014859	warfarin	ChemicalEntity	81	82	3	D005492	folic acid	ChemicalEntity	87	89	3	1:NR:2	L2R	NON-CROSS	81-82	94-95	D014859	warfarin	ChemicalEntity	81	82	3	D013974	levothyroxine	ChemicalEntity	94	95	3	1:NR:2	L2R	NON-CROSS	81-82	100-101	D014859	warfarin	ChemicalEntity	81	82	3	C064276	pantoprazole	ChemicalEntity	100	101	3	1:NR:2	L2R	CROSS	81-82	127-129	D014859	warfarin	ChemicalEntity	81	82	3	D001281	atrial fibrillation	DiseaseOrPhenotypicFeature	127	129	4	1:NR:2	L2R	CROSS	81-82	213-214	D014859	warfarin	ChemicalEntity	81	82	3	D012964	sodium	ChemicalEntity	213	214	9	1:NR:2	L2R	CROSS	81-82	244-245	D014859	warfarin	ChemicalEntity	81	82	3	1565	CYP2D6|CYP2D6|CYP2D6|CYP2D6	GeneOrGeneProduct	244:251:324:337	245:252:325:338	10:10:13:13	1:NR:2	L2R	CROSS	81-82	312-313	D014859	warfarin	ChemicalEntity	81	82	3	D064420	toxicity	DiseaseOrPhenotypicFeature	312	313	13	1:NR:2	L2R	NON-CROSS	87-89	94-95	D005492	folic acid	ChemicalEntity	87	89	3	D013974	levothyroxine	ChemicalEntity	94	95	3	1:NR:2	L2R	NON-CROSS	87-89	100-101	D005492	folic acid	ChemicalEntity	87	89	3	C064276	pantoprazole	ChemicalEntity	100	101	3	1:NR:2	L2R	CROSS	87-89	127-129	D005492	folic acid	ChemicalEntity	87	89	3	D001281	atrial fibrillation	DiseaseOrPhenotypicFeature	127	129	4	1:NR:2	L2R	CROSS	87-89	213-214	D005492	folic acid	ChemicalEntity	87	89	3	D012964	sodium	ChemicalEntity	213	214	9	1:NR:2	L2R	CROSS	87-89	244-245	D005492	folic acid	ChemicalEntity	87	89	3	1565	CYP2D6|CYP2D6|CYP2D6|CYP2D6	GeneOrGeneProduct	244:251:324:337	245:252:325:338	10:10:13:13	1:NR:2	L2R	CROSS	87-89	312-313	D005492	folic acid	ChemicalEntity	87	89	3	D064420	toxicity	DiseaseOrPhenotypicFeature	312	313	13	1:NR:2	L2R	NON-CROSS	94-95	100-101	D013974	levothyroxine	ChemicalEntity	94	95	3	C064276	pantoprazole	ChemicalEntity	100	101	3	1:NR:2	L2R	CROSS	94-95	127-129	D013974	levothyroxine	ChemicalEntity	94	95	3	D001281	atrial fibrillation	DiseaseOrPhenotypicFeature	127	129	4	1:NR:2	L2R	CROSS	94-95	213-214	D013974	levothyroxine	ChemicalEntity	94	95	3	D012964	sodium	ChemicalEntity	213	214	9	1:NR:2	L2R	CROSS	94-95	244-245	D013974	levothyroxine	ChemicalEntity	94	95	3	1565	CYP2D6|CYP2D6|CYP2D6|CYP2D6	GeneOrGeneProduct	244:251:324:337	245:252:325:338	10:10:13:13	1:NR:2	L2R	CROSS	94-95	312-313	D013974	levothyroxine	ChemicalEntity	94	95	3	D064420	toxicity	DiseaseOrPhenotypicFeature	312	313	13	1:NR:2	L2R	CROSS	100-101	127-129	C064276	pantoprazole	ChemicalEntity	100	101	3	D001281	atrial fibrillation	DiseaseOrPhenotypicFeature	127	129	4	1:NR:2	L2R	CROSS	100-101	213-214	C064276	pantoprazole	ChemicalEntity	100	101	3	D012964	sodium	ChemicalEntity	213	214	9	1:NR:2	L2R	CROSS	100-101	244-245	C064276	pantoprazole	ChemicalEntity	100	101	3	1565	CYP2D6|CYP2D6|CYP2D6|CYP2D6	GeneOrGeneProduct	244:251:324:337	245:252:325:338	10:10:13:13	1:NR:2	L2R	CROSS	100-101	312-313	C064276	pantoprazole	ChemicalEntity	100	101	3	D064420	toxicity	DiseaseOrPhenotypicFeature	312	313	13	1:NR:2	L2R	CROSS	127-129	213-214	D001281	atrial fibrillation	DiseaseOrPhenotypicFeature	127	129	4	D012964	sodium	ChemicalEntity	213	214	9	1:NR:2	L2R	CROSS	127-129	244-245	D001281	atrial fibrillation	DiseaseOrPhenotypicFeature	127	129	4	1565	CYP2D6|CYP2D6|CYP2D6|CYP2D6	GeneOrGeneProduct	244:251:324:337	245:252:325:338	10:10:13:13	1:NR:2	L2R	CROSS	213-214	244-245	D012964	sodium	ChemicalEntity	213	214	9	1565	CYP2D6|CYP2D6|CYP2D6|CYP2D6	GeneOrGeneProduct	244:251:324:337	245:252:325:338	10:10:13:13	1:NR:2	L2R	CROSS	213-214	312-313	D012964	sodium	ChemicalEntity	213	214	9	D064420	toxicity	DiseaseOrPhenotypicFeature	312	313	13	1:NR:2	L2R	NON-CROSS	312-313	324-325	1565	CYP2D6|CYP2D6|CYP2D6|CYP2D6	GeneOrGeneProduct	244:251:324:337	245:252:325:338	10:10:13:13	D064420	toxicity	DiseaseOrPhenotypicFeature	312	313	13
24114426	Depression , impulsiveness , sleep , and memory in past and present polydrug users of 3 , 4 - methylenedioxymethamphetamine ( MDMA , ecstasy ) .|RATIONALE : Ecstasy ( 3 , 4 - methylenedioxymethamphetamine , MDMA ) is a worldwide recreational drug of abuse .|Unfortunately , the results from human research investigating its psychological effects have been inconsistent .|OBJECTIVES : The present study aimed to be the largest to date in sample size and 5HT - related behaviors ; the first to compare present ecstasy users with past users after an abstinence of 4 or more years , and the first to include robust controls for other recreational substances .|METHODS : A sample of 997 participants ( 52 % male ) was recruited to four control groups ( non - drug ( ND ) , alcohol / nicotine ( AN ) , cannabis / alcohol / nicotine ( CAN ) , non - ecstasy polydrug ( PD ) ) , and two ecstasy polydrug groups ( present ( MDMA ) and past users ( EX - MDMA ) .|Participants completed a drug history questionnaire , Beck Depression Inventory , Barratt Impulsiveness Scale , Pittsburgh Sleep Quality Index , and Wechsler Memory Scale - Revised which , in total , provided 13 psychometric measures .|RESULTS : While the CAN and PD groups tended to record greater deficits than the non - drug controls , the MDMA and EX - MDMA groups recorded greater deficits than all the control groups on ten of the 13 psychometric measures .|Strikingly , despite prolonged abstinence ( mean , 4 . 98 ; range , 4 - 9 years ) , past ecstasy users showed few signs of recovery .|Compared with present ecstasy users , the past users showed no change for ten measures , increased impairment for two measures , and improvement on just one measure .|CONCLUSIONS : Given this record of impaired memory and clinically significant levels of depression , impulsiveness , and sleep disturbance , the prognosis for the current generation of ecstasy users is a major cause for concern .	1:Positive_Correlation:2	R2L	NON-CROSS	15-20	0-1	D018817	3 , 4 - methylenedioxymethamphetamine|MDMA|ecstasy|Ecstasy|3 , 4 - methylenedioxymethamphetamine|MDMA|ecstasy|ecstasy|ecstasy|MDMA|MDMA|MDMA|MDMA|ecstasy|ecstasy|ecstasy	ChemicalEntity	15:21:23:28:30:36:87:157:166:172:180:240:244:283:294:348	20:22:24:29:35:37:88:158:167:173:181:241:245:284:295:349	0:0:0:1:1:1:3:4:4:4:4:6:6:7:8:9	D003866	Depression|depression	DiseaseOrPhenotypicFeature	0:333	1:334	0:9	1:NR:2	L2R	CROSS	0-1	77-78	D003866	Depression|depression	DiseaseOrPhenotypicFeature	0:333	1:334	0:9	D012701	5HT	ChemicalEntity	77	78	3	1:NR:2	L2R	CROSS	0-1	139-140	D003866	Depression|depression	DiseaseOrPhenotypicFeature	0:333	1:334	0:9	D000431	alcohol|alcohol	ChemicalEntity	139:148	140:149	4:4	1:NR:2	L2R	CROSS	0-1	141-142	D003866	Depression|depression	DiseaseOrPhenotypicFeature	0:333	1:334	0:9	D009538	nicotine|nicotine	ChemicalEntity	141:150	142:151	4:4	1:NR:2	L2R	CROSS	0-1	143-144	D003866	Depression|depression	DiseaseOrPhenotypicFeature	0:333	1:334	0:9	D000431,D009538	AN	ChemicalEntity	143	144	4	1:NR:2	L2R	CROSS	0-1	146-147	D003866	Depression|depression	DiseaseOrPhenotypicFeature	0:333	1:334	0:9	D002188	cannabis	ChemicalEntity	146	147	4	1:NR:2	L2R	CROSS	223-224	333-334	D003866	Depression|depression	DiseaseOrPhenotypicFeature	0:333	1:334	0:9	D000431,D002188,D009538	CAN|CAN	ChemicalEntity	152:223	153:224	4:6	1:Positive_Correlation:2	R2L	NON-CROSS	15-20	2-3	D018817	3 , 4 - methylenedioxymethamphetamine|MDMA|ecstasy|Ecstasy|3 , 4 - methylenedioxymethamphetamine|MDMA|ecstasy|ecstasy|ecstasy|MDMA|MDMA|MDMA|MDMA|ecstasy|ecstasy|ecstasy	ChemicalEntity	15:21:23:28:30:36:87:157:166:172:180:240:244:283:294:348	20:22:24:29:35:37:88:158:167:173:181:241:245:284:295:349	0:0:0:1:1:1:3:4:4:4:4:6:6:7:8:9	D010554	impulsiveness|impulsiveness	DiseaseOrPhenotypicFeature	2:335	3:336	0:9	1:NR:2	L2R	CROSS	2-3	77-78	D010554	impulsiveness|impulsiveness	DiseaseOrPhenotypicFeature	2:335	3:336	0:9	D012701	5HT	ChemicalEntity	77	78	3	1:NR:2	L2R	CROSS	2-3	139-140	D010554	impulsiveness|impulsiveness	DiseaseOrPhenotypicFeature	2:335	3:336	0:9	D000431	alcohol|alcohol	ChemicalEntity	139:148	140:149	4:4	1:NR:2	L2R	CROSS	2-3	141-142	D010554	impulsiveness|impulsiveness	DiseaseOrPhenotypicFeature	2:335	3:336	0:9	D009538	nicotine|nicotine	ChemicalEntity	141:150	142:151	4:4	1:NR:2	L2R	CROSS	2-3	143-144	D010554	impulsiveness|impulsiveness	DiseaseOrPhenotypicFeature	2:335	3:336	0:9	D000431,D009538	AN	ChemicalEntity	143	144	4	1:NR:2	L2R	CROSS	2-3	146-147	D010554	impulsiveness|impulsiveness	DiseaseOrPhenotypicFeature	2:335	3:336	0:9	D002188	cannabis	ChemicalEntity	146	147	4	1:NR:2	L2R	CROSS	223-224	335-336	D010554	impulsiveness|impulsiveness	DiseaseOrPhenotypicFeature	2:335	3:336	0:9	D000431,D002188,D009538	CAN|CAN	ChemicalEntity	152:223	153:224	4:6	1:NR:2	L2R	NON-CROSS	77-78	87-88	D018817	3 , 4 - methylenedioxymethamphetamine|MDMA|ecstasy|Ecstasy|3 , 4 - methylenedioxymethamphetamine|MDMA|ecstasy|ecstasy|ecstasy|MDMA|MDMA|MDMA|MDMA|ecstasy|ecstasy|ecstasy	ChemicalEntity	15:21:23:28:30:36:87:157:166:172:180:240:244:283:294:348	20:22:24:29:35:37:88:158:167:173:181:241:245:284:295:349	0:0:0:1:1:1:3:4:4:4:4:6:6:7:8:9	D012701	5HT	ChemicalEntity	77	78	3	1:NR:2	L2R	NON-CROSS	148-149	157-158	D018817	3 , 4 - methylenedioxymethamphetamine|MDMA|ecstasy|Ecstasy|3 , 4 - methylenedioxymethamphetamine|MDMA|ecstasy|ecstasy|ecstasy|MDMA|MDMA|MDMA|MDMA|ecstasy|ecstasy|ecstasy	ChemicalEntity	15:21:23:28:30:36:87:157:166:172:180:240:244:283:294:348	20:22:24:29:35:37:88:158:167:173:181:241:245:284:295:349	0:0:0:1:1:1:3:4:4:4:4:6:6:7:8:9	D000431	alcohol|alcohol	ChemicalEntity	139:148	140:149	4:4	1:NR:2	L2R	NON-CROSS	150-151	157-158	D018817	3 , 4 - methylenedioxymethamphetamine|MDMA|ecstasy|Ecstasy|3 , 4 - methylenedioxymethamphetamine|MDMA|ecstasy|ecstasy|ecstasy|MDMA|MDMA|MDMA|MDMA|ecstasy|ecstasy|ecstasy	ChemicalEntity	15:21:23:28:30:36:87:157:166:172:180:240:244:283:294:348	20:22:24:29:35:37:88:158:167:173:181:241:245:284:295:349	0:0:0:1:1:1:3:4:4:4:4:6:6:7:8:9	D009538	nicotine|nicotine	ChemicalEntity	141:150	142:151	4:4	1:NR:2	L2R	NON-CROSS	143-144	157-158	D018817	3 , 4 - methylenedioxymethamphetamine|MDMA|ecstasy|Ecstasy|3 , 4 - methylenedioxymethamphetamine|MDMA|ecstasy|ecstasy|ecstasy|MDMA|MDMA|MDMA|MDMA|ecstasy|ecstasy|ecstasy	ChemicalEntity	15:21:23:28:30:36:87:157:166:172:180:240:244:283:294:348	20:22:24:29:35:37:88:158:167:173:181:241:245:284:295:349	0:0:0:1:1:1:3:4:4:4:4:6:6:7:8:9	D000431,D009538	AN	ChemicalEntity	143	144	4	1:NR:2	L2R	NON-CROSS	146-147	157-158	D018817	3 , 4 - methylenedioxymethamphetamine|MDMA|ecstasy|Ecstasy|3 , 4 - methylenedioxymethamphetamine|MDMA|ecstasy|ecstasy|ecstasy|MDMA|MDMA|MDMA|MDMA|ecstasy|ecstasy|ecstasy	ChemicalEntity	15:21:23:28:30:36:87:157:166:172:180:240:244:283:294:348	20:22:24:29:35:37:88:158:167:173:181:241:245:284:295:349	0:0:0:1:1:1:3:4:4:4:4:6:6:7:8:9	D002188	cannabis	ChemicalEntity	146	147	4	1:NR:2	L2R	NON-CROSS	152-153	157-158	D018817	3 , 4 - methylenedioxymethamphetamine|MDMA|ecstasy|Ecstasy|3 , 4 - methylenedioxymethamphetamine|MDMA|ecstasy|ecstasy|ecstasy|MDMA|MDMA|MDMA|MDMA|ecstasy|ecstasy|ecstasy	ChemicalEntity	15:21:23:28:30:36:87:157:166:172:180:240:244:283:294:348	20:22:24:29:35:37:88:158:167:173:181:241:245:284:295:349	0:0:0:1:1:1:3:4:4:4:4:6:6:7:8:9	D000431,D002188,D009538	CAN|CAN	ChemicalEntity	152:223	153:224	4:6	1:Positive_Correlation:2	L2R	NON-CROSS	326-328	348-349	D018817	3 , 4 - methylenedioxymethamphetamine|MDMA|ecstasy|Ecstasy|3 , 4 - methylenedioxymethamphetamine|MDMA|ecstasy|ecstasy|ecstasy|MDMA|MDMA|MDMA|MDMA|ecstasy|ecstasy|ecstasy	ChemicalEntity	15:21:23:28:30:36:87:157:166:172:180:240:244:283:294:348	20:22:24:29:35:37:88:158:167:173:181:241:245:284:295:349	0:0:0:1:1:1:3:4:4:4:4:6:6:7:8:9	D008569	impaired memory	DiseaseOrPhenotypicFeature	326	328	9	1:Positive_Correlation:2	L2R	NON-CROSS	338-340	348-349	D018817	3 , 4 - methylenedioxymethamphetamine|MDMA|ecstasy|Ecstasy|3 , 4 - methylenedioxymethamphetamine|MDMA|ecstasy|ecstasy|ecstasy|MDMA|MDMA|MDMA|MDMA|ecstasy|ecstasy|ecstasy	ChemicalEntity	15:21:23:28:30:36:87:157:166:172:180:240:244:283:294:348	20:22:24:29:35:37:88:158:167:173:181:241:245:284:295:349	0:0:0:1:1:1:3:4:4:4:4:6:6:7:8:9	D020920	sleep disturbance	DiseaseOrPhenotypicFeature	338	340	9	1:NR:2	L2R	CROSS	77-78	139-140	D012701	5HT	ChemicalEntity	77	78	3	D000431	alcohol|alcohol	ChemicalEntity	139:148	140:149	4:4	1:NR:2	L2R	CROSS	77-78	141-142	D012701	5HT	ChemicalEntity	77	78	3	D009538	nicotine|nicotine	ChemicalEntity	141:150	142:151	4:4	1:NR:2	L2R	CROSS	77-78	143-144	D012701	5HT	ChemicalEntity	77	78	3	D000431,D009538	AN	ChemicalEntity	143	144	4	1:NR:2	L2R	CROSS	77-78	146-147	D012701	5HT	ChemicalEntity	77	78	3	D002188	cannabis	ChemicalEntity	146	147	4	1:NR:2	L2R	CROSS	77-78	152-153	D012701	5HT	ChemicalEntity	77	78	3	D000431,D002188,D009538	CAN|CAN	ChemicalEntity	152:223	153:224	4:6	1:NR:2	L2R	CROSS	77-78	326-328	D012701	5HT	ChemicalEntity	77	78	3	D008569	impaired memory	DiseaseOrPhenotypicFeature	326	328	9	1:NR:2	L2R	CROSS	77-78	338-340	D012701	5HT	ChemicalEntity	77	78	3	D020920	sleep disturbance	DiseaseOrPhenotypicFeature	338	340	9	1:NR:2	L2R	NON-CROSS	139-140	141-142	D000431	alcohol|alcohol	ChemicalEntity	139:148	140:149	4:4	D009538	nicotine|nicotine	ChemicalEntity	141:150	142:151	4:4	1:NR:2	L2R	NON-CROSS	139-140	143-144	D000431	alcohol|alcohol	ChemicalEntity	139:148	140:149	4:4	D000431,D009538	AN	ChemicalEntity	143	144	4	1:NR:2	L2R	NON-CROSS	146-147	148-149	D000431	alcohol|alcohol	ChemicalEntity	139:148	140:149	4:4	D002188	cannabis	ChemicalEntity	146	147	4	1:NR:2	L2R	NON-CROSS	148-149	152-153	D000431	alcohol|alcohol	ChemicalEntity	139:148	140:149	4:4	D000431,D002188,D009538	CAN|CAN	ChemicalEntity	152:223	153:224	4:6	1:NR:2	L2R	CROSS	148-149	326-328	D000431	alcohol|alcohol	ChemicalEntity	139:148	140:149	4:4	D008569	impaired memory	DiseaseOrPhenotypicFeature	326	328	9	1:NR:2	L2R	CROSS	148-149	338-340	D000431	alcohol|alcohol	ChemicalEntity	139:148	140:149	4:4	D020920	sleep disturbance	DiseaseOrPhenotypicFeature	338	340	9	1:NR:2	L2R	NON-CROSS	141-142	143-144	D009538	nicotine|nicotine	ChemicalEntity	141:150	142:151	4:4	D000431,D009538	AN	ChemicalEntity	143	144	4	1:NR:2	L2R	NON-CROSS	146-147	150-151	D009538	nicotine|nicotine	ChemicalEntity	141:150	142:151	4:4	D002188	cannabis	ChemicalEntity	146	147	4	1:NR:2	L2R	NON-CROSS	150-151	152-153	D009538	nicotine|nicotine	ChemicalEntity	141:150	142:151	4:4	D000431,D002188,D009538	CAN|CAN	ChemicalEntity	152:223	153:224	4:6	1:NR:2	L2R	CROSS	150-151	326-328	D009538	nicotine|nicotine	ChemicalEntity	141:150	142:151	4:4	D008569	impaired memory	DiseaseOrPhenotypicFeature	326	328	9	1:NR:2	L2R	CROSS	150-151	338-340	D009538	nicotine|nicotine	ChemicalEntity	141:150	142:151	4:4	D020920	sleep disturbance	DiseaseOrPhenotypicFeature	338	340	9	1:NR:2	L2R	NON-CROSS	143-144	146-147	D000431,D009538	AN	ChemicalEntity	143	144	4	D002188	cannabis	ChemicalEntity	146	147	4	1:NR:2	L2R	NON-CROSS	143-144	152-153	D000431,D009538	AN	ChemicalEntity	143	144	4	D000431,D002188,D009538	CAN|CAN	ChemicalEntity	152:223	153:224	4:6	1:NR:2	L2R	CROSS	143-144	326-328	D000431,D009538	AN	ChemicalEntity	143	144	4	D008569	impaired memory	DiseaseOrPhenotypicFeature	326	328	9	1:NR:2	L2R	CROSS	143-144	338-340	D000431,D009538	AN	ChemicalEntity	143	144	4	D020920	sleep disturbance	DiseaseOrPhenotypicFeature	338	340	9	1:NR:2	L2R	NON-CROSS	146-147	152-153	D002188	cannabis	ChemicalEntity	146	147	4	D000431,D002188,D009538	CAN|CAN	ChemicalEntity	152:223	153:224	4:6	1:NR:2	L2R	CROSS	146-147	326-328	D002188	cannabis	ChemicalEntity	146	147	4	D008569	impaired memory	DiseaseOrPhenotypicFeature	326	328	9	1:NR:2	L2R	CROSS	146-147	338-340	D002188	cannabis	ChemicalEntity	146	147	4	D020920	sleep disturbance	DiseaseOrPhenotypicFeature	338	340	9	1:NR:2	L2R	CROSS	223-224	326-328	D000431,D002188,D009538	CAN|CAN	ChemicalEntity	152:223	153:224	4:6	D008569	impaired memory	DiseaseOrPhenotypicFeature	326	328	9	1:NR:2	L2R	CROSS	223-224	338-340	D000431,D002188,D009538	CAN|CAN	ChemicalEntity	152:223	153:224	4:6	D020920	sleep disturbance	DiseaseOrPhenotypicFeature	338	340	9
24717468	A comparison of severe hemodynamic disturbances between dexmedetomidine and propofol for sedation in neurocritical care patients .|OBJECTIVE : Dexmedetomidine and propofol are commonly used sedatives in neurocritical care as they allow for frequent neurologic examinations .|However , both agents are associated with significant hemodynamic side effects .|The primary objective of this study is to compare the prevalence of severe hemodynamic effects in neurocritical care patients receiving dexmedetomidine and propofol .|DESIGN : Multicenter , retrospective , propensity - matched cohort study .|SETTING : Neurocritical care units at two academic medical centers with dedicated neurocritical care teams and board - certified neurointensivists .|PATIENTS : Neurocritical care patients admitted between July 2009 and September 2012 were evaluated and then matched 1 : 1 based on propensity scoring of baseline characteristics .|INTERVENTIONS : Continuous sedation with dexmedetomidine or propofol .|MEASUREMENTS AND MAIN RESULTS : A total of 342 patients ( 105 dexmedetomidine and 237 propofol ) were included in the analysis , with 190 matched ( 95 in each group ) by propensity score .|The primary outcome of this study was a composite of severe hypotension ( mean arterial pressure < 60 mm Hg ) and bradycardia ( heart rate < 50 beats / min ) during sedative infusion .|No difference in the primary composite outcome in both the unmatched ( 30 % vs 30 % , p = 0 . 94 ) or matched cohorts ( 28 % vs 34 % , p = 0 . 35 ) could be found .|When analyzed separately , no differences could be found in the prevalence of severe hypotension or bradycardia in either the unmatched or matched cohorts .|CONCLUSIONS : Severe hypotension and bradycardia occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or propofol .|Providers should similarly consider the likelihood of hypotension or bradycardia before starting either sedative .	1:Comparison:2	L2R	NON-CROSS	7-8	9-10	D020927	dexmedetomidine|Dexmedetomidine|dexmedetomidine|dexmedetomidine|dexmedetomidine|dexmedetomidine	ChemicalEntity	7:19:69:139:155:300	8:20:70:140:156:301	0:1:3:7:8:12	D015742	propofol|propofol|propofol|propofol|propofol|propofol	ChemicalEntity	9:21:71:141:158:302	10:22:72:142:159:303	0:1:3:7:8:12	1:Positive_Correlation:2	L2R	NON-CROSS	300-301	311-312	D020927	dexmedetomidine|Dexmedetomidine|dexmedetomidine|dexmedetomidine|dexmedetomidine|dexmedetomidine	ChemicalEntity	7:19:69:139:155:300	8:20:70:140:156:301	0:1:3:7:8:12	D007022	hypotension|hypotension|hypotension|hypotension	DiseaseOrPhenotypicFeature	190:273:287:311	191:274:288:312	9:11:12:13	1:Positive_Correlation:2	L2R	NON-CROSS	289-290	300-301	D020927	dexmedetomidine|Dexmedetomidine|dexmedetomidine|dexmedetomidine|dexmedetomidine|dexmedetomidine	ChemicalEntity	7:19:69:139:155:300	8:20:70:140:156:301	0:1:3:7:8:12	D001919	bradycardia|bradycardia|bradycardia|bradycardia	DiseaseOrPhenotypicFeature	201:275:289:313	202:276:290:314	9:11:12:13	1:Positive_Correlation:2	L2R	NON-CROSS	302-303	311-312	D015742	propofol|propofol|propofol|propofol|propofol|propofol	ChemicalEntity	9:21:71:141:158:302	10:22:72:142:159:303	0:1:3:7:8:12	D007022	hypotension|hypotension|hypotension|hypotension	DiseaseOrPhenotypicFeature	190:273:287:311	191:274:288:312	9:11:12:13	1:Positive_Correlation:2	L2R	NON-CROSS	302-303	313-314	D015742	propofol|propofol|propofol|propofol|propofol|propofol	ChemicalEntity	9:21:71:141:158:302	10:22:72:142:159:303	0:1:3:7:8:12	D001919	bradycardia|bradycardia|bradycardia|bradycardia	DiseaseOrPhenotypicFeature	201:275:289:313	202:276:290:314	9:11:12:13
24739405	Effects of dehydroepiandrosterone in amphetamine - induced schizophrenia models in mice .|OBJECTIVE : To examine the effects of dehydroepiandrosterone ( DHEA ) on animal models of schizophrenia .|METHODS : Seventy Swiss albino female mice ( 25 - 35 g ) were divided into 4 groups : amphetamine - free ( control ) , amphetamine , 50 , and 100 mg / kg DHEA .|The DHEA was administered intraperitoneally ( ip ) for 5 days .|Amphetamine ( 3 mg / kg ip ) induced hyper locomotion , apomorphine ( 1 . 5 mg / kg subcutaneously [ sc ] ) induced climbing , and haloperidol ( 1 . 5 mg / kg sc ) induced catalepsy tests were used as animal models of schizophrenia .|The study was conducted at the Animal Experiment Laboratories , Department of Pharmacology , Medical School , Eskisehir Osmangazi University , Eskisehir , Turkey between March and May 2012 .|Statistical analysis was carried out using Kruskal - Wallis test for hyper locomotion , and one - way ANOVA for climbing and catalepsy tests .|RESULTS : In the amphetamine - induced locomotion test , there were significant increases in all movements compared with the amphetamine - free group .|Both DHEA 50 mg / kg ( p < 0 . 05 ) , and 100 mg / kg ( p < 0 . 01 ) significantly decreased all movements compared with the amphetamine - induced locomotion group .|There was a significant difference between groups in the haloperidol - induced catalepsy test ( p < 0 . 05 ) .|There was no significant difference between groups in terms of total climbing time in the apomorphine - induced climbing test ( p > 0 . 05 ) .|CONCLUSION : We observed that DHEA reduced locomotor activity and increased catalepsy at both doses , while it had no effect on climbing behavior .|We suggest that DHEA displays typical neuroleptic - like effects , and may be used in the treatment of schizophrenia .	1:Comparison:2	L2R	NON-CROSS	2-3	4-5	D003687	dehydroepiandrosterone|dehydroepiandrosterone|DHEA|DHEA|DHEA|DHEA|DHEA|DHEA	ChemicalEntity	2:19:21:64:67:209:302:325	3:20:22:65:68:210:303:326	0:1:1:2:3:8:11:12	D000661	amphetamine|amphetamine|amphetamine|Amphetamine|amphetamine|amphetamine|amphetamine	ChemicalEntity	4:48:55:78:187:203:241	5:49:56:79:188:204:242	0:2:2:4:7:7:8	1:Negative_Correlation:2	L2R	NON-CROSS	2-3	7-8	D003687	dehydroepiandrosterone|dehydroepiandrosterone|DHEA|DHEA|DHEA|DHEA|DHEA|DHEA	ChemicalEntity	2:19:21:64:67:209:302:325	3:20:22:65:68:210:303:326	0:1:1:2:3:8:11:12	D012559	schizophrenia|schizophrenia|schizophrenia|schizophrenia	DiseaseOrPhenotypicFeature	7:27:126:341	8:28:127:342	0:1:4:12	1:NR:2	L2R	CROSS	67-68	87-89	D003687	dehydroepiandrosterone|dehydroepiandrosterone|DHEA|DHEA|DHEA|DHEA|DHEA|DHEA	ChemicalEntity	2:19:21:64:67:209:302:325	3:20:22:65:68:210:303:326	0:1:1:2:3:8:11:12	D006948	hyper locomotion|hyper locomotion	DiseaseOrPhenotypicFeature	87:169	89:171	4:6	1:NR:2	L2R	CROSS	284-285	302-303	D003687	dehydroepiandrosterone|dehydroepiandrosterone|DHEA|DHEA|DHEA|DHEA|DHEA|DHEA	ChemicalEntity	2:19:21:64:67:209:302:325	3:20:22:65:68:210:303:326	0:1:1:2:3:8:11:12	D001058	apomorphine|apomorphine	ChemicalEntity	90:284	91:285	4:10	1:NR:2	L2R	CROSS	67-68	107-108	D003687	dehydroepiandrosterone|dehydroepiandrosterone|DHEA|DHEA|DHEA|DHEA|DHEA|DHEA	ChemicalEntity	2:19:21:64:67:209:302:325	3:20:22:65:68:210:303:326	0:1:1:2:3:8:11:12	D006220	haloperidol|haloperidol	ChemicalEntity	107:256	108:257	4:9	1:Positive_Correlation:2	L2R	NON-CROSS	302-303	308-309	D003687	dehydroepiandrosterone|dehydroepiandrosterone|DHEA|DHEA|DHEA|DHEA|DHEA|DHEA	ChemicalEntity	2:19:21:64:67:209:302:325	3:20:22:65:68:210:303:326	0:1:1:2:3:8:11:12	D002375	catalepsy|catalepsy|catalepsy|catalepsy	DiseaseOrPhenotypicFeature	118:180:259:308	119:181:260:309	4:6:9:11	1:Positive_Correlation:2	L2R	NON-CROSS	4-5	7-8	D000661	amphetamine|amphetamine|amphetamine|Amphetamine|amphetamine|amphetamine|amphetamine	ChemicalEntity	4:48:55:78:187:203:241	5:49:56:79:188:204:242	0:2:2:4:7:7:8	D012559	schizophrenia|schizophrenia|schizophrenia|schizophrenia	DiseaseOrPhenotypicFeature	7:27:126:341	8:28:127:342	0:1:4:12	1:Positive_Correlation:2	L2R	NON-CROSS	78-79	87-89	D000661	amphetamine|amphetamine|amphetamine|Amphetamine|amphetamine|amphetamine|amphetamine	ChemicalEntity	4:48:55:78:187:203:241	5:49:56:79:188:204:242	0:2:2:4:7:7:8	D006948	hyper locomotion|hyper locomotion	DiseaseOrPhenotypicFeature	87:169	89:171	4:6	1:NR:2	L2R	NON-CROSS	78-79	90-91	D000661	amphetamine|amphetamine|amphetamine|Amphetamine|amphetamine|amphetamine|amphetamine	ChemicalEntity	4:48:55:78:187:203:241	5:49:56:79:188:204:242	0:2:2:4:7:7:8	D001058	apomorphine|apomorphine	ChemicalEntity	90:284	91:285	4:10	1:NR:2	L2R	NON-CROSS	241-242	256-257	D000661	amphetamine|amphetamine|amphetamine|Amphetamine|amphetamine|amphetamine|amphetamine	ChemicalEntity	4:48:55:78:187:203:241	5:49:56:79:188:204:242	0:2:2:4:7:7:8	D006220	haloperidol|haloperidol	ChemicalEntity	107:256	108:257	4:9	1:NR:2	L2R	NON-CROSS	180-181	187-188	D000661	amphetamine|amphetamine|amphetamine|Amphetamine|amphetamine|amphetamine|amphetamine	ChemicalEntity	4:48:55:78:187:203:241	5:49:56:79:188:204:242	0:2:2:4:7:7:8	D002375	catalepsy|catalepsy|catalepsy|catalepsy	DiseaseOrPhenotypicFeature	118:180:259:308	119:181:260:309	4:6:9:11	1:NR:2	L2R	NON-CROSS	90-91	126-127	D012559	schizophrenia|schizophrenia|schizophrenia|schizophrenia	DiseaseOrPhenotypicFeature	7:27:126:341	8:28:127:342	0:1:4:12	D001058	apomorphine|apomorphine	ChemicalEntity	90:284	91:285	4:10	1:NR:2	L2R	NON-CROSS	107-108	126-127	D012559	schizophrenia|schizophrenia|schizophrenia|schizophrenia	DiseaseOrPhenotypicFeature	7:27:126:341	8:28:127:342	0:1:4:12	D006220	haloperidol|haloperidol	ChemicalEntity	107:256	108:257	4:9	1:NR:2	L2R	NON-CROSS	87-89	90-91	D006948	hyper locomotion|hyper locomotion	DiseaseOrPhenotypicFeature	87:169	89:171	4:6	D001058	apomorphine|apomorphine	ChemicalEntity	90:284	91:285	4:10	1:NR:2	L2R	NON-CROSS	87-89	107-108	D006948	hyper locomotion|hyper locomotion	DiseaseOrPhenotypicFeature	87:169	89:171	4:6	D006220	haloperidol|haloperidol	ChemicalEntity	107:256	108:257	4:9	1:NR:2	L2R	NON-CROSS	90-91	107-108	D001058	apomorphine|apomorphine	ChemicalEntity	90:284	91:285	4:10	D006220	haloperidol|haloperidol	ChemicalEntity	107:256	108:257	4:9	1:NR:2	L2R	NON-CROSS	284-285	308-309	D001058	apomorphine|apomorphine	ChemicalEntity	90:284	91:285	4:10	D002375	catalepsy|catalepsy|catalepsy|catalepsy	DiseaseOrPhenotypicFeature	118:180:259:308	119:181:260:309	4:6:9:11	1:Positive_Correlation:2	L2R	NON-CROSS	256-257	259-260	D006220	haloperidol|haloperidol	ChemicalEntity	107:256	108:257	4:9	D002375	catalepsy|catalepsy|catalepsy|catalepsy	DiseaseOrPhenotypicFeature	118:180:259:308	119:181:260:309	4:6:9:11
24840785	Aconitine - induced Ca2 + overload causes arrhythmia and triggers apoptosis through p38 MAPK signaling pathway in rats .|Aconitine is a major bioactive diterpenoid alkaloid with high content derived from herbal aconitum plants .|Emerging evidence indicates that voltage - dependent Na ( + ) channels have pivotal roles in the cardiotoxicity of aconitine .|However , no reports are available on the role of Ca ( 2 + ) in aconitine poisoning .|In this study , we explored the importance of pathological Ca ( 2 + ) signaling in aconitine poisoning in vitro and in vivo .|We found that Ca ( 2 + ) overload lead to accelerated beating rhythm in adult rat ventricular myocytes and caused arrhythmia in conscious freely moving rats .|To investigate effects of aconitine on myocardial injury , we performed cytotoxicity assay in neonatal rat ventricular myocytes ( NRVMs ) , as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats .|The results showed that aconitine resulted in myocardial injury and reduced NRVMs viability dose - dependently .|To confirm the pro - apoptotic effects , we performed flow cytometric detection , cardiac histology , transmission electron microscopy and terminal deoxynucleotidyl transferase - mediated dUTP - biotin nick end labeling assay .|The results showed that aconitine stimulated apoptosis time - dependently .|The expression analysis of Ca ( 2 + ) handling proteins demonstrated that aconitine promoted Ca ( 2 + ) overload through the expression regulation of Ca ( 2 + ) handling proteins .|The expression analysis of apoptosis - related proteins revealed that pro - apoptotic protein expression was upregulated , and anti - apoptotic protein BCL - 2 expression was downregulated .|Furthermore , increased phosphorylation of MAPK family members , especially the P - P38 / P38 ratio was found in cardiac tissues .|Hence , our results suggest that aconitine significantly aggravates Ca ( 2 + ) overload and causes arrhythmia and finally promotes apoptotic development via phosphorylation of P38 mitogen - activated protein kinase .	1:Positive_Correlation:2	L2R	NON-CROSS	247-248	249-254	D000157	Aconitine|Aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine	ChemicalEntity	0:19:54:72:92:132:176:227:247:327	1:20:55:73:93:133:177:228:248:328	0:1:2:3:4:6:7:9:10:13	D002118	Ca2 +|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )	ChemicalEntity	3:66:85:103:238:249:260:330	5:71:90:108:243:254:265:335	0:3:4:5:10:10:10:13	1:Positive_Correlation:2	L2R	NON-CROSS	0-1	7-8	D000157	Aconitine|Aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine	ChemicalEntity	0:19:54:72:92:132:176:227:247:327	1:20:55:73:93:133:177:228:248:328	0:1:2:3:4:6:7:9:10:13	D001145	arrhythmia|arrhythmia|arrhythmia	DiseaseOrPhenotypicFeature	7:121:338	8:122:339	0:5:13	1:Association:2	L2R	NON-CROSS	12-14	19-20	D000157	Aconitine|Aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine	ChemicalEntity	0:19:54:72:92:132:176:227:247:327	1:20:55:73:93:133:177:228:248:328	0:1:2:3:4:6:7:9:10:13	81649	p38 MAPK|MAPK|P38|P38|P38 mitogen - activated protein kinase	GeneOrGeneProduct	12:303:311:313:347	14:304:312:314:353	0:12:12:12:13	1:NR:2	L2R	NON-CROSS	19-20	24-26	D000157	Aconitine|Aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine	ChemicalEntity	0:19:54:72:92:132:176:227:247:327	1:20:55:73:93:133:177:228:248:328	0:1:2:3:4:6:7:9:10:13	-	diterpenoid alkaloid|dUTP	ChemicalEntity	24:215	26:216	1:8	1:NR:2	L2R	NON-CROSS	42-46	54-55	D000157	Aconitine|Aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine	ChemicalEntity	0:19:54:72:92:132:176:227:247:327	1:20:55:73:93:133:177:228:248:328	0:1:2:3:4:6:7:9:10:13	D012964	Na ( + )	ChemicalEntity	42	46	2	1:Positive_Correlation:2	L2R	NON-CROSS	52-53	54-55	D000157	Aconitine|Aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine	ChemicalEntity	0:19:54:72:92:132:176:227:247:327	1:20:55:73:93:133:177:228:248:328	0:1:2:3:4:6:7:9:10:13	D066126	cardiotoxicity	DiseaseOrPhenotypicFeature	52	53	2	1:NR:2	L2R	NON-CROSS	72-73	73-74	D000157	Aconitine|Aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine	ChemicalEntity	0:19:54:72:92:132:176:227:247:327	1:20:55:73:93:133:177:228:248:328	0:1:2:3:4:6:7:9:10:13	D011041	poisoning|poisoning	DiseaseOrPhenotypicFeature	73:93	74:94	3:4	1:Positive_Correlation:2	L2R	NON-CROSS	132-133	134-136	D000157	Aconitine|Aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine	ChemicalEntity	0:19:54:72:92:132:176:227:247:327	1:20:55:73:93:133:177:228:248:328	0:1:2:3:4:6:7:9:10:13	D009202	myocardial injury|myocardial injury	DiseaseOrPhenotypicFeature	134:179	136:181	6:7	1:NR:2	L2R	NON-CROSS	132-133	139-140	D000157	Aconitine|Aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine	ChemicalEntity	0:19:54:72:92:132:176:227:247:327	1:20:55:73:93:133:177:228:248:328	0:1:2:3:4:6:7:9:10:13	D064420	cytotoxicity	DiseaseOrPhenotypicFeature	139	140	6	1:NR:2	L2R	NON-CROSS	154-156	176-177	D000157	Aconitine|Aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine	ChemicalEntity	0:19:54:72:92:132:176:227:247:327	1:20:55:73:93:133:177:228:248:328	0:1:2:3:4:6:7:9:10:13	24533	lactate dehydrogenase	GeneOrGeneProduct	154	156	6	1:NR:2	L2R	CROSS	217-218	227-228	D000157	Aconitine|Aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine	ChemicalEntity	0:19:54:72:92:132:176:227:247:327	1:20:55:73:93:133:177:228:248:328	0:1:2:3:4:6:7:9:10:13	D001710	biotin	ChemicalEntity	217	218	8	1:NR:2	L2R	CROSS	291-294	327-328	D000157	Aconitine|Aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine|aconitine	ChemicalEntity	0:19:54:72:92:132:176:227:247:327	1:20:55:73:93:133:177:228:248:328	0:1:2:3:4:6:7:9:10:13	24224	BCL - 2	GeneOrGeneProduct	291	294	11	1:Positive_Correlation:2	L2R	NON-CROSS	3-5	7-8	D002118	Ca2 +|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )	ChemicalEntity	3:66:85:103:238:249:260:330	5:71:90:108:243:254:265:335	0:3:4:5:10:10:10:13	D001145	arrhythmia|arrhythmia|arrhythmia	DiseaseOrPhenotypicFeature	7:121:338	8:122:339	0:5:13	1:NR:2	L2R	NON-CROSS	3-5	12-14	D002118	Ca2 +|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )	ChemicalEntity	3:66:85:103:238:249:260:330	5:71:90:108:243:254:265:335	0:3:4:5:10:10:10:13	81649	p38 MAPK|MAPK|P38|P38|P38 mitogen - activated protein kinase	GeneOrGeneProduct	12:303:311:313:347	14:304:312:314:353	0:12:12:12:13	1:NR:2	L2R	CROSS	3-5	24-26	D002118	Ca2 +|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )	ChemicalEntity	3:66:85:103:238:249:260:330	5:71:90:108:243:254:265:335	0:3:4:5:10:10:10:13	-	diterpenoid alkaloid|dUTP	ChemicalEntity	24:215	26:216	1:8	1:NR:2	L2R	CROSS	42-46	66-71	D002118	Ca2 +|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )	ChemicalEntity	3:66:85:103:238:249:260:330	5:71:90:108:243:254:265:335	0:3:4:5:10:10:10:13	D012964	Na ( + )	ChemicalEntity	42	46	2	1:NR:2	L2R	CROSS	52-53	66-71	D002118	Ca2 +|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )	ChemicalEntity	3:66:85:103:238:249:260:330	5:71:90:108:243:254:265:335	0:3:4:5:10:10:10:13	D066126	cardiotoxicity	DiseaseOrPhenotypicFeature	52	53	2	1:NR:2	L2R	NON-CROSS	66-71	73-74	D002118	Ca2 +|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )	ChemicalEntity	3:66:85:103:238:249:260:330	5:71:90:108:243:254:265:335	0:3:4:5:10:10:10:13	D011041	poisoning|poisoning	DiseaseOrPhenotypicFeature	73:93	74:94	3:4	1:NR:2	L2R	CROSS	103-108	134-136	D002118	Ca2 +|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )	ChemicalEntity	3:66:85:103:238:249:260:330	5:71:90:108:243:254:265:335	0:3:4:5:10:10:10:13	D009202	myocardial injury|myocardial injury	DiseaseOrPhenotypicFeature	134:179	136:181	6:7	1:NR:2	L2R	CROSS	103-108	139-140	D002118	Ca2 +|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )	ChemicalEntity	3:66:85:103:238:249:260:330	5:71:90:108:243:254:265:335	0:3:4:5:10:10:10:13	D064420	cytotoxicity	DiseaseOrPhenotypicFeature	139	140	6	1:NR:2	L2R	CROSS	103-108	154-156	D002118	Ca2 +|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )	ChemicalEntity	3:66:85:103:238:249:260:330	5:71:90:108:243:254:265:335	0:3:4:5:10:10:10:13	24533	lactate dehydrogenase	GeneOrGeneProduct	154	156	6	1:NR:2	L2R	CROSS	217-218	238-243	D002118	Ca2 +|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )	ChemicalEntity	3:66:85:103:238:249:260:330	5:71:90:108:243:254:265:335	0:3:4:5:10:10:10:13	D001710	biotin	ChemicalEntity	217	218	8	1:NR:2	L2R	CROSS	260-265	291-294	D002118	Ca2 +|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )|Ca ( 2 + )	ChemicalEntity	3:66:85:103:238:249:260:330	5:71:90:108:243:254:265:335	0:3:4:5:10:10:10:13	24224	BCL - 2	GeneOrGeneProduct	291	294	11	1:Association:2	L2R	NON-CROSS	7-8	12-14	D001145	arrhythmia|arrhythmia|arrhythmia	DiseaseOrPhenotypicFeature	7:121:338	8:122:339	0:5:13	81649	p38 MAPK|MAPK|P38|P38|P38 mitogen - activated protein kinase	GeneOrGeneProduct	12:303:311:313:347	14:304:312:314:353	0:12:12:12:13	1:NR:2	L2R	CROSS	7-8	24-26	D001145	arrhythmia|arrhythmia|arrhythmia	DiseaseOrPhenotypicFeature	7:121:338	8:122:339	0:5:13	-	diterpenoid alkaloid|dUTP	ChemicalEntity	24:215	26:216	1:8	1:NR:2	L2R	CROSS	7-8	42-46	D001145	arrhythmia|arrhythmia|arrhythmia	DiseaseOrPhenotypicFeature	7:121:338	8:122:339	0:5:13	D012964	Na ( + )	ChemicalEntity	42	46	2	1:NR:2	L2R	CROSS	121-122	154-156	D001145	arrhythmia|arrhythmia|arrhythmia	DiseaseOrPhenotypicFeature	7:121:338	8:122:339	0:5:13	24533	lactate dehydrogenase	GeneOrGeneProduct	154	156	6	1:NR:2	L2R	CROSS	121-122	217-218	D001145	arrhythmia|arrhythmia|arrhythmia	DiseaseOrPhenotypicFeature	7:121:338	8:122:339	0:5:13	D001710	biotin	ChemicalEntity	217	218	8	1:NR:2	L2R	CROSS	291-294	338-339	D001145	arrhythmia|arrhythmia|arrhythmia	DiseaseOrPhenotypicFeature	7:121:338	8:122:339	0:5:13	24224	BCL - 2	GeneOrGeneProduct	291	294	11	1:NR:2	L2R	CROSS	12-14	24-26	81649	p38 MAPK|MAPK|P38|P38|P38 mitogen - activated protein kinase	GeneOrGeneProduct	12:303:311:313:347	14:304:312:314:353	0:12:12:12:13	-	diterpenoid alkaloid|dUTP	ChemicalEntity	24:215	26:216	1:8	1:NR:2	L2R	CROSS	12-14	42-46	81649	p38 MAPK|MAPK|P38|P38|P38 mitogen - activated protein kinase	GeneOrGeneProduct	12:303:311:313:347	14:304:312:314:353	0:12:12:12:13	D012964	Na ( + )	ChemicalEntity	42	46	2	1:NR:2	L2R	CROSS	12-14	52-53	81649	p38 MAPK|MAPK|P38|P38|P38 mitogen - activated protein kinase	GeneOrGeneProduct	12:303:311:313:347	14:304:312:314:353	0:12:12:12:13	D066126	cardiotoxicity	DiseaseOrPhenotypicFeature	52	53	2	1:NR:2	L2R	CROSS	12-14	73-74	81649	p38 MAPK|MAPK|P38|P38|P38 mitogen - activated protein kinase	GeneOrGeneProduct	12:303:311:313:347	14:304:312:314:353	0:12:12:12:13	D011041	poisoning|poisoning	DiseaseOrPhenotypicFeature	73:93	74:94	3:4	1:NR:2	L2R	CROSS	12-14	134-136	81649	p38 MAPK|MAPK|P38|P38|P38 mitogen - activated protein kinase	GeneOrGeneProduct	12:303:311:313:347	14:304:312:314:353	0:12:12:12:13	D009202	myocardial injury|myocardial injury	DiseaseOrPhenotypicFeature	134:179	136:181	6:7	1:NR:2	L2R	CROSS	12-14	139-140	81649	p38 MAPK|MAPK|P38|P38|P38 mitogen - activated protein kinase	GeneOrGeneProduct	12:303:311:313:347	14:304:312:314:353	0:12:12:12:13	D064420	cytotoxicity	DiseaseOrPhenotypicFeature	139	140	6	1:NR:2	L2R	CROSS	12-14	154-156	81649	p38 MAPK|MAPK|P38|P38|P38 mitogen - activated protein kinase	GeneOrGeneProduct	12:303:311:313:347	14:304:312:314:353	0:12:12:12:13	24533	lactate dehydrogenase	GeneOrGeneProduct	154	156	6	1:NR:2	L2R	CROSS	217-218	303-304	81649	p38 MAPK|MAPK|P38|P38|P38 mitogen - activated protein kinase	GeneOrGeneProduct	12:303:311:313:347	14:304:312:314:353	0:12:12:12:13	D001710	biotin	ChemicalEntity	217	218	8	1:NR:2	L2R	CROSS	291-294	303-304	81649	p38 MAPK|MAPK|P38|P38|P38 mitogen - activated protein kinase	GeneOrGeneProduct	12:303:311:313:347	14:304:312:314:353	0:12:12:12:13	24224	BCL - 2	GeneOrGeneProduct	291	294	11	1:NR:2	L2R	CROSS	24-26	42-46	-	diterpenoid alkaloid|dUTP	ChemicalEntity	24:215	26:216	1:8	D012964	Na ( + )	ChemicalEntity	42	46	2	1:NR:2	L2R	CROSS	24-26	52-53	-	diterpenoid alkaloid|dUTP	ChemicalEntity	24:215	26:216	1:8	D066126	cardiotoxicity	DiseaseOrPhenotypicFeature	52	53	2	1:NR:2	L2R	CROSS	24-26	73-74	-	diterpenoid alkaloid|dUTP	ChemicalEntity	24:215	26:216	1:8	D011041	poisoning|poisoning	DiseaseOrPhenotypicFeature	73:93	74:94	3:4	1:NR:2	L2R	CROSS	179-181	215-216	-	diterpenoid alkaloid|dUTP	ChemicalEntity	24:215	26:216	1:8	D009202	myocardial injury|myocardial injury	DiseaseOrPhenotypicFeature	134:179	136:181	6:7	1:NR:2	L2R	CROSS	139-140	215-216	-	diterpenoid alkaloid|dUTP	ChemicalEntity	24:215	26:216	1:8	D064420	cytotoxicity	DiseaseOrPhenotypicFeature	139	140	6	1:NR:2	L2R	CROSS	154-156	215-216	-	diterpenoid alkaloid|dUTP	ChemicalEntity	24:215	26:216	1:8	24533	lactate dehydrogenase	GeneOrGeneProduct	154	156	6	1:NR:2	L2R	NON-CROSS	215-216	217-218	-	diterpenoid alkaloid|dUTP	ChemicalEntity	24:215	26:216	1:8	D001710	biotin	ChemicalEntity	217	218	8	1:NR:2	L2R	CROSS	215-216	291-294	-	diterpenoid alkaloid|dUTP	ChemicalEntity	24:215	26:216	1:8	24224	BCL - 2	GeneOrGeneProduct	291	294	11	1:Association:2	L2R	NON-CROSS	42-46	52-53	D012964	Na ( + )	ChemicalEntity	42	46	2	D066126	cardiotoxicity	DiseaseOrPhenotypicFeature	52	53	2	1:NR:2	L2R	CROSS	42-46	73-74	D012964	Na ( + )	ChemicalEntity	42	46	2	D011041	poisoning|poisoning	DiseaseOrPhenotypicFeature	73:93	74:94	3:4	1:NR:2	L2R	CROSS	42-46	134-136	D012964	Na ( + )	ChemicalEntity	42	46	2	D009202	myocardial injury|myocardial injury	DiseaseOrPhenotypicFeature	134:179	136:181	6:7	1:NR:2	L2R	CROSS	42-46	139-140	D012964	Na ( + )	ChemicalEntity	42	46	2	D064420	cytotoxicity	DiseaseOrPhenotypicFeature	139	140	6	1:NR:2	L2R	CROSS	42-46	154-156	D012964	Na ( + )	ChemicalEntity	42	46	2	24533	lactate dehydrogenase	GeneOrGeneProduct	154	156	6	1:NR:2	L2R	CROSS	42-46	217-218	D012964	Na ( + )	ChemicalEntity	42	46	2	D001710	biotin	ChemicalEntity	217	218	8	1:NR:2	L2R	CROSS	42-46	291-294	D012964	Na ( + )	ChemicalEntity	42	46	2	24224	BCL - 2	GeneOrGeneProduct	291	294	11	1:NR:2	L2R	CROSS	52-53	154-156	D066126	cardiotoxicity	DiseaseOrPhenotypicFeature	52	53	2	24533	lactate dehydrogenase	GeneOrGeneProduct	154	156	6	1:NR:2	L2R	CROSS	52-53	217-218	D066126	cardiotoxicity	DiseaseOrPhenotypicFeature	52	53	2	D001710	biotin	ChemicalEntity	217	218	8	1:NR:2	L2R	CROSS	52-53	291-294	D066126	cardiotoxicity	DiseaseOrPhenotypicFeature	52	53	2	24224	BCL - 2	GeneOrGeneProduct	291	294	11	1:NR:2	L2R	CROSS	93-94	154-156	D011041	poisoning|poisoning	DiseaseOrPhenotypicFeature	73:93	74:94	3:4	24533	lactate dehydrogenase	GeneOrGeneProduct	154	156	6	1:NR:2	L2R	CROSS	93-94	217-218	D011041	poisoning|poisoning	DiseaseOrPhenotypicFeature	73:93	74:94	3:4	D001710	biotin	ChemicalEntity	217	218	8	1:NR:2	L2R	CROSS	93-94	291-294	D011041	poisoning|poisoning	DiseaseOrPhenotypicFeature	73:93	74:94	3:4	24224	BCL - 2	GeneOrGeneProduct	291	294	11	1:NR:2	L2R	NON-CROSS	134-136	154-156	D009202	myocardial injury|myocardial injury	DiseaseOrPhenotypicFeature	134:179	136:181	6:7	24533	lactate dehydrogenase	GeneOrGeneProduct	154	156	6	1:NR:2	L2R	CROSS	179-181	217-218	D009202	myocardial injury|myocardial injury	DiseaseOrPhenotypicFeature	134:179	136:181	6:7	D001710	biotin	ChemicalEntity	217	218	8	1:NR:2	L2R	CROSS	179-181	291-294	D009202	myocardial injury|myocardial injury	DiseaseOrPhenotypicFeature	134:179	136:181	6:7	24224	BCL - 2	GeneOrGeneProduct	291	294	11	1:NR:2	L2R	NON-CROSS	139-140	154-156	D064420	cytotoxicity	DiseaseOrPhenotypicFeature	139	140	6	24533	lactate dehydrogenase	GeneOrGeneProduct	154	156	6	1:NR:2	L2R	CROSS	139-140	217-218	D064420	cytotoxicity	DiseaseOrPhenotypicFeature	139	140	6	D001710	biotin	ChemicalEntity	217	218	8	1:NR:2	L2R	CROSS	139-140	291-294	D064420	cytotoxicity	DiseaseOrPhenotypicFeature	139	140	6	24224	BCL - 2	GeneOrGeneProduct	291	294	11	1:NR:2	L2R	CROSS	154-156	217-218	24533	lactate dehydrogenase	GeneOrGeneProduct	154	156	6	D001710	biotin	ChemicalEntity	217	218	8	1:NR:2	L2R	CROSS	154-156	291-294	24533	lactate dehydrogenase	GeneOrGeneProduct	154	156	6	24224	BCL - 2	GeneOrGeneProduct	291	294	11	1:NR:2	L2R	CROSS	217-218	291-294	D001710	biotin	ChemicalEntity	217	218	8	24224	BCL - 2	GeneOrGeneProduct	291	294	11
